2019”N“x –k—¢‘åŠwˆãŠw•”E‘åŠw•a‰@Œ€‹†‹ÆÑW(HTML”Å)


i’FŒŽ–{‚ÅŒäŠm”F‰º‚³‚¢j



‰ð–UŠw (¬ì’PˆÊ)

[Šwp˜_•¶]

110001. [ŒŽ’˜] Parallel Evolution of Two dmrt1-Derived Genes, dmy and dm-W, for Vertebrate Sex Determination. Ogita Y, Mawaribuchi S, Nakasako K, Tamura K, Matsuda M, Katsumura T1, Oota H, Watanabe G, Yoneda S, Takamatsu N, Ito M: iScience 2020/1; 23 (1): 100757. (Ÿ‘ºŒ[Žj1: 1‰ð–U)

[Šw‰ïEŒ€‹†‰ï“™]

713001. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) The fine structural approach to clarify the pathophysiological mechanism of orthopedic diseases by analyzing the spinal excurved Medaka mutant, wavy (wy). Nishimaki T1, Uchida K2, Yamada M, Oda S, Oga A, Oota H, Katsumura T3, Takaso M2, Ogawa M3: The 19th Congress of the International Federation of Associations of Anatomists (2019/8/9), London, UK. (Œê r”V1, “à“cŒ’‘Ÿ˜Y2, Ÿ‘ºŒ[Žj3, ‚‘Š»Žm2, ¬ìŒ³”V3: 1Œ`‘ÔŒn, 2®ŠO, 3‰ð–U)

713002. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) CHANGES IN BLOOD COMPONENT AND DNA METHYLATION PATTERNS IN HEALTHY MEN EXPOSED HYPOBARIC HYPOXIA. Motoi M, Toyoshima H, Nakayama K, Kishida F, Shin S, Nishimura T, Yasukochi Y, Katsumura T1, Oota H, Maeda T, Watanuki S: 14TH INTERNATIONAL CONGRESS OF PHYSIOLOGICAL ANTHROPOLOGY 2019 (ICPA2019) (2019/9/24), Singapore. (Ÿ‘ºŒ[Žj1: 1‰ð–U)

723001. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Œ’í’j«‚É‚š‚¯‚é’ሳ’áŽ_‘f”˜˜IŽž‚ÌŒŒ’†–ƉuŒnŽw•W‚̕ω». –{ˆä@•É, –L“‡G•v, ŠÝ“c@•¶, Shin S, Œ‘º‹MF, ˆÀ‰Í“à•F‹P, Ÿ‘ºŒ[Žj1, ’†ŽRˆê‘å, ‘Ÿ“c”ŽŽ÷, ‘O“c‹Žj, –ȊіΊì (1‰ð–U): “ú–{¶—l—ÞŠw‰ï‘æ79‰ñ‘å‰ï (2019/6/1), ‚—Ö.

723002. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒƒ_ƒJW’c‚ð—p‚¢‚œƒqƒgVŠï«’Ç‹s“®‚ÉŠÖ‚í‚éƒQƒmƒ€—̈æ‚Ì’Tõ. Ÿ‘ºŒ[Žj1, ”ö“c³“ñ, ã‰ªŽj‹, ŽO’JŒ[Žu, ¬ìŒ³”V1, ‘Ÿ“c”ŽŽ÷, ’|“àG–Ÿ (1‰ð–U): “ú–{i‰»Šw‰ï‘æ21‰ñ‘å‰ï (2019/8/7), ŽD–y.

723003. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) V‹K‘€œ^Çƒ‚ƒfƒ‹‚Æ‚µ‚Äwyƒƒ_ƒJ‚Ì—L—p«‚ÌŒŸ“¢. Ÿ‘ºŒ[Žj1, “à“cŒ’‘Ÿ˜Y2, ŽR“c@–«, Œê r”V3, ”ö“c³“ñ, ¬‰êŒú“¿, ‘Ÿ“c”ŽŽ÷, ‚‘Š»Žm2 (1‰ð–U, 2®ŠO, 3Œ`‘ÔŒn): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

723004. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) V‹K‘€œ]Çƒ‚ƒfƒ‹‚Æ‚µ‚Äwyƒƒ_ƒJ‚Ì—L—p«‚ÌŒŸ“¢. Ÿ‘ºŒ[Žj1, “à“cŒ’‘Ÿ˜Y2, ŽR“c@–«, Œê r”V3, ”ö“c³“ñ, ¬‰êŒú“¿, ‘Ÿ“c”ŽŽ÷, ‚‘Š»Žm2, ¬ìŒ³”V1 (1‰ð–U, 2®ŠO, 3Œ`‘ÔŒn): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17), ‰¡•l.

723005. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒAƒ}ƒSEƒTƒcƒLƒ}ƒX‚É‚š‚¯‚é‰ñ—V‘œŒ^‚̈â“`Šî”Õ‚Ì’Tõ. ã“c‚é‚¢, “c’†’B–ç, Ÿ‘ºŒ[Žj1, ‹ŽŒûN”V, •“‡O•F, Michael R MILLER, ²“¡‘ñÆ (1‰ð–U): ‘æ67‰ñ“ú–{¶‘ÔŠw‰ï‘å‰ï (2020/3/7), –ŒŒÃ‰®.

'18”N“xˆÈ‘O•ª

[Šw‰ïEŒ€‹†‰ï“™]

'18-723001. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) LAMP–@‚ðŽg—p‚µ‚œ‰ð–U‘Ì‚É‚š‚¯‚錋Šj‹Û‚̐v‘¬ŒŸž. ŽO‰Y³–Ÿ1, Vˆä—Y‘Ÿ1, ‹Ê–؉p–Ÿ1,2, Ÿ‘ºŒ[Žj1, ¬ìŒ³”V1 (1‰ð–U, 2—Տ°‰ð–U‹³ˆç): ‘æ124‰ñ“ú–{‰ð–UŠw‰ï‘‰ïE‘S‘ŠwpW‰ï (2019/3/27), VŠƒ.


‰ð–UŠw (ãã’PˆÊ)

[Šwp˜_•¶]

110002. [ŒŽ’˜] Regulation of Ca2+/calmodulin-dependent protein kinase kinase ƒÀ by cAMP signaling. Takabatake S, Ohtsuka S, Sugawara T1, Hatano N, Kanayama N, Magari M, Sakagami H1, Tokumitsu H: Biochim Biophys Acta Gen Subj 2019/4; 1863 (4): 672-80 (›ŒŽŒ’”V1, ãã—ms1: 1‰ð–U)

110003. [ŒŽ’˜] Localization of phosphatidylinositol 4-phosphate 5-kinase (PIP5K) ƒ¿, ƒÀ, ƒÁ in the three major salivary glands in situ of mice and their response to ƒÀ-adrenoceptor stimulation. Khrongyut S, Rawangwong A, Pidsaya A, Sakagami H1, Kondo H, Hipkaeo W: J Anat 2019/4; 234 (4): 502-14. (ãã—ms1: ‰ð–U1)

110004. [ŒŽ’˜] Mice lacking EFA6C/Psd2, a guanine nucleotide exchange factor for Arf6, exhibit lower Purkinje cell synaptic density but normal cerebellar motor functions. Saegusa S1, Fukaya M2, Kakegawa W, Tanaka M3, Katsumata O, Sugawara T2, Hara Y2, Itakura M4, Okubo T5, Sato T5, Yuzaki M, Sakagami H2: PLoS One 2019/5; 14 (5): e0216960. (ŽOŽ}M‘å˜Y1, [’J¹O2, “c’†@Šw3, ›ŒŽŒ’”V2, ŒŽ@–FL2, ”‘q@œ4, ‘å‹v•Û’Œ5, ²“¡rÆ5, ãã—ms2: 1ˆãŠw•”, 2‰ð–U, 3ƒoƒCƒIƒCƒ[ƒWŒ€‹†ƒZ, 4¶‰», 5ŽÀ“®)

110005. [ŒŽ’˜] Data on the effects of Charcot-Marie-Tooth disease type 2N-associated AARS missense mutation (Arg329-to-His) on the cell biological properties. Imaizumi N, Takeuchi Y, Hirano H, Torii T, Seki Y, Morimoto T, Miyamoto Y, Sakagami H1, Yamauchi J: Data Brief 2019/5; 25: 104029. (ãã—ms1: ‰ð–U1)

110006. [ŒŽ’˜] Aberrant Amygdala-Dependent Cued Fear Memory in Na+/Ca2+ Exchanger 1 Heterozygous Mice. Moriguchi S, Kita S, Inagaki R, Yabuki Y, Sasaki Y, Ishikawa S, Sakagami H1, Iwamoto T, Fukunaga K: Mol Neurobiol 2019/6; 56 (6): 4381-94. (ãã—ms1: 1‰ð–U)

[Šw‰ïEŒ€‹†‰ï“™]

723006. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠC”n_Œo×–E‚É‚š‚¯‚éBRAG2-Arf6ƒVƒOƒiƒ‹Œo˜H‚ð‰î‚µ‚œAMPAŽó—e‘̂̃VƒiƒvƒX”­Œ»’²ß‹@\. [’J¹O1, ãã—ms1 (1‰ð–U): ‘æ125‰ñ“ú–{‰ð–UŠw‰ï‘‰ïE‘S‘ŠwpW‰ï (2020/3/27), ŽRŒû.

'18”N“xˆÈ‘O•ª

[Šwp˜_•¶]

H25-110001. [ŒŽ’˜] Type 1 inositol trisphosphate receptor regulates cerebellar circuits by maintaining the spine morphology of purkinje cells in adult mice. Sugawara T1, Hisatsune C, Le TD, Hashikawa T, Hirono M, Hattori M, Nagao S, Mikoshiba K: J Neurosci 2013/7; 33 (30): 12186-96. (›ŒŽŒ’”V1: 1‰ð–U)

H25-110002. [ŒŽ’˜] IP3R1 deficiency in the cerebellum/brainstem causes basal ganglia-independent dystonia by triggering tonic Purkinje cell firings in mice. Hisatsune C, Miyamoto H, Hirono M, Yamaguchi N, Sugawara T1, Ogawa N, Ebisui E, Ohshima T, Yamada M, Hensch TK, Hattori M, Mikoshiba K: Front Neural Circuits 2013/10; 7: 156. (›ŒŽŒ’”V1: 1‰ð–U)

H29-110001. [ŒŽ’˜] Regulation of spinogenesis in mature Purkinje cells via mGluR/PKC-mediated phosphorylation of CaMKIIƒÀ. Sugawara T1, Hisatsune C, Miyamoto H, Ogawa N, Mikoshiba K: Proc Natl Acad Sci U S A 2017/6; 114 (26): E5256-65. (›ŒŽŒ’”V1: 1‰ð–U)

'18-110001. [ŒŽ’˜] Hyperactivation of mTORC1 disrupts cellular homeostasis in cerebellar Purkinje cells. Sakai Y, Kassai H, Maeda T, Nakayama H, Fukaya M1, Maeda T, Nakao K, Hashimoto K, Sakagami H1, Kano M, Aiba A: Sci Rep 2019/2; 9 (1): 2799. ([’J¹O1, ãã—ms1: 1‰ð–U)


¶—Šw (ìã’PˆÊ)

[’˜@‘]

620001. [Šwp‘ (•ª’SŽ·•M)] y¶‚«•š‚Ɖ¹‚ÌŽ–“Tz‘æ5Í ’¹—ށ@5-23 ƒIƒEƒ€EƒCƒ“ƒR‚Ì”­º‹@\, p.224-5. ²“¡—º•œ (¶—), •Ò: ¶•š‰¹‹¿Šw‰ï, ’©‘q‘“X, “Œ‹ž, 2019/11”­s.

620002. [Šwp‘ (•ª’SŽ·•M)] y¶‚«•š‚Ɖ¹‚ÌŽ–“Tz‘æ5Í ’¹—ށ@5-27 ƒIƒEƒ€EƒCƒ“ƒR‚̃R[ƒ‹ŠwK, p.230-1. “¡ŒŽGŽq, ²“¡—º•œ1 (1¶—), •Ò: ¶•š‰¹‹¿Šw‰ï, ’©‘q‘“X, “Œ‹ž, 2019/11”­s.

[Šw‰ïEŒ€‹†‰ï“™]

723007. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒ}ƒEƒX‚̐VŠï‹°•|‚Ì‹­“x‚š‚æ‚Ñ–¡ŠoŒ™ˆ«ŠwK‹L‰¯Šl“Ÿ‚̏T—îˆË‘¶“I‚È‘Šˆá. ‹g“cÊ”T, “c•ê_‰À“Þ, “n•Óˆ€Žq, “¡ŒŽGŽq, ²“¡—º•œ1, ‹{–{•“T (1¶—): “ú–{“®•šŠw‰ï‘æ90‰ñ‘åã‘å‰ï 2019 (2019/9/12), ‘åã.

723008. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒZƒLƒZƒCƒCƒ“ƒR‚̃Rƒ“ƒ^ƒNƒgEƒR[ƒ‹ŠwK‚ƍ‚ŽŸ’®Šo—̈æ. ²“¡—º•œ1, “¡ŒŽGŽq, “n•Óˆ€Žq, “c•ê_‰À“Þ, Matthijs A Zandbergen, Johan J Bolhuis, ‹{–{•“T (1¶—): “ú–{“®•šŠw‰ï‘æ90‰ñ‘åã‘å‰ï 2019 (2019/9/14), ‘åã.

723009. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒLƒiƒNƒŠƒ“‚ƐFŒõ‚É‚æ‚éŽîᇍזEŽ€ Acute death of tumor cells induced by quinacrine with blue light. ”ä—¯ŠÔO”ü (¶—): ‘æ97‰ñ“ú–{¶—Šw‰ï‘å‰ï (2020/3/19), ‘啪 (ŽãŠJÃ).

'18”N“xˆÈ‘O•ª

[Šw‰ïEŒ€‹†‰ï“™]

'18-713001. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Different expression of Olig2 and O4 in cultured mouse brain cells. Hiruma H1: 9th FAOPS Congress (2019/3/30), Kobe, Japan. (”ä—¯ŠÔO”ü1: 1¶—)


¶—Šw (‚‹Ž’PˆÊ)

[Šwp˜_•¶]

110007. [ŒŽ’˜] Bidirectional in vivo structural dendritic spine plasticity revealed by two-photon glutamate uncaging in the mouse neocortex. Noguchi J, Nagaoka A, Hayama T, Ucar H, Yagishita S, Takahashi N1, Kasai H: Sci Rep 2019/9; 9 (1): 13922. (‚‹Ž—ÏŽq1: 1¶—)

110008. [ŒŽ’˜] Involvement of inflammasome activation via elevation of uric acid level in nociception in a mouse model of muscle pain. Yoshida S, Hagiwara Y, Tsuchiya M, Shinoda M, Koide M, Hatakeyama H1, Chaweewannakorn C, Suzuki K, Yano T, Sogi Y, Itaya N, Sekiguchi T, Yabe Y, Sasaki K, Kanzaki M, Itoi E: Mol Pain 2019/1-12; 15: 1744806919858797. (”©ŽR—TN1: 1¶—)

110009. [ŒŽ’˜] Extracellular ƒ¿-synuclein enters dopaminergic cells by modulating flotillin-1-assisted dopamine transporter endocytosis. Kobayashi J, Hasegawa T, Sugeno N, Yoshida S, Akiyama T, Fujimori K, Hatakeyama H1, Miki Y, Tomiyama A, Kawata Y, Fukuda M, Kawahata I, Yamakuni T, Ezura M, Kikuchi A, Baba T, Takeda A, Kanzaki M, Wakabayashi K, Okano H, Aoki M: FASEB J 2019/9; 33 (9): 10240-56. (”©ŽR—TN1: 1¶—)

110010. [ŒŽ’˜] Thy1 promoter activity in the Rosa26 locus in mice: lessons from Dre-rox conditional expression system. Tamura S, Yasuoka Y1, Miura H, Takahashi G, Sato M, Ohtsuka M: Exp Anim 2020/8; 69 (3): 287-94. doi: 10.1538/expanim.20-0002. Epub 2020 Feb 11. (ˆÀ‰ª—L‹IŽq1: 1¶—)

522001. [uÀ]y“ÁW: äX“‡Œ€‹†updatezƒCƒ“ƒXƒŠƒ“•ª”å‚̃_ƒCƒiƒ~ƒNƒX. ‚‹Ž—ÏŽq (¶—): “œ”A•aE“à•ª”å‘ãŽÓ‰È 2020/2; 50 (2): 71-6.

522002. [uÀ]y“ÁW Cl-: “d‰ðŽ¿‚̃NƒC[ƒ“z[˜˜_] Cl-‚Æ‚»‚Ì–ðŠ„. ‰ÍŒŽŽ‰ë, ˆÀ‰ª—L‹IŽq1 (1¶—): t‚Æ“§Í 2020/3; 88 (3): 316-21.

522003. [uÀ]y“ÁW Cl-: “d‰ðŽ¿‚̃NƒC[ƒ“z[Še˜_] W‡ŠÇ‚ÌŽ_‰–Šî’²ß”\@2) ƒAƒ‹ƒhƒXƒeƒƒ“-MRŽ²‚É‚æ‚é“d‰ðŽ¿EŽ_‰–Šî’²ß. –ìXŒû”ŽŽj, ˆÀ‰ª—L‹IŽq1, ò—Tˆê˜Y (1¶—): t‚Æ“§Í 2020/3; 88 (3): 377-81.

522004. [uÀ]y“ÁW Cl-: “d‰ðŽ¿‚̃NƒC[ƒ“z[Še˜_] W‡ŠÇ‚ÌŽ_‰–Šî’²ß”\ 4) tW‡ŠÇŠÔÝ×–Etype-B: ŠÇo–ŒƒAƒjƒIƒ“ŒðŠ·‘Ì (Pendrin) ‚Ì’²ß‹@”\. ˆÀ‰ª—L‹IŽq1, ‰ÍŒŽŽ‰ë (1¶—): t‚Æ“§Í 2020/3; 88 (3): 390-5.

540001. [‚»‚Ì‘Œ (ˆÏˆõ‰ï•ñ)] “œ”A•aê–åˆã‚Ì“­‚«•û‚Ɛ¶ŠˆŒ»ó’²ž, Šw‰ï‚É‹‚ß‚ç‚ê‚éŽæ‘g‚݂ɂ‚¢‚ā`2017”N“xu“œ”A•aˆã‚̃LƒƒƒŠƒA‚É‚š‚¯‚錻ó’²ž‚ƍ¡Œã‚Ì“W–]‚ÉŒü‚¯‚œƒAƒ“ƒP[ƒgvŒ‹‰Ê‚æ‚è`. ¬£ŒjŽq1, ˆÀ‘·ŽqˆŸ’ÃŽq1, ’†ŽR‚ЂƂÝ1, “c’†LŽ}1, ’r“cD1, ˆä’¬m”ü1, ‹žŒb”ü1, ”n‰®ŒŽ–L1, ‘Ÿ“c@ß1, ‰ª“c—R‹IŽq1, ¬’J‹IŽq1, ‚‹Ž—ÏŽq1,2, Ž›ˆä@ˆ€1, ’†‘ººL1, “¡ì‚é‚Ý1, ŽO‰Y‡”V•1, X“cŒb”üŽq1, –ö’¬@K1, A–؍_“ñ˜Y1 (1—«“œ”A•aˆã‚ðpromote‚·‚éˆÏˆõ‰ï, 2¶—): “œ”A•a 2019/5; 62 (5): 337-46.

[’˜@‘]

621001. [Šwp‘ (ŠÄCE•ÒWE‚»‚Ì‘Œ)] yƒRƒXƒ^ƒ“ƒ]–Ÿ‰ð¶—Šw ŒŽ’˜‘æ6”Łz6 t‘Ÿ‚̐¶—Šw, 7 Ž_‰–Šî‚̐¶—Šw, 8Á‰»ŠíŒn‚̐¶—Šw, 9“à•ª”åŒn‚̐¶—Šw, 10 ¶B‚̐¶—Šw, p.271-550. ŠÄ–ó: —с@rG, ‚‹Ž—ÏŽq1 (1¶—), ƒGƒ‹ƒ[ƒrƒAEƒWƒƒƒpƒ“, “Œ‹ž, 2019/9”­s.

622001. [Šwp‘ (–|–ó)]yƒRƒXƒ^ƒ“ƒ]–Ÿ‰ð¶—Šw ŒŽ’˜‘æ6”Łz6 t‘Ÿ‚̐¶—Šw, p.271-305. ˆÀ‰ª—L‹IŽq1, •Ÿ“c‰pˆê1 (1¶—), ŠÄ–ó: —с@rG, ‚‹Ž—ÏŽq1 (1¶—), ƒGƒ‹ƒ[ƒrƒAEƒWƒƒƒpƒ“, “Œ‹ž, 2019/9”­s.

622002. [Šwp‘ (–|–ó)]yƒRƒXƒ^ƒ“ƒ]–Ÿ‰ð¶—Šw ŒŽ’˜‘æ6”Łz9 “à•ª”åŒn‚̐¶—Šw, p.439-512. ”©ŽR—TN1 (1¶—), ŠÄ–ó: —с@rG, ‚‹Ž—ÏŽq1 (1¶—), ƒGƒ‹ƒ[ƒrƒAEƒWƒƒƒpƒ“, “Œ‹ž, 2019/9”­s.

[Šw‰ïEŒ€‹†‰ï“™]

722001. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€Šé‰æ)yÀ’·zMechanosensing of the enlargement of dendritic spines by presynaptic terminals in rat hippocampus. Ucar Hasan, “n•Ó@œš, –ìŒû@, –ö‰º@Ë, Žç–{—Sˆê, ‚‹Ž—ÏŽq1, ‰ÍŒt˜Y (1¶—): ‘æ97‰ñ“ú–{¶—Šw‰ï‘å‰ï (2020/3/18), ‘啪.

723010. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) äXƒÀ×–E§Œä‚É‚š‚¯‚éMek/ErkƒVƒOƒiƒ‹‚Ì–ðŠ„‚Ì‰ð–Ÿ. ¶“‡–FŽq, ¬—Ñ’ŒŽ÷, ˆŸàVŒ³°, z–K“à_Ð, “Y“cŒõ‘Ÿ˜Y, ‘º’J‹§Žj, ‚‹Ž—ÏŽq1, A–؍_“ñ˜Y (1¶—): ‘æ62‰ñ“ú–{“œ”A•aŠw‰ï”NŽŸŠwpW‰ï (2019/5/23), å‘ä.

723011. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’჊ƒ“H—U”­ƒAƒ‹ƒJƒŠ”A‚Í, W‡ŠÇIC-BŠÇo–ŒPendrin‚©‚ç‚ÌHCO3-‰ßè•ª”傪ŒŽˆö‚Å‚ ‚é. ˆÀ‰ª—L‹IŽq1, ‘哈—F”ü2, ²“¡—Yˆê3, ‚‹Ž—ÏŽq1, –ìXŒû”ŽŽj, ‰ÍŒŽŽ‰ë (1¶—, 2¶•š•š—Œn, 3ˆã—Éq¶Šw•”): ‘æ62‰ñ“ú–{t‘ŸŠw‰ïŠwp‘‰ï (2019/6/23), –ŒŒÃ‰®.

723012. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) MEK/ERKƒVƒOƒiƒ‹‚ÍäXƒÀ×–E‚Ì—Ê‚Æ•ª”å”\‚𐧌䂷‚é. ¶“‡–FŽq, ¬—Ñ’ŒŽ÷, ˆŸàVŒ³°, z–K“à_Ð, “Y“cŒõ‘Ÿ˜Y, ‘º’J‹§Žj, ‚‹Ž—ÏŽq1, A–؍_“ñ˜Y (1¶—): ‘æ31‰ñ•ªŽq“œ”A•aŠwƒVƒ“ƒ|ƒWƒEƒ€ (2019/12/7), “Œ‹ž.

723013. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒJƒ‹ƒVƒEƒ€ (Ca) ‰–ŒoŒûÛŽæ‚̉h—{Šw“IŽ‹“_‚Æ‹tà“Iœ‹zŽû. ‰ÍŒŽŽ‰ë, ˆÀ‰ª—L‹IŽq1, –ìXŒû”ŽŽj, ŒËP˜al, ŠÖ–ì@T (1¶—): ‘æ23‰ñ“ú–{•a‘Ô‰h—{Šw‰ï”NŽŸŠwpW‰ï (2020/1/24), ‹ž“s.

723014. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) MEK/ERK ƒVƒOƒiƒ‹‚É‚æ‚éäXƒÀ×–E§Œä. ¶“‡–FŽq, ¬—Ñ’ŒŽ÷, ˆŸàVŒ³°, z–K“à_Ð, “Y“cŒõ‘Ÿ˜Y, ‘º’J‹§Žj, ‚‹Ž—ÏŽq1, A–؍_“ñ˜Y (1¶—): ‘æ34‰ñ“ú–{“œ”A•aE”ì–ž“®•šŠw‰ï”NŽŸŠwpW‰ï (2020/2/1), ŒQ”n.

723015. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰“ˆÊ”A×ŠÇ‚É‚š‚¯‚é‘gDƒJƒŠƒNƒŒƒCƒ“‚Ì”­Œ»‚ƃJƒ‹ƒVƒEƒ€—A‘—. ˆÀ‰ª—L‹IŽq1, ‘哈—F”ü2, ²“¡—Yˆê3, ‚‹Ž—ÏŽq1, –ìXŒû”ŽŽj, ‰ÍŒŽŽ‰ë (1¶—, 2¶•š•š—Œn, 3ˆã—Éq¶Šw•”): ‘æ97‰ñ“ú–{¶—Šw‰ï‘å‰ï (2020/3/19), ŽãŠJÃ.

723016. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) GLUT4—A‘—‚É‚š‚¢‚ăCƒ“ƒXƒŠƒ“‰ž“š«‚É‹N‚±‚é‰ð•ú‰ß’ö‚ƈَ포–EŠÔ—Z‡‚Ì“¯Žž‰ÂŽ‹‰»‰ðÍ. ”©ŽR—TN1, _è@“W (1¶—): ‘æ97‰ñ“ú–{¶—Šw‰ï‘å‰ï (2020/3/19), ŽãŠJÃ.

732001. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) Šî‘bˆãŠw‚©‚ç“œ”A•aŠw‚ւ̃Aƒvƒ[ƒ`. ‚‹Ž—ÏŽq (¶—): “ú–{“œ”A•aŠw‰ïŠÖ“ŒbM‰z’n•û‰ïŠé‰æ Young Diabetologists Research Forum (2019/7/6), “Œ‹ž.

733001. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “œ—A‘—’S‘̂̍זE“à—A‘—ƒVƒXƒeƒ€‚ðˆê•ªŽqƒŒƒxƒ‹‚Å‚Ý‚éE‚Í‚©‚é. ”©ŽR—TN (¶—): –k—¢‘åŠwˆãŠw•”‘æ11‰ñƒvƒƒOƒŒƒXƒŒƒ|[ƒg‰ï‹c (2019/9/18), ‘Š–ÍŒŽ.

733002. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) TASK2KOƒ}ƒEƒX‚ÌŽ_‰–ŠîƒCƒ“ƒoƒ‰ƒ“ƒX‚͑㏞«ƒAƒ“ƒ‚ƒjƒAŽY¶‚𔺂í‚È‚¢. ˆÀ‰ª—L‹IŽq1, ‘哈—F”ü2, ‚‹Ž—ÏŽq1, ²“¡—Yˆê3, –ìXŒû”ŽŽj, ‹Ñ’J‚Ü‚èŽq, ŒËP˜al, ŠÖª@T, ‰ÍŒŽŽ‰ë (1¶—, 2¶•š•š—Œn, 3ˆã—Éq¶Šw•”): ‘æ49‰ñ“ú–{t‘ŸŠw‰ï“Œ•”Šwp‘å‰ï (2019/10/4), “Œ‹ž.

733003. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‰ß‹Ž‚ÌŒ€‹†Šˆ“®‚ðU‚è•Ô‚Á‚ā`‰œ‚ª¡‚ɂ‚Ȃª‚Á‚Ä‚¢‚é‚©?`. ”©ŽR—TN (¶—): ˜AŒgŒ^”ŽŽmŒ€‹†lÞ‘‡ˆç¬ƒVƒXƒeƒ€ ŽŸ¢‘㌀‹†ŽÒƒVƒ“ƒ|ƒWƒEƒ€2019 (2019/10/31), –ŒŒÃ‰®.


¶‰»Šw (ä’PˆÊ)

[Šwp˜_•¶]

110011. [ŒŽ’˜] IƒÈB kinase 2 is not essential for platelet activation. Salzmann M, Bleichert S, Moser B, Mussbacher M, Haase M, Hoesel B, Schrottmaier WC, Kral-Pointner JB, Itakura M1, Schmidt K, Assinger A, Schmid JA: Blood Adv 2020/2; 4 (4): 638-43. (”‘q@œ1: 1¶‰»)

110012. [ŒŽ’˜] Electron Microscopic Detection of Single Membrane Proteins by a Specific Chemical Labeling. Tabata S, Jevtic M, Kurashige N, Fuchida H, Kido M, Tani K, Zenmyo N, Uchinomiya S, Harada H, Itakura M1, Hamachi I, Shigemoto R, Ojida A: iScience 2019/12; 22: 256-68. (”‘q@œ1: 1¶‰»)

[Šw‰ïEŒ€‹†‰ï“™]

713002. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Identification and functional analysis of FGFR2 binding proteins in diffuse-type gastric carcinoma. Shirakihara T1: American Association for Cancer Research Annual Meeting 2019 (2019/4/1), Atlanta, GA, USA. (”’–ØŒŽ‘ôÆ1: 1¶‰»)

723017. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒXƒLƒ‹ƒXˆÝ‚ª‚ñ‚̐i“W‚ÉŠÖ‚í‚éFGFŽó—e‘ÌŒ‹‡ƒ^ƒ“ƒpƒNŽ¿TfR1‚Ì‹@”\‰ðÍ. ”’–ØŒŽ‘ôÆ (¶‰»): ‘æ28‰ñ“ú–{‚ª‚ñ“]ˆÚŠw‰ïŠwpW‰ïE‘‰ï (2019/7/26), Ž­Ž™“‡.

723018. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚Ñ‚Ü‚ñ«ˆÝ‚ª‚ñ‚̐i“W‚ÉŠÖ‚í‚éFGFR2Œ‹‡ƒ^ƒ“ƒpƒNŽ¿‚Ì’Tõ‚Æ‹@”\‰ðÍ. ”’–ØŒŽ‘ôÆ (¶‰»): ‘æ78‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï (2019/9/26), ‹ž“s.

723019. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚Ñ‚Ü‚ñ«ˆÝ‚ª‚ñ‚̐i“W‚ÉŠÖ‚í‚éFGFR2Œ‹‡ƒ^ƒ“ƒpƒNŽ¿‚Ì’Tõ‚Æ‹@”\‰ðÍ. ”’–ØŒŽ‘ôÆ (¶‰»): ‘æˆê‰ñ“ú–{ŠàŠw‰ïŽáŽè‚̉ï (2020/2/11), Ã‰ª.

731001. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ƒXƒLƒ‹ƒXˆÝ‚ª‚ñ×–EŠ”‚É‚š‚¯‚éFGFŽó—e‘ÌŒ‹‡ƒ^ƒ“ƒpƒNŽ¿‚Ì’Tõ‚Æ‹@”\‰ðÍ. ”’–ØŒŽ‘ôÆ (¶‰»): ŽáŽèŒ€‹†ŽÒ”­•\E“¢˜_‰ï@ƒvƒƒOƒŒƒXƒŒƒ|[ƒg‰ï‹c (2019/5/22), ‘Š–ÍŒŽ.


¶‰»Šw (äݑã’PˆÊ)

[’˜@‘]

610001. [Šwp‘ (•ª’SŽ·•M)]yKetamine: From abused drug to rapid-acting antidepressantzSynaptic modulation in the effect of ketamine, p.69-87. Okada D1, Editors: Hashimoto K2, Ide S3, Ikeda K3 (2Chiba University, 3Tokyo Metropolitan Institute of Medical Science), Springer Nature Singapore Pte Ltd., Singapore, 2020 /1. (‰ª“c‘叕1: 1¶‰»)

[Šw‰ïEŒ€‹†‰ï“™]

723020. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒXƒgƒŒƒXŽhŒƒ‚É‚æ‚é”]“àSNAP-25‚̃Šƒ“Ž_‰»‚ƃ‚ƒmƒAƒ~ƒ“•úo‚̕ω». ŽRX‘D1, ˆÀ“cCˆê2, “n•Ó@Ž , ‹{‰ª@“™3, äݑ㌀“ñ1 (1¶‰», 2¶•š•š—Œn, 3ž_): ‘æ92‰ñ“ú–{¶‰»Šw‰ï‘å‰ï (2019/9/20), ‰¡•l.


•ªŽqˆâ“`Šw

[Šwp˜_•¶]

110013. [ŒŽ’˜] Dysregulated DNA methylation of GLA gene was associated with dysfunction of autophagy. Yanagisawa H, Hossain MA, Miyajima T, Nagao K1, Miyashita T1, Eto Y: Mol Genet Metab 2019/4; 126 (4): 460-5. (’·”ö˜a‰E1, ‹{‰ºr”V1: 1•ªŽqˆâ“`)

110014. [ŒŽ’˜] MicroRNAs profiling in fibroblasts derived from patients with Gorlin syndrome. Shiohama T, Fujii K, Miyashita T1, Takatani T, Ikehara H, Uchikawa H, Motojima T, Uchida T, Shimojo N: J Hum Genet 2019/8; 64 (8): 757-65. (‹{‰ºr”V1: 1•ªŽqˆâ“`)

210001. [€ŒŽ’˜] (Data Report) A novel PTCH1 mutation in basal cell nevus syndrome with rare craniofacial features. Murata Y, Kurosaka H, Ohata Y, Aikawa T, Takahata S, Fujii K, Miyashita T1, Morita C, Inubushi T, Kubota T, Sakai N, Ozono K, Kogo M, Yamashiro T: Hum Genome Var 2019/4; 6: 16. (‹{‰ºr”V1: 1•ªŽqˆâ“`)

310001. [Ç—á•ñ] A familial case of overgrowth syndrome caused by a 9q22.3 microdeletion in a mother and daughter. Yamada H, Shimuraa M, Takahashi H, Nara S, Morishima Y, Go S, Miyashita T1, Numabe H, Kawashima H: Eur J Med Genet 2020/5; 63 (5): 103872. (‹{‰ºr”V1: 1•ªŽqˆâ“`)

[Šw‰ïEŒ€‹†‰ï“™]

722002. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒwƒbƒWƒzƒbƒOˆÙíÇ‚ÌiPS×–E‚ƃQƒmƒ€•ÒW. ‹{‰ºr”V (•ªŽqˆâ“`): ‘æ61‰ñ“ú–{¬Ž™_ŒoŠw‰ïŠwpW‰ï (2019/6/1), –ŒŒÃ‰®.

723021. [Šw‰ï (‘S‘)] (ˆê”ʉ‰‘è) PTCH1ˆâ“`Žq‚Ì‘SŒ‡Žž‚𔺂€GorlinÇŒóŒQ (9q22.3”÷×Œ‡Žž) ‚̐eŽq—á. Žu‘º@—D, ŽR“c‚Ђ©‚è, ’·’Jì—¢“Þ, ‚‹Ž‰pé, “ޗǏž”T•, X“‡–õs, Œà@@Œ›, ‹{‰ºr”V1, À•””Ž’Œ, ‰Í“‡®Žu (1•ªŽqˆâ“`): ‘æ122‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï (2019/4/19-21), ‹à‘ò.

732002. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰) ƒwƒbƒWƒzƒbƒOƒVƒOƒiƒ‹“`’B‚̘Ži‚ÆŽŸŠ³. ‹{‰ºr”V (•ªŽqˆâ“`): ‚š’ƒ‚̐…‚ª‚ñŠwƒAƒJƒfƒ~ƒA‘æ161‰ñW‰ï (2020/2/26), “Œ‹ž.

'18”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'18-522001. [uÀ]y“ÁW: GorlinÇŒóŒQ|”­¶‚©‚玡—Â܂Ł|zGorlinÇŒóŒQ‚̈â“`Žqf’f. ‹{‰ºr”V1, ‚ŽR‹g‰i1 (1•ªŽqˆâ“`):TŠ§ˆãŠw‚Ì•à‚Ý 2019/1; 268 (2): 123-6.


–ò—Šw

[Šwp˜_•¶]

110015. [ŒŽ’˜] VEGF Receptor 1-Expressing Macrophages Recruited from Bone Marrow Enhances Angiogenesis in Endometrial Tissues. Sekiguchi K1, Ito Y2, Hattori K3, Inoue T4, Hosono K2, Honda M3, Numao A, Amano H2, Shibuya M, Unno N1, Majima M2: Sci Rep 2019/5; 9 (1): 7037. (ŠÖŒû˜aŠé1, ˆÉ“¡‹`–ç2, •ž•”‹¿Žq3, ˆäã’qm4, ×–ì‰Á“ÞŽq2, –{“c‰ëŽq3, “V–ì‰pŽ÷2, ŠC–ìM–ç1, ”n“ˆ³—²2: 1ŽY‰È, 2–ò—, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 4Á‰»Ší“à)

110016. [ŒŽ’˜] RAMP1 signaling in immune cells regulates inflammation-associated lymphangiogenesis. Tsuru S1, Ito Y2, Matsuda H3, Hosono K2, Inoue T4, Nakamoto S1, Kurashige C3, Mishima T5, Tsujikawa K, Okamoto H3, Majima M2: Lab Invest 2020/5; 100 (5): 738-50. (’ׯ¢—¢1, ˆÉ“¡‹`–ç2, Œ“cO”ü3, ×–ì‰Á“ÞŽq2, ˆäã’qm4, ’†–{CŽi1, åUdçŠG3, ”ü“‡—˜º5, ‰ª–{_Žk3, ”n“ˆ³—²2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–ò—, 3–ƒŒ, 4Á‰»Ší“à, 5S‘ŸŒŒŠÇŠO)

110017. [ŒŽ’˜] The role of vascular endothelial growth factor receptor 1 tyrosine kinase signaling in bleomycin-induced pulmonary fibrosis. Amano H1, Mastui Y2, Ito Y1, Shibata Y, Betto T3, Eshima K4, Ogawa F, Satoh Y2, Shibuya M, Majima M1: Biomed Pharmacother 2019/9; 117: 109067. (“V–ì‰pŽ÷1, ŒˆäŒ[•v2, ˆÉ“¡‹`–ç1, •Êác•üL3, ]“‡k“ñ4, ²“¡”Vr2, ”n“ˆ³—²1: 1–ò—, 2ŒÄ‹zŠíŠO, 3Á‰»Ší“à, 4–Ɖu)

110018. [ŒŽ’˜] Thromboxane A 2 receptor signaling in endothelial cells attenuates monocrotaline-induced liver injury. Otaka F1, Ito Y2, Inoue T3, Ohkubo H4, Nishizawa N5, Kojo K6, Betto T3, Yamane S3, Narumiya S, Koizumi W3, Majima M2: Toxicol Appl Pharmacol 2019/10; 381: 114733. (‘卂Žj¹1, ˆÉ“¡‹`–ç2, ˆäã’qm3, ‘å‹v•Û”Ž¢4, ŒàVL‹±5, ŒÃé@Œ›6, •Êác•üL3, ŽRª‘‹IŽq3, ¬ò˜aŽO˜Y3, ”n“ˆ³—²2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–ò—, 3Á‰»Ší“à, 4S‘ŸŒŒŠÇŠO, 5ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 6‰º•”Á‰»ŠÇŠO)

110019. [ŒŽ’˜] Microsomal prostaglandin E synthase-1 promotes lung metastasis via SDF-1/CXCR4-mediated recruitment of CD11b+ Gr1+ MDSCs from bone marrow. Takahashi R1, Amano H1, Ito Y1, Eshima K2, Satoh T3, Iwamura M3, Nakamura M4, Kitasato H4, Uematsu S, Raouf J, Jakobsson PJ, Akira S, Majima M1: Biomed Pharmacother 2020/1; 121: 109581. doi: 10.1016/j.biopha.2019.109581. Epub 2019 Nov 10. (‚‹Ž@—º1, “V–ì‰pŽ÷1, ˆÉ“¡‹`–ç1, ]“‡k“ñ2, ²“¡ˆÐ•¶3, Šâ‘º³Žk3, ’†‘º³Ž÷4, –k—¢‰p˜Y4, ”n“ˆ³—²1: 1–ò—, 2–Ɖu, 3”å”AŠí, 4ˆã—Éq¶Šw•”)

110020. [ŒŽ’˜] EP3 signaling in dendritic cells promotes liver repair by inducing IL-13-mediated macrophage differentiation in mice. Nakamoto S1, Ito Y2, Nishizawa N3, Goto T1, Kojo K4, Kumamoto Y3, Watanabe M5, Narumiya S, Majima M2: FASEB J 2020/4; 34 (4): 5610-27. doi: 10.1096/fj.201901955R. Epub 2020 Feb 28. (’†–{CŽi1, ˆÉ“¡‹`–ç2, ŒàVL‹±3, Œã“¡‘ì–ç1, ŒÃé@Œ›4, ŒGŒ³—Y‰î3, “n粏¹•F5, ”n“ˆ³—²2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–ò—, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 4‰º•”Á‰»ŠÇŠO, 5–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@)

220001. [€ŒŽ’˜] ƒŠƒ“ƒpŠÇV¶‚𐧌䂷‚é_Œoƒyƒvƒ`ƒhCGRP‚Ì–ðŠ„. ˆÉ“¡‹`–ç1, ’ׯ¢—¢2, ×–ì‰Á“ÞŽq1, “V–ì‰pŽ÷1, ”n“ˆ³—²1 (1–ò—, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ƒŠƒ“ƒpŠw 2019/12; 42 (2): 72-5.

[Šw‰ïEŒ€‹†‰ï“™]

722003. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ‰ŠÇŽž‚̃Šƒ“ƒpŠÇV¶‚𐧌䂷‚é_Œoƒyƒvƒ`ƒhCGRP‚Ì–ðŠ„ (Neuropeptide CGRP regulates inflammation by increasing lymphangiogenesis). ×–ì‰Á“ÞŽq1, ˆÉ“¡‹`–ç1, “V–ì‰pŽ÷1, ”n“ˆ³—²1 (1–ò—): ‘æ93‰ñ“ú–{–ò—Šw‰ï”N‰ï (2020/3/16-18), Ž†ãŠJÃ.

723022. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“EP3Žó—e‘̃VƒOƒiƒ‹‚ð‰î‚µ‚œŠÌŽ÷ó×–E‚̊̏C•œ‘£iì—p. ’†–{CŽi1, ˆÉ“¡‹`–ç2, ŒàVM‹±3, ‘卂Žj¹1, ’ׯ¢—¢1, •ž•”‹¿Žq4, –{“c‰ëŽq1, “V–ì‰pŽ÷2, ”n“ˆ³—²2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–ò—, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 4ŽY‰È): ‘æ40‰ñ“ú–{‰ŠÇ¥Ä¶ˆãŠw‰ï (2019/7/16), _ŒË.

723023. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹•ŒŒ‰ü‘P‚É‚š‚¯‚émPGES-1/PGE2-EP4 signal‚̉ðÍ. “V–ì‰pŽ÷1, ]“‡k“ñ2, ˆÉ“¡‹`–ç1, R—ǐÒj, ¬‹{@Žü, ”n“ˆ³—²1 (1–ò—, 2–Ɖu): ‘æ40‰ñ“ú–{‰ŠÇ¥Ä¶ˆãŠw‰ï (2019/7/16), _ŒË.

723024. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • –Œ‰ŠŽž‚̉¡Šu–ŒƒŠƒ“ƒpŠÇV¶‚𐧌䂷‚éŽó—e‘ÌŠˆ«’²ß’`”’1 (RAMP1) ‚Ì–ðŠ„. ’ׯ¢—¢1, ˆÉ“¡‹`–ç2, ×–ì‰Á“ÞŽq2, ˆäã’qm3, Œ“cO”ü4, åUdçŠG4, ’†–{CŽi1, ‘卂Žj¹1, ‰ª–{_Žk4, ”n“ˆ³—²2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–ò—, 3Á‰»Ší“à, 4–ƒŒ): ‘æ40‰ñ“ú–{‰ŠÇ¥Ä¶ˆãŠw‰ï (2019/7/16), _ŒË.

723025. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Žq‹{“à–ŒÇ‚É‚š‚¯‚郊ƒ“ƒpŠÇV¶‚𐧌䂷‚éVEGFR1‚Ì–ðŠ„‰ð–Ÿ. •ž•”‹¿Žq1, ˆÉ“¡‹`–ç2, –{“c‰ëŽq3, ŠÖŒû˜aŠé1, ×–ì‰Á“ÞŽq2, ŠC–ìM–ç1, ”n“ˆ³—²2 (1ŽY‰È, 2–ò—, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ40‰ñ“ú–{‰ŠÇ¥Ä¶ˆãŠw‰ï (2019/7/16), _ŒË.

723026. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒgƒƒ“ƒ{ƒLƒTƒ“A2Žó—e‘̃VƒOƒiƒ‹‚ÌŠÌ—Þ“Ž•ÂÇÇŒóŒQ‚É‚š‚¯‚é–ðŠ„. ˆÉ“¡‹`–ç1, ‘卂Žj¹2, ‘å‹v•Û”Ž¢3, ”n“ˆ³—²1 (1–ò—, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3S‘ŸŒŒŠÇŠO): ‘æ33‰ñŠÌ—Þ“Ž•Ç×–EŒ€‹†‰ïŠwpW‰ï (2019/11/30), ‘åã.

723027. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠÌ—Þ“Ž•ÂÇÇŒóŒQ‚É‚š‚¯‚éƒgƒƒ“ƒ{ƒLƒTƒ“A2Žó—e‘Ì‚Ì–ðŠ„‚É‚Â‚¢‚Ä (Thromboxane A2 receptor signaling attenuates monocrotaline-induced liver injury by affecting endothelial cells, but not platelets). ‘卂Žj¹1, ˆÉ“¡‹`–ç2, ˆäã’qm3, ‘å‹v•Û”Ž¢4, ’ׯ¢—¢1, ×–ì‰Á“ÞŽq2, ¬ò˜aŽO˜Y3, ”n“ˆ³—²2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–ò—, 3Á‰»Ší“à, 4S‘ŸŒŒŠÇŠO): ‘æ93‰ñ“ú–{–ò—Šw‰ï”N‰ï (2020/3/16-18), Ž†ãŠJÃ.

723028. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) EP4ƒVƒOƒiƒ‹‚̓Šƒ“ƒpŠÇV¶‚𑝋­‚µ‚ÄDSS—U“±’°‰Š‚̏C•œ‚𑣐i‚·‚é (EP4 signaling facilitates mucosal repair after DSS-induced colitis by enhancement of lymphangiogenesis). ˆÉ“¡‹`–ç1, ×–ì‰Á“ÞŽq1, ŒÃé@Œ›2, ”n“ˆ³—²1 (1–ò—, 2‰º•”Á‰»ŠÇŠO): ‘æ93‰ñ“ú–{–ò—Šw‰ï”N‰ï (2020/3/16-18), Ž†ãŠJÃ.

723029. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –Ɖu×–E‚ÌTPƒVƒOƒiƒ‹‚Í• –Œ‰ŠŽž‚̉¡Šu–ŒƒŠƒ“ƒpŠÇV¶‚𑣐i‚·‚é (TP signaling in immune cells promotes lymphangiogenesis in the diaphragm during peritonitis). ’ׯ¢—¢1, ˆÉ“¡‹`–ç2, Œ“cO”ü3, ×–ì‰Á“ÞŽq2, ‰ª–{_Žk3, ”n“ˆ³—²2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–ò—, 3–ƒŒ): ‘æ93‰ñ“ú–{–ò—Šw‰ï”N‰ï (2020/3/16-18), Ž†ãŠJÃ.

723030. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) RAMP1‚É‚æ‚éƒ}ƒEƒXŽq‹{“à–ŒÇ‚É‚š‚¯‚錌ŠÇEƒŠƒ“ƒpŠÇV¶‘£iì—p (RAMP1 signaling facilitates angiogenesis and lymphangiogenesis in the endometriotic lesions in mice). –{“c‰ëŽq1, ˆÉ“¡‹`–ç2, •ž•”‹¿Žq3, ×–ì‰Á“ÞŽq2, ’†–{CŽi1, ‘卂Žj¹1, ’ׯ¢—¢1, ”n“ˆ³—²2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–ò—, 3ŽY‰È): ‘æ93‰ñ“ú–{–ò—Šw‰ï”N‰ï (2020/3/16-18), Ž†ãŠJÃ.

733004. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ŠÌ—Þ“Ž•ÂÇÇŒóŒQ‚É‚š‚¯‚éƒgƒƒ“ƒ{ƒLƒTƒ“Žó—e‘Ì‚Ì–ðŠ„. ‘卂Žj¹1, ˆÉ“¡‹`–ç2, ˆäã’qm3, ŒàVL‹±4, ’†–{CŽi1, ’ׯ¢—¢1, •ž•”‹¿Žq5, –{“c‰ëŽq1, ×–ì‰Á“ÞŽq2, ¬ò˜aŽO˜Y3, ”n“ˆ³—²2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–ò—, 3Á‰»Ší“à, 4ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 5ŽY‰È): ‘æ140‰ñ“ú–{–ò—Šw‰ïŠÖ“Œ•”‰ï (2019/7/6), “Œ‹ž.

733005. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) Žq‹{“à–ŒÇ‚É‚š‚¯‚é–¬ŠÇV¶‚𐧌䂷‚é_Œoƒyƒvƒ`ƒhCGRP‚Ì–ðŠ„. –{“c‰ëŽq1, ˆÉ“¡‹`–ç2, •ž•”‹¿Žq3, ×–ì‰Á“ÞŽq2, ’†–{CŽi1, ‘卂Žj¹1, ’ׯ¢—¢1, ”n“ˆ³—²2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–ò—, 3ŽY‰È): ‘æ140‰ñ“ú–{–ò—Šw‰ïŠÖ“Œ•”‰ï (2019/7/6), “Œ‹ž.


”÷¶•šŠw

[Šwp˜_•¶]

110021. [ŒŽ’˜] Kozupeptins, Antimalarial Agents Produced by Paracamarosporium Species: Isolation, Structural Elucidation, Total Synthesis, and Bioactivity. Hayashi Y, Fukasawa W, Hirose T1, Iwatsuki M1, Hokari R1, Ishiyama A1, Kanaida M, Nonaka K1, TakŽ A2, Otoguro K, Omura S1, Shiomi K1, Sunazuka T1: Org Lett 2019/4; 21 (7): 2180-84. (œA£—F–õ1, ŠâŒŽ³l1, •äŠ @—æ1, ÎŽRˆŸ‹I1, –ì’†Œ’ˆê1, •@@W2, ‘呺@’q1, ‰–Œ©˜a˜N1, »’Ë•q–Ÿ1: 1–k—¢¶–œ‰ÈŠwŒ€‹†Š, 2”÷¶•š)

110022. [ŒŽ’˜] Saccharopolyspora rhizosphaerae sp. nov., an actinomycete isolated from rhizosphere soil in Thailand. Intra B, Euanorasetr J, TakŽ A1, Inahashi Y2, Mori M2, Panbangred W, Matsumoto A2: Int J Syst Evol Microbiol 2019/5; 69 (5): 1299-305. (•@@W1, ˆî‹Ž—C‹N2, X”ü•äŽq2, Œ–{ŒúŽq2: 1”÷¶•š, 2–k—¢¶–œ‰ÈŠwŒ€‹†Š)

110023. [ŒŽ’˜] Nanaomycin I and J: New nanaomycins generated by mycothiol-mediated compounds from "Streptomyces rosa subsp. notoensis" OS-3966. Matsuo H1, Noguchi Y1, TakŽ A2, Nakanishi J, Shigemura K, Sunazuka T1, Takahashi Y1, Omura S1, Nakashima T1: J Biosci Bioeng 2019/5; 127 (5): 549-53. (Œ”ö—mF1, –ìŒû‹g•F1, •@@W2, »’Ë•q–Ÿ1, ‚‹Ž—mŽq1, ‘呺@’q1, ’†“‡‘ôŽ©1: 1–k—¢¶–œ‰ÈŠwŒ€‹†Š, 2”÷¶•š)

110024. [ŒŽ’˜] Therapeutic Potential of an Endolysin Derived from Kayvirus S25-3 for Staphylococcal Impetigo. Imanishi I1, Uchiyama J, Tsukui T, Hisatsune J, Ide K, Matsuzaki S, Sugai M, Nishifuji K: Viruses 2019/8; 11 (9): 769. (¡ŒŽs˜N1: 1”÷¶•š)

110025. [ŒŽ’˜] Exfoliative toxin E, a new Staphylococcus aureus virulence factor with host-specific activity. Imanishi I1, Nicolas A, Caetano AB, Castro TLP, Tartaglia NR, Mariutti R, GuŽdon E, Even S, Berkova N, Arni RK, Seyffert N, Azevedo V, Nishifuji K, Le Loir Y: Sci Rep 2019/11; 9 (1): 16336. (¡ŒŽs˜N1: 1”÷¶•š)

110026. [ŒŽ’˜] Fodinicola acaciae sp. nov., an Endophytic Actinomycete Isolated from the Roots of Acacia mangium Willd. and Its Genome Analysis. Thanh Pham HT, Suwannapan W, Koomsiri W, Inahashi Y1, TakŽ A2, Matsumoto A1, Thamchaipenet A: Microorganisms 2020/3; 8 (4): 467. (ˆî‹Ž—C‹N1, •@@W2, Œ–{ŒúŽq1: 1–k—¢¶–œ‰ÈŠwŒ€‹†Š, 2”÷¶•š)

310002. [Ç—á•ñ] Spontaneous regression of canine papillomavirus type 2-related papillomatosis on footpads in a dog. Iyori K, Inai K, Shimakura H, Haga T, Shimoura H, Imanishi I1, Imai A, Iwasaki T: J Vet Med Sci 2019/6; 81 (6): 933-6. (¡ŒŽs˜N1: 1”÷¶•š)

310003. [Ç—á•ñ] Clinical and histopathological presentation and successful treatment with ciclosporin for canine sarcoidosis: a case report. Iyori K, Kinoshita M, Imai A, Imanishi I1, Shirota K: Vet Dermatol 2019/10; 30 (5): 438-e136. (¡ŒŽs˜N1: 1”÷¶•š)

520001. [‘à] —Δ^‹Û‚É‚æ‚é‰@“àŠŽõ. ²“¡r˜Y, —с@rŽ¡1 (1”÷¶•š): –k—¢ˆãŠw 2019/12; 49 (2): 73-8.

521001. [‰ðà]yHelicobacterV‹ÛŽí”­Œ©!z2016”N‚š‚æ‚Ñ2017”N‚ɏ³”F‚³‚ê‚œHelicobacter‘®‚̐V‹ÛŽí‚̏Љî|•ñ˜_•¶‚æ‚è|. —с@rŽ¡ (”÷¶•š): Helicobacter Research 2019/5; 23 (1): 74-8.

522005. [uÀ]yPractical“ÁW: ‰˜‚ê‚œô‘ó‹@, ‰B‚ê‚œ‹ó’²Œû, …“¹ŠÇ‚̉œcƒŠƒU[ƒo[‚ðŒ©”²‚­ ŠÂ‹«®”õ‚ÌŠm”Fƒ|ƒCƒ“ƒgz[8] ƒŠƒU[ƒo[’T‚µ‚ɍ׋ۉ®‚³‚ñ‚ð—U‚Á‚Ä‚Ý‚æ‚€ Šm”Fƒ|ƒCƒ“ƒg3. —с@rŽ¡ (”÷¶•š): INFECTION CONTROL 2019/6; 28 (6): 580-5.

530001. [‚»‚Ì‘Œ (Published Erratum)] Author Correction: Exfoliative toxin E, a new Staphylococcus aureus virulence factor with host-specific activity. Imanishi I1, Nicolas A, Caetano AB, Castro TLP, Tartaglia NR, Mariutti R, GuŽdon E, Even S, Berkova N, Arni RK, Seyffert N, Azevedo V, Nishifuji K, Le Loir Y: Sci Rep 2020/2; 10 (1): 2460. (¡ŒŽs˜N1: 1”÷¶•š)

540002. [‚»‚Ì‘Œ (L•ñŽ)] •ÒWŒã‹L. ãŒû‹`•F (”÷¶•š): –k—¢‘åŠwˆãŠw•”ƒjƒ…[ƒY 2019/4; 392: 16.

540003. [‚»‚Ì‘Œ (Œ€‹†•ñ‘)]y‰ÈŠwŒ€‹†”ï•â•‹àEŠî”ÕŒ€‹† (C)uCŒ^‚ÆDŒ^ƒ{ƒcƒŠƒkƒX“Å‘fˆâ“`Žq‚ð“`’B‚·‚éƒtƒ@[ƒW‚̏hŽå”FŽ¯‹@\‚̉𖟂Ƃ»‚̉ž—p (Œ€‹†ŠúŠÔ: 2016”N“x`2018”N“x)vzŒ€‹†‘ã•\ŽÒ: âŒû‹`•F1, Œ€‹†•ª’SŽÒ: —с@rŽ¡1, ‰Á“¡‚Í‚é, ‘å‹{’Œ–Ø, “àŽR~•œ, –…”ö[•q (1”÷¶•š):uCŒ^‚ÆDŒ^ƒ{ƒcƒŠƒkƒX“Å‘fˆâ“`Žq‚ð“`’B‚·‚éƒtƒ@[ƒWhŽå”FŽ¯‹@\‚̉𖟂Ƃ»‚̉ž—pv2018”N“xŽÀÑ•ñ‘ 2019/5; http://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-16K08785/16K087852018jisseki/.

540004. [‚»‚Ì‘Œ (Œ€‹†•ñ‘)]y‰ÈŠwŒ€‹†”ï•â•‹àEŠî”ÕŒ€‹† (C)uƒtƒ@[ƒW“àÝ‰»‚É‚æ‚éƒsƒƒŠ‹Û‚ÌŽ‘±ŠŽõ‹@\‚ÌŒŸØ (Œ€‹†ŠúŠÔ: 2018”N“x`2020”N“x)vzŒ€‹†‘ã•\ŽÒ: “àŽR~•œ, Œ€‹†•ª’SŽÒ: Œè–ΓW, —с@rŽ¡1, ãŒû‹`•F1, ŽOŽºm”ü (1”÷¶•š):uƒtƒ@[ƒW“àÝ‰»‚É‚æ‚éƒsƒƒŠ‹Û‚ÌŽ‘±ŠŽõ‹@\‚ÌŒŸØv2018”N“xŽÀŽ{ó‹µ•ñ‘ 2019/5; https://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-18K07127/18K071272018hokoku/.

540005. [‚»‚Ì‘Œ (Œ€‹†•ñ‘)]y‰ÈŠwŒ€‹†”ï•â•‹àEŠî”ÕŒ€‹† (C)uCŒ^‚ÆDŒ^ƒ{ƒcƒŠƒkƒX“Å‘fˆâ“`Žq‚ð“`’B‚·‚éƒtƒ@[ƒW‚̏hŽå”FŽ¯‹@\‚̉𖟂Ƃ»‚̉ž—p (Œ€‹†ŠúŠÔ: 2016”N“x`2018”N“x)vzŒ€‹†‘ã•\ŽÒ: âŒû‹`•F1, Œ€‹†•ª’SŽÒ: —с@rŽ¡1, ‰Á“¡‚Í‚é, ‘å‹{’Œ–Ø, “àŽR~•œ, –…”ö[•q (1”÷¶•š):uCŒ^‚ÆDŒ^ƒ{ƒcƒŠƒkƒX“Å‘fˆâ“`Žq‚ð“`’B‚·‚éƒtƒ@[ƒWhŽå”FŽ¯‹@\‚̉𖟂Ƃ»‚̉ž—pv2016”N`2018”N“xŒ€‹†¬‰Ê•ñ‘ 2019/6.

540006. [‚»‚Ì‘Œ (L•ñŽ)] ‚­‚·‚Ì‚«. ãŒû‹`•F (”÷¶•š): –k—¢‘åŠwˆãŠw•”ƒjƒ…[ƒY 2019/9; 396: 12.

540007. [‚»‚Ì‘Œ (L•ñŽ)] ˆãŠw•”‚¯‚â‚«‰ïŒ€‹†•¬‚ðŽó‚¯‚Ä. •@@W (”÷¶•š): –k—¢‘åŠwˆãŠw•”ƒjƒ…[ƒY 2019/10; 397: 8-9.

540008. [‚»‚Ì‘Œ (L•ñŽ)] 2019”N“x•¶•”‰ÈŠwÈ‰ÈŠwŒ€‹†”¬‚ðŽó‚¯‚Ä. ãŒû‹`•F (”÷¶•š): –k—¢‘åŠwˆãŠw•”ƒjƒ…[ƒY 2019/11; 398: 10.

540009. [‚»‚Ì‘Œ (Œ€‹†•ñ‘)]yŒö‰và’c–@l ˆÉ“¡‹L”Oà’cE2018”N“xŒö‰và’c–@lˆÉ“¡‹L”Oà’c•¬‹àu–ì’¹‚ª”}‰î‚·‚é‰Æ’{‚̃{ƒcƒŠƒkƒXÇ‚Ì•ªŽq‰uŠw“I‰ðÍ (Œ€‹†‹@ŠÖ: 2018”N“x)vzŒ€‹†‘ã•\ŽÒ: âŒû‹`•F1, Œ€‹†•ª’SŽÒ: —с@rŽ¡1, Œü–{‰ëˆè, K“c’mŽq, ŽOàV®–Ÿ, “àŽR~•œ, –…”ö[•q, Œã“¡˜a‹` (1”÷¶•š): 2018”N“x H“÷‚ÉŠÖ‚·‚鏕¬Œ€‹†’²ž¬‰Ê•ñ‘ 2019/11; VOL.37: 371-5.

540010. [‚»‚Ì‘Œ (L•ñŽ)] •ÒWŒã‹L. ãŒû‹`•F (”÷¶•š): –k—¢‘åŠwˆãŠw•”ƒjƒ…[ƒY 2020/1; 399: 20.

540011. [‚»‚Ì‘Œ (Œ€‹†•ñ‘)]yŒö‰và’c–@l —é–ØŒªŽO‹L”Oˆã‰ÈŠw‰ž—pŒ€‹†à’cE2018”N“x’²žŒ€‹†•¬‹àuƒNƒƒXƒgƒŠƒfƒBƒIƒCƒfƒX (ƒNƒƒXƒgƒŠƒWƒEƒ€)EƒfƒBƒtƒBƒVƒ‹ŠŽõÇ‚Ì’°“à×‹Û‘p‚ðŠh—‚µ‚È‚¢V‹KŽ¡—Ö@‚ÌŠJ”­ (Œ€‹†ŠúŠÔ: 2018”N“x)vzŒ€‹†‘ã•\ŽÒ: âŒû‹`•F1, ‹€“¯Œ€‹†ŽÒ: —с@rŽ¡1, ‰Á“¡‚Í‚é, Œã“¡˜a‹`, “àŽR~•œ, –…”ö[•q, âŒû­Ž (1”÷¶•š):uƒNƒƒXƒgƒŠƒfƒBƒIƒCƒfƒX (ƒNƒƒXƒgƒŠƒWƒEƒ€)EƒfƒBƒtƒBƒVƒ‹ŠŽõÇ‚Ì’°“à×‹Û‘p‚ðŠh—‚µ‚È‚¢V‹KŽ¡—Ö@‚ÌŠJ”­v‹ÆÑ•ñ‘ 2020/3; p.80-4.

[’˜@‘]

620003. [Šwp‘ (•ª’SŽ·•M)] yŒ¢‚Ì“à‰Èf—à Part1z‘æ7Í ”畆ŽŸŠ³@7.3 ”^”çÇ, p.374-82. ¡ŒŽs˜N (”÷¶•š), ‘ŠÄC: Î“c‘ì•v, —Ώ‘–[, “Œ‹ž, 2020/3”­s.

[Šw‰ïEŒ€‹†‰ï“™]

713004. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Bacterial Transmission via Phlebotomy Tourniquets. Ito M, Suzuki R, Ishii K, Ikeda N, Ninomiya A, Ueno Y, Umemura Y, Shimada A, Sanada M, Hayashi S1: The 17th East Asian Conference on Infection Control and Prevention (EACIC2020) (2020/2/15), Yokohama, Japan. (—с@rŽ¡1: 1”÷¶•š)

713005. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Bactericidal and Sporicidal Effects of Aerosolized Hydrogen Peroxide. Hayashi S1, Sasahara T, Ito M, Morisawa Y: The 17th East Asian Conference on Infection Control and Prevention (EACIC2020) (2020/2/15), Yokohama, Japan. (—с@rŽ¡1: 1”÷¶•š)

713006. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Ability of Disinfectant Wipes to Remove Bacillus cereus Spores. Hayashi S1, Sasahara T, Ito M, Morisawa Y: The 17th East Asian Conference on Infection Control and Prevention (EACIC2020) (2020/2/15), Yokohama, Japan. (—с@rŽ¡1: 1”÷¶•š)

723031. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Analysis of gut therapy microbiota and metabolite in fecal transplantation for Clostridioides difficile infection. ãŒû‹`•F1, Œã“¡˜a‹`, –…”ö[•q, “àŽR~•œ, ”öè”¹l, é‘ãN‹M, —с@rŽ¡1, ‘å‹{’Œ–Ø, ‰Á“¡‚Í‚é (1”÷¶•š): ‘æ92‰ñ“ú–{×‹ÛŠw‰ï‘‰ï (2019/4/23), ŽD–y.

723032. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒ{ƒcƒŠƒkƒX_Œo“Å‘f‚ÌŽO³_Œoß‚ł̍ì—p‹@\‚̉ðÍ. ŽR–{—R–íŽq, ŠÛà_Œ÷‘Ÿ˜Y, Œ–FŽO, ”üŠÔŒ’•F, Œã“¡˜a‹`, Arief Waskitho, ‰¡“cŒ›Ž¡, ãŒû‹`•F1, Œ‰º@Ž¡, ¬ŒFœš“ñ (1”÷¶•š): ‘æ92‰ñ“ú–{×‹ÛŠw‰ï‘‰ï (2019/4/23), ŽD–y.

723033. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Potential improvement of prenatal Group B Streptococcus screening using phages. “àŽR~•œ, ŒˆäGm, “ߐ{ì’‰–í, ãŒû‹`•F1, …ãŒ\“ñ˜Y, ãŒû‰ëO, Œè–ΓW, ‰Ô–؏G–Ÿ2 (1”÷¶•š, 2–k—¢¶–œŒ€‹†Š): ‘æ92‰ñ“ú–{×‹ÛŠw‰ï‘‰ï (2019/4/23), ŽD–y.

723034. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Lysozyme“Y‰Á”|’n‚É‚æ‚蕪—£‚³‚ê‚œMicromonosporaceae‰È‚É‘®‚·‚éOK19-0010Š”‚Ì•ª—ÞŒ€‹†. ›“¡—T‹M, •@@W1, ˆî‹Ž—C‹N, ‘呺@’q, Œ–{ŒúŽq (1”÷¶•š): 2019”N“x (‘æ34‰ñ) “ú–{•úü‹ÛŠw‰ï‘å‰ï (2019/9/23), ŽD–y.

723035. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Micromonosporaceae‰È•úü‹Û‚Ì–¢’m×–E•ÇƒAƒ~ƒmŽ_‚Ì’P—£‚ƍ\‘¢‰ðÍ. •@@W1, ˆî‹Ž—C‹N, ‚‹Ž—mŽq, ‘呺@’q, Œ–{ŒúŽq (1”÷¶•š): 2019”N“x (‘æ34‰ñ) “ú–{•úü‹ÛŠw‰ï‘å‰ï (2019/9/23), ŽD–y.

723036. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Œ°”÷ƒ‰ƒ}ƒ“‘œ•Ï—ʃXƒyƒNƒgƒ‹•ª‰ð–@‚ð—p‚¢‚œ•úü‹ÛS. avermitilis‚É‚š‚¯‚鐶—Šˆ«•šŽ¿avermectin‚Ì‹Û‘Ì“àŒŸo. –xˆär•œ, ’†“‡‘ôŽ©, •@@W1, ˆÀ“¡³_, Œ–{ŒúŽq, ‚‹Ž—mŽq, ’|ŽRtŽq (1”÷¶•š): 2019”N“x (‘æ34‰ñ) “ú–{•úü‹ÛŠw‰ï‘å‰ï (2019/9/24), ŽD–y.

723037. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) A•š‚̍ª‚æ‚蕪—£‚³‚ê‚œStreptosporangiaceae‰È‚É‘®‚·‚éK14-0274Š”‚Ì•ª—ÞŒ€‹†. ŽR“c—S‹P, ˆî‹Ž—C‹N, •@@W1, ’r“cãĈê, ‘呺@’q, Œ–{ŒúŽq (1”÷¶•š): 2019”N“x (‘æ34‰ñ) “ú–{•úü‹ÛŠw‰ï‘å‰ï (2019/9/24), ŽD–y.

723038. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Analysis of gut microbiome in dairy cows infected with bovine leukemia virus. Uchiyama J, Murakami H, Sato R, Mizukami K, Suzuki T, Shima A, Ishihara G, Sakaguchi Y1, Sogawa K, Sakaguchi M: ‘æ93‰ñ“ú–{×‹ÛŠw‰ï‘‰ï (2020/2/19), ˆ€’m. (ãŒû‹`•F1: 1”÷¶•š)

723039. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰ßŽ_‰»…‘f•¬–¶‚̊‹«Á“ÅŒø‰Ê‚ÌŒŸ“¢. —с@rŽ¡1, ùŒŽ“S•œ, ˆÉ“¡“¹Žq, XàV—YŽi (1”÷¶•š): ‘æ35‰ñ“ú–{ŠÂ‹«ŠŽõŠw‰ï‘‰ïEŠwpW‰ï (2020/2/15), ‰¡•l.

723040. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠÅŒìŽt‚ªŽg—p‚·‚é‹ìŒŒ‘т̍׋ۉ˜õ‚ÆŠÇ—ó‹µ‚ÌŒŸ“¢. ˆÉ“¡“¹Žq, “ñ‹{@ˆ©, ^“c–ƒ”ü, Îˆä˜aŽq, —é–Ø—ŠG, ã–ì‰êŽq, ”~‘º—TŽq, “‡“c–ŸŒb, ’r“c‹IŽq, —с@rŽ¡1 (1”÷¶•š): ‘æ35‰ñ“ú–{ŠÂ‹«ŠŽõŠw‰ï‘‰ïEŠwpW‰ï (2020/2/15), ‰¡•l.

723041. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Analysis of gut microbiota and metabolite in fecal transplantation therapy for Clostridioides difficile infection. ãŒû‹`•F1, Œã“¡˜a‹`, –…”ö[•q, •@@W1, “àŽR~•œ, ”öè”¹l, é‘ãN‹M, —с@rŽ¡1, ‘å‹{’Œ–Ø, ‰Á“¡‚Í‚é (1”÷¶•š): ‘æ93‰ñ“ú–{×‹ÛŠw‰ï‘‰ï (2020/2/19), –ŒŒÃ‰®.

723042. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Analysis of gut microbiome in dairy cows infected with bovine leukemia virus. Uchiyama J, Murakami H, Sato R, Mizukami K, Suzuki T, Shima A, Ishihara G, ãŒû‹`•F1, Sogawa K, Sakaguchi M (1”÷¶•š): ‘æ93‰ñ“ú–{×‹ÛŠw‰ï‘‰ï (2020/2/19), –ŒŒÃ‰®.

723043. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) (”­•\—DGÜ) ‘gŠ·‚Šendolysin‚̃uƒhƒE‹…‹Û‚ɑ΂·‚é—n‹Ûì—p‚È‚ç‚Ñ‚É”^áo] ƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚š‚¯‚é”­Ç—}§Œø‰Ê. ¡ŒŽs˜N1, “àŽR~•œ, ’Ëvˆä—˜L, ‹vP‡ŽO, ˆäŽèD, Œè–ΓW, ›ˆäŠîs, Œ“¡ŒöŽi (1”÷¶•š): ‘æ93‰ñ“ú–{×‹ÛŠw‰ï‘‰ï (2020/2/19), –ŒŒÃ‰®.

723044. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒCƒk‚̏ƒŒŒƒRƒƒj[‚ð—˜—p‚µ‚œƒAƒgƒs[«”畆‰Š‚ÉŠÖ˜A‚µ‚œŒûoE’°“à×‹Û‘p‚̉ðÍ. ŠC–ì’©, ¡ŒŽs˜N1, …ãŒ\“ñ˜Y, ‘å‹÷‘žŽj, ŒÜ\—’Š°‚, ‘ºã—TM, “‡@ˆ», ‰Fª—L”ü, ãŒû‰ëO, “àŽR~•œ (1”÷¶•š): ‘æ93‰ñ“ú–{×‹ÛŠw‘‰ï (2019/2/19), –ŒŒÃ‰®.

723045. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Clostridioides difficileŠŽõÇŠ³ŽÒ‚ɑ΂·‚镳•Ö”÷¶•šˆÚA‚ÌŒø‰Ê`ƒqƒg’°“à”÷¶•š‘p‚š‚æ‚уƒ^ƒ{ƒ[ƒ€‚̉ðÍ`. ãŒû‹`•F1, Œã“¡˜a‹`, –…”ö[•q, •@@W1, “àŽR~•œ, ”öè”¹l, é‘ãN‹M, —с@rŽ¡1, ‘å‹{’Œ–Ø, ‰Á“¡‚Í‚é (1”÷¶•š): ‘æ140”N‰ï“ú–{–òŠw‰ï (2020/3/25), ‹ž“s.

733006. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‹ìŒŒ‘т̍׋ۉ˜õ‚ÆŠÇ—ó‹µ‚ÌŒŸ“¢. ˆÉ“¡“¹Žq, “ñ‹{@ˆ©, Îˆä˜aŽq, ’r“c‹IŽq, ^“c–ƒ”ü, —é–Ø—ŠG, ã–ì‰êŽq, ”~‘º—TŽq, “‡“c–ŸŒb, —с@rŽ¡1 (1”÷¶•š): ‘æ86‰ñ_“ސ쌧ŠŽõÇˆãŠw‰ï (2019/9/7), ‰¡•l.

733007. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‰ßŽ_‰»…‘f•¬–¶‚ÌŽE‹ÛŒø‰Ê‚ÌŒŸ“¢. —с@rŽ¡1, ˆÉ“¡“¹Žq (1”÷¶•š): ‘æ86‰ñ_“ސ쌧ŠŽõÇˆãŠw‰ï (2019/9/7), ‰¡•l.

733008. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) 2018”N“ú–{×‹ÛŠw‰ïŠÖ“ŒŽx•”ƒCƒ“ƒ^[ƒ‰ƒ{ƒZƒ~ƒi[, ‘æ7‰ñƒtƒ@[ƒWŒ€‹†‰ï‡“¯‘å‰ïŠJÃ•ñ. ãŒû‹`•F1, “àŽR~•œ (1”÷¶•š): ‘æ102‰ñ“ú–{×‹ÛŠw‰ïŠÖ“ŒŽx•”‘‰ï (2019/10/3), ’·–ì.

733009. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ƒEƒV‚É‚š‚¯‚éŠO—ˆ«ƒŒƒgƒƒEƒCƒ‹ƒXŠŽõ‚É‚æ‚é’°“à×‹Û‘p‚̉ðÍ. “àŽR~•œ, ‘ºã—TM, ²“¡—çˆê˜Y, ‘]ìˆêK, ãŒû‹`•F1, “‡@ˆ», ÎŒŽŒºŠî, ãŒû‰ëO (1”÷¶•š): ‘æ102‰ñ“ú–{×‹ÛŠw‰ïŠÖ“ŒŽx•”‘‰ï (2019/10/3), ’·–ì.

733010. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) –òÜ‘ϐ«‚ÉŠÖ—^‚·‚éStreptococcus suis‚Ì–Œ¬–E‚ÌŒ€‹†. “ߐ{ì’‰–í, “àŽR~•œ, “‡‘qGŸ, ¬•û‰ë–ç, ãŒû‹`•F1, •Ÿ“c@Œ›, Œè–ΓW (1”÷¶•š): ‘æ102‰ñ“ú–{×‹ÛŠw‰ïŠÖ“ŒŽx•”‘‰ï (2019/10/3), ’·–ì.

733011. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‹ìŒŒ‘Ñ‚ÌŒŒ‰t‰˜õ‚ÆŠÇ—ó‹µ‚ÌŒŸ“¢. ˆÉ“¡“¹Žq, “‡“c–ŸŒb, ”~‘º—TŽq, ã–ì‰êŽq, —é–Ø—ŠG, ^“c–ƒ”ü, ’r“c‹IŽq, Îˆä˜aŽq, “ñ‹{@ˆ©, —с@rŽ¡1 (1”÷¶•š): ‘æ87‰ñ_“ސ쌧ŠŽõÇˆãŠw‰ï (2020/2/29), ‰¡•l.


Šñ¶’ŽŠwE”M‘шãŠw

[Šwp˜_•¶]

110027. [ŒŽ’˜] Tick infestation and hemoparasitic infections in cattle in some selected areas of Bangladesh. Akter MTD, Alim MA, Md. MG, Haque MH, Farjana T, Hatta T1, Anisuzzaman, Tsuji N1, Mondal MMH: Jpn J Vet Parasitol 2019/6; 18 (1): 26-34. (”ª“cŠxŽm1, ’ҁ@®—˜1: 1Šñ¶’ŽE”M‘шãŠw)

110028. [ŒŽ’˜] Characterization of an iron-inducible Haemaphysalis longicornis tick-derived promoter in an Ixodes scapularis-derived tick cell line (ISE6). Hernandez EP, Kusakisako K, Hatta T1, Tanaka T: Parasit Vectors 2019/6; 12 (1): 321. (”ª“cŠxŽm1: 1Šñ¶’ŽE”M‘шãŠw)

110029. [ŒŽ’˜] Characterization of the RAGE-binding protein, Strongyloides venestatin, produced by the silkworm-baculovirus expression system. Tsubokawa D1, Lee JM, Hatta T1, Mikami F, Maruyama H, Arakawa T, Kusakabe T, Tsuji N1: Infect Genet Evol 2019/11; 75: 103964. (’ؐì‘åŒå1, ”ª“cŠxŽm1, ’ҁ@®—˜1: 1Šñ¶’ŽE”M‘шãŠw)

110030. [ŒŽ’˜] Snail-borne trematodiasis in cattle in Barind Tract of Bangladesh, an overlooked problem. Rahman MA, Alim MA, Hossain MM, Yasin MG, Alam MZ, Hatta T1, Anisuzzaman, Tsuji N1, Mondal MMH: Jpn J Vet Parasitol 2019/12; 18 (2): 53-64. (”ª“cŠxŽm1, ’ҁ@®—˜1: 1Šñ¶’ŽE”M‘шãŠw)

110031. [ŒŽ’˜] Transitions in morphological forms and rapid development of the asexual schizonts of Eimeria tenella through serial passaging in chicks. Matsubayashi M, Yamaguchi H, Hatta T1, Kawahara F, Hatabu T, Iseki H, Yamagishi J, Isobe T, Teramoto I, Kaneko A, Kita K, Tsuji N1, Sasai K: Infect Genet Evol 2019/11; 75: 103993. (”ª“cŠxŽm1, ’ҁ@®—˜1: 1Šñ¶’ŽE”M‘шãŠw)

540012. [‚»‚Ì‘Œ (Šw¶˜_•¶)] Œo”çN“ü«ü’ŽStrongyloides venezuelensis‚̏hŽå‘Ì“àˆÚs‚É‚š‚¯‚éI––“œ‰»ŽY•šŽó—e‘Ì‚Ì–ðŠ„. ’Ø“c—‰›, ’ؐì‘åŒå1, ”ª“cŠxŽm1, ’ҁ@®—˜1 (1Šñ¶’ŽE”M‘шãŠw): –k—¢ˆãŠw 2019/12; 49 (2): 111-3.

[Šw‰ïEŒ€‹†‰ï“™]

723046. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Š”“ÁˆÙ“I‚ȖƉu‰ž“š‚ðˆø‚«‹N‚±‚·“Á’èƒnƒvƒƒ^ƒCƒv‚ð—L‚·‚éƒlƒYƒ~•Ú’ŽTrichuris murisV‹KŠ”ì¬‚ÌŽŽ‚Ý. Šâè@x, ¬ŽR_ˆê1, •œ@Œ’‰î, ‰©@ƒŒ˜ (1Šñ¶’ŽE”M‘шãŠw): ‘æ162‰ñ“ú–{bˆãŠw‰ïŠwpW‰ï (2019/9/11), ‚‚­‚Î.

723047. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ZŒŒ‹z’ŽÇ‚É‚š‚¯‚é“÷‰èŽî«‰ŠÇ‚ƏI––“œ‰»ŽY•šŽó—e‘Ì (RAGE) ‚Æ‚ÌŠÖ—^. ¬òèñ‰Ì, ’ؐì‘åŒå1, ”ª“cŠxŽm1, ŽOã–[Žq, ’†‘º@Œ’, ŽR–{–õ•F, ’ҁ@®—˜1 (1Šñ¶’ŽE”M‘шãŠw): ‘æ60‰ñ“ú–{”M‘шãŠw‰ï‘å‰ï (2019/11/9), ‰«“ê.

733012. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ƒxƒlƒYƒGƒ‰•³ü’Ž‚̐¬’ŽŠñ¶‚É‚š‚¯‚éI––“œ‰»ŽY•šŽó—e‘Ì (RAGE) ‚Ì–ðŠ„. ’ؐì‘åŒå1, ”ª“cŠxŽm1, ¬òèñ‰Ì, ŠÖŒû’q–ç, ŽOã–[Žq, ŽR–{–õ•F, ’ҁ@®—˜1 (1Šñ¶’ŽE”M‘шãŠw): ‘æ13‰ñ埒ŽŒ€‹†‰ï (2019/7/14), ‹{è.

733013. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ƒ}ƒ“ƒ\ƒ“ZŒŒ‹z’ŽÇ‚É‚æ‚é“÷‰èŽîŒ`¬‚ւ̏I––“œ‰»ŽY•šŽó—e‘Ì (RAGE) ‚ÌŠÖ—^. ¬òèñ‰Ì, ’ؐì‘åŒå1, ”ª“cŠxŽm1, ŽOã–[Žq, ’†‘º@Œ’, ŽR–{–õ•F, ’ҁ@®—˜1 (1Šñ¶’ŽE”M‘шãŠw): ‘æ79‰ñ“ú–{Šñ¶’ŽŠw‰ï“Œ“ú–{Žx•”‘å‰ï (2019/10/12), “Œ‹ž.


•a—Šw (‘º‰_’PˆÊ)

[Šwp˜_•¶]

110032. [ŒŽ’˜] Clinicopathological and prognostic significance of nuclear UGDH localization in lung adenocarcinoma. Hagiuda D, Nagashio R1, Ichinoe M2, Tsuchiya B1, Igawa S3, Naoki K3, Satoh Y4, Murakumo Y2, Saegusa M2, Sato Y1: Biomed Res 2019; 40 (1): 17-27. (’·‰–@—º1, ˆêŒË¹–Ÿ2, “y‰®g1, ˆäì@‘3, —P–؍Ž•F3, ²“¡”Vr4, ‘º‰_–FŽ÷2, ŽOŽ}@M2, ²“¡—Yˆê1: 1ˆã—Éq¶Šw•”, 2•a—, 3ŒÄ‹zŠí“à, 4ŒÄ‹zŠíŠO)

510001. [‘à] Proposal for an Organ-Specific Chronic Inflammation-Remodeling-Carcinoma Sequence. Okayasu I, Ichinoe M1, Yoshida T1: Gastrointestinal Disorders 2019/8; 1 (3): 341-57. (ˆêŒË¹–Ÿ1, ‹g“c@Œ÷1: 1•a—)

[Šw‰ïEŒ€‹†‰ï“™]

723048. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”xG•œã”çŠà‚É‚š‚¯‚éCD109‚Ì‹@”\‰ðÍ. ‰Á“¡‘ôÆ1, Žµ‰Y“Þ“sŽÀ, ‹{‰ºŒ‹‰H, ŸNˆä–õ‚1, ‘º‰_–FŽ÷1 (1•a—): ‘æ108‰ñ“ú–{•a—Šw‰ï‘‰ï (2019/5/9), “Œ‹ž.

723049. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬×–E”xŠà‚̐¶•šŠw“I“Á«‚É‚š‚¯‚éREV7”­Œ»‚̈Ӌ`. áÁŽR@“ž1, ‘º‰_–FŽ÷1, ˆêŒË¹–Ÿ1, ŸNˆä–õ‚1 (1•a—): ‘æ78‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï (2019/9/26-28), ‹ž“s.

723050. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆ««•FŽî‚É‚š‚¯‚éREV7‚Ì‹@”\‰ðÍ. ¯–쏺–F1, ˆêŒË¹–Ÿ1, ŸNˆä–õ‚1, ‘º‰_–FŽ÷1 (1•a—): ‘æ78‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï (2019/9/26-28), ‹ž“s.

723051. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) äX‘ŸŠà‚Ì—\Œã‚É‚š‚¯‚éCD109”­Œ»‚̈Ӌ`‚̉ðÍ. ˆÀ’B@‰õ1, ŸNˆä–õ‚2, ‰Á“¡‘ôÆ2, ˆêŒË¹–Ÿ2, ‘º‰_–FŽ÷2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2•a—): ‘æ78‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï (2019/9/26-28), ‹ž“s.

723052. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŽèpŒŸ‘Ì‚ð—p‚¢‚œäXŠà‚É‚š‚¯‚éBRCAness‚̉ðÍ. äøŒŽ«—Ç1, ‰Á“¡‘ôÆ2, ˆÀ’B@‰õ1, ŸNˆä–õ‚2, ˆêŒË¹–Ÿ2, ‘º‰_–FŽ÷2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2•a—): ‘æ78‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï (2019/9/26-28), ‹ž“s.


•a—Šw (ŽOŽ}’PˆÊ)

[Šwp˜_•¶]

110033. [ŒŽ’˜] Nodal induces apoptosis and inhibits proliferation in ovarian endometriosis-clear cell carcinoma lesions. Miura R1, Yokoi A1, Matsumoto T2, Oguri Y3, Hashimura M3, Tochimoto M1, Kajita S2, Saegusa M2: BMC Cancer 2019/4; 19 (1): 308. (ŽO‰Y—“ìŽq1, ‰¡ˆäˆ€1, Œ–{r‰p2, ¬ŒINŽq3, ‹Ž‘º”ü‹I3, “È–{¹F1, Š“cç”ü”T2, ŽOŽ}@M2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2•a—, 3Œ`‘ÔŒn)

110034. [ŒŽ’˜] Alterations in ƒÀ-catenin, microsatellite instability, and HNF-1ƒÀ levels are independently associated with ovarian endometriosis-associated tumorigenesis. Tomohiro M1, Matsumoto T2, Miura R1, Oguri Y3, Yokoi A1, Tochimoto M1, Saegusa M2: Hum Pathol 2019/7; 89: 10-23. (—FLŠ²‹v1, Œ–{r‰p2, ŽO‰Y—“ìŽq1, ¬ŒINŽq3, ‰¡ˆäˆ€1, “È–{¹F1, ŽOŽ}@M2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2•a—, Œ`‘ÔŒn)

110035. [ŒŽ’˜] S100A4/non-muscle myosin II signaling regulates epithelial-mesenchymal transition and stemness in uterine carcinosarcoma. Tochimoto M1, Oguri Y2, Hashimura M2, Konno R, Matsumoto T3, Yokoi A1, Kodera Y, Saegusa M3: Lab Invest 2020/5; 100 (5): 682-95. doi: 10.1038/s41374-019-0359-x. Epub 2019 Dec 19. (“È–{¹F1, ¬ŒINŽq2, ‹Ž‘º”ü‹I2, Œ–{r‰p3, ‰¡ˆäˆ€1, ŽOŽ}@M3: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2Œ`‘ÔŒn, 3•a—)

310004. [Ç—á•ñ] Case of Calcifying Pseudoneoplasms of the Neuraxis Coexisting with Interhemispheric Lipoma and Agenesis of the Corpus Callosum: Involvement of Infiltrating Macrophages. Inukai M1, Shibahara I2, Hotta M, Miyasaka K2, Sato S2, Hide T2, Saegusa M1, Kumabe T2: World Neurosurg 2020/2; 134: 635-40.e1. (Œ¢Ž”@‰~1, ŽÄŒŽˆê—z2, ‹{â˜aO2, ²“¡Ÿl2, G‘ñˆê˜Y2, ŽOŽ}@M1, ŒG•”rG2: 1•a—, 2”]ŠO)

[’˜@‘]

610002. [Šwp‘ (•ª’SŽ·•M)]yVitamin AzThe Role of Vitamin A-Storing Cells (Stellate Cells) in Inflammation and Tumorigenesis. Okayasu I, Fujiwara M, Yoshida T1, Editor: Zepka LQ, InTech, UK, Published: 2019/5. (‹g“c@Œ÷1: 1•a—)

[Šw‰ïEŒ€‹†‰ï“™]

723053. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) äP‰èŽî‚ÌS100A4‚É‚æ‚邪‚ñŠ²×–E‰»—U“±‹@\‚̉ð–Ÿ. Œ¢Ž”@‰~1, Îˆäá”ü, ‹Ž‘º”ü‹I2, ŽOŽ}@M1 (1•a—, 2Œ`‘ÔŒn): ‘æ108‰ñ“ú–{•a—Šw‰ï‘‰ï (2019/5/9), “Œ‹ž.

723054. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) HNF1ƒÀ+Ep53+EARID1A+Œ^—‘‘ƒŠà‚Í—\Œã•s—Ç‚Å‚ ‚é. ‰¡ˆäˆ€1, ¬ŒINŽq2, Œ–{r‰p3, ŽOŽ}@M3 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2Œ`‘ÔŒn, 3•a—): ‘æ108‰ñ“ú–{•a—Šw‰ï‘‰ï (2019/5/9), “Œ‹ž.

723055. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆÝŠà‚ÌŽèpŒŸ‘̂̃Šƒ“ƒpŠÇNP‚Ì•a—‘gDŠw“I•]‰¿‚Í•K—v‚©? ŽOŽ}@M (•a—): ‘æ108‰ñ“ú–{•a—Šw‰ï‘‰ï (2019/5/9), “Œ‹ž.

723056. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Žq‹{“à–ŒÇ«—‘‘ƒ”X–E‚Ì”­Šà‰ß’ö‚É‚š‚¯‚éƒÀ-ƒJƒeƒjƒ“, HNF-1ƒ¿, ‹y‚шâ“`Žq•sˆÀ’萫‚Ì‘ŠŒÝŠÖ˜A«. —FLŠ²‹v1, Œ–{r‰p2, ŽO‰Y—“ìŽq, ¬ŒINŽq3, ŽOŽ}@M2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2•a—, 3Œ`‘ÔŒn): ‘æ108‰ñ“ú–{•a—Šw‰ï‘‰ï (2019/5/10), “Œ‹ž.

723057. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) EBP50‚Í—‘‘ƒ–Ÿ×–EŠà‚̍Ĕ­E—\Œã•s—LjöŽq‚Å‚ ‚é. Œ–{r‰p1, ‰¡ˆäˆ€2, ®–ì@—º, ¬Ž›‹`’j, ŽOŽ}@M1 (1•a—, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ108‰ñ“ú–{•a—Šw‰ï‘‰ï (2019/5/10), “Œ‹ž.

723058. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —‘‘ƒŸ÷‰tŠà‚̐i“W‰ß’ö‚É‚š‚¯‚éS100A4/p53 axis‚̉ʂœ‚·–ðŠ„. •g“c@ˆ€1, ‰¡ˆäˆ€1, Œ–{r‰p2, ‹Ž‘º”ü‹I3, ŽOŽ}@M2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2•a—, 3Œ`‘ÔŒn): ‘æ108‰ñ“ú–{•a—Šw‰ï‘‰ï (2019/5/11), “Œ‹ž.

723059. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) isŠú’Œ’°Šà‚̃À-ƒJƒeƒjƒ“‚ÆPD1/PDL1‚É‚æ‚éŠàŠ²×–Eƒjƒbƒ`Œ`¬‚̏ؖŸ. “n糓s”T1, ‚‹Ž”Ž”V2, ‹Ž‘º”ü‹I3, Œ¢Ž”@‰~4, M‘ŸºŽq4, ŽOŽ}@M4 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ˆã—Éq¶Šw•”, 3Œ`‘ÔŒn, 4•a—): ‘æ108‰ñ“ú–{•a—Šw‰ï‘‰ï (2019/5/11), “Œ‹ž.

723060. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —‘‘ƒŸ÷‰tŠà‚Å‚Í‘S’·Œ^ALK”­Œ»‚ª—\Œã•s—LjöŽq‚É‚È‚é. ¬“c—S‰î1, Œ–{r‰p2, ‹Ž‘º”ü‹I3, ’·’Jì‹vŽq2, “È–{¹F1, ŽOŽ}@M2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2•a—, 3Œ`‘ÔŒn): ‘æ108‰ñ“ú–{•a—Šw‰ï‘‰ï (2019/5/11), “Œ‹ž.

723061. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰ŠÇ«ƒoƒCƒIƒ}[ƒJ[OLFM4‚©‚ç‚Ý‚œ‰ŠÇ«’°ŽŸŠ³ŠÖ˜AŽîᇂ̓ÁˆÙ«‚̉ð–Ÿ. ‰¡ŽR@Œd1, ‹g“c@Œ÷2, ‹Ž‘º”ü‹I3, ŽOŽ}@M2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2•a—, 3Œ`‘ÔŒn): ‘æ108‰ñ“ú–{•a—Šw‰ï‘‰ï (2019/5/11), “Œ‹ž.

723062. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒIƒŠ[ƒuŠj”ì‘å•Ï«‚𐶂¶‚œ”]Š²•”ˆ««ƒŠƒ“ƒpŽî‚Ì2—á. H’J¹Žj1, ²“¡Ÿl2, ‹{â˜aO2, ŽÄŒŽˆê—z2, ¬òŠ°”V3, G‘ñˆê˜Y2, ŒG•”rG2 (1•a—, 2”]ŠO, 3‹~–œ): ‘æ37‰ñ“ú–{”]Žîᇕa—Šw‰ï (2019/6/1), –ŒŒÃ‰®.

723063. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ”]—ÀŒ`¬•s‘SEŽ‰–bŽî‚ÉCalcifying pseudoneoplasms of the neuroaxis (CAPNON) ‚ð‡•¹‚µ‚œˆê—á. Œ¢Ž”@‰~1, ‹{â˜aO2, ŽÄŒŽˆê—z2, ²“¡Ÿl2, G‘ñˆê˜Y2, ŽOŽ}@M1, ŒG•”rG2 (1•a—, 2”]ŠO): ‘æ37‰ñ“ú–{”]Žîᇕa—Šw‰ï (2019/6/1), –ŒŒÃ‰®.

723064. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚š‚¯‚éƒKƒCƒhƒ‰ƒCƒ“•ñ—lŽ®‚É‚æ‚é‘Á‰t‘B×–Ef‚̐ž“xŠÇ—. ‹g“c@Œ÷ (•a—): ‘æ60‰ñ“ú–{—Տ°×–EŠw‰ï‘‰ï (tŠú‘å‰ï) (2019/6/9), “Œ‹ž.

723065. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) A multi-center retrospective study to evaluate PD-L1 protein expression, EBV positivity and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan. ‹g“c@Œ÷1, Ogura G, Tanabe M, Hayashi T, Ohbayashi C, Azuma M, Kunisaki C, Akazawa Y, Ozawa S, Matsumoto S, Suzuki T, Mitoro A, Fukunaga T, Shimizu A, Fujimoto G, Yao T (1•a—): ‘æ57‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï (2019/10/24), •Ÿ‰ª.


‰q¶Šw

[Šwp˜_•¶]

110036. [ŒŽ’˜] Effects of electrical muscle stimulation in frail elderly patients during haemodialysis (DIAL): rationale and protocol for a crossover randomised controlled trial. Suzuki Y1, Kamiya K2, Tanaka S1, Hoshi K3, Watanabe T1, Harada M1, Matsuzawa R4, Shimoda T1, Yamamoto S1, Matsunaga Y, Yoneki K, Yoshida A, Matsunaga A2: BMJ Open 2019/5; 9 (5): e025389. (—é–Ø—T‘Ÿ1, _’JŒ’‘Ÿ˜Y2, “c’†L–í1, ¯@‰À–F3, “n粍F–Ÿ1, ŒŽ“cˆ€‰i1, Œ‘ò—Ç‘Ÿ4, ‰º“c—²‘å1, ŽR–{®•œ1, Œ‰i“Ä•F2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ˆã—Éq¶Šw•”, 3‰q¶, 4ƒŠƒnƒrƒŠ•”)

110037. [ŒŽ’˜] Triclosan-induced alteration of gut microbiome and aggravation of asthmatic airway response in aeroallergen-sensitized mice. Hirota R, Ohya Y, Yamamoto-Hanada K, Fukutomi Y, Muto G1, Ngatu NR, Nakamura T, Nakamura H: Allergy 2019/5; 74 (5): 996-9. (•“¡@„1: 1‰q¶)

110038. [ŒŽ’˜] Effect of frequency-modulated electromagnetic therapy on increasing deep vein blood flow in the lower extremities and improving edema: a randomized, crossover, triple-blind, placebo-controlled trial. Uchida Y1, Sakamoto Y, Hoshi K2, Takahira N3: Kitasato Med J 2019/9; 49 (2): 91-8. (“à“c‘U”Ž1, ¯@‰À–F2, ‚•œ®L3: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2‰q¶, 3ˆã—Éq¶Šw•”)

110039. [ŒŽ’˜] Recurrent sick leave and resignation rates among female cancer survivors after return to work: the Japan sickness absence and return to work (J-SAR) study. Endo M, Haruyama Y, Muto G1, Imai Y, Mitsui K, Mizoue T, Wada H, Kobashi G, Tanigawa T: BMC Public Health 2019/9; 19 (1): 1248. (•“¡@„1: 1‰q¶)

110040. [ŒŽ’˜] Utility of Regular Management of Physical Activity and Physical Function in Hemodialysis Patients. Yamamoto S1, Matsuzawa R, Abe Y, Hoshi K2, Yoneki K, Harada M, Watanabe T1, Shimoda T1, Suzuki Y1, Matsunaga Y, Kamiya K3, Yoshida A, Matsunaga A3: Kidney Blood Press Res 2018/10; 43 (5): 1505-15. (ŽR–{®•œ1, ¯@‰À–F2, “n粍F–Ÿ1, ‰º“c—²‘å1, —é–Ø—T‘Ÿ1, _’JŒ’‘Ÿ˜Y3, Œ‰i“Ä•F3: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2‰q¶, 3ˆã—Éq¶Šw•”)

110041. [ŒŽ’˜] Trajectory of Lean Body Mass Assessed Using the Modified Creatinine Index and Mortality in Hemodialysis Patients. Suzuki Y1, Matsuzawa R, Kamiya K2 Hoshi K3, Harada M, Watanabe T1, Shimoda T1, Yamamoto S1, Matsunaga Y, Yoshida A, Matsunaga A2: Am J Kidney Dis 2020/2; 75 (2): 195-203. (—é–Ø—T‘Ÿ1, _’JŒ’‘Ÿ˜Y2, ¯@‰À–F3, “n粍F–Ÿ1, ‰º“c—²‘å1, ŽR–{®•œ1, Œ‰i“Ä•F2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ˆã—Éq¶Šw•”, 3‰q¶)

522006. [uÀ]yƒVƒŠ[ƒY: ŠwpŒ€‹†‚©‚ç‚̏­Žq‰»‘΍ô|“ú–{‰q¶Šw‰ï‚©‚ç‚Ì’ñŒŸ‚ÉŒü‚¯‚āz“ú–{‰q¶Šw‰ï‚É‚š‚¯‚鏭Žq‰»‘΍ô’ñŒŸ‚ÉŒü‚¯‚Ä: “ú–{‰q¶Šw‰ï­Žq‰»‘΍ôƒ[ƒLƒ“ƒOƒOƒ‹[ƒv‚É‚æ‚é‚Æ‚è‚Ü‚Æ‚ß. –쑺‹±Žq, Š¡“c•c, r–Ø“ÖŽq, Œ‰ªÎŽq, •“¡@„1, Šâˆä”üK, ‹Ñ’J‚܂肱, ˆäã‚Ü‚èŽq, ’߃––삵‚Ì‚Ô, –k–쏮”ü, ’Ґ^‹|, ”Ñ“‡²’mŽq, ã“c‰À‘ã, ã“‡’ʍ_, ŽRãp‘R‘Ÿ˜Y, â“cŽ”ü, ˆÉ–؉ë”V, –öàV—T”V, ‰Á“¡¹Žu, ‰¡ŽR˜am, ¬òº•v, ‘å’΍„–€ (1‰q¶): “ú–{‰q¶ŠwŽGŽ 2019/12; 74: 18034.

522007. [uÀ]y“ÁW: IoTEAI, ‰“Šu‹@Ší‚ðŠˆ—p‚µ‚œ•ÛŒ’Eˆã—ʈ“®zIoT‚≓ŠuƒVƒXƒeƒ€‚ðŠˆ—p‚µ‚œ’nˆæ^‚—îŽÒ•ÛŒ’‚Æ’nˆæ•ïŠ‡ƒPƒAƒVƒXƒeƒ€. ’·—ä—RˆßŽq, •“¡@„1 (1‰q¶): •ÛŒ’‚̉Ȋw 2020/1; 62 (1ŒŽ†): 23-9.

522008. [uÀ]y“ÁW: IoTEAI, ‰“Šu‹@Ší‚ðŠˆ—p‚µ‚œ•ÛŒ’Eˆã—ʈ“®z‰“Šu‹@Ší‚âIoTEAI“™‚ðŠˆ—p‚µ‚œŽY‹Æ•ÛŒ’Šˆ“®‚Ì“WŠJ. •“¡@„1, Îˆä—“Þ, _“c‹ŽGŽ¡, ‘å–î‚ß‚®‚Ý, ‰¡ŽR˜am (1‰q¶): •ÛŒ’‚̉Ȋw 2020/1; 62 (1ŒŽ†): 45-51.

530002. [‚»‚Ì‘Œ (LETTER TO THE EDITOR)] Triclosan-induced alteration of gut microbiome and aggravation of asthmatic airway response in aeroallergen-sensitized mice. Hirota R, Ohya Y, Yamamoto-Hanada K, Fukutomi Y, Muto G1, Ngatu NR, Nakamura T, Nakamura H: Allergy 2019/5; 74 (5): 996-99. (•“¡@„1: 1‰q¶)

530003. [‚»‚Ì‘Œ (ƒRƒƒ“ƒg)] Probable involvement of iron deficiency in the association between low blood cadmium levels and preterm births in pregnant women. Horiguchi H1: Environ Res 2019/5; 172: 615. (–xŒû•º„1: 1‰q¶)

540013. [‚»‚Ì‘Œ (Œ€‹†•ñ‘)] —ߘaŒ³”N“xE“ü‰@Š³ŽÒ•aE—𒲍žŠî‘b‰ðÍ (2005 ”N“x`2017”N“x•aE—ðƒf[ƒ^Žg—p). —§“¹¹K, ¬“‡ŒŽ“TŽq, ¯@‰À–F1, –L“cÍG (1‰q¶): “Æ—§s­–@l˜J“­ŽÒŒ’NˆÀ‘S‹@\ 2020/3; https://www.research.johas.go.jp/bs/doc/20200319.pdf.

540014. [‚»‚Ì‘Œ (Œ€‹†•ñ‘)]yŒú¶˜J“­È˜JÐŽŸ•a—Տ°Œ€‹†Ž–‹Æ”ï•â•‹àuŽ––±Š‘¥‰q¶Šî€‚ÉŠÖ‚·‚錀‹†|‘Ó–«‚ƍ‘ÛŠî€‚Ì’²˜avz•“¡@„ (Œ€‹†‘ã•\ŽÒ)1, ‰Ô—¢^“¹, ‹Ž–{°’j, Ö“¡G”V, ’†‘º—T”V, ‰¡ŽR˜am,Œ•œ@_, ‰““¡Œ¹Ž÷ (1‰q¶): —ߘaŒ³”N“x‘Š‡EŒ€‹†•ñ‘ 2020/3.

540015. [‚»‚Ì‘Œ (Œ€‹†•ñ‘)]yŒú¶˜J“­È˜JÐŽŸ•a—Տ°Œ€‹†Ž–‹Æ”ï•â•‹àuE‹Æ«ƒXƒgƒŒƒXŠÈˆÕ’²ž•[‚ÌŠO‘Œê”ł̍쐬‚ÉŠÖ‚·‚錀‹†vz‰¡ŽR˜am (Œ€‹†‘ã•\ŽÒ), “’óŽ‘”V, ˜a“ckŽ¡, ’Jì@•, ‰““¡Œ¹Ž÷, ‰Yì‰Á‘ãŽq, •“¡@„1, ¬“cØ—DŽq, “c’†Œõ‹I (1‰q¶): —ߘaŒ³”N“x‘Š‡E•ª’SŒ€‹†•ñ‘ 2020/3.

540016. [‚»‚Ì‘Œ (Œ€‹†•ñ‘)]yŒú¶˜J“­‰ÈŠwŒ€‹†”ï•â•‹àu‚ª‚ñŠ³ŽÒ‚̏A˜JŒp‘±‹y‚ѐEê•œ‹A‚ÉŽ‘‚·‚錀‹†vz‰““¡Œ¹Ž÷ (Œ€‹†‘ã•\ŽÒ), âV“¡Œõ], •“c@È, Ž›”ö‘׋v, —с@˜a•F, Œ‘ºŸŽ¡, ãa“N–ç, XŒûŽŸ˜Y, ŒKŒŽŒb‰î, •“¡@„1 (1‰q¶): —ߘaŒ³”N“x‘Š‡E•ª’SŒ€‹†•ñ‘ 2020/3.

540017. [‚»‚Ì‘Œ (Œ€‹†•ñ‘)]yŒú¶˜J“­È˜JÐŽŸ•a—Տ°Œ€‹†Ž–‹Æ”ï•â•‹àuŠé‹ÆEŽY‹Æ•ÛŒ’ƒXƒ^ƒbƒtEˆã—Ë@ŠÖ‚̘AŒg‚É‚æ‚é—Œ—§Žx‰‡ƒVƒXƒeƒ€ŠJ”­vzŒ•œ@_ (Œ€‹†‘ã•\ŽÒ), ‰““¡Œ¹Ž÷, XŒûŽŸ˜Y, ¬ŽR‘PŽq, ‚‹Ž”ü•Û, –쑺‘쐶, ‰ª@Œh”V, •“¡@„1 (1‰q¶): —ߘaŒ³”N“x‘Š‡ 2020/3.

540018. [‚»‚Ì‘Œ (Plain language summary–|–ó)] ‹Ö‰ŒƒRƒ“ƒeƒXƒg‚Í’†E’·Šú“I‚É‹Ö‰Œ‚ɑ΂µ‚ÄŒø‰Ê‚ª‚ ‚é‚©? (Competitions for smoking cessation. Fanshawe TR, Hartmann-Boyce J, Perera R, Lindson N). –|–ó: ¯@‰À–F1, ŠÄ–ó: ŽŒŽN‰î (1‰q¶): Cochrane Database of Systematic Reviews 2019, Issue 2. Art. No.: CD013272. DOI:10.1002/14651858.CD013272. 2019/4; https://www.cochrane.org/ja/CD013272/jin-yan-kontesutohazhong-chang-qi-de-nijin-yan-nidui-sitexiao-guo-gaaruka.

540019. [‚»‚Ì‘Œ (Plain language summary–|–ó)] Å‚à‹Ö‰ŒŒø‰Ê‚ª‚‚¢ƒjƒRƒ`ƒ“‘ã‘֗Ö@‚͉œ‚©? (Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Lindson N, Chepkin SC, Ye W, Fanshawe TR, Bullen C, Hartmann-Boyce J). –|–ó: ¯@‰À–F1, ŠÄ–ó: ŽŒŽN‰î (1‰q¶): Cochrane Systematic Review - Intervention Version: https://doi.org/10.1002/14651858.CD013308. 2019/4; https://www.cochrane.org/ja/CD013308/TOBACCO_zui-mojin-yan-xiao-guo-gagao-inikotindai-ti-liao-fa-hahe-ka.

540020. [‚»‚Ì‘Œ (Plain language summary–|–ó)] ŒûoŠà (Œû‚Ì‚ª‚ñ) ‚ð—\–h‚·‚é‚œ‚ß‚ÌŒûo”’”ǂɑ΂·‚鎡—ÓI‰î“ü (Interventions for treating oral leukoplakia to prevent oral cancer. Lodi G, Franchini R, Warnakulasuriya S, Varoni EM, Sardella A, Kerr AR, Carrassi A, MacDonald LCI, Worthington HV). –|–ó: ¯@‰À–F1, ŠÄ–ó: ‘«—§‰ë—˜ (1‰q¶): Cochrane Database of Systematic Reviews 2016, Issue 7. Art. No.: CD001829. DOI: 10.1002/14651858.CD001829.pub4. 2019/8; https://www.cochrane.org/ja/CD001829/ORAL_kou-qiang-yan-kou-noganwoyu-fang-surutamenokou-qiang-bai-ban-zheng-nidui-suruzhi-liao-de-jie-ru.

540021. [‚»‚Ì‘Œ (Plain language summary–|–ó)] —Œe‚â—{ˆçŽÒ‚ւ̉î“ü‚É‚æ‚Á‚ÄŽq‚Ç‚à‚̃^ƒoƒR‚̉Œ‚Ö‚Ì”˜˜I‚ðŒž‚ç‚¹‚é‚©? (Family and carer smoking control programmes for reducing children's exposure to environmental tobacco smoke. Behbod B, Sharma M, Baxi R, Roseby R, Webster P). –|–ó: ¯@‰À–F1, ŠÄ–ó: ŽŒŽN‰î (1‰q¶): Cochrane Database of Systematic Reviews 2018, Issue 1. Art. No.: CD001746. DOI: 10.1002/14651858.CD001746.pub4. 2018/8; https://www.cochrane.org/ja/CD001746/TOBACCO_liang-qin-yayang-yu-zhe-henojie-ru-niyotutezi-domonotabakonoyan-henopu-lu-wojian-raseruka.

540022. [‚»‚Ì‘Œ (Plain language summary–|–ó)] •ñV‚ð—^‚Š‚邱‚Æ‚Å‹Ö‰Œ‚É’·Šú“IŒø‰Ê‚ª‚ ‚é‚©? (Incentives for smoking cessation. Notley C, Gentry S, Livingstone-Banks J, Bauld L, Perera R, Hartmann-Boyce J). –|–ó: ¯@‰À–F1, ŠÄ–ó: ŽŒŽN‰î (1‰q¶): Cochrane Database of Systematic Reviews 2019, Issue 7. Art. No.: CD004307.DOI: 10.1002/14651858.CD004307.pub6. 2019/9; https://www.cochrane.org/ja/CD004307/TOBACCO_bao-chou-woyu-erukotodejin-yan-nichang-qi-de-xiao-guo-gaaruka.

540023. [‚»‚Ì‘Œ (Plain language summary–|–ó)] ‹Ö‰Œ‚ɐ¬Œ÷‚µ‚œl‚ªÄ‹i‰Œ‚µ‚È‚¢‚æ‚€‚É‚·‚é‚œ‚ß‚É—LŒø‚ȉî“ü‚Í‚ ‚é‚©? (Relapse prevention interventions for smoking cessation. Livingstone-Banks J, Norris E, Hartmann-Boyce J, West R, Jarvis M, Chubb E, Hajek P). –|–ó: ¯@‰À–F1, ŠÄ–ó: ŽŒŽN‰î (1‰q¶): Cochrane Database of Systematic Reviews 2019, Issue 10. Art. No.: CD003999. DOI: 10.1002/14651858.CD003999.pub6. 2019/12; https://www.cochrane.org/ja/CD003999/TOBACCO_jin-yan-nicheng-gong-sitaren-gazai-chi-yan-sinaiyounisurutameniyou-xiao-najie-ru-haaruka.

540024. [‚»‚Ì‘Œ (Plain language summary–|–ó)] “®‹@‚¯–ʐڂ͋։Œ‚É—LŒø‚©? (Motivational interviewing for smoking cessation. Lindson N, Thompson TP, Ferrey A, Lambert JD, Aveyard P). –|–ó: ¯@‰À–F1, ŠÄ–ó: ŽŒŽN‰î (1‰q¶): Cochrane Database of Systematic Reviews 2019, Issue 7. Art. No.: CD006936. DOI: 10.1002/14651858.CD006936.pub4. 2019/12; https://www.cochrane.org/ja/CD006936/dong-ji-dukemian-jie-hajin-yan-niyou-xiao-ka.

540025. [‚»‚Ì‘Œ (Plain language summary–|–ó)] ‹Ö‰Œ‚ɐ¬Œ÷‚µ‚œl‚ªÄ‹i‰Œ‚µ‚È‚¢‚æ‚€‚É‚·‚é‚œ‚ß‚É—LŒø‚ȉî“ü‚Í‚ ‚é‚©? (Relapse prevention interventions for smoking cessation. Livingstone-Banks J, Norris E, Hartmann-Boyce J, West R, Jarvis M, Chubb E, Hajek P). –|–ó: ¯@‰À–F1, ŠÄ–ó: ŽŒŽN‰î (1‰q¶): Cochrane Database of Systematic Reviews 2019, Issue 10. Art. No.: CD003999. DOI: 10.1002/14651858.CD003999.pub6. 2019/12; https://www.cochrane.org/ja/CD003999/jin-yan-nicheng-gong-sitaren-gazai-chi-yan-sinaiyounisurutameniyou-xiao-najie-ru-haaruka.

540026. [‚»‚Ì‘Œ (Plain language summary–|–ó)] ’nˆæ‚Ì–ò‹ÇƒXƒ^ƒbƒt‚É‚æ‚é‹Ö‰ŒŽx‰‡‚Í—LŒø‚©? (Community pharmacy personnel interventions for smoking cessation. Carson-Chahhoud KV, Livingstone-Banks J, Sharrad KJ, Kopsaftis Z, Brinn MP, To-A-Nan R, Bond CM). –|–ó: ¯@‰À–F1, ŠÄ–ó: ŽŒŽN‰î (1‰q¶): Cochrane Database of Systematic Reviews 2019, Issue 10. Art. No.: CD003698.DOI: 10.1002/14651858.CD003698.pub3. 2020/2; https://www.cochrane.org/ja/CD003698/TOBACCO_di-yu-noyao-ju-sutatuhuniyorujin-yan-zhi-yuan-hayou-xiao-ka.

540027. [‚»‚Ì‘Œ (Plain language summary–|–ó)] ‰^“®‚Í‹Ö‰Œ‚ɑ΂µ‚ÄŒø‰Ê‚ª‚ ‚é‚©? (Exercise interventions for smoking cessation. Ussher MH, Faulkner GEJ, Angus K, Hartmann-Boyce J, Taylor AH). –|–ó: ¯@‰À–F1, ŠÄ–ó: ŽŒŽN‰î (1‰q¶): Cochrane Database of Systematic Reviews 2019, Issue 10. Art. No.:CD002295.DOI: 10.1002/14651858.CD002295.pub6. 2020/2; https://www.cochrane.org/ja/CD002295/TOBACCO_yun-dong-hajin-yan-nidui-sitexiao-guo-gaaruka.

540028. [‚»‚Ì‘Œ (Plain language summary–|–ó)] ƒŠƒAƒ‹ƒ^ƒCƒ€‚̃rƒfƒIƒJƒEƒ“ƒZƒŠƒ“ƒO‚Í, “d˜bƒJƒEƒ“ƒZƒŠƒ“ƒO‚É”ä‚ׂċ։ŒŽx‰‡‚ÉŒø‰Ê‚ª‚ ‚é‚©? (Real-time video counselling for smoking cessation. Tzelepis F, Paul CL, Williams CM, Gilligan C, Regan T, Daly J, Hodder RK, Byrnes E, Byaruhanga J, McFadyen T, Wiggers J). –|–ó: ¯@‰À–F1, ŠÄ–ó: ŽŒŽN‰î (1‰q¶): Cochrane Database of Systematic Reviews 2019, Issue 10. Art. No.: CD012659. DOI: 10.1002/14651858.CD012659.pub2. 2020/2; https://www.cochrane.org/ja/CD012659/TOBACCO_riarutaimunobideokaunseringuhadian-hua-kaunseringunibi-betejin-yan-zhi-yuan-nixiao-guo-gaaruka.

540029. [‚»‚Ì‘Œ (Plain language summary–|–ó)] lH‹@ŠBŠ·‹C‚ð•K—v‚Æ‚·‚鐬l‚É‚š‚¢‚Ä, ƒxƒbƒh‚Ì“ªˆÊ’u‚Ì‹“ã‚́A…•œˆÊ‚ð•Û‚‚̂ɔä‚ׂĐlHŒÄ‹zŠíŠÖ˜A”x‰Š‚Ì—\–h‚ÉŒø‰Ê‚ª‚ ‚é‚©? (Semi-recumbent position versus supine position for the prevention of ventilator-associated pneumonia in adults requiring mechanical ventilation. Wang L, Li X, Yang Z, Tang X, Yuan Q, Deng L, Sun X). ¯@‰À–F1, ŠÄ–ó: ’Jè—²‘Ÿ˜Y (1‰q¶): Cochrane Database of Systematic Reviews 2016, Issue 1. Art. No.:CD009946.DOI:10.1002/14651858.CD009946.pub2. 2020/2; https://www.cochrane.org/ja/CD009946/ARI_ren-gong-ji-jie-huan-qi-wobi-yao-tosurucheng-ren-nioitebetudonotou-wei-zhi-noju-shang-hashui-ping.

540030. [‚»‚Ì‘Œ (Plain language summary–|–ó)] Š³ŽÒƒPƒA‚É‚š‚¯‚銎õ‚ðŒž­‚³‚¹‚é‚œ‚߂̈ã—Ï]Ž–ŽÒ‚ÌŽèŽw‰q¶‚ð‰ü‘P‚·‚é•û–@ (Interventions to improve hand hygiene compliance in patient care. Gould DJ, Moralejo D, Drey N, Chudleigh JH, Taljaard M). –|–ó: ¯@‰À–F1, ŠÄ–ó: ˆä‘ºtŽ÷ (1‰q¶): Cochrane Database of Systematic Reviews 2017, Issue 9. Art. No.: CD005186.DOI: 10.1002/14651858.CD005186.pub4. 2020/3; https://www.cochrane.org/ja/CD005186/EPOC_huan-zhe-keaniokerugan-ran-wojian-shao-saserutamenoyi-liao-cong-shi-zhe-noshou-zhi-wei-sheng-wogai.

540031. [‚»‚Ì‘Œ (Plain language summary–|–ó)] “d˜bƒJƒEƒ“ƒZƒŠƒ“ƒO‚Í‹Ö‰ŒŽx‰‡‚ÉŒø‰Ê‚ª‚ ‚é‚©? (Telephone counselling for smoking cessation. Matkin W, Ord??ez-Mena JM, Hartmann-Boyce J). –|–ó: ¯@‰À–F1, ŠÄ–ó: ŽŒŽN‰î (1‰q¶): Cochrane Database of Systematic Reviews 2019, Issue 5. Art. No.: CD002850. DOI: 10.1002/14651858.CD002850.pub4. 2020/3; https://www.cochrane.org/ja/CD002850/TOBACCO_dian-hua-kaunseringuhajin-yan-zhi-yuan-nixiao-guo-gaaruka.

540032. [‚»‚Ì‘Œ (Plain language summary–|–ó)] ‹Ö‰Œ‚Ì–ò•š—Ö@‚ðŽó‚¯‚Ä‚¢‚él‚É, X‚ÉŽx‰‡‚ð’ljÁ‚·‚邱‚Æ‚Å‹Ö‰Œ‚̐¬Œ÷—Š‚ðã‚°‚ç‚ê‚é‚©? (Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation. Hartmann-Boyce J, Hong B, Livingstone-Banks J, Wheat H, Fanshawe TR). –|–ó: ¯@‰À–F1, ŠÄ–ó: ŽŒŽN‰î (1‰q¶): Cochrane Database of Systematic Reviews 2019, Issue 6. Art. No.: CD009670.DOI: 10.1002/14651858.CD009670.pub4. 2020/3; https://www.cochrane.org/ja/CD009670/TOBACCO_jin-yan-noyao-wu-liao-fa-woshou-keteiruren-nigeng-nizhi-yuan-wozhui-jia-surukotodejin-yan-nocheng.

[Šw‰ïEŒ€‹†‰ï“™]

713007. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Renal Anemia in itai-itai disease: a case series study of medical records of the patients. Horiguchi H1, Aoshima K, Oguma E: The 59th Annual Meeting of the Society of Toxicology (2020/3/18), Anaheim, CA, USA (ŽãŠJÃ). (–xŒû•º„1: 1‰q¶)

722004. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ’X…ŠÇ—ŽÀŽ{’nˆæ‚É‚š‚¯‚é•Ä’†ƒJƒhƒ~ƒEƒ€‚ƃq‘f”Z“x‹y‚Ñ‚»‚Ì”_‰Æ‚ւ̉e‹¿. –xŒû•º„ (‰q¶): ‘æ46‰ñ“ú–{“Ő«Šw‰ïŠwp”N‰ï (2019/6/27), “¿“‡, J Toxicol Sci 2019; 44 (Suppl): S74.

722005. [Šw‰ï (‘S‘)] (‹³ˆçu‰‰) Ž¡—ÂƎdŽ–‚Ì—Œ—§Žx‰‡‚ÉŠÖ‚·‚鍑Û“I’ª—¬|Œ’NŒo‰c (healthy company) ‚âŽÐ‰ï“Iˆ•û‚݂̍è•û. •“¡@„1, ‰““¡Œ¹Ž÷ (1‰q¶): ‘æ67‰ñ“ú–{E‹ÆEÐŠQˆãŠw‰ïŠwp‘å‰ï (2019/11/9-10), “Œ‹ž.

722006. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yÀ’·zÐŠQ‚ÆŒ’N‰e‹¿. @‘œ³“¿, •“¡@„1 (1‰q¶): ‘æ67‰ñ“ú–{E‹ÆEÐŠQˆãŠw‰ïŠwp‘å‰ï (2019/11/9-10), “Œ‹ž.

723066. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Œ’NŒo‰c“ŠŽ‘‚Í, Œ’fŒãŽó—Ís“®‚Ɛ³‚É‘ŠŠÖ‚·‚éˆê––Ž¡—ÃŽÒ53–œl‚ÌŒ’fƒŒƒZƒvƒg‰ðÍ. •“¡@„1, •Ð‹Ë—ÈŽq, ‰¡ŽR˜am, ‰““¡Œ¹Ž÷, Œ•œ@_, Îˆä—“Þ, •Ÿ“c@—m, ‘åX—R‹I1, –xŒû•º„1 (1‰q¶): ‘æ92‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï (2019/5/22-25), –ŒŒÃ‰®.

723067. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚—îŽÒ‚ÌŒy“x”F’máŠQEŽåŠÏ“I”F’m‹@”\’ቺ‚͎ЉïŽQ‰Á‚ʼnü‘P‚·‚é‚©. “¡ŒŽ‘Žq, •“¡@„1, ‹ß“¡Ž‘¥ (1‰q¶): ‘æ78‰ñ“ú–{ŒöO‰q¶Šw‰ï‘‰ï (2019/10/24), ‚’m.

723068. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ç—tŒ§ŒŒËŽs, •ïŠ‡‹æ•ÊƒTƒƒ“Ý’uó‹µ‚ÆŒ’NŽw•W‚̘A‘±‰¡’fŒ€‹†: 2”NŠÔ‚̒ǐՒ²ž‚Ì•ªÍ. ŸN’돥Žq, ’·•ô—RˆßŽq, •“¡@„1, ‹ß“¡Ž‘¥ (1‰q¶): ‘æ78‰ñ“ú–{ŒöO‰q¶Šw‰ï‘‰ï (2019/10/24), ‚’m.

723069. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) lH’m”\‚ÆJAGESƒf[ƒ^‚ð—p‚¢‚œ”F’mÇ”­ÇƒŠƒXƒN—\‘ªƒAƒ‹ƒSƒŠƒYƒ€ŠJ”­. ‹ß“¡Ž‘¥, ’ҁ@‘åŽm, ’·•ô—RˆßŽq, •“¡@„1, ‰¡ŽR‰èˆßŽq, ‚£@—É, •l“c@“N, ì£^ŽÑŽq, ŒŽ@@V (1‰q¶): ‘æ78‰ñ“ú–{ŒöO‰q¶Šw‰ï‘‰ï (2019/10/24), ‚’m.

723070. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰)yÀ’·z—\–h. •“¡@„ (‰q¶): ‘æ67‰ñ“ú–{E‹ÆEÐŠQˆãŠw‰ïŠwp‘å‰ï (2019/11/9-10), “Œ‹ž.

723071. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’á”Z“x‰””˜˜I‚É‚æ‚郉ƒbƒgŠC”n’†D, L-ƒZƒŠƒ“‚ւ̉e‹¿. ‘åX—R‹I1, ãŒE—T“ñ, ŠÖª³Œb, ŒìŠx‹v, ¬—Ñ“Žq2, •“¡@„1, ‰¡ŽR˜am, Šp“c³Žj, •Ðª^Ÿ, âV“¡Nº, ‹{–{“N–ç, ‰Á“¡‚­‚ÝŽq, –{ŠÔ@_, –xŒû•º„1 (1‰q¶, 2—\–hˆãŠwŒn): ‘æ90‰ñ“ú–{‰q¶Šw‰ïŠwp‘‰ï (2020/3/28), ŠâŽè (ŽãŠJÃ), “ú–{‰q¶ŠwŽGŽ‘æ 2020; 75: S191.

723072. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒ‰ƒbƒg‚É‚š‚¯‚éƒJƒhƒ~ƒEƒ€‚̐t‘ŸƒGƒŠƒXƒƒ|ƒGƒ`ƒ“ŽY¶×–E‚ɑ΂·‚é—}§ì—p. –xŒû•º„1, ¬ŒF‰xŽq, ˆÀ‰ª—L‹IŽq2, ‘åX—R‹I1, ‰ÍŒŽŽ‰ë, –ìXŒû”ŽŽj3 (1‰q¶, 2¶—, 3–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)F‘æ90‰ñ“ú–{‰q¶Šw‰ïŠwp‘‰ï (2020/3/28), ŠâŽè (ŽãŠJÃ), “ú–{‰q¶ŠwŽGŽ‘æ 2020; 75: S191.

723073. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆã—Ï]Ž–ŽÒ‚̐E‹Æ«ŽèŽŒ]‚̉uŠw|R‹Û«•šŽ¿ƒpƒ‰ƒxƒ“—Þ‚Ì”˜˜I‰e‹¿•]‰¿. •“¡@„1, ‘åX—R‹I1, –xŒû•º„1, ‰¡ŽR˜am, O“c—Ê“ñ, ’†‘º—T”V (1‰q¶): ‘æ90‰ñ“ú–{‰q¶Šw‰ïŠwp‘‰ï (2020/3/26-28), ŠâŽè (ŽãŠJÃ).

723074. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •xŽRŒ§_’ʐ여ˆæƒJƒhƒ~ƒEƒ€‰˜õ’nˆæZ–¯‚É‚š‚¯‚é”A×ŠÇ‹@”\áŠQ‚Æ•nŒŒ‚Æ‚ÌŠÖ˜A. Â“‡ŒbŽq, –xŒû•º„1 (1‰q¶) : ‘æ90‰ñ“ú–{‰q¶Šw‰ïŠwp‘‰ï (2020/3/26-28), ŠâŽè (ŽãŠJÃ), “ú–{‰q¶ŠwŽGŽ‘æ 2020; 75: S191.

732003. [Šw‰ï (’n•û‰ïŒ€‹†‰ï)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŠT—v|ŒöO‰q¶EŽÐ‰ïˆãŠw‚Ì—§ê‚©‚ç. •“¡@„ (‰q¶): ‘æ49‰ñ_“ސ쌧SgˆãŠw‰ï‘‰ïEŠwpW‰ï (2019/9/14), ‰¡•l.

733014. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “dŽq‰»ƒA[ƒJƒCƒuŽ‘—¿‚ð—p‚¢‚œƒCƒ^ƒCƒCƒ^ƒC•a‚Ì•nŒŒ‚ɂ‚¢‚Ă̗Տ°“IŒŸ“¢. –xŒû•º„1, Â“‡ŒbŽq, ¬ŒF‰xŽq (1‰q¶): ƒƒ^ƒ‹ƒoƒCƒIƒTƒCƒGƒ“ƒXŒ€‹†‰ï2019 (2019/10/30), “Œ‹ž, Fund Toxicol Sci 2019; 6: 146.

'18”N“xˆÈ‘O•ª

[Šwp˜_•¶]

H29-110002. [ŒŽ’˜] Factors Affecting the Occurrence of Complications in the Early Stages After Dental Implant Placement: A Retrospective Cohort Study. Okamoto T, Hoshi K1, Fukada K, Kataoka T, Kumasaka A, Kaibuchi N, Fukuzawa S, Ando T: Implant Dent 2018/3. doi: 10.1097/ID.0000000000000753. Online ahead of print. (¯@‰À–F1: 1‰q¶)

'18-110002. [ŒŽ’˜] Association between frailty and bone loss in patients undergoing maintenance hemodialysis. Yoneki K, Kitagawa J, Hoshi K1, Harada M, Watanabe T2, Shimoda T2, Matsuzawa R, Yoshida A, Matsunaga Y, Takeuchi Y3, Kamiya K, Matsunaga A4: J Bone Miner Metab 2019/1; 37 (1): 81-9. (¯@‰À–F1, “n粍F–Ÿ2, ‰º“c—²‘å2, ’|“àN—Y3, Œ‰i“Ä•F4: 1‰q¶, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†, 3t‘Ÿ“à, 4ˆã—Éq¶Šw•”)

'18-110003. [ŒŽ’˜] Exposure to paraben and triclosan and allergic diseases in Tokyo: A pilot cross-sectional study. Mitsui-Iwama M, Yamamoto-Hanada K, Fukutomi Y, Hirota R, Muto G1, Nakamura T, Yoshikawa T, Nakamura H, Mikami M, Morioka I, Ohya Y: Asia Pac Allergy 2019/1; 9 (1): e5. (•“¡@„1: 1‰q¶)

'18-511001. [‰ðà] For making a declaration of countermeasures against the falling birth rate from the Japanese Society for Hygiene: summary of discussion in the working group on academic research strategy against an aging society with low birth rate. Nomura, Karita K, Araki A, Nishioka E, Muto G1, Iwai-Shimada M, Nishikitani, Inoue M, Tsurugano S, Kitano N, Tsuji M, Iijima S, Ueda K, Kamijima M, Yamagata Z, Sakata K, Iki M, Yanagisawa H, Kato M, Inadera H, Kokubo Y, Yokoyama K, Koizumi A, Otsuki T: Environ Health Prev Med 2019/3; 24 (1): 14. (•“¡@„1: 1‰q¶)

'18-540001. [‚»‚Ì‘Œ (Œ€‹†•ñ‘)]yŒú¶˜J“­È˜JÐŽŸ•a—Տ°Œ€‹†Ž–‹Æ”ï•â•‹àuE‹Æ«ƒXƒgƒŒƒXŠÈˆÕ’²ž•[‚ÌŠO‘Œê”ł̍쐬‚ÉŠÖ‚·‚錀‹†vz‰¡ŽR˜am (Œ€‹†‘ã•\ŽÒ), “’óŽ‘”V, ˜a“ckŽ¡, ’Jì•, ‰““¡Œ¹Ž÷, ‰Yì‰Á‘ãŽq, •“¡@„1, ¬“cØ—DŽq, “c’†Œõ‹I (1‰q¶): •œ¬30”N“x ‘Š‡E•ª’SŒ€‹†•ñ‘ 2019/3.

'18-540002. [‚»‚Ì‘Œ (Œ€‹†•ñ‘)]yŒú¶˜J“­‰ÈŠwŒ€‹†”ï•â•‹àu‚ª‚ñŠ³ŽÒ‚̏A˜JŒp‘±‹y‚ѐEê•œ‹A‚ÉŽ‘‚·‚錀‹†vz‰““¡Œ¹Ž÷ (Œ€‹†‘ã•\ŽÒ),âV“¡Œõ], •“c@È, Ž›”ö‘׋v, —с@˜a•F, Œ‘ºŸŽ¡, ãa“N–ç, XŒûŽŸ˜Y, ŒKŒŽŒb‰î, •“¡@„1 (1‰q¶): •œ¬30”N“x ‘Š‡E•ª’SŒ€‹†•ñ‘ 2019/3.

'18-540003. [‚»‚Ì‘Œ (Œ€‹†•ñ‘)]yŒú¶˜J“­È˜JÐŽŸ•a—Տ°Œ€‹†Ž–‹Æ”ï•â•‹àuŠé‹ÆEŽY‹Æ•ÛŒ’ƒXƒ^ƒbƒtEˆã—Ë@ŠÖ‚̘AŒg‚É‚æ‚é—Œ—§Žx‰‡ƒVƒXƒeƒ€‚ÌŠJ”­vzŒ•œ@_ (Œ€‹†ŽÒ‘ã•\), ‰““¡Œ¹Ž÷, XŒûŽŸ˜Y, ¬ŽR‘PŽq, ‚‹Ž”ü•Û, –쑺‘쐶 ,‰ª@Œh”V, •“¡@„1 (1‰q¶): •œ¬30”N“x ‘Š‡E•ª’S•ñ‘ 2019/3.

[’˜@‘]

'18-620001. [Šwp‘ (•ª’SŽ·•M)]yu—LŒø«•]‰¿‚ÉŠî‚­‚ª‚ñŒŸfƒKƒCƒhƒ‰ƒCƒ“v‚Ì‚œ‚߂̃Gƒrƒfƒ“ƒXƒŒƒ|[ƒgì¬•û–@ 2018”N“x”Łzp.1-65. à_“‡‚¿‚³‚Æ1, Ž›àVW•F1, ×–ìŠo‘ã1, •ÐŽR‹M•¶1, ²X–ؐŽŽõ1, ’†ŽR•x—Y1, ¯@‰À–F1,2, óˆä~Žq1, •y‰iˆçŽq1, ’†ì—R”üŽq1, ”ó“c‹LŽq1, Œ“‡‰À”TŽq1 (1•¶Œ£ƒŒƒrƒ…[ˆÏˆõ‰ï, 2‰q¶), •Ò: ‘—§‚ª‚ñŒ€‹†ƒZƒ“ƒ^[ŽÐ‰ï‚ÆŒ’NŒ€‹†ƒZƒ“ƒ^[ŒŸfŒ€‹†•”‚ª‚ñŒŸfƒKƒCƒhƒ‰ƒCƒ“Ž––±‹Ç, ‘—§‚ª‚ñŒ€‹†ƒZƒ“ƒ^[ŽÐ‰ï‚ÆŒ’NŒ€‹†ƒZƒ“ƒ^[, “Œ‹ž, 2019/3”­s.

[Šw‰ïEŒ€‹†‰ï“™]

'18-723002. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¶ŠˆKŠµ•a‚ÌŽó—Ã’†’f‚É”º‚€ƒAƒEƒgƒJƒ€‚̉ðÍ‚Æ‰ðŒˆô‚Ì•]‰¿-ŽY‹Æˆã‚Ǝ厡ˆã‚̘AŒg‹­‰»‰î“ü‚ÌŒø‰Ê. •“¡@„1, •Ð‹Ë—ÈŽq (1‰q¶): ‘æ29‰ñ“ú–{‰uŠw‰ïŠwp‘‰ï (2019/1/30-2/1), “Œ‹ž.

'18-723003. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Šé‹Æ‚É‚š‚¯‚éA˜J‰îŒìŽÒ‚ւ̏A˜JŽx‰‡‚ÌŽÀ‘Ô’²ž. m‰È¹Žq, ‰¡ŽR˜am, Îˆä—“Þ, •“¡@„1 (1‰q¶): ‘æ89‰ñ“ú–{‰q¶Šw‰ïŠwp‘‰ï (2019/2/1-3), –ŒŒÃ‰®.

'18-723004. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŽdŽ–‚ƉîŒì‚𗌗§‚µ‚Ä‚¢‚é]‹Æˆõ‚Ö‚ÌŽY‹Æ•ÛŒ’ê–åE‚ÌŽx‰‡. m‰È¹Žq, ‰¡ŽR˜am, Îˆä—“Þ, •“¡@„1 (1‰q¶): ‘æ89‰ñ“ú–{‰q¶Šw‰ïŠwp‘‰ï (2019/2/1-3), –ŒŒÃ‰®.

'18-723005. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹z“üRŒŽŠŽì‚³‚ê‚œƒ}ƒEƒX‚ւ̃gƒŠƒNƒƒTƒ““Š—^‚É‚æ‚é’°“à×‹Û‚̕ω»‚Æšb‘§”œ‰ž‚̈«‰». O“c—Ê“ñ, ‘å–îKO, ŽR–{‹M˜aŽq, •Ÿ•x—F”n, •“¡@„1, Nagata NIandu Roger, ’†‘º@„, ’†‘º—T‰î (1‰q¶): ‘æ89‰ñ“ú–{‰q¶Šw‰ïŠwp‘‰ï (2019/2/1), –ŒŒÃ‰®.


ŒöO‰q¶Šw

[Šwp˜_•¶]

110042. [ŒŽ’˜] Effects of two types of smartphone-based stress management programmes on depressive and anxiety symptoms among hospital nurses in Vietnam: a protocol for three-arm randomised controlled trial. Imamura K, Tran TTT, Nguyen HT Kuribayashi K, Sakuraya A Nguyen AQ, Bui TM, Nguyen QT, Nguyen KT Nguyen GTH, Tran XTN, Truong TQ Zhang MWB, Minas H, Sekiya Y, ;Sasaki N, Tsutsumi A1, Kawakami N: BMJ Open 2019/4; 9 (4): e025138. (’ç@–Ÿƒ1: 1ŒöO‰q¶)

110043. [ŒŽ’˜] Caregiver Burden and Work Productivity Among Japanese Working Family Caregivers of People with Dementia. Fujihara S1, Inoue A1, Kubota K, Yong KFR, Kondo K: Int J Behav Med 2019/4; 26 (2): 125-35. (ˆäã²b1: 1ŒöO‰q¶)

110044. [ŒŽ’˜] Social Support During Emergency Work and Subsequent Serious Psychological Distress: A Cross-Sectional Study Among Emergency Workers who Responded to the Fukushima Daiichi Nuclear Power Plant Accident. Mafune K, Hiro H, Inoue A1, Hino A, Shigemura J, Yamada M, Okubo T: J Occup Environ Med 2019/6; 61 (6): e240-6. (ˆäã²b1: 1ŒöO‰q¶)

110045. [ŒŽ’˜] Association Between Reported Long Working Hours and History of Stroke in the CONSTANCES Cohort. Fadel M, Sembajwe G, Gagliardi D, Pico F, Li J, Ozguler A, Siegrist J, Evanoff BA, Baer M, Tsutsumi A1, Iavicoli S, Leclerc A, Roquelaure Y, Descatha A: Stroke 2019/7; 50 (7): 1879-82. (’ç@–Ÿƒ1: 1ŒöO‰q¶)

110046. [ŒŽ’˜] The effect of changes in overtime work hours on depressive symptoms among Japanese white-collar workers: A 2-year follow-up study. Hino A, Inoue A1, Mafune K, Hiro H: J Occup Health 2019/7; 61 (4): 320-7. (ˆäã²b1: 1ŒöO‰q¶)

110047. [ŒŽ’˜] Long working hours and depressive symptoms: moderating effects of gender, socioeconomic status, and job resources. Tsuno K1, Kawachi I1, Inoue A1,2, Nakai S1, Tanigaki T1, Nagatomi H1, Kawakami N1 (1JSTRESS Group): Int Arch Occup Environ Health 2019/7; 92 (5): 661-72. (ˆäã²b1,2: 2ŒöO‰q¶)

110048. [ŒŽ’˜] Association between psychosocial factors at work and health outcomes after retirement: a protocol for a systematic review and meta-analysis. Imamura K, Tsutsumi A1, Asai Y, Arima H, Ando E, Inoue A1, Inoue R, Iwanaga M, Eguchi H1, Otsuka Y, Kobayashi Y, Sakuraya A, Sasaki N, Tsuno K, Hino A, Watanabe K, Shimazu A, Kawakami N: BMJ Open 2019/8; 9 (8): e030773. (’ç@–Ÿƒ1, ˆäã²b1, ]Œû@®1: 1ŒöO‰q¶)

110049. [ŒŽ’˜] Links between organizational preparedness and employee action to seek support among a Japanese working population with chronic diseases. Eguchi H1, Tsutsumi A1, Inoue A1, Kachi Y1: J Occup Health 2019/9; 61 (5): 407-14. (]Œû@®1, ’ç@–Ÿƒ1, ˆäã²b1, ‰Â’m—IŽq1: 1ŒöO‰q¶)

110050. [ŒŽ’˜] Organizational justice and illness reporting among Japanese employees with chronic diseases. Eguchi H1, Tsutsumi A1, Inoue A1, Kachi Y1: PLoS One 2019/10; 14 (10): e0223595. (]Œû@®1, ’ç@–Ÿƒ1, ˆäã²b1, ‰Â’m—IŽq1: 1ŒöO‰q¶)

110051. [ŒŽ’˜] Job satisfaction and intention to remain on the job among Japanese nursing assistants. Kudo Y, Toyoda T, Terao R, Suzuki S, Tsutsumi A1: J Rural Med 2019/11; 14 (2): 181-90. (’ç@–Ÿƒ1: 1ŒöO‰q¶)

110052. [ŒŽ’˜] Validation of the Japanese Version of the Multidimensional Measure of Family Supportive Supervisor Behaviors (FSSB-J). Eguchi H1, Kachi Y1, Koga HK, Sakka M, Tokita M, Shimazu A: Front Psychol 2019/11; 10: 2628. (]Œû@®1, ‰Â’m—IŽq1: 1ŒöO‰q¶)

110053. [ŒŽ’˜] Validation of the Job Content Questionnaire among hospital nurses in Vietnam. Sasaki N, Imamura K, Thuy TTT, Watanabe K, Huong NT, Kuribayashi K, Sakuraya A, Thu BM, Quynh NT, Kien NT, Nga NT, Giang NTH, Tien TQ, Minas H, Zhang M, Tsutsumi A1, Kawakami N: J Occup Health 2020/1; 62 (1): e12086. (’ç@–Ÿƒ1: 1ŒöO‰q¶)

110054. [ŒŽ’˜] Occupational stress and the risk of turnover: a large prospective cohort study of employees in Japan. Kachi Y1, Inoue A1, Eguchi H1, Kawakami N, Shimazu A, Tsutsumi A1: BMC Public Health 2020/4; 20 (1): 174. (‰Â’m—IŽq1, ˆäã²b1, ]Œû@®1, ’ç@–Ÿƒ1: 1ŒöO‰q¶)

110055. [ŒŽ’˜] Measuring eudemonic well-being at work: a validation study for the 24-item the University of Tokyo Occupational Mental Health (TOMH) well-being scale among Japanese workers. Watanabe K, Imamura K, Inoue A1, Otsuka Y, Shimazu A, Eguchi H1, Adachi H, Sakuraya A, Kobayashi Y, Arima H, Kawakami N: Ind Health 2020/4; 58 (2): 107-31. doi: 10.2486/indhealth.2019-0074. Epub 2019 Aug 1. (ˆäã²b1, ]Œû@®1: 1ŒöO‰q¶)

120001. [ŒŽ’˜] “­‚«‚œ‚¢‚Ì‚É“­‚¯‚È‚¢l‚Í‚Ç‚Ì‚æ‚€‚È“­‚«•û‚ð–]‚ñ‚Å‚¢‚é‚Ì‚©|ˆçŽ™E‰îŒì‚Æ‚ÌŠÖ˜A‚©‚ç”ñ³‹KŒÙ—p‚̉”\«‚ðl‚Š‚é|. ‚‹Ž”ü•Û, ‰Â’m—IŽq1 (1ŒöO‰q¶): ŽY‹ÆE‘gDS—ŠwŒ€‹† 2019; 33 (1): 51-64.

120002. [ŒŽ’˜] ‰^“®Œp‘±ŽÒ‚ÉŒ©‚ç‚ê‚éŒp‘±——R‚Ì“ÁF|˜J“­ŽÒ‚É‚š‚¯‚é‰^“®Œp‘±‚ւ̍s“®•Ï—eƒAƒvƒ[ƒ`‚ÉŠÖ‚·‚錀‹†|. ]Œû‘א³, ˆäã²b1, ‘Ÿ“c‰ë‹K, ‘å˜a@_ (1ŒöO‰q¶): “ú–{Œ’N‹³ˆçŠw‰ïŽ 2019/8; 27 (3): 256-70.

120003. [ŒŽ’˜] Ž©ŽE‘΍ô‚ÉŠÖ‚µ‚Ĉã—Ã, •ÛŒ’•ŸŽƒ, S—“™‚̐ê–å‰Æ‚ð–ÚŽw‚·Šw¶‚ª—L‚·‚é‚ׂ«’mŽ¯‚Æ‹ZpŒüã‚Ì‚œ‚ß‚Ì‹³ÞŠJ”­. ˆäã²b1, ’ç@–Ÿƒ1, Žç‰®—˜‰À2, ç—tG‹B2, “‡’ÖŸl, ¬“cŒŽK, Žs‘q‰Á“ÞŽq3 (1ŒöO‰q¶, 2ˆãŠw‹³ˆç, 3ˆã—Éq¶Šw•”): Ž©ŽE‘‡­ôŒ€‹† 2019/11; 2 (1): 5-11.

220002. [€ŒŽ’˜] ¬E’†Šw¶‚Ì•ÛŒìŽÒ‚ð‘ΏۂƂµ‚œuŽq‚Ç‚àH“°v‚ÉŠÖ‚·‚éƒCƒ“ƒ^[ƒlƒbƒg’²ž. •’J‰À‘ã, V™’m¹, ç—t@„, ŽRŒû–ƒˆß, ‰Â’m—IŽq1, ‘ë–{G”ü, ‹ß“¡®ŒÈ (1ŒöO‰q¶): “ú–{ŒöO‰q¶ŽGŽ 2019/9; 66 (9): 593-602.

220003. [€ŒŽ’˜] ÐŠQŽž‚̃ƒ“ƒ^ƒ‹ƒwƒ‹ƒX‚ÆŽ©ŽE—\–h. ‘å—ސ^Žk, “c’†‰pŽO˜Y, ‘O“c³Ž¡, ”ª–؏~Žq, ‹ß“¡Ž‘¥, –쑺‹±Žq, ˆÉ“¡Ol, ‘å•œ“N–ç, ˆäã²b1, ’ç@–Ÿƒ1 (1ŒöO‰q¶): “ú–{ŒöO‰q¶ŽGŽ 2020/2; 67 (2): 101-10.

510002. [‘à] Proposed guidelines for primary prevention for mental health at work: an update. Tsutsumi A1, Shimazu A, Yoshikawa T: Environ Occup Health Practice 2019/10; 1 (1): 2-12. (’ç@–Ÿƒ1: 1ŒöO‰q¶)

520002. [‘à] ƒXƒgƒŒƒXƒ`ƒFƒbƒN§“x‚ÌŽÀŽ{ó‹µ‚Æ‚»‚ÌŒø‰Ê; ƒVƒXƒeƒ}ƒeƒBƒbƒNƒŒƒrƒ…[. ’ç@–Ÿƒ1, ²X–Ø“ß’Ã, ‹î£@—D, “n•Ó˜aL, ˆäã²b1, ¡‘ºK‘Ÿ˜Y, ìãŒ›l (1ŒöO‰q¶): ŽY‹ÆˆãŠwƒŒƒrƒ…[ 2019/9; 32 (2): 65-81.

522009. [uÀ]y“ÁW: Ž¡—ÂƎdŽ–‚Ì—Œ—§Žx‰‡Œ€‹†‚ÌŒ»Ýz1. Ž¡—ÂƏA˜J‚Ì—Œ—§Žx‰‡‚Ì‚œ‚ß‚ÌŽ–‹Æê“àŠO‚ÌŽY‹Æ•ÛŒ’ƒXƒ^ƒbƒt‚ƈã—Ë@ŠÖ‚̘AŒgƒ‚ƒfƒ‹‚Æ‚»‚ÌŠˆ“®•]‰¿Žw•W‚ÌŠJ”­‚ÉŠÖ‚·‚錀‹†. ’ç@–Ÿƒ (ŒöO‰q¶): ŽY‹ÆˆãŠwƒWƒƒ[ƒiƒ‹ 2019/7; 42 (4): 5-9.

522010. [uÀ]y“ÁW: ŽY‹ÆƒXƒgƒŒƒX2040zlH’m”\‚ƐEê‚̃ƒ“ƒ^ƒ‹ƒwƒ‹ƒX‘΍ô ˆäã²b (ŒöO‰q¶): ŽY‹ÆƒXƒgƒŒƒXŒ€‹† 2019/7; 26 (3): 269-70.

522011. [uÀ]y¬“ÁW: ŒÃ“T‚ð’m‚ézŽdŽ–‚Ì—v‹“x|ƒRƒ“ƒgƒ[ƒ‹ƒ‚ƒfƒ‹. ˆäã²b (ŒöO‰q¶): ŽY‹ÆƒXƒgƒŒƒXŒ€‹† 2019/7; 26 (3): 335-9.

522012. [uÀ]y“ÁW:uŒ’NŠi·v‚ðl‚Š‚ézŒÙ—p‚ÆŒ’NŠi·‚Ì—vˆö`“­‚­l‚ÌŒ’N‚ðŽç‚é‚œ‚߂Ɂ`. ’ç@–Ÿƒ (ŒöO‰q¶): ˜A‡‘Œ€ƒŒƒ|[ƒg 2020/1; 353: 6-9.

522013. [uÀ]y˜AÚ: Œ’N12ƒ•ŒŽNo.396z‚ ‚È‚œ‚̐Eê‘gD‚́uŒö³v‚Å‚·‚©?`‘gD“IŒö³‚ƘJ“­ŽÒ‚ÌŒ’N`. ˆäã²b (ŒöO‰q¶): ˜J–±ˆÀ‘S‰q¶‚©‚È‚ª‚í 2020/1; 65 (1): 14-16.

530004. [‚»‚Ì‘Œ (Editorial)] Preventing overwork-related deaths and disorders-needs of continuous and multi-faceted efforts. Tsutsumi A1: J Occup Health 2019/7; 61 (4): 265-6. (’ç@–Ÿƒ1: 1ŒöO‰q¶)


[’˜@‘]

610003. [Šwp‘ (•ª’SŽ·•M)]yHandbook of Socioeconomic Determinants of Occupational Health (Handbook Series in Occupational Health Science)zSocial Inequalities in Health Among Older Adults After Retirement, p.1-14. Tsutsumi A1, Editor: Theorell T, Springer, Switzerland, First Online: 2020/2. (’ç@–Ÿƒ1: 1ŒöO‰q¶)

610004. [Šwp‘ (•ª’SŽ·•M)]yHandbook of Disability, Work and Health (Handbook Series in Occupational Health Sciences (1))zReturn to Work After Stroke, p.1-16. Tsutsumi A1, Editor: BŸltmann U, Siegrist J, Springer, Switzerland, First Online: 2020/2. (’ç@–Ÿƒ1: 1ŒöO‰q¶)

620004. [Šwp‘ (•ª’SŽ·•M)]yŽÐ‰ïEŠÂ‹«‚ÆŒ’N ŒöO‰q¶Šw 2020”N”ŁzCHAPTER 9@ž_ŽŸŠ³@ž_•ÛŒ’‘΍ô, p.95-100. ’ç@–Ÿƒ (ŒöO‰q¶), •Ò’˜: –öì@—m, ”ö“‡r”V, ˆãŽ•–òo”ÅŠ”Ž®‰ïŽÐ, “Œ‹ž, 2020/1”­s.

620005. [Šwp‘ (•ª’SŽ·•M)]yŽÐ‰ïEŠÂ‹«‚ÆŒ’N ŒöO‰q¶Šw 2020”N”ŁzCHAPTER 10@Ž©ŽEC•s—¶‚ÌŽ–ŒÌC‹s‘ҁC–\—Í, p.101-4. ’ç@–Ÿƒ (ŒöO‰q¶), •Ò’˜: –öì@—m, ”ö“‡r”V, ˆãŽ•–òo”ÅŠ”Ž®‰ïŽÐ, “Œ‹ž, 2020/1”­s.

620006. [Šwp‘ (•ª’SŽ·•M)]yŽg‚Š‚é! Œ’N‹³ˆçE˜J“­‰q¶‹³ˆç65‘Iz‘æ2•” ‹³ˆçƒe[ƒ}•Ò@sŒ’N‹³ˆçt‚̏ê–Ê 15 ƒXƒgƒŒƒXƒ}ƒlƒWƒƒ“ƒg, p.104-9. ’ç@–Ÿƒ (ŒöO‰q¶), •Ò: X@WŽ¢, ˆê”ÊŽÐ’c–@l“ú–{˜J–±Œ€‹†‰ï, “Œ‹ž, 2020/2”­s.

620007. [Šwp‘ (•ª’SŽ·•M)]yŠî‘b‚©‚çŠw‚ÔŒ’NŠÇ—ŠT˜_z13 Eê‚ÌŒ’NŠÇ—, p.197-210. ’ç@–Ÿƒ1 (1ŒöO‰q¶), •Ò: ”ö“‡r”V, ’ç@–Ÿƒ1, “ì]“°, “Œ‹ž, 2020/3”­s.

[Šw‰ïEŒ€‹†‰ï“™]

712001. [Šw‰ï (‘Û)] (µ‘ҍu‰‰“™) Mental health service in the workplace: Japanese experience. Tsutsumi A1: 5th International Conference of Occupational Health Services (2019/9/2), Taipei, Taiwan. (’ç@–Ÿƒ1: 1ŒöO‰q¶)

712002. [Šw‰ï (‘Û)] (µ‘ҍu‰‰“™) Work-life Balance in the Current Japanese Context. Tsutsumi A1: 7th International congress of person centered medicine (2019/11/2), Tokyo, Japan. (’ç@–Ÿƒ1: 1ŒöO‰q¶)

713008. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Association between PTSD symptoms and stress related factors among nuclear emergency workers over a long period. Hiro H, Hino A, Mafune K, Inoue A1, Shigemura J, Yamada M, Ookubo T: 19th World Psychiatric Association World Congress of Psychiatry (2019/8/21), Lisbon, Portugal. (œA@®“T, “ú–숟–íŽq, ^‘D_‰î, ˆäã²b1, d‘º@~, ŽR“c”ü’qŽq, ‘å‹v•Û—˜W: 1ŒöO‰q¶)

721001. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ŽY‹Æž_•ÛŒ’‚̍‘Û’ª—¬‚©‚ç‚Ý‚Š‚éGood Practice Approach. ’ç@–Ÿƒ (ŒöO‰q¶): ‘æ26‰ñ“ú–{ŽY‹Æž_•ÛŒ’Šw‰ï (2019/8/31), “Œ‹ž.

721002. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) Decent work for all`Ž‘±‰Â”\‚È’nˆæˆã—Â̂œ‚߂Ɂ`. ’ç@–Ÿƒ (ŒöO‰q¶): ‘æ13‰ñJADECOMŠwp‘å‰ï in Yokosuka (2019/9/14), ‰¡{‰ê.

722007. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) Eê‚É‚š‚¯‚é‘gD—vˆö‚ƘJ“­ŽÒ‚ÌŒ’N‚Æ‚ÌŠÖ˜A|Cü—vˆö‚ðŠÜ‚ß‚œ•ïŠ‡“IŒŸ“¢|. ˆäã²b (ŒöO‰q¶): ‘æ30‰ñ“ú–{ˆãŠw‰ï‘‰ï 2019’†•” (2019/4/28), –ŒŒÃ‰®.

722008. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) Eê‚ÅRCT‚ðŽÀŽ{‚µ‚ÄŠw‚ñ‚ŸŽ–. ’ç@–Ÿƒ (ŒöO‰q¶): ‘æ92‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï (2019/5/23), –ŒŒÃ‰®.

722009. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) •ÒWˆÏˆõ‰ï‚̐V‚œ‚È’§í‚ÆŒ€‹†Šˆ«‰»‚ÉŒü‚¯‚Ä. ’ç@–Ÿƒ (ŒöO‰q¶): ‘æ92‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï (2019/5/24), –ŒŒÃ‰®.

722010. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) –k—¢‘åŠwˆãŠw•”‚É‚š‚¯‚és“®‰ÈŠwEs“®ˆãŠw‹³ˆç‚ÌŽÀ‘H. ˆäã²b1, ’ç@–Ÿƒ1, Žç‰®—˜‰À2, ç—tG‹B2, ¬“cŒŽK, “‡’ÖŸl (1ŒöO‰q¶, 2ˆãŠw‹³ˆç): ‘æ26‰ñ“ú–{s“®ˆãŠw‰ïŠwp‘‰ï (2019/12/6), “Œ‹ž.

723075. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’j«˜J“­ŽÒ‚É‚š‚¯‚éŽdŽ–‚̃XƒgƒŒƒX—vˆö‚ƃƒ^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€‚Æ‚ÌŠÖ˜A: 1”NŠÔ‚Ì‘OŒü‚«ƒRƒz[ƒgŒ€‹†. ˆäã²b1, ]Œû@®1, ‘å’ˑא³, ŸNˆäŒ€Ži, ’ç@–Ÿƒ1, ’†“cŒõ‹I (1ŒöO‰q¶): ‘æ55‰ñ“ú–{zŠÂŠí•a—\–hŠw‰ïŠwpW‰ï (2019/5/12), ‹v—¯•Ä.

723076. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒxƒgƒiƒ€Œê”ÅJCQ (Job Content Questionnaire) ‚ÌŠJ”­‚È‚ç‚тɐM—Š«E‘Ó–«‚ÌŒŸ“¢. ²X–Ø“ß’Ã, ¡‘ºK‘Ÿ˜Y, Tran Thi Thu Thuy, Nguyen Thanh Huong, ŒI—шêl, ŸN’J‚ ‚·‚©, Bui Minh Thu, Nguyen Thuy Quynh, Nguyen Trung Kien, Nguyen Thi Huong Giang, Tran Thi Ngoc Xuyen, Truong Quang Tien, Harry Minas, ’ç@–Ÿƒ1, ìãŒ›l (1ŒöO‰q¶): ‘æ92‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï (2019/5/23), –ŒŒÃ‰®.

723077. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Ž©Ž¡‘̐Eê‚É‚š‚¯‚éOSHMS’è’…‚ƈÀ‘S‰q¶Žw•W‚⊈“®‚ւ̉e‹¿•]‰¿ ‘æ25•ñ. “n•Ó—TW, b“c–ÎŽ÷, ²X–Ø‹B, Œ—tŽjŽq, ˆÉ“¡ºD, ŒF’JM“ñ, ŒŽ@–M•v, ’ç@–Ÿƒ1, ŠÛŽR³Ž¡, ŽRŒûGŽ÷ (1ŒöO‰q¶): ‘æ92‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï (2019/5/23), –ŒŒÃ‰®.

723078. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Eê‚Ì‘žd“x (ƒVƒrƒŠƒeƒB) ŽÚ“x“ú–{Œê”ł̐M—Š«E‘Ó–«ŒŸØ‚Æ‘®«•Ê“Ÿ“_”äŠr. ’Ö썁“Þ”ü, “‡’ÖŸl, “‡“c‹±Žq, ˆÀ“¡ŠG”üŽq, ˆäã²b1, ŒI‰ªZŽq, ìãŒ›l (1ŒöO‰q¶): ‘æ92‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï (2019/5/23), –ŒŒÃ‰®.

723079. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Šé‹ÆŠO˜J“­‰q¶‹@ŠÖ‚É‚š‚¯‚鎡—ÂƐE‹Æ¶Šˆ‚Ì—Œ—§Žx‰‡‚̐„i‚Ì‚œ‚߂̃c[ƒ‹‚ÌŠJ”­. éꌎ—RŽq, XŒûŽŸ˜Y, ]Œû@®1, ˆäã²b1, ’ç@–Ÿƒ1 (1ŒöO‰q¶): ‘æ92‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï (2019/5/23), –ŒŒÃ‰®.

723080. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŽžŠÔŠO˜J“­ŽžŠÔ‚Æ7‚‚̌’NKŠµ‚Ì‘g‚ݍ‡‚킹‚ªŽåŠÏ“IŒ’NŠŽ‚É—^‚Š‚é‰e‹¿. “ú–숟–íŽq, ˆäã²b1, ‘å{‰ê~, ™–ì”ü—R‹I, ˜e“c—SŽÀ, –ìŒû—T•ã, ^‘D_‰î, œA@®“T (1ŒöO‰q¶): ‘æ92‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï (2019/5/23), –ŒŒÃ‰®.

723081. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚ƒXƒgƒŒƒX”»’è‚Æ—£E‚Æ‚ÌŠÖ˜A: lŽ–ƒf[ƒ^‚ð—p‚¢‚œ4”NŠÔ‚̃Rƒz[ƒgŒ€‹†. ‰Â’m—IŽq1, ’ç@–Ÿƒ1, ]Œû@®1, ˆäã²b1 (1ŒöO‰q¶): ‘æ92‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï (2019/5/24), –ŒŒÃ‰®.

723082. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Šé‹Æ‚É‚š‚¯‚é‘gD“IŒö³‚ƘJ“­ŽÒ‚Ì”F’m“IŽž”ss“®‚Æ‚ÌŠÖ˜A. ˆäã²b1, ]Œû@®1, ‰Â’m—IŽq1, ’ç@–Ÿƒ1 (1ŒöO‰q¶): ‘æ92‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï (2019/5/24), –ŒŒÃ‰®.

723083. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) \‘¢‰»–ʐږ@‚ð—p‚¢‚œŒŽ”­‹Ù‹}ì‹Æ]Ž–ŽÒ‚̐ž_Œ’N‚Ì•]‰¿‚ÉŠÖ‚·‚錀‹†. œA@®“T, ^‘D_‰î, “ú–숟–íŽq, ˆäã²b1, ‰º“c—zŽ÷, ‘å‹v•Û—˜W (1ŒöO‰q¶): ‘æ92‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï (2019/5/24), –ŒŒÃ‰®.

723084. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) E‹Æ«ƒXƒgƒŒƒX—vˆö‚ªŽdŽ–‚̐¶ŽY«‚É—^‚Š‚é‰e‹¿: ‘OŒü‚«ƒRƒz[ƒgŒ€‹†. ”Ñ“c^Žq, ìãŒ›l, ¡‘ºK‘Ÿ˜Y, “n•Ó˜aL, ˆäã²b1, “‡’ÖŸl, ‹gì@“O, œA@®“T, óˆä—T”ü, ¬“cØ—DŽq, ‹gì‰xŽq, ’ç@–Ÿƒ1 (1ŒöO‰q¶): ‘æ92‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï (2019/5/25), –ŒŒÃ‰®.

723085. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŽdŽ––ž‘«“x‚Æ’·ŠúŽŸ•a‹x‹Æ‚Æ‚ÌŠÖ˜A: 1”NŠÔ‚Ì‘OŒü‚«ƒRƒz[ƒgŒ€‹†. ˆäã²b1, ’ç@–Ÿƒ1, ‰Â’m—IŽq1, ]Œû@®1, “‡’ÖŸl, ìãŒ›l (1ŒöO‰q¶): ‘æ26‰ñ“ú–{ŽY‹Æž_•ÛŒ’Šw‰ï (2019/8/31), “Œ‹ž.

723086. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŽžŠÔŠO˜J“­ŽžŠÔ‚Ɛž_“IŒ’N‚Æ‚ÌŠÖ˜A: ’PˆêŠé‹Æ‚É‚š‚¯‚é1”NŠÔ‚̏c’fŒ€‹†. ˆäã—äŽq1, ’ç@–Ÿƒ2, ˆäã²b2, ]Œû@®2, ‰Â’m—IŽq2, rˆä—L”ü3 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ŒöO‰q¶, 3ˆã—Â̎¿EˆÀ‘S„iŽº): ‘æ29‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï‘S‘‹Š‹c‰ï (2019/9/13), å‘ä.

723087. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –k—¢‘åŠw•a‰@‚É‚š‚¯‚éA˜JŽx‰‡’S“–ˆãŽt‚ÌŠˆ“®‚Ì•ñ. ]Œû@®1, ’ç@–Ÿƒ1, ˆäã²b1, ‘â—R”üŽq, ‹ß“¡‚Ü‚ä‚Ý2, Ž™‹Ê”ü—R‹I2, “c糁@‘3,4 (1ŒöO‰q¶, 2ŠÅŒì•”, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã, 4Á‰»Ší“à): ‘æ29‰ñ“ú–{ŽY‹Æ‰q¶Šw‰ï‘S‘‹Š‹c‰ï (2019/9/13), å‘ä.

723088. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˜J“­ŽÒ‚̐g‘ÌŠˆ“®—ÊŒüãŽw“±‚̉î“üŒø‰Ê|Œ‹‰ÊdŽ‹Œ^Žx‰‡‚ƉߒödŽ‹Œ^Žx‰‡‚̈Ⴂ|. ]Œû‘א³, ˆäã²b1, •â’mŠG, ŽR“cW•œ, ŒŽ‰ê”ü‹I, ’†’J~Žq (1ŒöO‰q¶): ‘æ37‰ñŽY‹Æˆã‰È‘åŠwŠw‰ï‘‰ï (2019/10/12), –k‹ãB.

723089. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŽžŠÔŠO˜J“­ŽžŠÔ‚Æ7‚‚̌’NKŠµ‚Ì‘g‚ݍ‡‚킹‚ªž_“IŒ’N‚É—^‚Š‚é‰e‹¿. “ú–숟–íŽq, ˆäã²b1, ^‘D_‰î, œA@®“T (1ŒöO‰q¶): ‘æ37‰ñŽY‹Æˆã‰È‘åŠwŠw‰ï‘‰ï (2019/10/12), –k‹ãB.

723090. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •Ä‘‚É‚š‚¯‚é‰Æ’ë‚̎ЉïŒoÏó‹µ‚ÆŽq‚Ç‚à‚̉^“®”\—Í‚Æ‚ÌŠÖ˜A. ”N‹g@—€, ‰Â’m—IŽq1, ˆäã²b1, ]Œû@®1, ŽR–k–žÆ, ’ç@–Ÿƒ1 (1ŒöO‰q¶): ‘æ26‰ñ“ú–{s“®ˆãŠw‰ïŠwp‘‰ï (2019/12/7), “Œ‹ž.

723091. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˜J“­ŽÒ‚̐«Ši“Á«‚ðl—¶‚µ‚œg‘ÌŠˆ“®—ÊŒüãŽw“±‚̉î“üŒ€‹†: ƒ‰ƒ“ƒ_ƒ€‰»”äŠrŽŽŒ±. ]Œû‘א³, ˆäã²b1, ’†’J~Žq, •â’mŠG, ŽR“cW•œ, ŒŽ‰ê”ü‹I (1ŒöO‰q¶): ‘æ26‰ñ“ú–{s“®ˆãŠw‰ïŠwp‘‰ï (2019/12/7), “Œ‹ž.

723092. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •êe‚Ì”ñ“TŒ^ŽžŠÔ‘јJ“­‚ÆŽq‚Ç‚à‚̔얞: 16-17Î‚ÌŽvtŠú‚ÌŽq‚Ç‚à‚É‚š‚¯‚錟“¢. ‰Â’m—IŽq1, ˆ¢•”@Ê, ]Œû@®1, ˆäã²b1, ‘ºŽRLŽq, ’ç@–Ÿƒ1 (1ŒöO‰q¶): ‘æ30‰ñ“ú–{‰uŠw‰ïŠwp‘‰ï (2020/2/20-22), ‹ž“s.

732004. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) “ú–{ŽY‹Æ‰q¶Šw‰ï•ÒWˆÏˆõ‰ï‚̍‘Û“®Œü‚ւ̑Ήž JAMJEˆãŠwŽGŽ•ÒWƒKƒCƒhƒ‰ƒCƒ“‚ւ̑ΉžŽ–—á. ’ç@–Ÿƒ (ŒöO‰q¶): 2019”N“x‘æ2‰ñ J-STAGEƒZƒ~ƒi[ (2019/10/21), “Œ‹ž.

732005. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) E‹Æ«ƒXƒgƒŒƒXŒ€‹†‚Ì‚±‚ê‚Ü‚Å‚Æ‚±‚ê‚©‚ç. ˆäã²b (ŒöO‰q¶): ‘æ60‰ñŽY‹Æž_‰q¶Œ€‹†‰ï (2020/2/29), –k‹ãB (ŽãŠJÃ).

733015. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) Šé‹ÆŠO˜J“­‰q¶‹@ŠÖ‚É‚š‚¯‚鎡—ÂƐE‹Æ¶Šˆ‚Ì—Œ—§Žx‰‡‚̐„i‚Ì‚œ‚߂̃c[ƒ‹‚ÌŠJ”­. XŒûŽŸ˜Y, éꌎ—RŽq, ]Œû@®1, ˆäã²b1, ’ç@–Ÿƒ1 (1ŒöO‰q¶): “ú–{ŽY‹Æ‰q¶Šw‰ï ’†¬Šé‹ÆˆÀ‘S‰q¶Œ€‹†‰ï ‘æ 53‰ñ‘S‘W‰ï (2019/11/23), •lŒ.


–@ˆãŠw

[Šwp˜_•¶]

110056. [ŒŽ’˜] Left-right difference in carboxyhemoglobin saturation in heart blood of cadavers and its significance. Irie W1, Murakami C1, Sasaki C1, Nakamaru N2, Sakamoto M2, Nagato J2, Satoh F1: Kitasato Med J 2019/9; 49 (2): 99-105. (“ü]@Â1, ‘ºãçŽq1, ²X–ؐçŽõŽq1, ’†ŠÛ®”ü2, ã–{“Žq2, ’·–參•œ2, ²“¡•¶Žq1: 1–@ˆã, 2Œ`‘ÔŒn)

110057. [ŒŽ’˜] Sudden Infant Death After Vaccination: Survey of Forensic Autopsy Files. Osawa M, Nagao R, Kakimoto Y, Kakiuchi Y, Satoh F1: Am J Forensic Med Pathol 2019/9; 40 (3): 232-7. (²“¡•¶Žq1: 1–@ˆã)

110058. [ŒŽ’˜] Emergence and Characterization of Acute Coronary Syndrome in Adults After Confirmed or Missed History of Kawasaki Disease in Japan: A Japanese Nationwide Survey. Mitani Y, Tsuda E, Kato H, Higaki T, Fujiwara M, Ogawa S, Satoh F1, Nakamura Y, Takahashi K, Ayusawa M, Kobayashi T, Ichida F, Matsushima M, Kamada M, Suda K, Ohashi H, Sawada H, Komatsu T, Waki K, Shinoda M, Tsunoda R, Yokoi H, Hamaoka K: Front Pediatr 2019/7; 7: 275. (²“¡•¶Žq1: 1–@ˆã)

[Šw‰ïEŒ€‹†‰ï“™]

721003. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) “ü—’†‚Ì‹}Ž€‚ƐS‘Ÿ‚̉Á—‚̕ω»‚Æ‚ÌŠÖ˜A‚ɂ‚¢‚Ä. ²“¡•¶Žq (–@ˆã): ‘æ84‰ñ“ú–{‰·ò‹CŒó•š—ˆãŠw‰ï‘‰ïEŠwpW‰ï (2019/5/18), ‰ªŽR.

722011. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) —«ˆãŽt‚ª–@ˆãŠw—̈æ‚ÅŠˆ–ô‚·‚é‚œ‚ß‚É. ²“¡•¶Žq (–@ˆã): ‘æ103ŽŸ“ú–{–@ˆãŠw‰ïŠwp‘S‘W‰ï (2019/6/14), å‘ä.

723093. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Œð’ÊŽ–ŒÌ‘¹‚É‚æ‚è‹}«S‹Ø[Ç‚ª”­¶‚µ‚œ1–UŒŸ—á. “ü]@Â1, ‘ºãçŽq1, ²X–ؐçŽõŽq1, ’†ŠÛ®”ü2, ã–{“Žq2, ’·–參•œ2, ²“¡•¶Žq1 (1–@ˆã, 2Œ`‘ÔŒn): ‘æ103ŽŸ“ú–{–@ˆãŠw‰ïŠwp‘S‘W‰ï (2019/6/13), å‘ä.

723094. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŽŸ¢‘ãƒV[ƒPƒ“ƒT[‚É‚æ‚鐅’†Ž€‘Ì‚Ì16S rRNAƒƒ^ƒQƒmƒ€‰ðÍ. ‘ºãçŽq1, “ü]@Â1, ²X–ؐçŽõŽq1, ’†ŠÛ®”ü2, ã–{“Žq2, ’·–參•œ2, ²“¡•¶Žq1 (1–@ˆã, 2Œ`‘ÔŒn): ‘æ103ŽŸ“ú–{–@ˆãŠw‰ïŠwp‘S‘W‰ï (2019/6/13), å‘ä.

723095. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –k—¢‘åŠw–@ˆã–ò•šƒXƒNƒŠ[ƒjƒ“ƒO•ªÍŒ‹‰Ê‚̏WŒv•ñ. ²X–ؐçŽõŽq1, ‘ºãçŽq1, “ü]@Â1, ’†ŠÛ®”ü2, ã–{“Žq2, ’·–參•œ2, ²“¡•¶Žq1 (1–@ˆã, 2Œ`‘ÔŒn): ‘æ103ŽŸ“ú–{–@ˆãŠw‰ïŠwp‘S‘W‰ï (2019/6/13), å‘ä.

723096. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¶‘ÌŽŽ—¿•ªÍ‚ðs‚Á‚œƒXƒCƒZƒ“‚ÌŒëH‚É‚æ‚éH’†“Å3—á. ‹g‘º‹vmŽq1, ŠÛ‹ŽFº2, ‘åˆä^—¢“Þ2, ŒIŒŽ—S‘Ÿ˜Y2, ²X–ؐçŽõŽq3, ˆîŠ_‘דl2, ²“¡•¶Žq3, ó—˜@–õ2 (1•a‘ԁEf—ÃŒn, 2‹~–œ, 3–@ˆã): ‘æ41‰ñ“ú–{’†“ÅŠw‰ï‘‰ïEŠwpW‰ï (2019/7/21), é‹Ê.

723097. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) LC-MS/MS‚ð—p‚¢‚œƒqƒgŒŒŽ’†ƒŠƒRƒŠƒ“‚š‚æ‚уKƒ‰ƒ“ƒ^ƒ~ƒ“‚Ì’è—Ê•ªÍ–@. ²X–ؐçŽõŽq1, ‹g‘º‹vmŽq2, ˆîŠ_‘דl3, ‘ºãçŽq1, “ü]@Â1, Ž›“c@Œ«, ŽÂ’Ë’B—Y, ó—˜@–õ3, ²“¡•¶Žq1 (1–@ˆã, 2•a‘ԁEf—ÃŒn, 3‹~–œ): ‘æ44‰ñ“ú–{ˆã—pƒ}ƒXƒXƒyƒNƒgƒ‹Šw‰ï”N‰ï (2019/9/12), –ŒŒÃ‰®.

733016. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) PFPƒJƒ‰ƒ€‚ð—p‚¢‚œƒŠƒRƒŠƒ“‚š‚æ‚уKƒ‰ƒ“ƒ^ƒ~ƒ“‚ÌLC-MS/MS•ªÍ–@‚ÌŒŸ“¢. ²X–ؐçŽõŽq1, ‘ºãçŽq1, “ü]@Â1, ’†ŠÛ®”ü2, ã–{“Žq2, ’·–參•œ2, ²“¡•¶Žq1 (1–@ˆã, 2Œ`‘ÔŒn): ‘æ88‰ñ“ú–{–@ˆãŠw‰ïŠwpŠÖ“Œ’n•ûW‰ï (2019/10/12), “Œ‹ž (‘ä•—‚Ì‚œ‚ߎãŠJÃ).

733017. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) •a—‘gD•W–{ì»Žž‚É‚š‚¯‚éƒLƒVƒŒƒ“‘ã‘Ö•i—˜—p‚ÌŽæ‚è‘g‚݂ɂ‚¢‚Ä. ’†ŠÛ®”ü1, ã–{“Žq1, ‘ºãçŽq2, “ü]@Â2, ²X–ؐçŽõŽq2, ’·–參•œ1, ²“¡•¶Žq2 (1Œ`‘ÔŒn, 2–@ˆã): ‘æ88‰ñ“ú–{–@ˆãŠw‰ïŠwpŠÖ“Œ’n•ûW‰ï (2019/10/12), “Œ‹ž (‘ä•—‚Ì‚œ‚ߎãŠJÃ).


ŽÀŒ±“®•šŠw

[Šw‰ïEŒ€‹†‰ï“™]

713009. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Application of CRISPR Cas9 based genome editing system in the spontaneous mutant mouse STR/Ort. Okubo T1, Uchida K2, Takaso M2: The 15th Transgenic Technology Meeting (TT2019) (2019/4/8), Kobe, Japan. (‘å‹v•Û’Œ1, “à“cŒ’‘Ÿ˜Y2, ‚‘Š»Žm2: 1ŽÀ“®, 2®ŠO)

723098. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) The effect of retinoic acid signaling on the expression of Ripply3 gene in pharyngeal arch development. ‘å‹v•Û’Œ1, ŒŽ@ŒiŽq, “Œ@’åG1, ‚“cTŽ¡ (1ŽÀ“®): ‘æ52‰ñ“ú–{”­¶¶•šŠw‰ï‘å‰ï (2019/5/15), ‘åã.

723099. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆâ“`«ƒp[ƒLƒ“ƒ\ƒ“•aŠ³ŽÒiPS×–E—R—ˆ’P‹…Œn×–E‚̍쐻‚š‚æ‚Ñ‹@”\‰ðÍ. V“c—Žl, ‘Ÿ“c‰x˜N1, •ž•”žl2, ‹v•Û@œ1, ‰iˆä^‹MŽq3, ²“¡rÆ4, ‰ª–ì‰h”V (1ˆã—Éq¶Šw•”, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3”]_Œo“à, 4ŽÀ“®): ‘æ14‰ñ“ú–{—Տ°ŒŸžŠw‹³ˆçŠw‰ïŠwp‘å‰ï (2019/8/22), ŒF–{.

733018. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ˆâ“`«ƒp[ƒLƒ“ƒ\ƒ“•aŠ³ŽÒiPS×–E—R—ˆ’P‹…Œn×–E‚̍쐻‚š‚æ‚Ñ‹@”\‰ðÍ. V“c—Žl, ‘Ÿ“c‰x˜N1, •ž•”žl2, ‹v•Û@œ1, ‰iˆä^‹MŽq3, ²“¡rÆ4, ‰ª–ì‰h”V (1ˆã—Éq¶Šw•”, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3”]_Œo“à, 4ŽÀ“®): ‘æ32‰ñ–k—¢‘åŠwƒoƒCƒIƒTƒCƒGƒ“ƒXƒtƒH[ƒ‰ƒ€E‘æ22‰ñ–k—¢”÷¶•šƒAƒJƒfƒ~[Œ€‹†W‰ï (2019/8/7), ”’‹à.

733019. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) TDP-43×–E“à‹ÇÝƒXƒCƒbƒ`§Œä‚É‚æ‚é‹ØˆÞk«‘€õd‰»Çƒ‚ƒfƒ‹‚̍쐬. ²“¡rÆ1, ‘å‹v•Û’Œ1 (1ŽÀ“®): 2019”N“x”]Œ€‹†Š‹€“¯—˜—p‹€“¯Œ€‹† (ù‰ª”Ç) (2020/1/8), VŠƒ.


–ƉuŠw

[Šwp˜_•¶]

110059. [ŒŽ’˜] Attenuation of experimental autoimmune uveoretinitis in mice by IKKƒÀ inhibitor IMD-0354. Liu Y, Kitaichi N, Wu D, Hase K, Satoh M1, Iwata D, Namba K, Kanda A, Noda K, Itai A, Iwabuchi K1, Ishida S: Biochem Biophys Res Commun 2020/2; 525 (3): 589-94. (²“¡@‰ë1, ŠâŸº˜a–ç1: 1–Ɖu)

110060. [ŒŽ’˜] NF-ƒÈB-inducing kinase contributes to normal development of cortical thymic epithelial cells: its possible role in shaping a proper T-cell repertoire. Eshima K1, Misawa K2, Ohashi C2, Noma H2, Iwabuchi K1: Immunology 2020/3; 160 (2): 198-208. doi. 10.1111/imm.13186. (]“‡k“ñ1, ŽOàV‰À“Þ2, ‘å‹Žçq2, –ìŠÔt2, ŠâŸº˜a–ç1: 1–Ɖu, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

110061. [ŒŽ’˜] The disruption of invariant natural killer T cells exacerbates cardiac hypertrophy and failure caused by pressure overload in mice. Takahashi M, Kinugawa S, Takada S, Kakutani N, Furihata T, Sobirin MA, Fukushima A, Obata Y, Saito A, Ishimori N, Iwabuchi K1, Tsutsui H: Exp Physiol 2020/3; 105 (3): 489-501. (ŠâŸº˜a–ç1: 1–Ɖu)

110062. [ŒŽ’˜] De novo generation of CD1d1-deficient NKT-cell hybridomas from CD1d-/- mice or by gene editing of CD1d+ hybridomas. Satoh M1, Saeki M2, Yoshino K3, Mita K3, Iizuka M4, Hattori A3, Takeuchi E1, Eshima K1, Iwabuchi K1: Kitasato Med J 2020/3; 50 (1): 34-43. (²“¡@‰ë1, ²”Œ”ü”¿2, ‹g–ì˜a‹v3, ŽO“cˆê”¿3, ”Ñ’Ë‚Ý‚³‚ð4, •ž•”žl3, ’|“àŒb”üŽq1, ]“‡k“ñ1, ŠâŸº˜a–ç1: 1–Ɖu, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 4—\–hˆãŠwŒn)

110063. [ŒŽ’˜] Leucine-Rich Repeat Kinase 2 Controls Inflammatory Cytokines Production through NF-ƒÈB Phosphorylation and Antigen Presentation in Bone Marrow-Derived Dendritic Cells. Kubo M1, Nagashima R, Kurihara M, Kawakami F, Maekawa T, Eshima K2, Ohta E1, Kato H, Obata F3: Int J Mol Sci 2020/3; 21 (5): 1890. (‹v•Û@œ1, ]“‡k“ñ2, ‘Ÿ“c‰x˜N1, ¬”Š•¶–í3: 1ˆã—Éq¶Šw•”, 2–Ɖu, 3–k—¢‘åŠw•ÛŒ’‰q¶ê–åŠw‰@)

110064. [ŒŽ’˜] Amelioration of experimental autoimmune myocarditis through activation of invariant natural killer T cells by administration of ƒ¿-galactosylceramide. Yoshino K1, Satoh M2, Iwayama T1, Kobayashi S1, Okamoto H3, Eshima K2, Watarai H, Iwabuchi K2: Kitasato Med J 2020/3; 50 (1): 60-72. (‹g–ì˜a‹v1, ²“¡@‰ë2, ŠâŽRrŽk1, ¬—яGô1, ‰ª–{_Žk3, ]“‡k“ñ2, ŠâŸº˜a–ç2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–Ɖu, 3–ƒŒ)

511001. [‰ðà]yEditorial on the Research TopiczEditorial: Role of CD1- and MR1-restricted T cells in Immunity and Disease. Iwabuchi K1, Van Kaer L: Front Immunol 2019/8; 10: 1837. (ŠâŸº˜a–ç1: 1–Ɖu)

522014. [uÀ]y“ÁW: –ƉuŒn‚ð‰î‚µ‚œƒVƒXƒeƒ€˜AŠÖ: Pí«‚̈ێ‚Æ”j’]zV. –Ɖu‚Æ‘ãŽÓ@NKT×–E‚ÆŽ‰–b‘gD. ŠâŸº˜a–ç1, ²“¡@‰ë1 (1–Ɖu): ¶‘̂̉Ȋw 2019/4; 70 (2): 130-4.

[Šw‰ïEŒ€‹†‰ï“™]

713010. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) The role of NKT cell-macrophage interaction in obesity. Satoh M1, Iwabuchi K1: EMBO Workshop CD1-MR1: Beyond MHC-restricted lymphocytes (2019/9/4), Oxford, UK. (²“¡@‰ë1, ŠâŸº˜a–ç1: 1–Ɖu)

723100. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) T×–E”æ•Ÿ‰»‚É‚š‚¯‚é, “]ŽÊˆöŽqEomesodermin‚Ì–ðŠ„‚Ì‰ðÍ. ‘ºã@“ì, Xì—DŽ÷1, ‘å‹Žçq1, ŠâŸº˜a–ç2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–Ɖu): ‘æ29‰ñKyoto T Cell Conference (2019/6/8), ‹ž“s.

723101. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) In vitro‚É‚š‚¯‚éƒ}ƒEƒXD’†‹…‚ÌNETosis—U“±‚ƍזEŠOƒJƒ‹ƒVƒEƒ€”Z“x‚ÌŠÖŒW‚ɂ‚¢‚Ä. ’|“àŒb”üŽq1, ’|“àN—Y2 (1–Ɖu, 2t‘Ÿ“à): ‘æ47‰ñ“ú–{—Տ°–ƉuŠw‰ï‘‰ï (2019/10/18), ŽD–y.

723102. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) The Roles of Eomesodermin in T cell exhaustion. ‘ºã@“ì1, ]“‡k“ñ2, ŠâŸº˜a–ç2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–Ɖu): ‘æ48‰ñ“ú–{–ƉuŠw‰ïŠwpW‰ï (2019/12/11), •lŒ.

723103. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) An overview of innate lymphocytes: unconventional T cells and innate lymphoid cells. ŠâŸº˜a–ç (–Ɖu): ‘æ48‰ñ“ú–{–ƉuŠw‰ïŠwpW‰ï (2019/12/12), •lŒ.

723104. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) The interaction of NKT cell and macrophage has regulatory function in obesity. ²“¡@‰ë1, ŠâŸº˜a–ç1 (1–Ɖu): ‘æ48‰ñ“ú–{–ƉuŠw‰ïŠwpW‰ï (2019/12/12), •lŒ.

723105. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Potential role of invariant NKT cells in experimental autoimmune myocarditis in mice. ‹g–ì˜a‹v1, ²“¡@‰ë2, Watarai H, ŠâŸº˜a–ç2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–Ɖu): ‘æ48‰ñ“ú–{–ƉuŠw‰ïŠwpW‰ï (2019/12/12), •lŒ.

723106. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Relapse of experimental autoimmune uveoretinitis (EAU) with super antigen is ameliorated by concomitant NKT-cell activation. “cK‰ÄŠC1, ²“¡@‰ë2, ŠâŸº˜a–ç2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–Ɖu): ‘æ48‰ñ“ú–{–ƉuŠw‰ïŠwpW‰ï (2019/12/12), •lŒ.

723107. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) The alteration of NKT-cell function in mice fed on high fat diet. ‰HªŒõŽi1, ²“¡@‰ë2, ŠâŸº˜a–ç2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–Æ): ‘æ48‰ñ“ú–{–ƉuŠw‰ïŠwpW‰ï (2019/12/12), •lŒ.

723108. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) MR1/MAIT cell alleviates allergic contact dermatitis through reduction of IL-17 production. ¡‹Ž®–ç1, ²“¡@‰ë2, ŠâŸº˜a–ç2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–Ɖu): ‘æ48‰ñ“ú–{–ƉuŠw‰ïŠwpW‰ï (2019/12/12), •lŒ.

723109. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Role of T-box transcription factor Eomesodermin, in Perforin/Granzyme exocytosis pathway of cytolysis by CD8+ CTLs. Xì—DŽ÷1, ]“‡k“ñ2, ‘ºã@“ì1, Kondou H, ŠâŸº˜a–ç2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–Ɖu): ‘æ48‰ñ“ú–{–ƉuŠw‰ïŠwpW‰ï (2019/12/12), •lŒ.

723110. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) The association between calcium influx and NETosis induced through the NADPH oxidase independent pathway. ’|“àŒb”üŽq1, ’|“àN—Y2, ŠâŸº˜a–ç1 (1–Ɖu, 2t‘Ÿ“à): ‘æ48‰ñ“ú–{–ƉuŠw‰ïŠwpW‰ï (2019/12/13), •lŒ.

733020. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) T×–E”æ•Ÿ‰»‚É‚š‚¯‚éT-boxƒtƒ@ƒ~ƒŠ[“]ŽÊˆöŽqEomesodermin‚Ì–ðŠ„‚Ì‰ðÍ. ]“‡k“ñ1, ‘ºã@“ì2, Xì—DŽ÷2, ŠâŸº˜a–ç1 (1–Ɖu, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ29‰ñ‹ž“sTƒZƒ‹ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (KTCC) (2019/6/8), ‹ž“s.

733021. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ×–EŠQ«×–E‚̍זEŠQ‹@”\‚É‚š‚¯‚éNkg7‚Ì–ðŠ„. Xì—DŽ÷1, ]“‡k“ñ2, ŠâŸº˜a–ç2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–Ɖu): ‘æ32‰ñ–k—¢‘åŠwƒoƒCƒIƒTƒCƒGƒ“ƒXƒtƒH[ƒ‰ƒ€E‘æ22‰ñ–k—¢”÷¶•šƒAƒJƒfƒ~[Œ€‹†W‰ï (2019/8/7), “Œ‹ž.

733022. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) T×–E”æ•Ÿ‰»‚É‚š‚¯‚éT-boxƒtƒ@ƒ~ƒŠ[“]ŽÊˆöŽqEomesodermin‚Ì–ðŠ„. ‘ºã@“ì1, ]“‡k“ñ2, ŠâŸº˜a–ç2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–Ɖu): ‘æ32‰ñ–k—¢‘åŠwƒoƒCƒIƒTƒCƒGƒ“ƒXƒtƒH[ƒ‰ƒ€E‘æ22‰ñ–k—¢”÷¶•šƒAƒJƒfƒ~[Œ€‹†W‰ï (2019/8/8), “Œ‹ž.

733023. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) Ž©ŒÈ–Ɖu«‚Ô‚Ç‚€–Œ‰ŠÄ”­ƒ‚ƒfƒ‹‚É‚æ‚éNKT×–E‚Ì‹@”\. “cK‰ÄŠC1, ²“¡@‰ë2, –kŽsL‹`, ŠâŸº˜a–ç2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–Ɖu): ‘æ32‰ñ–k—¢‘åŠwƒoƒCƒIƒTƒCƒGƒ“ƒXƒtƒH[ƒ‰ƒ€E‘æ22‰ñ–k—¢”÷¶•šƒAƒJƒfƒ~[Œ€‹†W‰ï (2019/8/8), “Œ‹ž.

733024. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) H‰a—U“±«”ì–ž‚É‚š‚¯‚éNKT×–E‚Ì‹@”\‰ðÍ. ‰HªŒõŽi1, ŽR–{–ƒ“Þ–¢, ²“¡@‰ë2, ŠâŸº˜a–ç2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–Ɖu): ‘æ32‰ñ–k—¢‘åŠwƒoƒCƒIƒTƒCƒGƒ“ƒXƒtƒH[ƒ‰ƒ€E‘æ22‰ñ–k—¢”÷¶•šƒAƒJƒfƒ~[Œ€‹†W‰ï (2019/8/8), “Œ‹ž.

733025. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) MAIT×–E/MR1‚É‚æ‚éÚG«”畆‰Š‚̐§Œä. ¡‹Ž®–ç1, ²“¡@‰ë2, ŠâŸº˜a–ç2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–Ɖu): ‘æ32‰ñ–k—¢‘åŠwƒoƒCƒIƒTƒCƒGƒ“ƒXƒtƒH[ƒ‰ƒ€E‘æ22‰ñ–k—¢”÷¶•šƒAƒJƒfƒ~[Œ€‹†W‰ï (2019/8/8), “Œ‹ž.


’nˆæŽ™“¶ž_‰Èˆã—Êw


Ä¶ˆã—ÃŒ`¬ŠO‰ÈŠw


’nˆæ‘‡ˆã—Êw


‰ŠÇ«’°ŽŸŠ³‹³ˆçE—Տ°Œ€‹†Šw


¬Ž™|¬Ž™zŠÂŠí’nˆæˆã—Êw


Á‰»Ší“à‰ÈŠw

[Šwp˜_•¶]

110065. [ŒŽ’˜] Analysis of BRCAness with multiplex ligation-dependent probe amplification using formalin-fixed and paraffin-embedded pancreatic ductal adenocarcinoma tissue obtained via endoscopic ultrasound-guided fine-needle aspiration biopsy. Okuwaki K1, Masutani H2, Imaizumi H1, Yoshida T3, Kida M1, Iwai T1, Yamauchi H1,4, Tadehara M2, Adachi K2, Watanabe M1, Kurosu T1, Koizumi W1: Pancreatology 2019/4; 19 (3): 419-23. (‰œ˜e‹»‰î1, ¡’JŠ°ˆÈ2, ¡ò@O1, ‹g“c@Œ÷3, –Ø“cŒõL1, Šâˆä’m‹v1, ŽR“à_Žj1,4, äøŒŽ«—Ç2, ˆÀ’B@‰õ2, “n•Ó^ˆè1, •{‹M_1, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3•a—, 4‹~–œ)

110066. [ŒŽ’˜] Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan. Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Tada T, Tsutsui A, Ikeda H, Abe H, Kato K, Uojima H1, Ikegami T, Asano T, Kondo C, Koeda M, Okubo T, Arai T, Iwashita-Nakagawa A, Itokawa N, Kumada T, Iwakiri K: Hepatol Res 2019/4; 49 (4): 369-76. (‹›“ˆ°‹I1: 1Á‰»Ší“à)

110067. [ŒŽ’˜] Current status of esophageal endoscopy including the evaluation of smoking and alcohol consumption in Japan: an analysis based on the Japan endoscopy database. Katada C1,2, Horimatsu T2, Muto M2, Tanaka K2,3, Matsuda K2,3, Fujishiro M2,3, Saito Y2,3, Ohtsuka K2, Oda I2, Kato M2, Kida M1,2, Kobayashi K1,2,4, Hoteya S2, Kodashima S2, Matsuda T2, Yamamoto H2, Ryozawa S2, Iwakiri R3, Kutsumi H3, Miyata H3, Kato M3, Haruma K3, Fujimoto K3, Uemura N3, Kaminishi M3, Tajiri H3 (2MSED-J (Minimal Standard Endoscopic Database) Creation Subcommittee, Japan Gastroenterological Endoscopy Society, 3JED (Japan Endoscopy Database) Project Committee, Japan Gastroenterological Endoscopy Society): Esophagus 2019/4; 16 (2): 174-9. (Œ˜“ce—˜1,2, –Ø“cŒõL1,2, ¬—ѐŽ“T1,2,4: 1Á‰»Ší“à, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

110068. [ŒŽ’˜] Trends and Efficacy of Interferon-Free Anti-hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan. Toyoda H, Atsukawa M, Uojima H1,2, Nozaki A, Tamai H, Takaguchi K, Fujioka S, Nakamuta M, Tada T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Yamashita N, Hiraoka A, Michitaka K, Shima T, Akahane T, Itobayashi E, Watanabe T, Ikeda H, Iio E, Fukunishi S, Asano T, Tachi Y, Ikegami T, Tsuji K, Abe H, Kato K, Mikami S, Okubo H, Shimada N, Ishikawa T, Matsumoto Y, Itokawa N, Arai T, Tsubota A, Iwakiri K, Tanaka Y, Kumada T: Open Forum Infect Dis 2019/4; 6 (5): ofz185. (‹›“ˆ°‹I1,2: 1Á‰»Ší“à, 2Ã“슙‘q‘‡•a‰@)

110069. [ŒŽ’˜] Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures. Hidaka H1, Kurosaki M, Tanaka H, Kudo M, Abiru S, Igura T, Ishikawa T, Seike M, Katsube T, Ochiai T, Kimura K, Fukuhara T, Kano T, Nagata T, Tanaka K, Kurokawa M, Yamamoto K, Osaki Y, Izumi N, Imawari M: Clin Gastroenterol Hepatol 2019/5; 17 (6): 1192-200. (“ú‚@‰›1: 1Á‰»Ší“à)

110070. [ŒŽ’˜] Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL). Hidaka H1, Izumi N, Aramaki T, Ikeda M, Inaba Y, Imanaka K, Okusaka T, Kanazawa S, Kaneko S, Kora S, Saito H, Furuse J, Matsui O, Yamashita T, Yokosuka O, Morita S, Arioka H, Kudo M, Arai Y: Med Oncol 2019/5; 36 (6): 52. (“ú‚@‰›1: 1Á‰»Ší“à)

110071. [ŒŽ’˜] Risk factors for loss of skeletal muscle mass in patients with cirrhosis. Sung JH1, Uojima H1,2, Hidaka H2, Tanaka Y2, Wada N2, Kubota K2, Nakazawa T2, Shibuya A2,3, Fujikawa T, Yamanoue H, Kako M1, Koizumi W2: Hepatol Res 2019/5; 49 (5): 550-8. (‹›“ˆ°‹I1,2, “ú‚@‰›2. “c’†Œ«–Ÿ2, ˜a“c®‹v2, ŒE“cK‰î2, ’†àV‹MG2, a’J–Ÿ—²2,3, ¬ò˜aŽO˜Y2: 1Ã“슙‘q‘‡•a‰@, 2Á‰»Ší“à, 3ˆã—ÊǗ)

110072. [ŒŽ’˜] The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study. Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Michitaka K, Ikegami T, Nozaki A, Uojima H1, Fukunishi S, Genda T, Abe H, Hotta N, Tsuji K, Ogawa C, Tachi Y, Shima T, Shimada N, Kondo C, Akahane T, Aizawa Y, Tanaka Y, Kumada T, Iwakiri K: Aliment Pharmacol Ther 2019/5; 49 (9): 1230-41. (‹›“ˆ°‹I1: 1Á‰»Ší“à)

110073. [ŒŽ’˜] Effectiveness and safety of endoscopic aspiration mucosectomy and endoscopic submucosal dissection in patients with superficial esophageal squamous-cell carcinoma. Furue Y1, Katada C1, Tanabe S1,2, Ishido K1, Kondo Y3, Kubota Y3, Kawanishi N1, Yamane S1, Watanabe A1, Moriya H4, Yamashita K4,5, Wada T1, Yano T1, Azuma M1, Koizumi W1: Surg Endosc 2019/5; 33 (5): 1433-440. (ŒÃ]N–Ÿ1, Œ˜“ce—˜1, “c糁@‘1,2, ÎŒËŒªŽŸ1, ‹ß“¡—Y‹I3, ‹v•Û“c—z3, ‰ÍŒ“Þ’ÃŽq1,ŽRª‘‹IŽq1, “n糍WŽ¯1, X’JGŒõ4, ŽR‰ºŒpŽk4,5, ˜a“c‘ñ–ç1, –î–ì‹MŽj1, “Œ@’q1, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 4ã•”Á‰»ŠÇŠO, 5V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

110074. [ŒŽ’˜] Failure Factors to Reach the Blind End Using a Short-Type Single-Balloon Enteroscope for ERCP with Roux-en-Y Reconstruction: A Multicenter Retrospective Study. Kawaguchi Y1,2, Yamauchi H2,3, Kida M1,2, Okuwaki K2, Iwai T2, Uehara K1,2, Hasegawa R2, Imaizumi H2, Kobayashi K2,4, Koizumi W2: Gastroenterol Res Pract 2019/5; 2019: 3536487. (ìŒû—C•ã1,2, ŽR“à_Žj2,3, –Ø“cŒõL1,2, ‰œ˜e‹»‰î2, Šâˆä’m‹v2, ãŒŽˆê”¿1,2, ’·’Jì—Í–ç2, ¡ò@O2, ¬—ѐŽ“T2,4, ¬ò˜aŽO˜Y2: 1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Á‰»Ší“à, 3‹~–œ, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

110075. [ŒŽ’˜] Assessing the characteristics and feasibility of preventing early mortality in patients with hepatocellular carcinoma. Watanabe M1,2, Yokomori H2,3, Takahashi Y2,4, Okada T2, Shibuya A1,5, Koizumi W1: Turk J Gastroenterol 2019/6; 30 (6): 541-8. (“n粐^²1,2, ‰¡XOº2,3, ‚‹Ž’õl2,4, ‰ª“c•—Ï2, a’J–Ÿ—²1,5, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3‘‡f—Ã, 4ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 5ˆã—ÊǗ)

110076. [ŒŽ’˜] Retrospective Assessment of the Diagnostic Accuracy of the Depth of Invasion by Narrow Band Imaging Magnifying Endoscopy in Patients with Superficial Esophageal Squamous Cell Carcinoma. Katada C1, Tanabe S1,2, Wada T1, Ishido K1, Yano T1, Furue Y1, Kondo Y3, Kawanishi N1, Yamane S1, Watanabe A1, Azuma M1, Koizumi W1: J Gastrointest Cancer 2019/6; 50 (2): 292-7. (Œ˜“ce—˜1, “c糁@‘1,2, ˜a“c‘ñ–ç1, ÎŒËŒªŽŸ1, –î–ì‹MŽj1, ŒÃ]N–Ÿ1, ‹ß“¡—Y‹I3, ‰ÍŒ“Þ’ÃŽq1, ŽRª‘‹IŽq1, “n糍WŽ¯1, “Œ@’q1, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

110077. [ŒŽ’˜] Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Yamada Y, Boku N, Mizusawa J, Iwasa S, Kadowaki S, Nakayama N, Azuma M1, Sakamoto T, Shitara K, Tamura T, Chin K, Hata H, Nakamori M, Hara H, Yasui H, Katayama H, Fukuda H, Yoshikawa T, Sasako M, Terashima M: Lancet Gastroenterol Hepatol 2019/7; 4 (7): 501-10. (“Œ@’q1: 1Á‰»Ší“à)

110078. [ŒŽ’˜] Stent-induced symptomatic pancreatic duct stricture after endoscopic prophylactic pancreatic duct stent placement for the normal pancreas. Adachi K1, Yamauchi H2,3, Kida M2,4, Okuwaki K2, Iwai T2, Tadehara M1, Uehara K2,4, Nakatani S2, Imaizumi H2, Koizumi W2: Pancreatology 2019/7; 19 (5): 665-71. (ˆÀ’B@‰õ11, ŽR“à_Žj2,3, –Ø“cŒõL2,4, ‰œ˜e‹»‰î2, Šâˆä’m‹v2, äøŒŽ«—Ç1, ãŒŽˆê”¿2,4, ’†’JªŒá2, ¡ò@O2, ¬ò˜aŽO˜Y2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2Á‰»Ší“à, 3‹~–œ, 4–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

110079. [ŒŽ’˜] Complications of Long-Term Indwelling Transmural Double Pigtail Stent Placement for Symptomatic Peripancreatic Fluid Collections. Complications of Long-Term Indwelling Transmural Double Pigtail Stent Placement for Symptomatic Peripancreatic Fluid Collections. Yamauchi H1,2, Iwai T2, Kida M2,3, Okuwaki K2, Kurosu T2, Watanabe M2, Adachi K4, Tadehara M4, Imaizumi H2, Koizumi W2: Dig Dis Sci 2019/7; 64 (7): 1976-84. (ŽR“à_Žj1,2, Šâˆä’m‹v2, –Ø“cŒõL2,3, ‰œ˜e‹»‰î2, •{‹M_2, “n•Ó^ˆè2, ˆÀ’B@‰õ4, äøŒŽ«—Ç4, ¡ò@O2, ¬ò˜aŽO˜Y2: 1‹~–œ, 2Á‰»Ší“à, 3–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 4‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

110080. [ŒŽ’˜] Predictors of invasive cancer of large laterally spreading colorectal tumors: A multicenter study in Japan. Kobayashi K1,2,3, Tanaka S1, Murakami Y1, Ishikawa H1, Sada M1,3, Oka S1, Saito Y1, Iishi H1, Kudo S1, Ikematsu H1, Igarashi M1, Saitoh Y1, Inoue Y1, Hisabe T1, Tsuruta O1, Sano Y1, Yamano H1, Shimizu S1, Yahagi N1, Matsuda K1, Nakamura H1, Fujii T1, Sugihara K1 (1the Colorectal Endoscopic Resection Standardization Implementation Working Group of the Japanese Society for Cancer of the Colon and Rectum): JGH Open 2019/7; 4 (1): 83-9 (¬—ѐŽ“T1,2,3, ²“c”ü˜a1,3: 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3Á‰»Ší“à)

110081. [ŒŽ’˜] Transpapillary Biliary Cannulation is Difficult in Cases with Large Oral Protrusion of the Duodenal Papilla. Watanabe M1, Okuwaki K1, Kida M1,2, Imaizumi H1, Yamauchi H1,3, Kaneko T1, Iwai T1, Hasegawa R1, Miyata E1, Masutani H4, Tadehara M4, Adachi K4, Koizumi W1: Dig Dis Sci 2019/8; 64 (8): 2291-9. (“n•Ó^ˆè1, ‰œ˜e‹»‰î1, –Ø“cŒõL1,2, ¡ò@O1, ŽR“à_Žj1,3, ‹àŽq@‹œ1, Šâˆä’m‹v1, ’·’Jì—Í–ç1, ‹{“c‰pŽ¡1, ¡’JŠ°ˆÈ4, äøŒŽ«—Ç4, ˆÀ’B@‰õ4, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3‹~–œ, 4‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

110082. [ŒŽ’˜] Efficacy of Endoscopic Resection and Selective Chemoradiotherapy for Stage I Esophageal Squamous Cell Carcinoma. Minashi K, Nihei K, Mizusawa J, Takizawa K, Yano T, Ezoe Y, Tsuchida T, Ono H, Iizuka T, Hanaoka N, Oda I, Morita Y, Tajika M, Fujiwara J, Yamamoto Y, Katada C1, Hori S, Doyama H, Oyama T, Nebiki H, Amagai K, Kubota Y, Nishimura K, Kobayashi N, Suzuki T, Hirasawa K, Takeuchi T, Fukuda H, Muto M: Gastroenterology 2019/8; 157 (2): 382-90.e3. (Œ˜“ce—˜1: 1Á‰»Ší“à)

110083. [ŒŽ’˜] Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam. Naganuma M1, Hirai F1, Kobayashi K1,2,3, Watanabe K1, Takeuchi K1, Aoyama N1, Nozawa H1, Motoya S1, Ohmori T1, Harada A1, Nagai Y1, Abe T1, Yamada Y1, Inagaki K1, Shimizu N1, Kanai T1, Watanabe M1 (1ESCORT study Group): PLoS One 2019/8; 14 (8): e0220413. (¬—ѐŽ“T1,2,3: 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3Á‰»Ší“à)

110084. [ŒŽ’˜] Gene expression profiles of genes related to canceration, invasion or conversion for metastasis in patients with poorly differentiated gastric adenocarcinoma treated by gastric endscopic submucosal dissection. Kawanishi N1, Azuma M1, Takeuchi A1, Yamane S1, Ishido K1, Katada C1, Tanabe S1,2, Yoshida T3, Koizumi W1: Kitasato Med J 2019/9; 49 (2): 125-33. (‰ÍŒ“Þ’ÃŽq1, “Œ@’q1, ’|“à“ÖŽq1, ŽRª‘‹IŽq1, ÎŒËŒªŽŸ 1, Œ˜“ce—˜1, “c糁@‘1,2, ‹g“c@Œ÷3, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3•a—)

110085. [ŒŽ’˜] Usefulness of serum lipase for early diagnosis of post-endoscopic retrograde cholangiopancreatography pancreatitis. Tadehara M1, Okuwaki K2, Imaizumi H2, Kida M2, Iwai T2, Yamauchi H2,3, Kaneko T2, Hasegawa R2, Miyata E2, Kawaguchi Y2, Masutani H1, Koizumi W2: World J Gastrointest Endosc 2019/9; 11 (9): 477-85. (äøŒŽ«—Ç1, ‰œ˜e‹»‰î2, ¡ò@O2, –Ø“cŒõL2, Šâˆä’m‹v2, ŽR“à_Žj2,3, ‹àŽq@‹œ2, ’·’Jì—Í–ç2, ‹{“c‰pŽ¡2, ìŒû—C•ã2, ¡’JŠ°ˆÈ1, ¬ò˜aŽO˜Y2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2Á‰»Ší“à, 3‹~–œ)

110086. [ŒŽ’˜] Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer. Yamada Y, Koizumi W1, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Hyodo I: Cancer Sci 2019/9; 110 (9): 2875-83. (¬ò˜aŽO˜Y1: 1Á‰»Ší“à)

110087. [ŒŽ’˜] Objective evaluation of the visibility of colorectal lesions using eye tracking. Kumahara K1, Ikematsu H1, Shinmura K1, Murano T1, Inaba A1, Okumura K1, Nishihara K1, Sunakawa H1, Furue Y1,2, Ito R1, Sato D1, Minamide T1, Okamoto N1, Yamamoto Y1, Suyama M1, Takashima K1, Nakajo K1, Yoda Y1, Hori K1, Oono Y1, Yano T1 (1Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East): Dig Endosc 2019/9; 31 (5): 552-7. (ŒÃ]N–Ÿ1,2: 2Á‰»Ší“à)

110088. [ŒŽ’˜] Comparison of the histopathological characteristics of large colorectal laterally spreading tumors according to growth pattern. Saito T1, Kobayashi K1,2, Sada M1, Matsumoto Y1, Mukae M1, Kawagishi K1, Yokoyama K1, Koizumi W1, Saegusa M3, Murakami Y: J Anus Rectum Colon 2019/10; 3 (4): 152-9. (âV“¡ŒöÆ1, ¬—ѐŽ“T1,2, ²“c”ü˜a1, Œ–{ˆçG1, Œ}@”üK1, ìŠÝ‰Á“Þ1, ‰¡ŽR@ŒO1, ¬ò˜aŽO˜Y1, ŽOŽ}@M3: 1Á‰»Ší“à‰È, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3•a—)

110018. [ŒŽ’˜] Thromboxane A 2 receptor signaling in endothelial cells attenuates monocrotaline-induced liver injury. Otaka F1, Ito Y2, Inoue T3, Ohkubo H4, Nishizawa N5, Kojo K6, Betto T3, Yamane S3, Narumiya S, Koizumi W3, Majima M2: Toxicol Appl Pharmacol 2019/10; 381: 114733. (‘卂Žj¹1, ˆÉ“¡‹`–ç2, ˆäã’qm3, ‘å‹v•Û”Ž¢4, ŒàVL‹±5, ŒÃé@Œ›6, •Êác•üL3, ŽRª‘‹IŽq3, ¬ò˜aŽO˜Y3, ”n“ˆ³—²2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–ò—, 3Á‰»Ší“à, 4S‘ŸŒŒŠÇŠO, 5ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 6‰º•”Á‰»ŠÇŠO)

110089. [ŒŽ’˜] Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial. Kondo M, Morimoto M, Kobayashi S, Ohkawa S, Hidaka H1, Nakazawa T1, Aikata H, Hatanaka T, Takizawa D, Matsunaga K, Okuse C, Suzuki M, Taguri M, Ishibashi T, Numata K, Maeda S, Tanaka K: BMC Cancer 2019/10; 19 (1): 954. (“ú‚@‰›1, ’†àV‹MG1: 1Á‰»Ší“à)

110090. [ŒŽ’˜] Impact of the Charlson Comorbidity Index on the treatment strategy and survival in elderly patients after non-curative endoscopic submucosal dissection for esophageal squamous cell carcinoma: a multicenter retrospective study. Nakajo K, Abe S, Oda I, Ishihara R, Tanaka M, Yoshio T, Katada C1, Yano T: J Gastroenterol 2019/10; 54 (10): 871-80. (Œ˜“ce—˜1: 1Á‰»Ší“à)

110091. [ŒŽ’˜] Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-na?ve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan. Ikeda H, Watanabe T, Atsukawa M, Toyoda H, Takaguchi K, Nakamuta M, Matsumoto N, Okuse C, Tada T, Tsutsui A, Yamashita N, Kondo C, Hayama K, Kato K, Itokawa N, Arai T, Shimada N, Asano T, Uojima H1, Ogawa C, Mikami S, Ikegami T, Fukunishi S, Asai A, Iio E, Tsubota A, Hiraoka A, Nozaki A, Okubo H, Tachi Y, Moriya A, Oikawa T, Matsumoto Y, Tsuruoka S, Tani J, Kikuchi K, Iwakiri K, Tanaka Y, Kumada T: J Viral Hepat 2019/11; 26 (11): 1266-75. (‹›“ˆ°‹I1: 1Á‰»Ší“à)

110092. [ŒŽ’˜] An international, multi-institution survey of the use of EUS in the diagnosis of pancreatic cystic lesions. Ge N, Brugge WR, Saxena P, Sahai A, Adler DG, Giovannini M, Pausawasdi N, Santo E, Mishra G, Tam W, Kida M1,2, de la Mora-Levy JG, Sharma M, Umar M, Katanuma A, Lee L, Garg PK, Eloubeidi MA, Yu HK, Raijman I, Arturo Arias BL, Bhutani M, Carrara S, Rai P, Mukai S, Palazzo L, Dietrich CF, Nguyen NQ, El-Nady M, Poley JW, Guaraldi S, Kalaitzakis E, Sabbagh LC, Lari?o-Noia J, Gress FG, Lee YT, Rana SS, Fusaroli P, Hocke M, Dhir V, Lakhtakia S, Ratanachu-Ek T, Chalapathi Rao AS, Vilmann P, Okasha HH , Irisawa A, Ponnudurai R, Leong AT, Artifon E, Iglesias-Garcia J, Saftoiu A, Larghi A, Robles-Medranda C, Sun S: Endosc Ultrasound 2019/11-12; 8 (6): 418-27. (–Ø“cŒõL1,2: 1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Á‰»Ší“à)

110093. [ŒŽ’˜] On-site stereomicroscope quality evaluations to estimate white core cutoff lengths using EUS-FNA biopsy sampling with 22-gauge needles. Masutani H1, Okuwaki K2, Kida M2,3, Yoshida T4, Imaizumi H2, Yamauchi H2,5, Iwai T2, Kaneko T2, Hasegawa R2, Miyata E2, Koizumi W2: Gastrointest Endosc 2019/12; 90 (6): 947-56. (¡’JŠ°ˆÈ1, ‰œ˜e‹»‰î2, –Ø“cŒõL2,3, ‹g“c@Œ÷4, ¡ò@O2, ŽR“à_Žj2,5, Šâˆä’m‹v2, ‹àŽq@‹œ2, ’·’Jì—Í–ç2, ‹{“c‰pŽ¡2, ¬ò˜aŽO˜Y2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2Á‰»Ší“à, 3–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 4•a—, 5‹~–œ)

110094. [ŒŽ’˜] Endoscopic Balloon Dilation for Benign Bilioenteric Stricture: Outcomes and Factors Affecting Recurrence. Yamauchi H1,2, Kida M2,3, Miyata E2, Okuwaki K2, Iwai T2, Minato N2, Tadehara M4, Watanabe M2, Imaizumi H2, Koizumi W2: Dig Dis Sci 2019/12; 64 (12): 3557-67. (ŽR“à_Žj1,2, –Ø“cŒõL2,3, ‹{“c‰pŽ¡2, ‰œ˜e‹»‰î2, Šâˆä’m‹v2, –©@®‹M2, äøŒŽ«—Ç4, “n•Ó^ˆè2, ¡ò@O2, ¬ò˜aŽO˜Y2: 1‹~–œ, 2Á‰»Ší“à, 3–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 4‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

110095. [ŒŽ’˜] A clinical trial to assess the feasibility and efficacy of nab-paclitaxel plus gemcitabine for elderly patients with unresectable advanced pancreatic cancer. Hasegawa R1, Okuwaki K1, Kida M1,2, Yamauchi H1,3, Kawaguchi Y1, Matsumoto T1, Kaneko T1, Miyata E1, Uehara K1,2, Iwai T1, Watanabe M1, Kurosu T1, Imaizumi H1, Ohno T4, Koizumi W1: Int J Clin Oncol 2019/12; 24 (12): 1574-81. (’·’Jì—Í–ç1,‰œ˜e‹»‰î1, –Ø“cŒõL1,2, ŽR“à_Žj1,3, ìŒû—C•ã1, Œ–{‚–Ÿ1, ‹àŽq@‹œ1, ‹{“c‰pŽ¡1, ãŒŽˆê”¿1,2, Šâˆä’m‹v1, “n•Ó^ˆè1, •{‹M_1, ¡ò@O1, ‘å–ì@—²4, ¬ò˜aŽO˜Y1: Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3‹~–œ, 4ˆÉšŒŽ‹Š“¯•a‰@)

110096. [ŒŽ’˜] Usefulness of autotaxin for the complications of liver cirrhosis. Shao X1, Uojima H1, Setsu T, Okubo T, Atsukawa M, Furuichi Y, Arase Y, Hidaka H1, Tanaka Y1, Nakazawa T1, Kako M, Kagawa T, Iwakiri K, Terai S, Koizumi W1: World J Gastroenterol 2020/1; 26 (1): 97-108. (Xue Shao1, ‹›“ˆ°‹I1, “ú‚@‰›1, “c’†Œ«–Ÿ1, ’†àV‹MG1,¬ò˜aŽO˜Y1: 1Á‰»Ší“à)

110097. [ŒŽ’˜] Meta-analysis of two randomized phase III trials (TCOG GI-0801 and ECRIN TRICS) of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer. Nishikawa K, Koizumi W1, Tsuburaya A, Yamanaka T, Morita S, Fujitani K, Akamaru Y, Shimada K, Hosaka H, Nakayama N, Tsujinaka T, Sakamoto J: Gastric Cancer 2020/1; 23 (1): 160-7. (¬ò˜aŽO˜Y1: 1Á‰»Ší“à)

110098. [ŒŽ’˜] Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma. Chuma M, Uojima H1, Numata K, Hidaka H1, Toyoda H, Hiraoka A, Tada T, Hirose S, Atsukawa M, Itokawa N, Arai T, Kako M, Nakazawa T1, Wada N1, Iwasaki S1, Miura Y, Hishiki S, Nishigori S, Morimoto M, Hattori N, Ogushi K, Nozaki A, Fukuda H, Kagawa T, Michitaka K, Kumada T, Maeda S: Cancers (Basel) 2020/1; 12 (2): 293. (‹›“ˆ°‹I1,“ú‚@‰›1, ’†àV‹MG1, ˜a“c®‹v1, ŠâèGˆê˜Y1: 1Á‰»Ší“à)

110099. [ŒŽ’˜] Furosemide Dose Changes Associated with Furosemide/Tolvaptan Combination Therapy in Patients with Cirrhosis. Uojima H1, Hidaka H1, Tanaka Y1, Wada N1, Kubota K1, Nakazawa T1, Shibuya A1,2, Sung JH, Kako M, Koizumi W1: Dig Dis 2020/1; 38 (1): 38-45. (‹›“ˆ°‹I1, “ú‚@‰›1, “c’†Œ«–Ÿ1, ˜a“c®‹v1, ŒE“cK‰î1, ’†àV‹MG1, a’J–Ÿ—²1,2, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2ˆã—ÊǗ)

110100. [ŒŽ’˜] Prediction of lymph-node metastasis and lymphatic invasion of superficial pharyngeal cancer on narrow band imaging with magnifying endoscopy. Katada C1, Okamoto T2, Ichinoe M3, Sakamoto Y4, Kano K2, Hosono H2, Miyamoto S2, Tanabe S1,5, Koizumi W1, Yamashita T2: Auris Nasus Larynx 2020/2; 47 (1): 128-34. (Œ˜“ce—˜1, ‰ª–{—·l2, ˆêŒË¹–Ÿ3, â–{‘×—4, ‰Á”[Fˆê2, ×–ì_Žj2, ‹{–{r•ã2, “c糁@‘1,5, ¬ò˜aŽO˜Y1, ŽR‰º@‘ñ2: 1Á‰»Ší“à, 2Žš•@ˆôAE“ªèò•”ŠO, 3•a—, 4—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg, 5V¢‹Iˆã—ÁEæ’[ˆã—Ã)

110101. [ŒŽ’˜] Surgical outcomes of elderly patients with Stage I gastric cancer from the nationwide registry of the Japanese Gastric Cancer Association. Nunobe S1, Oda I1, Ishikawa T1, Akazawa K1, Katai H1, Isobe Y1, Miyashiro I1, Tsujitani S1, Ono H1, Tanabe S1,2,3, Fukagawa T1, Suzuki S1, Kakeji Y1 (1Registration Committee of the Japanese Gastric Cancer): Gastric Cancer 2020/3; 23 (2): 328-38. (“c糁@‘1,2,3: 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3Á‰»Ší“à)

210002. [€ŒŽ’˜] The large-balloon occlusion technique: A new method for conversion to EUS-guided hepaticogastrostomy in patient with prior self-expanding metal stent placement The large-balloon occlusion technique: A new method for conversion to EUS-guided hepaticogastrostomy in patient with prior self-expanding metal stent placement. Okuwaki K1, Yamauchi H1,2, Kida M1,3, Imaizumi H1, Matsumoto T1, Tadehara M4, Iwai T1, Kaneko T1, Hasegawa R1, Miyata E1, Koizumi W1: Endosc Ultrasound 2019/5-6; 8 (3): 209-10. (‰œ˜e‹»‰î1, ŽR“à_Žj1,2, –Ø“cŒõL1,3, ¡ò@O1, Œ–{‚–Ÿ1, äøŒŽ«—Ç4, Šâˆä’m‹v1, ‹àŽq@‹œ1, ’·’Jì—Í–ç1, ‹{“c‰pŽ¡1, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2‹~–œ, 3–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 4‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

210003. [€ŒŽ’˜] The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study. Nozaki A1, Atsukawa M1, Kondo C1, Toyoda H1, Chuma M1, Nakamuta M1, Uojima H1,2, Takaguchi K1, Ikeda H1, Watanabe T1, Ogawa S1, Itokawa N1, Arai T1, Hiraoka A1, Asano T1, Fujioka S1, Ikegami T1, Shima T1, Ogawa C1, Akahane T1, Shimada N1, Fukunishi S1, Abe H1, Tsubota A1, Genda T1, Okubo H1, Mikami S1, Morishita A1, Moriya A1, Tani J1, Tachi Y1, Hotta N1, Ishikawa T1, Okanoue T1, Tanaka Y1, Kumada T1, Iwakiri K1, Maeda S1 (1KTK49 Liver Study Group): Hepatol Int 2020/3; 14 (2): 225-38. (‹›“ˆ°‹I1,2: 2Á‰»Ší“à)

210004. [€ŒŽ’˜] ALBI-U grading, which integrates albumin-bilirubin grade (ALBI) and the up-to-seven criteria (UTS), is a simple and useful prognostic prediction model for a small patient group with hepatocellular carcinoma (HCC): a single-center, retrospective analysis. Watanabe M1,2, Yokomori H2,3: Turk J Gastroenterol 2019/9; 30 (Suppl 3): S234-6. (“n粐^²1,2, ‰¡XOº2,3: 1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3‘‡f—Ã)

310005. [Ç—á•ñ] A suspected case of Clostridium perfringens sepsis with intravascular hemolysis after transhepatic arterial chemoembolization: a case report. Uojima H1, Onoue M1, Hidaka H1, Wada N1, Tanaka Y1, Inoue T1, Kubota K1, Nakazawa T1, Shibuya A1,2, Koizumi W1: J Med Case Rep 2019/4; 13 (1): 125. (‹›“ˆ°‹I1, ”öã”üŒb1, “ú‚@‰›1. ˜a“c®‹v1, “c’†Œ«–Ÿ1, ˆäã’qm1, ŒE“cK‰î1, ’†àV‹MG1, a’J–Ÿ—²1,2, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2ˆã—ÊǗ)

310006. [Ç—á•ñ] Hepatic methotrexate-associated lymphoproliferative disorders identified by multiple liver tumors: a case report and review of the literature. Ono R, Kumagae T, Uojima H1,2, Teshima S, Kudo M, Kitagawa I, Yoshizawa M: J Med Case Rep 2019/6; 13 (1): 196. (‹›“ˆ°‹I1,2: 1Á‰»Ší“à, 2Ã“슙‘q‘‡•a‰@)

310007. [Ç—á•ñ] Comparison of narrow-band imaging, volumetric laser endomicroscopy, and pathologic findings in Barrett's esophagus. Comparison of Narrow Band Imaging, Volumetric Laser Endomicroscopy and Pathological Findings in Barrett's Esophagus. Katada C1, Pai RK, Fukami N: VideoGIE 2019/7; 4 (7): 319-22. (Œ˜“ce—˜1: 1Á‰»Ší“à)

310008. [Ç—á•ñ] Pancreatic granular cell tumor diagnosed by endoscopic ultrasound-guided fine needle aspiration biopsy. Krutsri C, Iwai T1, Kida M1,2, Imaizumi H1, Kawano T1, Tadehara M3, Watanabe M1, Okuwaki K1, Yamauchi H1,4, Koizumi W1: Clin J Gastroenterol 2019/8; 12 (4): 347-54. (Šâˆä’m‹v1, –Ø“cŒõL1,2, ¡ò@O1, ì–ìšæ’ˆ1, äøŒŽ«—Ç3, “n•Ó^ˆè1, ‰œ˜e‹»‰î1, ŽR“à_Žj1,4, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 4‹~–œ)

310009. [Ç—á•ñ] A case of extrahepatic bile duct cancer with distant metastases showing pathological complete response to treatment combining gemcitabine and cisplatin. Adachi K1, Okuwaki K2, Nishiyama R2, Kida M2,3, Imaizumi H2, Iwai T2, Yamauchi H2,4, Kaneko T2, Hasegawa R2, Miyata E2, Kumamoto Y5, Koizumi W2: Clin J Gastroenterol 2019/10; 12 (5): 466-72. (ˆÀ’B@‰õ1, ‰œ˜e‹»‰î2, ŒŽR@—³2, –Ø“cŒõL2,3, ¡ò@O2, Šâˆä’m‹v2, ŽR“à_Žj2,4, ‹àŽq@‹œ2, ’·’Jì—Í–ç2, ‹{“c‰pŽ¡2, ŒGŒ³—Y‰î5, ¬ò˜aŽO˜Y2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2Á‰»Ší“à, 3–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 4‹~–œ, 5ˆê”ʁE¬Ž™EŠÌ’_äXŠO)

310010. [Ç—á•ñ] Ischemic pancreatitis with infected walled-off necrosis with a colonic fistula after cardiopulmonary bypass successfully treated by endoscopic ultrasound-guided drainage. Masuda S1, Koizumi K1, Uojima H1,2, Tazawa T1, Tasaki J1, Ichita C1, Nishino T1, Kimura K1 Sasaki A1, Egashira H1, Kako M1: Clin J Gastroenterol 2020/2; 13 (1): 127-33. (‹›“ˆ°‹I1,2: 1Á‰»Ší“à, 2Ã“슙‘q‘‡•a‰@)

320001. [Ç—á•ñ] “àŽ‹‹Ÿ“I“û“ªØœp‚ɂĐf’f‚µ“Ÿ‚œ“û“ª•”_Œo“à•ª”åŽîᇂ̈ê—á. •œ—ÇŽÑŒŽ1, ìŒû—C•ã1,2, áÁ•”—Dì1,2, ãŒŽˆê”¿1,2, ‘å’ˏr˜a1,2, “cŒŽ‹v”üŽq1, “n粐^²1,2, –Ø“cŒõL1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Á‰»Ší“à): Progress of Digestive Endoscopy 2019/6; 94 (1): 81-3.

320002. [Ç—á•ñ] L“‡Š¿•û‚ÅŠ°‰ðˆÛŽE”S–ŒŽ¡–ü‚ð”F‚ß‚œ’×ᇐ«‘å’°‰Š‚̈êÇ—á. ŽOŽ}—zˆê1, ¡ò@O1, ‹à@–Ÿ“N, Îèƒ˜Y, ‰Á“¡@Ê, ŒK”ö’èm, ŽO‹Ž—˜‰·, ŒŒ³Ž›ŽâX1, ‘åˆä“c³l1 (1Á‰»Ší“à): Progress of Digestive Endoscopy 2019/6; 94 (1): 119-21.

320003. [Ç—á•ñ] EUS‚Å’áƒGƒR[ŽîᎂƂµ‚Ä•`o‰Â”\‚Å‚ ‚Á‚œäXã”ç“àŠà‚Ì1—á. áÁ•”—Dì1,2, ãŒŽˆê”¿1,2, •œ—ÇŽÑŒŽ2, ìŒû—C•ã1,2, ‘å’ˏr˜a1,2, “cŒŽ‹v”üŽq2, “n粐^²1,2, –Ø“cŒõL1,2 (1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): Progress of Digestive Endoscopy 2019/6; 94 (1): 149-51.

320004. [Ç—á•ñ] EUS-FNB‚É‚Ä•a—f’f‚ð“Ÿ‚œ‘œ”­«œ‘Žî‚ÌäX“]ˆÚ‚Ì1—á. ²–ì’BÆ1, ‰œ˜e‹»‰î1, –Ø“cŒõL1,2, –©@®‹M1, ŒŒŽ‰ÀØ, ‹{“c‰pŽ¡1, ’·’Jì—Í–ç1, ‹àŽq@‹œ1, ŽR“à_Žj1,3, Šâˆä’m‹v1, ¡ò@O1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3‹~–œ): Progress of Digestive Endoscopy 2019/6; 94 (1): 155-7.

320005. [Ç—á•ñ] äXŠÇŠà‚É—ÞŽ—‚µ‚œ’Ž‰¹”g“àŽ‹‹Ÿ‰æ‘œ‚ð’悵‚œäX_Œo“à•ª”åŽîᇂÌ1—á. ‹Ê’u–ŸŠ°1, ‰œ˜e‹»‰î1, –Ø“cŒõL1,2, •{‹M_1, –©@®‹M1, “n•Ó^ˆè1, ’†’JªŒá1, ‹{“c‰pŽ¡1, Œ–{‚–Ÿ1, ’·’Jì—Í–ç1, ‹àŽq@‹œ1, ŽR“à_Žj1,3, Šâˆä’m‹v1, ¡ò@O1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3‹~–œ): Progress of Digestive Endoscopy 2019/6; 94 (1): 161-3.

320006. [Ç—á•ñ] p‘Of’f‚ª¢“ï‚Å‚ ‚Á‚œäXŸ÷‰t«”X–E‘BŽî‚Ì1—á. Œ‰º¹—T1, ’·’Jì—Í–ç1, ‹{“c‰pŽ¡1, ‹àŽq@‹œ1, ŽR“à_Žj1,2, ‰œ˜e‹»‰î1, Šâˆä’m‹v1, ¡ò@O1, ŠC’ËMŽj3, ŒGŒ³—Y‰î3, –Ø“cŒõL1,4, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2‹~–œ, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 4–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): Progress of Digestive Endoscopy 2019/6; 94 (1): 167-9.

510003. [‘à] Current status of endoscopic retrograde cholangiopancreatography in patients with surgically altered anatomy. Krutsri C, Kida M1,2, Yamauchi H1,3, Iwai T1, Imaizumi H1, Koizumi W1: World J Gastroenterol 2019/7; 25 (26): 3313-33. (–Ø“cŒõL1,2, ŽR“à_Žj1,3, Šâˆä’m‹v1, ¡ò@O1, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3‹~–œ)

510004. [‘à] Recent innovations in therapeutic endoscopy for pancreatobiliary diseases. Irisawa A, Miyoshi H, Itoi T, Ryozawa S, Kida M1,2, Inui K: Dig Endosc 2020/3; 32 (3): 309-15. (–Ø“cŒõL1,2: 1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Á‰»Ší“à)

520003. [‘à]y–å–¬ˆ³˜ŽiÇup to datez–å–¬ˆ³˜ŽiÇ‚ɑ΂·‚é“àŽ‹‹Ÿ“IŽ¡—Ã. “ú‚@‰›1, ‹›“ˆ°‹I1, š •ª–ΔŽ (1Á‰»Ší“à): “ú–{Á‰»Ší•aŠw‰ïŽGŽ 2019/5; 116 (5): 395-403.

520004. [‘à]yŽå‘è: ’×ᇐ«‘å’°‰ŠŠÖ˜AŽîᇁ|f’fEŽ¡—Â̌»ó‚Ɖۑèz’ʏí“àŽ‹‹Ÿ‚É‚æ‚é’×ᇐ«‘å’°‰ŠŠÖ˜AŽîᇐf’f‚ÌŒ»ó‚Ɖۑè. ¬—ѐŽ“T1,2, ‹ààV@2, •Êác•üL2, ìŠÝ‰Á“Þ2, Œ}@”üK2, ‰¡ŽR@ŒO2, ²“c”ü˜a2, ¬ò˜aŽO˜Y2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2Á‰»Ší“à): ˆÝ‚Æ’° 2020/2; 55 (2): 133-41.

522015. [uÀ]yÀ’k‰ï: ¡IBDƒNƒŠƒjƒJƒ‹ƒJƒ“ƒtƒ@ƒŒƒ“ƒX ‘æ2‰ñzƒXƒeƒƒCƒh’ïR«dÇUC‚Í‚Ç‚Ì‚æ‚€‚ɐf—·‚ׂ«‚©. ‰¡ŽR@ŒO1, ‘åX“S•œ, ‹gàV@”É, ’C–€Œ’Žu, ŽR‰º^K (1Á‰»Ší“à): IBDƒNƒŠƒjƒJƒ‹ƒJƒ“ƒtƒ@ƒŒƒ“ƒX 2019/5; 1 (2): 47-58.

522016. [uÀ]y‚±‚ñ‚È‚É‚ ‚é–òÜ«Á‰»ŠÇŠQz[Še˜_] 3. ¬’°‚š‚æ‚Ñ‘å’°@S-1‚É‚æ‚éÁ‰»ŠÇŠQ. Œ}@”üK1, ¬—ѐŽ“T1,2, •Êác•üL1, ìŠÝ‰Á“Þ1, ‰¡ŽR@ŒO1, ²“c”ü˜a1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): Á‰»Ší“àŽ‹‹Ÿ 2019/6; 31 (6): 934-8.

522017. [uÀ]y“ÁW: ‰ŠÇ«’°ŽŸŠ³f—ÂÌupdate| f’fEŽ¡—Â̍ŐV’mŒ©z‰ŠÇ«’°ŽŸŠ³‚ÌŒŸž–@: XüŒŸž. ‰¡ŽR@ŒO (Á‰»Ší“à): —ÕଏÁ‰»Ší“à‰È 2019/6; 34 (7): 736-40.

522018. [uÀ]ypŒã“àŽ‹‹Ÿf—Â̂·‚ׂāz[Še˜_] 1. Á‰»ŠíŽèpŒã‚Ì“àŽ‹‹ŸŒŸž|ƒT[ƒxƒCƒ‰ƒ“ƒX‚ƈَž«•a•Ï‚̐f’f|@‰ŠÇ«’°ŽŸŠ³ŽèpŒã‚Ì“àŽ‹‹ŸŒŸž. ¬—ѐŽ“T1,2, •Êác•üL2, ìŠÝ‰Á“Þ2, Œ}@”üK2, ‰¡ŽR@ŒO2, ²“c”ü˜a2, ¬ò˜aŽO˜Y2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2Á‰»Ší“à): Á‰»Ší“àŽ‹‹Ÿ 2019/9; 31 (9): 1318-23.

522019. [uÀ]yuÀ: IBD‚̃XƒyƒVƒƒƒ‹ƒVƒ`ƒ…ƒG[ƒVƒ‡ƒ“‚ð‚Ç‚€f‚é‚©?z‘æ1‰ñ@”DPEoŽY‚ðŠó–]‚·‚éIBDŠ³ŽÒ‚³‚ñ‚ð‚Ç‚€f‚é‚©?|‚»‚Ì2|. ‰¡ŽR@ŒO (Á‰»Ší“à): IBD Research 2019/9; 13 (3): 173-6.

522020. [uÀ]y“ÁW: Á‰»ŠíƒXƒeƒ“ƒg‚ÌŒ»‹µ‚Ɖۑèz3. Interventional EUS‚É‚æ‚éƒXƒeƒ“ƒg—¯’u. –Ø“cŒõL1,2, “n•Ó^ˆè2, •{‹M_2, ãŒŽˆê”¿1,2, ìŒû—C•ã1,2, ’·’Jì—Í–ç2, ‹{“c‰pŽ¡2, ‹àŽq@‹œ2, ŽR“à_Žj2,3, ‰œ˜e‹»‰î2, Šâˆä’m‹v2, ¡ò@O2, (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Á‰»Ší“à, 3‹~–œ): —ÕଏÁ‰»Ší“à‰È 2019/9; 34 (10): 1285-94.

522021. [uÀ]y‚·‚ׂĂª‚í‚©‚éIBD‚Ì“àŽ‹‹Ÿz[Še˜_] ’×ᇐ«‘å’°‰Š‚Ì“àŽ‹‹Ÿ@dÇ“x•]‰¿‚Æ”S–ŒŽ¡—Â̔»’è. ‰¡ŽR@ŒO1, ¬—ѐŽ“T1,2, •Êác•üL1, ìŠÝ‰Á“Þ1, Œ}@”üK1, ²“c”ü˜a1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): Á‰»Ší“àŽ‹‹Ÿ 2020/2; 32 (2): 206-12.

522022. [uÀ]y˜AÚ: ESD‚ÌŽÀÛ (65)zNBIŠg‘å“àŽ‹‹Ÿ‚ð—p‚¢‚œ“àŽ‹‹ŸŠÏŽ@‚Æ‘Šú‘å’°ŠàESDŠî–{Žè‹Z. ŒÃ]N–Ÿ1,2, ‘º–ì—³˜N1, V‘ºŒ’‰î1, ’rŒO˜N1 (1‘—§‚ª‚ñŒ€‹†ƒZƒ“ƒ^[“Œ•a‰@, 2Á‰»Ší“à): Á‰»Ší‚̗Տ° 2020/2; 23 (1): 54-9.

522023. [uÀ]y“ÁW: EUS‚ÌŒ»ó‚Ə«—ˆzŽ¡—Á@6. EUSƒKƒCƒh‰ºäXŠÇƒhƒŒƒi[ƒW. Šâˆä’m‹v1, –Ø“cŒõL1,2, ‰œ˜e‹»‰î1, ŽR“à_Žj1,3, ‹àŽq@‹œ1, ’·’Jì—Í–ç1, “n•Ó^ˆè1, •{‹M_1, ¡ò@O1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3‹~–œ): ŠÌ’_äX 2020/3; 80 (3): 503-10.

522024. [uÀ]y’_äX“àŽ‹‹ŸŽ¡—Âɂš‚¯‚éƒgƒ‰ƒuƒ‹ƒVƒ…[ƒeƒBƒ“ƒOz1. ERCPŠÖ˜AŽ¡—Âɂš‚¯‚é‹ô”­Ç—\–h‚ƃgƒ‰ƒuƒ‹ƒVƒ…[ƒeƒBƒ“ƒO@ƒoƒ‹[ƒ““àŽ‹‹Ÿ‚ð—p‚¢‚œERCPŠÖ˜AŽ¡—ẪRƒc‚Æ‹ô”­Ç‘΍ô. ŽR“à_Žj1,2, –Ø“cŒõL2,3, Šâˆä’m‹v2, ‰œ˜e‹»‰î2, ’·’Jì—Í–ç2, ¡ò@O2, ¬ò˜aŽO˜Y2 (1‹~–œ, 2Á‰»Ší“à, 3–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): Á‰»Ší“àŽ‹‹Ÿ 2020/3; 32 (3): 408-13.

[’˜@‘]

610005. [Šwp‘ (•ª’SŽ·•M)]yThe Evolving Landscape of Liver Cirrhosis ManagementzChapter 11: Esophagogastric Varices in Liver Cirrhosis, p.131-9. Hidaka H1, Uojima H1, Eds: Yoshiji H, Kaji K, Springer, Japan, 2019/8. (“ú‚@‰›1, ‹›“ˆ°‹I1: 1Á‰»Ší“à)

620008. [Šwp‘ (•ª’SŽ·•M)]yÁ‰»ŠÇŽŸŠ³‚Ì•ª—Þ2019|Žg‚¢•û, Žg‚í‚ê•û (ˆÝ‚Æ’°2019”N5ŒŽ‘Š§†)z¡¬’°E‘å’°@Crohn•a@CDEIS (“àŽ‹‹ŸŠŒ©‚É‚æ‚镪—Þ), p.724. ¬—ѐŽ“T1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2Á‰»Ší“à), ˆãŠw‘‰@, “Œ‹ž, 2019/5”­s.

620009. [Šwp‘ (•ª’SŽ·•M)]yÁ‰»ŠÇŽŸŠ³‚Ì•ª—Þ2019|Žg‚¢•û, Žg‚í‚ê•û (ˆÝ‚Æ’°2019”N5ŒŽ‘Š§†)z¡¬’°E‘å’°@Crohn•a@SES-CD (“àŽ‹‹ŸŠŒ©‚É‚æ‚镪—Þ), p.725. ¬—ѐŽ“T1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2Á‰»Ší“à), ˆãŠw‘‰@, “Œ‹ž, 2019/5”­s.

620010. [Šwp‘ (•ª’SŽ·•M)]yÁ‰»ŠÇŽŸŠ³‚Ì•ª—Þ2019|Žg‚¢•û, Žg‚í‚ê•û (ˆÝ‚Æ’°2019”N5ŒŽ‘Š§†)z¡¬’°E‘å’°@Crohn•a@Rutgeerts score (“àŽ‹‹ŸŠŒ©‚É‚æ‚镪—Þ), p.726 ¬—ѐŽ“T1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2Á‰»Ší“à), ˆãŠw‘‰@, “Œ‹ž, 2019/5”­s.

620011. [Šwp‘ (•ª’SŽ·•M)]y‚±‚ê‚Ÿ‚¯‚Í“Ç‚ñ‚Å‚š‚«‚œ‚¢!@Á‰»Šíˆã‚Ì‚œ‚߂̏d—v˜_•¶240•Ñ <‰ŠÇ«’°ŽŸŠ³•Ò>zŒo‰ßE—\Œã@Q195. ¬Ž™Šú”­Ç‚ÌIBD‚ÍŽ€–S—Š‚ª‚Œ‚€‚©‚·‚é‚Ì‚©?, p.204. Q196. UC‚É‚š‚¯‚é‘å’°Šà‚Ì”­Œ»•p“x‚Í?, p.205. Q197. UC‚É‚š‚¯‚é“KØ‚ȃT[ƒxƒCƒ‰ƒ“ƒX‚Ì•ûŒü‚Í?, p.206. Q198. UC‚É‚š‚¯‚é‘å’°Šà‚Ì”­¶—Š‚Í?, p.207. Q199. ‚±‚Ì30”NŠÔ‚ÅIBD‚É‚š‚¯‚é‘å’°Šà‚̃ŠƒXƒN‚ÍŒž­‚µ‚œ‚Ì‚©?, p.208. ‰¡ŽR@ŒO (Á‰»Ší“à), •ÒWŽåŠ²: Œ–{Žå”V, ƒV[ƒr[ƒA[ƒ‹, “Œ‹ž, 2019/11”­s.

620012. [Šwp‘ (•ª’SŽ·•M)]yŠÌd•ÏŽ¡—Ã}ƒjƒ…ƒAƒ‹@ƒGƒLƒXƒp[ƒg‚̃Rƒc‚Æ‚³‚¶‰ÁŒžz‘æ3Í ‡•¹ÇŽ¡—ẪRƒc‚Æ‚³‚¶‰ÁŒž@3. Á‰»ŠÇoŒŒ (H“¹ˆÝÃ–¬áŽ, PHG), p.140-6. “ú‚@‰› (Á‰»Ší“à), •Ò: ‹gŽ¡mŽu, “ì]“°, “Œ‹ž, 2019/12”­s.

620013. [Šwp‘ (•ª’SŽ·•M)]yÁ‰»ŠÇÇŒóŒQ (‘æ3”Å) II|‚»‚Ì‘Œ‚̏Á‰»ŠÇŽŸŠ³‚ðŠÜ‚߂ā| (•Êû“ú–{—Õଁ@—̈æ•ÊÇŒóŒQƒVƒŠ[ƒY No.10)zIV. ’Ž‚@1. ŠŽõÇ@(1) ’Ž‚Œ‹Šj, p.197-8. ¬—ѐŽ“T1,2, ‰¡ŽR@ŒO2, ²“c”ü˜a2, ¬ò˜aŽO˜Y2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2Á‰»Ší“à), “ú–{—Õ଎Ð, “Œ‹ž, 2020/2”­s.

[Šw‰ïEŒ€‹†‰ï“™]

712003. [Šw‰ï (‘Û)] (µ‘ҍu‰‰“™)yLuncheon Symposium FujifilmzOiagnostic EUS`Basic and application to clinical practice`. Iwai T1: Asian EUS Congress 2019 (2019/4/13), Tokyo, Japan. (Šâˆä’m‹v1: 1Á‰»Ší“à)

712004. [Šw‰ï (‘Û)] (µãٍu‰‰) Diagnostic EUS for pancreatobiliary disease. Iwai T1: ‘æ16‰ñ’†‘Á‰»Ší“àŽ‹‹ŸŠw‰ï (2019/6/22), Yangzhou, China. (Šâˆä’m‹v1: 1Á‰»Ší“à)

712005. [Šw‰ï (‘Û)] (ƒ[ƒNƒVƒ‡ƒbƒv) BONASTENT M-Intraductal for benign biliary strictures. Iwai T1: “úŠØ’_äX“àŽ‹‹Ÿf—ρ[ƒNƒVƒ‡ƒbƒv (2019/12/6), Korea. (Šâˆä’m‹v1: 1Á‰»Ší“à)

713011. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) A new method of sample isolation processing by stereo microscopy for improve tissue diagnosis performance in EUS-FNA. Okuwaki K1, Kida M1,2, Masutani H3, Imaizumi H1,4, Iwai T1, Yamauchi H1,5, Kaneko T1, Hasegawa R1, Miyata E1, Watanabe M1, Minato N1, Kurosu T1, Koizumi W1: Asian EUS Congress 2019 (2019/4/12), Tokyo, Japan. (‰œ˜e‹»‰î1, –Ø“cŒõL1, ¡’JŠ°ˆÈ3, ¡ò@O1,4, Šâˆä’m‹v1, ŽR“à_Žj1,5, ‹àŽq@‹œ1, ’·’Jì—Í–ç1, ‹{“c‰pŽ¡1, “n粐^ˆè1, –©@®‹M1, •{‹M_1, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 4‘Š–Í–ì•a‰@, 5‹~–œ)

713012. [Šw‰ï (‘Û)] (ˆê”ÊŒû‰‰) Role of Forward-Viewing EUS. Imaizumi H1,2, Iwai T2, Okuwaki K2, Yamauchi H1,3, Kaneko T2, Hasegawa R2, Miyata E2, Kida M2,4, Koizumi W2: Asian EUS Congress 2019 (2019/4/12), Tokyo, Japan. (¡ò@O1,2, Šâˆä’m‹v2, ‰œ˜e‹»‰î2, ŽR“à_Žj1,3, ‹àŽq@‹œ2, ’·’Jì—Í–ç2, ‹{“c‰pŽ¡2, –Ø“cŒõL2,4, ¬ò˜aŽO˜Y2: 1‘Š–Í–ì•a‰@, 2Á‰»Ší“à, 3‹~–œ, 4–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

713013. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) EUS hands-on training in a small-scale hospital- Examination with learning curve analysis. Ishizaki J1, Imaizumi H1,2, Kim M1, Saegusa Y1, Watanabe M2, Kurosu T2, Miyata E2, Hasegawa R2, Kaneko T2, Yamauchi H2,3, Okuwaki K2, Iwai T2, Kida M2,4: Asian EUS Congress 2019 (2019/4/12), Tokyo, Japan. (¡ò@O1,2, “n•Ó^ˆè2, •{‹M_2, ‹{“c‰pŽ¡2, ’·’Jì—Í–ç2, ‹àŽq@‹œ2, ŽR“à_Žj2,3, ‰œ˜e‹»‰î2, Šâˆä’m‹v2, –Ø“cŒõL2,4: 1‘Š–Í–ì•a‰@, 2Á‰»Ší“à, 3‹~–œ, 4–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

713014. [Šw‰ï (‘Û)] (ˆê”ÊŒû‰‰) Role of EUS in the Management of Colorectal Lesions. Kobayashi K1,2: Asian EUS Congress 2019 (2019/4/12), Tokyo, Japan. (¬—ѐŽ“T1,2: 1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2Á‰»Ší“à)

713015. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Balloon enteroscopy assisted ERCP and EUS-guided biliary drainage in patients with surgically altered gastrointestinal anatomy. Iwai T1: Asian EUS Congress 2019 (2019/4/13), Tokyo, Japan. (Šâˆä’m‹v1: 1Á‰»Ší“à)

713016. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Technical feasibility of ESD for superficial esophageal squamous cell carcinoma (SESCC) on the scar of the previous endoscopic resection (ER). Furue Y1, Yoda Y, Hori K, Nakajo K, Ito R, Sato D, Minamide T, Suyama M, Yamamoto Y, Takashima K, Shinmura K, Ikematsu H, Yano T: DDW2019 (•Ä‘Á‰»Ší•aTŠÔ) (2019/5/18), San Diego, USA. (ŒÃ]N–Ÿ1: 1Á‰»Ší“à)

713017. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Clinical significance and problems related to the diagnosis of early colorectal cancer on endoscopic ultrasonography. Kobayashi K1,2, Kawagishi K2, Mukae M2, Yokoyama K2, Kubota M2, Koizumi W2: DDW 2019 (•Ä‘Á‰»Ší•aTŠÔ) (2019/5/18-21), San Diego, USA. (¬—ѐŽ“T1,2, ìŠÝ‰Á“Þ2, Œ}@”üK2, ‰¡ŽR@ŒO2, ‹v•Û“c (²“c) ”ü˜a2, ¬ò˜aŽO˜Y2: 1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2Á‰»Ší“à)

713018. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Short-term Response to the Anti-TNF-agent Golimumab in Patients With Ulcerative Colitis in Daily Clinical Practice. Yokoyama K1, Kawagishi K1, Mukae M1, Kubota M1, Kobayashi K1,2, Koizumi W1: The 7th Annual Meeting of Asian Organization for Crohn's & Colitis (2019/6/15), Taipei, Taiwan. (‰¡ŽR@ŒO1, ìŠÝ‰Á“Þ1, Œ}@”üK1, ‹v•Û“c”ü˜a1, ¬—ѐŽ“T1,2, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

713019. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Usefulness of Narrow Band Imaging Magnifying Endoscopy for the Diagnosis of Ulcerative Colitis-associated Tumors. Mukae M1, Kobayashi K1,2, Kawagishi K1, Yokoyama K1, Kubota M1, Koizumi W1: The 7th Annual Meeting of Asian Organization for Crohn's & Colitis (2019/6/15), Taipei, Taiwan. (Œ}@”üK1, ¬—ѐŽ“T1,2, ìŠÝ‰Á“Þ1, ‰¡ŽR@ŒO1, ‹v•Û“c (²“c) ”ü˜a1, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

713020. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Outcomes of Single Balloon Dilatation for Small Bowel Strictures in Patients With Crohn's Disease. Kawagishi K1, Mukae M1, Yokoyama K1, Kobayashi K1,2: The 7th Annual Meeting of Asian Organization for Crohn's & Colitis (2019/6/15), Taipei, Taiwan. (ìŠÝ‰Á“Þ1, Œ}@”üK1, ‰¡ŽR@ŒO1, ¬—ѐŽ“T1,2: 1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

713021. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) EUS-guided transjejunal drainage using forward-viewing echoendoscope in the patients with surgically altered anatomy. Iwai T1, Kida M1,2, Okuwaki K1, Yamauchi H1,3, Kaneko T1, Hasegawa R1, Imaizumi H1,4, Koizumi W1: UEGW 2019 (‘æ27‰ñ‰¢BÁ‰»Ší•aTŠÔ) (2019/10/19), Barcelona, Spain. (Šâˆä’m‹v1, –Ø“cŒõL1,2, ‰œ˜e‹»‰î1, ŽR“à_Žj1,3, ‹àŽq@‹œ1, ’·’Jì—Í–ç1, ¡ò@O1,4, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3‹~–œ, 4‘Š–Í–ì•a‰@)

713022. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Metachronous Multiple Lesions Developing Near Scars After ESD for Early Gastric Cancer. Tanabe S1,2, Kitahara G2, Ishido K2, Kubota Y3, Wada T2, Watanabe A2, Azuma M2, Katada C2, Koizumi W2: UEGW 2019 (‘æ27‰ñ‰¢BÁ‰»Ší•aTŠÔ) (2019/10/21), Barcelona, Spain. (“c糁@‘1,2, –kŒŽ@ŒŸ2, ÎŒËŒªŽŸ2, ‹v•Û“c—z3, ˜a“c‘ñ–ç2, “n糍WŽ¯2, “Œ@’q2, Œ˜“ce—˜2, ¬ò˜aŽO˜Y2: 1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2Á‰»Ší“à, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

713023. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Sample Isolation Processing Using Stereomicroscopy as an Alternative to Rapid On-site Evaluation in Endoscopic Ultrasound-guided Fine-needle Aspiration Biopsy for the Diagnosis of Pancreatic Malignant Neoplasms. Tamaki A1, Okuwaki K1, Kida M1,2, Masutani H3, Iwai T1, Yamauchi H1,4, Kaneko T1, Hasegawa R1, Miyata E1, Watanabe M1, Kurosu T1, Imaizumi H1,5, Koizumi W1: The 50th Anniversary Joint Meeting of American Pancreatic Association (APA) and Japan Pancreas Society (JPS) (2019/11/9), Maui, USA. (‹Ê’u–ŸŠ°1, ‰œ˜e‹»‰î1, –Ø“cŒõL1,2, ¡’JŠ°ˆÈ3, Šâˆä’m‹v1, ŽR“à_Žj1,4, ‹àŽq@‹œ1, ’·’Jì—Í–ç1, ‹{“c‰pŽ¡1, “n•Ó^ˆè1, •{‹M_1, ¡ò@O1,5, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 4‹~–œ, 5‘Š–Í–ì•a‰@)

713024. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Efficacy of Sample Isolation Processing by Stereomicroscopy as a Novel Procedure in Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsy for the Diagnosis of Malignant Neoplasms of the Pancreas. Okuwaki K1, Kida M1,2, Masutani H3, Kurosu T1, Iwai T1, Yamauchi H1,4, Kaneko T1, Hasegawa R1, Miyata E1, Watanabe M1, Imaizumi H1,5, Koizumi W1: The 50th Anniversary Joint Meeting of American Pancreatic Association (APA) and Japan Pancreas Society (JPS) (2019/11/6-9), Maui, USA. (‰œ˜e‹»‰î1, –Ø“cŒõL1,2, ¡’JŠ°ˆÈ3, •{‹M_1, Šâˆä’m‹v1, ŽR“à_Žj1,4, ‹àŽq@‹œ1, ’·’Jì—Í–ç1, ‹{“c‰pŽ¡1, “n•Ó^ˆè1, ¡ò@O1,5, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 4‹~–œ, 5‘Š–Í–ì•a‰@)

713025. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Diagnostic Efficacy of a Novel Franseen Needle in EUS-Guided Fine-Needle Aspiration Biopsy of Malignant Neoplasms of the Pancreas. Watanabe M1, Okuwaki K1, Kida M1,2, Imaizumi H1,3, Iwai T1, Yamauchi H1,4, Kaneko T1, Hasegawa R1, Miyata E1, Kurosu T1, Tamaki A1, Koizumi W1: The 50th Anniversary Joint Meeting of American Pancreatic Association (APA) and Japan Pancreas Society (JPS) (2019/11/6-9), Maui, USA. (“n•Ó^ˆè1, ‰œ˜e‹»‰î1, –Ø“cŒõL1,2, ¡ò@O1,3, Šâˆä’m‹v1, ŽR“à_Žj1,4, ‹àŽq@‹œ1, ’·’Jì—Í–ç1, ‹{“c‰pŽ¡1, •{‹M_1, ‹Ê’u–ŸŠ°1, ¬ò˜aŽO˜Y1: 1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3‘Š–Í–ì•a‰@, 4‹~–œ)

713026. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Clinical usefulness of Wisteria Floribunda agglutinin-positive human Mac-2 binding protein in patients with liver cirrhosis. Uojima H1: AASLD2019 (‘æ70‰ñ•Ä‘ŠÌ‘ŸŠw‰ï‹c) (2019/11/8-12), Boston, USA. (‹›“ˆ°‹I1: 1Á‰»Ší“à)

721004. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) —Ï—RžˆÏˆõ‰ï‚©‚ç‚Ì•ñ|“ú–{‘å’°ãè–å•aŠw‰ï‚Ì—Ï—Žwj‚ÉŒW‚é\¿‚ɂ‚¢‚Ä. ¬—ѐŽ“T1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2Á‰»Ší“à): “ú–{‘å’°ãè–å•aŠw‰ï‘æ28‰ñ‹³ˆçƒZƒ~ƒi[ (2019/5/26), “Œ‹ž.

721005. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) “àŽ‹‹Ÿ‚É‚æ‚éˆô“ªƒXƒNƒŠ[ƒjƒ“ƒO. Œ˜“ce—˜ (Á‰»Ší“à): ‘æ73‰ñ“ú–{H“¹Šw‰ïŠwpW‰ï‹³ˆçƒZƒ~ƒi[ (2019/6/5), •Ÿ‰ª.

721006. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ‚—îŽÒ‚̈ÝESD‚ÌŒ»ó‚Ɖۑè. “c糁@‘1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2Á‰»Ší“à): ‘æ22‰ñ“ú–{‚—îÁ‰»Ší•aŠw‰ï‘‰ï (2019/8/2), _ŒË.

721007. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) “ú–{‘å’°ãè–å•aŠw‰ï‚Ì—Ï—Žwj‚Ɖ‰‘è“o˜^‚É‚ ‚œ‚Á‚Ä‚Ì’ˆÓŽ–€. ¬—ѐŽ“T1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2Á‰»Ší“à): ‘æ74‰ñ“ú–{‘å’°ãè–å•aŠw‰ïŠwpW‰ï (2019/10/12), “Œ‹ž.

721008. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ŠÌd•Ï‚Ì•a‘Ô‚©‚ç–å–¬ŒŒðÇ‚ðl‚Š‚é. “ú‚@‰› (Á‰»Ší“à): JDDW2019 KOBE (2019/11/21), _ŒË.

722012. [Šw‰ï (‘S‘)] (Šî’²u‰‰) –å–¬ˆ³˜ŽiÇf—Â̐V‚µ‚¢’ª—¬. “ú‚@‰› (Á‰»Ší“à): ‘æ105‰ñ“ú–{Á‰»Ší•aŠw‰ï‘‰ï (2019/5/10), Îì.

722013. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yIBDf—Â̍őOüzIBD‚ÌŠà‰». ¬—ѐŽ“T1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2Á‰»Ší“à): “ú–{‘å’°ãè–å•aŠw‰ï‘æ28‰ñ‹³ˆçƒZƒ~ƒi[ (2019/5/26), “Œ‹ž.

722014. [Šw‰ï (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ŠÌ«”]Ç‚ɑ΂·‚éB-RTO‚Ì“ž’B“_‚Ɖۑè. “c’†Œ«–Ÿ1, “ú‚@‰›1, ‹›“ˆ°‹I1 (1Á‰»Ší“à): ‘æ55‰ñ“ú–{ŠÌ‘ŸŠw‰ï‘‰ï (2019/5/30), “Œ‹ž.

722015. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) Strategy for treatments of biliary tract diseases in patients with surgically altered intestinal anatomy. Šâˆä’m‹v (Á‰»Ší“à): ‘æ97‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ï‘‰ï (2019/5/31), “Œ‹ž.

722016. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‚—îŽÒ‘ŠúˆÝŠàESDŒã”ñŽ¡–üØœÇ—á‚Ì—\Œã. ”öã”üŒb1,2, ˜a“c‘ñ–ç2, “c糁@‘2,3 (1‘—§•a‰@‹@\‘Š–ÍŒŽ•a‰@Á‰»Ší“à‰È, 2Á‰»Ší“à, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ22‰ñ“ú–{‚—îÁ‰»Ší•aŠw‰ï‘‰ï (2019/8/2), _ŒË.

722017. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŠÌd•ÏŠ³ŽÒ‚É‚š‚¯‚éL-FABP‚æ‚茟“¢‚µ‚œ• …‚Ì—L—p«. ‹›“ˆ°‹I1, “ú‚@‰›1, “c’†Œ«–Ÿ1 (1Á‰»Ší“à): ‘æ26‰ñ“ú–{–å–¬ˆ³˜ŽiÇŠw‰ï‘‰ï (2019/9/12), ŽRŒû.

722018. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) RGPIIb/IIIaR‘ÌŽY¶B×–E”‚ªƒgƒƒ“ƒ{ƒ|ƒGƒ`ƒ“Žó—e‘̃AƒSƒjƒXƒg“Š—^Œã‚ÌŽ¡—ÃŒø‰Ê‚É—^‚Š‚é‰e‹¿. ‹›“ˆ°‹I1, “ú‚@‰›1, ‰êŒÃ@áÁ, ˜a“c®‹v1, ŒE“cK‰î1, “c’†Œ«–Ÿ1 (1Á‰»Ší“à): ‘æ26‰ñ“ú–{–å–¬ˆ³˜ŽiÇŠw‰ï‘‰ï (2019/9/12), ŽRŒû.

722019. [Šw‰ï (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ŠÌüˆÛ‰»i“W‚É‚š‚¯‚éAutotaxin‚Ì“Á’¥‚ÉŠÖ‚·‚錟“¢. ‹›“ˆ°‹I1, “ú‚@‰›1, ‰êŒÃ@áÁ, ˜a“c®‹v1, ŒE“cK‰î1, “c’†Œ«–Ÿ1 (1Á‰»Ší“à): ‘æ26‰ñ“ú–{–å–¬ˆ³˜ŽiÇŠw‰ï‘‰ï (2019/9/12), ŽRŒû.

722020. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) ƒTƒ‹ƒRƒyƒjƒA‚ɑ΂·‚郌ƒ“ƒoƒ`ƒjƒu“±“üŽž‚̉h—{—Ö@‚Ì•K—v«. ‹›“ˆ°‹I1, ‹e’rØ•äŽq2, “ú‚@‰›1 (1Á‰»Ší“à, 2‰h—{•”): ‘æ26‰ñ“ú–{–å–¬ˆ³˜ŽiÇŠw‰ï‘‰ï (2019/9/13), ŽRŒû.

722021. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ”ñØœˆ««ŠÌ–å•”’_ŠÇ‹·ó‚ɑ΂·‚éƒhƒŒƒi[ƒWí—ª. Šâˆä’m‹v1, –Ø“cŒõL1,2, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ55‰ñ“ú–{’_“¹Šw‰ïŠwpW‰ï (2019/10/4), –ŒŒÃ‰®.

722022. [Šw‰ï (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) RŒŒð–ò•ž—pŠ³ŽÒ‚ɑ΂·‚éCold polypectomy‚̈À‘S«‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ìŠÝ‰Á“Þ1, ‹v•Û“c (²“c) ”ü˜a1, •Êác•üL1, Œ}@”üK1, ‰¡ŽR@ŒO1, ¬—ѐŽ“T1,2, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ74‰ñ“ú–{‘å’°ãè–å•aŠw‰ïŠwpW‰ï (2019/10/11), “Œ‹ž.

722023. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ’×ᇐ«‘å’°‰Š‚ɑ΂·‚é“úíf—Âɂš‚¯‚é•Ö’†ƒJƒ‹ƒvƒƒeƒNƒ`ƒ“‚Ì—L—p«. ‰Ô‰ª‘Ÿ˜Y1, ‰¡ŽR@ŒO1, ¬—ѐŽ“T1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2Á‰»Ší“à): ‘æ37‰ñ“ú–{‘å’°ŒŸžŠw‰ï‘‰ï (2019/11/2), “Œ‹ž.

722024. [Šw‰ï (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ‘å’°T1Šà‚̐[’B“xf’f‚š‚æ‚ÑŽ¡—Ö@‚Ì‘I‘ð‚É‚š‚¯‚é’Ž‰¹”g“àŽ‹‹Ÿ‚̗Տ°“I—L—p«. Œ}@”üK1, ¬—ѐŽ“T1,2 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): JDDW2019 KOBE (2019/11/21), _ŒË.

722025. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) äXE’_ŠÇ‹ó’°•«‡•”‹·ó‚ɑ΂·‚é“àŽ‹‹Ÿ“IŽ¡—Â̍H•v. ŽR“à_Žj1,2, ‰œ˜e‹»‰î2, ¬ò˜aŽO˜Y2 (1‹~–œ, 2Á‰»Ší“à): JDDW2019 KOBE (2019/11/21), _ŒË.

722026. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) ŠÌüˆÛ‰»i“W‚É‚š‚¯‚éAutotaxin‚̕ω»‚ÉŠÖ‚·‚錟“¢. ‹›“ˆ°‹I1, “ú‚@‰›1, ‰êŒÃ@^2 (1Á‰»Ší“à, 2Ã“슙‘q‘‡•a‰@EÁ‰»Ší•aƒZƒ“ƒ^[): JDDW2019 KOBE (2019/11/22), _ŒË.

722027. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) S‘ŸƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Ž{sŠ³ŽÒ‚É‚š‚¯‚é“àŽ‹‹ŸŠŒ©‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ˜a“c‘ñ–ç1, “c糁@‘1,2, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): JDDW2019 KOBE (2019/11/22), _ŒË.

722028. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‚—îŽÒ’×ᇐ«‘å’°‰Š‚Ì“ü‰@—á|“à‰ÈŽ¡—Âð‚Ç‚±‚܂ōs‚€‚©?|. ˆÉ“¡—²Žm1, ‰¡ŽR@ŒO1, ¬—ѐŽ“T1,2 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ10‰ñ“ú–{‰ŠÇ«’°ŽŸŠ³ŠwpW‰ï (2019/11/29), •Ÿ‰ª.

723111. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ’×ᇐ«‘å’°‰Š‚É‚š‚¯‚é•Ö’†ƒJƒ‹ƒvƒƒeƒNƒ`ƒ“’l‚Æ“àŽ‹‹ŸŠŒ©‚ÌŒŸ“¢. ‰Ô‰ª‘Ÿ˜Y1, ‰¡ŽR@ŒO1, Œ–{ˆçG1, ìŠÝ‰Á“Þ1, Œ}@”üK1, ‹v•Û“c (²“c) ”ü˜a1, ¬—ѐŽ“T1,2, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ105‰ñ“ú–{Á‰»Ší•aŠw‰ï‘‰ï (2019/5/10), Îì.

723112. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ALBI grade‚ÆUp-to-seven criteria‚Ì‘g‚ݍ‡‚킹‚É‚æ‚éŠÌ×–EŠà‚Ì—\Œã—\‘ª. “n粐^²1,2, ‰¡XOº1,3 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Á‰»Ší“à, 3‘‡f—Ã): ‘æ105‰ñ“ú–{Á‰»Ší•aŠw‰ï‘‰ï (2019/5/10), Îì.

723113. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) Crohn•a‚É‚š‚¯‚éadalimumab”{—Ê“Š—^‚ÍŽ¡—ÊúŠÔ‚ð‰„’·‚Å‚«‚é‚©? ‹ààV@1, ‰¡ŽR@ŒO1, ¬—ѐŽ“T1,2 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ105‰ñ“ú–{Á‰»Ší•aŠw‰ï‘‰ï (2019/5/10), Îì.

723114. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) CŒ^ŠÌ‰Š‚ɑ΂·‚é’ŒÚì—pŒ^RƒEƒCƒ‹ƒX–ò“±“üŒã‚̍RGPIIb/IIIaR‘ÌŽY¶B×–E‚̕ω»‚ÉŠÖ‚·‚錟“¢. ˜a“c®‹v1, ‹›“ˆ°‹I1, ŒE“cK‰î1, “c’†Œ«–Ÿ1, ’†àV‹MG1, a’J–Ÿ—²1,2, “ú‚@‰›1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2ˆã—ÊǗ): ‘æ55‰ñ“ú–{ŠÌ‘ŸŠw‰ï‘‰ï (2019/5/31), “Œ‹ž.

723115. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ŠÌ«”]Ç‚ɑ΂·‚郊ƒtƒ@ƒLƒVƒ~ƒ“ + ƒJƒ‹ƒjƒ`ƒ“•¹—p‚̈Ӌ`. ŠâèGˆê˜Y1, ‹›“ˆ°‹I1,2, “c’†Œ«–Ÿ1, ˜a“c®‹v1, ŒE“cK‰î1, “ú‚@‰›1 (1Á‰»Ší“à, 2Ã“슙‘q‘‡•a‰@): ‘æ55‰ñ“ú–{ŠÌ‘ŸŠw‰ï‘‰ï (2019/5/31), “Œ‹ž.

723116. [Šw‰ï (‘S‘)] (ˆê”ʉ‰‘è) ƒ_ƒrƒKƒgƒ‰ƒ“‹Nˆö«H“¹‰Š‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ˜a“c‘ñ–ç1, “c糁@‘1,2, ‹yì@~3, “n糍WŽ¯1, ÎŒËŒªŽŸ1, [’J‰p•œ3, “Œ@’q1, Œ˜“ce—˜1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3zŠÂŠí“à): ‘æ97‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ï‘‰ï (2019/6/1), “Œ‹ž.

723117. [Šw‰ï (‘S‘)] (ˆê”ʉ‰‘è) ‘å’°Žîᇂɑ΂·‚éJNETŠg‘åNBI•ª—ނ̗Տ°“I—L—p«‚ɂ‚¢‚Ä‚ÌŒŸ“¢. Œ}@”üK1, ¬—ѐŽ“T1,2, ‹v•Û“c (²“c) ”ü˜a1, Œ–{ˆçG1, ìŠÝ‰Á“Þ1, ‰¡ŽR@ŒO1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ97‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ï‘‰ï (2019/6/1), “Œ‹ž.

723118. [Šw‰ï (‘S‘)] (ˆê”ʉ‰‘è) EUS-HGSŽ{sŽž‚Ì‹à‘®ƒXƒeƒ“ƒg‚ƃvƒ‰ƒXƒ`ƒbƒNƒXƒeƒ“ƒg‚Ì”äŠr. ‹àŽq@‹œ1, –Ø“cŒõL1,2, ‹{“c‰pŽ¡1, ’·’Jì—Í–ç1, ŽR“à_Žj1,3, ‰œ˜e‹»‰î1, Šâˆä’m‹v1, ¡ò@O1,4 (1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3‹~–œ, 4‘Š–Í–ì•a‰@): ‘æ97‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ï‘‰ï (2019/6/1), “Œ‹ž.

723119. [Šw‰ï (‘S‘)] (ˆê”ʉ‰‘è) ¬äXŠà‚̐f’f‚É‚š‚¯‚é’_äX“àŽ‹‹Ÿ‚Ì—L—p«. –©@®‹M1, ‰œ˜e‹»‰î1, –Ø“cŒõL1,2, Œ–{‚–Ÿ1, Šâˆä’m‹v1, ŽR“à_Žj1,3, ‹àŽq@‹œ1, ’·’Jì—Í–ç1, ‹{“c‰pŽ¡1, •{‹M_1, “n•Ó^ˆè1, ¡ò@O1,4, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3‹~–œ, 4‘Š–Í–ì•a‰@): ‘æ97‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ï‘‰ï (2019/6/2), “Œ‹ž.

723120. [Šw‰ï (‘S‘)] (ˆê”ʉ‰‘è) ‰“ˆÊˆ««’_“¹‹·ó‚ɑ΂·‚éSelf-expandable metallic stent—¯’uŒã‚Ì’_ùN‰Š”­Ç‚̊댯ˆöŽq‚ÉŠÖ‚·‚錟“¢. “n•Ó^ˆè1, ‰œ˜e‹»‰î1, –Ø“cŒõL1,2, Šâˆä’m‹v1, ŽR“à_Žj1,3, ‹àŽq@‹œ1, ’·’Jì—Í–ç1, Œ–{‚–Ÿ1, ‹{“c‰pŽ¡1, ìŒû—C•ã1,2, ãŒŽˆê”¿1,2, ¡’JŠ°ˆÈ4, ˆÀ’B@‰õ4, äøŒŽ«—Ç4, ’†’JªŒá1, •{‹M_1, –©@®‹M1, ¡ò@O1,5, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3‹~–œ, 4‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 5‘Š–Í–ì•a‰@): ‘æ97‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ï‘‰ï (2019/6/2), “Œ‹ž.

723121. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) “àŽ‹‹ŸØœŒãፍ­ã‚Ì•\ÝŒ^H“¹G•œã”çŠà‚ɑ΂·‚éESD‚ÌŽ¡—ЬÑ. ŒÃ]N–Ÿ1,2, ˆË“c—Y‰î1, –x@Œ\‰î1, –å“c’q—T1, ’†žŠŒbˆê˜Y1, V‘ºŒ’‰î1, ’rŒO˜N1, –î–ì—F‹K1 (1‘—§‚ª‚ñŒ€‹†ƒZƒ“ƒ^[“Œ•a‰@, 2Á‰»Ší“à): ‘æ73‰ñ“ú–{H“¹Šw‰ïŠwpW‰ï (2019/6/6), •Ÿ‰ª.

723122. [Šw‰ï (‘S‘)] (ˆê”ʉ‰‘è) ‚—îŽÒ’×ᇐ«‘å’°‰Š‚ɑ΂·‚鐶•šŠw“I»ÜŽ¡—Â̎ÀÛ. ˆÉ“¡—²Žm1, ‰¡ŽR@ŒO1, ¬—ѐŽ“T1,2 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ74‰ñ“ú–{‘å’°ãè–å•aŠw‰ïŠwpW‰ï (2019/10/11), “Œ‹ž.

723123. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) •¡”‰ñ“àŽ‹‹ŸŒŸž‚ðŽ{s‚µ, f’f‚É“ïa‚µ‚œ¬’°“®Ã–¬ŠïŒ`‚Ì1—á. –kì”Ž”V1, Îè‚ ‚â“ß1, â•”—E‘Ÿ1, “y‹“í‘Ÿ˜Y1, Ž›“c¹O2, ‰ÍŒèû‘Ÿ˜Y2, ‹e’nG•F2, —¢“¹“N•F2, ŒŽR@—³2, ŽRèDŠì2, –ì“o@œ2, ì糑׈ê, ‰H’¹T—S2, ’J@˜as2, ŒŒŽ@C (1Á‰»Ší“à, 2•œ’Ë‹€Ï•a‰@): ‘æ68‰ñ‹€ÏˆãŠw‰ï (2019/10/23), ŽD–y.

723124. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ’†‹K–Í•a‰@‚É‚š‚¯‚鉊Ç«’°ŽŸŠ³‚̃`[ƒ€ˆã—ƒnˆæˆã—ÍvŒ£ ŽOŽ}—zˆê1, ¡ò@O1,2, ‹à@–Ÿ“N1,2, ˆä‰ô—C‰î1,2, ‘åˆä“c³l1 (1JCHO‘Š–Í–ì•a‰@, 2Á‰»Ší“à): ‘æ5‰ñJCHO’nˆæˆã—э‡ˆãŠw‰ï (2119/11/2), ‰¡•l.

723125. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) “àŽ‹‹ŸØœŒãፍ­ã‚Ì•\ÝŒ^H“¹G•œã”çŠà‚ɑ΂·‚éESD‚ÌŽ¡—ЬÑ. ŒÃ]N–Ÿ1,2, ˆË“c—Y‰î2, –x@Œ\‰î2, –å“c’q—T2, ’†žŠŒbˆê˜Y2, V‘ºŒ’‰î2, ’rŒO˜N2, –î–ì—F‹K2 (1Á‰»Ší“à, 2‘—§‚ª‚ñŒ€‹†ƒZƒ“ƒ^[“Œ•a‰@): JDDW2019 KOBE (2019/11/21), _ŒË.

723126. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) R‹ÃŒÅ–ò•ž—pŽÒ‚Ì‘Šúã•”Á‰»ŠÇŽîᇂɑ΂·‚éESDŒãoŒŒ‚ÌŒŸ“¢. Îèƒ˜Y1, ˜a“c‘ñ–ç1, “n糍WŽ¯1, ÎŒËŒªŽŸ1, “Œ@’q1, Œ˜“ce—˜1, “c糁@‘1,2, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): JDDW2019 KOBE (2019/11/21), _ŒË.

723127. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ‚—îŽÒ’×ᇐ«‘å’°‰Š‚ɑ΂·‚é–Ɖu“Œä—Ö@‚ÌŽÀÛ‚ÆŽž‘ã“I•Ï‘J. ˆÉ“¡—²Žm1, ‰¡ŽR@ŒO1, ’|’J@Ê1, Œ–{ˆçG1, ìŠÝ‰Á“Þ1, Œ}@”üK1, ‹v•Û“c (²“c) ”ü˜a1, ¬—ѐŽ“T1,2, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): JDDW2019 KOBE (2019/11/21), _ŒË.

723128. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) –«ŠÌŽŸŠ³‚É‚š‚¯‚éŠÌƒTƒ‹ƒRƒyƒjƒAf’f‚̈Ӌ`‚ÉŠÖ‚·‚é‘œŽ{Ý‘OŒü‚«ŒŸ“¢. ŠâèGˆê˜Y1, “ú‚@‰›1, ‹›“ˆ°‹I1 (1Á‰»Ší“à): JDDW2019 KOBE (2019/11/21), _ŒË.

723129. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚É‚š‚¯‚éØœ•s”\EÄ”­ˆÝ‚ª‚ñ‚ɑ΂·‚éNivolumab‚ÌŽ¡—ЬÑ. –kŒŽ@ŒŸ1, ÎŒËŒªŽŸ1, ‹v•Û“c—z2, “n糍WŽ¯1, ˜a“c‘ñ–ç1, “Œ@’q1, Œ˜“ce—˜1, “c糁@‘1,3, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã): JDDW2019 KOBE (2019/11/22), _ŒË.

723130. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚É‚š‚¯‚éØœ•s”\isEÄ”­ˆÝŠà‚ɑ΂·‚énab-PTX + RAM—Ö@‚ÌŽ¡—ЬÑ. ‹v•Û“c—z1, “Œ@’q2, Î‹Ž@˜Ð2, “n糍WŽ¯2, ˜a“c‘ñ–ç2, ÎŒËŒªŽŸ2, Œ˜“ce—˜2, “c糁@‘2,3, ¬ò˜aŽO˜Y2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2Á‰»Ší“à, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã): JDDW2019 KOBE (2019/11/22), _ŒË.

723131. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ’_ŠÇŒ‹Î‚ɑ΂·‚é“àŽ‹‹Ÿ“I“û“ªƒ‰[ƒWƒoƒ‹[ƒ“Šg’£p‚É‚š‚¯‚é‹ô”­Ç‚ÌŒŸ“¢. ‹Ê’u–ŸŠ°1, ŽR“à_Žj1,2, –Ø“cŒõL1,3, ãŒŽˆê”¿1,3, ‰œ˜e‹»‰î1, Šâˆä’m‹v1, ¡ò@O1,4, ‹{“c‰pŽ¡1, ’·’Jì—Í–ç1, ‹àŽq@‹œ1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2‹~–œ, 3–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 4‘Š–Í–ì•a‰@): JDDW2019 KOBE (2019/11/23), _ŒË.

723132. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ‘å’°ƒ|ƒŠ[ƒv‚ɑ΂·‚éCold polypectomy‚Ì—L—p«‚ɂ‚¢‚Ä‚ÌŒŸ“¢. “c糔ü“Þ1, ìŠÝ‰Á“Þ1, ‹v•Û“c (²“c) ”ü˜a1, •Êác•üL1, Œ}@”üK1, ‰¡ŽR@ŒO1, ¬—ѐŽ“T1,2, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): JDDW2019 KOBE (2019/11/23), _ŒË.

723133. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) pŒãÄŒš’°ŠÇ‚ð—L‚·‚鈫«’_“¹‹·ó‚ɑ΂·‚郁ƒ^ƒŠƒbƒNƒXƒeƒ“ƒg—¯’up‚ƃvƒ‰ƒXƒ`ƒbƒNƒXƒeƒ“ƒg—¯’up‚ÌŽ¡—ЬÑ‚Ì”äŠrŒŸ“¢. ’·’Jì—Í–ç1, –Ø“cŒõL1,2, •{‹M_1, “n•Ó^ˆè1, ‹{“c‰pŽ¡1, ‹àŽq@‹œ1, ŽR“à_Žj1,3, ‰œ˜e‹»‰î1, Šâˆä’m‹v1, ¡ò@O1,4, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3‹~–œ, 4‘Š–Í–ì•a‰@): JDDW2019 KOBE (2019/11/23), _ŒË.

723134. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) äXˆ««Žîᇂɑ΂·‚éEUS-FNAB‚É‚š‚¯‚錟‘̏ˆ—–@: Sample Isolation Processing by Stereo-microscope‚Ì—L—p«. •{‹M_1, ‰œ˜e‹»‰î1, –Ø“cŒõL1,2, ¡’JŠ°ˆÈ3, Šâˆä’m‹v1, ŽR“à_Žj1,4, ‹àŽq@‹œ1, ’·’Jì—Í–ç1, ‹{“c‰pŽ¡1, “n•Ó^ˆè1, ¡ò@O1,5, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 4‹~–œ, 5‘Š–Í–ì•a‰@): JDDW2019 KOBE (2019/11/23), _ŒË.

723135. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ’×ᇐ«‘å’°‰Š‚É‚š‚¯‚é•Ö’†ƒJƒ‹ƒvƒƒeƒNƒ`ƒ“‘ª’è‚Í“úíf—Âɂš‚¢‚Ä—L—p‚©? ‰Ô‰ª‘Ÿ˜Y1, ‰¡ŽR@ŒO1, Œ–{ˆçG1, ìŠÝ‰Á“Þ1, Œ}@”üK1, ‹v•Û“c (²“c) ”ü˜a1, ¬—ѐŽ“T1,2, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ10‰ñ“ú–{‰ŠÇ«’°ŽŸŠ³Šw‰ïŠwpW‰ï (2019/11/29), •Ÿ‰ª.

723136. [Šw‰ï (‘S‘)] (ˆê”ʉ‰‘è) ’¹”§ˆÝ‰Š‚ð’悵‚œHelicobacter pylori‰A«‚̈ê—á. “c糔ü“Þ1, ìŠÝ‰Á“Þ1, “c糁@‘1,2, ‰¡ŽR@ŒO1, ‹v•Û“c—z3, “n糍WŽ¯1, ˜a“c‘ñ–ç1, ÎŒËŒªŽŸ1, “Œ@’q1, Œ˜“ce—˜1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ16‰ñ“ú–{Á‰»ŠÇŠw‰ï‘‰ïŠwpW‰ï (2020/2/7), •ºŒÉ.

723137. [Šw‰ï (‘S‘)] (ˆê”ʉ‰‘è) ‘ŠúˆÝŠà‚ɑ΂µ‚ÄESD ‚ðŽ{s‚µ‚œ‚—ŽÒ‚Å, ”ñŽ¡–üØœ‚Å‚ ‚Á‚œÇ—á‚ÌŒŸ“¢. –kŒŽ@ŒŸ (Á‰»Ší“à): ‘æ92‰ñ“ú–{ˆÝŠàŠw‰ï‘‰ï (2020/3/5), _“ސì.

723027. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠÌ—Þ“Ž•ÂÇÇŒóŒQ‚É‚š‚¯‚éƒgƒƒ“ƒ{ƒLƒTƒ“A2Žó—e‘Ì‚Ì–ðŠ„‚É‚Â‚¢‚Ä (Thromboxane A2 receptor signaling attenuates monocrotaline-induced liver injury by affecting endothelial cells, but not platelets). ‘卂Žj¹1, ˆÉ“¡‹`–ç2, ˆäã’qm3, ‘å‹v•Û”Ž¢4, ’ׯ¢—¢1, ×–ì‰Á“ÞŽq2, ¬ò˜aŽO˜Y3, ”n“ˆ³—²2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–ò—, 3Á‰»Ší“à, 4S‘ŸŒŒŠÇŠO): ‘æ93‰ñ“ú–{–ò—Šw‰ï”N‰ï (2020/3/16-18), Ž†ãŠJÃ.

731002. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ‘‰Á‚·‚鉊Ç«’°ŽŸŠ³|¡, ’nˆæ˜AŒg‚ðl‚Š‚é|. ‰¡ŽR@ŒO (Á‰»Ší“à): Takeda Ulcerative Colitis‘S‘WebƒZƒ~ƒi[ (2019/4/9), Web.

731003. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ƒGƒ“ƒ^ƒCƒrƒI‚ÌPh‡VŽŽŒ±¬Ñ‚Æ’×ᇐ«‘å’°‰Š‚ÌŽ¡—Âɂ‚¢‚Ä. ‰¡ŽR@ŒO (Á‰»Ší“à): ’×ᇐ«‘å’°‰Š‚̐V‚µ‚¢Ž¡—Ð헪 (2019/4/17), “Œ‹ž.

731004. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) IBD‚É‚š‚¯‚鎡—ÃStep Up‚̃^ƒCƒ~ƒ“ƒO. ‰¡ŽR@ŒO (Á‰»Ší“à): –k‘«—§ŒSIBDƒZƒ~ƒi[ (2019/4/18), é‹Ê.

731005. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) V‹KIBDŽ¡—Öò‚ÌŽg—pŒoŒ±. ‰¡ŽR@ŒO (Á‰»Ší“à): ‘æ52‰ñ_“ސìIBDƒ~ƒjƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2019/5/13), _“ސì.

731006. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ƒNƒ[ƒ“•af—Âɂš‚¯‚錌ŽˆŸ‰”ƒ‚ƒjƒ^ƒŠƒ“ƒO. ‰¡ŽR@ŒO (Á‰»Ší“à): ’ሟ‰”ŒŒÇWEBu‰‰‰ï (2019/5/23), Web.

731007. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ƒGƒ“ƒ^ƒCƒrƒI‚Ì‘æ3‘ŠŽŽŒ±¬Ñ‚Æ’×ᇐ«‘å’°‰Š‚ÌŽ¡—Âɂ‚¢‚Ä. ‰¡ŽR@ŒO (Á‰»Ší“à): ŒÃEŒ§‰›Á‰»Ší•aŒ€‹†‰ï (2019/6/19), _“ސì.

731008. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ‚Ý‚ñ‚ȂŐf‚æ‚€IBDf—Ã. ‰¡ŽR@ŒO (Á‰»Ší“à): IBDŒ€‹†‰ï (2019/7/26), ç—t.

731009. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ‘‚Š‘±‚¯‚é’×ᇐ«‘å’°‰Š`¡‚±‚»‚Ý‚ñ‚ȂŐf‚é‚œ‚߂Ɂ`. ‰¡ŽR@ŒO (Á‰»Ší“à): ‘æ2‰ñ‚³‚¢‚œ‚ÜIBD•af˜AŒgƒZƒ~ƒi[ (2019/8/29), é‹Ê.

731010. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ’×ᇐ«‘å’°‰Š‚ɑ΂·‚é“à‰ÈŽ¡—Ö@‚̐i•à. ¬—ѐŽ“T1,2 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): “ŒŠ‹’n‹æUCƒZƒ~ƒi[ (2019/9/5), ç—t.

731011. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ¡‚±‚»IBD‚̃`[ƒ€ˆã—Âðl‚Š‚é. ‰¡ŽR@ŒO (Á‰»Ší“à): IBDƒlƒbƒgƒtƒH[ƒ‰ƒ€ (2019/9/6), Web.

731012. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ’×ᇐ«‘å’°‰Š‚̗Տ°‘œ‚Æ“à‰ÈŽ¡—Â̎ÀÛ. ‰¡ŽR@ŒO (Á‰»Ší“à): ‘å˜aŽsÁ‰»Ší•aŒ€‹†‰ï (2019/9/18), _“ސì.

731013. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ’×ᇐ«‘å’°‰Š‚É‚š‚¯‚éCAP‚Ì–ðŠ„`“–‰@‚ÌŽ¡—ÃŒoŒ±‚©‚çl‚Š‚é`. ‰¡ŽR@ŒO (Á‰»Ší“à): ŠÖ–å“sŽsŒ—IBDƒZƒ~ƒi[ (2019/9/20), •Ÿ‰ª.

731014. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ƒNƒ[ƒ“•a‚É‚š‚¯‚é“à‰È“IEŠO‰È“IƒAƒvƒ[ƒ`‚Ì‘ŠŒÝ—‰ð. ‰¡ŽR@ŒO (Á‰»Ší“à): Crohn's Disease Web seminar (2019/9/25), Web.

731015. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) IBDf—Â̌»ó‚Ɖۑè`’nˆæ‚Őf‚é’×ᇐ«‘å’°‰Š`. ‰¡ŽR@ŒO (Á‰»Ší“à): _“ސì Ulcerative colitis Conference (2019/9/26), _“ސì.

731016. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ƒNƒ[ƒ“•aŽ¡—Âɂš‚¯‚鐶•šŠw“I»Ü‚ÌŽ¡—Ð헪. ‰¡ŽR@ŒO (Á‰»Ší“à): ‘æ114‰ñ“ú–{Á‰»Ší•aŠw‰ï‹ãBŽx•”—á‰ïE‘æ108‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ï‹ãBŽx•”—á‰ï (2019/11/9), ‹{è.

731017. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ’×ᇐ«‘å’°‰Š‚Ì“úíf—ÂŃxƒhƒŠƒYƒ}ƒu‚ð‚Ç‚€Žg‚Á‚Ä‚¢‚­‚©. ‰¡ŽR@ŒO (Á‰»Ší“à): ‘æ109‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ïŠÖ“ŒŽx•”—á‰ï (2019/12/14), “Œ‹ž.

731018. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) IBDf—Âɂš‚¯‚éShared-decision making. ‰¡ŽR@ŒO (Á‰»Ší“à): ‹ãBIBD up-to-date Meeting (2020/1/11), •Ÿ‰ª.

731019. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ’×ᇐ«‘å’°‰ŠŽ¡—Â̊î–{–ò`5-ASA»Ü‚ð‚Ç‚€Žg‚€‚©`. ‰¡ŽR@ŒO (Á‰»Ší“à): Ã“ì’×ᇐ«‘å’°‰ŠŽ¡—ÃZƒ~ƒi[ (2020/1/16), _“ސì.

731020. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ƒNƒ[ƒ“•aŽ¡—Âɂš‚¯‚鐶•šŠw“I»Ü‚ÌŽ¡—Ð헪. ‰¡ŽR@ŒO (Á‰»Ší“à): ‘æ2‰ñ”ö“¹ IBD-Meeting (2020/2/4), L“‡.

732006. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) Šg‘å“àŽ‹‹ŸŠÏŽ@‚ª‘¶Ýf’f‚É—L—p‚Å‚ ‚Á‚œUCŠÖ˜AŽîᇂÌ1—á. •Êác•üL1, ‹v•Û“c (²“c) ”ü˜a1, ¬—ѐŽ“T1,2 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ108‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ïŠÖ“ŒŽx•”—á‰ï (2019/6/8), “Œ‹ž.

732007. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ’j«‚Ì‘ŠúH“¹Šà‚ɑ΂·‚é“àŽ‹‹ŸØœŒã‚َ̈ž«H“¹Šà‚Ì”­¶‚ÆMacrocytosis‚ÌŠÖ˜A. Œ˜“ce—˜1, ‰¡ŽR“OŽ¢2, •“¡@Šw3 (1Á‰»Ší“à, 2‘—§•ÛŒ’ˆã—ÉȊw‰@¶ŠUŒ’NŒ€‹†•”, 3‹ž“s‘啍‘®•a‰@Žîᇓà‰È): ‘æ108‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ïŠÖ“ŒŽx•”—á‰ï (2019/6/9), “Œ‹ž.

732008. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒrƒfƒIƒ[ƒNƒVƒ‡ƒbƒv) EUS-FNA‚É‚š‚¯‚éúŽh¢“ï—á‚ɑ΂·‚éƒgƒ‰ƒuƒ‹ƒVƒ…[ƒeƒBƒ“ƒO. •{‹M_1, ’·’Jì—Í–ç1, Šâˆä’m‹v1, –Ø“cŒõL1,2, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ108‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ïŠÖ“ŒŽx•”—á‰ï (2019/6/9), “Œ‹ž.

732009. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) “ú–{l’×ᇐ«‘å’°‰ŠŠ³ŽÒ‚ð‘ΏۂƂµ‚œƒGƒ“ƒ^ƒCƒrƒI‘æ1‘ŠŽŽŒ±‚ɂ‚¢‚Ä‚ÌŒ‹‰Ê•ñ. ¬—ѐŽ“T1,2 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ŒÃEŒ§‰›Á‰»Ší•aŒ€‹†‰ï (2019/6/19), ŠC˜V–Œ.

732010. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒVƒ“ƒ|ƒWƒEƒ€) ’ÁÃ‘Oƒ`ƒFƒbƒNƒŠƒXƒg‚É‚æ‚é“àŽ‹‹Ÿf—Â̒ÁÃ‘OŠ³ŽÒ•]‰¿‚ÌŽæ‚è‘g‚Ý. ÎŒËŒªŽŸ1, “c糁@‘1,2, •Šâ­”V3 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3–ƒŒ): ‘æ109‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ïŠÖ“ŒŽx•”—á‰ï (2019/12/14), “Œ‹ž.

732011. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ’×ᇐ«‘å’°‰ŠŠÖ˜AŽîᇂɑ΂·‚éNBIŠg‘å“àŽ‹‹Ÿf’f‚Ì—L—p«‚ɂ‚¢‚Ä‚ÌŒŸ“¢. Œ}@”üK1, ¬—ѐŽ“T1,2, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ109‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ïŠÖ“ŒŽx•”—á‰ï (2019/12/14), “Œ‹ž.

732012. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) äXˆ««Žîᇂɑ΂·‚éEUS-FNAB‚É‚š‚¯‚éRapid on-site evaluation‚Ì—L—p«‚ÉŠÖ‚·‚錟Ø. ‹Ê’u–ŸŠ°1, ‰œ˜e‹»‰î1, Šâˆä’m‹v1, –Ø“cŒõL1,2, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ109‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ïŠÖ“ŒŽx•”—á‰ï (2019/12/14), “Œ‹ž.

732013. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“)yHelicobacter pylori–¢ŠŽõEœ‹ÛŒãˆÝ‚ª‚ñ‚Ì“àŽ‹‹Ÿf’fz“–‰@‚É‚š‚¯‚éHP‰A«ˆÝŠàf’f‚ÌŽÀÛ. ˆä‰ô—C‰î1, ‹à@–Ÿ“N1,2, ŽOŽ}—zˆê2, ¡ò@O1,2, “c糁@‘1,3 (1Á‰»Ší“à, 2JCHO‘Š–Í–ì•a‰@, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ109‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ïŠÖ“ŒŽx•”—á‰ï (2019/12/15), “Œ‹ž.

732014. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒrƒfƒIƒ[ƒNƒVƒ‡ƒbƒv) ‘å’°ŒeŽºoŒŒ‚ɑ΂·‚é“àŽ‹‹Ÿ“IŽ~ŒŒ–@‚ÌŽ¡—ЬÑ. ìŠÝ‰Á“Þ1, ¬—ѐŽ“T1,2, Œ–{ˆçG1, ‹v•Û“c (²“c) ”ü˜a1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ109‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ïŠÖ“ŒŽx•”—á‰ï (2019/12/15), “Œ‹ž.

733026. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (êCˆãƒZƒbƒVƒ‡ƒ“) ŠÌŒŒŠÇ“÷Žî‚Æ‚ÌŠÓ•Ê‚ª¢“ï‚Å‚ ‚Á‚œŠÌŽ‡”Á•a‚Ì1–UŒŸ—á. ˆÉ“¡—²Žm1, ‹›“ˆ°‹I1, “ú‚@‰›1, ˜a“c®‹v1, ŒE“cK‰î1, “c’†Œ«–Ÿ1, a’J–Ÿ—²1,2, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2ˆã—ÊǗ): “ú–{Á‰»Ší•aŠw‰ïŠÖ“ŒŽx•”‘æ354‰ñ—á‰ï (2019/4/13), “Œ‹ž.

733027. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (Œ€CˆãƒZƒbƒVƒ‡ƒ“) ”­ÇŒã’ZŠúŠÔ‚Å‘Šú¬’°Šà‚ð‡•¹‚µ‚œƒNƒ[ƒ“•a‚Ì1—á. ¬•ô—C“Þ1, ¬‹àˆäˆê—²1, ’C–€Œ’Žu1, “ñ–؁@—¹1, •–Ø”Ž‰î1, ™“c@º1, —с@Gs2, ‰¡ŽR@ŒO3 (1‰¡•lŽs—§Žs–¯•a‰@‰ŠÇ«’°ŽŸŠ³‰È, 2‰¡•lŽs—§Žs–¯•a‰@•a—f’f‰È, 3Á‰»Ší“à): “ú–{Á‰»Ší•aŠw‰ïŠÖ“ŒŽx•”‘æ354‰ñ—á‰ï (2019/4/13), “Œ‹ž.

733028. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è) ’¹”§ˆÝ‰Š‚̏ŠŒ©‚ð’悵‚œƒNƒ[ƒ“•a‚Ì1—á. ˆä‰ô‰ÀØ1, “c糔ü“Þ1, ìŠÝ‰Á“Þ1, “c糁@‘1,2, Œ}@”üK1, ‰¡ŽR@ŒO1, ‹v•Û“c (²“c) ”ü˜a1, ¬—ѐŽ“T1,3, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): “ú–{“à‰ÈŠw‰ï‘æ650‰ñŠÖ“Œ’n•û‰ï (2019/5/18), “Œ‹ž.

733029. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) “–‰@‚ÅŒoŒ±‚µ‚œˆÝ’ê‘BŒ^ˆÝŠà‚ɂ‚¢‚Ä‚ÌŒŸ“¢. Îèƒ˜Y1, ˜a“c‘ñ–ç1, H’J¹Žj2, “n糍WŽ¯1, ÎŒËŒªŽŸ1, “Œ@’q1, Œ˜“ce—˜1, “c糁@‘1,3, ‹g“c@Œ÷2, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2•a—, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ108‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ïŠÖ“ŒŽx•”—á‰ï (2019/6/9), “Œ‹ž.

733030. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) EUS-FNB‚Őf’f‚µ“Ÿ‚œ‘ŠO«Œ`Ž¿×–EŽî‚Ì1—á. ²–ì’BÆ (Á‰»Ší“à): ‘æ146‰ñ_“ސìŠÌ’_äXŽŸŠ³Œ€‹†‰ï (2019/6/27), ‰¡•l.

733031. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) p‘Of’f‚É‹ê—¶‚µL”͈͂Ìdyspiasia‚𔺂Á‚œcolitis associated rectal cancer‚Ì1—á. “c糔ü“Þ1, ¬—ѐŽ“T1,2, ìŠÝ‰Á“Þ1, Œ}@”üK1, ‰¡ŽR@ŒO1, ‹v•Û“c (²“c) ”ü˜a1, ¬ò˜aŽO˜Y1, ŽO‰YŒ[šæ3, ŽOŽ}@M4 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3‰º•”Á‰»ŠÇŠO, 4•a—): ‘æ64‰ñ_“ސ쌧Á‰»Ší•aŒ€‹†‰ï (2019/7/6), ‰¡•l.

733032. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) 14Î¬Ž™‘’_ŠÇŒ‹ÎÇ‚Ì1—á. “y‹“í‘Ÿ˜Y1, ŒŽR@—³1,2, â•”—E‘Ÿ1,2, –kì”Ž”V2, Ž›“c¹O2, ‰ÍŒèû‘Ÿ˜Y2, ‹e’nG•F2, —¢“¹“N•F2, ŽRèDŠì2 (1Á‰»Ší“à, 2•œ’Ë‹€Ï•a‰@): ‘æ64‰ñ_“ސ쌧Á‰»Ší•aŒ€‹†‰ï (2019/7/6), ‰¡•l.

733004. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ŠÌ—Þ“Ž•ÂÇÇŒóŒQ‚É‚š‚¯‚éƒgƒƒ“ƒ{ƒLƒTƒ“Žó—e‘Ì‚Ì–ðŠ„. ‘卂Žj¹1, ˆÉ“¡‹`–ç2, ˆäã’qm3, ŒàVL‹±4, ’†–{CŽi1, ’ׯ¢—¢1, •ž•”‹¿Žq5, –{“c‰ëŽq1, ×–ì‰Á“ÞŽq2, ¬ò˜aŽO˜Y3, ”n“ˆ³—²2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–ò—, 3Á‰»Ší“à, 4ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 5ŽY‰È): ‘æ140‰ñ“ú–{–ò—Šw‰ïŠÖ“Œ•”‰ï (2019/7/6), “Œ‹ž.

733033. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) Ž©ŒÈ–Ɖu«äX‰Š‚ɑ΂·‚éƒXƒeƒƒCƒh‰Á—Ã’†‚ÉäXŠà‚𔭏ǂµ‚œ1—á. ¬–쎛—§1, “n•Ó^ˆè1, ŽR“à_Žj1,2, •{‹M_1, ’·’Jì—Í–ç1, ‹àŽq@‹œ1, ‰œ˜e‹»‰î1, Šâˆä’m‹v1, ¡ò@O1,3, –Ø“cŒõL1,4, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2‹~–œ, 3JCHO‘Š–Í–ì•a‰@, 4–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): “ú–{Á‰»Ší•aŠw‰ïŠÖ“ŒŽx•”‘æ355‰ñ—á‰ï (2019/7/13), “Œ‹ž.

733034. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è) S”x’âŽ~‘h¶Œã‚É”­Ç‚µ‚œ‹•ŒŒ«¬’°‰Š‚Ì1—á. â•”—E‘Ÿ1, Œ}@”üK1, •Êác•üL1, ìŠÝ‰Á“Þ1, ‰¡ŽR@ŒO1, ‹v•Û“c (²“c) ”ü˜a1, ¬ò˜aŽO˜Y1, ¬—ѐŽ“T1,2, ’†‘º—²r3 (1Á‰»Ší“à, 2¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3‰º•”Á‰»ŠÇŠO): “ú–{“à‰ÈŠw‰ï‘æ653‰ñŠÖ“Œ’n•û‰ï (2019/9/14), “Œ‹ž.

733035. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (êCˆãƒZƒbƒVƒ‡ƒ“) Øœ‰Â”\‚ȐH“¹_Œo“à•ª”傪‚ñ‚ɑ΂µ‚ĉ»Šw•úŽËü—Ö@‚ª—LŒø‚Å‚ ‚Á‚œ1—á. ŒŽ@—E•ã1, “n糍WŽ¯1, Œ˜“ce—˜1, ‹v•Û“c—z2, ˜a“c‘ñ–ç1, ÎŒËŒªŽŸ1, “Œ@’q1, “c糁@‘1,3 (1Á‰»Ší“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã): “ú–{Á‰»Ší•aŠw‰ïŠÖ“ŒŽx•”‘æ356‰ñ—á‰ï (2019/9/21), “Œ‹ž.

733036. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è) •¡”‰ñ‚ÌsalvagePDT‚Å“ïa‚µsalvageŽèp‚ðŽÀŽ{‚µ‚œH“¹Šà‚̈ê—á. ŒÃ]N–Ÿ1,2, ˆË“c—Y‰î2, –å“c’q—T2, –î–ì—F‹K2, “¡“c•˜Y2, “¡ŒŽ®Žu2, ‘åKGK2 (1Á‰»Ší“à, 2‘—§‚ª‚ñŒ€‹†ƒZƒ“ƒ^[“Œ•a‰@): ‘æ44‰ñH“¹ŠàWŠw“IŽ¡—ÃŒŸ“¢‰ï (2019/10/18), “Œ‹ž.

733037. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è) H“¹’ʉߏáŠQ‚ðŒ_‹@‚ɐf’f‚µ“Ÿ‚œäX”ö•”Šà‚Ì1—á. ”ä—¯ŠÔ’q‹I1, •{‹M_1, “n•Ó^ˆè1, ’·’Jì—Í–ç1, ‹àŽq@‹œ1, ŽR“à_Žj1,2, ‰œ˜e‹»‰î1, Šâˆä’m‹v1, –Ø“cŒõL1,3, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2‹~–œ, 3–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): “ú–{“à‰ÈŠw‰ï‘æ655‰ñŠÖ“Œ’n•û‰ï (2019/11/9), “Œ‹ž.

733038. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ”A•Â‚É‚æ‚荂ƒAƒ“ƒ‚ƒjƒAŒŒÇ, ˆÓŽ¯áŠQ‚𐶂¶‚œ1—á. ˆä‰ô—C‰î1, ‰i‰ª–¢—ˆ2, ‚‹Ž@—É2, •ÐŽR‘쎢3,4, Îˆä—²Ži3,4, –î“àŒŽ’qŽq4, ¡è‹M¶4, ŽOŽ}—zˆê4, ¡ò@O1,4, ‹à@–Ÿ“N1,4 (1Á‰»Ší“à, 2t‘Ÿ“à, 3ŒŒ‰t“à, 4JCHO‘Š–Í–ì•a‰@): “ú–{“à‰ÈŠw‰ï‘æ655‰ñŠÖ“Œ’n•û‰ï (2019/11/9), “Œ‹ž.

733039. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ˆÝ”S–Œ‰ºŽîᇂ̐f’f. ŒŽR@—³1,2, “y‹“í‘Ÿ˜Y2, â•”—E‘Ÿ2, Ž›“c¹O1, –kì”Ž”V1, ‰ÍŒŒ°‘Ÿ˜Y1, ‹e’nG•F1, —¢“¹“N•F1, ŽRú±DŠì1 (1•œ’Ë‹€Ï•a‰@, 2Á‰»Ší“à): ‘æ51‰ñ•œ’Ë‹€Ï•a‰@E•œ’ËŽsˆãŽt‰ï‡“¯—Տ°§˜b‰ï (2019/11/20), •œ’Ë.

733040. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (êCˆãƒZƒbƒVƒ‡ƒ“) “–‰@‚É‚š‚¯‚é’×ᇐ«‘å’°‰Š‚ɑ΂·‚évedolizumab‚Ì’ZŠúŽ¡—ЬÑ‚ɂ‚¢‚Ä. ‹ààV@1, ‰¡ŽR@ŒO1, •Êác•üL1, Œ–{ˆçG1, ìŠÝ‰Á“Þ1, Œ}@”üK1, ‹v•Û“c (²“c) ”ü˜a1, ¬ò˜aŽO˜Y1, ¬—ѐŽ“T1,2 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): “ú–{Á‰»Ší•aŠw‰ïŠÖ“ŒŽx•”‘æ357‰ñ—á‰ï (2019/12/7), “Œ‹ž.

733041. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (êCˆãƒZƒbƒVƒ‡ƒ“) Žq‹{•œŠŠ‹Ø“÷ŽîpŒã‚É‘Sg“]ˆÚÄ”­‚ð”F‚ß, EUS-FNA‚Őf’f‚ÉŽŠ‚Á‚œˆê—á. ˆä‰ô—C‰î1,2, ¡ò@O1,2, ‹à@–Ÿ“N1,2, ŽOŽ}—zˆê2, Vˆä³G2,3, äøŒŽ«—Ç4, ¡’JŠ°ˆÈ4, “n•Ó^ˆè1, •{‹M_1, ˆÀ’B@‰õ4, ’·’Jì—Í–ç1, ‹àŽq@‹œ1, ŽR“à_Žj1,5, ‰œ˜e‹»‰î1, Šâˆä’m‹v1, –Ø“cŒõL1,6 (1Á‰»Ší“à, 2‘Š–Í–ì•a‰@, 3•wl, 4‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 5‹~–œ, 6–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): “ú–{Á‰»Ší•aŠw‰ïŠÖ“ŒŽx•”‘æ357‰ñ—á‰ï (2019/12/7), “Œ‹ž.

733042. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è) f’f‚É“ïa‚µ‚œŠÌ–¢•ª‰»‘ÙŽ™«“÷Žî‚Ì1—á. áÁ•”—Dì1, “ú‚@‰›1, ˜a“c®‹v1, ŒE“cK‰î1, ‹›“ˆ°‹I1, “c’†Œ«–Ÿ1, ’†àV‹MG1, a’J–Ÿ—²1,2, ¬ò˜aŽO˜Y1, ŠC’ËMŽj3, ŒGŒ³—Y‰î3 (1Á‰»Ší“à, 2ˆã—ÊǗ, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO): “ú–{Á‰»Ší•aŠw‰ïŠÖ“ŒŽx•”‘æ357‰ñ—á‰ï (2019/12/7), “Œ‹ž.

733043. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è) ’Ž‰¹”g“àŽ‹‹Ÿ‰º‚ɂăGƒ^ƒm[ƒ‹’“ü—Ö@‚ðŽ{s‚µ‚œ”öó—t‚̊̍זEŠà‚Ì1—á. –kŒŽ@ŒŸ1, ‹àŽq@‹œ1, •{‹M_1, “n•Ó^ˆè1, ’·’Jì—Í–ç1, ‰œ˜e‹»‰î1, Šâˆä’m‹v1, –Ø“cŒõL1,2, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): “ú–{Á‰»Ší•aŠw‰ïŠÖ“ŒŽx•”‘æ357‰ñ—á‰ï (2019/12/7), “Œ‹ž.

733044. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è)uV‹KƒKƒCƒhƒƒCƒ„[—U“±Ž®ƒuƒ‰ƒVv‚ðŽg—p‚µ‚œ’_ŠÇ‹·ó‚ɑ΂·‚éƒuƒ‰ƒVŽC‰ß×–Ef‚̐f’f”\‚ɂ‚¢‚Ä. ‹{“c‰pŽ¡1, –Ø“cŒõL1,2, Šâˆä’m‹v1, ‰œ˜e‹»‰î1, ŽR“à_Žj1,3, ‹àŽq@‹œ1, ’·’Jì—Í–ç1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3‹~–œ): “ú–{Á‰»Ší•aŠw‰ïŠÖ“ŒŽx•”‘æ357‰ñ—á‰ï (2019/12/7), “Œ‹ž.

733045. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è) •ªßŒ^’_”X‘B‹ØŽîÇ‚ɍ‡•¹‚µ‚œ’_”XŠà‚̈ê—á. ˆä‰ô‰ÀØ1, Šâˆä’m‹v1, “c糁@‘1,2, •{‹M_1, “n•Ó^ˆè1, ‹{“c‰pŽ¡1, ’·’Jì—Í–ç1, ‹àŽq@‹œ1, ŽR“à_Žj1,3, ‰œ˜e‹»‰î1, ¡ò@O1,4, –Ø“cŒõL1,5, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3‹~–œ, 4‘Š–Í–ì•a‰@, 5–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): “ú–{Á‰»Ší•aŠw‰ïŠÖ“ŒŽx•”‘æ357‰ñ—á‰ï (2019/12/7), “Œ‹ž.

733046. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è) p‘Of’f‚ª¢“ï‚Å‚ ‚Á‚œƒNƒ[ƒ“•a‡•¹¬’°Šà‚Ì1—á. ²–ì’BÆ1, •Êác•üL1, ìŠÝ‰Á“Þ1, Œ}@”üK1, ‰¡ŽR@ŒO1, ‹v•Û“c (²“c) ”ü˜a1, ¬ò˜aŽO˜Y1, ¬—ѐŽ“T1,2, ’†‘º—²r3, ŽOŽ}@M4 (1Á‰»Ší“à, 2¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3‰º•”Á‰»ŠÇŠO, 4•a—): “ú–{Á‰»Ší•aŠw‰ïŠÖ“ŒŽx•”‘æ357‰ñ—á‰ï (2019/12/7), “Œ‹ž.

733047. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) 14Î¬Ž™‘’_ŠÇŒ‹ÎÇ‚Ì1—á. “y‹“í‘Ÿ˜Y1, ŒŽR@—³1,2, â•”—E‘Ÿ1,2, –kì”Ž”V2, Ž›“c¹O2, ‰ÍŒŒ°‘Ÿ˜Y2, ‹e’nG•F2, —¢“¹“N•F2, ŽRèDŠì2 (1Á‰»Ší“à, 2•œ’Ë‹€Ï•a‰@): “ú–{Á‰»Ší•aŠw‰ïŠÖ“ŒŽx•”‘æ357‰ñ—á‰ï (2019/12/7), “Œ‹ž.

733048. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (êCˆãƒZƒbƒVƒ‡ƒ“) ˆÝƒ|ƒŠ[ƒv‚Æ‚µ‚Ä”­Œ©‚³‚ê‚œt×–EŠàˆÝ“]ˆÚ‚ɑ΂µ“àŽ‹‹ŸŽ¡—ÂðŽ{s‚µ‚œ—Տ°ŒoŒ±. Îèƒ˜Y1, “Œ@’q1, ‹v•Û“c—z2, ˜a“c‘ñ–ç1, “n糍WŽ¯1, ÎŒËŒªŽŸ1, Œ˜“ce—˜1, “c糁@‘1,3, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ109‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ïŠÖ“ŒŽx•”—á‰ï (2019/12/14), “Œ‹ž.

733049. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (êCˆãƒZƒbƒVƒ‡ƒ“) ˆÝ“]ˆÚ‚𗈂œ‚µ‚œt×–EŠà‚̈ê—á. ƒã‘Ÿ˜Y1,2, ìŒû—C•ã1,2, [ìØ‰›”ü1,2, ãŒŽˆê”¿1,2, ‘å’ˏr˜a1,2, “n粐^²1,2, “cŒŽ‹v”üŽq2, –Ø“cŒõL1,2 (1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ109‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ïŠÖ“ŒŽx•”—á‰ï (2019/12/14), “Œ‹ž.

733050. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (êCˆãƒZƒbƒVƒ‡ƒ“) EUS‚ð—p‚¢‚Ä’Ž‚”S‰t”XŽî‚ðf’f‚µ• o‹Ÿ‰º“Eop‚ðŽ{s‚µ‚œˆê—á. [ìØ‰›”ü1,2, ãŒŽˆê”¿1,2, ƒã‘Ÿ˜Y1,2, ìŒû—C•ã1,2, ‘å’ˏr˜a1,2, “cŒŽ‹v”üŽq2, “n粐^²1,2, –Ø“cŒõL1,2 (1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ109‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ïŠÖ“ŒŽx•”—á‰ï (2019/12/14), “Œ‹ž.

733051. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (êCˆãƒZƒbƒVƒ‡ƒ“) äXŠàpŒã• –Œ”dŽíÄ”­‚É‚æ‚é—A“ü‹rÇŒóŒQ‚ɑ΂µ‚Ä“àŽ‹‹Ÿ‰ºSelf-expandable metallic stent—¯’u‚ª—L—p‚Å‚ ‚Á‚œˆê—á. “y‹“í‘Ÿ˜Y1, “n•Ó^ˆè1, •{‹M_1, ’·’Jì—Í–ç1, ‹àŽq@‹œ1, ŽR“à_Žj1,2, ‰œ˜e‹»‰î1, Šâˆä’m‹v1, ¡ò@O1,3, –Ø“cŒõL1,4, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2‹~–œ, 3‘Š–Í–ì•a‰@, 4–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ109‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ïŠÖ“ŒŽx•”—á‰ï (2019/12/14), “Œ‹ž.

733052. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (êCˆãƒZƒbƒVƒ‡ƒ“) EUS-FNB‚ɂĐf’f‚µ“Ÿ‚œ“]ˆÚ«äX•œŠŠ‹Ø“÷Žî‚Ì1—á. Îè‚ ‚â“ß1, ‰œ˜e‹»‰î1, “n•Ó^ˆè1, •{‹M_1, ’·’Jì—Í–ç1, ‹àŽq@‹œ1, ŽR“à_Žj1,2, Šâˆä’m‹v1, ¡ò@O1,3, –Ø“cŒõL1,4, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2‹~–œ, 3‘Š–Í–ì•a‰@, 4–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ109‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ïŠÖ“ŒŽx•”—á‰ï (2019/12/14), “Œ‹ž.

733053. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (êCˆãƒZƒbƒVƒ‡ƒ“) “]ˆÚ«äXŽîᇂɂæ‚é•ÂÇ«äX‰Š‚ɑ΂µ‚ÄEUS-PD rendezvous–@‚ð—p‚¢‚œŒo“û“ª“IäXŠÇƒhƒŒƒi[ƒW‚ðŽ{s‚µ‚œ1—á. ¬–쎛—§1, ‰œ˜e‹»‰î1, “n•Ó^ˆè1, •{‹M_1, ’·’Jì—Í–ç1, ‹àŽq@‹œ1, ŽR“à_Žj1,2, Šâˆä’m‹v1, ¡ò@O1,3, –Ø“cŒõL1,4, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2‹~–œ, 3‘Š–Í–ì•a‰@, 4–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ109‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ïŠÖ“ŒŽx•”—á‰ï (2019/12/14), “Œ‹ž.

733054. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (Œ€CˆãƒZƒbƒVƒ‡ƒ“) Á‰»ŠÇˆÙ•š‚É‚æ‚鏬Ž™‚̕ǐ«ƒCƒŒƒEƒX‚ɑ΂µ“àŽ‹‹Ÿ“IˆÙ•šœ‹Žp‚ðŽ{s‚µ‚œ1—á. ŒÃ‰®@ˆ©1, ìŠÝ‰Á“Þ1, •Êác•üL1, Œ}@”üK1, ‰¡ŽR@ŒO1, ‹v•Û“c (²“c) ”ü˜a1, ¬—ѐŽ“T1,2, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ109‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ïŠÖ“ŒŽx•”—á‰ï (2019/12/14), “Œ‹ž.

733055. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ¬’°“®Ã–¬ŠïŒ`‚Ì1—á. â•”—E‘Ÿ1,2, –kì”Ž”V2, “y‹“í‘Ÿ˜Y1, Ž›“c¹O2, ‰ÍŒŒ°‘Ÿ˜Y2, ‹e’nG•F2, —¢“¹“N•F2, ŽRèDŠì2, ŒŽR@—³1,2, ŒŒŽ@C2 (1Á‰»Ší“à, 2•œ’Ë‹€Ï•a‰@): ‘æ109‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ïŠÖ“ŒŽx•”—á‰ï (2019/12/14), “Œ‹ž.

733056. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ƒEƒXƒeƒLƒkƒ}ƒu‚ª‘Šú‚É—LŒø‚Å‚ ‚Á‚œƒTƒCƒgƒƒKƒŠŽõ‡•¹, ƒNƒ[ƒ“•a‚̏Ǘá. ŽOŽ}—zˆê1, ¡ò@O1,2, ‰Á“¡@Ê3, ‹à@–Ÿ“N1,2, ˆä‰ô—C‰î1,2, ŒK”ö’èm1, ŽO‹Ž—˜‰·1, ŒŒ³Ž›ŽâX1, Ÿ–””º‰h1, ‘åˆä“c³l1 (1JCHO‘Š–Í–ì•a‰@, 2Á‰»Ší“à, 3“ì’¬“c•a‰@): ‘æ109“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ïŠÖ“ŒŽx•”—á‰ï (2019/12/15), “Œ‹ž.

733057. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è) ’×ᇐ«‘å’°‰Š‚ÌŒo‰ß’†‚É’°Œ‹Šj‚ð‡•¹‚µ‚œ1—á. áÁ•”—Dì1, ¬—ѐŽ“T1,2, •Êác•üL1, ìŠÝ‰Á“Þ1, Œ}@”üK1, ‰¡ŽR@ŒO1, ‹v•Û“c (²“c) ”ü˜a1, ¬ò˜aŽO˜Y1, ŽOŽ}@M3 (1Á‰»Ší“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3•a—): ‘æ109‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ïŠÖ“ŒŽx•”—á‰ï (2019/12/15), “Œ‹ž.

733058. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è) ƒCƒŒƒEƒX‚ðŒ_‹@‚ɐf’f, Ž¡—ÂɎŠ‚Á‚œŒŽ”­«¬’°Šà‚Ì1—á. ‰Ô‰ª‘Ÿ˜Y1, ‹v•Û“c—z2, ÎŒËŒªŽŸ1, “n糍WŽ¯1, ˜a“c‘ñ–ç1, “Œ@’q1, Œ˜“ce—˜1, “c糁@‘1,3, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ109‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ïŠÖ“ŒŽx•”—á‰ï (2019/12/15), “Œ‹ž.

733059. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è) Child•Ï–@Œã‚Ì•«‡•”‹·ó‚ɑ΂µ‚Ä, ’ŒŽ‹Œ^ƒRƒ“ƒxƒbƒNƒX‚ð—p‚¢‚Ä’Ž‰¹”g“àŽ‹‹Ÿ‰ºäXŠÇ‹ó’°•«‡p‚ðŽ{s‚µ‚œ1—á. “c糔ü“Þ1, ‹àŽq@‹œ1, –Ø“cŒõL1,2, •{‹M_1, “n•Ó^ˆè1, ’·’Jì—Í–ç1, ŽR“à_Žj1,3, ‰œ˜e‹»‰î1, Šâˆä’m‹v1, ¬ò˜aŽO˜Y1 (1Á‰»Ší“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3‹~–œ): ‘æ109‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ïŠÖ“ŒŽx•”—á‰ï (2019/12/15), “Œ‹ž.


‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È@Á‰»Ší“à‰ÈŠw
Šñ•uÀu‰ŠÇ«’°ŽŸŠ³—Տ°Œ€‹†uÀv

[Šwp˜_•¶]

110102. [ŒŽ’˜] Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis. Okabayashi S, Kobayashi T1,2, Saito E, Toyonaga T, Ozaki R, Sagami S, Nakano M, Tanaka J, Yagisawa K, Kuronuma S, Takeuchi O, Hibi T1,2: Intest Res 2019/4; 17 (2): 218-26. (¬—с@‘ñ1,2, “ú”ä‹I•¶1,2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–k—¢Œ€‹†Š•a‰@)

110103. [ŒŽ’˜] Risk Factors for Mortality in Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease. Yoshida A1, Kamata N, Yamada A, Yokoyama Y, Omori T, Fujii T, Hayashi R, Kinjo T, Matsui A, Fukata N, Takahashi S, Sakemi R, Ogata N, Ashizuka S, Bamba S, Ooi M, Kanmura S, Endo K, Yoshino T, Tanaka H, Morizane T, Shinzaki S, Kobayashi T1,2: Inflamm Intest Dis 2019/4; 3 (4): 167-2. (¬—с@‘ñ1,2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–k—¢Œ€‹†Š•a‰@)

110104. [ŒŽ’˜] Efficacy and safety of abrilumab, an ƒ¿4ƒÀ7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study. Hibi T1,2, Motoya S, Ashida T, Sai S, Sameshima Y, Nakamura S, Maemoto A, Nii M, Sullivan BA, Gasser RA Jr, Suzuki Y: Intest Res 2019/7; 17 (3): 375-86. (“ú”ä‹I•¶1,2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–k—¢Œ€‹†Š•a‰@)

110105. [ŒŽ’˜] Certolizumab pegol for induction of remission in Crohn's disease. Yamazaki H, So R, Matsuoka K, Kobayashi T1,2, Shinzaki S, Matsuura M, Okabayashi S, Kataoka Y, Tsujimoto Y, Furukawa TA, Watanabe N: Cochrane Database Syst Rev 2019/8; 8 (8): CD012893. (¬—с@‘ñ1,2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@)

110106. [ŒŽ’˜] Concerns and Side Effects of Azathioprine During Adalimumab Induction and Maintenance Therapy for Japanese Patients With Crohn's Disease: A Subanalysis of a Prospective Randomised Clinical Trial [DIAMOND Study]. Hisamatsu T1, Matsumoto T1, Watanabe K1, Nakase H1, Motoya S1, Yoshimura N1, Ishida T1, Kato S1, Nakagawa T1, Esaki M1, Nagahori M1, Matsui T1, Naito Y1, Kanai T1, Suzuki Y1, Nojima M1, Watanabe M1, Hibi T1,2 (1DIAMOND study group): J Crohns Colitis 2019/9; 13 (9): 1097-104. (“ú”ä‹I•¶1,2: 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@)

110107. [ŒŽ’˜] Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C, UNIFI?Study Group (Kobayashi T1,2): N Engl J Med 2019/9; 381 (13): 1201-14. (¬—с@‘ñ1,2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@)

110108. [ŒŽ’˜] Phosphoinositide 3-Kinase P110ƒÂ-Signaling Is Critical for Microbiota-Activated IL-10 Production by B Cells that Regulate Intestinal Inflammation. Oka A, Mishima Y, Liu B, Herzog JW, Steinbach EC, Kobayashi T1,2, Plevy SE, Sartor RB: Cells 2019/9; 8 (10): 1121. (¬—с@‘ñ1,2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@)

110109. [ŒŽ’˜] Ulcerative colitis outcomes research in Japan: protocol for an observational prospective cohort study of YOURS (YOu and Ulcerative colitis: Registry and Social network). Yamazaki H, Matsuoka K, Fernandez J, Hibi T1, Watanabe M, Hisamatsu T, Shunichi Fukuhara S: BMJ Open 2019/9; 9 (9): e030134. (“ú”ä‹I•¶1: 1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@)

110110. [ŒŽ’˜] Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice. Nakagawa T, Kobayashi T1,2, Nishikawa K, Yamada F, Asai S, Sameshima Y, Suzuki Y, Watanabe M, Hibi T2: Intest Res 2019/10; 17 (4): 504-15. (¬—с@‘ñ1,2, “ú”ä‹I•¶2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@)

110111. [ŒŽ’˜] Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2). Hisamatsu T, Kato S, Kunisaki R, Matsuura M, Nagahori M, Motoya S, Esaki M, Fukata N, Inoue S, Sugaya T, Sakuraba H, Hirai F, Watanabe K, Kanai T, Naganuma M, Nakase H, Suzuki Y, Watanabe M, Hibi T1, Nojima M, Matsumoto T, DIAMOND2 Study Group (Kobayashi T1,2): J Gastroenterol 2019/10; 54 (10): 860-70. (“ú”ä‹I•¶1, ¬—с@‘ñ1,2: 1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

110112. [ŒŽ’˜] Adverse events in patients with ulcerative colitis treated with indigo naturalis: a Japanese nationwide survey. Naganuma M, Sugimoto S, Suzuki H, Matsuno Y, Araki T, Shimizu H, Hayashi R, Fukuda T, Nakamoto N, Iijima H, Nakamura S, Kataoka M, Tamura Y, Tatsumi K, Hibi T1, Suzuki Y, Kanai T, INDIGO survey Group: J Gastroenterol 2019/10; 54 (10): 891-6. (“ú”ä‹I•¶1: 1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@)

110113. [ŒŽ’˜] Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis. Suzuki Y, Watanabe M, Matsui T, Motoya S, Hisamatsu T, Yuasa H, Tabira J, Isogawa N, Tsuchiwata S, Arai S, Hibi T1: Inflamm Intest Dis 2019/10; 4 (4): 131-43. (“ú”ä‹I•¶1: 1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@)

510005. [‘à] Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. Schreiner P, Neurath MF, Ng SC, El-Omar EM, Sharara AI, Kobayashi T1,2, Hisamatsu T, Hibi T2, Rogler G: Inflamm Intest Dis 2019/8; 4 (3): 79-96. (¬—с@‘ñ1,2, “ú”ä‹I•¶2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@)

[Šw‰ïEŒ€‹†‰ï“™]

713027. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Does switching between 5-aminosalicylates affest thiopurine metabolism and clinical outcomes in patients with ulcerative colitis? Morikubo H1, Kobayashi T1,2, Ozaki R, Okabayashi S, Kiyohara H1, Matsubayashi M1, Sagami S1,3, Nakano M1, Ikezaki O, Hisamatsu T, Hibi T1: Digestive Disease Week 2019 (2019/5/18-21), San Diego, USA. (X‹v•Û‘ñ1, ¬—с@‘ñ1,2, ŽŒŽ—T‹M1, Œ—ѐ^‰›1, ²ãW‘Ÿ˜Y1,3, ’†–ì@‰ë1, “ú”ä‹I•¶1: 1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3‰ŠÇ«’°ŽŸŠ³)

713028. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Clinical characteristics and outcomes of 5-ASA intolerance in patients with ulcerative colitis. Kiyohara H1, Kobayashi T1,2, Morikubo H1, Matsubayashi M1, Sagami S1,3, Koike Y, Hibi T1: AOCC 2019 (2019/6/14-16), Taipei, Taiwan. (ŽŒŽ—T‹M1, ¬—с@‘ñ1,2, X‹v•Û‘ñ1, Œ—ѐ^‰›1, ²ãW‘Ÿ˜Y1,3, ¬’r—SŽi, “ú”ä‹I•¶1: 1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3‰ŠÇ«’°ŽŸŠ³)

722029. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)yŽi‰ïzUCŽ¡—Âɂš‚¯‚éTNF‘jŠQ—Ö@‚̐V‚œ‚Ȉʒu•t‚¯‚ð‹‚ß‚Ä. “ú”ä‹I•¶ (–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ105‰ñ“ú–{Á‰»Ší•aŠw‰ï‘‰ï (2019/5/9), ‹à‘ò.

722030. [Šw‰ï (‘S‘)] (ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[ )yŽi‰ïzIBD‚É‚š‚¯‚é•ÖƒoƒCƒIƒ}[ƒJ[‚Ì“W–]‚Ɖۑè. “ú”ä‹I•¶ (–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ105‰ñ“ú–{Á‰»Ší•aŠw‰ï‘‰ï (2019/5/9), ‹à‘ò.

722031. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)uIBD‚̐V‹KŽ¡—Ö@vDrug-tolerant assay‚É‚æ‚éRƒCƒ“ƒtƒŠƒLƒVƒ}ƒuR‘Ì‘ª’è‚Ì—L—p«. “ú”ä‘¥F, ¬—с@‘ñ1,2, X‹v•Û‘ñ2, ŽŒŽ—T‹M2, Œ—ѐ^‰›2, ²ãW‘Ÿ˜Y2,3, ’†–ì@‰ë2, ‹vŒ—ˆê, “ú”ä‹I•¶2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 3‰ŠÇ«’°ŽŸŠ³): ‘æ56‰ñ“ú–{Á‰»Ší–ƉuŠw‰ï‘‰ï (2019/8/2), ‹ž“s.

722032. [Šw‰ï (‘S‘)] (‹³ˆçu‰‰)yŽi‰ïzIBD‚Æ”DP|•êŽq‚É‹y‚Ú‚·–ò•šŽ¡—Ẩe‹¿. “ú”ä‹I•¶ (–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ56‰ñ“ú–{Á‰»Ší–ƉuŠw‰ï‘‰ï (2019/8/2), ‹ž“s.

722033. [Šw‰ï (‘S‘)] (ƒuƒŒƒbƒNƒtƒ@[ƒXƒgƒZƒ~ƒi[)yŽi‰ïzChallenge! ’°ŠÇ”S–Œ“§‰ß«‚©‚çIBDŽ¡—ÂðÄl‚·‚é. “ú”ä‹I•¶ (–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ61‰ñ“ú–{Á‰»Ší•aŠw‰ï‘å‰ï (JDDW 2019 KOBE) (2019/11/21), _ŒË.

722034. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰)yŽi‰ïzCommon mistakes in the treatment of the gospitalized patient with UC. “ú”ä‹I•¶ (–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ61‰ñ“ú–{Á‰»Ší•aŠw‰ï‘å‰ï (JDDW 2019 KOBE) (2019/11/21), _ŒË.

722035. [Šw‰ï (‘S‘)] (ƒTƒeƒ‰ƒCƒgƒVƒ“ƒ|ƒWƒEƒ€)yÀ’·zJAK‘jŠQÜ‚ÌŠî‘b‚ƗՏ°. “ú”ä‹I•¶ (–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ61‰ñ“ú–{Á‰»Ší•aŠw‰ï‘å‰ï (JDDW 2019 KOBE) (2019/11/23), _ŒË.

723138. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’×ᇐ«‘å’°‰ŠŠ³ŽÒ‚É‚š‚¯‚é5-ASA»ÜƒXƒCƒbƒ`‚ªƒ`ƒIƒvƒŠƒ“»Ü‘ãŽÓ‚È‚ç‚Ñ‚É–ò—Œø‰Ê‚É—^‚Š‚é‰e‹¿. X‹v•Û‘ñ1, ”öè@—Ç, ŽŒŽ—T‹M1, Ÿºãˆ»Žq, Œ—ѐ^‰›1, ²ãW‘Ÿ˜Y1,2, ’†–ì@‰ë1, ‹vŒ—ˆê, “ú”ä‹I•¶1, ¬—с@‘ñ1,3 (1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2‰ŠÇ«’°ŽŸŠ³, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ105‰ñ“ú–{Á‰»Ší•aŠw‰ï‘‰ï (2019/5/9), ‹à‘ò.

723139. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Drug-tolerant assay‚É‚æ‚éRƒCƒ“ƒtƒŠƒLƒVƒ}ƒuR‘Ì‘ª’è‚Ì—L—p«. “ú”ä‘¥F, ¬—с@‘ñ1,2, X‹v•Û‘ñ1, ŽŒŽ—T‹M1, Œ—ѐ^‰›1, ²ãW‘Ÿ˜Y1,3, ’†–ì@‰ë1, “ú”ä‹I•¶1 (1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3‰ŠÇ«’°ŽŸŠ³): ‘æ56‰ñ“ú–{Á‰»Ší–ƉuŠw‰ï‘‰ï (2019/8/1-2), ‹ž“s.

723140. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰ŠÇ«’°ŽŸŠ³‚É‚š‚¯‚é‘ÌŠOŽ®’Ž‰¹”gŒŸž‚Ì—L—p«. ²ãW‘Ÿ˜Y1,2, ¬—с@‘ñ2,3, ‘ŠŒŽ‰À“ߎq, ‹à‘ò“O—Y, —с@‹K—², ’†–ì@‰ë2, “ú”ä‹I•¶2 (1‰ŠÇ«’°ŽŸŠ³, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ37‰ñ“ú–{‘å’°ŒŸžŠw‰ï‘‰ï (2019/11/2), “Œ‹ž.

723141. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŽÀ—Տ°‚É‚š‚¯‚éƒuƒfƒ\ƒjƒh’’°‚ÌŽg—p‚Æ‚»‚Ì—L—p«. Œ—ѐ^‰›1, ¬—с@‘ñ1,2, “ú”ä‹I•¶1 (1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ61‰ñ“ú–{Á‰»Ší•aŠw‰ï‘å‰ï (JDDW 2019 KOBE) (2019/11/21), _ŒË.

723142. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Mirikizumab (RIL23p19R‘̐»Ü) ‚Ì“ú–{l‚ðŠÜ‚ÞƒNƒ[ƒ“•a (CD) Š³ŽÒ‚Å‚Ì‘æII‘ŠŽŽŒ±‚Ì52T‚Ì—LŒø«‹y‚шÀ‘S«. –{’J@‘, “n•Ó@Žç, “ú”ä‹I•¶1 (1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ61‰ñ“ú–{Á‰»Ší•aŠw‰ï‘å‰ï (JDDW 2019 KOBE) (2019/11/21), _ŒË.

723143. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Drug-tolerant assay ‚É‚æ‚éRƒCƒ“ƒtƒŠƒLƒVƒ}ƒuR‘Ì‘ª’è‚Ì—L—p«. “ú”ä‘¥F, ¬—с@‘ñ1,2, X‹v•Û‘ñ2, ŽŒŽ—T‹M2, Œ—ѐ^‰›2, ²ãW‘Ÿ˜Y2,3, ’†–ì@‰ë2, ‹vŒ—ˆê, “ú”ä‹I•¶2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 3‰ŠÇ«’°ŽŸŠ³): ‘æ61‰ñ“ú–{Á‰»Ší•aŠw‰ï‘å‰ï (JDDW 2019 KOBE) (2019/11/22), _ŒË.

723144. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’×ᇐ«‘å’°‰Š‚É‚š‚¯‚éŒo‰ï‰A’Ž‰¹”g‚̐f’fž“x. ‘ŠŒŽ‰À“ߎq, ²ãW‘Ÿ˜Y1,2, ”~“c”üç, ‹à‘ò“O—Y, —с@‹K—², X‹v•Û‘ñ2, Œ—ѐ^‰›2, ŽŒŽ—T‹M2, ’†–ì@‰ë2, “ú”ä‹I•¶2, ¬—с@‘ñ2,3 (1‰ŠÇ«’°ŽŸŠ³, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ10‰ñ“ú–{‰ŠÇ«’°ŽŸŠ³Šw‰ïŠwpW‰ï (2019/11/29), •Ÿ‰ª.

723145. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’×ᇐ«‘å’°‰ŠŠ³ŽÒ‚ª•ø‚Š‚鍢‚莖|web ‚É‚æ‚éƒAƒ“ƒP[ƒg’²žŒ‹‰Ê|. Î‹Ž‚Æ‚æ‚Ý, ¬—с@‘ñ1,2, ’rã—R‰À, ‹gŒŽ—Ljê, “ú”ä‹I•¶2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ10‰ñ“ú–{‰ŠÇ«’°ŽŸŠ³Šw‰ïŠwpW‰ï (2019/11/29), •Ÿ‰ª.

723146. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Mirikizumab (RIL23p19R‘̐»Ü) ‚Ì“ú–{l‚ðŠÜ‚ÞƒNƒ[ƒ“•a (CD) Š³ŽÒ‚Å‚Ì‘æII‘ŠŽŽŒ±‚Ì12T‚Ì—LŒø«‹y‚шÀ‘S«. •œˆäˆèm, Bruce E Sands, William J Sandborn, Laurent Peyrin-Biroulet, Peter DR Higgins, ’†žŠ@q, —¢ˆä—mˆê, Ruth Belin, Elisa Gomez Valderas, Debra Miller, MaryAnn Morgan-Cox, April Naegeli, Paul Pollack, Jay Tuttle, “n•Ó@Žç, “ú”ä‹I•¶1 (1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ10‰ñ“ú–{‰ŠÇ«’°ŽŸŠ³Šw‰ïŠwpW‰ï (2019/11/29), •Ÿ‰ª.

723147. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’×ᇐ«‘å’°‰Š‚É‚š‚¯‚éŒo‰ï‰A’Ž‰¹”g‚ÌŽó—e«: ƒAƒ“ƒP[ƒg’²ž. ”~“c”üç, ²ãW‘Ÿ˜Y1,2, ‘ŠŒŽ‰À“ߎq, ‹à‘ò“O—Y, —с@‹K—², X‹v•Û‘ñ2, Œ—ѐ^‰›2, ŽŒŽ—T‹M2, ’†–ì@‰ë2, “ú”ä‹I•¶2, ¬—с@‘ñ2,3 (1‰ŠÇ«’°ŽŸŠ³, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ10‰ñ“ú–{‰ŠÇ«’°ŽŸŠ³Šw‰ïŠwpW‰ï (2019/11/29), •Ÿ‰ª.

723148. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’×ᇐ«‘å’°‰Š‚ɑ΂·‚é‘SgƒXƒeƒƒCƒhŽ¡—ÂɊւ·‚éˆãŽt‚̈ӎ¯‚š‚æ‚ÑŽÀî: ƒEƒFƒu’²žŒ‹‰Ê‚æ‚è. ¬—с@‘ñ1,2, ”‹ŒŽ—²Žk, ‹Ž–{FŽj, ¬—ѐ^—Žq (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ10‰ñ“ú–{‰ŠÇ«’°ŽŸŠ³Šw‰ïŠwpW‰ï (2019/11/29), •Ÿ‰ª.

723149. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) UCf—Âɂš‚¯‚é•Ö’†ƒJƒ‹ƒvƒƒeƒNƒ`ƒ“‚ÌŠˆ—p. ¬—с@‘ñ1,2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ10‰ñ“ú–{‰ŠÇ«’°ŽŸŠ³Šw‰ïŠwpW‰ï (2019/11/29), •Ÿ‰ª.

723150. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹‘匋’°Ç‚ð‚«‚œ‚µ‚œƒXƒeƒƒCƒh’ïR«‚̏dÇ‰”­’×ᇐ«‘å’°‰Š‚ɑ΂µ‚ăCƒ“ƒtƒŠƒLƒVƒ}ƒu‚ª‘tŒ÷‚µ‚œˆê—á. ‹{’J˜Ð—C1, ¬—с@‘ñ1,2, ‰ª—ѐT“ñ, ”öè@—Ç, ²ãW‘Ÿ˜Y1,3, ’†–ì@‰ë1, “ú”ä‹I•¶1 (1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3‰ŠÇ«’°ŽŸŠ³): ‘æ16‰ñ“ú–{Á‰»ŠÇŠw‰ï‘‰ïŠwpW‰ï (2020/2/7-8), •ºŒÉ.

723151. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”ñŠˆ“®Šú’×ᇐ«‘å’°‰ŠŠ³ŽÒ‚Ì’·Šú—\Œã—\‘ª‚ÉCapsule Scoring of Ulcerative Colitis (CSUC) ‚Í—L—p‚Å‚ ‚é. Œ—ѐ^‰›1, ‰ª—ѐT“ñ, ¬—с@‘ñ1,2, ’†–ì@‰ë1, ²ãW‘Ÿ˜Y1,3, ”öè@—Ç, ŽŒŽ—T‹M1, X‹v•Û‘ñ1, ˆ¢‘]À–M‰›1,3, ‹{’J˜Ð—C1, “ú”ä‹I•¶1 (1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3‰ŠÇ«’°ŽŸŠ³): ‘æ13‰ñ“ú–{ƒJƒvƒZƒ‹“àŽ‹‹ŸŠw‰ïŠwpW‰ï (2020/2/9), •ºŒÉ.


zŠÂŠí“à‰ÈŠw

[Šwp˜_•¶]

110114. [ŒŽ’˜] Incidence, factors, and clinical significance of cholesterol crystals in coronary plaque: An optical coherence tomography study. Fujiyoshi K1, Minami Y1, Ishida K1, Kato A2, Katsura A2, Muramatsu Y2, Sato T2, Kakizaki R1, Nemoto T1, Hashimoto T1, Sato N1, Meguro K1, Shimohama T1, Tojo T1, Ako J1: Atherosclerosi. 2019/4; 283: 79-84. (“¡‹g˜a”Ž1, “ì@®Œ«1, Î“cO‹B1, ‰Á“¡Ê”ü2, Œj@—L’q2, ‘ºŒ—T‰î2, ²“¡r[2, Š`è—Ç‘Ÿ1, ª–{Æ¢Žu1, ‹Ž–{‘ñ–í1, ²“¡L—m1, –ڍ•Œ’‘Ÿ˜Y1, ‰º•lF˜Y1, “ŒžŠ‘åŽ÷1, ˆ¢ŒÃÆ1: 1zŠÂŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

110115. [ŒŽ’˜] Frequency and prognostic impact of intravascular imaging-guided urgent percutaneous coronary intervention in patients with acute myocardial infarction: results from J-MINUET. Okura H1, Saito Y1, Soeda T1, Nakao K1, Ozaki Y1, Kimura K1, Ako J1,2, Noguchi T1, Yasuda S1, Suwa S1, Fujimoto K1, Nakama Y1, Morita T1, Shimizu W1, Hirohata A1, Morita Y1, Inoue T1, Okamura A1, Uematsu M1, Hirata K1, Tanabe K1, Shibata Y1, Owa M1, Tsujita K1, Nishimura K1, Miyamoto Y1, Ishihara M1 (1J-MINUET investigators): Heart Vessels 2019/4; 34 (4): 564-71. (ˆ¢ŒÃÆ1,2: 2zŠÂŠí“à)

110116. [ŒŽ’˜] Admission Heart Rate Is a Determinant of Effectiveness of Beta-Blockers in Acute Myocardial Infarction Patients. Okuno T1, Aoki J1, Tanabe K1, Nakao K1, Ozaki Y1, Kimura K1, Ako J1,2, Noguchi T1, Yasuda S1, Suwa S1, Fujimoto K1, Nakama Y1, Morita T1, Shimizu W1, Saito Y1, Hirohata A1, Morita Y1, Inoue T1, Okamura A1, Mano T1, Hirata K1, Shibata Y1, Owa M1, Tsujita K1, Funayama H1, Kokubu N1, Kozuma K1, Uemura S1, Tobaru T1, Saku K1, Ohshima S1, Nishimura K1, Miyamoto Y1, Ogawa H1, Ishihara M1 (1J-MINUET Investigators): Circ J 2019/4; 83 (5): 1054-63. (ˆ¢ŒÃÆ1,2: 2zŠÂŠí“à)

110117. [ŒŽ’˜] Impaired Flow-Mediated Dilation and Severity and Vulnerability of Culprit Plaque in Patients with Coronary Artery Disease. Nemoto T1, Minami Y1, Yamaoka-Tojo M2, Sato T3, Muramatsu Y3, Kakizaki R1, Fujiyoshi K1, Hashimoto T1, Meguro K1, Shimohama T1, Tojo T1, Ako J1: Int Heart J 2019/5; 60 (3): 539-45. (ª–{Æ¢Žu1, “ì@®Œ«1, “ŒžŠ”ü“ÞŽq2, ²“¡r[3, ‘ºŒ—T‰î3, Š`è—Ç‘Ÿ1, “¡‹g˜a”Ž1, ‹Ž–{‘ñ–í1, –ڍ•Œ’‘Ÿ˜Y1, ‰º•lF˜Y1, “ŒžŠ‘åŽ÷1, ˆ¢ŒÃÆ1: 1zŠÂŠí“à, 2ˆã—Éq¶Šw•”, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

110118. [ŒŽ’˜] Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation. Okishige K, Yamauchi Y, Hanaki Y, Inoue K, Tanaka N, Yamaji H, Murakami T, Manita M, Tabata K, Ooie T, Tatsukawa Y, Sakai H, Yamaki M, Murakami M, Takada T, Osaka Y, Ono Y, Handa K, Sugiyama K, Yoshizawa T1, Fukaya H1, Tashiro H, Takase S, Harada M, Watanabe E, Yamane T, Yamashita S, Aonuma K: J Thromb Thrombolysis 2019/5; 47 (4): 487-94. (–öàV’q‹`1, [’J‰p•œ1: 1zŠÂŠí“à)

110119. [ŒŽ’˜] Investigation into Lipid Management in Acute Coronary Syndrome Patients from the EXPLORE-J Study. Nakamura M, Ako J1, Arai H, Hirayama A, Murakami Y, Nohara A, Uno K, Ozaki A, Harada-Shiba M: J Atheroscler Thromb 2019/6; 26 (6): 559-72. (ˆ¢ŒÃÆ1: 1zŠÂŠí“à)

110120. [ŒŽ’˜] Lipoprotein (a) level is associated with plaque vulnerability in patients with coronary artery disease: An optical coherence tomography study. Muramatsu Y1, Minami Y2, Kato A1, Katsura A1, Sato T1, Kakizaki R2, Nemoto T2, Hashimoto T2, Fujiyoshi K2, Meguro K2, Shimohama T2, Ako J2: Int J Cardiol Heart Vasc 2019/6; 24: 100382. (‘ºŒ—T‰î1, “ì@®Œ«2, ‰Á“¡Ê”ü1, Œj@—L’q1, ²“¡r[1, Š`è—Ç‘Ÿ2, ª–{Æ¢Žu2, ‹Ž–{‘ñ–í2, “¡‹g˜a”Ž2, –ڍ•Œ’‘Ÿ2, ‰º•lF˜Y2, ˆ¢ŒÃÆ2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2zŠÂŠí“à)

110121. [ŒŽ’˜] Liraglutide suppresses atrial electrophysiological changes. Nakamura H1, Niwano S1, Niwano H, Fukaya H1, Murakami M1, Kishihara J1, Satoh A1, Yoshizawa T1, Ishizue N1, Igarashi T1, Fujiishi T1, Ako J1: Heart Vessels 2019/8; 34 (8): 1389-93. (’†‘º—m”Í1, ’ë–ìTˆê1, [’J‰p•œ1, ‘ºã‰ë”ü1, ŠÝŒŽ@~1, ²“¡@—z1, ‹gàV’qŽ¡1, Î––¬Æ1, ŒÜ\—’Œš1, “¡ÎŽì”ü1, ˆ¢ŒÃÆ1: 1zŠÂŠí“à)

110122. [ŒŽ’˜] Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Ray KK1, Colhoun HM1, Szarek M1, Baccara-Dinet M1, Bhatt DL1, Bittner VA1, Budaj AJ1, Diaz R1, Goodman SG1, Hanotin C1, Harrington RA1, Jukema JW1, Loizeau V1, Lopes RD1, Moryusef A1, Murin J1, Pordy R1, Ristic AD1, Roe MT1, Tun—n J1, White HD1, Zeiher AM1, Schwartz GG1, Steg PG1 (1ODYSSEY OUTCOMES Committees and Investigators, Collaborators: Ako J2): Lancet Diabetes Endocrinol 2019/8; 7 (8): 618-28. (ˆ¢ŒÃÆ2: 2zŠÂŠí“à)

110123. [ŒŽ’˜] Contrast Volume and Decline in Kidney Function in Optical Coherence Tomography-Guided Percutaneous Coronary Intervention. Nemoto T1, Minami Y1, Sato T2, Muramatsu Y2, Kakizaki R1, Hashimoto T1, Oikawa J1, Fujiyoshi K1, Meguro K1, Shimohama T1, Tojo T1, Ako J1: Int Heart J 2019/9; 60 (5): 1022-9. (ª–{Æ¢Žu1, “ì@®Œ«1, ²“¡r[2, ‘ºŒ—T‰î2, Š`è—Ç‘Ÿ1, ‹Ž–{‘ñ–í1, ‹yì@~1, “¡‹g˜a”Ž1, –ڍ•Œ’‘Ÿ˜Y1, ‰º•lF˜Y1, “ŒžŠ‘åŽ÷1, ˆ¢ŒÃÆ1: 1zŠÂŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

110124. [ŒŽ’˜] Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. Yasuda S1, Kaikita K1, Akao M1, Ako J1,2, Matoba T1, Nakamura M1, Miyauchi K1, Hagiwara N1, Kimura K1, Hirayama A1, Matsui K1, Ogawa H1 (1AFIRE Investigators): N Engl J Med 2019/9; 381 (12): 1103-13. (ˆ¢ŒÃÆ1,2: 2zŠÂŠí“à)

110125. [ŒŽ’˜] Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome - The ODYSSEY J-IVUS Trial. Ako J1, Hibi K, Tsujita K, Hiro T, Morino Y, Kozuma K, Shinke T, Otake H, Uno K, Louie MJ, Takagi Y, Miyauchi K: Circ J 2019/9; 83 (10): 2025-33. (ˆ¢ŒÃÆ1: 1zŠÂŠí“à)

110126. [ŒŽ’˜] Efficacy and Safety of Ivabradine in Japanese Patients With Chronic Heart Failure - J-SHIFT Study. Tsutsui H1, Momomura SI1, Yamashina A1, Shimokawa H1, Kihara Y1, Saito Y1, Hagiwara N1, Ito H1, Yano M1, Yamamoto K1, Ako J1,2, Inomata T1,2, Sakata Y1, Tanaka T1, Kawasaki Y1 (1J-SHIFT Study Investigators): Circ J 2019/9; 83 (10): 2049-60. (ˆ¢ŒÃÆ1,2, ’––”FŒ³1,2: 2zŠÂŠí“à)

110127. [ŒŽ’˜] Real-World Antithrombotic Therapy in Atrial Fibrillation Patients with a History of Percutaneous Coronary Intervention. Horiguchi A1, Fukaya H2, Oikawa J2, Shirakawa Y1, Kobayashi S1, Arakawa Y1, Nishinarita R1, Nakamura H2, Ishizue N2, Igarashi G, Satoh A2, Kishihara J2, Niwano S2, Ako J2: Int Heart J 2019/11; 60 (6): 1321-7. (–xŒû@ˆ€1, [’J‰p•œ2, ‹yì@~2, ”’ì—TŠî1, ¬—ÑŽü•œ1, rì—Y‹I1, Œ¬“c—º1, ’†‘º—m”Í2, Î––¬Æ2, ²“¡@—z2, ŠÝŒŽ@~2, ’ë–ìTˆê2, ˆ¢ŒÃÆ2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2zŠÂŠí“à)

110128. [ŒŽ’˜] Current Status and Clinical Outcomes of Oral Anticoagulant Discontinuation After Ablation for Atrial Fibrillation in Japan - Findings From the AF Frontier Ablation Registry. Okumura Y1, Nagashima K1, Arai M1, Watanabe R1, Yokoyama K1, Matsumoto N1, Otsuka T1, Suzuki S1, Hirata A1, Murakami M1, Takami M1, Kimura M1, Fukaya H1,2, Nakahara S1, Kato T1, Shimizu W1, Iwasaki YK1, Hayashi H1, Harada T1, Nakajima I1, Okumura K1, Koyama J1, Tokuda M1, Yamane T1, Momiyama Y1, Tanimoto K1, Soejima K1, Nonoguchi N1, Ejima K1, Hagiwara N1, Harada M1, Sonoda K1, Inoue M1, Kumagai K1, Hayashi H1, Satomi K1, Yazaki Y1, Watari Y1 (1AF Ablation Frontier Registry): Circ J 2019/11; 83 (12): 2418-27. ([’J‰p•œ1,2: 2zŠÂŠí“à)

110129. [ŒŽ’˜] Effect of combination of non-slip element balloon and drug-coating balloon for in-stent restenosis lesions (ELEGANT study). Aoki J1, Nakazawa G1, Ando K1, Nakamura S1, Tobaru 1, Sakurada M1, Okada H1, Hibi K1, Zen K1, Habara S1, Fujii K1, Habara M1, Ako J1,2, Asano T1, Ozaki S1, Fusazaki T1, Kozuma K1 (1ELEGANT Investigators): J Cardiol 2019/11; 74 (5): 436-42. (ˆ¢ŒÃÆ1,2: 2zŠÂŠí“à)

110130. [ŒŽ’˜] Clinical and Laboratory Predictors for Plaque Erosion in Patients With Acute Coronary Syndromes. Yamamoto E, Yonetsu T, Kakuta T, Soeda T, Saito Y, Yan BP, Kurihara O, Takano M, Niccoli G, Higuma T, Kimura S, Minami Y1, Ako J1, Adriaenssens T, Boeder NF, Nef HM, Fracassi F, Sugiyama T, Lee H, Crea F, Kimura T, Fujimoto JG, Fuster V, Jang IK: J Am Heart Assoc 2019/11; 8 (21): e012322. (“ì@®Œ«1, ˆ¢ŒÃÆ1: 1zŠÂŠí“à)

110131. [ŒŽ’˜] Association of onset-season with characteristics and long-term outcomes in acute myocardial infarction patients: results from the Japanese registry of acute myocardial infarction diagnosed by universal definition (J-MINUET) substudy. Okuno T1, Aoki J1, Tanabe K1, Nakao K1, Ozaki Y1, Kimura K1, Ako J1,2, Noguchi T1, Yasuda S1, Suwa S1, Fujimoto K1, Nakama Y1, Morita T1, Shimizu W1, Saito Y1, Hirohata A1, Morita Y1, Inoue T1, Okamura A1, Mano T1, Hirata K1, Shibata Y1, Owa M1, Tsujita K1, Funayama H1, Kokubu N1, Kozuma K1, Uemura S1, Tobaru T1, Saku K1, Ohshima S1, Nishimura K1, Miyamoto Y1, Ogawa H1, Ishihara M1 (1J-MINUET investigators): Heart Vessels 2019/12; 34 (12): 1899-908. (ˆ¢ŒÃÆ1,2: 2zŠÂŠí“à)

110132. [ŒŽ’˜] Risk Factors of In-Hospital Lethal Arrhythmia Following Acute Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention -Insight From the J-MINUET Study-. Oikawa J1, Fukaya H1, Ako J1, Nakao K, Ozaki Y, Kimura K, Noguchi T, Suwa S, Fujimoto K, Nakama Y, Morita T, Shimizu W, Saito Y, Hirohata A, Morita Y, Inoue T, Okamura A, Mano T, Miyamoto Y, Ogawa H, Ishihara M, on behalf the J-MINUET investigators: Circulation Reports 2020/1; 2 (1): 17-23. (‹yì@~1, [’J‰p•œ1, ˆ¢ŒÃÆ1: 1zŠÂŠí“à)

110133. [ŒŽ’˜] Guideline adherence and long-term clinical outcomes in patients with acute myocardial infarction: a Japanese Registry of Acute Myocardial Infarction Diagnosed by Universal Definition (J-MINUET) substudy. Wada H1, Ogita M1, Suwa S1, Nakao K1, Ozaki Y1, Kimura K1, Ako J1,2, Noguchi T1, Yasuda S1, Fujimoto K1, Nakama Y1, Morita T1, Shimizu W1, Saito Y1, Hirohata A1, Morita Y1, Inoue T1, Okamura A1, Mano T1, Hirata K1, Tanabe K1, Shibata Y1, Owa M1, Tsujita K1, Funayama H1, Kokubu N1, Kozuma K1, Uemura S1, Toubaru T1, Saku K1, Oshima S1, Nishimura K1, Miyamoto Y1, Ogawa H1, Ishihara M1 (1J-MINUET investigators): Eur Heart J Acute Cardiovasc Care 2020/1; 2048872620902024. (ˆ¢ŒÃÆ1,2: 2zŠÂŠí“à)

110134. [ŒŽ’˜] Age- and Gender-Related Differences in Coronary Lesion Plaque Composition on Optical Coherence Tomography. Sato T1, Minami Y2, Asakura K1, Katamine M1, Kato A1, Katsura A1, Muramatsu Y1, Kakizaki R2, Nemoto T2, Hashimoto T2, Fujiyoshi K2, Kameda R2, Meguro K2, Shimohama T2, Ako J2: Circ J 2020/2; 84 (3): 463-70. (²“¡r[1, “ì@®Œ«2, ’©‘qŽŽj1, •Ð•ô³á©1, ‰Á“¡Ê”ü1, Œj@—L’q1, ‘ºŒ—T‰î1, Š`è—Ç‘Ÿ2, ª–{Æ¢Žu2, ‹Ž–{‘ñ–í2, “¡‹g˜a”Ž2, ‹T“c@—Ç2, –ڍ•Œ’‘Ÿ˜Y2, ‰º•lF˜Y2, ˆ¢ŒÃÆ2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2zŠÂŠí“à)

110135. [ŒŽ’˜] Novel volumetric analysis for stent expansion after drug-eluting stent implantation: An optical coherence tomography study. Katsura A1, Minami Y2, Kato A1, Muramatsu Y1, Sato T1, Hashimoto T2, Meguro K2, Shimohama T2, Ako J2: Catheter Cardiovasc Interv 2020/11; 96 (5): E501-7. doi: 10.1002/ccd.28871. Epub 2020 Mar 23. (Œj@—L’q1, “ì@®Œ«2, ‰Á“¡Ê”ü1, ‘ºŒ—T‰î1, ²“¡r[1, ‹Ž–{‘ñ–í2, –ڍ•Œ’‘Ÿ˜Y2, ‰º•lF˜Y2, ˆ¢ŒÃÆ2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2zŠÂŠí“à)

110136. [ŒŽ’˜] Wearable Cardioverter Defibrillator -Initial Experience in the Outpatient Setting in Japan. Horiguchi A1, Kishihara J2, Niwano S2, Saito D1, Matsuura G1, Sato T1, Shirakawa Y1, Kobayashi S1, Arakawa Y1, Nishinarita R1, Nakamura H2, Ishizue N2, Oikawa J2, Satoh A2, Fukaya H2, Ako J2: Circulation Reports 2020/3; 2 (3): 137-142. (–xŒû@ˆ€1, ŠÝŒŽ@~2, ’ë–ìTˆê2, âV“¡‘åŽ÷1, Œ‰Y@Œ³1, ²“¡r[1, ”’ì—TŠî1, ¬—ÑŽü•œ1, rì—Y‹I1, Œ¬“c—º1, ’†‘º—m”Í2, Î––¬Æ2, ‹yì@~2, ²“¡@—z2, [’J‰p•œ2, ˆ¢ŒÃÆ2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2zŠÂŠí“à)

110137. [ŒŽ’˜] Admission During Off-Hours Does Not Affect Long-Term Clinical Outcomes of Japanese Patients with Acute Myocardial Infarction. Suwa S1, Ogita M1, Ebina H1, Nakao K1, Ozaki Y1, Kimura K1, Ako J1,2, Noguchi T1, Yasuda S1, Fujimoto K1, Nakama Y1, Morita T1, Shimizu W1, Saito Y1, Hirohata A1, Morita Y1, Inoue T1, Okamura A1, Mano T1, Hirata K1, Tanabe K1, Shibata Y1, Owa M1, Tsujita K1, Funayama H1, Kokubu N1, Kozuma K1, Uemura S1, Toubaru T1, Saku K1, Oshima S1, Nishimura K1, Miyamoto Y1, Ogawa H1, Ishihara M1 (1J-MINUET investigators): Int Heart J 2020/3; 61 (2): 215-22. (ˆ¢ŒÃÆ1,2: 2zŠÂŠí“à)

120004. [ŒŽ’˜] –k—¢‘åŠw•a‰@‹~‹}•”–å‚É‚š‚¯‚鎞_f—Â̌»ó. Œ¬“c—º1, ’ë–ìTˆê2, Œ‰Y@Œ³1, rì—Y‹I1, ¬—ÑŽü•œ1, ”’ì—TŠî1, –xŒû@ˆ€1, ’†‘º—m”Í2, Î––¬Æ2, ‹yì@~2, ŒÜ\—’Œµ2, ŠÝŒŽ@~2, ²“¡@—z2, [’J‰p•œ2, ÂŽR’Œ‘P3, ˆ¢ŒÃÆ2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2zŠÂŠí“à, 3‘‡f—Ã): S“d} 2019/8; 39 (suppl 2): 4147.

310011. [Ç—á•ñ] Use of idarucizumab for dabigatran reversal in cardiac tamponade during atrial fibrillation ablation: A case report. Yoshizawa T1, Niwano S1, Fukaya H1, Saitoh D2, Fujiyoshi K1, Nakamura H1, Igarashi T1, Oikawa J1, Satoh A1, Kishihara J1, Ako J1: J Cardiol Cases 2019/5; 20 (1): 27-9. (‹gàV’qŽ¡1, ’ë–ìTˆê1, [’J‰p•œ1, âV“¡‘åŽ÷2, “¡‹g˜a”Ž1, ’†‘º—m”Í1, ŒÜ\—’Œš1, ‹yì@~1, ²“¡@—z1, ŠÝŒŽ@~1, ˆ¢ŒÃÆ1: 1zŠÂŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

310012. [Ç—á•ñ] Early inappropriate shock in a subcutaneous cardiac defibrillator due to subcutaneous air. Nishinarita R1, Kishihara J2, Matsuura G1, Arakawa Y1, Kobayashi S1, Shirakawa Y1, Horiguchi A1, Nakamura H2, Ishizue N2, Oikawa J2, Fukaya H2, Niwano S2, Ako J2: J Arrhythm 2019/6; 35 (4): 682-4. (Œ¬“c—º1, ŠÝŒŽ@~2, Œ‰Y@Œ³1, rì—Y‹I1, ¬—ÑŽü•œ1, ”’ì—TŠî1, –xŒû@ˆ€1, ’†‘º—m”Í2, Î––¬Æ2, ‹yì@~2, [’J‰p•œ2, ’ë–ìTˆê2, ˆ¢ŒÃÆ2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2zŠÂŠí“à)

310013. [Ç—á•ñ] Transaortic Access Using Vascular Graft for Transcatheter Aortic Valve Implantation. Kakizaki R1, Meguro K1, Kitamura T2, Hashimoto T1, Ako J1: Int Heart J 2019/7; 60 (4): 990-3. (Š`è—Ç‘Ÿ1, –ڍ•Œ’‘Ÿ˜Y1, –k‘º@—¥2, ‹Ž–{‘ñ–í1, ˆ¢ŒÃÆ1: 1zŠÂŠí“à, 2S‘ŸŒŒŠÇŠO)

310014. [Ç—á•ñ] Early Safety and Efficacy of Sapien 3 20 mm Transcatheter Heart Valve Implantation in Small Japanese Body Size. Meguro K1, Kakizaki R1, Hashimoto T1, Yanagisawa T1, Koitabashi T1, Kitamura T2, Ako J1: Heart Surg Forum 2018/8; 21 (5): E341-4. (–ڍ•Œ’‘Ÿ˜Y1, Š`è—Ç‘Ÿ1, ‹Ž–{‘ñ–í1, –öàV’q‹`1, ¬”‹Žr”ü1, –k‘º@—¥2, ˆ¢ŒÃÆ1: 1zŠÂŠí“à, 2S‘ŸŒŒŠÇŠO)

310015. [Ç—á•ñ] Zero-Contrast Optical Coherence Tomography- and Physiology-Guided Percutaneous Coronary Intervention for Severely Calcified Lesion. Asakura K1, Minami Y2, Shimohama T2, Ako J2: Circ J 2019/10; 83 (11): 2326. (’©‘qŽŽj1, “ì@®Œ«2, ‰º•lF˜Y2, ˆ¢ŒÃÆ2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2zŠÂŠí“à)

310016. [Ç—á•ñ] Coronary Artery Injury Caused by Leadless Pacemaker Implantation. Fukaya H1, Kishihara J1, Ishizue N1, Kameda R1, Shimohama T1, Arakawa Y2, Nishinarita R2, Horiguchi A2, Oikawa J1, Niwano S1, Ako J1: Circ J 2020/2; 84 (3): 530. ([’J‰p•œ1, ŠÝŒŽ@~1, Î––¬Æ1, ‹T“c@—Ç1, ‰º•lF˜Y1, rì—Y‹I2, Œ¬“c—º2, –xŒû@ˆ€2, ‹yì@~1, ’ë–ìTˆê1, ˆ¢ŒÃÆ1: 1zŠÂŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

511002. [‰ðà]yEditorialzBleeding risk score in Japanese patients on antiplatelets plus an anticoagulant. Fukaya H1, Ako J1: J Cardiol 2019/6; 73 (6): 466-7. ([’J‰p•œ1, ˆ¢ŒÃÆ1: 1zŠÂŠí“à)

511003. [‰ðà] Editorial to ""Bipolar radiofrequency catheter ablation between the left ventricular endocardium and great cardiac vein for refractory ventricular premature complexes originating from the left ventricular summit"". Niwano S1: J Arrhythm 2020/2; 36 (2): 367. (’ë–ìTˆê1: 1zŠÂŠí“à)

522025. [uÀ] Epoch-making: CABANA trial‚ðŽó‚¯‚ẴJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚Ì“K‰ž. [’J‰p•œ (zŠÂŠí“à): CATH LAB JIN 2019/8; 2 (3): 81-4.

522026. [uÀ]y“ÁW: Š¥“®–¬ŒŒsÄŒšŒã‚̍RŒŒ¬”ER‹ÃŒÅ—Ö@‚ɂ‚¢‚āzoŒŒƒŠƒXƒN‚𔺂€Ç—á‚ɑ΂·‚éPCIŽ¡—Ã: “Á‚ɏoŒŒ‚𔺂€Á‰»Šíˆ««Žîᇂ̏p‘O‚ÉPCI‚ðs‚€‚æ‚€‚ȃP[ƒX‚Å, ‚Ç‚ê‚Ÿ‚¯‘Ò‚Ä‚ÎŽèp‚ª‰Â”\‚È‚Ì‚©? ‰º•lF˜Y1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à): “ú–{Š¥ŽŸŠ³Šw‰ïŽGŽ 2019/9; 1: 38-41.

522027. [uÀ]y“ÁWu¶ŠˆKŠµ•avf—Â̐V’ª—¬: ‚±‚Ì10”N‚ʼnœ‚ª•Ï‚í‚Á‚œzŸŒŒŠÇáŠQ‚Ì‘Šúf’fEVŽ¡—ÂƏdÇ‰»—\–h@Š¥“®–¬ŽŸŠ³. ‰º•lF˜Y1, ‹T“c@—Ç1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à): f’f‚ÆŽ¡—à 2019/9; 107 (9): 1059-67.

522028. [uÀ]y“ÁW: ‹}«Š¥ÇŒóŒQ@ŽÀ—Տ°‚ÉŠˆ‚«‚é–ò•šŽ¡—Â̒mŽ¯‚ƃXƒLƒ‹‚ðg‚ɂ‚¯‚éz¡Œo”ç“IŠ¥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Œã‚̍RŒŒð—Ö@Q&A@5. R‹ÃŒÅ–ò (ŒoŒûR‹ÃŒÅ–ò‚àŠÜ‚Þ) ‚Í‚¢‚E‚Ç‚ÌŠ³ŽÒ‚ɁE‚Ç‚€Žg‚€‚©? ‹T“c@—Ç1, ‰º•lF˜Y1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à): –ò‹Ç 2019/11; 70 (12): p.61-70.

530005. [‚»‚Ì‘Œ (Guideline)] JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome. Kimura K1, Kimura T1, Ishihara M1, Nakagawa Y1, Nakao K1, Miyauchi K1, Sakamoto T1, Tsujita K1, Hagiwara N1, Miyazaki S1, Ako J1,2, Arai H1, Ishii H1, Origuchi H1, Shimizu W1, Takemura H1, Tahara Y1, Morino Y1, Iino K1, Itoh T1, Iwanaga Y1, Uchida K1, Endo H1, Kongoji K1, Sakamoto K1, Shiomi H1, Shimohama T1,2, Suzuki A1, Takahashi J1, Takeuchi I1, Tanaka A1, Tamura T1, Nakashima T1, Noguchi T1, Fukamachi D1, Mizuno T1, Yamaguchi J1, Yodogawa K1, Kosuge M1, Kohsaka S1, Yoshino H1, Yasuda S1, Shimokawa H1, Hirayama A1, Akasaka T1, Haze K1, Ogawa H1, Tsutsui H1, Yamazaki T1 (1Japanese Circulation Society Joint Working Group): Circ J 2019/4; 83 (5): 1085-96. (ˆ¢ŒÃÆ1,2, ‰º•lF˜Y1,2: 2zŠÂŠí“à)

[’˜@‘]

620014. [Šwp‘ (•ª’SŽ·•M)]yzŠÂŠíÇŒóŒQ (‘æ3”Å) I|‚»‚Ì‘Œ‚̏zŠÂŠíŽŸŠ³‚ðŠÜ‚߂ā| (•Êû“ú–{—Õଠ—̈æ•ÊÇŒóŒQƒVƒŠ[ƒY No.5)zII. S‹ØŽŸŠ³@43. ‹×–E«S‹Ø‰Š, p.308-11. “ç“c@Œ’1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à), “ú–{—Õ଎Ð, “Œ‹ž, 2019/9”­s.

620015. [Šwp‘ (•ª’SŽ·•M)]yzŠÂŠíÇŒóŒQ (‘æ3”Å) II|‚»‚Ì‘Œ‚̏zŠÂŠíŽŸŠ³‚ðŠÜ‚߂ā| (•Êû“ú–{—Õଠ—̈æ•ÊÇŒóŒQƒVƒŠ[ƒY No.6)zVI. Š¥“®–¬EÃ–¬ŽŸŠ³E‘–sˆÙí@39. ƒXƒeƒ“ƒg“àŒŒðÇ (‹}«EˆŸ‹}«E’x”­«), p.193-7. ‰º•lF˜Y1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à), “ú–{—Õ଎Ð, “Œ‹ž, 2019/10”­s.

620016. [Šwp‘ (•ª’SŽ·•M)]y“úíf—ÂɊˆ‚©‚·f—ÃKƒCƒhƒ‰ƒCƒ“UP-TO-DATE 2020-2021zIII. zŠÂŠíŽŸŠ³@3. ‹·SÇ, p.163-7. ‘ºŒ—T‰î1, ‰º•lF˜Y2, ˆ¢ŒÃÆ2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2zŠÂŠí“à), ŠÄC: –å˜e@F, ¬Žºˆê¬, ‹{’n—ÇŽ÷, ƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽÐ, “Œ‹ž, 2020/2”­s.

620017. [Šwp‘ (•ª’SŽ·•M)]yzŠÂŠíƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì—˜_‚Æ‹Zp ‰ü’ù‘æ2”ŁzI ‰ð–UŠw‚Ì’mŽ¯@S‘Ÿ‚̍\‘¢‚Æ‹@”\, p.2-18. IV ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì‚œ‚ß‚ÌŠ³ŽÒ•]‰¿@S“d}‚̐f•û, p.135-65. ‘“c@‘ì1 (1ˆã—Éq¶Šw•”), •Ò: ‘“c@‘ì1, Œ‰i“Ä•F1, ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2020/3”­s.

620018. [Šwp‘ (•ª’SŽ·•M)]yzŠÂŠíƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì—˜_‚Æ‹Zp ‰ü’ù‘æ2”ŁzIII zŠÂŠíŽŸŠ³‚Ì•a‘Ô‚ÆŽ¡—Á@‚ŒŒˆ³«SŽŸŠ³, p.75-83. “ŒžŠ”ü“ÞŽq1 (1ˆã—Éq¶Šw•”), •Ò: ‘“c@‘ì1, Œ‰i“Ä•F1, ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2020/3”­s.

620019. [Šwp‘ (•ª’SŽ·•M)]yzŠÂŠíƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì—˜_‚Æ‹Zp ‰ü’ù‘æ2”ŁzIII zŠÂŠíŽŸŠ³‚Ì•a‘Ô‚ÆŽ¡—Á@S•s‘S, p.84-93. ’––”FŒ³1 (1zŠÂŠí“à), •Ò: ‘“c@‘ì2, Œ‰i“Ä•F2 (2ˆã—Éq¶Šw•”), ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2020/3”­s.

620020. [Šwp‘ (•ª’SŽ·•M)]yzŠÂŠíƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì—˜_‚Æ‹Zp ‰ü’ù‘æ2”ŁzIII zŠÂŠíŽŸŠ³‚Ì•a‘Ô‚ÆŽ¡—Á@‘匌ŠÇŽŸŠ³, p.94-108. V ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ (‘˜_)@‹Ö‰Œ, p.307-13. –ì“cçt1 (1zŠÂŠí“à), •Ò: ‘“c@‘ì2, Œ‰i“Ä•F2 (2ˆã—Éq¶Šw•”), ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2020/3”­s.

620021. [Šwp‘ (•ª’SŽ·•M)]yzŠÂŠíƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì—˜_‚Æ‹Zp ‰ü’ù‘æ2”ŁzIV ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì‚œ‚ß‚ÌŠ³ŽÒ•]‰¿@S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚ÉŠÖ‚·‚éSƒGƒR[ŠŒ©‚Ì—‰ð, p.211-25. ‘OìŒb”ü1 (1zŠÂŠí“à), •Ò: ‘“c@‘ì2, Œ‰i“Ä•F2 (2ˆã—Éq¶Šw•”), ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2020/3”­s.

[Šw‰ïEŒ€‹†‰ï“™]

713029. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) The one-year follow-up of SAPIEN 3 20 mm Transcatheter Heart Valve Implantation in Asian, small body size patients. Meguro K1, Kakizaki R1, Hashimoto T1, Yanagisawa T1, Ako J1: Euro PCR 2019 (2019/5/21), Paris, France. (–ڍ•Œ’‘Ÿ˜Y1, Š`è—Ç‘Ÿ1, ‹Ž–{‘ñ–í1, –öàV’q‹`1, ˆ¢ŒÃÆ1: 1zŠÂŠí“à)

713030. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Coronary Stenosis & Plaque Characterization. Ako J1: Asian Pacific Society of Cardiology 2019 (APSC 2019) (2019/5/24), Manila, Philippines. (ˆ¢ŒÃÆ1: 1zŠÂŠí“à)

713031. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) The outcome of transcatheter aortic valve implantation in patients with small annulus and the comparison between intra-annular and supra-annular devices in small annulus@From the analysis of the Japanese nationwide registry (J-TVT registry). Meguro K1, Hashimoto T1, Kitamura T2, Ako J1: European Society of Cardiology (2019/9/1), Paris, France. (–ڍ•Œ’‘Ÿ˜Y1, ‹Ž–{‘ñ–í1, –k‘º@—¥2, ˆ¢ŒÃÆ1: 1zŠÂŠí“à, 2S‘ŸŒŒŠÇŠO)

713032. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) CORONARY ARTERY DISEASE Updates & Controversies in ACS. Ako J1: ACC Asia Conference 2019 (2019/9/13), Nagoya, Japan. (ˆ¢ŒÃÆ1: 1zŠÂŠí“à)

713033. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) PCI For HBR Patients In Japan: Current Clinical Treatment And Post-Market Treatment. Ako J1: CRT 2020 (2020/2/24), Washington DC, USA. (ˆ¢ŒÃÆ1: 1zŠÂŠí“à)

722036. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ‰pŒê˜_•¶‚ð‘‚±‚€! ˆ¢ŒÃÆ (zŠÂŠí“à): Tokyo Percutaneous cardiovascular Intervention Conference (TOPIC) 2019 (2019/7/12), “Œ‹ž.

722037. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)y“O’ê“¢˜_z’·ŠúŽ‘±«S–[×“®‚ɑ΂·‚鎡—Ð헪@“Ž’²—¥‚ðŠú‘Ò‚Å‚«‚éÇ—á‚ð”»•Ê‚Å‚«‚é‚©. [’J‰p•œ1, ’ë–ìTˆê1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à): ‘æ67‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï (2019/9/14), –ŒŒÃ‰®.

722038. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ACSŠ³ŽÒ‚É‚š‚¯‚錵ŠiŽ‰Ž¿ŠÇ—. ˆ¢ŒÃÆ (zŠÂŠí“à): ‘æ67‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï (2019/9/15), –ŒŒÃ‰®.

722039. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) St˜AŠÖ‚ðl—¶‚µ‚œ“œ”A•aŽ¡—Ã. ˆ¢ŒÃÆ (zŠÂŠí“à): ‘æ67‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï (2019/9/15), –ŒŒÃ‰®.

722040. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) SŒŒŠÇƒCƒxƒ“ƒg—}§‚ðl—¶‚µ‚œŽ‰Ž¿ˆÙíÇŽ¡—Ð헪. ˆ¢ŒÃÆ (zŠÂŠí“à): ‘æ28‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ï: CVIT2019 (2019/9/20), –ŒŒÃ‰®.

722041. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) PCI‚̍‡•¹Ç|ƒXƒeƒ“ƒgŒŒðÇ. ˆ¢ŒÃÆ (zŠÂŠí“à): ‘æ28‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ï: CVIT2019 (2019/9/20), –ŒŒÃ‰®.

722042. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients with Acute Coronary Syndrome: The ODYSSEY J-IVUS Trial. ˆ¢ŒÃÆ (zŠÂŠí“à): ‘æ28‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ï: CVIT2019 (2019/9/20), –ŒŒÃ‰®.

722043. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) PCSK9‘jŠQÜ. ˆ¢ŒÃÆ (zŠÂŠí“à): ‘æ60‰ñ“ú–{–¬ŠÇŠw‰ï‘‰ï (2019/10/10), “Œ‹ž.

722044. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) zŠÂŠí—̈æ‚É‚š‚¯‚éæ‹ì“IŽ¡—Ã. ˆ¢ŒÃÆ (zŠÂŠí“à): ‘æ16‰ñ“ú–{zŠÂŠíŠÅŒìŠw‰ïŠwpW‰ï (2019/11/2), “Œ‹ž.

722045. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ŒŒ‰tƒTƒ‰ƒTƒ‰‚Á‚ĉœ? NOAC? DOAC? ˆ¢ŒÃÆ (zŠÂŠí“à): ‘æ16‰ñ“ú–{zŠÂŠíŠÅŒìŠw‰ïŠwpW‰ï (2019/11/2), “Œ‹ž.

722046. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ‚È‚ºzŠÂŠíˆã‚͍RŒŒð–ò‚ðŽg‚€‚Ì‚©. ˆ¢ŒÃÆ (zŠÂŠí“à): JDDW 2019 KOBE (‘æ27‰ñ“ú–{Á‰»ŠíŠÖ˜AŠw‰ïTŠÔ) (2019/11/22), _ŒË.

722047. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) TWILIGHTŽŽŒ±. ˆ¢ŒÃÆ (zŠÂŠí“à): ARIA (Alliance for Revolution and Interventional Cardiology Advancement) 2019 (2019/11/23), •Ÿ‰ª.

722048. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) AFIREŽŽŒ±. ˆ¢ŒÃÆ (zŠÂŠí“à): ARIA (Alliance for Revolution and Interventional Cardiology Advancement) 2019 (2019/11/23), •Ÿ‰ª

723152. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) S–[SŽº˜AŠÖ‚̉ü‘P‚É‚æ‚è‰^“®ŽžŽüŠú«ŒÄ‹z•Ï“®‚ªÁŽž‚µ‚œS–[’†ŠuŒ‡‘¹ÇpŒã‚Ì1—á. ‘OìŒb”ü1, _’JŒ’‘Ÿ˜Y2, Žsì‹M•¶3, –ìèN•œ3, •lèL–Ÿ3, ŽR–{˜ÐŽq4, ™–ì‰Á“ÞŽq3, ŒÜ\—’ˆŸŠóŽq4, –ڍ•Œ’‘Ÿ˜Y1, –ì“cçt1, ‰º•lF˜Y1, “ŒžŠ”ü“ÞŽq2, ‘“c@‘ì2, ˆ¢ŒÃÆ1 (1zŠÂŠí“à, 2ˆã—Éq¶Šw•”, 3ƒŠƒnƒrƒŠ•”, 4ŠÅŒì•”): ‘æ25‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ï (2019/7/14), ‘åã.

723153. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Zero-Contrast Optical Coherence Tomography- and Physiology- Guided Percutaneous Coronary Intervention for Severe Calcified Lesion. ’©‘qŽŽj1, “ì@®Œ«2, ‰º•lF˜Y2, ˆ¢ŒÃÆ2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2zŠÂŠí“à): ‘æ28‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ï: CVIT2019 (2019/9/19), –ŒŒÃ‰®.

723154. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Subsequent accumulation of organized thrombus overlying irregular protrusion caused restenosis after drug-eluting stent implantation. Î––¬Æ1, “ì@®Œ«1, –ڍ•Œ’‘Ÿ˜Y1, ‰º•lF˜Y1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à): ‘æ28‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ï: CVIT2019 (2019/9/19), –ŒŒÃ‰®.

723155. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Biodegradable polymer SES had greater incidence of target lesion revascularization than 2nd-generation DES in a real-world cohort. Š`è—Ç‘Ÿ1, “ì@®Œ«1, ’©‘qŽŽj2, Œj@—L’q2, ‰Á“¡Ê”ü2, ‘ºŒ—T‰î2, ²“¡r[2, ª–{Æ¢Žu1, “¡‹g˜a”Ž1, Î“cO‹B1, ‹Ž–{‘ñ–í1, –ڍ•Œ’‘Ÿ˜Y1, ‰º•lF˜Y1, ˆ¢ŒÃÆ1 (1zŠÂŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ28‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ï: CVIT2019 (2019/9/19), –ŒŒÃ‰®.

723156. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) The efficacy and safety of dextran-based optical coherence tomography-guided percutaneous coronary intervention in patients with chronic kidney disease. •Ð•ô³á©1, “ì@®Œ«2, ª–{Æ¢Žu2, ‘ºŒ—T‰î1, ’©‘qŽŽj1, ‰Á“¡Ê”ü1, Œj@—L’q1, ²“¡r[1, Š`è—Ç‘Ÿ2, ‹Ž–{‘ñ–í2, “¡‹g˜a”Ž2, –ڍ•Œ’‘Ÿ˜Y2, ‰º•lF˜Y2, ˆ¢ŒÃÆ2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2zŠÂŠí“à): ‘æ28‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ï: CVIT2019 (2019/9/19), –ŒŒÃ‰®.

723157. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰)yYIAƒmƒ~ƒl[ƒgz“ü‰@Žž‚É‚š‚¯‚é•às‘¬“x‚̉ü‘P‚͍‚—îS•s‘SŠ³ŽÒ‚̐¶–œ—\Œã‚ð—ǍD‚É‚·‚é. “c’†L–í1, _’JŒ’‘Ÿ˜Y2, •lèL–Ÿ3, –ìèN•œ3, ‘OìŒb”ü4, –ì“cçt4, “ŒžŠ”ü“ÞŽq2, Œ‰i“Ä•F2, ˆ¢ŒÃÆ4 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ˆã—Éq¶Šw•”, 3ƒŠƒnƒrƒŠ•”, 4zŠÂŠí“à): ‘æ23‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ï (2019/10/4), L“‡.

731021. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) IVUS guide‚̐^‘. ‰º•lF˜Y (zŠÂŠí“à): Tokyo Live Demonstration 2019 (2019/10/11), “Œ‹ž.

732015. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) STENTA‚Šž‚ÝŒãRŒŒð—Ö@‚̉ߋŽ‚Æ–¢—ˆ. ˆ¢ŒÃÆ (zŠÂŠí“à): ‘æ46‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ï“Œ–k’n•û‰ï (2019/8/17), H“c.

732016. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) Safety and effectiveness of transcatheter mitral leaflet approximation with MitraClip in heart failure patients with secondary mitral regurgitation. ˆ¢ŒÃÆ (zŠÂŠí“à): PCR Tokyo Valves 2020 (2020/2/16), “Œ‹ž.

'18”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'18-110004. [ŒŽ’˜] Dual Anti-Thrombotic Therapy With Dabigatran After Percutaneous Coronary Intervention in Atrial Fibrillation - Japanese and East-Asian Subgroup Analysis of the RE-DUAL PCI Trial. Ako J1,2, Okumura K1, Nakao K1, Kozuma K1, Morino Y1, Okazaki K1, Fukaya T1, Kimura T1 (1RE-DUAL PCI Trial Investigators): Circ J 2019/1; 83 (2): 327-33. (ˆ¢ŒÃÆ1,2: 2zŠÂŠí“à)

'18-110005. [ŒŽ’˜] Calcified Plaques in Patients With Acute Coronary Syndromes. Sugiyama T, Yamamoto E, Fracassi F, Lee H, Yonetsu T, Kakuta T, Soeda T, Saito Y, Yan BP, Kurihara O, Takano M, Niccoli G, Crea F, Higuma T, Kimura S, Minami Y1, Ako J1, Adriaenssens T, Boeder NF, Nef HM, Fujimoto JG, Fuster V, Finn AV, Falk E, Jang IK.: JACC Cardiovasc Interv 2019/3; 12 (6): 531-40. (“ì@®Œ«1, ˆ¢ŒÃÆ1: 1zŠÂŠí“à)

'18-522002. [uÀ]y˜AÚz ¡‚±‚»‚â‚ë‚€SƒGƒR[! ¬”‹Žr”ü (zŠÂŠí“à): Medical Practice 2019/1; 36 (1): .153.

'18-522003. [uÀ]y“ÁW: Common disease‚Æ‚µ‚Ă̐S–[×“®zIII. S–[×“®‚̏‰f‚©‚çê–åˆãÐ‰î‚Ü‚Å. [’J‰p•œ (zŠÂŠí“à): “ú–{“à‰ÈŠw‰ïŽGŽ 2019/2; 108 (2); 212-8.

[’˜@‘]

'18-620002. [Šwp‘ (•ª’SŽ·•M)]yŽüŽYŠúS‹ØÇf—Â̎èˆø‚«z‘æVIIIÍ ”DŽY•w‚É‚š‚¯‚éÇóEg‘̏ŠŒ©‚̐f•û‚ÆŒŸž‚̐i‚ß•û, p.54-61. ¬”‹Žr”ü (zŠÂŠí“à), ’†ŠOˆãŠwŽÐ, “Œ‹ž, 2019/3”­s.

'18-620003. [Šwp‘ (•ª’SŽ·•M)]yŽüŽYŠúS‹ØÇf—Â̎èˆø‚«z‘æIXÍ ŠÓ•Êf’f, p62-70. ¬”‹Žr”ü (zŠÂŠí“à), ’†ŠOˆãŠwŽÐ, “Œ‹ž, 2019/3”­s.

[Šw‰ïEŒ€‹†‰ï“™]

'18-713002. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Antithrombotic therapy in atrial fibrillation patients undergoing PCI. Ako J1: Taiwan Transcatheter Therapeutics 2019 (2019/1/13), Taipei, Taiwan. (ˆ¢ŒÃÆ1: 1zŠÂŠí“à)

'18-713003. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Perspectives of AF patients with Acute Coronary Syndrome. Ako J1: 5th Myanmar Cardiac Society Conference (2019/3/3), Yangon, Myanmar. (ˆ¢ŒÃÆ1: 1zŠÂŠí“à)

'18-722001. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) The trend of double/triple therapy from Japanese investigation. ˆ¢ŒÃÆ (zŠÂŠí“à): ‘æ83‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï (2019/3/30), ‰¡•l.


”]_Œo“à‰ÈŠw

[Šwp˜_•¶]

110138. [ŒŽ’˜] A cluster of disseminated small cortical lesions in MELAS: its distinctive clinical and neuroimaging features. Hongo Y1, Kaneko J1, Suga H1, Ishima D1, Kitamura E1, Akutsu T1, Onozawa Y2, Kanazawa N3, Goto T, Nishiyama K1, Iizuka T1: J Neurol 2019/6; 266 (6): 1459-72. (–{‹œ@—I1, ‹àŽq~‘Ÿ˜Y1, {‰ê—TŽ÷1, ˆä“‡‘å•ã1, –k‘º‰p“ñ1, ˆ¢‹v’Óñ•v1, ¬–ìàV—T–ç2, ‹ààV’Œ”ü3, ŒŽR˜a—˜1, ”ђˍ‚_1: 1”]_Œo“à, 2—ÕŒŸ•”, 3•a‘ԁEf—ÃŒn)

110139. [ŒŽ’˜] Effectiveness of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin for Preventing Further Cerebral Microbleeds in Acute Ischemic Stroke Patients with Nonvalvular Atrial Fibrillation and At Least One Microbleed: CMB-NOW Multisite Pilot Trial. Yokoyama M1, Mizuma A1, Terao T1, Tanaka F1, Nishiyama K1,2, Hasegawa Y1, Nagata E1, Nogawa S1, Kobayashi H1, Yanagimachi N1, Okazaki T1, Kitagawa K1, Takizawa S1 (1CMB-NOW Study Investigators): J Stroke Cerebrovasc Dis 2019/7; 28 (7): 1918-25. (ŒŽR˜a—˜1,2: 2”]_Œo“à)

110140. [ŒŽ’˜] Transplantation of Mesenchymal Stem Cells Improves Amyloid-ƒÀ Pathology by Modifying Microglial Function and Suppressing Oxidative Stress. Yokokawa K, Iwahara N, Hisahara S, Emoto MC, Saito T, Suzuki H, Manabe T, Matsumura A, Matsushita T, Suzuki S, Kawamata J1, Sato-Akaba H, Fujii HG, Shimohama S: J Alzheimers Dis 2019/11; 72 (3): 867-84. (ì–”@ƒ1: 1”]_Œo“à)

110141. [ŒŽ’˜] A mutant MATR3 mouse model to explain multisystem proteinopathy. Zhang X, Yamashita S, Hara K, Doki T, Tawara N, Ikeda T, Misumi Y, Zhang Z, Matsuo Y, Nagai M1, Kurashige T, Maruyama H, Ando Y: J Pathol 2019/10; 249 (2): 182-92. (‰iˆä^‹MŽq1: 1_Œo“à)

110142. [ŒŽ’˜] Differences in clinical features of cluster headache between drinkers and nondrinkers in Japan. Imai N, Kitamura E1: PLoS One 2019/11; 14 (11): e0224407. (–k‘º‰p“ñ1: 1”]_Œo“à)

110143. [ŒŽ’˜] CD14 and Toll-Like Receptor 4 Promote Fibrillar AƒÀ42 Uptake by Microglia Through A Clathrin-Mediated Pathway. Fujikura M, Iwahara N, Hisahara S, Kawamata J1, Matsumura A, Yokokawa K, Saito T, Manabe T, Matsushita T, Suzuki S, Shimohama S: J Alzheimers Dis 2019/12; 68 (1): 323-37. (ì–”@ƒ1: 1”]_Œo“à)

110144. [ŒŽ’˜] Early administration of galantamine from preplaque phase suppresses oxidative stress and improves cognitive behavior in APPswe/PS1dE9 mouse model of Alzheimer's disease. Saito T, Hisahara S, Iwahara N, Emoto MC, Yokokawa K, Suzuki H, Manabe T, Matsumura A, Suzuki S, Matsushita T, Kawamata J1, Sato-Akaba H, Fujii HG, Shimohama S: Free Radic Biol Med 2019/12; 145: 20-32. (ì–”@ƒ1: 1”]_Œo“à)

110145. [ŒŽ’˜] Safety of tapering tacrolimus dose in patients with well-controlled anti-acetylcholine receptor antibody-positive myasthenia gravis. Nishida Y, Takahashi YK, Kanai T, Nose Y, Ishibashi S, Sanjo N, Uzawa A, Oda F, Ozawa Y, Kuwabara S, Noguchi E, Suzuki S, Nakahara J, Suzuki N, Ogawa T, Yokoyama K, Hattori N, Konno S, Fujioka T, Kawaguchi N, Hatanaka Y, Sonoo M, Kaneko J1, Ogino M, Nishiyama K1, Nomura K, Yokota T: Eur J Neurol 2020/1; 27 (1): 100-4. (‹àŽq~‘Ÿ˜Y1, ŒŽR˜a—˜1: 1”]_Œo“à)

110146. [ŒŽ’˜] Cognitive and behavioral status in Japanese ALS patients: a multicenter study. Watanabe Y1, Raaphorst J1, Izumi Y1, Yoshino H1, Ito S1, Adachi T1, Takigawa H1, Masuda M1, Atsuta N1, Adachi Y1, Isose S1, Arai K1, Yokota O1, Oda M1, Ogino M1, Ichikawa H1, Hasegawa K1, Kimura H1, Shimizu T1, Aiba I1, Yabe H1, Kanba M1, Kusumi K1, Aoki T1, Hiroe Y1, Watanabe H1, Nishiyama K1,2, Nomoto M1, Sobue G1, Beeldman E1, Hanajima R1, Nakashima K1 (1ALS-FTD-Q-J research group): J Neurol 2020/5; 267 (5): 1321-30. doi: 10.1007/s00415-019-09655-9. Epub 2020 Jan 18. (ŒŽR˜a—˜1,2: 2”]_Œo“à)

110147. [ŒŽ’˜] Effect of rovatirelin in patients with cerebellar ataxia: two randomised double-blind placebo-controlled phase 3 trials. Nishizawa M1, Onodera O1, Hirakawa A1, Shimizu Y1, Yamada M1 (1Rovatirelin Study Group, Collaborators: Nishiyama K2): J Neurol Neurosurg Psychiatry 2020/3; 91 (3): 254-62. (ŒŽR˜a—˜2: 2”]_Œo“à)

310017. [Ç—á•ñ] Autoimmune Encephalitis as an Extra-articular Manifestation of Rheumatoid Arthritis. Kitamura E1, Kondo Y1, Kanazawa N2, Akutsu T1, Nishiyama K1, Iizuka T1: Intern Med 2019/4; 58 (7): 1007-9. (–k‘º‰p“ñ1, ‹ß“¡—TŽq1, ‹ààV’Œ”ü2, ˆ¢‹v’Óñ•v1, ŒŽR˜a—˜1, ”ђˍ‚_1: 1”]_Œo“à, 2•a‘ԁEf—ÃŒn)

310018. [Ç—á•ñ] An autopsy case of MM2-thalamic subtype of sporadic Creutzfeldt-Jakob disease with Lewy bodies presenting as a sleep disorder mimicking anti-IgLON5 disease. Hongo Y1, Iizuka T1, Kaneko A1, Suga H1, Uchino A1, Murayama S, Namba K, Inoue Y, Nishiyama K1: J Neurol Sci 2019/9; 404: 36-9. (–{‹œ@—I1, ”ђˍ‚_1, ‹àŽq@Œú1, {‰ê—TŽ÷1, “à–쏲Žq1, ŒŽR˜a—˜1: 1”]_Œo“à)

310019. [Ç—á•ñ] Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immune-related adverse events of nivolumab: a case report. Sakoh T, Kanzaki M1, Miyamoto A, Mochizuki S, Kakumoto T, Sato K, Uesaka Y, Kishi K: BMC Cancer 2019/12; 19 (1): 1220. (_è^ŽÀ1: 1”]_Œo“à)

310020. [Ç—á•ñ] An autopsy case of G M1 gangliosidosis type II in a patient who survived a long duration with artificial respiratory support. Uchino A, Nagai M1, Kanazawa N2, Ichinoe M3, Yanagisawa N, Adachi K, Nanba E, Ishiura H, Mitsui J, Tsuji S, Suzuki K, Murayama S, Nishiyama K1: Neuropathology 2020/8; 40 (4): 379-88. doi: 10.1111/neup.12651. Epub 2020 Mar 27. (‰iˆä^‹MŽq1, ‹ààV’Œ”ü2, ˆêŒË¹–Ÿ3, ŒŽR˜a—˜1: 1”]_Œo“à, 2•a‘ԁEf—ÃŒn, 3•a—)

310021. [Ç—á•ñ] Focal hyperperfusion and elevated lactate in the cerebral lesions with anti-GABAaR encephalitis: A serial MRI study. Ueno H, Iizuka T1, Tagane Y, Yamasaki F, Akiyama Y, Hosomi N, Maruyama H: J Neuroradiol 2020/5; 47 (3): 243-6. doi: 10.1016/j.neurad.2019.10.001. Epub 2019 Nov 5. (”ђˍ‚_1: 1”]_Œo“à)

410001. [—Տ°ŽŽŒ±] Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients. Imamura K, Izumi Y, Banno H, Uozumi R, Morita S, Egawa N, Ayaki T, Nagai M1, Nishiyama K1, Watanabe Y, Hanajima R, Oki R, Fujita K, Takahashi N, Ikeda T, Shimizu A, Morinaga A, Hirohashi T, Fujii Y, Takahashi R, Inoue H: BMJ Open 2019/12; 9 (12): e033131. (‰iˆä^‹MŽq1, ŒŽR˜a—˜1: 1”]_Œo“à)

520005. [‘à] ”]_Œo“à‰È—̈æ‚É‚š‚¯‚é“«ƒTƒ‹ƒRƒCƒh[ƒVƒX‚ÌŽ¡—Ó®Œü. ŒŽR˜a—˜ (”]_Œo“à): “ú–{ƒTƒ‹ƒRƒCƒh[ƒVƒXŠw‰ïŽ 2019/9; 39 (1/2): 29-32.

520006. [‘à] Ž©ŒÈ–Ɖu«”]‰Š‚š‚æ‚Ñ‚»‚Ì—Þ‰ŽŸŠ³‚É‚š‚¯‚éÅ‹ß‚̐i•à. ”ђˍ‚_ (”]_Œo“à): —Տ°_ŒoŠw 2019/8; 59 (8): 491-501.

520007. [‘à] ”]_Œo“à‰È—̈æ‚É‚š‚¯‚é“«ƒTƒ‹ƒRƒCƒh[ƒVƒX‚ÌŽ¡—Ó®Œü. ŒŽR˜a—˜ (”]_Œo“à): “ú–{ƒTƒ‹ƒRƒCƒh[ƒVƒX^“÷‰èŽî«ŽŸŠ³Šw‰ïŽGŽ 2019/9; 39 (1/2): 29-32.

522029. [uÀ]y“ÁW: –Ɖu«_ŒoŽŸŠ³‚ÌŽ¡—ÊwzŽ©ŒÈ–Ɖu«”]‰Š‚̐f’f‚ÆŽ¡—Ã. ”ђˍ‚_ (”]_Œo“à): BIO Clinica 2019/4; 34 (5): 480-4.

530006. [‚»‚Ì‘Œ (Correction)] Correction to: A cluster of disseminated small cortical lesions in MELAS: its distinctive clinical and neuroimaging features. Hongo Y1, Kaneko J1, Suga H1, Ishima D1, Kitamura E1, Akutsu T1, Onozawa Y2, Kanazawa N3, Goto T, Nishiyama K1, Iizuka T1: J Neurol 2019/6; 266 (6): 1473. (–{‹œ@—I1, ‹àŽq~‘Ÿ˜Y1, {‰ê—TŽ÷1, ˆä“‡‘å•ã1, –k‘º‰p“ñ1, ˆ¢‹v’Óñ•v1, ¬–ìàV—T–ç2, ‹ààV’Œ”ü3, ŒŽR˜a—˜1, ”ђˍ‚_1: 1”]_Œo“à, 2—ÕŒŸ•”, 3•a‘ԁEf—ÃŒn)

540033. [‚»‚Ì‘Œ]y“ú–{_ŒoŠw‰ï‡“¯ƒVƒ“ƒ|ƒWƒEƒ€: _Œo‹~‹}EW’†Ž¡—Âɂš‚¯‚é”]_Œo“à‰Èˆã‚̃vƒŒƒ[ƒ“ƒX‚ð‚‚ß‚é‚œ‚߂ɁzŽi‰ï‚ÌŒŸ—t. ŒŽR˜a—˜1, ‰iŽR³—Y (1”]_Œo“à): _ŒoŽ¡—Êw 2019/4; 36 (4): 478.

[’˜@‘]

620022. [Šwp‘ (•ª’SŽ·•M)] y1361ê–å‰Æ‚É‚æ‚é Ž„‚ÌŽ¡—à [2019-20”N“x”Å]z˜8 _ŒoE‹ØŽŸŠ³@Ž©ŒÈ–Ɖu«”]‰Š, p.588-90. ”ђˍ‚_ (”]_Œo“à), ŠÄC: ‰Ž“c‹’j, –k‘º‘yˆê˜Y, “ú–{ˆãŽ–V•ñŽÐ, “Œ‹ž, 2019/7”­s.

620023. [Šwp‘ (•ª’SŽ·•M)]y“à‰ÈŠw‘‰ü’è‘æ9”Å (Vol.6)z_ŒoŽŸŠ³@14. ––œ_ŒoŽŸŠ³ (ƒjƒ…[ƒƒpƒ`[)@’†“Ő«ƒjƒ…[ƒƒpƒ`[, p.572-4. _è^ŽÀ1, ŠC“cŒ«ˆê (1”]_Œo“à), ‘•ÒW: “ìŠw³b, •ÒW‹Š—Í: ‰–‘ò¹‰p, •Ò: “c’†ÍŒi, ’†ŽR‘“X, “Œ‹ž, 2019/8”­s.

620024. [Šwp‘ (•ª’SŽ·•M)] yPTEOT‚Ì‚œ‚߂̉摜‚Ì‚Ý‚©‚œ [‘æ2”Å]z‘æ2Í ’†•_ŒoŽŸŠ³@V. ’E‘E•Ï«ŽŸŠ³@Ò‘‹ó“ŽÇ, p.103. ì–”@ƒ (”]_Œo“à), ŠÄC: ŽR‰º•q•F, ‰ºà_@r, ‹àŒŽo”Å, “Œ‹ž, 2019/12”­s.

[Šw‰ïEŒ€‹†‰ï“™]

713034. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) A clinically-based score that predicts cryptogenic new-onset refractory status epilepticus (C-NORSE). Iizuka T1, Kaneko J1, Kaneko A1, Yanagida A2, Nonoda Y3, Onozawa Y4, Kanazawa N5, Dalmau J, Nishiyama K1: AAN 2019 (The 71st AAN Annual Meeting) (2019/5/5), Philadelphia, USA. (”ђˍ‚_1, ‹àŽq~‘Ÿ˜Y1, ‹àŽq@Œú1, –ö“c“ÖŽq2, –ìX“c–L3, ¬–ìàV—T–ç4, ‹ààV’Œ”ü5, ŒŽR˜a—˜1: 1”]_Œo“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3¬Ž™, 4—ÕŒŸ•”, 5•a‘ԁEf—ÃŒn)

713035. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Atypical Clinical Manifestations and Overlapping Immunities associated with NMDA Receptor Antibodies. Kaneko A1, Iizuka T1, Suga H1, Kaneko J1, Yamaguchi Y2, Arai H2, Matsumoto Y, Tokimura R, Murakami T, Nakatani-Enomoto S, Kanai K, Ugawa Y, Amano E, Kitamura E1, Kanazawa N3, Dalmau J, Nishiyama K1: AAN 2019 (The 71st AAN Annual Meeting) (2019/5/5), Philadelphia, USA. (‹àŽq@Œú1, ”ђˍ‚_1, {‰ê—TŽ÷1, ‹àŽq~‘Ÿ˜Y1, ŽRŒû—F‹I—Y2, Vˆä‹v–«2, –k‘º‰p“ñ1, ‹ààV’Œ”ü3, ŒŽR˜a—˜1: 1”]_Œo“à, 2ž_, 3•a‘ԁEf—ÃŒn)

713036. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Neuronal Autoantibodies and Clinical Significance in Stiff-Person Spectrum Disorder. Kaneko J1, Iizuka T1, Kondo Y1, Abe Y1, Kaneko A1, Hattori K, Kobayashi S, Ugawa Y, Sekiguchi K, Maeda K, Matsumoto Y, Kanazawa N2, Kitamura E1, Dalmau J, Nishiyama K1: AAN 2019 (The 71st AAN Annual Meeting) (2019/5/5), Philadelphia, USA. (‹àŽq~‘Ÿ˜Y1, ”ђˍ‚_1, ‹ß“¡—TŽq1, ˆ¢•”—L‹N1, ‹àŽq@Œú1, ‹ààV’Œ”ü2, –k‘º‰p“ñ1, ŒŽR˜a—˜1: 1”]_Œo“à, 2•a‘ԁEf—ÃŒn)

713037. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) A cluster of disseminated small cortical lesions in MELAS: its distinctive clinical and neuroimaging features. Iizuka T1, Hongo H, Kaneko J1, Suga H1, Ishima D1, Kitamura E1, Akutsu T1, Kanazawa N2, Nishiyama K1: The 16th Conference of Asian Society for Mitochondrial Research and Medicine [ASMRM] and The 19th conference of Japanese Society of Mitochondrial Research and Medicine [J-mit] (2019/10/3-5), Fukuoka, Japan. (”ђˍ‚_1, ‹àŽq~‘Ÿ˜Y1, {‰ê—TŽ÷1, ˆä“‡‘å•ã1, –k‘º‰p“ñ1, ˆ¢‹v’Óñ•v1, ‹ààV’Œ”ü2, ŒŽR˜a—˜1: 1”]_Œo“à, 2•a‘ԁEf—ÃŒn)

721009. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ž_áŠQ‚𗈂·RNMDAŽó—e‘Ì”]‰Š|f’f‚ÆŽ¡—Ïã‚̃sƒbƒgƒtƒH[ƒ‹ƒNƒgƒ‰ƒ€|. ”ђˍ‚_ (”]_Œo“à): ‘æ66‰ñ“ú–{‹ž³ˆãŠw‰ï‘‰ï (2019/10/24), “Œ‹ž.

722049. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) Ž©ŒÈ–Ɖu«”]‰Š‚̃XƒyƒNƒgƒ‰ƒ€‚ÆŽ¡—Ã. ”ђˍ‚_ (”]_Œo“à): ‘æ31‰ñ“ú–{_Œo–ƉuŠw‰ïŠwpW‰ï (2019/9/26), ç—t.

723158. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Physician Lead Clinical Trial of Bosutinib in ALS: iPSC-based Drug Repurposing for ALS Medicine (iDReAM) study. Imamura K, Izumi Y, Banno H, Uozumi R, Morita S, ‰iˆä^‹MŽq1, ŒŽR˜a—˜1, Watanabe Y, Hanajima R, Takahashi N, Ikeda T, Ito T, Kusunoki Y, Shimizu A, Morinaga A, Koide Y, Hirohashi T, Fujii Y, Takahashi R, Inoue H (1”]_Œo“à): ‘æ60‰ñ“ú–{_ŒoŠw‰ïŠwp‘å‰ï (2019/5/24), ‘åã.

723159. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) SOD1ˆâ“`Žq•ÏˆÙ‚ð”F‚ß‚œALSŠ³ŽÒ5—á‚̗Տ°Œo‰ß. ŒI“c‰l—¢Žq1, ‰iˆä^‹MŽq1, ì˜Q@•¶1, ‹ß“¡—TŽq1, ŒŽR˜a—˜1 (1”]_Œo“à): ‘æ60‰ñ“ú–{_ŒoŠw‰ïŠwp‘å‰ï (2019/5/24), ‘åã.

723160. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) A clinically-based sacore predicting cryptogenic new-onset refractory status epilepticus (CNORSE). –ö“c“ÖŽq1, ”ђˍ‚_1, ‹àŽq~‘Ÿ˜Y1, ‹àŽq@Œú1, –ìX“c–L2, ¬–ìàV—T–ç3, ‹ààV’Œ”ü4, ŒŽR˜a—˜1 (1”]_Œo“à, 2¬Ž™, 3—ÕŒŸ•”, 4•a‘ԁEf—ÃŒn): ‘æ60‰ñ“ú–{_ŒoŠw‰ïŠwp‘å‰ï (2019/5/25), ‘åã.

723161. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’Ž‹}«ŠúÄŸó—¬—Ö@‚ðŽ{s‚µ‚œŽá”N«”][Ç‚ÌŒŸ“¢. ˆ¢‹v’Óñ•v1, ‹àŽq@Œú1, {‰ê—TŽ÷1, ‰iˆärs1, ‰Oˆä@—É1, ˆä“‡‘å•ã1, ‹àŽq~‘Ÿ˜Y1, –{‹œ@—I, –k‘º‰p“ñ1, ”ђˍ‚_1, ŽR–{‘å•ã2, ŒŽR˜a—˜1 (1”]_Œo“à, 2”]ŠO): ‘æ60‰ñ“ú–{_ŒoŠw‰ïŠwp‘å‰ï (2019/5/25), ‘åã.

723162. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Zonisamide suppression effect on CSD in a rat CSD model. –k‘º‰p“ñ1, ”ђˍ‚_1, ‹ààV’Œ”ü2, ŒŽR˜a—˜1 (1”]_Œo“à, 2•a‘ԁEf—ÃŒn): ‘æ60‰ñ“ú–{_ŒoŠw‰ïŠwp‘å‰ï (2019/5/25), ‘åã.

723163. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚—îŽÒ“ü‰@Š³ŽÒ‚É‚š‚¯‚邹‚ñ–Ï‘J‰„‚Æ‘Šú—£°‚ÉŠÖ‚·‚錟“¢. ŒŠ“c@‘, ”у–’J”ü•ô1, ‚‹Ž@Œb2, ¶‰E“c˜aŽ}, ˜a“c“Þ”üŽq (1”]_Œo“à, 2ž_): ‘æ61‰ñ“ú–{˜V”NˆãŠw‰ïŠwpW‰ï (2019/6/8), å‘ä.

723164. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Autoimmune Post-Herpes Simplex Encephalitis (Post-HSE) ‚ÉŠÖ‚·‚éÇ—áWÏŒ€‹†. ‹àŽq~‘Ÿ˜Y1, ”ђˍ‚_1, Šâ£—ÈŽq1, –k‘º‰p“ñ1, •y“cm”ü, ŒÜ\—’§, “ü‰ª@—², ‹ààV’Œ”ü2, ŒŽR˜a—˜1 (1”]_Œo“à, 2•a‘ԁEf—ÃŒn): ‘æ31‰ñ“ú–{_Œo–ƉuŠw‰ïŠwpW‰ï (2019/9/26-27), ç—t.

723165. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”­ÇŽžŒŽˆö•s–Ÿ‚Ì‚Ä‚ñ‚©‚ñdÏó‘Ô‚É‚š‚¯‚éR_Œo×–E•\–ʍRŒŽR‘Ì‚ÌŠÖ—^: Œã•ûŽ‹“IŒŸ“¢. {‰ê—TŽ÷1, ”ђˍ‚_1, ‹àŽq@Œú1, –ö“c“ÖŽq1, ‹àŽq~‘Ÿ˜Y1, –k‘º‰p“ñ1, ‹ààV’Œ”ü2, ŒŽR˜a—˜1 (1”]_Œo“à, 2•a‘ԁEf—ÃŒn): ‘æ31‰ñ“ú–{_Œo–ƉuŠw‰ïŠwpW‰ï (2019/9/26-27), ç—t.

723166. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Cryptogenic NORSE 27—á‚ÉŽÀŽ{‚³‚ê‚œ‹}«Šú–Ɖu—Ö@‚ÉŠÖ‚·‚éŒã•ûŽ‹“IŒ€‹†: Œ»ó‚Ɖۑè. –ö“c“ÖŽq1, ”ђˍ‚_2, ‹ààV’Œ”ü3, –k‘º‰p“ñ2, ˆ¢‹v’Óñ•v2, ŒŽR˜a—˜2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2”]_Œo“à, 3•a‘ԁEf—ÃŒn): ‘æ37‰ñ“ú–{_ŒoŽ¡—Êw‰ïŠwpW‰ï (2019/11/6), ‰¡•l.

723167. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰·“xãž‚Æcortical spreading depression‚ÌŠÖŒW‚ɂ‚¢‚Ä. –k‘º‰p“ñ1, ‹ààV’Œ”ü2, –Ø‹–‘ñ”n1, ’·“‡@œ1, ”ђˍ‚_1, ŒŽR˜a—˜1 (1”]_Œo“à, 2•a‘ԁEf—ÃŒn): ‘æ47‰ñ“ú–{“ª’ÉŠw‰ï‘‰ï (2019/11/16), ‰Y˜a.

731022. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) Ž©ŒÈ–Ɖu«”]‰Š‚š‚æ‚Ñ‚»‚Ì—Þ‰ŽŸŠ³‚Ì•a‘Ô‚ÆŽ¡—Ã. ”ђˍ‚_ (”]_Œo“à): ‘æ3‰ñNeuro Rescue Meeting (2019/6/22), ‘q•~.

731023. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) Ž©ŒÈ–Ɖu«‰^“®áŠQ‚̗Տ°‚Æ•a‘Ô. ”ђˍ‚_ (”]_Œo“à): ‘æ15‰ñKOSHIEN Movement Disorder Seminar (2019/9/12), ‘q•~.

731024. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) Stroke mimics•Ð–ƒáƒ«•Ð“ª’É‚Æ”]‘²’†—l”­ì‚Ì•a‘Ô‚ðl‚Š‚é. ”ђˍ‚_ (”]_Œo“à): ‘æ43‰ñMetropolitan Stroke ForumŠwpu‰‰‰ï (2019/11/19), “Œ‹ž.

732017. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) II •Ð“ª’ɂ̐f’f‚ÆŠÇ—|‘O’›‚Ì‚ ‚é•Ð“ª’Ɂ|. ”ђˍ‚_ (”]_Œo“à): HMSJ 2019: Headache Master School Japan 2019 (2019/7/14), å‘ä.

733060. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ”]Š²EÒ‘‚ÉŽUÝ‚·‚é’E‘•a•Ï‚ð”F‚ß, RMOGR‘Ì‚ª‘‰t‚Ì‚Ý‚©‚猟o‚³‚ê‚œ32Î’j«. ’·“‡@œ1, ‹àŽq~‘Ÿ˜Y1, ˆÀ’B’q”ü1, ˆ¢•”—L‹N1, ‹ààV’Œ”ü2, ”ђˍ‚_1, ŒŽR˜a—˜1 (1”]_Œo“à, 2•a‘ԁEf—ÃŒn): ‘æ229‰ñ“ú–{_ŒoŠw‰ïŠÖ“ŒEbM‰z’n•û‰ï (2019/6/1), “Œ‹ž.

733061. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‘œŒ^”畆ˆÞkÇEäFSk‹y‚Ñ”xüˆÛÇ‚ð‡•¹‚µ‚œ‰“ˆÊŒ^ƒ~ƒIƒpƒ`[‚Ì62Î—«—á. ŽR–{’q”ü1, ‰iˆä^‹MŽq1, ‰Pˆäk‘Ÿ˜Y1, ˆÀ’B’q”ü1, ˆ¢•”—L‹N1, ‰Oˆä@—É1, –k‘º‰p“ñ1, ŒŽR˜a—˜1 (1”]_Œo“à): ‘æ230‰ñ“ú–{_ŒoŠw‰ïŠÖ“Œ EbM‰z’n•û‰ï (2019/9/7), “Œ‹ž.

733162. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ”]’ê“®–¬‚̕Nj@“]‚ÉŠÖ‚·‚錟“¢. ˆ¢‹v’Óñ•v (”]_Œo“à): ŒÃ-Œ§‰›_Œoƒlƒbƒgƒ[ƒN (2019/9/12), ŠC˜V–Œ.

733063. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ’Pƒƒwƒ‹ƒyƒX”]‰Š”­Ç6TŒã‚ɐ_ŒoÇó‚ª‘ˆ«‚µ‚œ45Î’j«. Šâ£—ÈŽq1, ‹àŽq~‘Ÿ˜Y1, ”ђˍ‚_1, rˆäŒ³”ü, ‹ààV’Œ”ü2, ŒŽR˜a—˜1 (1”]_Œo“à, 2•a‘ԁEf—ÃŒn): ‘æ21‰ñ_“ސ쌧_Œo–ƉuƒtƒH[ƒ‰ƒ€ (2019/12/4), ‰¡•l.

733064. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) Propionibacterium acnesR‘Ì (PABR‘Ì) –ƉuõF‚ª—z«‚Å‚ ‚Á‚œ”]ŽÀŽ¿Œ^ƒTƒ‹ƒRƒCƒh[ƒVƒX‚Ì27Î’j«—á. ŽOàV—C‰î1, –Ø‘º•¶«1, ‹àŽq~‘Ÿ˜Y1, ˆÀ’B’q”ü1, –Ø‹–‘ñ”n1, ’·“‡@œ1, ”ђˍ‚_1, ŒŽR˜a—˜1 (1”]_Œo“à): ‘æ231‰ñ“ú–{_ŒoŠw‰ïŠÖ“ŒEbM‰z’n•û‰ï (2019/12/7), “Œ‹ž.

733065. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) •Ï‚í‚è‚ä‚­”][Ç‚Ì’Ž‹}«ŠúŽ¡—ÂƍĔ­—\–h‚ɂ‚¢‚Ä. ˆ¢‹v’Óñ•v (”]_Œo“à): Face to Face ”]ŒŒŠÇESŽŸŠ³ƒJƒ“ƒtƒ@ƒŒƒ“ƒX in ‘Š–ÍŒŽ (2019/12/9), ‘Š–ÍŒŽ.

'18”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'18-110006. [ŒŽ’˜] Evaluation of Mitochondrial Oxidative Stress in the Brain of a Transgenic Mouse Model of Alzheimer's Disease by in vitro Electron Paramagnetic Resonance Spectroscopy. Manabe T, Matsumura A, Yokokawa K, Saito T, Fujikura M, Iwahara N, Matsushita T, Suzuki S, Hisahara S, JKawamata J1, Suzuki H, Emoto MC, Fujii HG, Shimohama S: J Alzheimers Dis 2019/2; 67 (3): 1079-87. (ì–”@ƒ1: 1”]_Œo“à)

'18-320001. [Ç—á•ñ] RglycineŽó—e‘̍R‘Ì—z«‚Ìstiff-limbÇŒóŒQ‚Ì1—á. ‘O“cŒ›Œá, Ž…–FŽ÷, ™ŒŽ–FŽq, ‹ààV’Œ”ü1, ”ђˍ‚_2 (1•a‘ԁEf—ÃŒn, 2”]_Œo“à): —Տ°_ŒoŠw 2019/2; 59 (2): 98-101.

'18-522004. [uÀ]y“ÁW: ”][Ç|ÅV‚Ì–ò•šŽ¡—Ð헪‚ÆŽÀ‘Hƒ|ƒCƒ“ƒg‘‚܂Ƃ߁z¡ÅV‚̃Gƒrƒfƒ“ƒX‚ÉŠî‚¢‚œ”][Ç‚Ì–ò•šŽ¡—Ð헪@ƒ‰ƒNƒi[Ç. ’·“‡@œ1, ŒŽR˜a—˜1 (1”]_Œo“à): –ò‹Ç 2019/3; 70 (3): 379-83.

[’˜@‘]

H29-620004. [Šwp‘ (•ª’SŽ·•M)]y1336ê–å‰Æ‚É‚æ‚é Ž„‚ÌŽ¡—à [2017-18”N“x”Å]z08 _ŒoE‹ØŽŸŠ³ (63ŽŸŠ³)@‰ŠÇ«E’E‘«ŽŸŠ³@[30] ×‹Û«‘–Œ‰Š (¬l), p.623-5. _è^ŽÀ1, ŠC“cŒ«ˆê, (1”]_Œo“à) ŠÄC: ‰Ž“c‹’j, –k‘º‘yˆê˜Y, “ú–{ˆãŽ–V•ñŽÐ, “Œ‹ž, 2017/7”­s.

'18-620005. [Šwp‘ (•ª’SŽ·•M)]yAnnual Review _Œo2019zII. –{”N‚Ì“®Œü@2 Ž©ŒÈ–Ɖu«”]‰ŠŒ€‹†‚̐i•à, p.72-81. ”ђˍ‚_ (”]_Œo“à), •ÒW: —é–Ø‘¥G, r–ؐM•v, ‰Fì‹`ˆê, ŒKŒŽ@‘, ‰–ì–Fº, ’†ŠOˆãŠwŽÐ, “Œ‹ž, 2019/3”­s.

[Šw‰ïEŒ€‹†‰ï“™]

'18-723006. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”]‘²’†”­ÇŒãˆÝ’°ŠÇ•ÂÇÇ‚̗Տ°“I“Á’¥‚Æ—\Œã. ²“¡@—I1, –k‘º‰p“ñ1, ‹àŽq@Œú1, {‰ê—TŽ÷1, ‰iˆärs1, ‰Oˆä@—É1, ˆä“‡‘å•ã1, ‹àŽq~‘Ÿ˜Y1, –{‹œ@—I1, ˆ¢‹v’Óñ•v1, ”ђˍ‚_1, ŒŽR˜a—˜1 (1”]_Œo“à): ‘æ44‰ñ“ú–{”]‘²’†Šw‰ïŠwpW‰ï (2019/3/21-23), ‰¡•l.


ŒŒ‰t“à‰ÈŠw

[Šwp˜_•¶]

110148. [ŒŽ’˜] Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study. Sakai R, Ohmachi K, Sano F, Watanabe R, Takahashi H, Takasaki H, Tanaka M, Hattori Y, Kimura H1, Takimoto M, Tachibana T, Tanaka E, Ishii Y, Ishiyama Y, Hagihara M, Miyazaki K2, Yamamoto K, Tomita N, Ando K: Ann Hematol 2019/9; 98 (9): 2131-8. (–Ø‘º—T˜a1, ‹{ø“_“ñ2: 1ŒŒ‰t“à, 2—AŒŒE×–EˆÚA)

110149. [ŒŽ’˜] Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes. Kawabata H1, Usuki K1, Shindo-Ueda M1, Kanda J1, Tohyama K1, Matsuda A1, Araseki K1, Hata T1, Suzuki T1,2, Kayano H1, Shimbo K1, Chiba S1, Ishikawa T1, Arima N1, Nohgawa M1, Miyazaki Y1, Kurokawa M1, Arai S1, Mitani K1, Takaori-Kondo A1 (1Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes): Int J Hematol 2019/11; 110 (5): 533-42. (—é–Ø—²_1,2: 2ŒŒ‰t“à)

522030. [uÀ]y˜AÚ: Ž„‚ÌŽ¡—Áz“SŒ‡–R«•nŒŒ. —é–Ø—²_ (ŒŒ‰t“à): “ú–{ˆãŽ–V•ñ 2019/7; 4970: 39.

522031. [uÀ]y˜AÚ: Ž„‚ÌŽ¡—Áz‹Ô‰è‹…«•nŒŒ. —é–Ø—²_ (ŒŒ‰t“à): “ú–{ˆãŽ–V•ñ 2019/8; 4971: 46.

522032. [uÀ]y“ÁW: œ‘ˆÙŒ`¬ÇŒóŒQ (MDS)|Šî‘bE—Տ°‚̍ŐV“®ŒüzIV. MDS‚ÌŽ¡—Á@1. –{–M‚É‚š‚¯‚鎡—Â̌»ó@(2) —AŒŒ—Ö@‚Æ“SƒLƒŒ[ƒgÜ. —é–Ø—²_ (ŒŒ‰t“à): “ú–{—Õଠ2019/9; 7 7(9): 1489-95.

522033. [uÀ]y“ÁW: ‘¢ŒŒ•s‘SÇ‚Ì•a‘Ô‰ðÍŒ€‹†‚ÆŽ¡—Â̐i•àupdatezœ‘•s‘SÇ (MDS/PNH/AA) ‚Ì•a‘Ԉڍs|l‚Š‚ç‚ê‚é1‚‚̃‚ƒfƒ‹|. —é–Ø—²_ (ŒŒ‰t“à): ŒŒ‰t“à‰È 2019/8; 79 (2): 127-33.

522034. [uÀ]y˜AÚ: ŽŸŠ³‚ÆŒŸž’l‚̐„ˆÚz“SŒ‡–R«•nŒŒ. —é–Ø—²_ (ŒŒ‰t“à): ŒŸž‚Æ‹Zp 2019/11; 47 (11): 1302-7.

[’˜@‘]

620025. [Šwp‘ (•ª’SŽ·•M)]yˆã–ò•i•›ì—pŠw (‘æ3”Å) ‰º|–òÜ‚̈À‘SŽg—pƒAƒbƒvƒf[ƒg| (“ú–{—Õà¬77Šª‘Š§†4)zVI. ‘ŸŠíEŒn“•Ê•›ì—pŠe˜_|d‘å‚È•›ì—p‚𒆐S‚Ɂ|@4. ŒŒ‰t@(10) ‹ÃŒÅáŠQ, p.210-7. –x•Ä—Cˆê (ŒŒ‰t“à), “ú–{—Õ଎Ð, “Œ‹ž, 2019/7”­s.

620026. [Šwp‘ (•ª’SŽ·•M)]y“à‰ÈŠw‘ ‰ü’ù‘æ9”Å (Vol.6)zŒŒ‰tE‘¢ŒŒŠíŒnŽŸŠ³@5. ÔŒŒ‹…Œn‚ðŽå•a•Ï‚Æ‚·‚鎟Š³@•nŒŒ‚̐¬ˆöE•ª—ށEf’f, p.104-9. —é–Ø—²_ (ŒŒ‰t“à), ‘•ÒW: “ìŠw³b, •ÒW‹Š—Í: ‰–‘ò¹‰p, ’†ŽR‘“X, “Œ‹ž, 2019/8”­s.

620027. [Šwp‘ (•ª’SŽ·•M)]y“à‰ÈŠw‘ ‰ü’ù‘æ9”Å (Vol.6)zŒŒ‰tE‘¢ŒŒŠíŒnŽŸŠ³@5. ÔŒŒ‹…Œn‚ðŽå•a•Ï‚Æ‚·‚鎟Š³@œ‘ˆÙŒ`¬ÇŒóŒQ, p.124-31. —é–Ø—²_ (ŒŒ‰t“à), ‘•ÒW: “ìŠw³b, •ÒW‹Š—Í: ‰–‘ò¹‰p, ’†ŽR‘“X, “Œ‹ž, 2019/8”­s.

620028. [Šwp‘ (•ª’SŽ·•M)]yŒŒ‰tê–åˆãƒeƒLƒXƒg ‰ü’ù‘æ3”Łz‘æIIIÍ Žå—v‚È’¥Œó‚ÆŒŸž’lˆÙí@2. •nŒŒ‚ÌŠÓ•Ê, p.33-8. —é–Ø—²_ (ŒŒ‰t“à), •Ò: “ú–{ŒŒ‰tŠw‰ï, “ì]“°, “Œ‹ž, 2019/10”­s.

620029. [Šwp‘ (•ª’SŽ·•M)]yŒŒ‰tê–åˆãƒeƒLƒXƒg ‰ü’ù‘æ3”Łz‘æVIIIÍ ÔŒŒ‹…ŒnŽŸŠ³@4. Ž©ŒÈ–Ɖu«—nŒ‹«•nŒŒ: ‰·Ž®, —⎮, p.183-5. —é–Ø—²_ (ŒŒ‰t“à), •Ò: “ú–{ŒŒ‰tŠw‰ï, “ì]“°, “Œ‹ž, 2019/10”­s.

620030. [Šwp‘ (•ª’SŽ·•M)]yŒŒ‰tê–åˆãƒeƒLƒXƒg ‰ü’ù‘æ3”Łz‘æIXÍ ”’ŒŒ‹…ŒnŽŸŠ³: Žîᇐ«ŽŸŠ³@8. œ‘ˆÙŒ`¬ÇŒóŒQ, p.263-8. —é–Ø—²_ (ŒŒ‰t“à), •Ò: “ú–{ŒŒ‰tŠw‰ï, “ì]“°, “Œ‹ž, 2019/10”­s.

620031. [Šwp‘ (•ª’SŽ·•M)]yŒŒ‰tê–åˆãƒeƒLƒXƒg ‰ü’ù‘æ3”Łz‘æXIIIÍ ŽxŽ—Ö@@4. “SƒLƒŒ[ƒg—Ö@, p.498-9. —é–Ø—²_ (ŒŒ‰t“à), •Ò: “ú–{ŒŒ‰tŠw‰ï, “ì]“°, “Œ‹ž, 2019/10”­s.

620032. [Šwp‘ (•ª’SŽ·•M)]y¡“ú‚ÌŽ¡—ÃŽwj@2020”N“x”Łz10. ŒŒ‰tŽŸŠ³@Ž©ŒÈ–Ɖu«—nŒŒ«ŽŸŠ³, p.678-80. —é–Ø—²_ (ŒŒ‰t“à), ‘•ÒW: •ŸˆäŽŸ–î, ‚–؁@œ, ¬Žºˆê¬, ˆãŠw‘‰@, “Œ‹ž, 2020/1”­s.

620033. [Šwp‘ (•ª’SŽ·•M)]yƒKƒCƒhƒ‰ƒCƒ“ŠO—ˆf—Ã2020@¡“ú‚̐f—Â̂œ‚ß‚É (‘æ20”Å)zII ê–åˆã‚ÌŠÇ—EŽ¡—ª•K—v‚ÈŽŸŠ³‚̃KƒCƒhƒ‰ƒCƒ“@ŒŒ‰tŽŸŠ³@13. œ‘ˆÙŒ`¬ÇŒóŒQ, p.490-3. —é–Ø—²_ (ŒŒ‰t“à), •ÒWŽåŠ²: ò@F‰p, “úŒoBP, “Œ‹ž, 2020/3”­s.

[Šw‰ïEŒ€‹†‰ï“™]

723168. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –«œ‘«”’ŒŒ•aŠ³ŽÒ‚É‚š‚¯‚éŠeƒ`ƒƒVƒ“ƒLƒi[ƒ[‘jŠQÜ‚É‚æ‚étáŠQ‚Ì”äŠr (Risk of Renal Dysfunction Induced by Each Tyrosine Kinase Inhibitor in CML). –{‹Ž’m”ü1, Š™“c_–«1, ‰¥@‘cœ1, “cŽ›”͍s1, –x•Ä—Cˆê1, “¹‰º—Y‰î1, ‰HŽRŒdˆÈ1, òŽR˜a‹v1, ]”šWˆê1, Î“c@—²2, ‹{ø“_“ñ2, —é–Ø—²_1 (1ŒŒ‰t“à, 2—AŒŒE×–EˆÚA): ‘æ81‰ñ“ú–{ŒŒ‰tŠw‰ïŠwpW‰ï (2019/10/11-13), “Œ‹ž, —Տ°ŒŒ‰tWEBŽ˜^2019; PS1-3-5: S255.

723169. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”DP‘æ2Šú‚É”­Ç‚µ‚œ‹}«”’ŒŒ•a‚Ì2Ç—á (Two cases of acute leukemia (AL) which occurred during the 2nd trimester of pregnancy). –x•Ä—Cˆê1, “cŽ›”͍s1, “¹‰º—Y‰î1, –{‹Ž’m”ü1, Î“c@—²2, ‰¥@‘cœ1, Š™“c_–«1, ‹{ø“_“ñ2, —é–Ø—²_1 (1ŒŒ‰t“à, 2—AŒŒE×–EˆÚA): ‘æ81‰ñ“ú–{ŒŒ‰tŠw‰ïŠwpW‰ï (2019/10/11-13), “Œ‹ž, —Տ°ŒŒ‰tWEBŽ˜^2019; PS2-8-8: S315.

733066. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ƒŠƒ“ƒpŒ`Ž¿×–E«ƒŠƒ“ƒpŽî (LPL) ‚ɑ΂µ‚ÄBR—Ö@‚ðŽ{s’†‚ÉKaposi“÷Žî (KS) ‚Ì‘ˆ«‚𗈂µ‚œˆê—á. –x•Ä—Cˆê1, ‰¥@‘cœ1, Š™“c_–«1, “cŽ›”͍s1, “¹‰º—Y‰î1, Î“c@—²2, ‰HŽRŒdˆÈ1, –{‹Ž’m”ü1, ]”šWˆê1, òŽR˜a‹v1, ‹{ø“_“ñ2, —é–Ø—²_1 (1ŒŒ‰t“à, 2—AŒŒE×–EˆÚA): ‘æ11‰ñ“ú–{ŒŒ‰tŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2019/7/27), “úŒõ, —Տ°ŒŒ‰t 2019; 60 (10): 1504.

'18”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'18-522005. [uÀ] œ‘ˆÙŒ`¬ÇŒóŒQ|f’f‚̃|ƒCƒ“ƒg|. —é–Ø—²_ (ŒŒ‰t“à): “ú–{ŒŸžŒŒ‰tŠw‰ïŽGŽ 2019/2; 20 (1): 99-109.


ŒÄ‹zŠí“à‰ÈŠw

[Šwp˜_•¶]

110150. [ŒŽ’˜] Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study. Ono T1, Igawa S1, Ozawa T1, Kasajima M1, Ishihara M1, Hiyoshi Y1, Kusuhara S1, Nishinarita N1, Fukui T1, Kubota M2, Sasaki J3, Hisashi M4, Katagiri M2, Naoki K1: Thorac Cancer 2019/4; 10 (4): 880-9. (¬–ì‘וœ1, ˆäì@‘1, ¬àV‹M—T1, Š}“‡^Žu1, ÎŒŽ–¢ŠóŽq1, “ú‹gNO1, “팎­ˆê˜Y1, Œ¬“cÙŽq1, •Ÿˆä•ü–ç1, ‹v•Û“cŸ2, ²X–ØŽ¡ˆê˜Y3, ŽO“¡@‹v4, •Ð‹Ë^l2, —P–؍Ž•F1: 1ŒÄ‹zŠí“à, 2ˆã—Éq¶Šw•”, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 4ŠÅŒìŠw•”)

110151. [ŒŽ’˜] Prognostic differences between oligometastatic and polymetastatic extensive disease-small cell lung cancer. Shirasawa M1, Fukui T1, Kusuhara S1, Harada S2, Nishinarita N1, Hiyoshi Y1, Ishihara M1, Kasajima M1, Igawa S1, Yokoba M3, Mitsufuji H4, Kubota M3, Katagiri M3, Sasaki J5, Naoki K1: PLoS One 2019/4; 14 (4): e0214599. (”’àV¹”V1, •Ÿˆä•ü–ç1, “팎­ˆê˜Y1, ŒŽ“c^–ç2, Œ¬“cÙŽq1, “ú‹gNO1, ÎŒŽ–¢ŠóŽq1, Š}“‡^Žu1, ˆäì@‘1, ‰¡ê³“T3, ŽO“¡@‹v4, ‹v•Û“cŸ3, •Ð‹Ë^l3, ²X–ØŽ¡ˆê˜Y5, —P–؍Ž•F1: 1ŒÄ‹z‹@“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ˆã—Éq¶Šw•”, 4ŠÅŒìŠw•”, 5V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

110152. [ŒŽ’˜] Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study. Igawa S1, Ono T1, Kasajima M1, Ishihara M1, Hiyoshi Y1, Kusuhara S1, Nishinarita N1, Fukui T1, Kubota M2, Sasaki J3, Mitsufuji H4, Yokoba M2, Katagiri M2, Naoki K1: Cancer Manag Res 2019/5; 11: 4883-92. (ˆäì@‘1, ¬–ì‘וœ1, Š}“‡^Žu1, ÎŒŽ–¢ŠóŽq1, “ú‹gNO1, “팎­ˆê˜Y1, Œ¬“cÙŽq1, •Ÿˆä•ü–ç1, ‹v•Û“cŸ2, ²X–ØŽ¡ˆê˜Y3, ŽO“¡@‹v4, ‰¡ê³“T2, •Ð‹Ë^l2, —P–؍Ž•F1: 1ŒÄ‹zŠí“à, 2ˆã—Éq¶Šw•”, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 4ŠÅŒìŠw•”)

110153. [ŒŽ’˜] Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study. Fukui T1, Okuma Y1, Nakahara Y1, Otani S1, Igawa S1, Katagiri M2, Mitsufuji H3, Kubota M2, Hiyoshi Y1, Ishihara M1, Kasajima M1, Sasaki J4, Naoki K1: Clin Lung Cancer 2019/5; 20 (3): 208-14.e2. (•Ÿˆä•ü–ç1, ‘åŒF—F—œŽq1, ’†ŒŽ‘P˜N1, ‘å’JçŽq1, ˆäì@‘1, •Ð‹Ë^l2, ŽO“¡@‹v3, ‹v•Û“cŸ2, “ú‹gNO1, ÎŒŽ–¢ŠóŽq1, Š}“‡^Žu1, ²X–ØŽ¡ˆê˜Y4, —P–؍Ž•F1: 1ŒÄ‹zŠí“à, 2ˆã—Éq¶Šw•”, 3ŠÅŒìŠw•”, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

110154. [ŒŽ’˜] Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab. Oashi A, Yasuda H, Kobayashi K, Tani T, Hamamoto J, Masuzawa K, Manabe T, Terai H, Ikemura S, Kawada I, Naoki K1, Soejima K: Mol Cancer Ther 2019/9; 18 (9): 1593-601. (—P–؍Ž•F1: 1ŒÄ‹zŠí“à)

110155. [ŒŽ’˜] Multicenter study of zoledronic acid administration in non-small-cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017. Nakahara Y1, Hosomi Y, Shibuya M, Mitsufuji H2, Katagiri M3, Naoki K1, Soejima K, Nogami N, Nagase S, Nishikawa M, Minato K, Takiguchi Y, Seki N, Yamada K, Seto T, Okamoto H: Mol Clin Oncol 2019/10; 11 (4): 349-53. (’†ŒŽ‘P˜N1, ŽO“¡@‹v2, •Ð‹Ë^l3, —P–؍Ž•F1: 1ŒÄ‹zŠí“à, 2ŠÅŒìŠw•”, 3ˆã—Éq¶Šw•”)

110156. [ŒŽ’˜] A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients. Tani T, Naoki K1, Yasuda H, Arai D, Ishioka K, Ohgino K, Yoda S, Nakayama S, Satomi R, Terai H, Ikemura S, Sato T, Soejima K: Cancer Chemother Pharmacol 2019/11; 84 (5): 1065-71. (—P–؍Ž•F1: 1ŒÄ‹zŠí“à)

110157. [ŒŽ’˜] Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Sugawara S, Inui N, Kanehara M, Morise M, Yoshimori K, Kumagai T, Fukui T1, Minato K, Iwashima A, Takeda Y, Kubota K, Saeki T, Tamura T: Cancer 2019/11; 125 (22): 4076-83. (•Ÿˆä•ü–ç1: 1ŒÄ‹zŠí“à)

110158. [ŒŽ’˜] Prognostic significance of IMMT expression in surgically-resected lung adenocarcinoma. Hiyoshi Y1, Sato Y2, Ichinoe M3, Nagashio R2, Hagiuda D, Kobayashi M, Kusuhara S1, Igawa S1, Shiomi K4, Goshima N, Murakumo Y3, Saegusa M3, Satoh Y4, Masuda N1, Naoki K1: Thorac Cancer 2019/11; 10 (11): 2142-51. (“ú‹gNO1, ²“¡—Yˆê2, ˆêŒË¹–Ÿ3, ’·‰–@—º2, “팎­ˆê˜Y1, ˆäì@‘1, ‰–Œ©@˜a4, ‘º‰_–FŽ÷3, ŽOŽ}@M3, ²“¡”Vr4, ‰v“c“TK1, —P–؍Ž•F1: 1ŒÄ‹zŠí“à, 2ˆã—Éq¶Šw•”, 3•a—, 4ŒÄ‹zŠíŠO)

110159. [ŒŽ’˜] TRAP1 is a predictive biomarker of platinum-based adjuvant chemotherapy benefits in patients with resected lung adenocarcinoma. Kuchitsu Y1, Nagashio R2, Igawa S3, Kusuhara S3, Tsuchiya B2, Ichinoe M4, Satoh Y5, Naoki K3, Murakumo Y4, Saegusa M4, Sato Y2: Biomed Res 2020/1; 41 (1): 53-65. (‹€’×L‹I1, ’·‰–@—º2, ˆäì@‘3, “팎­ˆê˜Y3, “y‰®g2, ˆêŒË¹–Ÿ4, ²“¡”Vr5, —P–؍Ž•F3, ‘º‰_–FŽ÷4, ŽOŽ}@M4, ²“¡—Yˆê2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ˆã—Éq¶Šw•”, 3ŒÄ‹zŠí“à, 4•a—, 5ŒÄ‹zŠíŠO)

110160. [ŒŽ’˜] The Clinical Impact of the Post-progression Survival on the Overall Survival in Elderly Patients or Those with a Poor Performance Status and Extensive-disease Small-cell Lung Cancer. Igawa S1, Yokoba M2, Fukui T1, Sasak J3, Naoki K1: Japanese Journal of Lung Cancer 2020/2; 60 (1): 10-6. (ˆäì@‘1, ‰¡ê³“T2, •Ÿˆä•ü–ç1, ²X–ØŽ¡ˆê˜Y3, —P–؍Ž•F1: 1ŒÄ‹zŠí“à, 2ˆã—Éq¶Šw•”, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

310022. [Ç—á•ñ] Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations. Ikemura S, Yasuda H, Matsumoto S, Kamada M, Hamamoto J, Masuzawa K, Kobayashi K, Manabe T, Arai D, Nakachi I, Kawada I, Ishioka K, Nakamura M, Namkoong H, Naoki K1, Ono F, Araki M, Kanada R, Ma B, Hayashi Y, Mimaki S, Yoh K, Kobayashi SS, Kohno T, Okuno Y, Goto K, Tsuchihara K, Soejima K: Proc Natl Acad Sci U S A 2019/5; 116 (20): 10025-30. (—P–؍Ž•F1: 1ŒÄ‹zŠí“à)

522035. [uÀ]y“ÁW: ”x‚ª‚ñE“ªèò•”‚ª‚ñzTMB high”x‚ª‚ñ‚ɑ΂·‚énivolumab‚Æipilimumab‚Ì•¹—p—Ö@. —P–؍Ž•F (ŒÄ‹zŠí“à): Žîᇓà‰È 2019/5; 23 (5): 503-8.

540034. [‚»‚Ì‘Œ (˜_•])] Chin, et al. ""A Complete Spontaneous Regression of Lung Cancer with Variations in Size over 38 Months"" (Chin‚çu38ƒ•ŒŽ‚É‚í‚œ‚éƒTƒCƒY‚Ì•Ï“®‚𔺂Á‚œ”xŠà‚ÌŠ®‘S‚ÈŽ©‘R‘ޏk). —P–؍Ž•F (ŒÄ‹zŠí“à): ‹CŠÇŽxŠw 2019/5; 41 (3): 231-2.

[Šw‰ïEŒ€‹†‰ï“™]

713038. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer: TORG1833. Nakahara Y1, Kato T, Isomura R, Seki N, Furuya N, Naoki K1, Yamanaka T, Okamoto H: 2019 ASCO Annual Meeting (2019/6/2), Chicago, USA. (’†ŒŽ‘P˜N1, —P–؍Ž•F1: 1ŒÄ‹zŠí“à)

713039. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Impact of EGFR Genotype on the Efficacy of Osimertinib in Patients with Non-Small Cell Lung Cancer: A Prospective Observational Study. Igawa S1, Ono T1, Ozawa T1, Sone H1, Kusuhara S1, Harada S, Ishihara M1, Kasajima M1, Hiyoshi Y1, Fukui T1, Kubota M2, Sasaki J3, Mitsufuji H4, Naoki K1: IASLC 2019 WCLC World Conference on Lung Cancer (2019/9/8), Barcelona, Spain. (ˆäì@‘1, ¬–ì‘וœ1, ¬àV‹M—T1, ‘]ª‰p”V1, “팎­ˆê˜Y1, ÎŒŽ–¢ŠóŽq1, Š}“‡^Žu1, “ú‹gNO1, •Ÿˆä•ü–ç1, ‹v•Û“cŸ2, ²X–ØŽ¡ˆê˜Y3, ŽO“¡@‹v4, —P–؍Ž•F1: 1ŒÄ‹zŠí“à, 2ˆã—Éq¶Šw•”, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 4ŠÅŒìŠw•”)

713040. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) MULTICENTER, SINGLE-ARM PHASE II STUDY OF@NAB-PACLITAXEL/CARBOPLATIN IN UNTREATED PS2@PATIENTS WITH ADVANCED NSCLC: TORG1426. Naoki K1, Ichikawa Y, Bessho A, Hosokawa S, Shimokawa T, Yomota M, Hosomi Y, Otani S1, Nakahara Y1, Iwasawa S, Tokito T, Seki N, Okamoto H: IASLC 2019 WCLC World Conference on Lung Cancer (2019/9/8), Barcelona, Spain. (—P–؍Ž•F1, ‘å’JçŽq1, ’†ŒŽ‘P˜N1: 1ŒÄ‹zŠí“à)

713041. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Efficacy of Immune Checkpoint Inhibitors for Locally Advanced Non-Small Cell Lung Cancer Patients Before Durvalumab Approval. Fukui T1, Hosotani S1, Soda I2, Kakegawa M1, Kasajima M1, Hiyoshi Y1, Igawa S1, Katagiri M3, Ishiyama H2, Naoki K1: IASLC 2019 WCLC World Conference on Lung Cancer (2019/9/9), Barcelona, Spain. (•Ÿˆä•ü–ç1, ×’J^Ži1, ‘“c@Ši2, Š|ì–¢ŠóŽq1, Š}“‡^Žu1, “ú‹gNO1, ˆäì@‘1, •Ð‹Ë^l3, ÎŽR”ŽžŠ2, —P–؍Ž•F1: 1ŒÄ‹zŠí“à, 2•úŽËü (Žîá‡), 3ˆã—Éq¶Šw•”)

713042. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) THE USEFULNESS OF "SERUM" SAMPLES TO DETECT EGFR T790M MUTATION IN EGFR-TKI-RESISTANT NON-SMALL CELL LUNG CANCER. Kobayashi K, Naoki K1, Ikemura S, Yasuda H, Kawada I, Soejima K: IASLC 2019 WCLC World Conference on Lung Cancer (2019/9/7-10), Barcelona, Spain (—P–؍Ž•F1: 1ŒÄ‹zŠí“à)

713043. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Prediction of FEV1 and DLco in lung cancer patients undergoing lobectomy: Comparison between quantitative computed tomography, scintigraphy, and anatomy. Yokoba M1, Ichikawa T, Harada S2, Fukui T3, Igawa S3, Mitsufuji H4, Kubota M1, Sasaki J5, Naoki K3, Sato Y1, Katagiri M1: ERS 2019 International Congress (2019/9/28-10/2), Madrid, Spain. (‰¡ê³“T1, ŒŽ“c^–ç2, •Ÿˆä•ü–ç3, ˆäì@‘3, ŽO“¡@‹v4, ‹v•Û“cŸ1, ²X–ØŽ¡ˆê˜Y5, —P–؍Ž•F3, ²“¡—Yˆê1, •Ð‹Ë^l1: 1ˆã—Éq¶Šw•”, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ŒÄ‹zŠí“à, 4ŠÅŒìŠw•”, 5V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

713044. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Prediction of FEV1 and DLCO in lung cancer patients undergoing lobectomy: comparison between anatomy, scintigraphy, and quantitative computed tomography. Yokoba M1, Ichikawa T, Harada S2, Fukui T3, Igawa S3, Mitsufuji H4, Kubota M1, Naoki K3, Sato Y1, Katagiri M1: APSR2019 The 24th Congress of the Asian Pasific Society of Respirology (2019/11/14-17), Hanoi, Vietnam. (‰¡ê³“T1, ŒŽ“c^–ç2, •Ÿˆä•ü–ç3, ˆäì@‘3, ŽO“¡@‹v4, ‹v•Û“cŸ1, —P–؍Ž•F3, ²“¡—Yˆê1, •Ð‹Ë^l1: 1ˆã—Éq¶Šw•”, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ŒÄ‹zŠí“à, 4ŠÅŒìŠw•”, 4ŒÄ‹zŠíŠO)

723170. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚—îŽÒŠùŽ¡—Ði“WŒ^¬×–E”xŠàŠ³ŽÒ‚ւ̃Aƒ€ƒ‹ƒrƒVƒ“’PÜ: Œø‰Ê‚ƈÀ‘S«‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‘]ª‰p”V1, ˆäì@‘1, ×’J^Ži1, ¬àV‹M—T1, ŠÔ’†”Ž–ç1, ‘å]r‘Ÿ˜Y1, ˆÉ“¡O‹I1, ŠL’Ë‹XŽ÷1, ‘q—ѐT‘Ÿ˜Y1, Œ¬“cÙŽq1, “팎­ˆê˜Y1, ŒŽ“c^–ç2, •Ÿˆä•ü–ç1, ŽO“¡@‹v3, ²X–ØŽ¡ˆê˜Y4, ‹v•Û“cŸ5, —P–؍Ž•F1 (1ŒÄ‹zŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ŠÅŒìŠw•”, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 5ˆã—Éq¶Šw•”): ‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï (2019/4/12), “Œ‹ž.

723171. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”x—tØœŠ³ŽÒ‚É‚š‚¯‚éØœ”x—t‚Ì‹CŽî—e—ʂƌċz‹@”\‚̕ω»‚ɂ‚¢‚Ä. ‰¡ê³“T1, Žsì@‹B, ŒŽ“c^–ç2, Š}“‡^Žu3, Š|ì–¢ŠóŽq3, “ú‹gNO3, ²“¡”Vr4, —P–؍Ž•F3, •Ð‹Ë^l1 (1ˆã—Éq¶Šw•”, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ŒÄ‹zŠí“à, 4ŒÄ‹zŠíŠO): ‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï (2019/4/12), “Œ‹ž.

723172. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠùŽ¡—Ôñ¬×–E”x‚ª‚ñŠ³ŽÒ‚ɑ΂·‚éƒjƒ{ƒ‹ƒ}ƒu—Ö@‚ÌŽ¡—ÃŒø‰Ê‚ƍD’†‹…/ƒŠƒ“ƒp‹…”ä (NLR) ‚Ì‘ŠŠÖ. ‘åŒF—F—œŽq1, •Ÿˆä•ü–ç1, ¬–ì‘וœ1, Š|ì–¢ŠóŽq1, Š}“‡^Žu1, “ú‹gNO1, ‰¡ê³“T2, •Ð‹Ë^l2, —P–؍Ž•F1 (1ŒÄ‹zŠí“à, 2ˆã—Éq¶Šw•”): ‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï (2019/4/13), “Œ‹ž.

723173. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) 75ÎˆÈã‚̍‚—îŽÒ‚ɑ΂·‚éƒAƒtƒ@ƒ`ƒjƒu‚Ì‘æII‘ŠŽŽŒ±. “¡“cŒ‹‰Ô, ‘åò‘Žj, …Š`G‹I, ŒŽ“c•q”V, ˆäì@‘1, ‚ŠK‘Ÿˆê, ‚@@—É, “n粌i–Ÿ, –x“c®œ, •õ‘º_”V, ²”Œ@Ë, –ö‰ºŒOŠ°, à_“c“N’š (1ŒÄ‹zŠí“à): ‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï (2019/4/14), “Œ‹ž.

723174. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) EGFR-TKI‘ϐ«”xŠà‚̃IƒVƒƒ‹ƒ`ƒjƒu‚ÌŒø‰Ê—\‘ª‚É‚š‚¯‚égŒŒŽhŒŸž‚Ì—L—p«. ¬—ÑŒdŒå, —P–؍Ž•F1, ‘àVŒ[‘Ÿ, áÁ“çˆÛŽu, ’r‘º’C”V‰î, ˆÀ“c_”V, ì“cˆê˜Y, •Ê–ð’qŽq, •›“‡Œ€‘¢ (1ŒÄ‹zŠí“à): ‘æ59‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠwpu‰‰‰ï (2019/4/12-14), “Œ‹ž.

723175. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –òÜ‘ãŽÓ‚ðl—¶‚µ‚œ•¹—pŽ¡—ª‘tŒø‚µ‚œ”ñŒ‹Šj«RŽ_‹ÛÇ‡•¹EGFR—z«”xŠà‚̈ê—á. ˆÉ“¡O‹I1, Š|ì–¢ŠóŽq1, ŠL’ːéŽ÷1, •Ÿˆä•ü–ç1, ˆäì@‘1, ‹v•Û“cŸ2, ²X–ØŽ¡ˆê˜Y3, ”ÑŒŽ‘å–«, —с@GŽ÷, —P–؍Ž•F1 (1ŒÄ‹zŠí“à, 2ˆã—Éq¶Šw•”, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ˆãŠw¶EŒ€Cˆã‚Ì“ú–{“à‰ÈŠw‰ï‚±‚Æ‚Í‚¶‚ß (‘æ116‰ñ“ú–{“à‰ÈŠw‰ï‘‰ïEu‰‰‰ï) (2019/4/27), –ŒŒÃ‰®.

723176. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŒÅŒ`‚ª‚ñ‚ɑ΂·‚éŽîᇈâ“`Žq–Ô—…“I‰ðÍŒ‹‰Ê‚ÉŠÖ‚·‚éŠÏŽ@Œ€‹†. •Ÿˆä•ü–ç1, ˆäì@‘1, âˆä˜aŽq, •“c^K, ‚à_—²K, ’†ì˜a•F, Œ”ö˜al, —P–؍Ž•F1 (1ŒÄ‹zŠí“à): ‘æ23‰ñ“ú–{‚ª‚ñ•ªŽq•W“IŽ¡—Êw‰ïŠwpW‰ï (2019/6/13), ‘åã.

723177. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ––œ”x–ì•a•Ï‚ɑ΂·‚é×Œa‹CŠÇŽx“àŽ‹‹Ÿ‚ð—p‚¢‚œtraction drive–@ (‰Œ) ‚ÌŠJ”­ (‰ï‹c˜^). ¬àV‹M—T1, ŽO“¡@‹v2, ŠL’Ë‹XŽ÷1, ×’J^Ži1, ŒŽ“c^–ç3, Œ¬“cÙŽq1, Š}“‡^Žu1, Š|ì–¢ŠóŽq1, •Ÿˆä•ü–ç1, ˆäì@‘1, ‰¡ê³“T4, ²X–ØŽ¡ˆê˜Y5, ‹v•Û“cŸ4, •Ð‹Ë^l4, —P–؍Ž•F1 (1ŒÄ‹zŠí“à, 2ŠÅŒìŠw•”, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 4ˆã—Éq¶Šw•”, 5V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ42‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹ŸŠw‰ïŠwpW‰ï (2019/7/4-5), “Œ‹ž, ‹CŠÇŽxŠw 2019/6; 41 (Suppl): S190.

723178. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) T790M‘gDÄ¶ŒŸ‰A«, ƒŠƒLƒbƒhƒoƒCƒIƒvƒV[—z«is”ñ¬×–E”xŠà‚É‚š‚¯‚éƒIƒVƒƒ‹ƒ`ƒjƒuŽ¡—ÃŒø‰Ê‚ÌŒŸ“¢. Š}“‡^Žu1, ŠÔ’†”Ž–ç1, ˆÉ“¡O‹I1, ‘å]r‘Ÿ˜Y1, ¬–ì‘וœ1, “팎­ˆê˜Y1, “ú‹gNO1, •Ÿˆä•ü–ç1, ˆäì@‘1, ‰¡ê³“T2, ŽO“¡@‹v3, ²X–ØŽ¡ˆê˜Y4, •Ð‹Ë^l2, ‹v•Û“cŸ2, —P–؍Ž•F1 (1ŒÄ‹zŠí“à, 2ˆã—Éq¶Šw•”, 3ŠÅŒìŠw•”, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ42‰ñ“ú–{ŒÄ‹zŠí“àŽ‹‹ŸŠw‰ïŠwpW‰ï (2019/7/4-5), “Œ‹ž, ‹CŠÇŽxŠw 2019/6; 41 (Suppl): S337.

723179. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Galectin-3 expression in patients with resected NSCLC treated with platinum-based adjuvant chemotherapy. “팎­ˆê˜Y1, ˆäì@‘1, “ú‹gNO1, ¬àV‹M—T1, Š|ì–¢ŠóŽq1, ŽO“¡@‹v2, •Ð‹Ë^l3, ‹v•Û“cŸ3, –ö“cŒ›Œá, ’·‰–@—º3, ²“¡—Yˆê3, —P–؍Ž•F1 (1ŒÄ‹zŠí“à, 2ŠÅŒìŠw•”, 3ˆã—Éq¶Šw•”): ‘æ17‰ñ“ú–{—Տ°Žîᇊw‰ïŠwpW‰ï (2019/7/18), ‹ž“s.

723180. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) EGFR•ÏˆÙ—z«NSCLC‚ɑ΂·‚é, ƒIƒVƒƒ‹ƒ`ƒjƒu + ƒ‰ƒ€ƒVƒ‹ƒ}ƒu‚ƃIƒVƒƒ‹ƒ`ƒjƒu‚̃‰ƒ“ƒ_ƒ€‰»‘æII‘ŠŽŽŒ± (TORG1833). –{“c@Œ’, ’†ŒŽ‘P˜N1, ˆé‘º—æŽq, ŒÃ‰®’ŒŽ÷, —P–؍Ž•F1, —t@Ž—², ŒF’J@—Z, ‘êŒû—Tˆê, –©@_ˆê, ‰ºìP¶, ŽR’†’|t, ‰ª–{_–Ÿ, ‰Á“¡WŽj (1ŒÄ‹zŠí“à): ‘æ17‰ñ“ú–{—Տ°Žîᇊw‰ïŠwpW‰ï (2019/7/18), ‹ž“s.

723181. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Evaluation of osimertinib efficacy according to BSA and BMI in patients with NSCLC harboring an EGFR mutation. ¬–ì‘וœ1, ˆäì@‘1, ˆÉ“¡O‹I1, ‘å]r‘Ÿ˜Y1, ‘q—ѐT‘Ÿ˜Y1, ŒŽ“c^–ç2, ‰¡ê³“T3, ‹v•Û“cŸ3, —P–؍Ž•F1 (1ŒÄ‹zŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ˆã—Éq¶Šw•”): ‘æ17‰ñ“ú–{—Տ°Žîᇊw‰ïŠwpW‰ï (2019/7/20), ‹ž“s.

723182. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Current Status of Concurrent Chemoradiotherapy in Patients with Unresectable Locally Advanced Non-Small Cell Lung Cancer. ×’J^Ži1, •Ÿˆä•ü–ç1, “c‘º’qŽq, ‘“c@Ši2, ¬àV‹M—T1, “팎­ˆê˜Y1, Š|ì–¢ŠóŽq1, Š}“‡^Žu1, “ú‹gNO1, ˆäì@‘1, —P–؍Ž•F1 (1ŒÄ‹zŠí“à, 2•úŽËü (Žîá‡)): ‘æ17‰ñ“ú–{—Տ°Žîᇊw‰ïŠwpW‰ï (2019/7/20), ‹ž“s.

723183. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Final results for TORG 1425: A Multicenter Phase II Study of Low-dose Erlotinib in Frail Patients with EGFR Mutation-positive, Non-small Cell Lung Cancer. Aono H, Yamada K, Miyamoto S, Tokito T, Bessho A, Misumi Y, Tanaka H, •Ÿˆä•ü–ç1, Kusaka K, Hosomi Y, Kikuchi N, Mori Y, Itani H, Kasai T, Ichiki M, Seki N, Kunitoh H, Okamoto H (1ŒÄ‹zŠí“à): ‘æ17‰ñ“ú–{—Տ°Žîᇊw‰ïŠwpW‰ï (2019/7/20), ‹ž“s.

723184. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) i“WŒ^¬×–E”xŠà‚É‚š‚¯‚é”­”M«D’†‹…Œž­Ç”­Ç•p“x‚ÆPeg-G-CSF»ÜŽg—p‚ª¶‘¶‚É‹y‚Ú‚·‰e‹¿‚ɂ‚¢‚Ä. Š|ì–¢ŠóŽq1, •Ÿˆä•ü–ç1, ¬–ì‘וœ1, ŽR–{_‹M1, áÁ糉p–Ÿ1, ”ªã—L—¢1, ŠL’ːéŽ÷1, ˆÉ“¡O‹I1, ×’J^Ži1, ™–{@—•1, ˆäì@‘1, ²X–ØŽ¡ˆê˜Y2, —P–؍Ž•F1 (1ŒÄ‹zŠí“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ4‰ñ“ú–{‚ª‚ñƒTƒ|[ƒeƒBƒuƒPƒAŠw‰ïŠwpW‰ï (2019/9/7), ÂX.

723185. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) PS2is”ñ¬×–EŠà‚ɑ΂·‚éƒJƒ‹ƒ{ƒvƒ‰ƒ`ƒ“ + ƒAƒuƒ‰ƒLƒTƒ“‚Ì‘æII‘ŠŽŽŒ± (TORG1426). ãŒ©—tŽq, Žsì–õŽq, “n粐Ž‚, •ÊŠºG, ×ì@”E, —P–؍Ž•F1, Žl•û“c^‹IŽq, ŠâàVrˆê˜Y, Žž”C‚Í, ŠÖ@‡•F, ‰ª–{_–Ÿ (1ŒÄ‹zŠí“à): ‘æ57‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï (2019/10/25), •Ÿ‰ª.

723186. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚—î‚Ü‚œ‚ÍPS•s—ǐi“WŒ^¬×–E”xŠàŠ³ŽÒ‚É‚š‚¯‚鏉‰ñ‰»Šw—Ö@Œã‚ÌPost progression survival time‚̉ðÍ. ‘q—ѐT‘Ÿ˜Y1, ˆäì@‘1, ”ªã—L—¢1, ŽR–{_‹M1, áÁ糉p–Ÿ1, ™–{@—•1, ¬–ì‘וœ1, •Ÿˆä•ü–ç1, ŽO“¡@‹v2, ‹v•Û“cŸ3, ²X–ØŽ¡ˆê˜Y4, —P–؍Ž•F1 (1ŒÄ‹zŠí“à, 2ŠÅŒìŠw•”, 3ˆã—Éq¶Šw•”, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ60‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï (2019/12/6), ‘åã.

723187. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŒÅŒ`‚ª‚ñ‚ɑ΂·‚éŽîᇈâ“`Žq–Ô—…“I‰ðÍŒ‹‰Ê‚ÉŠÖ‚·‚éŠÏŽ@Œ€‹†. ™–{@—•1, •Ÿˆä•ü–ç1, ²X–ØŽ¡ˆê˜Y2, Š|ì–¢ŠóŽq1, “ú‹gNO1, ˆäì@‘1, âˆä˜aŽq, •“c^K, ‚à_—²K, ’†ì˜a•F, Œ”ö˜al, —P–؍Ž•F1 (1ŒÄ‹zŠí“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ60‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï (2019/12/6), ‘åã.

723188. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘æ1, 2, 3¢‘ãEEGFR-TKI‘ϐ«”xŠà×–EŠ”‚ÌŽ÷—§‚ÆŠl“Ÿ‘ϐ«‹@˜‚̉ðÍ. Š|ì–¢ŠóŽq1, “c’†^Ÿ, “ì•”»Žq, ¬àV‹M—T1, “팎­ˆê˜Y1, ŒŽ“c^–ç2, “ú‹gNO1, Š}“‡^Žu1, •Ÿˆä•ü–ç1, ˆäì@‘1, ²X–ØŽ¡ˆê˜Y3, —P–؍Ž•F1 (1ŒÄ‹zŠí“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ60‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï (2019/12/6), ‘åã.

731025. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ”xŠàŽ¡—Â̍ŋ߂̐i•à (–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQ–ò‚𒆐S‚É). —P–؍Ž•F (ŒÄ‹zŠí“à): ‘æ60‰ñ“ú–{“à‰ÈŠw‰ïŠÖ“ŒŽx•”ŽåÃ¶ŠU‹³ˆçu‰‰‰ï (2019/7/14), “Œ‹ž.

733067. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ŒžŠŽì‚É‚æ‚èƒNƒŠƒ]ƒ`ƒjƒuÄ“Š—^‚ª‰Â”\‚Å‚ ‚Á‚œROS1“]À—z«”xŠà‚̈ê—á. Šâé‘å•ã, “팎­ˆê˜Y1, áÁ糉p–Ÿ1, ŽR–{_‹M1, ”ªã—L—¢1, ™–{@—•1, ‘q—ѐT‘Ÿ˜Y1, ¬–ì‘וœ1, ¬àV‹M—T1, Š|ì–¢ŠóŽq1, “ú‹gNO1, Š}“‡^Žu1, •Ÿˆä•ü–ç1, ˆäì@‘1, ŽO“¡@‹v2, ‹v•Û“cŸ3, ²X–ØŽ¡ˆê˜Y4, —P–؍Ž•F1 (1ŒÄ‹zŠí“à, 2ŠÅŒìŠw•”, 3ˆã—Éq¶Šw•”, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ185‰ñ“ú–{”xŠàŠw‰ïŠÖ“ŒŽx•”ŠwpW‰ï (2019/7/6), “Œ‹ž.

733068. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ƒVƒ“ƒOƒ‹ƒj[ƒhƒ‹“§Í‚É‚š‚¯‚éÝ’茌—¬—ʂƐÖ¬ˆ³‚ÉŠÖ‚·‚éŠî‘b“IŒŸ“¢. Žç“cŒ›’1, ‘ºã‰À–í, —Lã’ŒÆ, ¬—Ñ‚±‚žŒb1, ¬‹v•ÛŒªˆê1, ‹v•Û“cŸ1, âj‰ªGŒŸ1 (1ˆã—Éq¶Šw•”): ‘æ22‰ñÝ‘‰t“§ÍŒ€‹†‰ï (2019/11/3), b•{.

733069. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ƒyƒ€ƒuƒƒŠƒYƒ}ƒu“Š—^Œã‚ÉŒŒ‹…æÐHÇŒóŒQ‚𔭏ǂµ‚œ”ñ¬×–E”xŠà‚Ì1—á‚̈ê—á. ŽR–{_‹M1, “ú‹gNO1, ”ªã—L—¢1, áÁ糉p–Ÿ1, ŠL’ːéŽ÷1, ˆÉ“¡O‹I1, ¬–ì‘וœ1, ˆäì@‘1, •Ÿˆä•ü–ç1, —P–؍Ž•F1 (1ŒÄ‹zŠí“à): ‘æ237‰ñ“ú–{ŒÄ‹zŠíŠw‰ïŠÖ“Œ’n•û‰ï (2019/11/23), “Œ‹ž.

'18”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'18-110007. [ŒŽ’˜] Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing Mizugaki H, Hamada A, Shibata T, Hosoda F, Nakamura H, Okuma Y, Shukuya T, Shigeki Umemura S, Horiike A, Fukui T1, Kogure Y, Daga H, Urata Y, Yamada K, Saeki S, Fujisaka Y, Nakamura Y, Sato M, Oizumi S, Fujiwara Y, Ohe Y, Fujiwara Y: Lung Cancer 2019/2; 128: 20-5. (•Ÿˆä•ü–ç1: 1ŒÄ‹zŠí“à)

[Šw‰ïEŒ€‹†‰ï“™]

'18-713004. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Phase II Study of Amrubicin Plus Erlotinib in Previously Treated, Advanced Non-Small Cell Lung Cancer Patients with Wild-Type EGFR: TORG 1320. Hosokawa S, Otani S1, Sasaki J2, Fukui T1, Nakahara Y1, Bessho A, Fukamatsu N, Nakamura Y, Kasai T, Sugiyama T, Tokitho T, Seki N, Hamada A, Masuda N, Okamoto H: The IASLC 19th World Conference on Lung Cancer (2018/9/23), Toronto, Canada. (‘å’JçŽq1, ²X–ØŽ¡ˆê˜Y2, •Ÿˆä•ü–ç1, ’†ŒŽ‘P˜N1: 1ŒÄ‹zŠí“à, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

'18-722002. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) Øœ•s”\‹ÇŠis”ñ¬×–E”x‚ª‚ñŠ³ŽÒ‚É‚š‚¯‚鎡—Â̌»ó‚Ɛi•à. •Ÿˆä•ü–ç1, “c‘º’qŽq, ×’J^Ži1, ‘“c@Ši2, Îã@–«3, —P–؍Ž•F1 (1ŒÄ‹zŠí“à, 2•úŽËü (Žîá‡), 3•úŽËü•”): ‘æ38‰ñ“ú–{‰æ‘œˆãŠw‰ïŠwpW‰ï (2019/3/8), “Œ‹ž.


“à•ª”å‘ãŽÓ“à‰ÈŠw

[Šwp˜_•¶]

110161. [ŒŽ’˜] Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease. Inoue M1, Hayashi A2, Taguchi T1, Arai R2, Sasaki S1, Takano K2, Inoue Y3, Shichiri M2: J Diabetes Investig 2019/7; 10 (4): 1004-11. (ˆäãŒõŽq1, —с@“N”Í2, “cŒû@•ü1, Vˆä—œˆß“ß2, ²X–؍¹–ç‰Á1, ‚–ìK˜H2, ˆäã—D‰î3, Žµ—¢áÁ‹`2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2“à•ª”å‘ãŽÓ“à, 3•úŽËü (‰æ‘œ))

110162. [ŒŽ’˜] Identification of plasma binding proteins for glucose-dependent insulinotropic polypeptide. Hoshiyama A1, Fujimoto K2, Konno R, Sasaki S1, Momozono A1, Kodera Y, Shichiri M2: Endocr J 2019/7; 66 (7): 621-8. (¯ŽRˆ»Žq1, “¡–{˜aŽÀ2, ²X–؍¹–ç‰Á1, “‰€@–Ÿ1, Žµ—¢áÁ‹`2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2“à•ª”å‘ãŽÓ“à)

110163. [ŒŽ’˜] Basal glucagon hypersecretion and response to oral glucose load in prediabetes and mild type 2 diabetes. Ichikawa R1, Takano K1, Fujimoto K1, Motomiya T, Kobayashi M, Kitamura T, Shichiri M1: Endocr J 2019/8; 66 (8): 663-75. (Žsì—‹Žt1, ‚–ìK˜H1, “¡–{˜aŽÀ1, Žµ—¢áÁ‹`1: 1“à•ª”å‘ãŽÓ“à)

110164. [ŒŽ’˜] Molecular form and concentration of serum ƒ¿2-macroglobulin in diabetes. Yoshino S1, Fujimoto K2, Takada T2,3, Kawamura S1, Ogawa J, Kamata Y2, Kodera Y, Shichiri M2: Sci Rep 2019/9; 9 (1): 12927. (‹g–쉑”ü1, “¡–{˜aŽÀ2, ‚“c“NG2,3, ì‘º¹—FŠó1, Š™“c—T“ñ2, Žµ—¢áÁ‹`2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2“à•ª”å‘ãŽÓ“à, 3–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

110165. [ŒŽ’˜] Oxidised Met147 of human serum albumin is a biomarker of oxidative stress, reflecting glycaemic fluctuations and hypoglycaemia in diabetes. Momozono A1, Kodera Y, Sasaki S1, Nakagawa Y, Konno R, Shichiri M2: Sci Rep 2020/1; 10 (1): 268. (“‰€@–Ÿ1, ²X–؍¹–ç‰Á1, Žµ—¢áÁ‹`2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2“à•ª”å‘ãŽÓ“à)

110166. [ŒŽ’˜] Role of oxidized Met111 of human serum albumin for an oxidative stress biomarker in diabetes. Momozono A1, Kodera Y, Sasaki S1, Nakagawa Y, Konno R, Shichiri M2: Kitasato Med J 2020/3; 50 (1): 80-5. (“‰€@–Ÿ1, ²X–؍¹–ç‰Á1, Žµ—¢áÁ‹`2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2“à•ª”å‘ãŽÓ“à)

120005. [ŒŽ’˜] “œ”A•a“§ÍŠ³ŽÒ‚É‚š‚¯‚铧ÍŠÖ˜AŒŒ“œ•Ï“®‚Ì“à•ª”åŠw“I•a‘Ô‚ÌŒŸ“¢. —с@“N”Í1, “IêŒ’‘Ÿ, ‘唩NG1, Ž…‡–ç1, —é–؍V–Œ1, ’ç@‹M‘å, “¡ˆä—¢]1, ²“¡‚Ü‚èd1, ‚–ìK˜H1, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à): “ú–{“§Íˆã‰ïŽGŽ 2019/5; 34 (2): 276-80.

320007. [Ç—á•ñ] ƒCƒ“ƒtƒ‹ƒGƒ“ƒUƒƒNƒ`ƒ“ÚŽíŒã‚É”­Ç‚µ‚œ‹}«”­Ç1Œ^“œ”A•a‚Ì1—á. ˆäãŒõŽq1, Š™“c—T“ñ2, ”“Œ@Œd1, “cŒû@•ü1, ‘º“cH•ä2, Vˆä—œˆß“ß2, ²X–ØŽÑ–ç‰Á1, —с@“N”Í2, ‚–ìK˜H2, Žµ—¢áÁ‹`2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2“à•ª”å‘ãŽÓ“à): “œ”A•a 2019/4; 62 (4): 214-9.

540035. [‚»‚Ì‘Œ (•ñ‘)]yŒö•åŒ€‹†•¬ 29”N“x•ñ‘z“œ”A•a“§ÍŠ³ŽÒ‚É‚š‚¯‚铧ÍŠÖ˜AŒŒ“œ•Ï“®‚Ì“à•ª”åŠw“I•a‘Ô‚ÌŒŸ“¢. —с@“N”Í1, “IêŒ’‘Ÿ2, ‘唩NG1, Ž…‡–ç1, —é–؍V–Œ1, ’ç@‹M‘å1, “¡ˆä—¢]1, ²“¡‚Ü‚èd1, ‚–ìK˜H1, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à, 2—ÕŒŸŠw): “ú–{“§Íˆã‰ïŽGŽ 2019/8; 34 (2): 276-80.

[’˜@‘]

620034. [Šwp‘ (•ª’SŽ·•M)] y—Տ°–òŠwƒeƒLƒXƒgƒVƒŠ[ƒY@zŠÂŠí/tE”å”AŠí/‘ãŽÓ/“à•ª”åz‘æ4Í “à•ª”原Š³@B. ŽŸŠ³Še˜_@1. Ž‹°‰º•”E‰º‚‘ÌŽŸŠ³, p.295-316. ‚–ìK˜H (“à•ª”å‘ãŽÓ“à), ŠÄC: Š£@Œ«ˆê, •Ò: Ô’rº‹I, ˆÉ“¡’å‰Ã, ã–ì˜as, ’†ŽR‘“X, “Œ‹ž, 2020/1”­s.

[Šw‰ïEŒ€‹†‰ï“™]

722050. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) “«ƒNƒbƒVƒ“ƒO•a‚ÌŽ¡—ÁE‘˜_. ‚–ìK˜H (“à•ª”å‘ãŽÓ“à): ‘æ92‰ñ“ú–{“à•ª”åŠw‰ïŠwp‘‰ï (2019/5/9-11), å‘ä.

722051. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) “à‰Èˆã‚ªl‚Š‚é_Œo“à•ª”åŽîᇂ̎èp“K‰ž. ‚–ìK˜H (“à•ª”å‘ãŽÓ“à): ‘æ31‰ñ“ú–{“à•ª”åŠO‰ÈŠw‰ï‘‰ï (2019/6/14), “Œ‹ž.

722052. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) äXEÁ‰»ŠÇ_Œo“à•ª”åŽîᇠ(NEN) f—ÃKƒCƒhƒ‰ƒCƒ“ (‘æ2”Å) f’f‚ɂ‚¢‚Ẳðà. ‚–ìK˜H (“à•ª”å‘ãŽÓ“à): ‘æ50‰ñ“ú–{äX‘ŸŠw‰ï‘å‰ï (2019/7/13), “Œ‹ž.

722053. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ‚È‚ºƒgƒ‰ƒ“ƒWƒVƒ‡ƒ“Šú‚Ɛ¬lŠú‚ÉGH•â[‚ª•K—v‚©. ‚–ìK˜H (“à•ª”å‘ãŽÓ“à): ‘æ61‰ñ“ú–{¬Ž™ŒŒ‰tE‚ª‚ñŠw‰ïŠwpW‰ï (2019/11/16), L“‡.

723189. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬l¬’·ƒzƒ‹ƒ‚ƒ“•ª”å•s‘SÇ‚É‚š‚¯‚ésomapacitanTˆê‰ñ“Š—^‚É‚æ‚é‹ëŠ²•”Ž‰–b—Ê‚ÌŒž­. ‚–ìK˜H (“à•ª”å‘ãŽÓ“à): ‘æ92‰ñ“ú–{“à•ª”åŠw‰ïŠwp‘‰ï (2019/5/9), å‘ä.

723190. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒqƒgzŠÂŒŒŸ÷’†ƒvƒƒŒƒjƒ“‚Ì•ªŽq‘¶Ý—lŽ®‚ƐV‹K‘ª’èŒn‚É‚š‚¯‚é‚»‚Ì”Z“x. “¡–{˜aŽÀ1, â“Œ@Œd2, ì‘º¹—FŠó2, ‹g–쉑”ü1, Š™“c—T“ñ1, ¬Ž›‹`’j, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ92‰ñ“ú–{“à•ª”åŠw‰ïŠwp‘‰ï (2019/5/9-11), å‘ä, “ú–{“à•ª”åŠw‰ïŽGŽ 2019; 95 (1): 385.

723191. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Graves•aŠ³ŽÒ‚ÌŽ¡—ÃŒo‰ß‚É‚æ‚éˆÀÃŽž‘ãŽÓ—ʂ̕ω»‚ÌŒŸ“¢`Œ’íŽÒ‚Æ‚Ì”äŠr`. ‘唩NG1, —с@“N”Í1, —é–؍V–Œ1, Ž…‡–ç1, ¯ŽRˆ»Žq2, Š™“c—T“ñ1, ‚–ìK˜H1, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ92‰ñ“ú–{“à•ª”åŠw‰ïŠwp‘‰ï (2019/5/9-11), å‘ä, “ú–{“à•ª”åŠw‰ïŽGŽ 2019; 95 (1): 393.

723192. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Œy”÷‚ÈcortisolŽY¶”\‚ð—L‚µ, p‘O‚ɕБ€‚Ì•›t”玿Šà‚ð‹^‚Á‚œ—Œ‘€•›t‘BŽî‚̈ê—á. —é–؍V–Œ1, Š™“c—T“ñ1, “cŒû@•ü2, ‚–ìK˜H1, ŽRè—Ll, ù–ìŒöL, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ92‰ñ“ú–{“à•ª”åŠw‰ïŠwp‘‰ï (2019/5/9-11), å‘ä, “ú–{“à•ª”åŠw‰ïŽGŽ 2019; 95 (1): 469.

723193. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) factitious hypoglycemia‚̊ӕʂɈقȂéƒCƒ“ƒXƒŠƒ“‘ª’èƒLƒbƒg‚ª—L—p‚Å‚ ‚Á‚œ1Ç—á. ¬ìŒ°Žj (“à•ª”å‘ãŽÓ“à): ‘æ68‰ñ“ú–{ˆãŠwŒŸžŠw‰ï (2019/5/18-19), ‰ºŠÖ.

723194. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “§ÍŠ³ŽÒ‚É‚š‚¯‚éƒtƒ‰ƒbƒVƒ…ƒOƒ‹ƒR[ƒXƒ‚ƒjƒ^ƒŠƒ“ƒO‚̐³Šm«‚ÌŒŸ“¢. “IêŒ’‘Ÿ1,2, —с@“N”Í2, ²“¡‚Ü‚èd2, ’ç@‹M‘å, ¬ìŒ°Žj2, Š™“c—T“ñ2, XŒû‚¢‚Ô‚«, ¬—Ñ’Œ”V, ‚–ìK˜H2, Žµ—¢áÁ‹`2 (1—ÕŒŸŠw, 2“à•ª”å‘ãŽÓ“à): ‘æ62‰ñ“ú–{“œ”A•aŠw‰ï”NŽŸŠwpW‰ï (2019/5/23-25), å‘ä, “œ”A•a 2019; 62: S138.

723195. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Sensor Augmented Pump 640G‚É‚š‚¯‚éPredictive Low Glucose‚ÌŒø‰Ê`’ጌ“œ‰ñ”ð‚ðŒŸ“¢‚·‚é`. Ž…‡–ç1, —с@“N”Í1, ‘唩NG1, —é–؍V–Œ1, “¡ˆä—¢]1, Vˆä—œˆß“ß, —é–Ø—z•F1, Žsì—‹Žt1, ‚–ìK˜H1, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à): ‘æ62‰ñ“ú–{“œ”A•aŠw‰ï”NŽŸŠwpW‰ï (2019/5/23-25), å‘ä, “œ”A•a 2019; 62: S182.

723196. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒvƒƒsƒ‹ƒ`ƒIƒEƒ‰ƒVƒ‹“Š—^ŠJŽnŒã‚Ɉê‰ß«‚É’˜–Ÿ‚ȍ‚ƒgƒŠƒOƒŠƒZƒ‰ƒCƒhŒŒÇ‚ð’悵‚œƒoƒZƒhƒE•a‚̈ê—á. Š™“c—T“ñ1, Ž…‡–ç1, ²“¡‚Ü‚èd1, “cŒû@•ü2, Š™“c—œˆß“ß, Žsì—‹Žt1, ‚–ìK˜H1, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ62‰ñ“ú–{bó‘BŠw‰ïŠwpW‰ï (2019/10/10-12), ‘O‹Ž.

723197. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) WŠw“IƒŠƒXƒNŠÇ—‚Å”DP‚ðŠ®‹‚µ‚Š‚œ”][ÇŠù‰”ì–ž‚ŒŒˆ³2Œ^“œ”A•a‡•¹”DP—á. –Ø‘º—¢1, Žsì—‹Žt1, ˆê“‡—R‰ÁŽq1, ‚–ìK˜H1, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à): ‘æ35‰ñ“ú–{“œ”A•aE”DPŠw‰ï”NŽŸŠwpW‰ï (2019/11/22-23), “Œ‹ž, “œ”A•a‚Æ”DP 2019; 19 (3): S105.

723198. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚š‚¯‚é“œ‘ãŽÓˆÙí‡•¹ŠO‘l”D•w‚ÌŽÀ‘Ԃɂ‚¢‚Ä. ˆê“‡—R‰ÁŽq1, Žsì—‹Žt1, –Ø‘º—¢1, ‚–ìK˜H1, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à): ‘æ35‰ñ“ú–{“œ”A•aE”DPŠw‰ï”NŽŸŠwpW‰ï (2019/11/22-23), “Œ‹ž, “œ”A•a‚Æ”DP 2019; 19 (3): S110.

723199. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –¢”j—ô“®–¬áŽ‚̍‡•¹‚ð”F‚ß‚œæ’[‹‘åÇ‚Ì1—á. ‘唩NG1, “cŒû@•ü2, ˆä‰º®Žq, ŽR“c³ŽO, ‚–ìK˜H1, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ29‰ñ“ú–{“à•ª”åŠw‰ï—Տ°“à•ª”å‘ãŽÓ Update (2019/11/29-30), ‚’m, “ú–{“à•ª”åŠw‰ïŽGŽ 2019; 95 (2): 713.

723200. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒoƒZƒhƒE•a‚̍Ĕ­‚ðŒ_‹@‚É”­Ç‚µ‚œ“àŠá‹ØáŠQ‚Ì1—á. ¬“c@Œd1, “yŠò‘ì–ç1, “¡ˆä—¢]1, Žsì—‹Žt1, Š™“c—T“ñ1, ‚–ìK˜H1, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à): ‘æ29‰ñ“ú–{“à•ª”åŠw‰ï—Տ°“à•ª”å‘ãŽÓ Update (2019/11/29-30), ‚’m, “ú–{“à•ª”åŠw‰ïŽGŽ 2019; 95 (2): 725.

723201. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) æ’[‹‘åÇ‚ÌŽ¡—Âɂæ‚è‰ü‘P‚µ‚œ’†“Ő«‘œŒ‹ß«bó‘BŽî‚̈ê—á. Ž…‡–ç1, “cŒû@•ü2, ‰Á“¡@O3, ŽR“c³ŽO, ‚–ìK˜H1, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3“û‘BEbó‘BŠO): ‘æ29‰ñ“ú–{“à•ª”åŠw‰ï—Տ°“à•ª”å‘ãŽÓ Update (2019/11/29-30), ‚’m, “ú–{“à•ª”åŠw‰ïŽGŽ 2019; 95 (2): 790.

731026. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ‰º‚‘ÌŽŸŠ³‚̐g‘̏ŠŒ©‚̐f‚©‚œ. ‚–ìK˜H (“à•ª”å‘ãŽÓ“à): ‘æ19‰ñ“ú–{“à•ª”åŠw‰ï–kŠC“¹Žx•”ŠwpW‰ï (2019/10/20), ŽD–y.

733070. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) GHRP-2•‰‰×ŽŽŒ±‚É‚š‚¯‚鍂”œ‰ž‚ƒᔜ‰žÇ—á‚Å‚ÌGH•â[—Ê‚ÌŒŸ“¢. “cŒû@•ü1, ‚–ìK˜H2, Žµ—¢áÁ‹`2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2“à•ª”å‘ãŽÓ“à): ‘æ20‰ñ“ú–{“à•ª”åŠw‰ïŠÖ“ŒbM‰zŽx•”ŠwpW‰ï (2019/9/13-14), “Œ‹ž.

733071. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) •@‘ù‚𔺂€–«•@•›•@o‰Š‚ð‡•¹‚µC•@”S–Œ‘gD¶ŒŸ‚É‚ÄIgG4ŠÖ˜AŽŸŠ³‚É‚æ‚é˜R“l‰º‚‘̉Š‚Ɛf’f‚µ‚œ1—á. –Ø‘º—¢1. Š™“c—T“ñ1, “¡ˆä—¢]1, Žsì—‹Žt1, ‚–ìK˜H1, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à): ‘æ20‰ñ“ú–{“à•ª”åŠw‰ïŠÖ“ŒbM‰zŽx•”ŠwpW‰ï (2019/9/13-14), “Œ‹ž.

733072. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) bó‘BƒNƒŠ[ƒ[‚ðŒ_‹@‚ɉ摜ŒŸž‚É‚ÄäX‚̍‚“xŽ‰–b’uŠ·‚ð”F‚ß‚œ1AŒ^“œ”A•a‚Ì1—á. ˆê“‡—R‰ÁŽq1, Š™“c—T“ñ1, Ž…‡–ç1, ¬“c@Œd1, –Ø‘º—¢1, ‰ºèmG‘1, ‚–ìK˜H1, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à): ‘æ57‰ñ“ú–{“œ”A•aŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2020/1/18), ‰¡•l, “œ”A•a 2020; 63 (7): 413.

733073. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “àˆö«ƒCƒ“ƒXƒŠƒ“•ª”å”\‚̒ቺ‚ð”F‚ß‚œ”ÓŠú”­ÇŒ^ˆÚAŒã“œ”A•a‚Ì1—á. ¬“c@Œd1, “¡ˆä—¢]1, “IêŒ’‘Ÿ2, ˆê“‡—R‰ÁŽq1, –Ø‘º—¢1, ‰ºèmG‘1, Š™“c—T“ñ1, ‚–ìK˜H1, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à, 2—ÕŒŸŠw): ‘æ57‰ñ“ú–{“œ”A•aŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2020/1/18), ‰¡•l, “œ”A•a 2020; 63 (7): 413.

733074. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “œ”A•a«ƒPƒgƒAƒVƒh[ƒVƒXŽ¡—ÃŒã‚ɒጌˆ³‚ª‘J‰„‚µ‚œ1—á. ‰ºèmG‘1, Žsì—‹Žt1, ‘唩NG1, ˆê“‡—R‰ÁŽq1, ¬“c@Œd1, –Ø‘º—¢1, ‚–ìK˜H1, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à): ‘æ57‰ñ“ú–{“œ”A•aŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2020/1/18), ‰¡•l, “œ”A•a 2020; 63 (7): 413.

733075. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ƒCƒ“ƒtƒ‹ƒGƒ“ƒU”x‰Š‚É‚æ‚éARDS‚ðECMO“±“ü‚Å‹~–œ‚µ‚œ2Œ^“œ”A•a‚Ì1—á. —é–؍V–Œ1, Žsì—‹Žt1, Š™“c—T“ñ1, ‚–ìK˜H1, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à): ‘æ57‰ñ“ú–{“œ”A•aŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2020/1/18), ‰¡•l, “œ”A•a 2020; 63 (7): 413.

733076. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) –TÒ’Œ‹Ø“÷“à‚ƍ¶t‘Ÿ‚É‘œ”­‚·‚é”^á‡‚ð‡•¹‚µ‚œ“œ”A•a«ƒPƒgƒAƒVƒh[ƒVƒX (DKA) ‚Ì1—á. ŽR“c@’ó1, “yŠò‘ì–ç1, “¡“ˆ@—à1, ‚–ìK˜H1, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à): ‘æ57‰ñ“ú–{“œ”A•aŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2020/1/18), ‰¡•l, “œ”A•a 2020; 63 (7): 413.

733077. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) 2Ží—ނ̃Cƒ“ƒXƒŠƒ“‘ª’èƒLƒbƒg‚ð—p‚¢‚Ä‹•‹U«’ጌ“œÇ‚ðf’f‚µ‚œ1—á. –Ø‘º—¢1, ¬ã–ž—¢ŠG1, ¬ìŒ°Žj1, Žsì—‹Žt1, Š™“c—T“ñ1, ‚–ìK˜H1, Žµ—¢áÁ‹`1, ˆê“‡—R‰ÁŽq1, ¬“c@Œd1, ‰ºèmG‘1 (1“à•ª”å‘ãŽÓ“à): ‘æ57‰ñ“ú–{“œ”A•aŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2020/1/18), ‰¡•l, “œ”A•a 2020; 63 (7): 413.

733078. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) Žîᇌž—ʏp‚ª‘tŒ÷‚µ‚œIGF-IIŽY¶ŽîᇂÌ1—á. ‘唩NG1, ¬ìŒ°Žj1, ˆê“‡—R‰ÁŽq1, –Ø‘º—¢1, ¬“c@Œd1, ‰ºèmG‘1, “yŠò‘ì–ç1, Žsì—‹Žt1, Š™“c—T“ñ1, ‚–ìK˜H1, Žµ—¢áÁ‹`1 (1“à•ª”å‘ãŽÓ“à): ‘æ57‰ñ“ú–{“œ”A•aŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2020/1/18), ‰¡•l, “œ”A•a 2020; 63 (7): 413.

'18”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'18-110008. [ŒŽ’˜] Serum ƒ¿2-macroglobulin levels in ischemic heart disease. Yoshino S1, Takada T1,2, Fujimoto K1, Shiono T2,3, Shichiri M1: Kitasato Med J 2019/3; 49 (1):46-51. (‹g–쉑”ü1, ‚“c“NG1,2, “¡–{˜aŽÀ1, ‰––ì•û–Ÿ2,3, Žµ—¢áÁ‹`1: 1“à•ª”å‘ãŽÓ“à, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3zŠÂŠí“à)

[Šw‰ïEŒ€‹†‰ï“™]

'18-713005. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Efficacy and Safety of Once-weekly Somapacitan in Adult Growth Hormone Deficiency (AGHD) Confirmed in a 53-week Real 1 Trial Extension. Johannsson G, Gordon MB, Rasmussen MH, HŒkonsson IH, SvŸrke C, Tahara S, Takano K1, Biller BMK: Endocrine Society 2019 (2019/3/23-26), New Orleans, USA. (‚–ìK˜H1: 1“à•ª”å‘ãŽÓ“à)


t‘Ÿ“à‰ÈŠw

[Šw‰ïEŒ€‹†‰ï“™]

723202. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŒŒŸ÷ŒðŠ·‚ƃXƒeƒƒCƒh—Ö@‚ª‘tŒ÷‚µ‚œŽ…‹…‘ÌIgA’Ÿ’…Ü‚𔺂€RGBMR‘ÌŒ^t‰Š‚̈ê—á. ŸN—с@r1, ²–ì@—²1, ˆä“c^¶Žq1, àV“c@Ê1, •x‰i‘åŽu1, ‰i‰ª–¢—ˆ1, ³–Ø‹M‹³1, ŽðˆäŒ’Žj1, “à“¡³‹g1, ÂŽR“ŒŒÜ1, ’|“àN—Y1 (1t‘Ÿ“à): ‘æ64‰ñ“ú–{“§ÍˆãŠw‰ïŠwpW‰ïE‘‰ï (2019/6/29), ‰¡•l.

723203. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) TNF-ƒ¿—U“±«“œœCü•s‘SƒlƒtƒŠƒ“‘‰Á‚É‚æ‚鏬–E‘̃XƒgƒŒƒXƒ}[ƒJ[‚Ì”­Œ»˜Ži. ì“‡‰iŽq1, “à“¡³‹g1 (1t‘Ÿ“à): ‘æ92‰ñ“ú–{¶‰»Šw‰ï‘å‰ï (2019/9/18), ‰¡•l.

733079. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‘ƒóŽ…‹…‘̍d‰»Ç‚ÌŽ¡—Ã’†‚ɃNƒŠƒIƒOƒƒuƒŠƒ“ŒŒÇ«Ž…‹…‘̐t‰Š‚ð‡•¹‚µ‚œˆê—á. àV“c@Ê1, ³–Ø‹M‹³1, ŸN—с@r1, ˆä“c^¶Žq1, •x‰i‘åŽu1, ‰i‰ª–¢—ˆ1, Š™“c•‡”ü2, ŽðˆäŒ’Žj1, “à“¡³‹g1, ÂŽR“ŒŒÜ1, ²–ì@—²1, ‰¥@‘cœ3, ’|“àN—Y1 (1t‘Ÿ“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ŒŒ‰t“à): ‘æ97‰ñ_“ސìtŒ€‹†‰ï (2019/6/1), ‰¡•l.

733080. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‰»”^«’ŊԔ‰Š‚ÌŽ¡—Ã’†‚É’°˜‹Ø”^ᇂƊŽõ«“®–¬áŽ‚ð‡•¹‚µŽ¡—Âɓïa‚µ‚œˆÛŽŒŒ‰t“§ÍŠ³ŽÒ‚̈ê—á. ŸN—с@r1, ŽðˆäŒ’Žj1, ˆä“c^¶Žq1, àV“c@Ê1, •x‰i‘åŽu1, ‹Ž–{ŒbŽq1, ‰i‰ª–¢—ˆ1, ³–Ø‹M‹³1, “à“¡³‹g1, ÂŽR“ŒŒÜ1, ²–ì@—²1, ’|“àN—Y1 (1t‘Ÿ“à): ‘æ97‰ñ_“ސìtŒ€‹†‰ï (2019/6/1), ‰¡•l.

733081. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) (Å—DG‰‰‘èÜ (2019) ŽóÜ) t‘Ÿ‚É‚š‚¯‚éŽ_«“œŽ‰Ž¿GM3‚̏d—v«. ŽRŒû˜a‰Ô, ì“‡‰iŽq1, ÎŠ_’ŒŽq, ‰iª‘劲, ŽR‰º@‹§, “à“¡³‹g1 (1t‘Ÿ“à): Free Radical Summer School 2019 (“ú–{Ž_‰»ƒXƒgƒŒƒXŠw‰ïƒtƒŠ[ƒ‰ƒWƒJƒ‹ƒXƒN[ƒ‹) (2019/8/10-11), VŠƒ.

733082. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ”÷¬•Ï‰»Œ^ƒlƒtƒ[ƒ[ÇŒóŒQ‚𔭏ǂµ‚œƒŒƒbƒNƒŠƒ“ƒOƒnƒEƒ[ƒ“•a‚Ì1—á. ŸN—с@r1, ²–ì@—²1, ˆä“c^¶Žq1, ‹Ž–{ŒbŽq1, Š™“c•‡”ü2, ŽðˆäŒ’Žj1, “à“¡³‹g1, ÂŽR“ŒŒÜ1, ’|“àN—Y1 (1t‘Ÿ“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ49‰ñ“ú–{t‘ŸŠw‰ï“Œ•”Šwp‘å‰ï (2019/10/4), “Œ‹ž.

733083. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “œ”A•a«tÇ‚É‚æ‚錌ð«”÷¬ŒŒŠÇÇ‚É‚æ‚蓧Í“±“ü‚Æ‚È‚Á‚œ1—á. ‹{â—³”n1, “à“¡³‹g1, ŸN—с@r1, ‰i‰ª–¢—ˆ1, •x‰i‘åŽu1, àV“c@Ê1, ˆä“c^¶Žq1, ‹Ž–{ŒbŽq1, ³–Ø‹M‹³1, ŽðˆäŒ’Žj1, ÂŽR“ŒŒÜ1, ²–ì@—²1, ’|“àN—Y1 (1t‘Ÿ“à): ‘æ49‰ñ“ú–{t‘ŸŠw‰ï“Œ•”Šwp‘å‰ï (2019/10/4), “Œ‹ž.

733084. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) _ŒoüˆÛŽîÇIŒ^‚Ƀlƒtƒ[ƒ[ÇŒóŒQ‚ð‡•¹‚µt¶ŒŸ‚É‚æ‚胋[ƒvƒXt‰Š‚Ɛf’f‚³‚ê‚œ1—á. ŽRè‘ñ–ç1, ŽðˆäŒ’Žj1, ì‘º¹—R”ü1, åŒŽ–ƒ—FŽq1, ŒŽRŒiŽq1, ‹{â—³”n1, ˆä“c^¶Žq1, ˆ¢•”“N–ç1, ‹Ž–{ŒbŽq1, Š™“c•‡”ü2, “à“¡³‹g1, ÂŽR“ŒŒÜ1, ²–ì@—²1, ’|“àN—Y1 (1t‘Ÿ“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ49‰ñ“ú–{t‘ŸŠw‰ï“Œ•”Šwp‘å‰ï (2019/10/4), “Œ‹ž.

733085. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ƒ‰ƒ€ƒVƒ‹ƒ}ƒu (VEGF‘jŠQ–ò) ‚É‚æ‚èƒlƒtƒ[ƒ[ÇŒóŒQ‚𗈂µ‚œˆê—á. ˆä“c^¶Žq1, “à“¡³‹g1, ŸN—с@r1, àV“c@Ê1, •x‰i‘åŽu1, ‰i‰ª–¢—ˆ1, ³–Ø‹M‹³1, ŽðˆäŒ’Žj1, ÂŽR“ŒŒÜ1, ²–ì@—²1, ’|“àN—Y1 (1t‘Ÿ“à): ‘æ49‰ñ“ú–{t‘ŸŠw‰ï“Œ•”Šwp‘å‰ï (2019/10/5), “Œ‹ž.

733086. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) —Œ‰ºŽˆŽ‡”Á‚Å”­Ç‚µˆÝŠà‚ª”»–Ÿ‚µ‚œIgAŒŒŠÇ‰Š‡•¹–Œ«tÇ‚̈ê—á. ì‘º¹—R”ü1, ²–ì@—²1, ŒŽRŒiŽq1, ‹{â—³”n1, ŽRè‘ñ–ç1, åŒŽ–ƒ—FŽq1, ˆä“c^¶Žq1, ‹Ž–{ŒbŽq1, Š™“c•‡”ü2, ˆ¢•”“N–ç1, ŽðˆäŒ’Žj1, “à“¡³‹g1, ÂŽR“ŒŒÜ1, ’|“àN—Y1 (1t‘Ÿ“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ49‰ñ“ú–{t‘ŸŠw‰ï“Œ•”Šwp‘å‰ï (2019/10/5), “Œ‹ž.

733087. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) G“‘B“Eop‚Ì‚Ý‚Å”AŠŒ©‚ªŒy‰õ‚µ‚œ¬l”­ÇIgAŒŒŠÇ‰Š‚̈ê—á. åŒŽ–ƒ—FŽq1, ÂŽR“ŒŒÜ1, ˆä“c^¶Žq1, ˆ¢•”“N–ç1, ŽðˆäŒ’Žj1, “à“¡³‹g1, ²–ì@—²1, ’|“àN—Y1 (1t‘Ÿ“à): ‘æ49‰ñ“ú–{t‘ŸŠw‰ï“Œ•”Šwp‘å‰ï (2019/10/5), “Œ‹ž.

733088. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) R‚€‚–ò‚É‚æ‚é–òÜ«“÷‰èŽî«ŠÔŽ¿«t‰Š‚ƍl‚Š‚ç‚ê‚œ1—á. ŒŽRŒiŽq1, ŽðˆäŒ’Žj1, ì‘º¹—R”ü1, åŒŽ–ƒ—FŽq1, ŽRè‘ñ–ç1, ‹{â—³”n1, ˆä“c^¶Žq1, ˆ¢•”“N–ç1, ‹Ž–{ŒbŽq1, Š™“c•‡”ü2, “à“¡³‹g1, ÂŽR“ŒŒÜ1, ²–ì@—²1, ’|“àN—Y1 (1t‘Ÿ“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ49‰ñ“ú–{t‘ŸŠw‰ï“Œ•”Šwp‘å‰ï (2019/10/5), “Œ‹ž.

733089. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ƒXƒeƒƒCƒhŽ¡—Ã’†‚É•³ü’ŽÇ‚𔭏ǂµ‚œ”÷¬•Ï‰»Œ^ƒlƒtƒ[ƒ[ÇŒóŒQ‚̈ê—á. ŒÕŠâ‚ß‚®‚Ý, ²–ì@—²1, ì‘º¹—R”ü1, åŒŽ–ƒ—FŽq1, ²–ìŒiŽq1, ‹{â—³”n1, ŽRè‘ñ–ç1, ˆä“c^¶Žq1, ˆ¢•”“N–ç1, ŽðˆäŒ’Žj1, “à“¡³‹g1, ÂŽR“ŒŒÜ1, ’|“àN—Y1 (1t‘Ÿ“à): “ú–{“à‰ÈŠw‰ï‘æ656‰ñŠÖ“Œ’n•û‰ï (2019/12/14), “Œ‹ž.

733090. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ƒoƒ‹ƒvƒŽ_‚É‚æ‚éRƒlƒtƒŠƒ“R‘Ì—U“±«FSGS‚Ì—\–hEŽ¡—ÃŒø‰Ê. ì“‡‰iŽq1, ’‡ŽRŒ«ˆê, ÎŠ_’ŒŽq, “à“¡³‹g1 (1t‘Ÿ“à): ‘æ4‰ñƒ|ƒhƒTƒCƒgŒ€‹†‰ï (2020/3/14), “Œ‹ž.

733091. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “œŽ‰Ž¿GM3‚̐t•ÛŒìŒø‰Ê‚ÌŒŸ“¢. ŽRŒû˜a‰Ô, ì“‡‰iŽq1, ŽR‰º@‹§, “à“¡³‹g1 (1t‘Ÿ“à): ‘æ4‰ñƒ|ƒhƒTƒCƒgŒ€‹†‰ï (2020/3/14), “Œ‹ž.


äPŒŽ•aEŠŽõ“à‰ÈŠw

[Šwp˜_•¶]

110167. [ŒŽ’˜] Anti-ribosomal P protein antibodies influence mortality of patients with diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematous involving a severe form of the disease. Arinuma Y1, Kikuchi H, Hirohata S1: Mod Rheumatol 2019/7; 29 (4): 612-8. (—LÀ—ǍK1, œA”šr¬1: 1äPŒŽ•aEŠŽõ“à)

110168. [ŒŽ’˜] Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data. Takeuchi T, Yamanaka H, Yamaoka K1, Arai S, Toyoizumi S, DeMasi R, Fukuma Y, Hirose T, Sugiyama N, Zwillich SH, Tanaka Y: Mod Rheumatol 2019/9; 29 (5): 756-66. (ŽR‰ª–MG1: 1äPŒŽ•aEŠŽõ“à)

110169. [ŒŽ’˜] Identification of a novel arthritis-associated osteoclast precursor macrophage regulated by FoxM1. Hasegawa T, Kikuta J, Sudo T, Matsuura Y, Matsui T, Simmons S, Ebina K, Hirao M, Okuzaki D, Yoshida Y, Hirao A, Kalinichenko VV, Yamaoka K1, Takeuchi T, Ishii M: Nat Immunol 2019/12; 20 (12): 1631-43. (ŽR‰ª–MG1: 1äPŒŽ•aEŠŽõ“à)

110170. [ŒŽ’˜] Skeletal unloading reduces cluster of differentiation (CD) 38 expression in the bone marrow and osteoblasts of mice. Moridera K, Uchida S, Tanaka S, Menuki K, Utsunomiya H, Yamaoka K1, Sonomoto K, Tanaka Y, Sakai A: J Orthop Sci 2020/3; 25 (2): 331-7. (ŽR‰ª–MG1: 1äPŒŽ•aEŠŽõ“à)

110171. [ŒŽ’˜] Synergistic effect of IgG4 antibody and CTLs causes tissue inflammation in IgG4-related disease. Sasaki T, Yajima T, Shimaoka T, Ogawa S, Saito T, Yamaoka K1, Takeuchi T, Kubo M: Int Immunol 2020/3; 32 (3): 163-74. (ŽR‰ª–MG1: 1äPŒŽ•aEŠŽõ“à)

110172. [ŒŽ’˜] Latent left ventricular dysfunction in patients with pulmonary arterial hypertension associated with systemic sclerosis. Tanaka S1, Matsueda Y1, Kondo J1, Yamaoka K1: Kitasato Med J 2020/3; 50 (1): 1-6. (“c’†Z–Ÿ1, ŒŽ}@—C1, ‹ß“¡“Õˆê1, ŽR‰ª–MG1: 1äPŒŽ•a¥ŠŽõ“à)

310023. [Ç—á•ñ] Reversible cerebral vasoconstriction syndrome triggered by tacrolimus mimicked neuropsychiatric involvement in systemic lupus erythematosus. Inamo J, Kikuchi J, Suzuki K, Kaneko Y, Yasuoka H, Fujiwara H, Yamaoka K1, Takeuchi T: Mod Rheum Case Rep 2019/6; 3 (2): 119-23. (ŽR‰ª–MG1: 1äPŒŽ•aEŠŽõ“à)

320008. [Ç—á•ñ] Œo‰ß’†‚ɉ‹t«”]ŒŒŠÇ¹kÇŒóŒQ (RCVS) ‚ð‡•¹‚µŽ¡—Âɓïa‚µ‚œRMDA5R‘Ì—z«”畆‹Ø‰Š‚̈ê—á. ‘ºŒ@ 1, “Œ–ìr—m2, ’·’Jì–õ_1, ‹àŽR–F˜Y2, ‹ß“¡“Õˆê1, ŒŽ}@—C2, ²‹vŠÔ—TŽq2, H“¡—Y‘å, ¯ŽR—²s2, ˜a“c’B•F2, —LÀ—ǍK2, ‰iˆä—§•v2, “c’†Z–Ÿ2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2äPŒŽ•aEŠŽõ“à): ŠÖ“ŒƒŠƒEƒ}ƒ` 2019; 52: 68-72.

510006. [‘à] Tofacitinib for the treatment of rheumatoid arthritis: an update. Yamaoka K1: Expert Rev Clin Immunol 2019/6; 15 (6): 577-88. (ŽR‰ª–MG1: 1äPŒŽ•aEŠŽõ“à)

520008. [‘à] ‰ŠÇ‚ƖƉu‚̐§Œä—Ö@. ŽR‰ª–MG (äPŒŽ•aEŠŽõ“à): –k—¢ˆãŠw 2019/6; 49 (1): 1-7.

522036. [uÀ]y“ÁW: ŠÖßƒŠƒEƒ}ƒ`@Ž¡—Öò‚ðŽg‚¢‚±‚È‚· "ƒƒU" ‚Æ "’mŒb"zV‚œ‚É“oê‚µ‚œŠÖßƒŠƒEƒ}ƒ`Ž¡—Öò‚ðŽg‚¢‚±‚È‚·ŠšŠ@ERANKL‘jŠQ–ò. ŽR‰ª–MG (äPŒŽ•aEŠŽõ“à): –ò‹Ç 2019/4; 70 (5): 1155-60.

522037. [uÀ]y“ÁW: JAK‘jŠQ–ò‚ÌŠî‘b‚ƗՏ°zƒTƒCƒgƒJƒCƒ“ƒVƒOƒiƒ‹“`’B‚É‚š‚¯‚éJAK-STAT‚Ì–ðŠ„. ŽR‰ª–MG (äPŒŽ•aEŠŽõ“à): ƒŠƒEƒ}ƒ`‰È 2019/7; 62 (1): 1-5.

522038. [uÀ]y“ÁW: ŠÖßƒŠƒEƒ}ƒ`|u^‚ÌŠ°‰ðv‚ƁuˆÀ‘S«v‚ð–ÚŽw‚·Ž¡—Á|z[Ž¡—Ã: ŽÀ’nˆã‰Æ‚ª’m‚Á‚Ä‚š‚­‚ׂ«ŠÖßƒŠƒEƒ}ƒ`‚̍ŐVŽ¡—Ã]@JAK‘jŠQ–ò. ŽR‰ª–MG (äPŒŽ•aEŠŽõ“à): Medical Practice 2019/7; 36 (7): 1115-9.

540036. [‚»‚Ì‘Œ (Šw‰ïŽ˜^)]y‘æ61‰ñMBƒŠƒEƒ}ƒ`äPŒŽ•a§’k‰ïz‹Ù–ž«…áv‚ð’悵‚œDŽ_‹…«‘œ”­ŒŒŠÇ‰Š«“÷‰èŽîÇ‚Ì1—á. Ž³ŒË‰l—, ”Ñ‘ºKÆ, ‘q‰È~ˆê, ˆÀ‘º‹§O, “c’†’mŽ÷1, ¬–ìÃˆê, ‰Y–ì–[ŽO, —é–ؒ唎 (1äPŒŽ•aEŠŽõ“à): MBˆãŠwŽGŽ 2019/4; 67 (2): 141.

540037. [‚»‚Ì‘Œ (Šw‰ïŽ˜^)]y‘æ61‰ñMBƒŠƒEƒ}ƒ`äPŒŽ•a§’k‰ïzL”͈Íáu’É‚ðŽå‘i‚Æ‚µ‚ÄŽóf‚µ‚œŠO‘lÒ’Ŋ֐߉ŠŠ³ŽÒ‚ÌŽÀ‘Ô. ‰Y–ì–[ŽO, ¬–ìÃˆê, ”Ñ‘ºKÆ, ‘q‰È~ˆê, ˆÀ‘º‹§O, “c’†’mŽ÷1, —é–ؒ唎 (1äPŒŽ•aEŠŽõ“à): MBˆãŠwŽGŽ 2019/4; 67 (2): 1429.

540038. [‚»‚Ì‘Œ (Šw‰ïŽ˜^)]y_“ސ슎õÇˆãŠw‰ï‘æ86‰ñˆãŠw‰ïzASTŠˆ“®‚̃AƒEƒgƒJƒ€•]‰¿‚ɂ‚¢‚Ä. ˜a“c’B•F1,2, ¬Œ•q²2,3, “ñ–{–öL2,4, Ž“cr–ç2, ²X–ØŒ°Žq2, ‚é—R”üŽq2, [–xMŽq2, ‚ŽR—zŽq2,5 (1äPŒŽ•aEŠŽõ“à, 2ŠŽõŠÇ—Žº, 3–òÜ•”, 4—ÕŒŸ•”, 5V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): _“ސìˆãŠw‰ïŽGŽ 2020/1; 47 (1): 115.

’˜@‘]

620035. [Šwp‘ (•ª’SŽ·•M)]y1336ê–å‰Æ‚É‚æ‚é@Ž„‚ÌŽ¡—à [2019-2020”N“x”Å]z€11@äPŒŽ•aEƒAƒŒƒ‹ƒM[ŽŸŠ³@¬‡«Œ‹‡‘gD•a, p. 843-4. ŽR‰ª–MG (äPŒŽ•aEŠŽõ“à), ŠÄC: ‰Ž“c‹’j, –k‘º‘yˆê˜Y, “ú–{ˆãŽ–V•ñŽÐ, “Œ‹ž, 2019/7”­s.

620036. [Šwp‘ (•ª’SŽ·•M)]y‘Sg«ƒGƒŠƒeƒ}ƒg[ƒfƒXf—ÃKƒCƒhƒ‰ƒCƒ“2019z‘æ3Í _Œož_ƒ‹[ƒvƒX@CQ11 f’fEŽ¡—ÃŒø‰Ê”»’f‚É‚š‚¢‚Ä•K—v‚ÈŒŸž‚͉œ‚©?, p. 70-3. —LÀ—ǍK1, œA”šr¬1 (1äPŒŽ•aEŠŽõ“à), •Ò: Œú¶˜J“­‰ÈŠwŒ€‹†”ï•â•‹à“«ŽŸŠ³“™­ôŒ€‹†Ž–‹Æ Ž©ŒÈ–ƉuŽŸŠ³‚ÉŠÖ‚·‚é’²žŒ€‹† (Ž©ŒÈ–Ɖu”Ç), “ú–{ƒŠƒEƒ}ƒ`Šw‰ï, “ìŽR“°, “Œ‹ž, 2019/10”­s.

620037. [Šwp‘ (•ª’SŽ·•M)]y‘Sg«ƒGƒŠƒeƒ}ƒg[ƒfƒXf—ÃKƒCƒhƒ‰ƒCƒ“2019z‘æ3Í _Œož_ƒ‹[ƒvƒX@CQ12“KØ‚ÈŠ°‰ð“±“ü‚ÌŽ¡—Â͉œ‚©?, p. 74-8. —LÀ—ǍK1, ‘å‹v•Û’Œ‹I, ã–싧—f, Šâ“c@Ž A“c’†—ǍÆ, œA”šr¬1 (1äPŒŽ•aEŠŽõ“à), •Ò: Œú¶˜J“­‰ÈŠwŒ€‹†”ï•â•‹à“«ŽŸŠ³“™­ôŒ€‹†Ž–‹Æ Ž©ŒÈ–ƉuŽŸŠ³‚ÉŠÖ‚·‚é’²žŒ€‹† (Ž©ŒÈ–Ɖu”Ç), “ú–{ƒŠƒEƒ}ƒ`Šw‰ï, “ìŽR“°, “Œ‹ž, 2019/10”­s.

[Šw‰ïEŒ€‹†‰ï“™]

712006. [Šw‰ï (‘Û)] (µãٍu‰‰) JAK inhibitors for Rheumatoid Arthritis and more. Yamaoka K1: MET International Seminar (2020/1/16), Finland. (ŽR‰ª–MG1: 1äPŒŽ•aEŠŽõ“à)

713045. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Anti-Sm Antibody Directly Decreases Tight Junction Protein Composing Blood Brain Barrier on Brain Endothelial Cells by MMP-2 Activation. Arinuma Y1, Hirohata S1, Matsueda Y1, Yamaoka K1: 21st The Asia Pacific League of Associations for Rheumatology 2019 (APLAR2019) (2019/4/8-11), Brisbane Australia. (—LÀ—ǍK1, œA”šr¬1, ŒŽ}@—C1, ŽR‰ª–MG1: 1äPŒŽ•aEŠŽõ“à)

713046. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Safety and efficacy of filgotinib in Japanese patients enrolled in a global phase 3 trial of patients with active rheumatoid arthritis and inadequate response or tolerance to biologic DMARDs. Takeuchi T, Matsubara T, Atsumi T, Amano K, Ishiguro N, Sugiyama E, Yamaoka K1, Genovese MC, Kalunian K, Walker D, Gottenberg J-E, de Vlam K, Mozaffarian N, Bartok B, Matzkies F, Gao J, Guo Y, Tasset C, Sundy J, Tanaka Y: EULAR Congress 2019-The European League Against Rheumatism (2019/6/12-15), Madrid, Spain. (ŽR‰ª–MG1: 1äPŒŽ•aEŠŽõ“à)

713047. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Interkeukin-6 Level in Cerebrospinal Fluid as a Biomarker for Systemic Lupus Erythematosus Patients with Longitudinally Extensive Transverse Myelitis like Neuromyelitis Optica Spectrum Disease. Hasegawa Y1, Arinuma Y2, Yamaoka K2: The 8th East Asian Group of Rheumatology (EAGOR 2019) (2019/9/6-7), Seoul, Korea. (’·’Jì–õ_1, —LÀ—ǍK2, ŽR‰ª–MG2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2äPŒŽ•aEŠŽõ“à)

713048. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) The Effects of Anti-glutamate Receptor Subunit Antiantibodies on Systemic Lupus Erythematosus Without Neuropsychiatric Involvement. Arinuma Y1, Hasegawa Y2, Muramatsu T2, Matsueda Y1, Yamaoka K1: 2019 ACR/ARP Annual Meeting (2019/11/8-13), Atlanta, GA, USA. (—LÀ—ǍK1, ’·’Jì–õ_2, ‘ºŒ@ 2, ŒŽ}@—C1, ŽR‰ª–MG1: 1äPŒŽ•aEŠŽõ“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

713049. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) The Safety Profile of Upadacitinib in Japanese Patients with Rheumatoid Arthritis. Yamaoka K1, Tanaka Y, Kameda H, Hendrickson B, Meerwein S, Zhang Y, Takeuchi T: 2019 ACR/ARP Annual Meeting (2019/11/8-13), Atlanta, GA, USA. (ŽR‰ª–MG1: 1äPŒŽ•aEŠŽõ“à)

722054. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ‹­”çÇ-3: ‹­”çÇ‚ɍ‡•¹‚·‚é‹«ŠEŒ^”x‚ŒŒˆ³‚Ì’·Šú—\Œã‚ÌŒŸ“¢. “c’†Z–Ÿ1, ŒŽ}@—C1, ‰iˆä—§•v1, ŽR‰ª–MG1 (1äPŒŽ•aEŠŽõ“à): ‘æ63‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï (2019/4/15), ‹ž“s.

722055. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)JAK‘jŠQ–ò‚Ì“oê‚É‚æ‚鍡Œã‚̊֐߃ŠƒEƒ}ƒ`Ž¡—Ã: JAK‘jŠQ–òŽs”ÌŒã‘S—á’²ž‚ƍ¡Œã‚ÌŽÀ—Տ° (tapering‚ðŠÜ‚ß‚Ä). ŽR‰ª–MG (äPŒŽ•aEŠŽõ“à): ‘æ63‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï (2019/4/16), ‹ž“s.

722056. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒƒRƒ‚ƒeƒBƒuƒVƒ“ƒhƒ[ƒ€‚Ì—\–h (g‘Ì‚Æ–œ‚ðŽx‚Š‚é‰^“®ŠíŒn‚̘AŠÂƒVƒXƒeƒ€‚©‚ç‚̃Aƒvƒ[ƒ`): ŠÖß‰Š•a‘Ԃ̐§Œä‹@\. ŽR‰ª–MG (äPŒŽ•aEŠŽõ“à): ‘æ92‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2019/5/12), ‰¡•l.

722057. [Šw‰ï (‘S‘)] (‹³ˆçu‰‰) ‹³ˆçu‰‰1. ŽR‰ª–MG (äPŒŽ•aEŠŽõ“à): ‘æ40‰ñ“ú–{‰ŠÇ¥Ä¶ˆãŠw‰ï (2019/7/16), _ŒË.

722058. [Šw‰ï (‘S‘)] (‹³ˆçu‰‰) ‹³ˆçu‰‰3. ŽR‰ª–MG: ‘æ6‰ñJCRƒx[ƒVƒbƒNƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2019/10/26), “Œ‹ž.

722059. [Šw‰ï (‘S‘)] (‹³ˆçu‰‰) –ƉuŽŸŠ³‚É‚š‚¯‚镪Žq•W“I—Ö@|JAK‘jŠQ–ò‚𒆐S‚Ɂ|. ŽR‰ª–MG (äPŒŽ•aEŠŽõ“à): ‘æ40‰ñ“ú–{—Տ°–ò—Šw‰ïŠwp‘‰ï (2019/12/5), “Œ‹ž, —Տ°–ò— 2019; 50 (suppl): S120.

723204. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠÖßƒŠƒEƒ}ƒ`‚É‚š‚¯‚éIL-6‘jŠQ‚Ì—L—p«. ŽR‰ª–MG (äPŒŽ•aEŠŽõ“à): ‘æ63‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï (2019/4/15-17), ‹ž“s.

723205. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠÖßƒŠƒEƒ}ƒ`Ž¡—Â̂±‚ê‚Ü‚Å‚Æ‚±‚ê‚©‚ç. ŽR‰ª–MG (äPŒŽ•aEŠŽõ“à): ‘æ63‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï (2019/4/15-17), ‹ž“s.

723206. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) JAK‘jŠQÜ‚ÌŠî‘b‚ƗՏ°. ŽR‰ª–MG (äPŒŽ•aEŠŽõ“à): ‘æ63‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï (2019/4/15-17), ‹ž“s.

723207. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠÖßÇó‚ð—L‚·‚éƒx[ƒ`ƒFƒbƒg•aŠ³ŽÒ‚̗Տ°“Á’¥. “Œ–ìr—m1, œA”šr¬1, ‹e’nO•q, ‘ò“c“NŽ¡, Šx–ìŒõ—m, ‰iŸº—TŽq, ‹Ë–ì—m•œ, ‹{ìˆê•œ, “c’†—ǍÆ, ŽR‰ª–MG1 (1äPŒŽ•aEŠŽõ“à): ‘æ63‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï (2019/4/15-17), ‹ž“s.

723208. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰È‚É‚š‚¯‚éDŽ_‹…«‘œ”­ŒŒŠÇ‰Š«“÷‰èŽîÇ‚̗Տ°‘œ‚ÌŒŸ“¢. ‘ºŒ@ 1, ˆÉ–ì˜a”n2, ’·’Jì–õ_1, ‹ß“¡“Õˆê1, ŒŽ}@—C2, ¯ŽR—²s2, “Œ–ìr—m2, —LÀ—ǍK2, ˜a“c’B•F2, ‰iˆä—§•v, “c’†Z–Ÿ2, ŽR‰ª–MG2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2äPŒŽ•aEŠŽõ“à): ‘æ63‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï (2019/4/15-17), ‹ž“s.

723209. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰È‚ł̍RMDA5R‘Ì—z«”畆‹Ø‰ŠŠ³ŽÒ‚̗Տ°‘œ‚ÌŒŸ“¢. ˆÉ–ì˜a”n1, ¯ŽR—²s1, ‘ºŒ@ 2, ’·’Jì–õ_2, ‹ß“¡“Õˆê2, “Œ–ìr—m1, —LÀ—ǍK1, ‰iˆä—§•v, “c’†Z–Ÿ1, ŽR‰ª–MG1 (1äPŒŽ•aEŠŽõ“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ63‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï (2019/4/15-17), ‹ž“s.

723210. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–Ž{Ý‚É‚š‚¯‚é‘Sg«ƒGƒŠƒeƒ}ƒg[ƒfƒX (SLE) ‚ɑ΂·‚éƒqƒhƒƒLƒVƒNƒƒƒLƒ“ (HCQ) ‚ÌŽ¡—ÂƌŸ“¢. ‹ß“¡“Õˆê1, ŒŽ}@—C2, ˆÉ–ì˜a”n2, ’·’Jì–õ_1, ‘ºŒ@ 1, ¯ŽR—²s2, “Œ–ìr—m2, —LÀ—ǍK2, ˜a“c’B•F2, ‰iˆä—§•v, “c’†Z–Ÿ2, ŽR‰ª–MG2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2äPŒŽ•aEŠŽõ“à): ‘æ63‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï (2019/4/15-17), ‹ž“s.

723211. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) RSmR‘̂ƍRRNPR‘Ì‚É‚æ‚é’P‹…‚̉ŠÇ«ƒTƒCƒgƒJƒCƒ“ŽY¶‚ɑ΂·‚é‘Šæ“I‘‹­Œø‰Ê‚ÌŒŸ“¢. ŒŽ}@—C1, —LÀ—ǍK1, ‰iˆä—§•v, “c’†Z–Ÿ1, œA”šr¬1, ŽR‰ª–MG1 (1äPŒŽ•aEŠŽõ“à): ‘æ63‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï (2019/4/15-17), ‹ž“s.

723212. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) SLE (Šî‘b) ”]ŒŒŠÇ“à”ç×–E‚É‚š‚¯‚éMMP-2”­Œ»ãž‚Æclaudin-5Œž­‚ɑ΂·‚éRSmR‘Ì‚Ì’ŒÚì—p. —LÀ—ǍK1, ŽR‰ª–MG1 (1äPŒŽ•aEŠŽõ“à): ‘æ63‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï (2019/4/15-17), ‹ž“s.

723213. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹­”çÇ-3 ‹­”çÇ‚ɍ‡•¹‚·‚é‹«ŠEŒ^”x‚ŒŒˆ³‚Ì’·Šú—\Œã‚ÌŒŸ“¢. “c’†Z–Ÿ1, ŒŽ}@—C1, ‰iˆä—§•v, ŽR‰ª–MG1 (1äPŒŽ•aEŠŽõ“à): ‘æ63‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï (2019/4/15-17), ‹ž“s.

723214. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) SLE (—Տ°) -1 ƒ}ƒNƒƒtƒ@[ƒWŠˆ«‰»ÇŒóŒQ‚ð’悵‚œ‘Sg«ƒGƒŠƒeƒ}ƒg[ƒfƒX‚̗Տ°“I“Á’¥‚ÌŒŸ“¢. ’·’Jì–õ_1, —LÀ—ǍK2, ˆÉ–ì˜a”n2, ‹ß“¡“Õˆê1, ‘ºŒ@ 1, ŒŽ}@—C2, ¯ŽR—²s2, “Œ–ìr—m2, ˜a“c’B•F2, ‰iˆä—§•v, “c’†Z–Ÿ2, ŽR‰ª–MG2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2äPŒŽ•aEŠŽõ“à): ‘æ63‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï (2019/4/15-17), ‹ž“s.

723215. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) JAK‘jŠQÜ (RCT) ]—ˆŒ^‡¬DMARD‚ÅŒø‰Ê•s\•ª‚È“ú–{lŠˆ“®«ŠÖßƒŠƒEƒ}ƒ`Š³ŽÒ‚ð‘ΏۂƂµ‚œ‘I‘ð“IJAK-1‘jŠQ–òƒEƒpƒ_ƒVƒ`ƒjƒu‚Ì‘æ2b/3‘Š–³ìˆ×‰»ƒvƒ‰ƒZƒ{‘ΏƓñd–ÓŒŸŽŽŒ±‚É‚š‚¯‚é’·Šú“Š—^Žž‚Ì—LŒø«‹y‚шÀ‘S«¬Ñ. ‹T“cGl, ’|“à@‹Î, ŽR‰ª–MG1, D•”Œ³œA, ì–ì[O, Zhou Yijie, Othman Ahmed A, Pangan Aileen L, ó•”Lˆê, –k‘º@§, Meerwein Sebastian, “c’†—ÇÆ (1äPŒŽ•aEŠŽõ“à): ‘æ63‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï (2019/4/15-17), ‹ž“s.

723216. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒŠƒEƒ}ƒ`«ŽŸŠ³‚̃KƒCƒhƒ‰ƒCƒ“ ƒx[ƒ`ƒFƒbƒg•af—ÃKƒCƒhƒ‰ƒCƒ“. Šx–ìŒõ—m, œA”šr¬1, ‹e’nO•q, ŒK–Œ³—², âV“¡˜a‹`, “c’†—ǍÆ, ‰iŸº—TŽq, ‘ò“c“NŽ¡, “Œ–ìr—m1, ‹Ë–ì—m•œ, ‹gŒ©—³‰î, “y‹Ž_Í, ŽRŒûŒ«ˆê, ‹àŽq‰À‘ãŽq, ˆÉ“¡Gˆê, ’|“à³Ž÷, Îƒ–’Ø—Ç–Ÿ, …–ؐM‹v, Œú¶˜J“­Èƒx[ƒ`ƒFƒbƒg•a‚ÉŠÖ‚·‚é’²žŒ€‹†”Ç (1äPŒŽ•aEŠŽõ“à): ‘æ63‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï (2019/4/15-17), ‹ž“s.

723217. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠÖßƒŠƒEƒ}ƒ`Ž¡—Âɂš‚¯‚鍜‘e頏ǎ¡—Â̎ÀÛ. ŽR‰ª–MG (äPŒŽ•aEŠŽõ“à): ‘æ47‰ñ“ú–{—Տ°–ƉuŠw‰ï‘‰ï (2019/10/17-19), ŽD–y.

723218. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘Sg«ƒGƒŠƒeƒ}ƒg[ƒfƒX‚É‚š‚¯‚éRNMDAŽó—e‘̃Tƒuƒ†ƒjƒbƒgGluN2R‘̂̐_Œož_ƒ‹[ƒvƒXˆÈŠO‚ÌŽŸŠ³Šˆ“®«‚É—^‚Š‚é‰e‹¿. —LÀ—ǍK1, ’·’Jì–õ_2, ‘ºŒ@ 2, ŒŽ}@—C1, ŽR‰ª–MG1 (1äPŒŽ•aEŠŽõ“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ47‰ñ“ú–{—Տ°–ƉuŠw‰ï‘‰ï (2019/10/17-19), ŽD–y.

723219. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘Sg«ƒGƒŠƒeƒ}ƒg[ƒfƒX‚É‚š‚¯‚éƒxƒŠƒ€ƒ}ƒu‚̃qƒhƒƒLƒVƒNƒƒƒLƒ“‚Æ‚Ì•¹—p‚š‚æ‚Ñ’PÜ—Ö@‚ÌŽ¡—ÃŒø‰Ê. ’·’Jì–õ_1, —LÀ—ǍK2, ‘ºŒ@ 1, ‹ß“¡“Õˆê1, ŒŽ}@—C2, ŽR‰ª–MG2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2äPŒŽ•aEŠŽõ“à): ‘æ47‰ñ“ú–{—Տ°–ƉuŠw‰ï‘‰ï (2019/10/17-19), ŽD–y.

723220. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •a—Šw“IŒŸ“¢‚ª‰Â”\‚Å‚ ‚Á‚œ¬’°úE‚ð‚«‚œ‚µ‚œIgG4ŠÖ˜AŽŸŠ³‚̈ê—á. ˆÉ–ì˜a”n1, —LÀ—ǍK1, ‰ºŽèŒö‰î1, i“¡—¹1, ‹àŽR–F˜Y1, ‘ºŒ@ 2, ’·’Jì–õ_2, “c’†’mŽ÷1, ¯ŽR—²s1, “Œ–ìr—m1, ˜a“c’B•F1, “c’†Z–Ÿ1, ŽR‰ª–MG1 (1äPŒŽ•aEŠŽõ“à, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ47‰ñ“ú–{—Տ°–ƉuŠw‰ï‘‰ï (2019/10/17-19), ŽD–y.

723221. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠÖßƒŠƒEƒ}ƒ`Š³ŽÒ‚É‚š‚¯‚éƒAƒ_ƒŠƒ€ƒ}ƒu‚ƃgƒVƒŠƒYƒ}ƒu‚ª‘яóáv]”­Ç‚É—^‚Š‚é‰e‹¿. ‘ºŒ@ 1, —LÀ—ǍK2, ’·’Jì–õ_1, ŽR‰ª–MG2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2äPŒŽ•aEŠŽõ“à): ‘æ34‰ñ“ú–{—Տ°ƒŠƒEƒ}ƒ`Šw‰ï (2019/11/30), –ŒŒÃ‰®.

732018. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (‹³ˆçu‰‰) ŠÖßƒŠƒEƒ}ƒ`Ž¡—Â̍ŐVŽ–î. ŽR‰ª–MG (äPŒŽ•aEŠŽõ“à): “ú–{“à‰ÈŠw‰ï‘æ61‰ñ–kŠC“¹Žx•”¶ŠU‹³ˆçu‰‰‰ï (2019/7/7), ŽD–y.

733092. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) RMDA5R‘̂ƍRARSR‘Ì‚ª‹€—z«‚Å‚ ‚Á‚œ–³‹ØÇ«”畆‹Ø‰Š‚Ì1—á. i“¡—¹1, “Œ–ìr—m1, ‰ºŽèŒö‰î1, ˆÉ–ì˜a”n1, ‹àŽR–F˜Y1, “c’†’mŽ÷1, ¯ŽR—²s1, —LÀ—ǍK1, “c’†Z–Ÿ1, ŽR‰ª–MG1 (1äPŒŽ•aEŠŽõ“à): ‘æ30‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ïŠÖ“ŒŽx•”ŠwpW‰ï (2019/12/7), “Œ‹ž.

733093. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) SLE‚̉Á—Ã’†‚É—Œ‰ºŽˆŠŽŠoˆÙí‚ð’æ‚·‚éNMOSD‚𕹔­‚µ‚œˆê—á. ‘å’ë—I‹M1, àV@’ŒŽ÷, “n糁@x, Œ¢ˆäŒ[‘Ÿ, ˆäŒF‘å•ã, …–ì—TŠî, •œŒ—¢‰ÀŽq, ŽR“à^”V, z–K•”’B–ç, Œì”ü•ä, —LÀ—ǍK2, ™–{@ò, ãâ‹`˜a, ŽR‰ª–MG2, “ûŒŽ‘P•¶ (1ŒÕ‚Ì–å•a‰@•ª‰@ƒŠƒEƒ}ƒ`äPŒŽ•a‰È, 2äPŒŽ•aEŠŽõ“à): ‘æ30‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ïŠÖ“ŒŽx•”ŠwpW‰ï (2019/12/7), “Œ‹ž.

'18”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'18-510001. [‘à] Janus kinases to jakinibs: from basic insights to clinical practice. Gadina M, Le MT, Schwartz DM, Silvennoinen O, Nakayamada S, Yamaoka K1, O'Shea JJ: Rheumatology (Oxford) 2019/2; 58 (Suppl 1): i4-i16. (ŽR‰ª–MG1: 1äPŒŽ•aEŠŽõ“à)

'18-522006. [uÀ]y“ÁW: Ž©ŒÈ–ƉuŽŸŠ³‚̌•ʉ»ˆã—Áz3. ŠÖßƒŠƒEƒ}ƒ`‚̌•ʉ»ˆã—Ã. ŽR‰ª–MG (äPŒŽ•aEŠŽõ“à): Precision Medicine 2018/12; 2 (1): 19-21.

[’˜@‘]

'18-620006. [Šwp‘ (•ª’SŽ·•M)yV–ò“W–]2019 (ˆã–òƒWƒƒ[ƒiƒ‹55Šª‘Š§†)z‘æIII•” Ž¡—Âɂš‚¯‚éÅ‹ß‚̐V–ò‚̈ʒu‚¯@<–òŒø•Ê> V–ò‚̍Lê@RƒŠƒEƒ}ƒ`–ò, p. 361-4. ŽR‰ª–MG (äPŒŽ•aEŠŽõ“à), ˆã–òƒWƒƒ[ƒiŽÐ. ‘åã, 2019/1”­s.

'18-620007. [Šwp‘ (•ª’SŽ·•M)]y¡“ú‚ÌŽ¡—ÃŽwj@Ž„‚Í‚±‚€Ž¡—µ‚Ä‚¢‚é@2019”N”Łz14DäPŒŽ•a‚š‚æ‚Ñ—Þ‰ŽŸŠ³@RƒŠƒEƒ}ƒ`–òE¶•šŠw“I»Ü‚Ì•›ì—p‚Ƒ΍ô, p. 858-9. ŽR‰ª–MG (äPŒŽ•aEŠŽõ), ‘•ÒW: •ŸˆäŽŸ–î, ‚–؁@œ, ¬Žºˆê¬, ˆãŠw‘‰@, “Œ‹ž, 2019/1”­s.

[Šw‰ïEŒ€‹†‰ï“™]

'18-713006. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Interkeukin-6 Level in Cerebrospinal Fluid As a Biomarker for Systemic Lupus Erythematosus Patients with Longitudinally Extensive Transverse Myelitis like Neuromyelitis Optica Spectrum Disease. Hasegawa Y1, Arinuma Y2, Ino K2, Muramatsu T1, Kondo J1, Matsueda Y2, Hoshiyama T2, Tono T2, Wada T2, Nagai T2, Tanaka S2, Yamaoka K2: 2018 ACR/ARHP Annual Meeting (2018/10/21), Chicago, USA. (’·’Jì–õ_1, —LÀ—ǍK2, ˆÉ–ì˜a”n2, ‘ºŒ@ 1, ‹ß“¡“Õˆê1, ŒŽ}@—C2, ¯ŽR—²s2, “Œ–ìr—m2, ˜a“c’B•F2, ‰iˆä—§•v2, “c’†Z–Ÿ2, ŽR‰ª–MG2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2äPŒŽ•aEŠŽõ“à)


“û‘BEbó‘BŠO‰ÈŠw

[Šwp˜_•¶]

110173. [ŒŽ’˜] Differential Prognostic Relevance of Promoter DNA Methylation of CDO1 and HOPX in Primary Breast Cancer. Tanaka Y1, Kosaka Y2, Waraya M2, Yokota K1, Harada H1, Kaida T1, Kikuchi M2, Minatani N, Nishimiya H2, Katoh H2, Sengoku N2, Watanabe M3, Yamashita K4,5: Anticancer Res 2019/5; 39 (5): 2289-98. (“c’†—uŽq1, ¬â–ùŒ«2, ˜m’J”ü“Þ2, ‰¡“c˜aŽq1, ŒŽ“cG‹P1, b”ã“c•Žu1, ‹e’r^—Žq2, Œ‹{—mŽj2, ‰Á“¡@O2, åÎ‹I•F2, “n粏¹•F3, ŽR‰ºŒpŽj4,5: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2“û‘BEbó‘BŠO, 3–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 5ã•”Á‰»ŠÇŠO)

110174. [ŒŽ’˜] Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101. Narui K, Ishikawa T, Shimizu D, Yamada A, Tanabe M, Sasaki T, Oba MS, Morita S, Nawata S, Kida K, Mogaki M, Doi T, Tsugawa K, Ogata H, Ota T, Kosaka Y1, Sengoku N1, Kuranami M, Niikura N, Saito Y, Suzuki Y, Suto A, Arioka H, Chishima T, Ichikawa Y, Endo I, Tokuda Y: Breast 2019/10; 47: 1-9. (¬â–ùŒ«1, åÎ‹I•F1: 1“û‘BEbó‘BŠO)

110175. [ŒŽ’˜] Epigenetic silencing of HOPX is critically involved in aggressive phenotypes and patient prognosis in papillary thyroid cancer. Ooizumi Y1, Katoh H2, Yokota M1, Watanabe M3, Yamashita K4,5: Oncotarget 2019/10; 10 (57): 5906-18. (‘åò—z‰î1, ‰Á“¡@O2, ‰¡“cŒõ‰›1, “n粏¹•F3, ŽR‰ºŒpŽj4,5: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2“û‘BEbó‘BŠO, 3–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 5ã•”Á‰»ŠÇŠO)

110176. [ŒŽ’˜] Analysis of the selection of CDK4/6 inhibitors based on experience using palbociclib. Kikuchi M1, Tanaka Y2, Yokota M2, Nishimiya H1, Katoh H1, Sengoku N1, Kosaka Y1: Biomed Rep 2019/12; 11 (6): 253-6. (‹e’r^—Žq1, “c’†—uŽq2, ‰¡“cŒõ‰›2, Œ‹{—mŽj1, ‰Á“¡@O1, åÎ‹I•F1, ¬â–ùŒ«1: 1“û‘BEbó‘BŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

110177. [ŒŽ’˜] Lymphocyte-Monocyte Ratio Significantly Predicts Recurrence in Papillary Thyroid Cancer. Yokota M1, Katoh H2, Nishimiya H2, Kikuchi M2, Kosaka Y2, Sengoku N2, Watanabe M3, Yamashita K4: J Surg Res 2020/2; 246: 535-43. (‰¡“cŒõ‰›1, ‰Á“¡@O2, Œ‹{—mŽj2, ‹e’r^—Žq2, ¬â–ùŒ«2, åÎ‹I•F2, “n粏¹•F3, ŽR‰ºŒpŽj4: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2“û‘BEbó‘BŠO, 3–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

110178. [ŒŽ’˜] BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study. Kosaka Y1, Yamamoto Y, Tanino H, Nishimiya H1, Yamamoto-Ibusuki M, Hirota Y, Iwase H, Nakamura S, Akashi-Tanaka S: Diagnostics (Basel) 2020/2; 10 (2): 119. (¬â–ùŒ«1, Œ‹{—mŽj1: 1“û‘BEbó‘BŠO)

320009. [Ç—á•ñ] ‘Sg—Ö@‚Ì‚Ý‚ÅClinical Complete Response‚ðŽ‘±‚µ‚Ä‚¢‚é“ûŠà‚Ì1—á. ŽR–{Œöˆê, —с@‹žŽq1, ˜m’J”ü“Þ1, ‰HœAŒ’m, ×’J@’q, ¬â–ùŒ«1, åÎ‹I•F1, ‘ì˜ad2, Œ¢Ž”@‰~3, “n粏¹•F4 (1“û‘BEbó‘BŠO, 2•úŽËü (Žîá‡), 3•a—, 4–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): Šà‚Ɖ»Šw—Ö@ 2019/4; 46 (4): 757-9.

511004. [‰ðà]yEditorial CommentaryzHistorical progress of the 8th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual in patients with breast cancer. Kosaka Y1, Nishimiaya H1, Kikuchi M1, Waraya M1, Katoh H1, Sengoku N1: Transl Cancer Res 2019/6; 8 (3): 719-21. (¬â–ùŒ«1, Œ‹{—mŽj1, ‹e’r^—Žq1, ˜m’J”ü“Þ1, ‰Á“¡@O1, åÎ‹I•F1: 1“û‘BEbó‘BŠO)

[Šw‰ïEŒ€‹†‰ï“™]

723222. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’Ž‰¹”gƒKƒCƒh‰º‹zˆøŽ®‘gD¶ŒŸ (VAB) ‚É‚š‚¯‚郊ƒ“ƒpŠÇNPŠŒ©‚ƃZƒ“ƒ`ƒlƒ‹ƒŠƒ“ƒpß¶ŒŸŒ‹‰Ê‚ÉŠÖ‚·‚錟“¢. “c’†—uŽq1, ¬â–ùŒ«2, “¡–쎍D, ‰¡“cŒõ‰›1, ‹e’r^—Žq2, Œ‹{—mŽj2, ’†‹{‹IŽq, ‰Á“¡@O2, åÎ‹I•F2, ¬–ì“c“o, åU•À@Ÿ, “n粏¹•F3 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2“û‘BEbó‘BŠO, 3–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ119‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/4/18), ‘åã.

723223. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) p‘O‰»Šw—Ö@‚ðŽ{s‚µ‚œHER2—z«“ûŠà‚ÌŽ¡—ЬÑ. æс@—T—º1, ¬â–ùŒ«1, ‰¡“cŒõ‰›2, “c’†—uŽq2, ‹e’r^—Žq1, Œ‹{—mŽj1, ‰Á“¡@O1, Š“cç”ü”T3, åÎ‹I•F1, “n粏¹•F4 (1“û‘BEbó‘BŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3•a—, 4–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ119‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/4/19), ‘åã.

723224. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “­‚«•û‰üŠv‚Ì•K—v«‚Æ–â‘è“_. Œ‹{—mŽj1, ‰ª–{Œõ‹FŽq2, “c’†—uŽq3, ‹e’r^—Žq1, ‰Á“¡@O1, ¬â–ùŒ«1, åÎ‹I•F1, “n粏¹•F4 (1“û‘BEbó‘BŠO, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 4–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ119‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/4/19), ‘åã.

723225. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “ú–{‚É‚š‚¯‚éV‹K“û‚ª‚ñŽ¡—Öò‚ÌŠJ”­@ƒgƒŠƒvƒ‹ƒlƒKƒeƒBƒu“ûŠàŽ¡—ẪRƒ“ƒpƒjƒIƒ“f’f–òŠJ”­‚ƃJƒ‹ƒ{ƒvƒ‰ƒ`ƒ“‚̍Ĕ­—}§Œø‰Ê‚Ì‘æ3‘Š—Տ°ŽŽŒ±. ’J–ì—Tˆê1, —é–ؐ³l1, ŠC£”ŽŽj1, ‹{‰º@Ÿ1, ç“‡—²Ži1, —с@ŒõO1, ŽODN—Y1, “ñ‘º@Šw1, ‘å’J²ˆê˜Y1, ‰i‹Ž¹K1, ‘Ÿ“c’q•F1, ¬â–ùŒ«1,2, Îì@F1, ’·’Jì‘PŽ}1, ŒE“c’qs1, ŽOŠK‹MŽj1,2, Šâ’Jˆû¶1, ŽR“cŒ°Œõ1, ÔàVG•œ1, ‰Í–ì”Í’j1 (1JONIEƒOƒ‹[ƒv, 2“û‘BEbó‘BŠO): ‘æ27‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï (2019/7/11), “Œ‹ž.

723226. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –ñ20”NŒã‚ɉ·‘¶“û–[“àÄ”­‚µ‚œ“ûŠà‚̃Zƒ“ƒ`ƒlƒ‹ƒŠƒ“ƒpß‚ª‘Α€ãüâ|‚É“¯’肳‚ê‚œÄ”­“ûŠà‚Ì1—á. ’†ŒF‘žŽm, ‚‹Ž“Þ, ã–쑏ˆê˜Y, ˆî“cG—m, ‹ß“¡NŽj1, ¬â–ùŒ«1, åÎ‹I•F1 (1“û‘BEbó‘BŠO): ‘æ27‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï (2019/7/11), “Œ‹ž.

723227. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒpƒ‹ƒ{ƒVƒNƒŠƒuŽg—pŒoŒ±‚É‚æ‚éCDK4/6‘jŠQ–ò‚Ì‘I‘ð‚ÉŠÖ‚·‚錟“¢. ‹e’r^—Žq1, ¬â–ùŒ«1, ‰¡“cŒõ‰›2, “c’†—uŽq2, Œ‹{—mŽj1, ‰Á“¡@O1, åÎ‹I•F1 (1“û‘BEbó‘BŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ27‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï (2019/7/11), “Œ‹ž.

723228. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚š‚¯‚édose-dense EC—Ö@‚ÌŽg—p¬Ñ‚Æ”E—e«‚ɂ‚¢‚Ä‚ÌŒŸ“¢. Œ‹{—mŽj1, ¬â–ùŒ«1, ‰¡“cŒõ‰›2, “c’†—uŽq2, ‹e’r^—Žq1, ‰Á“¡@O1, åÎ‹I•F1 (1“û‘BEbó‘BŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ27‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï (2019/7/11), “Œ‹ž.

723229. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚š‚¯‚éBRACAnalysis‚̐f’f‚ÆŽ{sÇ—á‚ÉŠÖ‚·‚錟“¢. ˜m’J”ü“Þ1, ¬â–ùŒ«1, “c’†—uŽq2, ‹e’r^—Žq1, Œ‹{—mŽj1, ‰Á“¡@O1, —с@‹žŽq1, åÎ‹I•F1, ‚“cŽj’j2 (1“û‘BEbó‘BŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ27‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï (2019/7/12), “Œ‹ž.

723230. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •s–@‘؍ݒ†‚Ì“ûŠàŠ³ŽÒŽ¡—Âɂš‚¯‚é–â‘è“_. åÎ‹I•F1, “c’†—uŽq2, ‹e’r^—Žq1, Œ‹{—mŽj1, X“c—zŽ}3, £ŒË–qŽq3, ¬â–ùŒ«1 (1“û‘BEbó‘BŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ŠÅŒì•”): ‘æ27‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï (2019/7/13), “Œ‹ž.

723231. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚š‚¯‚éisÄ”­“ûŠà‚ɑ΂·‚éEribulin“Š—^‚Ì—LŒø«EˆÀ‘S«‚ɂ‚¢‚Ä. ¬â–ùŒ«1, “c’†—uŽq2, ‰¡“cŒõ‰›2, ‹e’r^—Žq1, Œ‹{—mŽj1, ‰Á“¡@O1, åÎ‹I•F1, “n粏¹•F3 (1“û‘BEbó‘BŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ27‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï (2019/7/13), “Œ‹ž.

723232. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “ûŠà‚É‚š‚¯‚éŠà/ž‘ƒRŒŽ‚̈â“`Žq”­Œ»‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‹ß“¡NŽj1,2, •ŸŽR@—², ŽR‘º—Úˆß, “ñ“nM], Žž”C’‘1,3, ’†”nŠî”Ž1,4, ç–ìTˆê˜Y3, ’†‘º˜a“¿1,5, ‹v•Û”CŽj5, ’r‰i@œ1,2, ¬—ÑŒ›’‰1, ŽRè@“™1,6, ‚‹Ž’õl1,5, Œ@”ªŽk1, “n粏¹•F7 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2“û‘BEbó‘BŠO, 3‰º•”Á‰»ŠÇŠO, 4ã•”Á‰»ŠÇŠO, 5ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 6•a—, 7–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ27‰ñ“ú–{“ûŠàŠw‰ïŠwp‘‰ï (2019/7/13), “Œ‹ž.

723233. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹@”\«Œ‹ß‚ª“û“ªŠà‚Å‚ ‚Á‚œMarine-LenhartÇŒóŒQ‚Ì1—á. ‰¡“cŒõ‰›1, ‰Á“¡@O2, Œ‹{—mŽj2, ‹e’r^—Žq2, ¬â–ùŒ«2, åÎ‹I•F2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2“û‘BEbó‘BŠO): ‘æ52‰ñ“ú–{“à•ª”åŠO‰ÈŠw‰ïŠwp‘å‰ï (2019/10/17), “Œ‹ž.

723234. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) FECŽ{s“ûŠàŠ³ŽÒ‚É‚š‚¯‚鎝‘±Œ^G-CSF“Š—^“±“ü‚É‚æ‚éˆÀ‘S«‚ÌŒŸ“¢. “à“¡‰Â“ÞŽq1, Œ‹{—mŽj2, ‹e’r^—Žq2, ¬â–ùŒ«2, ‰Á“¡@O2, åÎ‹I•F2 (1‰º•”Á‰»ŠÇŠO, 2“û‘BEbó‘BŠO): ‘æ81‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2019/11/16), ‚’m.


ˆê”ʁE¬Ž™EŠÌ’_äXŠO‰ÈŠw

[Šwp˜_•¶]

110179. [ŒŽ’˜] Validation of index-based IWATE criteria as an improved difficulty scoring system for laparoscopic liver resection. Tanaka S, Kawaguchi Y, Kubo S, Kanazawa A, Takeda Y, Hirokawa F, Nitta H, Nakajima T, Kaizu T1, Kaibori M, Kojima T, Otsuka Y, Fuks D, Hasegawa K, Kokudo N, Kaneko H, Gayet B, Wakabayashi G: Surgery 2019/4; 165 (4): 731-40. (ŠC’ËMŽj1: 1ˆê”ʁE¬Ž™EŠÌ’_äXŠO)

110180. [ŒŽ’˜] Diagnostic potential of hypermethylation of the cysteine dioxygenase 1 gene (CDO1) promoter DNA in pancreatic cancer. Nishizawa N1, Harada H2, Kumamoto Y1, Kaizu T1, Katoh H3, Tajima H1, Ushiku H2, Yokoi K2, Igarashi K, Fujiyama Y4, Okuwaki K5, Iwai T5, Watanabe M6, Yamashita K2,7: Cancer Sci 2019/9; 110 (9): 2846-55. (ŒàVL‹±1, ŒŽ“cG‹P2, ŒGŒ³—Y‰î1, ŠC’ËMŽj1, ‰Á“¡@O3, “c“‡@O1, ‹‹vGŽ÷2, ‰¡ˆäŒ\Œå2, “¡ŽR–FŽ÷4, ‰œ˜e‹»‰î5, Šâˆä’m‹v5, “n粏¹•F6, ŽR‰ºŒpŽj2,7: 1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2ã•”Á‰»ŠÇŠO, 3“û‘BEbó‘BŠO, 4‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 5Á‰»Ší“à, 6–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 7V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

110181. [ŒŽ’˜] Expression of Kita-Kyushu Lung Cancer Antigen-1 as Detected by a Novel Monoclonal Antibody in Gastric Cancer. Takahashi Y1,2, Fukuyama T, Futawatari N, Ichiki Y, Ohmiya H, Chuman M1,3, Yamashita T, Hiki N3, Kumamoto Y2, Yamazaki H1,4: Anticancer Res 2019/11; 39 (11): 6259-63. (‚‹Ž’õl1,2, ’†”nŠî”Ž1,3, ”äŠé’ŒŽ÷3, ŒGŒ³—Y‰î2, ŽRè@“™1,4: 1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 3ã•”Á‰»ŠÇŠO, 4•a—)

110020. [ŒŽ’˜] EP3 signaling in dendritic cells promotes liver repair by inducing IL-13-mediated macrophage differentiation in mice. Nakamoto S1, Ito Y2, Nishizawa N3, Goto T1, Kojo K4, Kumamoto Y3, Watanabe M5, Narumiya S, Majima M2: FASEB J 2020/4; 34 (4): 5610-27. doi: 10.1096/fj.201901955R. Epub 2020 Feb 28. (’†–{CŽi1, ˆÉ“¡‹`–ç2, ŒàVL‹±3, Œã“¡‘ì–ç1, ŒÃé@Œ›4, ŒGŒ³—Y‰î3, “n粏¹•F5, ”n“ˆ³—²2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–ò—, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 4‰º•”Á‰»ŠÇŠO, 5–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@)

310024. [Ç—á•ñ] Colorectal cancer with peritoneal carcinomatosis in a teenager. Nakamoto S1, Tanaka K2,3, Watanabe E, Takeda N, Nakamura T4, Kumamoto Y3: Journal of Pediatric Surgery Case Reports 2020/3; 54: 101385. (’†–{CŽi1, “c’†@Œ‰2,3, ’†‘º—²r4, ŒGŒ³—Y‰î3: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2V¢‹Iˆã—ÁEæ’[’f“Iˆã—Ã, 3ˆê”ʁE¬Ž™EŠÌ’_äX, 4‰º•”Á‰»ŠÇŠO)

320010. [Ç—á•ñ] •¡”‚̃lƒIƒWƒ€Ž¥Î‚ðŒëˆù‚µ, ˆÝ‹ó’°ú’ʂ𗈂µ‚œ1—á. ’ǖ؍Gé1, “c’†@Œ‰1,2, ŽR–{—T‹P1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): “ú–{¬Ž™‹~‹}ˆãŠw‰ïŽGŽ 2019/10; 18 (3): 366-9.

320011. [Ç—á•ñ] • o‹Ÿ‰º‘å’°ŠàŒŽ”­‘ƒŠÌ“]ˆÚ‘ƒ“¯ŽžØœpŽ{sŒã‚É–D‡•s‘S‚Ì”­Œ©‚ª’x‚ê‚œˆê—á. ‰i@Ž ‹³1, ŠC’ËMŽj1, ŽR—œ‚L2, ŒàVL‹±1, “c“‡@O1, ŒGŒ³—Y‰î1, “n粏¹•F3 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2‰º•”Á‰»ŠÇŠO, 3–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): _“ސìˆãŠw‰ïŽGŽ 2019/7; 46 (2): 190.

320012. [Ç—á•ñ] HALSˆÚs‚őΉž‚µ‚œ• o‹Ÿ‰ºŠÌØœ’†’YŽ_ƒKƒXÇð‚Ì1—á. â–{ƒˆê1, ‰i@Ž ‹³1, ŠC’ËMŽj1, “c“‡@O1, ŒGŒ³—Y‰î1, “n粏¹•F2 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): “ú–{—Տ°ŠO‰ÈŠw‰ïŽGŽ 2020/1; 81 (1): 65-71.

520009. [‘à] äXŠà‚ÌŠO‰ÈŽ¡—Â̕ϑJ. ŒGŒ³—Y‰î1, ŠC’ËMŽj1, “c“‡@O1, ‹v•Û”CŽj1, ŒàVL‹±1, ’†–{CŽi2, “¡ŽR–FŽ÷2, ŒÜ\—’ˆê°, ‰ª–{Œõ‹FŽq1, æс@ —T—º3 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3“û‘BEbó‘BŠO): –k—¢ˆãŠw 2019/12; 49 (2): 67-71.

521002. [‰ðà]yŠÌ’_äXŠO‰ÈŽèp‚É‚š‚¯‚éƒgƒ‰ƒuƒ‹ƒVƒ…[ƒeƒBƒ“ƒO (Žèp2019”N6ŒŽ‘‘卆)z¡ŽèpŽè‹Z@• o‹Ÿ‰º¶”öó—tØœ‚ÌŽèpŽè‹Z, p.1099-104. ŠC’ËMŽj1, ŒGŒ³—Y‰î1, “c“‡@O1, ‰i@Ž ‹³1, ŒàVL‹±1, “n粏¹•F2 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‹àŒŽo”Å, “Œ‹ž, 2019/6”­s.

522039. [uÀ]y“Á•ÊŠé‰æ: ‘æ55‰ñ“ú–{’_“¹Šw‰ïŠwpW‰ï‚æ‚èz‘å‰ü’ù‚ª‚È‚³‚ê‚œ‹}«’_ùN‰Š‚̐f—Ãtƒ[ƒ`ƒƒ[ƒg. óˆä_Ži, ‚“c’‰Œh, ‰ª–{DŽi, —é–ØŒ›ŽŸ, ”~àVºŽq, X@‘׎õ, ˆ¢•”—Y‘Ÿ, ŒGŒ³—Y‰î1, –{ŠÔ—TŽ÷ (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ŠÌ’_äX 2020/1; 80 (1): 202-207.

522040. [uÀ]y“Á•ÊŠé‰æ: ‘æ55‰ñ“ú–{’_“¹Šw‰ïŠwpW‰ï‚æ‚èz‹}«’_ùN‰Š‚ɑ΂·‚é• o‹Ÿ‰º’_ùN“Eop‚ÅTG18‚ª„§‚·‚éŠëŒ¯‰ñ”ðŽè‹Z‚š‚æ‚щñ”ðŽèp. ”~àVºŽq, ‚“c’‰Œh, ˆ¢•”—Y‘Ÿ, ŒGŒ³—Y‰î1, ŠÛ”öŒ[•q, ‘åŽR“NŽi, ó–ì”V•v, –{ŠÔ—SŽ÷, X@‘׎õ (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ŠÌ’_äX 2020/1; 80 (1): 208-14.

522041. [uÀ]y“ÁW: ‚»‚±‚ª’m‚è‚œ‚¢ƒVƒŠ[ƒY: Žèp‚Å•K—v‚ȋǏŠ‰ð–U (• •”•Ò)zRamstedtŽèp (”ìŒú«—H–å‹·óÇ). “c’†@Œ‰1,2, ŽR–{—T‹P2, o‰Æ‹œˆê2, ’ǖ؍Gé2, ãŒ—R¹2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ¬Ž™ŠO‰È 2020/2; 52 (2): 114-7.

522042. [uÀ]y“ÁW: ¬Ž™ŠO‰È‚É‚š‚¯‚é‘œf—ÉȘAŒgz“–‰@‚É‚š‚¯‚éŽüŽY•êŽq¬ˆçˆã—ÃZƒ“ƒ^[‚̘AŒg|V¶Ž™ŠO‰ÈŽŸŠ³‚̏o¶‘Of’f‚ÌŒ»ó|. ’ǖ؍Gé1, “c’†@Œ‰1,2, ŽR–{—T‹P1, o‰Æ‹œˆê1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ¬Ž™ŠO‰È 2020/3; 52 (3): 231-3.

[’˜@‘]

620038. [Šwp‘ (•ª’SŽ·•M)]yŠÌ’_äXŠO‰ÈŽèp‚É‚š‚¯‚éƒgƒ‰ƒuƒ‹ƒVƒ…[ƒeƒBƒ“ƒO (Žèp2019”N6ŒŽ‘‘卆)z¡ŽèpŽè‹Z@• o‹Ÿ‰º¶”öó—tØœ‚ÌŽèpŽè‹Z, p.1099-104. ŠC’ËMŽj1, ŒGŒ³—Y‰î1, “c“‡@O1, ‰i@Ž ‹³1, ŒàVL‹±1, “n粏¹•F2 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‹àŒŽo”Å, “Œ‹ž, 2019/6”­s.

[Šw‰ïEŒ€‹†‰ï“™]

713050. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Utero-vesical anastomosis: A novel operation for a girl of cloacal exstrophy with vaginal agenesis. Tanaka K1,2, Yamamoto Y2, Deie K2, Oiki H2: The 6th World Congress of the World Federation of Associations of Pediatric Surgery (WOFAPS 2019) (2019/11/2), Doha, Qatar. (“c’†@Œ‰1,2, ŽR–{—T‹P2, o‰Æ‹œˆê2, ’ǖ؍Gé2: 1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO)

713051. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) A case of penile duplication with ectopic intestinal tissue. Oiki H1, Tanaka K1,2, Yamamoto Y1, Deie K1: The 6th World Congress of the World Federation of Associations of Pediatric Surgery (WOFAPS 2019) (2019/11/3), Doha, Qatar. (’ǖ؍Gé1, “c’†@Œ‰1,2, ŽR–{—T‹P1, o‰Æ‹œˆê1: 1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã)

722060. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) CDO1ˆâ“`ŽqDNAƒƒ`ƒ‹‰»‚É’–Ú‚µ‚œäXŠàf’f–@‚ÌŒŸ“¢. ŒàVL‹±1, ŽR‰ºŒpŽj2,3, “¡ŽR–FŽ÷4, ’†–{CŽi4, ŒÜ\—’ˆê°, “c“‡@O1, ŠC’ËMŽj1, ŒGŒ³—Y‰î1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3ã•”Á‰»ŠÇŠO, 4‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ50‰ñ“ú–{äX‘ŸŠw‰ï‘å‰ï (2019/7/12), “Œ‹ž.

722061. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ã• •”ŽèpŠù‰‚Ì‚ ‚éÇ—á‚ɑ΂·‚é• o‹Ÿ‰ºŠÌØœ. ŠC’ËMŽj1, ŒGŒ³—Y‰î1, “c“‡@O1, ŒàVL‹±1, ‰i@Ž ‹³1, “n粏¹•F2 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ74‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2019/7/18), “Œ‹ž.

723235. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • o‹Ÿ‰ºäB‰·‘¶”ö‘€äXØœ (äB“®Ã–¬) ‚Å‚ÌConvesion‚ÌŒŸ“¢. “c“‡@O1, ŒGŒ³—Y‰î1, ŒàVL‹±1, ‰i@Ž ‹³1, ŠC’ËMŽj1, “n粏¹•F2 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ119‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/4/18), ‘åã.

723236. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • o‹Ÿ‰ºŠÌØœp‚̍¢“ïÇ—á‚ÉŠÖ‚·‚錟“¢. ‰i@Ž ‹³1, ŠC’ËMŽj1, ŒàVL‹±1, “c“‡@O1, ŒGŒ³—Y‰î1, “n粏¹•F2 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ119‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/4/18), ‘åã.

723237. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) IPMC‚É‚š‚¯‚éCDO1ˆâ“`Žqƒƒ`ƒ‹‰»‚̗Տ°•a—Šw“IˆÓ‹`. “¡ŽR–FŽ÷1, ŽR‰ºŒpŽj2,3, “Y–ìl•¶1, ‰¡“cŒõ‰›1, ’†–{CŽi1, b”ã“c•Žu1, ‰¡“c˜aŽq1, “c’†—uŽq1, ŒŽ“cG‹P1, ‰i@Ž ‹³, ŒàVL‹±4, “c“‡@O4, ŠC’ËMŽj4, ŒGŒ³—Y‰î4, “n粏¹•F5 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3ã•”Á‰»ŠÇŠO, 4ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 5–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ119‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/4/18), ‘åã.

723238. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰AŒs”A“¹, ”A“¹‹·ó, HŒ^äNã÷äTᑂ𔺂Á‚œ”å”A¶B“ŽŠïŒ`‚̏—Ž™2—á. ãŒ—R¹1, “c’†@Œ‰1,2, ŽR–{—T‹P1, ’ǖ؍Gé1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ119‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/4/19), ‘åã.

723239. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • o‹Ÿ‰ºŠÌØœ¢“ïÇ—á‚ɑ΂·‚éHALS‚̐ϋɓI—˜—p. ŠC’ËMŽj1, ŒGŒ³—Y‰î1, “c“‡@O1, ‰i@Ž ‹³1, ŒàVL‹±1, “n粏¹•F2 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ119‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/4/20), ‘åã.

723240. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) V¶Ž™ŠúE“ûŽ™Šú‚ÉŽèp‚ðs‚Á‚œ—œóâ|á‘4—á‚ÌŒŸ“¢. ’ǖ؍Gé1, “c’†@Œ‰1,2, ŽR–{—T‹P1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ56‰ñ“ú–{¬Ž™ŠO‰ÈŠw‰ïŠwpW‰ï (2019/5/23), •Ÿ‰ª.

723241. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) IIIŒ^äXŠO‚ɑ΂·‚鎡—Ð헪\Žèp? •Û‘¶Ž¡—Ã? “c’†@Œ‰1,2, ŽR–{—T‹P2, ’ǖ؍Gé2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ56‰ñ“ú–{¬Ž™ŠO‰ÈŠw‰ïŠwpW‰ï (2019/5/25), •Ÿ‰ª.

723242. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹É’áo¶‘̏dŽ™‚̃Xƒgƒ}•ÂœŽžŠú‚ÉŠÖ‚·‚錟“¢. ŽR–{—T‹P1, “c’†@Œ‰1,2, ’ǖ؍Gé1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ56‰ñ“ú–{¬Ž™ŠO‰ÈŠw‰ïŠwpW‰ï (2019/5/25), •Ÿ‰ª.

723243. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’x”­«æ“V«‰¡Šu–Œƒwƒ‹ƒjƒA‚ɑ΂·‚é“àŽ‹‹ŸŽèp|‹¹o‹Ÿ? • o‹Ÿ? ãŒ—R¹1, “c’†@Œ‰1,2, ŽR–{—T‹P1, ’ǖ؍Gé1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ56‰ñ“ú–{¬Ž™ŠO‰ÈŠw‰ïŠwpW‰ï (2019/5/25), •Ÿ‰ª.

723244. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Clinical significance of promoter DNA hypermethylation of the cysteine dioxygenase 1 (CDO1) gene in pancreatic ductal adenocarcinoma. ŒàVL‹±1, ŽR‰ºŒpŽj2,3, “¡ŽR–FŽ÷4, ’†–{CŽi4, “c“‡@O1, ŠC’ËMŽj1, ŒGŒ³—Y‰î1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2ã•”Á‰»ŠÇŠO, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 4‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ31‰ñ“ú–{ŠÌ’_äXŠO‰ÈŠw‰ïEŠwpW‰ï (2019/6/14), ì.

723245. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Laparoscopic distal pancreatectomy for pancreatic cancers put the emphasis on the distal margin. “c“‡@O1, ŠC’ËMŽj1, ‰i@Ž ‹³1, ŒàVL‹±1, ŒGŒ³—Y‰î1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ31‰ñ“ú–{ŠÌ’_äXŠO‰ÈŠw‰ïEŠwpW‰ï (2019/6/15), ì.

723246. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Hand-assisted laparoscopic surgery (HALS) for the troubleshooting in laparoscopic liver resection. ŠC’ËMŽj1, ŒGŒ³—Y‰î1, “c“‡@O1, ŒàVL‹±1, ‰i@Ž ‹³1, “n粏¹•F2 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ31‰ñ“ú–{ŠÌ’_äXŠO‰ÈŠw‰ïEŠwpW‰ï (2019/6/15), ì.

723247. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬Ž™‹}«’Ž‚‰Š‚É‚š‚¯‚é’Ž‰¹”gŒŸžECTŒŸž‚̈Ӌ`. “c’†@Œ‰1,2, ŽR–{—T‹P2, ’ǖ؍Gé2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ33‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ïŠwpW‰ï (2019/6/21), é‹Ê.

723248. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) úE«’Ž‚‰Š, ”Ä”­«• –Œ‰Š‚É‚æ‚é”sŒŒÇ«ƒVƒ‡ƒbƒN‚©‚çS”x’âŽ~‚ÉŽŠ‚Á‚œ1—á. ’ǖ؍Gé1, “c’†@Œ‰1,2, ŽR–{—T‹P1, ˆÀ“¡@Žõ3, •ô”öŒb—œ3 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3¬Ž™): ‘æ33‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ïŠwpW‰ï (2019/6/22), é‹Ê.

723249. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) V¶Ž™Šú‚ɈêŠú“IªŽ¡p‚ðŽ{s‚µ‚œ–³á‘EŒ^œãè‚Ì3—á. “c’†@Œ‰1,2, ŽR–{—T‹P2, ’ǖ؍Gé2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ55‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŠwpW‰ï (2019/7/13), ’·–ì.

723250. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹ó’°•ÂœÇ‚Əo¶‘Of’f‚³‚ê, ä`‘Ñ’×á‡‚ð‡•¹‚µ‚œ’°‰ñ“]ˆÙíÇE’†’°Ž²”P“]‚Ì1—á. ’ǖ؍Gé1, “c’†@Œ‰1,2, ŽR–{—T‹P1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ55‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŠwpW‰ï (2019/7/14), ’·–ì.

723251. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) V¶Ž™ƒƒbƒPƒ‹ŒeŽºúE‚Ì1—á. ‹à“c’—Ç1, “c’†@Œ‰2,3, ŽR–{—T‹P3, ’ǖ؍Gé3 (1‰º•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ55‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŠwpW‰ï (2019/7/14), ’·–ì.

723022. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“EP3Žó—e‘̃VƒOƒiƒ‹‚ð‰î‚µ‚œŠÌŽ÷ó×–E‚̊̏C•œ‘£iì—p. ’†–{CŽi1, ˆÉ“¡‹`–ç2, ŒàVM‹±3, ‘卂Žj¹1, ’ׯ¢—¢1, •ž•”‹¿Žq4, –{“c‰ëŽq1, “V–ì‰pŽ÷2, ”n“ˆ³—²2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–ò—, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 4ŽY‰È): ‘æ40‰ñ“ú–{‰ŠÇ¥Ä¶ˆãŠw‰ï (2019/7/16), _ŒË.

723252. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰È‚É‚š‚¯‚é‘å’°ŠàŠÌ“]ˆÚÇ—á‚ɑ΂·‚éŠÌØœŽèp¬Ñ‚ÌŒŸ“¢. “¡ŽR–FŽ÷1, ‰i@Ž ‹³2, ŠC’ËMŽj2, ’†–{CŽi1, ŒàVL‹±2, “c“‡@O2, ŒGŒ³—Y‰î2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ74‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2019/7/17), “Œ‹ž.

723253. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • o‹Ÿ‰º”ö‘€äXØœ‚ÌPitfall‚ƃgƒ‰ƒuƒ‹ƒVƒ…[ƒeƒBƒ“ƒO. “c“‡@O1, ŠC’ËMŽj1, ‰i@Ž ‹³1, ŒàVL‹±1, ŒGŒ³—Y‰î1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ74‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2019/7/18), “Œ‹ž.

723254. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) äXŽîᇂɑ΂·‚éLiquid biopsy CDO1ˆâ“`Žqƒƒ`ƒ‹‰»‚̐f’fƒ}[ƒJ[‚Æ‚µ‚Ä‚Ì—L—p«. “¡ŽR–FŽ÷1, ŒàVL‹±2, ’†–{CŽi1, “Y–ìF•¶1, ‰¡“cŒõ‰›1, b”ã“c•Žu1, ‰œ˜e‹»‰î3, Šâˆä’m‹v3, “c“‡@O2, ‹v•Û”CŽj2, ŠC’ËMŽj2, ŒGŒ³—Y‰î2, ŽR‰ºŒpŽj4,5 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 3Á‰»Ší“à, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 5ã•”Á‰»ŠÇŠO): ‘æ78‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï (2019/9/27), ‹ž“s.

723255. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) œ‘Ž‰–bŽî‚Æ‚ÌŠÓ•Ê‚ª¢“ï‚Å‚ ‚Á‚œ‰E•›tŒŽ”­Žîᇂ̈ê—á. ŽR–{—T‹P1, “c’†@Œ‰1,2, o‰Æ‹œˆê1, ’ǖ؍Gé1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ61‰ñ“ú–{¬Ž™ŒŒ‰tE‚ª‚ñŠw‰ïŠwpW‰ï (2019/11/14), L“‡.

723256. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’x”­«æ“V«‰¡Šu–Œƒwƒ‹ƒjƒA‚ɑ΂·‚é“àŽ‹‹ŸŽèp|‹¹o‹Ÿ? • o‹Ÿ? ãŒ—R¹1, “c’†@Œ‰1,2, ŽR–{—T‹P1, o‰Æ‹œˆê1, ’ǖ؍Gé3 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ32‰ñ“ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ï‘‰ï (2019/12/5), ‰¡•l.

723257. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • o‹Ÿ‰ºŠÌS7ˆŸ‹æˆæØœ‚ÌŽèpŽè‹Z‚š‚æ‚Ñ‚»‚̈À‘S«. ŠC’ËMŽj1, “c“‡@O1, ŒàVL‹±1, ‹v•Û”CŽj1, ŒGŒ³—Y‰î1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ32‰ñ“ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ï‘‰ï (2019/12/7), ‰¡•l.

723258. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • o‹Ÿ‰ºäX“ª\“ñŽw’°Øœp‚Ì“±“ü. “c“‡@O1, ŒàVL‹±1, ‹v•Û”CŽj1, ŠC’ËMŽj1, ŒGŒ³—Y‰î1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ32‰ñ“ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ï‘‰ï (2019/12/7), ‰¡•l.

723259. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) äXŠà‚ɑ΂·‚é• o‹Ÿ‰ºäX‘Ì”ö•”Øœ‚ÌŽè‹Z‚ÆŽ¡—ЬÑ. ŒàVL‹±1, “c“‡@O1, ‹v•Û”CŽj1, ŠC’ËMŽj1, ŒGŒ³—Y‰î1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ32‰ñ“ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ï‘‰ï (2019/12/7), ‰¡•l.

732019. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) ‘å’°ŠàŠÌ“]ˆÚ• o‹Ÿ‰ºŽèp114Ç—á‚ÌŒŸ“¢. “¡ŽR–FŽ÷1, ŠC’ËMŽj2, ’†–{CŽi1, ‰i@Ž ‹³2, ŒàVL‹±2, ‹v•Û”CŽj2, “c“‡@O2, ŒGŒ³—Y‰î2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ13‰ñŠÌ‘Ÿ“àŽ‹‹ŸŠO‰ÈŒ€‹†‰ïE‘æ11‰ñäX‘Ÿ“àŽ‹‹ŸŠO‰ÈŒ€‹†‰ï (2019/12/4), ‰¡•l.

732020. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) “ž’B–Ú•W‚ð‹€’Ê”FŽ¯‚µ‚œp–ì“WŠJ|• o‹Ÿ‰ºäX‘Ì”ö•”Øœp|. ŒàVL‹±1, “c“‡@O1, ‹v•Û”CŽj1, ŠC’ËMŽj1, ŒGŒ³—Y‰î1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ13‰ñŠÌ‘Ÿ“àŽ‹‹ŸŠO‰ÈŒ€‹†‰ïE‘æ11‰ñäX‘Ÿ“àŽ‹‹ŸŠO‰ÈŒ€‹†‰ï (2019/12/4), ‰¡•l.

733094. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) • •Ç•ÂœŒã‚Ìä`Œ‡‘¹‚ɑ΂·‚銁ì1–@‚É‚æ‚éä`Œ`¬p‚ÌŒoŒ±. “c’†@Œ‰1,2, ŽR–{—T‹P2, ’ǖ؍Gé2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ5‰ñ“ú–{¬Ž™‚Ö‚»Œ€‹†‰ï (2019/4/19), ‘åã.

733095. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) • o‹Ÿ‰ºŠÌS7ˆŸ‹æˆæØœ‚É‚š‚¯‚éŽèpŽè‹Z‚̍H•v. ŠC’ËMŽj1, ŒGŒ³—Y‰î1, “c“‡@O1, ŒàVL‹±1, ‰i@Ž ‹³1, “n粏¹•F2 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ73‰ñŽèpŽè‹ZŒ€‹†‰ï (2019/5/24), “Œ‹ž.

733096. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “–‰@‚É‚š‚¯‚é• o‹Ÿ‰º’_ŠÇ‹ó’°•«‡p‚̍H•v. “c“‡@O1, ŒGŒ³—Y‰î1, ‰i@Ž ‹³1, ŒàVL‹±1, ŠC’ËMŽj1, “n粏¹•F2 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ73‰ñŽèpŽè‹ZŒ€‹†‰ï (2019/5/24), “Œ‹ž.

733097. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) • o‹Ÿ‰º’_ŠÇ‹ó’°•«‡‚̍H•v. “c“‡@O1, æс@—T—º2, ŒàVL‹±1, ‹v•Û”CŽj1, ŠC’ËMŽj1, ŒGŒ³—Y‰î1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2“û‘BEbó‘BŠO): ‘æ8‰ñƒTƒ}[ƒZƒ~ƒi[in‰«“ê (2019/6/29), ‰«“ê.

733098. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) • o‹Ÿ‰º”ö‘€äXØœ‚ÌŽ©“®–D‡Ší‚ð—p‚¢‚Ä‚ÌäXØ—£‚Æ‚»‚Ìpitfall. æс@—T—º1, “c“‡@O2, ŒàVL‹±2, ‹v•Û”CŽj2, ŠC’ËMŽj2, ŒGŒ³—Y‰î2 (1“û‘BEbó‘BŠO, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ8‰ñƒTƒ}[ƒZƒ~ƒi[in‰«“ê (2019/6/29), ‰«“ê.

733099. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) o¶‘Of’fÇ—á‚É‚š‚¯‚éŽüŽY•êŽq¬ˆçˆã—ÃZƒ“ƒ^[‚̘AŒg. ’ǖ؍Gé1, “c’†@Œ‰1,2, ŽR–{—T‹P1, o‰Æ‹œˆê1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ117‰ñ“Œ‹ž¬Ž™ŠO‰ÈŒ€‹†‰ï (2019/6/4), “Œ‹ž.

733100. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ŒŽ”­«äXŠà‚É‚š‚¯‚ép‘O×–EfŒŸ‘Ì‚ð—p‚¢‚œCDO1ˆâ“`ŽqDNAƒƒ`ƒ‹‰»‚̈Ӌ`. ’†–{CŽi1, “¡ŽR–FŽ÷1, ŒàVL‹±2, “c“‡@O2, ‹v•Û”CŽj2, ŠC’ËMŽj2, ŒGŒ³—Y‰î2, ŽR‰ºŒpŽj3,4 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 4ã•”Á‰»ŠÇŠO): ‘æ39‰ñ“ú–{•ªŽqŽîᇃ}[ƒJ[Œ€‹†‰ï (2019/9/25), ‹ž“s.

733101. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ¬Ž™ŠO‰È—̈æ‚É‚š‚¯‚é“àŽ‹‹ŸŠO‰È‹Zp”F’莎Œ±‚̐S\‚Š‚ƃ|ƒCƒ“ƒg. o‰Æ‹œˆê1, “c’†@Œ‰1,2, ŽR–{—T‹P1, ’ǖ؍Gé1, ãŒ—R¹1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ155‰ñ_“ސ쌧—Տ°ŠO‰ÈˆãŠw‰ïW’k‰ï (2019/9/28), _“ސì.

733102. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ˆÙŠ«’°ŠÇ‘gD‚𔺂€‰ï‰A•”ŽîáŽ‚ð‡•¹‚µ‚œd•¡‰AŒs‚Ì1—á. ’ǖ؍Gé1, “c’†@Œ‰1,2, o‰Æ‹œˆê1, ŽR–{—T‹P1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ54‰ñ“ú–{¬Ž™ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2019/10/12), é‹Ê.

733103. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ’°‰ñ“]ˆÙíÇ’†’°Ž²”P“]‚𔺂Á‚œV¶Ž™ˆÝ”j—ô‚̈ê—á. ‘Ÿ“c@—œ1, “c’†@Œ‰2,3, ŽR–{—T‹P3, o‰Æ‹œˆê3, ’ǖ؍Gé3 (1‰º•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ54‰ñ“ú–{¬Ž™ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2019/10/12), é‹Ê.

733104. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ŒoƒJƒe[ƒeƒ‹“®–¬Çðp‚É‚æ‚ézŠÂ“®‘ÔˆÀ’艻Œã, ÄoŒŒ‚ªŒ°Ý‰»‚µ‹Ù‹}ŠJ• Ž~ŒŒp‚ð—v‚µ‚œ‘œ”­ŠO‚Ì1—á. ãŒ—R¹1, ‰Ô“‡@Ž‘2, •Ð‰ª—Sˆê2, Š~Œ©•¶Ž}2, “c‘º@’q2, ‘“c’q¬2, ‹à@@I2, “c’†@Œ‰3,4, ó—˜@–õ2 (1‰º•”Á‰»ŠÇŠO, 2‹~–œ, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã, 4ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ39‰ñ“ú–{¬Ž™“àŽ‹‹ŸŠO‰ÈEŽèpŽè‹ZŒ€‹†‰ï (2019/10/18), ‘åã.

733105. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ¬Ž™‚É‚š‚¯‚éŽåäXŠÇ‘¹‚𔺂Á‚œäXŠO‚ɑ΂·‚é•Û‘¶Ž¡—Ã. “c’†@Œ‰1,2, ŽR–{—T‹P2, o‰Æ‹œˆê2, ’ǖ؍Gé2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ39‰ñ“ú–{¬Ž™“àŽ‹‹ŸŠO‰ÈEŽèpŽè‹ZŒ€‹†‰ï (2019/10/18), ‘åã.

733106. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “–‰@‚̐V¶Ž™æ“V«‰¡Šu–Œƒwƒ‹ƒjƒA‚ɑ΂·‚éW’†Ž¡—ÊǗ‚ÌŒŸ“¢. o‰Æ‹œˆê1, “c’†@Œ‰1,2, ŽR–{—T‹P1, ’ǖ؍Gé1, ãŒ—R¹1, ˆÀ“¡@Žõ3, •ô”öŒb—œ3 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3¬Ž™): ‘æ27‰ñ¬Ž™W’†Ž¡—ρ[ƒNƒVƒ‡ƒbƒv (2019/10/19-20), ‘åã.

733107. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ’Eo‘ŸŠí‚ÌŠÒ”[‚ª¢“ï‚È‹‘åä`‘уwƒ‹ƒjƒA‚ɑ΂µ‚Ä•Û‘¶“IŽ¡—Âðs‚Á‚œ1—á. ’ǖ؍Gé1, “c’†@Œ‰1,2, ŽR–{—T‹P1, o‰Æ‹œˆê1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ11‰ñ_“ސìƒwƒ‹ƒjƒAŒ€‹†‰ï (2019/11/30), _“ސì.

733108. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) • o‹Ÿ‰ºÄŠÌØœ‚ÌŽèp¬Ñ‚š‚æ‚Ñ—¯ˆÓ“_. ŠC’ËMŽj1, “c“‡@O1, ŒàVL‹±1, ‹v•Û”CŽj1, ŒGŒ³—Y‰î1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ13‰ñŠÌ‘Ÿ“àŽ‹‹ŸŠO‰ÈŒ€‹†‰ïE‘æ11‰ñäX‘Ÿ“àŽ‹‹ŸŠO‰ÈŒ€‹†‰ï (2019/12/4), ‰¡•l.

733109. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) äXŠà‚É‚š‚¯‚é• o‹Ÿ‰ºäX‘Ì”ö•”Øœ‚ÌŠsŽ‚̍H•v. “c“‡@O1, ŒàVL‹±1, ‹v•Û”CŽj1, ŠC’ËMŽj1, ŒGŒ³—Y‰î1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ13‰ñŠÌ‘Ÿ“àŽ‹‹ŸŠO‰ÈŒ€‹†‰ïE‘æ11‰ñäX‘Ÿ“àŽ‹‹ŸŠO‰ÈŒ€‹†‰ï (2019/12/4), ‰¡•l.

733110. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) • o‹Ÿ‰ºäX‘Ì”ö•”Øœp (LDP) ‚É‚š‚¯‚éäXØ—£‚̍H•v. “c“‡@O1, ŒàVL‹±1, ‹v•Û”CŽj1, ŠC’ËMŽj1, ŒGŒ³—Y‰î1 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ13‰ñŠÌ‘Ÿ“àŽ‹‹ŸŠO‰ÈŒ€‹†‰ïE‘æ11‰ñäX‘Ÿ“àŽ‹‹ŸŠO‰ÈŒ€‹†‰ï (2019/12/4), ‰¡•l.

733111. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‹}«äX‰Š‚𔭏ǂµCŽèp‚É“ïa‚µ‚œ—V‘–äBEˆÝŽ²”P‚Ì1—á. “c’†@Œ‰1,2, ŽR–{—T‹P2, o‰Æ‹œˆê2, ’ǖ؍Gé2, ãŒ—R¹2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ33‰ñ“ú–{¬Ž™äB‘ŸE–å–¬Œ€‹†‰ï (2020/3/8), “Œ‹ž (ŽãŠJÃ).

'18”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'18-320002. [Ç—á•ñ] • o‹Ÿ‰º’_”X“EopŽž‚Ì—Ž‰ºŒ‹Î‚É‚æ‚èpŒã9”N‚Å• o“à”^á‡, • •Ç”^ᇂðŒ`¬‚µ‚œ1—á. “‡’Á@«, ˆÉ–ì˜a”n, ŒGŒ³—Y‰î1, ŠC’ËMŽj1, “c“‡@O1, ‰Í–”@Š°, ŒŽR@—º, “n粏¹•F2 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): _“ސìˆãŠw‰ïŽGŽ 2019/1; 46 (1): 18.


ã•”Á‰»ŠÇŠO‰ÈŠw

[Šwp˜_•¶]

110182. [ŒŽ’˜] Cancer-specific promoter DNA methylation of Cysteine dioxygenase type 1 (CDO1) gene as an important prognostic biomarker of gastric cancer. Harada H1, Hosoda K2, Moriya H2, Mieno H2, Ema A2, Ushiku H2, Washio M2, Nishizawa N3, Ishii S2, Yokota K1, Tanaka Y1, Kaida T1, Soeno T1, Kosaka Y4, Watanabe M5, Yamashita K2,6: PLoS One 2019/4; 14 (4): e0214872. (ŒŽ“cG‹P1, ×“c@Œj2, X’JGŒõ2, ŽOd–ì_˜N2, ]ŠÔ@—æ2, ‹‹vGŽ÷2, ˜h”ö^—ˆ€2, ŒàVL‹±3, Îˆä@’q2, ‰¡“c˜aŽq1, “c’†—uŽq1, b”ã“c•Žu1, “Y–ìF•¶1, ¬â–ùŒ«4, “n粏¹•F5, ŽR‰ºŒpŽj2,6: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ã•”Á‰»ŠÇŠO, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 4“û‘BEbó‘BŠO, 5–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 6V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

110183. [ŒŽ’˜] Lymph Node Progression and Optimized Node Dissection of Middle Thoracic Esophageal Squamous Cell Carcinoma in the Latest Therapeutic Surgical Strategy. Soeno T1, Harada H1, Hosoda K2, Mieno H2, Ema A2, Ushiku H2, Washio M2, Kosaka Y3, Watanabe M4, Yamashita K2,5: Ann Surg Oncol 2019/4; 26 (4): 996-1004. (“Y–ìF•¶1, ŒŽ“cG‹P1, ×“c@Œj2, ŽOd–ì_˜N2, ]ŠÔ@—æ2, ‹‹vGŽ÷2, ˜h”ö^—ˆ€2, ¬â–ùŒ«3, “n粏¹•F4, ŽR‰ºŒpŽj2,5: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ã•”Á‰»ŠÇŠO, 3“û‘BEbó‘BŠO, 4–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 5V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

110184. [ŒŽ’˜] A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial. Hosoda K1, Azuma M2, Katada C2, Moriya H1, Mieno H1, Ishido K2, Ema A1, Ushiku H1, Wada T2, Washio M1, Watanabe A2, Higuchi K2, Tanabe S2,3, Koizumi W2, Watanabe M4, Yamashita K1,5: Gastric Cancer 2019/5; 22 (3): 598-606. (×“c@Œj1, “Œ@’q2, Œ˜“ce—˜2, X’JGŒõ1, ŽOd–ì_˜N1, ÎŒËŒªŽŸ2, ]ŠÔ@—æ1, ‹‹vGŽ÷1, ˜a“c‘ñ–ç2, ˜h”ö^—ˆ€1, “n糍WŽ¯2, ”óŒûŸ•F2, “c糁@‘2,3, ¬ò˜aŽO˜Y2, “n粏¹•F4, ŽR‰ºŒpŽk1,5: 1ã•”Á‰»ŠÇŠO, 2Á‰»Ší“à, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã, 4–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 5V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

110185. [ŒŽ’˜] Safety and Feasibility of Robotic Distal Gastrectomy for Stage IA Gastric Cancer: A Phase II Trial. Hosoda K1, Mieno H1, Ema A1, Ushiku H1, Washio M1, Song I, Watanabe M2, Yamashita K1,3: J Surg Res 2019/6; 238: 224-31. (×“c@Œj1, ŽOd–ì_˜N1, ]ŠÔ@—æ1, ‹‹vGŽ÷1, ˜h”ö^—ˆ€1, “n粏¹•F2, ŽR‰ºŒpŽj1,3: 1ã•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

110186. [ŒŽ’˜] Prospective feasibility study for single-tracer sentinel node mapping by ICG (indocyanine green) fluorescence and OSNA (one-step nucleic acid amplification) assay in laparoscopic gastric cancer surgery. Shoji Y, Kumagai K, Kamiya S, Ida S, Nunobe S, Ohashi M, Yoshimizu S, Horiuchi Y, Yoshio T, Ishiyama A, Hirasawa T, Osako T, Yamamoto N, Fujisaki J, Sano T, Hiki N1: Gastric Cancer 2019/7; 22 (4): 873-80. (”äŠé’ŒŽ÷1: 1ã•”Á‰»ŠÇŠO)

110187. [ŒŽ’˜] Epstein-Barr virus status is a promising biomarker for endoscopic resection in early gastric cancer: proposal of a novel therapeutic strategy. Osumi H, Kawachi H, Yoshio T, Ida S, Yamamoto N, Horiuchi Y, Ishiyama A, Hirasawa T, Tsuchida T, Hiki N1, Takeuchi K, Fujisaki J: J Gastroenterol 2019/9; 54 (9): 774-83. (”äŠé’ŒŽ÷1: 1ã•”Á‰»ŠÇŠO)

110188. [ŒŽ’˜] Surgical outcomes and risk assessment for anastomotic complications after laparoscopic proximal gastrectomy with double-flap technique for upper-third gastric cancer. Shoji Y, Nunobe S, Ida S, Kumagai K, Ohashi M, Sano T, Hiki N1: Gastric Cancer 2019/9; 22 (5): 1036-43. (”äŠé’ŒŽ÷1: 1ã•”Á‰»ŠÇŠO)

110189. [ŒŽ’˜] Duodenal stump reinforcement might reduce both incidence and severity of duodenal stump leakage after laparoscopic gastrectomy with Roux-en-Y reconstruction for gastric cancer. Ri M, Hiki N1, Ishizuka N, Ida S, Kumagai K, Nunobe S, Ohashi M, Sano T: Gastric Cancer 2019/9; 22 (5): 1053-9. (”äŠé’ŒŽ÷1: 1ã•”Á‰»ŠÇŠO)

110190. [ŒŽ’˜] Oncological feasibility of laparoscopic subtotal gastrectomy compared with laparoscopic proximal or total gastrectomy for cT1N0M0 gastric cancer in the upper gastric body. Kano Y, Ohashi M, Ida S, Kumagai K, Nunobe S, Sano T, Hiki N1: Gastric Cancer 2019/9; 22 (5): 1060-8. (”äŠé’ŒŽ÷1: 1ã•”Á‰»ŠÇŠO)

110191. [ŒŽ’˜] Should pylorus-preserving gastrectomy be performed for overweight/obese patients with gastric cancer? Tsujiura M, Hiki N1, Ohashi M, Nunobe S, Kumagai K, Ida S, Ohashi T, Sano T, Yamaguchi T: Gastric Cancer 2019/11; 22 (6): 1247-55. (”äŠé’ŒŽ÷1: 1ã•”Á‰»ŠÇŠO)

110192. [ŒŽ’˜] Timing and site-specific trends of recurrence in patients with pathological stage II or III gastric cancer after curative gastrectomy followed by adjuvant S-1 monotherapy. Takahashi R, Ohashi M, Kano Y, Ida S, Kumagai K, Nunobe S, Chin K, Yamaguchi K, Nagino M, Sano T, Hiki N1: Gastric Cancer 2019/11; 22 (6): 1256-62. (”äŠé’ŒŽ÷1: 1ã•”Á‰»ŠÇŠO)

110193. [ŒŽ’˜] Development of a novel tool to assess skills in laparoscopic gastrectomy using the Delphi method: the Japanese operative rating scale for laparoscopic distal gastrectomy (JORS-LDG). Kurashima Y, Watanabe Y, Hiki N1, Poudel S, Kitagami H, Ebihara Y, Murakami S, Shichinohe T, Hirano S: Surg Endosc 2019/12; 33 (12): 3945-52. (”äŠé’ŒŽ÷1: 1ã•”Á‰»ŠÇŠO)

110194. [ŒŽ’˜] Comprehensive Exploration to Identify Predictive DNA Markers of ƒ¢Np63/SOX2 in Drug Resistance in Human Esophageal Squamous Cell Carcinoma. Ooizumi Y1, Kojima K 2, Igarashi K, Tanaka Y1, Harada H1, Yokota K1, Kaida T1, Ishii S3, Tanaka T 2, Yokoi K 2, Nishizawa N4, Washio M3, Ushiku H3, Katoh H5, Kosaka Y5, Mieno H3, Hosoda K3, Watanabe M6, Katada C7, Hiki N3, Yamashita K3,8: Ann Surg Oncol 2019/12; 26 (13): 4814-25. (‘åò—z‰î1, ¬›žŒc‘Ÿ 2, “c’†—uŽq1, ŒŽ“cG‹P1, ‰¡“c˜aŽq1, b”ã“c•Žu1, Îˆä@’q3, “c’†r“¹ 2, ‰¡ˆäŒ\Œå 2, ŒàVL‹±4, ˜h”ö^—ˆ€3, ‹‹vGŽ÷3, ‰Á“¡@O5, ¬â–ùŒ«5, ŽOd–ì_˜N3, ×“c@Œj3, “n粏¹•F6, Œ˜“ce—˜7, ”äŠé’ŒŽ÷3, ŽR‰ºŒpŽj3,8: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2‰º•”Á‰»ŠÇŠO, 3ã•”Á‰»ŠÇŠO, 4ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 5“û‘BEbó‘BŠO, 6–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 7Á‰»Ší“à, 8V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

110195. [ŒŽ’˜] CD33+ Immature Myeloid Cells Critically Predict Recurrence in Advanced Gastric Cancer. Soeno T1, Katoh H2, Ishii S3, Ushiku H3, Hosoda K3, Hiki N3, Watanabe M4, Yamashita K3,5: J Surg Res 2020/1; 245: 552-63. (“Y–ìF•¶1, ‰Á“¡@O2, Îˆä@’q3, ‹‹vGŽ÷3, ×“c@Œj3, ”äŠé’ŒŽ÷3, “n粏¹•F4, ŽR‰ºŒpŽj3,5: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2“û‘BEbó‘BŠO, 3ã•”Á‰»ŠÇŠO, 4–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 5V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

110196. [ŒŽ’˜] Billroth-I vs Roux-en-Y after distal gastrectomy: A comparison of long-term nutritional status and survival rates from a large-scale multicenter cohort study. Kinoshita T, Honda M, Matsuki A, Enomoto N, Aizawa M, Nunobe S, Yabusaki H, Abe T, Hiki N1: Ann Gastroenterol Surg 2020/2; 4 (2): 142-50. (”äŠé’ŒŽ÷1: 1ã•”Á‰»ŠÇŠO)

310025. [Ç—á•ñ] Two cases of a perforated duodenal diverticulum after gastrectomy with Roux-en-Y reconstruction. Yagi S, Ida S, Ohashi M, Kumagai K, Hiki N1, Sano T, Nunobe S: Surg Case Rep 2019/11; 5 (1): 169. (”äŠé’ŒŽ÷1: 1ã•”Á‰»ŠÇŠO)

320013. [Ç—á•ñ] Ramucirumab + Paclitaxel•¹—p—Ö@‚É‚æ‚ècCR‚ª“Ÿ‚ç‚ê‚œpŒãÄ”­ˆÝŠà‚Ì1—á. ’†”nŠî”Ž1,2, ‚‹Ž’õl1,3, Žž”C’‘1,4, ç–ìTˆê˜Y1,4, ]ŠÔ@—æ2, ‹‹vGŽ÷2, ’†‘º˜a“¿1,3, ‹v•Û”CŽj3, “à“¡³‹K1,4, ‹ß“¡NŽj1,5, Œ@”ªŽk1, ”äŠé’ŒŽ÷2: 1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2ã•”Á‰»ŠÇŠO, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 4‰º•”Á‰»ŠÇŠO, 5“û‘BEbó‘BŠO) Šà‚Ɖ»Šw—Ö@ 2019/12; 46 (13): 1931-3.

522043. [uÀ]yŽãƒfƒBƒx[ƒg‘æ18‰ñ: —H–å‘€ˆÝØœŒã‚ÅBillroth-I–@ÄŒš‚ª‚Å‚«‚È‚¢ê‡‚̍Čš•û–@‚Ì‘I‘ðzRoux-en-Y–@ vs. Billroth-II–@: Roux-en-Y–@‚Ì—§ê‚©‚ç. ˜h”ö^—ˆ€1, ”äŠé’ŒŽ÷1 (1ã•”Á‰»ŠÇŠO): Á‰»ŠíŠO‰È 2019/10; 42 (11): 1600-2.

522044. [uÀ]y“ÁW: • o‹Ÿ‰ºˆÝŽèp‚Ì‚·‚ׂāz¡Šî‘b•Ò@äX‰tᑃ[ƒ‚ð‚ß‚Ž‚µ‚œƒŠƒ“ƒpßŠsŽp. ˜h”ö^—ˆ€1, ”äŠé’ŒŽ÷1 (1ã•”Á‰»ŠÇŠO): —Տ°ŠO‰È 2019/10; 74 (10): 1156-62.

522045. [uÀ]y“ÁW: Á‰»ŠíŽîᇂɑ΂·‚é• o‹ŸE“àŽ‹‹Ÿ‡“¯Žèp (LECS) up datezI. ‘˜_@LECSŠT˜_|LECSŠJ”­‚ÌŒoˆÜ‚Æ‚»‚ÌŒã‚Ì”­“W. ”äŠé’ŒŽ÷ (ã•”Á‰»ŠÇŠO): —Տ°ŽGŽŠO‰È 2019/10; 81 (11): 1105-8.

522046. [uÀ]y“ÁW: ŽüpŠúENP‰º‚É‚š‚¯‚éƒGƒrƒfƒ“ƒX‚Æ–â‘è“_zŽüpŠúPPN‚̐¥”ñ. VŒŽ³‘å1, ”äŠé’ŒŽ÷1 (1ã•”Á‰»ŠÇŠO): ŠO‰È‚Æ‘ãŽÓ¥‰h—{ 2020/2; 54 (1): 31-5.

[’˜@‘]

620039. [Šwp‘ (•ª’SŽ·•M)]y•ÊûuˆãŠw‚Ì‚ ‚ä‚݁vƒƒ{ƒbƒgŽx‰‡Žèp‚̍őOüzŠe˜_@15. ˆÝŠà‚ɑ΂·‚郍ƒ{ƒbƒgŽx‰‡ˆÝØœp, p.76-82. ×“c@Œj1, ŽR‰ºŒpŽj1,2 (1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã), •Ò: ‹v•ÄtŠì, ˆãŽ•–òo”Å, “Œ‹ž, 2019/8”­s.

620040. [Šwp‘ (•ª’SŽ·•M)]y“à‰Èˆã‚É‹‚ß‚ç‚ê‚é‘Œ‰È‚Ì’mŽ¯ (—Տ°ŽGŽ“à‰È2019”N9ŒŽ‘‘卆)z<‘æ1Í ŠO‰È>@C. Á‰»ŠíŠO‰È@ˆÝ‚ª‚ñ, p.1749-51. ×“c@Œj1, ”äŠé’ŒŽ÷1 (1ã•”Á‰»ŠÇŠO), “ì]“°, “Œ‹ž, 2019/9”­s.

620041. [Šwp‘ (•ª’SŽ·•M)]y“à‰Èˆã‚É‹‚ß‚ç‚ê‚é‘Œ‰È‚Ì’mŽ¯|ê–å‰Æ‚ª“`‚Š‚éDo/Don't (—Տ°ŽGŽ“à‰È2019”N9ŒŽ‘‘卆)z‘æ1Í ŠO‰È@C. Á‰»ŠíŠO‰È@ˆÝ‚ª‚ñ, p.1749-51. ×“c@Œj1, ”äŠé’ŒŽ÷1 (1ã•”Á‰»ŠÇŠO), “ì]“°, “Œ‹ž, 2019/9”­s.

620042. [Šwp‘ (•ª’SŽ·•M)]y‚·‚®‚ÉŽg‚Š‚éŽüpŠúŠÇ—ƒ}ƒjƒ…ƒAƒ‹ (—Տ°ŠO‰È2019”N10ŒŽ‘Š§†)z¡IÍ ŽüpŠúŠÇ—E‘˜_@p‘OpŒã‰h—{ŠÇ—, p.11-4. ‹‹vGŽ÷1, ”äŠé’ŒŽ÷1, ×“c@Œj1, VŒŽ³‘å1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ€1, ŒŽ“cG‹P1, ŽR‰ºŒpŽj1,2 (1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã), ˆãŠw‘‰@, “Œ‹ž, 2019/10”­s.

[Šw‰ïEŒ€‹†‰ï“™]

721010. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) LECS‚ÌŒ»‹µ‚Æ“W–]. ”äŠé’ŒŽ÷ (ã•”Á‰»ŠÇŠO): ‘æ97‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ï‘‰ï (2019/6/1), “Œ‹ž.

721011. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) Žæ‚ê‚é‚©‚çŽæ‚ç‚È‚¢ˆÝŠO‰Èˆã, ƒxƒbƒhƒTƒCƒh‚ōl‚Š‚éˆÝŠO‰Èˆã‚É‚È‚Á‚Ä‚Ù‚µ‚¢. ”äŠé’ŒŽ÷ (ã•”Á‰»ŠÇŠO): ‘æ81‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2019/11/16), ‚’m.

722062. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) Á‰»ŠÇŠO‰ÈŽèp‚É‚š‚¯‚é–D‡•s‘S‘΍ô‚ɂ‚¢‚čl‚Š‚é1@—H–å‘€ˆÝØœ, Billroth-1ÄŒš‚É‚š‚¯‚é’ZˆÝ“®–¬‰·‘¶Tension free•«‡‚̍H•v. ˜h”ö^—ˆ€1, ×“c@Œj1, “Y–ìF•¶2, ŒŽ“cG‹P1, ŸN’J”ü‹MŽq1, ‹‹vGŽ÷1, VŒŽ³‘å1, ŽR‰ºŒpŽj1,3, ”äŠé’ŒŽ÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ81‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2019/11/14), ‚’m.

722063. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) “àŽ‹‹ŸŠO‰ÈŽèp“Á—L‚̍‡•¹Ç‚ɂ‚¢‚čl‚Š‚é@• o‹ŸˆÝØœ‚É‚š‚¯‚éäXã‰ŠsŽŽž‚ÌäX“]‚ª‚µ–@‚̍H•v. ‹‹vGŽ÷1, ×“c@Œj1, VŒŽ³‘å1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ€1, ŒŽ“cG‹P1, ŽR‰ºŒpŽj1,2, ”äŠé’ŒŽ÷1 (1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ81‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2019/11/14), ‚’m.

722064. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ƒƒ{ƒbƒgŽèp‚Ì“K‰ž‚ƍ‡•¹Ç‚ɂ‚¢‚čl‚Š‚é@ƒƒ{ƒbƒgŽx‰‡• o‹Ÿ‰ºˆÝØœp‚̏p’†EpŒã‡•¹Ç. ˜h”ö^—ˆ€1, ×“c@Œj1, “Y–ìF•¶2, ŒŽ“cG‹P1, ŸN’J”ü‹MŽq1, ‹‹vGŽ÷1, VŒŽ³‘å1, ŽR‰ºŒpŽj1,3, ”äŠé’ŒŽ÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ81‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2019/11/14), ‚’m.

722065. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ˆÝØœŒã‚̍Čš•û–@‚ɂ‚¢‚čl‚Š‚é@• o‹Ÿ‰º•¬–å‘€ˆÝØœp, pŒã‡•¹Ç‚ÌŒŸ“¢. “Y–ìF•¶1, ŒŽ“cG‹P2, ˜h”ö^—ˆ€2, ŸN’J”ü‹MŽq2, ‹‹vGŽ÷2, VŒŽ³‘å2, ×“c@Œj2, ŽR‰ºŒpŽj2,3, ”äŠé’ŒŽ÷2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ã•”Á‰»ŠÇŠO, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ81‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2019/11/15), ‚’m.

723260. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆÝŠàŠ³ŽÒ‚É‚š‚¯‚éABCf’f‚ÆKK-LC-1”­Œ»‚ÌŠÖ˜A«‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ’†”nŠî”Ž1,2, M‘ŸºŽq3, •ŸŽR@—², “ñ“nM], ŽR‘º—Úˆß, Žž”C’‘1,4, ç–ìTˆê˜Y4, ‹v•Û”CŽj5, ‹ß“¡NŽj1,6, Œ@”ªŽk1, ’r‰i@œ1,6, ‚‹Ž’õl1,5, ¬—ÑŒ›’‰1, ŽRè@“™1,3, “n粏¹•F7 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2ã•”Á‰»ŠÇŠO, 3•a—, 4‰º•”Á‰»ŠÇŠO, 5ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 6“û‘BEbó‘BŠO, 7–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ119‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/4/18), ‘åã.

723261. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒƒ{ƒbƒgŽx‰‡• o‹Ÿ‰ºˆÝØœp‚Ì—L—p«‚Æ–â‘è“_. ×“c@Œj1, ŽOd–ì_˜N1, ]ŠÔ@—æ1, ‹‹vGŽ÷1, ˜h”ö^—ˆ€1, “n粏¹•F2, ŽR‰ºŒpŽj1,3 (1ã•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ119‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/4/18), ‘åã.

723262. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) H“¹ˆÝÚ‡•”Šà‚ÌŽ¡—Ð헪. r–؈ꕺ‘Ÿ1, ×“c@Œj1, ˜h”ö^—ˆ€1, ‹‹vGŽ÷1, ]ŠÔ@—æ1, ŽOd–ì_˜N1, “n粏¹•F2, ŽR‰ºŒpŽj1,3 (1ã•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ119‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/4/18), ‘åã.

723263. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) H“¹ŠàŽèp‚É‚š‚¯‚éŽüpŠúƒTƒ|[ƒg‚ÌŒŸ“¢: e-sheet‚Ì“±“ü. ‹‹vGŽ÷1, ‹e’r“Þ•äŽq2, ×“c@Œj1, ˜h”ö^—ˆ€1, ]ŠÔ@—æ1, ŽOd–ì_˜N1, X’JGŒõ1, ŽR‰ºŒpŽj1,3, “n粏¹•F4 (1ã•”Á‰»ŠÇŠO, 2‰h—{•”, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 4–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ119‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/4/18), ‘åã.

723264. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) H“¹G•œã”çŠà‚ɑ΂·‚鍪Ž¡“I‰»Šw•úŽËü—Ö@Œã‚ÌSalvageŽèp‚ÌŒŸ“¢. ŒŽ“cG‹P1, “Y–ìF•¶2, ˜h”ö^—ˆ€1, ‹‹vGŽ÷1, ]ŠÔ@—æ1, ŽOd–ì_˜N1, ×“c@Œj1, “n粏¹•F3, ŽR‰ºŒpŽj1,4, ”äŠé’ŒŽ÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ73‰ñ“ú–{H“¹Šw‰ïŠwpW‰ï (2019/6/6), •Ÿ‰ª

723265. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒƒ{ƒbƒgŽx‰‡‹¹o‹Ÿ‰ºH“¹Øœp‚̈À‘S‚È“±“ü. ×“c@Œj1, ŽOd–ì_˜N1, ]ŠÔ@—æ1, ‹‹vGŽ÷1, ˜h”ö^—ˆ€1, ŽR‰ºŒpŽj1,2, “n粏¹•F3, ”äŠé’ŒŽ÷1 (1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ73‰ñ“ú–{H“¹Šw‰ïŠwpW‰ï (2019/6/7), •Ÿ‰ª

723266. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) èò‹¹•”‹«ŠEH“¹Šà‚ÌŽ¡—ЬÑ, í—ª. “Y–ìF•¶1, ŽR‰ºŒpŽj2,3, ŒŽ“cG‹P3, ˜h”ö^—ˆ€3, ‹‹vGŽ÷3, ]ŠÔ@—æ3, ŽOd–ì_˜N3, ×“c@Œj3, “n粏¹•F4, ”äŠé’ŒŽ÷3 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3ã•”Á‰»ŠÇŠO, 4–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ73‰ñ“ú–{H“¹Šw‰ïŠwpW‰ï (2019/6/7), •Ÿ‰ª

723267. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) H“¹ŠàŽèp‚É‚š‚¯‚éŽüpŠúƒTƒ|[ƒg‚ÌŒŸ“¢: e-sheet‚Ì“±“ü. ŒŽ“cG‹P1, ‹‹vGŽ÷1, ‹e’r“Þ•äŽq2, ×“c@Œj1, ˜h”ö^—ˆ€1, ŸN’J”ü‹MŽq1, VŒŽ³‘å1, X’JGŒõ1, ŽR‰ºŒpŽj1,3, ”äŠé’ŒŽ÷1 (1ã•”Á‰»ŠÇŠO, 2‰h—{•”, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): “ú–{ŠO‰È‘ãŽÓ‰h—{Šw‰ï‘æ56‰ñŠwpW‰ï (2019/7/5), •ºŒÉ.

723268. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒƒ{ƒbƒgŽx‰‡ˆÝŠàŽèp‚Ì“Á’¥‚ƍ¡Œã‚̉ۑè. ×“c@Œj1, ŽOd–ì_˜N1, ]ŠÔ@—æ1, ‹‹vGŽ÷1, ˜h”ö^—ˆ€1, ŽR‰ºŒpŽj1,2, “n粏¹•F3 (1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ74‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2019/7/17), “Œ‹ž.

723269. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Á‰»ŠÇŠO‰È—̈æ‚É‚š‚¯‚éV‹KƒoƒCƒIƒ}[ƒJ[@H“¹G•œã”çŠà‚É‚š‚¯‚é–òÜ‘ϐ«‚ÉŠÖ—^‚·‚郢Np63/SOX2ˆâ“`Žq‚Ì—\‘ªƒ}[ƒJ[‚Æ‚µ‚Ä‚ÌŒŸ“¢. ŒŽ“cG‹P1, ‘åò—z‰î2, “Y–ìF•¶2, ˜h”ö^—ˆ€1, ‹‹vGŽ÷1, ]ŠÔ@—æ1, ŽOd–ì_˜N1, ×“c@Œj1, “n粏¹•F3, ŽR‰ºŒpŽj1,4 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ74‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2019/7/17), “Œ‹ž.

723270. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Øœ•s”\isˆÝŠà‚ɑ΂·‚éDocetaxel + CDDP + S-1 (DCS) conversion surgery. ˜h”ö^—ˆ€1, ×“c@Œj1, “Y–ìF•¶2, ŒŽ“cG‹P1, ‹‹vGŽ÷1, ]ŠÔ@—æ1, ŽOd–ì_˜N1, “n粏¹•F3, ŽR‰ºŒpŽj1,4 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ74‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2019/7/18), “Œ‹ž.

723271. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • –Œ”dŽíˆÝŠà‚ɑ΂·‚éDocetaxel + CDDP + S-1 (DCS) —Ö@Œã‚̐؏œ—á‚ÉŠÖ‚·‚錟“¢. ‹‹vGŽ÷1, ×“c@Œj1, ŽOd–ì_˜N1, ˜h”ö^—ˆ€1, ŒŽ“cG‹P1, ]ŠÔ@—æ1, ŽR‰ºŒpŽj1,2, “n粏¹•F3 (1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ74‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2019/7/19), “Œ‹ž.

723272. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) isˆÝŠà‚É‚š‚¯‚épŒã•â•‰»Šw—Ö@‚ÌŒø‰Ê—\‘ªƒ}[ƒJ[‚Å‚ ‚éŠà“ÁˆÙ“ICDO1ˆâ“`Žq‚ÌDNAƒƒ`ƒ‹‰»‚̈Ӌ` (Prediction of efficacy of postoperative chemotherapy by promoter DNA methylation of CDO1 gene in advanced gastric cancer). ŒŽ“cG‹P1, “Y–ìF•¶2, ‰¡ˆäŒ\Œå3, ˜h”ö^—ˆ€1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, ×“c@Œj1, ”äŠé’ŒŽ÷1, ŽR‰ºŒpŽj1,4 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3‰º•”Á‰»ŠÇŠO, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ78‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï (2019/9/27), ‹ž“s.

723273. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Á‰»ŠÇŠO‰È—̈æ‚É‚š‚¯‚郍ƒ{ƒbƒgŽx‰‡Žèp‚̈ʒu‚¯: ã•”Á‰»ŠÇŠO‰È—̈æ‚É‚š‚¯‚郍ƒ{ƒbƒgŽèp. ×“c@Œj1, “Y–ìF•¶2, ŒŽ“cG‹P1, ˜h”ö^—ˆ€1, ŸN’J”ü‹MŽq1, ‹‹vGŽ÷1, VŒŽ³‘å1, ŽR‰ºŒpŽj1,3, ”äŠé’ŒŽ÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ81‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2019/11/14), ‚’m.

723274. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) pŒã‡•¹Ç‚ŋꂵ‚ñ‚ŸÇ—á1 (ã•”Á‰»ŠÇ): ŽcˆÝ‘S“EpŒã‚Ì’x”­«• o“àoŒŒ‚ɑ΂µ, p’†ŒoƒJƒe[ƒeƒ‹“®–¬Çð‚ðŽ{s‚µ‚œˆê—á. ŒŽ“cG‹P1, “Y–ìF•¶2, ˜h”ö^—ˆ€1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, VŒŽ³‘å1, ×“c@Œj1, ŽR‰ºŒpŽj1,3, ”äŠé’ŒŽ÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ81‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2019/11/14), ‚’m.

723275. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) H“¹ŠàªŽ¡p‚ɑ΂µ‚Ä–D‡•s‘Sƒ[ƒ‚ð–ÚŽw‚µ‚œH•v. VŒŽ³‘å1, ×“c@Œj1, ‹‹vGŽ÷1, ˜h”ö^—ˆ€1, ŸN’J”ü‹MŽq1, ŒŽ“cG‹P1, ŽR‰ºŒpŽj1,2, ”äŠé’ŒŽ÷1 (1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ81‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2019/11/16), ‚’m.

723276. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • o‹Ÿ‰º•¬–å‘€ˆÝØœp‚̍Čš@• o‹Ÿ‰º•¬–å‘€ˆÝØœp: ãì–@ vs Orvil–@. “Y–ìF•¶1, ŒŽ“cG‹P2, ˜h”ö^—ˆ€2, ŸN’J”ü‹MŽq2, ‹‹vGŽ÷2, VŒŽ³‘å2, ×“c@Œj2, ŽR‰ºŒpŽj2,3, ”äŠé’ŒŽ÷2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ã•”Á‰»ŠÇŠO, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ32‰ñ“ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ï‘‰ï (2019/12/5), ‰¡•l.

723277. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰ü‚߂đ̈ʂɂæ‚éãcŠuŠsŽ‚̈Ⴂ‚ðl‚Š‚é: ƒƒ{ƒbƒgŽx‰‡Žèp‚ÉŒü‚¯‚Ä. VŒŽ³‘å1, ×“c@Œj1, ‹‹vGŽ÷1, ˜h”ö^—ˆ€1, ŸN’J”ü‹MŽq1, ŒŽ“cG‹P1, ŽR‰ºŒpŽj1,2, ”äŠé’ŒŽ÷1 (1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ32‰ñ“ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ï‘‰ï (2019/12/5), ‰¡•l.

723278. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒƒ{ƒbƒgŽx‰‡‹¹o‹Ÿ‰ºH“¹Øœp‚Ì—L—p«. ×“c@Œj1, “Y–ìF•¶2, ŒŽ“cG‹P1, ˜h”ö^—ˆ€1, ŸN’J”ü‹MŽq1, ‹‹vGŽ÷1, VŒŽ³‘å1, ŽR‰ºŒpŽj1,3, ”äŠé’ŒŽ÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ32‰ñ“ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ï‘‰ï (2019/12/5), ‰¡•l.

723279. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) 80ÎˆÈã‚—îŽÒˆÝŠà‚ÌŠO‰ÈŽ¡—ЬÑ‚Æ‚»‚ÌŒ»‹µ. ŒŽ“cG‹P1, “Y–ìF•¶2, ˜h”ö^—ˆ€1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, VŒŽ³‘å1, ×“c@Œj1, ŽR‰ºŒpŽj1,3, ”äŠé’ŒŽ÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ32‰ñ“ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ï‘‰ï (2019/12/6), ‰¡•l.

723280. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) H“¹ˆÝÚ‡•”Šà‚ɑ΂·‚éÄŒš‚̍H•v: ‹¹o‹Ÿ‰ºãì–@ÄŒš. ‹‹vGŽ÷1, ×“c@Œj1, VŒŽ³‘å1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ€1, ŒŽ“cG‹P1, “Y–ìF•¶2, ŽR‰ºŒpŽj1,3, ”äŠé’ŒŽ÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ32‰ñ“ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ï‘‰ï (2019/12/7), ‰¡•l.

723281. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆÝŠà‚ɑ΂·‚郍ƒ{ƒbƒgŽx‰‡Žèp‚Ì’ZŠú¬Ñ. ŸN’J”ü‹MŽq1, ×“c@Œj1, “Y–ìF•¶2, ŒŽ“cG‹P1, ˜h”ö^—ˆ€1, ‹‹vGŽ÷1, VŒŽ³‘å1, ŽR‰ºŒpŽj1,3, ”äŠé’ŒŽ÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ32‰ñ“ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ï‘‰ï (2019/12/7), ‰¡•l.

723282. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • o‹Ÿ“àŽ‹‹Ÿ‡“¯Žèp (LECS) ‚̐V“WŠJ: ƒnƒCƒŠƒXƒN•¹‘¶Ç‚ð—L‚·‚éisˆÝŠàŠ³ŽÒ‚ɑ΂·‚éŠÉ˜aLECS‚̈ê—á. ˜h”ö^—ˆ€1, ”äŠé’ŒŽ÷1, “Y–ìF•¶2, ŒŽ“cG‹P1, ŸN’J”ü‹MŽq1, ‹‹vGŽ÷1, VŒŽ³‘å1, ×“c@Œj1, ŽR‰ºŒpŽj1,3 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ32‰ñ“ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ï‘‰ï (2019/12/7), ‰¡•l.

732021. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) “àŽ‹‹Ÿ‚ð—p‚¢‚œŠO‰È‚Æ“à‰È‚̃Rƒ‰ƒ{ƒŒ[ƒVƒ‡ƒ“Ž¡—Ã: LECS‚͈݋ǏŠØœ‚Ì’èŒ^Žè‹Z‚Æ‚È‚é‚©? ”äŠé’ŒŽ÷ (ã•”Á‰»ŠÇŠO): ‘æ108‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ïŠÖ“ŒŽx•”—á‰ï (2019/6/8), “Œ‹ž.

733112. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) • o‹Ÿ•â•‰º•¬–å‘€ˆÝØœpÄŒšŽž‚̈ݐH“¹‹t—¬‚Ì—\–h‚É‚š‚¯‚éDouble-flap–@ÄŒš‚ÆOrvil–@ÄŒš‚ÌŒŸ“¢. ×“c@Œj1, ‹‹vGŽ÷1, ŽOd–ì_˜N1, ]ŠÔ@—æ1, ˜h”ö^—ˆ€1, ŒŽ“cG‹P1, VŒŽ³‘å1, ŸN’J”ü‹MŽq1, ŽR‰ºŒpŽj1,2, ”äŠé’ŒŽ÷1 (1ã•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ28‰ñÁ‰»ŠíŽŸŠ³•a‘ÔŽ¡—ÃŒ€‹†‰ï (2019/9/7), ˆ€’m.

733113. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) CDO1ˆâ“`Žqƒƒ`ƒ‹‰»‚ð—˜—p‚µ‚œV‹Kf’f–@: ˆÝŠàDNA• …ôò×–Ef‚ÌŠm—§. ŒŽ“cG‹P1, “Y–ìF•¶2, ˜h”ö^—ˆ€1, ŸN’J”ü‹MŽq1, ‹‹vGŽ÷1, VŒŽ³‘å1, ×“c@Œj1, ŽR‰ºŒpŽj1,3, ”äŠé’ŒŽ÷1 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ39‰ñ“ú–{•ªŽqŽîᇃ}[ƒJ[Œ€‹†‰ï (2019/9/25), ‹ž“s.

733114. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “–‰@‚É‚š‚¯‚éˆÝØœŒãERAS‚ÌŠm—§‚ÉŒü‚¯‚ā`Œ»ó‚ƍ¡Œã‚Ì“W–]‚ɂ‚¢‚ā`. ŸN’J”ü‹MŽq1, ”äŠé’ŒŽ÷1, “Y–ìF•¶2, ŒŽ“cG‹P1, ˜h”ö^—ˆ€1, ‹‹vGŽ÷1, VŒŽ³‘å1, ×“c@Œj1, ŽR‰ºŒpŽj1,3 (1ã•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ8‰ñ_“ސìŽüpŠúŠÇ—Œ€‹†‰ï (2020/2/12), _“ސì

'18”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'18-110009. [ŒŽ’˜] Comparison of double-flap and OrVil techniques of laparoscopy-assisted proximal gastrectomy in preventing gastroesophageal reflux: a retrospective cohort study. Hosoda K1, Washio M1, Mieno H1, Moriya H1, Ema A1, Ushiku H1, Watanabe M2, Yamashita K1,3: Langenbecks Arch Surg 2019/2; 404 (1): 81-91. (×“c@Œj1, ˜h”ö^—ˆ€1, ŽOd–ì_˜N1, X’JGŒõ1, ]ŠÔ@—æ1, ‹‹vGŽ÷1, “n粏¹•F2, ŽR‰ºŒpŽj1,3: 1ã•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

'18-110010. [ŒŽ’˜] Prediction of onset of remnant gastric cancer by promoter DNA methylation of CDO1/ HOPX/ Reprimo/ E-cadherin. Kojima K, Minatani N, Ushiku H1, Ishii S1, Tanaka T2, Yokoi K2, Nishizawa N3, Ooizumi Y, Igarashi K, Hosoda K2, Moriya H2, Mieno H, Watanabe M4, Yamashita K1,5: Oncotarget 2019/3; 10 (25): 2423-34. (¬›žŒc‘Ÿ1, ‹‹vGŽ÷2, Îˆä@’q2, “c’†r“¹3, ‰¡ˆäŒ\Œå3, ŒàVL‹±4, ×“c@Œj2, X’JGŒõ2, ŽOd–ì_˜N, “n粏¹•F5, ŽR‰ºŒpŽj2,6: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ã•”Á‰»ŠÇŠO, 3‰º•”Á‰»ŠÇŠO, 4ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 5–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 6V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

[Šw‰ïEŒ€‹†‰ï“™]

'18-723007. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) cStage II/III H“¹G•œã”çŠà‚ɑ΂·‚éDCF‚É‚æ‚éneoadjuvant chemotherapy‚ÌŒø‰Ê. ŽR‰ºŒpŽj1,2, X’JGŒõ2, ŽOd–ì_˜N2, ]ŠÔ@—æ2, ˜h”ö^—ˆ€2, ŒŽ“cG‹P2, “n粏¹•F3 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2ã•”Á‰»ŠÇŠO, 3–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ73‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2018/7/12), “Œ‹ž.

'18-723008. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) H“¹G•œã”çŠà‚É‚š‚¯‚éHDAC‘jŠQÜ‚ÌŠŽŽó«‹K’èˆöŽqŒó•â‚Ì“¯’èSOX2/¢Np63”­Œ»‚̈Ӌ`. ‘åò—z‰î1, ŽR‰ºŒpŽj2,3, ‰Á“¡@O4, ŒÜ\—’ˆê°, ¬›žŒc‘Ÿ, “c’†—uŽq1, ŒŽ“cG‹P3, ‰¡“c˜aŽq1, ’†–{CŽi1, “n粏¹•F5 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3ã•”Á‰»ŠÇŠO, 4“û‘BEbó‘BŠO, 5–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ38‰ñ“ú–{•ªŽqŽîᇃ}[ƒJ[Œ€‹†‰ï (2018/9/26), ‘åã.


‰º•”Á‰»ŠÇŠO‰ÈŠw

[Šwp˜_•¶]

110197. [ŒŽ’˜] Short-term and midterm outcomes of single-incision laparoscopic surgery for right-sided colon cancer. Ishii Y1,2, Yahagi M2, Ochiai H2, Sako H2, Amemiya R2, Maeda H2, Ogiri M2, Kamiya N2,3, Watanabe M1,2 (1Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, 2Department of Surgery, Kitasato University Kitasato Institute Hospital, 3Department of Thoracic Surgery, Kitasato University School of Medicine): Surg Laparosc Endosc Percutan Tech 2019/7; 12 (3): 275-80. (Îˆä—ǍK1,2, _’J‹I‹P2,3, “n粏¹•F1,2: 1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 3ŒÄ‹zŠíŠO)

110198. [ŒŽ’˜] Influence of chemoradiotherapy on nutritional status in locally advanced rectal cancer: Prospective multicenter study. Yamano T, Tomita N, Sato T1, Hayakawa K, Kamikonya N, Matoba S, Uki A, Baba H, Oya N, Hasegawa H, Shigematsu N, Hiraoka M, Shimada M, Noda M, Sakai Y, Sato H, Saegusa M2, Takeuchi M, Oguchi M, Oya M, Watanabe M1,3: Nutrition 2020/9; 77: 110807. doi: 10.1016/j.nut.2020.110807. Epub 2020 Mar 19. (²“¡•˜Y1, ŽOŽ}@M2, “n粏¹•F1,3: 1‰º•”Á‰»ŠÇŠO, 2•a—, 3–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@)

110199. [ŒŽ’˜] Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer. Hamaguchi T, Denda T, Kudo T, Sugimoto N, Ura T, Yamazaki K, Fujii H, Kajiwara T, Nakajima TE, Takahashi S, Otsu S, Komatsu Y, Nagashima F, Moriwaki T, Esaki T, Sato T1, Itabashi M, Oki E, Sasaki T, Chiron M, Yoshino T: Cancer Sci 2019/11; 110 (11): 3565-72. (²“¡•˜Y1: 1‰º•”Á‰»ŠÇŠO)

110200. [ŒŽ’˜] WiNTRLINC1/ASCL2/c-Myc Axis Characteristics of Colon Cancer with Differentiated Histology at Young Onset and Essential for Cell Viability. Yokota K1, Tanaka Y1, Harada H1, Kaida T1, Nakamoto S1, Soeno T1, Fujiyama Y1, Yokota M1, Kojo K2, Miura H2, Yamanashi T2, Sato T2, Nakamura T2, Watanabe M2,3, Yamashita K4,5: Ann Surg Oncol 2019/12; 26 (13): 4826-34. (‰¡“c˜aŽq1, “c’†—uŽq1, ŒŽ“cG‹P1, b”ã“c•Žu1, ’†–{CŽi1, “Y–ìF•¶1, “¡ŽR–FŽ÷1, ‰¡“cŒõ‰›1,ŒÃé@Œ›2, ŽO‰YŒ[šæ2, ŽR—œ‚L2, ²“¡•˜Y2, ’†‘º—²r2, “n粏¹•F2,3, ŽR‰ºŒpŽj4,5: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2‰º•”Á‰»ŠÇŠO, 3–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 5ã•”Á‰»ŠÇŠO)

110201. [ŒŽ’˜] Laparoscopic surgery to treat leiomyosarcomas of the sigmoid colon:a case report and literature review. Yahagi M1, Ishii Y1,2, Hara A, Watanabe M1,2 (1Department of Surgery, Kitasato University Kitasato Institute Hospital, 2Department of Surgery, Kitasato University School of Medicine): Surg Case Rep 2019/12; 5: 20. (Îˆä—ǍK1,2, “n粏¹•F1,2: 1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2‰º•”Á‰»ŠÇŠO)

110202. [ŒŽ’˜] Risk Factors for Wound Infection After Laparoscopic Surgery for Colon Cancer. Nakamura T1, Takayama Y2, Sato T1, Watanabe M1,3: Surg Laparosc Endosc Percutan Tech 2020/2; 30 (1): 45-8. (’†‘º—²r1, ‚ŽR—zŽq2, ²“¡•˜Y1, “n粏¹•F1,3: 1‰º•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 3–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@)

110203. [ŒŽ’˜] The superior approach with the stomach roll-up technique improves intraoperative outcomes and facilitates learning laparoscopic distal pancreatectomy: a comparative study between the superior and inferior approach. Morikawa T, Ishida M, Takadate T, Hata T, Iseki M, Kawaguchi K, Ohtsuka H, Mizuma M, Hayashi H, Nakagawa K, Motoi F, Kamei T, Naitoh T1, Unno M: Surg Today 2020/2; 50 (2): 153-62. (“à“¡@„1: 1‰º•”Á‰»ŠÇŠO)

310026. [Ç—á•ñ] Mixed adenoneuroendocrine carcinoma of the ampulla of Vater: a case report and literature review. Yoshimachi S, Ohtsuka H, Aoki T, Miura T, Ariake K, Masuda K, Ishida M, Mizuma M, Hayashi H, Nakagawa K, Morikawa T, Motoi F, Kanno A, Masamune A, Fujishima F, Sasano H, Kamei T, Naitoh T1, Unno M: Clin J Gastroenterol 2020/2; 13 (1): 37-45. (“à“¡@„1: 1‰º•”Á‰»ŠÇŠO)

320014. [Ç—á•ñ] ãè–åŠÇG•œã”çŠà‚ɑ΂·‚éWŠw“IŽ¡—Â̑I‘ð|3—á‚ÌŒŸ“¢|. ŒÃé@Œ›1, ¬‘q’Œl1, ª–{¹”V, Š™“cOŽ÷, ×“c“ÄŽu1, “¡–ìŽjD1, X£¹Ž÷, ’†‘º—²r1, “n粏¹•F1,2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): –k—¢ˆãŠw 2019/6; 49 (1): 15-9.

320015. [Ç—á•ñ] Š®‘S“à‘Ÿ‹tˆÊ‚ɍ‡•¹‚µ‚œSóŒ‹’°Šà‚ɑ΂µ• o‹Ÿ‰ºSóŒ‹’°Øœ‚ðŽ{s‚µ‚œ1—á. ç–ìTˆê˜Y1,2, “à“¡³‹K1,2, ‹‹vGŽ÷3, b”ã“c•Žu4, ‹v•Û”CŽj5, ŽR‰º@q1, ’†”nŠî”Ž1,3, Žž”C’‘1,2, ‹ß“¡NŽj1,6, Œ@”ªŽk1, ‚‹Ž’õl1,5, “n粏¹•F2,7 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2‰º•”Á‰»ŠÇŠO, 3ã•”Á‰»ŠÇŠO, 4‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 5ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 6“û‘BEbó‘BŠO, 7–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@) Šà‚Ɖ»Šw—Ö@ 2019/6; 46 (6): 1073-5.

320016. [Ç—á•ñ] Mesodiverticular band‚𔺂€MeckelŒeŽº‚É‚æ‚éiN«’°•ÂÇ‚Ì1—á. Œã“¡‘ì–ç1, ’†‘º—²r2, “Y–ìF•¶1, Îˆä@’q3 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2‰º•”Á‰»ŠÇŠO, 3ã•”Á‰»ŠÇŠO): “ú–{• •”‹~‹}ˆãŠw‰ïŽGŽ 2019/9; 39 (6): 1091-3.

320017. [Ç—á•ñ] ¬’°Žq‹{“à–ŒÇ‚ðf’f‚µ• o‹Ÿ‰º‰ñ–Ó•”Øœp‚ðŽ{s‚µ‚œ1—á. ¬‹Ë‰ë¢1, —Ž‡‘åŽ÷1, Îˆä—ǍK1,2, ‰J‹{—²‰î1, ”—@—T”V1, ‘O“c“úØŽq1, _’J‹I‹P1,3, ‘åì¹‹`1, ŒÜŒŽ—Œbˆê1, ’†–ì@‰ë1, “n粏¹•F1,2 (1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2‰º•”Á‰»ŠÇŠO, 3ŒÄ‹zŠíŠO): Progress of Digestive Endoscopy 2019/12; 95 (1): 87-9.

320018. [Ç—á•ñ] ‰»Šw—Ö@‚ª‘tŒø‚µäNã÷‚ð‰·‘¶‚µ“Ÿ‚œäNã÷Z’Œ’°Šà‚Ì1Øœ—á. ¬‹v•ÛãĎu, “‚àVG–Ÿ, ŠŒŽ‘å‹P, ‘åÀ@”E, —é–؏GK, _ŽR“ÄŽj, “n•Ó˜aG, Î“cFé, ‹Tˆä@®, “à“¡@„1, ŠC–ì—Ï–Ÿ (1‰º•”Á‰»ŠÇŠO): Šà‚Ɖ»Šw—Ö@ 2020/1; 47 (1): 135-7.

522047. [uÀ]y“ÁW: Innovative‚È‘å’°Šàf’fEŽ¡—Áz6. ‹ÇŠis’Œ’°Šà‚ɑ΂·‚鉻Šw•úŽËü—Ö@Ž{sŒã‚Ìwatch and wait‚ÌŽÀÛ. ²“¡•˜Y1, ’†‘º—²r1, ŽR—œ‚L1, ŽO‰YŒ[šæ1, ŒÃé@Œ›1, ‰¡ˆäŒ\Œå1, ”‹ŒŽçŒb1, ŠÛŽR³—T2, â–{ƒˆê3 (1‰º•”Á‰»ŠÇŠO, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 3“û‘BEbó‘BŠO): —Տ°ŽGŽŠO‰È 2019/9; 81 (10): 1036-41.

522048. [uÀ]y“ÁW: IPMNEMCN‘Ûf—ÃKƒCƒhƒ‰ƒCƒ“‘‚܂Ƃ߁zk¬Žèp. Î“c»Œº, XìF‘¥, ‚ŠÙ’B”V, Œ³ˆä“~•F, “à“¡@„1, ŠC–ì—Ï–Ÿ (1‰º•”Á‰»ŠÇŠO): ’_‚ÆäX 2020/1; 41 (1): 59-64.

522049. [uÀ]y“ÁW: Á‰»ŠíŠO‰È‚É‚š‚¯‚ére-doŽèpzI. Á‰»ŠÇ@2. Œž—ÊŽèp‚É‚š‚¯‚érevision surgery. ˆä–{”Ž•¶, “à“¡@„1 (1‰º•”Á‰»ŠÇŠO): —Տ°ŽGŽŠO‰È 2020/2; 82 (2): 106-10.

522050. [uÀ]y“ÁW: ˆê”ʁEÁ‰»ŠíŠO‰Èˆã‚Ì‚œ‚߂́@‚Å‚«‚é! Š¿•ûz¡ŽüpŠú‚ðŠ¿•û‚ŃTƒ|[ƒg‚·‚é@ã•”Á‰»ŠÇŽèp@• o‹Ÿ‰º—H–å‘€ˆÝØœpŒãŠÇ—‚ւ̘ZŒNŽq“’‚Ì“±“üŒø‰Ê. •ŽÒGº, ˆä–{”Ž•¶, ŽR‘º–ŸŠ°, Â–؁@‹, “c’†’ŒŽ÷, “à“¡@„1, ‹Tˆä@®, ŠC–ì—Ï–Ÿ (1‰º•”Á‰»ŠÇŠO): —Տ°ŠO‰È 2020/3; 75 (3): 292-8.

530007. [‚»‚Ì‘Œ (Comment)] ASO Author Reflections: ASCL2, a Marker of Dynamic Colon Stem Cell, Involved in Wnt Pathway Activation Reflects Anti-cancer Drug Resistance in Primary Colorectal Cancer. Tanaka T1, Yamashita K2,3: Ann Surg Oncol 2019/12; 26 (Suppl 3): 634. (“c’†r“¹1, ŽR‰ºŒpŽj2,3: 1‰º•”Á‰»ŠÇŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3ã•”Á‰»ŠÇŠO)

[’˜@‘]

620043. [Šwp‘ (•ª’SŽ·•M)]y’S“–ˆã‚Æ‚µ‚Ä‚±‚Ì‚æ‚€‚É“š‚Š‚œ‚¢ ‚ª‚ñŠ³ŽÒE‰Æ‘°‚©‚ç‚ÌŽ¿–âz‘æ2Í Še˜_: ‘ŸŠí•Ê‚Ì‚ª‚ñ@¬’°E‘å’°‚Ì‚ª‚ñ@Q74. lHãè–å‚ÌŽí—Þ‚Æ“Á’¥‚ɂ‚¢‚Ä‹³‚Š‚Ä‚­‚Ÿ‚³‚¢, p.154-5. Îˆä—ǍK1,2, –îì‰ëŽj2, “n粏¹•F1,2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@ŠO‰È), ŠÄC: ŽRŒûr°3 (3‚ª‚ñŒ€—L–Ÿ•a‰@), •Ò: ¡‘º³”V4, ‹à”ö—S”V3, Ž…‰pŽ¡5, Œüˆä”Ž•¶6, ”nêG•v7, •œ–ì@‘8, •Ä£~“ñ3, “n粏¹•F1,2 (4ŠÖŒ“d—Í•a‰@, 5•œ¬”Žˆ€‰ï”Žˆ€‹L”O•a‰@, 6‘—§‚ª‚ñŒ€‹†ƒZƒ“ƒ^[“Œ•a‰@, 7ŒF–{‘åŠw‘åŠw‰@Á‰»ŠíŠO‰ÈŠw‹³Žº, 8–kŠC“¹‘åŠw‘åŠw‰@Á‰»ŠíŠO‰ÈŠw‹³Žº), ‚Ö‚é‚·o”Å, “Œ‹ž, 2019/4”­s.

620044. [Šwp‘ (•ª’SŽ·•M)]y¡“ú‚̐f’fŽwj (‘æ8”Å)zII ŽŸŠ³•Ò@24. ŠO—ˆ‚̏¬ŠO‰È“IŽŸŠ³@ŒŒð«ŠOŽ€Šj, p.1970-1. Îˆä—ǍK1,2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@), ‘•ÒW: ‰iˆä—ÇŽO3 (3Ž©Ž¡ˆã‰È‘åŠw), ˆãŠw‘‰@, “Œ‹ž, 2020/3”­s.

[Šw‰ïEŒ€‹†‰ï“™]

722066. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) ŠÌØœ‚É‚š‚¯‚éƒVƒ~ƒ…ƒŒ[ƒVƒ‡ƒ“EƒiƒrƒQ[ƒVƒ‡ƒ“‚̉ž—p: Right intersectional plane‚ðˆÓŽ¯‚µ‚œŠÌ—£’f. ‰J‹{—²‰î1, ˆ¢•”—Y‘Ÿ2, ¬‹Ë‰ë‘ã1, ‘O“c“úØŽq1, ”—@—T”V1, —Ž‡‘åŽ÷1, ‘åì¹‹`1, _’J‹I‹P1,3, Îˆä—ǍK1,4, “n粏¹•F1,4 (1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2Œcœä‹`m‘åŠwˆãŠw•”ˆê”ʁEÁ‰»ŠíŠO‰È, 3ŒÄ‹zŠíŠO, 4‰º•”Á‰»ŠÇŠO): ‘æ119‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/4/19), ‘åã, “ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ïŽ˜^W 119‰ñŽ˜^W 2019/4; WS10-10.

722067. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) • o‹Ÿ‰ºŒ‹’°ŠàŽèp‚Ì‘nŠŽõ‘΍ô (ICT‚Æ‹Š—͑̐§‚̍\’z). ’†‘º—²r1, ²“¡•˜Y1, ŽR—œ‚L1, ŽO‰YŒ[šæ1, ŒÃé@Œ›1, “à“¡³‹K1, “n粏¹•F1,2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ74‰ñ“ú–{‘å’°ãè–å•aŠw‰ïŠwpW‰ï (2019/10/11), “Œ‹ž.

722068. [Šw‰ï (‘S‘)] (ŠwpƒZƒ~ƒi[) l¶100”NŽž‘㠏Á‰»Ší—ǐ«ŽŸŠ³‚ðl‚Š‚é. Îˆä—ǍK1,2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ81‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2019/11/15), ‚’m, “ú–{—Տ°ŠO‰ÈŠw‰ïŽGŽ 2019/10; 80 (‘Š§): 37.

722069. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) ‹}«’Ž‚‰Š‚ɑ΂·‚éŽèp|ŠJ• ? • o‹Ÿ?|: ‹}«’Ž‚‰Š‚ɑ΂·‚鎡—Õûj‚ÌŒŸ“¢. ‰J‹{—²‰î1, Îˆä—ǍK1,2, –k@‰p“T1, ”—@—T”V1, —Ž‡‘åŽ÷1, _’J‹I‹P1,3, “n粏¹•F1,2 (1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@ŠO‰È, 2‰º•”Á‰»ŠÇŠO, 3ŒÄ‹zŠíŠO): ‘æ32‰ñ“ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ï‘‰ï (2019/12/6), ‰¡•l, “ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ïŽGŽ 2019/12; 24 (7): WS13-6.

722070. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) ˆã—Íޗ¿‚̃}ƒlƒWƒƒ“ƒg “–‰@‚É‚š‚¯‚éˆã—Íޗ¿ƒ}ƒlƒWƒƒ“ƒg‚ÌŒ»ó‚ÆŒüŒã. Îˆä—ǍK1,2, ‰J‹{—²‰î2, ”—@—T”V2, —Ž‡‘åŽ÷2, _’J‹I‹P2,3, “n粏¹•F1,2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 3ŒÄ‹zŠíŠO): ‘æ32‰ñ“ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ï‘‰ï (2019/12/7), ‰¡•l, “ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ïŽGŽ 2019/12; 24 (7): WS35-4.

722071. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) • o‹Ÿ‰ºŽž‘ã‚É‚š‚¯‚éStoma‘¢Ý‚̃gƒŒƒ“ƒh. ²“¡•˜Y1, ŽO‰YŒ[šæ1, ŒÃé@Œ›1, ‰¡ˆäŒ\Œå1, ”‹ŒŽçŒb1, ŽR—œ‚L1, ’†‘º—²r1 (1‰º•”Á‰»ŠÇŠO): ‘æ37‰ñ“ú–{ƒXƒg[ƒ}E”rŸ•ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ï‘‰ï (JSSCR) (2020/2/8), Ã‰ª.

723283. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰º•”’Œ’°Šà‚ɑ΂·‚ép‘O•úŽËü‰»Šw—Ö@Œã‚Ì• o‹Ÿ‰ºŽèp‚Ì—L—p«. ŒÃé@Œ›1, ’†‘º—²r1, ²“¡•˜Y1, ŽR—œ‚L1, ŽO‰YŒ[šæ1, “‡’Á@«, “n粏¹•F1,2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ119‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/4/18), ‘åã.

723284. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • o‹Ÿ‰ºŒ‹’°ŠàpŒã‚Ì‘n•”ŠŽõÇŠëŒ¯ˆöŽq‚ÌŒŸ“¢. ’†‘º—²r1, ²“¡•˜Y1, ŽR—œ‚L1, ŽO‰YŒ[šæ1, ŒÃé@Œ›1, “‡’Á@«, “n粏¹•F1,2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ119‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/4/18), ‘åã.

723285. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ƒNƒ[ƒ“•a‚ɑ΂·‚éQOLŒüã‚ð–ÚŽw‚µ‚œIBDƒZƒ“ƒ^[“à‰Èˆã‚Æ‘å’°ŠO‰Èˆã‚Ƃ̃Rƒ“ƒrƒl[ƒVƒ‡ƒ“. —Ž‡‘åŽ÷1, Îˆä—ǍK1,2, _’J‹I‹P1,3, ‘åì¹‹`1, ”—@—T”V1, ‰J‹{—²‰î1, ‘O“c“úØŽq1, ¬‹Ë‰ë‘ã1, “n粏¹•F1,2 (1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2‰º•”Á‰»ŠÇŠO, 3ŒÄ‹zŠíŠO): ‘æ119‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/4/18), ‘åã, “ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ïŽ˜^W 119‰ñ 2019/4; SF023-8.

723286. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) žô‘€”çÃ–¬ƒJƒbƒgƒ_ƒEƒ“–@‚É‚æ‚é’†SÃ–¬ƒ|[ƒg‘}“ü‚ɑ΂·‚éˆÀ‘S«‚Æ—L—p«‚ÌŒŸ“¢. “à“¡³‹K1,2, ç–ìTˆê˜Y1,2, ‹ß“¡NŽj1,3, ‹v•Û”CŽj1,4, ’†”nŠî”Ž1,5, Žž”C’‘1,2, ’†‘º˜a“¿1,4, Œ@”ªŽk1, ‚‹Ž’õl1,4, “n糏¹•F6 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2‰º•”Á‰»ŠÇŠO, 3“û‘BEbó‘BŠO, 4ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 5ã•”Á‰»ŠÇŠO, 6–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ119‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/4/19), ‘åã.

723287. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) American joint committee on Cancer (AJCC) ‘æ8”ŁuPathologic Prognostic Stage•ª—Þ (ppStage)v‚ÉŠî‚­•aŠú•Ê—\Œã‚ÌŒŸ“¢. ‘O“c“úØŽq1, ’r“c@³1, ¬‹Ë‰ë¢1, ‰J‹{—²‰î1, ”—@—T”V1, —Ž‡‘åŽ÷1, _’J‹I‹P1,2, ‘åì¹‹`1, Îˆä—ǍK1,3, “n粏¹•F1,3 (1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2ŒÄ‹zŠíŠO, 3‰º•”Á‰»ŠÇŠO): ‘æ119‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/4/20), ‘åã, “ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ïŽ˜^W 119‰ñ 2019/4; PS1924.

723288. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ICT‚Æ•à‚ސV‚µ‚¢‰º•”Á‰»ŠÇŽèp‚Ì‘nŠŽõ‘΍ô. ’†‘º—²r1, ²“¡•˜Y1, ŽR—œ‚L1, ŽO‰YŒ[šæ1, ŒÃé@Œ›1, “n粏¹•F1,2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ74‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2019/7/17), “Œ‹ž.

723289. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘å’°ŠàŽæ‚舵‚¢‹K–ñ‘æ9”Å‚É‚š‚¯‚éStage III‘å’°Šà‚ÌŒŸ“¢. ŒÃé@Œ›1, ’†‘º—²r1, ²“¡•˜Y1, ŽR—œ‚L1, ŽO‰YŒ[šæ1, “‡’Á@«, “n粏¹•F1,2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ74‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2019/7/17), “Œ‹ž.

723290. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) pStage II, III‰¡sŒ‹’°Šà‚ɑ΂·‚é• o‹Ÿ‰ºŽèp‚ÌŽ¡—ЬÑ. ŽO‰YŒ[šæ1, ²“¡•˜Y1, “‡’Á@«, ŒÃé@Œ›1, ŽR—œ‚L1, ’†‘º—²r1, “n粏¹•F1,2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ74‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2019/7/17), “Œ‹ž.

723291. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) “«’×ᇐ«‘å’°‰Š‚ɑ΂·‚é“–‰@IBDÁ‰»ŠÇ“à‰Èˆã‚ÆŠO‰Èˆã‚̃Rƒ‰ƒ{ƒŒ[ƒVƒ‡ƒ“. —Ž‡‘åŽ÷1, Îˆä—ǍK1,2, ‘åì¹‹`1, ”—@—T”V1, ‰J‹{—²‰î1, ‘O“c“úØŽq1, ¬‹Ë‰ë‘ã1, _’J‹I‹P1,3, “n粏¹•F1,2 (1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2‰º•”Á‰»ŠÇŠO, 3ŒÄ‹zŠíŠO): ‘æ74‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2019/7/17), “Œ‹ž, “ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï74‰ñŽ˜^W 2019/7; P96-3.

723292. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ŠÌ‰E—t‚É‚š‚¯‚éRight intersectional planeETransverse plane‚ƐV‚œ‚ȈŸ‹æˆæ‚Ì’ñ¥. ‰J‹{—²‰î1, ˆ¢•”—Y‘Ÿ2, ¬‹Ë‰ë‘ã1, ‘O“c“úØŽq1, ”—@—T”V1, —Ž‡‘åŽ÷1, ‘åì¹‹`1, _’J‹I‹P1,3, Îˆä—ǍK1,4, “n粏¹•F1,4 (1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2Œcœä‹`m‘åŠwˆãŠw•”ˆê”ʁEÁ‰»ŠíŠO‰È, 3ŒÄ‹zŠíŠO, 4‰º•”Á‰»ŠÇŠO): ‘æ74‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2019/7/17), “Œ‹ž, “ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï74‰ñŽ˜^W 2019/7; RS8-3.

723293. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • o‹Ÿ‰ºSóŒ‹’°ØœŒã‚Ì–D‡•s‘SÇ—á‚ÌŒŸ“¢. ”‹ŒŽçŒb1, ’†‘º—²r1, ŒÃé@Œ›1, ŽO‰YŒ[šæ1, ŽR—œ‚L1, ²“¡•˜Y1, “n粏¹•F1,2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ74‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2019/7/18), “Œ‹ž.

723294. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) lHãè–å‘¢ÝpE•Âœp‚É‚š‚¯‚é“–‰@‚̍H•v‚š‚æ‚ÑPitfall. ¬‹Ë‰ë¢1, —Ž‡‘åŽ÷1, Îˆä—ǍK1,2, ‘O“c“úØŽq1, ‰J‹{—²‰î1, ”—@—T”V1, _’J‹I‹P1,3, ‘åì¹‹`1, “n粏¹•F1,2 (1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2‰º•”Á‰»ŠÇŠO, 3ŒÄ‹zŠíŠO): ‘æ74‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2019/7/18), “Œ‹ž, “ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï74‰ñŽ˜^W2019/7; P127-5.

723295. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ŽcˆÝŠà‚̗Տ°•a—Šw“IŒŸ“¢‚ÆäB“E‚̈Ӌ`. ”—@—T”V1, ‘åì¹‹`1, ¬‹Ë‰ë¢1, ‘O“c“úØŽq1, ‰J‹{—²‰î1, —Ž‡‘åŽ÷1, Îˆä—ǍK1,2, _’J‹I‹P1,3, ‹e’rŽj˜Y1,4, “n粏¹•F1,2 (1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2‰º•”Á‰»ŠÇŠO, 3ŒÄ‹zŠíŠO, 44•a‰@˜AŒg‹³ˆç): ‘æ74‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2019/7/18), “Œ‹ž, “ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï74‰ñŽ˜^W 2019/7; P32-1.

723296. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’Œ’°Žîᇂɑ΂·‚郍ƒ{ƒbƒgŽx‰‡• o‹Ÿ‰ºŽèp‚Ì’ZŠú¬Ñ. ‰¡ˆäŒ\Œå1, ’†‘º—²r1, “‡’Á@«, ŒÃé@Œ›1, ŽO‰YŒ[šæ1, “à“¡³‹K1, ²“¡•˜Y1, “n粏¹•F1,2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ74‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï (2019/7/19), “Œ‹ž.

723297. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆãŠw•”ƒfƒBƒvƒ[ƒ}ƒ|ƒŠƒV[‚ÉŠî‚¢‚œŽáŽèˆãŽt‚É‚š‚¯‚éƒAƒ“ƒP[ƒg’²ž‚É‚æ‚éŠwC¬‰Ê‚Ì•]‰¿. ‹e’rŽj˜Y1, Žç‰®—˜‰À2, ’|“àº”Ž, ¬ìŒ³”V3 (14•a‰@˜AŒg‹³ˆç, 2ˆãŠw‹³ˆç, 3‰ð–U): ‘æ51‰ñ“ú–{ˆãŠw‹³ˆçŠw‰ï‘å‰ï (2019/7/26), ‹ž“s, ‘æ51‰ñ“ú–{ˆãŠw‹³ˆçŠw‰ï‘å‰ï—\eW 2019; 50: 96.

723298. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Œ‹’°Šà‚É‚š‚¯‚éWiNTRLINC1/Ascl 2/c-mycŽ²‚̗Տ°“IˆÓ‹`. ‰¡“c˜aŽq1, “c’†—uŽq1, ŒŽ“cG‹P2, b”ã“c•Žu1, ŒÃé@Œ›2, ŽO‰YŒ[šæ2, ŽR—œ‚L2, ²“¡•˜Y2, ’†‘º—²r2, “n粏¹•F2,3, ŽR‰ºŒpŽj4,5 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2‰º•”Á‰»ŠÇŠO, 3–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 5ã•”Á‰»ŠÇŠO): ‘æ78‰ñ“ú–{ŠàŠw‰ïŠwp‘‰ï (2019/9/28), ‹ž“s.

723299. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • o‹Ÿ‰º‘å’°Øœp‚©‚çŠJ• ˆÚs‚Ö‚Ì“KØ‚ȃ^ƒCƒ~ƒ“ƒO. ²“¡•˜Y1, ’†‘º—²r1, ŽR—œ‚L1, ŽO‰YŒ[šæ1, ŒÃé@Œ›1, ‰¡ˆäŒ\Œå1, ”‹ŒŽçŒb1, ŠÛŽR³—T2, â–{ƒˆê3, “n粏¹•F1,4 (1‰º•”Á‰»ŠÇŠO, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 3“û‘BEbó‘BŠO, 4–k—¢Œ€‹†Š•a‰@): ‘æ74‰ñ“ú–{‘å’°ãè–å•aŠw‰ïŠwpW‰ï (2019/10/11), “Œ‹ž.

723300. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • o‹Ÿ‰º‘å’°Øœp‚É‚š‚¯‚éŽüpŠúáu’ÉŠÇ—–@‚̍d–ŒŠO–ƒŒ–@ vs ƒAƒZƒgƒAƒ~ƒmƒtƒFƒ“Ã–¬“à“Š—^–@‚Ì”äŠrŒŸ“¢. ŽO‰YŒ[šæ1, ²“¡•˜Y1, ŒÃé@Œ›1, ŽR—œ‚L1, ’†‘º—²r1, “n粏¹•F1,2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ74‰ñ“ú–{‘å’°ãè–å•aŠw‰ïŠwpW‰ï (2019/10/11), “Œ‹ž.

723301. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • o‹Ÿ‰º‘å’°Øœp‚ðŽ{s‚µ‚œƒXƒe[ƒWIIŒ‹’°Šà‚É‚š‚¯‚éÄ”­ƒŠƒXƒNˆöŽq‚ÌŒŸ“¢. ŒÃé@Œ›1, ’†‘º—²r1, ²“¡•˜Y1, ŽR—œ‚L1, ŽO‰YŒ[šæ1, ‰¡ˆäŒ\Œå1, ”‹ŒŽçŒb1, “n粏¹•F1,2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ74‰ñ“ú–{‘å’°ãè–å•aŠw‰ïŠwpW‰ï (2019/10/11), “Œ‹ž.

723302. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Gant-ŽO—Ö + Thiersch–@‚É‚æ‚é’Œ’°’EŽèpŒã‚É’Œ’°úE‚𗈂µ‚œ1—á. ç–ìTˆê˜Y1, “à“¡³‹K1,2, Žž”C’‘1,2, ’†”nŠî”Ž2,3, ’†‘º˜a“¿2,4, ‹v•Û”CŽj4, ‹ß“¡NŽj2,5, Œ@”ªŽk2, ‚‹Ž’õl2,4, “n粏¹•F6 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3ã•”Á‰»ŠÇŠO, 4ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 5“û‘BEbó‘BŠO, 6–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ74‰ñ“ú–{‘å’°ãè–å•aŠw‰ïŠwpW‰ï (2019/10/11), “Œ‹ž.

723303. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’áNP«‚ð–ÚŽw‚µ‚œ‹ÇŠis’Œ’°Šà‚ɑ΂·‚鎡—Ð헪. ŒÃé@Œ›1, ’†‘º—²r1, ²“¡•˜Y1, ŽR—œ‚L1, ŽO‰YŒ[šæ1, ‰¡ˆäŒ\Œå1, ”‹ŒŽçŒb1 (1‰º•”Á‰»ŠÇŠO): ‘æ57‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï (2019/10/24), •Ÿ‰ª.

723304. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –„‚ߍž‚ÝŒ^’†SÃ–¬ƒ|[ƒg‚̏pŒãŠŽõ‚̊댯ˆöŽq‚Æ‚»‚̑΍ô. ’†‘º—²r1, ²“¡•˜Y1, ŽR—œ‚L1, ŽO‰YŒ[šæ1, ŒÃé@Œ›1, “n粏¹•F1,2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ57‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï (2019/10/24), •Ÿ‰ª.

723305. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) pT1’Œ’°Šà‚ɑ΂·‚é• o‹Ÿ‰ºŽèp¬Ñ‚ɏp‘O“àŽ‹‹ŸŽ¡—ª—^‚Š‚é‰e‹¿. ”‹ŒŽçŒb1, ’†‘º—²r1, ‰¡ˆäŒ\Œå1, ŒÃé@Œ›1, ŽO‰YŒ[šæ1, ŽR—œ‚L1, ²“¡•˜Y1, “n粏¹•F1,2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ57‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï (2019/10/24), •Ÿ‰ª.

723306. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Œ‹’°Šà‚ɑ΂·‚é•â•‰»Šw—Ö@‚̐„§‚ɍĔ­ƒXƒRƒA‚ª—^‚Š‚é‰e‹¿ (SUNRISE-DIŽŽŒ±). ‰êì‹`‹K, ‰«@‰pŽŸ, ŽO“‡¹D, ’r“c³F, ã–ìGŽ÷, ‰Á“¡Œ’Žu, “í–{“N–ç, ‘CÎrŽ÷, ŽRŒûŒ€¬, ‹ààVˆ®é, m‰È’q—T, ‘Ÿ“cv—R, ²“¡•˜Y1, ŽR’†’|t, ‹g–ìF”V (1‰º•”Á‰»ŠÇŠO): ‘æ57‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï (2019/10/24), •Ÿ‰ª.

723307. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹ÇŠis’Œ’°Šà‚ɑ΂·‚鉻Šw•úŽËü—Ö@‚ł̉h—{ó‘Ô‚Æ•›ì—pEŽüpŠú‡•¹Ç‚ÌŠÖŒW. ŽR–ì’qŠî, ²“¡•˜Y1, ‘ì˜ad2, •y“c®—T, “IêŽüˆê˜Y, ”nêG•v, ’·’Jì”Žr, ”ì“cŒò–î, ŒÃ”š’q‹v, “à“¡@„1, “‡“cŒõ¶, ‘å’ˍKŠì, ‹ŽŒû—z“ñ˜Y, ’|“à³O, “n粏¹•F1,3 (1‰º•”Á‰»ŠÇŠO, 2•úŽËü (Žîá‡), 3–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ57‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï (2019/10/24), •Ÿ‰ª.

723308. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) Š®‘SŽ©‘RŠÉ‰ð‚ð‚«‚œ‚µ‚œŠÌ×–EŠà‚Æ–Ó’°Šà‚Æ‚Ì“¯Žž«d•¡Šà‚Ì1—á. –k@‰p“T1, ‰J‹{—²‰î1, Îˆä—ǍK1,2, ‘å•”@œ1, _’J‹I‹P1,3, ŒÜŒŽ—Œbˆê1, —Ž‡‘åŽ÷1, ”—@—T”V1, ‘O“c“úØŽq1, “n粏¹•F1,2 (1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2‰º•”Á‰»ŠÇŠO, 3ŒÄ‹zŠíŠO): ‘æ81‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2019/11/14), ‚’m, “ú–{—Տ°ŠO‰ÈŠw‰ïŽGŽ 2019/10; 80 (‘Š§): 599.

723309. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ãŠ{ŠàÄ”­žž’†‚É”­Œ©‚³‚ê‚œ‰¡sŒ‹’°_Œo“à•ª”å×–EŠà‚̈ê—á. –¥‰YG”V1, ’†‘º—²r1, “¡”örˆò1, ‰ª–{Œõ‹FŽq2, ”‹ŒŽçŒb1, ‰¡ˆäŒ\Œå1, ŒÃé@Œ›1, ŽO‰YŒ[šæ1, ŽR—œ‚L1, ²“¡•˜Y1 (1‰º•”Á‰»ŠÇŠO, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO): ‘æ81‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2019/11/14-16), ‚’m.

723310. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) pŒã’°•ÂÇ‚ɑ΂·‚é• o‹Ÿ‰ºŽèp‚Ì—L—p«‚ÆŒÀŠE. ’†‘º—²r1, ²“¡•˜Y1, ŽO‰YŒ[šæ1, ŽR—œ‚L1, ŒÃé@Œ›1, ‰¡ˆäŒ\Œå1, ”‹ŒŽçŒb1 (1‰º•”Á‰»ŠÇŠO): ‘æ81‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2019/11/16), ‚’m.

723311. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • o‹Ÿ‰ºŒ‹’°ŠàŽèp‚Ì—L—p« (’ZŠúE’·Šú¬Ñ). ’†‘º—²r1, ²“¡•˜Y1, ŽR—œ‚L1, ŽO‰YŒ[šæ1, ŒÃé@Œ›1, “n粏¹•F1,2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): JDDW 2019 (‘æ17‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘å‰ï) (2019/11/23), _ŒË.

723312. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹ÇŠis’Œ’°Šà‚ɑ΂·‚ép‘O‰»Šw•úŽËüŽ¡—ÃŒã‚ÉWatch-and-wait approach‚ðs‚Á‚œ17—á‚ÌŒŸ“¢. ŒÃé@Œ›1, ’†‘º—²r1, ²“¡•˜Y1, ŽR—œ‚L1, ŽO‰YŒ[šæ1, ‰¡ˆäŒ\Œå1, ”‹ŒŽçŒb1, ‰ª–{Œõ‹FŽq2, “‡’Á@«, “n粏¹•F1,3 (1‰º•”Á‰»ŠÇŠO, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 3–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): JDDW 2019 (‘æ17‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘å‰ï) (2019/11/23), _ŒË.

723313. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) pŒã’°•ÂÇ‚ɑ΂µ‚Ä• o‹Ÿ‰ºŽèp‚Í–{“–‚É—L—p‚©? ²“¡•˜Y (‰º•”Á‰»ŠÇŠO): ‘æ32‰ñ“ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ï‘‰ï (2019/12/5-7), ‰¡•l.

723314. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’Œ’°Šà‚ɑ΂·‚郍ƒ{ƒbƒgŽx‰‡‰ºŽèp‚Ì’ZŠú¬Ñ. ²“¡•˜Y (‰º•”Á‰»ŠÇŠO): ‘æ32‰ñ“ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ï‘‰ï (2019/12/6), ‰¡•l.

723315. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹ÇŠis’Œ’°Šà‚ɑ΂·‚ép‘O‰»Šw•úŽËüŽ¡—ÃŒã‚ÌSalvageŽèp. ŒÃé@Œ›1, ”‹ŒŽçŒb1, ‰¡ˆäŒ\Œå1, ŽO‰YŒ[šæ1, ŽR—œ‚L1, ²“¡•˜Y1, ’†‘º—²r1 (1‰º•”Á‰»ŠÇŠO): ‘æ32‰ñ“ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ï‘‰ï (2019/12/6), ‰¡•l.

723316. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹•ŒŒ«’°‰Š‚É‚æ‚é’`”’˜Ro«ˆÝ’°‰Š‚ɑ΂µ‚ÄŠO‰È“IØœ‚ðŽ{s‚µ‚œ1—á. ŠC£—‰Â1, ”‹ŒŽçŒb1, ‰¡ˆäŒ\Œå1, ŒÃé@Œ›1, ŽO‰YŒ[šæ1, ŽR—œ‚L1, ²“¡•˜Y1, ’†‘º—²r1 (1‰º•”Á‰»ŠÇŠO): ‘æ32‰ñ“ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ï‘‰ï (2019/12/6), ‰¡•l.

723317. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ’PEŽ®‰ñ–Ó•”Øœ‚ðŽ{s‚µ‚œ“«ƒNƒ[ƒ“•a‚Ì1—á. –k@‰p“T1, —Ž‡‘åŽ÷1, Îˆä—ǍK1,2, ‰J‹{—²‰î1, ”—@—T”V1, ‘åì¹‹`1, _’J‹I‹P1,3, “n粏¹•F1,2 (1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2‰º•”Á‰»ŠÇŠO, 3ŒÄ‹zŠíŠO): ‘æ32‰ñ“ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ï‘‰ï (2019/12/6), ‰¡•l, “ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ïŽGŽ 2019/12; 24 (7): MO221-2.

723318. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • o‹Ÿ‰ºSóŒ‹’°ØœŒã‚Ì–D‡•s‘S‚̊댯ˆöŽq. ”‹ŒŽçŒb1, ’†‘º—²r1, ‰¡ˆäŒ\Œå1, ŒÃé@Œ›1, ŽO‰YŒ[šæ1, ŽR—œ‚L1, ²“¡•˜Y1 (1‰º•”Á‰»ŠÇŠO): ‘æ32‰ñ“ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ï‘‰ï (2019/12/7), ‰¡•l.

723319. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚š‚¯‚éãsŒ‹’°Šà‚ɑ΂·‚é• o‹Ÿ‰º‰E”ŒŒ‹’°Øœp‚ÌŒŸ“¢. ‰¡ˆäŒ\Œå1, ’†‘º—²r1, ”‹ŒŽçŒb1, ŒÃé@Œ›1, ŽO‰YŒ[šæ1, ŽR—œ‚L1, ²“¡•˜Y1 (1‰º•”Á‰»ŠÇŠO): ‘æ32‰ñ“ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ï‘‰ï (2019/12/7), ‰¡•l.

723320. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ‚—îŽÒ‚ɑ΂·‚é• o‹ŸˆÝØœp‚̈À‘S«‚ÌŒŸ“¢. ”—@—T”V1, ‘åì¹‹`1, –k@‰p“T1, ‰J‹{—²‰î1, —Ž‡‘åŽ÷1, Îˆä—ǍK1,2, _’J‹I‹P1,3, ‹e’rŽj˜Y1,4, “n粏¹•F1,2 (1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2‰º•”Á‰»ŠÇŠO, 3ŒÄ‹zŠíŠO, 44•a‰@˜AŒg‹³ˆç): ‘æ32‰ñ“ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ï‘‰ï (2019/12/7), ‰¡•l, “ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ïŽGŽ 2019/12; 24 (7): MO239-5.

723321. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) SóŒ‹’°ŒeŽº‰Š‚É‚æ‚錋’°äNã÷ᑂ̕ o‹ŸŽèpŒoŒ±. —Ž‡‘åŽ÷1, Îˆä—ǍK1,2, ”—@—T”V1, ‰J‹{—²‰î1, ‘åì¹‹`1, –k@‰p“T1, _’J‹I‹P1,3, “n粏¹•F1,2 (1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2‰º•”Á‰»ŠÇŠO, 3ŒÄ‹zŠíŠO): ‘æ32‰ñ“ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ï‘‰ï (2019/12/7), ‰¡•l, “ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ïŽGŽ 2019/12; 24 (7): SF104-4.

723322. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ’PEŽ®‰E”ŒŒ‹’°Øœ‚É‚š‚¯‚éD3ƒŠƒ“ƒpßŠsŽ‚ÌŽèpŽè‹Z‚ÆŽ¡—ЬÑ. Îˆä—ǍK1,2, —Ž‡‘åŽ÷2, ”—@—T”V2, ‰J‹{—²‰î2, “n粏¹•F1,2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ32‰ñ“ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ï‘‰ï (2019/12/7), ‰¡•l, “ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ïŽGŽ 2019/12; 24 (7): SF098-4.

723323. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) MeckelŒeŽº‚ðŒŽˆö‚Æ‚·‚éiN«’°•ÂÇ‚𕠍o‹Ÿ‰º‚ÉŽ¡—µ‚œ1—á. ç–ìTˆê˜Y1, “à“¡³‹K1,2, ŠÛŽR³—T2,3, Žž”C’‘1,2, ’†”nŠî”Ž2,4, ’†‘º˜a“¿2,3, ‹v•Û”CŽj3, Œ@”ªŽk2, ‚‹Ž’õl2,3, “n粏¹•F5 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 4ã•”Á‰»ŠÇŠO, 5–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ32‰ñ“ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ï‘‰ï (2019/12/7), ‰¡•l.

723324. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆÞk×Œa’°ŠÇ‚ɑ΂·‚é“Œ–k‘厮•«‡‚É‚æ‚éƒXƒg[ƒ}•ÂœŽè‹Z. “n•Ó˜aG, ‘åÀ@”E, _ŽR“ÄŽj, “‚àVG–Ÿ, —é–؏GK, ŠŒŽ‘å‹P, “n粗ÁŽq, ‹Tˆä@®, “à“¡@„1, ŠC–ì—Ï–Ÿ (1‰º•”Á‰»ŠÇŠO): ‘æ37‰ñ“ú–{ƒXƒg[ƒ}E”rŸ•ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ï‘‰ï (JSSCR) (2020/2/7), Ã‰ª.

723325. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’Œ’°ŠàpŒã‚̃Xƒg[ƒ}ƒgƒ‰ƒuƒ‹‚É‚š‚¯‚éŠëŒ¯ˆöŽq‚ÌŒŸ“¢. _ŽR“ÄŽj, “n•Ó˜aG, —é–؏GK, “‚àVG–Ÿ, ŠŒŽ‘å‹P, ‘åÀ@”E, ‚‹Ž^‹I, “n•Ó—ÁŽq, ‹Tˆä@®, “à“¡@„1, ŠC–ì—Ï–Ÿ (1‰º•”Á‰»ŠÇŠO): ‘æ37‰ñ“ú–{ƒXƒg[ƒ}E”rŸ•ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ï‘‰ï (JSSCR) (2020/2/7), Ã‰ª.

732022. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) Stage IIŒ‹’°Šà‚̍וª‰»‹y‚яpŒã•â•‰»Šw—Ö@‚ÌŒŸ“¢. ”‹ŒŽçŒb1, ’†‘º—²r1, ‰¡ˆäŒ\Œå1, ŒÃé@Œ›1, ŽO‰YŒ[šæ1, ²“¡•˜Y1 (1‰º•”Á‰»ŠÇŠO): ‘æ92‰ñ‘å’°ŠàŒ€‹†‰ï (2020/1/24), L“‡.

733115. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ’Œ’°Šà‚ɑ΂·‚郍ƒ{ƒbƒgŽx‰‡• o‹Ÿ‰ºŽèp|TMEŽè‹Z‚Ì•W€‰»‚ÉŒü‚¯‚ā|. ŽR—œ‚L1, ’†‘º—²r1, ²“¡•˜Y1, ŽO‰YŒ[šæ1, ŒÃé@Œ›1, “n粏¹•F1,2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ73‰ñŽèpŽè‹ZŒ€‹†‰ï (2019/5/24), “Œ‹ž.

733116. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) • o‹Ÿ‰ºŒ‹’°ŠàŽèp‚Ì’èŒ^‰»‚ð–ÚŽw‚µ‚œŽèpŽè‹Z (’ZŠúE’·ŠúŽ¡—ЬÑ). ŽR—œ‚L1, ’†‘º—²r1, ²“¡•˜Y1, ŽO‰YŒ[šæ1, ŒÃé@Œ›1, “n粏¹•F1,2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ73‰ñŽèpŽè‹ZŒ€‹†‰ï (2019/5/24), “Œ‹ž.

733117. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‰º•”’Œ’°Šà‚ɑ΂µ‚ďp‘O•úŽËü‰»Šw—Ö@Œã‚ÉŽ{s‚µ‚œ• o‹Ÿ‰ºŽèp‚ÌŽ¡—ЬÑ. ŒÃé@Œ›1, ”‹ŒŽçŒb1, ‰¡ˆäŒ\Œå1, “‡’Á@«, ŽO‰YŒ[šæ1, ŽR—œ‚L1, ²“¡•˜Y1, ’†‘º—²r1, “n粏¹•F1,2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ73‰ñŽèpŽè‹ZŒ€‹†‰ï (2019/5/24), “Œ‹ž.

733118. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‘å’°Šà“¯Žž«ŠÌ“]ˆÚØœŒã‚ɑ΂·‚é•â•‰»Šw—Ö@‚Í—LŒø‚©. ‰¡ˆäŒ\Œå1, ²“¡•˜Y1, ŒÃé@Œ›1, ŽO‰YŒ[šæ1, ŽR—œ‚L1, ’†‘º—²r1 (1‰º•”Á‰»ŠÇŠO): ‘æ91‰ñ‘å’°ŠàŒ€‹†‰ï (2019/7/5), “Œ‹ž.

'18”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'18-320003. [Ç—á•ñ] \“ñŽw’°Šà‚ðŒ_‹@‚ɐf’f‚µØœ‚µ‚Š‚œLynchÇŒóŒQ‚Ì2—á. ˆ¢•”h‘å1, —é–ØŒcˆê1, –îì‰ëŽj1, ‘º“c@Œ’1, ”—@—T”V1, Îˆä—ǍK1,2, ŒŽ@“ÖŽq (1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2‰º•”Á‰»ŠÇŠO): “ú–{Á‰»ŠíŠO‰ÈŠw‰ïŽGŽ 2019/1; 52 (1): 27-35.

'18-320004. [Ç—á•ñ] • o‹Ÿ•â•‰º‚ɐ؏œ‚µ‚Š‚œ¬’°ƒfƒXƒ‚ƒCƒhŽîᇂÌ1—á. “n•”WŽq1, ’†‘º—²r1, “›ˆä“ÖŽq1, ŽO‰YŒ[šæ1, ŽR—œ‚L1, ²“¡•˜Y1, “n粏¹•F2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): “ú–{ŠO‰ÈŒn˜A‡Šw‰ïŽ 2019/2; 44 (1): 136-42.

[Šw‰ïEŒ€‹†‰ï“™]

'18-723009. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • o“à”^ᇂðŒ_‹@‚É”­Œ©‚³‚ê‚œŒ‹’°ŠÔ–ŒƒfƒXƒ‚ƒCƒhŽîᇂÌ1—á. óŒÃ—L‹IŽq, “à“¡³‹K1,2, ç–ìTˆê˜Y1,2, ’†”nŠî”Ž1,3, Žž”C’‘1,2, ‹v•Û”CŽj1,4, Œ@”ªŽk1, ‚‹Ž’õl1,4, “n粏¹•F5 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2‰º•”Á‰»ŠÇŠO, 3ã•”Á‰»ŠÇŠO, 4ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 5–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ55‰ñ“ú–{• •”‹~‹}ˆãŠw‰ï‘‰ï (2019/3/7-8), å‘ä, “ú–{• •”‹~‹}ˆãŠw‰ïŽGŽ 2019/2; 39 (2): 413.

'18-723010. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) p‘Of’f‚µ‚Š‚œ–Ó’°Ž²”P“]Ç‚Ì1—á. Žž”C’‘1,2, “à“¡³‹K1,2, ’†”nŠî”Ž1,3, ç–ìTˆê˜Y1,2, ’†‘º˜a“¿1,4, ‹v•Û”CŽj1,4, ‹ß“¡NŽj1,5, Œ@”ªŽk1, ‚‹Ž’õl1,4, “n粏¹•F6 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2‰º•”Á‰»ŠÇŠO, 3ã•”Á‰»ŠÇŠO, 4ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 5“û‘BEbó‘BŠO, 6–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ55‰ñ“ú–{• •”‹~‹}ˆãŠw‰ï‘‰ï (2019/3/7-8), å‘ä, “ú–{• •”‹~‹}ˆãŠw‰ïŽGŽ 2019/2; 39 (2): 418.

'18-723011. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”^ᇌ`¬‚É‚æ‚éŒÀ‹Ç«• –Œ‰Š‚ð‚«‚œ‚µ‚œMeckelŒeŽº‰Š‚̈ê—á. –¥‰YG”V1, ’†‘º—²r1, “‡’Á@«, ŠÛŽR³—T2, Œã“¡‘ì–ç3, ”‹ŒŽçŒb1, ŒÃé@Œ›1, ŽO‰YŒ[šæ1, ŽR—œ‚L1, ²“¡•˜Y1 (1‰º•”Á‰»ŠÇŠO, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ55‰ñ“ú–{• •”‹~‹}ˆãŠw‰ï‘‰ï (2019/3/7), å‘ä.

'18-723012. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’°•ÂÇ‚ðŒJ‚è•Ô‚µ‚œ¬’°ŒeŽº‚ɑ΂µ‚Ä• o‹Ÿ‰ºŽèp‚ðŽ{s‚µ‚œˆê—á. ŽÄ–؏r•œ1, ŠÛŽR³—T2, ’†‘º—²r1, ”‹ŒŽçŒb1, “‡’Á@«, ŒÃé@Œ›1, ŽO‰YŒ[šæ1, ŽR—œ‚L1, ²“¡•˜Y1, “n粏¹•F1,3 (1‰º•”Á‰»ŠÇŠO, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 3–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ55‰ñ“ú–{• •”‹~‹}ˆãŠw‰ï‘‰ï (2019/3/7), å‘ä.

'18-723013. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’`”’˜Ro«ˆÝ’°Ç‚ð’悵‚œ¬’°‹·ó‚ɑ΂µ‚ÄŠO‰È“IØœ‚ðŽ{s‚µ‚œˆê—á. ”‹ŒŽçŒb1, ’†‘º—²r1, Œã“¡‘ì–ç2, ŠÛŽR³—T3, “‡’Á@«, ŒÃé@Œ›1, ŽO‰YŒ[šæ1, ŽR—œ‚L1, ²“¡•˜Y1, “n粏¹•F1,4 (1‰º•”Á‰»ŠÇŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 4–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ55‰ñ“ú–{• •”‹~‹}ˆãŠw‰ï‘‰ï (2019/3/7), å‘ä.

'18-723014. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰ñ’°lHãè–å‘¢ÝŒã‚ÌOutlet obstructionÇ—á‚ÌŒŸ“¢. ŠÛŽR³—T1, ’†‘º—²r2, ”‹ŒŽçŒb2, “‡’Á@«, ŒÃé@Œ›2, ŽO‰YŒ[šæ2, ŽR—œ‚L2, ²“¡•˜Y2, “n粏¹•F2,3 (1ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 2‰º•”Á‰»ŠÇŠO, 3–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ55‰ñ“ú–{• •”‹~‹}ˆãŠw‰ï‘‰ï (2019/3/7), å‘ä.

'18-723015. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) pŒã’°•ÂÇ‚ɑ΂µ‚Ä• o‹Ÿ‰ºŽèp‚Í—L—p‚©? ’†‘º—²r1, ²“¡•˜Y1, ŽR—œ‚L1, ŽO‰YŒ[šæ1, ŒÃé@Œ›1, “‡’Á@«, “n粏¹•F1,2 (1‰º•”Á‰»ŠÇŠO, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ55‰ñ“ú–{• •”‹~‹}ˆãŠw‰ï‘‰ï (2019/3/8), å‘ä.

'18-733001. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) p‘O‰»Šw•úŽËü—Ö@Ž{sŒã‚ɍs‚Á‚œ• o‹ŸŽèp‚ÌŽ¡—ЬÑ. ²“¡•˜Y1, ’†‘º—²r1, ŽR—œ‚L1, ŽO‰YŒ[šæ1, ŒÃé@Œ›1, “‡’Á@«, ”‹ŒŽçŒb1, ŠÛŽR³—T2, â–{ƒˆê3, “n粏¹•F1,4 (1‰º•”Á‰»ŠÇŠO, 2ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 3“û‘BEbó‘BŠO, 4–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ90‰ñ‘å’°ŠàŒ€‹†‰ï (2019/1/25), ‹ž“s.

'18-733002. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “–‰@‚Å‚ÌT1’Œ’°Šà‚ɑ΂·‚é• o‹Ÿ‰ºŽèp‚ÌŒ»ó‚Æ’ZŠú¬Ñ. ²“¡•˜Y (‰º•”Á‰»ŠÇŠO): ‘æ90‰ñ‘å’°ŠàŒ€‹†‰ï (2019/1/25), ‹ž“s.

S‘ŸŒŒŠÇŠO‰ÈŠw

[Šwp˜_•¶]

110204. [ŒŽ’˜] Novel Surgical Strategy for Complicated Pulmonary Stenosis Using Haemodynamic Analysis Based on a Virtual Operation With Numerical Flow Analysis. Miyaji K1, Miyazaki S, Itatani K2, Oka N1, Kitamura T1, Horai T1: Interact Cardiovasc Thorac Surg 2019/5; 28 (5): 775-82. (‹{’n@ŠÓ1, ”Â’JŒcˆê2, ‰ª@“¿•F1, –k‘º@—¥1, •ó—ˆ“N–ç1: S‘ŸŒŒŠÇŠO, 2‹ž“s•{—§‘åŠw)

310027. [Ç—á•ñ] Ketoacidosis related to sodium glucose cotransporter 2 inhibitors after emergency coronary surgery. Horikoshi R1, Kitamura T1, Miyaji K1: Interact Cardiovasc Thorac Surg 2019/8; 29 (2): 323-4. (–x‰z—m1, –k‘º@—¥1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO)

310028. [Ç—á•ñ] The Modified Ross Reversal Operation: A New Approach for Preserving the Autograft Wall. Horikoshi R1, Kitamura T1, Miyaji K1: Interact Cardiovasc Thorac Surg 2020/2; 30 (2): 324-6. (–x‰z—m1, –k‘º@—¥1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO)

522051. [uÀ]y“ÁW: ¬læ“V«SŽŸŠ³‚ÌŠO‰ÈŽ¡—Ázæ“V«SŽŸŠ³C•œpŒã‰“ŠuŠú”x“®–¬•Ù‹t—¬‚ɑ΂·‚é”x“®–¬•Ù’uŠ·p‚Ì—L—p«. ‰ª@“¿•F1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO): ‹¹•”ŠO‰È 2019/4; 72 (4): 248-50.

[Šw‰ïEŒ€‹†‰ï“™]

713052. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Surgical Indications of Adult Ebstein Anomaly with NYHA IV. Miyamoto T1: The 10thEuropean Meeting onAdult Congenital Heart Disease (Euro GUCH) (2019/4/5-6), Zagreb, Croatia. (‹{–{—²Ži1: 1S‘ŸŒŒŠÇŠO)

713053. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Is BNP Biomarker in Reoperation of Grown-Up Congnital Heart Disease? Fukunishi T1: The 10thEuropean Meeting onAdult Congenital Heart Disease (Euro GUCH) (2019/4/5-6), Zagreb, Croatia. (•ŸŒ‘ô^1: 1S‘ŸŒŒŠÇŠO)

713054. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Chimney aortic repair for ruptured TAAA in a high-risk patient. Ohkubo H1: The 5th Asia-Pacific Angiology Academic Alliance Conference and 2019 International Annual Congress of Macau Health Bureau & Medical Doctors' Association (2019/6/21), Macau. (‘å‹v•Û”Ž¢1: 1S‘ŸŒŒŠÇŠO)

713055. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Surgical repair of vascular ring. Tadokoro Y1, Ohkubo H1, Miyamoto T1: The 5th Asia-Pacific Angiology Academic Alliance Conference and 2019 International Annual Congress of Macau Health Bureau & Medical Doctors' Association (2019/6/21), Macau. (“cŠ—S‹I1, ‘å‹v•Û”Ž¢1, ‹{–{—²Ži1: 1S‘ŸŒŒŠÇŠO)

713056. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Wait-and-watch strategy for type A intramural haematoma and acute aortic dissection with thrombosed false lumen of the ascending aorta: 50 mm or less, pain under control and no ulcer-like projection. Kitamura T1, Torii S2, Miyamoto T1, Fujioka S1, Araki H1, Tadokoro Y1, Onishi Y1, Miyaji K1: The33th Annual Meeting of European Association for Cardio-Thoracic Surgery (EACTS) (2019/10/3-5), Lisbon, Portugal. (–k‘º@—¥1, ’¹ˆäWŽO2, ‹{–{—²Ži1, “¡‰ªrˆê˜Y1, r‹Lt“Þ1, “cŠ—S‹I1, ‘同‹`•F1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç)

713057. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Preoperative Factors for Acute Lung Injury After Pediatric Open-Heart Surgery. Fukunishi T1, Kohira S2, Inoue N1, Miyamoto T1, Kitamura T1, Miyaji K1: The 56th Annual Meeting of Society of Thoracic Surgeons (STS) (2020/1/25-28), New Orleans, USA. (•ŸŒ‘ô^1, ŒÃ•œ@‘2, ˆäãMK1, ‹{–{—²Ži1, –k‘º@—¥1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO, 2ME•”)

713058. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Staged open repair for chronic thoracoabdominal aortic dissection. Fujioka S1, Kitamura T1, Onishi Y1, Tadokoro Y1, Araki H1, Matushiro T1, Yakuwa K1, Ohkubo H1, Mishima T1, Miyamoto T1, Torii S2, Miyaji K1: The 28th Congress of the Asian Society for Cardiovascular and Thoracic Surgery (ASCVTS) (2020/2/7-10), Chiang Mai, Thailand. (“¡‰ªrˆê˜Y1, –k‘º@—¥1, ‘同‹`•F1, “cŠ—S‹I1, r‹Lt“Þ1, Œ‘ã‘ì–ç1, ”ªŒLˆê‹M1, ‘å‹v•Û”Ž¢1, ”ü“‡—˜º1, ‹{–{—²Ži1, ’¹ˆäWŽO2, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç)

713059. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Preoperative Neutrophil-Lymphocyte Ratio Predicts Bleeding Tendency During Elective Total Arch Replacement. Kitamura T1, Torii S2, Miyamoto T1, Mishima T1, Ohkubo H1, Fujioka S1, Matsushiro T1, Yakuwa K1, Araki H1, Tadokoro Y1, Onishi Y1, Miyaji K1: The 28th Congress of the Asian Society for Cardiovascular and Thoracic Surgery (ASCVTS) (2020/2/7-10), Chiang Mai, Thailand. (–k‘º@—¥1, ’¹ˆäWŽO2, ‹{–{—²Ži1, ”ü“‡—˜º1, ‘å‹v•Û”Ž¢1, “¡‰ªrˆê˜Y1, Œ‘ã‘ì–ç1, ”ªŒLˆê‹M1, r‹Lt“Þ1, “cŠ—S‹I1, ‘同‹`•F1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç

713060. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Surgical strategy for thoraco-abdominal aortic aneurysm in high risk patient. Onishi Y1, Fujioka S1, Kitamura T1, Torii S2, Miyamoto T1, Mishima T1, Ohkubo H1, Yakuwa K1, Araki H1, Kondo S1, Tamura Y1, Tadokoro Y1, Miyaji K1: The 28th Congress of the Asian Society for Cardiovascular and Thoracic Surgery (ASCVTS) (2020/2/7-10), Chiang Mai, Thailand. (‘同‹`•F1, “¡‰ªrˆê˜Y1, –k‘º@—¥1, ’¹ˆäWŽO2, ‹{–{—²Ži1, ”ü“‡—˜º1, ‘å‹v•Û”Ž¢1, ”ªŒLˆê‹M1, r‹Lt“Þ1, ‹ß“¡@^1, “c‘ºK•ä1, “cŠ—S‹I1,‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç)

713061. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Effectiveness of Simultaneous Reconstructions in Congenital Open-Heart Surgery: Blalock-Taussig Shunt with Pulmonary Artery Plasty. Fukunishi T1, Inoue N1, Miyamoto T1, Kitamura T1, Miyaji K1: The 28th Congress of the Asian Society for Cardiovascular and Thoracic Surgery (ASCVTS) (2020/2/7-10), Chiang Mai, Thailand. (•ŸŒ‘ô^1, ˆäãMK1, ‹{–{—²Ži1, –k‘º@—¥1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO)

713062. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Initiating of Perioperative Inhaled Nitric Oxide Therapy in Patients with Open Heart Surgery. Inoue N1, Fukunishi T1, Kondo S1, Ohtomo Y1, Kitamura T1, Miyaji K1: The 28th Congress of the Asian Society for Cardiovascular and Thoracic Surgery (ASCVTS) (2020/2/7-10), Chiang Mai, Thailand. (ˆäãMK1, •ŸŒ‘ô^1, ‹ß“¡@^1, ‘å—F—EŽ÷1, –k‘º@—¥1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO)

713063. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Chimney aortic repair for ruptured TAAA in a high-risk patient. Ohkubo H1, Fujioka S1, Kitamura T1, Onishi Y1, Araki H1, Mishima T1, Miyamoto T1, Torii S2, Miyaji K1: The 28th Congress of the Asian Society for Cardiovascular and Thoracic Surgery (ASCVTS) (2020/2/7-10), Chiang Mai, Thailand. (‘å‹v•Û”Ž¢1, “¡‰ªrˆê˜Y1, –k‘º@—¥1, ‘同‹`•F1, r‹Lt“Þ1, ”ü“‡—˜º1, ‹{–{—²Ži1, ’¹ˆäWŽO2, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç)

713064. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Effectiveness of Intraoperative Pulmonary Artery Pressure Monitoring in Patients with Ventricular Septal Defect and Pulmonary Hypertension. Araki H1, Miyaji K1, Miyamoto T1, Torii S2, Kitamura T1, Mishima T1, Ohkubo H1, Fujioka S1, Matsushiro T1, Yakuwa K1: The 28th Congress of the Asian Society for Cardiovascular and Thoracic Surgery (ASCVTS) (2020/2/7-10), Chiang Mai, Thailand. (r‹Lt“Þ1, ‹{’n@ŠÓ1, ‹{–{—²Ži1, ’¹ˆäWŽO2, –k‘º@—¥1, ”ü“‡—˜º1, ‘å‹v•Û”Ž¢1, “¡‰ªrˆê˜Y1, Œ‘ã‘ì–ç1, ”ªŒLˆê‹M1: 1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç)

713065. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Newly created canine model of sinus node dysfunction by minimally invasive procedure. Miyamoto T1, Ishido H1, Aoki T, Miyaji K1: 49. Jahrestagung der DGTHG/52. Jahrestagung der DGPK (HERZMEDIZIN) (2020/2/29-3/3), Wiesbaden, Germany. (‹{–{—²Ži1, Î“°”ŽŒh1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO)

723326. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Consideration for indications and procedures in adult congenital heart disease. ‹{–{—²Ži1, •ŸŒ‘ô^1, ŒˆäŒª‘Ÿ1, Î“°”ŽŒh1, ‘ºˆä—C‘Ÿ1, –L“c^Žõ1, ’†‘º—D”ò1, –x‰z—m1, r‹Lt“Þ1, “¡‰ªrˆê˜Y1, ‘å‹v•Û”Ž¢1, ˆäãMK1, ¬—ÑŒ’‰î1, ”ü“‡—˜º1, –k‘º@—¥1, ’¹ˆäWŽO2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç): ‘æ119‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/4/18-20), ‘åã, “ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ïŽ˜^W 2020/4; 119: PD-3-4.

723327. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Challenging neck ‚ɑ΂·‚é• •”‘å“®–¬áŽƒXƒeƒ“ƒgƒOƒ‰ƒtƒg“à‘}p‚ÌŒŸ“¢. ‘å‹v•Û”Ž¢1, “¡‰ªrˆê˜Y1, ”ü“‡—˜º1, ŒˆäŒª‘Ÿ1, ’†‘º—D”ò1, –L“c^Žõ1, –x‰z—m1, r‹Lt“Þ1, •ŸŒ‘ô^1, ¬—ÑŒ’‰î1, –k‘º@—¥1, ‹{–{—²Ži1, ’¹ˆäWŽO2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç): ‘æ119‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/4/18-20), ‘åã, “ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ïŽ˜^W 2020/4; 119: PS-147-2.

723328. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) LupiaeƒOƒ‰ƒtƒg҂ð—p‚¢‚œ‘å“®–¬ŽÕ’f‚É‚æ‚é‹|•”‘å“®–¬‘S’uŠ·p‚ðŽ{s‚µ‚œ2Ç—á. •ŸŒ‘ô^1, –k‘º@—¥1, ’¹ˆäWŽO2, ”ü“‡—˜º1, ˆäãMK1, ‘å‹v•Û”Ž¢1, “¡‰ªrˆê˜Y1, r‹Lt“Þ1, ‹{–{—²Ži1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç): ‘æ47‰ñ“ú–{ŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï (2019/5/22-24), –ŒŒÃ‰®, “ú–{ŒŒŠÇŠO‰ÈŠw‰ïŽGŽ 2019/5; 28iSuppl): 89.

723329. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Iliac Branch Endoprosthesis (IBE) ‚ð—p‚¢‚œƒXƒeƒ“ƒgƒOƒ‰ƒtƒgŽ¡—Â̌Ÿ“¢. “¡‰ªrˆê˜Y1, ‘å‹v•Û”Ž¢1, ”ü“‡—˜º1, Î“°”ŽŒh1, ‘ºˆä—C‘Ÿ1, r‹Lt“Þ1, •ŸŒ‘ô^1, ˆäãMK1, –k‘º@—¥1, ‹{–{—²Ži1, ’¹ˆäWŽO2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç): ‘æ47‰ñ“ú–{ŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï (2019/5/22-24), –ŒŒÃ‰®, “ú–{ŒŒŠÇŠO‰ÈŠw‰ïŽGŽ 2019/5; 28iSuppl): 90.

723330. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”j—ô«• •”‘å“®–¬áŽE’°œ“®–¬áŽ‚ɑ΂·‚éƒXƒeƒ“ƒgƒOƒ‰ƒtƒg“à‘}p. ‘å‹v•Û”Ž¢1, ”ü“‡—˜º1, “¡‰ªrˆê˜Y1, ‘ºˆä—C‘Ÿ1, Î“°”ŽŒh1, r‹Lt“Þ1, •ŸŒ‘ô^1, ˆäãMK1, –k‘º@—¥1, ‹{–{—²Ži1, ’¹ˆäWŽO2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç): ‘æ47‰ñ“ú–{ŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï (2019/5/22-24), –ŒŒÃ‰®, “ú–{ŒŒŠÇŠO‰ÈŠw‰ïŽGŽ 2019/5; 28iSuppl): 92.

723331. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • •”‘å“®–¬áŽE’°œ“®–¬áŽ‚ɑ΂·‚éAFX‚Ì’†Šú¬Ñ‚ÌŒŸ“¢. ‘ºˆä—C‘Ÿ1, ‘å‹v•Û”Ž¢1, “¡‰ªrˆê˜Y1, ”ü“‡—˜º1, Î“°”ŽŒh1, r‹Lt“Þ1, •ŸŒ‘ô^1, ˆäãMK1, –k‘º@—¥1, ‹{–{—²Ži1, ’¹ˆäWŽO2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç): ‘æ47‰ñ“ú–{ŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï (2019/5/22-24), –ŒŒÃ‰®, “ú–{ŒŒŠÇŠO‰ÈŠw‰ïŽGŽ 2019/5; 28iSuppl): 112.

723332. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚š‚¯‚éˆâŽc¿œ“®–¬áŽ‚ÌŽ¡—ÃŒoŒ±. “y“c—E‘Ÿ1, ‰º‰ÍŒŽ’B–ç2, ‘ºˆä—C‘Ÿ1, a’JT‘Ÿ˜Y2, ]ì’q‹v2 (1S‘ŸŒŒŠÇŠO, 2Ï¶‰ï‰¡•lŽs“Œ•”•a‰@): ‘æ60‰ñ“ú–{–¬ŠÇŠw‰ï‘‰ï (2019/10/10-12), “Œ‹ž, –¬ŠÇŠw 2019/10; 59 (Suppl): S84.

723333. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Pulmonary coarctation‚ɑ΂·‚éV¶Ž™Šú‘Ì”x’Z—Žèp‚Æ”x“®–¬Œ`¬p“¯ŽžŽèp. ‹{’n@ŠÓ1, ‹{–{—²Ži1, ”ªŒLˆê‹M1, “cŠ—S‹I1, ’¹ˆäWŽO2, –k‘º@—¥1, “¡‰ªrˆê˜Y1, r‹Lt“Þ1, ‹ß“¡@^1, ‘同‹`•F1 (1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç): ‘æ72‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/10/30-11/2), ‹ž“s, “ú–{‹¹•”ŠO‰ÈŠw‰ïŽGŽ 2019/10; (Suppl): 158.

723334. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “ñSŽºC•œŒQ‚É‚š‚¯‚é—Œ‘€”x“®–¬iNp‚É‚æ‚鉓ŠuŠú––œ”x“®–¬‹·ó‚ÌŒŸ“¢. ‰ª@“¿•F1, —F•Û‹M”Ž1, —с@GŒ›1, ‹{–{—²Ži1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO): ‘æ72‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/10/30-11/2), ‹ž“s, “ú–{‹¹•”ŠO‰ÈŠw‰ïŽGŽ 2019/10; (Suppl): 158.

723335. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ãs‘å“®–¬‹Uo•ÂÇŒ^Stanford AŒ^‹}«‘å“®–¬‰ð—£‚ɑ΂·‚鏉Šú•Û‘¶—Ö@‚ÌŒŸ“¢. r‹Lt“Þ1 –k‘º@—¥1, ‘同‹`•F1, “cŠ—S‹I1, “c‘º‰À”ü1, ‹ß“¡@^1, ”ªŒLˆê‹M1, “¡‰ªrˆê˜Y1, ‘å‹v•Û”Ž¢1, ”ü“‡—˜º1, ‹{–{—²Ži1, ’¹ˆäWŽO2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç): ‘æ72‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/10/30-11/2), ‹ž“s, “ú–{‹¹•”ŠO‰ÈŠw‰ïŽGŽ 2019/10; (Suppl): 223.

723336. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) V¶Ž™ŠJSppŒã‚Ì“û‚Ñ‹¹…‚ɑ΂·‚郊ƒ“ƒpŠÇ‘¢‰e‚Ì—L—p«. “cŠ—S‹I1, ‹{–{—²Ži1, ”ªŒLˆê‹M1, ’¹ˆäWŽO2, –k‘º@—¥1, “¡‰ªrˆê˜Y1, r‹Lt“Þ1, ‹ß“¡@^1, “c‘º‰À”ü1, ‘同‹`•F1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç): ‘æ72‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/10/30-11/2), ‹ž“s, “ú–{‹¹•”ŠO‰ÈŠw‰ïŽGŽ 2019/10; (Suppl): 237.

723337. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬lŠJSp‚É‚š‚¯‚éˆêŽ_‰»’‚‘f‹z“ü—Ö@ŠJŽnŽžŠú‚ÌŒŸ“¢. ˆäãMK1, ‘å—F—EŽ÷1, r‹Lt“Þ1, •ŸŒ‘ô^1, “¡‰ªrˆê˜Y1, ‘å‹v•Û”Ž¢1, ”ü“‡—˜º1, –k‘º@—¥1, ‹{–{—²Ži1, ’¹ˆäWŽO2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç): ‘æ72‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/10/30-11/2), ‹ž“s, “ú–{‹¹•”ŠO‰ÈŠw‰ïŽGŽ 2019/10; (Suppl): 238.

723338. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˜A‘±–D‡‚ð—p‚¢‚œTrifecta, Magna EASE, Inspiris‚É‚æ‚é‘å“®–¬•Ù’uŠ·p‚Ì’†Šú¬Ñ‚Ì”äŠrŒŸ“¢. ‘同‹`•F1, –k‘º@—¥1, ’¹ˆäWŽO2, ‹{–{—²Ži1, ”ü“‡—˜º1, ˆäãMK1, ‘å‹v•Û”Ž¢1, “¡‰ªrˆê˜Y1, •ŸŒ‘ô^1, ”ªŒLˆê‹M1, r‹Lt“Þ1, ‹ß“¡@^1, “c‘º‰À”ü1, “cŠ—S‹I1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç): ‘æ72‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/10/30-11/2), ‹ž“s, “ú–{‹¹•”ŠO‰ÈŠw‰ïŽGŽ 2019/10; (Suppl): 245.

723339. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Low risk‚ÌASŠ³ŽÒ‚ɑ΂·‚éTAVI“K‰ž‚̑Ó–«. –k‘º@—¥1, ’¹ˆäWŽO2, ‹{–{—²Ži1, ”ü“‡—˜º1, ‘å‹v•Û”Ž¢1, “¡‰ªrˆê˜Y1, ”ªŒLˆê‹M1, r‹Lt“Þ1, ‹ß“¡@^1, “c‘º‰À”ü1, “cŠ—S‹I1, ‘同‹`•F1, ˆ¢ŒÃÆ3, –ڍ•Œ’‘Ÿ˜Y3, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç, 3zŠÂŠí“à): ‘æ72‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/10/30-11/2), ‹ž“s, “ú–{‹¹•”ŠO‰ÈŠw‰ïŽGŽ 2019/10; (Suppl): 289.

723340. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “§ÍŠ³ŽÒ‚̐S‘Ÿ‘匌ŠÇŽèp‚É‚š‚¯‚鎀–S‚̊댯ˆöŽq‚ɂ‚¢‚Ä‚ÌŒŸ“¢. “c‘º‰À”ü1, –k‘º@—¥1, ’¹ˆäWŽO2, ‹{–{—²Ži1, ”ü“‡—˜º1, ˆäãMK1, ‘å‹v•Û”Ž¢1, “¡‰ªrˆê˜Y1, •ŸŒ‘ô^1, ”ªŒLˆê‹M1, r‹Lt“Þ1, ‹ß“¡@^1, “cŠ—S‹I1, ‘同‹`•F1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç): ‘æ72‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/10/30-11/2), ‹ž“s, “ú–{‹¹•”ŠO‰ÈŠw‰ïŽGŽ 2019/10; (Suppl): 294.

723341. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚š‚¯‚éˆâŽc¿œ“®–¬áŽ‚ÌŽ¡—ÃŒoŒ±. ‹{’n@ŠÓ1, ‹{–{—²Ži1, ”ªŒLˆê‹M1, “cŠ—S‹I1, ’¹ˆäWŽO2, –k‘º@—¥1, “¡‰ªrˆê˜Y1, r‹Lt“Þ1, ‹ß“¡@^1, ‘同‹`•F1 (1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç): ‘æ72‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/10/30-11/2), ‹ž“s.

723342. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) SóŒ‹’°Šà‚ð‡•¹‚µ‚œ•Ð‘€‘’°œ“®–¬áŽ‚ɑ΂µ, —Œ‘€“à’°œ“®–¬‚ð‰·‘¶‚µ‚œEVAR‚ðŽ{s‚µ‚œˆê—á. “y“c—E‘Ÿ1, ‰º‰ÍŒŽ’B–ç2, ‘ºˆä—C‘Ÿ1, a’JT‘Ÿ˜Y2, ]ì’q‹v2 (1S‘ŸŒŒŠÇŠO, 2Ï¶‰ï‰¡•lŽs“Œ•”•a‰@): ‘æ81‰ñ“ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ï (2019/11/14-16), ‚’m, “ú–{—Տ°ŠO‰ÈŠw‰ï‘‰ïŽGŽ 2019/11; 80 (‘Š§): 807.

723343. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘SlHŒÒŠÖß’uŠ·pŒã‚É‹‘å•Âœ“®–¬áŽ‚ð‚«‚œ‚µ‚œ1—á. ‘å‹v•Û”Ž¢1, “¡‰ªrˆê˜Y1, ”ü“‡—˜º1, ŒˆäŒª‘Ÿ1, –L“c^Žõ1, ’†‘º—D”ò1, ¬—ÑŒ’‰î1, –k‘º@—¥1, ‹{–{—²Ži1, ’¹ˆäWŽO2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç): ‘æ182‰ñŒŒŠÇŠO‰ÈÇ—ጟ“¢‰ï (2019/12/14), ìè, ŒŒŠÇŠO‰È 2019/11; 38 (1): 142.

723344. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹‘åt“®–¬áŽ‚ɑ΂·‚錌ŠÇ“àŽ¡—ÂÌ1—á. ‘å‹v•Û”Ž¢1, ”ü“‡—˜º1, “¡‰ªrˆê˜Y1, ‘ºˆä—C‘Ÿ1 ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO): ‘æ182‰ñŒŒŠÇŠO‰ÈÇ—ጟ“¢‰ï (2019/12/14), ìè, ŒŒŠÇŠO‰È 2019/11; 38 (1): 170-1.

723345. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬læ“V«SŽŸŠ³‚ÌŽèp’†‚̐S‘Ÿ‘匌ŠÇ‘¹‚̑Ώˆ–@‚ɂ‚¢‚Ä. ‹{–{—²Ži1, ”ªŒLˆê‹M1, “cŠ—S‹I1, ‘同‹`•F1, “¡“c“S•œ2, ¬”‹Žr”ü2, –k‘º@—¥1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2zŠÂŠí“à): ‘æ22‰ñ“ú–{¬læ“V«SŽŸŠ³Šw‰ï‘‰ïEŠwpW‰ï (2020/1/17-19), “Œ‹ž, “ú–{æ“V«SŽŸŠ³Šw‰ïŽGŽ 2020/1; 9 (1): 195.

723346. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Â”NŠú‚É‚š‚¯‚éTOFpŒã”x“®–¬¶‘Ì•Ù’uŠ·p‚Ì’†Šú‰“Šu¬Ñ. ‹{’n@ŠÓ1, ‹{–{—²Ži1, ”ªŒLˆê‹M1, “cŠ—S‹I1, ¬”‹Žr”ü2, “¡“c“S•œ2, ˆ¢ŒÃÆ2 (1S‘ŸŒŒŠÇŠO, 2zŠÂŠí“à): ‘æ22‰ñ“ú–{¬læ“V«SŽŸŠ³Šw‰ï‘‰ïEŠwpW‰ï (2020/1/17-19), “Œ‹ž, “ú–{æ“V«SŽŸŠ³Šw‰ïŽGŽ 2020/1; 9 (1): 209.

733119. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) MRIŽB‘œ‚ð—p‚¢‚œŒŒ—¬‰ðÍ‚Őf’fEŽèpí—ª‚𗧂Ăœ‰EŽº“ñoÇ‚Ì1—á. Œ‰iŒc—õ1, –L“c^Žõ1, ¬—ÑŒ’‰î1, ¬ŒŽ–M‹`, æс@³Šî, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO): ‘æ180‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2019/6/8), “Œ‹ž, “ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï—vŽ|W 2019/6; 180: 9.

733120. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‹¹•”‰ºs‘å“®–¬lHŒŒŠÇ’uŠ·pŒã, lHŒŒŠÇŠŽõ‚𕹔­‚µ‹Ù‹}TEVAR‹y‚ѐH“¹”²‹Ž‚ÉŽŠ‚Á‚œˆêÇ—á. ’†“‡Œõ‹M1, ”g—¢—z‰î1, ‚–ØŽõl1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO): ‘æ180‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2019/6/8), “Œ‹ž, “ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï—vŽ|W 2019/6; 180: 15.

733121. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ACTA2ˆâ“`Žq•ÏˆÙ‚ð‹^‚í‚ê‚œ‘å“®–¬•Ù—ÖŠg’£Ç‚Ì1—á. ‘同‹`•F1, r‹Lt“Þ1, –k‘º@—¥1, ’¹ˆäWŽO2, ‹{–{—²Ži1, ”ü“‡—˜º1, ‘å‹v•Û”Ž¢1, “¡‰ªrˆê˜Y1, ”ªŒLˆê‹M1, ‹ß“¡@^1, “c‘º‰À”ü1, “cŠ—S‹I1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç): ‘æ180‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2019/6/8), “Œ‹ž, “ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï—vŽ|W 2019/6; 180: 21.

733122. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ”œ•œ‚·‚é”xÃ–¬‹·ó‚ð’悵‚œ¬‡Œ^‘”xÃ–¬ŠÒ—¬ˆÙíÇ‚Ì1—á. “cŠ—S‹I1, ”ªŒLˆê‹M1, ‹{–{—²Ži1, –k‘º@—¥1, ’¹ˆäWŽO2, ”ü“‡—˜º1, ‘å‹v•Û”Ž¢1, “¡‰ªrˆê˜Y1, r‹Lt“Þ1, ‹ß“¡@^1, “c‘º‰À”ü1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç): ‘æ180‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2019/6/8), “Œ‹ž, “ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï—vŽ|W 2019/6; 180: 26.

733123. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ŒJ‚è•Ô‚µ”][Ç‚ð‚«‚œ‚µ‚œ”ñ×‹Û«ŒŒð«S“à–Œ‰Š‚Ì1—á. ‘同‹`•F1, r‹Lt“Þ1, ’¹ˆäWŽO2, ‹{–{—²Ži1, –k‘º@—¥1, ”ü“‡—˜º1, ‘å‹v•Û”Ž¢1, “¡‰ªrˆê˜Y1, ”ªŒLˆê‹M1, ‹ß“¡@^1, “c‘º‰À”ü1, “cŠ—S‹I1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç): ‘æ181‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2019/11/9), “Œ‹ž, “ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï—vŽ|W 2019/11; 181: 14.

733124. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ƒvƒƒ^ƒ~ƒ“ƒVƒ‡ƒbƒNŠ³ŽÒ‚ɑ΂·‚é2DebranchTEVAR‚ðs‚¢Ž¡—µ‚œˆêÇ—á. ’†“‡Œõ‹M1, ”g—¢—z‰î1, ‚–ØŽõl, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO): ‘æ181‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2019/11/9), “Œ‹ž, “ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï—vŽ|W 2019/11; 181: 15.

733125. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ’uŠ·pŒã‚ɑ̈ʕϊ·‚É”º‚€’áŽ_‘fŒŒÇ‚ðŒ_‹@‚É”­Œ©‚³‚ê‚œS–[’†ŠuŒ‡‘¹Ç‚̈ê—á. Œ‰iŒc—õ1, ¬—ÑŒ’‰î1, “c‘ºK•ä1, ¬ŒŽ–M‹`, æс@³Šî, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO): ‘æ181‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2019/11/9), “Œ‹ž, “ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï—vŽ|W 2019/11; 181: 20.

733126. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) Š®‘SŒ^d•¡‘å“®–¬‹|‚̈ê—á. “cŠ—S‹I1, ‹{–{—²Ži1, ”ªŒLˆê‹M1, ’¹ˆäWŽO2, –k‘º@—¥1, “¡‰ªrˆê˜Y1, r‹Lt“Þ1, ‹ß“¡@^1, “c‘º‰À”ü1, ‘同‹`•F1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç): ‘æ181‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2019/11/9), “Œ‹ž, “ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï—vŽ|W 2019/11; 181: 23.

733127. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) Ebstein•a‚ɑ΂µ‚ÄConeŽèp‚ðŽ{s‚µ‚œ1—á. ‘同‹`•F1, ‹{–{—²Ži1, ’¹ˆäWŽO2, –k‘º@—¥1, ”ü“‡—˜º1, ‘å‹v•Û”Ž¢1, “¡‰ªrˆê˜Y1, Œ‘ã‘ì–ç1, ”ªŒLˆê‹M1, r‹Lt“Þ1, “cŠ—S‹I1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç): ‘æ182‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2020/3/7), ŽãŠJÃ, “ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï—vŽ|W 2020/3; 182: 9.

733128. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‘å“®–¬‰ð—£p’†‚ÉMalperfusion‚Ɋׂè‹}篏ãs‘å“®–¬’ŒÚ‘—ŒŒ‚ɕύX‚µ‚ÄŽèp‚ðŠ®‹‚µ‚œˆêÇ—á. ’†“‡Œõ‹M1, ”g—¢—z‰î1, ‚–ØŽõl1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO): ‘æ182‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2020/3/7), ŽãŠJÃ, “ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï—vŽ|W 2020/3; 182: 14.

733129. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ”]”^á‡‚ð‡•¹‚µ‚œŠŽõ«S“à–Œ‰Š‚ÌŽ¡—ÃŒoŒ±. Œ‰iŒc—õ1, ¬—ÑŒ’‰î1, “c‘ºK•ä1, ¬ŒŽ–M‹`, æс@³Šî, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO): ‘æ182‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2020/3/7), ŽãŠJÃ, “ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï—vŽ|W 2020/3; 182: 30.

733130. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‘å“®–¬•Ù’uŠ·ppŒã‘Šú‚É‘m–X•Ù‹t—¬‚ð’悵‚œŠŽõ« S“à–Œ‰Š‚Ì1—á. “cŠ—S‹I1, r‹Lt“Þ1, ’¹ˆäWŽO2, ‹{–{—²Ži1, –k‘º@—¥1, ”ü“‡—˜º1, ‘å‹v•Û”Ž¢1, “¡‰ªrˆê˜Y1, Œ‘ã‘ì–ç1, ”ªŒLˆê‹M1, ‘同‹`•F1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2ˆã—ÈÀ‘SŠw‹³ˆç): ‘æ182‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2020/3/7), ŽãŠJÃ, “ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï—vŽ|W 2020/3; 182: 31.


ŒÄ‹zŠíŠO‰ÈŠw

[Šwp˜_•¶]

110205. [ŒŽ’˜] Ultra-late recurrence of non-small cell lung cancer over 10 years after curative resection. Sonoda D1, Matsuura Y, Ichinose J, Nakao M, Ninomiya H, Mun M, Ishikawa Y, Nakagawa K, Satoh Y2, Okumura S: Cancer Manag Res 2019/7; 11: 6765-74. (‰€“c@‘å1, ²“¡”Vr2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ŒÄ‹zŠíŠO)

110206. [ŒŽ’˜] EGFR mutation genotyping and ALK status determination in liquid-based cytology samples of non-small cell lung cancer. Satoh Y1, Matsuo Y2, Kuba T3, Yamashita K3, Sawano M, Tozaka S, Yamazaki H1, Sonoda D4, Mikubo M1, Naito M1, Matsui Y1, Shiomi K1, Yoshida T5, Murakumo Y5: Virchows Arch 2020/5; 476 (5): 753-62. doi: 10.1007/s00428-019-02692-9. Epub 2019 Dec 10. (²“¡”Vr1, Œ”ö—R‹IŽq2, ‹vê@Ž÷3, ŽR‰º˜a–ç3, ŽRèGŒp1, ‰€“c@‘å4, ŽOŒE«Žj1, “à“¡‰ëm1, ŒˆäŒ[•v1, ‰–Œ©@˜a1, ‹g“c@Œ÷5, ‘º‰_–FŽ÷5: 1ŒÄ‹zŠíŠO, 2•a‘ԁEf—ÃŒn, 3•a—•”, 4‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 5•a—)

310029. [Ç—á•ñ] A case report of a thymic neuroblastoma associated with syndrome of inappropriate secretion of antidiuretic hormone: Ten-year follow-up results after surgical treatment. Satoh Y1: Int J Surg Case Rep 2019/5; 58: 45-7. (²“¡”Vr1: 1ŒÄ‹zŠíŠO)

310030. [Ç—á•ñ] Ciliated muconodular papillary tumors of the lung: Cytologic features and diagnostic pitfalls in intraoperative examinations. Mikubo M1, Maruyama R1, Kakinuma H2, Yoshida T3, Satoh Y1: Diagn Cytopathol 2019/7; 47 (7): 716-9. (ŽOŒE«Žj1, ŠÛŽR—ˆô1, Š`ÀœA–M2, ‹g“c@Œ÷3, ²“¡”Vr1: 1ŒÄ‹zŠíŠO, 2•a—•”, 3•a—)

540039. [‚»‚Ì‘Œ (‘•])] ×–Ef‚ðŠw‚Ԑl‚Ì‚œ‚ß‚É. ²“¡”Vr (ŒÄ‹zŠíŠO): ŒŸž‚Æ‹Zp 2019/12; 47 (12): 1403.

540040. [‚»‚Ì‘Œ (‘•])] PICO‚©‚çŽn‚ß‚éˆãŠw•¶Œ£ŒŸõ‚Ì‚·‚·‚ß. ²“¡”Vr (ŒÄ‹zŠíŠO): ‹¹•”ŠO‰È 2019/6; 72 (6): 454.

540041. [‚»‚Ì‘Œ (‘•])] bó‘B×–EfƒAƒgƒ‰ƒX@•ñ—lŽ®‰^—p‚ÌŽÀÛ. ²“¡”Vr (ŒÄ‹zŠíŠO): —Տ°ŒŸž 2020/1; 64 (1): 44.

[’˜@‘]

621002. [Šwp‘ (•ÒW)]y×–EŒŸžŽm×–E‘œŽŽŒ±–â‘èW ‘æ2”ŁzŒÄ‹zŠí@–â‘èE‰ð“šE‰ðà. •Ò: ²“¡”Vr1,2 (1ŒÄ‹zŠíŠO, 2Œö‰vŽÐ’c–@l“ú–{—Տ°×–EŠw‰ï), ˆãŽ•–òo”Å, “Œ‹ž, 2019/4”­s.

621003. [Šwp‘ (•ÒW)]y”ñˆ««ŒÄ‹zŠí×–EfƒAƒgƒ‰ƒX: ”xŠà‚Æ‚ÌŠÓ•Ê‚É”Y‚ñ‚Ÿ‚Æ‚«‚Ɂz•Ò: ²“¡”Vr1, ‰–àV@“N (1ŒÄ‹zŠíŠO), “ì]“°, “Œ‹ž, 2020/2”­s.

[Šw‰ïEŒ€‹†‰ï“™]

712007. [Šw‰ï (‘Û)] (µ‘ҍu‰‰“™) Consensus Terminology in Cytology Symposium. International Cytology Reporting System of Lung Tumors. Satoh Y1: The 42nd European Congress of Cytology (2019/6/16-19), Malmo, Sweden. (²“¡”Vr1: 1ŒÄ‹zŠíŠO)

713066. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Effect of formaldehyde in liquid-based cytology preservation solutions on molecular testing of lung cancer specimens. Satoh Y1, Matsuo Y2, Yamashita K3, Yoshida T4: The 20th International Congress Of Cytology 2019 (2019/5/5-9), Sydney, Australia. (²“¡”Vr1, Œ”ö—R‹IŽq2, ŽR‰º˜a–ç3, ‹g“c@Œ÷4: 1ŒÄ‹zŠíŠO, 2•a‘ԁEf—ÃŒn, 3•a—•”, 4•a—)

713067. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Clinical genomic test on cytology: Current status and future perspective in Japan (JSCC Working Group on cytological roles in genome medicine era). Motoi N, Hatanaka Y, Hamakawa S, Kawahara A, Nagatomo T, Kuwata T, Oda Y, Okamoto A, Maeda I, Satoh Y1, Morii E: The 20th International Congress Of Cytology 2019 (2019/5/5-9), Sydney, Australia. (²“¡”Vr1: 1ŒÄ‹zŠíŠO)

713068. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) International cytology reporting system of lung tumors. Satoh Y1: The 20th International Congress Of Cytology 2019 (2019/5/5-9), Sydney, Australia. (²“¡”Vr1: 1ŒÄ‹zŠíŠO)

713069. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Typical Carcinoid with Pleural Dissemination: report of a rare case. Mitsui A1, Tamagawa S1, Hayashi S1, Naito M1, Mathui Y1, Shiomi K1, Satoh Y1, Tochimoto M2, Ichinohe M2, Nakagawa H3, Kakinuma Y3, Kakinuma H3: 18th Japan-Korea Joint Meeting for Diagnostic Cytopathology (2019/9/7), Korea. (ŽOˆä@ˆ€1, ‹Êì@’B1, —с@ËŽq1, “à“¡‰ëm1, ŒˆäŒ[•v1, ‰–Œ©@˜a1, ²“¡”Vr1, “È–{¹F2, ˆêŒË¹–Ÿ2, ’†ìm”ü3, Š`À—D”üŽq3, Š`ÀœA–M3: 1ŒÄ‹zŠíŠO, 2•a—, 3•a—•”)

713070. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Clinical significances of intra-tumor CD8+ lymphocytes in NSCLCs (”ñ¬×–E”xŠà‚É‚š‚¯‚éŽîᇐZCD8—z«ƒŠƒ“ƒp‹…‚̈Ӌ`). Shiomi K1: IASLC 20th World Conference on Lung Cancer (WCLC 2019) (2019/9/9), Barcelona, Spain. (‰–Œ©@˜a1: 1ŒÄ‹zŠíŠO)

713071. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) The Possible Clinical Significances of Infiltration of CD8+ Lymphocytes in Non-Small Cell Lung Cancers. Shiomi K1, Ichinohe M2, Jiang SX, Naito M1, Mikubo M1, Matsui Y1, Tamagawa S1, Mitsui A1, Hayashi S1, Satoh Y1, Matsuo Y3: IASLC 20th World Conference on Lung Cancer (WCLC 2019) (2019/9/7-10), Barcelona, Spain. (‰–Œ©@˜a1, ˆêŒË¹–Ÿ2, “à“¡‰ëm1, ŽOŒE«Žj1, ŒˆäŒ[•v1, ‹Êì@’B1, ŽOˆä@ˆ€1, —с@ËŽq1, ²“¡”Vr1, Œ”ö—R‹IŽq3: 1ŒÄ‹zŠíŠO, 2•a—, 3•a‘ԁEf—ÃŒn)

722072. [Šw‰ï (‘S‘)] (—v–]u‰‰) ŒÄ‹zŠí. ²“¡”Vr (ŒÄ‹zŠíŠO): ‘æ60‰ñ“ú–{—Տ°×–EŠw‰ï‘‰ï (tŠú‘å‰ï) (2019/6/7-9), “Œ‹ž.

722073. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ¡Œã‚̃Qƒmƒ€f—Âɂš‚¯‚é×–Ef‚Ì‚ ‚è•û: Šw‰ï‚É‚š‚¯‚éŽæ‚è‘g‚Ý. ”š’†@–L, Œ³ˆä‹IŽq, à_ì^Ž¡, ‰ÍŒŽ–Ÿ•F, ’·—F’‰‘Š, ŒK“c@Œ’, ¬“c‹`’Œ, ‰ª–{ˆ€Œõ, ‘O“cˆê˜Y, ²“¡”Vr1, Xˆä‰pˆê (1ŒÄ‹zŠíŠO): ‘æ60‰ñ“ú–{—Տ°×–EŠw‰ï‘‰ï (tŠú‘å‰ï) (2019/6/7-9), “Œ‹ž.

722074. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) JSCC-JLCS‚É‚æ‚éV‚œ‚È”»’èŠî€‚Ì’ñˆÄ. œA“‡Œ’ŽO, ²“¡”Vr1, ‹g“c@Œ÷2, Š`ÀœA–M3, ’·”örF, Œ—с@ƒ, ŽO‘î^Ži, ’†’ːLˆê, áÁ”\³K, ’|’†–Ÿ”ü, Œ³ˆä‹IŽq, àF–؍N—Y, “ì@—DŽq, ‹gàV–Ÿ•F, ‰Hê—玟, ‰ÍŒŽ–MŒõ (1ŒÄ‹zŠíŠO, 2•a—, 3•a—•”): ‘æ60‰ñ“ú–{—Տ°×–EŠw‰ï‘‰ï (tŠú‘å‰ï) (2019/6/9), “Œ‹ž.

722075. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) uŠe‘ŸŠí‚̍זEf•ñ—lŽ®@‚»‚Ì—pŒê‚Æ”wŒi‚ɂ‚¢‚Ä‹c˜_‚·‚év`”xŠà×–Ef‚Ì•ñ—lŽ®`. àF–؍N—Y, ²“¡”Vr1, œA“‡Œ’ŽO, “ì@—DŽq, ‹gàV–Ÿ•F, ‰Hê—玟, ‰ÍŒŽ–MŒõ, ’|’†–Ÿ”ü, ŽO‘î^Ži, Š`ÀœA–M2 (1ŒÄ‹zŠíŠO, 2•a—•”): ‘æ58‰ñ“ú–{—Տ°×–EŠw‰ïHŠú‘å‰ï (2019/11/16-17), ‰ªŽR.

723347. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) [ŽÀ«ŽîᇖE‘ƒ“à‚ɐZ‚·‚éCD8—z«×–E‚̐”‚ƏpŒãÄ”­‚ÌŠÖ˜A«‚ÌŒŸ“¢. ‰–Œ©@˜a1, ˆêŒË¹–Ÿ2, “à“¡‰ëm1, ŽOŒE«Žj1, —с@ËŽq1, Œ“‡Œ\Œá1, ŠÛŽR—ˆ‹P1, ‹Êì@’B1, ŽOˆä@ˆ€1, Ó@¢ˆ®, ŒˆäŒ[•v1, ²“¡”Vr1 (1ŒÄ‹zŠíŠO, 2•a—): ‘æ36‰ñ“ú–{ŒÄ‹zŠíŠO‰ÈŠw‰ïŠwpW‰ï (2019/5/16), ‘åã.

723348. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) cŠuH“¹•a•Ï‚ɑ΂·‚鋹o‹ŸŽèp. _’J‹I‹P1,2, ¬‹Ë‰ë¢1, ‘O“c“úØŽq1, ‰J‹{—²‰î1, ”—@—T”V2, —Ž‡‘åŽ÷1, Îˆä—ǍK1,3, ‘åì¹‹`1, “n粏¹•F1 (1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2ŒÄ‹zŠíŠO, 3‰º•”Á‰»ŠÇŠO): ‘æ36‰ñ“ú–{ŒÄ‹zŠíŠO‰ÈŠw‰ïŠwpW‰ï (2019/5/16), ‘åã, “ú–{ŒÄ‹zŠíŠO‰ÈŠw‰ïŽGŽ 2019/5; 3 (3): P57-5.

723349. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆ««ƒŠƒ“ƒpŽî‚̏d•¡Šà‚Æ‚µ‚Ä‚ÌŒŽ”­«”xŠà‚ɑ΂µŠ®‘SØœ‚µ‚œ13—á‚ÌŒŸ“¢. Œ“‡Œ\Œá1, ŠÛŽR—ˆ‹P1, —с@ËŽq1, “à“¡‰ëm1, ŽOŒE«Žj1, ŒˆäŒ[•v1, ‰–Œ©@˜a1, ²“¡”Vr1 (1ŒÄ‹zŠíŠO): ‘æ36‰ñ“ú–{ŒÄ‹zŠíŠO‰ÈŠw‰ïŠwpW‰ï (2019/5/16-17), ‘åã.

723350. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) äX‘ŸEUS-FNA‚Å–¢•ª‰»Šà‚Æ‚ÌŠÓ•Ê‚ª¢“ï‚Å‚ ‚Á‚œ–¢•ª‰»‘å×–EŒ^ƒŠƒ“ƒpŽî‚Ì1Ç—á. ŠâŒO•¶, ’†ŽR•üH, ²“¡Œ›r, Œ—Yˆê‹M, ˆäoL–ç, ‰–àV@“N, Â–ö‘åŽ÷, Î‹TœAŽ÷, ›–ì—CK, ²“¡”Vr1 (1ŒÄ‹zŠíŠO): ‘æ60‰ñ“ú–{—Տ°×–EŠw‰ï‘‰ï (tŠú‘å‰ï) (2019/6/7-9), “Œ‹ž.

723351. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”xŠàp‘O‚É‚š‚¯‚镉‰×S“d}ŒŸž‚̈Ӌ`‚ÌŒŸ“¢. ‹Êì@’B1, ŽOˆä@ˆ€1, —с@ËŽq1, “à“¡‰ëm1, ŒˆäŒ[•v1, ‰–Œ©@˜a1, ²“¡”Vr1 (1ŒÄ‹zŠíŠO): ‘æ72‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ï’èŠúŠwpW‰ï (2019/10/31), ‹ž“s.

723352. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŒÄ‹zŠí×–EfÞ—¿‚É‚š‚¯‚éJSCC-JLCS•ñ—lŽ®‚ɂ‚¢‚Ä. ‹gàV–Ÿ•F, œA“‡Œ’ŽO, ²“¡”Vr1 (1ŒÄ‹zŠíŠO)‘æ58‰ñ“ú–{—Տ°×–EŠw‰ïHŠú‘å‰ï (2019/11/16-17), ‰ªŽR.

723353. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) V‚œ‚È”xŠà×–Ef”»’è‹æ•ª‚Ì’ñˆÄ. œA“‡Œ’ŽO, ²“¡”Vr1 (1ŒÄ‹zŠíŠO): ‘æ60‰ñ“ú–{”xŠàŠw‰ïŠwpW‰ï (2019/12/6-8), ‘åã.

733131. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‹¹–Œ”dŽí‚ð”F‚ß‚œ”x’èŒ^ƒJƒ‹ƒ`ƒmƒCƒh‚Ì1—á. ŽOˆä@ˆ€1, ‹Êì@’B1, —с@ËŽq1, “à“¡‰ëm1, ŒˆäŒ[•v1, ‰–Œ©@˜a1, ²“¡”Vr1, “È–{¹F2, ˆêŒË¹–Ÿ2 (1ŒÄ‹zŠíŠO, 2•a—): ‘æ185‰ñ“ú–{”xŠàŠw‰ïŠÖ“ŒŽx•”ŠwpW‰ï (2019/7/6), “Œ‹ž.

733132. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ŒÄ‹zŠí×–Ef‚É‚š‚¯‚é•ñ—lŽ®‚ɂ‚¢‚Ä: ‘ÛŠî€‚Ì’ñ¥. ²“¡”Vr (ŒÄ‹zŠíŠO): ‘æ33‰ñŠÖ“Œ—Տ°×–EŠw‰ïŠwpW‰ï/‘æ38‰ñ“Œ‹ž“s—Տ°×–EŠw‰ï‘‰ïEŠwpW‰ï (2019/9/28), “Œ‹ž.

733133. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‹¹•ÇüˆÛŽîÇ‚Ì1Øœ—á. —с@ËŽq1, ŽOˆä@ˆ€1, ‹Êì@’B1, “à“¡‰ëm1, ŒˆäŒ[•v1, ‰–Œ©@˜a1, ²“¡”Vr1 (1ŒÄ‹zŠíŠO): ‘æ181‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2019/11/9), “Œ‹ž.

733134. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‘O‹¹•ÇŠC–ȏ󃊃“ƒpŠÇŽî‚Ì1Øœ—á. –ö“c‘ñ˜Y, ŽOˆä@ˆ€1, ‹Êì@’B1, —с@ËŽq1, “à“¡‰ëm1, ŒˆäŒ[•v1, ‰–Œ©@˜a1, ²“¡”Vr1 (1ŒÄ‹zŠíŠO): ‘æ182‰ñ“ú–{‹¹•”ŠO‰ÈŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2020/3/7), “Œ‹ž.


”]_ŒoŠO‰ÈŠw

[Šwp˜_•¶]

110207. [ŒŽ’˜] Novel concept of the border niche: glioblastoma cells use oligodendrocytes progenitor cells (GAOs) and microglia to acquire stem cell-like features. Hide T1, Shibahara I1, Kumabe T1: Brain Tumor Pathol 2019/4; 36 (2): 63-73. (G‘ñˆê˜Y1, ŽÄŒŽˆê—z1, ŒG•”rG1: 1”]ŠO)

110208. [ŒŽ’˜] Clinically practical formula for preoperatively estimating the cutting rate of the spinal nerve root in a functional posterior rhizotomy. Morota N1: Childs Nerv Syst 2019/4; 35 (4): 665-72. (Žt“cMl1: 1”]ŠO)

110209. [ŒŽ’˜] Intraoperative neurophysiological monitoring of the bulbocavernosus reflex during surgery for conus spinal lipoma: what are the warning criteria? Morota N1: J Neurosurg Pediatr 2019/5; 23 (5): 369-47. (Žt“cMl1: 1”]ŠO)

110210. [ŒŽ’˜] Half-tied Stay Suture Technique for Cerebrovascular End-to-side Anastomosis: A Technique to Expand the View of the Hidden Ostium. Shimizu S1,2, Osawa S2, Kuroda H1,2, Koizumi H1, Mochizuki T2, KumabeT1: Neurol Med Chir (Tokyo) 2019/8; 59 (8): 326-29. (Ž…@ú1,2, ‘åàV¬”V2, •“c”Ž‹I1,2, ¬òŠ°”V1,3, –]ŒŽ’O2, ŒG•”rG1: 1”]ŠO, 2‰¡•lŽs—§”]‘²’†E_ŒoÒ’ŃZƒ“ƒ^[, 3‹~–œ)

110211. [ŒŽ’˜] Visual disorders caused by cranial arteriovenous fistula with venous drainage into the superior ophthalmic vein. Kondo R, Kumabe T1, Yamamoto D1, Koizumi H1,2, Kuroda H1, Miyasaka K1: Interv Neuroradiol 2019/8; 25 (4): 460-8. (ŒG•”rG1, ŽR–{‘å•ã1, ¬òŠ°”V1,2, •“c”Ž‹I1, ‹{â˜aO1: 1”]ŠO, 2‹~–œ)

110212. [ŒŽ’˜] Temporal Glioblastoma Mimicking Basal Ganglia Invasion: Distinguishing Removable and Unremovable Tumors. Shibahara I1, Hanihara M, Miyasaka K1, Sato S1, Hide T1, Kumabe T1: World Neurosurg 2019/10; 130: e213-21. (ŽÄŒŽˆê—z1, ûŒŽŒõl, ‹{â˜aO1, ²“¡Ÿl1, G‘ñˆê˜Y1, ŒG•”rG1: 1”]ŠO)

110213. [ŒŽ’˜] Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma. Suzuki H, Kumar SA, Shuai S, Diaz-Navarro A, Gutierrez-Fernandez A, De Antonellis P, Cavalli FMG, Juraschka K, Farooq H, Shibahara I1, Vladoiu MC, Zhang J, Abeysundara N, Przelicki D, Skowron P, Gauer N, Luu B, Daniels C, Wu X, Forget A, Momin A, Wang J, Dong W, Kim SK, Grajkowska WA, Jouvet A, F`evre-Montange M, Garr`e ML, Rao AAN, Giannini C, Kros JM, French PJ, Jabado N, Ng HK, Poon WS, Eberhart CG, Pollack IF, Olson JM, Weiss WA, Kumabe T1, L—pez-Aguilar E, Lach B, Massimino M, Van Meir EG, Rubin JB, Vibhakar R, Chambless LB, Kijima N, Klekner A, Bogn‡ L, Chan JA, Faria CC, Ragoussis J, Pfister SM, Goldenberg A, Wechsler-Reya RJ, Bailey SD, Garzia L, Morrissy AS, Marra MA, Huang X, Malkin D, Ayrault O, Ramaswamy V, Puente XS, Calarco JA, Stein L, Taylor MD: Nature 2019/10; 574 (7780): 707-11. (ŽÄŒŽˆê—z1, ŒG•”rG1: 1”]ŠO)

110214. [ŒŽ’˜] Angiographic Characterization of the External Carotid Artery: Special Attention to Variations in Branching Patterns. Yamamoto D1, Koizumi H1,2, Ishima D3, Kuroda H1, Shibahara I1, Niki J1, Miyasaka K1, Watanabe T, Kondo R, Kumabe T1: Tohoku J Exp Med 2019/11; 249 (3): 185-92. (ŽR–{‘å•ã1, ¬òŠ°”V1,2, ˆä“‡‘å•ã3, ŽÄŒŽˆê—z1, m–؁@~1, ‹{â˜aO1, ŒG•”rG1: 1”]ŠO, 2‹~–œ, 3”]_Œo“à)

110215. [ŒŽ’˜] Medulloblastoma has a global impact on health related quality of life: Findings from an international cohort. de Medeiros CB, Moxon-Emre I, Scantlebury N, Malkin D, Ramaswamy V, Decker A, Law N, Kumabe T1, Leonard J, Rubin J, Jung S, Kim SK, Gupta N, Weiss W, Faria CC, Vibhakar R, Lafay-Cousin L, Chan J, Kros JM, Janzen L, Taylor MD, Bouffet E, Mabbott DJ: Cancer Med 2020/1; 9 (2): 447-59. (ŒG•”rG1: 1”]ŠO)

110216. [ŒŽ’˜] Intratumoural immune cell landscape in germinoma reveals multipotent lineages and exhibits prognostic significance. Takami H1, Fukushima S1, Aoki K1, Satomi K1, Narumi K1, Hama N1, Matsushita Y1, Fukuoka K1, Yamasaki K1, Nakamura T1, Mukasa A1, Saito N1, Suzuki T1, Yanagisawa T1, Nakamura H1, Sugiyama K1, Tamura K1, Maehara T1, Nakada M1, Nonaka M1, Asai A1, Yokogami K1, Takeshima H1, Iuchi T1, Kanemura Y1, Kobayashi K1, Nagane M1, Kurozumi K1, Yoshimoto K1, Matsuda M1, Matsumura A1, Hirose Y1, Tokuyama T1, Kumabe T1,2, Ueki K1, Narita Y1, Shibui S1, Totoki Y, Shibata T, Nakazato Y, Nishikawa R1, Matsutani M1, Ichimura K1 (1Intracranial Germ Cell Tumor Genome Analysis Consortium (the iGCT Consortium)): Neuropathol Appl Neurobiol 2020/2; 46 (2): 111-24. (ŒG•”rG1,2: 2”]ŠO)

110217. [ŒŽ’˜] Phase I trial of convection-enhanced delivery of nimustine hydrochloride (ACNU) for brainstem recurrent glioma. Saito R, Kanamori M, Sonoda Y, Yamashita Y, Nagamatsu K, Murata T, Mugikura S, Kumabe T, Wembacher-Schršder E, Thomson R, Tominaga T: Neurooncol Adv 2020 /3; 2 (1): vdaa033. (ŒG•”rG1: 1”]ŠO)

120006. [ŒŽ’˜] “‡•ÙŠO•”_ŒoäPŽî“Eo‚É‚š‚¯‚ép’†‘¢‰eCT‚ð—p‚¢‚œú’ÊŽ}•`ŽÊ‚Ì—L—p«. ’h@@[, ŽÄŒŽˆê—z1, ûŒŽŒõl, ‹{â˜aO1, •“c”Ž‹I1, ²“¡Ÿl1, ŒG•”rG1 (1”]ŠO): CIŒ€‹† 2019/6; 41 (1): 7-15.

120007. [ŒŽ’˜] ŠO‘€Œã“ªŠWâ|ƒAƒvƒ[ƒ`‚É‚š‚¯‚ép‘O“àŒzÃ–¬‚Æ‘€•›ŒŒs˜H•]‰¿‚̏d—v«. ‹v{”ü^—1,2, ‰ª@GG1,2, ²“¡Ÿl2, ‹ß“¡GŽ¡1,2, ŒG•”rG2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2”]ŠO): ”]_ŒoŠO‰È‘¬ 2019/11; 29 (11): 1190-6.

310031. [Ç—á•ñ] Characteristics of Recurrent Congenital Sinus Pericranii: Case Report and Review of the Literature. Tamura G, Ogiwara H, Morota N1: Pediatr Neurosurg 2019/8; 54 (4): 265-9. (Žt“cMl1: 1”]ŠO)

320019. [Ç—á•ñ] ”j—ô“®–¬áŽ‚ɑ΂·‚錌ŠÇ“àŽ¡—ÃŒã‚É”ñ•ÂÇ«’°ŠÇ‹•ŒŒ‚𔭏ǂµ‚œ1—á. ¬òŠ°”V1,2, ŽR–{‘å•ã2, ‰Ô“‡@Ž‘1, ŠÛ‹ŽFº1, •Ð‰ª—Sˆê1, ó—˜@–õ1, ŒG•”rG2 (1‹~–œ, 2”]ŠO): ”]_ŒoŠO‰È‘¬•ñ 2019/10; 29 (10): 1110-5.

320020. [Ç—á•ñ] “Ý“I“ª•”ŠO‚É‚æ‚è’†‘å”]“®–¬M2‹NŽn•”‚ɉŒ«“®–¬áŽ‚𐶂¶‚œ1—á. Ž…@ú1,2, –]ŒŽ’O2, •“c”Ž‹I1,2, ‰ª@GG1,3, ŒG•”rG1 (1”]ŠO, 2‰¡•lŽs—§”]‘²’†E_ŒoÒ’ŃZƒ“ƒ^[, 3–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ”]_ŒoŠO‰È 2019/11; 47 (11): 1185-91.

320021. [Ç—á•ñ] Šáâ|“à_ŒoâŽî‚ɂĐf’f‚³‚ê‚œ‰Æ‘°«schwannomatosis‚Ì1—á. ‹{â˜aO1, ŽÄŒŽˆê—z1, G‘ñˆê˜Y1, Œ¢Ž”@‰~2, ŽOŽ}@M2, ’†–ì‰ÃŽq, Žs‘ºKˆê, ‚‘Š»Žm3, ŒG•”rG1: (1”]ŠO, 2•a—, 3®ŠO): ”]_ŒoŠO‰È 2020/1; 48 (1): 71-7.

510007. [‘à] Oligodendrocyte Progenitor Cells in the Tumor Microenvironment. Hide T1, Komohara Y: Adv Exp Med Biol 202/1; 1234: 107-22. (G‘ñˆê˜Y1: 1”]ŠO)

522052. [uÀ]yCurrent Knowledge: ”]ŠO‰È“úíf—à Ž„‚̍H•vzŠJ“ªƒhƒŒ[ƒv‚Ì— ‘€‚ɘR‚ê‚œ‰t‘Ì‚ð‰ñŽû‚µ°‰˜õ‚ð–hŽ~‚·‚éH•v. Ž…@ú1,2, –]ŒŽ’O2, •“c”Ž‹I1,2, ‘åàV¬”V2, ¬òŠ°”V1,3, ŠÖŒû•üŽq1, ŒG•”rG1 (1”]ŠO, 2‰¡•lŽs—§”]‘²’†E_ŒoÒ’ŃZƒ“ƒ^[, 3‹~–œ): ”]_ŒoŠO‰È‘¬•ñ 2019/10; 29 (10): 1104-6.

522053. [uÀ]y”]ŠO‰È“úíf—Ã: Ž„‚̍H•vzŠJ“ªƒhƒŒ[ƒv‚Ì— ‘€‚ɘR‚ê‚œ‰t‘Ì‚ð‰ñŽû‚µ°‰˜õ‚ð–hŽ~‚·‚éH•v. Ž…@ú1, –]ŒŽ’O, •“c”Ž‹I1, ‘åàV¬”V, ¬òŠ°”V1,2, ŠÖŒû•üŽq1, ŒG•”rG1 (1”]ŠO, 2‹~–œ): ”]_ŒoŠO‰È‘¬•ñ 2019/10; 29 (10): 1104-6.

522054. [uÀ]y˜AÚ: ŽãƒtƒH[ƒ‰ƒ€z¬Ž™Ò’ÅŽŸŠ³. š œA—_¢, â–{”Žº, ’JŒû ^, ‰¬ŒŽ‰pŽ÷, ‹v•Û“cŠî•v, ’|—ÑŒ€l, Žt“cMl1 (1”]ŠO): Ò‘ŠO‰È 2019/12; 33 (3): 258-266.

[’˜@‘]

610006. [Šwp‘ (•ª’SŽ·•M)]yPediatric HydrocephaluszPrenatal Hydrocephalus, p.1-19. Morota N, Editors: Cinalli Giuseppe, …zek MM, Sainte-Rose C, Springer, Switzerland AG, Published: 2019. (Žt“cMl1: 1”]ŠO)

620045. [Šwp‘ (•ª’SŽ·•M)]y”]ŽîᇊO‰È ŒoŒ±‚µ‚œ‚¢Žèp16 ƒXƒ^ƒ“ƒ_[ƒh‚©‚çƒAƒhƒoƒ“ƒXzIII Žèp‚ÌŽÀÛ@[ƒeƒ“ƒgã[•”Žîá‡] ‘€”]ŽºŽîá‡: ŠJ“ªŽèp, p.146-60. ‹v{”ü^—1,2, ‰ª@GG1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2”]ŠO), •Ò: ’†”ö’Œ”V, ˆäì–[•v, ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2019/4”­s.

620046. [Šwp‘ (•ª’SŽ·•M)]y”]ŽîᇊO‰È ŒoŒ±‚µ‚œ‚¢Žèp16 ƒXƒ^ƒ“ƒ_[ƒh‚©‚çƒAƒhƒoƒ“ƒXzIII Žèp‚ÌŽÀÛ@[ƒOƒŠƒI[ƒ}] Low grade glioma, p.314-29. ŒG•”rG (”]ŠO), •Ò: ’†”ö’Œ”V, ˆäì–[•v, ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2019/4”­s.

620047. [Šwp‘ (•ª’SŽ·•M)]y”]_ŒoŠO‰È ŽüpŠúŠÇ—‚Ì‚·‚ׂā@‘æ5”ŁzIII ”]Žîᇁ@ŠoÁ‰ºŽèp, p.301-14. ŒG•”rG (”]ŠO), •Ò: Œ’J‰ë¶, “c‘º@W, “¡Šª‚Œõ, X“c–Ÿ•v, ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2019/5”­s.

620048. [Šwp‘ (•ª’SŽ·•M)]y”]Žîᇐf—ÃKƒCƒhƒ‰ƒCƒ“ 2019”N”Å 2019”N”Ł@1 ¬l”]ŽîᇕҁE2 ¬Ž™”]Žîᇕҁz2 ¬Ž™”]Žîᇕҁ@1. ‰æ‘œf’f, p.175-80. Žt“cMl1, ˆäŒŽ@“N (1”]ŠO), ŠÄC: “ú–{”]_ŒoŠO‰ÈŠw‰ï, •Ò: “ú–{”]Žîᇊw‰ï, ‹àŒŽo”Å, “Œ‹ž, 2019/5”­s.

[Šw‰ïEŒ€‹†‰ï“™]

711001. [Šw‰ï (‘Û)] (“Á•Êu‰‰) The Chiari malformation. Morota N1: AASPN2019 - 3rd Congress of Asian-Australasian Society for Pediatric Neurosurgery (2019/5/11), Incheon, Korea. (Žt“cMl1: 1”]ŠO)

711002. [Šw‰ï (‘Û)] (“Á•Êu‰‰) Epidemiology of cervical spine traumatic lesions in children. Morota N1: The 3rd European Society for Pediatric Neurosurgery Hands-on workshop on craniovertebral junction surgery (2019/6/30), Lyon, France. (Žt“cMl1: 1”]ŠO)

711003. [Šw‰ï (‘Û)] (“Á•Êu‰‰) Posterior fossa decompression, when, why and how I perform a duraplasty. Morota N1: The 3rd European Society for Pediatric Neurosurgery Hands-on workshop on craniovertebral junction surgery (2019/7/2), Lyon, France. (Žt“cMl1: 1”]ŠO)

711004. [Šw‰ï (‘Û)] (“Á•Êu‰‰) Spinal lipoma and tethered cord - when and what to intervene. Morota N1: Neurosurgeons Association of Sri Lanka Annual Academic Sessions - 2019 (2019/9/29), Colombo, Sri Lanka. (Žt“cMl1: 1”]ŠO)

711005. [Šw‰ï (‘Û)] (“Á•Êu‰‰) Complex hydrocephalus and management of shunt complications. Morota N1: Neurosurgeons Association of Sri Lanka Annual Academic Sessions - 2019 (2019/9/29), Colombo, Sri Lanka. (Žt“cMl1: 1”]ŠO)

711006. [Šw‰ï (‘Û)] (“Á•Êu‰‰) Neurosurgical management of midline and posterior fossa cyst. Morota N1: Neurosurgeons Association of Sri Lanka Annual Academic Sessions - 2019 (2019/9/29), Colombo, Sri Lanka. (Žt“cMl1: 1”]ŠO)

712008. [Šw‰ï (‘Û)] (µ‘ҍu‰‰“™) Surgery for spinal lipoma: New classification and the use of intraoperative neurophysiology. Morota N1: The 6th Listserv Webinar (The International Pediatric Neurosurgery Series) (2019/9/1), Webinar. (Žt“cMl1: 1”]ŠO)

713072. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Craniovertebral junction surgery associated with craniosynostosis. Morota N1: 47th Annual Meeting of the International Society for Pediatric Neurosurgery (2019/10/21), Birmingham, UK. (Žt“cMl1: 1”]ŠO)

713073. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) How to treat the incidental thalamic presumed low-grade gliomas. Kumabe T1, Shibahara I1, Kanamori M, Saito R, Hide T1, Sonoda Y, Tominaga T: The 24th Annual Meeting of the Society for Neuro-Oncology (2019/11/23), Phoenix, USA. (ŒG•”rG1, ŽÄŒŽˆê—z1, G‘ñˆê˜Y1: 1”]ŠO)

713074. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Immunohistochemical analysis of tumor associated macrophage induced after carmustine wafer implantation in human glioblastoma. Shibahara I1, Miyasaka K1, Sato S1, Inukai M2, Hide T1, Kumabe T1: The 24th Annual Meeting of the Society for Neuro-Oncology (2019/11/24), Phoenix, USA. (ŽÄŒŽˆê—z1, ‹{â˜aO1, ²“¡Ÿl1, Œ¢Ž”@‰~2, G‘ñˆê˜Y1, ŒG•”rG1: 1”]ŠO, 2•a—)

722076. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) –{–M‰‚ÌKeyholeE‹Ù‹}ŽèpŽg—p‰Â”\‚ȐV¬Œ^FIAGONƒiƒrƒQ[ƒVƒ‡ƒ“ƒVƒXƒeƒ€. ‰ª@GG1,2, ‹v{”ü^—1,2, ‹ß“¡GŽ¡1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2”]ŠO): ‘æ28‰ñ”]_ŒoŠO‰ÈŽèp‚Æ‹@ŠíŠw‰ï (CNTT) (2019/4/13), ‰ªŽR.

722077. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) DORO JƒA[ƒ€ƒŒƒgƒ‰ƒNƒ^[ƒVƒXƒeƒ€‚Ì‚¢‚ë‚¢‚ë‚ȃAƒvƒ[ƒ`‚Ö‚ÌŽg—p–@. ‹v{”ü^—1,2, ‰ª@GG1,2, ‹ß“¡GŽ¡1,2, ŒG•”rG2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2”]ŠO): ‘æ28‰ñ”]_ŒoŠO‰ÈŽèp‚Æ‹@ŠíŠw‰ï (CNTT) (2019/4/13), ‰ªŽR.

722078. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ”]Š²•”Žîᇂ̐f’fEŽ¡—ÂÌparadigm shift‚ƍ¡Œã‚Ì“W–]. Žt“cMl (”]ŠO): ‘æ47‰ñ“ú–{¬Ž™_ŒoŠO‰ÈŠw‰ïŠwpW‰ï (2019/6/14), VŠƒ.

722079. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ¬Ž™“ªŠWèò’ňڍs•”ŒÅ’èp: Œ»ó‚Ɖۑè. Žt“cMl (”]ŠO): ‘æ34‰ñ“ú–{Ò‘ŠO‰ÈŠw‰ï (2019/6/20), ŽD–y.

722080. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ‘O“ª|“ª’ž•ÙŠW•”_ŒoäPŽî“EoŽž‚Ì‹•ŒŒ‡•¹Ç. ŒG•”rG1, ŽÄŒŽˆê—z1, âV“¡—³‘Ÿ, ‹àX­”V, ²“¡Ÿl1, G‘ñˆê˜Y1, ‰€“c‡•F, •y‰i’î“ñ (1”]ŠO): ‘æ24‰ñ“ú–{”]Žîᇂ̊O‰ÈŠw‰ï (2019/9/13), •lŒ.

722081. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) 2010-2017”N‚ÉŒö•\‚³‚ê‚œ˜_•¶‚©‚çŠm”F‚³‚ê‚éŠoÁ‰ºŽèp‚ÌŽž‘ã•Ï‘J. ŒG•”rG (”]ŠO): ‘æ17‰ñ“ú–{Awake SurgeryŠw‰ï (2019/10/12), ‘åã.

722082. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) “ªŠW’êŽèp‚É‚š‚¯‚é’ŒŒa4 mm ICG“àŽ‹‹Ÿ‚Ì—L—p«. G‘ñˆê˜Y1, ”Œ“c@”£1, ‹{â˜aO1, ŽÄŒŽˆê—z1, ¬òŠ°”V1, ŒG•”rG1 (1”]ŠO): ‘æ26‰ñˆê”ÊŽÐ’c–@l“ú–{_Œo“àŽ‹‹ŸŠw‰ï (2019/11/8), ‰¡•l.

723354. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Cyanoacrylate Skin Sealant‚ð—p‚¢‚œÄŠJ“ªp‚̃hƒŒ[ƒsƒ“ƒO: Šù‘¶‚̔畆ØŠJü‚ÌŽ‹”F«‚ð‚‚ß‚éH•v. Ž…@‹Å1, –]ŒŽ’O, •“c”Ž‹I1, ŒG•”rG1 (1”]ŠO): ‘æ12‰ñ“ú–{®—e”]_ŒoŠO‰ÈŠw‰ï (2019/4/13), ‰ªŽR.

723355. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’®_ŒoŽîᇂ́gsubperineuriumhdissection‚É‚š‚¯‚éãŽRŽ®”—£ƒxƒ‰‚Ì—L—p«. ‹v{”ü^—1,2, ‰ª@GG1,2, ‹ß“¡GŽ¡1,2, ŒG•”rG2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2”]ŠO): ‘æ28‰ñ”]_ŒoŠO‰ÈŽèp‚Æ‹@ŠíŠw‰ï (CNTT) (2019/4/13), ‰ªŽR.

723356. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒJƒ‹ƒ€ƒXƒ`ƒ“”]“à—¯’u—pÜ—¯’uŒã”]‘gDZƒ}ƒNƒƒtƒ@[ƒW‚Ì•a—Šw“IŒŸ“¢. ŽÄŒŽˆê—z1, ‹{â˜aO1, ²“¡Ÿl1, Œ¢Ž”@‰~2, ˆÀˆä”ü]3, G‘ñˆê˜Y1, ŒG•”rG1 (1”]ŠO, 2•a—, 3Œ`‘ÔŒn): ‘æ37‰ñ“ú–{”]Žîᇕa—Šw‰ï (2019/6/1), –ŒŒÃ‰®.

723063. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ”]—ÀŒ`¬•s‘SEŽ‰–bŽî‚ÉCalcifying pseudoneoplasms of the neuroaxis (CAPNON) ‚ð‡•¹‚µ‚œˆê—á. Œ¢Ž”@‰~1, ‹{â˜aO2, ŽÄŒŽˆê—z2, ²“¡Ÿl2, G‘ñˆê˜Y2, ŽOŽ}@M1, ŒG•”rG2 (1•a—, 2”]ŠO): ‘æ37‰ñ“ú–{”]Žîᇕa—Šw‰ï (2019/6/1), –ŒŒÃ‰®.

723357. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) IDHˆâ“`Žq•ÏˆÙŒ^¯×–EŽî‚Ì—\ŒãˆöŽq. ‹àX­”V, “n•Ó‚Ý‚©, âV“¡—³‘Ÿ, ’·“c‰À®, ŽÄŒŽˆê—z1, ‰€“c‡•F, ŒG•”rG1, •y‰i’î“ñ (1”]ŠO): ‘æ37‰ñ“ú–{”]Žîᇕa—Šw‰ï (2019/6/1), –ŒŒÃ‰®.

723358. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Šáâ|“àŽîᇂɑ΂·‚é“Eop: ˜A‘±10—á‚ÌŒoŒ±‚©‚ç. ŽÄŒŽˆê—z1, G‘ñˆê˜Y1, ‹{â˜aO1, ”Œ“c@”£1, ²“¡Ÿl1, ŒG•”rG1 (1”]ŠO): ‘æ24‰ñ“ú–{”]Žîᇂ̊O‰ÈŠw‰ï (2019/9/13), •lŒ.

723359. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ‹}«Šú”][Ç‚ւ̍ĊJ’ʗÖ@Œã‰ßŸó—¬‚É”º‚€cortical neural loss Iomazenil SPECT‚É‚æ‚錟“¢. •“c”Ž‹I1, ŽR–{‘å•ã1, ¬òŠ°”V1,2, Ž…@ú1, ŒG•”rG1 (1”]ŠO, 2‹~–œ): “ú–{”]_ŒoŠO‰ÈŠw‰ï‘æ78‰ñŠwp‘‰ï (2019/10/9), ‘åã.

723360. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŽåŠ²“®–¬‚ªŠÖ—^‚µ‚œäP‰èŽî‚ÌŽ¡—ЬÑ. ‰€“c‡•F, Œ“cŒ›ˆê˜N, âV“¡—³‘Ÿ, ‹àX­”V, ŒG•”rG1, •y‰i’î“ñ (1”]ŠO): ˆê”ÊŽÐ’c–@l“ú–{”]_ŒoŠO‰ÈŠw‰ï‘æ78‰ñŠwp‘‰ï (2019/10/9), ‘åã.

723361. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “ªŠWˆô“ªŽî‚ɑ΂·‚éŽèp•ûj‚Ì•Ï—e. ‹v{”ü^—1,2, ‰ª@GG1,2, ‹ß“¡GŽ¡1,2, ŒG•”rG2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2”]ŠO): “ú–{”]_ŒoŠO‰ÈŠw‰ï‘æ78‰ñŠwp‘‰ï (2019/10/10), ‘åã.

723362. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ‰”­äP‰èŽî‚ɑ΂·‚é“EopEƒMƒŠƒAƒfƒ‹—¯’uŒã•úŽËüEƒeƒ‚ƒ]ƒƒ~ƒh•¹—p—Ö@Œã‚ÌŽîᇐi“WŒ`Ž®‚ÌŒŸ“¢. ŽÄŒŽˆê—z1, ‹{â˜aO1, ŠÖŒûˆ©ˆß2, ÎŽR”ŽžŠ2, ²“¡Ÿl1, G‘ñˆê˜Y1, ŒG•”rG1 (1”]ŠO, 2•úŽËü (Žîá‡)): “ú–{”]_ŒoŠO‰ÈŠw‰ï‘æ78‰ñŠwp‘‰ï (2019/10/10), ‘åã.

723363. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “ªŠW“àãóŽîŽ¡—ÃŒã‚Ì“à•ª”åáŠQE“ñŽŸ«ŽîᇁE”]‘²’†. ‹àX­”V, âV“¡—³‘Ÿ, ‰€“c‡•F, ŒG•”rG1, •y‰i’î“ñ (1”]ŠO): ˆê”ÊŽÐ’c–@l“ú–{”]_ŒoŠO‰ÈŠw‰ï‘æ78‰ñŠwp‘‰ï (2019/10/10), ‘åã.

723364. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –k—¢‘åŠw•a‰@‚ÌŒŒð‰ñŽû—Ö@‚É‚š‚¯‚é”]ŒŒŠÇ“àŽ¡—Èã‚̊‹«‚ÆŽ¡—ЬÑ. ŽR–{‘å•ã1, ˆä“‡‘å•ã2, ‰Oˆä@—É2, ”Œ“c@”£1, ‹{â˜aO1, ŽÄŒŽˆê—z1, m–؁@~1, ‰Ž“c˜a‹MŽq1, ¬òŠ°”V1,3, ó—˜@–õ3, ŒŽR˜a—˜2, ŒG•”rG1 (1”]ŠO, 2”]_Œo“à, 3‹~–œ): “ú–{”]_ŒoŠO‰ÈŠw‰ï‘æ78‰ñŠwp‘‰ï (2019/10/11), ‘åã.

723365. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) “ªŠW’êŽîᇂɑ΂·‚é‘Œ‰È‡“¯Žèp‚̈Ӌ`‚Æ—L—p«. G‘ñˆê˜Y1, ‹{â˜aO1, ‰Ž“c˜a‹MŽq1, ”Œ“c@”£1, ŽÄŒŽˆê—z1, ²“¡Ÿl1, ŽR‰º@‘ñ2, ŒG•”rG1 (1”]ŠO, 2Žš•@ˆôAE“ªèòŠO): “ú–{”]_ŒoŠO‰ÈŠw‰ï‘æ78‰ñŠwp‘‰ï (2019/10/11), ‘åã.

723366. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ƒ`ƒ^ƒ“ƒvƒŒ[ƒg‚ðŽg—p‚µ‚È‚¢‚œ‚ß‚ÌŠJ“ª‚̍H•v: “Á‚É–¢”j—ô”]“®–¬áŽƒNƒŠƒbƒsƒ“ƒOp‚É‚š‚¢‚Ä. ¬òŠ°”V1, ŽR–{‘å•ã1, ‰Ž“c˜a‹MŽq1, ”Œ“c@”£1, ‹{â˜aO1, Ž…@ú1, ²“¡Ÿl1, G‘ñˆê˜Y1, ŒG•”rG1 (1”]ŠO): “ú–{”]_ŒoŠO‰ÈŠw‰ï‘æ78‰ñŠwp‘‰ï (2019/10/11), ‘åã.

723367. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ŠJ“ªŽîᇓEop‚É‚š‚¯‚鉺ŽˆMEP‚Ì—L—p«. ²“¡Ÿl1, ŽÄŒŽˆê—z1, ‹{â˜aO1, G‘ñˆê˜Y1, ¬–ìàV—T–ç2, ŒG•”rG1 (1”]ŠO, 2—ÕŒŸ•”): “ú–{”]_ŒoŠO‰ÈŠw‰ï‘æ78‰ñŠwp‘‰ï (2019/10/11), ‘åã.

723368. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ‹ô‘R”­Œ©‚³‚ê‚œ’ራ«“x_ŒoäPŽî‚ªŽŠŽ‚³‚ê‚鎋°•a•Ï‚ɑ΂µ‚Ä‚¢‚©‚ÉŽ¡—Éî“ü‚·‚é‚©? ŒG•”rG1, ŽÄŒŽˆê—z1, ‹àX­”V, âV“¡—³‘Ÿ, G‘ñˆê˜Y1, ²“¡Ÿl1, ‰€“c‡•F, •y‰i’î“ñ (1”]ŠO): “ú–{”]_ŒoŠO‰ÈŠw‰ï‘æ78‰ñŠwp‘‰ï (2019/10/11), ‘åã.

723369. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰”­Grade 2/3 _ŒoäPŽî—á‚É‚š‚¯‚éIDH•ÏˆÙ‚ÆŽîᇊ֘A‚Ä‚ñ‚©‚ñ‚š‚æ‚ѐ[•”Ã–¬ŒŒðÇ‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ’·“cŒj®, âV“¡—³‘Ÿ, ¯Ži‘ñ‘å, ’·“ì‰ëŽu, ŽÄŒŽˆê—z1, ‹àX­”V, ‰€“c‡•F, ŒG•”rG1, “n糂݂©, •y‰i’î“ñ (1”]ŠO): ˆê”ÊŽÐ’c–@l“ú–{”]_ŒoŠO‰ÈŠw‰ï‘æ78‰ñŠwp‘‰ï (2019/10/11), ‘åã.

723370. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •sK‚È“]‹A‚ð‚Æ‚Á‚œ’†•_ŒoƒAƒXƒyƒ‹ƒMƒ‹ƒXÇ‚Ì1—á. ”Œ“c@”£1, G‘ñˆê˜Y1, ‹{â˜aO1, ‰Ž“c˜a‹MŽq1, Œ¢Ž”@‰~2, ŒG•”rG1 (1”]ŠO, 2•a—): ‘æ26‰ñˆê”ÊŽÐ’c–@l“ú–{_Œo“àŽ‹‹ŸŠw‰ï (2019/11/7), ‰¡•l.

723371. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “ªŠWˆô“ªŽî‚ɑ΂·‚éŽèp•ûj‚Ì•Ï—e. ‹v{”ü^—1,2, ‰ª@GG1,2, ‹ß“¡GŽ¡1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2”]ŠO): ‘æ26‰ñˆê”ÊŽÐ’c–@l“ú–{_Œo“àŽ‹‹ŸŠw‰ï (2019/11/8), ‰¡•l.

723372. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ”]ŒŒŠÇŽB‰e‚É‚æ‚éŒo‰ßŠÏŽ@’†‚ÉŽ©‘RÁŽž‚µ‚œd–Œ“®Ã–¬á‘3—á‚ÌŒŸ“¢. m–؁@~ (”]ŠO): ‘æ35‰ñNPO–@l“ú–{”]_ŒoŒŒŠÇ“àŽ¡—Êw‰ïŠwp‘‰ï (2019/11/22), •Ÿ‰ª.

723373. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –k—¢‘åŠw•a‰@‚ÌŒŒð‰ñŽû—Ö@‚É‚š‚¯‚é”]ŒŒŠÇ“àŽ¡—Èã‚̊‹«‚ÆŽ¡—ЬÑ. ŽR–{‘å•ã (”]ŠO): ‘æ35‰ñNPO–@l“ú–{”]_ŒoŒŒŠÇ“àŽ¡—Êw‰ïŠwp‘‰ï (2019/11/23), •Ÿ‰ª.

723374. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹}«Šú”][Ç‚ւ̍ĊJ’ʗÖ@Œã‰ßŸó—¬‚É”º‚€_Œo×–E’E—Ž. •“c”Ž‹I1, ŽR–{‘å•ã1, ¬òŠ°”V1,2, Ž…@ú1, ŒG•”rG1 (1”]ŠO, 2‹~–œ): ‘æ62‰ñ“ú–{”]zŠÂ‘ãŽÓŠw‰ïŠwpW‰ï (2019/11/30), å‘ä.

731027. [Šw‰ï (Œ€‹†‰ïE’n•û‰ï)] (“Á•Êu‰‰) NTRK—Z‡ˆâ“`Žq—z«ŒÅŒ`Šà‚ɑ΂·‚éƒGƒkƒgƒŒƒNƒ`ƒjƒu: ”]Žîᇎ¡—Âւ̊ú‘Ò. ŒG•”rG (”]ŠO): ’·è”]Žîᇎ¡—ÃJƒ“ƒtƒ@ƒ‰ƒ“ƒX (2019/9/19), ’·è.

731028. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) NTRK—Z‡ˆâ“`Žq—z«ŒÅŒ`Šà‚ɑ΂·‚éƒGƒkƒgƒŒƒNƒ`ƒjƒu: ”]Žîᇎ¡—Âւ̊ú‘Ò. ŒG•”rG (”]ŠO): ’·è”]Žîᇎ¡—ÃJƒ“ƒtƒ@ƒ‰ƒ“ƒX (2019/9/19), ’·è.

731029. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ”œ•œŽèp‚É‚æ‚鏬Ž™”]ŽîᇋǏŠƒRƒ“ƒgƒ[ƒ‹. ŒG•”rG (”]ŠO): ‚Ý‚ñ‚È‚ÅŠw‚Ú‚€ˆ««”]Žîᇠ(2020/1/10), ‹ž“s.

733135. [Šw‰ï (Œ€‹†‰ïE’n•û‰ï)] (ˆê”ʍu‰‰) ’®_ŒoŽîᇎèp‚É‚š‚¢‚ĐÖ¬“Ž‘¹‚ÆŠç–ʐ_Œo–ƒáƒ‚ð”ð‚¯‚é‚œ‚ß‚É. ‹v{”ü^—1,2, ‰ª@GG1,2, ‹ß“¡GŽ¡1,2, ŒG•”rG2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2”]ŠO): ‘æ28‰ñ“ú–{’®_ŒoŽîᇌ€‹†‰ï (2019/6/8), “Œ‹ž.

733136. [Šw‰ï (Œ€‹†‰ïE’n•û‰ï)] (ˆê”ʍu‰‰) •sK‚È“]‹A‚ð‚Æ‚Á‚œ’†•_ŒoƒAƒXƒyƒ‹ƒMƒ‹ƒXÇ‚Ì1—á. ”Œ“c@”£1, G‘ñˆê˜Y1, ‹{â˜aO1, ‰Ž“c˜a‹MŽq1, Œ¢Ž”@‰~2, ŒG•”rG1 (1”]ŠO, 2•a—): ‘æ139‰ñ“ú–{”]_ŒoŠO‰ÈŠw‰ïŠÖ“ŒŽx•”‰ï (2019/9/21), “Œ‹ž.

733137. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) f’f‚É‹ê—¶‚µ•sK‚È“]‹A‚ð‚Æ‚Á‚œ’†•_ŒoƒAƒXƒyƒ‹ƒMƒ‹ƒXÇ‚Ì1—á. ”Œ“c@”£1, G‘ñˆê˜Y1, ‹{â˜aO1, ‰Ž“c˜a‹MŽq1, Œ¢Ž”@‰~2, ŒG•”rG1 (1”]ŠO, 2•a—): ‘æ139‰ñ“ú–{”]_ŒoŠO‰ÈŠw‰ïŠÖ“ŒŽx•”‰ï (2019/9/21), “Œ‹ž.

733138. [Šw‰ï (Œ€‹†‰ïE’n•û‰ï)] (ˆê”ʍu‰‰) ”]“®Ã–¬ŠïŒ`”j—ô‚É‚æ‚é”]“àoŒŒ‚ɑ΂·‚é‹}«Šú_Œo“àŽ‹‹Ÿ‰ºŒŒŽîœ‹ŽpŒã, ŒŒŠÇ“àŽ¡—š‚æ‚Ñ’Œ’Bp‚ðs‚Á‚œ2Ç—á. ¬òŠ°”V1,2, ŽR–{‘å•ã2, G‘ñˆê˜Y2, ŒG•”rG2 (1‹~–œ, 2”]ŠO): ‘æ32‰ñ_“ސì”]_ŒoŠO‰ÈŽèpŽè‹ZŒ€‹†‰ï (2020/1/18), ‰¡•l.

'18”N“xˆÈ‘O•ª

[Šw‰ïEŒ€‹†‰ï“™]

'18-711001. [Šw‰ï (‘Û)] (“Á•Êu‰‰) Septostomy: Anatomy and indications. Morota N1: IFNE-JSNE-GLEN-ISNE Hands-on workshop on cerebral and ventricular neuroendoscopy (2019/1/21), Naples, Italy. (Žt“cMl1: 1”]ŠO)

'18-711002. [Šw‰ï (‘Û)] (“Á•Êu‰‰) Intravetrivular, quadrigeminal and posterior fossa cysts: endoscopic surgical technique. Morota N1: IFNE-JSNE-GLEN-ISNE Hands-on workshop on cerebral and ventricular neuroendoscopy (2019/1/22), Naples, Italy. (Žt“cMl1: 1”]ŠO)

'18-731001. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ¬Ž™“ªŠWèò’ňڍs•”•a•Ï‚ÌŠO‰ÈŽ¡—Ã. Žt“cMl (”]ŠO): ‘æ26‰ñˆ€’mÒ’ŐҐ‘ŽŸŠ³Œ€‹†‰ïŠwpu‰‰‰ï (2019/2/21), –ŒŒÃ‰®.


¬Ž™‰ÈŠw

[Šwp˜_•¶]

110218. [ŒŽ’˜] Toll-Like Receptor 9 Plays a Pivotal Role in Angiotensin II-Induced Atherosclerosis. Fukuda D, Nishimoto S, Aini K, Tanaka A, Nishiguchi T, Kim-Kaneyama JR, Lei XF, Masuda K, Naruto T, Tanaka K, Higashikuni Y, Hirata Y1, Yagi S, Kusunose K, Yamada H, Soeki T, Imoto I, Akasaka T, Shimabukuro M, Sata M: J Am Heart Assoc 2019/4; 8 (7): e010860. (•œ“c—zˆê˜Y1: 1¬Ž™)

110219. [ŒŽ’˜] Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study). Shima Y1, Nakanishi K1, Sako M1, Saito-Oba M1, Hamasaki Y1, Hataya H1, Honda M1, Kamei K1, Ishikura K1,2, Ito S1, Kaito H1, Tanaka R1, Nozu K1, Nakamura H1, Ohashi Y1, Iijima K1, Yoshikawa N1 (1Japanese Study Group of Kidney Disease in Children (JSKDC)): Pediatr Nephrol 2019/5; 34 (5): 837-46. (Î‘qŒ’Ži1,2: 2¬Ž™)

110220. [ŒŽ’˜] Clinicopathological features of TAFRO syndrome complicated by acquired hemophilia A and development of cardiopulmonary arrest that were successfully treated with VA-ECMO and tocilizumab. Suzuki K, Matsumoto T, Iwashita Y, Ishikura K1, Fujioka M, Wada H, Katayama N, Imai H: Int J Hematol 2019/6; 109 (6): 737-43. (Î‘qŒ’Ži1: 1¬Ž™)

110221. [ŒŽ’˜] Evaluation of the optimal timing of VATS-PDA in preterm infants before 28 weeks of gestation. Kemmochi M1, Senzaki H1,2, Miyaji K3, Hashimoto M1, Yamaguchi A1, Ooka M1, Yokozeki Y1, Ishii M1: Pediatr Int 2019/6. DOI: 10.1111/ped.13909 (çݎ@Šw1, æèG–Ÿ1,2, ‹{’n@ŠÓ3, ‹Ž–{‰è‹v”ü1, ŽRŒûˆ»”T1, ‘剪–ƒ—1, ‰¡ŠÖ—Sˆê˜Y1, Îˆä³_1: 1¬Ž™, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3S‘ŸŒŒŠÇŠO)

110222. [ŒŽ’˜] Cardiac Rhythm Disturbances in Heterotaxy Syndrome. Ozawa Y, Asakai H, Shiraga K, Shindo T, Hirata Y1, Hirata Y, Inuzuka R: Pediatr Cardiol 2019/6; 40 (5): 909-13. (•œ“c—zˆê˜Y1: 1¬Ž™)

110223. [ŒŽ’˜] Estimated GFR at Dialysis Initiation and Mortality in Children and Adolescents. Okuda Y1, Soohoo M, Tang Y, Obi Y, Laster M, Rhee CM, Streja E, Kalantar-Zadeh K: Am J Kidney Dis 2019/6; 73 (6): 797-805. (‰œ“c—Y‰î1: 1¬Ž™)

110224. [ŒŽ’˜] Nurses' perceptions regarding transitional care for adolescents and young adults with childhood-onset chronic diseases. Suzuki S, Kita S, Morisaki M, Kikuchi R, Sato I, Iwasaki M, Otomo E, Sekiguchi H, Hirata Y1, Sato A, Sugiyama M, Kamibeppu K: Jpn J Nurs Sci 2020/7; 17 (3): e12323. (•œ“c—zˆê˜Y1: 1¬Ž™)

110225. [ŒŽ’˜] Association between the clinical presentation of congenital anomalies of the kidney and urinary tract (CAKUT) and gene mutations: an analysis of 66 patients at a single institution. Ishiwa S, Sato M, Morisada N, Nishi K, Kanamori T, Okutsu M, Ogura M, Sako M, Kosuga M, Kamei K, Ito S, Nozu K, Iijima K, Ishikura K1: Pediatr Nephrol 2019/8; 34 (8): 1457-64. (Î‘qŒ’Ži1: 1¬Ž™)

110226. [ŒŽ’˜] Favorable Kidney Function in Pediatric Liver Transplant Recipients: Results of a Single-center Cohort Study. Sato M, Kaneko T, Ogura M, Kamei K, Ito S, Fukuda A, Sakamoto S, Kasahara M, Ishikura K1: Transplantation 2019/8; 103 (8): 1655-62. (Î‘qŒ’Ži1: 1¬Ž™)

110227. [ŒŽ’˜] Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial). Nagano C, Sako M, Kamei K, Ishikura K1, Nakamura H, Nakanishi K, Omori T, Nozu K, Iijima K: BMC Nephrol 2019/8; 20 (1): 293. (Î‘qŒ’Ži1: 1¬Ž™)

110228. [ŒŽ’˜] Optimal timing of video-assisted thoracoscopic surgery for patent ductus arteriosus in preterm infants born at £ 28 weeks of gestation. Kemmochi M1, Senzaki H1,2, Miyaji K3, Hashimoto M1, Yamaguchi A1, Ooka M1, Yokozeki Y1, Ishii M1: Pediatr Int 2019/8; 61 (8): 792-6. (™›Ž@Šw1, æèG–Ÿ1,2, ‹{’n@ŠÓ3, ‹Ž–{‰è‹v”ü1, ŽRŒûˆ»”T1, ‘剪–ƒ—1, ‰¡ŠÖ—Sˆê˜Y1, Îˆä³_1: 1¬Ž™, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3S‘ŸŒŒŠÇŠO)

110229. [ŒŽ’˜] Detailed clinical manifestations at onset and prognosis of neonatal-onset Denys-Drash syndrome and congenital nephrotic syndrome of the Finnish type. Nishi K, Inoguchi T, Kamei K, Hamada R, Hataya H, Ogura M, Sato M, Yoshioka T, Ogata K, Ito S, Nakanishi K, Nozu K, Hamasaki Y, Ishikura K1: Clin Exp Nephrol 2019/8; 23 (8): 1058-65. (Î‘qŒ’Ži1: 1¬Ž™)

110230. [ŒŽ’˜] Fenestration in the Fontan circulation as a strategy for chronic cardioprotection. Saiki H1, Kuwata S1, Iwamoto Y, Ishido H, Taketazu M, Masutani S, Nishida T1, Senzaki H1,2: Heart 2019/8; 105 (16): 1266-72. (âV–؍G•¶1, øv“c¹Žq1, Œ“c®Žj1, æèG–Ÿ1,2: 1¬Ž™, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã)

110231. [ŒŽ’˜] Clinical characteristics of HNF1B-related disorders in a Japanese population. Nagano C, Morisada N, Nozu K, Kamei K, Tanaka R, Kanda S, Shiona S, Araki Y, Ohara S, Matsumura C, Kasahara K, Mori Y, Seo A, Miura K, Washiyama M, Sugimoto K, Harada R, Tazoe S, Kourakata H, Enseki M, Aotani D, Yamada T, Sakakibara N, Yamamura T, Minamikawa S, Ishikura K1, Ito S, Hattori M, Iijima K: Clin Exp Nephrol 2019/9; 23 (9): 1119-29. (Î‘qŒ’Ži1: 1¬Ž™)

110232. [ŒŽ’˜] Prognosis and acute complications at the first onset of idiopathic nephrotic syndrome in children: a nationwide survey in Japan (JP-SHINE study). Sato M, Ishikura K1, Ando T, Kikunaga K, Terano C, Hamada R, Ishimori S, Hamasaki Y, Araki Y, Gotoh Y, Nakanishi K, Nakazato H, Matsuyama T, Iijima K, Yoshikawa N, Ito S, Honda M: Nephrol Dial Transplant 2019/9; gfz185. doi: 10.1093/ndt/gfz185. Online ahead of print. (Î‘qŒ’Ži1: 1¬Ž™)

110233. [ŒŽ’˜] Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis in Nondiabetic Apolipoprotein E-Deficient Mice. Aini K, Fukuda D, Tanaka K, Higashikuni Y, Hirata Y1, Yagi S, Kusunose K, Yamada H, Soeki T, Sata M: Int Heart J 2019/11; 60 (6): 1421-9. (•œ“c—zˆê˜Y1: 1¬Ž™)

110234. [ŒŽ’˜] Ultrafiltration Rate Effects Declines in Residual Kidney Function in Hemodialysis Patients. Lee Y, Okuda Y1, Sy J, Kim SR, Obi Y, Kovesdy CP, Rhee CM, Streja E, Kalantar-Zadeh K: Am J Nephrol 2019/10; 50 (6): 481-8. (‰œ“c—Y‰î1: 1¬Ž™)

110235. [ŒŽ’˜] Serum albumin and hospitalization among pediatric patients with end-stage renal disease who started dialysis therapy. Okuda Y1, Obi Y, Streja E, Laster M, Rhee C, Langman CB, Jernigan SM, Salusky IB, Tentori F, Schreiber MJ, Brunelli SM, Kalantar-Zadeh K: Pediatr Nephrol 2019/10; 34 (10): 1799-809. (‰œ“c—Y‰î1: 1¬Ž™)

110236. [ŒŽ’˜] Brain-type natriuretic peptide level in pregnant women with congenital heart disease predicts SGA offspring. Ishida S1, Uchiyama A, Imai K, Kusuda S: Pediatr Int 2019/12; 61 (12): 1221-6. (Î“c@Ži1: 1¬Ž™)

110237. [ŒŽ’˜] Association of Mineral Bone Disorder With Decline in Residual Kidney Function in Incident Hemodialysis Patients. Lee YJ, Okuda Y1, Sy J, Obi Y, Kang DH, Nguyen S, Hsiung JT, Park C, Rhee CM, Kovesdy CP, Streja E, Kalantar-Zadeh K: J Bone Miner Re. 2020/2; 35 (2): 317-25. (‰œ“c—Y‰î1: 1¬Ž™)

110238. [ŒŽ’˜] Biodegradable Extremely-Small-Diameter Vascular Graft Made of Silk Fibroin can be Implanted in Mice. Tanaka K, Fukuda D, Higashikuni Y, Hirata Y1, Komuro I, Saotome T, Yamashita Y, Asakura T, Sata M: J Atheroscler Thromb 2020/2. doi: 10.5551/jat.52720. Online ahead of print. (•œ“c—zˆê˜Y1: 1¬Ž™)

110239. [ŒŽ’˜] Levels of Adiponectin Expression in Peri-Renal and Subcutaneous Adipose Tissue and Its Determinants in Human Biopsied Samples. Maimaituxun G, Fukuda D, Izaki H, Hirata Y1, Kanayama HO, Masuzaki H, Sata M, Shimabukuro M: Front Endocrinol (Lausanne) 2020/2; 10: 897. (•œ“c—zˆê˜Y1: 1¬Ž™)

110240. [ŒŽ’˜] Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes. Chan EY, Webb H, Yu E, Ghiggeri GM, Kemper MJ, Ma AL, Yamamura T, Sinha A, Bagga A, Hogan J, Dossier C, Vivarelli M, Liu ID, Kamei K, Ishikura K1, Saini P, Tullus K: Kidney Int 2020/2; 97 (2): 393-401. (Î‘qŒ’Ži1: 1¬Ž™)

110241. [ŒŽ’˜] Long-term outcomes of pediatric kidney transplantation: A single-center experience over the past 34 years in Japan. Aoki Y, Hamasaki Y, Satoh H, Matsui Z, Muramatsu M, Hamada R, Harada R, Ishikura K1, Hataya H, Honda M, Sakai K, Shishido S: Int J Urol 2020/2; 27 (2): 172-8. (Î‘qŒ’Ži1: 1¬Ž™)

110242. [ŒŽ’˜] Primary causes of kidney disease and mortality in dialysis-dependent children. Okuda Y1, Soohoo M, Ishikura K1, Tang Y, Obi Y, Laster M, Rhee CM, Streja E, Kalantar-Zadeh K: Pediatr Nephrol 2020/5; 35 (5): 851-60. doi: 10.1007/s00467-019-04457-7. Epub 2020 Feb 4. (‰œ“c—Y‰î1, Î‘qŒ’Ži1: 1¬Ž™)

110243. [ŒŽ’˜] Ultrafiltration Rate, Residual Kidney Function, and Survival Among Patients Treated With Reduced-Frequency Hemodialysis. Lee YJ, Okuda Y1, Sy J, Lee YK, Obi Y, Cho S, Chen JLT, Jin A, Rhee CM, Kalantar-Zadeh K, Streja E: Am J Kidney Dis 2020/3; 75 (3): 342-50. (‰œ“c—Y‰î1: 1¬Ž™)

110244. [ŒŽ’˜] Kidney function of Japanese children undergoing kidney transplant with preemptive therapy for cytomegalovirus infection. Gotoh Y, Shishido S, Hamasaki Y, Watarai Y, Hattori M, Miura K, Ishizuka K, Fujita N, Saito K, Nakagawa Y, Hotta K, Hataya H, Hamada R, Sato H, Kitayama H, Ishikura K1, Honda M, Uemura O: Transpl Infect Dis 2020/6; 22 (3): e13271. doi: 10.1111/tid.13271. Epub 2020 Mar 11. (Î‘qŒ’Ži1: 1¬Ž™)

110245. [ŒŽ’˜] Nonosmotic secretion of arginine vasopressin and salt loss in hyponatremia in Kawasaki disease. Miura K, Harita Y, Takahashi N, Tsurumi H, Yasudo H, Isojima T, Hirata Y1, Inuzuka R, Takizawa K, Toyofuku E, Nishimoto H, Takamizawa M, Ando T, Sugawa M, Yanagisawa A, Inatomi J, Nogimori Y, Kinumaki A, Namai Y, Hattori M, Oka A: Pediatr Int 2020/3; 62 (3): 363-70. (•œ“c—zˆê˜Y1: 1¬Ž™)

110246. [ŒŽ’˜] Noonan syndrome-associated biallelic LZTR1 mutations cause cardiac hypertrophy and vascular malformations in zebrafish. Nakagama Y, Takeda N, Ogawa S, Takeda H, Furutani Y, Nakanishi T, Sato T, Hirata Y1, Oka A, Inuzuka R: Mol Genet Genomic Med 2020/3; 8 (3): e1107. (•œ“c—zˆê˜Y1: 1¬Ž™)

110247. [ŒŽ’˜] Hypoxic activation of glucose-6-phosphate dehydrogenase controls the expression of genes involved in the pathogenesis of pulmonary hypertension through the regulation of DNA methylation. Joshi SR, Kitagawa A1, Jacob C, Hashimoto R, Dhagia V, Ramesh A, Zheng C, Zhang H, Jordan A, Waddell I, Leopold J, Hu CJ, McMurtry IF, D'Alessandro A, Stenmark KR, Gupte SA: Am J Physiol Lung Cell Mol Physiol 2020/4; 318 (4): L773-86. doi: 10.1152/ajplung.00001.2020. Epub 2020 Mar 11. (–kì“ÄŽj1: 1¬Ž™)

110248. [ŒŽ’˜] Recombinant Measles AIK-C Vaccine Strain Expressing Influenza HA Protein. Ito T1, Kumagai T, Yamaji Y, Sawada A, Nakayama T: Vaccines (Basel) 2020/3; 8 (2): 149. (ˆÉ“¡®Žu1: 1¬Ž™)

120008. [ŒŽ’˜] V¶Žeƒ}ƒEƒX‚”Z“xŽ_‘f–\˜I”xáŠQƒ‚ƒfƒ‹‚É‚š‚¯‚é”x–E”÷¬ŒŒŠÇáŠQ‚ÌŒ`‘ÔŠw“I“Á’¥. ’†ŒG•F1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2¬Ž™): “Œ‹ž—Žqˆã‰È‘åŠwŽGŽ 2019/7; 89 (Extra1): E123]33.

310032. [Ç—á•ñ] No preventive or therapeutic efficacy of infliximab against macrophage activation syndrome due to systemic juvenile idiopathic arthritis. Kiuchi Z, Ogura M, Sato M, Kamei K, Ishikura K1, Abe J, Ito S: Scand J Rheumatol 2019/5; 48 (3): 246-8. (Î‘qŒ’Ži1: 1¬Ž™)

310033. [Ç—á•ñ] Successful salvage of the left pulmonary artery in a neonate with isolated unilateral absence of the pulmonary artery. Kawada K, Saiki H1, Kemmochi M1, Kuwata S, Takanashi M1, Miyaji K2, Senzaki H1,3: J Cardiol Cases 2020/1; 21 (5): 169-71. (âV–؍G•¶1, ™›Ž@Šw1, ‚—œ@Šw1, ‹{’n@ŠÓ2, æèG–Ÿ1,3: 1¬Ž™, 2S‘ŸŒŒŠÇŠO, 3V¢‹Iˆã—ÁEæ’[“Iˆã—Ã)

320022. [Ç—á•ñ] ”ŒŒŽ‘ÌŒ`¬«t‰Š‚ð’悵‚œC3t‰Š‚Ì4Î—Ž™. ‹TˆäGˆê, ²“¡@•‘, ‹àX@“§, ‰œ’Ôü‰Ä, Î˜a@ãÄ, ŒŒ’‘Ÿ˜N, ¬–ž‰ë•v, àVˆärG, ‰œ“c—Y‰î1, ‹`‰ªFŽq, •ûŒª‘Ÿ˜Y, Î‘qŒ’Ži1 (1¬Ž™): “ú–{¬Ž™t•s‘SŠw‰ïŽGŽ 2019/7; 39: 119-22.

320023. [Ç—á•ñ] –³ÇŒó«’`”’”A‚̐žž‚ÅWT1ˆâ“`ŽqˆÙí‚ª”»–Ÿ‚µ‚œ17Î—Ž™—á. ‹àX@“§, ‹TˆäGˆê, ŒŒ’‘Ÿ˜N, ‰œ’Ôü‰Ä, Î˜a@ãÄ, ²“¡@•‘, ¬–ž‰ë•v, ˆÉ“¡Gˆê, ’†ŒŒ[‘Ÿ, –ì’Ê°‘å, ”Ñ“‡ˆêœ, Î‘qŒ’Ži1 (1¬Ž™): “ú–{¬Ž™t•s‘SŠw‰ïŽGŽ 2019/7; 39: 207-10.

510008. [‘à] Treatment guidelines for persistent cloaca, cloacal exstrophy, and Mayer-Rokitansky-K?ster-H?user syndrome for the appropriate transitional care of patients. Kubota M, Osuga Y, Kato K, Ishikura K1, Kaneko K, Akazawa K, Yonekura T, Tazuke Y, Ieiri S, Fujino A, Ueno S, Hayashi Y, Yoshino K, Yanai T, Iwai J, Yamaguchi T, Amae S, Yamazaki Y, Sugita Y, Kohno M, Kanamori Y, Bitoh Y, Shinkai M, Ohno Y, Kinoshita Y: Surg Today 2019/12; 49 (12): 985-1002. (Î‘qŒ’Ži1: 1¬Ž™)

510009. [‘à] Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children. Kamei K, Ishikura K1, Sako M, Ito S, Nozu K, Iijima K: Pediatr Nephrol 2020/1; 35 (1): 17-24. (Î‘qŒ’Ži1: 1¬Ž™)

510010. [‘à] History and Future of Treatment for Acute Stage Kawasaki Disease. Ishii M, Ebato T1, Kato H: Korean Circ J 2020/2; 50 (2): 112-19. (]”gŒËF•ã1: 1¬Ž™)

520010. [‘à] —¬s«‹Ø’ɏǂƃqƒgƒpƒŒƒRƒEƒCƒ‹ƒX. Î“c—Ï–ç, ”’ˆäGK1, ”’ˆäG’Œ1, “yŠò@•œ1, –ìX“c–L1, Šâèr”V1, Î‘qŒ’Ži1, –ìXŽRŸl, ²–ì‹MŽq (1¬Ž™): ¬Ž™‰È 2019/9; 60 (10): 1395-400.

522055. [uÀ]y“ÁW: V¶Ž™E“ûŽ™‚̔畆•az—Տ°—á: “û—cŽ™Šú‚É”­Ç‚µ‚œ“«‚Ì“€áŒ. ]”gŒËF•ã1, â“Œ—R‹I1,2 (1¬Ž™, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ”畆•af—à 2019/5; 41 (5): 453-6.

522056. [uÀ]yV¶Ž™‚̌ċzáŠQ ÇóE¶ŒãŽžŠÔ•Ê‚ʼnŸ‚³‚Š‚é‘Ώˆ‚̃Rƒcz‘˜_: V¶Ž™‚̌ċz‚Ì“Á’¥. ’†ŒG•F1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2¬Ž™): with NEO 2019/8; 32 (4): 496-9.

522057. [uÀ]yƒVƒ“ƒ|ƒWƒEƒ€: ƒXƒyƒVƒƒƒŠƒXƒg‚É•·‚­! ¬Ž™“§ÍŠÅŒìEŽw“±‚̃Rƒcz•êŽq‚̈€’…Œ`¬‚É’…–Ú‚µ‚œ“ûŽ™Šú‚É‚ ‚éPDŠ³ŽÒ‚ÌŠÅŒì. Œ“cŠ²Žq, ²“¡@•‘, ¬–ž‰ë•v, ‹TˆäGˆê, Î‘qŒ’Ži1 (1¬Ž™): “ú–{¬Ž™PDEHDŒ€‹†‰ïŽGŽ 2019/10; 31: 17-21.

522058. [uÀ]y“ÁW: ""with NEO"" Update ""’Ž"" ‚í‚©‚é! Žg‚Š‚é! V¶Ž™‚ÌŒŒ‰tƒKƒXŒŸžzV¶Ž™‚ÌŒŒ‰tƒKƒXŠî€’l/ˆÙí’l‚©‚ç—\‘ª‚µ“Ÿ‚é•a‘Ô/V¶Ž™‚ÌŒŒ‰tƒKƒX—pŒêˆê——. ’†ŒG•F1,2 (1V¢‹Iˆã—ÁEæ’[“Iˆã—Ã, 2¬Ž™): with NEO 2020/2; 33 (1): 6-7.

522059. [uÀ]y“ÁW: ""with NEO"" Update ""’Ž"" ‚í‚©‚é! Žg‚Š‚é! V¶Ž™‚ÌŒŒ‰tƒKƒXŒŸžzƒvƒƒ[ƒO ‚€|Žq‚Æ‚±‚Ձ|‚̏o‰ï‚¢. ’†ŒG•F1,2 (1V¢‹Iˆã—ÁEæ’[“Iˆã—Ã, 2¬Ž™): with NEO 2020/2; 33 (1): 8.

522060. [uÀ]y“ÁW: ""with NEO"" Update ""’Ž"" ‚í‚©‚é! Žg‚Š‚é! V¶Ž™‚ÌŒŒ‰tƒKƒXŒŸžz1. ‚Ü‚ž‚Í‚±‚±‚©‚ç! ŒŒ‰tƒKƒXŒ‹‰Ê‚ð“Ç‚Þ‚œ‚ß‚É‚Í. ’†ŒG•F1,2 (1V¢‹Iˆã—ÁEæ’[“Iˆã—Ã, 2¬Ž™): with NEO 2020/2; 33 (1): 9-19.

522061. [uÀ]y“ÁW: ""with NEO"" Update ""’Ž"" ‚í‚©‚é! Žg‚Š‚é! V¶Ž™‚ÌŒŒ‰tƒKƒXŒŸžz6. ŽÀ‘H! (2) V¶Ž™ŒŒ‰tƒKƒX‚©‚牜‚ª‚í‚©‚é? ‚Ç‚€•â³‚·‚é? Î“c@Ži1 (1¬Ž™): with NEO 2020/2; 33 (1): 52-62.

522062. [uÀ]y“ÁW: ""with NEO"" Update ""’Ž"" ‚í‚©‚é! Žg‚Š‚é! V¶Ž™‚ÌŒŒ‰tƒKƒXŒŸžz7. ŽÀ‘H! (3) ŒŒ‰tƒKƒX‚ð“Ç‚ñ‚Å‚Ý‚æ‚€. ’†ŒG•F1,2 (1V¢‹Iˆã—ÁEæ’[“Iˆã—Ã, 2¬Ž™): with NEO 2020/2; 33 (1): 64-78.

522063. [uÀ]y“ÁW: ""with NEO"" Update ""’Ž"" ‚í‚©‚é! Žg‚Š‚é! V¶Ž™‚ÌŒŒ‰tƒKƒXŒŸžzƒGƒsƒ[ƒO ‚ ‚肪‚Æ‚€, ‚±‚Ձ|. ’†ŒG•F1,2 (1V¢‹Iˆã—ÁEæ’[“Iˆã—Ã, 2¬Ž™): with NEO 2020/2; 33 (1): 79.

[’˜@‘]

620049. [Šwp‘ (•ª’SŽ·•M)]y¬Ž™ ˆêŽŸ‹~‹}ƒ}ƒjƒ…ƒAƒ‹|‹A‘î‰Â”\‚©? “ñŽŸ‹~‹}‚©? ”»’f‚Ì‚œ‚ß‚ÌŽèˆø‚«|(¬Ž™‰È2019”N4ŒŽ—ÕŽž‘Š§†)z3. ˆêŽŸ‹~‹}‚Å‚Ý‚ç‚ê‚éŽå‚ÈŽŸŠ³@tE”å”AŠí—̈æ, p.742-7. ‹àX@“§, ’·’Jì—Yˆê, Î‘qŒ’Ži1 (1¬Ž™), ‹àŒŽo”Å, “Œ‹ž, 2019/4”­s.

620050. [Šwp‘ (•ª’SŽ·•M)]y¬Ž™‚Ì•‰‰×ŽŽŒ±2019 (¬Ž™“à‰È4ŒŽ‘‘卆)z[t‹@”\ŒŸž]@“ú–{l¬Ž™‚ÌeGFR‚ÌŽZo–@|ƒNƒŒƒAƒ`ƒjƒ“, ƒVƒXƒ^ƒ`ƒ“C, ƒÀ2ƒ~ƒNƒƒOƒƒuƒŠƒ“|, p.539-41. ‹àX@“§, Î‘qŒ’Ži1 (1¬Ž™), “Œ‹žˆãŠwŽÐ, “Œ‹ž, 2019/4”­s.

620051. [Šwp‘ (•ª’SŽ·•M)]y‚±‚ê‚Å‚í‚©‚é, V¶Ž™ŒÄ‹zŠÇ— (ŽüŽYŠúˆãŠw4ŒŽ‘‘卆)z<ŒÄ‹zŠÇ—‚ÌŽÀÛ>@lHŒÄ‹zŠí‚É‚æ‚éŒÄ‹zŠÇ—@CLiO2: closed-loop inspired oxygen, p.430-5. ’†ŒG•F1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2¬Ž™), “Œ‹žˆãŠwŽÐ, “Œ‹ž, 2019/4”­s.

620052. [Šwp‘ (•ª’SŽ·•M)]y¬Ž™‚̐f—ÃŽè‹Z (¬Ž™‰Èf—Ã82Šª‘Š§†)zI. ‹~–œ@“M…‚̏¬Ž™‚ɑ΂·‚éˆêŽŸ‹~–œˆ’u, p.33-6. “ì–쏉 (¬Ž™), f’f‚ÆŽ¡—ÃŽÐ, “Œ‹ž, 2019/4”­s.

620053. [Šwp‘ (•ª’SŽ·•M)]yS•s‘S (‘æ2”Å) ‰º|ÅV‚ÌŠî‘bE—Տ°Œ€‹†‚̐i•à| (“ú–{—Õà¬77Šª‘Š§†2)zXXII. ‚»‚Ì‘Œ•a‘ԁE”N—î‘w‚̐S•s‘S‚̗Տ°“IŽ–€@2. –¢nŽ™EV¶Ž™S•s‘S (S“àŠïŒ`‚𔺂í‚È‚¢), p.496-502. Î“c@Ži1, ŠÖ’J—¢‰À1, “yŠò”ü‹v1, ì“cF•œ1, ™™Ž@Šw1, æèG–Ÿ1,2 (1¬Ž™, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã), “ú–{—Õ଎Ð, “Œ‹ž, 2019/5”­s.

620054. [Šwp‘ (•ª’SŽ·•M)]yŽw’è“ï•aƒyƒfƒBƒA2019 (“ú–{ˆãŽt‰ïŽGŽ148ŠªE“Á•Ê† (1))zIII. ŒÂ•Ê‚ÌŽw’è“ï•a@F. zŠÂŠíŒn@14. SŽº’†ŠuŒ‡‘¹Ç‚𔺂€”x“®–¬•ÂœÇ [Žw’è“ï•a214], p.217-8. ‚—œ@Šw1, æèG–Ÿ1,2 (1¬Ž™, 2V¢‹Iˆã—ÁEæ’[“Iˆã—Ã), “ú–{ˆãŽt‰ï, “Œ‹ž, 2019/6”­s.

620055. [Šwp‘ (•ª’SŽ·•M)]yŽw’è“ï•aƒyƒfƒBƒA2019 (“ú–{ˆãŽt‰ïŽGŽ148ŠªE“Á•Ê† (1))zIII. ŒÂ•Ê‚ÌŽw’è“ï•a@H. tE”å”AŠíŒn@12. ƒMƒƒƒƒEƒFƒCEƒ‚ƒƒgÇŒóŒQ [Žw’è“ï•a219], p.251. ’ËŒû—TN, Î‘qŒ’Ži1 (1¬Ž™), “ú–{ˆãŽt‰ï, “Œ‹ž, 2019/6”­s.

620056. [Šwp‘ (•ª’SŽ·•M)]y“à‰ÈŠw‘ ‰ü’ù‘æ9”Å (Vol.3 zŠÂŠíŽŸŠ³)z11. æ“V«SŽŸŠ³@ƒ~ƒgƒRƒ“ƒhƒŠƒAS‹ØÇ, p.255-6. ”’ˆäG’Œ1, æèG–Ÿ1,2 (1¬Ž™, 2V¢‹Iˆã—ÁEæ’[“Iˆã—Ã), ’†ŽR‘“X, “Œ‹ž, 2019/8”­s.

620057. [Šwp‘ (•ª’SŽ·•M)]y“à‰ÈŠw‘ ‰ü’ù‘æ9”Å (Vol.3 zŠÂŠíŽŸŠ³)z11. æ“V«SŽŸŠ³@æ“V«‘m–X•ÙŽŸŠ³ (æ“V«‘m–X•Ù‹·óÇ, æ“V«‘m–X•Ù•Âœ•s‘SÇ), p. 256-7. ‚—œ@Šw1, æèG–Ÿ1,2 (1¬Ž™, 2V¢‹Iˆã—ÁEæ’[“Iˆã—Ã), ’†ŽR‘“X, “Œ‹ž, 2019/8”­s.

620058. [Šwp‘ (•ª’SŽ·•M)]yŽüŽYŠú‘Š’k310 ‚š•ê‚³‚ñ‚ւ̉ñ“šƒ}ƒjƒ…ƒAƒ‹ ‘æ3”Å (ŽüŽYŠúˆãŠw2019”N49Šª‘Š§†)zV¶Ž™¥“ûŽ™•Ò@III.”å”A¶BŠí@¡¶Œã1ƒJŒŽ @Q203. ‚š‚¿‚ñ‚¿‚ñ‚̐æ‚̔炪Ô‚­Žî‚ê‚Ä‚¢‚Ü‚·‚ª?, p.467-68. ‘剪–ƒ—1, ’†ŒG•F1,2 (1¬Ž™, 2V¢‹Iˆã—ÁEæ’[“Iˆã—Ã), “Œ‹žˆãŠwŽÐ, “Œ‹ž, 2019/12”­s.

620059. [Šwp‘ (•ª’SŽ·•M)]yŽüŽYŠú‘Š’k310 ‚š•ê‚³‚ñ‚ւ̉ñ“šƒ}ƒjƒ…ƒAƒ‹ ‘æ3”Å (ŽüŽYŠúˆãŠw2019”N49Šª‘Š§†)zV¶Ž™¥“ûŽ™•Ò@III.”å”A¶BŠí@¡¶Œã1ƒJŒŽ @Q204. ’j‚ÌŽq‚Ì’pC‚Í‚Æ‚Á‚œ‚Ù‚€‚ª‚æ‚¢‚Å‚·‚©? ‚»‚Ì•û–@‚Í?, p.469-70. ‘剪–ƒ—1, ’†ŒG•F1,2 (1¬Ž™, 2V¢‹Iˆã—ÁEæ’[“Iˆã—Ã), “Œ‹žˆãŠwŽÐ, “Œ‹ž, 2019/12”­s.

[Šw‰ïEŒ€‹†‰ï“™]

711007. [Šw‰ï (‘Û)] (“Á•Êu‰‰) Role of nasal high flow post-extubation in neonates-Current status in Japan-. Nakanishi H1,2: International Meeting Pediatric and neonatal nasal high flow (2019/4/13-14), New Deli, India. (’†ŒG•F1,2: 1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2¬Ž™)

712009. [Šw‰ï (‘Û)] (ƒVƒ“ƒ|ƒWƒEƒ€) Epidemiology of CKD and ESKD according to Registry data Data from the Japanese Registry. Ishikura K1: IPNA2019 (2019/10/17-21), Venice, Italy. (Î‘qŒ’Ži1: 1¬Ž™)

713075. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) WT1 gene mutation might cause thrombotic microangiopathy which is not responsive to Eculizumab. Tomari K, Terano C, Hamada R, Okuda Y1, Harada R, Nozu K, Ishikura K1, Hataya H, Iijima K, Ogata K, Joseph L Alge, Honda M: The 17th China-Japan-Korea Pediatric Nephrology Seminar 2019 (2019/4/13), Hangzhou, China. (‰œ“c—Y‰î1, Î‘qŒ’Ži1: 1¬Ž™)

713076. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Rasmussen syndrome: Assessment of clinical features in patients with different intellectual levels. Toki T1, Shimizu-Motohashi Y, Sumitomo N, Takeshita E, Ishiyama A, Saito T, Sugai K, Komaki H, Nakagawa E, Sasaki M: Child Neuro 2019 in Nagoya (The 20th annual meeting of infantile seizure society) (2019/5/31-6/2), Nagoya, Japan. (“yŠò@•œ1: 1¬Ž™)

713077. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) A case of fatal legionella pneumonia during ACTH therapy for West syndrome. Toki T1, Shirai H1, Nonoda Y1, Iwasaki T1: Child Neuro 2019 in Nagoya (The 20th annual meeting of infantile seizure society) (2019/5/31-6/2), Nagoya, Japan. (“yŠò@•œ1, ”’ˆäG’Œ1, –ìX“c–L1, Šâèr”V1: 1¬Ž™)

713078. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Trends in the incidence and pathology of pedi-atric PD peritonitis: a single center experience spanning 30 years. Hamada R, Hataya H, Inoguchi T, Terano C, Harada R, Aoki Y, Sato H, Hamasaki Y, Ishikura K1, Honda M: The 9th Asia Pacific Chapter Meeting of International Society for Peritoneal Dialysis (APCM-ISPD2019) (2019/9/5-7), Nagoya, Japan. (Î‘qŒ’Ži1: 1¬Ž™)

713079. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Subepithelial electron-dense deposits do not predict treatment response in C3 Glomerulopathy. Tomari K, Hamada R, Omori N, Mikami N, Anno A, Shimabukuro W, Shirane S, Inoguchi T, Okuda Y1, Terano C, Harada R, Hamasaki Y, Ishikura K1, Hataya H, Honda M: IPNA2019 (2019/10/17-21), Venice, Italy. (‰œ“c—Y‰î1, Î‘qŒ’Ži1: 1¬Ž™)

713080. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Adolescent age and risk of first and subsequent allograft failure among pediatric kidney transplant recipients. Okuda Y1, Streja E, Rhee CM, Tantisattamo E, Reddy U, Laster M, Tang Y, Rajpoot D, Molnar MZ, Ichii H, Obi Y, Kalantar-Zadeh K: IPNA2019 (2019/10/17-21), Venice, Italy. (‰œ“c—Y‰î1: 1¬Ž™)

713081. [Šw‰ï (‘Û)] (ˆê”ÊŒû‰‰) Predictors of Kidney and liver morbidity in patients with autosomal recessive polycystic Kidney disease. Sato M, Ishikura K1, Ogura M, Nishi K, Kanamori T, Kamae C, Suzuki R, Murakoshi M, Sako M, Ito Sakamoto S, Kasahara M, Kamei K: IPNA2019 (2019/10/17-21), Venice, Italy. (Î‘qŒ’Ži1: 1¬Ž™)

713082. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Intelligence quotient in eskd children: comparison between pre-emptive Kidney transplantation and transplantation after dialysis. Kikunaga K, Hamada R, Inoguchi T, Terano C, Harada R, Hamasaki Y, Ishikura K1, Hataya H, Matsuyama T, Honda M: IPNA2019 (2019/10/17-21), Venice, Italy. (Î‘qŒ’Ži1: 1¬Ž™)

713083. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) A cross-sectional nationwide survey of congenital and infantile nephrotic syndrome in Japan. Hamasaki Y, Hamada R, Matsumoto S, Muramatsu M, Aya K, Ishikura K1, Iijima K: IPNA2019 (2019/10/17-21), Venice, Italy. (Î‘qŒ’Ži1: 1¬Ž™)

713084. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Presenting clinical features of pediatric renovascular hypertension at diagnosis: a single-center experience fromjapan. Inoguchi T, Hamada R, Anno A, Shimabukuro W, Shirane S, Tomari K, Akamine K, Terano C, Harada R, Hamasaki Y, Hataya H, Ishikura K1, Honda M: IPNA2019 (2019/10/17-21), Venice, Italy. (Î‘qŒ’Ži1: 1¬Ž™)

713085. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Prospective examinationof relationship between clinical features and relapse of Nephrotic syndrome after flu vaccines. Ishimori S, Horinouchi T, Fujimura J, Minamikawa S, Yamamura T, Matsunoshita N, Kamiyoshi N, Ogura M, Kaito H, Nozu K, Kamei K, Ishikura K1, Iijima K: IPNA2019 (2019/10/17-21), Venice, Italy. (Î‘qŒ’Ži1: 1¬Ž™)

713086. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) National survey of live attenuated vaccines for patients receiving Immunosuppressive agents or biological agents. Kamei K, Miyairi I, Shoji K, Ishikura K1, Sako M, Nakamura H: IPNA2019 (2019/10/17-21), Venice, Italy. (Î‘qŒ’Ži1: 1¬Ž™)

713087. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) A nation-wide survey of long-term prognosis of epstein syndrome. Miura K, Shirai Y, Kunishima S, Ishiguro A, Hamada R, Ishikura K1, Hattori M: IPNA2019 (2019/10/17-21), Venice, Italy. (Î‘qŒ’Ži1: 1¬Ž™)

713088. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Strategy for discontinuing steroids in pediatric patients with lupus nephritis: a single center experience. Nishi K, Ogura M, Kamei K, Kanamori T, Ishiwa S, Okutsu M, Sato M, Ishikura K1, Ito S: IPNA2019 (2019/10/17-21), Venice, Italy. (Î‘qŒ’Ži1: 1¬Ž™)

713089. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Clinical significance of collapsing variant in childhood focal segmental Glomerulosclerosis. Okutsu M, Kamei K, Sato M, Ishiwa S, Kanamori T, Nishi K, Ogura M, Sako M, Ito S, Yoshioka T, Ogata K, Ishikura K1: IPNA2019 (2019/10/17-21), Venice, Italy. (Î‘qŒ’Ži1: 1¬Ž™)

713090. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) C1q nephropathy in siblings with nphs1 gene mutations. Omori T, Kamei K, Nozu K, Ogata K, Takahashi M, Nagano C, Ishikura K1, Iijima K, Misawa M: IPNA2019 (2019/10/17-21), Venice, Italy. (Î‘qŒ’Ži1: 1¬Ž™)

713091. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Epidemiologyand treatment protocol of henoch-sch?nlein purpura nephritis: a Nationwide survey in japan. Terano C, Hamada R, Kaneko T, Honda M, Koichi N, Ishikura K1: IPNA2019 (2019/10/17-21), Venice, Italy. (Î‘qŒ’Ži1: 1¬Ž™)

713092. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Neutrophil-to-lymphocyte ratio and hospitalization among pediatric dialysis patients. Tang Y, Okuda Y1, Park C, Hsiung J, Streja E, Wu Y, Kalantar-Zadeh K: IPNA2019 (2019/10/17-21), Venice, Italy. (‰œ“c—Y‰î1: 1¬Ž™)

713093. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) A faster decline of residual kidney function and erythropoietin hyporesponsiveness in incident hemodialysis patients. Kimura H, Okuda Y1, Rhee C, Kovesdy CP, Streja E, Kalantar-Zadeh K: American Society of Nephrology Kidney Week 2019 (2019/11/5-10), Washington DC, USA. (‰œ“c—Y‰î1: 1¬Ž™)

713094. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) A rapid decline of residual kidney function and anemia in incident hemodialysis patients. Kimura H, Okuda Y1, Rhee C, Kovesdy CP, Streja E, Kalantar-Zadeh K: American Society of Nephrology Kidney Week 2019 (2019/11/5-10), Washington DC, USA. (‰œ“c—Y‰î1: 1¬Ž™)

713095. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Rates of prevalent fracture differ by race and ethnicity in children with CKD. Laster M, Denburg M, Okuda Y1, Kumar J, Furth S, Norris K, Kalantar-Zadeh K, Warady B, Salusky I: American Society of Nephrology Kidney Week 2019 (2019/11/5-10), Washington DC, USA. (‰œ“c—Y‰î1: 1¬Ž™)

713096. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Dietary protein intake, kidney function, and mortality in a nationally representative cohort. Narasaki Y, Okuda Y1, Moore L, You A, Nakata T, Nguyen D, Kalantar-Zadeh K, Rhee C: American Society of Nephrology Kidney Week 2019 (2019/11/5-10), Washington DC, USA. (‰œ“c—Y‰î1: 1¬Ž™)

713097. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Association of lower dietary potassium intake with higher death risk in a prospective hemodialysis cohort. Narasaki Y, Okuda Y1, Kalantar S, You A, Novoa A, Nguyen T, Streja E, Nakata T, Colman S, Nguyen D, Rhee C: American Society of Nephrology Kidney Week 2019 (2019/11/5-10), Washington DC, USA. (‰œ“c—Y‰î1: 1¬Ž™)

713098. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Nonpreemptive vs Preemptive "Second" Kidney Transplant with Graft Failure Risk among Pediatric Kidney Transplant Recipients. Okuda Y1, Rhee CM, Tantisattamo E, Laster M, Tang Y, Rajpoot D, Molnar MZ, Ichii H, Obi Y, Kalantar-Zadeh K, Streja E: American Society of Nephrology Kidney Week 2019 (2019/11/5-10), Washington DC, USA. (‰œ“c—Y‰î1: 1¬Ž™)

713099. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Effect of Remote Ischemic Postconditioning on Inflammatory Cytokines, Cardiac Damage, Ventricular Function, and Mortality in Lipopolysaccharide-Induced Sepsis. Honda T1, He Q, Wang F, Redington AN: American Heart Association Scientific Sessions 2019 (2019/11/16-18), Philadelphia, USA. (–{“c@’1: 1¬Ž™)

721012. [Šw‰ï (‘S‘)] (‰ï’·Ü‘I•Êu‰‰)y‘œ—̈æê–åE•”–å‰ï’·ÜŽóÜz¬Ž™zŠÂŠíŽŸŠ³Š³ŽÒ‚É‚š‚¯‚éˆÚsŠúŽx‰‡ŠO—ˆ‚ÌŽófŒø‰Ê: ƒ‰ƒ“ƒ_ƒ€‰»”äŠrŽŽŒ±‚ÌŒ‹‰Ê‚©‚ç. Xè^—R”ü, —é–ؐªŒá, ¬—Ñ–Ÿ“ú, Šâè”ü˜a, •œ“c—zˆê˜Y1, ²“¡“ÖŽu, Œ¢’ˁ@—º, ƒLƒ^KŽq, ²“¡ˆÉD, ‰ª@@–Ÿ, ã•Ê•{Œ\Žq (1¬Ž™): ‘æ55‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï (2019/6/27-29), ŽD–y.

722083. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[“¢˜_)yÀ’·z–ƉuEäPŒŽ•a: ŒŒŠÇ‰ŠE‚»‚Ì‘Œ. â“Œ—R‹I (¬Ž™): ‘æ122‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï (2019/4/19-21), ‹à‘ò.

722084. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) ¬Ž™tŽŸŠ³‚̃KƒCƒhƒ‰ƒCƒ“‚ÌŒ»ó‚ƍ¡Œã@¬Ž™“Á”­«ƒlƒtƒ[ƒ[ÇŒóŒQf—ÃKƒCƒhƒ‰ƒCƒ“2019. Î‘qŒ’Ži (¬Ž™): ‘æ54‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ïŠwpW‰ï (2019/6/7-8), ‘åã.

722085. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒJƒe[ƒeƒ‹ŒŸž‚𒆐S‚É”ñNP“I‘ª’è‚Ö‚Ì“WŠJ. –{“c@’1, ‚—œ@Šw1, øw“c¹Žq, Ö–؍G•¶1, ›–{Œ’Ži, Šâ–{—mˆê, ÎŒË”Ž—², ‘’J@‘, æèG–Ÿ1,2 (1¬Ž™, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ55‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï (2019/6/27-29), ŽD–y.

722086. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Post tolvaptan era‚Ì‚€‚ÁŒŒ‰ðœíp`¬Ž™‚É‚š‚¯‚éƒgƒ‰ƒZƒ~ƒh, ƒgƒ‹ƒoƒvƒ^ƒ“‚ÌŒø‰Ê`. ‚—œ@Šw1, âV–؍G•¶1, øw“c¹Žq, •ŸŒ‘ô^2, Šâ–{—mˆê, ÎŒË”Ž—², ‘’J@‘, ‹{–{—²Ži2, ‹{’n@ŠÓ2, ›–{Œ’Ži, æèG–Ÿ1,3 (1¬Ž™, 2S‘ŸŒŒŠÇŠO, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ55‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï (2019/6/27-29), ŽD–y.

722087. [Šw‰ï (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“)yÀ’·z¬Ž™Šú‚©‚çs‚€ˆÚsŽx‰‡|ˆÚsŠú‚ð‚Ý‚·‚Š‚Ä, ‘ÙŽ™Šú‚©‚ç‰Æ‘°‚Æ‚Ç‚€‚©‚©‚í‚é‚©|. •œ“c—zˆê˜Y (¬Ž™): ‘æ55‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï (2019/6/27-29), ŽD–y.

722088. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) “­‚«•û‰üŠv‚ª‚à‚œ‚ç‚·ŽüŽYŠúˆã—Ã’ñ‹Ÿ‘̐§‚Ì•ÏŠv. ’†ŒG•F1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2¬Ž™): ‘æ55‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŠwpW‰ï (2019/7/13-15), ’·–ì.

722089. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) pŒã‡•¹Ç‚©‚ç‚Ý‚œ–¢nŽ™“®–¬ŠÇŠJ‘¶Ç‚ɑ΂·‚éŠO‰È“IŽ¡—Éî“üŽžŠú‚ÌŒŸ“¢. Î“c@Ži1, ŽRŒûˆ»”T1, ‘剪–ƒ—1, çݎ@Šw1, ’†ŒG•F1,2, ‹{’n@ŠÓ3 (1¬Ž™, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3S‘ŸŒŒŠÇŠO): ‘æ55‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŠwpW‰ï (2019/7/13-15), ’·–ì, “ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŽGŽ 2019; 55 (2): 476.

722090. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yÀ’·z”ç]‚©‚çl‚Š‚錩“Š‚µ‚â‚·‚¢¬Ž™”畆ŽŸŠ³. â“Œ—R‹I1,2, (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2¬Ž™): ‘æ43‰ñ“ú–{¬Ž™”畆‰ÈŠw‰ïŠwp‘å‰ï (2019/7/20-21), ‘å‹{.

722091. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yˆÚsŽx‰‡‚Ì“úíŽÀ‘H‚ÉŒü‚¯‚āz‘‡•a‰@ (‘åŠw•a‰@) ‚É‚š‚¯‚éˆÚsŽx‰‡ƒ`[ƒ€‚Ì–ðŠ„‚ÆŠˆ“®‚ÌŽÀÛ. â“Œ—R‹I1,2, (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2¬Ž™): ‘æ29‰ñ“ú–{¬Ž™ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï (2019/10/4-6), ŽD–y.

722092. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yÀ’·z¬Ž™ƒŠƒEƒ}ƒ`ˆã‚ð‚‚¯‚é‚œ‚߂ɃLƒƒƒŠƒAŒ`¬‚ƃvƒƒtƒFƒbƒVƒ‡ƒiƒŠƒYƒ€‚ð‚Ç‚€l‚Š‚é? â“Œ—R‹I1,2, (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2¬Ž™): ‘æ29‰ñ“ú–{¬Ž™ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï (2019/10/4-6), ŽD–y.

722093. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yÀ’·z‘œÊ‚ÈŽ©ŒÈ‰ŠÇ«ŽŸŠ³‚ð•R‰ð‚­. â“Œ—R‹I1,2, (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2¬Ž™): ‘æ29‰ñ“ú–{¬Ž™ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï (2019/10/4-6), ŽD–y.

722094. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‘œÊ‚ÈŽ©ŒÈ‰ŠÇ«ŽŸŠ³‚ð•R‰ð‚­Type I Interferonopathy. ]”gŒËF•ã1, ‹àŽq‰ë‹I1, â“Œ—R‹I1,2, Î‘qŒ’Ži1 (1¬Ž™, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ29‰ñ“ú–{¬Ž™ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï (2019/10/4-6), ŽD–y.

722095. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) “«ìè•a‚ɑ΂·‚éƒXƒeƒƒCƒhƒpƒ‹ƒX•¹—p—Ö@‚ð—p‚¢‚œŽ¡—Ð헪`“–‰@‚Å‚ÌŒ€‹†¬‰Ê‚𓥂܂Š‚ā`. ]”gŒËF•ã (¬Ž™): ‘æ39‰ñ“ú–{ìè•aŠw‰ïEŠwpW‰ï (2019/10/25-26), “Œ‹ž.

723375. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Trends in morbidity and mortality in 22-24 weeks from 2003-2012: A retrospective cohort study in Neonatal Research Network, Japan (NRNJ). ’†ŒG•F1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2¬Ž™): ‘æ122‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï (2019/4/19-21), ‹à‘ò.

723376. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) NRNJ10”NŠÔ‚̉ðÍ‚É‚æ‚é‹É’áo¶‘̏dŽ™‚É‚š‚¯‚é”sŒŒÇ‚Ì•p“x‚ÆŠÖ˜AˆöŽq. ‘åé@œ, ’†ŒG•F1,2, “í“c@‘ (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2¬Ž™): ‘æ122‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï (2019/4/19-21), ‹à‘ò.

723377. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) •s‘SŒ^CantrelÇŒóŒQ‚É‹}«‘Oœ‘‹…«”’ŒŒ•a (APL) ‚𔭏ǂµ‚œŠw“¶‚̈ê—á. çݎ@Šw1, ]”gŒËF•ã1, ŒŽŒûŒ[”V‰î1, ’†‘º@q, Œã“¡—T–Ÿ, ’†ŒG•F1,2 (1¬Ž™, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ122‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï (2019/4/19-21), ‹à‘ò.

723378. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) IgAŒŒŠÇ‰Š‚̃XƒeƒƒCƒhˆË‘¶«‚Ì• •”Çó‚ɃAƒUƒ`ƒIƒvƒŠƒ“‚ª—LŒø‚Å‚ ‚Á‚œ2—á. ‰Á”[—DŽ¡, ¬–ž‰ë•v, ŒŒ’‘Ÿ˜N, ‹àX@“§, ‰œ’Ôü‰Ä, Î˜a@ãÄ, ²“¡@•‘, ‹TˆäGˆê, ‹gŒŽd”ü, Î‘qŒ’Ži1 (1¬Ž™): ‘æ122‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï (2019/4/19-21), ‹à‘ò.

723379. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –Ɖu—}§–ò‚␶•šŠw“I»ÜŽg—p‰º‚ł̐¶ƒƒNƒ`ƒ“ÚŽí‘S‘ŽÀ‘Ô’²ž. ‹TˆäGˆê, ‹{“ü@—ó, ¯ŽiŒ’‰î, ²ŒÃ‚Ü‚ä‚Ý, ’†‘ºG•¶, Î‘qŒ’Ži1 (1¬Ž™): ‘æ122‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï (2019/4/19-21), ‹à‘ò.

723380. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) MFN2ƒwƒeƒÚ‡‘̕ψق𔺂€Charcot-Marie-tooth•a‚ɍRMDA5R‘Ì—z«‚ÌŽá”N«”畆‹Ø‰Š‚ð‡•¹‚µ‚œ1—á. ‹àX@“§, ¬–ž‰ë•v, ŒŒ’‘Ÿ˜N, ‰œ@”ü, Î˜a@ãÄ, ²“¡@•‘, ‹TˆäGˆê, ˆÉ“¡Gˆê, Î‘qŒ’Ži1 (1¬Ž™): ‘æ122‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï (2019/4/19-21), ‹à‘ò.

723381. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬Ž™“Á”­«ƒlƒtƒ[ƒ[ÇŒóŒQŠ³ŽÒ‚̃XƒeƒƒCƒhŽ¡—Ì㕛t‹@”\•]‰¿. ŒŽ“c—ÁŽq, ‹e‰i‰ÀD, ‹TˆäGˆê, à_“c@—€, ‰i“c—TŽq, Ž›–ìçŽq, ²“¡@•‘, ¬–ž‰ë•v, Œã“¡³”Ž, ’·’Jìs—m, ˆÀ“¡‚Žu, ”Š’J_Žj, Î‘qŒ’Ži1, –{“c‰ëŒh (1¬Ž™): ‘æ122‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï (2019/4/19-21), ‹à‘ò.

723382. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “û—cŽ™Šú‚É”­Ç‚µ‚œ“«“€áŒ—l”ç]‚Ì2Ç—á. ]”gŒËF•ã1, â“Œ—R‹I1,2 (1¬Ž™, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ122‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï (2019/4/19-21), ‹à‘ò.

723383. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬Ž™Šú”­ÇtŽŸŠ³Š³ŽÒ‚ÌŽŸŠ³—‰ð, Ž©—§“x‚͐¬lŠú”­ÇŠ³ŽÒ‚Æ“¯“™‚Å‚ ‚é. Ž›–ìçŽq, ”Š’J_Žj, ‹v•Û“c˜j, ˆäŒû’q—m, ‹e‰i‰ÀD, ŒŽ“c—ÁŽq, à_“c@—€, à_@—SŽq, Î‘qŒ’Ži1, –{“c‰ëŒh (1¬Ž™): ‘æ122‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï (2019/4/19-21), ‹à‘ò.

723384. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) V¶Ž™Šú‚ɐt‹@”\áŠQ‚ð’æ‚·‚éæ“V«t”A˜HˆÙí‚É‚š‚¯‚éƒNƒŒƒAƒ`ƒjƒ“’l‚Ɛt—\Œã‚ÌŠÖŒW. ŒŒ’‘Ÿ˜N, ¬–ž‰ë•v, ‹àX@“§, Î˜a@ãÄ, ‰œ’Ôü‰Ä, ²“¡@•‘, ²ŒÃ‚Ü‚ä‚Ý, ŠÐŽR“NÆ, ‹TˆäGˆê, ˆÉ“¡Gˆê, ˆÉ“¡—TŽi, Î‘qŒ’Ži1 (1¬Ž™): ‘æ122‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï (2019/4/19-21), ‹à‘ò.

723385. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@PICU‚É‚š‚¯‚鏬Ž™dÇŠ³ŽÒŒ}‚Š”À‘—‚ÌŽÀ‘Ô. •ô”öŒb—œ1, ˆÀ“¡@Žõ1, “c‘º—C•œ1, ©@L–ç1,2, ‹àŽq’‰O, Î‘qŒ’Ži1 (1¬Ž™, 2‹~–œ): ‘æ122‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï (2019/4/19-21), ‹à‘ò.

723386. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŒŒð«”÷¬ŒŒŠÇáŠQÇ‚𔭏ǂµ‚œ‘Sg«ƒGƒŠƒeƒ}ƒg[ƒfƒX—lÇŒóŒQ‚Ì“ûŽ™—á. –©@‰‘Žq, “c’†—Yˆê˜Y, “c”šŒ’Žm˜Y, ŒŒ’‘Ÿ˜N, Îì‘žŽm, ¬–ž‰ë•v, ‰Í‡—˜®, Î‘qŒ’Ži1, ŒE“c@–ž, Î•@ž (1¬Ž™): ‘æ122‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï (2019/4/19-21), ‹à‘ò.

723387. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) NP«”x‰Š‹…‹ÛŠŽõÇ‚©‚犎õ«S“à–Œ‰Š‚ð‹N‚±‚µ‚œ‘å“®–¬kóÇ‚Ì—cŽ™—á. ‚—œ@Šw1, âV–؍G•¶1, øw“c¹Žq, –{“c@’1, –Ø‘ºƒl1, ›–{Œ’Ži1, •ŸŒ‘ô^2, ‹{–{—²Ži2, ‹{’n@ŠÓ2, X@‘PŽ÷1,3, æèG–Ÿ1,4, Î‘qŒ’Ži1 (1¬Ž™, 2S‘ŸŒŒŠÇŠO, 3–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 4V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ122‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï (2019/4/19-21), ‹à‘ò.

723388. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚ÅŠJÝ‚µ‚œ¬Ž™ƒAƒŒƒ‹ƒM[‰fŠO—ˆ‚ðU‚è•Ô‚Á‚Ä. Î“cãēñ1, ®–ì@Žõ1,2, “¡–{‚Ü‚ä1,2, ˆîŠ_@“µ1,2, ‘å’JŽF1, Ž…r–Ÿ1 (1‘Š–ÍŒŽ‹Š“¯•a‰@, 2¬Ž™): ‘æ122‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï (2019/4/19-21), ‹à‘ò, “ú–{¬Ž™‰ÈŠw‰ïŽGŽ 2019/2; 123 (2): 428.

723389. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚š‚¯‚éH•šŒoŒû•‰‰×ŽŽŒ±—z«—á‚ÌŒŸ“¢(‰ï‹c˜^) ®–ì@Žõ1,2, Î“cãēñ2, “¡–{‚Ü‚ä1,2, ˆîŠ_@“µ1,2, ‘å’JŽF2 (1¬Ž™, 2‘Š–ÍŒŽ‹Š“¯•a‰@): ‘æ122‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï (2019/4/19-21), ‹à‘ò, “ú–{¬Ž™‰ÈŠw‰ïŽGŽ 2019/2; 123 (2): 429.

723390. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒRƒbƒgƒ“ƒ‰ƒbƒg‚ւ̃€ƒ“ƒvƒXƒEƒCƒ‹ƒXŒo•@ÚŽí‚ƖƉuŒŽ«•]‰¿. ˆÉ“¡®Žu1, ŽR˜HËW, àV“c¬Žj, ’†ŽR“N•v (1¬Ž™): ‘æ60‰ñ“ú–{—Տ°ƒEƒCƒ‹ƒXŠw‰ï (2019/5/25-26), ˆ€’m.

723391. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘ƒó•ªß«Ž…‹…‘̍d‰»ÇColumbia•ª—Þ‚É‚š‚¯‚écollapsing variant‚̗Տ°“IˆÓ‹`. ‰œ’Ôü‰Ä, ‹TˆäGˆê, Î˜a@ãÄ, ²“¡@•‘, ‹àX@“§, ŒŒ’‘Ÿ˜N, ¬–ž‰ë•v, ²ŒÃ‚Ü‚ä‚Ý, ˆÉ“¡Gˆê, ‹`‰ªFŽq, •ûŒª‘Ÿ˜Y, Î‘qŒ’Ži1 (1¬Ž™): ‘æ54‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ïŠwpW‰ï (2019/6/7-8), ‘åã.

723392. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒlƒtƒ[ƒ[ÇŒóŒQ‚ւ̃ŠƒcƒLƒVƒ}ƒu“Š—^Œã‚É, B×–EŒÍŠ‰‚Ì‘J‰„, –³ƒOƒƒuƒŠƒ“ŒŒÇ, ‘œ”­«äFâŠŠ–Œ‰Š, œ‘üˆÛÇ‚𗈂µ‚œˆê—á. ˆÉ“¡Gˆê, ˆî—t@Ê, ’¬“c—T”V, ²“¡@•‘, ¬–ž‰ë•v, Î‘qŒ’Ži1, ‹TˆäGˆê (1¬Ž™): ‘æ54‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ïŠwpW‰ï (2019/6/7-8), ‘åã.

723393. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒŠƒcƒLƒVƒ}ƒu’P‰ñ“Š—^ŒãB×–EŒÍŠ‰’†‚ɍĔ­‚µ‚œ“«ƒlƒtƒ[ƒ[ÇŒóŒQ‚̗Տ°“I“Á’¥. ‹TˆäGˆê, ²“¡@•‘, ‹àX@“§, ‰œ’Ôü‰Ä, Î˜a@ãÄ, ŒŒ’‘Ÿ˜N, ¬–ž‰ë•v, ˆÉ“¡Gˆê, Î‘qŒ’Ži1 (1¬Ž™): ‘æ54‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ïŠwpW‰ï (2019/6/7-8), ‘åã.

723394. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬Ž™tˆÚAŠ³ŽÒ‚Ì’m”\Žw”@tˆÚA‘O“§Í‚Ì—L–³‚É‚æ‚é”äŠr. ‹e‰i‰ÀD, à_“c@—€, œA£@•¶, ”’ª³ˆê˜Y, ”‘@O‹B, _Š_@—C, Ô—äŒhŽ¡, “ì@—T‰À, o—ˆ¹D, ˆäŒû’q—m, ŽOã’Œ˜N, Ž›–ìçŽq, ŒŽ“c—ÁŽq, à_è—SŽq, Î‘qŒ’Ži1, –{“c‰ëŒh (1¬Ž™): ‘æ54‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ïŠwpW‰ï (2019/6/7-8), ‘åã.

723395. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬Ž™Šú”­Ç“«ƒlƒtƒ[ƒ[ÇŒóŒQ‚É‚š‚¯‚郊ƒcƒLƒVƒ}ƒu“Š—^Œã‚ÌT×–EƒTƒuƒZƒbƒg‚̉ðÍ129—á‚ÌŒŸ“¢. ‹àX@“§, ‹TˆäGˆê, ŒŒ’‘Ÿ˜N, ‰œ’Ôü‰Ä, Î˜a@ãÄ, ²“¡@•‘, ¬–ž‰ë•v, ²ŒÃ‚Ü‚ä‚Ý, ‰Í‡—˜®, ˆÉ“¡Gˆê, Î‘qŒ’Ži1 (1¬Ž™): ‘æ54‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ïŠwpW‰ï (2019/6/7-8), ‘åã,

723396. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚š‚¯‚鏬Ž™‘Sg«ƒGƒŠƒeƒ}ƒg[ƒfƒX‚̗Տ°“IŒŸ“¢. ©@L–ç1,2, ’†‘ºM–ç2, Œì‹ÅŽq2, Šâ”g’Œ”ü, ‘åŒF_], Žç‰®r‰î, ‰ÍŒ‹Iº, Î‘qŒ’Ži2 (1‹~–œ, 2¬Ž™): ‘æ54‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ïŠwpW‰ï (2019/6/7-8), ‘åã.

723397. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚š‚¯‚éƒlƒtƒ[ƒ[ó‘Ô‚ð’悵‚œŽ‡”Á•a«t‰Š‚ÌŒŸ“¢. o—ˆ¹D, à_“c@—€, Ô•ôŒhŽ¡, _Š_@—C, ”’ª³ˆê˜Y, ”‘@O‹B, “ì@—T‰À, ˆäŒû’q—m, ‹e‰i‰ÀD, ŽOã’Œ˜N, Ž›–ìçŽq, ŒŽ“c—ÁŽq, à_è—SŽq, Î‘qŒ’Ži1, ”Š’J_Žj, –{“c‰ëŒh (1¬Ž™): ‘æ54‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ïŠwpW‰ï (2019/6/7-8), ‘åã.

723398. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —n˜A‹ÛŠŽõŒ_‹@‚É”­Ç‚µ, ƒXƒeƒƒCƒhÜ‚ƃ^ƒNƒƒŠƒ€ƒX•¹—p‚ª’˜Œø‚ð’悵‚œC3NeF—z«C3t‰Š‚Ì1—á. Œ‘ºçŒbŽq, ›’J‰ël, ¡“c^ˆË, ¬—щë‘ã, ‰L–ì—Tˆê, ‹à–{Ÿ‹`, –k‘º”ŽŽi, àVˆärG, ‰œ“c—Y‰î1, Ë“c@Œª, –ì’Ê°‘å, ”ö“c‚Žu (1¬Ž™): ‘æ54‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ïŠwpW‰ï (2019/6/7-8), ‘åã.

723399. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬Ž™“Á”­«ƒlƒtƒ[ƒ[ÇŒóŒQ‚É‚š‚¯‚éƒCƒ“ƒtƒ‹ƒGƒ“ƒUƒEƒCƒ‹ƒXƒƒNƒ`ƒ“ÚŽí‚ƃlƒtƒ[ƒ[•aš‚Æ‚ÌŠÖ˜A@‘œŽ{Ý‹€“¯Œ€‹†. ÎX^Œá, –x”V“à’qŽq, “¡‘º‡–ç, “ìì«Œá, ŽR‘º’q•F, Œ–쉺‰ÄŽ÷, _‹g’Œ’ˆ, ¬–ž‰ë•v, ŠL“¡—TŽj, –ì’Ê°‘å, ‹TˆäGˆê, Î‘qŒ’Ži1, ”Ñ“‡ˆêœ (1¬Ž™): ‘æ54‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ïŠwpW‰ï (2019/6/7-8), ‘åã.

723400. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒXƒeƒƒCƒh’ïR«ƒlƒtƒ[ƒ[ÇŒóŒQ‚É‚š‚¯‚édÇ‹}«táŠQ: ’PŽ{Ý62—á‚̉ðÍ. Î˜a@ãÄ, ²“¡@•‘, ŒŒ’‘Ÿ˜N, ‹àX@“§, ‰œ’Ôü‰Ä, ¬–ž‰ë•v, ²ŒÃ‚Ü‚ä‚Ý, ‹TˆäGˆê, ˆÉ“¡Gˆê, Î‘qŒ’Ži1 (1¬Ž™): ‘æ54‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ïŠwpW‰ï (2019/6/7-8), ‘åã.

723401. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —Œ‘€”x“®–¬ÇðÇ‚©‚çS”x’âŽ~‚Æ‚È‚Á‚œ“«•p‰ñÄ”­Œ^ƒlƒtƒ[ƒ[ÇŒóŒQ‚Ì1—á. “ì@—T‰À, à_“c@—€, œA£@•¶, ”’ª³ˆê˜Y, ”‘@O‹B, _Š_@—C, Ô•ôŒhŽ¡, o—ˆ¹D, ˆäŒû’q—m, ‹e‰i‰ÀD, Ž›–ìçŽq, ŒŽ“c—ÁŽq, Î‘qŒ’Ži1, ”Š’J_Žj, ã–q@—E, –{“c‰ëŒh (1¬Ž™): ‘æ54‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ïŠwpW‰ï (2019/6/7-8), ‘åã.

723402. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “ûŽ™‘Šú‚ɐAž‚ÝŒ^œ×“®Ší (ICD) Až‚Ý‚ðs‚Á‚œ2—á. “yŠò”ü‹v1, ˆÀ“¡@Žõ1, •ô”öŒb—œ1, –Ø‘ºƒl1, ‚—œ@Šw1, Î‘qŒ’Ži1 (1¬Ž™): ‘æ33‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ïŠwpW‰ï (2019/6/21-22), ‘å‹{.

723403. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒŠƒcƒLƒVƒ}ƒu’P‰ñ“Š—^ŒãB×–EŒÍŠ‰’†‚ɍĔ­‚µ‚œ“«ƒlƒtƒ[ƒ[ÇŒóŒQŠ³ŽÒ‚̗Տ°“I“Á’¥. ‹TˆäGˆê, ²“¡@•‘, ‹àX@“§, ‰œ’Ôü‰Ä, Î˜a@ãÄ, ŒŒ’‘Ÿ˜N, ¬–ž‰ë•v, ˆÉ“¡Gˆê, Î‘qŒ’Ži1 (1¬Ž™): ‘æ62‰ñ“ú–{t‘ŸŠw‰ïŠwp‘‰ï (2019/6/21-23), –ŒŒÃ‰®.

723404. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒGƒvƒXƒ^ƒCƒ“ÇŒóŒQ‚Ì’·Šú—\Œã‚ÉŠÖ‚·‚é’ǐՒ²ž. ŽO‰YŒ’ˆê˜Y, ”’ˆä—zŽq, š “‡LŽ¡, à_“c@—€, Î‘qŒ’Ži1, •ž•”Œ³Žj (1¬Ž™): ‘æ62‰ñ“ú–{t‘ŸŠw‰ïŠwp‘‰ï (2019/6/21-23), –ŒŒÃ‰®.

723405. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬Ž™“Á”­«ƒlƒtƒ[ƒ[ÇŒóŒQ‘S‘‰uŠw’²ž (JP-SHINE study) ƒCƒ“ƒtƒ‹ƒGƒ“ƒUƒEƒCƒ‹ƒXƒƒNƒ`ƒ“‚É‚æ‚éÄ”­Œž­Œø‰Ê. ÎX^Œá, Î‘qŒ’Ži1, ²“¡@•‘, ‹e‰iD, Ž›–ìçŽq, à_è—SŽq, ˆÀ“¡‚Žu, ˆÉ“¡Gˆê, –{“c‰ëŒh (1¬Ž™): ‘æ62‰ñ“ú–{t‘ŸŠw‰ïŠwp‘‰ï (2019/6/21-23), –ŒŒÃ‰®.

723406. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬Ž™“«ƒlƒtƒ[ƒ[ÇŒóŒQ‚ɑ΂·‚郊ƒcƒLƒVƒ}ƒuŽ¡—Âɂš‚¯‚éB×–EŒÍŠ‰‚ÆŠ°‰ðˆÛŽ‚ÌŠÖŒW. à_“c@—€, ”Š’J_Žj, ”‘@O‹B, Ž›–ìçŽq, ŒŽ“c—ÁŽq, à_è—SŽq, Î‘qŒ’Ži1, –{“c‰ëŒh (1¬Ž™): ‘æ62‰ñ“ú–{t‘ŸŠw‰ïŠwp‘‰ï (2019/6/21-23), –ŒŒÃ‰®.

723407. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) f’fƒJƒe[ƒeƒ‹•û–@‚̍H•v‚É‚æ‚é•ïŠ‡“ISŒŒŠÇ‹@”\•]‰¿‚ƏzŠÂ“®‘Ô—‰ð. Œ‘º@s, Šâ–{—mˆê, ÎŒË”Ž—², ‘’J@‘, øw“c¹Žq, –{“c@’1, ‚—œ@Šw1, ›–{Œ’Ži, âV–؍G•¶1, æèG–Ÿ1,2 (1¬Ž™, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ55‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï (2019/6/27-29), ŽD–y.

723408. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) NT/BNP‚ÌFontanŠ³ŽÒ‚É‚š‚¯‚éS•s‘Sƒ}[ƒJ[‚Æ‚µ‚Ä‚Ì—L—p«. –{“c@’1, ‚—œ@Šw1, øw“c¹Žq, âV–؍G•¶1, ›–{Œ’Ži, Šâ–{—mˆê, ÎŒË”Ž—², ‘’J@‘, X@‘PŽ÷1, æèG–Ÿ1,2 (1¬Ž™, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ55‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï (2019/6/27-29), ŽD–y.

723409. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •‰‰×”ñˆË‘¶‚̐V‚µ‚¢Žûk«‚ÌŽw•W`SŽºˆ³Å¬•Ï‰»—Š|Žûk––Šú—eÏŠÖŒW`. ‚—œ@Šw1, âV–؍G•¶1, øw“c¹Žq, –{“c@’1, –Ø‘ºƒl1, ›–{Œ’Ži, X@‘PŽ÷1, æèG–Ÿ1,2 (1¬Ž™, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ55‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï (2019/6/27-29), ŽD–y.

723410. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ’PˆêS”‚©‚çŽûk––Šúˆ³—eÏŠÖŒW‚ð‹‚ß‚éŽaV‚È•û–@. ‚—œ@Šw1, âV–؍G•¶1, øw“c¹Žq, –{“c@’1, –Ø‘ºƒl1, ›–{Œ’Ži, X@‘PŽ÷1, æèG–Ÿ1,2 (1¬Ž™, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ55‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï (2019/6/27-29), ŽD–y.

723411. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Post tolvaptan era‚Ì‚€‚ÁŒŒ‰ðœíp`¬Ž™‚É‚š‚¯‚éƒgƒ‰ƒZƒ~ƒh, ƒgƒ‹ƒoƒvƒ^ƒ“‚ÌŒø‰Ê`. ‚—œ@Šw1, âV–؍G•¶1, øw“c¹Žq1, •ŸŒ‘ô^2, Šâ–{—mˆê, ›–{Œ’Ži, ÎŒË”Ž—², ‘’J@‘, ‹{–{—²Ži2, ‹{’n@ŠÓ2, æèG–Ÿ1,3 (1¬Ž™, 2S‘ŸŒŒŠÇŠO, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ55‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï (2019/6/27-29), ŽD–y, “ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ 2019/6; 35 (Suppl 1): s1-128.

723412. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’†SÃ–¬ˆ³‚Ì’á‚¢FontanpŒã’`”’˜Ro«ˆÝ’°Ç‚ɑ΂·‚鎡—Ð헪. ‚—œ@Šw1, âV–؍G•¶1, øw“c¹Žq, •ŸŒ‘ô^2, ›–{Œ’Ži, ‹{–{—²Ži2, ‹{’n@ŠÓ2, æèG–Ÿ1,3 (1¬Ž™, 2S‘ŸŒŒŠÇŠO, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ55‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï (2019/6/27-29), ŽD–y, “ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ 2019/6; 35 (Suppl 1): s1-387.

723413. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘å“®–¬•Âœ‚𔺂€Š®‘S‘匌ŠÇ“]ˆÊÇ|‘ÙŽ™zŠÂ‚Əo¶ŒãŒo‰ß‚©‚ç‚̍lŽ@|. øw¹Žq1, âV–؍G•¶1, ‚—œ@Šw1, •ŸŒ‘ô^2, ›–{Œ’Ži, ‹{–{—²Ži2, ‹{’n@ŠÓ2, æèG–Ÿ1,3 (1¬Ž™, 2S‘ŸŒŒŠÇŠO, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ55‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï (2019/6/27-29), ŽD–y, “ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ 2019/6; 35 (Suppl 1): s1-394.

723414. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚ÌPD“±“üŠ³ŽÒ70–Œ‚ÌŒŽŽŸŠ³E“±“üŽž”N—îE—\Œã. ‹TˆäGˆê, ‹àX@“§, ‰œ’Ôü‰Ä, Î˜a@ãÄ, ŒŒ’‘Ÿ˜N, ²“¡@•‘, ¬–ž‰ë•v, Î‘qŒ’Ži1 (1¬Ž™): ‘æ64‰ñ“ú–{“§ÍˆãŠw‰ïŠwpW‰ïE‘‰ï (2019/6/28-30), ‰¡•l.

723415. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) pŒã‡•¹Ç‚©‚ç‚Ý‚œ–¢nŽ™“®–¬ŠÇŠJ‘¶Ç‚ɑ΂·‚éŠO‰È“IŽ¡—Éî“üŽžŠú‚ÌŒŸ“¢. Î“c@Ži1, ŽRŒûˆ»”T1, ‘剪–ƒ—1, çݎ@Šw1, ’†ŒG•F1,2, ‹{’n@ŠÓ3 (1¬Ž™, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3S‘ŸŒŒŠÇŠO): ‘æ55‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŠwpW‰ï (2019/7/13-15), ’·–ì, “ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŽGŽ 2019/7; 55 (2): 476.

723416. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚ŒŒ“œ‹Ù‹}Ç‚𔭏ǂµ‚œMELAS‚Ì3Ç—á‚ÌŒŸ“¢. “yŠò@•œ1, –{‹Ž—TŽq, Z—F“TŽq, ’|‰ºŠG—¢, ÎŽRº•F, ¬–qG•¶, ’†ì‰h“ñ, ²X–ؐªs (1¬Ž™): ‘æ45‰ñ“ú–{dÇSgáŠQŠw‰ïŠwpW‰ï (2019/9/20-21), ‰ªŽR.

723417. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) 22q11.2Œ‡ŽžÇŒóŒQ‚ɍ‡•¹‚µ‚œŽá”N«“Á”­«ŠÖß‰Š‚Ì1—á. •Ÿ“c~“Þ, ]”gŒËF•ã1 (1¬Ž™): ‘æ29‰ñ“ú–{¬Ž™ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï (2019/10/4-6), ŽD–y.

723418. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Â”NŠútˆÚA‚Ə‰‰ñ‹y‚Ñ‚»‚̌㕡”‰ñ‚̈ڐAt‘rŽžƒŠƒXƒN, Ž€–S‚ÌŠÖ˜A. ‰œ“c—Y‰î1, Î‘qŒ’Ži1, ƒGƒ‰ƒjEƒXƒgƒŒ[ƒWƒƒ, ƒJƒ€EƒJƒ‰ƒ“ƒ^[ (1¬Ž™): ‘æ55‰ñ“ú–{ˆÚAŠw‰ï‘‰ï (2019/10/10-12), L“‡.

723419. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ìè•a‚̐f’fŠî€‚ð–ž‚œ‚µ‚œHPVB19ŠŽõÇ‚Ì1—á. ŠÖ’J—¢‰À1, ]”gŒËF•ã1, ‘Œ (1¬Ž™): ‘æ39‰ñ“ú–{ìè•aŠw‰ïEŠwpW‰ï (2019/10/25-26), “Œ‹ž.

723420. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ACTH—Ö@’†‚ɃŒƒWƒIƒlƒ‰”x‰Š‚𔭏ǂµ‚œ“ûŽ™‚̈ê—á. çݎ@Šw1, ‘剪–ƒ—1, –ìX“c–L1, ”’ˆäG’Œ1, ]”gŒËF•ã1, ’†ŒG•F1,2 (1¬Ž™, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ51‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï‘‰ïEŠwpW‰ï (2019/10/26-27), ˆ®ì, “ú–{¬Ž™ŠŽõÇŠw‰ï‘‰ï¥ŠwpW‰ïƒvƒƒOƒ‰ƒ€¥Ž˜^W 2019; 51: 269.

723421. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Eculizumab“Š—^Œã‚ÌKlebsiella pneumoniae‹ÛŒŒÇ. ¬ì‰p‹P, ¯ŽiŒ’‰î, ²“¡@•‘, Î‘qŒ’Ži1, Š}ŒŽŒQ¶, ‹{“ü@—ó (1¬Ž™): ‘æ51‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï‘‰ïEŠwpW‰ï (2019/10/26-27), ˆ®ì.

723422. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ¬Ž™ƒAƒŒƒ‹ƒM[Š³ŽÒ‘î‚̊‹«®”õ‚É‚æ‚éƒ_ƒj‹y‚у_ƒjƒAƒŒƒ‹ƒQƒ“‰ñ”ð‚ƏǏó‰ü‘P‚Ì‚œ‚ß‚Ì’²žŒ€‹†. â“Œ—R‹I1,2, ‘Œ (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2¬Ž™): ‘æ56‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŠwp‘å‰ï (2019/11/2-3), ç—t.

723423. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚š‚¯‚éu’·ˆø‚­ŠPvf—Â̌»ó. “ì–쏉 (¬Ž™): ‘æ52‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï (2019/11/15-16), Ž­Ž™“‡.

723424. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) A“ª‹CŠÇ•ª—£pŒã‚É‹CŠÇ˜r“ª“®–¬á‘‚𔭏ǂµ‹~–œ‚µ“Ÿ‚œˆê—á. ‹ËŒË—Y‹I, “ì–쏉1 (1¬Ž™): ‘æ52‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï (2019/11/15-16), Ž­Ž™“‡.

723425. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –³‹C”x‚ðŒJ‚è•Ô‚·Ç—á‚ɑ΂µ•a‰@, Ž{Ý, –K–âƒXƒ^ƒbƒt‚̌ċzƒPƒA‚𓝈ꂷ‚邱‚Æ‚ª—LŒø‚Å‚ ‚Á‚œ1—á. ‘å‹È³Ž÷, “ì–쏉1 (1¬Ž™): ‘æ52‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï (2019/11/15-16), Ž­Ž™“‡.

723426. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • ‰çˆÊ—Ö@‚ª—LŒø‚Ÿ‚Á‚œcŠu‹CŽî‚𔺂€ƒCƒ“ƒtƒ‹ƒGƒ“ƒUA”x‰Š‚Ì1—cŽ™—á. ‹àŽq’‰O1, ã“cN‹v, •ô”öŒb—œ2, ˆÀ“¡@Žõ2, Î—§œl, •Ÿ“‡’‹`, ŒŽ@^l, ”~ŒŽ@ŽÀ, Î‘qŒ’Ži2 (1Œö—§’uŽ’‘‡•a‰@‹~‹}‰È, 2¬Ž™): ‘æ52‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï (2019/11/15-16), Ž­Ž™“‡.

723427. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) LoweÇŒóŒQ‚Ì’·Šú“It—\Œã‚ÉŠÖ‚·‚錟“¢. –÷“à’q˜N, Î˜a@ãÄ, ŽO‰YŒ’ˆê˜Y, ’£“c@–L, Î’ˊ쐢L, _“cËˆê˜Y, ²“¡“ÖŽu, ˆé“‡@‹, à_“c@—€, Î‘qŒ’Ži1, ŒÜ\—’—², •ž•”Œ³Žj (1¬Ž™): ‘æ41‰ñ“ú–{¬Ž™t•s‘SŠw‰ïŠwpW‰ï (2019/11/28-29), ‚’m.

723428. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰)uHFO‚ÌŠî‘b‚ƍŋ߂̒ª—¬vHFO‚É‚æ‚éCLDŠÇ—‚ðlŽ@‚µ‚æ‚€`—\–h‚©‚çd—vŽ–—á‚ÌŽ¡—Â܂Ł`. ’†ŒG•F1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2¬Ž™): ‘æ22‰ñV¶Ž™ŒÄ‹z—Ö@Eƒ‚ƒjƒ^ƒŠƒ“ƒOƒtƒH[ƒ‰ƒ€ (2020/2/13-15), ’·–ì.

723429. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) PIƒJƒe[ƒeƒ‹ƒVƒ‡[ƒgƒ^ƒCƒv‚Ì—L—p«‚ɂ‚¢‚Ä: PIƒJƒe[ƒeƒ‹‚̂‚܂ç‚È‚¢˜b`ƒp[ƒgIII`. ’†ŒG•F1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2¬Ž™): ‘æ22‰ñV¶Ž™ŒÄ‹z—Ö@Eƒ‚ƒjƒ^ƒŠƒ“ƒOƒtƒH[ƒ‰ƒ€ (2020/2/13-15), ’·–ì

731030. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) V¶Ž™‚Ì‘Ì‚Ì‚Ý‚©‚œ. ’†ŒG•F1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2¬Ž™): ƒƒfƒBƒJo”ŃZƒ~ƒi[ (2019/5/12), ‘åã.

731031. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ’Ž‘ŽYŽ™‚ÌŠÇ—. ’†ŒG•F1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2¬Ž™): V¶Ž™W’†ƒPƒA”F’èŠÅŒìŽtƒtƒHƒ[ƒAƒbƒvŒ€C (2019/6/15), “Œ‹ž.

731032. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) V¶Ž™‚Ì‘Ì‚Ì‚Ý‚©‚œ. ’†ŒG•F1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2¬Ž™): ƒƒfƒBƒJo”ŃZƒ~ƒi[ (2019/7/27), “Œ‹ž.

731033. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ¬Ž™‚Ì–«t‘Ÿ•a`‰uŠw‚Ɛt‹@”\‚Ì•]‰¿‚ɂ‚¢‚Ä. Î‘qŒ’Ži (¬Ž™): ‘æ358‰ñ“ú–{¬Ž™‰ÈŠw‰ï_“ސ쌧’n•û‰ï (2019/9/21), ‰¡•l.

731034. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) —¯ˆÓ‚·‚ׂ«¬Ž™‚Ì–«tŽŸŠ³‚Æ‘Šú”­Œ©‚Ì‚œ‚߂̐³Šm‚Ȑt‹@”\•]‰¿. Î‘qŒ’Ži (¬Ž™): _“ސ쌧ŠwZtŽŸŠ³ŠÇ—Œ€‹†‰ïu‰‰‰ï (2019/9/28), ‰¡•l.

731035. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ¬Ž™‚Ì•—Ž×. ‰œ“c—Y‰î (¬Ž™): ”MŠCŠwZ•ÛŒ’Œ€C‰ï@Zˆã‚Æ—{Œì‹³—@‚̏W‚¢ (2019/11/12), ”MŠC.

731036. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ƒtƒ[ƒTƒCƒgƒƒgƒŠ[‚ð—p‚¢‚œPBMCs‚Ì–Ô—…“I‰ðÍ: ìè•a‚Ì•a‘Ô‚É”—‚é. ]”gŒËF•ã (¬Ž™): –k—€ìè•aŒ€‹†‰ï (2019/12/7), ‹à‘ò.

731037. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ‚Æ‚±‚Æ‚ñ‚₳‚µ‚¢V¶Ž™ŒÄ‹zŠÇ—‚Ì‚·‚ׂÄ. ’†ŒG•F1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2¬Ž™): ƒƒfƒBƒJo”ŃZƒ~ƒi[ (2019/12/14), ‘åã.

731038. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ¬‚³‚È–œ‚ð‹~‚€ˆÓ–¡. ’†ŒG•F1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2¬Ž™): ‘æ11‰ñ–k—¢‘åŠwˆãŠw•”•‘®V¢‹Iˆã—ÊJ”­ƒZƒ“ƒ^[ƒVƒ“ƒ|ƒWƒEƒ€ (2019/12/15), ‘Š–Í‘å–ì.

732023. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (‹³ˆçu‰‰) H•šƒAƒŒƒ‹ƒM[‚̍ŐVî•ñ‚Æ‚±‚ê‚©‚ç‚Ì–ˆ“ú‚ÉŒü‚¯‚Ä. â“Œ—R‹I1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2¬Ž™): ƒ‘ƒŽsŽqˆç‚ÄŽx‰‡’c‘Ì H•šƒAƒŒƒ‹ƒM[‚ÁŽqŒð—¬‰ï (2019/4/13), ƒ‘ƒ.

732024. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (‹³ˆçu‰‰) “ï•af—ØAŒg‚ÆCKDƒRƒz[ƒg. Î‘qŒ’Ži (¬Ž™): ‹ãB¬Ž™t‘Ÿ•aƒZƒ~ƒi[2019 in Fukuoka (2019/5/11), •Ÿ‰ª.

732025. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (‹³ˆçu‰‰) ˜_•¶‚ð“Ç‚Þ‚Æ‚«‚à‘‚­‚Æ‚«‚à–ð‚É—§‚¶•š“ŒvŠw. Î‘qŒ’Ži1, ‹àŽq“OŽ¡ (1¬Ž™): ‹ãB¬Ž™t‘Ÿ•aƒZƒ~ƒi[2019 in Fukuoka (2019/5/11), •Ÿ‰ª.

732026. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (‹³ˆçu‰‰) ŠwZ‚É‚š‚¯‚é“KØ‚ȐH•šƒAƒŒƒ‹ƒM[EƒAƒiƒtƒBƒ‰ƒLƒV[‘Ήž‚݂̍è•û. â“Œ—R‹I1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2¬Ž™): –k–{Žs‹³ˆçˆÏˆõ‰ï H•šƒAƒŒƒ‹ƒM[EƒAƒiƒtƒBƒ‰ƒLƒV[‘ΉžŒ€C‰ï (2019/8/8), é‹Ê.

732027. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰) ¬Ž™‚ÌCKD‚ƈâ“`«tŽŸŠ³|CAKUT‚𒆐S‚Ɂ|. Î‘qŒ’Ži (¬Ž™): ‘æ2‰ñˆâ“`tŽŸŠ³‚ðl‚Š‚é‰ï (2019/10/4), ‘Š–ÍŒŽ.

732028. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (Žs–¯ŒöŠJuÀ) ƒyƒbƒg‚Æ‚Ì–L‚©‚È•é‚炵‚ð’m‚Á‚Ä‚š‚«‚œ‚¢: ‚±‚±‚Ü‚Å‚í‚©‚Á‚Ä‚¢‚錢E”LƒAƒŒƒ‹ƒM[. â“Œ—R‹I1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2¬Ž™): 2019”N“xŒö‰vŽÐ’c–@l“ú–{“®•š•a‰@‹Š‰ï (JAHA) ”NŽŸ‘å‰ï (2019/10/13-14), “Œ‹ž.

732029. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (‹³ˆçu‰‰) ¬Ž™t—̈æ‚̊󏭁E“«ŽŸŠ³‚ÆCKDƒRƒz[ƒg. Î‘qŒ’Ži (¬Ž™): –kŠC“¹¬Ž™t‘Ÿ•aƒZƒ~ƒi[2019 in Sapporo (2019/11/9), ŽD–y.

732030. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (‹³ˆçu‰‰) ƒƒ“ƒ|ƒCƒ“ƒg“ŒvŠw. Î‘qŒ’Ži1, ‹àŽq“OŽ¡ (1¬Ž™): –kŠC“¹¬Ž™t‘Ÿ•aƒZƒ~ƒi[2019 in Sapporo (2019/11/10), ŽD–y.

732031. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (Žs–¯ŒöŠJuÀ) –¢—ˆ‚ðŽx‚Š‚é (’Ž‘ŽYŽ™AŠwó‹µƒAƒ“ƒP[ƒgŒ‹‰Ê). çݎ@Šw (¬Ž™): ‘æ11‰ñ–k—¢‘åŠwˆãŠw•”•‘®V¢‹Iˆã—ÊJ”­ƒZƒ“ƒ^[ƒVƒ“ƒ|ƒWƒEƒ€ (2019/12/15), ‘Š–Í‘å–ì.

732032. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (‹³ˆçu‰‰) “®•š‰îÝ—Ö@‚ÌŒ»ó‚š‚æ‚ÑŒ€‹†‹³ˆç‚̉ۑè: –k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[‚É‚š‚¯‚é“®•š‰îÝ—Ö@‚ÌŽÀÛ. â“Œ—R‹I1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2¬Ž™): ŠâŽè‘åŠw‘åŠw‰@bˆãŠwŒ€‹†‰ÈŒöŠJƒVƒ“ƒ|ƒWƒEƒ€ (2019/12/4), ŠâŽè.

732033. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (‹³ˆçu‰‰) “–‰@‚Ì–¢Žóf”D•w (“Á’è”D•w) ‚©‚ç‚Ý‚œ—{ŽqE—¢e§“x. çݎ@Šw (¬Ž™): —{Žq‰‘g–¯ŠÔ‚ ‚Á‚¹‚ñ‹@ŠÖ•¬Ž–‹Æ (2020/1/14), “¡‘ò.

732034. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰) ŠwZŒŸ”A: ‚݂‚©‚鎟Š³, Œ©“Š‚·ŽŸŠ³. Î‘qŒ’Ži (¬Ž™): ’¬“cŽsˆãŽt‰ïŠwpu‰‰‰ï (2020/2/19), “Œ‹ž.

733139. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ¬Ž™“§ÍŠ³ŽÒ‚É‚š‚¯‚é, “§Í“±“üŽž‚Ì•¹‘¶Ç‚Æ‚µ‚Ă̍‚ŒŒˆ³‚ÆŽ€–S‚ÌŠÖ˜A. ‰œ“c—Y‰î1, ©@L–ç1,2, Î‘qŒ’Ži1 (1¬Ž™, 2‹~–œ): ‘æ26‰ñ“ú–{¬Ž™‚ŒŒˆ³Œ€‹†‰ï (2019/9/14), “Œ‹ž.

733140. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ìè•a‚ÌŽå—vÇó‚ð’悵‚œ–ƒ]‚Ì1’jŽ™—á. “c‘º—C•œ1, ²“¡‰Á‘ãŽq1, –Ø‘ºƒl1, –¥‰YŽ‘¥1 (1¬Ž™): ‘æ358‰ñ“ú–{¬Ž™‰ÈŠw‰ï_“ސ쌧’n•û‰ï (2019/9/21), ‰¡•l.

733141. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) S•s‘S‚ðŒ_‹@‚É”­Œ©‚³‚ê, “§Í“±“ü‚³‚ê‚œƒlƒtƒƒ“ᔋ^‚¢‚ÌŽvtŠú—Ž™—á. ‰œ“c—Y‰î1, ©@L–ç1,2, Î‘qŒ’Ži1 (1¬Ž™, 2‹~–œ): ‘æ12‰ñ“ú–{¬Ž™CKDŒ€‹†‰ï (2019/9/29), “Œ‹ž.

733142. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) íõF‘Ì—ò«‘œ”­«ùN–Et‚Ì’·Šú—\Œã: ŠÌˆÚA‚ƐtˆÚA‚̐헪. ²“¡@•‘, ‹TˆäGˆê, Î‘qŒ’Ži1, Š}ŒŽŒQ¶ (1¬Ž™): ‘æ33‰ñ“ú–{¬Ž™PDEHDŒ€‹†‰ï (2019/11/1-2), –ŒŒÃ‰®.

733143. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) V¶Ž™Šú‚ɐt‹@”\áŠQ‚ð’æ‚·‚éæ“V«t”A˜HˆÙí‚É‚š‚¢‚ăNƒŒƒAƒ`ƒjƒ“’l‚͐t‹@”\—\Œã—\‘ª‚É—L—p‚©. ŒŒ’‘Ÿ˜N, ¬–ž‰ë•v, ‹àX@“§, Î˜a@ãÄ, ‰œ’Ôü‰Ä, ²“¡@•‘, ²ŒÃ‚Ü‚ä‚Ý, ŠÐŽR“NÆ, ‹TˆäGˆê, ˆÉ“¡Gˆê, ˆÉ“¡—TŽi, Î‘qŒ’Ži1 (1¬Ž™): ‘æ33‰ñ“ú–{¬Ž™PDEHDŒ€‹†‰ï (2019/11/1-2), –ŒŒÃ‰®.

733144. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ƒlƒtƒƒ“á”. ‰œ“c—Y‰î1, ‰œ’Ôü‰Ä, ™–{Œ\‘Š, à_è—SŽq (1¬Ž™): –kŠC“¹¬Ž™t‘Ÿ•aƒZƒ~ƒi[2019 in Sapporo. (2019/11/9-10), ŽD–y.

733145. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “–‰@‚É‚š‚¯‚éìè•af—Ã. ‹{–ì^–ØŽq, “ì–쏉1, –Ø•”“N–ç (1¬Ž™): “ú–{¬Ž™‰ÈŠw‰ïÃ‰ª’n•û‰ï (2019/11/10), Ã‰ª.

733146. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ¬lˆÚsŽx‰‡‚ÌŒ»ó‚Ɖۑè. •œ“c—zˆê˜Y (¬Ž™): ‘æ440‰ñ‘Š–ÍŒŽ¬Ž™‰Èˆã‰ïŒŽ—፧˜b‰ï (2019/11/20), ‘Š–ÍŒŽ.

733147. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ƒXƒeƒƒCƒhŽ¡—ɺ‚ʼnü‘P‚Æ‘ˆ«‚ðŒJ‚è•Ô‚µ‚Ä‚¢‚é‹}«”A×ŠÇŠÔŽ¿«t‰Š‚Ì13Î—Ž™—á. ‰œ“c—Y‰î1, ‹ÚàV—zØ1, ©@L–ç1,2, ’†‘ºM–ç1, Î‘qŒ’Ži1 (1¬Ž™, 2‹~–œ): ‘æ440‰ñ‘Š–ÍŒŽ¬Ž™‰Èˆã‰ïŒŽ—፧˜b‰ï (2019/11/20), ‘Š–ÍŒŽ.

'18”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'18-120001. [ŒŽ’˜] “ÆŽ©‚ɍ쐬‚µ‚œ’²ž•[‚ð—p‚¢‚œ“ú‹A‚è“ü‰@‚̐H•šŒoŒû•‰‰×ŽŽŒ±‚ÉŠÖ‚·‚éˆÓŽ¯’²ž. Î“cãēñ1, •ÄŽRr”V1, ®–ì@Žõ1,2, “¡–{‚Ü‚ä1,2, ˆîŠ_@“µ1,2, ‘å’JŽF1 (1‘Š–ÍŒŽ‹Š“¯•a‰@, 2¬Ž™): “ú–{”_‘ºˆãŠw‰ïŽGŽ 2019/3; 67 (6): 669-77.

'18-540004. [‚»‚Ì‘Œ (Œ€‹†•ñ‘)] IgAtÇ‚Æ”÷¬•Ï‰»Œ^ƒlƒtƒ[ƒ[ÇŒóŒQ‚̐f—ÃKƒCƒhƒ‰ƒCƒ“‚Ì”F’m“x‚ÆŠˆ—pó‹µ‚ÉŠÖ‚·‚éƒAƒ“ƒP[ƒg’²ž‚Ì•ñ. ŽO‰YŒ’ˆê˜Y, ²ŒÃ‚Ü‚ä‚Ý, ˆ°“c@–Ÿ, Î‘qŒ’Ži1, ˆäã@•×, Œã“¡–F[, ¬ŒNG, dŒ@—², ™ŽR@Ä, Ž›–ìçŽq, ’†Œ_ˆê, Œ”ö–­D, ”Š’J_Žj, “¡Œ³ºˆê, ŒüŽR­Žu, ‹g–î–M•F, –{“c‰ëŒh, Šâ–쐳”V, •ž•”Œ³Žj (1¬Ž™): “ú–{t‘ŸŠw‰ïŽ 2019/3; 61 (2): 51-7.

[’˜@‘]

'18-620009. [Šwp‘ (•ª’SŽ·•M)]y“à•ª”åÇŒóŒQ (‘æ3”Å) IV|‚»‚Ì‘Œ‚Ì“à•ª”原Š³‚ðŠÜ‚߂ā| (•Êû“ú–{—Õଠ—̈æ•ÊÇŒóŒQƒVƒŠ[ƒY No.4)zXII. «‹@”\’ቺ‚𔺂€ˆâ“`« (æ“V«) ÇŒóŒQ@2. Denys-DrashÇŒóŒQ, p.480-3. ŒŒ’‘Ÿ˜N, –xì—æŽq, Î‘qŒ’Ži1 (1¬Ž™), “ú–{—Õ଎Ð, “Œ‹ž, 2019/3”­s.

[Šw‰ïEŒ€‹†‰ï“™]

'18-723016. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬Ž™‚É‚š‚¯‚éƒfƒNƒXƒƒfƒgƒ~ƒWƒ“‚ÌŒø‰Ê. •ô”öŒb—œ1, ˆÀ“¡@Žõ1, “c‘º—C•œ1, æèG–Ÿ1,2 (1¬Ž™, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ46‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ï (2019/3/1-3), ‹ž“s.

'18-731002. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ‚Æ‚±‚Æ‚ñ‚₳‚µ‚¢V¶Ž™ŒÄ‹zŠÇ—‚Ì‚·‚ׂÄ. ’†ŒG•F1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2¬Ž™): ƒƒfƒBƒJo”ŃZƒ~ƒi[ (2019/1/12), “Œ‹ž.

'18-733003. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ACTH—Ö@’†‚ɃŒƒWƒIƒlƒ‰”x‰Š‚ÅŽ€–S‚µ‚œWestÇŒóŒQ‚̈ê—á. ”’ˆäG’Œ1, –ìX“c–L1, Î“c—Ï–ç (1¬Ž™): ‘æ61‰ñ_“ސ쏬Ž™_Œo§˜b‰ï (2019/3/2), ‰¡•l.


ŽY‰ÈŠw^•wl‰ÈŠw

[Šwp˜_•¶]

110249. [ŒŽ’˜] Autophagy is a new protective mechanism against the cytotoxicity of platinum nanoparticles in human trophoblasts. Nakashima A, Higashisaka K, Kusabiraki T, Aoki A, Ushijima A, Ono Y, Tsuda S, Shima T, Yoshino O1,2, Nagano K, Yoshioka Y, Tsutsumi Y, Saito S: Sci Rep 2019/4; 9 (1): 5478. (‹g–ì@C1,2: 1ŽY‰È, 2•wl)

110250. [ŒŽ’˜] Serum Brain-derived Neurotrophic Factor Levels Mirror Bone Mineral Density in Amenorrheic and Eumenorrheic Athletes. Nose S, Yoshino O1,2, Nomoto K, Harada M, Dohi M, Kawahara T, Osuga Y, Fujii T, Saito S: Int J Sports Med 2019/4; 40 (4): 276-82. (‹g–ì@C1,2: 1ŽY‰È, 2•wl)

110015. [ŒŽ’˜] VEGF Receptor 1-Expressing Macrophages Recruited from Bone Marrow Enhances Angiogenesis in Endometrial Tissues. Sekiguchi K1, Ito Y2, Hattori K1, Inoue T3, Hosono K2, Honda M4, Numao A1, Amano H2, Shibuya M, Unno N1, Majima M2: Sci Rep 2019/5; 9 (1): 7037. (ŠÖŒû˜aŠé1, ˆÉ“¡‹`–ç2, •ž•”‹¿Žq1, ˆäã’qm3, ×–ì‰Á“ÞŽq2, –{“c‰ëŽq4, À”ö²Žq1, “V–ì‰pŽ÷2, ŠC–ìM–ç1, ”n“ˆ³—²2: 1ŽY‰È, 2–ò—, 3Á‰»Ší“à, 4‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

110251. [ŒŽ’˜] Uterine receptivity, embryo attachment, and embryo invasion: Multistep processes in embryo implantation. Fukui Y, Hirota Y, Matsuo M, Gebril M, Akaeda S, Hiraoka T1, Osuga Y: Reprod Med Biol 2019/5; 18 (3): 234-40. (•œ‰ª‹B‘å1: 1•wl)

110252. [ŒŽ’˜] Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial. Onda T1, Satoh T, Ogawa G, Saito T, Kasamatsu T, Nakanishi T, Mizutani T, Takehara K, Okamoto A, Ushijima K, Kobayashi H, Kawana K, Yokota H, Takano M, Kanao H, Watanabe Y, Yamamoto K, Yaegashi N, Kamura T, Yoshikawa H: Eur J Cancer 2020/5; 130: 114-25. (‰¶“c‹MŽu1: 1•wl)

110253. [ŒŽ’˜] The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1). Murakami R, Matsumura N, Michimae H, Tanabe H, Yunokawa M, Iwase H1, Sasagawa M, Nakamura T, Tokuyama O, Takano M, Sugiyama T, Sawasaki T, Isonishi S, Takehara K, Nakai H, Okamoto A, Mandai M, Konishi I: Gynecol Oncol 2019/5; 153 (2): 312-9. (Šâ£tŽq1: 1•wl)

110254. [ŒŽ’˜] Decreased effector regulatory T cells and increased activated CD4+ T cells in premature ovarian insufficiency. Kobayashi M, Nakashima A, Yoshino O1,2, Yoshie M, Ushijima A, Ito M, Ono Y, Shima T, Kawamura K, Ishizuka B, Saito S: Am J Reprod Immunol 2019/6; 81 (6): e13125. (‹g–ì@C1,2: 1ŽY‰È, 2•wl)

110255. [ŒŽ’˜] Real prevalence of neural tube defects in Japan: How many of such pregnancies have been terminated? Kondo A, Akada S, Akiyama K, Arakawa M, Ichi S, Inamoto Y, Ishida T, Ishikawa H, Itoh T, Izumi A, Kimura F, Kondo AS, Matsuoka R, Miyauchi A, Mochizuki J1, Momohara Y, Morikawa S, Morioka M, Morota N2, Nakabe K, Obayashi S, Oku M, Samura O, Sasahara J, Sase M, Shimamoto K, Shimamura K, Sumigama S, Tada K, Takahashi H, Tani A, Wada S, Wada-HIraike O, Watanabe T, Yamaguchi M, Yasui T, Yokomine M: Congenit Anom (Kyoto) 2019/7; 59 (4): 118-24. (–]ŒŽƒŽq1, Žt“cMl2: 1ŽY‰È, 2”]ŠO)

110256. [ŒŽ’˜] Endoplasmic reticulum stress disrupts lysosomal homeostasis and induces blockade of autophagic flux in human trophoblasts. Nakashima A, Cheng SB, Kusabiraki T, Motomura K, Aoki A, Ushijima A, Ono Y, Tsuda S, Shima T, Yoshino O1,2, Sago H, Matsumoto K, Sharma S, Saito S: Sci Rep 2019/8; 9 (1): 11466. (‹g–ì@C1,2: 1ŽY‰È, 2•wl)

110257. [ŒŽ’˜] PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy. Matsumoto K, Nishimura M, Onoe T, Sakai H, Urakawa Y, Onda T1, Yaegashi N: Jpn J Clin Oncol 2019/8; 49 (8): 703-7. (‰¶“c‹MŽu1: 1•wl)

110258. [ŒŽ’˜] Risk factors of stress fractures due to the female athlete triad: Differences in teens and twenties. Nose-Ogura S, Yoshino O1,2, Dohi M, Kigawa M, Harada M, Hiraike O, Onda T2, Osuga Y, Fujii T, Saito S: Scand J Med Sci Sports 2019/10; 29 (10): 1501-10. (‹g–ì@C1,2, ‰¶“c‹MŽu2: 1ŽY‰È, 2•wl)

110259. [ŒŽ’˜] Sphingosine 1 Phosphate (S1P) Increased IL-6 Expression and Cell Growth in Endometriotic Cells. Yoshino O1,2, Yamada-Nomoto K, Kano K, Ono Y, Kobayashi M, Ito M, Yoneda S, Nakashima A, Shima T, Onda T2, Osuga Y, Aoki J, Saito S: Reprod Sci 2019/11; 26 (11): 1460-7. (‹g–ì@C1,2, ‰¶“c‹MŽu2: 1ŽY‰È, 2•wl)

110260. [ŒŽ’˜] Endometriosis Triggers Excessive Activation of Primordial Follicles via PI3K-PTEN-Akt-Foxo3 Pathway. Takeuchi A, Koga K, Satake E, Makabe T, Taguchi A, Miyashita M, Takamura M, Harada M, Hirata T, Hirota Y, Yoshino O1,2, Wada-Hiraike O, Fujii T, Osuga Y: J Clin Endocrinol Metab 2019/11; 104 (11): 5547-54. (‹g–ì@C1,2: 1ŽY‰È, 2•wl)

110261. [ŒŽ’˜] Quantitative analysis of ovarian cysts and tumors by using T2 star mapping. Takahashi N, Yoshino O1,2, Hayashida E, Nakamura M, Hori M, Iwahata S2, Onda T2, Unno N1, Fujii T, Osuga Y: J Obstet Gynaecol Res 2020/1; 46 (1): 140-6. (‹g–ì@C1,2, Šâ’[r•ã2, ‰¶“c‹MŽu2, ŠC–ìM–ç1: 1ŽY‰È, 2•wl)

110262. [ŒŽ’˜] Levonorgestrel Inhibits Embryo Attachment by Eliminating Uterine Induction of Leukemia Inhibitory Factor. Matsuo M, Hirota Y, Fukui Y, Fujita H, Saito-Fujita T, Kaku T, Gebril M, Hirata T, Akaeda S, Hiraoka T1, Tanaka T, Haraguchi H, Saito-Kanatani M, Shimizu-Hirota R, Takeda N, Fujii T, Osuga Y: Endocrinology 2020/2; 161 (2): bqz005. (•œ‰ª‹B‘å1: 1•wl)

110263. [ŒŽ’˜] IL-33 Exacerbates Endometriotic Lesions via Polarizing Peritoneal Macrophages to M2 Subtype. Ono Y, Yoshino O1,2, Hiraoka T2, Akiyama I, Sato E3, Ito M, Kobayashi M, Nakashima A, Wada S, Onda T2, Unno N1, Osuga Y: Reprod Sci 2020/3; 27 (3): 869-76. (‹g–ì@C1,2, •œ‰ª‹B‘å2, ²“¡ŠG—¢“Þ3, ‰¶“c‹MŽu2, ŠC–ìM–ç1: 1ŽY‰È, 2•wl, 3•a‘ԁEf—ÃŒn3)

120009. [ŒŽ’˜] Žá”NŽq‹{‘ÌŠàÇ—á‚É‚š‚¯‚é—‘‘ƒ‰·‘¶‚̉”\«‚ɂ‚¢‚Ä: Logistic‰ñ‹A•ªÍ‚ð—p‚¢‚œŒŸ“¢. ŒÃ]–ŸŽq1, Šâ£tŽq1, ‰““¡^ˆê1, ŒÃì³‹`1, ²“¡‰p‹M, “cŽG—L‹I1, ‚“c‹±b1, Vˆä³G1, ‰¶“c‹MŽu1 (1•wl): “ú–{•wl‰ÈŽîᇊw‰ïŽGŽ 2019/4; 37 (2): 131-9.

120010. [ŒŽ’˜] Žq‹{èòŠàIB2/IIA2, IIBŠúL”ÄŽq‹{‘S“EpÇ—á‚̗Տ°“IŒŸ“¢‚Æ•úŽËü—Ö@Ç—á‚Æ‚Ì—\Œã‚Ì”äŠr. ‚“c‹±b1, ‰““¡^ˆê1, ŒÃì³‹`1, “cŽG—L‹I1, ²“¡‰p‹M, Vˆä³G1, Šâ£tŽq1, ‰¶“c‹MŽu1 (1•wl): “ú–{•wl‰ÈŽîᇊw‰ïŽGŽ 2019/10; 37 (4): 723-30.

120011. [ŒŽ’˜] •œ¬30”N“x@_“ސìŽY‰È•wl‰ÈŠw‰ï@•wl‰Èˆ««Žîᇓo˜^WŒv•ñ. Àè—ߎq, ƒ‹ƒCƒY‰¡“c“Þ•ü, ‹g“c@_, ™‰Y Œ«, ‘匎@Ž÷, ‚“c‹±b1, –ؔҍvŽœ, ²X–؍N, •ÄŽR„ˆê, —с@NŽq, •œàV@–Ò, X‰ª@Š², ˆéè‘Ÿˆê, “n粖LŽ¡, ŽOãŠ²’j, ‰Á“¡‹v·, ’†–ìáÁ²’j, —é–؁@’Œ, ‚‹ŽP’j (1•wl): _“ސìŽY‰È•wl‰ÈŠw‰ïŽ 2019/10; 56 (1): 50-8.

310034. [Ç—á•ñ] Prenatal skeletal sonographic findings of Jeune syndrome. Mochizuki J1, Kanai Y1, Onishi Y1, Kishimoto Y, Hata K, Unno N1: Jpn J Med Ultrasonics 2019/12; 46 (6): 551-4. (–]ŒŽƒŽq1, ‹àˆä—Y“ñ1, ‘同—fŽq1, ŠC–ìM–ç1: 1ŽY‰È)

320024. [Ç—á•ñ] —¬ŽYŽèp‚̏p‘OŒŸž‚ðŒ_‹@‚ÉTAFROÇŒóŒQ‚̐f’f‚ÉŽŠ‚Á‚œ1—á. ŽRè@—D1, –]ŒŽƒŽq1, ‘同—fŽq1, ‹g‘º‰ÃL1, ’†‹à˜NŽq1, ŠÖŒû˜aŠé1, Îì—²ŽO1, ‹àˆä—Y“ñ1, ŠC–ìM–ç1 (1ŽY‰È): ŠÖ“Œ˜A‡ŽY‰È•wl‰ÈŠw‰ïŽ 2019/11; 56 (4): 507-13.

320025. [Ç—á•ñ] “Óª‚ðŒ_‹@‚ɐf’f‚ÉŽŠ‚Á‚œƒeƒXƒgƒXƒeƒƒ“ŽY¶Žîᇂ̈ê—á. ŒÜ“‡—T”V1, ‚“c‹±b1, ’†‘ºŠîŠ°2, ‰““¡^ˆê2, ŒÃì³‹`2, “cŽG—L‹I2 ²“¡‰p‹M, Vˆä³G2, Šâ£tŽq2, ‰¶“c‹MŽu2, ŠC–ìM–ç1 (1ŽY‰È, 2•wl): _“ސìŽY‰È•wl‰ÈŠw‰ïŽ 2020/2; 56 (2): 13-8.

320026. [Ç—á•ñ] “–‰@‚É‚š‚¯‚é”~“ō‡•¹”DP‚Ì3—á. Œ“‡ƒˆê1, ’†‘ºŠîŠ°2, HŽRŠG—¢Žq1,3, ÎˆäŠG从q, ª’ÍK•ä1, ‹v“ˆ‘¥s3, ŽO–Ø–Ÿ“¿1,3 (1ŽY‰È, 2•wl, 3–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): é‹ÊŽY‰È•wl‰ÈŠw‰ïŽGŽ 2020/3; 50 (1): 26-32.

410002. [—Տ°ŽŽŒ±] The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1). Murakami R, Matsumura N, Michimae H Tanabe H, Yunokawa M, Iwase H1, Sasagawa M, Nakamura T, Tokuyama O, Takano M, Sugiyama T, Sawasaki T, Isonishi S, Takehara K, Nakai H, Okamoto A, Mandai M, Konishi I: Gynecol Oncol 2019/5; 153 (2): 312-9. (Šâ£tŽq1: 1•wl)

522064. [uÀ]y“ÁW: ŽüŽYŠú‚ƈã—ÈÀ‘SzŠe˜_ [ŽY‰È]@–³’É•ª•Ø. ŠC–ìM–ç (ŽY‰È): ŽüŽYŠúˆãŠw 2019/5; 49 (5): 696-701.

522065. [uÀ]y‘æ63‰ñŠwpW‰ïu‰‰˜^z‹³ˆçu‰‰: ˆãŽt‚Ì“­‚«•û‰üŠv‚ÆŽüŽYŠúˆã—Ã. ŠC–ìM–ç (ŽY‰È): “ú–{V¶Ž™¬ˆçˆãŠw‰ïŽGŽ 2019/6; 31 (2): 356-8.

522066. [uÀ] y“ÁW: ˆÀ‘S‚ňÀS‚È–³’É•ª•Ø‚ð‹É‚ß‚éz4. –³’É•ª•ØŽž‚Ì‹}‘¬‹•Ø–@. ‹àˆä—Y“ñ (ŽY‰È): ŽY•wl‰È‚ÌŽÀÛ 2019/6; 68 (6): 579-87.

522067. [uÀ]y“ÁW: L‚ª‚éŽq‹{“à–ŒÇ‚̐¢ŠEzIII. •aˆöE•a‘Ԃ̍ŐV’mŒ©@15. Žq‹{“à–ŒÇ‚É‚š‚¯‚é_ŒoˆöŽq. ‹g–ì@C1,2, ‘å{‰êõ, âV“¡@Ž , ‰¶“c‹MŽu2 (1ŽY‰È, 2•wl): ŽY‰È‚Æ•wl‰È 2019/7; 86 (7): 873-7.

522068. [uÀ]y“ÁW: Female genital tract‚ÌŽûk‚ðÄl‚·‚éz”ñ”DPŽž‚É‚š‚¯‚éƒqƒgŽq‹{Žûk‚ÌŠÏŽ@@(1) Žq‹{‹ØŽî‚𔺂€Žq‹{‚ÌŽûk. ‹g–ì@C1,2, ‘å{‰êõ, ‰¶“c‹MŽu2 (1ŽY‰È, 2•wl): HORMONE FRONTIER IN GYNECOLOGY 2019/9; 26 (3): 223-8.

530008. [‚»‚Ì‘Œ (Guidelines)] Guidelines for office gynecology in Japan: Japan Society of Obstetrics and Gynecology (JSOG) and Japan Association of Obstetricians and Gynecologists (JAOG) 2017 edition. Kawaguchi R, Matsumoto K, Akira S, Ishitani K, Iwasaku K, Ueda Y, Okagaki R, Okano H, Oki T, Koga K, Kido M, Kurabayashi T, Kuribayashi Y, Sato Y, Shiina K, Takai Y, Tanimura S, Chaki O, Terauchi M, Todo Y, Noguchi Y, Nose-Ogura S, Baba T, Hirasawa A, Fujii T, Fujii T, Maruyama T, Miyagi E, Yanagida K, Yoshino O1,2, Iwashita M, Maeda T, Minegishi T, Kobayashi H: J Obstet Gynaecol Res 2019/4; 45 (4): 766-86. (‹g–ì@C1,2: 1ŽY‰È, 2•wl)

[’˜@‘]

620060. [Šwp‘ (•ª’SŽ·•M)] yŽY•wl‰È ‹~‹}E“–’Œ ‘Ήžƒ}ƒjƒ…ƒAƒ‹ (—Տ°•wl‰ÈŽY‰È2019”N‘Š§†)z¡III. ŽY‰È•Ò@”DŽYåñ•w‚̍‡•¹ŽŸŠ³‚ւ̑Ώˆ–@@tE”å”AŠíŽŸŠ³ ”A˜HŒ‹Î, p302-5. ‹àˆä—Y“ñ (ŽY‰È), ˆãŠw‘‰@, “Œ‹ž, 2019/4”­s.

620061. [Šwp‘ (•ª’SŽ·•M)]y•wl‰È‚ª‚ñ|Œ€‹†E—Տ°‚̐V“WŠJ (•ÊûEˆãŠw‚Ì‚ ‚ä‚Ý)z—‘‘ƒŠàE—‘ŠÇŠàE• –ŒŠà@17. ã”琫—‘‘ƒŠàE—‘ŠÇŠàE• –ŒŠà: Žèp—Ö@‚̃^ƒCƒ~ƒ“ƒO, p.127. ‰¶“c‹MŽu (•wl), •Ò: ‰Á“¡¹Žq, ˆãŽ•–òo”Å, “Œ‹ž, 2019/5”­s.

620062. [Šwp‘ (•ª’SŽ·•M)]y‹Ù‹}ŽY‰ÈŽèp‚Ì–ƒŒ‚É”õ‚Š‚é ‰ü’ù‘æ2”ŁzIIÍ Ç—á’ñŽŠ@12. ”DPŠÖ˜A‚Ì”]‘²’†, p.174-83. –]ŒŽƒŽq1, ²“¡Œör, ŒG•”rG2, ‰Á“¡—¢ŠG (1ŽY‰È, 2”]ŠO), •Ò: ‰œ•xr”V3, ‰Á“¡—¢ŠG, “V–ì@Š® (3–ƒŒ), Žœ“°o”Å, “Œ‹ž, 2019/11”­s.

[Šw‰ïEŒ€‹†‰ï“™]

712010. [Šw‰ï (‘Û)] (µãٍu‰‰) Infertility Workup Overview in Japan/ Japanese Lipiodol? HSG experience. Yoshino O1,2: International Federation of Fertility Societies (IFFS) Guerbet Conference (2019/4/11-14), Shanghai, China. (‹g–ì@C1,2: 1ŽY‰È, 2•wl)

712011. [Šw‰ï (‘Û)] (µãٍu‰‰) Oil-Soluble Contrast Medium (OSCM) for Hysterosalpingography Modulates Dendritic Cell and Regulatory T Cell Profiles in the Peritoneal Cavity: A Possible Mechanism by Which OSCM Enhances Fertility. Yoshino O1,2, Izumi G, Koga K, Fujii T, Osuga Y: International Federation of Fertility Societies (IFFS) World Congress (2019/4/11-14), Shanghai, China. (‹g–ì@C1,2: 1ŽY‰È, 2•wl)

712012. [Šw‰ï (‘Û)] (ƒVƒ“ƒ|ƒWƒEƒ€) The involvement of Damage-associated molecular patterns (DAMP) and macrophages on the etiology of endometriosis. Yoshino O1,2, Ono Y, Unno N1, Onda T2, Saito S, Osuga Y: the 39th annual meeting of the American Society for Reproductive Immunology (2019/6/12-15), Grand Rapids, USA. (‹g–ì@C1,2, ŠC–ìM–ç1, ‰¶“c‹MŽu2: 1ŽY‰È, 2•wl)

712013. [Šw‰ï (‘Û)] (µ‘ҍu‰‰“™) Water-based, or Oil-based medium for hysterosalpingography (HSG), that is the question. Yoshino O1,2: Taiwan Guerbet Conference (2019/9/23), Taiwan. (‹g–ì@C1,2: 1ŽY‰È, 2•wl)

712014. [Šw‰ï (‘Û)] (ƒVƒ“ƒ|ƒWƒEƒ€) Endometriosis, from where the initial inflammation comes? Yoshino O1,2: the 14th Congress of the International Society for Immunology of Reproduction (ISIR) 2019 (2019/11/15), Nara, Japan. (‹g–ì@C1,2: 1ŽY‰È, 2•wl)

713100. [Šw‰ï (‘Û)] (ˆê”ʉ‰‘è) Efficacy of salvage hysterectomy following radiotherapy for uterine cervical adenocarcinoma. Iwase H1, Furukawa S1, Endo S1 Tazo Y1, Sato H, Takada T1, Arai M1, Onda T1: International Meeting of the Europian Society of Gynaecological Oncology (ESGO 2019) (2019/11/2-5), Athens, Greek. (Šâ£tŽq1, ŒÃì³‹`1, ‰““¡^ˆê1, “cŽG—L‹I1, ‚“c‹±b1, Vˆä³G1, ‰¶“c‹MŽu1: 1•wl)

713101. [Šw‰ï (‘Û)] (ˆê”ʉ‰‘è) The significance of positive peritoneal cytology in G1/G2 endometrioid carcinoma of uterine body. Furukawa S1, Iwase H1, Endo S1, Ohnishi K1, Tazo Y1, Sato H, Takada T1, Arai M1, Yoshino O1,2, Onda T1: International Meeting of the Europian Society of Gynaecological Oncology (ESGO 2019) (2019/11/2-5), Athens, Greek. (ŒÃì³‹`1, Šâ£tŽq1, ‰““¡^ˆê1, ‘同Œ«l1, “cŽG—L‹I1, ‚“c‹±b1, Vˆä³G1, ‹g–ì@C1,2, ‰¶“c‹MŽu1: 1•wl, 2ŽY‰È)

721013. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ÐŠQŽž¬Ž™ŽüŽYŠúƒŠƒGƒ]ƒ“˜A—‹Š‹c‰ï. ŠC–ìM–ç (ŽY‰È): ‘æ71‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2019/4/14), –ŒŒÃ‰®.

721014. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ŽüŽYŠúˆã—ÁE•ÛŒ’‚É‚š‚¯‚éˆãŽt‚Ə•ŽYŽt‚̘AŒg. ŠC–ìM–ç (ŽY‰È): 2019”N“x“ú–{•ŽYŽt‰ï‘‰ïE‘æ75‰ñ“ú–{•ŽYŽtŠw‰ï (2019/5/25), “È–Ø.

721015. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) •wl‰È—ǐ«ŽŸŠ³‚É‚š‚¯‚éŽèp“K‰žÇ—á‚Ì‘I’è‚ð–ÚŽw‚µ‚Ä. ‹g–ì@C1,2, ‰¶“c‹MŽu1, ‘å{‰êõ (1ŽY‰È, 2•wl): JSAWI 2019 (2019/9/7), •ºŒÉ.

721016. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) Patient-centered medicine‚©‚ç‚Ý‚œŒŽŒo¢“ïÇ. ‹g–ì@C1,2 (1ŽY‰È, 2•wl): ‘S‘ƒWƒFƒ~[ƒiWEBu‰‰‰ï (2020/3/2), WEBu‰‰.

722096. [Šw‰ï (‘S‘)] (Žw“±ˆãuK‰ï)uŽY•wl‰Èˆã‚Ì“­‚«•û‰üŠv@éŒŸ‚Æ’ñŒŸv‚ɂ‚¢‚Ä. ŠC–ìM–ç (ŽY‰È): ‘æ71‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2019/4/14), –ŒŒÃ‰®.

722097. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŽY•wl‰Èˆã‚Ì—§ê‚Å, “ú–{ŽÐ‰ï‚Ì’†‚Å‚ÌNIPT‚Ì‚ ‚è•û‚ɂ‚¢‚čl‚Š‚é. ŠC–ìM–ç (ŽY‰È): ‘æ55‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŠwpW‰ï (2019/7/14), Œ–{.

722098. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŽüŽYŠúˆã—Âɂš‚¯‚é“­‚«•û‰üŠv‚̉ۑè. ŠC–ìM–ç (ŽY‰È): ‘æ55‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŠwpW‰ï (2019/7/14), Œ–{.

722099. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ÐŠQŽž‚É•êŽq‚ðŽç‚é‚œ‚ß‚ÌŽæ‚è‘g‚݁|•œŽž‚̏€”õ‚Æ”­ÐŽž‚̑Ήž‚ɂ‚¢‚ā|. ŠC–ìM–ç (ŽY‰È): ‘æ55‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŠwpW‰ï (2019/7/15), Œ–{.

722100. [Šw‰ï (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) r‘åÐŠQ‚ɑ΂·‚éê–åf—Ã‰È (Šw‰ï) ‚̑ΉžƒVƒXƒeƒ€‚ÌŒ»ó‚Æ–¢—ˆ. ŠC–ìM–ç (ŽY‰È): ‘æ25‰ñ“ú–{ÐŠQˆãŠw‰ï‘‰ïEŠwpW‰ï (2020/2/21), _ŒË.

722101. [Šw‰ï (‘S‘)]yƒVƒ“ƒ|ƒWƒEƒ€2: —‘‘ƒ‚ª‚ñŽèp|“K³‚ÈŽèp‚̃^ƒCƒ~ƒ“ƒO‚Ɛ؏œ”͈́zÄ”­—‘‘ƒŠà‚ɑ΂·‚éSDS‚̈Ӌ`. ‰¶“c‹MŽu (•wl): ‘æ42‰ñ“ú–{ŽY•wl‰ÈŽèpŠw‰ï (2020/2/22), ‹ž“s.

722102. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŽŸ‘ã‚ð’S‚€•ŽYŽt‚É‹‚ß‚ç‚ê‚鎑Ž¿‚Æ‚Í. ŠC–ìM–ç (ŽY‰È): ‘æ34‰ñ“ú–{•ŽYŠw‰ïŠwpW‰ï (2020/3/20-22), webŠJÃ.

723430. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) PUBS‚ÌŒ‹‰Ê‚ÅŒJ‚è•Ô‚µ‘ÙŽ™Ž¡—Âðs‚Á‚œ‘ÙŽ™bó‘BŽî5Ç—á‚ÌŒŸ“¢. ˆ¢•”@‰1, ‹àˆä—Y“ñ1, ‘同—fŽq1, ‹g‘º‰ÃL1, ’†‹à˜NŽq1, ŠÖŒû˜aŠé1, Îì—²ŽO1, –]ŒŽƒŽq1, ŠC–ìM–ç1 (1ŽY‰È): ‘æ71‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2019/4/13), –ŒŒÃ‰®.

723431. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ‘å‹K–͐kÐ‚É”õ‚Š‚œ’nˆæŽüŽYŠúˆã—Ñ̐§®”õ‚Ö‚ÌŽæ‚è‘g‚Ý. •ž•”‹¿Žq1, –]ŒŽƒŽq1, …’J”ü‹M, ‰Í–ìÆŽq1, Vˆä@“w2, “à“c”\ˆÀ, çݎ@–«, Ö“¡@Ž, ’·’Jì„Žu, ŠC–ìM–ç1 (1ŽY‰È, 2•wl): ‘æ71‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2019/4/13), –ŒŒÃ‰®.

723432. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ”DP‰Šú‚ɐ[•”Ã–¬ŒŒðÇ‚𔭏ǂµ‚œ7Ç—á‚ÌŒŸ“¢. ¬“‡@ˆè1, ‘同—fŽq1, ŠÖŒû˜aŠé1, Îì—²ŽO1, ’†‹à˜NŽq1, •ž•”‹¿Žq1, ‹g‘º‰ÃL1, ‹àˆä—Y“ñ1, –]ŒŽƒŽq1, ŠC–ìM–ç1 (1ŽY‰È): ‘æ71‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2019/4/13), –ŒŒÃ‰®.

723433. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) Šù‰’鉀ØŠJŒãŒoäT•ª•ØŽŽs—á‚É‚š‚¯‚é–³’É•ª•Ø•¹—p‚̉e‹¿. ŠÖŒû˜aŠé1, –]ŒŽƒŽq1, ‹g‘º‰ÃL1, •ž•”‹¿Žq1, ’†‹à˜NŽq1, Îì—²ŽO1, ‘同—fŽq1, ‹àˆä—Y“ñ1, ŠC–ìM–ç1 (1ŽY‰È): ‘æ71‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2019/4/13), –ŒŒÃ‰®.

723434. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) Žq‹{èò•”‘BŠà‚ɑ΂·‚铯Žž‰»Šw•úŽËü—Ç”\‚ÉŠÖ‚·‚é‘œŽ{Ý‹€“¯’²žŒ€‹†. ’·ˆä@—T, ŽOãŠ²’j, •ŒG@F, Šì‘œì—º, ’·”ö¹“ñ, ŒËàVWŽq, Œ”ö@^, ¬—щhm, ¶…^‹I•v, ‹{é‰xŽq, ‰¡“cŽ¡d, Š}Œ—R‰À, Â–Ø—zˆê, Šâ£tŽq1, ŽRŒû@‘, ‰ÕŒŽ@–«, ‰¡ŽR³r, ”ªdŠ~L¶, ‘ŽR@Žõ, ’|ŒŽ˜aG, ’†‘ºrº, Â‘§‘å•ã, ‘£—Ç“ñ, ’†‘º˜al, “c”š@–±, ã‰YËŽi, Šâ²®”ü, •œàV@–Ò, ™–ì–@L, ‰–‘ò’O—¢, ¬—с@_, ŒŒ³@—², XdŒ’ˆê˜Y, –k@³l, ”ÂŽL–Ÿ, ‹e’r@˜N, ™‰Y^‹|, “¡ŒŽ—tˆê˜Y, “¿ŽR@Ž¡, ‘åÎ“O˜Y, ¬—Ñ—T–Ÿ, “n—˜‰p“¹, …–ì”ü, ‹g“cD—Y, ‘ºã•¶—m, ‚‹ŽŒcs, ‰¡ˆä@–Ò, “茎‹vŽi, ¬Ž›G•œ, ‰¡ŽR—ǐm, ‰«@–Ÿ“T, ’†ŒŒcŠì, …”V]’mÆ, ™ŽR@“O (1•wl): ‘æ71‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2019/4/13), –ŒŒÃ‰®.

723435. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ”DP20TˆÈ‘O‚É”j…‚µ”DP22TˆÈ~‚ɏo¶‚µ‚œ3Ç—á‚Ì“]‹A. ŒÜ“‡—T”V1, ‹g‘º‰ÃL1, ŠÖŒû˜aŠé1, ˆ¢•”@‰1, ŒÜ\”šmŽu1, ’†‹à˜NŽq1, Îì—²ŽO1, ‘同—fŽq1, ‹àˆä—Y“ñ1, –]ŒŽƒŽq1, ŠC–ìM–ç1 (1ŽY‰È): ‘æ71‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2019/4/14), –ŒŒÃ‰®.

723436. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) Žq‹{‘Ì•”—Þ“à–ŒŠàG1‚š‚æ‚ÑG2‚̏p’†• …×–Ef•]‰¿‚ðs‚€—Տ°“IˆÓ‹`. ŒÃì³‹`1, Šâ£tŽq1, “cŽG—L‹I1, ‚“c‹±b1, Vˆä³G1, ‰¶“c‹MŽu1 (1•wl): ‘æ60‰ñ“ú–{—Տ°×–EŠw‰ï‘‰ï (tŠú‘å‰ï) (2019/6/8), “Œ‹ž.

723437. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Two cases of malignant mixed germ cell tumors of ovary in young girls. Mary NHEB, Wakasa T, Kalyan M, Aun K, Yahata H, “cŽG—L‹I1, Šâ£tŽq1, Enoki E, Banno K, Kawai T (1•wl): ‘æ60‰ñ“ú–{—Տ°×–EŠw‰ï‘‰ï (tŠú‘å‰ï) (2019/6/8), “Œ‹ž.

723438. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Peritoneal neoplasm with massive ascites. Vitou L, Kawai T, Wakasa T, Sophana S, Linka K, “cŽG—L‹I1, Šâ£tŽq1, Katayama H, Hiroi S, Enoki E (1•wl): ‘æ60‰ñ“ú–{—Տ°×–EŠw‰ï‘‰ï (tŠú‘å‰ï) (2019/6/8), “Œ‹ž.

723439. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚É‚š‚¯‚éŽq‹{èòŠà‚ɑ΂·‚铯Žž‰»Šw•úŽËü–@‚Ìfeasibility‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‰““¡^ˆê1, ‚“c‹±b1, ŒÃì³‹`1, “cŽG—L‹I1, Vˆä³G1, ‹g–ì@C1,2, Šâ£tŽq1, ‰¶“c‹MŽu1 (1•wl, 2ŽY‰È): ‘æ61‰ñ“ú–{•wl‰ÈŽîᇊw‰ïŠwpu‰‰‰ï (2019/7/4), VŠƒ.

723440. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) Žq‹{èòŠà‚É‚š‚¯‚éD’†‹…/ƒŠƒ“ƒp‹…”ä‚Æ—\Œã‚Æ‚ÌŠÖŒW. “cŽG—L‹I1, Šâ£tŽq1, ‰““¡^ˆê1, ŒÃì³‹`1, ²“¡‰p‹M, ‚“c‹±b1, Vˆä³G1, ‹g–ì@C1,2, ‰¶“c‹MŽu1 (1•wl, 2ŽY‰È): ‘æ61‰ñ“ú–{•wl‰ÈŽîᇊw‰ïŠwpu‰‰‰ï (2019/7/4), VŠƒ.

723441. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) äTŒŽ”­ˆ««•FŽî‚Ì7—á. ¬“‡@ˆè1, “cŽG—L‹I2, ‰““¡^ˆê2, ŒÃì³‹`2, ‚“c‹±b2, Vˆä³G2, ‹g–ì@C1,2, Šâ£tŽq2, ‰¶“c‹MŽu2 (1ŽY‰È, 2•wl): ‘æ61‰ñ“ú–{•wl‰ÈŽîᇊw‰ïŠwpu‰‰‰ï (2019/7/5), VŠƒ.

723442. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) —‘‘ƒŠàÄ”­‰»Šw—Ö@’†‚É”­Ç‚µ‚œƒjƒ…[ƒ‚ƒVƒXƒ`ƒX”x‰Š‚̈ê—á. Žž”CòŒÎ1, Šâ£tŽq2, ‰““¡^ˆê2, ŒÃì³‹`2, “cŽG—L‹I2, ‚“c‹±b2, Vˆä³G2, ‹g–ì@C1,2, ‰¶“c‹MŽu2 (1ŽY‰È, 2•wl): ‘æ61‰ñ“ú–{•wl‰ÈŽîᇊw‰ïŠwpu‰‰‰ï (2019/7/5), VŠƒ.

723443. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ”DPŒãŠú‚©‚çŽYåñŠú‚É‘ª’肵‚œBNP’l‚ƗՏ°Œo‰ß. ‹g‘º‰ÃL1, –]ŒŽƒŽq1, •ž•”‹¿Žq1, ’†‹à˜NŽq1, ŠÖŒû˜aŠé1, ‘同—fŽq1, ‹àˆä—Y“ñ1, ŠC–ìM–ç1 (1ŽY‰È): ‘æ55‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŠwpW‰ï (2019/7/13), Œ–{.

723444. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ‘å‹K–͐kÐ‚ÉŒü‚¯‚œ“–‰@ŽüŽYŠú•êŽqˆã—ÃZƒ“ƒ^[‚ÌŽæ‚è‘g‚Ý. •ž•”‹¿Žq1, –]ŒŽƒŽq1, ‹g‘º‰ÃL1, ŽRŒûˆ»”T2, ’†‹à˜NŽq1, ŠÖŒû˜aŠé1, ‘剪–ƒ—2, Îì—²ŽO1, ‘同—fŽq1, ‹àˆä—Y“ñ1, çݎ@Šw2, ’†ŒG•F2,3, ŠC–ìM–ç1 (1ŽY‰È, 2¬Ž™, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ55‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŠwpW‰ï (2019/7/13-15), ’·–ì, “ú–{ŽüŽYŠú¥V¶Ž™ˆãŠw‰ïŽGŽ 2019; 55 (2): 609.

723445. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “œ”A•a‡•¹”D•w‚Ì”DP‘OŒŒ“œŠÇ—‚ÌŽÀ‘Ô. –]ŒŽƒŽq1, ‘同—fŽq1, çݎ@Šw2, ŽRŒûˆ»”T2, ‘剪–ƒ—2, ‹g‘º‰ÃL1, ’†‹à˜NŽq1, ŒàVW‘ã1, ŠÖŒû˜aŠé1, ‹àˆä—Y“ñ1, ŠC–ìM–ç1 (1ŽY‰È, 2¬Ž™): ‘æ55‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŠwpW‰ï (2019/7/13-15), ’·–ì.

723025. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Žq‹{“à–ŒÇ‚É‚š‚¯‚郊ƒ“ƒpŠÇV¶‚𐧌䂷‚éVEGFR1‚Ì–ðŠ„‰ð–Ÿ. •ž•”‹¿Žq1, ˆÉ“¡‹`–ç2, –{“c‰ëŽq3, ŠÖŒû˜aŠé1, ×–ì‰Á“ÞŽq2, ŠC–ìM–ç1, ”n“ˆ³—²2 (1ŽY‰È, 2–ò—, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ40‰ñ“ú–{‰ŠÇ¥Ä¶ˆãŠw‰ï (2019/7/16), _ŒË.

723446. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) Žq‹{Ã–¬“à•œŠŠ‹ØŽîÇ (IVL) ‚ðp‘Of’f‚µ• o‹Ÿ‚É‚ÄŽq‹{‘S“E‚ð‚š‚±‚È‚Á‚œˆê—á. ’†‘ºŠîŠ°1, ª’ÍK•ä2, ¬“‡@ˆè2, ŒÜ“‡—T”V2, ˆÉ“¡ŽÀ1,3, HŽRŠG—¢Žq2,3, ‹v“ˆ‘¥s3, ŽO–Ø–Ÿ“¿2,3 (1•wl, 2ŽY‰È, 3–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ59‰ñ“ú–{ŽY‰È•wl‰È“àŽ‹‹ŸŠw‰ïŠwpu‰‰‰ï (2019/9/12), ‹ž“s.

723447. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) Œo‹Ø‘w“IãóˆÚA–@‚ɂ‚¢‚Ă̍čl. Šâ’[r•ã1, ‹g–ì@C1,2, ˆÉ“¡ŽÀ1, •œ‰ª‹B‘å1, –{“c‰ëŽq3, ‰º“c—²m2 (1•wl, 2ŽY‰È, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ64‰ñ“ú–{¶BˆãŠw‰ïŠwpu‰‰‰ïE‘‰ï (2019/11/7), _ŒË.

723448. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) M2 Macrophage‚Í, ’…°‘OŠú‚ÌŽq‹{“à–Œ‚Ìproliferation differentiation switching (PDS) ‚𐧌䂷‚邱‚Æ‚Å’…°¬—§‚ÉŠñ—^‚·‚é. ¬–ì—m•ã, ‹g–ì@C1,2, ˆÉ“Œ‰ë”ü, •œ‰ª‹B‘å1, •Ÿˆä‘å˜a, ÔŽ}@r, ˜a“c^ˆê˜Y, œA“c@‘×, ‘å{‰êõ, âV“¡@Ž  (1•wl, 2ŽY‰È): ‘æ64‰ñ“ú–{¶BˆãŠw‰ïŠwpu‰‰‰ïE‘‰ï (2019/11/8), _ŒË.

723449. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) JALAu–³’É•ª•ØŠÖŒWŠw‰ïE’c‘̘A—‹Š‹c‰ïvŠˆ“®•ñ. ŠC–ìM–ç (ŽY‰È): ‘æ123‰ñ“ú–{ŽY‰È–ƒŒŠw‰ïŠwpW‰ï (2019/11/23), “Œ‹ž.

723450. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) —‘‘ƒŽq‹{“à–ŒÇ«”X–E‚ÌŠà‰»‚É‚š‚¯‚é—‘‘ƒƒzƒ‹ƒ‚ƒ“Žó—e‘Ì‚Ì‹@”\“IˆÓ‹`‚ÉŠÖ‚·‚錟“¢. •œ‰ª‹B‘å1, ‹g–ì@C1,2, Œ–{r‰p3, ²“¡ŠG—¢“Þ4, Šâ’[r•ã1, ˆÉ“¡ŽÀ1, –{“c‰ëŽq5, Šâ£tŽq1, Žž”CòŒÎ2, ŽOŽ}@M3, ‰¶“c‹MŽu1 (1•wl, 2ŽY‰È, 3•a—, 4•a‘ԁEf—ÃŒn, 5‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ41‰ñ“ú–{ƒGƒ“ƒhƒƒgƒŠƒI[ƒVƒXŠw‰ïŠwpu‰‰‰ï (2020/1/19), ‰ºŠÖ.

723451. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ‹t—¬ŒŽŒoŒŒ’†‚ÌSphingosine 1-phosphate (S1P) ‚Í, • o“àŠÂ‹«‚ðM2Macrophage—DˆÊ‚É‚³‚¹, Žq‹{“à–ŒÇ‚̐i“W‚ÉŠñ—^‚·‚é. ¬–ì—m•ã, ‹g–ì@C1,2, ˆÉ“Œ‰ë”ü, ‰Â–ì–Ms, ’†“‡²r, ‘Ÿ“c@‘n, •ŸŽm‹`«, ˜a“c^ˆê˜Y, “¡–ìŒhŽj, Â–؏~Œ«, âV“¡@Ž  (1ŽY‰È, 2•wl): ‘æ41‰ñ“ú–{ƒGƒ“ƒhƒƒgƒŠƒI[ƒVƒXŠw‰ïŠwpu‰‰‰ï (2020/1/19), ‰ºŠÖ.

723030. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) RAMP1‚É‚æ‚éƒ}ƒEƒXŽq‹{“à–ŒÇ‚É‚š‚¯‚錌ŠÇEƒŠƒ“ƒpŠÇV¶‘£iì—p (RAMP1 signaling facilitates angiogenesis and lymphangiogenesis in the endometriotic lesions in mice). –{“c‰ëŽq1, ˆÉ“¡‹`–ç2, •ž•”‹¿Žq3, ×–ì‰Á“ÞŽq2, ’†–{CŽi1, ‘卂Žj¹1, ’ׯ¢—¢1, ”n“ˆ³—²2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–ò—, 3ŽY‰È): ‘æ93‰ñ“ú–{–ò—Šw‰ï”N‰ï (2020/3/16-18), Ž†ãŠJÃ.

731039. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) Ž„‚̍s‚Á‚Ä‚¢‚éŽq‹{“à–ŒÇf—Ã. ‹g–ì@C1,2 (1ŽY‰È, 2•wl): ‘Š–ÍŒŽŽY•wl‰Èˆã‰ï (2019/4/4), ‘Š–ÍŒŽ.

731040. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ƒzƒ‹ƒ‚ƒ“‚ɐ§Œä‚³‚ê‚鐶B¶—‚É–£‚¹‚ç‚ê‚Ä. ‹g–ì@C1,2 (1ŽY‰È, 2•wl): _“ސìŽY•wl‰Èˆã‰ï” ªƒZƒ~ƒi[ (2019/4/27), ” ª.

731041. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) Œ€‹†‚É—§‹r‚µ‚œŽq‹{“à–ŒÇŽ¡—ẪXƒgƒ‰ƒeƒW[. ‹g–ì@C1,2 (1ŽY‰È, 2•wl): •œ’ËŽY•wl‰Èˆã‰ï (2019/7/18), •œ’Ë.

731042. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) Ž„‚̍s‚Á‚Ä‚¢‚éŽq‹{“à–ŒÇŽ¡—Ã. ‹g–ì@C1,2 (1ŽY‰È, 2•wl): ÀŠÔˆ»£ŽY•wl‰Èˆã‰ï (2019/7/23), ŠC˜V–Œ.

731043. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) Žq‹{“à–ŒÇ‚É‚š‚¯‚éHR-QOL. ‹g–ì@C1,2 (1ŽY‰È, 2•wl): WEB conference: •wl‰ÈŽŸŠ³‚É‚š‚¯‚éQOL‚̈Ӌ`‚ðl‚Š‚é (2019/9/5), “Œ‹ž.

731044. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ŽüŽYŠú—̈æ‚̍ЊQ‘΍ô|Ž©•E‹€•EŒö•‚Ì‚ ‚è•û. ŠC–ìM–ç (ŽY‰È): Š‹ü‹æŽY•wl‰Èˆã‰ï (2019/9/20), Š‹ü.

731045. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) –³’É•ª•Ø‚̈À‘S«Œüã‚Ì‚œ‚ß‚Ì•ûô. ŠC–ìM–ç (ŽY‰È): —ߘaŒ³”N“x‘æ2‰ñŽ ‰êŒ§ŽY‰È•wl‰Èˆã‰ïŠwpŒ€C‰ï (2019/9/21), ‘å’Ã.

731046. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) —‘‘ƒ—\”õ”\—Í‚©‚ç‚Ý‚œ¶Bˆã—Ã. ‹g–ì@C1,2 (1ŽY‰È, 2•wl): ‘æ27‰ñ_“ސ쌧Œ§ˆæ’n‹æŽY•wl‰ÈŒ€C‰ï (2019/10/17), ‘Š–ÍŒŽ.

731047. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) Ž„‚œ‚¿‚̍s‚Á‚Ä‚¢‚é“àŽ‹‹ŸŽ¡—Â̍H•v. ‹g–ì@C1,2 (1ŽY‰È, 2•wl): ‘æ11‰ñ‚Ý‚È‚ÆŽY•wl‰È“àŽ‹‹ŸŒ€‹†‰ï (2019/10/18), “Œ‹ž.

731048. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) Ž„‚̍s‚Á‚Ä‚¢‚éŽq‹{“à–ŒÇf—Ã. ‹g–ì@C1,2 (1ŽY‰È, 2•wl): ‘æ3‰ñ_“ސìŽq‹{“à–ŒÇE‘B‹ØÇŒ€‹†‰ï (2019/10/23), ‰¡•l.

732035. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µãٍu‰‰) Ž„‚̍s‚Á‚Ä‚¢‚éŽq‹{“à–ŒÇŒ€‹†‚š‚æ‚їՏ°. ‹g–ì@C1,2 (1ŽY‰È, 2•wl): ‘Š–ÍŒŽŽY•wl‰Èˆã‰ï (2019/4/1), ‘Š–ÍŒŽ.

732036. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) Functional MRI techniques to evaluate uterine fibroid. ‹g–ì@C1,2, Takahashi N, ‰¶“c‹MŽu2, Osuga Y (1ŽY‰È, 2•wl): ‘æ10‰ñ•wl‰Èƒzƒ‹ƒ‚ƒ“ˆË‘¶«ŽŸŠ³Œ€‹†‰ï (2019/6/8), “Œ‹ž.

733148. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‘å‹K–͍ЊQŽž‚ÌŽüŽYŠúˆã—Ã’ñ‹Ÿ‘̐§‚ÌŠm•Û‚ɂ‚¢‚Ä: ŽY‰È‚Ì—§ê‚©‚ç. ŠC–ìM–ç (ŽY‰È): –ŒŒÃ‰®‘æˆêÔ\Žš•a‰@‘‡ŽüŽYŠú•êŽqˆã—ÃZƒ“ƒ^[20Žü”N‹L”Ou‰‰‰ï (2019/6/15), –ŒŒÃ‰®.

733149. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) Œo”ç“IS”x•â•‘•’u‚𓱓ü‚µ‚œ’鉀ØŠJ4Ç—á‚̏oŒŒ—Ê. ˆ¢•”@‰1, ŽRè@—D1, Œ“‡ƒˆê1, ‹g‘º‰ÃL1, •ž•”‹¿Žq1, ŠÖŒû˜aŠé1, ’†‹à˜NŽq1, Îì—²ŽO1, ‘同—fŽq1, ‹àˆä—Y“ñ1, –]ŒŽƒŽq1, ŠC–ìM–ç1 (1ŽY‰È): ‘æ137‰ñŠÖ“Œ˜A‡ŽY‰È•wl‰ÈŠw‰ï‘‰ïEŠwpW‰ï (2019/6/16), “Œ‹ž.

733150. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) dÇ—‘‘ƒ‰ßèŽhŒƒÇŒóŒQ (OHSS) ‚Ì2Ç—á. ŒÜ\”šmŽu1, Šâ’[r•ã2, ‰º“c—²m1, –{“c‰ëŽq3, ì“à”Žl, ‹g–ì@C1,2, ‰¶“c‹MŽu2, ŠC–ìM–ç1 (1ŽY‰È, 2•wl, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ137‰ñŠÖ“Œ˜A‡ŽY‰È•wl‰ÈŠw‰ï‘‰ïEŠwpW‰ï (2019/6/16), “Œ‹ž.

733151. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ŽüŽYŠúˆã—Â̈À‘S«Œüã‚Ö‚Ì‚Æ‚è‚­‚݁|–³’É•ª•ØŠÖŒWŠw‰ïE’c‘̘A—‹Š‹c‰ï (JALA) ‚ÌŠˆ“®‚Ì‚²Ð‰î‚Æ–ƒŒ‰È‚̐搶•û‚Ö‚Ì‚šŠè‚¢|. ŠC–ìM–ç (ŽY‰È): ‘æ6‰ñ“Œ–k–ƒŒƒZƒ~ƒi[ (2019/6/22), å‘ä.

733152. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) “–‰@‚Ì•wl‰Èˆ««Žîᇂɂš‚¯‚é”D›s«‰·‘¶‚ɂ‚¢‚Ä. ˆÉ“¡ŽÀ1, ‚“c‹±b1, ŒÃì³‹`1, ‘同Œ«l1, “cŽG—L‹I1, ‹g–ì@C1,2, Šâ£tŽq1, ‰¶“c‹MŽu1, ŠC–ìM–ç2 (1•wl, 2ŽY‰È): ‘æ381‰ñŽl…‰ï (2019/6/26), “Œ‹ž.

733153. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) “–Ž{Ý‚ÅŒoŒ±‚µ‚œŽq‹{“à”œÇ‚̏oŒŒ—Ê‚ÉŠÖ‚·‚錟“¢. ’J@‘ì–ç1, –]ŒŽƒŽq1, ‹g‘º‰ÃL1, •ž•”‹¿Žq1, ’†‹à˜NŽq1, ŠÖŒû˜aŠé1, Îì—²ŽO1, ‘同—fŽq1, ‹àˆä—Y“ñ1, ŠC–ìM–ç1 (1ŽY‰È): ‘æ426‰ñ_“ސìŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2019/6/29), ‰¡•l.

733154. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) •œ¬30”N“x _“ސìŽY‰È•wl‰ÈŠw‰ï •wl‰Èˆ««Žîᇓo˜^WŒv•ñ. Àè—ߎq, ƒ‹ƒCƒY‰¡“c“Þ•ü, ‹g“c@_, ™‰Y@Œ«, ‘匎@Ž÷, ‚“c‹±b1, Vˆä@“w1, –ؔҍvŽœ, ²X–؍N, •ÄŽR„ˆê, —с@NŽq, •œàV@–Ò, X‰ª@Š², ˆéè‘Ÿˆê, “n粖LŽ¡, ŽOãŠ²’j, ‰Á“¡‹v·, ’†–ìáÁ²’j, —é–؁@’Œ, ‚‹ŽP’j (1•wl): ‘æ426‰ñ_“ސìŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2019/6/29), ‰¡•l.

733005. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) Žq‹{“à–ŒÇ‚É‚š‚¯‚é–¬ŠÇV¶‚𐧌䂷‚é_Œoƒyƒvƒ`ƒhCGRP‚Ì–ðŠ„. –{“c‰ëŽq1, ˆÉ“¡‹`–ç2, •ž•”‹¿Žq3, ×–ì‰Á“ÞŽq2, ’†–{CŽi1, ‘卂Žj¹1, “s—¯¢—¢1, ”n“ˆ³—²2 (1‘åŠw‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–ò—, 3ŽY‰È): ‘æ140‰ñ“ú–{–ò—Šw‰ïŠÖ“Œ•”‰ï (2019/7/6), “Œ‹ž.

733155. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ƒjƒRƒ`ƒ“‚ªãó‚ÌŽq‹{“à–Œ’…°‚É—^‚Š‚é‰e‹¿‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‹g–ì@C1,2, ¬–ì—m•ã, ˆÉ“Œ‰ë”ü, âV“¡@Ž  (1ŽY‰È, 2•wl): •¬Œ€‹†”­•\‰ï (‹i‰Œ‰ÈŠwŒ€‹†à’c) (2019/7/23), “Œ‹ž.

733156. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) EXIT‚ðŽ{s‚µ‚œ‘ÙŽ™Œz•”Žîᇂ̈ê—á. ŒÜ\”šmŽu1, ‘同—fŽq1, ‹g‘º‰ÃL1, •ž•”‹¿Žq1, ’†‹à˜NŽq1, ŠÖŒû˜aŠé1, Îì—²ŽO1, ‹àˆä—Y“ñ1, –]ŒŽƒŽq1, ŠC–ìM–ç1 (1ŽY‰È): ‘æ427‰ñ_“ސìŽY‰È•wl‰ÈŠw‰ï (2019/9/21), ìè.

733157. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) Klippel-Trenanay-WeberÇŒóŒQ‚̈ê—á. ŽRè@—D1, Îì—²ŽO1, Žž”CòŒÎ1, ‹g‘º‰ÃL1, •ž•”‹¿Žq1, ’†‹à˜NŽq1, ŠÖŒû˜aŠé1, ‘同—fŽq1, ‹àˆä—Y“ñ1, –]ŒŽƒŽq1, ŠC–ìM–ç1 (1ŽY‰È): ‘æ427‰ñ_“ސìŽY‰È•wl‰ÈŠw‰ï (2019/9/21), ìè.

733158. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) Žq‹{èò•”‰~ØœpŒã‚ɒljÁŽ¡—Âð—v‚µ‚œ4—á. Œ“‡ƒˆê1, Vˆä³G2, ŒŽRD1, ŒàVW‘ã1, ”nêªˆê, ‰Í–ìÆŽq1, ‘å–ì@•×, –]ŒŽˆ€˜Y, ‹gŒŽ@ˆê, ã–V•qŽq (1ŽY‰È, 2•wl): ‘æ427‰ñ_“ސìŽY‰È•wl‰ÈŠw‰ï (2019/9/21), ìè.

733159. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) Žq‹{‹ŸŽèp‘O‚ÉGnRHƒAƒ“ƒ^ƒSƒjƒXƒg (ƒŒƒ‹ƒOƒŠƒNƒX) ‚ð“Š—^‚µ‚œ6Ç—á. ˆÉ“¡ŽÀ1, Šâ’[r•ã1, •œ‰ª‹B‘å1, ‰º“c—²m2, –{“c‰ëŽq3, ‹g–ì@C1,2, ‰¶“c‹MŽu1 (1•wl, 2ŽY‰È, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ427‰ñ_“ސìŽY‰È•wl‰ÈŠw‰ï (2019/9/21), ìè.

733160. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ˆÀ‘S‚È–³’É•ª•Ø’ñ‹Ÿ‘̐§‚̍\’z‚Ì‚œ‚ß‚É. ŠC–ìM–ç (ŽY‰È): —ߘaŒ³”N“xÃ‰ªŒ§•ê‘Ì•ÛŒì–@Žw’èˆãŽtŒ€C‰ï (2019/9/23), Ã‰ª.

733161. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒ|ƒXƒ^[) ”DP’†‚ɍRMDA5R‘Ì—z«”畆‹Ø‰Š‚𔭏ǂµ‚œ‘ÙŽ™”­ˆç•s‘S‚Ì1—á. ŒÜ“‡—T”V1, –]ŒŽƒŽq1, ‹g‘º‰ÃL1, ’†‹à˜NŽq1, ŠÖŒû˜aŠé1, Îì—²ŽO1, ‘同—fŽq1, ‹àˆä—Y“ñ1, ŠC–ìM–ç1 (1ŽY‰È): ‘æ138‰ñŠÖ“Œ˜A‡ŽY‰È•wl‰ÈŠw‰ï‘‰ïEŠwpW‰ï (2019/10/19), ‘O‹Ž.

733162. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒ|ƒXƒ^[) Žå•a•Ï‚ª¶Œã• –Œo‚É‘¶Ý‚µ, p‘Of’f‚ª¢“ï‚Å‚ ‚Á‚œŽq‹{‘B‹ØÇ—R—ˆ‚ƍl‚Š‚ç‚ê‚é—Þ“à–ŒŠàGI‚̈ê—á. ’J@‘ì–ç1, Šâ£tŽq2, ¬“‡@ˆè1, Œ“‡ƒˆê1, ‰““¡^ˆê2, ŒÃì³‹`2, ‘同Œ«l2, “cŽG—L‹I2, ‚“c‹±b2, ‹g–ì@C1,2, ‰¶“c‹MŽu2 (1ŽY‰È, 2•wl): ‘æ138‰ñŠÖ“Œ˜A‡ŽY‰È•wl‰ÈŠw‰ï‘‰ïEŠwpW‰ï (2019/10/19), ‘O‹Ž.

733163. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒ|ƒXƒ^[) Dysgerminoma‚ð‡•¹‚µ‚œ46, XY pure gonadal dysgenesis (SwyerÇŒóŒQ) ‚̈ê—á. ŽRè@—D1, Šâ£tŽq2, ŒÃì³‹`2, ‘同Œ«l2, Šâ’[r•ã2, “cŽG—L‹I2, ‚“c‹±b2, ‹g–ì@C1,2, ‰¶“c‹MŽu2 (1ŽY‰È, 2•wl): ‘æ138‰ñŠÖ“Œ˜A‡ŽY‰È•wl‰ÈŠw‰ï‘‰ïEŠwpW‰ï (2019/10/19), ‘O‹Ž.

733164. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒ|ƒXƒ^[) ƒtƒBƒuƒŠƒmƒQƒ“»Ü‚ðŽg—p‚µ‚œ•ª•ØŒãˆÙíoŒŒ8Ç—á‚Ì—\Œã. ŒÜ\”šmŽu1, –]ŒŽƒŽq1, ‘同—fŽq1, •ž•”‹¿Žq1, ‹g‘º‰ÃL1, ’†‹à˜NŽq1, ŠÖŒû˜aŠé1, Îì—²ŽO1, ‹àˆä—Y“ñ1, ŠC–ìM–ç1 (1ŽY‰È): ‘æ138‰ñŠÖ“Œ˜A‡ŽY‰È•wl‰ÈŠw‰ï‘‰ïEŠwpW‰ï (2019/10/19), ‘O‹Ž.

733165. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ƒxƒoƒVƒcƒ}ƒu‚É‚æ‚è’·ŠúŠ°‰ð‚ð“Ÿ‚ç‚ê‚œ—‘‘ƒŠàÄ”­‚̈ê—á. ŒÜ\”šmŽu1, “‡‰ª‹¶1, ’F@‰pŽ÷, Vˆä@“w2 (1ŽY‰È, 2•wl): ‘æ428‰ñ_“ސìŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2019/11/10), ‘Š–Í‘å–ì.

733166. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) pŒã12”N‚ōĔ­‚µ‚œŽq‹{•œŠŠ‹Ø“÷Žî‚Ì1—á. ŽRè@—D1, Vˆä³G2, ŒŽRD1, ŒàVW‘ã1, ”nêªˆê, ‰Í–ìÆŽq1, ‘å–ì@•×, –]ŒŽˆ€˜Y, ‹gŒŽ@ˆê, ã–V•qŽq (1ŽY‰È, 2•wl): ‘æ428‰ñ_“ސìŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2019/11/10), ‘Š–Í‘å–ì.

733167. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ’Ž‹Ù‹}’鉀ØŠJp‚ðŽ{s‚µ‚œŒŒ¬”ÂŒž­Ç‚Ì1—á. Œã“¡—Sˆê˜N1, ‹g‘º‰ÃL2, ’†‹à˜NŽq2, •ž•”‹¿Žq2, ŠÖŒû˜aŠé2, Îì—²ŽO2, ‘同—fŽq2, ‹àˆä—Y“ñ2, –]ŒŽƒŽq2, ŠC–ìM–ç2 (1Œ€Cˆã, 2ŽY‰È): ‘æ428‰ñ_“ސìŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2019/11/10), ‘Š–Í‘å–ì.

733168. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) p‘OŒŸž‚Å–³ÇŒó«’áƒtƒBƒuƒŠƒmƒQƒ“ŒŒÇ‚Æ”»–Ÿ‚µ‚œŽq‹{‘ÌŠà‚̈ê—á. •œ“cŠxŽj1, Šâ£tŽq2, ŒÜ“‡—T”V3, ŒÃì³‹`2, ‘同Œ«l2, “cŽG—L‹I2, ‚“c‹±b2, ‹g–ì@C2,3, ‰¶“c‹MŽu2 (1Œ€Cˆã, 2•wl, 3ŽY‰È): ‘æ428‰ñ_“ސìŽY‰È•wl‰ÈŠw‰ïŠwpu‰‰‰ï (2019/11/10), ‘Š–Í‘å–ì.

733169. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ‰äX‚ªs‚Á‚Ä‚¢‚é• o‹Ÿf—Ã. Šâ’[r•ã1, ‹g–ì@C1,2, ˆÉ“¡ŽÀ1, •œ‰ª‹B‘å1, –{“c‰ëŽq3, ‰¶“c‹MŽu1 (1•wl, 2ŽY‰È, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ382‰ñŽl…‰ï (2019/11/20), “Œ‹ž.

'18”N“xˆÈ‘O•ª

[Šw‰ïEŒ€‹†‰ï“™]

H29-722001. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) ‘å‹K–͐kÐ”­¶Žž‚É‚š‚¯‚éŽüŽYŠú•êŽqˆã—ÃZƒ“ƒ^[‚Ì‹Æ–±Œp‘±Œv‰æ (BCP) ì¬‚̉ۑè. •ž•”‹¿Žq1, ŠC–ìM–ç1 (1ŽY‰È): ‘æ23‰ñ“ú–{W’cÐŠQˆãŠw‰ï‘‰ïEŠwpW‰ï (2018/2/3), ‰¡•l

H29-723001. [Šw‰ï (‘S‘)] (ˆê”ʉ‰‘è) ”DP’†‚ÉFBN1•ÏˆÙ (c.364C>T) ‚ð‚à‚ƒ}ƒ‹ƒtƒ@ƒ“ÇŒóŒQ‚Ɛf’f‚µ‚œˆê—á. ‘同—fŽq1,2, –]ŒŽƒŽq1,2, –x‚ ‚·‚©2, ŠC–ìM–ç1, ‚“cŽj’j2,3 (1ŽY‰È, 2•a‰@ˆâ“`f—Õ”, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): “ú–{l—Þˆâ“`Šw‰ï‘æ62‰ñ‘å‰ï (2017/11/16), _ŒË.

'18-733004. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) Massive ovarian edema‚ɑ΂µ‚Ä• o‹Ÿ‰ºŽèp‚ðŽ{s‚µ‚œ2Ç—á. ŽRè@—D1, ŽO–Ø–Ÿ“¿1,2, ª’ÍK•ä1, ÎˆäŠG从q, HŽRŠG—¢Žq1, ’†‘ºŠîŠ°3, ‹v“ˆ‘¥s2, â“Œ—R‹I2,4 (1ŽY‰È, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3•wl, 4¬Ž™): ‘æ56‰ñé‹ÊŒ§ˆãŠw‰ï‘‰ï (2019/2/24), é‹Ê.


®Œ`ŠO‰ÈŠw

[Šwp˜_•¶]

110264. [ŒŽ’˜] Hooks at the Upper Instrumented Vertebra Can Adjust Postoperative Shoulder Balance in Patients with Adolescent Idiopathic Scoliosis: 5 Years or More of Follow-up. Kuroya S, Akazawa T, Kotani T, Sakuma T, Minami S, Torii Y, Umehara T, Iinuma M, Murakami K, Orita S, Inage K, Eguchi Y, Fujimoto K, Shiga Y, Nakamura J, Inoue G1, Miyagi M1, Saito W1, Ohtori S, Niki H: Asian Spine J 2019/5; 13 (5): 793-800. (ˆäã@Œº1, ‹{é³s1, âV“¡@˜j1: 1®ŠO)

110265. [ŒŽ’˜] ISSLS PRIZE IN CLINICAL SCIENCE 2019: clinical importance of trunk muscle mass for low back pain, spinal balance, and quality of life-a multicenter cross-sectional study. Hori Y, Hoshino M, Inage K, Miyagi M1, Takahashi S, Ohyama S, Suzuki A, Tsujio T, Terai H, Dohzono S, Sasaoka R, Toyoda H, Kato M, Matsumura A, Namikawa T, Seki M, Yamada K, Habibi H, Salimi H, Yamashita M, Yamauchi T, Furuya T, Orita S, Maki S, Shiga Y, Inoue M, Inoue G1, Fujimaki H, Murata K2, Kawakubo A2, Kabata D, Shintani A, Ohtori S, Takaso M1, Nakamura H: Eur Spine J 2019/5; 28 (5): 914-21. (‹{é³s1, ˆäã@Œº1, ‘º“cK—C2, ì‹v•Û•à2, ‚‘Š»Žm1: 1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

110266. [ŒŽ’˜] Elevated leptin levels induce inflammation through IL-6 in skeletal muscle of aged female rats. Tazawa R1, Uchida K2, Fujimaki H, Miyagi M2, Inoue G2, Sekiguchi H2, Murata K1, Takata K1, Kawakubo A1, Takaso M2: BMC Musculoskelet Disord 2019/5; 20 (1): 199. (“càV@—È1, “à“cŒ’‘Ÿ˜Y2, ‹{é³s2, ˆäã@Œº2, ŠÖŒû—T”V2, ‘º“cK—C1, ‚“c@Œ€1, ì‹v•Û•à1, ‚‘Š»Žm2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO)

110267. [ŒŽ’˜] Transforming growth factor-ƒÀ stimulates nerve growth factor production in osteoarthritic synovium. Takano S1, Uchida K1, Itakura M2, Iwase D1, Aikawa J1, Inoue G1, Mukai M3, Miyagi M1, Murata K3, Sekiguchi H1, Takaso M1: BMC Musculoskelet Disord 2019/5; 20 (1): 204. (‚–쏞‘Ÿ˜Y1, “à“cŒ’‘Ÿ˜Y1, ”‘q@œ2, Šâ£@‘å1, ‘Šì@~1, ˆäã@Œº1, Œ}@@Šw3, ‹{é³s1, ‘º“cK—C3, ŠÖŒû—T”V1, ‚‘Š»Žm1: 1®ŠO, 2¶‰», 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

110268. [ŒŽ’˜] Minimally invasive manganese-enhanced magnetic resonance imaging for the sciatic nerve tract tracing used intra-articularly administrated dextran-manganese encapsulated nanogels. Eguchi Y, Murayama S, Kanamoto H, Abe K, Miyagi M1, Takahashi K, Ohtori S, Aoki I: JOR Spine 2019/6; 2 (2): e1059. (‹{é³s1: 1®ŠO)

110269 [ŒŽ’˜] Long-term outcomes of Wagner self-locking stem with bone allograft for Paprosky type II and III bone defects in revision total hip arthroplasty: A mean 15.7-year follow-up. Zang J, Uchiyama K1, Moriya M1, Fukushima K1, Takahira N2, Takaso M1: J Orthop Surg (Hong Kong) 2019/6; 27 (2): 2309499019854156. (“àŽRŸ•¶1, X’JŒõr1, •Ÿ“‡Œ’‰î1, ‚•œ®L2, ‚‘Š»Žm1: 1®ŠO, 2ˆã—Éq¶Šw•”)

110270. [ŒŽ’˜] Osteoarthritis patients with high haemoglobin A1c have increased Toll-like receptor 4 and matrix metalloprotease-13 expression in the synovium. Murata K1, Uchida K2, Takano S2, Shoji S1, Iwase D2, Inoue G2, Aikawa J2, Yokozeki Y1, Sekiguchi H2, Takaso M2: Diabetes Metab Syndr Obes 2019/7; 12: 1151-9. (‘º“cK—C1, “à“cŒ’‘Ÿ˜Y2, ‚–쏞‘Ÿ˜Y2, ¯Ži^‘Ÿ˜Y1, Šâ£@‘å2, ˆäã@Œº2, ‘Šì@~2, ‰¡ŠÖ—YŽi1, ŠÖŒû—T”V2, ‚‘Š»Žm2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO)

110271. [ŒŽ’˜] Spinal Alignments of Residual Lumbar Curve Affect Disc Degeneration after Spinal Fusion in Patients with Adolescent Idiopathic Scoliosis: Follow-up after 5 or More Years. Akazawa T, Umehara T, Iinuma M, Asano K, Kuroya S, Torii Y, Murakami K, Kotani T, Sakuma T, Minami S, Orita S, Inage K, Shiga Y, Nakamura J, Inoue G1, Miyagi M1, Saito W1, Eguchi Y, Fujimoto K, Takahashi H, Ohtori S, Niki H: Spine Surg Relat Res 2019/8; 4 (1): 50-6. (ˆäã@Œº1, ‹{é³s1, âV“¡@˜j1: 1®ŠO)

110272. [ŒŽ’˜] Changes in Nerve Growth Factor Expression and Macrophage Phenotype Following Intervertebral Disc Injury in Mice. Nakawaki M1, Uchida K2, Miyagi M2, Inoue G2, Kawakubo A1, Sato M3, Takaso M2: J Orthop Res 2019/8; 37 (8): 1798-804. (’†˜e[Í1, “à“cŒ’‘Ÿ˜Y2, ‹{é³s2, ˆäã@Œº2, ì‹v•Û•à1, ²“¡@‰ë3, ‚‘Š»Žm2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO, 3–Ɖu)

110273. [ŒŽ’˜] IL-1ƒÀ mediates NGF and COX-2 expression through transforming growth factor-activating kinase 1 in subacromial bursa cells derived from rotator cuff tear patients. Nagura N, Uchida K1, Kenmoku T1, Inoue G1, Nakawaki M2, Miyagi M1, Takaso M1: J Orthop Sci 2019/9; 24 (5): 925-9. “à“cŒ’‘Ÿ˜Y1, Œ©–Ú’q‹I1,ˆäã@Œº1, ’†˜e[Í2, ‹{é³s1, ‚‘Š»Žm1: 1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

110274. [ŒŽ’˜] Vascular Endothelial Growth Factor Is Regulated by the Canonical and Noncanonical Transforming Growth Factor-ƒÀ Pathway in Synovial Fibroblasts Derived from Osteoarthritis Patients. Takano S1, Uchida K1, Shoji S2, Itakura M3, Iwase D1, Aikawa J1, Mukai M2, Sekiguchi H1, Inoue G1, Takaso M1: Biomred Res Int 2019/9; Article ID 6959056. https://doi.org/10.1155/2019/6959056 (‚–쏞‘Ÿ˜Y1, “à“cŒ’‘Ÿ˜Y1, ¯Ži^‘Ÿ˜Y2, ”‘q@œ3, Šâ£@‘å1, ‘Šì@~1, Œ}@@Šw2, ŠÖŒû—T”V1, ˆäã@Œº1, ‚‘Š»Žm1: 1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3¶‰»)

110275. [ŒŽ’˜] Clinical usefulness of multiplex PCR-lateral flow for the diagnosis of orthopedic-related infections. Minegishi Y1, Uchiyama K1, Sakurai K2, Ibe S, Kanda H, Nihonyanagi S2,3, Nakamura M4, Ikeda S, Takaso M1: Mod Rheumatol 2019/9; 29 (5): 867-73. (•õŠÝ—mŽŸ˜Y1, “àŽRŸ•¶1, ŸNˆäŒc‘¢2, “ñ–{–öL2,3, ’†‘º³Ž÷4, ‚‘Š»Žm1: 1®ŠO, 2—ÕŒŸ•”, 3ŠŽõŠÇ—Žº, 4ˆã—Éq¶Šw•”)

110276. [ŒŽ’˜] Wrapping With Basic Fibroblast Growth Factor-Impregnated Collagen Sheet Reduces Rat Sciatic Nerve Allodynia. Mukai M, Uchida K1, Hirosawa N, Murakami K, Kuniyoshi K, Inoue G1, Miyagi M1, Sekiguchi H1, Shiga Y, Inage K, Orita S, Suzuki T, Matsuura Y, Takaso M1, Ohtori S: J Orthop Res 2019/10; 37 (10) :2258-63. (“à“cŒ’‘Ÿ˜Y1, ˆäã@Œº1, ‹{é³s1, ŠÖŒû—T”V1, ‚‘Š»Žm1: 1®ŠO)

110277. [ŒŽ’˜] Comparison of glenohumeral joint rotation between asymptomatic subjects and patients with subacromial impingement syndrome using cine-magnetic resonance imaging: a cross-sectional study. Kenmoku T1,2, Matsuki K, Ochiai N, Sonoda M, Ishida T, Sasaki S, Tanaka Y, Nakawaki M3, Nagura N, Tazawa R3, Sasaki u, Takaso M2: BMC Musculoskelet Disord 2019/10; 20 (1): 475. (Œ©–Ú’q‹I1,2, ’†˜e[Í3, “càV@—È3, ‚‘Š»Žm2: 1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2®ŠO, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

110278. [ŒŽ’˜] Differential mRNA Expression of COX-2 and Proinflammatory Mediators in Patients with Rotator Cuff Tears and Osteoarthritis of the Hip. Kenmoku T1,2, Uchida K2, Nagura N, Fujimaki H, Nakawaki M3, Takahira N4, Fukushima K2, Tazawa R3, Muneshige K3, Inoue G2, Takaso M2: Open Journal of Orthopaedics 2019/11; 9 (11): 254-63. (Œ©–Ú’q‹I1,2, “à“cŒ’‘Ÿ˜Y2, ’†˜e[Í3, ‚•œ®L4, •Ÿ“‡Œ’‰î2, “càV@—È3, @d‹¿Žq3, ˆäã@Œº2, ‚‘Š»Žm2: 1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2®ŠO, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 4ˆã—Éq¶Šw•”)

110279. [ŒŽ’˜] Surgical outcomes of spinal fusion for osteoporotic vertebral fracture in the thoracolumbar spine: Comprehensive evaluations of 5 typical surgical fusion techniques. Watanabe K, Katsumi K, Ohashi M, Shibuya Y, Hirano T, Endo N, Kaito T, Yamashita T, Fujiwara H, Nagamoto Y, Matsuoka Y, Suzuki H, Nishimura H, Terai H, Tamai K, Tagami A, Yamada S, Adachi S, Yoshii T, Ushio S, Harimaya K, Kawaguchi K, Yokoyama N, Oishi H, Doi T, Kimura A, Inoue H, Inoue G1, Miyagi M1, Saito W1, Nakano A, Sakai D, Nukaga T, Ikegami S, Shimizu M, Futatsugi T, Ohtori S, Furuya T, Orita S, Imagama S, Ando K, Kobayashi K, Kiyasu K, Murakami H, Yoshioka K, Seki S, Hongo M, Kakutani K, Yurube T, Aoki Y, Oshima M, Takahata M, Iwata A, Endo H, Abe T, Tsukanishi T, Nakanishi K, Watanabe K, Hikata T, Suzuki S, Isogai N, Okada E, Funao H, Ueda S, Shiono Y, Nojiri K, Hosogane N, Ishii K: J Orthop Sci 2019/11; 24 (6): 1020-6. (ˆäã@Œº1, ‹{é³s1, âV“¡@˜j1: 1®ŠO)

110280. [ŒŽ’˜] Complications after spinal fixation surgery for osteoporotic vertebral collapse with neurological deficits: Japan Association of Spine Surgeons with ambition multicenter study. Sakai Y, Kaito T, Takenaka S, Yamashita T, Makino T, Hosogane N, Nojiri K, Suzuki S, Okada E, Watanabe K, Funao H, Isogai N, Ueda S, Hikata T1,2, Shiono Y, Watanabe K, Katsumi K, Fujiwara H, Nagamoto Y, Terai H, Tamai K, Matsuoka Y, Suzuki H, Nishimura H, Tagami A, Yamada S, Adachi S, Ohtori S, Orita S, Furuya T, Yoshii T, Ushio S, Inoue G2, Miyagi M2, Saito W2, Imagama S, Ando K, Sakai D, Nukaga T, Kiyasu K, Kimura A, Inoue H, Nakano A, Harimaya K, Doi T, Kawaguchi K, Yokoyama N, Oishi H, Ikegami S, Futatsugi T, Shimizu M, Kakutani K, Yurube T, Oshima M, Uei H, Aoki Y, Takahata M, Iwata A, Seki S, Murakami H, Yoshioka K, Endo H, Hongo M, Nakanishi K, Abe T, Tsukanishi T, Ishii K: J Orthop Sci 2019/11; 24 (6): 985-90. (“ú•û’qG1,2, ˆäã@Œº2, ‹{é³s2, âV“¡@˜j2: 1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2®ŠO)

110281. [ŒŽ’˜] MRI evaluation of dural sac enlargement by interspinous process spacers in patients with lumbar spinal stenosis: Does it play a role in the long term? Akazawa T, Kotani T, Sakuma T, Torii Y, Iinuma M, Asano K, Ueno J, Yoshida A, Murakami K, Minami S, Orita S, Inage K, Shiga Y, Nakamura J, Inoue G1, Miyagi M1, Saito W1, Eguchi Y, Fujimoto K, Takahashi H, Ohtori S, Niki H: J Orthop Sci 2019/11; 24 (6): 979-84. (ˆäã@Œº1, ‹{é³s1, âV“¡@˜j1: 1®ŠO)

110282. [ŒŽ’˜] Effect of Single Injection of Recombinant Human Bone Morphogenetic Protein-2-Loaded Artificial Collagen-Like Peptide in a Mouse Segmental Bone Transport Model. Tazawa R1, Minehara H2, Matsuura T3, Kawamura T3, Uchida K3, Saito W3, Inoue G3, Takaso M3: Biomed Res Int 2019/12; 2019: 1014594. doi: 10.1155/2019/1014594. eCollection 2019. (“càV@—È1, •ôŒŽG¹2, Œ‰YW³3, ì‘º@’Œ3, “à“cŒ’‘Ÿ˜Y3, ˆäã@Œº3, âV“¡@˜j3, ‚‘Š»Žm3: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2‹~–œ, 3®ŠO)

110283. [ŒŽ’˜] Occupational Characteristics of Low Back Pain Among Standing Workers in a Japanese Manufacturing Company. Inoue G1, Uchida K1, Miyagi M1, Saito W1, Nakazawa T1, Imura T1, Shirasawa E1, Akazawa T, Orita S, Inage K, Takaso M1, Ohtori S: Workplace Health Saf 2020/1; 68 (1): 13-23. (ˆäã@Œº1, “à“cŒ’‘Ÿ˜Y1, ‹{é³s1, âV“¡@˜j1, ’†àVr”V1, ˆä‘º‹M”V1, ”’àV‰hŽ÷1, ‚‘Š»Žm1: 1®ŠO)

110284. [ŒŽ’˜] Polyglycolic acid-collagen tube combined with collagen-binding basic fibroblast growth factor accelerates gait recovery in a rat sciatic nerve critical-size defect model. Fujimaki H, Uchida K1, Inoue G1, Matsushita O, Nemoto N, Miyagi M1, Inage K, Takano S1, Orita S, Ohtori S, Tanaka K, Sekiguchi H1, Takaso M1: J Biomed Mater Res B Appl Biomater 2020/2; 108 (2): 326-32. (“à“cŒ’‘Ÿ˜Y1, ˆäã@Œº1, ‹{é³s1, ‚–쏞‘Ÿ˜Y1, ŠÖŒû—T”V1, ‚‘Š»Žm1: 1®ŠO)

120012. [ŒŽ’˜] •êŽwCMŠÖßÇ‚ɑ΂·‚郍ƒbƒLƒ“ƒOƒvƒŒ[ƒg‚ðŽg—p‚µ‚œCMŠÖßŒÅ’èp‚ÌŽ¡—ÃŒoŒ±. ¬ÀŒ«Ž¡1, •ì_Žm1, ‘å’|—IÆ1, “¡ŠªŽõŽq, ‚‘Š»Žm1 (1®ŠO): “ú–{ŽèŠO‰ÈŠw‰ïŽGŽ 2019; 36 (2): 16-20.

120013. [ŒŽ’˜] DupuytrenSk‚ɑ΂·‚éŽèp—Ö@|–D‡Œã‚̔畆‹Ù’£‚ɉž‚¶‚Ä•”•ª“IŠJ•ú—Ö@‚ƈêŠú“I•Âœ—Ö@‚ð‘I‘ð‚·‚é•û–@‚ɂ‚¢‚ā|. ¬ÀŒ«Ž¡1, •ì_Žm1, ‘å’|—IÆ1, ¬—Ñ–Ÿ³, ‚‘Š»Žm1 (1®ŠO): “ú–{ŽèŠO‰ÈŠw‰ïŽGŽ 2019; 36 (2): 59-63.

120014. [ŒŽ’˜] Neer type IIœœ‰“ˆÊ’[œÜ‚ɑ΂·‚é•Û‘¶—Ö@‚ÆŽèp—Ö@‚Ì”äŠr. “à–쐳—², è•”@Œ›1,2, ¬£NŽ¡, •œì‹IŽq1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2®ŠO): œÜ 2019/6; 41 (3): 807-10.

120015. [ŒŽ’˜] Remplissage–@‚É‚æ‚錚ŠÖß‘O•û§“®Œø‰Ê‚ÉŠÖ‚·‚錟“¢. “càV@—È1, Œ©–Ú’q‹I2,3, –Œ‘q’Œd, ’†˜e[Í1, •ì_Žm3, ‚‘Š»Žm3 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 3®ŠO): ŒšŠÖß 2019/9; 43 (3): 688-92.

120016. [ŒŽ’˜] Periacetabular osteotomy‚ªC7 plumb line‚É—^‚Š‚é‰e‹¿. ‘å’|—IÆ1, •Ÿ“‡Œ’‰î1, ˆäã@Œº1, ‹{é³s1, “àŽRŸ•¶1, ‚•œ®L2, ‚‘Š»Žm1 (1®ŠO, 2ˆã—Éq¶Šw•”): Hip Joint 2019/9; 45 (1): 231-3.

120017. [ŒŽ’˜] ’p¿œœÜ‚̐f’f‚É‚š‚¯‚鑁Šú‚Ì•àsŒP—û‚̊댯«|åœEœ”ՍœÜ‚̍‡•¹|. Ä“¡Œc‘Ÿ, •Ÿ“‡Œ’‰î1 (1®ŠO): Hip Joint 2019/9; 45 (2): 263-5.

120018. [ŒŽ’˜] ƒZƒƒ“ƒgƒŒƒXlHŒÒŠÖßƒVƒFƒ‹‚ÌŒ`ó‚ª‰ŠúŒÅ’è—Í‚š‚æ‚ÑPolar gap‚Ö—^‚Š‚é‰e‹¿|”Œ‹…Œ`‚š‚æ‚Ñ”Œ‘ȉ~‹…Œ^ŠÔ‚Ì”äŠr|. ‹g“c˜aO1, •Ÿ“‡Œ’‰î2, Žðˆä—˜“Þ1, “àŽRŸ•¶2, ‚•œ®L1, Ž•œ­L1 (1ˆã—Éq¶Šw•”, 2®ŠO): —Տ°ƒoƒCƒIƒƒJƒjƒNƒX 2019/10; 40: 135-9.

120019. [ŒŽ’˜] ãøœƒRƒ“ƒ|[ƒlƒ“ƒg‚̃Zƒƒ“ƒgŒÅ’è‚É‚æ‚éˆÊ’u‚̈ړ®‚ƍœˆÚA‚É‚æ‚é‚»‚̐§Œä. •C“c‹M‰ë, ¬£NŽ¡, •œì‹IŽq1,2, è•”@Œ›1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2®ŠO): “ú–{lHŠÖßŠw‰ïŽ 2019/12; 48: 137-8.

310035. [Ç—á•ñ] Regression of Retro-odontoid Pseudotumor Using External Orthosis without Atlantoaxial Fusion: A Case Report. Nakazawa T1, Inoue G1, Imura T1, Miyagi M1, Saito W1, Shirasawa E1, Kawakubo A2, Takaso M1: JBJS Case Connect 2019/7-9; 9 (3): e0329. (’†àVr”V1, ˆäã@Œº1, ˆä‘º‹M”V1, ‹{é³s1, âV“¡@˜j1, ”’àV‰hŽ÷1, ì‹v•Û•à2, ‚‘Š»Žm1: 1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

320027. [Ç—á•ñ] ‘å‘ڍœ“]Žq•”œÜpŒã‚ɉŒ«“®–¬áŽ‚𐶂¶‚œ1—á. ‹Ž’܍F“T1, X’JŒõr1, ‚“c@Œ€2, Šâ£@‘å1, •“cŒ«“ñ, “àŽRŸ•¶1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ŠÖ“Œ®Œ`ÐŠQŠO‰ÈŠw‰ïŽGŽ 2019/8; 50 (4): 194-8.

522069. [uÀ]y“ÁW: ŒÒŠÖß‚Æ‚»‚ÌŽüˆÍ‚̃Xƒ|[ƒcŠQzŠÖß“à•a•Ï‚̐f’f. •Ÿ“‡Œ’‰î1, ‚•œ®L2, “àŽRŸ•¶1, ‚‘Š»Žm1 (1®ŠO, 2ˆã—Éq¶Šw•”): ®Œ`EÐŠQŠO‰È 2019/7; 62 (8): 959-65.

522070. [uÀ]y“ÁW: ƒXƒ|[ƒcf—Âɂš‚¯‚é‰æ‘œf’f|ˆã—ÈÀ‘Sã•K—v‚ȃRƒc‚Æ—Ž‚Æ‚µŒŠ|zII. Še˜_: •”ˆÊ‚²‚Ƃ̃Xƒ|[ƒcŠOEáŠQ@œ”Õ, ŒÒŠÖß, ‘å‘Ú•”‚̃Xƒ|[ƒcŠOEáŠQ. •Ÿ“‡Œ’‰î1, ‚•œ®L2, ‚‘Š»Žm1 (1®ŠO, 2ˆã—Éq¶Šw•”): ŠÖßŠO‰È 2019/10; 38 (11): 1190-7.

522071. [uÀ]y“ÁW: _Œo‹ØŽŸŠ³, V‚œ‚ÈŽ¡—Â̎ž‘ã‚ցzIII. ‡•¹Ç‚ւ̉î“ü@Ò’Œ•ÏŒ`‚ւ̃Aƒvƒ[ƒ`. ‚‘Š»Žm1, Ö“¡@˜j1, ‹{é³s1, ˆäã@Œº1, ’†àVr”V1, ˆä‘º‹M”V1, ”’àV‰hŽ÷1, ì‹v•Û•à2 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ¬Ž™‰Èf—à 2019/12; 83 (1): 113-22.

522072. [uÀ]y“ÁW: œ‘e頏ǐ«’ő̍œÜŽ¡—Â̍ŐV’mŒ©zœ‘e頏ǁE’ő̍œÜ‚ƍ˜‹È‚ª‚è ‹{é³s1, “à“cŒ’‘Ÿ˜Y1, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO): ®Œ`EÐŠQŠO‰È 2020/2; 63 (2): 195-202.

522073. [uÀ]y“ÁW: ‘ÛƒRƒ“ƒZƒ“ƒTƒX‚©‚ç‚Ý‚œ®Œ`ŠO‰ÈŠŽõ‘΍ô‚É‚š‚¯‚éÅV’mŒ©zlHŠÖßŽüˆÍŠŽõ‚̍R‹Û–ò‚ðŠÜ‚ß‚œŽ¡—Ã. “àŽRŸ•¶1, ’r“cM‰î1, X’JŒõr1, •Ÿ“‡Œ’‰î1, ‚‘Š»Žm1, ‚•œ®L2 (1®ŠO, 2ˆã—Éq¶Šw•”): ®Œ`¥ÐŠQŠO‰È 2020/3; 63 (3): 281-6.

540042. [‚»‚Ì‘Œ (Šw‰ïŽ˜^)] ŠÖß–Ê‚ðŠÜ‚ލL”͈͓Œ‡‘¹‚ɑ΂·‚éV‚µ‚¢ÄŒš•û–@‚ÌŽŽ‚Ý è•”@Œ›1,2, •œì‹IŽq1,2, •ôŠÝ—mŽŸ˜Y1,2, ‹{•”@Šî (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2®ŠO): “ú–{‘gDˆÚAŠw‰ïŽGŽ 2019/7; 18 (1): 63.

540043. [‚»‚Ì‘Œ (Šw‰ïŽ˜^)] ƒoƒ“ƒRƒ}ƒCƒVƒ“ŠÜ—LƒŠƒ“Ž_ƒJƒ‹ƒVƒEƒ€ƒZƒƒ“ƒg‚ñ¶‘Ì“à–„“üŒã‚̃oƒ“ƒRƒ}ƒCƒVƒ“R‹ÛŠˆ«•]‰¿ “à“cŒ’‘Ÿ˜Y1, ’†“‡••F, ŠÖŒû_”V1, è•”@Œ›1,2, ‚‘Š»Žm1 (1®ŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): “ú–{®Œ`ŠO‰ÈŠw‰ïŽ 2019/9; 93 (8): 1746.

540044. [‚»‚Ì‘Œ (Šw‰ïŽ˜^)] ~ˆ³–ò“à•ž’†‚̐lH•GŠÖß‘S’uŠ·p‘OŒã‚Ì”ñƒXƒeƒƒCƒh«R‰ŠÇ–ò‚Ɛt‹@”\•Ï‰»‚ÌŒŸ“¢. •œì‹IŽq1,2, è•”@Œ›1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2®ŠO): “ú–{ŠÖß•aŠw‰ïŽ 2019/10; 38 (3): 256.

[’˜@‘]

620063. [Šwp‘ (‹€’˜)]yTEXTƒVƒŠ[ƒY TEXT®Œ`ŠO‰ÈŠw ‘æ5”Łz‘Š‡. ‚‘Š»Žm1 (1®ŠO), •Ò: ‘å’¹žŽi, ‚‘Š»Žm1, o‰Æ³—², ‹g–îWˆê, “ì]“°, “Œ‹ž, 2019/8”­s.

620064. [Šwp‘ (•ª’SŽ·•M)]yƒŒƒWƒfƒ“ƒg‚Í‚Ç‚ÌŽ¡—Ö@‚ð‘I‘ð‚·‚ê‚΂悢‚Ì‚©|“úí‚æ‚­‘˜‹ö‚·‚鎟Š³|(ŠÖßŠO‰È2019”N10ŒŽ‘Š§†)zII. Še˜_@1. •Ï«ŽŸŠ³, œ‘ãŽÓŽŸŠ³, ŽîᇂȂǁ@•ÏŒ`«ŒÒŠÖßÇ, p.30-44. ŽR–{‹–Ÿ, “àŽRŸ•¶1, ‚•œ®L2 (1®ŠO, 2ˆã—Éq¶Šw•”), Šé‰æE•ÒW: ’Ÿ²‰x’j, ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2019/9”­s.

620065. [Šwp‘ (•ª’SŽ·•M)]yŽq‚Ç‚à‚©‚ç‘ål‚Ü‚Å‚±‚Ì1û!@ŽófŽž”N—î•Ê ”­ˆç«ŒÒŠÖßŒ`¬•s‘S‚̐f‚©‚œEŽ¡‚µ‚©‚œzƒgƒsƒbƒNƒX@…Dƒ{[ƒ_[ƒ‰ƒCƒ“DDH‚É‚š‚¯‚鏔–â‘è, p.107. •Ÿ“‡Œ’‰î (®ŠO), •Ò: ˆî—t@—T, ’†“‡N°, ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2019/11”­s.

620066. [Šwp‘ (•ª’SŽ·•M)]yOS NEXUS 20@ŠÖß‹ŸŽèp‚ÌŠî–{@ƒ‹[ƒ`ƒ“‘€ì‚ƃfƒoƒCƒX‚̈µ‚¢•ûzII ‰ºŽˆ@ŒÒŠÖß‹Ÿ‚̃‹[ƒ`ƒ“‘€ì, p.88-95. •Ÿ“‡Œ’‰î (®ŠO), ’S“–•ÒWˆÏˆõ: @“c@‘å, ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2019/11”­s.

620067. [Šwp‘ (•ª’SŽ·•M)]y—\–h‚É“±‚­ƒXƒ|[ƒc®Œ`ŠO‰ÈzIV. ŒÒŠÖß’Ɂ@2. ‘å‘ڍœŠ°œ‰PƒCƒ“ƒsƒ“ƒWƒƒ“ƒg m‰uŠwn “ú–{l‚É‚š‚¯‚éFAI, p.375-8. •Ÿ“‡Œ’‰î (®ŠO), •Ò: ŒÃ‰ê‰p”V, “ñ‘ººŒ³, âV“c—Ç’m, ŽR“¡@’, ‰Á“¡‹ÔŽu, •¶Œõ“°, “Œ‹ž, 2019/11”­s.

620068. [Šwp‘ (•ª’SŽ·•M)]y¡“ú‚ÌŽ¡—ÃŽwj 2020”N”Ł@Ž„‚Í‚±‚€Ž¡—µ‚Ä‚¢‚éz18. ®Œ`ŠO‰ÈŽŸŠ³@œÜ‚Ì•Û‘¶“IŽ¡—Ã, p.1116. è•”@Œ›1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2®ŠO), ‘•ÒW: •ŸˆäŽŸ–î, ‚–؁@œ, ¬Žºˆê¬, ˆãŠw‘‰@, “Œ‹ž, 2020/1”­s.

622003. [Šwp‘ (–|–ó)]y®Œ`ŠO‰ÈŠŽõ‘΍ô‚É‚š‚¯‚鍑ÛƒRƒ“ƒZƒ“ƒTƒX@lHŠÖßŽüˆÍŠŽõ‚ðŠÜ‚ދ؍œŠiŒnŠŽõ‘S”ʁ|Proceeding of the Second International Consensus Meeting on Musculoleletal Infection|zPART 1 GENERAL ASSEMBRY@SECTION 1: PREVENTION@1.10. —\–h: ŽèpŽº, –ƒŒ, p.13. 1.11. —\–h: ŽèpŽº, ƒXƒ^ƒbƒt, p.13-5. 1.12. —\–h: ŽèpŽº, ŠÂ‹«, p.15-6. ’r“cM‰î1, “àŽRŸ•¶2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO), •Ò: “c’†Nm, @–{@[, ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2019/9”­s.

622004. [Šwp‘ (–|–ó)]y®Œ`ŠO‰ÈŠŽõ‘΍ô‚É‚š‚¯‚鍑ÛƒRƒ“ƒZƒ“ƒTƒX@lHŠÖßŽüˆÍŠŽõ‚ðŠÜ‚ދ؍œŠiŒnŠŽõ‘S”ʁ|Proceeding of the Second International Consensus Meeting on Musculoleletal Infection|zPART 1 GENERAL ASSEMBRY@SECTION 1: PREVENTION@1.13. —\–h: ŽèpŽº, ŠO‰ÈŽèp, p.16-7. 1.14. —\–h: ŽèpŽº, Žèp—̈æ, p.17-8. 1.15. —\–h: ôò‰t, p.18-9. 1.16. —\–h: ŽèpŽº, ŽèpŽè‹Z, p.19-20. •õŠÝ—mŽŸ˜Y1,2, “àŽRŸ•¶2, ‚‘Š»Žm2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2®ŠO), •Ò: “c’†Nm, @–{@[, ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2019/9”­s.

[Šw‰ïEŒ€‹†‰ï“™]

712015. [Šw‰ï (‘Û)] (µ‘ҍu‰‰“™) The Patho-mechanism of Pain due to Aging Intervertebral Disc and Muscle. Miyagi M1: 2019 ISSLS (2019/6/3-7), Kyoto, Japan. (‹{é³s1: 1®ŠO)

712016. [Šw‰ï (‘Û)] (µ‘ҍu‰‰“™) The present situation of allograft bone graft in Japan. Inoue G1: AOA-JOA fellowship (2019/7/1), Reno Orthopaedic Clinic, Nevada, USA. (ˆäã@Œº1: 1®ŠO)

712017. [Šw‰ï (‘Û)] (µ‘ҍu‰‰“™) Can Teriparatide Contribute to Success Fusion Surgery in Patients with Osteoporosis? Inoue G1: AOA-JOA fellowship (2019/7/3), Cedars-Sinai Medical Center, California, USA. (ˆäã@Œº1: 1®ŠO)

712018. [Šw‰ï (‘Û)] (µ‘ҍu‰‰“™) The present situation of allograft bone graft in Japan. Inoue G1: AOA-JOA fellowship (2019/7/5), Mayo Clinic, Minnesota, USA. (ˆäã@Œº1: 1®ŠO)

712019. [Šw‰ï (‘Û)] (µ‘ҍu‰‰“™) Application of the Allograft Bone for Orthopaedic Surgery. Inoue G1: AOA-JOA fellowship (2019/7/9), Stanford University, California, USA. (ˆäã@Œº1: 1®ŠO)

712020. [Šw‰ï (‘Û)] (µ‘ҍu‰‰“™) The present situation of allograft bone graft in Japan. Inoue G1: AOA-JOA fellowship (2019/7/12), University of California, California, USA. (ˆäã@Œº1: 1®ŠO)

712021. [Šw‰ï (‘Û)] (µ‘ҍu‰‰“™) Treatment for osteoprosis to success fusion surgery in patients in elderly. Inoue G1: AOA-JOA fellowship (2019/7/12), University of California, Sanfrancisco, Fresno, California, USA. (ˆäã@Œº1: 1®ŠO)

712022. [Šw‰ï (‘Û)] (µ‘ҍu‰‰“™) Application of the Allograft Bone for Spinal Surgery - Differences Between the US and Japan. Inoue G1: AOA-JOA fellowship (2019/7/17), University of Washington, Seatle, Washington, USA. (ˆäã@Œº1: 1®ŠO)

712023. [Šw‰ï (‘Û)] (µ‘ҍu‰‰“™) Radiological and clinical results of corrective surgery in patients with parkinson disease. Inoue G1, Saito W1, Miyagi M1, Imura T1, Shirasawa E1, Kawakubo A2, Nakazawa T1, Takaso M1: 1st Society of Lateral Access Surgery Asia Pacific & Japan Combined Meeting (2019/10/5), Tokyo, Japan. (ˆäã@Œº1, âV“¡@˜j1, ‹{é³s1, ˆä‘º‹M”V1, ”’àV‰hŽ÷1, ì‹v•Û•à2, ’†àVr”V1, ‚‘Š»Žm1: 1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

713102. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Factors Associated with Low Back Pain in Osteoporosis. Miyagi M1, Murata K2, Koyama T2, Kawakubo A2, Fujimaki H, Uchida K1, Inoue G1, Takaso M1: The World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2019) (2019/4/4-7), Paris, France. (‹{é³s1, ‘º“cK—C2, ¬ŽR’q‹v2, ì‹v•Û•à2, “à“cŒ’‘Ÿ˜Y1, ˆäã@Œº1, ‚‘Š»Žm1: 1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

713103. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Relationships among spinal alignment, bone mineral density, and muscle mass@in elderly patients with osteoporosis. Kawakubo A1, Miyagi M2, Fujimaki H, Inoue G2, Nakazawa T2, Imura T2, Saito W2, Uchida K2, Shirasawa E2, Ohtori S, Inage K, Takaso M2: The World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2019) (2019/4/4-7), Paris, France. (ì‹v•Û•à1, ‹{é³s2, ˆäã@Œº2, ’†àVr”V2, ˆä‘º‹M”V2, âV“¡@˜j2, “à“cŒ’‘Ÿ˜Y2, ”’àV‰hŽ÷2, ‚‘Š»Žm2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO)

713104. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Does Body Mass Index Affect Spinal Alignment and Low Back Pain in Patients with Primary Osteoporosis? Inoue S1, Miyagi M1, Murata K2, Koyama T2, Otake Y1, Kuroda A2, Kawakubo A2, Ohtori S, Inage K, Uchida K1, Inoue G1, Takaso M1: 2019 ISSLS (2019/6/3-7), Kyoto, Japan. (ˆäã@ãÄ1, ‹{é³s1, ‘º“cK—C2, ¬ŽR’q‹v2, ‘å’|—IÆ1, •“cW‹`2, ì‹v•Û•à2, “à“cŒ’‘Ÿ˜Y1, ˆäã@Œº1, ‚‘Š»Žm1: 1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

713105. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Incidence and characteristics of postoperative vertebral fractures after fusion surgery in elderly patients. Inoue G1, Miyagi M1, Saito W1, Imura T1, Shirasawa E1, Kawakubo A2, Nakazawa T1, Takaso M1: 2019 ISSLS (2019/6/3-7), Kyoto, Japan. (ˆäã@Œº1, ‹{é³s1, âV“¡@˜j1, ˆä‘º‹M”V1, ”’àV‰hŽ÷1, ì‹v•Û•à2, ’†àVr”V1, ‚‘Š»Žm1: 1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

713106. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Relationship among spinal alignment, bone mineral density, and muscle mass in elderly osteoporosis patients. Kawakubo A1, Miyagi M2, Fujimaki H, Inoue G2, Nakazawa T2, Imura T2, Saito W2, Uchida K2, Shirasawa E2, Ohtori S, Inage K, Takaso M2: 2019 ISSLS (2019/6/3-7), Kyoto, Japan. (ì‹v•Û•à1, ‹{é³s2, ˆäã@Œº2, ’†àVr”V2, ˆä‘º‹M”V2, âV“¡@˜j2, “à“cŒ’‘Ÿ˜Y2, ”’àV‰hŽ÷2, ‚‘Š»Žm2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO)

713107. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Impact of Total Hip Arthroplasty for Low Back Pain and Radiological Spinopelvic Sagittal Parameters in Patients with Hip Diseases. Shoji S1, Inoue G2, Miyagi M2, Saito W2, Uchiyama K22, Nakazawa T2, Imura T2, Fukushima K2, Shirasawa E2, Uchida K2, Takahira N3, Takaso M2: 2019 ISSLS (2019/6/3-7), Kyoto, Japan. (¯Ži^‘Ÿ˜Y1, ˆäã@Œº2, ‹{é³s2, âV“¡@˜j2, “àŽRŸ•¶2, ’†àVr”V2, ˆä‘º‹M”V2, •Ÿ“‡Œ’‰î2, ”’àV‰hŽ÷2, “à“cŒ’‘Ÿ˜Y2, ‚•œ®L3, ‚‘Š»Žm2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO, 3ˆã—Éq¶Šw•”)

713108. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) The effect of total hip arthroplasty on the low back pain and lumbar spine function in hip patients with or without scoliosis in lumbar spine. Shirasawa E1, Inoue G1, Miyagi M1, Saito W1, Imura T1, Nkazawa T1, Shoji S2, Takaso M1: 2019 ISSLS (2019/6/3-7), Kyoto, Japan. (”’àV‰hŽ÷1, ˆäã@Œº1, ‹{é³s1, âV“¡@˜j1, ˆä‘º‹M”V1, ’†àVr”V1, ¯Ži^‘Ÿ˜Y2, ‚‘Š»Žm1: 1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

713109. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Possible regulation of nerve growth factor by M1 and M2 macrophages following intervertebral disc injury in mice. Nakawaki M1, Uchida K2, Miyagi M2, Inoue G2, Takaso M2: 2019 ISSLS (2019/6/3-7), Kyoto, Japan. (’†˜e[Í1, “à“cŒ’‘Ÿ˜Y2, ‹{é³s2, ˆäã@Œº2, ‚‘Š»Žm2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO)

713110. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) The Relationship between Degree of Scoliosis and Body Composition In Adolescent Idiopathic Scoliosis. Takei S1, Miyagi M1, Saito W1, Inoue G1, Nakazawa T1, Imura T1, Shirasawa E1, Uekusa Y1, Inage K, Ohtori S, Uchida K1, Takaso M1: 2019 ISSLS (2019/6/3-7), Kyoto, Japan. (•ˆä³ˆê˜Y1, ‹{é³s1, âV“¡@˜j1, ˆäã@Œº1, ’†àVr”V1, ˆä‘º‹M”V1, ”’àV‰hŽ÷1, A‘—RˆÉ1, “à“cŒ’‘Ÿ˜Y1, ‚‘Š»Žm1: 1®ŠO)

713111. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Assessment Of The Relationship Between Hip Pain And Bone Marrow Edema Lesion In Hip Joint In The Patients With Pre-And/Or Early Osteoarthritis. Koyama T1, Fukushima K2, Ohashi Y1, Uchiyama K2, Takahira N3, Takaso M2: 20th European Federation of National Associations of Orthopaedics and Traumatology (EFORT) 2019 (2019/6/6), Lisbon, Portugal. (¬ŽR’q‹v1, •Ÿ“‡Œ’‰î2, ‘å‹ŽŒc‹v1, “àŽRŸ•¶2, ‚•œ®L3, ‚‘Š»Žm2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO, 3ˆã—Éq¶Šw•”)

713112. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Hip arthroscopy versus periacetabular osteotomy in patients with borderline dysplasia: A comparative study involving a minimum of 3years of follow-up. Fukushima K1, Takahira N2, Koyama T1, Ohashi Y1, Tsuchiya M1, Uchiyama K1, Takaso M1: 20th European Federation of National Associations of Orthopaedics and Traumatology (EFORT) 2019 (2019/6/6), Lisbon, Portugal. (•Ÿ“‡Œ’‰î1, ‚•œ®L2, ¬ŽR’q‹v1, ‘å‹ŽŒc‹v1, “y‰®^•ä1, “àŽRŸ•¶1, ‚‘Š»Žm1: 1®ŠO, 2ˆã—Éq¶Šw•”)

713113. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Efficacy of arthroscopic treatment for acute septic arthritis of hip joints in adult patients. Uekusa Y1, Fukushima K1, Koyama T2, Ohashi Y2, Matsumoto M1, Uchiyama K1, Takahira N3, Takaso M1: 20th European Federation of National Associations of Orthopaedics and Traumatology (EFORT) 2019 (2019/6/7), Lisbon, Portugal. (A‘—RˆÉ1, •Ÿ“‡Œ’‰î1, ¬ŽR’q‹v2, ‘å‹ŽŒc‹v2, Œ–{ŒõŒ\1, “àŽRŸ•¶1, ‚•œ®L3, ‚‘Š»Žm1: 1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ˆã—Éq¶Šw•”)

713114. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) The incidence of deep vein thrombosis (DVT) during hip arthroscopic surgery. Matsumoto M1, Fukushima K1, Takahira N2, Uchiyama K1, Moriya M1, Minato T1, Takaso M1: 20th European Federation of National Associations of Orthopaedics and Traumatology (EFORT) 2019 (2019/6/7), Lisbon, Portugal. (Œ–{ŒõŒ\1, •Ÿ“‡Œ’‰î1, ‚•œ®L2, “àŽRŸ•¶1, X’JŒõr1, –©@„Ž÷1, ‚‘Š»Žm1: 1®ŠO, 2ˆã—Éq¶Šw•”)

713115. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Thumb Carpometacarpal Arthrodesis using Locking Plate for Thumb Base Osteoarthritis. Onuma K1, Sukegawa K1, Otake Y1, Takaso M1: American Society for Surgery of the Hand (ASSH) Annual Meeting 2019 (2019/9/5), Las Vegas, USA. (¬ÀŒ«Ž¡1, •ì_Žm1, ‘å’|—IÆ1, ‚‘Š»Žm1: 1®ŠO)

713116. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Melting temperature mapping method for rapid identification of unknown pathogenic microorganisms for periprosthetic hip joint infection. Uchiyama K1, Niimi H, Sakurai K2, Ikeda S1, Fukushima K1, Moriya M1, Takahira N3, Kitajima I, Takaso M1: SICOT 2019 (2019/12/5), Muscat, Oman. (“àŽRŸ•¶1, mˆäŒ©‰pŽ÷, ŸNˆäŒc‘¢2, ’r“cM‰î1, •Ÿ“‡Œ’‰î1, X’JŒõr1, ‚•œ®L3, –k“‡@ŒM, ‚‘Š»Žm1: 1®ŠO, 2—ÕŒŸ•”, 3ˆã—Éq¶Šw•”)

721017. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ‚킪‘‚É‚š‚¯‚é, FAI‚̐f’f‚ÆŽ¡—Ã. •Ÿ“‡Œ’‰î (®ŠO): ‘æ46‰ñ“ú–{ŒÒŠÖßŠw‰ïŠwpW‰ï (2019/10/25), ‹{è.

721018. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ŠÈ’PEŠmŽÀ‚ɃtƒFƒAƒEƒFƒC‚ðƒL[ƒv‚·‚éTHA|HipGrid Drone‚ð—p‚¢‚œp’†Žx‰‡|. •Ÿ“‡Œ’‰î (®ŠO): ‘æ50‰ñ“ú–{lHŠÖßŠw‰ï (2020/2/22), •Ÿ‰ª.

722103. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) lHŠÖßŽüˆÍŠŽõ‚É‚š‚¯‚év‘¬f’f‚ÌŽŽ‚݁|PCR–@‚ƃ¿-Defensin|. “àŽRŸ•¶1, ŸNˆäŒc‘¢2, mˆäŒ©‰pŽ÷, _“cG”ü, •õŠÝ—mŽŸ˜Y1, ’r“cM‰î3, •Ÿ“‡Œ’‰î1, ‚•œ®L4, ‚‘Š»Žm1, ‚ŽR—zŽq5, ˜a“c’B•F6, ’†‘º³Ž÷4, ‰Ô–؏G–Ÿ (1®ŠO, 2—ÕŒŸ•”, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 4ˆã—Éq¶Šw•”,5V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 6äPŒŽ•aEŠŽõ“à): ‘æ93‰ñ“ú–{ŠŽõÇŠw‰ï‘‰ïEŠwpu‰‰‰ï (2019/4/4), –ŒŒÃ‰®.

722104. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) “ú–{‚Ì‘gDˆÚA‚ÌŒ»ó@œˆÚA‚ÌŒ»ó. è•”@Œ›1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2®ŠO): ‘æ92‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2019/5/9), ‰¡•l.

722105. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) lHŒÒŠÖßŽüˆÍŠŽõ‚Ì—\–h‚©‚猩‚œŽüpŠú‚Ì’ˆÓ“_. “àŽRŸ•¶1, ’r“cM‰î2, •õŠÝ—mŽŸ˜Y1, •Ÿ“‡Œ’‰î1, X’JŒõr1, ‚•œ®L3, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ˆã—Éq¶Šw•”): ‘æ92‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2019/5/10), ‰¡•l.

722106. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) Ò’ÅŠO‰È—̈æ‚ÌŽYŠ¯Šw˜AŒg‚É‚š‚¯‚é—Տ°ˆã‚Ì–ðŠ„@Ò’ÅŠO‰È—̈æ‚É‚š‚¯‚és­‚ƗՏ°Œ»ê‚Ì‹Ž“n‚µ‚ÉŠÖ‚·‚é—Տ°ˆã‚Ì–ðŠ„. ‹{é³s1, “à“cŒ’‘Ÿ˜Y1, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO): ‘æ93‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2019/6/11-8/31), webŠJÃ.

722107. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) Diagnosis for femoroacetabular impingement (FAI) in Japan. •Ÿ“‡Œ’‰î1, ‚•œ®L2, “àŽRŸ•¶1, ‚‘Š»Žm1 (1®ŠO, 2ˆã—Éq¶Šw•”): ‘æ11‰ñ“ú–{ŠÖß‹ŸE•GEƒXƒ|[ƒc®Œ`ŠO‰ÈŠw‰ï (JOSKAS2019) (2019/6/13), ŽD–y.

722108. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) lHŒÒŠÖßŽüˆÍŠŽõ‘΍ô|f’f‚ÆŽ¡—Á|. “àŽRŸ•¶1, ’r“cM‰î2, •õŠÝ—mŽŸ˜Y1, X’JŒõr1, •Ÿ“‡Œ’‰î1, ‚•œ®L3, ŸNˆäŒc‘¢4, mˆäŒ©‰pŽ÷, ‚‘Š»Žm (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ˆã—Éq¶Šw•”, 4—ÕŒŸ•”): ‘æ42‰ñ“ú–{œEŠÖßŠŽõÇŠw‰ï (2019/7/20), ‰¡•l.

722109. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ’ŊԔ«˜’É–«‰»‹@˜‚ÉŠÖ‚·‚錟“¢. ‹{é³s1, “à“cŒ’‘Ÿ˜Y1, ’†˜e[Í2, ì‹v•Û•à2, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ27‰ñ“ú–{˜’ÉŠw‰ï (2019/9/13-14), _ŒË.

722110. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) lHŠÖßŽüˆÍŠŽõ‚̐f’f|ƒoƒCƒIƒ}[ƒJ[‚ÆPCR|. “àŽRŸ•¶1, ŸNˆäŒc‘¢2, mˆäŒ©‰pŽ÷, _“cG”ü, •õŠÝ—mŽŸ˜Y1, ’r“cM‰î3, •Ÿ“‡Œ’‰î1, X’JŒõr1, Žë–ì—Lì4, ‚•œ®L5, ‚‘Š»Žm1 (1®ŠO, 2—ÕŒŸ•”, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 4—ÕŒŸŠw, 5ˆã—Éq¶Šw•”): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/18), ‰¡•l

722111. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ˜’Ƀ‚ƒfƒ‹‚ÌŠm—§‚ÆŽ¡—Ã^[ƒQƒbƒg. ‹{é³s1, ’†˜e[Í2, ì‹v•Û•à2, “à“cŒ’‘Ÿ˜Y1, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

722112. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) “«‘€œ^Ç‚ÌŽ¡—Á|ÇŒó«‚ðŠÜ‚߂ā|. ‚‘Š»Žm1, ’†àVr”V1, ˆä‘º‹M”V1, ˆäã@Œº1, ꎓ¡@˜j1, ‹{é³s1, ”’àV‰hŽ÷1 (1®ŠO): ‘æ53‰ñ“ú–{‘€œ]ÇŠw‰ïŠwpW‰ï (2019/11/8-9), ŒQ”n.

723452. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’ŊԔ‚ւ̉׏d•‰‰×‚ªáu’ÉŠÖ˜A•šŽ¿‚Ì”­Œ»‚ðŽä‹N‚·‚é. ‹{é³s1, ’†˜e[Í2, “à“cŒ’‘Ÿ˜Y1, ‚–쏞‘Ÿ˜Y1, ˆäã@Œº1, ’†àVr”V1, ˆä‘º‹M”V1, âV“¡@˜j1, ”’àV‰hŽ÷1, ì‹v•Û•à2, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ48‰ñ“ú–{Ò’ŐҐ‘•aŠw‰ïŠwpW‰ï (2019/4/18-20), ‰¡•l.

723453. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Ò’Œ•ÏŒ`‹ž³ŒÅ’èpŒã‚̍Ďèp—á‚ÌŒŸ“¢. •“cW‹`1, ˆä‘º‹M”V2, ˆäã@Œº2, âV“¡@˜j2, ’†àVr”V2, ‹{é³s2, ”’àV‰hŽ÷2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO): ‘æ48‰ñ“ú–{Ò’ŐҐ‘•aŠw‰ïŠwpW‰ï (2019/4/18-20), ‰¡•l.

723454. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) lHŒÒŠÖß‘S’uŠ·p‚ªÒ’Œœ”ÕƒAƒ‰ƒCƒƒ“ƒg‚È‚ç‚тɍ˜’É‚Ö—^‚Š‚é‰e‹¿. ¯Ži^‘Ÿ˜Y1, ˆäã@Œº2, “àŽRŸ•¶2, ’†àVr”V2, ‹{é³s2, âV“¡@˜j2, ˆä‘º‹M”V2, •Ÿ“‡Œ’‰î2, ”’àV‰hŽ÷2, ‚•œ®L3, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO, 3ˆã—Éq¶Šw•”): ‘æ48‰ñ“ú–{Ò’ŐҐ‘•aŠw‰ïŠwpW‰ï (2019/4/18-20), ‰¡•l.

723455. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “]ˆÚ«Ò’ÅŽîᇂɂæ‚é_Œo–ƒáƒ‚ɑ΂µ‹Ù‹}Žèp‚ð—v‚µ‚œ42—á‚ÌŽèp¬Ñ‚ÌŒŸ“¢. Šz‰ê—BŽŠ, ”’àV‰hŽ÷1, Žðˆä‘å•ã, ˆäã@Œº1, žwŽR–Ÿ•F, “c’†^O, ‰Á“¡—TK, ²“¡³l, ’†àVr”V1, ˆä‘º‹M”V1, ‹{é³s1, âV“¡@˜j1, ‚‘Š»Žm1, “n•Ó‰ë•F (1®ŠO): ‘æ48‰ñ“ú–{Ò’ŐҐ‘•aŠw‰ïŠwpW‰ï (2019/4/18-20), ‰¡•l.

723456. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘ÌŠ²‹Ø—Ê‚Ì•a‘ÔˆÓ‹`@˜’É, ˜’Å‹@”\, Ò’Œƒoƒ‰ƒ“ƒX‚É‹y‚Ú‚·‰e‹¿. –x@—I‰î, ¯–ì‰ër, ‚‹Ž^Ž¡, —é–Ø‹œ’š, ’Ò”ö—B—Y, Ž›ˆäG•x, “°‰€@«, Žu‰êN_, ˆî–шêG, Ü“cƒ‹v, ‘º“cK—C1, ‹{é³s2, ˆäã@Œº2, ‘å’¹žŽi, ‚‘Š»Žm2, ’†‘º”Ž—º (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO): ‘æ48‰ñ“ú–{Ò’ŐҐ‘•aŠw‰ïŠwpW‰ï (2019/4/18-20), ‰¡•l.

723457. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) œ‘e頏NJ³ŽÒ‚̐ҒŒŒãœ]Çg˜‚Ü‚ª‚èh‚Ì—L•a—Š‚Æ‚»‚Ì“Á’¥. Œ‰iV”V1, ‹{é³s1, ‘º“cK—C2, ˆäã@ãÄ1, ¬ŽR’q‹v2, ‘å’|—IÆ1, •“cW‹`2, ì‹v•Û•à2, ‘å’¹žŽi, ˆî–шêG, ŠÖŒû—T”V1, “à“cŒ’‘Ÿ˜Y1, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ48‰ñ“ú–{Ò’ŐҐ‘•aŠw‰ïŠwpW‰ï (2019/4/18-20), ‰¡•l.

723458. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒTƒ‹ƒRƒyƒjƒA‚ð‡•¹‚µ‚œŒŽ”­«œ‘e頏NJ³ŽÒ‚̍˜’ɂƉh—{ó‘Ô. –î–씎”V1, ‹{é³s1, ‘º“cK—C2, ˆäã@ãÄ1, ¬ŽR’q‹v2, ‘å’|—IÆ1, •“cW‹`2, ì‹v•Û•à2, ‘å’¹žŽi, ˆî–шêG, ŠÖŒû—T”V1, “à“cŒ’‘Ÿ˜Y1, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ48‰ñ“ú–{Ò’ŐҐ‘•aŠw‰ïŠwpW‰ï (2019/4/18-20), ‰¡•l.

723459. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –«t‘Ÿ•a‚ªœ‘e頏NJ³ŽÒ‚̍˜’É‚âÒ’ŒƒAƒ‰ƒCƒƒ“ƒg‚É‹y‚Ú‚·‰e‹¿. Œ–{ŒõŒ\1, ‹{é³s1, ‘º“cK—C2, ˆäã@ãÄ1, ¬ŽR’q‹v2, ‘å’|—IÆ1, •“cW‹`2, ‘å’¹žŽi, “à“cŒ’‘Ÿ˜Y1, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ48‰ñ“ú–{Ò’ŐҐ‘•aŠw‰ïŠwpW‰ï (2019/4/18-20), ‰¡•l.

723460. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) lHŒÒŠÖß‘S’uŠ·pŠ³ŽÒ‚̏p‘OÒ’Œ‘€œ]‚͏pŒã˜’ɁE˜’Å‹@”\‚ɉe‹¿‚ð—^‚Š‚é‚©? ”’àV‰hŽ÷1, ˆäã@Œº1, âV“¡@˜j1, ‹{é³s1, ˆä‘º‹M”V1, ’†àVr”V1, ‚‘Š»Žm1 (1®ŠO): ‘æ48‰ñ“ú–{Ò’ŐҐ‘•aŠw‰ïŠwpW‰ï (2019/4/18-20), ‰¡•l.

723461. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŽvtŠú“Á”­«‘€œ]Ç‚̈âŽc•ÏŒ`‚ɑ΂·‚é“Á’¥: Žèp—á‚É‚š‚¯‚錟“¢. âV“¡@˜j1, ˆäã@Œº1, ‹{é³s1, ˆä‘º‹M”V1, ’†àVr”V1, ”’àV‰hŽ÷1, “à“cŒ’‘Ÿ˜Y1, ‚‘Š»Žm1 (1®ŠO): ‘æ48‰ñ“ú–{Ò’ŐҐ‘•aŠw‰ïŠwpW‰ï (2019/4/18-20), ‰¡•l.

723462. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŒÒŠÖßO‘¹‚š‚æ‚Ñfemoroacetabular impingement (FAI) ‚Æ‚µ‚ďЉ‚ê‚œŠ³ŽÒ‚̍ŏIf’f‚ÌŒŸ“¢. ‰¡ŠÖ—YŽi1, •Ÿ“‡Œ’‰î2, ¬ŽR’q‹v1, ‘å‹ŽŒc‹v1, “àŽRŸ•¶2, ‚•œ®L3, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO, 3ˆã—Éq¶Šw•”): ‘æ92‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwpW‰ï (2019/5/11), ‰¡•l.

723463. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Šw“¶ŠúƒXƒ|[ƒcŠQ‚ɑ΂·‚éŒÒŠÖß‹ŸŽ‹‰ºŽèp. ¬ŽR’q‹v1, •Ÿ“‡Œ’‰î2, ‘å‹ŽŒc‹v1, “àŽRŸ•¶2, ‚•œ®L3, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO, 3ˆã—Éq¶Šw•”): ‘æ92‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwpW‰ï (2019/5/11), ‰¡•l.

723464. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Š°œ‰P”í•¢‚ƐҒōœ”Õ–îó–ʃAƒ‰ƒCƒƒ“ƒg‚Æ‚ÌŠÖ˜A‚ÌŒŸ“¢. •Ÿ“‡Œ’‰î1, ‹{é³s1, ˆäã@Œº1, ”’àV‰hŽ÷1, ‘å’|—IÆ1, “àŽRŸ•¶1, ‚•œ®L2, ‚‘Š»Žm1 (1®ŠO, 2ˆã—Éq¶Šw•”): ‘æ92‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwpW‰ï (2019/5/11), ‰¡•l.

723465. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’ŊԔ‚ւ̃ƒJƒjƒJƒ‹ƒXƒgƒŒƒX‚Æáu’ÉŠÖ˜A•šŽ¿‚Ì”­Œ»‚Æ‚ÌŠÖŒW. ‹{é³s1, ’†˜e[Í2, “à“cŒ’‘Ÿ˜Y1, ‚–쏞‘Ÿ˜Y1, ˆäã@Œº1, ŠÖŒû—T”V1, ’†àVr”V1, ˆä‘º‹M”V1, âV“¡@˜j1, ”’àV‰hŽ÷1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ93‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2019/6/11-8/31), webŠJÃ.

723466. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Ò’ÅŽèp‚É‚š‚¯‚é‘å—ʏoŒŒ‚̊댯ˆöŽq‚ÉŠÖ‚·‚錟“¢. “팎Œ’Žj1, ˆäã@Œº1, âV“¡@˜j1, ’†àVr”V1, ‹{é³s1, ˆä‘º‹M”V1, ”’àV‰hŽ÷1, ˆäã@ãÄ1, Ž›–{—m•œ1, ‚‘Š»Žm1 (1®ŠO): ‘æ93‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2019/6/11-8/31), webŠJÃ.

723467. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŒãŠú‚—îŽÒ‚ɑ΂·‚鐬lÒ’Œ•ÏŒ`Žèp‚̐¬Ñ. âV“¡@˜j1, ˆäã@Œº1, ˆä‘º‹M”V1, ’†àVr”V1, ‹{é³s1, ”’àV‰hŽ÷1, “à“cŒ’‘Ÿ˜Y1, ‚‘Š»Žm1 (1®ŠO): ‘æ93‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2019/6/11-8/31), webŠJÃ.

723468. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •ÏŒ`«•GŠÖßÇŠ³ŽÒ‚ÌŠŠ–Œ‘gD‚É‚š‚¢‚ÄTGF-ƒÀ‚͐_Œo¬’·ˆöŽq‚ÌŽå‚œ‚é”­Œ»§ŒäˆöŽq‚Å‚ ‚é. ‚–쏞‘Ÿ˜Y1, “à“cŒ’‘Ÿ˜Y1, Œ}@@Šw2, Šâ£@‘å1, ‘Šì@~1, ‹{é³s1, ˆäã@Œº1, ŠÖŒû—T”V1, ‘åŠÑ—TŽq3, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3•a‘ԁEf—ÃŒn): ‘æ93‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2019/6/11-8/31), webŠJÃ.

723469. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) lHŒÒŠÖß‘S’uŠ·p‚ª˜’É‚âÒ’ōœ”Õƒpƒ‰ƒ[ƒ^[‚É—^‚Š‚é‰e‹¿. ¯Ži^‘Ÿ˜Y1, ˆäã@Œº2, “àŽRŸ•¶2, ’†àVr”V2, ‹{é³s2, âV“¡@˜j2, ˆä‘º‹M”V2, •Ÿ“‡Œ’‰î2, ”’àV‰hŽ÷2, ‚•œ®L3, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO, 3ˆã—Éq¶Šw•”): ‘æ93‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2019/6/11-8/31), webŠJÃ.

723470. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) œ‘e頏NJ³ŽÒ‚̐ҒŒŒãœ]Çu˜‚Ü‚ª‚èv—L•a—Š‚Æ“Á’¥. Œ‰iV”V1, ‹{é³s1, ‘º“cK—C2, “à“cŒ’‘Ÿ˜Y1, ˆäã@Œº1, ‚‘Š»Žm1, ‘å’¹žŽi, ˆî–шêG, ŠÖŒû—T”V1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ93‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2019/6/11-8/31), webŠJÃ.

723471. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) lHŒÒŠÖß‘S’uŠ·p (THA) Š³ŽÒ‚̏p‘O‚̐ҒŒ‘€œ]‚ªpŒã˜’ɁE˜’Å‹@”\‚É—^‚Š‚é‰e‹¿. ”’àV‰hŽ÷1, ˆäã@Œº1, ¯Ži^‘Ÿ˜Y2, ‹{é³s1, âV“¡@˜j1, ˆä‘º‹M”V1, ’†àVr”V1, •Ÿ“‡Œ’‰î1, “àŽRŸ•¶1, ‚•œ®L3, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3•a‘ԁEf—ÃŒn): ‘æ93‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2019/6/11-8/31), webŠJÃ.

723472. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Ò’Œ•ÏŒ`‹ž³ŒÅ’èpŒã‚̍Ďèp—á‚ÌŒŸ“¢. •“cW‹`1, ˆä‘º‹M”V2, ˆäã@Œº2, âV“¡@˜j2, ‹{é³s2, ’†àVr”V2, ”’àV‰hŽ÷2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO): ‘æ93‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2019/6/11-8/31), webŠJÃ.

723473. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Ò’Œ•ÏŒ`‚ɑ΂·‚鍜Ø‚èp‚̃Aƒvƒ[ƒ`‚ÉŠÖ‚·‚錟“¢. ˆäã@Œº1, ˆä‘º‹M”V1, âV“¡@˜j1, ‹{é³s1, ’†àVr”V1, ”’àV‰hŽ÷1, ì‹v•Û•à2, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ93‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2019/6/11-8/31), webŠJÃ.

723474. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) œ‘e頏ǂƌ’NŠÖ˜AQOL‚ÌŠÖŒW. ŽO‘º—I—S1, ‹{é³s1, ‘º“cK—C2, ˆäã@ãÄ1, ¬ŽR’q‹v2, ‘å’|—IÆ1, •“cW‹`2, ì‹v•Û•à2, “à“cŒ’‘Ÿ˜Y1, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ93‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2019/6/11-8/31), webŠJÃ.

723475. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒrƒXƒtƒHƒXƒtƒHƒl[ƒg»Ü‚Ì‘O“Š—^‚ªweekly PTH»Ü‚ÌŽ¡—ÃŒø‰Ê‚É—^‚Š‚é‰e‹¿. ‘º“cK—C1, ‹{é³s2, •Ä“c¹L2, “c“‡Gˆê˜Y2, ¬ŽR’q‹v1, ˆäã@ãÄ2, ì‹v•Û•à1, “à“cŒ’‘Ÿ˜Y2, ˆäã@Œº2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO): ‘æ93‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2019/6/11-8/31), webŠJÃ.

723476. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Š°œ‰P”í•¢‚ƐҒōœ”Õ–îó–ʃAƒ‰ƒCƒƒ“ƒg‚Æ‚ÌŠÖŒW‚ÌŒŸ“¢. •Ÿ“‡Œ’‰î1, ‹{é³s1, ˆäã@Œº1, ”’àV‰hŽ÷1, ‘å’|—IÆ1, “àŽRŸ•¶1, ‚•œ®L2, ‚‘Š»Žm1 (1®ŠO, 2ˆã—Éq¶Šw•”): ‘æ93‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2019/6/11-8/31), webŠJÃ.

723477. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) œ‘e頏ǎ¡—×ð‚Ì‚È‚¢Š³ŽÒ‚ɑ΂·‚élH•GŠÖß’uŠ·p‘OŒã‚É‚š‚¯‚é‹ßˆÊ‘å‘ڍœœ–§“x‚ÌŒoŽž“I•Ï‰»‚ÌŒŸ“¢. –©²‘ãŽq1, Šâ£@‘å1, ‘Šì@~11, “ŒŽR—玡1, ‹{é³s1, “à“cŒ’‘Ÿ˜Y1, ‚–쏞‘Ÿ˜Y1, Œ}@@Šw2, –ÚŽž—LŠóŒb1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ93‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2019/6/11-8/31), webŠJÃ.

723478. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰È‚É‚š‚¯‚éŒÒŠÖßO‘¹‚ɑ΂·‚éŒÒŠÖß‹ŸŽ‹‰ºƒfƒuƒŠƒhƒ}ƒ“‚Ì5”N¬Ñ. •ˆä³ˆê˜Y1, •Ÿ“‡Œ’‰î1, ¬ŽR’q‹v2, ‘å‹ŽŒc‹v2, “àŽRŸ•¶1, ‚•œ®L3, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ˆã—Éq¶Šw•”): ‘æ11‰ñ“ú–{ŠÖß‹ŸE•GEƒXƒ|[ƒc®Œ`ŠO‰ÈŠw‰ï (JOSKAS2019) (2019/6/14), ŽD–y.

723479. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) èò’Å’E‰PœÜpŒã‚ɐ¶‚¶‚œ”]Š²[Ç‚̈ê—á. ’Ë“cˆŸ—T”ü1, ‹{é³s1, ˆä‘º‹M”V1, ˆäã@Œº1, ’†àVr”V1, ꎓ¡@˜j1, ”’àV‰hŽ÷1, •ôŒŽG¹2, Œ‰YW³1, ‚‘Š»Žm1 (1®ŠO, 2‹~–œ): ‘æ45‰ñ“ú–{œÜŽ¡—Êw‰ï (2019/6/28-29), •Ÿ‰ª.

723480. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒ‰ƒbƒg¿œ_Œo‘¹ƒ‚ƒfƒ‹‚ɑ΂·‚鉖Šî«üˆÛ‰è×–E‘BˆöŽq“Y‰ÁƒRƒ‰[ƒQƒ“ƒV[ƒg‚Ì’ÉŠo‰ß•q—}§Œø‰Ê‚ÆHO-1—U“±”\‚ÌŒŸ“¢. Œüˆä–±W, “à“cŒ’‘Ÿ˜Y1, œAàV’Œ–ç, Žu‰êN_, ˆî–шêG, Ü“cƒ‹v, Žu‰êN_, ‹{é³s1, ˆäã@Œº1, ‚‘Š»Žm1, ‘å’¹žŽi (1®ŠO): ‘æ41‰ñ“ú–{áu’ÉŠw‰ï (2019/7/12-13), –ŒŒÃ‰®.

723481. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠÖß–Ê‚ðŠÜ‚ލL”͈͍œ“Œ‡‘¹‚ɑ΂·‚éV‚µ‚¢ÄŒš•û–@‚ÌŽŽ‚Ý. è•”@Œ›1,2, •œì‹IŽq1,2, •ôŠÝ—mŽŸ˜Y1,2, ‹{•”@Šî (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2®ŠO): ‘æ18‰ñ“ú–{‘gDˆÚAŠw‰ï‘‰ïEŠwpW‰ï (2019/8/3), –ŒŒÃ‰®.

723482. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “¯ŽíœˆÚA‚ÆŠŠ–ŒŠÔ—tŒn×–EˆÚA‚𕹗p‚µ‚œœ“Œ‡‘¹Ä¶–@‚Ì—L—p«‚ÌŒŸ“¢. ¬ÀŒ«Ž¡1, “à“cŒ’‘Ÿ˜Y1, ‘º“cK—C2, •ì_Žm1, Š}ŒŽ‚Ý‚Ç‚è, ’†ŽR»Žq, Œ–{@•‘, ˆäã@Œº1, è•”@Œ›1,3, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ18‰ñ“ú–{‘gDˆÚAŠw‰ï‘‰ïEŠwpW‰ï (2019/8/3), –ŒŒÃ‰®.

723483. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’j«œ‘e頏ǂ̍˜’É‚Æ•às‹@”\áŠQ‚ÉŠÖ—^‚·‚éˆöŽq. ‹gàV@‘×1, ‹{é³s1, ‰¡ŠÖ—YŽi2, ‘º“cK—C2, ¬ŽR’q‹v2, ì‹v•Û•à2, ‘å’¹žŽi, ˆî–шêG, “à“cŒ’‘Ÿ˜Y1, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ27‰ñ“ú–{˜’ÉŠw‰ï (2019/9/13-14), _ŒË.

723484. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚—‘e頏NJ³ŽÒ‚É‚š‚¯‚錒NŠÖ˜AQOL‚ÌŒŸ“¢. ŽO‘º—I—S1, ‹{é³s1, “c“‡Gˆê˜Y1, ‘º“cK—C2, ˆäã@ãÄ1, ¬ŽR’q‹v2, “¡ŠªŽõŽq, “à“cŒ’‘Ÿ˜Y1, {ŠÖ@Š]1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ27‰ñ“ú–{˜’ÉŠw‰ï (2019/9/13-14), _ŒË.

723485. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) œ‘e頏NJ³ŽÒ‚̈ݐH“¹‹t—¬Çó‚ƐҒŒ–îó–ʃAƒ‰ƒCƒƒ“ƒg. Œ–{ŒõŒ\1, •ˆä³ˆê˜Y1, ‹{é³s1, ‘º“cK—C2, ¬ŽR’q‹v2, ì‹v•Û•à2, “à“cŒ’‘Ÿ˜Y1, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ27‰ñ“ú–{˜’ÉŠw‰ï (2019/9/13-14), _ŒË.

723486. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –«t‘Ÿ•a‚ªœ‘e頏NJ³ŽÒ‚̗Տ°ŠŒ©‚É‹y‚Ú‚·‰e‹¿‚ÌŒŸ“¢. •ˆä³ˆê˜Y1, ‹{é³s1, Œ–{ŒõŒ\1, ‘º“cK—C2, ¬ŽR’q‹v2, ‘å’|—IÆ1, ꎓ¡LŽ÷1, ì‹v•Û•à2, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ21‰ñ“ú–{œ‘e頏NJw‰ï (2019/10/11-13), _ŒË.

723487. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) lH•GŠÖß’uŠ·p‘OŒã‚É‚š‚¯‚é‹ßˆÊ‘å‘ڍœœ–§“x‚ÌŒoŽž“I•Ï‰»‚ɂ‚¢‚Ä. –©²‘ãŽq1, Šâ£@‘å1, Œ}@@Šw2, ‘Šì@~1, “ŒŽR—玡1, ‚–쏞‘Ÿ˜Y1, ‹{é³s1, “à“cŒ’‘Ÿ˜Y1, –ÚŽž—LŠóŒb1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ21‰ñ“ú–{œ‘e頏NJw‰ï (2019/10/11-13), _ŒË.

723488. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒfƒmƒXƒ}ƒu“Š—^‚É‚š‚¯‚镹—pƒrƒ^ƒ~ƒ“D»Ü‚ª—^‚Š‚é‰e‹¿‚ÉŠÖ‚·‚錟“¢: ƒfƒmƒ^ƒX‚ƃGƒ‹ƒfƒJƒ‹ƒVƒg[ƒ‹‚̈Ⴂ. ꎓ¡LŽ÷1, ‘å’|—IÆ1, ‹{é³s1, ÎìhŽi, ‰iˆä—²Žm, ’J@‘“ñ, “y‰®OŽ÷, ˆäã@Œº1, ˆîŠ_Ž‹L, ‚‘Š»Žm1 (1®ŠO): ‘æ21‰ñ“ú–{œ‘e頏NJw‰ï (2019/10/11-13), _ŒË.

723489. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒXƒeƒƒCƒh«œ‘e頏ǂɑ΂·‚éƒfƒmƒXƒ}ƒu“Š—^‚ÌŒø‰Ê‚ÌŒŸ“¢: ŒŽ”­«œ‘e頏ǂƂ̔äŠr. ‘å’|—IÆ1, ꎓ¡LŽ÷1, ‹{é³s1, ÎìhŽi, ‰iˆä—²Žm, ’J@‘“ñ, “y‰®OŽ÷, ˆäã@Œº1, ˆîŠ_Ž‹L, ‚‘Š»Žm1 (1®ŠO): ‘æ21‰ñ“ú–{œ‘e頏NJw‰ï (2019/10/11-13), _ŒË.

723490. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) œ‘e頏NJ³ŽÒ‚̍˜’ɂɑ΂·‚éWeekly PTH»Ü‚ÌŒø‰Ê. ‘º“cK—C1, ‹{é³s2, ¬ŽR’q‹v1, ì‹v•Û•à1, Œ–{ŒõŒ\2, •Ä“c¹L2, ‚‰ªƒˆê2, “à“cŒ’‘Ÿ˜Y2, ˆäã@Œº2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO): ‘æ21‰ñ“ú–{œ‘e頏NJw‰ï (2019/10/11-13), _ŒË.

723491. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) œ‘e頏NJ³ŽÒ‚̐ҒŒ–îó–ʃAƒ‰ƒCƒƒ“ƒgˆÙíg˜‚Ü‚ª‚èh‚Ì—L•a—Š‚Æ‚»‚Ì“Á’¥. Œ‰iV”V1, ‹{é³s1, ‘º“cK—C2, ¬ŽR’q‹v2, •ˆä³ˆê˜Y1, ’Ë“cˆŸ—T”ü1, ì‹v•Û•à2, “à“cŒ’‘Ÿ˜Y1, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ21‰ñ“ú–{œ‘e頏NJw‰ï (2019/10/11-13), _ŒË.

723492. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Ò’ÅŽèp’†‚Ì‹¹’ōd–ŒŠOŽ‰–bŽî‚É‚æ‚èf’f‚µ“Ÿ‚œ‘±”­«œ‘e頏ǂÌ1—á. “c’†ŒcG1, ‹{é³s1, –©²‘ãŽq1, ˆäã@Œº1, ’†àVr”V1, ˆä‘º‹M”V1, ꎓ¡@˜j1, ”’àV‰hŽ÷1, ì‹v•Û•à2, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ21‰ñ“ú–{œ‘e頏NJw‰ï (2019/10/11-13), _ŒË.

723493. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) œ‘e頏NJ³ŽÒ‚ÌŒ’NŠÖ˜AQOL‚É—^‚Š‚é‰e‹¿ˆöŽq‚ÌŒŸ“¢. ¬ŽR’q‹v1, ‹{é³s2, ‘º“cK—C1, •“cW‹`1, ì‹v•Û•à1, ‘å’¹žŽi, ˆî–шêG, “à“cŒ’‘Ÿ˜Y2, ˆäã@Œº2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO): ‘æ21‰ñ“ú–{œ‘e頏NJw‰ï (2019/10/11-13), _ŒË.

723494. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰Á—î‚É”º‚€œŠi‹ØƒŒƒvƒ`ƒ“”­Œ»ãž‚Í, ‹Ø‘gD“à‚É‚š‚¯‚éIL-6ŽY¶‚ð—U“±‚·‚é. “càV@—È1, “à“cŒ’‘Ÿ˜Y2, ‹{é³s2, “¡ŠªŽõŽq, ˆäã@Œº2, ‘º“cK—C1, ŠÖŒû—T”V2, ‚“c@Œ€1, ì‹v•Û•à1, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO): ‘æ21‰ñ“ú–{œ‘e頏NJw‰ï (2019/10/11-13), _ŒË.

723495. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰Á—‹Ø“÷Œž­ÇƒTƒ‹ƒRƒyƒjƒA‚ð‡•¹‚µ‚œŒŽ”­«œ‘e頏NJ³ŽÒ‚̍˜’ɂƉh—{ó‘Ô. –î–씎”V1, ‹{é³s1, ‘º“cK—C2, ¬ŽR’q‹v2, ‹{“c@Ž÷1, ‘å’¹žŽi, ˆî–шêG, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ21‰ñ“ú–{œ‘e頏NJw‰ï (2019/10/11-13), _ŒË.

723496. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˜•”Ò’ŒŠÇ‹·óÇŽèp‚É‚š‚¯‚é‹Ø“÷—ʂ̉e‹¿‚ÌŒŸ“¢. ì‹v•Û•à1, ‹{é³s2, ’†àVr”V2, ˆä‘º‹M”V2, âV“¡@˜j2, ”’àV‰hŽ÷2, ‘å’¹žŽi, ˆî–шêG, ˆäã@Œº2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO): ‘æ21‰ñ“ú–{œ‘e頏NJw‰ï (2019/10/11-13), _ŒË.

723497. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰–Šî«üˆÛ‰è×–E‘BˆöŽqŠÜ—L‹ÇŠd‰»ƒqƒAƒ‹ƒƒ“Ž_ƒQƒ‹, ‹ÇŠd‰»ƒfƒLƒXƒgƒ‰ƒ“ƒQƒ‹‚̍œŒ`¬‘£i”\‚Ì”äŠrŒŸ“¢. ¯Ži^‘Ÿ˜Y1, “à“cŒ’‘Ÿ˜Y2, ŠÖŒû—T”V2, ˆäã@Œº2, ‹{é³s2, ‘º“cK—C1, ì‹v•Û•à1, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

723498. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒ‰ƒbƒg¿œ_Œo‘¹ƒ‚ƒfƒ‹‚ɑ΂·‚鉖Šî«‘@ˆÛ‰è×–E‘BˆöŽq“Y‰ÁƒRƒ‰[ƒQƒ“ƒV[ƒg‚Ì’ÉŠo‰ß•q—}§Œø‰Ê‚ÆHO-1—U“±”\‚ÌŒŸ“¢. Œüˆä–±W, “à“cŒ’‘Ÿ˜Y1, œAàV’Œ–ç, ‘ºãŒ«ˆê, ˆî–шêG, Ü“cƒ‹v, Œ‰Y—S‰î, ˆäã@Œº1, š ‹gˆêŽ÷, ‚‘Š»Žm1, ‘å’¹žŽi (1®ŠO): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

723499. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) äF”Â’f—ôŠ³ŽÒ‚ÌŠŠ–Œ‘gD‚É‚š‚¢‚ÄNGF”­Œ»‚ªãž‚·‚é. “càV@—È1, Œ©–Ú’q‹I2, “à“cŒ’‘Ÿ˜Y2, –Œ‘q’Œd, ’†˜e[Í1, ‘åŠÑ—TŽq3, ˆäã@Œº2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO, 3•a‘ԁEf—ÃŒn): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

723500. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’ŊԔ“àÝ«ƒ}ƒNƒƒtƒ@[ƒW‚Ì•ª‰»”\‚ÌŒŸ“¢. ì‹v•Û•à1, “à“cŒ’‘Ÿ˜Y2, ‹{é³s2, ’†˜e[Í1, ˆäã@Œº2, âV“¡@˜j2, ŠÖŒû—T”V2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

723501. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) GFPœ‘ƒLƒƒ‰ƒ}ƒEƒX‚ð—p‚¢‚œ’ŊԔáŠQŒã‚É‘‰Á‚·‚éƒ}ƒNƒƒtƒ@[ƒW‚Ì‹NŒ¹‰ðÍ. ì‹v•Û•à1, “à“cŒ’‘Ÿ˜Y2, ‹{é³s2, ’†˜e[Í1, ˆäã@Œº2, âV“¡@˜j2, ŠÖŒû—T”V2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

723502. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •ÏŒ`«•GŠÖßÇ‚ÌŠŠ–Œ‘gD‚É‚š‚¢‚ÄTGF-ƒÀ‚É‚æ‚Á‚Ä—U“±‚³‚ê‚é_Œoƒyƒvƒ`ƒh‚Ì’Tõ. ‚–쏞‘Ÿ˜Y1, “à“cŒ’‘Ÿ˜Y1, ‘Šì@~1, Šâ£@‘å1, Œ}@@Šw2, ‹{é³s1, ˆäã@Œº1, ŠÖŒû—T”V1, ‘åŠÑ—TŽq3, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3•a‘ԁEf—ÃŒn): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

723503. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) äF”Â’f—ôŽž‚ÌApelin‚Ì”­Œ»‚ÌŒŸ“¢. ’†˜e[Í1, Œ©–Ú’q‹I2, “à“cŒ’‘Ÿ˜Y2, –Œ‘q’Œd, “càV@—È1, @d‹¿Žq1, ˆäã@Œº2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

723504. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) äF”Â’f—ôŒã‚Ì–«Šú‚É‚š‚¯‚éTGF-ƒÀãž‚ÍNGFŽY¶‚ÉŠÖ—^‚·‚é. –Œ‘q’Œd, Œ©–Ú’q‹I1, ’†˜e[Í2, “à“cŒ’‘Ÿ˜Y1, “càV@—È2, @d‹¿Žq2, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

723505. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒoƒ“ƒRƒ}ƒCƒVƒ“ŠÜ—LƒŠƒ“Ž_ƒJƒ‹ƒVƒEƒ€ƒZƒƒ“ƒg‚̐¶‘Ì“à–„“üŒã‚̃oƒ“ƒRƒ}ƒCƒVƒ“R‹ÛŠˆ«•]‰¿. “à“cŒ’‘Ÿ˜Y1, ›¶@Œ’, ’†“‡••F, ŠÖŒû—T”V1, è•”@Œ›1,2, ‚‘Š»Žm1 (1®ŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

723506. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) BMP-2ŠÜ—LlHƒRƒ‰[ƒQƒ“ƒQƒ‹‚͍œˆÚ“®p‚É‚š‚¯‚édocking site‚̍œ–ü‡‚𑣐i‚·‚é. “càV@—È1, •ôŒŽG¹2, Œ‰YW³3, ‰Í‘º@’Œ3, “à“cŒ’‘Ÿ˜Y3, ˆäã@Œº3, ¯Ži^‘Ÿ˜Y1, âŒûŽµŠC1, ‘åŠÑ—TŽq4, ‚‘Š»Žm3 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2‹~–œ, 3®ŠO, 4•a‘ԁEf—ÃŒn): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

723507. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”ì–žŠ³ŽÒ‚ÌŠŠ–Œ‰ºŒ‹‡‘gD‚Å‚ÍCOL1A1, COL3A1‚Ì”­Œ»‚ª˜Ži‚µ‚Ä‚¢‚é. ’†˜e[Í1, “à“cŒ’‘Ÿ˜Y2, ¬ÀŒ«Ž¡2, •ì_Žm2, Œ©–Ú’q‹I2, –Œ‘q’Œd, “càV@—È1, ‘åŠÑ—TŽq3, ˆäã@Œº2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO, 3•a‘ԁEf—ÃŒn): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

723508. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒqƒg’ŊԔ‘gD‚É‚š‚¯‚éTGF-ƒÀ‚ð‰î‚µ‚œNGF”­Œ»§Œä. ‹{é³s1, “à“cŒ’‘Ÿ˜Y1, ’†˜e[Í2, ì‹v•Û•à2, ˆäã@Œº1, ’†àVr”V1, ˆä‘º‹M”V1, âV“¡@˜j1, ”’àV‰hŽ÷1, ŠÖŒû—T”V1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

723509. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰h—{ó‘Ô•s—ǂŒŊԔ‚ɂš‚¯‚鉊Ç«ƒTƒCƒgƒJƒCƒ“‚Ì”­Œ»‚ªãž‚·‚é. ‰¡ŠÖ—YŽi1, ‹{é³s2, “à“cŒ’‘Ÿ˜Y2, ì‹v•Û•à1, ‘åŠÑ—TŽq3, ˆäã@Œº2, ’†àVr”V2, ˆä‘º‹M”V2, âV“¡@˜j2, ”’àV‰hŽ÷2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO, 3•a‘ԁEf—ÃŒn): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

723510. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠÖßƒŠƒ…ƒEƒ}ƒ`Š³ŽÒ‚ÌŠŠ–Œƒ}ƒNƒƒtƒ@[ƒW‚É‚š‚¢‚ÄCŒ^ƒŒƒNƒ`ƒ“Žó—e‘Ìmacrophage inducible C-type lectin‚Ì”­Œ»‚͘Ži‚µ‚Ä‚¢‚é. X’JŒõr1, “à“cŒ’‘Ÿ˜Y1, ‚–쏞‘Ÿ˜Y1, Šâ£@‘å1, ˆäã@Œº1, ‹{é³s1, ŠÖŒû—T”V1, ‘åŠÑ—TŽq2, ‚‘Š»Žm1 (1®ŠO, 2•a‘ԁEf—ÃŒn): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

723511. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Vein wrapping‚É‚æ‚é’ÉŠo‰ß•q—}§Œø‰Ê, _Œo•ÛŒìŒø‰Ê‚Ívein—R—ˆ‰t«ˆöŽq‚ÆwrappingŒø‰Ê‚É‚æ‚è—U“±‚³‚ê‚é. Œüˆä–±W, “à“cŒ’‘Ÿ˜Y1, œAàV’Œ–ç, Žu‰êN_, Ü“cƒ‹v, ‹{é³s1, ‘ºãŒ«ˆê, Œ‰Y—C‰î, š ‹gˆêŽ÷, ‚‘Š»Žm1, ‘å’¹žŽi (1®ŠO): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

723512. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒEƒTƒM‰ºŽˆäF‰„’·ƒ‚ƒfƒ‹‚ð—p‚¢‚œƒƒbƒLƒ“ƒO‹@\‚ð—L‚·‚éƒXƒ‰ƒCƒh‰„’·‚̌Œ苭“x‚ÌŒŸ“¢. Šâ£@‘å1, “à“cŒ’‘Ÿ˜Y1, ‘Šì@~1, ŠÖŒû—T”V1, –ÚŽž—LŠóŒb1, –©²‘ãŽq1, Œ”ö@“Ä, Œ”ö@—², ‚‘Š»Žm1 (1®ŠO): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

723513. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒrƒXƒ}ƒXŠÜ—LƒlƒXƒvƒƒ“ƒP[ƒuƒ‹‚̐¶‘Ì“K‡«‚ÉŠÖ‚·‚錟“¢. ì‹v•Û•à1, âV“¡@˜j2, “à“cŒ’‘Ÿ˜Y2, ˆäã@Œº2, ’†àVr”V2, ˆä‘º‹M”V2, ‹{é³s2, ”’àV‰hŽ÷2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

723514. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •ÏŒ`«•GŠÖßÇŠ³ŽÒ‚ÌŠŠ–Œ‘gD‚É‚š‚¯‚éƒCƒ“ƒXƒŠƒ“—l¬’·ˆöŽq1‚̐§Œä‹@\. Œ}@@Šw1, “à“cŒ’‘Ÿ˜Y2, ‚–쏞‘Ÿ˜Y2, Šâ£@‘å2, ‘Šì@~2, ‹{é³s2, ˆäã@Œº2, ŠÖŒû—T”V2, ‘åŠÑ—TŽq3, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO, 3•a‘ԁEf—ÃŒn): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

723515. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”ì–ž•ÏŒ`«•GŠÖßÇŠ³ŽÒ‚ÌŠŠ–Œ‘gD‚É‚š‚¢‚Ä‘‰Á‚·‚émast cell‚Ì–ðŠ„‚ÌŒŸ“¢. “à“cŒ’‘Ÿ˜Y1, ‚–쏞‘Ÿ˜Y1, Šâ£@‘å1, ‘Šì@~1, ˆäã@Œº1, ‹{é³s1, ŠÖŒû—T”V1, ‘åŠÑ—TŽq2, ‚‘Š»Žm1 (1®ŠO, 2•a‘ԁEf—ÃŒn): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

723516. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) HbA1c‚’l‚Ì•ÏŒ`«•GŠÖßÇŠ³ŽÒ‚ÌŠŠ–Œ‘gD‚Å‚ÍToll-like receptor-4‚ÆMMP-13‚ª˜Ži‚µ‚Ä‚¢‚é. ‘º“cK—C1, “à“cŒ’‘Ÿ˜Y2, ‚–쏞‘Ÿ˜Y2, ‘Šì@~2, Šâ£@‘å2, ˆäã@Œº2, ŠÖŒû—T”V2, ‘åŠÑ—TŽq3, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO, 3•a‘ԁEf—ÃŒn): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

723517. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠŠ–ŒüˆÛ‰è×–E‚É‚š‚¯‚éŒÃ“TŒo˜H‚Æ”ñŒÃ“TŒo˜H‚̃NƒƒXƒg[ƒN‚ð‰î‚µ‚œTGF-ƒÀ‚É‚æ‚éVEGF§Œä‹@\. ‚–쏞‘Ÿ˜Y1, “à“cŒ’‘Ÿ˜Y1, ¯Ži^‘Ÿ˜Y2, ‘Šì@~1, Šâ£@‘å1, Œ}@@Šw2, ‹{é³s1, ŠÖŒû—T”V1, ‘åŠÑ—TŽq3, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3•a‘ԁEf—ÃŒn): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

723518. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚ƒRƒŒƒXƒeƒ[ƒ‹ŒŒÇ‚ð—L‚·‚é•ÏŒ`«•GŠÖßÇŠ³ŽÒ‚Ì•GŠŠ–Œ‘gD‚Å‚Íapoptpsis inhibitor of macrophage‚ªãž‚·‚é. ¯Ži^‘Ÿ˜Y1, “à“cŒ’‘Ÿ˜Y2, ‚–쏞‘Ÿ˜Y2, ‘Šì@~2, Šâ£@‘å2, Œ}@@Šw1, ‹{é³s2, ˆäã@Œº2, ŠÖŒû—T”V2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

723519. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) œë•aŠúŠÔ‚̈قȂéiN«_ŒoáŠQ‚ɏœˆ³p‚ðs‚Á‚œƒ‚ƒfƒ‹‚Æ‚µ‚Ă̐V‹Kƒ‰ƒbƒgƒ‚ƒfƒ‹ì¬‚ÌŽŽ‚Ý. Œüˆä–±W, “à“cŒ’‘Ÿ˜Y1, œAàV’Œ–ç, ˆî–шêG, ‘ºãŒ«ˆê, Ü“cƒ‹v, ˆäã@Œº1, Œ‰Y—C‰î, š ‹gˆêŽ÷, ‚‘Š»Žm1, ‘å’¹žŽi (1®ŠO): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

723520. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŒŽ”­œ‘e頏ǃ‚ƒfƒ‹‚É‚š‚¯‚é_Œo¬’·ˆöŽq‚Ì”­Œ»‚Æ‚»‚̐§Œä‹@\ŒŸ“¢. “càV@—È1, “à“cŒ’‘Ÿ˜Y2, ‹{é³s2, “¡ŠªŽõŽq, ˆäã@Œº2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

723521. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) œŒ`¬’`”’ (BMP-2) ŠÜ—LlHƒRƒ‰[ƒQƒ“ƒQƒ‹‚̓}ƒEƒX“«œÜƒ‚ƒfƒ‹‚É‚š‚¯‚鍜Œ`¬‚ƍœ–ü‡‚𑣐i‚·‚é. ŠÖŒû—T”V1, “à“cŒ’‘Ÿ˜Y1, ˆäã@Œº1, ¯Ži^‘Ÿ˜Y2, ‹{é³s1, âV“¡@˜j1, ‘åŠÑ—TŽq3, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3•a‘ԁEf—ÃŒn): ‘æ34‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/10/17-18), ‰¡•l.

723522. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹Â‰çˆÊƒ|[ƒ^ƒuƒ‹ƒiƒrƒQ[ƒVƒ‡ƒ“HipAlign‚Ì“±“ü‘OŒã‚É‚š‚¯‚éƒJƒbƒvÝ’už“x‚ÌŒŸ“¢. ŽÄ“c’Œ–í1, “àŽRŸ•¶1, ꎓ¡LŽ÷1, •Ÿ“‡Œ’‰î1, X’JŒõr1, ‘å‹ŽŒc‹v2, ¬ŽR’q‹v2, ‹Ž’܍F“T1, ‚•œ®L3, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ˆã—Éq¶Šw•”): ‘æ46‰ñ“ú–{ŒÒŠÖßŠw‰ïŠwpW‰ï (2019/10/25), ‹{è.

723523. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘å‘ڍœ“]Žq•”œÜ‚É‚æ‚菬“]Žqœ•Ð“]ˆÚ‚Ì—L–³‚ª•àsŒ`‘Ô‚É—^‚Š‚é‰e‹¿. ¬–ö‰À‘ã, •Ÿ“‡Œ’‰î1, ‰Á“¡¹’mŽq, ‘åèKŽq, Ö“¡Œc‘Ÿ (1®ŠO): ‘æ46‰ñ“ú–{ŒÒŠÖßŠw‰ïŠwpW‰ï (2019/10/26), ‹{è.

723524. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŽvtŠú“Á”­«‘€œ^Ç‚̈âŽc•ÏŒ`Žèp—á‚Ì“Á’¥. âV“¡@˜j1, ˆäã@Œº1, ‹{é³s1, ˆä‘º‹M”V1, ’†àVr”V1, ”’àV‰hŽ÷1, “à“cŒ’‘Ÿ˜Y1, ‚‘Š»Žm1 (1®ŠO): ‘æ53‰ñ“ú–{‘€œ]ÇŠw‰ïŠwpW‰ï (2019/11/8-9), ŒQ”n.

723525. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒXƒ}[ƒgƒtƒHƒ“ƒAƒvƒŠ‚ð—p‚¢‚œŽvtŠú“Á”­«‘€œ^ÇŒŸo‚ÌŽŽ‚Ý. ˆäã@Œº1, ˆä‘º‹M”V1, âV“¡@˜j1, ‹{é³s1, ’†àVr”V1, ”’àV‰hŽ÷1, ÔàV@“w, ’¹‹—Ǐº, ”яÀ‰ë‰›, ‰““¡ˆŸ¹Žq, ¬’Jr–Ÿ, ²‹vŠÔ‹B, ’†ŽRŒh‘Ÿ, ”Ñ“‡@–õ, ‚‘Š»Žm1 (1®ŠO): ‘æ53‰ñ“ú–{‘€œ]ÇŠw‰ïŠwpW‰ï (2019/11/8-9), ŒQ”n.

723526. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) œ‘e頏NJ³ŽÒ‚̐ҒŒŒãœ^Çg ˜‚Ü‚ª‚èh‚Ì—L•a—Š‚Æ‚»‚Ì“Á’¥. ”’àV‰hŽ÷1, ‹{é³s1, Œ‰iV”V1, ‘º“cK—C2, ˆäã@ãÄ1, •“cW‹`2, ì‹v•Û•à2, ‘å’¹žŽi, ˆî–Ñ ˆêG, ŠÖŒû—T”V1, “à“cŒ’‘Ÿ˜Y1, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ53‰ñ“ú–{‘€œ]ÇŠw‰ïŠwpW‰ï (2019/11/8-9), ŒQ”n.

723527. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ~ˆ³–ò“à•ž’†‚̐lH•GŠÖß‘S’uŠ·p‘OŒã‚Ì”ñƒXƒeƒƒCƒh«R‰ŠÇ–ò‚Ɛt‹@”\•Ï‰»‚ÌŒŸ“¢. •œì‹IŽq1,2, è•”@Œ›1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2®ŠO): ‘æ47‰ñ“ú–{ŠÖß•aŠw‰ï (2019/11/21), •Ÿ‰ª.

723528. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŒÒŠÖßŽèpŠ³ŽÒ‚É‚š‚¯‚é’†•«ŠŽì‚Ì‘¶Ý. ‘å‹ŽŒc‹v1, •Ÿ“‡Œ’‰î2, ˆäã@Œº2, ‹{é³s2, “à“cŒ’‘Ÿ˜Y2, ¬ŽR’q‹v1, “àŽRŸ•¶2, ‚•œ®L3, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO, 3ˆã—Éq¶Šw•”): ‘æ12‰ñ“ú–{‰^“®Šíáu’ÉŠw‰ï (2019/11/30-12/1), “Œ‹ž.

731049. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) “úíŠO—ˆ‚É‚š‚¯‚éꋌa•”’ɂ̐f—Ã-g‘̏ŠŒ©‚𒆐S‚É. •Ÿ“‡Œ’‰î (®ŠO): HIP Total Solution Seminar (2019/5/25), “Œ‹ž.

731050. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) “úíŠO—ˆ‚É‚š‚¯‚éꋌa•”’ɂ̐f—Á|ƒfƒBƒƒLƒZƒ`ƒ“‚̗Տ°ŒoŒ±‚ðŠÜ‚߂ā|. •Ÿ“‡Œ’‰î (®ŠO): ‘æ3‰ñ Mt.Fuji PainƒZƒ~ƒi[ (2019/5/28), •xŽm.

731051. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ŠÖß‰·‘¶p‚Æ‚µ‚Ă̌Ҋ֐ߋŸŽ‹‰ºŽèp. •Ÿ“‡Œ’‰î (®ŠO): ‘æ4‰ñ_“ސìŒÒŠÖßŒ€‹†‰ï (2019/6/1), ‰¡•l.

731052. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) •a‘ÔƒƒJƒjƒYƒ€‚ðl—¶‚µ‚œ•ÏŒ`ŠÖßÇ‚̐f—ÂƃfƒBƒƒLƒZƒ`ƒ“‚̈ʒu‚¯. •Ÿ“‡Œ’‰î (®ŠO): Lilly Kanagawa OA Expert Conference (2019/6/20), ’¬“c.

731053. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) •a‘ÔƒƒJƒjƒYƒ€‚ðl—¶‚µ‚œ•ÏŒ`«ŒÒŠÖßÇ‚̐f—Âƃfƒ…ƒƒLƒZƒ`ƒ“‚̈ʒu‚¯. •Ÿ“‡Œ’‰î (®ŠO): ’ɂ݂ɑ΂·‚éƒAƒvƒ[ƒ`‚ðl‚Š‚é‰ï (2019/7/18), •xŽR.

731054. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ˜’ŕϐ«ŽŸŠ³‚̐f’f‚ÆŽ¡—ÃI. ˆäã@Œº (®ŠO): ‘æ17‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïEÒ’ŐҐ‘•aˆãŒ€C‰ï (2019/8/25), ‘åã.

731055. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) •a‘ÔƒƒJƒjƒYƒ€‚ðl—¶‚µ‚œ•ÏŒ`«ŒÒŠÖßÇ‚̐f—Âƃfƒ…ƒƒLƒZƒ`ƒ“‚̈ʒu‚¯. •Ÿ“‡Œ’‰î (®ŠO): Lilly Pain webƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2019/9/18), ‰¡•l.

731056. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) HipGrid Drone. •Ÿ“‡Œ’‰î (®ŠO): 3rd THA Users Seminar 2019 (2019/9/28), “Œ‹ž.

731057. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) History and design concept of fully HA stem. •Ÿ“‡Œ’‰î (®ŠO): Avenir Complete Stem Seminar (2019/10/25), ‹{è.

731058. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) Clinical experience of Avenir stem in Japan. •Ÿ“‡Œ’‰î (®ŠO): Avenir Complete Stem Seminar (2019/10/25), ‹{è.

732037. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) ‘å‘ڍœèò•”œÜ‚ɑ΂·‚éƒCƒ“ƒvƒ‰ƒ“ƒgŽèp (lHœ“ª’uŠ·p, lHŒÒŠÖß‘S’uŠ·p) –k—¢‘åŠw•a‰@‚É‚š‚¯‚é‘å‘ڍœ‹ßˆÊ•”œÜ‚ɑ΂·‚鎡—Ð헪2019. “àŽRŸ•¶1, •Ÿ“‡Œ’‰î1, X’JŒõr1, •ôŒŽG¹2, ‰Í‘º@’Œ1, Œ‰YW³1, ‚‘Š»Žm1, ‚•œ®L3 (1®ŠO, 2‹~–œ, 3ˆã—Éq¶Šw•”): ‘æ166‰ñ_“ސ쐮Œ`ÐŠQŠO‰ÈŒ€‹†‰ï (2019/7/13), ‰¡•l, _“ސ쐮Œ`ÐŠQŠO‰ÈŒ€‹†‰ïŽGŽŽ˜^@2019; 32 (1): 12.

732038. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) lHŒÒŠÖß (lHœ“ª) ŽüˆÍŠŽõ‚ÌŽ¡—Ã. “àŽRŸ•¶ (®ŠO): ‘æ29‰ñO‘O‘åŠw®Œ`ŠO‰È‰Ä‚ÌŒ€C‰ï (2019/8/2), O‘O.

732039. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) lHŒÒŠÖßŽüˆÍMRSAŠŽõ (PJI) ‘΍ô 2019|‘ÛƒRƒ“ƒZƒ“ƒTƒXƒ~[ƒeƒBƒ“ƒO‚Ì“à—e‚àŠÜ‚߂ā|. “àŽRŸ•¶ (®ŠO): VŠƒpŒãŠŽõÇƒZƒ~ƒi[ (2019/11/28), VŠƒ.

732040. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) •ÏŒ`«•GŠÖßÇ‚ɑ΂·‚é‘œŒŒ¬”ÂŒŒÇ‚É‚æ‚鎡—Ã. è•”@Œ›1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2®ŠO): ˆê”ÊŽÐ’c–@l –k‘«—§ŒSŽsˆãŽt‰ïu‰‰‰ï (2019/12), é‹Ê.

733170. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ˆÚA‚µ‚œ•Û‘¶“¯Žíœ‚ɑ΂µŽ©‰Æœ“’ŒˆÚAp‚ðs‚Á‚œ1—á. è•”@Œ›1,2, ‰Í–ìŠJ‹I2, •œì‹IŽq1,2, •ôŠÝ—mŽŸ˜Y1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2®ŠO): ‘æ68‰ñ“Œ“ú–{®Œ`ÐŠQŠO‰ÈŠw‰ï (2019/9/6), “Œ‹ž.

733171. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‹¹’ōd–ŒŠOŽ‰–bŽî‚É‚æ‚èf’f‚µ“Ÿ‚œƒNƒbƒVƒ“ƒOÇŒóŒQ‚É‚æ‚鑱”­«œ‘e頏ǂÌ1—á. •ˆä@—T1, ‹{é³s1, “c’†ŒcG1, –©²‘ãŽq1, ˆäã@Œº1, ’†àVr”V1, ˆä‘º‹M”V1, âV“¡@˜j1, ”’àV‰hŽ÷1, ì‹v•Û•à2, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ68‰ñ“Œ“ú–{®Œ`ÐŠQŠO‰ÈŠw‰ï (2019/9/5-6), “Œ‹ž.

733172. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) œ‘e頏NJ³ŽÒ‚̍˜’ɂɑ΂·‚éWeekly PTH»Ü‚ÌŒø‰Ê. ‘º“cK—C1, ‹{é³s2, ¬ŽR’q‹v1, ì‹v•Û•à1, Œ–{ŒõŒ\2, •Ä“c¹L2, ‚‰ªƒˆê2, “à“cŒ’‘Ÿ˜Y2, ˆäã@Œº2, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO): ‘æ68‰ñ“Œ“ú–{®Œ`ÐŠQŠO‰ÈŠw‰ï (2019/9/5-6), “Œ‹ž.

733173. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) –«t‘Ÿ•a‚ªœ‘e頏NJ³ŽÒ‚̗Տ°ŠŒ©‚É‹y‚Ú‚·‰e‹¿. Îˆä‘å•ã1, ‹{é³s1, Œ–{ŒõŒ\1, •ˆä³ˆê˜Y1, ‘º“cK—C2, ¬ŽR’q‹v2, ì‹v•Û•à2, ‘å’¹žŽi, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ68‰ñ“Œ“ú–{®Œ`ÐŠQŠO‰ÈŠw‰ï (2019/9/5-6), “Œ‹ž.

733174. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ŒÒŠÖß‹ŸŽ‹‰ºŠÖß“à‘€ì‚Ì‚Ý‚ÅŽ¡—µ‚Š‚œ’°’pŠŠ‰t•ï‰Š‚Ì1—á. ‘å‹ŽŒc‹v1, •Ÿ“‡Œ’‰î2, ¬ŽR’q‹v1, “àŽRŸ•¶2, ‚•œ®L3, ‚‘Š»Žm2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO, 3ˆã—Éq¶Šw•”): ‘æ15‰ñ“ú–{ŒÒŠÖß‹ŸŒ€‹†‰ï (2019/9/7), ŽD–y.

733175. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) 20”NˆÈã•sˆÀ’萫‚ð—L‚µ‚Ä‚¢‚œ•IŠÖßŒãŠO‘€‰ñù•sˆÀ’èÇ|’·¶‹ØäF‚Æ•I‹Ø‚ɂčČš‚µ‚œ1—á|. ’¬“cŽü•œ1, •ì_Žm1, ¬ÀŒ«Ž¡1, ‘å’|—IÆ1, Œ©–Ú’q‹I1, ‚‘Š»Žm1 (1®ŠO): ‘æ25‰ñ_“ސìãŽˆŠO‰ÈŒ€‹†‰ï (2019/10/5), ‰¡•l.

733176. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ƒTƒbƒJ[‚̃S[ƒ‹ƒL[ƒp[‚ɐ¶‚¶‚œMóœ‹ßˆÊ•”œÜ‚Ì2—á. ‘œ“c‘ñ–î1, ¬ÀŒ«Ž¡1, •ì_Žm1, ‘å’|—IÆ1, Œ©–Ú’q‹I1, ‚‘Š»Žm1 (1®ŠO): ‘æ25‰ñ_“ސìãŽˆŠO‰ÈŒ€‹†‰ï (2019/10/5), ‰¡•l.

733177. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ƒS[ƒ‹ƒL[ƒp[‚̎菶•”‚ɃVƒ…[ƒgƒ{[ƒ‹‚ª“–‚œ‚èŽó‚µ‚œ‚ƍl‚Š‚ç‚ê‚œMóœœÜ‚Ì2—á. ‘œ“c‘ñ–î1, ¬ÀŒ«Ž¡1, •ì_Žm1, ‘å’|—IÆ1, ’¬“cC•œ1, ‚‘Š»Žm1 (1®ŠO): ‘æ34‰ñ“Œ“ú–{ŽèŠO‰ÈŒ€‹†‰ï (2020/2/1), “Œ‹ž.

733178. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ƒTƒbƒJ[‚̃S[ƒ‹ƒL[ƒp[‚ɐ¶‚¶‚œã˜rŽO“ª‹Ø”牺’f—ô‚Ì1—á. ŽÄ“c’Œ–í1, ¬ÀŒ«Ž¡1, •ì_Žm1, ‘å’|—IÆ1, ‚‘Š»Žm1 (1®ŠO): ‘æ696‰ñŠÖ“Œ®Œ`ÐŠQŠO‰ÈŠw‰ïŒŽ—á‰ï (2020/2/22), “Œ‹ž.

'18”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'18-110011. [ŒŽ’˜] Transforming Growth Factor-Beta (TGF-ƒ ) Regulates Nerve Growth Factor and Cyclooxygenase-2 Expression in Subsynovial Connective Tissue in Patients with Carpal Tunnel Syndrome. Nakawaki M1, Uchida K2, Onuma K2, Sukegawa K2, Matsumoto T3, Inoue G2, Sekiguchi H2, Takaso M2: Int Arch Orthop Surg 2018/9; DOI: 10.23937/iaos-2017/1710002. (’†˜e[Í1, “à“cŒ’‘Ÿ˜Y2, ¬ÀŒ«Ž¡2, •ì_Žm2, Œ–{r‰p3, ˆäã@Œº2, ŠÖŒû—T”V2, ‚‘Š»Žm2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2®ŠO, 3•a—)

'18-110012. [ŒŽ’˜] Electromyographic analysis of infraspinatus and scapular muscles during external shoulder rotation with different weight loads and positions. Sasaki S, Kenmoku T1, Otera A, Miyajima G, Nagura N, Nakawaki M2, Nakazawa T1, Takaso M1, Fukuda M3, Takahira N3: J Orthop Sci 2019/1; 24 (1): 75-80. (Œ©–Ú’q‹I1, ’†˜e[Í2, ’†àVr”V1, ‚‘Š»Žm1, •Ÿ“c—Ï–ç3, ‚•œ®L3: 1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ˆã—Éq¶Šw•”)

'18-110013. [ŒŽ’˜] Surgical outcomes of spinal fusion for osteoporotic thoracolumbar vertebral fractures in patients with Parkinson's disease: what is the impact of Parkinson's disease on surgical outcome? Watanabe K, Katsumi K, Ohashi M, Shibuya Y, Izumi T, Hirano T, Endo N, Kaito T, Yamashita T, Fujiwara H, Nagamoto Y, Matsuoka Y, Suzuki H, Nishimura H, Terai H, Tamai K, Tagami A, Yamada S, Adachi S, Yoshii T, Ushio S, Harimaya K, Kawaguchi K, Yokoyama N, Oishi H, Doi T, Kimura A, Inoue H, Inoue G1, Miyagi M1, Saito W1, Nakano A, Sakai D, Nukaga T, Ikegami S, Shimizu M, Futatsugi T, Ohtori S, Furuya T, Orita S, Imagama S, Ando K, Kobayashi K, Kiyasu K, Murakami H, Yoshioka K, Seki S, Hongo M, Kakutani K, Yurube T, Aoki Y, Oshima M, Takahata M, Iwata A, Endo H, Abe T, Tsukanishi T, Nakanishi K, Watanabe K, Hikata T, Suzuki S, Isogai N, Okada E, Funao H, Ueda S, Shiono Y, Nojiri K, Hosogane N, Ishii K: BMC Musculoskelet Disord 2019/3; 20 (1): 103. (ˆäã@Œº1, ‹{é³s1, âV“¡@˜j1: 1®ŠO)

'18-110014. [ŒŽ’˜] Surgical Treatment of Osteoporotic Vertebral Fracture with Neurological Deficit-A Nationwide Multicenter Study in Japan. Hosogane N, Nojiri K, Suzuki S, Funao H, Okada E, Isogai N, Ueda S, Hikata T, Shiono Y, Watanabe K, Watanabe K, Kaito T, Yamashita T, Fujiwara H, Nagamoto Y, Terai H, Tamai K, Matsuoka Y, Suzuki H, Nishimura H, Tagami A, Yamada S, Adachi S, Ohtori S, Orita S, Furuya T, Yoshii T, Ushio S, Inoue G1, Miyagi M1, Saito W1, Imagama S, Ando K, Sakai D, Nukaga T, Kiyasu K, Kimura A, Inoue H, Nakano A, Harimaya K, Kawaguchi K, Yokoyama N, Oishi H, Doi T, Ikegami S, Shimizu M, Futatsugi T, Kakutani K, Yurube T, Oshima M, Uei H, Aoki Y, Takahata M, Iwata A, Seki S, Murakami H, Yoshioka K, Endo H, Hongo M, Nakanishi K, Abe T, Tsukanishi T, Ishii K: Spine Surg Relat Res 2019/3; 3 (4): 3617. (ˆäã@Œº1, ‹{é³s1, âV“¡@˜j1: 1®ŠO)

'18-110015. [ŒŽ’˜] Increase in mast cell marker expression in the synovium of obese patients with osteoarthritis of the knee. Uchida K1, Takano S1, Inoue G1, Iwase D1, Aikawa J1, Takata K2, Tazawa R2, Kawakubo A2, Sekiguchi H1, Takaso M1: Diabetes Metab Syndr Obes 2019/3; 12: 377-82. (“à“cŒ’‘Ÿ˜Y1, ‚–쏞‘Ÿ˜Y1, ˆäã@Œº1, Šâ£@‘å1, ‘Šì@~1, ‚“c@Œ€2, “càV@—È2, ì‹v•Û•à2, ŠÖŒû—T”V1, ‚‘Š»Žm1: 1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

'18-110016. [ŒŽ’˜] Surgical Treatment of Osteoporotic Vertebral Fracture with Neurological Deficit-A Nationwide Multicenter Study in Japan. Hosogane N, Nojiri K, Suzuki S, Funao H, Okada E, Isogai N, Ueda S, Hikata T1,2, Shiono Y, Watanabe K, Watanabe K, Kaito T, Yamashita T, Fujiwara H, Nagamoto Y, Terai H, Tamai K, Matsuoka Y, Suzuki H, Nishimura H, Tagami A, Yamada S, Adachi S, Ohtori S, Orita S, Furuya T, Yoshii T, Ushio S, Inoue G2, Miyagi M2, Saito W2, Imagama S, Ando K, Sakai D, Nukaga T, Kiyasu K, Kimura A, Inoue H, Nakano A, Harimaya K, Kawaguchi K, Yokoyama N, Oishi H, Doi T, Ikegami S, Shimizu M, Futatsugi T, Kakutani K, Yurube T, Oshima M, Uei H, Aoki Y, Takahata M, Iwata A, Seki S, Murakami H, Yoshioka K, Endo H, Hongo M, Nakanishi K, Abe T, Tsukanishi T, Ishii K: Spine Surg Relat Res 2019/3; 3 (4): 361-7. (“ú•û’qG1,2, ˆäã@Œº2, ‹{é³s2, âV“¡@˜j2: 1–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@, 2®ŠO)

'18-120002. [ŒŽ’˜] ƒXƒeƒƒCƒh«œ‘e頏NJ³ŽÒ‚̍˜’É‚Æ‹Ø“÷—Ê‚Ì“Á’¥. “c“‡Gˆê˜Y1, ‹{é³s1, ‘º“cK—C2, ˆäã@ãÄ1, ¬ŽR’q‹v2, ì‹v•Û•à2, A‘—RˆÉ1, Ö“¡LŽ÷1, “y‰®^•ä, ŽO‘º—I—C1, ‰¡ŠÖ—YŽi2, •Ä“c¹O1, “¡ŠªŽõŽq, “à“cŒ’‘Ÿ˜Y1, ˆî–шêG, ‘å’¹žŽi, ˆäã@Œº1, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): _“ސ쐮Œ`ÐŠQŠO‰ÈŒ€‹†‰ïŽGŽ 2018/; 31 (4): 103-6.

'18-522007. [uÀ]y“ÁW: lHŒšŠÖß’uŠ·pupdatezGrammontŒ^RSA (reverse shoulder arthroplasty) ‚Ì‘Š‡: ’B¬‚Å‚«‚œ‚±‚Æ, ‚Å‚«‚È‚©‚Á‚œ‚±‚Æ. Œ©–Ú’q‹I (®ŠO): Monthly Book Orthopaedics 2019/3; 32 (3): 1-6.

[Šw‰ïEŒ€‹†‰ï“™]

H29-733001. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) —L’ɐ«’e”­‚𔺂Á‚œ—Œ‘€«žôœ‘e–ʍœ“Žî‚Ì1—á. –ÚŽž—LŠóŒb1, •ì_Žm1, ¬ÀŒ«Ž¡1, ‘å’|—IÆ1, •“cW‹`2, “c“‡Gˆê˜Y1, ‰¡ŠÖ—YŽi2, Œ©–Ú’q‹I1, ‚•œ®L3, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ˆã—Éq¶Šw•”): ‘æ58‰ñŠÖ“Œ®Œ`ÐŠQŠO‰ÈŠw‰ï (2018/3/16), “Œ‹ž.

'18-723017. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’Ž’e«Þ—¿“Á«‚ð—p‚¢‚œŽèªŠÇ‚Ì’Pƒ3ŽŸŒ³—LŒÀ—v‘fƒ‚ƒfƒ‹ì¬‚ÌŽŽ‚Ý. •ì_Žm1, Œ‰Y—C‰î, ”ª“c‘ì‹v, ¬ÀŒ«Ž¡1, ‚‘Š»Žm1, Kai-Nan An (1®ŠO): ‘æ91‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwp‘‰ï (2018/5/24), _ŒË.

'18-723018. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “¯Ží”ŒŒŽ”ˆڐAŒã‚̊֐ߍSk‚ɑ΂µ‚Ä‹Š“¯“I„˜_‚É‚æ‚è—ǍD‚ÈROMŠl“Ÿ‚ÉŽŠ‚Á‚œÇ—á. –ڍ•’qN, ŒKŒŽŒc‘Ÿ, è•”@Œ›1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2®ŠO): ‘æ53‰ñ“ú–{—Šw—Ö@Šwp‘å‰ï (2018/7/16-12/23).

'18-723019. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) lHŒÒŠÖß‘S’uŠ·pŠ³ŽÒ‚̏p‘OÒ’Œ‘€œ^‚ªpŒã˜’ɁE˜’Å‹@”\‚É—^‚Š‚é‰e‹¿. ”’àV‰hŽ÷1, ˆäã@Œº1, ‹{é³s1, âV“¡@˜j1, ˆä‘º‹M”V1, ’†àVr”V1, ¯Ži^‘Ÿ˜Y2, •Ÿ“‡Œ’‰î1, “àŽRŸ•¶1, ‚•œ®L3, ‚‘Š»Žm1 (1®ŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ˆã—Éq¶Šw•”): ‘æ9‰ñ“ú–{¬lÒ’Œ•ÏŒ`Šw‰ï (2019/3/2), “Œ‹ž.

'18-733005. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) lHŒÒŠÖß‘S’uŠ·p‚ðŽ{s‚µ‚œŠÖßƒŠƒEƒ}ƒ`Š³ŽÒ‚É‚š‚¯‚épŒã14“úˆÈ“à‚ÌŽ©‘î‘Þ‰@‰Â”ۂɉe‹¿‚ð‹y‚Ú‚·—vˆö. “àŽRŸ•¶1, •Ÿ“‡Œ’‰î1, ‚‘Š»Žm1, ¬ÀŒ«Ž¡1, ‚•œ®L2 (1®ŠO, 2ˆã—Éq¶Šw•”): ‘æ21‰ñ_“ސ샊ƒEƒ}ƒ`‚̃ŠƒnEƒPƒAŒ€‹†‰ï (2019/1/25), ‰¡•l.

'18-733006. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”œ“]‚µ‚œ¶‘€—ô—£œ•Ð‚𔺂Á‚œžôœŽèªŠÖß”w‘€’E‰P‚Ì1—á. ‘å’|—IÆ1, •ì_Žm1, ¬ÀŒ«Ž¡1, ‚‘Š»Žm1 (1®ŠO): ‘æ33‰ñ“Œ“ú–{ŽèŠO‰ÈŒ€‹†‰ï (2019/2/2), VŠƒ.

'18-733007. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) AŒQƒÀ—n˜A‹Û‚É‚æ‚é•êŽw‰óŽ€«“î•”‘gDŠŽõÇ‚ÌŽ¡—ÃŒoŒ±. ‘å’|—IÆ1, •ì_Žm1, ¬ÀŒ«Ž¡1, ‚‘Š»Žm1 (1®ŠO): ‘æ33‰ñ“Œ“ú–{ŽèŠO‰ÈŒ€‹†‰ï (2019/2/2), VŠƒ.

'18-733008. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”œ“]‚µ‚œ¶‘€—ô—£œ•Ð‚𔺂Á‚œžôœŽèªŠÖß”w‘€’E‰PœÜ‚Ì1—á. ‘å’|—IÆ1, •ì_Žm1, ¬ÀŒ«Ž¡1, –ÚŽž—LŠóŒb1, Œ©–Ú’q‹I1, ‚‘Š»Žm1 (1®ŠO): ‘æ59‰ñŠÖ“Œ®Œ`ÐŠQŠO‰ÈŠw‰ï (2019/3/22), “Œ‹ž.


Œ`¬ŠO‰ÈE”ü—eŠO‰ÈŠw

[Šwp˜_•¶]

110285. [ŒŽ’˜] An in Vitro Long-Term Study of Cryopreserved Umbilical Cord Blood-Derived Platelet-Rich Plasma Containing Growth factors-PDGF-BB, TGF-ƒÀ, and VEGF. Baba K1,2, Yamazaki Y2, Sone Y3, Sugimoto Y2, Moriyama K2, Sugimoto T2, Kumazawa K2,4, Shimakura Y2,5, Takeda A2: J Craniomaxillofac Surg 2019/4; 47 (4): 668-75. (”nêŽq1,2, ŽRèˆÀ°2, ‘]ª—R”üŽq3, ™–{‰À2, XŽR˜a‚Ì2, ™–{F”V2, ŒFàVŒ›ˆê2,4, “‡‘qNl2,5, •“c@Œ[2: 1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO, 3•a‘ԁEf—ÃŒn, 4‹~–œ, 5–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@)

110286. [ŒŽ’˜] Long term(10-year) efficacy of finasteride in 523 Japanese men with androgenic alopecia. Yanagisawa M, Fujimaki H, Takeda A1, Nemoto M1, Sugimoto T1, Sato A: Clin Res Trials 2019/10; 5 (5): 1-5. (•“c@Œ[1, ª–{@[1, ™–{F”V1: 1Œ`¬E”üŠO)

110287. [ŒŽ’˜] Differences in pluripotency of jawbone- and iliac bone-derived mesenchymal cells. Moriyama K1, Yamazaki Y1, Sugimoto Y1, Sugimoto T1, Kumazawa K1, Baba K1,2, Sone Y3, Takeda A1: Kitasato Med J 2020/3; 50 (1) :18-26. (XŽR˜a‚Ì1, ŽRèˆÀ°1, ™–{‰À1, ™–{F”V1, ”nêŽq1,2, ‘]ª—R”üŽq3, •“c@Œ[1: 1Œ`¬E”üŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3•a‘ԁEf—ÃŒn)

120020. [ŒŽ’˜] “–‰È‚É‚š‚¯‚é“ü‰@‚Å‚ÌŽîᇓEop53—á‚ÌŒŸ“¢. “n粈ŸŠóŽq, ”nêŽq1 (1Œ`¬E”üŠO): “ú–{E‹ÆEÐŠQˆãŠw‰ïŽ 2019/6; 67 (3): 217-23.

120021. [ŒŽ’˜] “–‰È‚É‚š‚¯‚éŽüŠú“IŽ‘±Ÿó—¬•¹—p‹ÇŠ‰Aˆ³•Âœ—Ö@ (Negative Pressure Wound Therapy with Instillation and Dwelling: NPWTid) ‚ÌŒŸ“¢. ”nêŽq1,2, ‹àŽq—F‹I2, ”–ؐT–ç2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): “ú–{E‹ÆÐŠQˆãŠw‰ïŽ 2020; 68: 56-62.

310036. [Ç—á•ñ] Extensive tenosynovial chondromatosis of the wrist: a case report Shimomura M1, Nemoto M1, Moriyama K1, Kounoike N1, Takeda A1: Kitasato Med J 2020/3; 50 (1): 100-4. (‰º‘ºŽÀ‹MŽq1, ª–{@[1, XŽR˜a‚Ì1, ƒ’r“Þ’ÃŽq1, •“c@Œ[1: 1Œ`¬E”üŠO)

522074. [uÀ] ’ʏí‚ÌŽ¡—Âł͓‚Å‚ ‚é‘n‚ɑ΂·‚éV‚œ‚ÈŽ¡—Ö@|‹ÇŠ‰Aˆ³•Âœ—Ö@‚ɂ‚¢‚ā|. ”nêŽq1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): –k‘«—§ŒSˆãŽt‰ï‰ï•ñ 2019; 306†: 19-22.

540045. [‚»‚Ì‘Œ (Œ€‹†•ñ‘)]y•¶•”‰ÈŠwÈ‰ÈŠwŒ€‹†”ï Šî”ÕŒ€‹† (C): V‚œ‚ȐOŠ{ŒûŠW—ôŽ¡—Ð헪‚ÌŠJ”­‚ÉŒü‚¯‚œä`‘сEä`‘ÑŒŒ‚ÆŽèp—]è‘gD‚É‚æ‚é‘gDÄ¶ (Œ€‹†ŠúŠÔ: 2016`2019)z2018”NŽÀŽ{ó‹µ•ñ‘. Œ€‹†‘ã•\ŽÒ: ”nêŽq1,2, Œ€‹†•ª’SŽÒ: ŽRèˆÀ°2, •“c@Œ[2, ™–{F”V2, ŒFàVŒ›ˆê2,3 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO, 3‹~–œ):y•¶•”‰ÈŠwÈ‰ÈŠwŒ€‹†”ï Šî”ÕŒ€‹† (C): V‚œ‚ȐOŠ{ŒûŠW—ôŽ¡—Ð헪‚ÌŠJ”­‚ÉŒü‚¯‚œä`‘сEä`‘ÑŒŒ‚ÆŽèp—]è‘gD‚É‚æ‚é‘gDÄ¶z2018”N“xŽÀŽ{ó‹µ•ñ‘ 2019/12; https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-16K11376/16K113762018hokoku/.

[Šw‰ïEŒ€‹†‰ï“™]

722113. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) pŒã”x“®–¬ŒŒðÇðÇ‚ÌŒoŒ±|ŽüpŠúÃ–¬ŒŒðÇðÇ—\–h‘΍ô‚ÌŒ»ó|. ª–{@[1, ”–ؐT–ç1, ŒFàVŒ›ˆê2, XŽR˜a‚Ì1, ‰º‘ºŽÀ‹MŽq1, Šâì‚³‚š‚è1, “cŒû¬”ü1, •“c@Œ[1 (1Œ`¬E”üŠO, 2‹~–œ): ‘æ62‰ñ“ú–{Œ`¬ŠO‰ÈŠw‰ï‘‰ïEŠwpW‰ï (2019/5/15), ŽD–y.

723529. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •êŽw‘œŽwÇŽèp‚É‚š‚¯‚é‘æ1ŽwŠÔŒ`¬p‚ÌŒŸ“¢. ª–{@[1, ŒFàVŒ›ˆê2, ‰º‘ºŽÀ‹MŽq1, “cŒû¬”ü1, ”–ؐT–ç1, •“c@Œ[1 (1Œ`¬E”üŠO, 2‹~–œ): ‘æ62‰ñ“ú–{ŽèŠO‰ÈŠw‰ïŠwpW‰ï (2019/4/18), ŽD–y.

723530. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰È‚É‚š‚¯‚鎝‘±Ÿó—¬•¹—p‹ÇŠ‰Aˆ³•Âœ—Ö@ (NPWT with Instillation and Dwelling) ‚ÌŒŸ“¢. ”nêŽq1,2, ”–ؐT–ç2, ª–{@[2, Î•‹§Žj, •“c@Œ[2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): ‘æ62‰ñ“ú–{Œ`¬ŠO‰ÈŠw‰ï‘‰ïEŠwpW‰ï (2019/5/15-17), ŽD–y.

723531. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”M‚ÌŒo‰ß’†‚É”ñ•ÂÇ«’°ŠÇ‹•ŒŒÇ‚ð‡•¹‚µ‚œ3Ç—á. ª–{@[1, ŒFàVŒ›ˆê2, ”–ؐT–ç1, ˜a“‚ƒ•œ1, H–{•ôŽ1, •“c@Œ[1, ŠÛ‹ŽFº2, •Ð‰ª—Sˆê2, ó—˜@–õ2 (1Œ`¬E”üŠO, 2‹~–œ): ‘æ45‰ñ“ú–{”MŠw‰ï‘‰ïŠwpW‰ï (2019/5/24), –k‹ãB.

723532. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —\–h“I‚ȃŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ƒvƒƒOƒ‰ƒ€‚â“®ìŽw“±‚ðŽæ‚è“ü‚ê‚œ“û‚ª‚ñ”ç•ÙŒ`¬pŒãŠ³ŽÒ‚̈ê—á. i“¡—¢Ø, “cÀŽu•Û, ”––ØŒ’Œá, ã“cG–Ÿ, –xì³‘ã, øwŒŽŒc‘Ÿ, ”nêŽq1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): ‘æ4‰ñ“ú–{‚ª‚ñƒTƒ|[ƒeƒBƒuƒPƒAŠw‰ïŠwpW‰ï (2019/9/6-7), ÂX.

723533. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹@”\‰ü‘P‚ð–Ú“I‚Æ‚µ‚œŠááىº‚ŽèpÇ—á‚ÌŒŸ“¢. ”nêŽq1,2, ‹àŽq—F‹I2, ”–ؐT–ç2, •“c@Œ[2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): ‘æ67‰ñ“ú–{E‹ÆEÐŠQˆãŠw‰ïŠwp‘å‰ï (2019/11/9-10), “Œ‹ž.

723534. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”A–ŒŠÇˆâŽcÇ‚Ì•a—‘gDŠw“IŒŸ“¢. ”nêŽq1,2, ‹àŽq—F‹I2, •º“ª“O–ç, ª–{@[2, Î•‹§Žj, •“c@Œ[2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): ‘æ28‰ñ“ú–{Œ`¬ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/11/14-15), å‘ä.

723535. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’·Šú“€Œ‹•Û‘¶‚µ‚œœ—R—ˆŠÔ—tŒn×–E‚Ì•ª‰»”\E‘B”\‚ÌŒŸ“¢|20”N, 15”N, 10”N, 5”N, 1”N‚Ì•Û‘¶ŒŸ‘Ì‚ð”äŠr‚µ‚ā|. ™–{‰À1, ŽRèˆÀ°1, XŽR˜a‚Ì1, ™–{F”V1, ŒFàVŒ›ˆê1,2, ”nêŽq1,3, ‘]ª—R”üŽq4, •“c@Œ[1 (1Œ`¬E”üŠO, 2‹~–œ, 3–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 4•a‘ԁEf—ÃŒn): ‘æ28‰ñ“ú–{Œ`¬ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2019/11/14-15), å‘ä.

723536. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Žwë•”Ø’f‚ÌŒ»ó‚©‚ç‚Ý‚œŽ¡—Õû–@‚ÌŒŸ“¢. ª–{@[1, ŒFàVŒ›ˆê2, ”–ؐT–ç1, Šâì‚³‚š‚è1, ˜a“‚ƒ•œ1, •“c@Œ[1, ó—˜@–õ2 (1Œ`¬E”üŠO, 2‹~–œ): ‘æ46‰ñ“ú–{ƒ}ƒCƒNƒƒT[ƒWƒƒƒŠ[Šw‰ïŠwpW‰ï (2019/11/28), Vh.

732041. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) Œ`¬ŠO‰Èˆã‚ª“`‚Š‚œ‚¢‘n‚Ì‚š˜b‚µ`Œ`¬ŠO‰È‚Ì‚²Ð‰î‚©‚çÅ‹ß‚̃gƒsƒbƒN‚܂Ł`. ”nêŽq1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): ‰±ì–k–{ˆÉ“Þ’n‹æˆãŽt‰ïŠwpu‰‰‰ï (2019/10/25), é‹Ê.

733179. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) dÇ”M‚ɉóás«’_ùN‰Š‚ð‡•¹‚µ‚œ1—á. ª–{@[1, ‹{–{—jŒ\1, ŒFàVŒ›ˆê2, V”ü—T‘Ÿ3, Šâì‚³‚š‚è1, ”–ؐT–ç1, •“c@Œ[1 (1Œ`¬E”üŠO, 2‹~–œ, 3ž_): ‘æ27‰ñVh”MƒtƒH[ƒ‰ƒ€ (2019/8/30), Vh.

733180. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‚—îŽÒ‚ɍs‚Á‚œ”A–ŒŠÇˆâŽc“EoEä`Œ`¬p‚Ì1—á. ‹àŽq—F‹I1, ”nêŽq1,2, ª–{@[1, •“c@Œ[1 (1Œ`¬E”üŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ22‰ñ–k—¢Œ`¬ŠO‰ÈƒtƒH[ƒ‰ƒ€ (2019/10/14), ‘Š–ÍŒŽ.

733181. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) –k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[Œ`¬ŠO‰È‚É‚š‚¯‚éŠááىº‚ÇŽèpÇ—á‚ÌŒŸ“¢. ‘åŒGÊ‰Á1, ”nêŽq1,2 (1Œ`¬E”üŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ31‰ñ–k‘«—§ŒS’nˆãŽt‰ïˆãŠw‰ï (2019/10/19), –k–{.

733182. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‰t‰»“V‘RƒKƒX‚É‚æ‚éL”͈͔M‚ÌŽ¡—ÃŒoŒ±. ª–{@[1, ŒFàVŒ›ˆê2, ˜a“‚ƒ•œ1, V”ü—T‘Ÿ3, Šâì‚³‚š‚è1, •“c@Œ[1 (1Œ`¬E”üŠO, 2‹~–œ, 3ž_): ‘æ28‰ñ“ú–{”MŠw‰ïŠÖ“Œ’n•û‰ï (2020/1/25), “Œ‹ž.

'18”N“xˆÈ‘O•ª

[Šwp˜_•¶]

H27-120001. [ŒŽ’˜] ã‰ºŠááق̋@”\‰ü‘P‚ð–Ú“I‚Æ‚µ‚œŽèp52Ç—á‚ÌŒŸ“¢. ”nêŽq1,2, Î•‹§Žj, Â–ö˜a–ç (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): é‹ÊŒ§ˆãŠw‰ïŽGŽ 2015; 50: 53-60.

H27-120002. [ŒŽ’˜] hˆÎŽ”x“’‚Ə¬Â—³“’‚Ì“à•ž‚ð—p‚¢‚œ•@œœÜ®•œpŒãŠÇ—‚̍H•v. ”nêŽq1,2, Î•‹§Žj (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): “ú–{E‹ÆEÐŠQˆãŠw‰ïŽGŽ 2015; 63 (2): 68-72.

H28-120001. [ŒŽ’˜] ”A–ŒŠÇˆâŽcÇ28—á‚ÌŒŸ“¢. ”nêŽq1,2, Î•‹§Žj, Â–ö˜a–ç (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): é‹ÊŒ§ˆãŠw‰ïŽGŽ 2016; 51: 263-8.

H29-120001. [ŒŽ’˜] “–‰È‚É‚š‚¯‚é‹ÇŠ‰Aˆ³•Âœ—Ö@; Negative Pressure Wound Therapy (NPWT) 107—á‚ÌŒŸ“¢. ”nêŽq1,2, Î•‹§Žj (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): “ú–{E‹ÆEÐŠQˆãŠw‰ïŽ 2017; 65 (2): 89-95.

H29-540001. [‚»‚Ì‘Œ (Œ€‹†•ñ‘)]y•¶•”‰ÈŠwÈ‰ÈŠwŒ€‹†”ï Šî”ÕŒ€‹† (C): V‚œ‚ȐOŠ{ŒûŠW—ôŽ¡—Ð헪‚ÌŠJ”­‚ÉŒü‚¯‚œä`‘сEä`‘ÑŒŒ‚ÆŽèp—]è‘gD‚É‚æ‚é‘gDÄ¶ (Œ€‹†ŠúŠÔ: 2016`2019)z2016”NŽÀŽ{ó‹µ•ñ‘. Œ€‹†‘ã•\ŽÒ: ”nêŽq1,2, Œ€‹†•ª’SŽÒ: ŽRèˆÀ°2, •“c@Œ[2, ™–{F”V2, ŒFàVŒ›ˆê2,3 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO, 3‹~–œ):y•¶•”‰ÈŠwÈ‰ÈŠwŒ€‹†”ï Šî”ÕŒ€‹† (C): V‚œ‚ȐOŠ{ŒûŠW—ôŽ¡—Ð헪‚ÌŠJ”­‚ÉŒü‚¯‚œä`‘сEä`‘ÑŒŒ‚ÆŽèp—]è‘gD‚É‚æ‚é‘gDÄ¶z2016”N“xŽÀŽ{ó‹µ•ñ‘ 2018/1; https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-16K11376/16K113762016hokoku/.

'18-120003. [ŒŽ’˜] “–‰È‚É‚š‚¯‚é“ü‰@‚Å‚ÌŽîᇓEop53—á‚ÌŒŸ“¢. “n粈ŸŠóŽq, ”nêŽq1,2, Î•‹§Žj (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): “ú–{E‹ÆEÐŠQˆãŠw‰ïŽ 2019; 67 (3): 217-23.

'18-540005. [‚»‚Ì‘Œ (Œ€‹†•ñ‘)]y•¶•”‰ÈŠwÈ‰ÈŠwŒ€‹†”ï Šî”ÕŒ€‹† (C): V‚œ‚ȐOŠ{ŒûŠW—ôŽ¡—Ð헪‚ÌŠJ”­‚ÉŒü‚¯‚œä`‘сEä`‘ÑŒŒ‚ÆŽèp—]è‘gD‚É‚æ‚é‘gDÄ¶ (Œ€‹†ŠúŠÔ: 2016`2019)z2017”NŽÀŽ{ó‹µ•ñ‘. Œ€‹†‘ã•\ŽÒ: ”nêŽq1,2, Œ€‹†•ª’SŽÒ: ŽRèˆÀ°2, •“c@Œ[2, ™–{F”V2, ŒFàVŒ›ˆê2,3 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO, 3‹~–œ):y•¶•”‰ÈŠwÈ‰ÈŠwŒ€‹†”ï Šî”ÕŒ€‹† (C): V‚œ‚ȐOŠ{ŒûŠW—ôŽ¡—Ð헪‚ÌŠJ”­‚ÉŒü‚¯‚œä`‘сEä`‘ÑŒŒ‚ÆŽèp—]è‘gD‚É‚æ‚é‘gDÄ¶z2017”N“xŽÀŽ{ó‹µ•ñ‘ 2018/12; https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-16K11376/16K113762017hokoku/.

[Šw‰ïEŒ€‹†‰ï“™]

H26-723001. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰)ƒƒ‹ƒtƒ@ƒŠƒ“ì—p‘‹­‚ªŠÖ—^‚µ‚œ‚—îŽÒBlue toeÇŒóŒQ‚Ì1—á. ”nêŽq1,2, Î•‹§Žj (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): ‘æ57‰ñ“ú–{Œ`¬ŠO‰ÈŠw‰ï‘‰ïEŠwpW‰ï (2014/4/9-11), ’·è.

H26-723002. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “€Œ‹•Û‘¶Œãä`‘Ñ—R—ˆŠÔ—tŒn×–E‚ÌŒŸ“¢. ”nêŽq1,2, ŒFàVŒ›ˆê2,3, ™–{F”V2, ‘]ª—R”üŽq4, ŽRèˆÀ°2, •“c@Œ[2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO, 3‹~–œ, 4•a‘ԁEf—ÃŒn): ‘æ14‰ñ“ú–{Ä¶ˆã—Êw‰ï‘‰ï (2015/3/19-21), ‰¡•l.

H26-733001. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ã‰ºŠááق̋@”\‰ü‘P‚ð–Ú“I‚Æ‚µ‚œŽèp52Ç—á‚ÌŒŸ“¢. ”nêŽq1,2, Î•‹§Žj (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): ‘æ52‰ñé‹ÊŒ§ˆãŠw‰ï‘‰ï (2015/2/22), ‰Y˜a.

H27-723001. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —Ü‘BŽî‘å‚É‚æ‚èf’f‚³‚ê‚œIgG4ŠÖ˜Aƒ~ƒNƒŠƒbƒc•a‚Ì1—á. ”nêŽq1,2, Î•‹§Žj, Â–ö˜a–ç (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): ‘æ58‰ñ“ú–{Œ`¬ŠO‰ÈŠw‰ï‘‰ïEŠwpW‰ï (2015/4/8-10), ‹ž“s.

H27-723002. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “€Œ‹•Û‘¶Œãä`‘Ñ—R—ˆŠÔ—tŒn×–E‚̈À‘S«‚ÌŒŸ“¢. ”nêŽq1,2, ŒFàVŒ›ˆê2,3, ™–{F”V2, ‘]ª—R”üŽq4, ŽRèˆÀ°2, •“c@Œ[2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO, 3‹~–œ, 4•a‘ԁEf—ÃŒn): ‘æ24‰ñ“ú–{Œ`¬ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2015/10/8-9), ·‰ª.

H27-723003. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰È‚É‚š‚¯‚é‹ÇŠ‰Aˆ³•Âœ—Ö@; Negative Pressure Wound Therapy (NPWT) ŠeŽíƒfƒoƒCƒX‚ÌŽg—pŒoŒ±. ”nêŽq1,2, Î•‹§Žj (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): ‘æ63‰ñ“ú–{E‹ÆEÐŠQˆãŠw‰ïŠwp‘å‰ï(2015/11/22-23), Šø‚Ì‘ä.

H27-733001. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ”A–ŒŠÇˆâŽcÇ28—á‚ÌŒŸ“¢. ”nêŽq1,2, Î•‹§ŽjEÂ–ö˜a–ç (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): ‘æ53‰ñé‹ÊŒ§ˆãŠw‰ï‘‰ï (2016/2/28), é‹Ê.

H28-723001. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”A–ŒŠÇˆâŽcÇ24—á‚ÌŒŸ“¢. ”nêŽq1,2, Î•‹§Žj, Â–ö˜a–ç (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): ‘æ59‰ñ“ú–{Œ`¬ŠO‰ÈŠw‰ï‘‰ïEŠwpW‰ï (2016/4/13-15), •Ÿ‰ª.

H28-723002. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “€Œ‹•Û‘¶Œãä`‘Ñ—R—ˆŠÔ—tŒn×–E‚̍œŒ`¬”\‚ƈÀ‘S« (‘æ2•ñ). ”nêŽq1,2, ŽRèˆÀ°2, ‘]ª—R”üŽq3, ŒFàVŒ›ˆê2,4, ™–{F”V2, Î•‹§Žj, •“c@Œ[2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO, 3•a‘ԁEf—ÃŒn, 4‹~–œ): ‘æ25‰ñ“ú–{Œ`¬ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2016/9/15-16), ‘åã.

H29-723002. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰È‚É‚š‚¯‚éŽîᇓEop“ü‰@Ç—á53—á‚ÌŒŸ“¢. ”nêŽq1,2, Î•‹§Žj, Â–ö˜a–ç, Žç’JˆŸŠóŽq (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): ‘æ60‰ñ“ú–{Œ`¬ŠO‰ÈŠw‰ï‘‰ïEŠwpW‰ï (2017/4/12-14), ‘åã.

H29-723003. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ä`‘Ñ—R—ˆŠÔ—tŒn×–E‚Ì‹€”|—{‚É‚š‚¯‚é‘gDŒ`¬. ”nêŽq1,2, ŽRèˆÀ°2, ‘]ª—R”üŽq3, ™–{F”V2, ŒFàVŒ›ˆê2,4, ™–{‰À2, XŽR˜a‚Ì2, •“c@Œ[2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO, 3•a‘ԁEf—ÃŒn, 4‹~–œ): ‘æ26‰ñ“ú–{Œ`¬ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ï (2017/10/19-20), ‘åã.

H29-723004. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰È‚É‚š‚¯‚éŽîᇓEop“ü‰@Ç—á96—á‚ÌŒŸ“¢. Žç’JˆŸŠóŽq, ”nêŽq1,2, Î•‹§Žj, Â–ö˜a–ç (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): ‘æ65‰ñ“ú–{E‹ÆEÐŠQˆãŠw‰ïŠwp‘å‰ï (2017/11/25-26), ¬‘q.

'18-732001. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (Žs–¯ŒöŠJuÀ) Œ`¬ŠO‰È‚ð‚²‘¶’m‚Å‚·‚©?|Œ`¬ŠO‰È‚Ì‚Ü‚Ô‚œ‚ÌŽ¡—Á|. ”nêŽq1,2 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`¬E”üŠO): –k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[Žs–¯uÀ (2018/7/11), é‹Ê.


”畆‰ÈŠw

[Šwp˜_•¶]

110288. [ŒŽ’˜] A potential significance of circ_0024169 down regulation in angiosarcoma tissue. Nakashima S, Jinnin M, Ide M, Kajihara I, Igata T, Harada M, Masuguchi S, Fukushima S, Masuzawa M, Masuzawa M1, Amoh Y1, Ihn H: Intractable Rare Dis Res. 2019/5; 8 (2): 129?33. (‘àV^ŽÀŽq1, “V‰HN”V1: 1”畆)

110289. [ŒŽ’˜] Hair-follicle-associated pluripotent stem cells derived from cryopreserved intact human hair follicles sustain multilineage differentiation potential. Obara K1, Tohgi N1, Mii S1, Hamada Y2, Arakawa N2, Aki R1, Singh SR, Hoffman R, Amoh Y1: Sci Rep 2019/7; 9: 9326. (¬ŒŽGÆ1, “Œ‹V“ß’ÃŽq1, ŽOˆäƒá1, •l“c—SŽq2, rìLŽq2, ˆÀåY—Ljê1, “V‰HN”V1: 1”畆, 2•a‘ԁEf—ÃŒn)

110290. [ŒŽ’˜] Expression of anti-aging type-XVII collagen (COL17A1/BP180) in hair follicle-associated pluripotent (HAP) stem cells during differentiation. Shirai K1, Obara K1, Tohgi N1, Yamazaki A, Aki R1, Hamada Y2, Arakawa N, Singh SR, Hoffman RM, Amoh Y1: Tissue Cell. 2019/8; 59: 33-8. (”’ˆä‹ž”ü1, ¬ŒŽGÆ1, “Œ‹V“ß’ÃŽq1, ˆÀåY—Ljê1, •l“c—SŽq2, “V‰HN”V1: 1”畆, 2•a‘ԁEf—ÃŒn)

110291. [ŒŽ’˜] Invasion of human microvascular endothelial cells by Mycobacterium leprae through Mce1A protein. Idris I, Abdurrahman AH, Fatulrachman, Aftitah VB, Fadlitha VB, Sato N1, Fujimura T1, Takimoto H: J Dermatol 2019/10; 46 (10): 853-8. (²“¡’ŒÆ1, “¡‘º‹¿’j1: 1”畆)

320028. [Ç—á•ñ] ’×ᇂð’悵‚œ–³F‘f«Šî’ê×–EŠà‚Ì1—á. “àŠC—F—1, ã“c‹ªŽm1, ”’ˆä‹ž”ü1 (1”畆): —Տ°”畆‰È 2019/4; 73 (4): 331-5.

320029. [Ç—á•ñ] ùN–EóƒŠƒ“ƒpß“]ˆÚ‚𔺂Á‚œ’܏°‚Ìpigmented epithelioid melanocytoma. “Œ‹V“ß’ÃŽq1, ‘àV^ŽÀŽq1, ƒ’r“Þ’ÃŽq1, “V‰HN”V1 (1”畆): ”畆•af—à 2019/9; 41 (9): 873-6.

320030. [Ç—á•ñ] ãèˆÍ’×ᇂ©‚çf’f‚ÉŽŠ‚Á‚œƒƒgƒgƒŒƒLƒT[ƒgŠÖ˜AƒŠƒ“ƒp‘B«ŽŸŠ³‚Ì1—á. ’r‘ºŸŽ}1, ‘àV^ŽÀŽq1, ‘ºŒ@ 2, ‰¥@‘cœ3, “V‰HN”V1 (1”畆, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ŒŒ‰t“à): Skin Cancer 2020/2; 34 (3): 215-8.

320031. [Ç—á•ñ] •¡”‚Ì—Z‡“_‚ð‚à‚ÂCOL1A1-PDGFB—Z‡ˆâ“`Žq‚ªŒŸo‚³‚ê‚œ‹‘å‚È—²‹N«”畆üˆÛ“÷Žî‚Ì1—á. t–؍ʌ©1, ‘àV^ŽÀŽq1, •l“c—SŽq2, ŽOˆäƒá1, Šâì‚³‚š‚è3, ”–ؐT–ç3, “V‰HN”V1 (1”畆, 2•a‘ԁEf—ÃŒn, 3Œ`¬E”üŠO): Skin Cancer 2020/2; 34 (3): 238-42.

540046. [‚»‚Ì‘Œ (Šw‰ïŽ˜^)]y“ú–{”畆‰ÈŠw‰ï“Œ‹ž’n•û‰ï‘æ883‰ñ—á‰ïzƒAƒvƒŒƒ~ƒ‰ƒXƒg‚ª‘tŒø‚µ‚œŠ£á«ŠÖß‰Š‚Ì1—á. Ž”ÀŽÀ—D1, ‘àV^ŽÀŽq1, ˆÀåY—Ljê1, “V‰HN”V1, ‘ºŒ@ 2, ó’J‰ë•¶ (1”畆, 2äPŒŽ•aEŠŽõ“à): “ú–{”畆‰ÈŠw‰ïŽGŽ 2019/5; 129 (6): 1355-6.

[Šw‰ïEŒ€‹†‰ï“™]

713117. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) FUnctional recovery of spinal cord injury promoted with hair-follicle-associated pluripotent (HAP) stem cells captured on polyvinylidence fluoride membranes (PFM). Obara K1, Tohgi N1, Shirai K1, Mii S1, Hamada Y2, Arakawa N, Aki R1, Hoffman RM, Amoh Y1: 11th World Congress for Hair Research (WCHR 2019) (2019/4/24-27), Barcelona, Spain. (¬ŒŽGÆ1, “Œ‹V“ß’ÃŽq1, ”’ˆä‹ž”ü1, ŽOˆäƒá1, •l“c—SŽq2, ˆÀåY—Ljê1, “V‰HN”V1: 1”畆, 2•a‘ԁEf—ÃŒn)

713118. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Lymphangiosarcoma as the distinguishable variant of angiosarcoma. Masuzawa M1, Tohgi N1, Hamada Y2, Mori M, Ishii M, Amoh Y1: 24th World Congress of Dermatology (2019/6/10), milano, Italy. (‘àV^ŽÀŽq1, “Œ‹V“ß’ÃŽq1, •l“c—SŽq2, “V‰HN”V1: 1”畆, 2•a‘ԁEf—ÃŒn)

713119. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Foreign body granuloma and temporal arterial stenosis secondary to gold thread facelift and facial injection of polyacrylamide hydrogel. Tohgi N1, Masuzawa M1, Amoh Y1: 24th World Congress of Dermatology (2019/6/10), milano, Italy. (“Œ‹V“ß’ÃŽq1, ‘àV^ŽÀŽq1, “V‰HN”V1: 1”畆)

723537. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒGƒŠƒuƒŠƒ“‚ª‘tŒø‚µ‚œƒŠƒ“ƒpŒ`Ž¿×–E«ƒŠƒ“ƒpŽî‡•¹‚ÌNon-AIDS Associated Kaposi“÷Žî. ‘àV^ŽÀŽq1, ŽR‰º˜a–ç2, ‘“c@Ši3, –x•Ä—Sˆê4, “V‰HN”V1 (1”畆, 2•a—•”, 3•úŽËü (Žîá‡), 4ŒŒ‰t“à): ‘æ35‰ñ“ú–{”畆ˆ««Žîᇊw‰ïŠwp‘å‰ï (2019/5/24), _ŒË, ‘æ35‰ñ“ú–{”畆ˆ««Žîᇊw‰ïŠwp‘å‰ïŽ˜^W 2019/5; p.146.

723538. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •¡”‚Ì—Z‡“_‚ð‚à‚ÂCOL1A1-PDGFB—Z‡ˆâ“`Žq‚ªŒŸo‚³‚ê‚œ‹‘å‚È—²‹N«”畆üˆÛ“÷Žî‚Ì1—á. ’·’JìÊŒ©1, ‘àV^ŽÀŽq1, •l“c—SŽq2, ŽOˆäƒá1, Šâì‚³‚š‚è3, ”–ؐT–ç3, “V‰HN”V1 (1”畆, 2•a‘ԁEf—ÃŒn, 3Œ`¬E”üŠO): ‘æ35‰ñ“ú–{”畆ˆ««Žîᇊw‰ïŠwp‘å‰ï (2019/5/25), _ŒË.

723539. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ãèˆÍ’×ᇂ©‚çf’f‚ÉŽŠ‚Á‚œƒƒgƒgƒŒƒLƒT[ƒgŠÖ˜AƒŠƒ“ƒp‘B«ŽŸŠ³‚Ì1—á. ’r‘ºŸŽ}1, ‘àV^ŽÀŽq1, ‘ºŒ@ 2, ‰¥@‘cœ3, “V‰HN”V1 (1”畆, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ŒŒ‰t“à): ‘æ35‰ñ“ú–{”畆ˆ««Žîᇊw‰ïŠwp‘å‰ï (2019/5/25), _ŒË.

723540. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘œŒ`Ÿøo«g”Á‚̗Տ°‚ð’悵‚œ‹à‘®ƒAƒŒƒ‹ƒM[‚É‚æ‚é‘Sg«ÚG”畆‰Š‚Ì2—á. ¬ŒŽGÆ1, ‘àV^ŽÀŽq1, ’†‘º”ü‰Ä, “V‰HN”V1 (1”畆): ‘æ118‰ñ“ú–{”畆‰ÈŠw‰ï‘‰ï (2019/6/6), –ŒŒÃ‰®.

723541. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) IgG4ŠÖ˜AŽŸŠ³‚Ì”­Ç‚ɐæs‚µ‚悶‚œŠç–ʂ̍g”Á‚Ì1—á. ã“c‹ªŽm1, Œj@—F—1, Œ‘º„ˆê, –Ñ’Ë—R”üŽq2, ²“¡—Yˆê˜Y, ‰Á“¡¶^, ²X–Ø—SK, ”’ˆä‹ž”ü1 (1”畆, 2“Œ•a‰@ŠÅŒì•”): ‘æ118‰ñ“ú–{”畆‰ÈŠw‰ï‘‰ï (2019/6/6), –ŒŒÃ‰®.

723542. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) pŒã8”N‚Å‘œ”­‰“Šu“]ˆÚ‚ð”F‚ß‚œ˜•”ŒŽ”­ˆ««ŒŒŠÇŽü”çŽî‚Ì1—á. ‹à•£—DŽ÷1, ‘àV^ŽÀŽq1, ‘å‹v•ÛŽu‚ž‚©1, ”’ˆä‹ž”ü1, “V‰HN”V1, ‰º‘ºº•F (1”畆): ‘æ118‰ñ“ú–{”畆‰ÈŠw‰ï‘‰ï (2019/6/6), –ŒŒÃ‰®.

733183. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) …áv«—Þ“Vávጂɑ΂µ‚ăAƒUƒ`ƒIƒvƒŠƒ“‚ðŽg—p’†‚ɍж•s—ǐ«•nŒŒ‚𗈂µ‚œ1—á. Ž”ÀŽÀ—D1, “V–ì“TŽq1, ‚‰ª“ޓߎq1, ¬ŒŽGÆ1, ”’ˆä‹ž”ü1, “V‰HN”V1, “cŽ›”͍s2 (1”畆, 2ŒŒ‰t“à): ‘æ884‰ñ“ú–{”畆‰ÈŠw‰ï“Œ‹ž’n•û‰ï (2019/5/8), _“ސì.

733184. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‚Ñ‚Ü‚ñ«’E–т𔺂Á‚œVogt-¬–ö-ŒŽ“c•a‚Ì1—á. ‹àŽR‚Ü‚è‚©1, ²X–؈²1, ‘àV^ŽÀŽq1, ˆÀåY—Ljê1, “V‰HN”V1, ‚‹Ž³‰p2 (1”畆, 2Šá‰È): ‘æ885‰ñ“ú–{”畆‰ÈŠw‰ï“Œ‹ž’n•û‰ï‡“¯—Տ°’n•û‰ï (2019/7/20), “Œ‹ž.

733185. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) Ž¡—Âɓïa‚µ‚œ¬Ž™ëŒ\ƒRƒ“ƒWƒ[ƒ}‚Ì1—á. ŠFì‘å•ã1, ¬ŒŽGÆ1, ”’ˆä‹ž”ü1, “V‰HN”V1, ’†”š–퐶 (1”畆): ‘æ886‰ñ“ú–{”畆‰ÈŠw‰ï“Œ‹ž’n•û‰ï (2019/10/19), _“ސì.

733186. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ’˜–Ÿ‚ÈŠÌ‹@”\áŠQ‚𐶂¶‚œƒTƒ‰ƒ]ƒXƒ‹ƒtƒ@ƒsƒŠƒWƒ“‚É‚æ‚é–òÜ«‰ß•qÇÇŒóŒQ‚Ì1—á. Ž”ÀŽÀ—D1, ‚‰ª“ޓߎq1, ”’ˆä‹ž”ü1, “V‰HN”V1, ‹›“ˆ°‹I2 (1”畆, 2Á‰»Ší“à): ‘æ887‰ñ“ú–{”畆‰ÈŠw‰ï“Œ‹ž’n•û‰ï (2019/12/14), _“ސì.

733187. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “ª•”ŒŒŠÇ“÷Žî”x“]ˆÚ‚ւ̃pƒ]ƒpƒjƒu“Š—^‚É‚æ‚èd“Ä‚ÈŒŒ¬”’ቺ‚ð‚«‚œ‚µ‚œˆê—á. ¬ŽR”ü•ä1, ‘àV^ŽÀŽq1, ‚‰ª“ޓߎq1, ”’ˆä‹ž”ü1, ‰¥@‘cœ2, “V‰HN”V1 (1”畆, 2ŒŒ‰t“à): ‘æ889‰ñ“ú–{”畆‰ÈŠw‰ï“Œ‹ž’n•û‰ï (2020/2/15), _“ސì.

'18”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'18-110017. [ŒŽ’˜] Hypoxia accelerates the progression of angiosarcoma through the regulation of angiosarcoma cells and tumor microenvironment. Maeda-Otsuka S, Kajihara I, Tasaki Y, Yamada-Kanazawa S, Sakamoto R, Sawamura S, Masuzawa M1, Masuzawa M, Amoh Y1, Hoshina D, Abe R, Komohara Y, Ihn H: J Dermatol Sci 2019/2; 93 (2): 123-32. (‘àV^ŽÀŽq1, “V‰HN”V1: 1”畆)

[Šw‰ïEŒ€‹†‰ï“™]

'18-733009. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ”^áv«Š£á‚Æ‚ÌŠÓ•Ê‚ð—v‚µ‚œ‹}«”Ä”­«”­]«”^ávÇ‚Ì1—á. ŠFì‘å•ã1, ‘å‹v•ÛŽu‚ž‚©1, ”’ˆä‹ž”ü1, ˆÀåY—Ljê1, “V‰HN”V1 (1”畆): ‘æ882‰ñ“ú–{”畆‰ÈŠw‰ï“Œ‹ž’n•û‰ï (2019/1/19), _“ސì.

'18-733010. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) RƒfƒXƒ‚ƒOƒŒƒCƒ“1R‘Ì, RƒfƒXƒ‚ƒRƒŠƒ“R‘Ì—z«‘B«“VávጂÌ1—á. ’r‘ºŸŽ}1, ‘å‹v•ÛŽu‚ž‚©1, ”’ˆä‹ž”ü1, ŽOˆäƒá1, “V‰HN”V1, “”I@‹B, Îˆä•¶l (1”畆): ‘æ882‰ñ“ú–{”畆‰ÈŠw‰ï“Œ‹ž’n•û‰ï (2019/1/19), _“ސì.

'18-733011. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ”畆’ŒÚZ‚æ‚è”­Œ©‚µ‚œ“ûŠà‚Ì1—á. a’J—º‘Ÿ1, ŠFì‘å•ã1, •ÄŽRŽõŽq1, ”’ˆä‹ž”ü1, “V‰HN”V1, Œ‹{—mŽj2 (1”畆, 2“û‘BEbó‘BŠO): ‘æ883‰ñ“ú–{”畆‰ÈŠw‰ï“Œ‹ž’n•û‰ï (2019/2/16), _“ސì.

'18-733012. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) Bowen•a‚ɍ‡•¹‚µ, ¶ŒŸŒãŠ®‘SÁ‘Þ‚µ‚œMerkel×–EŠà‚Ì1—á. ²X–؈²1, ‘àV^ŽÀŽq1, ˆÀåY—Ljê1, “V‰HN”V1 (1”畆): ‘æ883‰ñ“ú–{”畆‰ÈŠw‰ï“Œ‹ž’n•û‰ï (2019/2/16), _“ސì.

'18-733013. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ƒAƒvƒŒƒ~ƒ‰ƒXƒg‚ª‘tŒø‚µ‚œŠ£á«ŠÖß‰Š‚Ì1—á Ž”ÀŽÀ—D1, ‘àV^ŽÀŽq1, ˆÀåY—Ljê1, “V‰HN”V1, ‘ºŒ@ 2, ó’J‰ë•¶ (1”畆, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ883‰ñ“ú–{”畆‰ÈŠw‰ï“Œ‹ž’n•û‰ï (2019/2/16), _“ސì.

'18-733014. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ¬…áv‚𔺂€ƒyƒ€ƒuƒƒŠƒYƒ}ƒu‚É‚æ‚éŸøo«g”ÁŒ^–ò]‚Ì1—á. ‹à•£—DŽ÷1, ”’ˆä‹ž”ü1, “V–ì“TŽq1, ¬ŒŽGÆ1, “V‰HN”V1, •Ÿˆä•ü–ç2 (1”畆, 2ŒÄ‹zŠí“à): ‘æ883‰ñ“ú–{”畆‰ÈŠw‰ï“Œ‹ž’n•û‰ï (2019/2/16), _“ސì.


”å”AŠí‰ÈŠw

[Šwp˜_•¶]

110292. [ŒŽ’˜] Histologic variants associated with biological aggressiveness and poor prognosis in patients treated with radical cystectomy. Koguchi D1,2, Matsumoto K1, Ikeda M1,3, Taoka Y1,2, Hirayama T1, Murakami Y1, Utsunomiya T, Matsuda D, Okuno N, Irie A1,3, Iwamura M1: Jpn J Clin Oncol 2019/4; 49 (4): 373-8. (‚Œû@‘å1,2, Œ–{˜a«1, ’r“cŸb1,3, “c‰ª‰ÀŒ›1,2, •œŽR‹M”Ž1, ‘ºã‘אŽ1, “ü]@Œ[1,3, Šâ‘º³Žk1: 1”å”AŠí, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@)

110293. [ŒŽ’˜] Tumor multifocality was associated with poor prognosisi in patients with upper urinary tract urothelial carcinoma after radical nephroureterectomy. Hirayama T1, Nomura M1, Matsumoto K1, Iwamura M1: Kitasato Med J 2019/9; 49 (2): 113-8. (•œŽR‹M”Ž1, –쑺@Œb1, Œ–{˜a«1, Šâ‘º³Žk1: 1”å”AŠí)

110294. [ŒŽ’˜] Outcome of third-line sunitinib after sequential therapy with cytokines and sorafenib in metastatic renal cell carcinoma. Fujita T1, Hirayama T1, Nishi M1, Matsumoto K1, Yoshida K1,2, Iwamura M1: Mol Clin Oncol 2019/11; 11 (5): 505-10. (“¡“c“N•v1, •œŽR‹M”Ž1, Œ@·G1, Œ–{˜a«1, ‹g“cˆê¬1,2, Šâ‘º³Žk1: 1”å”AŠí, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã)

110295. [ŒŽ’˜] Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy. Zamboni S1, Foerster B1, Abufaraj M1, Seisen T1, Roupret M1, Colin P1, la Taille AD1, Bona CD1, Peyronnet B1, Bensalah K1, Herout R1, Wirth MP1, Novotny V1, Soria F1, Chlosta P1, Antonelli A1, Simeone C1, Baumeister P1, Mattei A1, Montorsi F1, Simone G1, Gallucci M1, Matsumoto K1,2, Karakiewicz PI1, Briganti A1, Xylinas E1, Shariat SF1, Marco Moschini M1 (1Upper Tract Urothelial Carcinoma Collaboration Group; European Association of Urology - Young Academic Urologists (EAU-YAU), Urothelial carcinoma working group): BJU Int 2019/11; 124 (5): 738-45. (Œ–{˜a«1,2: 2”å”AŠí)

110296. [ŒŽ’˜] Impact of histologic variants on the oncological outcomes of patients with upper urinary tract cancers treated with radical surgery: a multi-institutional retrospective study. Murakami Y1, Matsumoto K1, Ikeda M1, Hirayama T1, Utsunomiya T, Koguchi D1, Matsuda D, Okuno N, Taoka Y1, Irie A1,2, Iwamura M1: Int J Clin Oncol 2019/11; 24 (11): 1412-8. (‘ºã‘אŽ1, Œ–{˜a«1, ’r“cŸb1, •œŽR‹M”Ž1, ‚Œû@‘å1, “c‰ª‰ÀŒ›1, “ü]@Œ[1,2, Šâ‘º³Žk1: 1”å”AŠí, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@)

110297. [ŒŽ’˜] Peri-operative efficacy and long-term survival benefit of robotic-assisted radical cystectomy in septuagenarian patients compared with younger patients: a nationwide multi-institutional study in Japan. Iwamoto H, Morizane S, Koie T, Shiroki R, Kawakita M, Gondo T, Matumoto K1, Habuchi T, Sunada H, Endo Y, Noma H, Takenaka A, Kanayama H: Int J Clin Oncol 2019/12; 24 (12): 1588-95. (Œ–{˜a«1: 1”å”AŠí)

110298. [ŒŽ’˜] Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. Antonarakis ES, Piulats JP, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, Vaishampayan U, Berger R, Sezer A, Alanko T, de Wit R, Li C, Omlin A, Procopio G, Fukasawa S, Tabata K1, Park SH, Feyerabend S, Drake CG, Wu H, Qiu P, Kim J, Poehlein C, Sebastian de Bono JS: J Clin Oncol 2020/2; 38 (5): 395-405. (“c”šŒ’ˆê1: 1”å”AŠí)

320032. [Ç—á•ñ] ”畆‹Ø‰Š—lÇó‚ðŒ_‹@‚ɐf’f‚³‚ê‚œ”AŠÇŠà‚Ì1—á. –쑺@Œb1, •œŽR‹M”Ž1, â“c—T‰î1, –Ȋс@ãÄ1, “V–쓝”V2, Œ–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ”å”AŠí‰È‹I—v 2019/11; 65 (11): 459-62.

320033. [Ç—á•ñ] Human immunodeficiency virus (HIV) ŠŽõ, human papilloma virus (HPV) ŠŽõ‚ð‡•¹‚µ‚œäNã÷Šà‚̈ê—á. –쑺@Œb1, •œŽR‹M”Ž1, â“c—T‰î1, Žt”ö”ɍF1, –Ȋс@ãÄ1, Œ–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí): –k—¢ˆãŠw 2019/12; 49 (2): 99-101.

320034. [Ç—á•ñ] • o‹Ÿ‰º•›t“Eœp‚É‚Ä“Eœ‚µ‚Š‚œŒã• –Œ¬nŠïŒ`Žî‚Ì1—á. •œ–ìC•œ1, “¡“c“N•v1, –쑺@Œb1, –]ŒŽN•œ1, Œ@·G1, ’ѺGN1, Œ–{˜a«1, ‹g“cˆê¬1,2, Šâ‘º³Žk1 (1”å”AŠí, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ”å”AŠí‰È‹I—v 2020/1; 66 (1): 5-8.

510011. [‘à] Quality of life outcomes after low dose-rate brachytherapy for localized prostate cancer: Current status and future perspectives. Murakami Y1, Satoh T1, Tsumura H1, Tabata K1, Matsumoto K1, Ishiyama H2, Iwamura M1: Int J Urol 2019/12; 26 (12): 1099-105. (‘ºã‘אŽ1, ²“¡ˆÐ•¶1, ’ѺGN1, “c”šŒ’ˆê1, Œ–{˜a«1, ÎŽR”ŽžŠ2, Šâ‘º³Žk1: 1”å”AŠí, 2•úŽËü‰ÈŠw (•úŽËüŽîᇊw)

520011. [‘à] tˆÚAˆã‚©‚猩‚œˆÚAˆã—Ã`[ƒ€ì‚è`ˆÚAˆã—ÃŽx‰‡Žº‚Ì–ðŠ„`. ‹g“cˆê¬1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2”å”AŠí): “ú–{ˆÚAEÄ¶ˆã—ÊŌìŠw‰ïŽ 2019/6; 14 (1): 2-9.

522075. [uÀ]y“ÁW: ƒnƒCƒŠƒXƒN‘O—§‘BŠà‚ð[Œ@‚è‚·‚é@‚»‚Ì•Ï‘J‚ÆM0 CRPC‚̍ŐVŽ¡—Áz¡HNPCŽ¡—Â̌»ó‚Ɖۑè@HNPC‚ɑ΂·‚éƒhƒZƒ^ƒLƒZƒ‹‚É‚æ‚鎡—Ã. “c”šŒ’ˆê (”å”AŠí): —Տ°”å”AŠí‰È 2019/7; 73 (8): 552-5.

522076. [uÀ]y“ÁW: tˆÚA‚ÌŒ»‹µ‚ÆŽc‚³‚ê‚œ‰Û‘èz[Žc‚³‚ê‚œ‰Û‘è]@tˆÚA‚É‚š‚¯‚鈫«Žîá‡. ‹g“cˆê¬1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2”å”AŠí): t‚Æ“§Í 2019/7; 87 (1): 103-7.

522077. [uÀ]y“ÁW2: • o‹ŸŽèp`‰SŽÒ‚ɉœ‚ð‚Ç‚€‹³‚Š‚é‚ׂ«‚©`z• o‹Ÿ‰ºtE•›tŽèp‚É‚š‚¯‚鏉SŽÒ‹³ˆç. “¡“c“N•v1, Šâ‘º³Žk1 (1”å”AŠí): Japanese Journal of Endourology 2019/12; 32 (1): 25-7.

530009. [‚»‚Ì‘Œ (Congress abstracts)] Peritoneal dialysis catheter insertion surgery and management. Yoshida K1,2, Ishii D2: The Journal of Vascular Access 2019/5; 20 (1_suppl): 97-9. (‹g“cˆê¬1,2, Îˆä‘å•ã2: 1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2”å”AŠí)

530010. [‚»‚Ì‘Œ (Comment)] Editorial Comment to Placement of SpaceOAR hydrogel spacer for prostate cancer patients treated with iodine-125 low-dose-rate brachytherapy. Tsumura H1: Int J Urol 2020/1; 27 (1): 66. (’ѺGN1: 1”å”AŠí)

540047. [‚»‚Ì‘Œ (Œ€‹†‰ï‹L˜^)]y‘æ11‰ñBCG ’“ü—Ö@Œ€‹†‰ï‹L˜^zBCGäNã÷“à’“ü—Ö@‚Ì“±“ü—Ö@‚Æ“±“üˆÛŽ—Ö@‚Ì”äŠrŒŸ“¢. Œ–{˜a«1, •œŽR‹M”Ž1, ’r“cŸb1, ’ѺGN1, Îˆä‘å•ã1, Šâ‘º³Žk1 (1”å”AŠí): ”å”AŠíŠO‰È 2019/4; 32 (4): 390-1.

[’˜@‘]

620069. [Šwp‘ (•ª’SŽ·•M)] y• –Œ“§Íf—ÃŽwjz• –Œ“§ÍŠ³ŽÒf—ÃŽwj@tˆÚApŽwj, p.125-7. ‹g“cˆê¬1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2”å”AŠí), ŠÄC: ‰ª“cˆê‹`, •Ò: ‰ª“cˆê‹`, ‹Ž–{Š°•¶, …Œû@, “Œ‹žˆãŠwŽÐ, “Œ‹ž, 2019/7”­s.

[Šw‰ïEŒ€‹†‰ï“™]

712024. [Šw‰ï (‘Û)] (µ‘ҍu‰‰“™) Laparoscopic Salvage Pyeloplasty. Iwamura M1: The 36th KOREA-JAPAN UROLOGICAL CONGRESS 2019 (2019/9/21), Seoul, Korea. (Šâ‘º³Žk1: 1”å”AŠí)

713120. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Important factors to prevent vascular access obstruction. Yoshida K1,2, Kuwata H, uemura K, Ishii D2, Asai T, Nakajima S, Motohashi S, Kaneda Y, Takeuchi Y3, Tabata K2, Yoshida A: 11th Congress of the Vascular Access Society 2019 (2019/4/12), Rotterdam, the Netherlands. (‹g“cˆê¬1,2, Îˆä‘å•ã2, ’|“àN—Y3, “c”šŒ’ˆê2: 1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2”å”AŠí, 3t‘Ÿ“à)

713121. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Exercise Therapy in the Early Stage After Kidney Transplantation Is Effective for Improving Physical Performance: A Prospective Cohort Study with Historical Control. Yamamoto S, Matsuzawa R, Ishii D1, Noguchi F2, Ichikawa T3, Matsunaga A3, Yoshida K1,4: 56th ERA-EDTA Congress (2019/6/14), Budapest, Hungary. (Îˆä‘å•ã1, –ìŒû•¶”T2, Žsì‘ž•¶3, Œ‰i“Ä•F3, ‹g“cˆê¬1,4: 1”å”AŠí, 2ŠÅŒì•”, 3ˆã—Éq¶Šw•”, 4V¢‹Iˆã—ÁEæ’[ˆã—Ã)

713122. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) EVALUATION OF JAPANESE-STYLE LOW-VOLUME ON-LINE POST-DILUTION HEMODIAFILTRATION. Sakurai K, Saito T, Hosoya H, Yamauchi F, Kurihara Y, Wakabayashi Y, Ishii D1, Yoshida K1,2, Kokubo K3: 56th ERA-EDTA Congress (2019/6/15), Budapest, Hungary. (Îˆä‘å•ã1, ‹g“cˆê¬1,2, ¬‹v•ÛŒªˆê3: 1”å”AŠí, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3ˆã—Éq¶Šw•”)

713123. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) CLINICAL BENEFITS OF ON-LINE HEMODIAFILTRATION FOR@THE IMPROVEMENT OF THE QUALITY OF LIFE OF DIALYSIS PATIENTS. Sakurai K, Saito T, Yamauchi F, Hosoya H, Suzuki A, Kurihara Y, Kurosawa K, Yoshinaga M, Iwadate Y, Tanibayashi Y, Kokubo K1, Ishii D2, Yoshida K2,3, Hydo T: 56th ERA-EDTA Congress (2019/6/15), Budapest, Hungary. (¬‹v•ÛŒªˆê1, Îˆä‘å•ã2, ‹g“cˆê¬2,3: 1ˆã—Éq¶Šw•”, 2”å”AŠí, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã)

713124. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) KEYNOTE-199: Updated Analysis of Pembrolizumab for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel. Jeffrey C Goh, Emmanuel S Antonarakis, Marine Gross-Goupil, Ulka N Vaishampayan, Josep M Piulats, Ronald de Wit, Tuomo Alanko, Fukasawa S, Tabata K1, Susan Feyerabend, Raanan Berger, Haiyan Wu, Jeri Kim, Christian H Poehlein, Johann S deBono: ANZUP Annual Scientific Meeting 2019 (2019/7/21), Brisbane, Australia. (“c”šŒ’ˆê1: 1”å”AŠí)

713125. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Clinical analysis of patients with PD-introduction after kidney allograft loss. Ishii D1, Shimura S1, Amano N2, Sakata Y1, Watanuki S1, Iwamura M1, Sakakibara M3, Takeuchi Y3, Yoshida K1,4: The 9th Asia Pacific Chapter Meeting of International Society for Peritoneal Dialysis (APCM-ISPD2019) (2019/9/6), Nagoya, Japan. (Îˆä‘å•ã1, Žu‘º‘sˆê˜N1, “V–쓝”V2, â“c—T‰î1, –Ȋс@ãÄ1, Šâ‘º³Žk1, åŒŽ–ƒ—FŽq3, ’|“àN—Y3, ‹g“cˆê¬1,4: 1”å”AŠí, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3t‘Ÿ“à, 4V¢‹Iˆã—ÁEæ’[ˆã—Ã)

713126. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Compared with treatment results between open surgery and laparoscopic surgery for upper tract urothelial carcinoma. Shimura S1, Matsumoto K1, Ikeda M1, Koguchi D1, Taoka Y1, Hirayama T1, Murakami Y1, Utsunomiya T, Matsuda D1, Okuno N, Irie A, Iwamura M1: The 37th World congress of Endourology (2019/10/31), Abu Dhabi, Uae. (Žu‘º‘sˆê˜N1, Œ–{˜a«1, ’r“cŸb1, ‚Œû@‘å1, “c‰ª‰ÀŒ›1, •œŽR‹M”Ž1, ‘ºã‘אŽ1, Œ“c‘å‰î1, Šâ‘º³Žk1: 1”å”AŠí)

713127. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Impact of membranous urethral length on the urinary continence outcomes of patients after robotic]assisted radical prostatectomy. Murakami Y1, Tabata K1, Tsumura H1, Hirayama T1, Matsumoto K1, Iwamura M1: The 37th World congress of Endourology (2019/10/31), Abu Dhabi, UAE. (‘ºã‘אŽ1, “c”šŒ’ˆê1, ’ѺGN1, •œŽR‹M”Ž1, Œ–{˜a«1, Šâ‘º³Žk1: 1”å”AŠí)

713128. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) –k—¢‘åŠw•a‰@‚É‚š‚¯‚é•ÛŒ¯Ø’ñŽŠ‚Ì‚È‚¢ŠO‘lŠO—ˆŽóf‚ÌŒ»ó|•ÄŒRŠÖŒWŽÒ‚Æ”ñ•ÄŒRŠÖŒWŽÒ‚Æ‚Ì”äŠr|. ’r“c¬]1, ŠÖª—ljî, Îˆä‘å•ã1, –k“‡˜aŽ÷1, Šâ‘º³Žk1, –ìŒû•¶”T2, ˆä‘º—[•P2, •º“¡@“§, ‹g“cˆê¬1,3 (1”å”AŠí, 2ŠÅŒì•”, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã): 4th Annual Meeting of International Society of Clinical Medicine (‘æ4‰ñ‘Û—Տ°ˆãŠw‰ïŠwpW‰ï) (2019/12/14), Fukuoka, Japan.

721019. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) Œo• –Œ“I“ž’B–@‚É‚æ‚é• o‹Ÿ‰º•›t“Eœp‚É‚š‚¯‚é‹Zp”F’èRž‚̃|ƒCƒ“ƒg. Šâ‘º³Žk (”å”AŠí): ‘æ107‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (2019/4/19), –ŒŒÃ‰®.

722114. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) pŒã‚ð•Ï‚Š‚é’É‚Ý‚ÌŠÇ—. ’JŒû‰pŠì, “¡“c“N•v1 (1”å”AŠí): ‘æ107‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (2019/4/18), –ŒŒÃ‰®.

722115. [Šw‰ï (‘S‘)] (‹³ˆçu‰‰) t•s‘SŽ¡—Âɂš‚¯‚éÝ‘îˆã—Ã. ‹g“cˆê¬1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2”å”AŠí): ‘æ1‰ñ“ú–{Ý‘îˆã—ØA‡Šw‰ï‘å‰ï (2019/7/14), “Œ‹ž.

722116. [Šw‰ï (‘S‘)] (‹³ˆçƒvƒƒOƒ‰ƒ€) ‰‰ñŽ¡—Õs¬Œ÷—á‚ɑ΂·‚éŒo• –Œ“I• o‹Ÿ‰ºt᱌`¬p. Œ@·G1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ33‰ñ“ú–{”å”AŠí“àŽ‹‹ŸŠw‰ï‘‰ï (2019/11/22), ‹ž“s.

722117. [Šw‰ï (‘S‘)] (“Á•ÊŠé‰æ) lH”A“¹Š‡–ñ‹ØAžp‚ÌŒ»ó‚Ɖۑè: Tips & Pitfalls ‰SŽÒ‚Å‚à¬Œ÷‚³‚¹‚éƒRƒc‚Í? •œŽR‹M”Ž1, ”‹ŒŽ³”Ž1, •âáÁ“ñ1, ’ѺGN1, “c”šŒ’ˆê1, Œ–{˜a«1, “ü]@Œ[1,2, Šâ‘º³Žk1 (1”å”AŠí, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ33‰ñ“ú–{”å”AŠí“àŽ‹‹ŸŠw‰ï‘‰ï (2019/11/23), ‹ž“s.

722118. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ƒƒ{ƒbƒgŽx‰‡‰ºt•”•ªØœpŒã‚É”ñ•ÂÇ«’°ŠÇ‹•ŒŒ‚𔭏ǂµ‚œ1—á. â“c—T‰î1, Îˆä‘å•ã1, Ži”n@o1, ŒŽ–ì‹MO1, ‰––ì@—T1, –Ȋс@ãÄ1, ’ѺGN1, “c”šŒ’ˆê1, “¡“c“N•v1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ33‰ñ“ú–{”å”AŠí“àŽ‹‹ŸŠw‰ï‘‰ï (2019/11/23), ‹ž“s.

722119. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) HoLEPŒã‚̃ƒ{ƒbƒgŽx‰‡ªŽ¡“I‘O—§‘B‘S“Eœ‚ւ̍H•v. ’ѺGN1, ‰““¡•¶N, ÝŠy•q–ç, “c”šŒ’ˆê1, “¡“c“N•v1, Œ–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ32‰ñ“ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ï‘‰ï (2019/12/6), ‰¡•l.

722120. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ƒƒ{ƒbƒgŽx‰‡• o‹Ÿ‰ºäNã÷‘S“Eœp‚Æ‘ÌŠO‰ñ’°“±ŠÇ‘¢Ýp. Œ–{˜a« (”å”AŠí): ‘æ32‰ñ“ú–{“àŽ‹‹ŸŠO‰ÈŠw‰ï‘‰ï (2019/12/6), ‰¡•l.

722121. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) Ý‘‰t“§ÍŠ³ŽÒ‚É‚š‚¯‚é‰^“®—Ö@‚Ì•K—v«‚Æ‹‚ß‚ç‚ê‚éŽÀŽ{•û–@‚ɂ‚¢‚Ä. Žáˆä—zŠó, ˆ¢•”“ޒÔü, “‡‘º’m¶, •º“¡@“§, ‹g“cˆê¬1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2”å”AŠí): ‘æ10‰ñ“ú–{t‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ï (2020/2/22), “Œ‹ž.

723543. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) t×–EŠà‚ɑ΂·‚é• o‹Ÿ‰ºªŽ¡“It“Eœp‚É‚š‚¯‚épŒãáu’ÉŠÇ—•û–@‚ÌŒŸ“¢. “¡“c“N•v1, •œŽR‹M”Ž1, Œ@·G1, ’ѺGN1, Îˆä‘å•ã1, Œ–{˜a«1, ‹g“cˆê¬1,2, Šâ‘º³Žk1 (1”å”AŠí, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ107‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (2019/4/18), –ŒŒÃ‰®.

723544. [Šw‰ï (‘S‘)] (‘‰ïÜƒ|ƒXƒ^[) Oligometastases‚ɑ΂·‚é‘O—§‘BŠà–§••¬üŒ¹—Ö@‚Æ“]ˆÚÆŽË‚Ì’·ŠúŽ¡—ЬÑ‚ÌŒŸ“¢. ’ѺGN1, “c”šŒ’ˆê1, ÎŽR”ŽžŠ2, ’†‘º^—˜]1, ‘ºã‘אŽ1, ìã³Œå2, “¡“c“N•v1, –k–ì‰ëŽj, ²“¡ˆÐ•¶, Šâ‘º³Žk1 (1”å”AŠí, 2•úŽËü (Žîá‡)): ‘æ107‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (2019/4/18), –ŒŒÃ‰®.

723545. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) äNã÷‘S“Ep•W–{‚É‚š‚¯‚éTROY”­Œ»‚ÌŒŸ“¢. –쑺@Œb, Œ–{˜a«1, Ž…‚ä‚èŽq, ¬—ÑŒ’‘Ÿ˜Y, ’r“cŸb1, “V–쓝”V2, Œ@^—RŽq, —À@–ŸG, ’·‰–@—º3, ²“¡—Yˆê3, Šâ‘º³Žk1 (1”å”AŠí, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ˆã—Éq¶Šw•”): ‘æ107‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (2019/4/18), –ŒŒÃ‰®.

723546. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ƒVƒXƒvƒ‰ƒ`ƒ“•¹—p‰»Šw—Ö@‚É‚š‚¯‚éƒVƒ‡[ƒgƒnƒCƒhƒŒ[ƒVƒ‡ƒ“–@‚ÌŒŸ“¢. ì‘º•ä1, Žá“c•”—zŽi1, •ÊŠ‰pŽ¡, ‚“cŽ¡Žq1, ‰œ–ì‹I•F (1”å”AŠí): ‘æ107‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (2019/4/18), –ŒŒÃ‰®.

723547. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ªŽ¡“IäNã÷‘S“EpŒã‚̍Ĕ­E“]ˆÚÇ—á‚ɑ΂·‚é‹~Ï‰»Šw—Ö@‚ÌŒŸ“¢. ’r“cŸb1, Œ–{˜a«1, •œŽR‹M”Ž1, ‚Œû@‘å1, ‘ºã‘אŽ1, Œ“c‘å‰î1, ‰œ–ì‹I•F, ‰©@‰p–Î, ‰F“s‹{‘ñŽ¡, “c‰ª‰ÀŒ›1, “ü]@Œ[1,2, Šâ‘º³Žk1 (1”å”AŠí, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ107‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (2019/4/18), –ŒŒÃ‰®.

723548. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) • o‹Ÿ‰ºt᱌`¬pŒã’·ŠúŒo‰ß‚µ‚čĔ­‚µ‚œ2Ç—á. Žt”ö”ɍF1, Œ@·G1, •œŽR‹M”Ž1, “¡“c“N•v1, Œ–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ107‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (2019/4/18), –ŒŒÃ‰®.

723549. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) de novo M1‘O—§‘BŠà‚Ì—\ŒãˆöŽq; mCNPCŽ¡—Â̍œK‰»‚ð–ÚŽw‚µ‚Ä. “c”šŒ’ˆê1, ’ѺGN1, ‘ºã‘אŽ1, •œŽR‹M”Ž1, Îˆä‘å•ã1, “¡“c“N•v1, Œ–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ107‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (2019/4/19), –ŒŒÃ‰®.

723550. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”ñ“]ˆÚ«‹Žš’ïR«‘O—§‘BŠà (NM-CRPC) “ú–{lÇ—á‚ɑ΂·‚éƒAƒpƒ‹ƒ^ƒ~ƒh‚Ì—LŒø«‹y‚шÀ‘S«: ‘Û‘œŽ{Ý‹€“¯“ñd–ÓŒŸƒ‰ƒ“ƒ_ƒ€‰»‘æ‡V‘ŠŽŽŒ±‚̃Tƒu‰ðÍ. ²“¡ˆÐ•¶, ¡’†Œ[ˆê˜Y, –ìŒû‰p‹v, ¬ŽR@—º, ’ѺGN1, Vˆä@Šw, ã‘º”ŽŽi (1”å”AŠí): ‘æ107‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (2019/4/19), –ŒŒÃ‰®.

723551. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ƒƒ{ƒbƒgŽx‰‡• o‹Ÿ‰º‘O—§‘B‘S“EœpŒã”AŽž‹Ö—Š (Urine loss ratio, ULR) ‚ÌŒŸ“¢. •œŽR‹M”Ž1, “c”šŒ’ˆê1, “V–쓝”V2, Žu‘º‘sˆê˜N1, Œ–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ107‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (2019/4/19), –ŒŒÃ‰®.

723552. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) • o‹Ÿ‰º‘O—§‘B‘S“Eœp‚©‚烍ƒ{ƒbƒgŽx‰‡• o‹Ÿ‰º‘O—§‘B‘S“Eœp‚̏pŽ®ˆÚs‚É‚š‚¯‚éØœ’f’[—z«‚ÉŠÖ‚·‚錟“¢. ‚“cŽ¡Žq1, “c”šŒ’ˆê1, ‘ºã‘אŽ1, •œŽR‹M”Ž1, ’ѺGN1, Îˆä‘å•ã1, Œ–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ107‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (2019/4/19), –ŒŒÃ‰®.

723553. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹Ø‘w”ñZ«äNã÷Šà‚ɑ΂·‚éBCGäNã÷“à’“ü—Ö@‚Ì“Š—^•û–@‚ɂ‚¢‚Ä‚ÌŒŸ“¢. Œ–{˜a«1, •œŽR‹M”Ž1, ’r“cŸb1, ’ѺGN1, Îˆä‘å•ã1, Œ@·G1, “c”šŒ’ˆê1, “¡“c“N•v1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ107‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (2019/4/19), –ŒŒÃ‰®.

723554. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) t᱁E”AŠÇŠà‚É‚š‚¯‚éhistologic variant‚Æ—\Œã‚ÉŠÖ‚·‚錟“¢. ‘ºã‘אŽ1, Œ–{˜a«1, ’r“cŸb1, •œŽR‹M”Ž1, ‚Œû@‘å1, Œ“c‘å‰î1, “c‰ª‰ÀŒ›1, “ü]@Œ[1,2, Šâ‘º³Žk1 (1”å”AŠí, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ107‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (2019/4/19), –ŒŒÃ‰®.

723555. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ‹}«’Pƒ«äNã÷‰Š‚ɑ΂·‚éƒZƒtƒ@ƒNƒƒ‹‚É‚æ‚鏉ŠúŽ¡—Â̌Ÿ“¢. ‚Œû@‘å1, “y‹Ž³l1, •œ–ìC•œ1, ’r“cŸb1, Îˆä~ˆê˜Y (1”å”AŠí): ‘æ107‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (2019/4/19), –ŒŒÃ‰®.

723556. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) –k—¢Œ€‹†Š•a‰@‚É‚š‚¯‚é”r”AŽ©—§Žw“±‚Ö‚ÌŽæ‚è‘g‚Ý. ŽR‰º‰p”V1, ”‹ŒŽ³”Ž1, ¬—Ñ“Žq1, ‚“ˆ—Í–í, ‚‹Ž—Tˆê˜Y, Œ‘º‚©‚š‚é, “ü]@Œ[1,2 (1”å”AŠí, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ107‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (2019/4/20), –ŒŒÃ‰®.

723557. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ‰AŒs‚ÉŒÀ‹Ç‚µŽ¡—Âɋꗶ‚µ‚œ‰óás«”^”çÇ‚Ì1—á. Ÿ–”—mŽ÷1, —§‰Ô‹MŽj1, “ì“c@—@1, “c‰ª‰ÀŒ›1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ107‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (2019/4/20), –ŒŒÃ‰®.

723558. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”ñ“]ˆÚ«‘O—§‘BŠà‚É‚š‚¯‚éƒfƒmƒXƒ}ƒu60mg”牺’‚Ì—LŒø«‚ƈÀ‘S«‚ÌŒŸ“¢. ’†‘º^—˜]1, ’ѺGN1, ‰––ì@—T1, Žt”ö”ɍF1, Žu‘º‘sˆê˜N1, “V–쓝”V2, ‚“cŽ¡Žq1, ‘ºã‘אŽ1, •œŽR‹M”Ž1, “c”šŒ’ˆê1, ²“¡ˆÐ•¶, Šâ‘º³Žk1 (1”å”AŠí, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ107‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (2019/4/20), –ŒŒÃ‰®.

723559. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ’·Šúƒzƒ‹ƒ‚ƒ“—Ö@•¹—p•úŽËüŽ¡—Âɂš‚¯‚ébone health; ƒ]ƒŒƒhƒƒ“Ž_…˜a•š 5 mg “_“HÃ’‚̏‰ŠúŽg—pŒoŒ±. Žu‘º‘sˆê˜N1, ’ѺGN1, ’†‘º^—˜]1, â“c—T‰î1, –Ȋс@ãÄ1, Œ@·G1, “c”šŒ’ˆê1, Îˆä‘å•ã1, Œ–{˜a«1, ²“¡ˆÐ•¶, ‹g“cˆê¬1,2, Šâ‘º³Žk1 (1”å”AŠí, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ107‰ñ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (2019/4/20), –ŒŒÃ‰®.

723560. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) •›tŠà‚ÆŠÓ•Ê‚ª¢“ï‚Å‚ ‚Á‚œ—ǐ«•›tŽîᇂÌ2—á. •œŽR‹M”Ž1, “¡“c“N•v1, Žt”ö”ɍF1, ‰––ì@—T1, Žu‘º‘sˆê˜N1, ’ѺGN1, Îˆä‘å•ã1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ31‰ñ“ú–{“à•ª”åŠO‰ÈŠw‰ï‘‰ï (2019/6/14), “Œ‹ž, “ú–{“à•ª”åŠO‰ÈŠw‰ïŽGŽ 2019; 36 (‘Š§†): 156.

723561. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) PAD‘Šú”­Œ©‚Ì‚œ‚߉ºŽˆPADƒ`ƒFƒbƒN‚ÆSPP“±“ü1”N–Ú‚ÌŒ‹‰Ê‚ƍ¡Œã‚̉ۑè. —Ž‡—¢“Þ, ‚‹Ž_—Y, ‹g“cˆê¬1,2, ‚‹Ž—Tˆê˜Y (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2”å”AŠí): ‘æ64‰ñ“ú–{“§ÍˆãŠw‰ïŠwpW‰ïE‘‰ï (2019/6/28), ‰¡•l, “§Í‰ïŽ 2019; 52 (Suppl 1): 665.

723562. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) is«tŠà‚ɑ΂·‚镪Žq•W“I–òŽ¡—ÃŒã‚É“§Í“±“ü‚Æ‚È‚Á‚œ1—á. Îˆä‘å•ã1, â“c—T‰î1, –Ȋс@ãÄ1, Žu‘º‘sˆê˜N1, “V–쓝”V2, “¡“c“N•v1, Šâ‘º³Žk1, ‹g“cˆê¬1,3 (1”å”AŠí, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ64‰ñ“ú–{“§ÍˆãŠw‰ïŠwpW‰ïE‘‰ï (2019/6/29), ‰¡•l, “§Í‰ïŽ 2019; 52 (Suppl 1): 708.

723563. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ˆãHŠw‹Zp‚̉ž—p‚É‚æ‚éÝ‘‰t“§Íf—Â̌ø—Š‰»‚ƈÀ‘S‘΍ô. Žáˆä—zŠó, ˆ¢•”“ޒÔü, ’†‘ºŽOÊ, ŠC˜VŒŽŒd, •º“¡@“§, ‹g“cˆê¬1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2”å”AŠí): ‘æ64‰ñ“ú–{“§ÍˆãŠw‰ïŠwpW‰ïE‘‰ï (2019/6/30), ‰¡•l, “§Í‰ïŽ 2019; 52 (Suppl 1): 782.

723564. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) “§ÍŽ{Ý‚É‚š‚¯‚é’ʉ@‘—Œ}‚̈Ӌ`‚Æ–â‘è“_‚ɂ‚¢‚Ä‚à‚€ˆê“xl‚Š‚é`“–‰@‚Å‚Ì10”NŠÔ‚ÌŒoŒ±‚ð‚à‚ƂɁ`. Žáˆä—zŠó, ŒŽ“c®Ž}, “n糗FŽq, ŽR’†—¢‰À, •º“¡@“§, ‹g“cˆê¬1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2”å”AŠí): ‘æ64‰ñ“ú–{“§ÍˆãŠw‰ïŠwpW‰ïE‘‰ï (2019/6/30), ‰¡•l, “§Í‰ïŽ 2019; 52 (Suppl 1): 817.

723565. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ƒJƒ“ƒ{ƒWƒA‰€‘Žñ“sƒvƒmƒ“ƒyƒ“‚É‚š‚¯‚鐅Ž¿ŒŸž‹y‚ьl—pRO‘•’uŽŽŒ±‰^“]‚ɂ‚¢‚Ä‚Ì•ñ. ŒÃ¿—S‰î, ˆ¢•”“ޒÔü, ŠC˜VŒŽŒd, Žáˆä—zŠó, •º“¡@“§, ‹g“cˆê¬1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2”å”AŠí): ‘æ64‰ñ“ú–{“§ÍˆãŠw‰ïŠwpW‰ïE‘‰ï (2019/6/30), ‰¡•l, “§Í‰ïŽ 2019; 52 (Suppl 1): 831.

723566. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ƒJƒ“ƒ{ƒWƒA‰€‘Še“sŽs‚É‚š‚¯‚鐅Ž¿ŒŸž‚ÌŒ‹‰Ê•ñ. ŠC˜VŒŽŒd, ŒÃ¿—S‰î, ˆ¢•”“ޒÔü, Žáˆä—zŠó, •º“¡@“§, ‹g“cˆê¬1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2”å”AŠí): ‘æ64‰ñ“ú–{“§ÍˆãŠw‰ïŠwpW‰ïE‘‰ï (2019/6/30), ‰¡•l, “§Í‰ïŽ 2019; 52 (Suppl 1): 832.

723567. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ƒJƒ“ƒ{ƒWƒA‚ł̃Zƒ~ƒi[ŠJÃ‚É‚æ‚錻’nŽáŽèˆã—ÃŽÒ‹³ˆçŽx‰‡‚ƏC—¹ŽŽŒ±Œ‹‰Ê‚ÌŒXŒü•ªÍ. ˆ¢•”“ޒÔü, Žáˆä—zŠó, ŠC˜VŒŽŒd, •º“¡@“§, ‹g“cˆê¬1,2, ìŒGŽ÷ (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2”å”AŠí): ‘æ64‰ñ“ú–{“§ÍˆãŠw‰ïŠwpW‰ïE‘‰ï (2019/6/30), ‰¡•l, “§Í‰ïŽ 2019; 52 (Suppl 1): 832.

723568. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ¶‘̐tˆÚAŒã‚ÉŠÔŽ¿«”x‰Š‚ª‘ˆ«‚µ‚œˆê—á. Îˆä‘å•ã1, ˆä“c^¶Žq2, ˆ¢•”“N–ç2, Žu‘º‘sˆê˜N1, •œŽR‹M”Ž1, Œ–{˜a«1, –ìŒû•¶”T3, ’r“c¬]1, Šâ‘º³Žk1, ²X–ØŽ¡ˆê˜Y4, ‹g“cˆê¬1,5 (1”å”AŠí, 2t‘Ÿ“à, 3ŠÅŒì•”, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 5V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ55‰ñ“ú–{ˆÚAŠw‰ï‘‰ï (2019/10/11), L“‡, ˆÚA 2019; 54 (‘‰ï—ÕŽž): 302.

723569. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) u‘PˆÓ‚Ì’ñ‹ŸvŒ£tˆÚAŒó•â‚ÌŽ«‘Þ‰ñ“š‚Ì•ªÍ‚ƍ¡Œã‚̑΍ô. ’r“c¬]1, Îˆä‘å•ã1, –k“‡˜aŽ÷1, Žu‘º‘sˆê˜N1, “V–쓝”V2, –ìŒû•¶”T3, ˆä‘º—[•P3, Šâ‘º³Žk1, ‹g“cˆê¬1,4 (1”å”AŠí, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ŠÅŒì•”, 4V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ55‰ñ“ú–{ˆÚAŠw‰ï‘‰ï (2019/10/12), L“‡, ˆÚA 2019; 54 (‘‰ï—ÕŽž): 328.

723570. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) t”AŠÇ‘S“Ep‚É”º‚€ƒŠƒ“ƒpßŠsŽ‚Ì—LŒø«‚ÉŠÖ‚·‚é‘œŽ{Ý‘OŒü‚«Œ€‹†: ’†ŠÔ‰ðÍ. ˆäã‚Œõ, ˆ¢•”‰ps, ”[’JK’j, ”É“c³M, Vˆä@Šw, ›@­Ž¡, ŽO“ckŽi, Œ–{˜a«1, ¬“cL‘Ÿ˜Y, “y’J‡•F, Šâ‘º³Žk1, ‰ª“c@O, Š˜ˆä—²’j, ‰HŸº—F‘¥ (1”å”AŠí): ‘æ57‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï (2019/10/24), •Ÿ‰ª.

723571. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ªŽ¡“IäNã÷‘S“EpŒã‚̍Ĕ­E“]ˆÚÇ—á‚ɑ΂·‚é‹~Ï‰»Šw—Ö@‚ÌŽ¡—ЬÑ. ’r“cŸb1, Œ–{˜a«1, •œŽR‹M”Ž1, ‚Œû@‘å1, ‘ºã‘אŽ1, Œ“c‘å‰î1, ‰œ–ì‹I•F, ‰F“s‹{‘ñŽ¡, “c‰ª‰ÀŒ›1, “ü]@Œ[1,2, Šâ‘º³Žk1 (1”å”AŠí, 2–k—¢‘åŠw–k—¢Œ€‹†Š•a‰@): ‘æ57‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï (2019/10/24), •Ÿ‰ª.

723572. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹Žš’ïR«‘O—§‘BŠàÇ—á‚É‚š‚¯‚é‘S¶‘¶—\‘ªƒmƒ‚ƒOƒ‰ƒ€. •ÄŽRãùŽq, ŽODNG, ‰ÍŒŽ’Ži, ã‘º”ŽŽi, ‰Á“¡^Žj, ¬“ˆˆê•œ, ŽR“c_Žj, ã•œ@C, “c”šŒ’ˆê1, ’ѺGN1, ŽOŽ}—S•ã (1”å”AŠí): ‘æ57‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï (2019/10/25), •Ÿ‰ª.

723573. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ’áü—Ê—Š–§••¬üŒ¹—Ö@‚ÌPSAÄ”­‚Æ“]ˆÚ”­¶‚Ö‰e‹¿‚·‚éˆöŽq‚ÌŒŸ“¢. ’ѺGN1, “c”šŒ’ˆê1, ‘ºã‘אŽ1, ‘ì–L˜a, ìã³Œå2, ŠÖŒûˆ©ˆß2, ²“¡ˆÐ•¶, ÎŽR”ŽžŠ2, Šâ‘º³Žk1 (1”å”AŠí, 2•úŽËü (Žîá‡)): ‘æ57‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï (2019/10/25), •Ÿ‰ª.

723574. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) f’f‚É‹ê—¶‚µ‚œäNã÷paraganglioma‚Ì2—á. ì‘º•ä1, ’†‘º^—˜]1, Žá“c•”—zŽi1, ‰œ–ì‹I•F (1”å”AŠí): ‘æ73‰ñ‘—§•a‰@‘‡ˆãŠw‰ï (2019/11/9), –ŒŒÃ‰®.

723575. [Šw‰ï (‘S‘)] (‘‰ïÜƒ|ƒXƒ^[) “àŽ‹‹ŸŽ¡—ÃŒãÄ”­‚ɑ΂µ, ‹CäNã÷‰ºäNã÷”AŠÇV•«‡p‚ðŽ{s‚µ‚œäNã÷”AŠÇ‹t—¬Ç‚Ì3—á. ‰––ì@—T1, Œ@·G1, â“c—T‰î1, –Ȋс@ãÄ1, •œŽR‹M”Ž1, Îˆä‘å•ã1, Œ–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ33‰ñ“ú–{”å”AŠí“àŽ‹‹ŸŠw‰ï‘‰ï (2019/11/21), ‹ž“s.

723576. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) da Vinci Si, X, Xi 3‹@Ží‚É‚æ‚郍ƒ{ƒbƒgŽx‰‡‰ºt•”•ªØœ‚̗Տ°“IŒŸ“¢. Îˆä‘å•ã1, “¡“c“N•v1, ‰œ“c’mŽj1, â“c—T‰î1, –Ȋс@ãÄ1, Žu‘º‘sˆê˜N1, Œ@·G1, •œŽR‹M”Ž1, Œ–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ33‰ñ“ú–{”å”AŠí“àŽ‹‹ŸŠw‰ï‘‰ï (2019/11/22), ‹ž“s.

723577. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) • o‹Ÿ‰º‘O—§‘B‘S“Eœp, ƒƒ{ƒbƒgŽx‰‡• o‹Ÿ‰º‘O—§‘B‘S“Eœp‚É‚š‚¯‚éPSAÄ”­‚ÌŒŸ“¢. “c”šŒ’ˆê1, ’ѺGN1, ‘ºã‘אŽ1, Îˆä‘å•ã1, Žu‘º‘sˆê˜N1, •œ–ìC•œ1, “¡“c“N•v1, Œ–{˜a«1, ‹g“cˆê¬1,2, Šâ‘º³Žk1 (1”å”AŠí, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ33‰ñ“ú–{”å”AŠí“àŽ‹‹ŸŠw‰ï‘‰ï (2019/11/22), ‹ž“s.

723578. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ƒƒ{ƒbƒgŽx‰‡• o‹Ÿ‰º‘O—§‘B‘S“EœpŒã”A‹Ö§‚É‚š‚¯‚éMRIœ”Õ’ê‰ð–UŠwˆöŽq‚ÌŒŸ“¢. ‘ºã‘אŽ1, “c”šŒ’ˆê1, ’ѺGN1, Žu‘º‘sˆê˜Y1, “V–쓝”V2, â“c—S‰î1, –Ȋс@ãÄ1, Œ–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ33‰ñ“ú–{”å”AŠí“àŽ‹‹ŸŠw‰ï‘‰ï (2019/11/22), ‹ž“s.

723579. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) t᱁E”AŠÇŠà‚ɑ΂·‚éŠJ• p‚Æ• o‹Ÿ‰ºp‚É‚š‚¯‚鎡—ЬÑ‚Ì”äŠrŒŸ“¢. Žu‘º‘sˆê˜N1, Œ–{˜a«1, ’r“cŸb1, ‚Œû@‘å1, •œŽR‹M”Ž1, ‘ºã‘אŽ1, ‰F“s‹{‘ñŽ¡, Œ“c‘å‰î1, ‰œ–ì‹I•F, Šâ‘º³Žk1 (1”å”AŠí): ‘æ33‰ñ“ú–{”å”AŠí“àŽ‹‹ŸŠw‰ï‘‰ï (2019/11/22), ‹ž“s.

723580. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) RŒŒð–ò‚𒆎~‚·‚邱‚Æ–³‚­HoLEP‚ðŽ{s‚µ‚œÇ—á‚̗Տ°ŒŸ“¢. ‘åŽR“N•œ1, ŽRŒû@‘, ‘ˆä‘¥º, ‹àì‹§ˆê, “¿Œõ³s, ˆ¢•”‹I”V, Î“c—T‘¥, a’JH•F (1”å”AŠí): ‘æ33‰ñ“ú–{”å”AŠí“àŽ‹‹ŸŠw‰ï‘‰ï (2019/11/23), ‹ž“s.

723581. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ¬l‚Ə¬Ž™‚É‚š‚¯‚é‹CäNã÷‰ºäNã÷”AŠÇV•«‡p‚Ì”äŠrŒŸ“¢. Žt”ö”ɍF1, Œ@·G1, “¡“c“N•v1, Œ–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ33‰ñ“ú–{”å”AŠí“àŽ‹‹ŸŠw‰ï‘‰ï (2019/11/23), ‹ž“s.

731059. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) “§Í‚©‚çtˆÚA, ‚»‚µ‚Ä“§ÍÄ“±“ü‚É‚š‚¯‚é—¯ˆÓ“_. ‹g“cˆê¬1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2”å”AŠí): Œ§–k’n‹æt•s‘StˆÚAŒ€‹†‰ï (2019/4/23), “ú—§.

731060. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) “–‰@‚É‚š‚¯‚étˆÚA‚ÌŽæ‚è‘g‚Ý. Îˆä‘å•ã (”å”AŠí): ‘æ21‰ñ‹{è”A˜H‹@”\Œ€‹†‰ï^‘æ220‰ñ‹{èŒ§”å”AŠí‰Èˆã‰ï`‹{èŒ§––Šút•s‘SEtˆÚA‚ðl‚Š‚é‰ï` (2019/5/23), ‹{è.

731061. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) “ú–{l‚É‚š‚¯‚郊ƒXƒNˆöŽq‚©‚çM1‘O—§‘BŠà‚ÌŽ¡—Ð헪‚ðl‚Š‚é. “c”šŒ’ˆê (”å”AŠí): Prostate Cancer Seminar in ’†‰z (2019/6/21), ’·‰ª.

731062. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) mHSPC‚ÌŽŽŒ±Œ‹‰Ê‚©‚çM1‘O—§‘BŠà‚ÌŽ¡—Ð헪‚ðŒê‚ç‚€. “c”šŒ’ˆê (”å”AŠí): FDPC (2019/6/28), “Œ‹ž.

731063. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ”å”AŠí‰È• o‹ŸŽèp‚̉ߋŽ‚Æ–¢—ˆ|ˆã—ÈÀ‘SŠÇ—‚ðŒ©˜‚Š‚ā|. Šâ‘º³Žk (”å”AŠí): ‰¡{‰êŽs”å”AŠí‰ÈˆãŠwŠwpu‰‰‰ï (2019/7/1), ‰¡{‰ê.

731064. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ”å”AŠí• o‹ŸŽèp‚ÌŠî–{Žè‹Z`‹Zp”F’èŽæ“Ÿ‚ð–ÚŽw‚µ‚ā`. Šâ‘º³Žk (”å”AŠí): ‘æ11‰ñ•Ÿ“‡Œ§”å”AŠíŽèpŽè‹ZŒ€‹†‰ï (2019/7/13), ŒSŽR.

731065. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ‘O—§‘BŠà‚É‚š‚¯‚é–ò•š—Ö@`ŒÂX‚Ì•a‘Ô‚É‚š‚¯‚鏈•ûⳓà—e`. ’ѺGN (”å”AŠí): Pharmacists study seminar in KITASATO (2019/8/7), ‘Š–ÍŒŽ.

731066. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ”r”Aƒgƒ‰ƒuƒ‹‚ɂ‚¢‚Ä. •œŽR‹M”Ž (”å”AŠí): 2019”N‚‚­‚µ‰ï‘‰ï (2019/10/17), “Œ‹ž.

731067. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) Ý‘îˆã—ÂƂµ‚Ă̐t•s‘SŽ¡—Á`Ý‘Í, • –Œ“§Í, ‚»‚µ‚ĐtˆÚA`. ‹g“cˆê¬1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2”å”AŠí): ‘æ61‰ñ_“ސìˆãŠw‰ï‘‰ïEŠwp‘å‰ï “ú–{ˆãŽt‰ï¶ŠU‹³ˆçuÀ (2019/11/23), ‰¡•l.

731068. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ‘O—§‘B‚ª‚ñ‚Ì–ò•š—Ö@‚ÆFNƒ}ƒlƒWƒƒ“ƒg. “c”šŒ’ˆê (”å”AŠí): Aomori Urology Cancer Seminar (AUCS) (2020/2/6), ÂX.

732042. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ‚ª‚ñ–Ɖu—Ö@‚ðÅ‘åŒÀ‚ɐ¶‚©‚·‚œ‚ß‚ÌŽ¡—Ð헪‚Ƃ́`“]ˆÚ«”A˜Hã”çŠà‚ɑ΂·‚éIO drug‚ÌŽg—pŽÀÑ‚ÌŒŸØ`. Œ–{˜a« (”å”AŠí): SEM for urothelial cancer 2019 (2019/7/9), ŠC˜V–Œ.

732043. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) ã•””A˜HÄŒš. Œ@·G1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ84‰ñ“ú–{”å”AŠí‰ÈŠw‰ï“Œ•”‘‰ï (2019/10/4), “Œ‹ž.

732044. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒfƒBƒx[ƒgƒZƒbƒVƒ‡ƒ“) ŠJ•úƒhƒŒƒi[ƒWp‚ÅŒy‰õ‚µ‚œ”牺‹CŽî‚𔺂€‹CŽî«t᱐t‰Š‚̈ê—á. Žu‘º‘sˆê˜N1, “c”šŒ’ˆê1, •œŽR‹M”Ž1, “¡“c“N•v1, Œ–{˜a«1, ‹g“cˆê¬1,2, Šâ‘º³Žk1 (1”å”AŠí, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ84‰ñ“ú–{”å”AŠí‰ÈŠw‰ï“Œ•”‘‰ï (2019/10/4), “Œ‹ž.

732045. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) p‘OŒã‚̐t‹@”\‚̕ω», t‹@”\‚ð‰·‘¶‚·‚é‚œ‚߂̍H•v. Îˆä‘å•ã1, –k“‡˜aŽ÷1, “¡“c“N•v1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ84‰ñ“ú–{”å”AŠí‰ÈŠw‰ï“Œ•”‘‰ï (2019/10/5), “Œ‹ž.

732046. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) “ñŽŸŽ¡—ÂƂµ‚Ẳ»Šw—Ö@. Œ–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ84‰ñ“ú–{”å”AŠí‰ÈŠw‰ï“Œ•”‘‰ï (2019/10/5), “Œ‹ž.

732047. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒVƒ‡[ƒgƒŒƒNƒ`ƒƒ[) ‘O—§‘BŠà‚ÌŽ¡—ÂÌOver view. ’ѺGN (”å”AŠí): ‘æ2‰ñ‘Š–ÍŒŽEŒÃƒGƒŠƒAHNPCu‰‰‰ï (2019/10/9), ‘Š–ÍŒŽ.

732048. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (‹³ˆçƒZƒ~ƒi[) ‰»Šw—Ö@‚ðŠˆ‚©‚·-•›ì—pŠÇ—‚ÅŒø‰Ê‚ðÅ‘å‚É! “c”šŒ’ˆê (”å”AŠí): ‘æ71‰ñŒ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (2019/11/9), Œ].

732049. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒpƒlƒŠƒXƒg) nmCRPC‚ÌŽ¡—Ð헪‚ɂ‚¢‚Ä. “c”šŒ’ˆê (”å”AŠí): ‘æ1‰ñProstate Cancer SAKURA Conference (2019/11/20), “Œ‹ž.

733188. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ALK—z«”ñ¬×–E”xŠàŽ¡—Ã’†‚É•¡ŽG«t‚Ì‚€–E‚ð”F‚ß‚œ1—á. ’r“cŸb1, ‰©@‰p–Î (1”å”AŠí): –k—¢‘åŠw”å”AŠí‰È§˜b‰ï (2019/4/6), ’¬“c.

733189. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) • –Œ“§ÍƒJƒe[ƒeƒ‹‚Ì—‘ŠÇÑŠª—‚Ì1—á. Ÿ–”—mŽ÷1, —§‰Ô‹MŽj1, “ì“c@—@1, “c‰ª‰ÀŒ›1, Šâ‘º³Žk1 (1”å”AŠí): –k—¢‘åŠw”å”AŠí§˜b‰ï (2019/4/6), ’¬“c.

733190. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) f’f‚É‹ê—¶‚µ‚œƒpƒ‰ƒKƒ“ƒOƒŠƒI[ƒ}‚Ì1—á. ’†‘º^—˜]1, Îˆä‘å•ã1, Žt”ö”ɍF1, Žu‘º‘sˆê˜N1, “V–쓝”V2, •œŽR‹M”Ž1, Œ–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): –k—¢‘åŠw”å”AŠí§˜b‰ï (2019/4/6), ’¬“c.

733191. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “–‰@‚É‚š‚¯‚é•v•wŠÔ¶‘̐tˆÚA‚̗Տ°“IŒŸ“¢. –k“‡˜aŽ÷1, Îˆä‘å•ã1, â“c—T‰î1, Žu‘º‘sˆê˜N1, “V–쓝”V2, ‰““¡’‰—Y, Šâ‘º³Žk1, ’r“c¬]1, –ìŒû•¶”T3, ˆä‘º—[•P3, ‹g“cˆê¬1,4 (1”å”AŠí, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ŠÅŒì•”, 4V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ35‰ñtˆÚAEŒŒŠÇŠO‰ÈŒ€‹†‰ï (2019/5/17), ‚ŽR.

733192. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ƒR[ƒfƒBƒl[ƒ^[‚Æ‚µ‚ă~ƒƒƒ“ƒ}[‚Ƃ̐tˆÚAˆã—ÂɊւ·‚éî•ñŒð—¬‚ÉŒg‚í‚Á‚œŒoŒ±. ’r“c¬]1, rì–@Žq2, ¬‹v•ÛŒªˆê3, Îˆä‘å•ã1, •º“¡@“§, Žáˆä—zŠó, Šâ‘º³Žk1, ‹g“cˆê¬1,4 (1”å”AŠí, 2ŠÅŒì•”, 3ˆã—Éq¶Šw•”, 4V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ35‰ñtˆÚAEŒŒŠÇŠO‰ÈŒ€‹†‰ï (2019/5/18), ‚ŽR.

733193. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) Pazopanib“Š—^‚Å’·Šú¬Ñ‚ð“Ÿ‚œˆê—á. •œ–ìC•œ1, “¡“c“N•v1, ‰––ì@—T1, â“c—T‰î1, “V–쓝”V2, Žu‘º‘sˆê˜N1, Îˆä‘å•ã1, Œ–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): West Kanagawa New Generation RCC seminar (2019/5/24), Œú–Ø.

733194. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) • o‹Ÿ‰ºt᱌`¬pŒã, ŠJ• t᱌`¬pŒã•s¬Œ÷—á‚ɑ΂µ, non-dismembered–@‚É‚æ‚é• o‹Ÿ‰ºt᱌`¬p‚ðs‚Á‚œ1—á. ‰––ì@—T1, Œ@·G1, Îˆä‘å•ã1, •œŽR‹M”Ž1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ16‰ñ”å”AŠí‰ÈÄŒšÄ¶Œ€‹†‰ï (2019/6/8), ‰¡•l.

733195. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “–‰@‚ōs‚Á‚Ä‚¢‚éÅ‹ß‚ÌŽèpEŽè‹Z‚ɂ‚¢‚ā|enbloc TUR-BT|. Žá“c•”—zŽi1, ’†‘º^—˜]1, ì‘º•ä1, ‰œ–ì‹I•F (1”å”AŠí): ‘æ6‰ñ‚³‚ª‚Ý”å”AŠí’nˆæ˜AŒg‚̉ï (2019/6/19), ‘Š–ÍŒŽ.

733196. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) œ“]ˆÚ‚ÌŠÇ—, ‚Ç‚€‚µ‚Ä‚Ü‚·‚©? “V–쓝”V (‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): FDPC (2019/6/28), “Œ‹ž.

733197. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) t”AŠÇ‘S“EŒã‚ɑΑ€t‚É”­¶‚µ‚œ”í–Œ‰ºŒŒŽî‚É‚æ‚蓧Í“±“ü‚Æ‚È‚Á‚œ¶t᱊à‚̈ê—á. Ži”n@o1, –k“‡˜aŽ÷1, ‰œ“c’mŽj1, ŒŽ–ì‹MO1, â“c—T‰î1, Žu‘º‘sˆê˜N1, “c”šŒ’ˆê1, Œ–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ96‰ñ_“ސ쌧”å”AŠí‰Èˆã‰ï (2019/7/13), ìè.

733198. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ƒƒ{ƒbƒgŽx‰‡• o‹Ÿ‰º‘O—§‘B‘S“EœpŒã”A‹Ö§‚É‚š‚¯‚éMRI‚ð—p‚¢‚œœ”Õ’ê‰ð–UŠwˆöŽq‚ÌŒŸ“¢. ‘ºã‘אŽ1, “c”šŒ’ˆê1, ’ѺGN1, Žu‘º‘sˆê˜N1, “V–쓝”V2, –Ȋс@ãÄ1, Œ–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): LUTS Seminar in Kanagawa (2019/8/29), ’¬“c.

733199. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) KI-TKI—Ö@‚É‚æ‚è’·Šú¶‘¶‚ª“Ÿ‚ç‚ê‚Ä‚¢‚émRCC‚̈ê—á. Žu‘º‘sˆê˜N1, “¡“c“N•v1, “V–쓝”V2, •œ–ìC•œ1, Îˆä‘å•ã1, ‹g“cˆê¬1,3, Šâ‘º³Žk1 (1”å”AŠí, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã): KANAGAWA mRCC skill up seminar (2019/9/3), ’¬“c.

733200. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ž‘ƒ“]ˆÚ‚𗈂µ‚œ‘O—§‘BŠà‚Ì1—á. ’†‘º^—˜]1, ì‘º•ä1, Žá“c•”—zŽi1, ‰œ–ì‹I•F (1”å”AŠí): ‘æ60‰ñ“ú–{”å”AŠí‰ÈŠw‰ï_“ސì’n•û‰ï (2019/9/5), ‰¡•l.

733201. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) L”͂Ȍ㕠–ŒƒŠƒ“ƒpß“]ˆÚ‚Å”­Ç‚µ‚œ”AŠÇŠà‚̈ê—á. ŒŽ–ì‹MO1, ‘ºã‘אŽ1, Žt”ö”ɍF1, Ži”n@o1, –Ȋс@ãÄ1, Îˆä‘å•ã1, “¡“c“N•v1, Œ–{˜a«1, ‹g“cˆê¬1,2, Šâ‘º³Žk1 (1”å”AŠí, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ60‰ñ“ú–{”å”AŠí‰ÈŠw‰ï_“ސì’n•û‰ï (2019/9/5), ‰¡•l.

733202. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) dÇŠŽõÇƒ[ƒNƒAƒbƒv’†‚ɂ݂‚©‚Á‚œ‘O•””A“¹•Ù‚̈ê—á. ¬—Ñ“Žq1, ‹œŒŽˆºŽq, ‰º–ØŒŽq‘Ÿ, ŽRè—Yˆê˜Y, ãŒŽŒ’Žj (1”å”AŠí): ‘æ60‰ñ“ú–{”å”AŠí‰ÈŠw‰ï_“ސì’n•û‰ï (2019/9/5), ‰¡•l.

733203. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) äNã÷Šà‚É‚š‚¯‚éPD-L1”­Œ»‚Æ—\Œã‚ÉŠÖ‚·‚錟“¢. ‘ºã‘אŽ1, Œ–{˜a«1, ’r“cŸb1, •œŽR‹M”Ž1, “¡“c“N•v1, Îˆä‘å•ã1, ²“¡—Yˆê2, Šâ‘º³Žk1 (1”å”AŠí, 2ˆã—Éq¶Šw•”): ‘æ37‰ñ–k—¢ŽîᇃtƒH[ƒ‰ƒ€ (2019/9/13), ‘Š–ÍŒŽ.

733204. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒ|ƒXƒ^[) ‘ÌŠOÕŒ‚”gÓÎpŒã‚̐t”í–Œ‰ºŒŒŽî‚ɑ΂µ‚ÄŒoƒJƒe[ƒeƒ‹“®–¬Çðp‚ðŽ{s‚µ‚œ1—á. ˆ¢•”‹I”V, ŽRŒû@‘, ‘åŽR“N•œ1, “¿Œõ³s, ‘ˆä‘¥º, Î“c—T‘¥, ‹Ê–؁@Šx, Š`èGG, ÎŒË’Jr‘Ÿ, ”ªŠª—˜O, ‰«è‹M‘ô (1”å”AŠí): ‘æ84‰ñ“ú–{”å”AŠí‰ÈŠw‰ï“Œ•”‘‰ï (2019/10/4), “Œ‹ž.

733205. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒ|ƒXƒ^[) ƒƒ{ƒbƒgŽx‰‡• o‹Ÿ‰ºt•”•ªØœ (RAPN) ‰Šú90—á‚É‚š‚¯‚épŒãŠ³‘€t‹@”\‚ÌŒŸ“¢. –k“‡˜aŽ÷1, Îˆä‘å•ã1, â“c—T‰î1, ŒŽ–ì‹MO1, “V–쓝”V2, Žu‘º‘sˆê˜N1, •œŽR‹M”Ž1, “¡“c“N•v1, Œ–{˜a«1, ‹g“cˆê¬1,3, Šâ‘º³Žk1 (1”å”AŠí, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ84‰ñ“ú–{”å”AŠí‰ÈŠw‰ï“Œ•”‘‰ï (2019/10/4), “Œ‹ž.

733206. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒ|ƒXƒ^[) ‘O—§‘BŠàpŒã‚̍œ“]ˆÚ‚ɑ΂µ‚Ä“]ˆÚ•”•úŽËü—Ö@‚ª’˜Œø‚µ‚œˆê—á. ‰œ“c’mŽj1, “c”šŒ’ˆê1, Ži”n@o1, ŒŽ–ì‹MO1, ‰––ì@—T1, –Ȋс@ãÄ1, â“c—T‰î1, ’ѺGN1, Œ–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ84‰ñ“ú–{”å”AŠí‰ÈŠw‰ï“Œ•”‘‰ï (2019/10/4), “Œ‹ž.

733207. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‹Žš’ïR«‘O—§‘BŠà (CRPC) ‚ɑ΂·‚éƒJƒoƒWƒ^ƒLƒZƒ‹‚Ì—\ŒãˆöŽq‚ÌŒŸ“¢. ‘ºã‘אŽ1, “c”šŒ’ˆê1, â“c—T‰î1, ’ѺGN1, ²“¡ˆÐ•¶, Œ–{˜a«1, –]ŒŽN•œ1, •âáÁ“ñ1, ‰F“s‹{‘ñŽ¡, Šâ‘º³Žk1 (1”å”AŠí): ‘æ84‰ñ“ú–{”å”AŠí‰ÈŠw‰ï“Œ•”‘‰ï (2019/10/5), “Œ‹ž.

733208. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒ|ƒXƒ^[) äNã÷‘S“EoŒã‚ÌŽ‘±–u‹NÇ‚ɂĐf’f‚³‚ê‚œ‰AŒsÄ”­‚̈ê—á. â“c—T‰î1, Œ–{˜a«1, •œŽR‹M”Ž1, ‚“cŽ¡Žq1, ‘ºã‘אŽ1, –k“‡˜aŽ÷1, ’ѺGN1, “¡“c“N•v1, Îˆä~ˆê˜Y, Šâ‘º³Žk1 (1”å”AŠí): ‘æ84‰ñ“ú–{”å”AŠí‰ÈŠw‰ï“Œ•”‘‰ï (2019/10/5), “Œ‹ž.

733209. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒ|ƒXƒ^[) Œo”A“¹“IŽèpƒVƒ~ƒ…ƒŒ[ƒ^[ (UrotrainerÒ) ‚É‚æ‚éŽèpŽè‹Z‘ÌŒ±. Žt”ö”ɍF1, •œŽR‹M”Ž1, –Ȋс@ãÄ1, •œ–ìC•œ1, Œ–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ84‰ñ“ú–{”å”AŠí‰ÈŠw‰ï“Œ•”‘‰ï (2019/10/5), “Œ‹ž.

733210. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒ|ƒXƒ^[) f’f‚É‹ê—¶‚µ‚œäNã÷Paraganglioma‚Ì2—á. ’†‘º^—˜]1, ‰œ–ì‹I•F, ì‘º•ä1, Žá“c•”—zŽi1, •œŽR‹M”Ž1, Îˆä‘å•ã1, Œ–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ84‰ñ“ú–{”å”AŠí‰ÈŠw‰ï“Œ•”‘‰ï (2019/10/5), “Œ‹ž.

733211. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒ|ƒXƒ^[) ƒnƒCƒŠƒXƒNmHNPC‚̈ê—á. ‘ºã‘אŽ1, “c”šŒ’ˆê1, ’ѺGN1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ2‰ñ‘Š–ÍŒŽEŒÃƒGƒŠƒAHNPCu‰‰‰ï (2019/10/9), ‘Š–ÍŒŽ.

733212. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “–‰@‚Ì–§••¬üŒ¹—Ö@‚©‚ç‚Ý‚œCRPCi“WƒŠƒXƒN‚ÌŒŸ“¢. ’ѺGN (”å”AŠí): –k—¢”å”AŠí‰È§e‰ï (2019/10/19), ‰¡•l.

733213. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‘O—§‘B‚ª‚ñ: ŒŸf‚̈Ӌ`‚Æ–ò•š—Ö@‚Ì–ðŠ„E•›ì—p‚ɂ‚¢‚Ä. ’ѺGN (”å”AŠí): ‘Š–ÍŒŽŽs“à‰Èˆã‰ïE”畆”å”AŠí‰Èˆã‰ï‡“¯Šwpu‰‰‰ï (2019/10/30), ’¬“c.

733214. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒ|ƒXƒ^[) Rivaroxaban“à•ž’†‚ÉHoLEP‚ðŽ{s‚µpŒãoŒŒ‚Å‹ê—¶‚µ‚œ1—á. –]ŒŽN•œ1, “y‹Ž³l1, ‚Œû@‘å1, â“c—T‰î1, ‰©@‰p–Î, Îˆä~ˆê˜Y (1”å”AŠí): ‘æ69‰ñ“ú–{”å”AŠí‰ÈŠw‰ï’†•”‘‰ï (2019/10/31), ‘åã.

733215. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “–‰@‚É‚š‚¯‚éƒJƒ‹ƒjƒ`ƒ“‚ÌŽg—pŒoŒ±. ™“c@“Ö (”å”AŠí): Carnitine Forum in Yokohama`“§ÍŠ³ŽÒ‚̏Ǐó‚ÆŽ¡—Âðl‚Š‚é` (2019/11/5), ‰¡•l.

733216. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒ|ƒXƒ^[) ‘O—§‘Bstromal tumor of uncertain malignant potential (STUMP) ‚Ì3—á. â“c—T‰î1, –]ŒŽN•œ1, ‚Œû@‘å1, “y‹Ž³l1, Îˆä~ˆê˜Y (1”å”AŠí): ‘æ71‰ñŒ“ú–{”å”AŠí‰ÈŠw‰ï‘‰ï (2019/11/9), “‡ª.

733217. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) • ’É‚ðŒ_‹@‚É”­Ç‚µ‚œ¶Œã• –ŒŽîá‡. Ži”n@o1, –k“‡˜aŽ÷1, ‰œ“c’mŽj1, ŒŽ–ì‹MO1, –Ȋс@ãÄ1, Îˆä‘å•ã1, Œ–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ97‰ñ_“ސ쌧”å”AŠí‰Èˆã‰ï (2019/11/9), ‰¡•l.

733218. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) • o‹Ÿ‰º‘O—§‘B‘S“EpŒã‚É’pœŒ‹‡‰Š‚𐶂¶‚œ1—á. ‰––ì@—T1, “c‰ª‰ÀŒ›1, —§‰Ô‹MŽj1, “ì“c@—@1 (1”å”AŠí): ‘æ83‰ñ“ú–{”å”AŠí‰ÈŠw‰ïé‹Ê’n•û‰ï (2019/11/16), é‹Ê.

733219. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ƒƒ{ƒbƒgŽx‰‡‰º• o‹Ÿ‰ºt•”•ªØœ (RAPN) ‚É‚š‚¯‚épŒãŠ³‘€t‹@”\‚ÌŒŸ“¢. ¬—Ñ“Žq1, Îˆä‘å•ã1, –k“‡˜aŽ÷1, –Ȋс@ãÄ1, Žu‘º‘sˆê˜N1, “c”šŒ’ˆê1, “¡“c“N•v1, Œ–{˜a«1, Šâ‘º³Žk1, ‹g“cˆê¬1,2 (1”å”AŠí, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ98‰ñ_“ސìtŒ€‹†‰ïE‘æ35‰ñ_“ސ쌧“§ÍŽ{Ý˜A—‹Š‹c‰ï‡“¯Œ€‹†‰ï (2019/11/17), ‰¡•l.

733220. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) M1‘O—§‘BŠà‚ɑ΂·‚é‹ÇŠŽ¡—Ã. “c”šŒ’ˆê (”å”AŠí): _“ސ쌧Œ•”urology seminar (2019/12/3), ŠC˜V–Œ.

733221. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) de novo—L“]ˆÚ‘O—§‘BŠà‚ɑ΂·‚錎”­‘ƒ‚Ö‚Ì•úŽËüŽ¡—Â̗LŒø«‚ÉŠÖ‚·‚錟“¢; ‘œŽ{Ý‹€“¯Œã‚ëŒü‚«Œ€‹†. “c”šŒ’ˆê1, ’ѺGN1, ”ђˏ~•œ, ‹Ž–{‹±L, ŽODNG, ã‘º”ŽŽi, ’†_‹`O, ‘å–ì–F³, –î–쏻‘å, ìã@— (1”å”AŠí): ‘æ35‰ñ‘O—§‘BƒVƒ“ƒ|ƒWƒEƒ€ (2019/12/15), “Œ‹ž.

733222. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “]ˆÚ«‘O—§‘BŠà‚ɑ΂·‚é‹ÇŠ•úŽËüÆŽË‚̐¶‘¶ŠúŠÔ‰„’·Œø‰Ê‚Æ”r”AŠÖ˜A—LŠQŽ–Û—}§Œø‰Ê‚ÌŒŸ“¢. Ž›“c’ŒŽ÷, a˜e®Žu, Ö“¡rO, ‰¡a@W, Œö•œ’ŒŽ÷, “c”šŒ’ˆê1, ‰–“c^ŒÈ, ‚‹Ž@“Ö, ’¹‹@“O, Œã“¡’”V, ‹Ž–{ˆÀO, “¡ˆä«l, –Ø‘º‚O, ¬“‡’G, ˆäã‹M”Ž, ™–{Š²Žj, ŒŽR”Ž”V, ‰ê–{•qs (1”å”AŠí): ‘æ35‰ñ‘O—§‘BƒVƒ“ƒ|ƒWƒEƒ€ (2019/12/15), “Œ‹ž.

733223. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒ|ƒXƒ^[) V‹K—\Œã—\‘ªƒ‚ƒfƒ‹‚©‚猩‚œƒIƒŠƒSƒƒ^‘O—§‘BŠà‚Ì—\Œã. ˆÀˆä«l, ŽODNG, ‰ÍŒŽ’Ži, ã‘º”ŽŽi, ’†_‹`O, ‘å–ì–F³, ”ђˏ~•œ, ‹Ž–{‹±L, ’ѺGN1, “c”šŒ’ˆê1 (1”å”AŠí): ‘æ35‰ñ‘O—§‘BƒVƒ“ƒ|ƒWƒEƒ€ (2019/12/15), “Œ‹ž.

733224. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) SHPTŽ¡—Â̊ǗŒüã‚ÉŒü‚¯‚œŽŽ‚Ý. ŒË’J‹`K, ˆî’Ϻm, ™“c@“Ö1, ˆÀ“c@Œ³ (1”å”AŠí): CKD-MBD‚ðl‚Š‚é‰ï ‰¡•l (2019/12/17), ‰¡•l.

733225. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) Œ£tˆÚAŒó•â‚ÌŽ«‘Þ‰ñ“š‚Ì•ªÍ‚Ƒ΍ô. ‰œ“c’mŽj (”å”AŠí): ‘æ37‰ñ_“ސìEtˆÚA‚ð•×‹­‚·‚é‰ï (2019/12/21), ‰¡•l.

733226. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒxƒXƒgƒvƒŒƒ[ƒ“ƒe[ƒVƒ‡ƒ“) •sŠ®‘Sd•¡t᱔AŠÇ‚É“¯‘€“¯Žž”­¶‚µ‚œt᱊à‚Ɛt×–EŠà‚Ì1—á. ŒŽ–ì‹MO1, ’r“cŸb1, ‰œ“c’mŽj1, Ži”n@o1, ¬—Ñ“Žq1, Žt”ö”ɍF1, “¡“c“N•v1, Œ–{˜a«1, Šâ‘º³Žk1 (1”å”AŠí): ‘æ61‰ñ“ú–{”å”AŠí‰ÈŠw‰ï_“ސì’n•û‰ï (2020/2/13), ‰¡•l.


Šá‰ÈŠw

[Šwp˜_•¶]

110299. [ŒŽ’˜] Evaluation of Pupil Fields Using a Newly Developed Perimeter in Glaucoma Patients. Totsuka K1, Asakawa K2, Ishikawa H2, Shoji N1: Curr Eye Res 2019/5; 44 (5): 527-32. (ŒË’˘aŽq1, óì@Œ«2, Îì@‹Ï2, ¯ŽiMs1: 1Šá‰È, 2ˆã—Éq¶Šw•”)

110300. [ŒŽ’˜] Visual Performance in Eyes Undergoing Femtosecond Laser-Assisted Keratoplasty for Advanced Keratoconus. Kamiya K1, Takahashi M2, Igarashi A2,3, Shoji N2: Sci Rep 2019/4; 9 (1): 6442 (6pages). (_’J˜aF1, ‚‹Ž³‰p2, ŒÜ\—’ÍŽj2,3, ¯ŽiMs2: 1ˆã—Éq¶Šw•”, 2Šá‰È, 3ŽR‰€•a‰@ƒAƒCƒZƒ“ƒ^[)

110301. [ŒŽ’˜] Repeatability of the Novel Intraocular Pressure Measurement From Corvis ST. Matsuura M1,2, Murata H1, Fujino Y1, Yanagisawa M1, Nakao Y3, Nakakura S4, Kiuchi Y1, Asaoka R1 (1The University of Tokyo, 3Hiroshima University, 4Saneikai Tsukazaki Hospital): Transl Vis Sci Technol 2019/6; 8 (3): 48 (1-8). (Œ‰Y«l1,2: 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

110302. [ŒŽ’˜] Adaptation time, electroretinography, and pupillography in healthy subjects. Asakawa K1, Ito A, Kobayashi H, Iwai A, Ito C, Ishikawa H1: Doc Ophthalmol 2019/8; 139 (1): 33-44. (óì@Œ«1, Îì@‹Ï1: 1ˆã—Éq¶Šw•”)

110303. [ŒŽ’˜] Predictability of the vault after posterior chamber phakic intraocular lens implantation using anterior segment optical coherence tomography. Igarashi A1,2, Shimizu K1,2, Kato S2, Kamiya K3: J Cataract Refract Surg 2019/8; 45 (8): 1099-104. (ŒÜ\—’ÍŽj1,2, Ž…Œö–ç1,2, _’J˜aF3,4: 1ŽR‰€•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È, 3ˆã—Éq¶Šw•”)

110304. [ŒŽ’˜] Challenges to detect glaucomatous visual field loss with pupil perimetry. Asakawa K1, Shoji N2: Clin Ophthalmol 2019/8; 13: 1621-5. (óì@Œ«1, ¯ŽiMs2: 1ˆã—Éq¶Šw•”, 2Šá‰È)

110305. [ŒŽ’˜] Piggyback implantable collamer lens implantation for the correction of residual refractive errors after cataract surgery: a multicenter study. Kamiya K1,2, Shimizu K1,3,4, Kojima T1, Nakamura T1, Ichikawa K1,4,5: (1Japan ICL Study Group): Acta Ophthalmol 2019/9; 97 (6): e946-7. (_’J˜aF1,2, Ž…Œö–ç1,3, Žsìˆê•v1,4,5: 2ˆã—Éq¶Šw•”, 3Šá‰È, 4ŽR‰€•a‰@ƒAƒCƒZƒ“ƒ^[, 5’†‹žŠá‰È)

110306. [ŒŽ’˜] Keratoconus detection using deep learning of colour-coded maps with anterior segment optical coherence tomography: a diagnostic accuracy study. Kamiya K1, Ayatsuka Y2, Kato Y2, Fujimura F1, Takahashi M3, Shoji N3, Mori Y4, Miyata K4 (2Cresco Ltd, Technology Laboratory, 4Miyata Eye Hospital): BMJ Open 2019/9; 9 (9): e031313 (7pages). (_’J˜aF1, “¡‘º•‡²Žq1, ‚‹Ž³‰p3, ¯ŽiMs3: 1ˆã—Éq¶Šw•”, 3Šá‰È)

110307. [ŒŽ’˜] Ocular Biometric Changes after Trabectome Surgery. Kono Y1, Kasahara M2, Iida Y2, Tsujisawa T1, Shoji N2: Clinics in Surgery 2019/10; 4: Article 2634 (4pages). (‰Í–ì—Y—º1, Š}ŒŽ³s2, ”Ñ“c‰Ã•F2, ’Ò‘ò’C•F1, ¯ŽiMs2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2Šá‰È)

110308. [ŒŽ’˜] Epidemiologic and Clinical Characteristics of Optic Neuritis in Japan. Ishikawa H1,2, Kezuka T1, Shikishima K1, Yamagami A1,3, Hiraoka M1, Chuman H1, Nakamura M1, Hoshi K1,4, Goseki T1,5, Mashimo K1,5, Mimura O1, Yoshitomi T1, Tanaka K1 (1Working Group on Diagnostic Criteria for Refractory Optic Neuritis Based on Neuroimmunological Perspective): Ophthalmology 2019/10; 126 (10): 1385-98. (Îì@‹Ï1,2, ŽRã–ŸŽq1,3, ¯@‰À–F1,4, ŒãŠÖ—˜–Ÿ1,5, áÁ‰º‹I”ü‘ã1,5: 2ˆã—Éq¶Šw•”, 3ˆäãŠá‰È•a‰@, 4‰q¶, 5Šá‰È)

110309. [ŒŽ’˜] Effects of 0.4% ripasudil hydrochloride hydrate on morphological changes in rabbit eyes. Limratchatamorn B1, Asakawa K2, Mashimo K1, Uga S1, Ishikawa H2: Int J Ophthalmol 2019/10; 12 (10): 1637-42. (óì@Œ«2, áÁ‰º‹I”ü‘ã1, ‰F‰ê–ÎŽO1, Îì@‹Ï2: 1Šá‰È, 2ˆã—Éq¶Šw•”)

110310. [ŒŽ’˜] Compression of the Choroid by Horizontal Duction. Chen JY1, Le A2,3,4, De Andrade LM2,4, Goseki T2,4,5, Demer JL2,3,4,6,7 (1Computational and Systems Biology Interdepartmental Program, University of California, 2Department of Ophthalmology, University of California, 3Bioengineering Interdepartmental Program, University of California, 4Stein Eye Institute, University of California, 6Department of Neurology, University of California, 7David Geffen Medical School, University of California): Invest Ophthalmol Vis Sci 2019/10; 60 (13): 4285-91. (ŒãŠÖ—˜–Ÿ2,4,5: 5Šá‰È)

110311. [ŒŽ’˜] Comparison of Humphrey Field Analyzer and imo visual field test results in patients with glaucoma and pseudo-fixation loss. Goukon H1,2, Hirasawa K2,3, Kasahara M2, Matsumura K2, Shoji N2: PLoS One 2019/11; 14 (11): e0224711. (‹œ‰E‹ß”ŽN1,2, •œàVˆê–@2,3, Š}ŒŽ³s2, Œ‘ºˆêO2, ¯ŽiMs2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2Šá‰È, 3Moorfields Eye Hospital)

110312. [ŒŽ’˜] Investigating the structure-function relationship using Goldmann V standard automated perimetry where glaucomatous damage is advanced. Yanagisawa M1, Murata H1, Matsuura M1, Fujino Y1, Hirasawa K1,2, Asaoka R1 (1The University of Tokyo): Ophthalmic Physiol Opt 2019/11; 39 (6): 441-50. (•œàVˆê–@1,2: 2Šá‰È)

110313. [ŒŽ’˜] Differences in accommodative response and pupillary constriction during the near response among various refractive errors. Onozato N, Hara N, Taguchi A, Matsuda S, Miyazaki K, Yanai R, Yoshino A, Asakawa K1, Mukuno K2,3: Ž©—¥_Œo 2019/12; 56 (4): 269273. (óì@Œ«1, Œü–ì˜a—Y2,3: 1ˆã—Éq¶Šw•”, 2Šá‰È, 3_“ސ쎕‰È‘åŠw•‘®‰¡•lƒNƒŠƒjƒbƒN)

110314. [ŒŽ’˜] Kinetic visual acuity, stereopsis, and ocular deviation with an implantable collamer lens. Kato S1, Shimizu K1,2, Igarashi A1,2, Kawamorita T3: J Cataract Refract Surg 2019/12; 45 (12): 1777-81. (Ž…Œö–ç1,2, ŒÜ\—’ÍŽj1,2, ìŽç“c‘ñŽu3: 1ŽR‰€•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È, 3ˆã—Éq¶Šw•”)

110315. [ŒŽ’˜] Prevalence of Sagging Eye Syndrome in Adults with Binocular Diplopia. Goseki T1,2, Suh SY2, Robbins L2, Pineles SL2, Velez FG3, Demer JL4 (2UCLA Stein Eye Institute, 3Duke University, 4David Geffen Medical School at University of California): Am J Ophthalmol 2020/1; 209: 55-61. (ŒãŠÖ—˜–Ÿ1,2: 1Šá‰È)

110316. [ŒŽ’˜] Predictability of intraocular lens power calculation in eyes after phototherapeutic keratectomy. Yoneyama R1, Kamiya K2, Iijima K1, Takahashi M1, Shoji N1: Jpn J Ophthalmol 2020/1; 64 (1): 62-7. (•ÄŽR@—È1, _’J˜aF2, ”Ñ“‡@Œh1, ‚‹Ž³‰p1, ¯ŽiMs1: 1Šá‰È, 2ˆã—Éq¶Šw•”)

120022. [ŒŽ’˜]yŠw‰ïŒŽ’˜: ‘æ72‰ñ“ú–{—Տ°Šá‰ÈŠw‰ïu‰‰W [4] u‰‰2-4zƒ‰ƒ^ƒmƒvƒƒXƒg“_Šá–ò‚©‚烉ƒ^ƒmƒvƒƒXƒg/ƒJƒ‹ƒeƒIƒ[ƒ‹‰–Ž_‰–”z‡“_Šá–ò‚ւ̕ύX. ’†–Ž“c‘uŽj1, ˆäãŒ«Ž¡1, ‰–ì”üØŽq1, Šâ²^‹|1,2, ŽR–{’qŒbŽq1, Î“c‹±Žq3, •x“c„Ži3 (1ˆäãŠá‰È•a‰@, 2Šá‰È, 3“Œ–M‘åŠwˆã—ÃZƒ“ƒ^[‘å‹Ž•a‰@Šá‰È): —Տ°Šá‰È 2019/6; 73 (6): 729-35.

120023. [ŒŽ’˜]y‘æ29‰ñ“ú–{—ΓàáŠw‰ï ŒŽ’˜zƒ‰ƒ^ƒmƒvƒƒXƒg+ƒJƒ‹ƒeƒIƒ[ƒ‹‚©‚烉ƒ^ƒmƒvƒƒXƒg/ƒJƒ‹ƒeƒIƒ[ƒ‹”z‡“_Šá–ò‚ւ̕ύX‚É‚æ‚é’·Šú“Š—^. ³ˆä’qŽq1, ˆäãŒ«Ž¡1, ‰–ì”üØŽq1, Šâ²^‹|1,2, Î“c‹±Žq1, •x“c„Ži3 (1ˆäãŠá‰È•a‰@, 2Šá‰È, 3“Œ–M‘åŠwˆã—ÃZƒ“ƒ^[‘å‹Ž•a‰@Šá‰È): ‚ ‚œ‚炵‚¢Šá‰È 2019/6; 36 (6): 804-9.

120024. [ŒŽ’˜] Šp–Œ‹üÜ—Í‚ª‘å‚«‚¢Ç—á‚É‚š‚¯‚éŠá“àƒŒƒ“ƒY“x”ŒvŽZ‚Ì—\‘ª«‚ÌŒŸ“¢. ”Ñ“‡@Œh1, ”Ñ“c‰Ã•F1, Î“c@‹Å1, ]•—Ft1, ¯ŽiMs1 (1Šá‰È): IOL&RS 2019/6; 33 (2): 289-93.

120025. [ŒŽ’˜]yŠw‰ïŒŽ’˜: ‘æ72‰ñ“ú–{—Տ°Šá‰ÈŠw‰ïu‰‰W [6]zŠá“àƒŒƒ“ƒY‘}“üŠá‚É‚š‚¯‚鎩Šo‹üÜ’l‚Æ—‡ŠáŽ‹—Í‚Ì•ª•z. ‰¡ŠÖ—S‰ÀŽq1, ”Ñ“c‰Ã•F1, ‹àŽRr‰î1, Š±ì—¢ŠG2, ”Ñ“‡@Œh1, ]•—Ft1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): —Տ°Šá‰È 2019/8; 73 (8): 1021-6.

120026. [ŒŽ’˜] VDTì‹Æ’†‚̃Kƒ€™ðš‚É‚æ‚éŠá”æ˜J’ጞ‚̉”\«. ›–ì@”Í1, ˆÀ“¡’q‹³1, óì@Œ«2, ‘åàVŒª“ñ1 (1(Š”) ƒƒbƒe, 2ˆã—Éq¶Šw•”): “ú–{™ðšŠw‰ïŽGŽ 2019/11; 29 (2): 58-64.

120027. [ŒŽ’˜] Kinect҃Zƒ“ƒT[‚ð—p‚¢‚œŽ‹ì‹Æ‹——£‚Ì‘ª’è. –îèØ1, Š±ì—¢ŠG1,2, ”Œ“c’m–ç2, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‚ ‚œ‚炵‚¢Šá‰È 2019/7; 36 (7): 962-5.

120028. [ŒŽ’˜] “¯ˆêÇ—á‚ɑ΂µ‚čs‚Á‚œPrecision Pulse Capsulotomy‚ÆContinuous Curvilinear Capsulorrhexis‚Ì‘œŽ{Ý‘OŒü‚«”äŠrŒŸ“¢. ŽO“c‘º–ƒ—¢1, ¬“‡—²Ži2, `œˆê˜Y3, áÁ“ç—mˆê4, “c’†–FŽ÷1, “Žˆä—¢ŠG1, ŽðˆäKO1, Žsì@Œc5, “à“¡®‹v1, Žsìˆê•v1,6 (1’†‹žŠá‰È, 2Œc‰ž‹`m‘åŠw, 3ƒXƒJƒCƒrƒ‹Šá‰È, 4‚܂Ȃ׊á‰ÈƒNƒŠƒjƒbƒN, 5Šò•ŒÔ\Žš•a‰@, 6Šá‰È): IOL&RS 2019/9; 33(3): 485-91.

120029. [ŒŽ’˜] Šá‹…ƒ‚ƒfƒ‹‚ðl—¶‚µ‚œVÝŒvŠá‹ŸƒŒƒ“ƒY‚̐݌v•û–@. •ŸˆäTˆê1, ‰Á“¡ˆêšæ1, ìŽç“c‘ñŽu2 (1ˆÉ“¡ŒõŠwH‹Æ, 2ˆã—Éq¶Šw•”): Šá‹ŸŠwƒWƒƒ[ƒiƒ‹ 2019/8; 23 (1): 61-6.

120030. [ŒŽ’˜] 2Ží—Þ‚Ì1“úŽg‚¢ŽÌ‚ĉ“‹ß—Œ—pƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‚̗Տ°•]‰¿. ‹g–쌒ˆê1, •šŒ©“TŽq2, ŒF”WŒä“°—²3,4, ŽÂãŽ¡•F5, “à“c@ŒO6, ²X–Ø‹IK6 (1‹g–ìŠá‰ÈƒNƒŠƒjƒbƒN, 2ƒtƒVƒ~Šá‰ÈƒNƒŠƒjƒbƒN, 3ƒNƒ}ƒmƒ~ƒh[Šá‰È, 4Šá‰È, 5Šá‰È‹TŒËƒNƒŠƒjƒbƒN, 6“ú–{ƒAƒ‹ƒRƒ“ (Š”)): ‚ ‚œ‚炵‚¢Šá‰È 2020/2; 37 (2): 209-16.

120031. [ŒŽ’˜]y‘æ58‰ñ“ú–{Ž‹”\‹ž³Šw‰ï: ˆê”ʍu‰‰z–¢nŽ™–Ô–ŒÇŠù‰Ž™‚Ì3Î‚É‚š‚¯‚éŠp–Œ‹üÜ—Í. Ö“¡@Ê1, ’r“c“N–ç2,3, Îì@‹Ï4, ŒË’ˁ@Œå1, ¯ŽiMs2 (1–k—¢‘åŠw•a‰@, 2Šá‰È, 3ŽR‰€•a‰@ƒAƒCƒZƒ“ƒ^[, 4ˆã—Éq¶Šw•”): “ú–{Ž‹”\ŒP—ûŽm‹Š‰ïŽ 2019/12; 48: 159-64.

220004. [€ŒŽ’˜ (u‰‰—vŽ|)] Šá‹…ƒ‚ƒfƒ‹‚ðl—¶‚µ‚œVÝŒvŠá‹ŸƒŒƒ“ƒY‚Ì—L—p«. ìŽç“c‘ñŽu1, •ŸˆäTˆê2, ‰Á“¡ˆêšæ2, _’J˜aF1, ”Œ“c’m–ç1, ‹›—¢@”Ž3, ¯ŽiMs4 (1ˆã—Éq¶Šw•”, 2ˆÉ“¡ŒõŠwH‹Æ, 3“Œ‹žŠá‹Ÿê–åŠwZ, 4Šá‰È): Šá‹ŸŠwƒWƒƒ[ƒiƒ‹ 2019/8; 23 (1): 73-6.

220005. [€ŒŽ’˜ (—Տ°Œ€‹†)] Ž©Šo‰ž“š‚ª¢“ï‚ȏǗá‚É‚š‚¯‚铵EŽ‹–쑪’è‚ÌŽŽ‚Ý. óì@Œ«1, ŒË’˘aŽq2, áÁ“ç—Y‘Ÿ3, Žs糋`Í2,4, Îì@‹Ï1 (1ˆã—Éq¶Šw•”, 2_“ސ쎕‰È‘åŠw•‘®‰¡•lƒNƒŠƒjƒbƒNŠá‰È, 3_“ސ쎕‰È‘åŠw•‘®‰¡•lƒNƒŠƒjƒbƒN”F’mÇE‚—îŽÒ‘‡“à‰È, 4Šá‰È): “ú–{Šá‰ÈŠw‰ïŽGŽ 2019/10; 123 (10): 977-80.

310037. [Ç—á•ñ] Child with congenital cataract living in the Bonin Islands. Ito M1, Shimizu K1,2, Shoji N2: JCRS Online Case Reports 2019/10; 7 (4): 61-4. (Ž…Œö–ç1,2, ¯ŽiMs2: 1ŽR‰€•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È)

320035. [Ç—á•ñ] Mesalazine‚É‚æ‚é–òÜ«Ž‹_ŒoÇ‚̈ê—á. ŽRã–ŸŽq1,2, Žá‘q‰ë“o1, ˆäãŒ«Ž¡1, Îì—Tl3 (1ˆäãŠá‰È•a‰@, 2Šá‰È, 3•ºŒÉˆã‰È‘åŠwŠá‰È): _ŒoŠá‰È 2019/6; 36 (2): 184-90.

320036. [Ç—á•ñ] ’·ŠúŒo‰ßŠÏŽ@‚ª‰Â”\‚Å‚ ‚Á‚œViciÇŒóŒQ‚̈ê—á. ‹àŽRr‰î1, ’r“c“N–ç1, ŒãŠÖ—˜–Ÿ1, Îì@‹Ï2, óì@Œ«2, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): _ŒoŠá‰È 2019/9; 36 (3): 330-4.

320037. [Ç—á•ñ] ¬Ž™‚Ì“Á”­«“®Šá_Œo–ƒáƒŒã‚É‚š‚¯‚铵EE’²ßáŠQ‚ð‹qŠÏ“I‚ÉŠÏŽ@‚Å‚«‚œˆê—á. –ìã‹Žu1,2, —é–ØŒ«Ž¡1,2, ŒŽ@’Œl1,2, “¡ŽR—R‹IŽq1,2, ²“¡@Ži1,2, Vˆä“cF—T1,2,3 (1‘Ûˆã—ÕŸŽƒ‘åŠw•ÛŒ’ˆã—Êw•”Ž‹‹@”\—Ö@Šw‰È, 2‘Ûˆã—ÕŸŽƒ‘åŠw•a‰@, 3Šá‰È): _ŒoŠá‰È 2019/9; 36 (3): 340-5.

320038. [Ç—á•ñ] m.4171C>A•ÏˆÙ‚ð’悵‚œƒŒ[ƒxƒ‹ˆâ“`«Ž‹_ŒoÇ‚̈ê—á. ‹Ž’J@—Õ1, ŽRã–ŸŽq1,2, Šâ²^‹|1,2, ˆäãŒ«Ž¡1, Žá‘q‰ë“o1, Œ–{@’Œ3, ˆÀ–{—Ž”n4, ŸNˆäŒc‘¢4, Îì@‹Ï5 (1ˆäãŠá‰È•a‰@, 2Šá‰È, 3“Œ–M‘åŠwˆã—ÃZƒ“ƒ^[‘åX•a‰@, 4—ÕŒŸ•”, 5ˆã—Éq¶Šw•”): _ŒoŠá‰È 2019/12; 36 (4): 421-8.

320039. [Ç—á•ñ] ŠO«Ž‹_ŒoÇ‚Ì•a‘Ԃɍ‡’v‚µ‚È‚¢Ž‹‹@”\áŠQ‚𗈂µ‚œ1—á. •x“c‹§•F1, Œ–{@’Œ1, “n•ÓŒ€l1, ŽÄ@—F–Ÿ1, –x@—Tˆê1, Îì@‹Ï2 (1“Œ–M‘åŠwˆã—ÃZƒ“ƒ^[‘åX•a‰@, 2ˆã—Éq¶Šw•”): _ŒoŠá‰È 2020/3; 37 (1): 58-63.

520012. [‘à] ‹üÜ‹ž³Žèp: “ú–{‚ÌŒ»ó, ¢ŠE‚Æ‚Ì”äŠr. _’J˜aF (ˆã—Éq¶Šw•”): “ú–{‚ÌŠá‰È 2019/4; 90 (4): 420-5.

520013. [‘à] 2019JSCRS Clinical Survey. ²“¡³Ž÷1, _’J˜aF1,2, ¬“‡—²Ži1, Œã“¡Œ›m1, “c•£mŽu1, ‰â“Þ’ÃŽq1, —с@@Œ€1 (1JSCRSƒf[ƒ^‰ðÍˆÏˆõ‰ï, 2ˆã—Éq¶Šw•”): IOL&RS 2019/9; 33 (3): 453-73.

520014. [‘à] Dysphotopsia. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): IOL&RS 2019/12; 33 (4): 627-32.

521003. [‰ðà] Šá‰Èˆã‚ÌŽèˆø <940> ŠwpˆÏˆõ‰ï•Ò@—L…»‘ÌŠá“àƒŒƒ“ƒY. _’J˜aF (ˆã—Éq¶Šw•”): “ú–{‚ÌŠá‰È 2019/7; 90 (7): 856-7.

521004. [‰ðà] ”’“àáE‹üÜŽèp‚̘_“_: SMILE. _’J˜aF (ˆã—Éq¶Šw•”): IOL&RS 2019/9; 33 (3): 505-10.

521005. [‰ðà] Šá‰Èˆã‚ÌŽèˆø <949> ŠwpˆÏˆõ‰ï•Ò@MIGS‚Ì‘I‘ð‚Æ“K‰ž. ¯ŽiMs (Šá‰È): “ú–{‚ÌŠá‰È 2019/12; 90 (12): 1549-50.

521006. [‰ðà] ‚±‚Ÿ‚í‚è‚̐f—Êí‹ï: PVDF–D‡Ž… –D’…—pƒ‹[ƒvj ASFLEX (MODEL I). ”Ñ“c‰Ã•F (Šá‰È): IOL&RS 2019/12; 33 (4): 691-3.

521007. [‰ðà] ƒRƒ“ƒTƒ‹ƒe[ƒVƒ‡ƒ“ƒR[ƒi[@ƒGƒLƒXƒp[ƒg‚É•·‚­: ‰ñ“š3. ŒÜ\—’ÍŽj1,2 (1ŽR‰€•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È): IOL&RS 2019/12; 33 (4): 694-9.

522078. [uÀ]yƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYƒZƒ~ƒi[: ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYˆ•û‚³‚ç‚È‚éˆê•à@54z.˜VŽ‹—pƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‚ÌŒõŠw“Á«. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): ‚ ‚œ‚炵‚¢Šá‰È 2019/4; 36 (4): 503-4.

522079. [uÀ]yÇ—á‚©‚çŠw‚ԁ@”’“àáŽèp‚ÌŽÀ‘HƒŒƒNƒ`ƒƒ[ (p’†•Ò15)zó‘O–[Ç—á. ”Ñ“c‰Ã•F (Šá‰È): —Տ°Šá‰È 2019/4; 73 (4): 415-21.

522080. [uÀ]y“ÁW: lH’m”\ (AI) ‚ƃrƒbƒOƒf[ƒ^zŠp–ŒE”’“àá•ª–ì‚É‚š‚¯‚éAI‰ž—p. _’J˜aF (ˆã—Éq¶Šw•”): ‚ ‚œ‚炵‚¢Šá‰È 2019/4; 36 (4): 465-70.

522081. [uÀ]y“ÁW: ‚±‚ê‚Å‚í‚©‚鎩ŒÈ–Ɖu«ŠáŽŸŠ³zŽ©ŒÈ–Ɖu«Ž‹_Œo‰Š. ŽRã–ŸŽq1,2 (1ˆäãŠá‰È•a‰@, 2Šá‰È): OCULISTA 2019/4; 73: 70-5.

522082. [uÀ]y‚í‚©‚è‚â‚·‚¢—Տ°uÀzŒã–[Œ^—L…»‘ÌŠá“àƒŒƒ“ƒY. ŒÜ\—’ÍŽj1,2 (1ŽR‰€•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È): “ú–{‚ÌŠá‰È 2019/4; 90 (4): 436-40.

522083. [uÀ]y‚í‚©‚è‚â‚·‚¢—Տ°uÀz‹üÜ‹ž³ŽèpŒã‚Ì”’“àáŽèp. ”Ñ“c‰Ã•F (Šá‰È): “ú–{‚ÌŠá‰È 2019/4; 90 (4): 442-7.

522084. [uÀ] “ÁW: Šá‚©‚çl‚Š‚éŒð’ʈÀ‘S`Ž‹‹@”\Ši·Žž‘ã‚É‚š‚¯‚鍂—îŽÒ‚ÌŒð’ʈÀ‘S`. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): Œð’ʈÀ‘S‹³ˆç 2019/5; 54 (5): 6-12.

522085. [uÀ] Šp–Œ‹üÜ‹ž³ƒAƒbƒvƒf[ƒg: ƒgƒ|ƒKƒCƒhŠp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO. ‚‹Ž³‰p (Šá‰È): IOL&RS 2019/6; 33 (2): 241-8.

522086. [uÀ]yƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYƒZƒ~ƒi[: ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYˆ•û‚³‚ç‚È‚éˆê•à@57zŒõ (”g’·) ‚ÆŠá. ”Œ“c’m–ç (ˆã—Éq¶Šw•”): ‚ ‚œ‚炵‚¢Šá‰È 2019/7; 36 (7): 905-6.

522087. [uÀ]y“ÁW2: Negative DysphotopsiazŒõŠwŽÀŒ±‚©‚çl‚Š‚éNegative Dysphotopsia. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): Šá‰ÈŽèp 2019/7; 32 (3): 332-7.

522088. [uÀ]yƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYƒZƒ~ƒi[: ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYˆ•û‚³‚ç‚È‚éˆê•à 58zῂµ‚³‚ÌŽí—Þ. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): ‚ ‚œ‚炵‚¢Šá‰È 2019/8; 36 (8): 1039-40.

522089. [uÀ]y‹üÜ‹ž³ŽèpƒZƒ~ƒi[: ƒXƒLƒ‹ƒAƒbƒvuÀ 231.z‘OŠá•”OCT‚ð—p‚¢‚œICLƒTƒCƒY‚ÌŒˆ’è. ŒÜ\—’ÍŽj1,2 (1ŽR‰€•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È): ‚ ‚œ‚炵‚¢Šá‰È 2019/8; 36 (8): 1043-4.

522090. [uÀ]y“ÁW: –òÜ‚Ì•›ì—p‚Ɛ_ŒoŠá‰ÈzR‚ª‚ñÜ‚Ɛ_ŒoŠá‰È. ”–؍LÆ1,2 (1Ã‰ªŒ§—§Ã‰ª‚ª‚ñƒZƒ“ƒ^[, 2Šá‰È): _ŒoŠá‰È 2019/9; 36 (3): 297-303.

522091. [uÀ]y“ÁW: ƒRƒ“ƒrƒl[ƒVƒ‡ƒ“‹üÜ‹ž³ŽèpzŠp–Œ•Ï«Ç PTKpŒã‚Ì”’“àáŽèp. •ÄŽR@—È1, _’J˜aF2 (1Šá‰È, 2ˆã—Éq¶Šw•”): IOL&RS 2019/9; 33 (3): 407-12.

522092. [uÀ]y“ÁW: ƒRƒ“ƒrƒl[ƒVƒ‡ƒ“‹üÜ‹ž³ŽèpzŽ‹‹@”\‚©‚猩‚œŠááىº‚Žèp. ’h”Vã˜a•F1, •œàVˆê–@1,2,3, ã‘ºŒiŽq1, ‚–ؐœ“ñ1,4 (1‚Ÿ‚ñ‚Ì‚€‚ŠŠá‰ÈƒNƒŠƒjƒbƒN, 2Moorfields Eye Hospital, 3Šá‰È, 4“Œ–M‘åŠwˆã—ÃZƒ“ƒ^[‘å‹Ž•a‰@): IOL&RS 2019/9; 33 (3): 427-33.

522093. [uÀ]y—Տ°ƒZƒ~ƒi[z”’“àápŒãŒŸž‚̃Rƒc. Š±ì—¢ŠG1, ìŽç“c‘ñŽu1 (1ˆã—Éq¶Šw•”): IOL&RS 2019/9; 33 (3): 516-21.

522094. [uÀ]y“ÁW: —ߘa‚Ì”’“àáŽèpzŠá“àƒŒƒ“ƒY“x”ŒvŽZ. ”Ñ“c‰Ã•F (Šá‰È): OCULISTA 2019/11; 80: 27-33.

522095. [uÀ]y“ÁW: “µE‚̉·ŒÌ’mVz“µEŽ‹–쑪’è‚̍ŐV‹Z–@. óì@Œ« (ˆã—Éq¶Šw•”): _ŒoŠá‰È 2019/12; 36 (4): 378-85.

522096. [uÀ]y“ÁW: —Γàá‚̐V‚µ‚¢f—Ö@‚Æ‚»‚Ì•]‰¿|ƒzƒ“ƒg‚Ì‚Æ‚±‚ë‚Í?z¡V‹Kf—Ö@‚ð•]‰¿‚·‚é@–Ñ—l‘ÌŒõ‹ÃŒÅp|ƒ}ƒCƒNƒƒpƒ‹ƒX–Ñ—l‘ÌŒõ‹ÃŒÅp‚̃zƒ“ƒg‚Ì‚Æ‚±‚ë. ’Ò‘ò’C•F1, ¯ŽiMs2 (1‘åŠw‰@‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2Šá‰È): —Տ°Šá‰È 2019/12; 73 (13): 1546-50.

522097. [uÀ]y“ÁW: ‚š‚³‚Š‚Ä‚š‚«‚œ‚¢V‚µ‚¢‘OŠá•”ŒŸžzŠp–Œ‚̃qƒXƒeƒŠƒVƒX‚Æ‚»‚Ì•]‰¿. _’J˜aF (ˆã—Éq¶Šw•”): OCULISTA 2019/12; 81: 55-60.

522098. [uÀ]y“ÁW: V‚µ‚¢‘OùNØŠJzCCC‚Ì‘˜_ (”­ˆÄ‚Æ—ðŽj). Ž…Œö–ç1,2,3 (1ŽR‰€•a‰@ƒAƒCƒZƒ“ƒ^[, 2‘Ûˆã—ÕŸŽƒ‘åŠw, 3Šá‰È): IOL&RS 2019/12; 33 (4): 604-7.

522099. [uÀ]y“ÁW: V‚µ‚¢‘OùNØŠJzPrecision Pulse Capsulotomy (ZEPTOÒ). ŽO“c‘º–ƒ—¢1, Žsìˆê•v1,2, ¬“‡—²Ži3 (1’†‹žŠá‰È, 2Šá‰È, 3Œcœä‹`m‘åŠwˆãŠw•”Šá‰ÈŠw‹³Žº•ªŽº) IOL&RS 2019/12; 33 (4): 613-8.

522100. [uÀ]y“ÁW: “µE‚̉·ŒÌ’mVz˜˜_. óì@Œ«1, ‘O“cŽj“Ä2 (1ˆã—Éq¶Šw•”, 2VŠƒˆã—ÕŸŽƒ‘åŠw): _ŒoŠá‰È 2019/12; 36 (4): 371.

522101. [uÀ]y“ÁW1: —Ž‹ûÇŒóŒQ‚ɑ΂·‚éŽèpí—ªz—Ž‹û—Γàá‚ɑ΂·‚é—¬o˜HÄŒšp. Š}ŒŽ³s1, ¯ŽiMs1 (1Šá‰È): Šá‰ÈŽèp 2020/1; 33 (1): 24-9.

522102. [uÀ]y“ÁW: ƒfƒWƒ^ƒ‹‰»‚ªi‚ÞŠá‰ÈŽèpz4. ”’“àáŽèp‚ւ̃fƒWƒ^ƒ‹‹ZpEAI‚̉ž—p. _’J˜aF (ˆã—Éq¶Šw•”): Šá‰È 2020/1; 62 (1): 29-34.

522103. [uÀ]y“ÁW: ŠááÙáz¹z˜˜_. Îì@‹Ï (ˆã—Éq¶Šw•”): Šá‰È 2020/2; 62 (2): 101-2.

522104. [uÀ]y“ÁW: ŠááÙáz¹z1. ŠááÙáz¹‚Æ‚Í. ŽRã–ŸŽq1,2 (1ˆäãŠá‰È•a‰@, 2Šá‰È): Šá‰È 2020/2; 62 (2): 103-6.

522105. [uÀ]y“ÁW: AI (lH’m”\)zƒfƒB[ƒvƒ‰[ƒjƒ“ƒO‚ð—p‚¢‚œ‰~Šp–Œ‚̐f’f‚š‚æ‚Ñ•aŠú•ª—Þ. _’J˜aF (ˆã—Éq¶Šw•”): IOL&RS 2020/3; 34 (1): 36-41.

530011. [‚»‚Ì‘Œ (’ù³)] Correction to: Causes, background, and characteristics of binocular diplopia in the elderly. Kawai M1, Goseki T2, Ishikawa H3, Hoshina M, Shoji N2: Jpn J Ophthalmol 2019/7; 63 (4): 352. (‰Í‡ˆ€ŽÀ1, ŒãŠÖ—˜–Ÿ2, Îì@‹Ï3, ¯ŽiMs2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2Šá‰È, 3ˆã—Éq¶Šw•”)

540048. [‚»‚Ì‘Œ (ƒjƒ…[ƒXƒŒƒ^[)] •ÒWˆÏˆõ’·A”C‚É‚ ‚œ‚Á‚Ä. _’J˜aF (ˆã—Éq¶Šw•”): “ú–{ŠáŒõŠw‰ïƒjƒ…[ƒXƒŒƒ^[2019/4; 2019 (1): 3.

540049. [‚»‚Ì‘Œ (ƒjƒ…[ƒXƒŒƒ^[)] V”C—Ž–‚̏Љî. Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): “ú–{ŠáŒõŠw‰ïƒjƒ…[ƒXƒŒƒ^[2019/4; 2019 (1): 5.

540050. [‚»‚Ì‘Œ]yŠwZ•ÛŒ’‚̕Łz_“ސ쌧‚ÌŠwZ•ÛŒ’‚ÌŒ»ó. ‰F’ÃŒ©‹`ˆê1,2 (1_“ސ쌧Šá‰Èˆã‰ï•›‰ï’·, 2Šá‰È): “ú–{‚ÌŠá‰È 2019/4; 90 (4): 463-5.

540051. [‚»‚Ì‘Œ]yŠCŠOˆãŠwî•ñz‹ßŽ‹Šá‚Ɛ³Ž‹Šá‚É‚š‚¯‚éperipheral blur‚ɑ΂·‚éneural adaptation. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): “ú–{‚ÌŠá‰È 2019/6; 90 (6): 711-2.

540052. [‚»‚Ì‘Œ] “ÁW‚É‚ ‚œ‚Á‚Ä. ’†‘º–M•F1, _’J˜aF2 (1‚œ‚È‚µ’†‘ºŠá‰È, 2ˆã—Éq¶Šw•”): IOL&RS 2019/6; 33 (2): 218.

540053. [‚»‚Ì‘Œ] –@l‚©‚ç‚Ì‚š’m‚点: •œ¬‚©‚ç—ߘa‚Ö. Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): IOL&RS 2019/6; 33 (2): 395.

540054. [‚»‚Ì‘Œ (Letter to the editor)] Letter to the editor: ‘å•œ–Ÿ•Fæ¶‚ւ̉ñ“š. ŒãŠÖ—˜–Ÿ1, Š—¶^—¢2, Žs粋`Í1,2, ŒN“‡^ƒ2, Œü–ì˜a—Y1,2 (1Šá‰È, 2_“ސ쎕‰È‘åŠw•‘®‰¡•lƒNƒŠƒjƒbƒN): _ŒoŠá‰È 2019/6; 36 (2): 240-2.

540055. [‚»‚Ì‘Œ] “ÁW‚É‚ ‚œ‚Á‚Ä. rˆäGK1, _’J˜aF2 (1‚Ý‚È‚Æ‚Ý‚ç‚¢ƒAƒCƒNƒŠƒjƒbƒN, 2ˆã—Éq¶Šw•”): IOL&RS 2019/9; 33 (3): 406.

540056. [‚»‚Ì‘Œ] CLƒoƒgƒ‹ƒƒCƒ„ƒ‹ƒT[ƒhƒXƒe[ƒW‘æ57‰ñ@ƒ}ƒ‹ƒ`ƒtƒH[ƒJƒ‹CL vs ƒ}ƒ‹ƒ`ƒtƒH[ƒJƒ‹IOL. ‹g–쌒ˆê, _’J˜aF1, Š“c‰ë‹`, “ñ‹{‚³‚ä‚è, “ñ‹{‹Ó•F (1ˆã—Éq¶Šw•”): “ú–{ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYŠw‰ïŽ 2019/9; 61 (3): 77-83.

540057. [‚»‚Ì‘Œ (ŽGŽ‹LŽ–)] ¢ŠE‚̈ãŠwŽ‚©‚çu—Γàá‚Ö‚Ì‘I‘ð“IƒŒ[ƒU[‘@ˆÛ’Œ‘ÑŒ`¬p”ï—p‘ÎŒø‰Ê‚Å–ò•š—Ö@‚ɏŸ‚év‰ðà@ŒŽ”­ŠJ•ú‹÷Šp—Γàá‚⍂Šáˆ³ÇŠ³ŽÒ‚ÉSLT‚ð‘æ1‘I‘ð‚Æ‚·‚錟“¢‚ð. ¯ŽiMs (Šá‰È): MMJ (The Mainichi Medical Journal) 2019/10; 15 (5): 158.

540058. [‚»‚Ì‘Œ (¡ŒŽ‚Ì•\Ž†)]y¡ŒŽ‚Ì•\Ž†z¬Œû•a. ‰i–ìKˆê1, ˆî’J@‘å2 (1Šá‰È, 2•Ÿˆä‘åŠw): —Տ°Šá‰È 2019/10; 73 (10): 1251.

540059. [‚»‚Ì‘Œ (ƒlƒbƒg‹LŽ–)] ƒŒ[ƒVƒbƒN‚ÉŽŸ‚®ƒu[ƒ€‚É? Šá“àƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYuICLv‚ÌŠó–]‚ÆŒÀŠE. _’J˜aF (ˆã—Éq¶Šw•”): DIAMOND online 2019/11; https://diamond.jp/articles/-/220614.

540060. [‚»‚Ì‘Œ (L)] ”ς킵‚¢Œõ‚©‚ç‚̉ð•ú‚Ö: ‚ ‚ç‚œ‚ȃj[ƒY‚É’…–Ú‚µ‚œƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY. ”Œ“c’m–ç1, Œ”ö”ü—LŠó2, šúŽR•üŽq2, John Buch2 (1ˆã—Éq¶Šw•”, 2ƒWƒ‡ƒ“ƒ\ƒ“ƒGƒ“ƒhƒWƒ‡ƒ“ƒ\ƒ“ (Š”) ƒrƒWƒ‡ƒ“ƒPƒAƒJƒ“ƒpƒj[): ‚ ‚œ‚炵‚¢Šá‰È 2019/12; 36 (12): ‘S–ʍL (5pages).

540061. [‚»‚Ì‘Œ (Šw‰ïˆóÛ‹L)] ˆóÛ‹L: ‘æ34‰ñJSCRSŠwp‘‰ï. _’J˜aF (ˆã—Éq¶Šw•”): IOL&RS 2019/12; 33 (4): 713-4.

540062. [‚»‚Ì‘Œ] –@l‚©‚ç‚Ì‚š’m‚点: ƒAƒWƒAŒ—‚Å‚ÌŠá‰Èˆã—ËŠ—Í. Žsìˆê•v1,2,3 (1JSCRS•›—Ž–’·, 2’†‹žŠá‰È, 3Šá‰È): IOL&RS 2019/12; 33 (4): 717.

540063. [‚»‚Ì‘Œ (¡ŒŽ‚Ì•\Ž†)]y¡ŒŽ‚Ì•\Ž†zTerdsonÇŒóŒQ. ŽRŒû@ƒ (Šá‰È): —Տ°Šá‰È 2020/3; 74 (3): 251.

540064. [‚»‚Ì‘Œ (ˆã‰ï‚Ÿ‚æ‚è)]yˆã‰ï‚Ÿ‚æ‚èz<“ú–{Šá‰ÈŽÐ‰ï•ÛŒ¯‰ï‹cƒVƒ“ƒ|ƒWƒEƒ€•ñ> ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï@“ú–{Šá‰ÈŽÐ‰ï•ÛŒ¯‰ï‹cƒVƒ“ƒ|ƒWƒEƒ€uf—ÕñV‰ü’èƒqƒAƒŠƒ“ƒO‚𓥂܂Š‚āv4. “ú–{—ΓàáŠw‰ï‚©‚ç‚Ì—v–]. ¯ŽiMs (Šá‰È): “ú–{‚ÌŠá‰È 2020/2; 91 (2): 87-91.

540065. [‚»‚Ì‘Œ (‘•])] ‘•]: S—Êá‰Èˆã‚ª‹³‚Š‚é@‚»‚Ì–Ú‚Ì•s’²‚Í”]‚ªŒŽˆö. ŽRã–ŸŽq1,2 (1ˆäãŠá‰È•a‰@, 2Šá‰È): _ŒoŠá‰È 2020/3; 37 (1): 76.

540066. [‚»‚Ì‘Œ (Šw‰ïŽ˜^)]y‘æ55‰ñ –k—¢‘åŠwE_“ސ쌧Šá‰Èˆã‰ï‡“¯ƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒXzƒIƒ~ƒfƒlƒpƒOƒCƒ\ƒvƒƒsƒ‹“_Šá–ò‚Ì’ZŠúŽg—p¬Ñ. ‚–ØŒ˜‘Ÿ˜Y1, Š}ŒŽ³s1, ‚‹Ž³‰p1, ‰Í–ì—Y—º2, ’Ò‘ò’C•F2, •ÄŽR@—È1, ¯ŽiMs1 (1Šá‰È, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): Šá‰È—Տ°‹I—v 2020/3; 13 (3): 218.

540067. [‚»‚Ì‘Œ (Šw‰ïŽ˜^)]y‘æ55‰ñ –k—¢‘åŠwE_“ސ쌧Šá‰Èˆã‰ï‡“¯ƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒXzƒŒ[ƒVƒbƒNpŒãŠO‚É‚æ‚éƒtƒ‰ƒbƒv–|“]‚𐶂¶‚œˆê—á. ŸNˆä—•Žq1, ‚‹Ž³‰p1, _’J˜aF2, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): Šá‰È—Տ°‹I—v 2020/3; 13 (3): 218.

540068. [‚»‚Ì‘Œ (Šw‰ïŽ˜^)]y‘æ55‰ñ –k—¢‘åŠwE_“ސ쌧Šá‰Èˆã‰ï‡“¯ƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒXzƒ_ƒuƒ‹ƒj[ƒhƒ‹ƒeƒNƒjƒbƒN‚ð—p‚¢‚œƒtƒ‰ƒ“ƒW–@‚É‚æ‚éŠá“àƒŒƒ“ƒY‹­–Œ“àŒÅ’èp‚ÌŽèp¬Ñ. ŠFì—FŒ›1, t–ؐ’G1, –ö“c’q•F1, ¯ŽiMs1 (1Šá‰È): Šá‰È—Տ°‹I—v 2020/3; 13 (3): 218.

540069. [‚»‚Ì‘Œ (Šw‰ïŽ˜^)]y‘æ55‰ñ –k—¢‘åŠwE_“ސ쌧Šá‰Èˆã‰ï‡“¯ƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒXzŠá‹…‰^“®áŠQ‚ð‡•¹‚µ‚œRMOGR‘Ì—z«Ž‹_Œo‰Š‚Ì1—á. —Žˆä‰‘Žq1, Îì‘å‹N1, ‹àŽRr‰î1, ŒãŠÖ—˜–Ÿ1, Îì@‹Ï2, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): Šá‰È—Տ°‹I—v 2020/3; 13 (3): 218.

540070. [‚»‚Ì‘Œ (Šw‰ïŽ˜^)]y‘æ55‰ñ –k—¢‘åŠwE_“ސ쌧Šá‰Èˆã‰ï‡“¯ƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒXzBarrett Universal IIŽ®‚ÆSRK/TŽ®‚Ì—\‘ª«‚Ì”äŠr. ”Ñ“‡@Œh1, _’J˜aF2, ”Ñ“c‰Ã•F1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): Šá‰È—Տ°‹I—v 2020/3; 13 (3): 218-219.

540071. [‚»‚Ì‘Œ (Šw‰ïŽ˜^)]y‘æ55‰ñ –k—¢‘åŠwE_“ސ쌧Šá‰Èˆã‰ï‡“¯ƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒXzŒõŠ±Â’f‘wŒv (OCT)ŠŒ©‚𒆐S‚Æ‚µ‚œ–Ô–ŒÉŽq‘ÌŽŸŠ³. t–ؐ’G (Šá‰È): Šá‰È—Տ°‹I—v 2020/3; 13 (3): 219.

[’˜@‘]

620070. [Šwp‘ (•ª’SŽ·•M)]yŽ¡—ÁEŒŸžEˆ’u‚̃V[ƒ“•Ê‚É‚í‚©‚é@Šá‰È‚Ì‚Æ‚Á‚Ä‚š‚«‚­‚·‚è‚ō¢‚Á‚œ‚Æ‚«‚ÉŠJ‚­–{ (Šá‰ÈƒPƒA2019”Nt‹G‘Š§)z3Í ŽŸŠ³‚ÌŽ¡—Âłǂ€Žg‚í‚ê‚é? ‚æ‚­Žg—p‚³‚ê‚é–ò@(2) Šááق¯‚¢‚ê‚ñ, p.62-71. ŒãŠÖ—˜–Ÿ1 (1Šá‰È), •Ò: Œ“‡”Ž”V2 (2àՋŠˆã‰È‘åŠwŠá‰È), ƒƒfƒBƒJo”Å, ‘åã, 2019/4”­s.

620071. [Šwp‘ (•ª’SŽ·•M)]y—Γàá“¹ê@f’fEŽ¡—Â̈êŽè‚²Žw“ìzƒRƒ‰ƒ€21 ’áNP—ΓàáŽèp (MIGS), p.205. ¯ŽiMs (Šá‰È), •Ò: –Ø“à—Ç–Ÿ, ˆãŠw‘‰@, “Œ‹ž, 2019/4”­s.

620072. [Šwp‘ (•ª’SŽ·•M)]y‘ŽŽ113|‘æ113‰ñˆãŽt‘‰ÆŽŽŒ±–â‘è‰ðà‘zA-14 Šááىº‚‚ÌŒŽˆö, p.14. A-21 ‰©”Á‰~E‚Å—\‘z‚³‚ê‚鎩ŠoÇó, p.27-8. C-35 “d‹C«Šá‰Š‚ւ̑Ήž, p.234. D-4 —Ž‹‚ÌŽ²‚ÌŒˆ’è‚É•K—v‚ÈŽ‹—Í•\‚Ì•”•ª, p.279. D-24 —ôEŒŽ¶–Ô–Œ”—£‚ɑ΂µ‚čs‚í‚ê‚œŽ¡—Ã, p.303-4. D-59 –Ô–Œ‘O–Œ‚̐f’f‚É—L—p‚ÈŒŸž, p.371-2. E-6 Šá‚̉Á—î‚É‚æ‚é’²ß—͒ቺ‚ÉŠÖ—^‚·‚é•”ˆÊ, p.411. E-18 ‚€‚ÁŒŒ“û“ª‚ɐ”º‚·‚鏉ŠúÇó, p.420. F-55 •ÂÇ‹÷Šp—Γàá‚ւ̑Ήž, p.521-2. ŒãŠÖ—˜–Ÿ1, Žs粋`Í1,2 (1Šá‰È, 2_“ސ쎕‰È‘åŠw•‘®‰¡•lƒNƒŠƒjƒbƒN), •Ò: ˆãŽt‘‰ÆŽŽŒ±–â‘è‰ðà‘•ÒWˆÏˆõ‰ï, ƒeƒRƒ€ ƒRƒ“ƒeƒ“ƒcŽ–‹Æ–{•”, “Œ‹ž, 2019/4”­s.

620073. [Šwp‘ (•ª’SŽ·•M)]yŽÔÚHMI‚ÌŠJ”­“®Œü‚ÆŽ©“®‰^“], ADAS‚ւ̉ž—p|ƒhƒ‰ƒCƒoó‘ÔŒŸo, ŠoÁˆÛŽ, Œ ŒÀˆÚ÷, ƒZƒLƒ…ƒŠƒeƒB‘΍ô|z‘æ10Í ƒwƒbƒhƒAƒbƒvƒfƒBƒXƒvƒŒƒC‚Ì•\ŽŠ‹Zp‚ÆŽ‹”F«Œüã, ˆÀ‘S«•]‰¿@‘æ3ß ¶—ŒõŠw‚Ì—§ê‚©‚猩‚œƒwƒbƒhƒAƒbƒvƒfƒBƒXƒvƒŒƒC‚̈À‘S«‚ÆŽ‹Šo’†SÝŒv, p.465-73. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”), ‹Zpî•ñ‹Š‰ï, “Œ‹ž, 2019/7”­s.

620074. [Šwp‘ (•ª’SŽ·•M)]yŠá‰È‚Æ–òÜ (Šá‰È2019”N9ŒŽ—ÕŽž‘Š§†)z‘æ1•” Å‹ß‚ÌŠá‰È–ò•šŽ¡—Á@VII. ._ŒoŠá‰ÈŽŸŠ³@3. –«Ä”­«‰ŠÇ«Ž‹_ŒoÇ (CRION), p.1169-72. ŽRã–ŸŽq1,2 (1ˆäãŠá‰È•a‰@, 2Šá‰È), •x“c„Ži, ’Ø“cˆê’j, Œã“¡@_, ”Ñ“c’mO, ŽG‰êŽiŽì–ç, –å”V‰€ˆê–Ÿ, Îì@‹Ï3 (3ˆã—Éq¶Šw•”), ‹àŒŽo”Å, “Œ‹ž, 2019/9”­s.

620075. [Šwp‘ (•ª’SŽ·•M)]y’†“rŽž–Ÿ‚Ì‚ ‚é‰Â”\«‚Ì‚ ‚鎟Š³Q&A (‚ ‚œ‚炵‚¢Šá‰È 36 (—ÕŽž‘Š§†))zI ’†“rŽž–Ÿ‚Ì‚ ‚é‰Â”\«‚Ì‚ ‚鎟Š³‚Æ‚»‚ÌŒŸž/Ž¡—Á@6. Ž‹_ŒoEŽ‹˜H@Q3 “Á”­«Ž‹_Œo‰Š‚Æ‚Í‚È‚ñ‚Å‚·‚©. ‚Ü‚œŽ¡—Â͂ǂ€‚µ‚Ü‚·‚©, p.215-8. ’†àV—S‘¥1, Îì@‹Ï2 (1Ž­Ž™“‡‘åŠw, 2ˆã—Éq¶Šw•”), •ÒWŽåŠ²: –؉º@–Î, •Ò: ŽR–{“N–ç, ”Ñ“c’mO, ŠO‰€çŒb, ƒƒfƒBƒJƒ‹ˆšo”Å, “Œ‹ž, 2019/11”­s.

620076. [Šwp‘ (•ª’SŽ·•M)]y’†“rŽž–Ÿ‚Ì‚ ‚é‰Â”\«‚Ì‚ ‚鎟Š³Q&A (‚ ‚œ‚炵‚¢Šá‰È 36 (—ÕŽž‘Š§†))zI ’†“rŽž–Ÿ‚Ì‚ ‚é‰Â”\«‚Ì‚ ‚鎟Š³‚Æ‚»‚ÌŒŸž/Ž¡—Á@6 .Ž‹_ŒoEŽ‹˜H@Q4 ‹•ŒŒ«Ž‹_ŒoÇ‚̐f’f‚ÆŽ¡—Âɂ‚¢‚Ä‹³‚Š‚Ä‚­‚Ÿ‚³‚¢, p.219-22. Šâ²^‹|1,2, ŽRã–ŸŽq1,2 (1ˆäãŠá‰È•a‰@, 2Šá‰È), •ÒWŽåŠ²: –؉º@–Î, •Ò: ŽR–{“N–ç, ”Ñ“c’mO, ŠO‰€çŒb, ƒƒfƒBƒJƒ‹ˆšo”Å, “Œ‹ž, 2019/11”­s.

620077. [Šwp‘ (•ª’SŽ·•M)]yCurrent Decision Support/CDS (ƒfƒWƒ^ƒ‹”Å)zÇó (”]_ŒoEž_)@•¡Ž‹: •š‚ª“ñd‚ÉŒ©‚Š‚é/Double vision (diplopia), https://www.cds.ai/docs/detail/s01500. ŒãŠÖ—˜–Ÿ (Šá‰È), ƒvƒŒƒVƒWƒ‡ƒ“, “Œ‹ž, 2019/12.

620078. [Šwp‘ (•ª’SŽ·•M)]yCurrent Decision Support/CDS (ƒfƒWƒ^ƒ‹”Å)zÇó (“ªèò•”)@Ž‹_Œo“û“ªŽî’¯ (Optic disc swelling), https://www.cds.ai/docs/detail/s05420. ŒãŠÖ—˜–Ÿ (Šá‰È), ƒvƒŒƒVƒWƒ‡ƒ“, “Œ‹ž, 2019/12.

620079. [Šwp‘ (•ª’SŽ·•M)]yŠáŽŸŠ³ƒAƒgƒ‰ƒXƒVƒŠ[ƒY ‘æ3Šª@ŠOŠá•”ƒAƒgƒ‰ƒXz5. Šá‹…‰^“®ˆÙí@Še˜_@4) ‹ØŒŽ¶Šá‹…‰^“®áŠQ@(5) Sagging eye syndrome, p.386-7. ŒãŠÖ—˜–Ÿ1 (1Šá‰È), ŠÄC: ‘厭“N˜Y2 (2’}”g‘åŠw), •Ò: –ì“cŽÀ3, “n•Ó²‰p4 (3Œc‰ž‘åŠw, 4‹ž“s•{—§ˆã‰È‘åŠw), ‘‡ˆãŠwŽÐ, 2019/10”­s.

621004. [Šwp‘ (•ÒW)]yŠá‰È‚Æ–òÜ (Šá‰È2019”N9ŒŽ—ÕŽž‘Š§†)z•Ò: •x“c„Ži, ’Ø“cˆê’j, Œã“¡@_, ”Ñ“c’mO, ŽG‰êŽiŽì–ç, –å”V‰€ˆê–Ÿ, Îì@‹Ï1 (1ˆã—Éq¶Šw•”), ‹àŒŽo”Å, “Œ‹ž, 2019/9”­s.

[Šw‰ïEŒ€‹†‰ï“™]

712025. [Šw‰ï (‘Û)] (ƒVƒ“ƒ|ƒWƒEƒ€) Epidemiological and Clinical Characteristics of Optic Neuritis in Japan. Ishikawa H1: The 8th Chinese Neuro-Ophthalmological Society Conference (2019/7/19), China. (Îì@‹Ï1: 1ˆã—Éq¶Šw•”)

712026. [Šw‰ï (‘Û)] (µ‘ҍu‰‰“™) Meet tha Experts Japan: Optical and fluid dynamics simulatin in Hole ICL. Kawamorita T1: STAAR Surgical 16th international EVO Visian ICL Experts Summit (2019/9/13), Paris, France. (ìŽç“c‘ñŽu1 :1ˆã—Éq¶Šw•”)

712027. [Šw‰ï (‘Û)] (MasterClasses) Mastering Minimally Invasive Glaucoma Surgery (MIGS)/KDB and Trabectome. Shoji N1: 32nd APACRS KYOTO2019 (2019/10/3), Kyoto, Japan. (¯ŽiMs1: 1Šá‰È)

712028. [Šw‰ï (‘Û)] (ƒVƒ“ƒ|ƒWƒEƒ€) Presbyopia Treatment for Phakic Eye (—L…»‘ÌŠá‚É‚š‚¯‚é˜VŽ‹‹ž³). Igarashi A1,2: 32nd APACRS KYOTO2019 (2019/10/4), Kyoto, Japan. (ŒÜ\—’ÍŽj1,2: 1ŽR‰€•a‰@, 2Šá‰È)

712029. [Šw‰ï (‘Û)] (ƒVƒ“ƒ|ƒWƒEƒ€)yÀ’·zSUMO-Wrestling with Challenges in Refractive Surgery (‹üÜ‹ž³Žèp‚É‚š‚¯‚é’§í‚Ƃ̃ŒƒXƒŠƒ“ƒO). Shimizu K1,2: 32nd APACRS KYOTO2019 (2019/10/5), Kyoto, Japan. (Ž…Œö–ç1,2: 1ŽR‰€•a‰@, 2Šá‰È)

712030. [Šw‰ï (‘Û)] (ƒVƒ“ƒ|ƒWƒEƒ€) 10Years Follow Up of KS-AquaPORT ICL KS-AquaPORT (ICL‚Ì10”NŒo‰ßŠÏŽ@). Shimizu K1,2: 32nd APACRS KYOTO2019 (2019/10/5), Kyoto, Japan. (Ž…Œö–ç1,2: 1ŽR‰€•a‰@, 2Šá‰È)

712031. [Šw‰ï (‘Û)] (Young Neuro-Ophthalmologists (YNO) Session) High Prevalence of Sagging Eye Syndrome with Binocular Diplopia. Goseki T1: the 10th Asian Neuro-Ophthalmology Society Congress (2019/12/3), Manila, Philippines. (ŒãŠÖ—˜–Ÿ1: 1Šá‰È)

722122. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yƒI[ƒKƒiƒCƒU[zÅ“_[“x‚ÌŠg’£‚͘VŽ‹Ž¡—ẪXƒ^ƒ“ƒ_[ƒh‚Æ‚È‚è‚€‚é‚©? _’J˜aF (ˆã—Éq¶Šw•”): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/18), “Œ‹ž.

722123. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) “µEŒa‚Əœ_[“x. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/18), “Œ‹ž.

722124. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yƒI[ƒKƒiƒCƒU[zImaging‚̐i•à‚Ɛ_ŒoŠá‰ÈŽŸŠ³. Îì@‹Ï (ˆã—Éq¶Šw•”): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/18), “Œ‹ž.

722125. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Šáâ|“àŒ‹‡D•Ï«‚É‚æ‚éŒã“V•¡Ž‹. ŒãŠÖ—˜–Ÿ (Šá‰È): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/18), “Œ‹ž.

722126. [Šw‰ï (‘S‘)] (International Symposium) Trabectome surgery: effects and limitations ¯ŽiMs (Šá‰È): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/18), “Œ‹ž.

722127. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yƒI[ƒKƒiƒCƒU[z—ΓàáŠá‚Ì‹÷ŠpüˆÛ’Œ‘тɑ΂·‚éƒAƒvƒ[ƒ`. ¯ŽiMs (Šá‰È): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/20), “Œ‹ž.

722128. [Šw‰ï (‘S‘)] (‹³ˆçƒZƒ~ƒi[) V‚µ‚¢ŽãŽ‹Ž¡—Á|—ŒŠáŠJ•ú‰ºŽãŽ‹ŒP—û|. ”Œ“c’m–ç (ˆã—Éq¶Šw•”): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/20), “Œ‹ž.

722129. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) Ž‹‹@”\ŒŸž‚̐V‚œ‚ȃvƒ‰ƒbƒgƒtƒH[ƒ€|EYENAC‚Æaccu-pad|. ”Œ“c’m–ç (ˆã—Éq¶Šw•”): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/20), “Œ‹ž.

722130. [Šw‰ï (‘S‘)] (ƒTƒuƒXƒyƒVƒƒƒŠƒeƒBƒTƒ“ƒf[)yƒI[ƒKƒiƒCƒU[z‚±‚ê‚Ń}ƒXƒ^[, Ž‹_ŒoŽŸŠ³. Îì@‹Ï (ˆã—Éq¶Šw•”): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/21), “Œ‹ž.

722131. [Šw‰ï (‘S‘)] (ƒTƒuƒXƒyƒVƒƒƒŠƒeƒBƒTƒ“ƒf[) Ž‹_Œo‰Š. —Žˆä‰‘Žq (Šá‰È): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/21), “Œ‹ž.

722132. [Šw‰ï (‘S‘)] (ƒTƒuƒXƒyƒVƒƒƒŠƒeƒBƒTƒ“ƒf[) ˆ³”—«, ˆâ“`«, ’†“Ő«Ž‹_ŒoÇ. ŽRã–ŸŽq1,2 (1ˆäãŠá‰È•a‰@, 2Šá‰È): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/21), “Œ‹ž.

722133. [Šw‰ï (‘S‘)] (ƒTƒuƒXƒyƒVƒƒƒŠƒeƒBƒTƒ“ƒf[) Šá“àƒŒƒ“ƒY“x”ŒvŽZ. ”Ñ“c‰Ã•F (Šá‰È): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/21), “Œ‹ž.

722134. [Šw‰ï (‘S‘)] (ƒTƒuƒXƒyƒVƒƒƒŠƒeƒBƒTƒ“ƒf[) •ªŒõ“§‰ß—Š‚ÆŽÕŒõŠá‹ŸE’…FŠá“àƒŒƒ“ƒY. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/21), “Œ‹ž.

722135. [Šw‰ï (‘S‘)] (uK‰ï) ‹üÜ‹ž³ŽèpE‘“àŠO‚ÌŒ»ó‚ƍ¡Œã‚Ì“W–]. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (“ú–{Šá‰ÈŠw‰ï‹üÜ‹ž³ŽèpuK‰ï) (2019/4/21), “Œ‹ž.

722136. [Šw‰ï (‘S‘)] (‹|íÜ‹L”Ou‰‰) Causes,background,and characteristics of binocular diplopia in the elderly (‚—îŽÒ‚Ì—ŒŠá«•¡Ž‹‚𐶂žŒŽˆö, ”wŒi‹y‚Ñ“Á’¥). ‰Í‡ˆ€ŽÀ1, ŒãŠÖ—˜–Ÿ1, Îì@‹Ï2, •Û‰È”üŠó3, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”, 3ŽR‰€•a‰@): ‘æ75‰ñ“ú–{ŽãŽ‹ŽÎŽ‹Šw‰ï‘‰ïE‘æ44‰ñ“ú–{¬Ž™Šá‰ÈŠw‰ï‘‰ï ‡“¯Šw‰ï (2019/6/14), Ã‰ª.

722137. [Šw‰ï (‘S‘)] (ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[) AŒ^ƒ{ƒcƒŠƒkƒX“Å‘f»Üƒ{ƒgƒbƒNƒXuKEŽÀ‹ZƒZƒ~ƒi[uŽÎŽ‹vŽŸŠ³•Ò. ŒãŠÖ—˜–Ÿ (Šá‰È): ‘æ75‰ñ“ú–{ŽãŽ‹ŽÎŽ‹Šw‰ï‘‰ïE‘æ44‰ñ“ú–{¬Ž™Šá‰ÈŠw‰ï‘‰ï ‡“¯Šw‰ï (2019/6/14), Ã‰ª.

722138. [Šw‰ï (‘S‘)] (ƒrƒfƒIƒvƒŒƒ[ƒ“ƒe[ƒVƒ‡ƒ“) ICLŽèp. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/28), ‹ž“s.

722139. [Šw‰ï (‘S‘)] (“Á•Ê•ñ) 2019 JSCRS Clinical Survey. ²“¡³Ž÷1, _’J˜aF2 (1ƒTƒgƒEŠá‰È, 2ˆã—Éq¶Šw•”): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/28), ‹ž“s.

722140. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yÀ’·z”’“àáŽèpŒã‚Ì‹üÜ‹ž³. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/28), ‹ž“s.

722141. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ”’“àápŒã‚̉“‹ß—Œ—pƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‘•—p. ”Ñ“‡@Œh1, _’J˜aF2, ”Ñ“c‰Ã•F1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/28), ‹ž“s.

722142. [Šw‰ï (‘S‘)] (‹³ˆçƒZƒ~ƒi[) ƒg[ƒŠƒbƒNŠá“àƒŒƒ“ƒYŽèp‚ÌŽÀÛ. Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/28), ‹ž“s.

722143. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒfƒB[ƒvƒ‰[ƒjƒ“ƒO‚Æ‘OŠá•”ŒõŠ±Â’f‘wŒv‚ð—p‚¢‚œ‰~Šp–Œ‚̐f’f. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/29), ‹ž“s.

722144. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‹üÜ‹ž³Žèp‚Æ‚µ‚Ẵgƒ|ƒKƒCƒhŠp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO. ‚‹Ž³‰p (Šá‰È): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/29), ‹ž“s.

722145. [Šw‰ï (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX)yƒI[ƒKƒiƒCƒU[EuŽtz¢ŠE‚̍ŐVƒgƒŒƒ“ƒh‚ð’m‚ë‚€! What's New in 2019. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/29), ‹ž“s.

722146. [Šw‰ï (‘S‘)] (ƒP[ƒXƒŒƒ|[ƒg)yÀ’·zƒP[ƒXƒŒƒ|[ƒg…@. ŒÜ\—’ÍŽj1,2 (1ŽR‰€•a‰@, 2Šá‰È): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/29), ‹ž“s.

722147. [Šw‰ï (‘S‘)] (ƒP[ƒXƒŒƒ|[ƒg) ƒgƒ|ƒKƒCƒhŠp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO‚ª‘tŒ÷‚µ‚œƒyƒ‹[ƒVƒhŠp–Œ•Ó‰•Ï«‚̈ê—á. ’Ò‘ò’C•F1, _’J˜aF2, ‚‹Ž³‰p1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/29), ‹ž“s.

722148. [Šw‰ï (‘S‘)] (ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[) “úíŽ‹‰º‚Ì‘œÅ“_Ž‹—́EƒRƒ“ƒgƒ‰ƒXƒgŠŽ“xŒŸž|accu-pad|. ”Œ“c’m–ç (ˆã—Éq¶Šw•”): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/29), ‹ž“s.

722149. [Šw‰ï (‘S‘)] (ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[)yÀ’·zƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[3@Äl!!˜VŽ‹`”’“àá¢‘ã‚ÌQOL. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/29), ‹ž“s.

722150. [Šw‰ï (‘S‘)] (ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[) –ŸŽ‹ˆæ‚ðŠg‘å‚·‚éIOL‚ÆCL‚́g‚¢‚ë‚¢‚ëh‚Æ‚»‚Ì’²˜a. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/29), ‹ž“s.

722151. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)yÀ’·zƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[11ƒvƒŒƒ~ƒAƒ€”’“àáŽèp‚Ì—Ž‹U—ª–@. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/29), ‹ž“s.

722152. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ”’“àáp‘O|Total Keratometry‚É‚æ‚闐Ž‹U—ª|. “¡‘º•‡²Žq (ˆã—Éq¶Šw•”): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/29), ‹ž“s.

722153. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yÀ’·zƒVƒ“ƒ|ƒWƒEƒ€7: ‘œÅ“_IOL|ÅV‚Ì‘œÅ“_Šá“àƒŒƒ“ƒY‚Æ‚»‚Ì“K³Žg—p|. Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/30), ‹ž“s.

722154. [Šw‰ï (‘S‘)] (‹³ˆçƒZƒ~ƒi[) pŒã‡•¹Ç‚ւ̑Ήž. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/30), ‹ž“s.

722155. [Šw‰ï (‘S‘)] (‹³ˆçƒZƒ~ƒi[) ‘O”XØŠJ‚ðì¬Žž‚Ì’ˆÓ“_‚Æ—¬‚ê‚»‚€‚ÈŽž‚̑Ώˆ–@. ”Ñ“c‰Ã•F (Šá‰È): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/30), ‹ž“s.

722156. [Šw‰ï (‘S‘)] (‹³ˆçƒZƒ~ƒi[) ‘O–[[“x—\‘ª‚©‚ç‚̐ž“xƒAƒbƒv. ŒÜ\—’ÍŽj1,2 (1ŽR‰€•a‰@, 2Šá‰È): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/30), ‹ž“s.

722157. [Šw‰ï (‘S‘)] (‹³ˆçƒZƒ~ƒi[) ’PÅ“_ƒŒƒ“ƒY‚Ì–ŸŽ‹ˆæ. Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/30), ‹ž“s.

722158. [Šw‰ï (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX)yƒI[ƒKƒiƒCƒU[z[ORT‚É‚æ‚éORT‚Ì‚œ‚ß‚ÌIC] ”’“àáE‹üÜ‹ž³Žèp‘OŒã‚É‚š‚¯‚錟ž‚Ì—¬‚ê. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/30), ‹ž“s.

722159. [Šw‰ï (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX)yuŽtz[ORT‚É‚æ‚éORT‚Ì‚œ‚ß‚ÌIC] ”’“àáE‹üÜ‹ž³Žèp‘OŒã‚É‚š‚¯‚錟ž‚Ì—¬‚ê. “¡‘º•‡²Žq (ˆã—Éq¶Šw•”): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/30), ‹ž“s.

722160. [Šw‰ï (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX)yuŽtzŠp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒOŠî‘b‚©‚çÅV‚̘b‘è‚Ü‚Å. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/30), ‹ž“s.

722161. [Šw‰ï (‘S‘)] (ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[)yÀ’·zƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[4: —Ž‹‚𐧂·‚éŽÒ‚ª‹üÜ‚𐧂·‚é|ƒg[ƒŠƒbƒNIOL‰ñ“]–hŽ~‚ÌŽæ‚è‘g‚݁|. Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/30), ‹ž“s.

722162. [Šw‰ï (‘S‘)] (ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[)yÀ’·zƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[5: Patient Oriented‚ɐi‰»‚·‚éTechnology. Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/30), ‹ž“s.

722163. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) Š®‘S‹ž³’l, ‚»‚̗Տ°“IˆÓ‹``Šî‘b‚©‚çÅV‚Ì’mŒ©‚܂Ł`. ”Œ“c’m–ç (ˆã—Éq¶Šw•”): ‘æ62‰ñ“ú–{ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYŠw‰ï‘‰ï (2019/7/6), ‹ž“s.

722164. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ˆÀ‘S«‚©‚ç‚Ý‚œ“K‰ž”͈Í. ‰F’ÃŒ©‹`ˆê1,2 (1‰F’ÃŒ©Šá‰Èˆã‰@, 2Šá‰È): ‘æ62‰ñ“ú–{ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYŠw‰ï‘‰ï (2019/7/7), ‹ž“s.

722165. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)gŒõ‚̃mƒCƒYh‚ðŒž‚ç‚µ‚ăNƒŠƒA‚ÈŽ‹ŠE‚ð!`QOVŒüã‚ð–ÚŽw‚µ‚œŒõŠw“Á«‚ð—L‚·‚éƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‚Ƃ́`. _’J˜aF1, ”Œ“c’m–ç1, ìŽç“c‘ñŽu1 (1ˆã—Éq¶Šw•”): ‘æ62‰ñ“ú–{ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYŠw‰ï‘‰ï (2019/7/7), ‹ž“s.

722166. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ‚æ‚è‚æ‚¢Ž‹‹@”\‚𓟂邱‚Ƃ̈Ӌ`. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): ‘æ58‰ñ“ú–{”’“àáŠw‰ï‘‰ïE‘æ45‰ñ…»‘ÌŒ€‹†‰ï (2019/7/19), ˜a‰ÌŽR.

722167. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ˜˜_|Ž‹”\ŒP—ûŽm‚Ì‚œ‚߂̗Տ°Œ€‹†ƒXƒLƒ‹|. ”Œ“c’m–ç (ˆã—Éq¶Šw•”): The JOVS (“ú–{—ŒŠáŽ‹‹ž³Œ€‹†‰ï) Seminar (2019/8/25), ˆ€’m.

722168. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) —Տ°Œ€‹†‚Ì‚œ‚ß‚ÌŠî‘b’mŽ¯|•ÏŠv‚·‚é‹ß”N‚̗Տ°Œ€‹†|. Šâ“c@—y (ˆã—Éq¶Šw•”): The JOVS (“ú–{—ŒŠáŽ‹‹ž³Œ€‹†‰ï) Seminar (2019/8/25), ˆ€’m.

722169. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) Ž‹”\ŒP—ûŽm‚Ì‚œ‚߂̃AƒEƒgƒvƒbƒgƒXƒLƒ‹. ”Œ“c’m–ç (ˆã—Éq¶Šw•”): The JOVS (“ú–{—ŒŠáŽ‹‹ž³Œ€‹†‰ï) Seminar (2019/8/25), ˆ€’m.

722170. [Šw‰ï (‘S‘)] (ƒf[ƒ^‰ðÍˆÏˆõ‰ï“Á•ÊƒZƒbƒVƒ‡ƒ“) A multicenter,randomized,trial to test non-inferiority of microhook trabeculotomy vs Trabectome/Trabectome vs Microhook (‘@ˆÛ’Œ‘ѐ؊Jp‚̊ሳ‰º~Œø‰Ê‚ƈÀ‘S«‚Ì‘œŽ{Ý‹€“¯ƒ‰ƒ“ƒ_ƒ€‰»‰î“ü”ñ—òšŒŸØŽŽŒ±). ’†‘º@œ1, aãŽu˜N2, “Œo•ü–€3, ¯ŽiMs4, Ô–Ø’‰“¹5, ¯Ži‘ñ•œ6, ‰¡ŽR@—I7, A“cr•F8, âV“¡—Y‘Ÿ9, ’JŒË³Ž÷10 (1_ŒË‘å, 2ˆ€•Q‘å, 3‹à‘ò‘å, 4Šá‰È, 5‹ž“s‘å, 6é‹Êˆã‘å, 7“Œ–k‘å, 8“ñ–{ŒŠá‰È, 9º˜a‘å, 10“‡ª‘å): ‘æ30‰ñ“ú–{—ΓàáŠw‰ï (2019/9/6), ŒF–{.

722171. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Trabectome surgery: probability and limitation/ƒgƒ‰ƒxƒNƒg[ƒ€Žèp‚̉”\«‚ÆŒÀŠE. ¯ŽiMs (Šá‰È): ‘æ30‰ñ“ú–{—ΓàáŠw‰ï (2019/9/6), ŒF–{.

722172. [Šw‰ï (‘S‘)] (ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[) Šáˆ³‰º~Ž¡—Á`—¬o˜HÄŒšp‚ƏpŒãŠÇ—`. ¯ŽiMs (Šá‰È): ‘æ30‰ñ“ú–{—ΓàáŠw‰ï (2019/9/7), ŒF–{.

722173. [Šw‰ï (‘S‘)] (ƒRƒƒfƒBƒJƒ‹ƒvƒƒOƒ‰ƒ€) How to use the Octopus Perimeter to detect early visual field deterioration/–Ÿ“ú‚©‚ç–𗧂Â! OctopusŽ‹–ìŒv‚̃|ƒCƒ“ƒg. “¡‘º•‡²Žq (ˆã—Éq¶Šw•”): ‘æ30‰ñ“ú–{—ΓàáŠw‰ï (2019/9/8), ŒF–{.

722174. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yÀ’·zƒVƒ“ƒ|ƒWƒEƒ€1uƒoƒCƒIƒ}[ƒJ[v. Îì@‹Ï (ˆã—Éq¶Šw•”): ‘æ39‰ñ“ú–{Šá–ò—Šw‰ï (2019/9/14), –ŒŒÃ‰®.

722175. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) RƒAƒNƒAƒ|ƒŠƒ“4R‘Ì‚ÆŽ‹_Œo‰Š. Îì@‹Ï (ˆã—Éq¶Šw•”): ‘æ39‰ñ“ú–{Šá–ò—Šw‰ï (2019/9/14), –ŒŒÃ‰®.

722176. [Šw‰ï (‘S‘)] (Global English session) The man with 30 spectacles. ŒãŠÖ—˜–Ÿ (Šá‰È): ‘æ57‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2019/10/5), ŽD–y.

722177. [Šw‰ï (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX) CTEMRI‚Å‚à‚Á‚Æ‚í‚©‚é! ŽÎŽ‹‚Ì•a‘Ô‚ÆŽ¡—Ã. ªŠÝ‹MŽu1, ²“¡”ü•Û2, ™ŽR”\Žq3, •F’J–ŸŽq2, Œ‘ºŸ4, ŒãŠÖ—˜–Ÿ5, _‘O‚ ‚¢6 (1‡“V‘å, 2•lŒˆã‘å, 3‹à‘ò‘å, 4¹—ê•lŒ•a‰@, 5Šá‰È, 6ƒIƒŠƒ“ƒsƒAŠá‰È•a‰@): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/24), ‹ž“s.

722178. [Šw‰ï (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX) ŽÀ‘H‚©‚çŠw‚Ô—L…»‘ÌŠá“àƒŒƒ“ƒY. Ž…Œö–ç1,2, _’J˜aF3, Žsìˆê•v2,4, ’†‘º—Fº5, –kàV¢Žu”Ž6 (1ŽR‰€•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È, 3ˆã—Éq¶Šw•”, 4’†‹žŠá‰È, 5–ŒŒÃ‰®ƒAƒCƒNƒŠƒjƒbƒN, 6ƒTƒsƒAƒ^ƒ[ƒAƒCƒNƒŠƒjƒbƒN“Œ‹ž): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/24), ‹ž“s.

722179. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)yÀ’·z”’“àáŽèpŒã‚ÌQOV‚ðl‚Š‚é|‘œÅ“_IOL VS ’PÅ“_IOLƒ‚ƒmƒrƒWƒ‡ƒ“|. Ž…Œö–ç1,2 (1ŽR‰€•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/24), ‹ž“s.

722180. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ƒ‚ƒmƒrƒWƒ‡ƒ“–@“±“üABC. ”Ñ“c‰Ã•F (Šá‰È): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/24), ‹ž“s.

722181. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)yÀ’·zƒ}ƒV[ƒ“‚Å•Ï‚í‚邱‚ê‚©‚ç‚Ì”’“àáŽèp. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/25), ‹ž“s.

722182. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) –k—¢‘åŠw‚É‚š‚¯‚é”’“àáŽèpŽè‹Z‚ÆWHITESTER SIGNATURE PRO‚̗Տ°ŒoŒ±. ”Ñ“c‰Ã•F (Šá‰È): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/25), ‹ž“s.

722183. [Šw‰ï (‘S‘)] (ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[)yÀ’·zThe 25th VISION TIMES SEMINAR ƒ[ƒrƒWƒ‡ƒ“ƒPƒA‚Ì–¢—ˆ. Ž…Œö–ç1,2, ”Ñ“c‰Ã•F2 (1ŽR‰€•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/25), ‹ž“s.

722184. [Šw‰ï (‘S‘)] (ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[) ”’“àáŽèpŒã‚̃}ƒ‹ƒ`ƒtƒH[ƒJƒ‹CL‚ÌŽ‹‹@”\•]‰¿. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/25), ‹ž“s.

722185. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) “ú–{—ΓàáŠw‰ï‚©‚ç‚Ì—v–]. ¯ŽiMs (Šá‰È): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/26), ‹ž“s.

722186. [Šw‰ï (‘S‘)] (ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[) “ïÇ—á‚ɑ΂·‚é”’“àáŽ¡—Ð헪`ƒAƒoƒ“ƒVƒB3ƒs[ƒX‚Ì—L—p«`. ”Ñ“c‰Ã•F (Šá‰È): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/26), ‹ž“s.

722187. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ACUVUE‰“‹ß—Œ—pƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY (CL) `Œ©‚Š‚éŽd‘g‚Ý‚©‚çŽg‚¢•û‚܂Ł`. _’J˜aF1, ìŽç“c‘ñŽu1 (1ˆã—Éq¶Šw•”): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/26), ‹ž“s.

722188. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yƒI[ƒKƒiƒCƒU[zƒVƒ“ƒ|ƒWƒEƒ€19@Åæ’[‚Ì”’“àáŽèp. ”Ñ“c‰Ã•F (Šá‰È): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/27), ‹ž“s.

722189. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) •ªŒõ“§‰ß—Š (F) ‚ðˆÓŽ¯‚µ‚œŠá“àƒŒƒ“ƒY‘I‘ð. Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/27), ‹ž“s.

722190. [Šw‰ï (‘S‘)] (uK‰ï) ‹üÜ‹ž³ŽèpE‘“àŠO‚ÌŒ»ó‚ƍ¡Œã‚Ì“W–]. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (“ú–{Šá‰ÈŠw‰ï‹üÜ‹ž³ŽèpuK‰ï) (2019/10/27), ‹ž“s.

722191. [Šw‰ï (‘S‘)] (Šî’²u‰‰)yƒ‚ƒfƒŒ[ƒ^[zAI‚ʼnœ‚ª•Ï‚í‚é? ‚±‚ê‚©‚ç‚ÌŠá‰Èˆã—Ã. _’J˜aF1, ìŽç“c‘ñŽu1 (1ˆã—Éq¶Šw•”): The 23rd IRSJ (2019) /‘æ19‰ñŠá‰È—Տ°‹@ŠíŒ€‹†‰ï (2019/11/9), ‰¡•l.

722192. [Šw‰ï (‘S‘)] (ƒAƒtƒ^ƒk[ƒ“ƒZƒ~ƒi[)yÀ’·z—Γàáf—Â̗Ž‚Æ‚µŒŠ. ¯ŽiMs (Šá‰È): The 23rd IRSJ (2019)/‘æ19‰ñŠá‰È—Տ°‹@ŠíŒ€‹†‰ï (2019/11/9), ‰¡•l.

722193. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™)yÀ’·zu‰‰I: ‹÷Šp‰æ‘œŒŸž‚Ì’·Š‚ÆŒÀŠE. Š}ŒŽ³s (Šá‰È): The 23rd IRSJ (2019)/‘æ19‰ñŠá‰È—Տ°‹@ŠíŒ€‹†‰ï (2019/11/9), ‰¡•l.

722194. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) CASIA2‚̗Տ°‰ž—p. ’Ò‘ò’C•F (Šá‰È): The 23rd IRSJ (2019)/‘æ19‰ñŠá‰È—Տ°‹@ŠíŒ€‹†‰ï (2019/11/9), ‰¡•l.

722195. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™)yÀ’·zu‰‰II: Swept Source OCT Triton. –ö“c’q•F (Šá‰È): The 23rd IRSJ (2019)/‘æ19‰ñŠá‰È—Տ°‹@ŠíŒ€‹†‰ï (2019/11/9), ‰¡•l.

722196. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) Swept Source OCT Triton‚ÌŽg—pŒoŒ±. t–ؐ’G (Šá‰È): The 23rd IRSJ (2019)/‘æ19‰ñŠá‰È—Տ°‹@ŠíŒ€‹†‰ï (2019/11/9), ‰¡•l.

722197. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™)yÀ’·zu‰‰III: IOL Update. ”Ñ“c‰Ã•F (Šá‰È): The 23rd IRSJ (2019)/‘æ19‰ñŠá‰È—Տ°‹@ŠíŒ€‹†‰ï (2019/11/9), ‰¡•l.

722198. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) Dysphotopsia. ŒÜ\—’ÍŽj1,2 (1ŽR‰€•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È): The 23rd IRSJ (2019)/‘æ19‰ñŠá‰È—Տ°‹@ŠíŒ€‹†‰ï (2019/11/9), ‰¡•l.

722199. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) AŠwŽžŒ’fEŠwZŒŸf‚Ƌߎ‹. “¡‘º•‡²Žq (ˆã—Éq¶Šw•”): ‘æ60‰ñ“ú–{Ž‹”\‹ž³Šw‰ï (2019/11/30), •Ÿ‰ª.

722200. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ÈƒXƒy[ƒXŽ©“®ŒŸŠáƒVƒXƒeƒ€‚ð—p‚¢‚œ—ŒŠáŠJ•ú‹üÜŒŸž‚ɂ‚¢‚Ä. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): ‘æ60‰ñ“ú–{Ž‹”\‹ž³Šw‰ï (2019/11/30), •Ÿ‰ª.

722201. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ÔEÂFŒõ‚É‚æ‚é‘ÎŒõ”œŽË‚ð—p‚¢‚œ–Ô–ŒŽŸŠ³‚Ì•]‰¿. óì@Œ« (ˆã—Éq¶Šw•”): “ú–{Ž‹ŠoŠw‰ï2020”N“~‹G‘å‰ï (2020/1/11), _“ސì.

722202. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yƒI[ƒKƒiƒCƒU[zƒVƒ“ƒ|ƒWƒEƒ€1: ’áNP—ΓàáŽèp (MIGS) ‚ÌŒø‰Ê‚Æ“K‰ž. ¯ŽiMs (Šá‰È): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/24), “Œ‹ž.

722203. [Šw‰ï (‘S‘)] (‹³ˆçƒZƒ~ƒi[) ‹üÜ‹ž³Žèp‚ÌŽí—Þ. ŒÜ\—’ÍŽj1,2 (1ŽR‰€•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/24), “Œ‹ž.

722204. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)yÀ’·zƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[3: JFC Cutting EdgeƒZƒ~ƒi[ Part6. Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/24), “Œ‹ž.

722205. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yƒI[ƒKƒiƒCƒU[zƒVƒ“ƒ|ƒWƒEƒ€8: lHŠp–ŒˆÚA‚ÌŒ»ó‚Æ–â‘è“_. ì–k“N–ç1,2 (1Šá‰È, 2–k—¢Œ€‹†Š•a‰@): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/25), “Œ‹ž.

722206. [Šw‰ï (‘S‘)] (‹³ˆçƒZƒ~ƒi[)yÀ’·z‹³ˆçƒZƒ~ƒi[10: ”’“àáŽèp‚̏p’†ƒgƒ‰ƒuƒ‹‚Æ‚»‚̑Ώˆ–@. Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/25), “Œ‹ž.

722207. [Šw‰ï (‘S‘)] (‹³ˆçƒZƒ~ƒi[)yÀ’·z‹³ˆçƒZƒ~ƒi[14: ƒtƒFƒ€ƒgƒZƒJƒ“ƒhƒŒ[ƒU[Žèp. Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/25), “Œ‹ž.

722208. [Šw‰ï (‘S‘)] (‹³ˆçƒZƒ~ƒi[) ƒtƒFƒ€ƒgƒZƒJƒ“ƒhƒŒ[ƒU[. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/25), “Œ‹ž.

722209. [Šw‰ï (‘S‘)] (‘‰ï’·Šé‰æ) Corneal biomechanics‚ÆŠp–ŒŽŸŠ³. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/25), “Œ‹ž.

722210. [Šw‰ï (‘S‘)] (ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[) ƒŒƒWƒFƒ“ƒh—ñ“`–{‰¹‚Ńg[ƒN. Ž…Œö–ç1,2 (1ŽR‰€•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/25), “Œ‹ž.

722211. [Šw‰ï (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX)yƒI[ƒKƒiƒCƒU[EuŽtzƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX@CCC‚ð‹É‚ß‚é! Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/25), “Œ‹ž.

722212. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)yÀ’·zƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[9: æŽæ‚è! ƒAƒhƒoƒ“ƒXƒg”’“àá‹üÜ‹ž³Žèp. Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/25), “Œ‹ž.

722213. [Šw‰ï (‘S‘)] (‹³ˆçƒZƒ~ƒi[) Šp–ŒˆÚA‚ÌŠî–{Žè‹Z: •\‘wˆÚA. ì–k“N–ç1,2 (1Šá‰È, 2–k—¢Œ€‹†Š•a‰@): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/26), “Œ‹ž.

722214. [Šw‰ï (‘S‘)] (ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[)yÀ’·zƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[8: i‰»‚·‚é”’“àáŽèp, ‚Ç‚±‚܂Őž“x‚ð‹É‚ß‚é‚©! Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/26), “Œ‹ž.

722215. [Šw‰ï (‘S‘)] (Žs–¯ŒöŠJuÀ) ”’“àá‚ÆŒŸ‚í‚ê‚œ‚ç. Ž…Œö–ç1,2 (1ŽR‰€•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/26), “Œ‹ž.

723582. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŒoŒ±‚̈قȂé3–Œ‚̏pŽÒ‚É‚æ‚éƒtƒFƒ€ƒgƒZƒJƒ“ƒhƒŒ[ƒU[”’“àáŽèp‚̏pŒã‘Šú¬Ñ. ŽO“c‘º–ƒ—¢1, ¬“‡—²Ži2, àV–؈»Žq3, Žsì@Œc4, “à“¡®‹v1, ŽðˆäKO1, ‰Á“¡Km1, Š–ìãČå1, “Žˆä—¢ŠG1, “c’†–FŽ÷1, Žsìˆê•v1,5 (1’†‹žŠá‰È, 2Œcœä‘å, 3JCHO’†‹ž•a‰@, 4Šò•ŒÔ\Žš•a‰@, 5Šá‰È): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/18), “Œ‹ž.

723583. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒtƒFƒ€ƒgƒZƒJƒ“ƒhƒŒ[ƒU[”’“àá‚É‚š‚¯‚éVŒ^I/Aƒ`ƒbƒv‚ÌŽg—p¬Ñ. Žsì@Œc1, ¬“‡—²Ži2, ‰Á“¡Km3, “Žˆä—¢ŠG3, ŽO“c‘º–ƒ—¢3, àV–؈»Žq4, Žsì—æŽq3, “à“¡®‹v3, Žsìˆê•v3,4,5 (1Šò•ŒÔ\Žš•a‰@, 2Œcœä‘å, 3’†‹žŠá‰È, 4’nˆæˆã—Єi‹@\’†‹ž•a‰@, 5Šá‰È): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/18), “Œ‹ž.

723584. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘}“ü‚³‚ê‚œŠá“àƒŒƒ“ƒY‚̈ʒu‚ðpŒãŠúŠÔ‚̈Ⴂ‚Å”äŠr‚·‚éV‚µ‚¢‰ðÍ–@. ”n“ˆ@Ž1, Žsì@Œc2, ŽðˆäKO3, “à“¡®‹v3, •Ð‰ª“”Ž4, ˆé’J®Ž÷4, ’†‘º—Fº4, ‹Ê’u–Ÿ–ì4, Žsìˆê•v3,5,6 (1Šá‰È–ŸŠá‰@, 2Šò•ŒÔ\Žš•a‰@, 3’†‹žŠá‰È, 4–ŒŒÃ‰®ƒAƒCƒNƒŠƒjƒbƒN, 5JCHO’†‹ž•a‰@, 6Šá‰È): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/18), “Œ‹ž.

723585. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒtƒ‰ƒbƒgŠp–ŒŠá‚ɑ΂·‚éBarrettŽ®‚Ì—\‘ª«‚ÌŒŸ“¢. ”Ñ“‡@Œh1, _’J˜aF2, ”Ñ“c‰Ã•F1, ]•—Ft1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/18), “Œ‹ž.

723586. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –Ú•W‹üÜ’l‚̕␳Ž®‚ð—p‚¢‚œŠá“àƒŒƒ“ƒY–D’…p‚É‚š‚¯‚épŒã‹üÜŒë·. ”Ñ“c‰Ã•F1, ²“¡M”V1,2, ‰¡ŠÖ—S‰ÀŽq1,3, –ö“c’q•F1, ¯ŽiMs1 (1Šá‰È, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3‘å˜aŽs—§•a‰@): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/18), “Œ‹ž.

723587. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) [‘wŠwK‚ð—p‚¢‚œ‰~Šp–Œ‚̐f’f”\‚ÌŒŸ“¢ (‘æ3•ñ: ƒvƒ‰ƒ`ƒhŽ®Šp–ŒŒ`ó‰ðÍ‚Å‚ÌŒŸ“¢). _’J˜aF1, ˆ»’Ë—S“ñ2, ‰Á“¡—Y‘å2, “¡‘º•‡²Žq1, ¯ŽiMs3, X@—mÄ4, ‹{“c˜a“T4 (1ˆã—Éq¶Šw•”, 2ƒNƒŒƒXƒRŽÐ, 3Šá‰È, 4‹{“cŠá‰È): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/18), “Œ‹ž.

723588. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒI[ƒgƒPƒ‰ƒgƒ[ƒ^‚ð—p‚¢‚œŒy“x‰~Šp–Œ‚̃XƒNƒŠ[ƒjƒ“ƒO (‘œŽ{Ý‹€“¯Œ€‹†). ¬“‡—²Ži1,2,3, Œ“c’m–ç2, ’†‘º—Fº2, ¯–쏲G4, ‚–Ø—E‹M4, ²“¡—T–ç5, “n•”@ŠÂ5, ’·’JìˆŸ—¢6, ‹Ê’u–Ÿ–ì6, Žsìˆê•v7,8 (1Œcœä‘å, 2–ŒŒÃ‰®ƒAƒCƒNƒŠƒjƒbƒN, 3Šò•ŒÔ\Žš•a‰@, 4”Ñ“cŽs—§•a‰@, 5²“¡—T–çŠá‰Èˆã‰@, 6JCHO’†‹ž•a‰@, 7’†‹žŠá‰È, 8Šá‰È): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/18), “Œ‹ž.

723589. [Šw‰ï (‘S‘)] (Šwp“WŽŠ) SS OCT Biometer‚É‚æ‚éŠp–Œ‚ÌŠ·ŽZ‹üÜ—Š‚ÆŽÀ‘ª’l‚É‚æ‚éŠp–Œ‘S‹üÜ—Í‚Ì”äŠr. ‹Ê’u–Ÿ–ì1,2, ¬“‡—²Ži3, ‹Ž’Ü—Ç‘Ÿ1, ’·’JìˆŸ—¢1, ‰Á‰ê’BŽu1, Žsìˆê•v1,4,5, “c’†@Ž2 (1’†‹žŠá‰È, 2MB‘åŠw‰@‘‡HŠwŒnŒ€‹†‰È, 3Œc‰ž‹`m‘åŠw, 4’†‹žŠá‰È, 5Šá‰È): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/18), “Œ‹ž.

723590. [Šw‰ï (‘S‘)] (Šwp“WŽŠ) ƒ‰ƒ^ƒmƒvƒƒXƒg/ƒ`ƒ‚ƒ[ƒ‹‚©‚烉ƒ^ƒmƒvƒƒXƒg/ƒJƒ‹ƒeƒIƒ[ƒ‹‚Ö‚Ì”z‡“_Šá–ò‚̕ύX. –p@@‰Ø1, ˆäãŒ«Ž¡1, Šâ²^‹|1,2, Î“c‹±Žq3, •x“c„Ži3 (1ˆäãŠá‰È•a‰@, 2Šá‰È, 3“Œ–M‘åE‘å‹Ž): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/18), “Œ‹ž.

723591. [Šw‰ï (‘S‘)] (Šwp“WŽŠ) Visual Snow Syndrome‚Ì6—á•ñ‚š‚æ‚Ñ‚»‚ÌŽŸŠ³ŠT”O. “c’†’L1, ŽRã–ŸŽq1,2, Žá‘q‰ë“o1, ˆäãŒ«Ž¡1, ÎˆäŒ«“ñ3 (1ˆäãŠá‰È•a‰@, 2Šá‰È, 3“Œ‹ž“sŒ’N’·Žõˆã—ÃZƒ“ƒ^[Œ€‹†Š): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/18), “Œ‹ž.

723592. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒgƒ‰ƒxƒNƒg[ƒ€ŽèpŒã‘Šú¬Ñ•s—Ç—á‚Ì”wŒiˆöŽq. ‰Í–ì—Y—º1, Š}ŒŽ³s1, ]•—Ft1, ¯ŽiMs1 (1Šá‰È): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/19), “Œ‹ž.

723593. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬l—ŒŠá«•¡Ž‹‚ð‘ΏۂƂµ‚œsagging eye syndrome‚Ì—L•a—Š. ŒãŠÖ—˜–Ÿ1,2, Soh Youn Suh2, Laura Robbins2, Stacy L Pineles2, Federico G Velez2, Joseph L Demer2 (1Šá‰È, 2Pediatric Ophthalmology and Adult Strabismus division, Stein Eye Institute, David Geffen School of Medicine, UCLA): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/19), “Œ‹ž.

723594. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –¢AŠwŽ™‚É‚š‚¯‚éŒõŠwŽ®ŠáŽ²’·‘ª’è‘•’u‚ð—p‚¢‚œ‹üÜˆÙí‚ÌŒŸož“x. ²“¡@Ži1, ˆÉ“¡”ü¹ŠG2, ‚‹Ž—RŽk1, –ìã‹Žu1, Žl”V‹{—C”n1, ]’ˍʉè3, Vˆä“cF—T1,4 (1‘Ûˆã—ÕŸŽƒ‘å, 2ŽR‰€•a‰@, 3‘Ûˆã—ÕŸŽƒ‘åŠw•a‰@, 4Šá‰È): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/19), “Œ‹ž.

723595. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Œã”­”’“àá‚ɑ΂·‚郌[ƒU[ŒãùNØŠJp‘OŒã‚Ì1•bŽ‹—Í‚Ì—L—p«. ‰Á“¡ŽÑ–1, Ž…Œö–ç1,2, ŒÜ\—’ÍŽj1,2, ìŽç“c‘ñŽu3 (1ŽR‰€•a‰@, 2Šá‰È, 3ˆã—Éq¶Šw•”): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/19), “Œ‹ž.

723596. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚‰ð‘œ“xƒ‚ƒjƒ^‚ðŽg—p‚µ‚œÂ”NŒ’íŽÒ‚ÌŒ`‘ÔŠo‹@”\‚Ì•]‰¿. —é–ØŒ«Ž¡1, ŒÜ\—’–¢K1, •Ÿäo‚Ù‚È‚Ý1, ¯@Œª¬1, Œ‰ºŽÑ—LŽÀ1, Vˆä“cF—T1,2 (1‘Ûˆã—ÕŸŽƒ‘åŠw, 2Šá‰È): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/19), “Œ‹ž.

723597. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —L…»‘ÌŠá“àƒŒƒ“ƒYŽèp‘OŒã‚É‚š‚¯‚é‹÷ŠpŠJ‘å“x‚ÌŒoŽž•Ï‰». ˆÀ“¡˜a‰ÌŽq1, _’J˜aF2, ‚‹Ž³‰p1, ’Ò‘ò’C•F1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/19), “Œ‹ž.

723598. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —L…»‘ÌŠá“àƒŒƒ“ƒY‘}“üŠá‚É‚š‚¯‚é‹÷ŠpŠJ‘å“x‚ªŠp–Œ“à”ç×–E–§“x‚âŠáˆ³‚É‹y‚Ú‚·‰e‹¿. ’Ò‘ò’C•F1, _’J˜aF2, ‚‹Ž³‰p1, ˆÀ“¡˜a‰ÌŽq1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/19), “Œ‹ž.

723599. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) KSŽ®‚ð—p‚¢‚œICLpŒãvault‚ÌŒŸ“¢. ŒÜ\—’ÍŽj1,2, Ž…Œö–ç1,2, ‰Á“¡ŽÑ–1 (1ŽR‰€•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È) ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/19), “Œ‹ž.

723600. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) is«‰~Šp–Œ‚ɑ΂·‚éƒgƒ|ƒKƒCƒhŠp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO‚Ə]—ˆ–@‚Ì‘Šú—Տ°¬Ñ‚Ì”äŠr. ‚‹Ž³‰p1, _’J˜aF2, ’Ò‘ò’C•F1, ˆÀ“¡˜a‰ÌŽq, Ö“¡@Ê, ‰z’n—¹Žq, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/19), “Œ‹ž.

723601. [Šw‰ï (‘S‘)] (Šwp“WŽŠ) “œ”A•a‰©”ÁÇ‚Ì’†Sâ|‰ºd«”’”Á‚ɑ΂·‚éƒiƒrƒQ[ƒVƒ‡ƒ“ƒŒ[ƒU[‚ÌŒø‰Ê. ²“¡—T”V1,2, “c’†–FŽ÷2, Žsìˆê•v2,3, “à“¡®‹v2, ‰Á‰ê’BŽu4, ‹g“c‘¥•F5, ‰¡ŽR@ãÄ4, X@r’j6, Œ“c‘וã4, ŽO“c‘º—El4, ŽO“c‘º–ƒ—¢2, ²“¡—T–ç1 (1²“¡—T–çŠá‰Èˆã‰@, 2’†‹žŠá‰È, 3Šá‰È, 4JCHO’†‹ž•a‰@, 5Šò•ŒÔ\Žš•a‰@, 6”Ñ“cŽs—§•a‰@): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/19), “Œ‹ž.

723602. [Šw‰ï (‘S‘)] (Šwp“WŽŠ) d“x‚̎㎋‚ɑ΂·‚éOcclu-pad҂ð—p‚¢‚œŽãŽ‹ŒP—û‚ÌŒŸ“¢. ŒË’ˁ@Œå1, ”Œ“c’m–ç2, Îì@‹Ï2, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/19), “Œ‹ž.

723603. [Šw‰ï (‘S‘)] (Šwp“WŽŠ) ‰“Ž‹—}§Ž¡—ÓIŠp–ŒØœp (Hyperopia Correcting-PTK) ‚̍lˆÄ‚Ə]—ˆPTK‚Æ‚Ì”äŠr. ‘ìG‹P1, _’J˜aF2, ‚‹Ž³‰p1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ123‰ñ“ú–{Šá‰ÈŠw‰ï‘‰ï (2019/4/19), “Œ‹ž.

723604. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Variational Bayes‚ð—p‚¢‚œŽ‹–쑪’èƒAƒ‹ƒSƒŠƒYƒ€. ‘º“c”ŽŽj1, “¡–ì—F—¢1, Œ‰Y«l1, “‡“c@Œ«2, “¡‘º•‡²Žq3, ¯ŽiMs4, ’©‰ª@—º1 (1“Œ‹ž‘å, 2‹»˜a, 3ˆã—Éq¶Šw•”, 4Šá‰È): ‘æ8‰ñ“ú–{Ž‹–ì‰æ‘œŠw‰ïŠwpW‰ï (2019/5/18), ‘åã.

723605. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Date augmentation‚ð—p‚¢‚œŽ‹–ìis—\‘ª‚Ì—L—p«‚ÌŒŸ“¢. Œ‰Y«l1,2, ‘º“c”ŽŽj1, “¡–ì—F—¢1,2, ŽO–Ø“Ä–ç3, ’JŒË³Ž÷4, aãŽu˜N5, X@˜a•F6, —é–؍Ž‰À9, ŽR‰º‚–Ÿ7, ”–ØŒ«Ž¡8, ¯ŽiMs2, ’©‰ª@—º1 (1“Œ‹ž‘å, 2Šá‰È, 3‘åã‘å, 4“‡ª‘å, 5ˆ€•Q‘å, 6‹ž“s•{ˆã‘å, 7Ž­Ž™“‡‘å, 8ŽR—œ‘å, 9ŽRŒû‘å): ‘æ8‰ñ“ú–{Ž‹–ì‰æ‘œŠw‰ïŠwpW‰ï (2019/5/18), ‘åã.

723606. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰)yÀ’·zˆê”ʍu‰‰III. ¯ŽiMs (Šá‰È): ‘æ8‰ñ“ú–{Ž‹–ì‰æ‘œŠw‰ïŠwpW‰ï (2019/5/19), ‘åã.

723607. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) üˆÛ’Œ‘ѐ؏œŒã‚ÌŠp–ŒƒqƒXƒeƒŠƒVƒX‚ƗΓàá«Ž‹–ìis‚Æ‚ÌŠÖŒW. “¡–ì—F—¢1,2, ‘º“c”ŽŽj1, Œ‰Y«l1,2, ’†‘qr—S2,3, ¯ŽiMs2, ’†”ö‹`—²4, –Ø“à—Ç–Ÿ1, ’©‰ª@—º1 (1“Œ‹ž‘å, 2Šá‰È, 3ƒcƒJƒUƒL•a‰@, 4L“‡‘å): ‘æ8‰ñ“ú–{Ž‹–ì‰æ‘œŠw‰ïŠwpW‰ï (2019/5/19), ‘åã.

723608. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Šá‹…ƒ‚ƒfƒ‹‚ðl—¶‚µ‚œVÝŒvŠá‹ŸƒŒƒ“ƒY‚̐݌v•û–@. •ŸˆäTˆê1, ‰Á“¡ˆêšæ1, ìŽç“c‘ñŽu2 (1ˆÉ“¡ŒõŠwH‹ÆŠ”Ž®‰ïŽÐ, 2ˆã—Éq¶Šw•”): ‘æ23‰ñ“ú–{Šá‹ŸŠw‰ï”NŽŸƒZƒ~ƒi[‚š‚æ‚ђ莞‘‰ï (2019/5/28), ‰ªŽR.

723609. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Šá‹…ƒ‚ƒfƒ‹‚ðl—¶‚µ‚œVÝŒvŠá‹ŸƒŒƒ“ƒY‚Ì—L—p«. ìŽç“c‘ñŽu1, •ŸˆäTˆê2, ‰Á“¡ˆêšæ2, _’J˜aF1, ”Œ“c’m–ç1, ‹›—¢@”Ž, ¯ŽiMs3 1ˆã—Éq¶Šw•”, 2ˆÉ“¡ŒõŠwH‹ÆŠ”Ž®‰ïŽÐ, 3Šá‰È): ‘æ23‰ñ“ú–{Šá‹ŸŠw‰ï”NŽŸƒZƒ~ƒi[‚š‚æ‚ђ莞‘‰ï (2019/5/28), ‰ªŽR.

723610. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰)yÀ’·zˆê”ÊŒû‰‰@ƒfƒWƒ^ƒ‹ƒfƒoƒCƒX‚ÆŽÎŽ‹. Vˆä“cF—T1,2 (1‘Ûˆã—ÕŸŽƒ‘åŠw, 2Šá‰È): ‘æ75‰ñ“ú–{ŽãŽ‹ŽÎŽ‹Šw‰ï‘‰ïE‘æ44‰ñ“ú–{¬Ž™Šá‰ÈŠw‰ï‘‰ï ‡“¯Šw‰ï (2019/6/14), Ã‰ª.

723611. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) Šw“¶Šú‚É”­Ç‚µ‚œƒQ[ƒ€ˆË‘¶Ç‚Æ‚µ‚Ä‚Ì‹}«Œã“V“àŽÎŽ‹2Ç—á‚̗Տ°“I“Á’¥. ]’ˍʉè1, ŒŽ@’Œl2, ‰ª–ì^‹|2, ’ËŒŽ–ƒ—R‰À1, ¬–ì—¢‹KŽq1, A’|ó–¢1, ‚’Ì˗C‹R1, ²’|‰ÂŽq1, Vˆä“cF—T2,3 (1‘Ûˆã—ÕŸŽƒ‘å•a‰@, 2‘Ûˆã—ÕŸŽƒ‘å, 3Šá‰È): ‘æ75‰ñ“ú–{ŽãŽ‹ŽÎŽ‹Šw‰ï‘‰ïE‘æ44‰ñ“ú–{¬Ž™Šá‰ÈŠw‰ï‘‰ï ‡“¯Šw‰ï (2019/6/14), Ã‰ª.

723612. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) VR‚É‚æ‚鍂ŽŸ”]‹@”\E‹ßŒ©”œ‰ž‚š‚æ‚Ñ”æ˜JŠŽ‚ւ̉e‹¿‚š‚æ‚Ñ‚»‚ÌŒoŽž“I‚ȕω»‚ÌŒŸ“¢. ŒŽ@’Œl1, Š™“c‘׏²1, •œŒŽÊ‰Ô1, …‘º@ˆ©1, ŽRè‰Ø—œ1, Vˆä“cF—T1,2 (1‘Ûˆã—ÕŸŽƒ‘å, 2Šá‰È): ‘æ75‰ñ“ú–{ŽãŽ‹ŽÎŽ‹Šw‰ï‘‰ïE‘æ44‰ñ“ú–{¬Ž™Šá‰ÈŠw‰ï‘‰ï ‡“¯Šw‰ï (2019/6/14), Ã‰ª.

723613. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) Ž‹ü‰ðÍ‘•’u‚É‚æ‚éADHDŽ™‚̏Փ®«Šá‹…‰^“®‚̐öŽžŒv‘ª. Žl”V‹{—C”n1, —é–ØŒ«Ž¡1, ¬–ì‹|ŠG2, Œlã‹±•F1, ²“¡–­Žq1, ŽOXçŽí1, Vˆä“cF—T1,3 (1‘Ûˆã—ÕŸŽƒ‘å, 2–ŸŽ¡‘å, 3Šá‰È): ‘æ75‰ñ“ú–{ŽãŽ‹ŽÎŽ‹Šw‰ï‘‰ïE‘æ44‰ñ“ú–{¬Ž™Šá‰ÈŠw‰ï‘‰ï ‡“¯Šw‰ï (2019/6/14), Ã‰ª.

723614. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) WilliamsÇŒóŒQ‚É‚š‚¯‚éŠáˆÙí‡•¹•p“x. åŒŽŽµd1, ‚‹Ž‘ãŽq1, Îì@‹Ï1 (1ˆã—Éq¶Šw•”): ‘æ75‰ñ“ú–{ŽãŽ‹ŽÎŽ‹Šw‰ï‘‰ïE‘æ44‰ñ“ú–{¬Ž™Šá‰ÈŠw‰ï‘‰ï ‡“¯Šw‰ï (2019/6/14), Ã‰ª.

723615. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰)yÀ’·zˆê”ÊŒû‰‰@‰ñùŽÎŽ‹E‘Œ. ŒãŠÖ—˜–Ÿ (Šá‰È): ‘æ75‰ñ“ú–{ŽãŽ‹ŽÎŽ‹Šw‰ï‘‰ïE‘æ44‰ñ“ú–{¬Ž™Šá‰ÈŠw‰ï‘‰ï ‡“¯Šw‰ï (2019/6/14), Ã‰ª.

723616. [Šw‰ï (‘S‘)] (Šwp“WŽŠ) 4`6ÎŽ™‚É‚š‚¯‚éŠá‹…¶‘ÌŒv‘ª’l‚Ì1”NŠÔ‚ÌŒoŽž•Ï‰». ²“¡@Ži1, ‚‹Ž—RŽk1, Vˆä“cF—T1,2 (1‘Ûˆã—ÕŸŽƒ‘å, 2Šá‰È): ‘æ75‰ñ“ú–{ŽãŽ‹ŽÎŽ‹Šw‰ï‘‰ïE‘æ44‰ñ“ú–{¬Ž™Šá‰ÈŠw‰ï‘‰ï ‡“¯Šw‰ï (2019/6/14), Ã‰ª.

723617. [Šw‰ï (‘S‘)] (Šwp“WŽŠ) Ž©Šo“I’²ß—Í‚Æ‘ŒŠo“I’²ß—͂̍Č»«‚Æ‘ª’è’l‚Ì”äŠr. –ìã‹Žu1, ²“¡@Ži1, ¬—э¹Œb1, ²“¡—[‰À1, ’|àV—DŽq1, ’†ŽR@x1, Vˆä“cF—T1,2 (1‘Ûˆã—ÕŸŽƒ‘å, 2Šá‰È): ‘æ75‰ñ“ú–{ŽãŽ‹ŽÎŽ‹Šw‰ï‘‰ïE‘æ44‰ñ“ú–{¬Ž™Šá‰ÈŠw‰ï‘‰ï ‡“¯Šw‰ï (2019/6/14), Ã‰ª.

723618. [Šw‰ï (‘S‘)] (Šwp“WŽŠ) Ž¿–⎆‚ð—p‚¢‚œŽÎŽ‹EŽãŽ‹‚ÌŽq‚Ç‚à‚ð‚à‚•یìŽÒ‚̃XƒgƒŒƒX’²ž. Šâ“c@—y1, –k—¢”ü˜a2, ã“c’qŠî2, [’J‰xŽq2, ŠâŸÞ—D”ü2, Îì@‹Ï1 (1ˆã—Éq¶Šw•”, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ75‰ñ“ú–{ŽãŽ‹ŽÎŽ‹Šw‰ï‘‰ïE‘æ44‰ñ“ú–{¬Ž™Šá‰ÈŠw‰ï‘‰ï ‡“¯Šw‰ï (2019/6/14), Ã‰ª.

723619. [Šw‰ï (‘S‘)] (Šwp“WŽŠ) 12”NŠÔ•ú’u‚³‚ê‚œŽÎŽ‹ŽãŽ‹‚̈ê—á. ‚‹Ž—RŽk1, ²’|‰ÂŽq2, “¡ŽR—R‹IŽq1, Vˆä“cF—T1,3 (1‘Ûˆã—ÕŸŽƒ‘å, 2‘Ûˆã—ÕŸŽƒ‘åŠw•a‰@, 3Šá‰È): ‘æ75‰ñ“ú–{ŽãŽ‹ŽÎŽ‹Šw‰ï‘‰ïE‘æ44‰ñ“ú–{¬Ž™Šá‰ÈŠw‰ï‘‰ï ‡“¯Šw‰ï (2019/6/14), Ã‰ª.

723620. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒg[ƒŠƒbƒN—L…»‘ÌŒã–[ƒŒƒ“ƒY‚̐‚’ŒŒÅ’è‚É‚æ‚épŒã¬Ñ. ‰Á“¡ŽÑ–1, Ž…Œö–ç1, ŒÜ\—’ÍŽj1,2 (1ŽR‰€•a‰@, 2Šá‰È): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/28), ‹ž“s.

723621. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) V‚µ‚¢IOL“x”ŒvŽZŽ®‚ÆŠù‘¶Ž®‚Ì—\‘ªž“x‚Ì”äŠr. ²“¡@Ži1,2, Ž…Œö–ç2, íœAr‘Ÿ˜Y2,3, ŒÜ\—’ÍŽj2,3, ‰Á“¡ŽÑ–2, •Û‰È”üŠó2, —`…@Šw2,3, Žl”V‹{—C”n1, Vˆä“cF—T1,3 (1‘Ûˆã—ÕŸŽƒ‘åŠwE•ÛŒ’ˆã—Êw, 2ŽR‰€•a‰@, 3Šá‰È): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/28), ‹ž“s.

723622. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) LASIK‘O‚ÌŒŸž’l‚Í”’“àápŒã‚Ì‹üÜŒë·‚ðŒž­‚³‚¹‚é‚©. íœAr‘Ÿ˜Y1,2, Ž…Œö–ç1,2, ŒÜ\—’ÍŽj1,2, —`…@Šw1,2, ‰Á“¡ŽÑ–1, •Û‰È”üŠó1, ²“¡@Ži1,3 (1ŽR‰€•a‰@, 2Šá‰È, 3‘Ûˆã—ÕŸŽƒ‘å): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/28), ‹ž“s.

723623. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Hole ICL‚’ŒŒÅ’莞‚É‚š‚¯‚éKSŽ®‚ð—p‚¢‚œpŒãvault‚Ì—\‘ª. ŒÜ\—’ÍŽj1,2, Ž…Œö–ç1,2, ‰Á“¡ŽÑ–1 (1ŽR‰€•a‰@, 2Šá‰È): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/28), ‹ž“s.

723624. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –³…»‘ÌŠá—p“øÊ— –ÊŽxŽŠá“àƒŒƒ“ƒY‚̏pŒã’·Šú¬Ñ. ŒŽ@CÆ1, ¬“‡—²Ži2, Žsìˆê•v3,4 (1‘å—Y‰ï‘æˆê•a‰@, 2Œcœä‘å, 3’†‹žŠá‰È, 4Šá‰È): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/28), ‹ž“s.

723625. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’·ŠáŽ²Šá‚É‘}“ü‚³‚ê‚œŠá“àƒŒƒ“ƒY‚Ì•ªŒõ“§‰ß“Á«‚̈Ⴂ‚É‚æ‚épŒã’·Šú‚̋ߎ‹‰»ŒXŒü‚ÌŒŸ“¢. ²“¡—T”V1, ’双—ǐ¬2, “à“¡®‹v3, Ö“¡@—T4, ‘厭@’q5, “n‘\P‹v6, ²“¡—T–ç1, Žsìˆê•v3,7 (1²“¡—T–çŠá‰Èˆã‰@, 2‚³‚Ÿ‚܂Šá‰ÈƒNƒŠƒjƒbƒN, 3’†‹žŠá‰È, 4Ö“¡Šá‰È, 5‘厭Šá‰È, 6‚í‚œ‚ç‚¢Šá‰È, 7Šá‰È): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/28), ‹ž“s.

723626. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰)yÀ’·zˆê”ʍu‰‰4@‘œÅ“_Eƒg[ƒŠƒbƒN…A. Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/28), ‹ž“s.

723627. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘œÅ“_Šá“àƒŒƒ“ƒYActive Focus҂̏pŒã‘Šú¬Ñ‚ÌŒŸ“¢. Žsì@Œc1, ¬“‡—²Ži2, Š–ìãČå3, “Žˆä—¢ŠG3, ŽO“c‘º–ƒ—¢3, àV–؈»Žq4, Žsì—æŽq3, ‹Ê’u–Ÿ–ì4, Žsìˆê•v3,5 (1Šò•ŒÔ\Žš•a‰@, 2Œcœä‘å, 3’†‹žŠá‰È, 4’†‹ž•a‰@, 5Šá‰È): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/28), ‹ž“s.

723628. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •¡”‚̏pŽÒŠÔ‚̃tƒFƒ€ƒgƒZƒJƒ“ƒhƒŒ[ƒU[”’“àáŽèpŽž‚ÌŽä‹N—Ž‹‚Ì”äŠr. ŽO“c‘º–ƒ—¢1, ¬“‡—²Ži2, Žsì@Œc3, ŽðˆäKO1, ‰Á“¡Km1, “à“¡®‹v1, Žsìˆê•v1,4 (1’†‹žŠá‰È, 2Œcœä‘å, 3Šò•ŒÔ\Žš•a‰@, 4Šá‰È): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/29), ‹ž“s.

723629. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰)yÀ’·zˆê”ʍu‰‰7@¶‘ÌŒv‘ª. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/29), ‹ž“s.

723630. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) …»‘̍Čšp‘O‚̐ԓ¹•”[“x‹y‚яp‘OŒã‚Ì‘O–[[“x‚ðŒv‘ª‚·‚éV‚µ‚¢•û–@. ”n“ˆŽ”@1, Žsì@Œc2, ŽðˆäKO3, “à“¡®‹v3, •Ð‰ª“”Ž4, ˆé’J®‹P4, ’†‘º—Fº4, ‹Ê’u–Ÿ–ì5, Žsìˆê•v3,6 (1Šá‰È–ŸŠá‰@, 2Šò•ŒÔ\Žš•a‰@, 3’†‹žŠá‰È, 4–ŒŒÃ‰®ƒAƒCƒNƒŠƒjƒbƒN, 5’†‹ž•a‰@, 6Šá‰È): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/29), ‹ž“s.

723631. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”’“àáp‘O¶‘ÌŒv‘ªƒf[ƒ^‚Ì”äŠrŒ€‹† (‘æ1•ñ: ‘“à2Ž{ÝŠÔ‚É‚š‚¯‚é”äŠr). _’J˜aF1, “¡‘º•‡²Žq1, Š±ì—¢ŠG1, ”Ñ“c‰Ã•F2, ¯ŽiMs2, X@—mÄ3, “ìŒcˆê˜Y3, ‹{“c˜a“T3 (1ˆã—Éq¶Šw•”, 2Šá‰È, 3‹{“cŠá‰È•a‰@): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/29), ‹ž“s.

723632. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ³íŠá‚É‚š‚¯‚éŠp–ŒŠ·ŽZ‹üÜ—Í‚š‚æ‚Ñ‘S‹üÜ—Í‚Ì”äŠr. Š±ì—¢ŠG1, _’J˜aF1, “¡‘º•‡²Žq1, ‚‹Ž³‰p2, ¯ŽiMs2 (1ˆã—Éq¶Šw•”, 2Šá‰È): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/29), ‹ž“s.

723633. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘OŠá•”OCT CASIA2‚É‚š‚¯‚é‰~Šp–ŒŠá‚Ɛ³íŠá‚̍Č»«‚Ì”äŠr. Ö“¡@Ê1, _’J˜aF2, “¡‘º•‡²Žq2, Š±ì—¢ŠG2, ‚‹Ž³‰p1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/29), ‹ž“s.

723634. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰~Šp–ŒŠá‚É‚š‚¯‚é2‹@Ží‚ÌŠp–ŒŒ`ó‰ðÍ‘•’u‚Ì‘ª’è’l‚Ì”äŠr. “¡‘º•‡²Žq1, _’J˜aF1, Š±ì—¢ŠG1, Ö“¡@Ê2, ‚‹Ž³‰p2, ¯ŽiMs2 (1ˆã—Éq¶Šw•”, 2Šá‰È): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/29), ‹ž“s.

723635. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) 2‚‚ÌSwept Source OCT‘•’u‚É‚æ‚éŠp–Œ‘S‹üÜ—Í‚Ì”äŠr. ‹Ž’Ü—Ç‘Ÿ1, ‹Ê’u–Ÿ–ì1, ¬“‡—²Ži2, ‰Á‰ê’BŽu1, Žsìˆê•v3,4 (1’†‹ž•a‰@, 2Œcœä‘å, 3’†‹žŠá‰È, 4Šá‰È): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/29), ‹ž“s.

723636. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”’“àáŽèp‘OŒã‚̗܉t–û‘w‚ÉŠÖ‚·‚é‘OŒü‚«Œ€‹†. ‰ª‘ºŽüŽq1, ¬“‡—²Ži2, ‰Á“¡‚ ‚©‚Ë1, ŽO“c‘º–ƒ—¢3, Žsìˆê•v3,4 (1Šò•ŒÔ\Žš•a‰@, 2Œcœä‘å, 3’†‹žŠá‰È, 4Šá‰È): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/29), ‹ž“s.

723637. [Šw‰ï (‘S‘)] (Šwp“WŽŠ) Šp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO‚ÌEpi-off–@‚ÆEpi-on–@‚̏pŒã‘Šú¬Ñ‚Ì”äŠr. ‹g“c—zŽq1, —L’|ˆŸ‹G‘ã1, Œ“c’m–ç1, •Ð‰ª“”Ž1, …–ì‘׎q1, ¬“‡—²Ži1,2, ’†‘º—Fº1, “n•”@ŠÂ3, ²“¡—T–ç3, Žsìˆê•v4,5 (1–ŒŒÃ‰®ƒAƒCƒNƒŠƒjƒbƒN, 2Œcœä‘å, 3²“¡—T–çŠá‰Èˆã‰@, 4’†‹žŠá‰È, 5Šá‰È): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/29), ‹ž“s.

723638. [Šw‰ï (‘S‘)] (Šwp“WŽŠ) ”’“àáŽèp‚Ì‹üÜ“x”Ý’è‚ɊᎲ·‚š‚æ‚ÑŽÎŽ‹‚ðl—¶‚µ‚œ2Ç—á. ‰i£x‹K1, ŒÜ\—’ÍŽj1,2, íœAr‘Ÿ˜Y1,2, ˆÉ“¡”ü¹ŠG1, Ž…Œö–ç1,2 (1ŽR‰€•a‰@, 2Šá‰È): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/29), ‹ž“s.

723639. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”’“àáŽèpŽ{Ý‚Ì•ª•z’²ž. ¬‘ìMˆê˜Y1, Îˆä@Ž2, Žsìˆê•v3,4, “¿“c–F_5 (1“ú–{ˆã‘åE•‘ ¬™, 2‚³‚¢‚œ‚ܐԏ\Žš•a‰@, 3’†‹žŠá‰È, 4Šá‰È, 5ˆäãŠá‰È•a‰@): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/30), ‹ž“s.

723640. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) NX70CH‚Ì‹­–ŒŒÅ’è‚É‚š‚¯‚é30Gj‚̐V‚µ‚¢Žg‚¢•û. ‹g“c‘¥•F1, Žsìˆê•v2,3 (1Šò•ŒÔ\Žš•a‰@, 2’†‹žŠá‰È, 3Šá‰È): ‘æ34‰ñJSCRSŠwp‘‰ï (2019/6/30), ‹ž“s.

723641. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –k—¢‘åŠwŠá‰È‚É‚š‚¯‚éÅ‹ß3”NŠÔ‚ł̉~Šp–Œ—pƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‘•—pó‹µ. ŒF”WŒä“°—²1, ‰z’n—¹Žq, ‚‹Ž³‰p1, ’Ò‘ò’C•F1, ˆÀ“¡˜a‰ÌŽq1, ‰F’ÃŒ©‹`ˆê1, _’J˜aF2, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ƒtƒH[ƒTƒ€2019‹ž“s (‘æ62‰ñ“ú–{ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYŠw‰ï‘‰ï) (2019/7/6), ‹ž“s.

723642. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) Association between glaucomatous optic disc change and Corvis ST-measured biomechanical property. Â–؏Cˆê˜Y1, “¿–щԍØ2, “¡–ì—F—¢3,4, Œ‰Y«l3,4, ‘º“c”ŽŽj4, ’†‘qr—S5, ’©‰ª@—º4, –Ø“à—Ç–Ÿ2 (1Žs—§ŽD–y•a‰@, 2L“‡‘å, 3Šá‰È, 4“Œ‹ž‘å, 5ƒcƒJƒUƒL•a‰@): ‘æ30‰ñ“ú–{—ΓàáŠw‰ï (2019/9/6), ŒF–{.

723643. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) Effects of the different spectral transmittance of yellow tinted lenses on the retinal sensitivities (ˆÙ‚Ȃ镪Œõ“§‰ß—Š‹Èü‚̉©F’…FƒŒƒ“ƒY‚Ì–Ô–ŒŠŽ“x‚ւ̉e‹¿). ŒŽŒûãđŸ1, ìŽç“c‘ñŽu2, ¯ŽiMs3 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ˆã—Éq¶Šw•”, 3Šá‰È): ‘æ30‰ñ“ú–{—ΓàáŠw‰ï (2019/9/6), ŒF–{.

723644. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰)yÀ’·zˆê”ÊŒû‰‰17: Žèp—Ö@6. ¯ŽiMs (Šá‰È): ‘æ30‰ñ“ú–{—ΓàáŠw‰ï (2019/9/7), ŒF–{.

723645. [Šw‰ï (‘S‘)] (Šwp“WŽŠ) Effect on the difference in visual acuity of both eyes in the binocular visual field tests (—ŒŠáŠJ•úŽ‹–쌟ž‚É‚š‚¯‚鎋—͂̍¶‰E·‚̉e‹¿). ‹œ‰E‹ß”ŽN1, “¡‘º•‡²Žq2, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ30‰ñ“ú–{—ΓàáŠw‰ï (2019/9/7), ŒF–{.

723646. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) Short term results of trabeculectomy for elevated intraocular pressure after CYCLO G6 (CYCLO G6Ž{sŒã‚̊ሳãž—á‚ɑ΂·‚é‘@ˆÛ’Œ‘ѐ؏œp‚Ì’ZŠú¬Ñ). ’Ò‘ò’C•F1, ¯ŽiMs1, Š}ŒŽ³s1, ‰Í–ì—Y—º1 (1Šá‰È): ‘æ30‰ñ“ú–{—ΓàáŠw‰ï (2019/9/8), ŒF–{.

723647. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) Predictability of Cataract Surgery with Trabeculectomy in Eyes using the Barrett Universal 2 formula (”’“àáŽèp•¹—p‘@ˆÛ’Œ‘ѐ؏œpÇ—á‚ɑ΂·‚éBarrett Universal 2Ž®‚Ì—\‘ª«‚ÌŒŸ“¢). ”Ñ“‡@Œh1, _’J˜aF2, ”Ñ“c‰Ã•F1, Š}ŒŽ³s1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ30‰ñ“ú–{—ΓàáŠw‰ï (2019/9/8), ŒF–{.

723648. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) RMOGR‘Ì—z«Ž‹_Œo‰Š‚̗Տ°‘œ‚ÌŒŸ“¢. ŽRã–ŸŽq1,2, Šâ²^‹|1,2, ˆäãŒ«Ž¡1, Žá‘q‰ë“o1, “c’†œšŽq3, ‚‹Ž—˜K4,5 (1ˆäãŠá‰È•a‰@, 2Šá‰È, 3VŠƒ‘åŠw”]Œ€‹†Š, 4“Œ–k‘åŠw_Œo“à‰È, 5•Ä‘ò•a‰@): ‘æ57‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2019/10/4), ŽD–y.

723649. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) “«Ž‹_Œo‰Š‚ɑ΂·‚é‘å—ʖƉuƒOƒƒuƒŠƒ“Ã’—Ö@. ŽO‘º@Ž¡1, ’†”ö—YŽO2, Îì@‹Ï3, –ђˍ„Žu4, •~“‡ŒhŒå5, —é–Ø—˜ª6, ’†‘º@œ7, ’†”nGŽ÷8, ˆäãŒ«Ž¡9, –Ø‘ºˆŸ‹IŽq1 (1•ºŒÉˆã‰È‘åŠw, 2‹ß‹E‘åŠw, 3ˆã—Éq¶Šw•”, 4“Œ‹žˆã‰È‘åŠw, 5“Œ‹žŽœŒb‰ïˆã‰È‘åŠw, 6àՋŠˆã‰È‘åŠwé‹Êˆã—ÃZƒ“ƒ^[, 7_ŒË‘åŠw, 8‹{è‘åŠw, 9ÏˆÀ“°ˆäãŠá‰È•a‰@): ‘æ57‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2019/10/4), ŽD–y.

723650. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) f’fEŽ¡—Âɓïa‚µ‚œƒAƒXƒyƒ‹ƒMƒ‹ƒXŠŽõÇ‚É‚æ‚é•@«Ž‹_ŒoÇ‚Ì1—á. Îì‘å‹N1, —Žˆä‰‘Žq1, Îì@‹Ï2, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ57‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2019/10/4), ŽD–y.

723651. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) –k—¢‘åŠw•a‰@Šá‰È‚É‚š‚¯‚éLeberˆâ“`ŽqŽ‹_ŒoÇ‚̍ŏIŽ‹—Í’ö“x•Ê, —Տ°“I“Á’¥. ÀàV—E‹P1, Îì@‹Ï2, —Žˆä‰‘Žq1, ˆÀ–{—Ž”n3, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”, 3—ÕŒŸ•”): ‘æ57‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2019/10/4), ŽD–y.

723652. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) Šá‹ØŒ^dÇ‹Ø–³—͏ǂÆdouble elevator palsy‚ÆŽ‹_Œo‘BŽîÇ2Œ^‚Őf’f‚ð–À‚€1—á: ‘æ2•ñ. •x“c‹§•F1, Œ–{@’Œ1, Xì—tŒŽ1, Œ÷“—tŽq1, ‰Á“¡ŒjŽq1, –x@—Tˆê1, Îì@‹Ï2 (1“Œ–M‘åŠwˆã—ÃZƒ“ƒ^[‘åX•a‰@, 2ˆã—Éq¶Šw•”): ‘æ57‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2019/10/4), ŽD–y.

723653. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰)yÀ’·zˆê”ÊŒû‰‰5: ƒŒ[ƒxƒ‹•a, Ž‹_ŒoŽŸŠ³. ŽRã–ŸŽq1,2 (1ˆäãŠá‰È•a‰@, 2Šá‰È): ‘æ57‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2019/10/5), ŽD–y.

723654. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) mt13051C>A•ÏˆÙ‚ð—L‚·‚郌[ƒxƒ‹ˆâ“`«Ž‹_ŒoÇ‚Ì1—á. Šâ²^‹|1,2, ŽRã–ŸŽq1,2, ˆäãŒ«Ž¡1, Žá‘q‰ë“o1, ˆÀ–{—Ž”n3, ŸNˆäŒc‘¢3, Îì@‹Ï4 (1ˆäãŠá‰È•a‰@, 2Šá‰È, 3—ÕŒŸ•”, 4ˆã—Éq¶Šw•”): ‘æ57‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2019/10/5), ŽD–y.

723655. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ƒXƒeƒƒCƒhƒpƒ‹ƒX, ŒŒŸ÷ŒðŠ·—Ö@‚É–³”œ‰ž‚Ÿ‚Á‚œƒ~ƒgƒRƒ“ƒhƒŠƒAˆâ“`Žq•ÏˆÙ‚ð—L‚·‚鎋_Œo‰Š‚Ì1—á. —Žˆä‰‘Žq1, Îì@‹Ï2, ‹àŽRr‰î1, ÀàV—E‹P1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ57‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2019/10/5), ŽD–y.

723656. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) •›•@o‰Š‚©‚ç‚Ì”g‹y‚É‚æ‚è”ìŒú«d–Œ‰Š‚Ɛ^‹Û«”]”^ᇂ𕹔­‚µ‚œ‚ƍl‚Š‚ç‚ê‚œŠáâ|æ’[•”ÇŒóŒQ‚̈ê—á. ‚‹Ž—m•œ1,2, ŽRã–ŸŽq3,4, ™ŽRŒb1, –Ø‘S“Þ“sŽq1 (1TMG‚ ‚³‚©ˆã—ÃZƒ“ƒ^[, 2“Œ‹ž—Žqˆã‰È‘åŠw•a‰@, 3ˆäãŠá‰È•a‰@, 4Šá‰È): ‘æ57‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2019/10/5), ŽD–y.

723657. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) “µE‹Ù’£Ç—lŠŒ©‚É‚Ä”­Ç‚µ‚œFisherÇŒóŒQ‚̈ê—á. Xì—tŒŽ1, Œ–{@’Œ1, Œ÷“—tŽq1, ‰Á“¡ŒjŽq1, –x@—Tˆê1, Îì@‹Ï2 (1“Œ–M‘åŠwˆã—ÃZƒ“ƒ^[‘åX•a‰@, 2ˆã—Éq¶Šw•”): ‘æ57‰ñ“ú–{_ŒoŠá‰ÈŠw‰ï‘‰ï (2019/10/5), ŽD–y.

723658. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) [‘wŠwK‚ð—p‚¢‚œ‰~Šp–Œ‚̐f’f”\‚ÌŒŸ“¢ (‘æ4•ñ: is—\‘ª). _’J˜aF1, ˆ»’Ë—S“ñ2, ‰Á“¡—Y‘å2, “¡‘º•‡²Žq1, ¯ŽiMs3, X@—mÄ4, ‹{“c˜a“T4 (1ˆã—Éq¶Šw•”, 2ƒNƒŒƒXƒRŽÐ, 3Šá‰È, 4‹{“cŠá‰È•a‰@): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/24), ‹ž“s.

723659. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘OŠá•”OCT‚É‚æ‚éƒVƒ…ƒŒƒ€ŽŠÇ“¯’è‰Â”ەʂ̃gƒ‰ƒxƒNƒg[ƒ€Žèp¬Ñ. ‘å’|—SŽ÷1, Š}ŒŽ³s1, ‰Í–ì—Y—º1, ’Ò‘ò’C•F1, ‚‹Ž³‰p1, •ÄŽR@—È1, ¯ŽiMs1 (1Šá‰È): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/24), ‹ž“s.

723660. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒtƒFƒ€ƒgƒZƒJƒ“ƒhƒŒ[ƒU[”’“àáŽèp‚ÌŠp–ŒØŠJ‘n‚Ì•]‰¿. Žsì@Œc1,2, ¬“‡—²Ži2,3, ‰Á“¡Km2, ŽðˆäKO2, ŽO“c‘º–ƒ—¢2, àV–؈»Žq4, Žsì—æŽq2, Žsìˆê•v2,5 (1Šò•ŒÔ\Žš•a‰@, 2’†‹žŠá‰È, 3Œcœä‘å, 4JHCO’†‹ž•a‰@, 5Šá‰È): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/24), ‹ž“s.

723661. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠááÙáz¹Š³ŽÒ‚Ì“úí¶Šˆ‚Ì•sŽ©—R“x, ŠëŒ¯“x. ‰Í–{‚Ђë”ü1, Šâ²^‹|1,2, ŽRã–ŸŽq1,2, ˆäãŒ«Ž¡1, Žá‘q‰ë“o1 (1ˆäãŠá‰È•a‰@, 2Šá‰È): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/24), ‹ž“s.

723662. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Visual Snow Syndrome‚Ì15—á‚Ì•ñ. Œõ”š‚Ý‚ž‚Ù1, “c’†’L1, Šâ²^‹|1,2, ŽRã–ŸŽq1,2, Žá‘q‰ë“o1, ˆäãŒ«Ž¡1, —é–؍K‹v3,4, ÎˆäŒ«“ñ4 (1ˆäãŠá‰È•a‰@, 2Šá‰È, 3JHCOŽO“‡‘‡•a‰@, 4“Œ‹ž“sŒ’N’·Žõˆã—ÃZƒ“ƒ^[Œ€‹†ŠE_Œo‰æ‘œŒ€‹†ƒ`[ƒ€): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/24), ‹ž“s.

723663. [Šw‰ï (‘S‘)] (Šwp“WŽŠƒVƒ‡[ƒgƒg[ƒN) ƒJƒ‰[ƒ}ƒbƒvì¬‚É‚æ‚éŠá“àƒŒƒ“ƒY‚ÌŒXŽÎ•ûŒü‚Æ’ö“x‚ÌŠÏŽ@. ”n“ˆŽ”@1, Žsì@Œc2, “à“¡®‹v3, ŽðˆäKO3, •Ð‰ª“”Ž4, ˆé’J®‹P4, ’†‘º—Fº4, ‹Ê’u–Ÿ–ì5, Žsìˆê•v3,6 (1Šá‰È–ŸŠá‰@, 2Šò•ŒÔ\Žš•a‰@, 3’†‹žŠá‰È, 4–ŒŒÃ‰®ƒAƒCƒNƒŠƒjƒbƒN, 5JHCO’†‹ž•a‰@, 6Šá‰È): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/24), ‹ž“s.

723664. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Hill-RBFŽ®Version2‚Ì—\‘ª«‚ÆBarrett Universal2Ž®ESRK/TŽ®‚Æ‚Ì”äŠr. ”Ñ“‡@Œh1, _’J˜aF2, ”Ñ“c‰Ã•F1, •ÄŽR@—È1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/25), ‹ž“s.

723665. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹ßŽ‹LASIKŒã‚Ì”’“àáŽèp‚É‚š‚¯‚éV‚µ‚¢Šá“àƒŒƒ“ƒY“x”ŒvŽZŽ®‚Ì—\‘ªž“x. íœAr‘Ÿ˜Y1,2,3, Ž…Œö–ç1,2,3, ²“¡@Ži1,3, ŒÜ\—’ÍŽj1,2,3, —`…@Šw1,2,3, ‰Á“¡ŽÑ–1, •Û‰È”üŠó1 (1ŽR‰€•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È, 3‘Ûˆã—ÕŸŽƒ‘å): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/25), ‹ž“s.

723666. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆÙ‚È‚éƒfƒUƒCƒ“‚ÌIOL‚É‚š‚¯‚éV‚µ‚¢“x”ŒvŽZŽ®‚Ì—\‘ªž“x‚ÌŒŸØ. ²“¡@Ži1,2, Ž…Œö–ç1,2,3, íœAr‘Ÿ˜Y1,2,3, ŒÜ\—’ÍŽj1,2,3, ‰Á“¡ŽÑ–2, •Û‰È”üŠó2, —`…@Šw1,2,3, Žl”V‹{—C”n1, Vˆä“cF—T1,3 (1‘Ûˆã—ÕŸŽƒ‘å, 2ŽR‰€•a‰@ƒAƒCƒZƒ“ƒ^[, 3Šá‰È): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/25), ‹ž“s.

723667. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰)yÀ’·zˆê”ʍu‰‰26: —L…»‘ÌŠá“àƒŒƒ“ƒY. Ž…Œö–ç1,2 (1ŽR‰€•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/25), ‹ž“s.

723668. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “Eo‚µ‚œŒã–[Œ^—L…»‘ÌŠá“àƒŒƒ“ƒYICL‚ÌŒŸ“¢. ’†‘º—Fº1, ‹g“c—zŽq1, …–ì‘׎q1, ¬“‡—²Ži1,2, ™ŽRN’j1, “c’†–FŽ÷3, Žsìˆê•v3,4 (1–ŒŒÃ‰®ƒAƒCƒNƒŠƒjƒbƒN, 2Œcœä‘å, 3’†‹žŠá‰È, 4Šá‰È): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/25), ‹ž“s.

723669. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “¯ˆêŒÂ‘Ì‚É‚š‚¯‚éŠÑ’ʍE•t‚«—L…»‘ÌŒã–[ƒŒƒ“ƒY‚̌ŒèˆÊ’u‚É‚æ‚épŒãvault‚Ì”äŠr. ‰Á“¡ŽÑ–1, Ž…Œö–ç1,2, ŒÜ\—’ÍŽj1,2 (1ŽR‰€•a‰@, 2Šá‰È): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/25), ‹ž“s.

723670. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) 45ÎˆÈã‚ÉŽ{s‚µ‚œŒã–[Œ^—L…»‘ÌŠá“àƒŒƒ“ƒY‘}“üp‚̏pŒã3”N¬Ñ. ‚‹Ž³‰p1, _’J˜aF2, ‘å’|—SŽ÷1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/25), ‹ž“s.

723671. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) 45ÎˆÈã‚É‚š‚¯‚éŠÑ’ʍE•t‚«—L…»‘ÌŒã–[ƒŒƒ“ƒY‚Ì‘œŽ{Ý—Տ°¬Ñ‚ÌŒŸ“¢. ŒÜ\—’ÍŽj1,2, Ž…Œö–ç1,2, _’J˜aF3, ‚‹Ž³‰p2, Žsìˆê•v2,4, ’†‘º—Fº5, ¬“‡—²Ži5, –kàV¢Žu”Ž6 (1ŽR‰€•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È, 3ˆã—Éq¶Šw•”, 4’†‹žŠá‰ÈŽ‹ŠoŒ€‹†Š, 5–ŒŒÃ‰®ƒAƒCƒNƒŠƒjƒbƒN, 6ƒTƒsƒAƒ^ƒ[ƒAƒCƒNƒŠƒjƒbƒN“Œ‹ž): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/25), ‹ž“s.

723672. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —L…»‘ÌŠá“àƒŒƒ“ƒYpŒãVault—\‘ª‰ñ‹AŽ®‚Ì”äŠr. ˆÀ“¡˜a‰ÌŽq1, _’J˜aF2, ‚‹Ž³‰p1, ‘å’|—SŽ÷1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/25), ‹ž“s.

723673. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹@ŠBŠwK‚ð—p‚¢‚œŒã–[Œ^—L…»‘ÌŠá“àƒŒƒ“ƒY‚Ìvault—\‘ª. “¡‘º•‡²Žq1, _’J˜aF1, ˆÀ“¡˜a‰ÌŽq2, ‚‹Ž³‰p2, ¯ŽiMs2, ŽR“à’m–[3, “c•£mŽu3 (1ˆã—Éq¶Šw•”, 2Šá‰È, 3ƒcƒJƒUƒL•a‰@): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/25), ‹ž“s.

723674. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”’“àáŠ³ŽÒ‚É‚š‚¯‚éŽÎŽ‹‚Ì—L•a—Š. ’r“c“N–ç1, ˆÉ“¡”ü¹ŠG1, âV“¡ˆÇ“Þ1, ŒÜ\—’ÍŽj1,2, Ž…Œö–ç1,2 (1ŽR‰€•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰È): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/26), ‹ž“s.

723675. [Šw‰ï (‘S‘)] (Šwp“WŽŠƒVƒ‡[ƒgƒg[ƒN)yÀ’·zŠwp“WŽŠƒVƒ‡[ƒgƒg[ƒN45@—Γàá: –ò•š. ¯ŽiMs (Šá‰È): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/26), ‹ž“s.

723676. [Šw‰ï (‘S‘)] (Šwp“WŽŠƒVƒ‡[ƒgƒg[ƒN) R—Γàá–òÜ”•Ê‚̃gƒ‰ƒxƒNƒg[ƒ€Žèp‚̐¬Ñ. ‰Í–ì—Y—º1, Š}ŒŽ³s1, ’Ò‘ò’C•F1, •ÄŽR@—È1, ‚–ØŒ˜‘Ÿ˜Y1, ¯ŽiMs1 (1Šá‰È): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/26), ‹ž“s.

723677. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Variational Bayes‚ð—p‚¢‚œŽ‹–쑪’èƒAƒ‹ƒSƒŠƒYƒ€. ‘º“c”ŽŽj1, “¡–ì—F—¢1, Œ‰Y«l1,2, “‡“c@Œ«3, ’©‰ª@—º1 (1“Œ‹ž‘å, 2Šá‰È, 3‹»˜a): ‘æ73‰ñ“ú–{—Տ°Šá‰ÈŠw‰ï (2019/10/27), ‹ž“s.

723678. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆê”ʐF‚š‚æ‚ÑŒuŒõF‚É‚š‚¯‚éFƒRƒ“ƒgƒ‰ƒXƒg‚ÆŽ‹”F«. ìŽç“c‘ñŽu1, ’|’†@’Œ2, ’ҁ@@‘n3, ‹àˆä”ŽK4, •œˆä—˜”Ž5, —é–Ø—T¶6, ”Œ“c’m–ç1, ¯ŽiMs7 (1ˆã—Éq¶Šw•”, 2ƒjƒbƒZƒ“ƒPƒ“•iŽ¿•]‰¿ƒZƒ“ƒ^[, 3ƒJƒPƒ“ƒeƒXƒgƒZƒ“ƒ^[, 4MB‘åŠw‘@ˆÛŠw•”, 5MB‘åŠw“Á”C‹³Žö, 6ƒAƒ[ƒAƒX (Š”), 7Šá‰È): ‘æ61‰ñ“ú–{ŽY‹ÆE˜J“­EŒð’ÊŠá‰ÈŠw‰ï (2019/11/16), “Œ‹ž.

723679. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) Å“_[“xŠg’£Œ^3Å“_Šá“àƒŒƒ“ƒY‚Æ’á‰Á“ü‰ñÜŒ^2Å“_Šá“àƒŒƒ“ƒY‚̏pŒã¬Ñ‚Ì”äŠr. Š–ìãČå1, ¬“‡—²Ži2, ‰F‘ÉŒbŽq1, ŽðˆäKO1, ‰Á“¡Km1, ŽO“c‘º–ƒ—¢1, “à“¡®‹v1, ‹Ê’u–Ÿ–ì3, Žsìˆê•v1,4 (1’†‹žŠá‰È, 2ŒcŒc‰ž‘å, 3JCHO’†‹ž•a‰@, 4Šá‰È): ‘æ60‰ñ“ú–{Ž‹”\‹ž³Šw‰ï (2019/11/30), •Ÿ‰ª.

723680. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ŒõŠwŽ®¶‘ÌŒv‘ª‘•’u‚Æ‘OŠá•”OCT‚É‚æ‚éƒg[ƒŠƒbƒNŠá“àƒŒƒ“ƒY‚Ì—Ž‹‹ž³Œø‰Ê‚Ì”äŠr. —]“cçŒb1, ŽðˆäKO1, ¬“‡—²Ži2, ‹Ê’u–Ÿ–ì3, ‰Á“¡Km1, ‰F‘ÉŒbŽq1, Š–ìãČå1, ŽR–{^Ø3, “à“¡®‹v1, Žsìˆê•v1,4 (1’†‹žŠá‰È, 2Œcœä‹`m‘åŠw, 3JCHO’†‹ž•a‰@, 4Šá‰È): ‘æ60‰ñ“ú–{Ž‹”\‹ž³Šw‰ï (2019/11/30), •Ÿ‰ª.

723681. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ŠOŽÎŽ‹‚𔺂€Š³ŽÒ‚Ì”’“àáp‘OŒã‚ÌŠáˆÊ•Ï‰». ÔÎ‘ò’q”¿1, Š±ì—¢ŠG2, ”Ñ“c‰Ã•F1, Îì@‹Ï2, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ60‰ñ“ú–{Ž‹”\‹ž³Šw‰ï (2019/11/30), •Ÿ‰ª.

723682. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) p’†”g–ÊŽû·‰ðÍ‘•’u‚ð—p‚¢‚œŠp–Œ‹üÜ‹ž³Šá‚É‚š‚¯‚é”’“àápŒã‹üÜŒë·‚Ì”äŠrŒŸ“¢. ì–ìŠoL1, ŽðˆäKO1, ¬“‡—²Ži2, ‹Ê’u–Ÿ–ì3, ‰Á“¡Km1, ˆé’J®‹P4, “c’†–FŽ÷1, “à“¡®‹v1, Žsìˆê•v1,5 (1’†‹žŠá‰È, 2Œc‰ž‘å, 3JCHO’†‹ž•a‰@, 4–ŒŒÃ‰®ƒAƒCƒNƒŠƒjƒbƒN, 5Šá‰È): ‘æ60‰ñ“ú–{Ž‹”\‹ž³Šw‰ï (2019/11/30), •Ÿ‰ª.

723683. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ¬Šw4E5”N¶‚É‚š‚¯‚銿Žš‚̏‘Žš‚ɉe‹¿‚·‚鎋‹@”\, Ž‹’mŠo‚ÌŒŸ“¢. ‰ª–ì^‹|1, “àì‹`˜a1, “c‘ºÈŒå2, âV“¡T”V‰î2, Vˆä“cF—T1,3 (1‘Ûˆã—ÕŸŽƒ‘å, 2‹ãB•ÛŒ’•ŸŽƒ‘åŠw•ÛŒ’‰ÈŠw•”Ž‹‹@”\—Ö@Šw‰È, 3Šá‰È): ‘æ60‰ñ“ú–{Ž‹”\‹ž³Šw‰ï (2019/11/30), •Ÿ‰ª.

723684. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) Õ“®«Šá‹…‰^“®‚š‚æ‚ÑŠŠ“®«’Ǐ]‰^“®‚ªÃ“I—§ˆÊŽž‚̏dS“®—h‚É‹y‚Ú‚·‰e‹¿. “àì‹`˜a1, ‰ªŽÀ”T—¢1, Ö“¡ç—T1, ’†“c仓Þ1, ‘º‰ªŽµŠC1, ‰ª–ì^‹|1, Vˆä“cF—T1,2 (1‘Ûˆã—ÕŸŽƒ‘å, 2Šá‰È): ‘æ60‰ñ“ú–{Ž‹”\‹ž³Šw‰ï (2019/11/30), •Ÿ‰ª.

723685. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) IOLMaster700‚Å‚Ì2‚‚̊p–Œ‹üÜ—Í‚ð—p‚¢‚œpŒã‹üÜŒë·‚Ì”äŠr. óˆä—D“Þ1, ¬“‡—²Ži2, ‹Ê’u–Ÿ–ì1, ‹Ž’Ü—Ç‘Ÿ1, ŽðˆäKO3, ‰Á‰ê’BŽu1, Žsìˆê•v3,4 (1JCHO’†‹ž•a‰@, 2Œc‰ž‘å, 3’†‹žŠá‰È, 4Šá‰È): ‘æ60‰ñ“ú–{Ž‹”\‹ž³Šw‰ï (2019/12/1), •Ÿ‰ª.

723686. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ƒŒ[ƒU[ƒXƒyƒbƒNƒ‹ƒtƒ[ƒOƒ‰ƒtƒB[‚É‚š‚¯‚鎋_Œo“û“ªŒŒ—¬‚̍Č»«‚š‚æ‚шê’v«. ¬ì仓Þ1, âV“¡@Ê1, ]•—Ft1,2, ‰i–ìKˆê1, ŽRŒû@ƒ1, ¯ŽiMs1 (1Šá‰È, 2ŽOƒc‹«Šá‰È): ‘æ60‰ñ“ú–{Ž‹”\‹ž³Šw‰ï (2019/12/1), •Ÿ‰ª.

723687. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰)yÀ’·zˆê”ʍu‰‰4: Šp–ŒEŒ‹–ŒE‹­–ŒuŠp–ŒEŒ‹–Œv. ì–k“N–ç1,2 (1–k—¢Œ€‹†Š•a‰@, 2Šá‰È): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/24), “Œ‹ž.

723688. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¶‘Ì—ÍŠw“Á«‚Æ‘OŠá•”OCT‚ð—p‚¢‚œFFKf’f‚Ì—L—p«‚ÌŒŸ“¢. Žu‰ê@—D1, ¬“‡—²Ži2, Œ“c’m–ç3, ’†‘º—Fº3, Žsìˆê•v4,5 (1Šò•ŒÔ\Žš•a‰@, 2Œcœä‘å, 3–ŒŒÃ‰®ƒAƒCƒNƒŠƒjƒbƒN, 4’†‹ž•a‰@, 5Šá‰È): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/24), “Œ‹ž.

723689. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰)yÀ’·zˆê”ʍu‰‰6: ¬Ž™EŽÎŽ‹u¬Ž™EŽÎŽ‹v. ŽRã–ŸŽq1,2 (1ˆäãŠá‰È•a‰@, 2Šá‰È): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/24), “Œ‹ž.

723690. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒXƒ}[ƒgƒtƒHƒ“•‹y‚É”º‚€‹}«“àŽÎŽ‹‚̐„ˆÚ. ì_ŠG—œŽq1, ŽRã–ŸŽq1,2, Šâ²^‹|1,2, ˆäãŒ«Ž¡1, Žá‘q‰ë“o1 (1ˆäãŠá‰È•a‰@, 2Šá‰È): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/24), “Œ‹ž.

723691. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰©”Á‰~E”ñ•Âœ—á‚ɑ΂·‚é‹ó‹C‰º“àŽ‹‹Ÿ‚ðŽg—p‚µ‚œ“à‹«ŠE–ŒŽ©‰ÆˆÚA–@. X@r’j1, ‰Á‰ê’BŽu2, ‹g“c‘¥•F3, ²“¡—T”V4, Œ“c‘וã2, ‰¡ŽR@ãÄ2, ŽO“c‘º—El1, Žsìˆê•v5,6 (1”Ñ“cŽs—§•a‰@, 2JCHO’†‹ž•a‰@, 3Šò•ŒÔ\Žš•a‰@, 4²“¡—T–çŠá‰È, 5’†‹žŠá‰È, 6Šá‰È): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/24), “Œ‹ž.

723692. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –Ô–ŒÃ–¬•ªŠò•ÂÇÇ‚̉©”Á•‚Žî‚ɑ΂·‚éƒiƒrƒQ[ƒVƒ‡ƒ“ƒŒ[ƒU[Ž¡—Â̒·ŠúŒo‰ß. ²“¡—T”V1, ŽO“c‘º–ƒ—¢2, Žsìˆê•v2,3, ‰Á‰ê’BŽu4, ‹g“c‘¥•F5, X@r’j6, ‰¡ŽR@ãÄ4, ²“¡—T–ç1 (1²“¡—T–çŠá‰È, 2’†‹žŠá‰È, 3Šá‰È, 4JCHO’†‹ž•a‰@, 5Šò•ŒÔ\Žš•a‰@, 6”Ñ“cŽs—§•a‰@): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/24), “Œ‹ž.

723693. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰)yÀ’·zˆê”ʍu‰‰18”’“àáu‘œÅ“_Šá“àƒŒƒ“ƒY1v. Ž…Œö–ç (ŽR‰€•a‰@): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/25), “Œ‹ž.

723694. [Šw‰ï (‘S‘)] (Šwp“WŽŠ) ŠÑ’ʍE•t‚«—L…»‘ÌŒã–[ƒŒƒ“ƒY‚̏‰ŠúŽ¡Œ±—á‚É‚š‚¯‚é’·Šú—Տ°¬Ñ. ŒÜ\—’ÍŽj1,2, Ž…Œö–ç1,2, ‚‹Ž³‰p2, _’J˜aF3 (1ŽR‰€•a‰@, 2Šá‰È, 3ˆã—Éq¶Šw•”): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/25), “Œ‹ž.

723695. [Šw‰ï (‘S‘)] (Šwp“WŽŠ) ŠÑ’ʍE•t‚«—L…»‘ÌŒã–[ƒŒƒ“ƒYpŒãlow vault—á‚É‚š‚¯‚é—Տ°¬Ñ. ‰Á“¡ŽÑ–1, Ž…Œö–ç1,2, ŒÜ\—’ÍŽj1,2 (1ŽR‰€•a‰@, 2Šá‰È): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/25), “Œ‹ž.

723696. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŽOdÅ“_Šá“àƒŒƒ“ƒY (PanOptixÒ) ‚̏pŒã‘Šú¬Ñ‚Ì•ñ. àV–؈»Žq1, ¬“‡—²Ži2, Š–ìãČå3, ˆé’J®‹P4, ŽO“c‘º–ƒ—¢3, Žsì@Œc5, ’†‘º—Fº4, Žsìˆê•v3,6 (1JCHO’†‹ž•a‰@, 2Œcœä‘å, 3’†‹žŠá‰È, 4–ŒŒÃ‰®ƒAƒCƒNƒŠƒjƒbƒN, 5‘‡ÂŽR•a‰@, 6Šá‰È): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/26), “Œ‹ž.

723697. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘œÅ“_Šá“àƒŒƒ“ƒYTorinova҂̏pŒã‘Šú¬Ñ‚Æ‹üÜŒë·. Žsì@Œc1, ¬“‡—²Ži2,3, Š–ìãČå2, ‰Á“¡‚ ‚©‚Ë4, àV–؈»Žq5, Žsì—æŽq2, ‹Ê’u–Ÿ–ì5, Žsìˆê•v2,5,6 (1‘‡ÂŽR•a‰@, 2’†‹žŠá‰È, 3Œcœä‘å, 4Šò•ŒÔ\Žš•a‰@, 5JCHO’†‹ž•a‰@, 6Šá‰È): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/26), “Œ‹ž.

723698. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰)yÀ’·zˆê”ʍu‰‰21‹üÜ‹ž³Žèpu‹üÜ‹ž³Žèpv. Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/26), “Œ‹ž.

723699. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) is«‰~Šp–Œ‚ɑ΂·‚éƒJƒXƒ^ƒ€Šp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO‚Ì‘Šú¬Ñ. ¬“‡—²Ži1,2, Œ“c’m–ç1, •Ð‰ª“”Ž1, ‹g“c—mŽq1, ’†‘º—Fº1, Žsìˆê•v3,4 (1–ŒŒÃ‰®ƒAƒCƒNƒŠƒjƒbƒN, 2Œcœä‘å, 3’†‹žŠá‰È, 4Šá‰È): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/26), “Œ‹ž.

723700. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Æ–ŸÝŒv‰ðÍƒ\ƒtƒg‚ð—p‚¢‚œHole ICL‚Ì–ÀŒõ‰ðÍ. ìŽç“c‘ñŽu1, ŽRè@Œ’1, Ž…Œö–ç1,2, ¯ŽiMs3 (1ˆã—Éq¶Šw•”, 2ŽR‰€•a‰@, 3Šá‰È): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/26), “Œ‹ž.

723701. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰)yÀ’·zˆê”ʍu‰‰23: ”’“àáuFLACS, ¶‘ÌŒv‘ªv. Žsìˆê•v1,2 (1’†‹žŠá‰È, 2Šá‰È): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/26), “Œ‹ž.

723702. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Hessƒ`ƒƒ[ƒg‚̐lH’m”\Ž¯•Ê—\”õ“IŒ€‹†EŠO“]_Œo–ƒáƒ‚Ɛ³í‚ÌŽ¯•Ê. ‘«—§«–å1, ¡–{_‹I1, Î”ò’ŒŽj1, ŒãŠÖ—˜–Ÿ2, “c•£mŽu1,3, ‹T‰ª^O1, ¬ŒD4, –Ø“à—Ç–Ÿ4 (1ƒcƒJƒUƒL•a‰@, 2Šá‰È, 3L“‡‘åDT2M, 4L“‡‘å): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/26), “Œ‹ž.

723703. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) 25ƒQ[ƒW“àŽ‹‹Ÿ•¹—pŒo–Ñ—l‘̝G•œ•”ƒA[ƒƒhƒoƒ‹ƒu‘}“ü‚̐¬Ñ. Œ“c‘וã1, ‰¡ŽR@ãÄ1, ¬“‡—²Ži2, “n糎OŒP3, ‰Á‰ê’BŽu1, Žsìˆê•v3,4 (1JCHO’†‹ž•a‰@, 2Œcœä‘å, 3’†‹žŠá‰È, 4Šá‰È): ‘æ43‰ñ“ú–{Šá‰ÈŽèpŠw‰ïŠwp‘‰ï (2020/1/26), “Œ‹ž.

731069. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ‹üÜ‹ž³ŽèpwŒ»ó‚ƍ¡Œã‚Ì“W–]x. _’J˜aF (ˆã—Éq¶Šw•”): OKINAWA Cataract&Corneal Seminar (2019/5/24), ‰«“ê.

731070. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ‚±‚±‚Ü‚Å•Ï‚í‚Á‚œ! ‰~Šp–ŒŽ¡—Â̍őOü. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ52‰ñ“¹“ìŠá‰ÈW’k‰ï (2019/6/1), –kŠC“¹.

731071. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) Ž‹—́E‹üÜŒŸžE”Y‚Ý‚Ì‰ðŒˆô. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): ‘æ20‰ñ‚݂€Ž‹”\ŒP—ûŽm‚̉ï (2019/6/9), ‹{é.

731072. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) —ΓàáŠ³ŽÒ‚É‚š‚¯‚éŽèpÐ‰î‚̃^ƒCƒ~ƒ“ƒO. Š}ŒŽ³s (Šá‰È): ‘æ13‰ñ‚³‚ª‚ÝŠá‰ÈŒ€‹†‰ï (2019/6/13), “Œ‹ž.

731073. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰)yÀ’·z“Á•Êu‰‰2. ¯ŽiMs (Šá‰È): ‘æ13‰ñ‚³‚ª‚ÝŠá‰ÈŒ€‹†‰ï (2019/6/13), “Œ‹ž.

731074. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ƒ}ƒCƒNƒƒpƒ‹ƒXƒŒ[ƒU[‚ÌŽg—pŒoŒ±‚Æ‚»‚̈ʒu‚¯. ¯ŽiMs (Šá‰È): ‘æ5‰ñFukuoka Glaucoma Council (2019/6/15), •Ÿ‰ª.

731075. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ‹üÜ‹ž³ŽèpƒAƒbƒvƒf[ƒg2019. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ23‰ñbMƒZƒ~ƒi[ (2019/6/23), ŽR—œ.

731076. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰)yÀ’·z“Á•Êu‰‰1. ¯ŽiMs (Šá‰È): ‘æ19‰ñ_“ސìŠá‰ÈƒZƒ~ƒi[ (2019/7/4), _“ސì.

731077. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ‹üÜ‹ž³ŽèpƒAƒbƒvƒf[ƒg2019. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ42‰ñàՋŠˆã‰È‘åŠwŠá‰ÈE“È–ØŒ§Šá‰Èˆã‰ï‡“¯u‰‰‰ï (2019/7/12), “È–Ø.

731078. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) “®‰æ‚ÅŒ©‚¹‚Ü‚·”’“àáŽèp@`Žèp‘OŒã‚̏ˆ•û–ò‚ɂ‚¢‚Ä‚à‰ðà‚µ‚Ü‚·`. ‘ŠàV‘å•ã1,2 (1ŠC˜V–Œ‘‡•a‰@ 2Šá‰È): ‘æ91‰ñ’¬“cŽs–òÜŽt‰ïŠwpu‰‰‰ï (2019/7/18), “Œ‹ž.

731079. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ‚í‚©‚è‚â‚·‚¢ŠáŒõŠw@Ž‹Šo‚ÌŽ¿‚ª•ª‚©‚éƒRƒ“ƒgƒ‰ƒXƒgŠŽ“xŒŸž. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): ‘æ2‰ñƒRƒƒfƒBƒJƒ‹ƒXƒLƒ‹ƒAƒbƒvƒZƒ~ƒi[in•xŽR (2019/7/21), •xŽR.

731080. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) —Γàá‚̐f’f‚Ɛis”»’è. ¯ŽiMs (Šá‰È): ‘æ20‰ñ•Ÿ‰ª—ΓàáƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2019/7/26), •Ÿ‰ª.

731081. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ‚±‚±‚Ü‚Å•Ï‚í‚Á‚œ! ‰~Šp–Œ‚ÌŽ¡—Á`CuRV, PiXL‚©‚çAIŽ¡—Â܂Å. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ18‰ñ‚ß‚Ž‚¹! ƒRƒ‹ƒlƒA‚Ì“Sl (2019/8/30), “Œ‹ž.

731082. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ’áNP—ΓàáŽèp. ¯ŽiMs (Šá‰È): 2019”N“xŠâŽèŠá‰ÈŠwpƒZƒ~ƒi[ (2019/8/31), ŠâŽè.

731083. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ’m‚Á‚Ä‚é‚‚à‚è‚Ì‘ÎŒõ”œŽË. óì@Œ« (ˆã—Éq¶Šw•”): ‘æ30‰ñ¬Ž™Šá‰È (ŽÎŽ‹EŽãŽ‹) Ç—ጟ“¢‰ïE•×‹­‰ï (2019/9/12), _“ސì.

731084. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰)yÀ’·z“Á•Êu‰‰. ŒãŠÖ—˜–Ÿ (Šá‰È): ESG`External Surgery Group` (2019/9/13), _“ސì.

731085. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰)yÀ’·z“Á•Êu‰‰I. _’J˜aF (ˆã—Éq¶Šw•”): SENJU Ocular surface Seminar (2019/9/27), _“ސì.

731086. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰)yÀ’·z“Á•Êu‰‰. ¯ŽiMs (Šá‰È): ‘æ55‰ñ–k—¢‘åŠwE_“ސ쌧Šá‰Èˆã‰ï‡“¯ƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2019/10/31), _“ސì.

731087. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ‚±‚±‚Ü‚Å•Ï‚í‚Á‚œ! ‰~Šp–Œ‚̍ŐVŽ¡—Á`CuRV, PiXL‚©‚çAIf’f‚܂Ł`. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ17‰ñ–kŠÖ“ŒŠá‰È•a‰@Œ€‹†‰ï (2019/11/7), “È–Ø.

731088. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) Šp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO‚Ì–¢—ˆ—\‘z}`CuRV, PiXL‚©‚çAIis—\‘ª‚܂Ł`. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ230‰ñŠÖŒŠá‰Èæiˆã—ÃŒ€‹†‰ï (2019/11/20), ‘åã.

731089. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ÅV‚ÌŽ‹_ŒoŽŸŠ³‚̍l‚Š•ûEˆµ‚¢•û`—Տ°—á‚ðŽQl‚É. Îì@‹Ï (ˆã—Éq¶Šw•”): ‘æ263‰ñŽ­Ž™“‡Šá‰ÈW’k‰ï (2019/11/30), Ž­Ž™“‡.

731090. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) MIGS‚ÌŒø‰Ê‚ÆŒÀŠE. ¯ŽiMs (Šá‰È): ‘æ16‰ñBay Ophthalmic Surgical Seminar (2019/11/30), _“ސì.

731091. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ‚—îŽÒ‚Ì•¡Ž‹|Sagging Eye Syndrome‚ð—‰ð‚·‚é|. ŒãŠÖ—˜–Ÿ (Šá‰È): ‘æ107‰ñH“cŒ§Šá‰ÈW’k‰ï (2019/12/15), H“c.

731092. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰)yÀ’·z“Á•Êu‰‰. ¯ŽiMs (Šá‰È): ‘æ17‰ñ–k—¢Šá‰È•af˜AŒg‰ï (2020/1/16), _“ސì.

731093. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) —ΓàáŽèp‚Ì“K‰ž‚ƏpŒãŠÇ—. Š}ŒŽ³s (Šá‰È): ‘æ17‰ñ–k—¢Šá‰È•af˜AŒg‰ï (2020/1/16), _“ސì.

731094. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) Œ©“Š‚¹‚È‚¢_ŒoŠá‰È‹~‹}ŽŸŠ³|—Γàá‚Æ‘ÎŒõ”œŽË|. Îì@‹Ï (ˆã—Éq¶Šw•”): ‘æ9‰ñSUSANOO‰ï (2020/1/19), “‡ª.

731095. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) Ð‰î‚·‚ׂ«_ŒoŠá‰ÈŽŸŠ³|‚»‚̃^ƒCƒ~ƒ“ƒO‚ð“Š‚ª‚³‚È‚¢‚œ‚߂Ɂ|. Îì@‹Ï (ˆã—Éq¶Šw•”): ‘æ6‰ñ•’ªŠá‰ÈƒtƒH[ƒ‰ƒ€ (2020/1/25), ‚’m.

731096. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) –k—¢‘åŠw‚É‚š‚¯‚éŠp–ŒŽŸŠ³Ž¡—Â̎ÀÛ`Ð‰î‚¢‚œ‚Ÿ‚«‚œ‚¢ŽŸŠ³‚Æ‚»‚ÌŽžŠú‚ɂ‚¢‚ā`. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ5‰ñ‰¡•lŽs—΋æŠá‰Èˆã‰ïŠwpu‰‰‰ï (2020/1/31), _“ސì.

732050. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (‹³ˆçuÀ) _ŒoŠá‰ÈŽŸŠ³|”wŒã‚ɉB‚ê‚鎟Š³‚ðŒ©“Š‚³‚È‚¢‚œ‚߂Ɂ|. Îì@‹Ï (ˆã—Éq¶Šw•”): “ú–{Šá‰Èˆã‰ï‘æ76‰ñ¶ŠU‹³ˆçuÀ (2019/4/13), ˆ€’m.

732051. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒ~[ƒeƒBƒ“ƒO) uŽt. ¯ŽiMs (Šá‰È): ‘æ2‰ñSENJU Glaucoma Seminarƒ{[ƒhƒ~[ƒeƒBƒ“ƒO (2019/4/23), _“ސì.

732052. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒAƒhƒoƒCƒU[) ƒAƒCƒtƒ@ƒKƒ““_Šá‰t0.1%, ƒKƒ`ƒtƒ“_Šá‰t0.3%‚̐»Ü“Á’¥‚ɂ‚¢‚Ä. Š}ŒŽ³s (Šá‰È): çŽõ»–òƒAƒhƒoƒCƒU[Dr.Šé‰æ (2019/4/25), _“ސì.

732053. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) ‰~Šp–Œ‚ɑ΂·‚éV‚œ‚ȃAƒvƒ[ƒ`. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ15‰ñ‘åãŠp–ŒƒtƒH[ƒ‰ƒ€ (2019/5/11), ‘åã.

732054. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) MIGS‚ƗΓàáŽ¡—Öò‚̃Aƒbƒvƒf[ƒg. Š}ŒŽ³s (Šá‰È): ‘æ18‰ñƒOƒ‰ƒlƒA‰ï (2019/5/16), _“ސì.

732055. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ŠJ‰ï‚̈¥ŽA) _“ސ쎕‰È‘åŠw•‘®‰¡•lƒNƒŠƒjƒbƒNŠá‰ÈÐ‰î (ŠJ‰ï‚̈¥ŽA). Žs粋`Í1,2 (1_“ސ쎕‰È‘åŠw•‘®‰¡•lƒNƒŠƒjƒbƒN, 2Šá‰È): ‘æ12‰ñ_“ސ쎕‰È‘åŠw‰¡•lŠá‰ÈfX˜AŒg‚̉ï (2019/5/31), _“ސì.

732056. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) —ΓàáŽèpƒAƒbƒvƒf[ƒg`MIGS`. Š}ŒŽ³s (Šá‰È): ‘æ12‰ñ_“ސ쎕‰È‘åŠw‰¡•lŠá‰ÈfX˜AŒg‚̉ï (2019/5/31), _“ސì.

732057. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (•Â‰ï‚̈¥ŽA) •Â‰ï‚̈¥ŽA. Œü–ì˜a—Y1,2 (1_“ސ쎕‰È‘åŠw•‘®‰¡•lƒNƒŠƒjƒbƒN, 2Šá‰È): ‘æ12‰ñ_“ސ쎕‰È‘åŠw‰¡•lŠá‰ÈfX˜AŒg‚̉ï (2019/5/31), _“ސì.

732058. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) –Ô–ŒŽŸŠ³‚̐f’f‚š‚æ‚ÑŽ¡—ÑI‘ðŽˆ. Žs粋`Í1,2, –ö“c’q•F2 (1_“ސ쎕‰È‘åŠw•‘®‰¡•lƒNƒŠƒjƒbƒN, 2Šá‰È): ‘æ14‰ñ_“ސ쉩”ÁŒ€‹†‰ï (2019/6/22), _“ސì.

732059. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (Šî’²u‰‰)yÀ’·zŠî’²u‰‰1. ”Ñ“c‰Ã•F (Šá‰È): ‘æ2‰ñ–k—¢‘åŠwŠá‰È’ƒ˜b‰ï (2019/7/13), “Œ‹ž.

732060. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (Šî’²u‰‰) Šp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO‚ÌŒ»ó‚Æ“W–]. ‚‹Ž³‰p (Šá‰È): ‘æ2‰ñ–k—¢‘åŠwŠá‰È’ƒ˜b‰ï (2019/7/13), “Œ‹ž.

732061. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (Šî’²u‰‰)yÀ’·zŠî’²u‰‰2. –ö“c’q•F (Šá‰È): ‘æ2‰ñ–k—¢‘åŠwŠá‰È’ƒ˜b‰ï (2019/7/13), “Œ‹ž.

732062. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (Šî’²u‰‰) •Ä‘ŽÎŽ‹f—Ã-ÅVƒgƒsƒbƒNƒX‚Æ—¯Šw•ñ-. ŒãŠÖ—˜–Ÿ (Šá‰È): ‘æ2‰ñ–k—¢‘åŠwŠá‰È’ƒ˜b‰ï (2019/7/13), “Œ‹ž.

732063. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (‹³ˆçu‰‰) …»‘̂̉Á—î•Ï‰»‚ÆŽ‹‹@”\. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): 2019ŠáŒõŠwƒ`ƒ…[ƒgƒŠƒAƒ‹ƒZƒ~ƒi[ (2019/8/3), “Œ‹ž.

732064. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ŽÐ“àƒ[ƒ~) ŠC˜V–Œ‘‡•a‰@‚É‚š‚¯‚é”’“àáŽèp‚ɂ‚¢‚Ä. ‘ŠàV‘å•ã1,2 (1ŠC˜V–Œ‘‡•a‰@, 2Šá‰È): ‹»˜aŠ”Ž®‰ïŽÐ@ŽÐ“àƒ[ƒ~ (2019/8/22), _“ސì.

732065. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) ‰“Ž‹—}§Ž¡—ÓIŠp–ŒØœp‚̍lˆÄ‚Ə]—ˆPTK‚Æ‚Ì”äŠr. ‘ìG‹P1,2 (1“ŒŽÅ—ÑŠÔ•a‰@, 2Šá‰È): ‘æ18‰ñ‚ß‚Ž‚¹! ƒRƒ‹ƒlƒA‚Ì“Sl (2019/8/30), “Œ‹ž.

732066. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (uK‰ï)yŽi‰ïz“ú–{_ŒoŠá‰ÈŠw‰ï”F’èuK‰ï. Îì@‹Ï (ˆã—Éq¶Šw•”): ‘æ35‰ñ^’߃Zƒ~ƒi[ (“ú–{_ŒoŠá‰ÈŠw‰ï”F’èuK‰ï) (2019/9/1), _“ސì.

732067. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (uK‰ï) “ú–{_ŒoŠá‰ÈŠw‰ï”F’èuK‰ï: ŠOŠá‹ØEŠáâ|pulley. ŒãŠÖ—˜–Ÿ (Šá‰È): ‘æ35‰ñ^’߃Zƒ~ƒi[ (“ú–{_ŒoŠá‰ÈŠw‰ï”F’èuK‰ï) (2019/9/1), _“ސì.

732068. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (Ç—ጟ“¢) Ž‹_Œo‰Š‚ƏЉ‚ê‚œŽãŽ‹‚Ì1—á. ˆÀ“¡˜a‰ÌŽq (Šá‰È): ‘æ30‰ñ¬Ž™Šá‰È (ŽÎŽ‹EŽãŽ‹) Ç—ጟ“¢‰ïE•×‹­‰ï (2019/9/12), _“ސì.

732069. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (À’k‰ï)yŽi‰ïz—ΓàáŽ¡—Ẩ·ŒÌ’mV`Žå—¬o˜H‚ð‰î‚·‚éŠáˆ³‰º~Ž¡—ÂƂ»‚̉ðŽß`. ¯ŽiMs (Šá‰È): _“ސ쌧À’k‰ï (‹»˜a) (2019/9/25), _“ސì.

732070. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒVƒ“ƒ|ƒWƒEƒ€)yÀ’·zTreatment (Medical&Surgical). ¯ŽiMs (Šá‰È): Asia Glaucoma Academy (AGA) 1st Conference (2019/9/28), “Œ‹ž.

732071. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) —Γàá. Š}ŒŽ³s (Šá‰È): –ڂ̈€Œìƒf[@Žs–¯ŒöŠJuÀ (2019/9/29), _“ސì.

732072. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™)yÀ’·zŽèp. ¯ŽiMs (Šá‰È): Keep The Visual Field in Tokyo (2019/10/5), “Œ‹ž.

732073. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) —ΓàáŽèp‚̏Љîƒ^ƒCƒ~ƒ“ƒO. Š}ŒŽ³s (Šá‰È): ‘æ3‰ñ‚ß‚ª‚݂̉ï (2019/10/6), _“ސì.

732074. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (Žs–¯ŒöŠJuÀ) ‚æ‚­‚í‚©‚é–Ú‚ÌŒ’N‚Ì‚š˜b`”’“àáE—Γàá‚̏Ǐó‚Æ‚»‚ÌŽ¡—Á`. ‘ŠàV‘å•ã1,2 (1ŠC˜V–Œ‘‡•a‰@, 2Šá‰È): ’m‚Á‚Ä“Ÿ‚·‚錒NuÀ^ŠC˜V–Œ‘‡•a‰@ (2019/10/19), _“ސì.

732075. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) —ΓàáŽ¡—ẪAƒbƒvƒf[ƒg. Š}ŒŽ³s (Šá‰È): ÃŒŠá‰ÈuK‰ï (2019/10/19), _“ސì.

732076. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™)yÀ’·zƒgƒ‰ƒxƒNƒg[ƒ€ŽèpŒ€‹†‰ï. ¯ŽiMs (Šá‰È): ƒgƒ‰ƒxƒNƒg[ƒ€ŽèpŒ€‹†‰ï2019 in Kyoto (2019/10/26), ‹ž“s.

732077. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) ¶—ŒõŠw‚Ì—§ê‚©‚猩‚œƒwƒbƒhƒAƒbƒvƒfƒBƒXƒvƒŒƒC‚̈À‘S«‚ÆŽ‹Šo’†SÝŒv. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): ‡Š‹Zpî•ñ‹Š‰ïƒZƒ~ƒi[ (ƒwƒbƒhƒAƒbƒvƒfƒBƒXƒvƒŒƒC‚̍œKî•ñ’ñŽŠ‚ÆŽ‹Šo“Á«) (2019/10/29), “Œ‹ž.

732078. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (‹³ˆçu‰‰)yÀ’·z‹³ˆçu‰‰. –ö“c’q•F (Šá‰È): ‘æ55‰ñ–k—¢‘åŠwE_“ސ쌧Šá‰Èˆã‰ï‡“¯ƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2019/10/31), _“ސì.

732079. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (‹³ˆçu‰‰) ŒõŠ±Â’f‘wŒv (OCT) ŠŒ©‚𒆐S‚Æ‚µ‚œ–Ô–ŒÉŽq‘ÌŽŸŠ³. t–ؐ’G (Šá‰È): ‘æ55‰ñ–k—¢‘åŠwE_“ސ쌧Šá‰Èˆã‰ï‡“¯ƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2019/10/31), _“ސì.

732080. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) —Γàá‚Ì•aŠú‚ɉž‚¶‚œŽ¡—Â̓±“ü. ¯ŽiMs (Šá‰È): ‘æ20‰ñ‹³ˆçƒtƒH[ƒ‰ƒ€ (2019/11/2), •Ÿ‰ª.

732081. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (‹³ŽöA”Cu‰‰) ’áNP—ΓàáŽèp: MIGS. ¯ŽiMs (Šá‰È): ‘æ45‰ñ–k—¢ˆãŠw‰ï‘‰ï (2019/11/16), _“ސì.

732082. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) ‹üÜ‹ž³ƒAƒbƒvƒf[ƒg. _’J˜aF (ˆã—Éq¶Šw•”): ƒGƒCƒGƒ€ƒI[EƒWƒƒƒpƒ“@ƒ†[ƒU[ƒYƒ~[ƒeƒBƒ“ƒO2019å‘ä (2019/11/24), ‹{é.

732083. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™)yÀ’·zu‰‰I. _’J˜aF (ˆã—Éq¶Šw•”): OS-GƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2019/11/27), _“ސì.

732084. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™)yÀ’·zu‰‰1. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ61‰ñÃŒŠá‰È—Տ°ƒtƒH[ƒ‰ƒ€ (2019/12/12), _“ސì.

732085. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™)yÀ’·zu‰‰2. ¯ŽiMs (Šá‰È): ‘æ61‰ñÃŒŠá‰È—Տ°ƒtƒH[ƒ‰ƒ€ (2019/12/12), _“ސì.

732086. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) Ç—á‚æ‚èŠw‚ԍŐV‚̐_ŒoŠá‰È. Îì@‹Ï (ˆã—Éq¶Šw•”): ‘æ433‰ñ‘åãŠá‰ÈW’k‰ï (2019/12/14), ‘åã.

732087. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒXƒyƒVƒƒƒŠƒXƒgu‰‰) Œ»ê‚̃j[ƒY‚©‚çl‚Š‚é‚í‚©‚è‚â‚·‚¢ŠáŒõŠw. ìŽç“c‘ñŽu (ˆã—Éq¶Šw•”): ‘æ2‰ñFuture of Orthoptist (2019/12/14), ŒF–{.

732088. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) —Γàá‚Ì•aŠú‚ɉž‚¶‚œŽ¡—Â̓±“ü. ¯ŽiMs (Šá‰È): Glaucoma Update Seminar ƒGƒCƒxƒŠƒX”­”„1Žü”N‹L”Ou‰‰‰ï (2020/1/30), _“ސì.

732089. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™)yÀ’·zu‰‰1. Îì@‹Ï (ˆã—Éq¶Šw•”): ‘æ7‰ñ_“ސ쏬Ž™Šá‰ÈE_ŒoŠá‰ÈƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2020/2/6), _“ސì.

732090. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™)yÀ’·z“Á•Êu‰‰2. _’J˜aF (ˆã—Éq¶Šw•”): ‘æ16‰ñÃ“ìŠá‰È‹äŠy•” (2020/2/13), _“ސì.

732091. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (Šî’²u‰‰) ŠOŠá•”Žèp‚É‚š‚¯‚銎õÇ‹y‚Ñ‚»‚Ì—\–h. —Žˆä‰‘Žq (Šá‰È): ESG`External Surgery Group` (2020/2/14), _“ސì.

732092. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (Ç—á•ñ) f’f‚É‹ê—¶‚µ‚œ“«Šááىº‚‚Ì1—á. ’r“c“N–ç (Šá‰È): ‘æ12‰ñ_“ސìƒNƒƒXƒI[ƒo[ƒVƒ“ƒ|ƒWƒEƒ€ (2020/2/15), _“ސì.

732093. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™)yÀ’·zµ‘ҍu‰‰. ¯ŽiMs (Šá‰È): ‘æ5‰ñŽ‹Šo¶—ŠwŠî‘bƒZƒ~ƒi[ (2020/2/16), ‘åã.

732094. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒAƒhƒoƒCƒUƒŠ[)yuŽtzƒAƒCƒx[ƒ^”z‡“_Šá‰t‚̃vƒƒ‚[ƒVƒ‡ƒ“‚ɂ‚¢‚Ä. ¯ŽiMs (Šá‰È): ƒAƒhƒoƒCƒUƒŠ[Dr.µãيé‰æ (2020/2/20), “Œ‹ž.

733227. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰)yÀ’·zˆê”ʍu‰‰. ¯ŽiMs (Šá‰È): ‘æ11‰ñ_“ސìŠá‰ÈŠw‰ï (2019/6/2), _“ސì.

733228. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ƒgƒ‰ƒxƒNƒg[ƒ€ŽèpŒã‚̊ሳÄãž—á‚ɑ΂·‚é’ljÁƒÊƒtƒbƒNƒƒgƒ~[‚Ì’ZŠú¬Ñ. ‰Í–ì—Y—º1, Š}ŒŽ³s1, ’Ò‘ò’C•F1, •ÄŽR@—È1, ¯ŽiMs1 (1Šá‰È): ‘æ11‰ñ_“ސìŠá‰ÈŠw‰ï (2019/6/2), _“ސì.

733229. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ŠOŽÎŽ‹‚𔺂€Š³ŽÒ‚Ì”’“àáp‘OŒã‚ÌŠáˆÊ•Ï‰». ÔÎ‘ò’q”¿1, Š±ì—¢ŠG2, ”Ñ“c‰Ã•F1, Îì@‹Ï2, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ11‰ñ_“ސìŠá‰ÈŠw‰ï (2019/6/2), _“ސì.

733230. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‹à‘®•Ð‚É‚æ‚éŠJ•ú«ŠáŠO‚ð‚«‚œ‚µ‚œˆê—á. ŠFì—FŒ›1, ”Ñ“‡@ˆ»1, t–ؐ’G1, –ö“c’q•F1, ¯ŽiMs1 (1Šá‰È): ‘æ11‰ñ_“ސìŠá‰ÈŠw‰ï (2019/6/2), _“ސì.

733231. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ƒjƒ{ƒ‹ƒ}ƒu’·Šú“Š—^’†‚É‚Ô‚Ç‚€–Œ‰Š‚𔭏ǂµ‚œ1—á. ‘å’|—S‹B1, •ÄŽR@—È1, ²“¡M”V1, –ö“c’q•F1, “n糍WŽ¯2, ¯ŽiMs1 (1Šá‰È, 2Á‰»Ší“à): ‘æ11‰ñ_“ސìŠá‰ÈŠw‰ï (2019/6/2), _“ސì.

733232. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ƒ~ƒgƒRƒ“ƒhƒŠƒAˆâ“`Žq11778‰–Šî‘Εψقð—L‚·‚鎡—Ã’ïR«Ž‹_Œo‰Š‚Ì1—á. —Žˆä‰‘Žq1, ‹àŽRr‰î1, ŒãŠÖ—˜–Ÿ1, Îì@‹Ï2, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ11‰ñ_“ސìŠá‰ÈŠw‰ï (2019/6/2), _“ސì.

733233. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) Photorefractive Intrastromal Cross-linking (PiXL) ‚É‚æ‚é‹ßŽ‹‹ž³‚ðŽ{s‚µ‚œˆê—á. ‚‹Ž³‰p1, _’J˜aF2, ’Ò‘ò’C•F1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ11‰ñ_“ސìŠá‰ÈŠw‰ï (2019/6/2), _“ސì.

733234. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ¬“µE‚ŏƖŸƒ€ƒ‰‚Ì‹N‚±‚Á‚œŠá’êŽÊ^‚Ì‹~Ï–@. ‰i–ìKˆê (Šá‰È): ‘æ31‰ñŠá‰ÈŽÊ^Œ€‹†‰ï (2019/7/7), “Œ‹ž.

733235. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è) ’vŽ€“I’†•«ƒAƒXƒyƒ‹ƒMƒ‹ƒXÇ‚É‚æ‚é•@«Ž‹_ŒoÇ‚̈ê—á. Îì‘å‹N1, ‹àŽRr‰î1, —Žˆä‰‘Žq1, ŒãŠÖ—˜–Ÿ1, Îì@‹Ï2 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ35‰ñ^’߃Zƒ~ƒi[ (_ŒoŠá‰Èh”‘•×‹­‰ï) (2019/8/31), _“ސì.

733236. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è) ’vŽ€“I’†•«ƒAƒXƒyƒ‹ƒMƒ‹ƒXÇ‚É‚æ‚éŠáâ|æ’[•”ÇŒóŒQ‚̈ê—á. Îì@‹Ï1, Îì‘å‹N2, ‹àŽRr‰î2, —Žˆä‰‘Žq2, ŒãŠÖ—˜–Ÿ2 (1ˆã—Éq¶Šw•”, 2Šá‰È), ‘æ35‰ñ^’߃Zƒ~ƒi[ (_ŒoŠá‰Èh”‘•×‹­‰ï) (2019/8/31), _“ސì.

733237. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è) Šá‹…‰^“®áŠQ‚ð‡•¹‚µ‚œRMOGR‘Ì—z«Ž‹_Œo‰Š‚̈ê—á. —Žˆä‰‘Žq1, Îì‘å‹N1, ‹àŽRr‰î1, ŒãŠÖ—˜–Ÿ1, Îì@‹Ï2 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ35‰ñ^’߃Zƒ~ƒi[ (_ŒoŠá‰Èh”‘•×‹­‰ï) (2019/8/31), _“ސì.

733238. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è) MRI‚Å‘å”]”’Ž¿‚ɍL”͂ȍ‚M†—̈æ‚ð”F‚ß‚œm11778“_•ÏˆÙ—z«Ž‹_ŒoÇ‚̈ê—á. ‹àŽRr‰î1, Îì‘å‹N1, —Žˆä‰‘Žq1, ŒãŠÖ—˜–Ÿ1, Îì@‹Ï2 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ35‰ñ^’߃Zƒ~ƒi[ (_ŒoŠá‰Èh”‘•×‹­‰ï) (2019/9/1), _“ސì.

733239. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è)yÀ’·zˆê”ʉ‰‘è. ŒãŠÖ—˜–Ÿ (Šá‰È): ‘æ55‰ñ–k—¢‘åŠwE_“ސ쌧Šá‰Èˆã‰ï‡“¯ƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2019/10/31), _“ސì.

733240. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è) ƒIƒ~ƒfƒlƒpƒOƒCƒ\ƒvƒƒsƒ‹“_Šá‰t‚Ì’ZŠúŽg—p¬Ñ. ‚–ØŒ˜‘Ÿ˜Y1, Š}ŒŽ³s1, ‚‹Ž³‰p1, ‰Í–ì—Y—º1, ’Ò‘ò’C•F1, •ÄŽR@—È1, ¯ŽiMs1 (1Šá‰È): ‘æ55‰ñ–k—¢‘åŠwE_“ސ쌧Šá‰Èˆã‰ï‡“¯ƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2019/10/31), _“ސì.

733241. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è) ƒŒ[ƒVƒbƒNpŒãŠO‚É‚æ‚éƒtƒ‰ƒbƒv–|“]‚𐶂¶‚œˆê—á. ŸNˆä—•Žq1, ‚‹Ž³‰p1, _’J˜aF2, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ55‰ñ–k—¢‘åŠwE_“ސ쌧Šá‰Èˆã‰ï‡“¯ƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2019/10/31), _“ސì.

733242. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è) ƒ_ƒuƒ‹ƒj[ƒhƒ‹ƒeƒNƒjƒbƒN‚ð—p‚¢‚œƒtƒ‰ƒ“ƒW–@‚É‚æ‚éŠá“àƒŒƒ“ƒY‹­–Œ“àŒÅ’èp‚ÌŽèp¬Ñ. ŠFì—FŒ›1, t–ؐ’G1, –ö“c’q•F1, ¯ŽiMs1 (1Šá‰È): ‘æ55‰ñ–k—¢‘åŠwE_“ސ쌧Šá‰Èˆã‰ï‡“¯ƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2019/10/31), _“ސì.

733243. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è) Šá‹…‰^“®áŠQ‚ð‡•¹‚µ‚œRMOGR‘Ì—z«Ž‹_Œo‰Š‚Ì1—á. —Žˆä‰‘Žq1, Îì‘å‹N1, ‹àŽRr‰î1, ŒãŠÖ—˜–Ÿ1, Îì@‹Ï2, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ55‰ñ–k—¢‘åŠwE_“ސ쌧Šá‰Èˆã‰ï‡“¯ƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2019/10/31), _“ސì.

733244. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è) Barrett Universal IIŽ®‚ÆSRK/TŽ®‚Ì—\‘ª«‚Ì”äŠr. ”Ñ“‡@Œh1, _’J˜aF2, ”Ñ“c‰Ã•F1, ¯ŽiMs1 (1Šá‰È, 2ˆã—Éq¶Šw•”): ‘æ55‰ñ–k—¢‘åŠwE_“ސ쌧Šá‰Èˆã‰ï‡“¯ƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2019/10/31), _“ސì.

733245. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è) “ïÇ—á”’“àáŽèp‚É‚š‚¢‚ÄŠmŽÀ‚É‘OùNØŠJ‚𐬌÷‚³‚¹‚é‚œ‚߂̐헪‚ƍH•v. ”Ñ“c‰Ã•F (Šá‰È): ‘æ16‰ñ Bay Ophthalmic Surgical Seminar (2019/11/30), _“ސì.

733246. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è) ƒAƒhƒoƒ“ƒXŠp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO (CuRVEPiXL). _’J˜aF (ˆã—Éq¶Šw•”): ‘æ16‰ñ Bay Ophthalmic Surgical Seminar (2019/11/30), _“ސì.

733247. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è)yÀ’·zˆê”ʉ‰‘è. Îì@‹Ï (ˆã—Éq¶Šw•”): ‘æ17‰ñ–k—¢Šá‰È•af˜AŒg‰ï (2020/1/16), _“ސì.

733248. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è)y‰ðàzSagging eye syndrome. ŒãŠÖ—˜–Ÿ (Šá‰È): ‘æ17‰ñ–k—¢Šá‰È•af˜AŒg‰ï (2020/1/16), _“ސì.

'18”N“xˆÈ‘O•ª

[Šwp˜_•¶]

H29-540002. [‚»‚Ì‘Œ (Œ€‹†•ñ‘)]y•œ¬27 (2015) ”N“x`•œ¬29 (2017) ”N“x Œú¶˜J“­‰ÈŠwŒ€‹†”ï•â•‹àuŽŸ•aEáŠQ‘΍ôŒ€‹†•ª–ì “ïŽ¡«ŽŸŠ³“™­ôŒ€‹† (“«ŽŸŠ³­ôŒ€‹†)vz_Œo–ƉuŠw“IŽ‹“_‚É‚æ‚é“«Ž‹_Œo‰Š‚̐f’fŠî€ì¬. Œ€‹†‘ã•\ŽÒ: Îì@‹Ï1, Œ€‹†•ª’SŽÒ: ŽO‘º@Ž¡,‹g•yŒ’Žu, •~“‡ŒhŒå, •œ‰ª”ü‹I, ’†”nGŽ÷, –ђˍ„Ži, ’†‘º@œ, ŒãŠÖ—˜–Ÿ2, “c’†œšŽq, Œ€‹†‹Š—ÍŽÒ: ŽRã–ŸŽq, ¯@‰À–F3, ^‰º‹I”ü‘ã, ˆÉ“¡@Œõ (1ˆã—Éq¶Šw•”, 2Šá‰È, 3‰q¶): •œ¬27 (2015) ”N“x`•œ¬29 (2017) ”N“x Œú¶˜J“­‰ÈŠwŒ€‹†”ï•â•‹àuŽŸ•aEáŠQ‘΍ôŒ€‹†•ª–ì “ïŽ¡«ŽŸŠ³“™­ôŒ€‹† (“«ŽŸŠ³­ôŒ€‹†) v‘Š‡Œ€‹†•ñ‘ 2018/3.


Žš•@ˆôA‰ÈE“ªèò•”ŠO‰ÈŠw

[Šwp˜_•¶]

110317. [ŒŽ’˜] Investigation of Stress Levels Before the Onset of Idiopathic Sudden Sensorineural Hearing Loss. Watanabe H1, Sano H2, Maki A1, Ino T1, Nakagawa T1, Okamoto M1, Yamashita T1: J Int Adv Otol 2019/4; 15 (1): 51-5. (“n•Ó—T”V1, ²–ì@”£2, –q@“ÖŽq1, ’–@Œ’Žu1, ’†ì‹Mm1, ‰ª–{–ql1, ŽR‰º@‘ñ1: 1Žš•@ˆôAE“ªèòŠO, 2ˆã—Éq¶Šw•”)

110318. [ŒŽ’˜] Classification of Tumors by Imaging Diagnosis and Preoperative Fine-Needle Aspiration Cytology in 120 Patients With Tumors in the Parapharyngeal Space. Matsuki T1, Miura K, Tada Y, Masubuchi T, Fushimi C, Kanno C, Takahashi H, Kamata S, Okamoto I, Miyamoto S1, Yamashita T1: Head Neck 2019/5; 41 (5): 1277-81. (Œ–؁@’1, ‹{–{r•ã1, ŽR‰º@‘ñ1: 1Žš•@ˆôAE“ªèòŠO)

110319. [ŒŽ’˜] Carboplatin and Docetaxel in Patients With Salivary Gland Carcinoma: A Retrospective Study. Okada T, Saotome T, Nagao T, Masubuchi T, Fushimi C, Matsuki T1, Takahashi H, Miura K, Tsukahara K, Tada Y: In Vivo 2019/5-6; 33 (3): 843-53. (Œ–؁@’1: 1Žš•@ˆôAE“ªèòŠO)

110320. [ŒŽ’˜] Oncolytic Sendai Virus-Induced Tumor-Specific Immunoresponses Suppress "Simulated Metastasis" of Squamous Cell Carcinoma in an Immunocompetent Mouse Model. Tanaka Y, Araki K, Tanaka S, Miyagawa Y, Suzuki H, Kamide D, Tomifuji M, Uno K, Harada E, Yamashita T1, Ueda Y, Inoue M, Shiotani A: Head Neck 2019/6; 41 (6): 1676-86. (ŽR‰º@‘ñ1: 1Žš•@ˆôAE“ªèòŠO)

110321. [ŒŽ’˜] Sentinel Lymph Node-Targeted Therapy by Oncolytic Sendai Virus Suppresses Micrometastasis of Head and Neck Squamous Cell Carcinoma in an Orthotopic Nude Mouse Model. Tanaka Y, Araki K, Tanaka S, Miyagawa Y, Suzuki H, Kamide D, Tomifuji M, Uno K, Kimura E, Yamashita T1, Ueda Y, Shiotani A: Mol Cancer Ther 2019/8; 18 (8): 1430-8. (ŽR‰º@‘ñ1: 1Žš•@ˆôAE“ªèòŠO)

110322. [ŒŽ’˜] Usefulness of Narrow Band Imaging With Magnifying Endoscopy for the Differential Diagnosis of Cancerous and Noncancerous Laryngeal Lesions. Hosono H1, Katada C2, Okamoto T1, Ichinoe M3, Sakamoto Y4, Matsuba H1, Kano K1, Ishido K2, Tanabe S2,5, Koizumi W2, Yamashita T1: Head Neck 2019/8; 41 (8): 2555-60. (×–ì_Žj1, Œ˜“ce—˜2, ‰ª–{—·l1, ˆêŒË¹–Ÿ3, â–{‘×—4, Œ—tG‹N1, ‰Á”[Fˆê1, ÎŒËŒªŽŸ2, “c糁@‘2,5, ¬ò˜aŽO˜Y2, ŽR‰º@‘ñ1: 1Žš•@ˆôAE“ªèòŠO, 2Á‰»Ší“à, 3•a—, 4—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg, 5V¢‹Iˆã—ÁEæ’[ˆã—Ã)

110323. [ŒŽ’˜] Induction of Cell fusion/apoptosis in Anaplastic Thyroid Carcinoma in Orthotopic Mouse Model by Urokinase-Specific Oncolytic Sendai Virus. Miyagawa Y, Araki K, Yamashita T1, Tanaka S, Tanaka Y, Tomifuji M, Ueda Y, Yonemitsu Y, Shimada H, Shiotani A: Head Neck 2019/9; 41 (9): 2873-82. (ŽR‰º@‘ñ1: 1Žš•@ˆôAE“ªèòŠO)

110324. [ŒŽ’˜] Value of Transoral Surgery for Human Papillomavirus-Mediated Oropharyngeal Cancer: Validation of a New Staging System in Japanese Patients. Kimura E, Araki K, Tomifuji M, Tanaka Y, Uno K, Yamashita T1, Shiotani A: J Int Med Res 2019/10; 47 (10): 5048-59. (ŽR‰º@‘ñ1: 1Žš•@ˆôAE“ªèòŠO)

110325. [ŒŽ’˜] Efficacy and Safety of Nivolumab in 100 Patients With Recurrent or Metastatic Head and Neck Cancer - A Retrospective Multicentre Study. Okamoto I, Sato H, Kondo T, Koyama N, Fushimi C, Okada T, Miura K, Matsuki T1, Yamashita T1, Omura G, Tsukahara K: Acta Otolaryngol 2019/110; 139 (10): 918-25. (Œ–؁@’1, ŽR‰º@‘ñ1: 1Žš•@ˆôAE“ªèòŠO)

110326. [ŒŽ’˜] Clinical Predictors of Descending Necrotizing Mediastinitis After Deep Neck Infections. Kimura A1, Miyamoto S1, Yamashita T1: Laryngoscope 2019/11. doi: 10.1002/lary.28406. Online ahead of print. (–Ø‘ºŽé—¢1, ‹{–{r•ã1, ŽR‰º@‘ñ1: 1Žš•@ˆôAE“ªèòŠO)

110327. [ŒŽ’˜] Venous malformation of the parapharyngeal space: Two surgical case reports and a literature review. Matsuki T1, Miura K, Tada Y, Masubuchi T, Fushimi C, Nitta Y, Kamata S, Okamoto I, Miyamoto S1, Yamashita T1: Otolayngology Case Reports 2019/11; 13: 100130. (Œ–؁@’1, ‹{–{r•ã1, ŽR‰º@‘ñ1: 1Žš•@ˆôAE“ªèòŠO)

110328. [ŒŽ’˜] Addition of S-1 to Radiotherapy for Treatment of T2N0 Glottic Cancer: Results of the Multiple-Center Retrospective Cohort Study in Japan With a Propensity Score Analysis. Sano D, Tanabe T, Kubota A, Miyamoto S1, Tanigaki Y, Okami K, Komatsu M, Ikoma R, Suzuki K, Akazawa Y, Kobayashi S, Yamada Y, Oridate N: Oral Oncol 2019/12; 99: 104454. (‹{–{r•ã1: 1Žš•@ˆôAE“ªèòŠO)

110329. [ŒŽ’˜] Post-operative Complications Due to Salvage Total Laryngectomy for Recurrent Laryngeal Cancer After Radiotherapy - A Multicentre Retrospective Study. Okamoto I, Matsuki T1, Sato H, Kondo T, Fushimi C, Okada T, Miura K, Yamashita T, Omura G, Tsukahara K: Acta Otolaryngol 2020/2; 140 (2): 170-4. (Œ–؁@’1: 1Žš•@ˆôAE“ªèòŠO)

120032. [ŒŽ’˜] ƒJƒjƒ…[ƒŒŽhŒƒ‚É‚æ‚é‹CŠÇ‹·ó‚ɑ΂µŽ­–쎮º–å•Âœp‚ðŽ{s‚µ‚œÇ—á. Ž–ì—R”y1, Ž­–ì^l, ×–ì_Žj1, ‘匎‘ìÆ1, ŒÃ–؏Ȍá1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO): “ªèò•”ŠO‰È 2019/4; 28 (3): 301-6.

120033. [ŒŽ’˜] ’ʏŠƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“—˜—p‚—îŽÒ‚Ì’®Šo•]‰¿|Žš“àfŽ@, ’®—ÍŒŸž, Ž¿–⎆’²ž‚É‚æ‚錟“¢|. —é–ØŒbŽq1, ”~ŒŽKŒb1, ˆäã—ŠG1, `@ŽáØ1, Ž…@•œ1, ²–ì@”£2, ’†ì‹Mm1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2ˆã—Éq¶Šw•”): Audiology Japan 2019/7; 62 (3): 240-7.

310038. [Ç—á•ñ] A Case of Gastric Meningeal Carcinomatosis Involving Bilateral Hearing Loss: The Difference Between Clinical Images and Autopsy Findings. Kimura A1, Takahashi Y, Mizutari K, Tsujimoto H, Nakanishi K, Shiotani A: J Int Adv Otol 2019/8; 15 (2): 333-6. (–Ø‘ºŽé—¢1: 1Žš•@ˆôAE“ªèòŠO)

320040. [Ç—á•ñ] Ž•ƒuƒ‰ƒV‚É‚æ‚éˆô“ªŠO‚©‚çcŠu‹CŽî‚𗈂œ‚µ‚œˆê—á. –Ø‘ºŽé—¢1, ŽR‰º@‘ñ1, Žç–{—ÏŽq (1Žš•@ˆôAE“ªèòŠO): “ú–{¬Ž™Žš•@ˆôA‰ÈŠw‰ïŽGŽ 2019/4; 40 (3): 271-7.

320041. [Ç—á•ñ] ƒIƒgƒKƒC‰º”ç•Ù‚É‚æ‚èŠg‘åA“ª‘S“EoŒã‚̈ô“ªÄŒš‚ðs‚Á‚œ‚—–åãŠà‚Ì2—á. ‹{–{r•ã1, Ž–ì—R”y1, Œ–؁@’1, ‰Á”[Fˆê1, ’ç@ãĕœ, —é–؈»Žq1, –àŽR•Û1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO): “ªèò•”ŠO‰È 2020/3; 29 (3): 311-20.

520015. [‘à] ’†E‰ºˆô“ª‚ÌŒoŒû“IŽ¡—Á@’†E‰ºˆô“ªŠà‚ɑ΂·‚éŒoŒû“IŽ¡—Á|ELPS, TOVS‚𒆐S‚Ɂ|. ŽR‰º@‘ñ1, ‰ª–{—·l1, ‰Á”[Fˆê1, Œ˜“ce—˜2 (1Žš•@ˆôAE“ªèòŠO, 2Á‰»Ší“à): “ú–{Žš•@ˆôA‰ÈŠw‰ï‰ï•ñ 2019/5; 122 (5): 750--6.

520016. [‘à] ƒXƒ|[ƒc‚ÆŽš•@ˆôA‰È|•@o¶—Šw‚©‚ç‰^“®”\—Í‚ÌŒüã‚ð–ÚŽw‚·|. ‘å–ØŠ²•¶1,2 (1Žš•@ˆôAE“ªèòŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): “ú–{Žš•@ˆôA‰ÈŠw‰ï‰ïŽ 2019/11; 122 (11): 1398-404.

521008. [‰ðà]y“ÁW: ‚¹‚«E‚œ‚ñ|ŠÓ•Êf’f‚̃|ƒCƒ“ƒg‚ÆŽ¡—Ð헪|z–òÜ«ŠÔŽ¿«”x‰Š. ‹{–{r•ã (Žš•@ˆôAE“ªèòŠO): ENTONI 2019/5; 232: 55-61.

521009. [‰ðà]y—pŒê‰ðàzLemierreÇŒóŒQ. ŽR‰º@‘ñ (Žš•@ˆôAE“ªèòŠO): “ú–{‹CŠÇH“¹‰ÈŠw‰ï‰ï•ñ 2019/12; 70 (6): 398-400.

522106. [uÀ]y‹³ˆçu‰‰Iz’Ž‚—îŽÐ‰ï‚É‚š‚¯‚é’®ŠoáŠQ‚Ì–â‘è“_. ²–ì@”£ (ˆã—Éq¶Šw•”):ƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“áŠQŠw 2019/4; 36 (1): 10-3.

522107. [uÀ]y˜AÚ: ŠO—ˆf—Âɂš‚¯‚鎄‚̏ˆ’uz•@‚̏ˆ’u6: •@‚̃lƒuƒ‰ƒCƒU[Ž¡—Ã. ‘å–ØŠ²•¶1,2 (1Žš•@ˆôAE“ªèòŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): JOHNS 2019/4; 35 (4); 503-8.

522108. [uÀ]y‘æ63‰ñ“ú–{’®ŠoˆãŠw‰ïŽå‘艉‘è“ÁWz’Ž‚—îŽÐ‰ï‚É‚š‚¯‚é’®ŠoˆãŠw‚̉ۑè‚ÆŽg–œ: ’ʏŠƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“—˜—p‚—îŽÒ‚Ì•â’®ŠíŽŽ’®. —é–ØŒbŽq1, ˆäã—ŠG1, ”~ŒŽKŒb1, `@ŽáØ1, Ž…@•œ1, ²–ì@”£2, ’†ì‹Mm1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2ˆã—Éq¶Šw•”): Audiology Japan Japan 2019/7; 62 (3): 196-204.

522109. [uÀ]y“ÁW: •@•Â‚ɂ܂‚í‚é–â‘è‚Æ‚»‚Ì‰ðŒˆôz‘˜_: •@ŒÄ‹z‚̐¶—. ‘å–ØŠ²•¶1,2 (1Žš•@ˆôAE“ªèòŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): JOHNS 2019/11; 35 (11): 1542-6.

522110. [uÀ]yƒVƒ“ƒ|ƒWƒEƒ€2: A“ªŠà‚̍A“ª‰·‘¶Ž¡—Á|“K‰ž‚ÆŒÀŠE‚ɂ‚¢‚ā|zA“ªˆŸ‘S“Eop (supracricoid laryngectomy) ‚Ì“K‰ž‚ÆŒÀŠE|Øœü‚ÌŠÏ“_‚©‚ç‚Ý‚œŒŸ“¢|. ‹{–{r•ã1, Ž–ì—R”y1, Œ–؁@’1, ‰ª–{—·l1, ‰Á”[Fˆê1, ’ç@ãĕœ1, —é–؈»Žq1, –àŽR•Û1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO): A“ª 2019/12; 31 (2): 84-91.

522111. [uÀ]yClinical Academic TopicszƒXƒM‰Ô•²RŒŽã‰º–Ɖu—Ö@‚Ì’·ŠúŒp‘±Ç—á‚É‚š‚¯‚éŒø‰Ê. ‘å‹ŽŒ’‘Ÿ˜Y1,2, ‘å–ØŠ²•¶1,2, ‹{‰ºŒ\ˆê1, ”g‘œ–ì‰l‘Ÿ1,2 (1Žš•@ˆôAE“ªèòŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ƒAƒŒƒ‹ƒM[‚̗Տ° 2019/12; 39 (12): 44-7.

540072. [‚»‚Ì‘Œ (Šw‰ï‹L˜^)]y‘æ37‰ñ“ú–{Žš•@ˆôA‰È–ƉuƒAƒŒƒ‹ƒM[Šw‰ï@”­•\‹L˜^WzƒXƒM‰Ô•²ÇŠ³ŽÒ‚É‚š‚¯‚é•â•—Ö@‚Æ‚µ‚Ă̍‚’£H‰–…ôò‚̈Ӌ`. ‘å–ØŠ²•¶1,2, —é–Ø—§r1, ‚–ì@èñ (1Žš•@ˆôAE“ªèòŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): Žš•@ˆôA‰È–ƉuƒAƒŒƒ‹ƒM[2019/6; 37 (2): 195-6.

540073. [‚»‚Ì‘Œ (Œ€‹†•ñ‘)]y•¶•”‰ÈŠwÈŒ€‹†”ï (2018”N“x`2019”N“xŽáŽèŒ€‹†)z”A’†ƒƒCƒRƒgƒŠƒGƒ“E4‚É‚æ‚éDŽ_‹…«•›•@o‰Šf’f. ŽRŒû’mŽq (Žš•@ˆôAE“ªèòŠO): 2018”N“xŽÀŽ{ó‹µ•ñ‘ 2019/12; https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-18K16855/18K168552018hokoku/.

[’˜@‘]

620080. [Šwp‘ (•ª’SŽ·•M)]y‘‚í‚©‚èIŽš•@ˆôA‰Èf—ÃKƒCƒhƒ‰ƒCƒ“, Žèˆø‚«Eƒ}ƒjƒ…ƒAƒ‹|Ž„‚ÌŠˆ—p–@| (ENTONI 236<‘‘卆>)z‹}«•@•›•@o‰Š‚ɑ΂·‚éƒlƒuƒ‰ƒCƒU[—Ö@‚ÌŽèˆø‚«2016@1. ŠT—ª, p.78-85. ‘å–ØŠ²•¶1,2 (1Žš•@ˆôAE“ªèòŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[), •Ò: Žsì‹âˆê˜Y, ‘S“ú–{•a‰@o”Å, “Œ‹ž, 2019/9”­s.

[Šw‰ïEŒ€‹†‰ï“™]

713129. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰)Long-term course of eosinophilic sinusitis: 3 cases study with urinary leukotriene E4. Yamaguchi T1, Ishii T1: 5th Congress of European ORL-HNS (2019/6/29-7/3), Brussels. (ŽRŒû’mŽq1, Îˆä–L‘Ÿ1: 1Žš•@ˆôAE“ªèòŠO)

713130. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Nasal Irrigation Therapy in patients with allergic patients. Ohki M1,2, Ohashi K1,2, Miyashita K1, Hatano A1,2: 15th Japan-Taiwan Conference on Otolaryngology-Head and Neck Surgery (2019/12/6-7), Fukuoka, Japan. (‘å–ØŠ²•¶1,2, ‘å‹ŽŒ’‘Ÿ˜Y1,2, ‹{‰ºŒ\ˆê1, ”g‘œ–ì‰l‘Ÿ1,2: 1Žš•@ˆôAE“ªèòŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

713131. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Activity-dependent Synaptopathy and Demyelination of Auditory Neurons following Conductive Hearring in Adult Mice. Kurioka T1, Mogi S2, Tanaka M, Yamashita T1: ARO 2020 43rd Annual MidWinter Meeting (2020/1/25), San Jose, USA. (ŒI‰ª—²b1, –Ζ؍¹ç‘ã2, ŽR‰º@‘ñ1: 1Žš•@ˆôAE“ªèòŠO, 2¶•š•š—Œn)

722216. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)uƒXƒ|[ƒc‚ÆŽš•@ˆôA‰Èv•@o¶—Šw‚©‚ç‰^“®”\—Í‚ÌŒüã‚ð–ÚŽw‚·. ‘å–ØŠ²•¶1,2 (1Žš•@ˆôAE“ªèòŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ120‰ñ“ú–{Žš•@ˆôA‰È‘‰ïEŠwpu‰‰‰ï (2019/5/9), ‘åã.

722217. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒAƒŒƒ‹ƒM[«•@‰Š‚É‚š‚¯‚éƒlƒuƒ‰ƒCƒU[—Ö@. ‘å–ØŠ²•¶1,2 (1Žš•@ˆôAE“ªèòŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ7‰ñ“ú–{Žš•@ˆôA‰ÈŠŽõÇEƒGƒAƒƒ]ƒ‹Šw‰ï‘‰ïEŠwpu‰‰‰ï (2019/9/5-6), ŽOd.

723704. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) º–åŒã•”–ü’…Ç‚ɑ΂µ—֏óŒã•””S–Œ•Ù‚ð—p‚¢‚Đº–åŠJ‘傪“Ÿ‚ç‚ê‚œ1—á. ’؈äG”V, •y“¡‰ë”V, Œ¢’Ë‹`—º, ŽRè’Œ–í, –Ø‘ºŽé—¢1, ‰F–ìŒõ—S, r–؍Km, ‰–’J²_ (1Žš•@ˆôAE“ªèòŠO): ‘æ120‰ñ“ú–{Žš•@ˆôA‰ÈŠw‰ï‘‰ïEŠwpu‰‰‰ï (2019/5/8), ‘åã.

723705. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) [èò•””^ᇂ©‚ç~‰º«‰óŽ€«cŠu‰Š‚ÉŽŠ‚éŠëŒ¯ˆöŽq‚͉œ‚©? –Ø‘ºŽé—¢1, ‹{–{r•ã1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO): ‘æ120‰ñ“ú–{Žš•@ˆôA‰È‘‰ïEŠwpu‰‰‰ï (2019/5/9), ‘åã.

723706. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Š{‰º•”Žîᎂ©‚çf’f‚³‚ê‚œ‘Sg«IgG4ŠÖ˜AŽŸŠ³‚̈ê—á. Ž–ì—R”y1, “¡ì’Œ–ç1, ”g‘œ–ì‰l‘Ÿ1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO): ‘æ120‰ñ“ú–{Žš•@ˆôA‰È‘‰ïEŠwpu‰‰‰ï (2019/5/9), ‘åã.

723707. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰È“ï’®ŠO—ˆ‚É‚š‚¯‚éŒyE’†“™“x“ï’®Š³ŽÒ‚Ì•â’®Ší‘•—pó‹µ‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‰¬ŒŽ“ÖŽq1, ŒÃ–؏Ȍá1, ’†ì‹Mm1, ŒI‰ª—²b1, ¬–ì—Yˆê, ²–ì@”£2, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2ˆã—Éq¶Šw•”): ‘æ120‰ñ“ú–{Žš•@ˆôA‰È‘‰ïEŠwpu‰‰‰ï (2019/5/10), ‘åã.

723708. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰È‚É‚š‚¯‚é•â’®Ší‘•—pŽÒ‚̃tƒBƒbƒeƒBƒ“ƒO‚Əˆ•ûƒ^[ƒQƒbƒg‚Ì”äŠr. ŒÃ–؏Ȍá1, ²–ì@”£2, ŒI‰ª—²b1, ‰¬ŒŽ“ÖŽq1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2ˆã—Éq¶Šw•”): ‘æ120‰ñ“ú–{Žš•@ˆôA‰È‘‰ïEŠwpu‰‰‰ï (2019/5/10), ‘åã.

723709. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰È‚ÅŒoŒ±‚µ‚œˆÙŠ«bó‘B‚Ì5—á. –àŽR•Û1, ‹{–{r•ã1, Ž–ì—R”y1, Œ–؁@’1, ‰Á”[Fˆê1, ’ç@ãĕœ2, —é–؈»Žq1, ”g‘œ–ì‰l‘Ÿ1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ120‰ñ“ú–{Žš•@ˆôA‰È‘‰ïEŠwpu‰‰‰ï (2019/5/11), ‘åã.

723710. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒJƒt•t‚«ƒXƒs[ƒ`ƒ^ƒCƒv‹CŠÇØŠJƒ`ƒ…[ƒu‚ðŽg—p‚µ”­º‚ª‰Â”\‚Æ‚È‚Á‚œlHŒÄ‹zŠÇ—’†‹ØƒWƒXƒgƒƒtƒB[¬Ž™—á. ‘匎‘ìÆ1, “¡ì’Œ–ç1, ”g‘œ–ì‰l‘Ÿ1, ‰¬ŒŽ“ÖŽq1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO): ‘æ14‰ñ“ú–{¬Ž™Žš•@ˆôA‰ÈŠw‰ï‘‰ïEŠwpu‰‰‰ï (2019/5/23), •Ÿ‰ª.

723711. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŒÄ‹z¢“ï‚𐶂¶‚œV¶Ž™ãˆô“ªŠïŒ`Žî‚̈ê—á. “¡ì’Œ–ç1, ‘匎‘ìÆ1, ‰¬ŒŽ“ÖŽq1, ”g‘œ–ì‰l‘Ÿ1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO): ‘æ14‰ñ“ú–{¬Ž™Žš•@ˆôA‰ÈŠw‰ï‘‰ïEŠwpu‰‰‰ï (2019/5/24), •Ÿ‰ª.

723712. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) HPVŠÖ˜A’†ˆô“ªŠà‚ÆREV7”­Œ»‚ÌŒŸ“¢. –àŽR•Û1, ‹{–{r•ã1, Ž–ì—R”y1, Œ–؁@’1, ‰Á”[Fˆê1, ’ç@ãĕœ2, —é–؈»Žq1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ43‰ñ“ú–{“ªèò•”ŠàŠw‰ï (2019/6/13), ‹à‘ò.

723713. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹CŠÇãA“ª•”•ªØœp‚É‚æ‚è‹@”\‰·‘¶‚µ‚œº–剺i“WÄ”­T4A“ªŠà‚Ì2—á. ‹{–{r•ã1, Ž–ì—R”y1, Œ–؁@’1, ‰Á”[Fˆê1, ’ç@ãĕœ2, —é–؈»Žq1, –àŽR•Û1, ŒŽ“c—YŠî1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ43‰ñ“ú–{“ªèò•”ŠàŠw‰ï (2019/6/13), ‹à‘ò.

723714. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “ªèò•”Šà‚É‚š‚¯‚éCD109”­Œ»‚ÌŒŸ“¢. ’ç@ãĕœ1, ‹{–{r•ã2, Ž–ì—R”y2, Œ–؁@’2, ‰Á”[Fˆê2, —é–؈»Žq2, –àŽR•Û2, ‘º‰_–FŽ÷3, ŽR‰º@‘ñ2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2Žš•@ˆôAE“ªèòŠO, 3•a—): ‘æ43‰ñ“ú–{“ªèò•”ŠàŠw‰ï (2019/6/13), ‹à‘ò.

723715. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒjƒ{ƒ‹ƒ}ƒu‚ð“Š—^‚µ‚œÄ”­“]ˆÚ‰ºˆô“ªŠà21—á‚Ì—LŒø«‚ƈÀ‘S«‚ÌŒŸ“¢|‘œŽ{Ý‹€“¯‚É‚æ‚éŒã•ûŽ‹“IŒ€‹†|. ‰ª“c‘ñ˜N, •šŒ©ç’ˆ, ‰ª–{ˆÉì, ²“¡GŽ÷, Œ–؁@’1, ‹ß“¡‹Mm, ¬‘º@‹, ¬ŽRM”V, ŽO‰YO‹K, ŽR‰º@‘ñ1, ’ËŒŽŽ² (1Žš•@ˆôAE“ªèòŠO): ‘æ43‰ñ“ú–{“ªèò•”ŠàŠw‰ï (2019/6/13), ‹à‘ò.

723716. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Nivolumab‚ð“Š—^‚µ‚œãˆô“ªŠà12—á‚Ì—LŒø«‚ƈÀ‘S«‚ÌŒŸ“¢|‘œŽ{Ý‹€“¯‚É‚æ‚éŒã•ûŽ‹“IŒ€‹†|. ²“¡GŽ÷, ‰ª–{ˆÉì, •šŒ©ç’ˆ, ‰ª“c‘ñ˜N, Œ–؁@’1, ‹ß“¡‹Mm, ¬ŽRM”V, ¬‘º@‹, ŽO‰YO‹K, ŽR‰º@‘ñ1, ’ËŒŽŽ² (1Žš•@ˆôAE“ªèòŠO): ‘æ43‰ñ“ú–{“ªèò•”ŠàŠw‰ï (2019/6/13), ‹à‘ò.

723717. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Nivolumab‚ð“Š—^‚µ‚œÄ”­E“]ˆÚ“ªèò•”Šà102—á‚Ì—LŒø«‚ƈÀ‘S«‚ÌŒŸ“¢|‘œŽ{Ý‹€“¯‚É‚æ‚éŒã•ûŽ‹“IŒ€‹†|. ‰ª–{ˆÉì, ’ËŒŽŽ², ²“¡GŽ÷, ‹ß“¡‹Mm, ¬ŽRM”V, •šŒ©ç’ˆ, ‰ª“c‘ñ˜N, ŽO‰YO‹K, ¬‘º@‹, Œ–؁@’1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO): ‘æ43‰ñ“ú–{“ªèò•”ŠàŠw‰ï (2019/6/13), ‹à‘ò.

723718. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Nivolumab‚ð“Š—^ŒãC‰»Šw—Ö@‚ðŽ{s‚µ‚œ“ªèò•”Šà‚Ì—LŒø«‚ƈÀ‘S«|‘œŽ{Ý‹€“¯‚É‚æ‚éŒã•ûŽ‹“IŒ€‹†|. •šŒ©ç’ˆ, ‰ª–{ˆÉì, Œ–؁@’1, ²“¡GŽ÷, ¬‘º@‹, ‹ß“¡‹Mm, ŽR‰º@‘ñ1, ’ËŒŽŽ², ‘œ“c—Yˆê˜Y, ‘•£’B•v, ‰ª“c‘ñ˜N, ”nê‘å•ã, ŽO‰YO‹K (1Žš•@ˆôAE“ªèòŠO): ‘æ43‰ñ“ú–{“ªèò•”ŠàŠw‰ï (2019/6/13), ‹à‘ò.

723719. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Nivolumab‚ð“Š—^‚µ‚œÄ”­“]ˆÚ“ªèò•”G•œã”çŠà88—á‚É‚š‚¯‚錌‰tŠw“I—\Œãƒ}[ƒJ[‚ÌŒŸ“¢|‘œŽ{Ý‹€“¯Œ€‹†|. Œ–؁@’1, ŽR‰º@‘ñ1, ‰ª–{ˆÉì, ²“¡GŽ÷, ’ËŒŽŽ², ‹ß“¡‹Mm, ŽO‰YO‹K, ‘œ“c—Yˆê˜Y, •šŒ©ç’ˆ, ‰ª“c‘ñ˜N, ì–k‘å‰î, àV•”@—Ï, ¬‘º@‹ (1Žš•@ˆôAE“ªèòŠO): ‘æ43‰ñ“ú–{“ªèò•”ŠàŠw‰ï (2019/6/13), ‹à‘ò.

723720. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆô“ªH“¹•\ÝŠà‚ɑ΂·‚éŒoŒû“IŽèp‚̈À‘S«‚Æ—LŒø«‚ÌŒŸ“¢. ‰Á”[Fˆê1, Œ˜“ce—˜2, ˆêŒË¹–Ÿ3, ÎŒËŒªŽŸ2, ‹{–{r•ã1, Ž–ì—R”y1, Œ–؁@’1, ’ç@ãĕœ4, —é–؈»Žq1, –àŽR•Û1, ŒŽ“c—YŠî1, “c糁@‘2,5, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2Á‰»Ší“à, 3•a—, 4‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 5V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ43‰ñ“ú–{“ªèò•”ŠàŠw‰ï (2019/6/14), ‹à‘ò.

723721. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰È‚É‚š‚¯‚铪èò•”‘B—l”X–EŠà‚ÌŒŸ“¢. —é–؈»Žq1, ‹{–{r•ã1, Ž–ì—R”y1, ‰ª–{—·l1, Œ–؁@’1, ‰Á”[Fˆê1, ’ç@ãĕœ2, –àŽR•Û1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ43‰ñ“ú–{“ªèò•”ŠàŠw‰ï (2019/6/14), ‹à‘ò.

723722. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹~ÏŒoŒûŽèpŒã‚ɏd“Ä‚È’x”­«pŒãoŒŒ‚𗈂µ‚œ’†ˆô“ªŠà‚Ì1—á. ŒŽ“c—YŠî1, ‹{–{r•ã1, Œ–؁@’1, Ž–ì—R”y1, ‰Á”[Fˆê1, –àŽR•Û1, ’ç@ãĕœ2, —é–؈»Žq1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ43‰ñ“ú–{“ªèò•”ŠàŠw‰ï (2019/6/14), ‹à‘ò.

723723. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŒŸŒê‚ªˆÙ‚È‚èƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“‚ª¢“ï‚Å‚ ‚Á‚œèò•””^ᇂÌ1Ç—á. ’†‘º‹g¬1, ‘å–ØŠ²•¶1,2, ‘å‹ŽŒ’‘Ÿ˜Y1,2, ‹{‰ºŒ\ˆê1, —é–Ø—§r1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ7‰ñ“ú–{Žš•@ˆôA‰ÈŠŽõÇEƒGƒAƒƒ]ƒ‹Šw‰ï‘‰ïEŠwpu‰‰‰ï (2019/9/5), ŽOd.

723724. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‡–°Žž–³ŒÄ‹z‚ɑ΂µ“ú‹A‚èŽèpŽ{sŒãˆô“ªoŒŒ‚É‚æ‚è‹~‹}Žóf‚µ‚œ1—á. ”g‘œ–ì‰l‘Ÿ1,2, ‹{‰ºŒ\ˆê1, ‘å–ØŠ²•¶1,2, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ32‰ñ“ú–{ŒûoEˆô“ª‰ÈŠw‰ï‘‰ï‚È‚ç‚Ñ‚ÉŠwpu‰‰‰ï (2019/9/12), ‘啪.

723725. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚š‚¯‚éIgG4ŠÖ˜AŽŸŠ³Š³ŽÒ‚ÌŒŸ“¢. Ž–ì—R”y1, ”g‘œ–ì‰l‘Ÿ1,2, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ32‰ñ“ú–{ŒûoEˆô“ª‰ÈŠw‰ï‘‰ï‚È‚ç‚Ñ‚ÉŠwpu‰‰‰ï (2019/9/12), ‘啪.

723726. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •›•@o‰ŠpŒãŠÇ—‚É‚š‚¯‚鎩“®•@oôòŠíŽg—p‚ÌŽŽ‚Ý. ”g‘œ–ì‰l‘Ÿ1,2, ‘å–ØŠ²•¶1,2, ‘å‹ŽŒ’‘Ÿ˜Y1,2, ‹{‰ºŒ\ˆê1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ58‰ñ“ú–{•@‰ÈŠw‰ï‘‰ïEŠwpu‰‰‰ï (2019/10/4), “Œ‹ž.

723727. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰¹‹¿•@oŒv‘ªŒŸž‚Ì“ú–{lŠî€’l‚ðô’è‚·‚é‚œ‚ß‚Ì‘œŽ{Ý‹€“¯Œ€‹†|‘æˆê•ñ|. ’|“à—T”ü, ’†‘º—z—S, ‘å–ØŠ²•¶1,2, —é–Ø—§r1, ‘Œ (1Žš•@ˆôAE“ªèòŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ58‰ñ“ú–{•@‰ÈŠw‰ï‘‰ïEŠwpu‰‰‰ï (2019/10/4), “Œ‹ž.

723728. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –«’†Žš‰Š‚É‚æ‚é“àŽš‚ւ̉e‹¿‚Ì•]‰¿. ŒÃ–؏Ȍá1, ŒI‰ª—²b1, ²–ì@”£2, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2ˆã—Éq¶Šw•”): ‘æ29‰ñ“ú–{Žš‰ÈŠw‰ï‘‰ïEŠwpu‰‰‰ï (2019/10/10), ŽRŒ`.

723729. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬‡“ï’®‚Ì“`‰¹¬•ª‚ªŒê‰¹–Ÿ—Ä“x‚É—^‚Š‚é‰e‹¿‚ɂ‚¢‚Ä. ŒI‰ª—²b1, ²–ì@”£2, ŒÃ–؏Ȍá1, “¡ì’Œ–ç1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2ˆã—Éq¶Šw•”): ‘æ29‰ñ“ú–{Žš‰ÈŠw‰ï‘‰ïEŠwpu‰‰‰ï (2019/10/10), ŽRŒ`.

723730. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰È‚É‚š‚¯‚éŠç–ʐ_Œo–ƒáƒ‚Ì—\Œã‹K’èˆöŽq‚ÌŒŸ“¢. “¡ì’Œ–ç1, ŒI‰ª—²b1, ŒÃ–؏Ȍá1, ²–ì@”£2, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2ˆã—Éq¶Šw•”): ‘æ29‰ñ“ú–{Žš‰ÈŠw‰ï‘‰ïEŠwpu‰‰‰ï (2019/10/10), ŽRŒ`.

723731. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Nivolumab‚ð“Š—^‚µ‚œÄ”­E“]ˆÚ“ªèò•”G•œã”çŠà88—á‚É‚š‚¯‚錌‰tŠw“Iƒ}[ƒJ[‚ÌŒ€‹†. Œ–؁@’1, ‰ª–{ˆÉì, •šŒ©ç’ˆ, àV•”@—Ï, ì–k‘å‰î, ²“¡GŽ÷, ’ËŒŽŽ², ‹ß“¡‹Mm, ‰ª“c‘ñ˜N, ‘œ“c—Yˆê˜Y, ŽO‰YO‹K, ¬‘º@‹, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO): ‘æ57‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï (2019/10/24), •Ÿ‰ª.

723732. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Nivolumab‚ð“Š—^‚µ‚œÄ”­E“]ˆÚ“ªèò•”Šà100‚Ì—LŒø«‚ƈÀ‘S«‚ÌŒŸ“¢. ‰ª–{ˆÉì, ²“¡GŽ÷, ‹ß“¡‹Mm, ¬ŽRM”V, •šŒ©ç’ˆ, ‰ª“c‘ñ˜N, ŽO‰YO‹K, ¬‘º@‹, Œ–؁@’1, ŽR‰º@‘ñ1, ’ËŒŽŽ² (1Žš•@ˆôAE“ªèòŠO): ‘æ57‰ñ“ú–{ŠàŽ¡—Êw‰ïŠwpW‰ï (2019/10/24), •Ÿ‰ª.

723733. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) bó‘B‹@”\’ቺÇ‚̐_ŒoŽš‰ÈŠw“IŒŸ“¢. —Ž‡@“Ö1, ’†ì‹M”V1, ’·À‰p–Ÿ1,2 (1Žš•@ˆôAE“ªèòŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ78‰ñ“ú–{‚ß‚Ü‚¢•œtˆãŠw‰ï‘‰ïŠwpu‰‰‰ï (2019/10/24), •xŽR.

723734. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒƒjƒG[ƒ‹•aÇ—á‚š‚¯‚éSDS (self-rating depression scale) ƒXƒRƒA‚ÌŒXŒü. ’†ì‹M”V1, —Ž‡@“Ö1, ’·À‰p–Ÿ1,2 (1Žš•@ˆôAE“ªèòŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ78‰ñ“ú–{‚ß‚Ü‚¢•œtˆãŠw‰ï‘‰ïEŠwpu‰‰‰ï (2019/10/24), •xŽR.

723735. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚š‚¯‚éVEMP‚ð—p‚¢‚œ‹…Œ`ùN/—‘Œ`ùN‚Ì‹@”\’ቺ‚É‚æ‚éÇó‚ÌŒŸ“¢. “c‘º¹–ç1, —Ž‡@“Ö1, ’†ì‹M”V1, ’·À‰p–Ÿ1,2 (1Žš•@ˆôAE“ªèòŠO, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ78‰ñ“ú–{‚ß‚Ü‚¢•œtˆãŠw‰ï‘‰ïEŠwpu‰‰‰ï (2019/10/24), •xŽR.

723736. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •â’®ŠíƒtƒBƒbƒeƒBƒ“ƒOƒ\ƒtƒg‚Å‚ÌNAL-NL, DSL–@‚̏‰ŠúÝ’è’l‚̑Ó–«. ŒÃ–؏Ȍá1, ²–ì@”£2, ŒI‰ª—²b1, ˆäã—ŠG, ”~ŒŽKŒb, ŒŽ@—R‹I2, —é–ØŒbŽq2, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2ˆã—Éq¶Šw•”): ‘æ64‰ñ“ú–{’®ŠoˆãŠw‰ï‘‰ïEŠwpu‰‰‰ï (2019/11/7), ‘åã.

723737. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’nˆæƒOƒ‹[ƒvŠˆ“®ŽQ‰Á‚—îŽÒ‚Ì’®Šo•]‰¿‚Æ•â’®ŠíŽŽ’®. —é–ØŒbŽq1, ˆäã—ŠG, ”~ŒŽKŒb, `@ŽáØ1, Ž…@•œ, ²–ì@”£1, ’†ì‹Mm2, ŽR‰º@‘ñ2 (1ˆã—Éq¶Šw•”, 2Žš•@ˆôAE“ªèòŠO): ‘æ64‰ñ“ú–{’®ŠoˆãŠw‰ï‘‰ïEŠwpu‰‰‰ï (2019/11/7), ‘åã.

723738. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) æ’[œ]‹ÈŒ^d«“àŽ‹‹Ÿ‰º‚ÅŒoŒû“I‚É“Eo‚µ‚œ•›ˆô“ªŠÔŒ„Ã–¬ŠïŒ`. –Ø‘ºŽé—¢1, Ž–ì—R”y1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO): ‘æ71‰ñ“ú–{‹CŠÇH“¹‰ÈŠw‰ï‘‰ï‚È‚ç‚Ñ‚ÉŠwpu‰‰‰ï (2019/11/28), “È–Ø.

723739. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ã•”Á‰»ŠÇ“àŽ‹‹Ÿ‚É‚æ‚鐺‘Ñ•a•Ï‚ɑ΂·‚鐞ž‚ÌŒŸ“¢. ×–ì_Žj1, Œ˜“ce—˜2, –Ø‘ºŽé—¢1, ’ç@ãĕœ3, ‰Á”[Fˆê1, Ž–ì—R”y1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2Á‰»Ší“à, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ71‰ñ“ú–{‹CŠÇH“¹‰ÈŠw‰ï‘‰ï‚È‚ç‚Ñ‚ÉŠwpu‰‰‰ï (2019/11/28), “È–Ø.

723740. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) A“ª‰·‘¶Ž¡—Â̎ž”s—á‚ÉŠw‚Ô: ŠOØŠJA“ª•”•ªØœŒã‚ÌŽž”s—á|A“ªˆŸ‘S“Eop‚ÌŽž”s—á‚Æ‚»‚̑Ήž|. ‹{–{r•ã1, Ž–ì—R”y1, Œ–؁@’1, ‰ª–{—·l, ‰Á”[Fˆê1, ’ç@ãĕœ2, —é–؈»Žq1, –àŽR•Û1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ71‰ñ“ú–{‹CŠÇH“¹‰ÈŠw‰ï‘‰ï‚È‚ç‚Ñ‚ÉŠwpu‰‰‰ï (2019/11/28), “È–Ø.

723741. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) A“ªˆŸ‘S“EopŒã‚Ìš‹‰ºáŠQ‚ɑ΂µ‚ĐVº–厉–b’“üp‚ðŽ{s‚µ‚œ1—á. Ž–ì—R”y1, ‹{–{r•ã1, ×–ì_Žj1, –Ø‘ºŽé—¢1, “¡ì’Œ–ç1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO): ‘æ71‰ñ“ú–{‹CŠÇH“¹‰ÈŠw‰ï‘‰ï‚È‚ç‚Ñ‚ÉŠwpu‰‰‰ï (2019/11/29), “È–Ø.

723742. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —Œ‘€V-Y‘Oi”S–Œ•Ù‚É‚æ‚èˆêŠú“IÄŒš‚µ‚œ‘Šú‰ºŒûOŠà‚Ì2—á. ‹{–{r•ã1, Œ–؁@’1, ‰Á”[Fˆê1, ’ç@ãĕœ2, ŒÃ–؈»Žq1, –àŽR•Û1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ30‰ñ“ú–{“ªèò•”ŠO‰ÈŠw‰ï‘‰ï‚È‚ç‚Ñ‚ÉŠwpu‰‰‰ï (2020/1/30), ‰«“ê.

723743. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Sistrunk–@‚ðs‚Á‚œbóãŠÇŠà‚Ì1—á. –àŽR•Û1, ‹{–{r•ã1, Œ–؁@’1, ‰Á”[Fˆê1, ’ç@ãĕœ2, —é–؈»Žq1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ30‰ñ“ú–{“ªèò•”ŠO‰ÈŠw‰ï‘‰ï‚È‚ç‚Ñ‚ÉŠwpu‰‰‰ï (2020/1/31), ‰«“ê.

731097. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ¶—Šw“IŠÏ“_‚©‚ç‚Ý‚œŽš•@ˆôA‰Èf—Á|•@ƒAƒŒƒ‹ƒM[E‡–°áŠQ‚𒆐S‚Ɂ|. ‘å–ØŠ²•¶1,2 (1Žš•@ˆôAE“ªèòŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): •œ¬31”N“x‘ŠŽš‰ï‘‰ïE‹L”Ou‰‰‰ï (2019/4/7), Vh.

731098. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) “ªèò•”Šàf—Â̒áNP‰». ŽR‰º@‘ñ (Žš•@ˆôAE“ªèòŠO):’¬“cŽsŽš•@‰Èˆã‰ïŠwpu‰‰‰ï (2019/7/31), “Œ‹ž.

731099. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) “ªèò•”Šà—̈æ‚É‚š‚¯‚éICI’·ŠúŽg—p—á‚ÆirAE‚ÌŒoŒ±. ‹{–{r•ã1, Œ–؁@’1, ‰Á”[Fˆê1, ’ç@ãĕœ2, —é–؈»Žq1, –àŽR•Û1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): Kitasato Immuno-Oncology Seminar (2019/7/12), ‘Š–ÍŒŽ.

731100. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) “ªèò•”Šà‚ɑ΂·‚é’áNPŽ¡—Âɂ‚¢‚Ä. ŽR‰º@‘ñ (Žš•@ˆôAE“ªèòŠO): ‘æ20‰ñ“¿“‡Œ§Žš•@ˆôA‰ÈŽŸŠ³Œ€‹†‰ï (2020/2/6), “¿“‡.

732095. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒ~ƒjƒŒƒNƒ`ƒƒ[) ƒAƒŒƒ‹ƒM[«•@‰Š‚ÌŽ¡—Á|–k—¢‘åŠw•a‰@‚̏ꍇ|. —é–Ø—§r (Žš•@ˆôAE“ªèòŠO): ‘æ18‰ñ“ìŠÖ“ŒŽš•@ˆôA‰ÈE“ªèò•”uK‰ï (2019/5/17), “Œ‹ž.

732096. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (‹³ˆçƒpƒlƒ‹)ug‚ß‚Ü‚¢h‚̃gƒŠƒZƒc (Žæˆµ‚¢à–Ÿ‘)v–k—¢‘åŠw•ûŽ®‚ß‚Ü‚¢ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“. —Ž‡@“Ö (Žš•@ˆôAE“ªèòŠO): “ú–{Žš•@ˆôA‰ÈŠw‰ï_“ސ쌧’n•û•”‰ï‘æ187‰ñŽš•@ˆôA‰ÈE“ªèò•”ŠO‰ÈŠwpu‰‰‰ï (2019/6/29), ‰¡•l.

732097. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒZƒ~ƒi[) “ªèò•”Šà—̈æ‚É‚š‚¯‚éICI’·ŠúŽg—p—á‚ÆirAE‚ÌŒoŒ±. ‹{–{r•ã1, Œ–؁@’1, ‰Á”[Fˆê1, ’ç@ãĕœ2, —é–؈»Žq1, –àŽR•Û1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): Kitasato immuno-oncology Seminar (2019/7/12), ‘Š–Í‘å–ì.

732098. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (‹³ˆçu‰‰) ‡–°Žž–³ŒÄ‹z‚ɑ΂µ“ú‹A‚èŽèpŽ{sŒãˆô“ªoŒŒ‚É‚æ‚è‹~‹}Žóf‚µ‚œÇ—á. ”g‘œ–ì‰l‘Ÿ (Žš•@ˆôAE“ªèòŠO): ‘æ8‰ñSleep surgeryŒ€‹†‰ï (2019/9/13), ‘啪.

732099. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (‹³ˆçu‰‰) “«ˆôA“ªŽŸŠ³‚̐f’f‚Ƒ΍ô. ‹{‰ºŒ\ˆê (Žš•@ˆôAE“ªèòŠO): ‘æ5‰ñé‹ÊŒ§‰›’nˆæŽš•@ˆôA‰ÈŒ€‹†‰ï (2019/10), –k–{.

732100. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒZƒ~ƒi[) “ï’®‚ÌŠî‘b‚ƗՏ°`“`‰¹“ï’®‚É‚æ‚é’®ŠoáŠQ‚Æ‚»‚Ì•a‘ԉ𖟁`. ŒI‰ª—²b (Žš•@ˆôAE“ªèòŠO): _“ސ쎚•@ˆôA‰ÈƒZƒ~ƒi[ (2019/11/8), ‰¡•l.

733249. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‰îŒì˜Vl•ÛŒ’Ž{Ý“üŠŽÒ‚Ì•â’®ŠíŽŽ’®@‘æ“ñ•ñ|•â’®Ší“K‡‚ÌŽŽ’®‚ÌŒ‹‰Ê|. ˆäã—ŠG (Žš•@ˆôAE“ªèòŠO): •œ¬31”N“x‘ŠŽš‰ï‘‰ïE‹L”Ou‰‰‰ï (2019/4/7), Vh.

733250. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) •›ˆô“ªŠÔŒ„Žîá‡120—á‚É‚š‚¯‚ép‘O‰æ‘œf’f‚ƐúŽh‹zˆø×–Ef‚ÌŒŸ“¢. Œ–؁@’ (Žš•@ˆôAE“ªèòŠO): •œ¬31”N“x‘ŠŽš‰ï‘‰ïE‹L”Ou‰‰‰ï (2019/4/7), Vh.

733251. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “ªèò•”Šà‚ƐH“¹Šà‚Ì“¯Žž«d•¡Šà‚ɑ΂·‚鎡—ÂɊւ·‚éŒã•ûŽ‹“IŒŸ“¢. ‰ª–{—·l (Žš•@ˆôAE“ªèòŠO): •œ¬31”N“x‘ŠŽš‰ï‘‰ïE‹L”Ou‰‰‰ï (2019/4/7), Vh.

733252. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) º‘ÑŽ‰–b’“üŒã‚ÉŠŽõ‚ð‹N‚±‚µ‹CŠÇØŠJŽ{s‚µ‚œÇ—á. ×–ì_Žj1, –Ø‘ºŽé—¢1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO): ‘æ40‰ñ“Œ“ú–{‰¹ºŠO‰ÈŒ€‹†‰ï (2019/4/13), “Œ‹ž.

733253. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ˆô“ªH“¹•\ÝŠà‚ɑ΂·‚éŒoŒû“IŽèp‚̈À‘S«‚Æ—LŒø«‚ÌŒŸ“¢. ‰Á”[Fˆê1, Œ˜“ce—˜2, ˆêŒË¹–Ÿ3, ÎŒËŒªŽŸ2, ‹{–{r•ã1, Ž–ì—R”y1, ’ç@ãĕœ4, —é–؈»Žq1, –àŽR•Û1, ŒŽ“c—YŠî1, “c糁@‘2,5, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2Á‰»Ší“à, 3•a—, 4‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 5V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ20‰ñ“ªèò•”•\ÝŠàŒ€‹†‰ï (2019/5/25), •iì.

733254. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) A“ª•a•Ï‚ÌŠàE”ñŠà‚̊ӕʐf’f‚É‚š‚¯‚éNBIŠg‘åŠÏŽ@‚Ì—L—p«. ×–ì_Žj1, Œ˜“ce—˜2, ‰Á”[Fˆê1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2Á‰»Ší“à): ‘æ20‰ñ“ªèò•”•\ÝŠàŒ€‹†‰ï (2019/5/25), “Œ‹ž.

733255. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‡–°Žž–³ŒÄ‹z‚ɑ΂µ“ú‹A‚èŽèpŽ{sŒãˆô“ªoŒŒ‚É‚æ‚è‹~‹}Žóf‚µ‚œ1Ç—á. ”g‘œ–ì‰l‘Ÿ1,2, ‘å–ØŠ²•¶1,2, ‘å‹ŽŒ’‘Ÿ˜Y1,2, ‹{‰ºŒ\ˆê1 (1Žš•@ˆôAE“ªèòŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ132‰ñ“ú–{Žš•@ˆôA‰ÈŠw‰ïé‹ÊŒ§’n•û•”‰ï (2019/6), ‰Y˜a.

733256. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‘˜_Eš‹‰º‘¢‰eŒŸž (VF) ‚ÌŽg—p–@‚ƑΉž–@. Ž–ì—R”y (Žš•@ˆôAE“ªèòŠO): ‘æ26‰ñ“úŽš•@_“ސ욋‰ºŒ€‹†‰ï (2019/6/8), ‰¡•l.

733257. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “–‰È‚É‚š‚¯‚éš‹‰ºf—Á`Ç—á‚©‚çl‚Š‚é`. Ž–ì—R”y (Žš•@ˆôAE“ªèòŠO): ‘æ88‰ñ‘Š•Žš•@‰ÈŒ€‹†‰ï (2019/6/22), Œú–Ø.

733258. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “–‰È‚É‚š‚¯‚é•â’®Šíf—Á|ŽÀŽš‘}“ü—˜“Ÿ‚É‚æ‚é•]‰¿‚𒆐S‚Ɂ|. ŒÃ–؏Ȍá1, ²–ì@”£2, ŒI‰ª—²b1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2ˆã—Éq¶Šw•”): ‘æ88‰ñ‘Š•Žš•@‰ÈŒ€‹†‰ï (2019/6/22), Œú–Ø.

733259. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) —Œ‘€‰º‹ÉŒ^G“ŽüˆÍ”^ᇂɑ΂µ‚Ä‘ŠŽž”^ᇝG““Eop‚ðs‚Á‚œ1—á. ŽR–{Œ«Œá1, Œ–؁@’1, ‹{“‡—æŽq1, Ž–ì—R”y1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO): “ú–{Žš•@ˆôA‰ÈŠw‰ï_“ސ쌧’n•û•”‰ï‘æ187‰ñŽš•@ˆôA‰ÈE“ªèò•”ŠO‰ÈŠwpu‰‰‰ï (2019/6/29), ‰¡•l.

733260. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) –k—¢‘åŠw•ûŽ®‚ß‚Ü‚¢ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“. —Ž‡@“Ö (Žš•@ˆôAE“ªèòŠO): “ú–{Žš•@ˆôA‰ÈŠw‰ï_“ސ쌧’n•û•”‰ï‘æ187‰ñŽš•@ˆôA‰ÈE“ªèò•”ŠO‰ÈŠwpu‰‰‰ï (2019/6/29), ‰¡•l.

733261. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “`‰¹“ï’®‚ª“àŽš‚É‹y‚Ú‚·‰e‹¿‚ɂ‚¢‚Ä. ŒI‰ª—²b1, –Ζ؍¹ç‘ã2, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2¶•š•š—Œn): ‘æ37‰ñŽš•@ˆôA‰Èƒjƒ…[ƒƒTƒCƒGƒ“ƒXŒ€‹†‰ï (2019/8/24), ‘åã.

733262. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) º‚ɂ‚¢‚Ä‚Ì‚š˜b. ‰iˆä_–€ (Žš•@ˆôAE“ªèòŠO): ‘å˜aŽsŽs–¯uÀ (2019/9/21), ‘å˜a.

733263. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “–‰È‚É‚š‚¯‚éƒXƒM‰Ô•²RŒŽã‰º–Ɖu—Ö@‚ÌŒø‰Ê. ‘å–ØŠ²•¶1,2, ‘å‹ŽŒ’‘Ÿ˜Y1,2, ‹{‰ºŒ\ˆê1, ”g‘œ–ì‰l‘Ÿ1,2 (1Žš•@ˆôAE“ªèòŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ133‰ñ“ú–{Žš•@ˆôA‰ÈŠw‰ïé‹ÊŒ§’n•û•”‰ï (2019/10/7), ‰Y˜a.

733264. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ’Ž‚—îŽÐ‰ï‚É‚š‚¯‚é“ï’®‚ւ̑Ήž|—v‰îŒì‚—îŽÒ‚Ì•â’®ƒj[ƒY‚Æ•â’®Ší‘•—pŒø‰Ê‚ÌŒ€‹†‚̐¬‰Ê‚ð‚à‚ƂɁ|. —é–ØŒbŽq1, ˆäã—ŠG, ”~ŒŽKŒb, `@ŽáØ1, Ž…@•œ, ²–ì@”£1, ’†ì‹Mm2, ‰ª–{–ql, ŽR‰º@‘ñ2 (1ˆã—Éq¶Šw•”, 2Žš•@ˆôAE“ªèòŠO): ‘æ42‰ñ•â’®Œ€‹†‰ï (2019/11/7), ‘åã.

733265. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) Ç—á‚©‚猩‚œš‹‰º“àŽ‹‹ŸŒŸž‚ÌŽg—p–@‚ƑΉž–@. ‰iˆä_–€ (Žš•@ˆôAE“ªèòŠO): ‘æ28‰ñ“úŽš•@_“ސ욋‰ºŒ€‹†‰ï (2019/11/30), ‰¡•l.

733266. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) Š{ŠÖß”^ᇂðŒ_‹@‚É”­Œ©‚³‚ê‚œ‰ŠÇ«’°ŽŸŠ³‚̈ê—á. óŒÃ—L‹IŽq1, “¡ì’Œ–ç1, ŒÃ–؏Ȍá1, ‹{–{r•ã1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO): “ú–{Žš•@ˆôA‰ÈŠw‰ï_“ސ쌧’n•û•”‰ï‘æ189‰ñŽš•@ˆôA‰ÈE“ªèò•”ŠO‰ÈŠwpu‰‰‰ï (2019/12/7), ‰¡•l.

733267. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ŒûO‚š‚æ‚Ñ‘œ”­èò•”Žîᎂð’悵‚œ“î•”DŽ_‹…“÷‰èŽî (–Ø‘º•a) ‚Ì1—á. ‹{“‡—æŽq1, Ž–ì—R”y1, ‰iˆä_–€1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO): ‘æ189‰ñ“ú–{Žš•@ˆôA‰ÈŠw‰ï_“ސ쌧’n•û•”‰ï (2019/12/7), ‰¡•l.

733268. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ¬Ž™ƒƒjƒG[ƒ‹•a‚ւ̌ܗèŽU“Š—^—á. —Ž‡@“Ö (Žš•@ˆôAE“ªèòŠO): ‘æ37‰ñ‚³‚ª‚ÝŠ¿•û§˜b‰ï (2019), ’¬“c.

'18”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'18-110018. [ŒŽ’˜] Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma. Takahashi H, Tada Y, Saotome T, Akazawa K, Ojiri H, Fushimi C, Masubuchi T, Matsuki T1, Tani K, Osamura RY, Hirai H, Yamada S, Kawakita D, Miura K, Kamata S, Nagao T: J Clin Oncol 2019/1; 37 (2): 125-34. (Œ–؁@’1: 1Žš•@ˆôAE“ªèòŠO)

'18-120004. [ŒŽ’˜] ¬Ž™•@•›•@oŽŸŠ³‚ɑ΂·‚é•@oôò—Ö@‚ɂ‚¢‚Ä. ‘å–ØŠ²•¶1,2, —é–Ø—§r2, ‚–ì@èñ (1Žš•@ˆôAE“ªèòŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): “ú–{Žš•@ˆôA‰ÈŠŽõÇEƒGƒAƒƒ]ƒ‹Šw‰ï‰ïŽ 2019/1; 7 (1): 17-20.

'18-320005. [Ç—á•ñ] ŒŸŒê‚ªˆÙ‚È‚èƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“‚ª¢“ï‚Å‚ ‚Á‚œèò•””^ᇂÌ1Ç—á. ’†‘º‹g¬1, ‘å–ØŠ²•¶1,2, ‘å‹ŽŒ’‘Ÿ˜Y1,2, ‹{‰ºŒ\ˆê1, —é–Ø—§r1, ŽR‰º@‘ñ1 (1Žš•@ˆôAE“ªèòŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): “ú–{Žš•@ˆôA‰ÈŠŽõÇEƒGƒAƒƒ]ƒ‹Šw‰ï‰ïŽ 2019/1; 7 (1); 42-6.

[Šw‰ïEŒ€‹†‰ï“™]

H29-723005. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‡–°Žž–³ŒÄ‹zÇŠ³ŽÒ‚Ì•@ƒAƒŒƒ‹ƒM[‚ÌŠÖŒW‚ƋǏŠƒXƒeƒƒCƒh“_•@–ò‚Ì—L—p«. ‘å–ØŠ²•¶1, —é–Ø—§r1 (1Žš•@ˆôAE“ªèòŠO): ‘æ36‰ñ“ú–{Žš•@ˆôA‰È–ƉuƒAƒŒƒ‹ƒM[Šw‰ï (2018/2/22-24), ‰ºŠÖ.

H29-723006. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’†ˆô“ªŠà‚ɑ΂·‚éTLO, TOVSŒã‚Ìš‹‰º‹@”\. Ž–ì—R”y (Žš•@ˆôAE“ªèòŠO): ‘æ30‰ñ“ú–{A“ª‰ÈŠw‰ï‘‰ïEŠwpu‰‰‰ï (2018/3/1), ‚’m.

'18-723020. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒXƒM‰Ô•²ÇŠ³ŽÒ‚É‚š‚¯‚é•â•—Ö@‚Æ‚µ‚Ă̍‚’£H‰–…ôò‚̈Ӌ`. ‘å–ØŠ²•¶1,2, —é–Ø—§r1 (1Žš•@ˆôAE“ªèòŠO, 2–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘æ37‰ñ“ú–{Žš•@ˆôA‰È–ƉuƒAƒŒƒ‹ƒM[Šw‰ï (2019/2/7-9), ‘åã.

'18-723021. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’†ˆô“ª”S–Œ‰ºŽîᇂɑ΂·‚éŒoŒû“IØœpŒã‚“xš‹‰ºáŠQ—á‚ÌŒP—ûŒo‰ß|‚‰ð‘œ“xƒ}ƒmƒƒgƒŠ[‚É‚æ‚é‰ðÍ|. ’J‡Mˆê, •y“¡‰ë”V, –Ø‘ºŽé—¢1, Œ–ì’ŒŽ÷, r–؍Km, ŽÄ–{@—E, ‰–’J²_ (1Žš•@ˆôAE“ªèòŠO): ‘æ42‰ñ“ú–{š‹‰ºˆãŠw‰ï‘‰ï‚È‚ç‚Ñ‚ÉŠwpu‰‰‰ï (2019/3/9), ‹v—¯•Ä.


ž_‰ÈŠw

[Šwp˜_•¶]

110330. [ŒŽ’˜] Associations between readmission and patient-reported measures in acute psychiatric inpatients: a study protocol for a multicenter prospective longitudinal study (the ePOP-J study). Yamaguchi S, Ojio Y, Koike J, Matsunaga A, Ogawa M, Tachimori H, Kikuchi A, Kimura H, Inagaki A, Watanabe H, Kishi Y, Yoshida K, Hirooka T1, Oishi S1, Matsuda Y, Fujii C: Int J Ment Health Syst 2019/6; 13: 40. (œA‰ªF—z1, ‘åÎ@’q1: 1ž_)

110331. [ŒŽ’˜] Improvement of psychiatrists' clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the 'Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)' project: A nationwide dissemination, education, and evaluation study. Takaesu Y, Watanabe K, Numata S, Iwata M, Kudo N, Oishi S1, Takizawa T1, Nemoto K, Yasuda Y, Tagata H, Tsuboi T, Tsujino N, Hashimoto N, Matsui Y, Hori H, Yamamori H, Sugiyama N, Suwa T, Kishimoto T, Hishimoto A, Usami M, Furihata R, Iwamoto K, Fujishiro H, Nakamura T, Mizuno K, Inagaki T, Katsumoto E, Tomita H, Ohi K, Muraoka H, Atake K,Iida H, Nagasawa T, Fujita J, Yamamura S, Onitsuka T, Murata A, Takayanagi Y, Noda H, Matsumura Y, Takezawa K, Iga J, Ichihashi K, Ogasawara K, Yamada H, Inada K, Hashimoto R: Psychiatry Clin Neurosci 2019/10; 73 (10): 642-8. (‘åÎ@’q1, ‘êàV‹B–î1: 1ž_)

110332. [ŒŽ’˜] A retrospective study on the diagnosis and treatment of dementia in patients referred to the Sagamihara Municipal Medical Center for Dementia for consultation. Kyou Y1,2, Oishi S2, Takizawa T2, Suzuki R2, Nakamura N3, Arai H2, Miyaoka 2: Psychogeriatrics 2020/5; 20 (3): 247-53. doi: 10.1111/psyg.12491. Epub 2019 Dec 4. (›I@‘P‹M1,2, ‘åÎ@’q2, ‘êàV‹B–î2, —é–Ø—Ž‘Ÿ˜Y2, ’†‘º“Þ“Þ3, Vˆä‹v–«2, ‹{‰ª@“™2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ž_, 3“Œ•a‰@ƒ\[ƒVƒƒƒ‹ƒ[ƒNŽº)

120034. [ŒŽ’˜] ¬lŽ©•ÂƒXƒyƒNƒgƒ‰ƒ€Çf’f‚ÆP-FƒXƒ^ƒfƒB‚̏W’cˆê’v“x‚ÌŠÖ˜A. ˆäãŸ•v1, •ûŒcŽO˜Y1, ‘êàV‹B–î1, ‹{‰ª@“™1 (1ž_): –k—¢ˆãŠw 2019/12; 49 (2): 79-85.

120035. [ŒŽ’˜] ‹~–œ‹~‹}ƒZƒ“ƒ^[‚É‚š‚¯‚éŽh‘nE’Ä—ŽŠOŽ©ŽEŠé}“ü‰@Š³ŽÒ‚̗Տ°“I“Á’¥. Vˆä‹v–«1, •Ð‰ª—Sˆê2, ˆäãŸ•v1, ‘êàV‹B–î1, ‘åÎ@’q1, ‰Ô“‡@Ž‘2, ó—˜@–õ2, ‹{‰ª@“™1 (1ž_, 2‹~–œ): ž_ˆãŠw 2019/12; 61 (12): 1485-92.

120036. [ŒŽ’˜] Žs–¯‚ð‘ΏۂƂµ‚œ”F’mÇŒ€C‚É‚æ‚éŽóuŽÒ‚Ì”F’mÇ‚Ö‚Ì—‰ð‚Ì’²ž‚ɂ‚¢‚ā|Ž–‘OEŽ–Œã‚ÌŽ¿–â•[’²ž‚©‚ç|. ›I@‘P‹M1,2, ‘åÎ@’q2, ˆäã•üŽq1,2, “‡–ì•ü–ç1,2, ’©‘q’•¶1,2, ‘êàV‹B–î2, ‹{‰ª@“™2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ž_): ˜V”Nž_ˆãŠwŽGŽ 2019/12; 30 (12): 1387-96.

320042. [Ç—á•ñ] •\o«ŒŸŒêáŠQŽ™‚̏áŠQ”wŒi: ”­˜b”œ‰ž‚Ɖ¹‰C”FŽ¯‚š‚æ‚Ñ•¶ŽšK“Ÿ‚ÌŠÖ˜A‚©‚ç. ŽÄ@—æŽq, “¡ŒŽ‰Á“ލ], ˆäãŸ•v1, ˜a“c^—Žq, ‘åÎŒhŽq (1ž_): ƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“áŠQŠw 2019/4; 36 (1): 1-9.

520017. [‘à] ƒvƒ‰ƒCƒ}ƒŠƒPƒA‚Å’ˆÓ‚µ‚Ä‚Ù‚µ‚¢ž_Çó‚̐f•û‚ƑΉž. ‹{‰ª@“™ (ž_): ‚’mŒ§ˆãŽ 2020/1; 25 (1): 68-75.

520018. [‘à] Basic Outcome Master (BOM) version 3.0‚̉ü’ù•ûj‚ƈӋ`. ’¬“c“ñ˜Y, ‰Í‘º@i, ˆä“àˆè‘ã, ˆÉ“¡~“ñ, ‘åÎ@’q1, ‰º‘º—TŒ©Žq, ‰ª–{‘׊x, ²“¡kˆê˜Y, “‡“c@Œ³, ”’’¹‹`@, ät“cçH, ’†“‡’ŒŽ÷, ‹g–{ç’ß, Žá“cDŽj, ‰ª•õ‰hŽq, ¬ÈK’j, ’†ŒF‰p‹M, Œ‰ª’q”ü, Xè^”ü, –x“ct”ü, •›“‡G‹v (1ž_): “ú–{ƒNƒŠƒjƒJƒ‹ƒpƒXŠw‰ïŽ 2020/3; 22 (1): 3-13.

522112. [uÀ]y“ÁW: –òÜŽt‚Ȃ猩“Š‚µŒµ‹Ö!@Œüž_–ò‚Ì•›ì—p‚Æ–òÜ«ž_Çóz“ÁW‚É‚ ‚œ‚Á‚Ä. ‹{‰ª@“™ (ž_): ŒŽŠÔ–òŽ– 2019/5; 61 (6): 15-6.

522113. [uÀ]y“ÁW: –òÜŽt‚Ȃ猩“Š‚µŒµ‹Ö!@Œüž_–ò‚Ì•›ì—p‚Æ–òÜ«ž_ÇózŒüž_–ò—Ö@‚ÌŒ»ó‚Æ–â‘è“_. ‹{‰ª@“™ (ž_): ŒŽŠÔ–òŽ– 2019/5; 61 (6): 17-20.

522114. [uÀ]y“ÁW: –òÜŽt‚Ȃ猩“Š‚µŒµ‹Ö!@Œüž_–ò‚Ì•›ì—p‚Æ–òÜ«ž_Çóz’ˆÓ‚·‚ׂ«Œüž_–ò‚ÌŒx, ‹ÖŠõ|ˆ•û‘O‚ÉŠm”F‚·‚ׂ«‰Û‘è. œA‰ªF—z (ž_): ŒŽŠÔ–òŽ– 2019/5; 61 (6): 21-30.

522115. [uÀ]y“ÁW: –òÜŽt‚Ȃ猩“Š‚µŒµ‹Ö!@Œüž_–ò‚Ì•›ì—p‚Æ–òÜ«ž_Çózˆ•û‚Ì–â‘è‚ð‚Ç‚€ˆãŽt‚É“`‚Š‚é‚©: ž_‰Èˆã‚Ì—§ê‚©‚ç. ‹{‰ª@“™ (ž_): ŒŽŠÔ–òŽ– 2019/5; 61 (6): 84-6.

522116. [uÀ]y“ÁW: Šë‹@ŠÇ—‚Æ•›Z’·E‹³“ª ƒp[ƒg1zŽ‹“_…A@Ž™“¶‹s‘Ò‚Ì”­Šo, ‚¢‚¶‚ß, Žq‹Ÿ‚ªŽ©ŽE‚µ‚œ‚Æ‚«‚ÌŠwZ‚ÌŠë‹@‘Ήž. ˆäãŸ•v (ž_): ŠwZ‰^‰c 2019/5; 694: 16-9.

522117. [uÀ]y“Á•ÊŠé‰æ: s“®‚̃AƒfƒBƒNƒVƒ‡ƒ“|uƒnƒ}‚év‚ðl‚Š‚éz¥uƒnƒ}‚év‚Æ‚¢‚€Œ»Û@‚»‚à‚»‚àuƒnƒ}‚év‚Ƃ͉œ‚©|us“®v‚ōl‚Š‚é. Š—¶—TŽi (ž_): ‚±‚±‚ë‚̉Ȋw 2019/5; 205: 17.

522118. [uÀ]y<‘æ59‰ñ“ú–{SgˆãŠw‰ï‘‰ï‚È‚ç‚Ñ‚ÉŠwpu‰‰‰ï>@ƒVƒ“ƒ|ƒWƒEƒ€: ‘ål‚Ì”­’BáŠQ: —Տ°‚Ì’m‚Æ•a‘ԍőOüz‘ål‚Ì”­’BáŠQ‚Ɛž_ŽŸŠ³‚̊ӕʂƍ‡•¹|‚»‚̈Ӌ`|. ‹{‰ª@“™1, ¬ì—zŽq (1ž_): SgˆãŠw 2019/7; 59 (5): 416-21.

522119. [uÀ]y“ÁW: Šë‹@ŠÇ—‚Æ•›Z’·E‹³“ª ƒp[ƒg2zŽ‹“_…A@‚¢‚¶‚ß‚ÌŠî–{“I—‰ð, —\–h‚Æ‘Šú”­Œ©EDV‰Æ’ë‚ÌŽ™“¶E¶“k‚Ì”íŠQ‚ð‚݂‚¯‚œ‚Æ‚«. ˆäãŸ•v (ž_): ŠwZ‰^‰c 2019/8; 697: 16-9.

522120. [uÀ]y“ÁW: ž_‰ÈŽ¡—Âł±‚ñ‚È‚±‚Æ‚ð‚µ‚Ä‚¢‚Ü‚¹‚ñ‚©?|ˆã—ʵK‚âgŒä–@“xh‚ðÄl|zƒ`ƒFƒbƒNƒŠƒXƒg‚Ÿ‚¯‚Őf’f‚ðŠm’肵‚Ä‚¢‚Ü‚¹‚ñ‚©? “V•Û‰p–Ÿ (ž_): ž_‰ÈŽ¡—Êw 2019/8; 34 (8): 861-4.

522121. [uÀ]y“ÁW: _Œo”­’BÇ‚̍ŐVƒgƒsƒbƒNƒX|f—ÁEŽx‰‡EŽÐ‰ïz<_Œo”­’BÇ‚̍L‚ª>@_Œo”­’BÇŒQ‚ƃp[ƒ\ƒiƒŠƒeƒBáŠQŒQ|‚Ç‚€l‚Š, ‰œ‚ð‹c˜_‚µ, ‰œ‚ðs‚€‚ׂ«‚©|. ˆäãŸ•v (ž_): —Տ°ž_ˆãŠw 2019/10; 48 (10): 1179-85.

522122. [uÀ]yPsychiatric Lecturezf’fEŒŸž@Ž©•ÂƒXƒyƒNƒgƒ‰ƒ€Çf’f‚É‚š‚¯‚éæ“üŠÏ‚̍Ž•ž. ˆäãŸ•v (ž_): ž_‰È—Տ° Legato 2019/11; 5 (3): 28-31.

522123. [uÀ]y“ÁWII: ¡‚³‚çl‚É•·‚¯‚È‚¢‚Ä‚ñ‚©‚ñf—ẪNƒGƒXƒ`ƒ‡ƒ“z‚Ä‚ñ‚©‚ñ”­ìŒã”]”g‚ª³í‰»‚·‚邱‚Æ‚ª‚ ‚é‚Ì‚Í? âV“¡³”Í (ž_): ž_‰È (S—Óà‰È) 2019/12; 35 (6): 579-83.

522124. [uÀ]y“ÁW: ž_‰È—Տ°‚É‚š‚¯‚éƒGƒrƒfƒ“ƒX‚Ì—L—p«‚Æ–â‘è“_zComorbidity ‚̐f’f‚͗Տ°ã‚Ç‚Ì‚æ‚€‚ȈӖ¡‚ª‚ ‚é‚Ì‚Ÿ‚ë‚€‚©. ‹{‰ª@“™ (ž_): ž_‰ÈŽ¡—Êw 2020/2; 35 (2): 153-5.

540074. [‚»‚Ì‘Œ (•ÒW)]y“Á•ÊŠé‰æ: s“®‚̃AƒfƒBƒNƒVƒ‡ƒ“|uƒnƒ}‚év‚ðl‚Š‚ézŠ—¶—TŽi1, ‹{‰ª@“™1 (1ž_): ‚±‚±‚ë‚̉Ȋw 2019/5; 205: 17•Å.

[Šw‰ïEŒ€‹†‰ï“™]

722218. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ¬lŽ©•ÂƒXƒyƒNƒgƒ‰ƒ€Ç—Տ°‚É‚š‚¯‚éS—E‚Ì–ðŠ„. ˆäãŸ•v (ž_): ‘æ115‰ñ“ú–{ž__ŒoŠw‰ïŠwp‘‰ï (2019/6/21), VŠƒ.

722219. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Œüž_–ò‚É‚æ‚é‹}«–ò•š’†“ÅŠ³ŽÒ‚̑Ήž‚ÉŠÖ‚µ‚Ä‹~–œ‹~‹}‚Ɛž_‰Èˆã—Ë@ŠÖ‚ł̘AŒg‚̉ۑè. Vˆä‹v–« (ž_): ‘æ41‰ñ“ú–{’†“ÅŠw‰ï‘‰ïEŠwpW‰ï (2019/7/20-21), ì‰z.

722220. [Šw‰ï (‘S‘)] (“Á•ÊŠé‰æ ƒZƒbƒVƒ‡ƒ“) SgˆãŠw‚ðê–å‚Æ‚·‚éˆãŽt‚É’m‚Á‚Ä‚à‚ç‚¢‚œ‚¢‚±‚Æ2@ž_ˆãŠw‚©‚ç. ‹{‰ª@“™1, ‹vZˆê˜Y, ˆäãK‹I (1ž_): ‘æ2‰ñ“ú–{SgˆãŠwŠÖ˜AŠw‰ï‡“¯W‰ï (2019/11/15), ‘åã.

722221. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™)yÀ’·z‘‡•a‰@‚É‚š‚¯‚éˆãŠw¶, ŽáŽèˆãŽt‚ɑ΂·‚鎙“¶ž_‰È—Տ°‚Ì‹³ˆç‚ðl‚Š‚é. ˆäãŸ•v (ž_): ‘æ32‰ñ“ú–{‘‡•a‰@ž_ˆãŠw‰ï‘‰ï (2019/11/15), ‘q•~.

723744. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’nˆæ‘‡•a‰@‚ł̐S—Óà‰È (ž_‰È) ŠO—ˆ‚É‚š‚¯‚é˜V”NŠúž_ŽŸŠ³‚̗Տ°“I“Á’¥. Vˆä‹v–«1, ‰Á“¡Œ[Žq, ‘å‹v•Û’z¢, “à“c@–], ‹{‰ª@“™1 (1ž_): ‘æ34‰ñ“ú–{˜V”Nž_ˆãŠw‰ï (2019/6/6-8), å‘ä.

723745. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”F’mÇŠ³ŽÒ‚̉Ƒ°‰îŒìŽÒ‚ɑ΂·‚éS—‹³ˆçƒvƒƒOƒ‰ƒ€‚Ì—LŒø«‚ÌŒŸ“¢. ›I@‘P‹M1, ‘åÎ@’q1, ‘êàV‹B–î1, ‹{‰ª@“™1 (1ž_): ‘æ115‰ñ“ú–{ž__ŒoŠw‰ïŠwp‘‰ï (2019/6/20), VŠƒ.

723746. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’nˆæ‚É‚š‚¯‚鑍‡•a‰@‚ł̐S—Óà‰È (ž_‰È) ŠO—ˆ‚É‚š‚¯‚é—Տ°“I“Á’¥. Vˆä‹v–«1, ‰Á“¡Œ[Žq, ‘å‹v•Û’z¢, “à“c@–], ‹{‰ª@“™1 (1ž_): ‘æ115‰ñ“ú–{ž__ŒoŠw‰ïŠwp‘‰ï (2019/6/20), VŠƒ.

723747. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “d‹C‚¯‚¢‚ê‚ñ—Ö@‚É‚š‚¯‚éŽg‚¢ŽÌ‚Ä“d‹Éƒpƒbƒh‚̔畆’ïR‚ð‰º‚°‚é‚œ‚ß‚ÉŽg—p‚·‚é–òÜ‚̉î“üŒ€‹†. “‡–ì•ü–ç1, àVŽRŒb”g1, ‰ÄŽR@‘ì2, ‘åÎ@’q1, âV“¡³”Í1, “c’†Žr2, ‹{‰ª@“™1 (1ž_, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ115‰ñ“ú–{ž__ŒoŠw‰ïŠwp‘‰ï (2019/6/21), VŠƒ.

723748. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘åŠw•a‰@‚É‚š‚¯‚éšn•ÈáŠQŠ³ŽÒ‚ɑ΂·‚éW’c—Ö@‚Ì“Á’¥ (–k—¢‘åŠw“Œ•a‰@‚̏ꍇ). ’©‘q’•¶1 í‰ªrº, Ž›“‡—æ“Þ, •ûŒcŽO˜Y2, Š—¶—TŽi1, ‘åÎ@’q1, Œ–{r•F, ‹{‰ª@“™1 (1ž_, 2—Տ°S—Žº): ‘æ115‰ñ“ú–{ž__ŒoŠw‰ïŠwp‘‰ï (2019/6/21), VŠƒ.

723749. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) eŽqƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“Žx‰‡‚Ì‚œ‚ß‚ÌSSTƒvƒƒOƒ‰ƒ€‚ÌŠJ”­‹y‚ÑŒø‰ÊŒ€‹†. äwŒŽ‘ã, ‚‹Ž@Œb1, Ž…—L, ‰·…”ü—R‹I (1ž_): ‘æ19‰ñ“ú–{”F’m—Ö@E”F’ms“®—Ö@Šw‰ï (2019/8/30), “Œ‹ž.

723750. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ž_‰È•a“‚É“ü‰@‚Æ‚È‚Á‚œ_Œo«–³H—~ÇŠ³ŽÒ‚ÌŽ¡—Á|Sg—Œ–ʂւ̑Ήž|. Vˆä‹v–«1, ‘åÎ@’q1, ŸNˆäGŽ÷1, ‘êàV‹B–î1, ˆäãŸ•v1, “V•Û‰p–Ÿ1, ‹{‰ª@“™1 (1ž_): ‘æ32‰ñ“ú–{‘‡•a‰@ž_ˆãŠw‰ï‘‰ï (2019/11/15), ‘q•~.

723751. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ž_‰È•a“‚É“ü‰@‚Æ‚È‚Á‚œdÇ_Œo«–³H—~ÇŠ³ŽÒ‚ÌŽ¡—Ã. Vˆä‹v–« (ž_): ‘æ32‰ñ“ú–{‘‡•a‰@ž_ˆãŠw‰ï‘‰ï (2019/11/15-16), ‘q•~.

723752. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘åŠw•a‰@ (‘‡•a‰@) ‚É‚š‚¯‚é•a‰@“à‚É‚š‚¯‚鎩ŽE‘΍ô‚ÉŠÖ‚µ‚Ä. Vˆä‹v–« (ž_): ‘æ32‰ñ“ú–{‘‡•a‰@ž_ˆãŠw‰ï‘‰ï (2019/11/15-16), ‘q•~.

723753. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) yÀ’·zž__Œo‰È, ƒƒ“ƒ^ƒ‹ƒwƒ‹ƒX…F. “V•Û‰p–Ÿ (ž_): ‘æ2‰ñ“ú–{SgˆãŠwŠÖ˜AŠw‰ï‡“¯W‰ï (2019/11/16), ‘åã.

723754. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) yÀ’·zž_•ªÍ“IƒAƒZƒXƒƒ“ƒg‚Æ“ûŽ™ŠÏŽ@. ˆäãŸ•v (ž_): ‘æ37‰ñ“ú–{Â”NŠúž_—Ö@Šw‰ï‘‰ï (2019/11/24), –ŒŒÃ‰®.

723755. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Œëš‹‚É‚æ‚é’‚‘§‚Ö‚Ì‹°•|‚©‚ç‘̏dŒž­‚ð‚«‚œ‚µ‚œ¬Šw¶‚ÌŽ¡—ÃŒo‰ß. ˆäãŸ•v1,2, _’Jr‰î2, ’†“‡N•ã2, ‹g—Ñ—˜•¶2, ‹{‰ª@“™1 (1ž_, 2’nˆæŽ™“¶ž_): ‘æ60‰ñ“ú–{Ž™“¶Â”Nž_ˆãŠw‰ï‘‰ï (2019/12/5), ‰«“ê.

723756. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰Æ‘°‚Ƃ͘b‚³‚È‚¢“Á’¥“I‚Èãg–ُǏó‚ð’悵‚œ’†Šw¶‚̈ê—á. ˆäãŸ•v1,2, _’Jr‰î2 ’†“‡N•ã2, ‹g—Ñ—˜•¶2, ‹{‰ª@“™1 (1ž_, 2’nˆæŽ™“¶ž_): ‘æ60‰ñ“ú–{Ž™“¶Â”Nž_ˆãŠw‰ï‘‰ï (2019/12/5), ‰«“ê.

723757. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Ž©‚çuŽ„‚̃gƒŠƒZƒcv‚ðì¬‚µ‚œŽ©•ÂƒXƒyƒNƒgƒ‰ƒ€Ç‚Z¶Ç—á‚©‚ç‚̗Տ°‹³ŒP. ˆäãŸ•v1,2, _’Jr‰î2, ’†“‡N•ã2, ‹g—Ñ—˜•¶2, ‹{‰ª@“™1 (1ž_, 2’nˆæŽ™“¶ž_): ‘æ60‰ñ“ú–{Ž™“¶Â”Nž_ˆãŠw‰ï‘‰ï (2019/12/6), ‰«“ê.

723758. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Ž™“¶ž_‰Èˆã—ÂƋ³ˆç‚É‚š‚¯‚é˜AŒgƒVƒXƒeƒ€‚Æ‚µ‚ẮuŽ™“¶ž_‰È‘Š’kŽ–‹Æv‚ÌŠˆ—p‚ÉŠÖ‚·‚éƒAƒ“ƒP[ƒg’²ž. _’Jr‰î1, ’†“‡N•ã1, ˆäãŸ•v1,2, ‹g—Ñ—˜•¶1, Î“c‹§G2, ‹{‰ª@“™2 (1’nˆæŽ™“¶ž_, 2ž_): ‘æ60‰ñ“ú–{Ž™“¶Â”Nž_ˆãŠw‰ï‘‰ï (2019/12/7), ‰«“ê.

731101. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) —Տ°ˆã‚Ì‚œ‚߂̐ž_‰Èˆã—Á`7‚‚̃|ƒCƒ“ƒg`. “V•Û‰p–Ÿ (ž_): ‘æ20‰ñ’†•”ƒƒRƒ‚ƒTƒCƒRƒ\ƒ}Œ€‹†‰ï (’†•”‰^“®ŠíSgˆã—ÃŒ€‹†‰ï: LPC) (2019/7/27), –ŒŒÃ‰®.

731102. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ‘ål‚ÆŽq‚Ç‚à‚̈ˑ¶Ç. ˆäãŸ•v (ž_): ‘æ21‰ñ“ú–{¬Ž™ž_ˆãŠwŒ€‹†‰ï‹³ˆçƒZƒ~ƒi[ (2019/8/23), _ŒË.

732101. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒvƒŒƒiƒŠ[ƒZƒbƒVƒ‡ƒ“) ƒxƒ“ƒ]ƒWƒAƒ[ƒsƒ“R•sˆÀ–òE‡–°–ò‚Ì’ˆÓ‚ÆŽg‚¢•û. ‹{‰ª@“™ (ž_): _“ސìˆãŠw‰ï‘‰ïEŠwp‘å‰ï (2019/11/23), ‰¡•l.

733269. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “ü‰@’†‚ÉŽ©ŽEŠé}‚ÉŽŠ‚Á‚œƒAƒ‹ƒR[ƒ‹Œ¶ŠoÇ‚ª‹^‚í‚ê‚œ1—á. Î“c‹§G1, Vˆä‹v–«1, ’†—¢—F1, —é–Ø—Ž‘Ÿ˜Y1, ‘åÎ@’q1, àVŽR@“§1, âV“¡³”Í1, ‹{‰ª@“™1 (1ž_): ‘æ116‰ñ“Œ‹žž_ˆãŠw‰ïŠwpW‰ï (2019/7/13), “Œ‹ž.

733270. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) –\—Í‚ÆŽ{Ý“üŠ‚É–òÜ‚ªŠÖ˜A‚µ‚œ‚ƍl‚Š‚ç‚ê‚鍂—îŽÒ‚̈ê—á. ‘åÎ@’q1, Vˆä‹v–«1, —é–Ø—Ž‘Ÿ˜Y1, Î“c‹§G1, o…—æ“Þ1, ¬ì—zŽq1, ‹Ž–{@Ž÷1, ›I@‘P‹M1, œA‰ªF—z1, ¯–ìr–í1, ˆêÂ—Ç‘Ÿ1, ²X–Ø“¹•v1, âV“¡³”Í1, ‹{‰ª@“™1 (1ž_): ‘æ49‰ñ_“ސ쌧SgˆãŠw‰ï‘‰ïEŠwpW‰ï (2019/9/14), ‰¡•l.

733271. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) yÀ’·zˆê”ʉ‰‘è. “V•Û‰p–Ÿ (ž_): ‘æ49‰ñ_“ސ쌧SgˆãŠw‰ï‘‰ïEŠwpW‰ï (2019/9/14), ‰¡•l.

733272. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) Œ¶’®‚Ì‚œ‚ß‚É“ü‰@‚ÉŽŠ‚Á‚œ“ï’®‚𔺂€‚—îŽÒ‚Ì1—á. ’†—¢—F1, Î“c‹§G1, Vˆä‹v–«1, —é–Ø—Ž‘Ÿ˜Y1, –Ø‘º—F•F1, ¬–ì@„1, ‹g—Ñ—˜•¶2, ‘åÎ@’q1, âV“¡³”Í1, ‹{‰ª@“™1 (1ž_, 2’nˆæŽ™“¶ž_): “Œ‹žž_ˆãŠw‰ï‘æ117‰ñŠwpW‰ï (2019/11/30), “Œ‹ž.

733273. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) «“I’E—}§sˆ×‚ðŒJ‚è•Ô‚µ‚œŒy“x”F’máŠQ‚Ì1—á. ¬–ì@„1, ›I@‘P‹M1, ’†—¢—F1, o…—æ“Þ1, ŸNˆäGŽ÷1, ‘åÎ@’q1, âV“¡³”Í1, ‹{‰ª@“™1 (1ž_): “Œ‹žž_ˆãŠw‰ï‘æ117‰ñŠwpW‰ï (2019/11/30), “Œ‹ž.

'18”N“xˆÈ‘O•ª

[Šwp˜_•¶]

H27-522001. [uÀ] y“ÁW: Žcˆâ‚·‚éÇó‚Í‚Ç‚±‚܂ʼnñ•œ‚·‚é‚©z“‡Žž’²Ç‚ÌŽcˆâÇó. Vˆä‹v–« (ž_): ž_‰ÈŽ¡—Êw 2015/6; 30 (6): 727-30.

'18-110019. [ŒŽ’˜] Effects of coaching skills training by occupational health staff on improving managers' communication behavior: a randomized controlled trial. Isojima M, Kimura R, Takahashi M1, Kiyotaki S, Fukuda M, Mizukoshi M, Araki H, Oshima Y, Iida D, Tanaka K2: Kitasato Med J 2018/9; 48 (2): 96-104. (‚‹Ž@Œb1, “c’†Žr2: 1ž_, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

[Šw‰ïEŒ€‹†‰ï“™]

'18-722003. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ŽY‹Æƒƒ“ƒ^ƒ‹ƒwƒ‹ƒX‚ɉž—p‚·‚éƒ}ƒCƒ“ƒhƒtƒ‹ƒlƒX‚ÆSST. ‚‹Ž@Œb (ž_): ‘æ114‰ñ“ú–{ž__ŒoŠw‰ïŠwp‘‰ï (2018/6/21), _ŒË.

'18-722004. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) S“IŠOŠ³ŽÒ‚ւ̏‰‰ñ–ʐÚ. ‚‹Ž@Œb (ž_): ‘æ114‰ñ“ú–{ž__ŒoŠw‰ïŠwp‘‰ï (2018/6/22), _ŒË.

'18-722005. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) SST (ƒ\[ƒVƒƒƒ‹EƒXƒLƒ‹ƒYEƒgƒŒ[ƒjƒ“ƒO) ‚ÌŠî‘b’mŽ¯. ‚‹Ž@Œb (ž_): ‘æ114‰ñ“ú–{ž__ŒoŠw‰ïŠwp‘‰ï (2018/6/23), _ŒË.

'18-722006. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ˆãŽtEŽY‹Æ•ÛŒ’ƒXƒ^ƒbƒt‚Ì‚œ‚ß‚ÌSST`SST“ü–å`. ‚‹Ž@Œb1, –ì––@_ (1ž_): ‘æ24‰ñSST‘S‘ŒoŒ±Œð—¬ƒ[ƒNƒVƒ‡ƒbƒv in “Œ‹ž (2018/7/29), “Œ‹ž.

'18-723022. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “ü‰@‚µ‚œ‚—îŽÒŽ{Ý“üŠŽÒ‚Ì‚¹‚ñ–Ï‚Í”F’mÇdÇ“x•ª—Þ‚ÆŠÖŒW‚·‚é. ŒŠ“c@‘, ‚‹Ž@Œb1, ”у–’J”ü•ô2, ¶‰E“c˜aŽ}, ˜a“c“Þ”üŽq (1ž_, 2”]_Œo“à): ‘æ60‰ñ“ú–{˜V”NˆãŠw‰ïŠwpW‰ï (2018/6/15), ‹ž“s.


•úŽËü‰ÈŠw (‰æ‘œf’fŠw)

[Šwp˜_•¶]

110333. [ŒŽ’˜] Effects of the scan range on radiation dose in the computed tomography component of oncology positron emission tomography/computed tomography. Inoue Y1, Nagahara K2, Kudo H2, Itoh H2: Radiat Prot Dosimetry 2019/11; 185 (1): 1-6. (ˆäã—D‰î1, ‰iŒŽ˜aŒ›2, H“¡Š°Žq2, ˆÉ“¡Š°‘×2: 1•úŽËü (‰æ‘œ), 2•úŽËü•”)

110334. [ŒŽ’˜] Effects of scout radiographic imaging conditions on tube current modulation in chest computed tomography. Inoue Y1, Itoh H2: J Radiol Prot 2020/3; 40 (1): 253-69. (ˆäã—D‰î1, ˆÉ“¡Š°‘×2: 1•úŽËü (‰æ‘œ), 2•úŽËü•”)

110335. [ŒŽ’˜] Basolateral amygdala connectivity with subgenual anterior cingulate cortex represents enhanced fear-related memory encoding in anxious humans. Hakamata Y, Mizukami S, Izawa S, Moriguchi Y, Hori H, Kim Y, Hanakawa T, Inoue Y1, Tagaya H2: Biol Psychiatry Cogn Neurosci Neuroimaging 2020/3; 5 (3): 301-10. (ˆäã—D‰î1, “cƒ–’J_–M2: 1•úŽËü (‰æ‘œ), 2ˆã—Éq¶Šw•”)

110336. [ŒŽ’˜] Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial. Hirota M, Shimosegawa T, Kitamura K, Takeda K, Takeyama Y, Mayumi T, Ito T, Takenaka M, Iwasaki E, Sawano H, Ishida E, Miura S, Masamune A, Nakai Y, Mitoro A, Maguchi H, Kimura K, Sanuki T, Ito T, Haradome H1, Kozaka K, Gabata T, Kataoka K, Hirota M, Isaji S, Nakamura R, Yamagiwa K, Kayaba C, Ikeda K: J Gastroenterol 2020/3; 55 (3): 342-52. (ŒŽ—¯OŽ÷1: 1V¢‹Iˆã—ÁEæ’[ˆã—Ã)

310039. [Ç—á•ñ] Lung perfusion scintigraphy in eisenmenger syndrome due to patent ductus arteriosus. Mitsui K1, Woodhams R1, Ukisu R1, Inoue Y1: Clin Nucl Med 2019/11; 44 (11): 879-80. (ŽOˆäN•œ1, ƒEƒbƒhƒnƒ€ƒX—æŽq1, •‚F—Ž‘Ÿ˜Y1, ˆäã—D‰î1: 1•úŽËü (‰æ‘œ))

320043. [Ç—á•ñ] èò•”Žh‘n‚É‚æ‚铪ŠWŠOèò•”ú’ʐ«èò“®–¬‘¹‚ɑ΂µCovered stent‚ð—p‚¢‚œŒŒŠÇ“àŽ¡—Âɂæ‚è‹~–œ‚µ‚œ1—á. ¡–ìTŒá1, ¡@–ŸG1, ‘q“c@²2, ƒEƒbƒhƒnƒ€ƒX—æŽq3 (1”ªŒËŽs—§Žs–¯•a‰@‹~–œ‹~‹}ƒZƒ“ƒ^[, 2Â—t‘ä”]_ŒoŠO‰ÈE“à‰È, 3•úŽËü (‰æ‘œ)): “ú–{ŠOŠw‰ïŽGŽ 2019/5; 33 (2): 45-9.

320044. [Ç—á•ñ] ’Pƒƒwƒ‹ƒyƒX”]‰Š‚É‚š‚¯‚é123I-IMP”]ŒŒ—¬SPECT’Ž‘Šú‘œ. ’–Žë’m”ü1, ˆäã—D‰î1, ŒŽ@•q«1, ŽOˆäN•œ1 (1•úŽËü (‰æ‘œ): —Տ°ŠjˆãŠw 2019/7; 52 (4): 50-3.

522125. [uÀ]y“ÁW: ŠÌ’_äX—̈æ‚̉摜f’f|—Lj««ŽŸŠ³‚̊ӕʂ𒆐S‚Ɂ|zŠÌ×–E‘BŽî‚ÌMRIf’f|‰æ‘œŠŒ©, ŠÓ•Êf’f, ÅVƒgƒsƒbƒNƒX. ŒŽ—¯OŽ÷1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2•úŽËü (‰æ‘œ)): —Տ°•úŽËü 2019/4; 64 (5): 649-62.

522126. [uÀ]y“ÁW1F‹~‹}IVR‚̍őOüzoŒŒ«ŽŸŠ³‚ɑ΂·‚éƒCƒ~ƒyƒlƒ€EƒVƒ‰ƒXƒ^ƒ`ƒ“ (IPM/CS) ‚̍ǐ𕚎¿‚Æ‚µ‚Ä‚Ì—L—p«. ƒEƒbƒhƒnƒ€ƒX—æŽq (•úŽËü (‰æ‘œ): Rad Fan 2019/4; 17 (5): 49-53.

522127. [uÀ]y¡ŒŽ‚̗Տ°: ŽY‰ÈŠë‹@“IoŒŒ‚̃xƒXƒgƒ}ƒlƒWƒƒ“ƒg@’m‚Á‚Ä‚š‚­‚ׂ«ÅV‚̑Ήžôz¡oŒŒ‚Ö‚Ì—\–h@—\–h“IIVR‚Ì“K‰ž‚ÆŽí—Þ, ‡•¹Ç. ƒEƒbƒhƒnƒ€ƒX—æŽq (•úŽËü (‰æ‘œ)): —Տ°•wl‰ÈŽY‰È 2019/9; 73 (9): 831-9.

[’˜@‘]

620081. [Šwp‘ (•ª’SŽ·•M)]y“ªèò•”‚ÌCTEMRI@‘æ3”ŁzI. “ªŠW’ê, p.1-30. VII. èò‹Ø–ŒEèò•”‘gDŠÔŒ„, p.361-424. •‚F—Ž‘Ÿ˜Y1 (1•úŽËü (‰æ‘œ), •Ò: ”öK”Ž–ç2, Žðˆä@C3 (2“Œ‹žŽœŒb‰ïˆã‰È‘åŠw•úŽËüˆãŠwuÀ, 3ƒ{ƒXƒgƒ“‘åŠwˆãŠw•”•úŽËü‰È), ƒƒfƒBƒJƒ‹EƒTƒCƒGƒ“ƒXEƒCƒ“ƒ^[ƒiƒVƒ‡ƒiƒ‹, “Œ‹ž, 2019/4”­s.

620082. [Šwp‘ (•ª’SŽ·•M)]y‹~‹}ŽŸŠ³‚̊ӕʐf’f‚̃|ƒCƒ“ƒg (‰æ‘œf’f‘Š§† Vol.39 No.11)z‘æ8Í ‘̍o“à‚̉t‘Ì’™—¯@‚”Z“x‚Ì• o“à‰t‘Ì’™—¯‚ÌŠÓ•Ê, p.A160-7. ƒEƒbƒhƒnƒ€ƒX—æŽq (•úŽËü (‰æ‘œ)), •Ò: ‘DžI’mO. ŠwŒ€ƒƒfƒBƒJƒ‹GŽÐ, “Œ‹ž, 2019/9”­s.

620083. [Šwp‘ (•ª’SŽ·•M)]yl‘̂̃ƒJƒjƒYƒ€‚©‚çŠw‚Ô ‰æ‘œf’f‹ZpŠwz4Í • •” (Á‰»ŠíC”å”AŠíE¶BŠí) ‚̉摜f’f‹Zp@5. ŠÌE’_“¹ŽŸŠ³‚Ì•a‘ԂƉ摜, p.326-59. 6. äX‘ŸŽŸŠ³‚Ì•a‘ԂƉ摜, p.360-71. ŒŽ—¯OŽ÷1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2•úŽËü (‰æ‘œ)), •Ò: X@@€, ¬‘q–Ÿ•v, ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2020/3”­s.

[Šw‰ïEŒ€‹†‰ï“™]

712032. [Šw‰ï (‘Û)] (µ‘ҍu‰‰) Çðp. Woodhams R1: CEPIR 2019: Continuous Education Program in Interventional Radiology 2019 (IVR¶ŠU‹³ˆçƒZƒ~ƒi[2019) (2019/10/26), Kanagawa, Japan. (ƒEƒbƒhƒnƒ€ƒX—æŽq1: 1•úŽËü (‰æ‘œ))

713132. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Activati on in the amygdala in a simple and short picture viewing task. Kotani Y1, Ohgami Y1, Yoshida N2, Kunimatsu A2, Kiryu S3, Inoue Y4: 2019 Annual Meeting of the Organization of Human Brain Mapping (2019/6/9-13), Rome, Italy, Abstract Book 2019/6; p.25. (¬’J‘ב¥1, ‘åãi”ü1, ‹g“c‹XŽ2, š Œ@‘2, ‹Ë¶@–Î3, ˆäã—D‰î4: 1“Œ‹žH‹Æ‘åŠwƒŠƒxƒ‰ƒ‹ƒA[ƒcŒ€‹†‹³ˆç‰@, 2“Œ‹ž‘åŠwˆã‰ÈŠwŒ€‹†Š, 3‘Ûˆã—ÕŸŽƒ‘åŠwˆãŠw•”, 4•úŽËü (‰æ‘œ))

713133. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Connectivity dynamics between the right anterior insula and the anterior cingulate cortex. Ohgami Y1, Kotani Y1, Yoshida N2, Kunimatsu A2, Kiryu S3, Inoue Y4: 2019 Annual Meeting of the Organization of Human Brain Mapping (2019/6/9-13), Rome, Italy, Abstract Book 2019/6; p.42. (‘åãi”ü1, ¬’J‘ב¥1, ‹g“c‹XŽ2, š Œ@‘2, ‹Ë¶@–Î3, ˆäã—D‰î4: 1“Œ‹žH‹Æ‘åŠwƒŠƒxƒ‰ƒ‹ƒA[ƒcŒ€‹†‹³ˆç‰@, 2“Œ‹ž‘åŠwˆã‰ÈŠwŒ€‹†Š, 3‘Ûˆã—ÕŸŽƒ‘åŠwˆãŠw•”, 4•úŽËü (‰æ‘œ))

713134. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Connectivity dynamics between the right anterior insula and the anterior cingulate cortex during anticipation of interoceptive response. Ohgami Y1, Kotani Y1, Yoshida N2, Kunimatsu A2, Kiryu S3, Inoue Y4: The 59th Annual Meeting of Society for Psychophysiological Research (2019/9/25-29), Washington DC, USA, Psychophysiology 2019/9; 56 (Suppl 1): p.S40. (‘åãi”ü1, ¬’J‘ב¥1, ‹g“c‹XŽ2, š Œ@‘2, ‹Ë¶@–Î3, ˆäã—D‰î4: 1“Œ‹žH‹Æ‘åŠwƒŠƒxƒ‰ƒ‹ƒA[ƒcŒ€‹†‹³ˆç‰@, 2“Œ‹ž‘åŠwˆã‰ÈŠwŒ€‹†Š, 3‘Ûˆã—ÕŸŽƒ‘åŠwˆãŠw•”, 4•úŽËü (‰æ‘œ))

713135. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Activation in the amygdala in a simple and short picture viewing task for clinical application. Kotani Y1, Ohgami Y1, Yoshida N2, Kunimatsu A2, Kiryu S3, Inoue Y4: The 59th Annual Meeting of Society for Psychophysiological Research (2019/9/25-29), Washington DC, USA, Psychophysiology 2019/9; 56 (Suppl 1): p.S49. (¬’J‘ב¥1, ‘åãi”ü1, ‹g“c‹XŽ2, š Œ@‘2, ‹Ë¶@–Î3, ˆäã—D‰î4: 1“Œ‹žH‹Æ‘åŠwƒŠƒxƒ‰ƒ‹ƒA[ƒcŒ€‹†‹³ˆç‰@, 2“Œ‹ž‘åŠwˆã‰ÈŠwŒ€‹†Š, 3‘Ûˆã—ÕŸŽƒ‘åŠwˆãŠw•”, 4•úŽËü (‰æ‘œ))

722222. [Šw‰ï (‘S‘)] (‹€ÃƒZƒ~ƒi[) ˆã—ÕúŽËü”í‚΂­‚Ɛü—ÊŠÇ—: Å‹ß‚Ì“®Œü. ˆäã—D‰î (•úŽËü (‰æ‘œ)): ‘æ78‰ñ“ú–{ˆãŠw•úŽËüŠw‰ï‘‰ï (2019/4/14), ‰¡•l.

722223. [Šw‰ï (‘S‘)] (‹³ˆçu‰‰) “ªŠW’ê‚Ì CTEMRI ³í‰ð–U: —Տ°“I‚ɏd—v‚ȃ|ƒCƒ“ƒg‚𒆐S‚É (The Normal Anatomy of the Skull Base on CT and MR Imaging: Focusing on Clinical Significance in Patients). •‚F—Ž‘Ÿ˜Y (•úŽËü (‰æ‘œ): ‘æ78‰ñ“ú–{ˆãŠw•úŽËüŠw‰ï (2019/4/14), ‰¡•l, “ú–{ˆãŠw•úŽËüŠw‰ïŠwpW‰ïŽ˜^W 2019/2; Page S139.

722224. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) —«ˆãŽt‚̉ï: IVRˆã‚Ì‚œ‚ß‚ÌŽÀ‘H“I”픘–hŒì. ƒEƒbƒhƒnƒ€ƒX—æŽq (•úŽËü (‰æ‘œ)): ‘æ47‰ñ“ú–{ŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï (2019/5/24), –ŒŒÃ‰®, “ú–{ŒŒŠÇŠO‰ÈŠw‰ïŽGŽ 2019; 28 (Suppl): P. SY13-Keynote Lecture.

722225. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰) •wl‰ÈŽŸŠ³‚̐f’f‚ÆIVR, NEXT, ‹~‹}. ƒEƒbƒhƒnƒ€ƒX—æŽq (•úŽËü (‰æ‘œ)): JCRƒ~ƒbƒhƒTƒ}[ƒZƒ~ƒi[2019 (2019/7/20), _ŒË.

722226. [Šw‰ï (‘S‘)] (‹€ÃƒZƒ~ƒi[) ˆã—ÕúŽËü‚̈À‘SŠÇ—: •úŽËü‰Èˆã‚Ì‚œ‚߂̃~ƒjƒ}ƒ€EƒGƒbƒZƒ“ƒX. ˆäã—D‰î (•úŽËü (‰æ‘œ)): ‘æ55‰ñ“ú–{ˆãŠw•úŽËüŠw‰ïH‹G—Տ°‘å‰ï (2019/10/20),–ŒŒÃ‰®.

722227. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰) ‹Ø–ŒEŠÔŒ„‰ð–U‚©‚ç“Ç‚Ý‰ð‚­“ªèò•”‰æ‘œf’f. •‚F—Ž‘Ÿ˜Y (•úŽËü (‰æ‘œ)): ‘æ33‰ñJCRƒ~ƒbƒhƒEƒBƒ“ƒ^[ƒZƒ~ƒi[ (2020/1/18) •Ÿ‰ª.

722228. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) “ªŠW’ê•a•Ï@“ªŠW’ê•a•Ï‚̉摜f’f. •‚F—Ž‘Ÿ˜Y (•úŽËü (‰æ‘œ)): ‘æ39‰ñ“ú–{‰æ‘œˆãŠw‰ïŠwpW‰ï (2020/2/14), “Œ‹ž, “ú–{‰æ‘œˆãŠw‰ïŽGŽ‘æ39‰ñ“ú–{‰æ‘œˆãŠw‰ïŽ˜^W 2020/1; 38 (1): p.37.

723759. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ‰E‘O•”“‡”玿‚Æ‘O•”‘яó”玿‚É‚š‚¯‚錋‡«‚ÌŽžŠÔ•Ï‰». ‘åãi”ü1, ¬’J‘ב¥1, ‹g“c‹XŽ2, š Œ@‘2, ‹Ë¶@–Î3, ˆäã—D‰î4 (1“Œ‹žH‹Æ‘åŠwƒŠƒxƒ‰ƒ‹ƒA[ƒcŒ€‹†‹³ˆç‰@, 2“Œ‹ž‘åŠwˆã‰ÈŠwŒ€‹†Š, 3‘Ûˆã—ÕŸŽƒ‘åŠwˆãŠw•”, 4•úŽËü (‰æ‘œ)): ‘æ37‰ñ“ú–{¶—S—Šw‰ï‘å‰ï (2019/5/25-26), é‹Ê, ‘æ36‰ñ“ú–{¶—S—Šw‰ï‘å‰ïƒvƒƒOƒ‰ƒ€E—\eW 2019; p.54.

723760. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ’Pƒ‚ÈŽ‹ŠoŽhŒƒ’掊‰Û‘è‚É‚š‚¯‚éG“‘Ì‚Ì•ŠŠˆ. ¬’J‘ב¥1, ‘åãi”ü1, ‹g“c‹XŽ2, š Œ@‘2, ‹Ë¶@–Î3, ˆäã—D‰î4 (1“Œ‹žH‹Æ‘åŠwƒŠƒxƒ‰ƒ‹ƒA[ƒcŒ€‹†‹³ˆç‰@, 2“Œ‹ž‘åŠwˆã‰ÈŠwŒ€‹†Š, 3‘Ûˆã—ÕŸŽƒ‘åŠwˆãŠw•”, 4•úŽËü (‰æ‘œ)): ‘æ37‰ñ“ú–{¶—S—Šw‰ï‘å‰ï(2019/5/25-26), é‹Ê, ‘æ36‰ñ“ú–{¶—S—Šw‰ï‘å‰ïƒvƒƒOƒ‰ƒ€E—\eW 2019; p.74.

723761. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ŽY‰ÈoŒŒ‚ɑ΂·‚é“®–¬ÇðpŒã‚Ì”DP—\Œã‚ÉŠÖ‚·‚錟“¢ (Pregnancy outcome following arterial embolization for obstetric bleeding). ƒEƒbƒhƒnƒ€ƒX—æŽq1, “¡ˆä@Š]1, ŒŽ@•q«1, ŽRª‘ñ˜Y1, ŽOˆäN•œ1, Šâè仉l1, ’–Žë’m”ü1, Žë–ì—m•ã1, ˆÀ’B‚Ý‚ž‚Ù1, Œ‰iŒh“ñ1, ‹g‘º‰ÃL2, ˆäã—D‰î1 (1•úŽËü (‰æ‘œ), 2ŽY‰È): ‘æ48‰ñ“ú–{IVRŠw‰ï‘‰ï (2019/5/31), •Ÿ‰ª, “ú–{ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒiƒ‹ƒ‰ƒWƒIƒƒW[Šw‰ïŽGŽ 2019/5; 34 (Suppl): p.214.

723762. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) äX_Œo“à•ª”åŽîᇂƊӕʂª–â‘è‚Æ‚È‚Á‚œsolid subtype‚ÌäXŸ÷‰t«ùN–EŽîᇂÌ1—á. âZ@@1, ŒŽ—¯OŽ÷2, ŠC’ËMŽj3, áÁŽR@“ž4, ˆäã—D‰î1 (1•úŽËü (‰æ‘œ), 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 4•a—): ‘æ33‰ñ“ú–{• •”•úŽËüŠw‰ï (2019/6/28), ‰ºŠÖ.

723763. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –jœ‚É”­¶‚µ‚œƒNƒŠƒvƒgƒRƒbƒJƒXÇ‚̉摜ŠŒ©. Žë–ì—m•ã1, •‚F—Ž‘Ÿ˜Y1, ˆäã—D‰î1, Œ–؁@’2, ŽR‰º@‘ñ2, Š“cç”ü”T3, ‚‹Ž”Ž”V4 (1•úŽËü (‰æ‘œ), 2Žš•@ˆôAE“ªèòŠO, 3•a—, 4ˆã—Éq¶Šw•”): ‘æ55‰ñ“ú–{ˆãŠw•úŽËüŠw‰ïH‹G—Տ°‘å‰ï (2019/10/18), –ŒŒÃ‰®.

723764. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) EOB-MRIŠÌ×–E‘Š‚Ì—L—p«‚ªŽŠŽ‚³‚ê‚œŠÌƒgƒLƒ\ƒJƒ‰Ç‚Ì1—á. âZ@@1, ŒŽ—¯OŽ÷1,2, ˆäã—D‰î1 (1•úŽËü (‰æ‘œ), 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ55‰ñ“ú–{ˆãŠw•úŽËüŠw‰ïH‹G—Տ°‘å‰ï (2019/10/18-20), –ŒŒÃ‰®, “ú–{ˆãŠw•úŽËüŠw‰ïH‹G—Տ°‘å‰ïŽ˜^W55‰ñ 2019/9; p.S475.

723765. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) 99mTc-HSADƒŠƒ“ƒpƒVƒ“ƒ`ƒOƒ‰ƒtƒB‚ŘRo•”ˆÊ‚𓯒è‚Å‚«‚œV¶Ž™pŒã“ûâô‹¹‚Ì1—á. âZ@@1, ƒEƒbƒhƒnƒ€ƒX—æŽq1, ˆäã—D‰î1 (1•úŽËü (‰æ‘œ)): ‘æ59‰ñ“ú–{ŠjˆãŠw‰ïŠwp‘‰ïE‘æ39‰ñ“ú–{ŠjˆãŠw‹ZpŠw‰ï‘‰ïŠwp‘å‰ï (2019/11/1), ˆ€•Q, ŠjˆãŠw 2019/10; 56 (Suppl): p.S169.

723766. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ƒgƒŒ[ƒTƒuƒ‹“_óüŒ¹‚ð—p‚¢‚œPEM‘•’uê—pQA/QCƒtƒ@ƒ“ƒgƒ€‚ÌŒŸ“¢. ‰ª–{”ü÷1, ‚‹ŽŒ’‘Ÿ˜Y1, ‹{•”ä˜CŽ÷2, ˆäã—D‰î3, D“cŒ\ˆê4, “‡@FŽŸ5, _—ÑŒ’Ž™5, ‹gˆä”ü•ä5, ›–ì’q”V5, ì–{‰ë”ü5, ’·’Jì’q”V6 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2•úŽËü•”, 3•úŽËü (‰æ‘œ), 4–kŠC“¹‰ÈŠw‘åŠw, 5‚ä‚€‚ ‚¢ƒNƒŠƒjƒbƒN, 6ˆã—Éq¶Šw•”): ‘æ59‰ñ“ú–{ŠjˆãŠw‰ïŠwp‘‰ïE‘æ39‰ñ“ú–{ŠjˆãŠw‹ZpŠw‰ï‘‰ïŠwp‘å‰ï (2019/11/2), ˆ€•Q, ŠjˆãŠw‹Zp 2019/10; 39 (—\eW): p.389.

723767. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ƒAƒNƒŠƒ‹‹zŽû‘ÌGe-68/Ga-68ƒ^ƒCƒvƒgƒŒ[ƒTƒuƒ‹“_óüŒ¹‚ð—p‚¢‚é’è—ʐ«EZ³’萔•]‰¿–@‚ÌŠJ”­ó‹µ•ñ. ’·’Jì’q”V1, ‰ª–{”ü÷2, ‚‹ŽŒ’‘Ÿ˜Y2, ‹{•”ä˜CŽ÷3, ‹e’r@Œh3, ˆäã—D‰î4, D“cŒ\ˆê5, ‰äÈ@Œd6, ˜a“cNO7 (1ˆã—Éq¶Šw•”, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3•úŽËü•”, 4•úŽËü (‰æ‘œ), 5–kŠC“¹‰ÈŠw‘åŠw, 6“Œ‹ž“sŒ’N’·Žõˆã—ÃZƒ“ƒ^[Œ€‹†Š, 7—‰»ŠwŒ€‹†Š¶–œ‹@”\‰ÈŠwŒ€‹†ƒZƒ“ƒ^[): ‘æ59‰ñ“ú–{ŠjˆãŠw‰ïŠwp‘‰ïE‘æ39‰ñ“ú–{ŠjˆãŠw‹ZpŠw‰ï‘‰ïŠwp‘å‰ï (2019/11/3), ˆ€•Q, ŠjˆãŠw 2019/10; 56 (Suppl): p.S165.

731103. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ˆã—ÕúŽËü‚̈À‘SŠÇ—‚ɂ‚¢‚Ä. ˆäã—D‰î (•úŽËü (‰æ‘œ)): ‘æ11‰ñL“‡‰æ‘œf’fŒ€‹†‰ï (2020/1/11), L“‡.

732102. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰) äXŽîᇂÌMRIf’f|ŽB‘œ‚Ɛf’f‚̃|ƒCƒ“ƒg|. ŒŽ—¯OŽ÷1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2•úŽËü (‰æ‘œ)): ‘æ42‰ñ_“ސìMRI‹ZpŒ€‹†‰ï (2019/7/19), ‰¡•l.

732103. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰) ˆã—Ôí‚΂­ü—ÊŠÇ—‚Ì–é–Ÿ‚¯: ˆã—Ö@Ž{s‹K‘¥‰ü³‚ðŽó‚¯‚Ä. ˆäã—D‰î (•úŽËü (‰æ‘œ)): ‘æ15‰ñImaging Now in KanagawaŠwpu‰‰‰ï (2019/8/3), ‰¡•l.

732104. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰) ŽÀ‘H“I“û–[‘¢‰eMRI‚̓lje. ƒEƒbƒhƒnƒ€ƒX—æŽq (•úŽËü (‰æ‘œ)): ‘æ34‰ñ˜a‰ÌŽRMRIƒZƒ~ƒi[ (2019/9/13), ˜a‰ÌŽR.

732105. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰) ˆã—ÃŒ»ê‚É‚š‚¯‚é–@—߉ü³‚É”º‚€‹ï‘Ì“I‚Ȉã—ÕúŽËüˆÀ‘SŠÇ—‘̐§‚̑Ήž‚ƈã—ÕúŽËüˆÀ‘SŠÇ—ŽÒ‚Ì–ðŠ„|–k—¢‘åŠw‚̏ꍇ|. ˆäã—D‰î (•úŽËü (‰æ‘œ)): —ߘaŒ³”N“x@ˆã—ÕúŽËüˆÀ‘SŠÇ—uK‰ï (2019/10/13), “Œ‹ž, ˆã—ÕúŽËü–hŒì 2020/3; 82: 31-2.

732106. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰) ŽY•wl‰È‹~‹}ŽŸŠ³‚̉摜f’f. ƒEƒbƒhƒnƒ€ƒX—æŽq (•úŽËü (‰æ‘œ)): ‘æ7‰ñ‹~‹}‰æ‘œƒŒƒNƒ`ƒƒ[ (2019/11/16), “ß”e.

732107. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰) ×ŒaŒŒŠÇÇð‚É‚š‚¯‚éGalaxy G3 mini‚Ì—L—p«. ƒEƒbƒhƒnƒ€ƒX—æŽq (•úŽËü (‰æ‘œ)): CERENOVUS Knowledge Up Seminar (2019/11/6), “Œ‹ž.

732108. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰) VŽž‘ã‚ÌŠjˆãŠw. ˆäã—D‰î (•úŽËü (‰æ‘œ)): _“ސìŠjˆãŠwŒ€‹†‰ï‘n—§50Žü”N‹L”O‘å‰ï (Œ“‘æ423‰ñ’è—á‰ï) (2019/11/9), ‰¡•l.

732109. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰) ŠjˆãŠw. ˆäã—D‰î (•úŽËü (‰æ‘œ)): ‘æ60‰ñRadiology UpdateŠwpu‰‰‰ï (2019/11/16), “Œ‹ž.

732110. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰) Žwj‚Ìà–Ÿ‚ÆŽÀ‰^—pŽ–—áÐ‰î. ˆäã—D‰î (•úŽËü (‰æ‘œ)): “ú–{•úŽËü‰Èê–åˆã‰ïEˆã‰ï (JCR) ˆã—ÕúŽËüˆÀ‘SŠÇ—uK‰ï (2020/1/19), •Ÿ‰ª.

732111. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰) ˆã—ÕúŽËü‚̈À‘S—˜—p: ü—ÊŠÇ—‚ÌŽÀ‘H. ˆäã—D‰î (•úŽËü (‰æ‘œ)): ìŒ§•úŽËü‰Èˆã‰ï (2020/1/25), ‚Œ.

732112. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰) •¡‡‹@CT‚̐ü—ÊŠÇ—‚ɂ‚¢‚Ä. ˆäã—D‰î (•úŽËü (‰æ‘œ)): 2019”N“x‘æ2‰ñŠÖ“ŒŠjˆãŠwŒ€‹†‰ïŠwpu‰‰‰ï (2020/2/2), ‰¡•l.

732113. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŠÌ×–E‘BŽî‚̐VˆŸ•ª—Þ‚ÆMRIf’f. ŒŽ—¯OŽ÷1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2•úŽËü (‰æ‘œ)): ‘æ26‰ñŠÌŒŒ—¬“®‘ԁE‹@”\ƒCƒ[ƒWŒ€‹†‰ï (2020/2/9), ‹à‘ò.

732114. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (‹³ˆçu‰‰) ˆã—ÃŒ»ê‚É‚š‚¯‚é–@—߉ü³‚É”º‚€‹ï‘Ì“I‚Ȉã—ÕúŽËüˆÀ‘SŠÇ—‘̐§‚̑Ήž‚ƈã—ÕúŽËüˆÀ‘SŠÇ—ŽÒ‚Ì–ðŠ„|–k—¢‘åŠw‚̏ꍇ|. ˆäã—D‰î (•úŽËü (‰æ‘œ)): ˆã—ÕúŽËü–hŒì˜A—‹Š‹c‰ï@‘æ41‰ñuˆã—ÕúŽËü‚̈À‘S—˜—pvƒtƒH[ƒ‰ƒ€ (2020/2/23), “Œ‹ž.

732115. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (Šî’²u‰‰) ˆã—ÕúŽËü‚É‚š‚¯‚é•úŽËüˆÀ‘S‚̍œK‰». ˆäã—D‰î (•úŽËü (‰æ‘œ)): ˆã—ÕúŽËü–hŒì˜A—‹Š‹c‰ï@‘æ41‰ñuˆã—ÕúŽËü‚̈À‘S—˜—pvƒtƒH[ƒ‰ƒ€ (2020/2/23), “Œ‹ž.

733724. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) •‰‰×S‹ØƒVƒ“ƒ`ƒOƒ‰ƒtƒB‚̓ljeŽè‡. ˆäã—D‰î (•úŽËü (‰æ‘œ): ‘æ9‰ñ–k—¢‹@”\‰æ‘œƒZƒ~ƒi[ (2019/4/16), ‘Š–ÍŒŽ.

733725. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ’†•_Œo‰æ‘œ‚̓ljeƒeƒNƒjƒbƒN. ŒŽ@•q« (•úŽËü (‰æ‘œ)): ‘æ7‰ñ‘Š–ÍŒŽˆã—p‰æ‘œƒZƒ~ƒi[ (2019/6/4), ‘Š–ÍŒŽ.

733726. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) •nŒŒ‚ðŒ_‹@‚É”­Œ©‚³‚êESD‚ðŽ{s‚µ‚œˆÝ•œŠŠ‹Ø“÷Žî‚̈ê—á. ‘º–Ø•q˜Y1, ‹{–{N—Y1, X‹v•Û‘ñ1, ŽŒŽ—T‹M1, Œ—ѐ^‰›1, –q“c—VŽq1, ²ãW‘Ÿ˜Y1, ¬—с@‘ñ1,2, ’†–ì@‰ë1, –î“àŒŽ‹v1,3, ‘å•”@œ1, íŒ@—ß1, “ú”ä‹I•¶1,2 (1–k—¢Œ€‹†Š•a‰@, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3•úŽËü (‰æ‘œ)): ‘æ108‰ñ“ú–{Á‰»Ší“àŽ‹‹ŸŠw‰ïŠÖ“ŒŽx•”—á‰ï (2019/6/8), “Œ‹ž, Progress of Digestive Endoscopy 2019/6; 95 (Suppl): p.s104.

733727. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) Žîᇐ«•a•Ï‚Æ‚ÌŠÓ•Ê‚É‹ê—¶‚µ‚œˆÙŠ«ŠÌ‰óŽ€‚Ì1—á. âZ@@1, ŒŽ—¯OŽ÷1,2, ˆäã—D‰î1 (1•úŽËü (‰æ‘œ), 2V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ455‰ñ“ú–{ˆãŠw•úŽËüŠw‰ïŠÖ“Œ’n•û‰ï’èŠú‘å‰ï (2019/6/15), ìè.

733728. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) A“ªŒŽ”­‚̐_Œo“à•ª”åŠà‚̉摜ŠŒ©. Žë–ì—m•ã1, •‚F—Ž‘Ÿ˜Y1, ˆäã—D‰î1, Ž–ì—R”y2, ŽR‰º@‘ñ2, ˆêŒË¹–Ÿ3, ‹g“c@Œ÷3 (1•úŽËü (‰æ‘œ), 2Žš•@ˆôAE“ªèòŠO, 3•a—): ‘æ48‰ñ“ªèò•”E‹¹•”‰æ‘œŒ€‹†‰ï (2019/6/22), “Œ‹ž

733729. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ’Pƒƒwƒ‹ƒyƒX”]‰Š‚É‚š‚¯‚é123I-IMP”]ŒŒ—¬SPECT’Ž‘Šú‘œ. ’–Žë’m”ü1, ŽOˆäN•œ1, ŒŽ@•q«1, ˆäã—D‰î1 (1•úŽËü (‰æ‘œ)): ‘æ91‰ñ“ú–{ŠjˆãŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2019/6/29), “Œ‹ž, ŠjˆãŠw 2019/9; 56 (1): p. 125.

733730. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) –jœ‚É”­¶‚µ‚œƒNƒŠƒvƒgƒRƒbƒJƒXÇ‚̉摜ŠŒ©. Žë–ì—m•ã1, •‚F—Ž‘Ÿ˜Y1, ˆäã—D‰î1, Œ–؁@’2, ŽR‰º@‘ñ2, Š“cç”ü”T3, ‚‹Ž”Ž”V4 (1•úŽËü (‰æ‘œ), 2Žš•@ˆôAE“ªèòŠO, 3•a—, 4ˆã—Éq¶Šw•”): ‘æ32‰ñ“ªèò•”•úŽËüŒ€‹†‰ï (2019/10/19), –ŒŒÃ‰®, “ú–{ˆãŠw•úŽËüŠw‰ïH‹G—Տ°‘å‰ïŽ˜^W55‰ñ 2019/9; p. S559.

733731. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ŒÛŽº“àŽîᎂð’悵‚œ‘–ŒŽî‚Ì1—á. ˆÀ’B‚Ý‚ž‚Ù1, •‚F—Ž‘Ÿ˜Y1, ˆäã—D‰î1, ‹{–{r•ã2, ŽR‰º@‘ñ2, ‹g“c@Œ÷3, H’J¹Žj3 (1•úŽËü (‰æ‘œ), 2Žš•@ˆôAE“ªèòŠO, 3•a—): 2019”N“x_“ސ쌧•úŽËüˆã‰ï‘‰ïE‘æ60‰ñ—á‰ï (2019/10/26), ‰¡•l, _“ސìˆãŠw‰ïŽGŽ 2020/1; 47 (1): 106.

733732. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ŠÌŽ‡”Á•a‚É—ÞŽ—‚µ‚œ‰æ‘œŠŒ©‚ð’悵C‹}Œƒ‚È“]‹A‚ð‚œ‚Ç‚Á‚œŠÌŒŒŠÇ“÷Žî‚̈ê—á. ŽOˆäN•œ1, ƒEƒbƒhƒnƒ€ƒX—æŽq1, ŒŽ@•q«1, Œ‰iŒh“ñ1, ˆäã—D‰î1 (1•úŽËü (‰æ‘œ)): ‘æ456‰ñ“ú–{ˆãŠw•úŽËüŠw‰ïŠÖ“Œ’n•û‰ï’èŠú‘å‰ï (2019/12/14), “Œ‹ž, ‘æ456‰ñ“ú–{ˆãŠw•úŽËüŠw‰ïŠÖ“Œ’n•û‰ï’èŠú‘å‰ïƒvƒƒOƒ‰ƒ€EŽ˜^W 2019/12; p. 37.

'18”N“xˆÈ‘O•ª

[Šw‰ïEŒ€‹†‰ï“™]

'18-713007. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) CT and MR imaging findings of Cholangiolocellula Carcinoma of the Liver: correlation with histopathologic features and differential diagnosis. Haradome H1,2, Woo J2, Inoue Y2: The European Society of Gastrointestinal and Abdominal Radiology 2018 (2018/6/12), Dublin, Ireland. (ŒŽ—¯OŽ÷1,2, âZ@@2, ˆäã—D‰î2: 1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2•úŽËü (‰æ‘œ))

'18-722007. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) MR imaging diagnosis of hepatocellular adenoma: imaging features, differential diagnosis, and recent topics. ŒŽ—¯OŽ÷1,2 (1V¢‹Iˆã—ÁEæ’[ˆã—Ã, 2•úŽËü (‰æ‘œ)): ‘æ77‰ñ“ú–{ˆãŠw•úŽËüŠw‰ï‘‰ï (2018/4/13), ‰¡•l.


•úŽËü‰ÈŠw (•úŽËüŽîᇊw)

[Šwp˜_•¶]

110337. [ŒŽ’˜] A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer. Kainuma T1, Kawakami S1, Tsumura H2, Satoh T2, Tabata K2, Iwamura M2, Hayakawa K1, Ishiyama H1: Radiat Oncol 2019/9; 14 (1): 158. (Ž”À‘ì˜N1, ìã³Œå1, ’ѺGN2, ²“¡ˆÐ•¶2, “c”šŒ’ˆê2, Šâ‘º³Žk2, ‘ì˜ad1, ÎŽR”ŽžŠ1: 1•úŽËü (Žîá‡), 2”å”AŠí)

110338. [ŒŽ’˜] Patient-reported health-related quality of life up to three years after the treatment with permanent brachytherapy: Outcome of the large-scale, prospective longitudinal study in Japanese-Prostate Cancer Outcome Study by Permanent I-125 Seed Implantation (J-POPS) Koga H1, Naito S1, Ishiyama H1,2, Yorozu A1, Saito S1, Kojima S1, Higashide S1, Kikuchi T1, Nakamura K1, Dokiya T1, Fukushima M1 (1J-POPS Study Group): Brachytherapy 2019/11-12; 18 (6): 806-13. (ÎŽR”ŽžŠ1,2: 2•úŽËü (Žîá‡)

110339. [ŒŽ’˜] Dosimetric factors associated with long-term patient-reported outcomes after definitive radiotherapy of patients with head and neck cancer. Hayakawa T1, Kawakami S1, Soda I1, Kainuma T1, Nozawa M1, Sekiguchi A1, Miyamoto S2, Yamashita T2, Ishiyama H1: Radiat Oncol 2019/12; 14 (1): 221. (‘ì–L˜a1, ìã³Œå1, ‘“c@Ši1, Ž”À‘ì˜N1, –ìàVää»‰Ô1, ŠÖŒûˆ©ˆß1, ‹{–{r•ã2, ŽR‰º@‘ñ2, ÎŽR”ŽžŠ1: 1•úŽËü (Žîá‡), 2Žš•@ˆôAE“ªèòŠO)

110340. [ŒŽ’˜] Imaging Cherenkov emission for quality assurance of high-dose-rate brachytherapy Yogo K, Matsushita A, Tatsuno Y, Shimo T, Hirota S, Nozawa M1, Ozawa S, Ishiyama H1, Yasuda H, Nagata Y, Hayakawa K1: Sci Rep 2020/2; 10 (1): 3572. (–ìàVää»‰Ô1, ÎŽR”ŽžŠ1, ‘ì˜ad1: 1•úŽËü (Žîá‡))

110341. [ŒŽ’˜] Potential Mechanisms for Protective Effect of D-Methionine on Plasmid DNA Damage Induced by Therapeutic Carbon Ions Katsunori Yogo K, Murayama C, Fujisawa Y, Maeyama T, Hirayama R, Ogawa Y, Matsumoto K, Nakanishi I, Yasuda H, Ishiyama H1, Hayakawa K1: Radiat Res 2020/3. doi: 10.1667/RR15502.1. Online ahead of print. (ÎŽR”ŽžŠ1, ‘ì˜ad1: 1•úŽËü (Žîá‡))

210005. [€ŒŽ’˜]yUrological NotezRelationship between the dose to the bulbomembranous urethra and stricture after high dose-rate brachytherapy for prostate cancer: Matched-pair analysis. Sekiguchi A1, Tsumura H2, Kawakami S1, Satoh T2, Iwamura M2, Ishiyama H1: Int J Urol 2019/9; 26 (9): 938-9. (ŠÖŒûˆ©ˆß1, ’ѺGN2, ìã³Œå1, ²“¡ˆÐ•¶2, Šâ‘º³Žk2, ÎŽR”ŽžŠ1 (1•úŽËü (Žîá‡), 2”å”AŠí)

522125. [uÀ]y“ÁW: ‚ƒŠƒXƒN‘O—§‘BŠà‚ÌŽ¡—Ð헪z5. ‚ü—Ê—Š¬üŒ¹Ž¡—Ã. ÎŽR”ŽžŠ (•úŽËü (Žîá‡)): Prostate Journal 2019/10; 6 (2): 183-7.

[Šw‰ïEŒ€‹†‰ï“™]

713136. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Treatment Outcomes and Risk Factors of Limited-Stage Small Cell Lung Cancer Patients Treated with Chemoradiotherapy. Hayakawa T1, Soda I1, Sekiguchi A1, Kawakami S1, Kubota M2, Mitsufuji H3, Igawa S4, Fukui T4, Naoki K4, Hayakawa K5, Ishiyama H1: IASLC 2019 World conference on lung cancer (2019/9/8), Barcelona, Spain. (‘ì–L˜a1, ‘“c@Ši1, ŠÖŒûˆ©ˆß1, ìã³Œå1, ‹v•Û“cŸ2, ŽO“¡@‹v3, ˆäì@‘4, •Ÿˆä•ü–ç4, —P–؍Ž•F4, ‘ì˜ad5, ÎŽR”ŽžŠ1: 1•úŽËü (Žîá‡), 2ˆã—Éq¶Šw•”, 3ŠÅŒìŠw•”, 4ŒÄ‹zŠí“à, 5ÐŠQˆã—ÃZƒ“ƒ^[•úŽËüŽ¡—ÉÈ)

713137. [Šw‰ï (‘Û)] (ˆê”ÊŒû‰‰) Usefulness of 3D-scanner in baseline and response evaluation of radiotherapy for scalp angiosarcoma. I Soda1, Masuzawa M2, Mamorita N, Sekiguchi A1, Kawakami S1, Hayakawa T1, Kainuma T1, IshiyamaH1 ESTRO meets ASIA 2019 (2019/12/6), Singapore. (‘“c@Ši1, ‘àV^ŽÀŽq2, ŠÖŒûˆ©ˆß1, ìã³Œå1, ‘ì–L˜a1, Ž”À‘ì˜N1, ÎŽR”ŽžŠ1: 1•úŽËü (Žîá‡), 2”畆)

722229. [Šw‰ï (‘S‘)] (‹³ˆçu‰‰) ‹³ˆçu‰‰1: ‘O—§‘B. ÎŽR”ŽžŠ (•úŽËü (Žîá‡)): “ú–{•úŽËüŽîᇊw‰ï‘æ32‰ñŠwp‘å‰ï (2019/11/21), –ŒŒÃ‰®.

723768. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰)yÀ’·zŽ¡—Ã2: ”å”AŠí. ÎŽR”ŽžŠ (•úŽËü (Žîá‡)): ‘æ78‰ñ“ú–{ˆãŠw•úŽËüŠw‰ï‘‰ï (2019/4/13), ‰¡•l, ‘æ78‰ñ“ú–{ˆãŠw•úŽËüŠw‰ï‘‰ïŽ˜^W 2019/4; p.69.

723769. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ‘O—§‘BŠà‰i‹v‘}“ü–§••¬üŒ¹Ž¡—ÃŒãCT‰æ‘œ‚©‚ç’Šo‚µ‚œRadiomics“Ÿ”÷—Ê‚Ì—\Œã—\‘ªˆöŽq‚Æ‚µ‚Ẳ”\«. ìã³Œå1, •Ð‘qŒ’•v2, ‹Ž–{¬¢2, ’·’Jì’q”V2, ’ѺGN3, “c”šŒ’ˆê3, ÎŽR”ŽžŠ1 (1•úŽËü (Žîá‡), 2ˆã—Éq¶Šw•”, 3”å”AŠí): ¬üŒ¹Ž¡—Õ”‰ï‘æ21‰ñŠwp‘å‰ï (2019/5/18), “¿“‡, ¬üŒ¹Ž¡—Õ”‰ï‘æ21‰ñŠwp‘å‰ïŽ˜^ 2019/5; p.46.

723770. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘O—§‘BŠàƒV[ƒhŽ¡—ÃŒãCT‰æ‘œ‚©‚ç’Šo‚µ‚œƒ‰ƒWƒIƒ~ƒNƒX“Á’¥—Ê‚Ì—\Œã—\‘ªˆöŽq‚Æ‚µ‚Ẳ”\«. •Ð‘qŒ’•v1, ìã³Œå2, ŠÖŒû¹l1, “c’†—Iˆê1, Œ–{—Y“o1, ‹Ž–{¬¢3, ’·’Jì’q”V3, ÎŽR”ŽžŠ2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2•úŽËü (Žîá‡), 3ˆã—Éq¶Šw•”): ‘æ47‰ñ“ú–{•úŽËü‹ZpŠw‰ïH‹GŠwp‘å‰ï (2019/10/17), ‘åã, Japanese Journal of Radiological Technology 2019/9; 75 (9): 987-8.

723771. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ŒÀ‹Ç«‘O—§‘BŠà‚ɑ΂·‚é4•ªŠ„‚ð—p‚¢‚œ’èˆÊ•úŽËüŽ¡—Â̑æI‘ŠŽŽŒ±. Ž”À‘ì˜N1, ìã³Œå1, ’ѺGN2, ²“¡ˆÐ•¶, “c”šŒ’ˆê2, Šâ‘º³Žk2, ‘ì˜ad3, ÎŽR”ŽžŠ1 (1•úŽËü (Žîá‡), 2”å”AŠí, 3ÐŠQˆã—ÃZƒ“ƒ^[•úŽËüŽ¡—ÉÈ): “ú–{•úŽËüŽîᇊw‰ï‘æ32‰ñŠwp‘å‰ï (2019/11/21), –ŒŒÃ‰®, “ú–{•úŽËüŽîᇊw‰ï‘æ32‰ñŠwp‘å‰ï•ñ•¶W 2019; p.233.

723772. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) “ª”猌ŠÇ“÷Žî•úŽËüŽ¡—Âɂš‚¯‚é3ŽŸŒ³ƒXƒLƒƒƒi[‚É‚æ‚éŽîᇕ]‰¿‚Ì—L—p«. ‘“c@Ši1, ‘àV^ŽÀŽq2, Žç“cŒ›’3, ìã³Œå1, ŠÖŒûˆ©ˆß1, ‘ì–L˜a1, Ž”À‘ì˜N1, ÎŽR”ŽžŠ1 (1•úŽËü (Žîá‡), 2”畆, 3ˆã—Éq¶Šw•”): “ú–{•úŽËüŽîᇊw‰ï‘æ32‰ñŠwp‘å‰ï (2019/11/21), –ŒŒÃ‰®, “ú–{•úŽËüŽîᇊw‰ï‘æ32‰ñŠwp‘å‰ï•ñ•¶W 2019; p.349.

723773. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[)yÀ’·z¬üŒ¹Ž¡—Ã1. ÎŽR”ŽžŠ (•úŽËü (Žîá‡)): “ú–{•úŽËüŽîᇊw‰ï‘æ32‰ñŠwp‘å‰ï (2019/11/22), –ŒŒÃ‰®.

723774. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ‘O—§‘BŠàseedŽ¡—ÃŒãCT‚©‚ç’Šo‚µ‚œRadiomics“Á’¥—Ê‚Ì—\Œã—\‘ªˆöŽq‚̉”\«. ìã³Œå1, •Ð‘qŒ’•v2, ‹Ž–{¬¢3, ’·’Jì’q”V3, ’ѺGN4, “c”šŒ’ˆê4, ŠÖŒûˆ©ˆß1, ‘ì–L˜a1, ‘“c@Ši1, Šâ‘º³Žk4, ÎŽR”ŽžŠ1 (1•úŽËü (Žîá‡), 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ˆã—Éq¶Šw•”, 4”å”AŠí): “ú–{•úŽËüŽîᇊw‰ï‘æ32‰ñŠwp‘å‰ï (2019/11/22), –ŒŒÃ‰®, “ú–{•úŽËüŽîᇊw‰ï‘æ32‰ñŠwp‘å‰ï•ñ•¶W 2019; p.375.

723775. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ŒÀ‹ÇŒ^¬×–E”xŠà‚̐f—ÃKƒCƒhƒ‰ƒCƒ“‚ÉŠî‚­Ž¡—ЬÑ‚Æ—\ŒãˆöŽq. ‘ì–L˜a1, ‘“c@Ši1, ŠÖŒûˆ©ˆß1, ìã³Œå1, —P–؍Ž•F2, ‘ì˜ad3, ÎŽR”ŽžŠ1 (1•úŽËü (Žîá‡), 2ŒÄ‹zŠí“à, 3ÐŠQˆã—ÃZƒ“ƒ^[•úŽËüŽ¡—ÉÈ): “ú–{•úŽËüŽîᇊw‰ï‘æ32‰ñŠwp‘å‰ï (2019/11/22), –ŒŒÃ‰®, “ú–{•úŽËüŽîᇊw‰ï‘æ32‰ñŠwp‘å‰ï•ñ•¶W 2019; p.388.

732116. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï) (µ‘ҍu‰‰“™) ‘O—§‘BŠà‚ɑ΂·‚éWŠw“IŽ¡—Âƃ‰ƒWƒEƒ€223. ÎŽR”ŽžŠ (•úŽËü (Žîá‡)): ‘æ915‰ñ•úŽËüf—ÃŒ€‹†‰ï (2019/5/27), “Œ‹ž.

732117. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï) (µ‘ҍu‰‰) “ªèò•”Šàƒgƒ‚ƒZƒ‰ƒs[Œã‚ÌQOL•Ï‰». ‘ì–L˜a (•úŽËü (Žîá‡)): ‘æ8‰ñTomoTherapyƒZƒ~ƒi[2019 (2019/6/15), “Œ‹ž.

732118. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï) (µ‘ҍu‰‰) •úŽËüŽ¡—Â̐i“W‚Æ”x‘Ÿ‰Šƒ}ƒlƒWƒƒ“ƒg. ‘“c@Ši (•úŽËü (Žîá‡)): Lung Cancer Academy (2019/6/25), _“ސì.

732119. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï) (ƒRƒƒ“ƒe[ƒ^) Ç—áƒfƒBƒXƒJƒbƒVƒ‡ƒ“. ‘“c@Ši (•úŽËü (Žîá‡)): Lung Cancer Academy (2019/6/25), _“ސì.

732120. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï) (µ‘ҍu‰‰“™)yƒ‰ƒCƒuƒfƒ‚ƒ“ƒXƒgƒŒ[ƒVƒ‡ƒ“zMeet The Experts3.4. ÎŽR”ŽžŠ (•úŽËü (Žîá‡)): ‘æ21‰ñƒˆƒE‘f125ƒV[ƒhüŒ¹‰i‹v‘}“ü‚É‚æ‚é‘O—§‘BŠà–§••¬üŒ¹—Ö@‹ZpuK‰ï (2019/6/29), “Œ‹ž.

732121. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï) (µ‘ҍu‰‰“™)yuŽtzMeet The Experts3. ÎŽR”ŽžŠ (•úŽËü (Žîá‡)): ‘æ21‰ñƒˆƒE‘f125ƒV[ƒhüŒ¹‰i‹v‘}“ü‚É‚æ‚é‘O—§‘BŠà–§••¬üŒ¹—Ö@‹ZpuK‰ï (2019/6/29), “Œ‹ž.

732122. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï) (uŽt) •úŽËüŽ¡—Êw. ÎŽR”ŽžŠ (•úŽËü (Žîá‡)): 2019ˆãŠw•š—Žmƒ~ƒjƒ}ƒ€uK‰ï (ˆãŠw¶•šŒn) (2019/7/13), “Œ‹ž.

732123. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï) (µ‘ҍu‰‰) CRT“KŠiÇ—á‚̐³‚µ‚¢—‰ð‚Æ•úŽËü”x‘Ÿ‰Š‚̃}ƒlƒWƒƒ“ƒg. ‘“c@Ši (•úŽËü (Žîá‡)): PACIFIC Regimen Academy in Yokohama (2019/8/27), _“ސì.

732124. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï) (µ‘ҍu‰‰“™) ‘O—§‘BŠà‚̏WŠw“IŽ¡—Ã. ÎŽR”ŽžŠ (•úŽËü (Žîá‡)): ‘æ16‰ñ’†•”•úŽËüŽ¡—ÃŒ€‹†‰ï (2019/10/5), –ŒŒÃ‰®.

732125. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï) (Šî’²u‰‰) CRT“KŠiÇ—á‚̐³‚µ‚¢—‰ð‚Æ•úŽËü”x‘Ÿ‰Š‚̃}ƒlƒWƒƒ“ƒg. ‘“c@Ši (•úŽËü (Žîá‡)): ‰¡{‰êLung Cancer Symposium 2019 (2019/10/30), _“ސì.

732126. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï) (ƒpƒlƒŠƒXƒg) Clinical Question. ‘ì–L˜a (•úŽËü (Žîá‡)): Stage III Lung Cancer Symposium (2020/1/23), _“ސì.


–ƒŒ‰ÈŠw

[Šwp˜_•¶]

110342. [ŒŽ’˜] Preoperative sepsis is a predictive factor for 30-day mortality after major lower limb amputation among patients with arteriosclerosis obliterans and diabetes. Otsuka T1, Arai M1,2, Sugimura K1, Sakai M1, Nishizawa Y1, Suzuki Y1, Okamoto H1, Kuroiwa M1: J Orthop Sci 2020/5; 25 (3): 441-5. doi: 10.1016/j.jos.2019.05.017. Epub 2019 Jun 18. (‘å’Ë’q‹v1, Vˆä³N1,2, ™‘ºŒ›—º1, ãˆä䝗LŽq1, ŒàV‹`”V1, —é–Ø—D‘Ÿ˜Y1, ‰ª–{_Žk1, •Šâ­”V1: 1–ƒŒ, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

110343. [ŒŽ’˜] The Initial Subjective Sensory Change in the Dermatome During Intrathecal Injection of Plain Bupivacaine Predicts the Spread of Sensory Blockade: A Prospective Multi-Level Modeling Study. Kanai A1,2, Niki Y, Hayashi N2, Maeda S, Horie K, Okamoto H2: Anesth Pain Med 2019/9; 9 (5): e91216. (‹àˆäº•¶1,2, —Ñ Œol2, ‰ª–{_Žk2: 1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ)

110064. [ŒŽ’˜] Amelioration of experimental autoimmune myocarditis through activation of invariant natural killer T cells by administration of ƒ¿-galactosylceramide. Yoshino K1, Satoh M2, Iwayama T1, Kobayashi S1, Okamoto H3, Eshima K2, Watarai H, Iwabuchi K2: Kitasato Med J 2020/3; 50 (1): 60-72. (‹g–ì˜a‹v1, ²“¡@‰ë2, ŠâŽRrŽk1, ¬—яGô1, ‰ª–{_Žk3, ]“‡k“ñ2, ŠâŸº˜a–ç2: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–Ɖu, 3–ƒŒ)

120037. [ŒŽ’˜] ‘nˆ’u’ɂɑ΂·‚éƒuƒvƒŒƒmƒ‹ƒtƒBƒ“‚Ì—L—p«. —с@Œol1, ‹àˆäº•¶1,2, ¯ŽR—LG1, ‰Í‘º’ŒŽ÷1, ‚‹Ž—Cˆê˜N1, ‰ª–{_Žk1 (1–ƒŒ, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): –k—¢ˆãŠw 2019/6; 49 (1): 9-13.

120038. [ŒŽ’˜] ŽY‰È•a“‚É‚š‚¯‚éRapid Response System‹N“®Šî€‚ÉŠÖ‚·‚éŒã•ûŽ‹“IŒŸ“¢. ×ìKŠó1, ‰Á“¡—¢ŠG, •Šâ­”V1, ¬’r•üF2, XˆÀŒbŽÀ3, ‰œ•xr”V1, Vˆä³N1,4 (1–ƒŒ, 2ƒŠƒnƒrƒŠ•”, 3ŠÅŒì•”, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): “ú–{W’†Ž¡—ÈãŠw‰ïŽGŽ 2020/1; 27 (1): 11-8.

120039. [ŒŽ’˜] ‘яóáv]ŠÖ˜A’É‚ð—L‚·‚鍂—îŽÒ‚Ì”F’m‹@”\. ¯ŽR—LG1, ‹àˆäº•¶1,2, —с@Œol1, ‰Í‘º’ŒŽ÷1, ‚‹Ž—Cˆê˜N1, ‰ª–{_Žk1 (1–ƒŒ, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): “ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ïŽ 2020/2; 27 (1): 21-6.

310040. [Ç—á•ñ] Awake fiberoptic intubation with an epidural catheter in a morbidly obese patient. Suzuki Y1, Takenami T1, Fujino S1, Nakazawa A1, Okamoto H1: J Anesth 2020/6; 34 (3): 468-71. doi: 10.1007/s00540-020-02760-4. Epub 2020 Mar 21 (—é–Ø—D‘Ÿ˜Y1, ’|˜Q–¯]1, “¡–ìŽÑ‹M1, ’†àVˆº”T1, ‰ª–{_Žk1: 1–ƒŒ)

320045. [Ç—á•ñ] ’áNPS‘ŸŽèp (MICS) ‚É‚š‚¯‚é•Ð”xŠ·‹C’†‚ÌSpO2’ቺ“x‚ÌŽŸŠ³•ÊŒŸ“¢. –{“c’h1, ˆÀ“¡ŽõŒb1, ŒË“c‰ë–ç1, ì’[ää»Žq1, ’†àVˆº”T1, ‰ª–{_Žk1 (1–ƒŒ): –ƒŒ 2020/3; 69 (3): 308-11.

522126. [uÀ]y“ÁW1. bó‘BŠO‰ÈŽ¡—Âɑ΂·‚éˆã—ÈÀ‘SzRapid Response System‚͍bó‘BŠO‰ÈpŒãèò•”ŒŒŽî‚É‚æ‚éS’âŽ~‰ñ”ð‚É—LŒø‚©? Vˆä³N1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): “ú–{“à•ª”åEbó‘BŠO‰ÈŠw‰ïŽ 2019; 36 (2): 68-73.

522127. [uÀ]yŽãŽ“ljïzS‘Ÿ–ƒŒ‚ÉŠÖ‚·‚é˜b‘è. ™‘ºŒ›—º1, ˆÀ“¡ŽõŒb1, Œ“cO”ü1, ŒË“c‰ë–ç1, •Šâ­”V1, ‰ª–{_Žk1 (1–ƒŒ): —Տ°–ƒŒ 2020/2; 44 (2): 179-84.

522128. [uÀ]y“ÁW: ˆã—Ã`[ƒ€‚É‚š‚¯‚é–ƒŒ‰Èˆã‚Ì–ðŠ„zŒŸ‚Æ‚Ü‚Æ‚ß. ‰ª–{_Žk (–ƒŒ): –ƒŒ 2020/3; 69 (3): 238-9.

522129. [uÀ] ‰@“àv‘¬‘ΉžƒVƒXƒeƒ€ (rapid response system: RRS) ‚Æ–ƒŒ‰Èˆã. ŒàV‹`”V1, ‘å’Ë’q‹v1, •Šâ­”V1 (1–ƒŒ): –ƒŒ 2020/3; 69 (3): 265-70.

540075. [‚»‚Ì‘Œ]yŠª“ªŒŸzŽ©•ª‚ªì‚éŠÂ‹«. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ):—Տ°–ƒŒ 2019/7; 43 (7): 923.

540076. [‚»‚Ì‘Œ (V•·‹LŽ–)] ƒIƒsƒIƒCƒh’Á’É–ò|’É‚Ý‚ÌŽí—Þ‚É‚æ‚Á‚Ä‚Í–³Œø—á‚à|. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): Medical Tribune 2019; 52 (7): 7.

540077. [‚»‚Ì‘Œ]yMember's SiestaszÈ‚ð÷‚é. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): “ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ïNews Letter 2020/1; ‘æ6†.

540078. [‚»‚Ì‘Œ (Šª“ªŒŸ)] ‚킪‘‚́g–ƒŒh‚Í‚Ç‚±‚©‚ç—ˆ‚œ‚Ì‚©, ‚Ç‚ñ‚È‚à‚Ì‚©, ‚Ç‚±‚ÖŒü‚©‚Á‚čs‚­‚Ì‚©. ‰œ•xr”V (–ƒŒ): –ƒŒ 2020/3; 69 (3): 237.

[’˜@‘]

620084. [Šwp‘ (’P’˜)]y’ɂ݂̍\‘¢‚ōl‚Š‚é’Á’É–ò‚Ì‘I‘ðz‹àˆäº•¶1,2, —с@Œol2, ‰ª–{_Žk2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ), ^‹»ŒðˆÕˆã‘o”Å•”, “Œ‹ž, 2019/7”­s.

620085. [Šwp‘ (•ª’SŽ·•M)] yICUŽ¡—ÃŽwj I (‹~‹}EW’†Ž¡—à 31 (2)zII. ŒÄ‹zŠíŽŸŠ³‚ÆŠÇ—@ŒÄ‹zŠÇ—@Œo”ç“I‹CŠÇØŠJ–@, ŠO‰È“I‹CŠÇØŠJ–@, ‹¹oúŽhE‹¹oƒhƒŒƒi[ƒW–@, p.476-87. Vˆä³N1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ), ‘ŠÄC: ‰ªŒ³˜a•¶, ‘‡ˆãŠwŽÐ, “Œ‹ž, 2019/7”­s.

[Šw‰ïEŒ€‹†‰ï“™]

712033. [Šw‰ï (‘Û)] (µ‘ҍu‰‰“™) Introduction and Effectiveness of a Rapid Response System for Patient Safety. Kuroiwa M1: 7Th meeting of East Asia anesthesia (2019/5/30), Kobe, Japan. (•Šâ­”V1: 1–ƒŒ)

712034. [Šw‰ï (‘Û)] (ƒVƒ“ƒ|ƒWƒEƒ€) Congenital heart surgery. Okamoto H1: ICCVA-ASCA 2019 (2019/6/6), Korea. (‰ª–{_Žk1: 1–ƒŒ)

713138. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Retrospective study of perioperative complicaions in noncardiac surgeries for children with congenital heart deseases. Amano A1, Matusa H, Toda M1 Okamoto H1: European Society of Anaesthesiology 2019 (2019/6/2), Vienna, Austria. (“V–ì–Ÿ’͹1, ŒË“c‰ë–ç1, ‰ª–{_Žk1: 1–ƒŒ)

713139. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) A case of re-operation at early postoperative period due to severe LV-LA shunt in infant with complete AVSD. Ozaki A1, Okamoto H1: ICCVA-ASCA 2019 (2019/6/8), Korea. (”öè@‰·1, ‰ª–{_Žk1: 1–ƒŒ)

713140. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Does intraocular pressure during prone spinal surgery differ according to the type of head-fixing device used (a horseshoe headrest versus a pinned head-holder) ? Yamashita A1, Takenami T1, Yamamoto S1, Ikeda T, Suzuki T, Okamoto H1: The American Society of Anesthesiologists (ASA 2019) (2019/10/20), Orlando, Florida. (ŽR‰º@“Ö1, ’|˜Q–¯]1, ŽR–{^–ç1, ‰ª–{_Žk1: 1–ƒŒ)

722230. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŠÉ˜aˆã—Âɂš‚¯‚é’É‚Ý‚ª‚à‚œ‚ç‚·‰e‹¿. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): ‘æ30‰ñ“ú–{ˆãŠw‰ï‘‰ï (2019/4/27), –ŒŒÃ‰®.

722231. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) –ƒŒ‰Èê–åˆã‚É•K—v‚ÈŒoH“¹SƒGƒR[–@ (TEE) ‚ÌŠî‘b’mŽ¯. ‰ª–{_Žk (–ƒŒ): “ú–{–ƒŒ‰ÈŠw‰ï‘æ66‰ñŠwpW‰ï (2019/5/30), _ŒË.

722232. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ’ɂ݂̍\‘¢‚ƕω». ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): ‘æ13‰ñ“ú–{ŠÉ˜aˆã—ÖòŠw‰ï”N‰ï (2019/6/1), ç—t.

722233. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) æ“V«SŽŸŠ³Š³ŽÒ‚ɑ΂·‚é”ñS‘ŸŽèp‚Ì–ƒŒŽž‚Ì‹ô”­Ç‚ÌŒŸ“¢. ‰ª–{_Žk (–ƒŒ): “ú–{—Տ°–ƒŒŠw‰ï‘æ39‰ñ‘å‰ï (2019/11/7), Œyˆä‘ò.

722234. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ŒoƒJƒe[ƒeƒ‹‚š‚æ‚ÑMICS‚É‚æ‚éASD•Âœp‚ÆTEE. ‰ª–{_Žk (–ƒŒ): “ú–{—Տ°–ƒŒŠw‰ï‘æ39‰ñ‘å‰ï (2019/11/8), Œyˆä‘ò.

722235. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ŽÎŽ‹Žèp‚̏pŒã’Á’É: ƒeƒmƒ“ùN‰ºƒuƒƒbƒN‚𒆐S‚É. Œ“cO”ü1, ‰ª–{_Žk1 (1–ƒŒ): “ú–{¬Ž™–ƒŒŠw‰ï‘æ25‰ñ‘å‰ï (2019/11/16), •ÄŽq.

722236. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) 3DTEE Šî‘b. ‰ª–{_Žk1, ‘Ÿ“c—²Žk (1–ƒŒ): “ú–{S‘ŸŒŒŠÇ–ƒŒŠw‰ï‘æ24‰ñŠwp‘å‰ï (2019/9/21), ‹ž“s.

722237. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ƒJƒe[ƒeƒ‹Žèp‚ÆTEE TAVI (TAVR) Mitral Clipping ASD occluder. ‰ª–{_Žk (–ƒŒ): “ú–{S‘ŸŒŒŠÇ–ƒŒŠw‰ï‘æ24‰ñŠwp‘å‰ï (2019/9/22), ‹ž“s.

723776. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Ò‘‚­‚à–Œ‰º–ƒŒŒã‚̌ċz—}§‚ɃXƒeƒƒCƒh‚ª’˜Œø‚µ‚œdÇ‹Ø–³—͏NJ³ŽÒ‚Ì1Ç—á. ’|’†~Œå1, ’|˜Q–¯]1, ŽR‰º@“Ö1, ì’[ää»Žq1, –x]ÊD1, ‰ª–{_Žk1 (1–ƒŒ): “ú–{‹æˆæ–ƒŒŠw‰ï‘æ6‰ñŠwpW‰ï (2019/4/18), ‚’m.

723777. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) d–ŒŠO‚Ü‚œ‚͐Ґ‘‚­‚à–Œ‰º‰–Ž_ƒ‚ƒ‹ƒqƒl“Š—^‚Í”DP‚É‚š‚¯‚é‹ô”­“Id–ŒúŽhŒã“ª’É‚Ì—\–h‚É—LŒø‚Å‚ ‚é. “¡–ìŽÑ‹M1, “úŒür•ã1, “¡“c“ߌb1, ×ìKŠó, ‰œ•xr”V1 (1–ƒŒ): “ú–{‹æˆæ–ƒŒŠw‰ï‘æ6‰ñŠwpW‰ï (2019/4/18-20), ‚’m.

723778. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬Ž™‚Ì–ƒŒ‘O“Š–ò‚Æ‚µ‚Ä‚ÌŒoŒûƒ~ƒ_ƒ]ƒ‰ƒ€‚ÌŒŒ’†”Z“x‚Æ’ÁÃ“x‚Ì”äŠr. ’|’†~Œå1, Œ“cO”ü1, ŽR‰º@“Ö1, ŽR–{^–ç1, ‰ª–{_Žk1 (1–ƒŒ): “ú–{–ƒŒ‰ÈŠw‰ï‘æ66‰ñŠwpW‰ï (2019/5/30), _ŒË.

723779. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’鉀ØŠJp‚̊ŒŒˆ³‚É‚Í“üŽºŽž‚ÌŒŒˆ³‚Í“K‚³‚È‚¢. ‘ºŒ–Ÿ“ú1, ×ìKŠó1, “¡–ìŽÑ‹M1, “úŒür•ã1, ‰œ•xr”V1, ‰ª–{_Žk1 (1–ƒŒ): “ú–{–ƒŒ‰ÈŠw‰ï‘æ66‰ñŠwpW‰ï (2019/5/30), _ŒË.

723780. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “ª’áˆÊ‚ōs‚€ƒƒ{ƒbƒgŽx‰‡• o‰º‘O—§‘B“Eœ (RALP) p’†‚̊ሳãž. ¬–ìçq1, ’|˜Q–¯]1, r@«’q1, ãˆä䝗LŽq1, ‰ª–{_Žk1 (1–ƒŒ): “ú–{–ƒŒ‰ÈŠw‰ï‘æ66‰ñŠwpW‰ï (2019/5/30), _ŒË.

723781. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”x“®–¬•Ù•a•Ï‚𔺂€æ“V«SŽŸŠ³‚̍Ďèp‚̃ŠƒXƒNˆöŽq‚Æ—\Œã‚ÌŒŸ“¢. ‰“ŽR@Œõ1, –x]ÊD1, ”öè@‰·1, ¬–ìçq1, ŒË“c‰ë–ç1, ‰ª–{_Žk1 (1–ƒŒ): “ú–{–ƒŒ‰ÈŠw‰ï‘æ66‰ñŠwpW‰ï (2019/5/31), _ŒË.

723782. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) TpŠú‚̃IƒsƒIƒCƒh“Š—^‚É‚š‚¯‚銎Šo臒l‚Ì’²ž. —é–؍¹—R”ü1, —с@Œol1, r@«’q1, ‹àˆäº•¶1,2, ‰ª–{_Žk1 (1–ƒŒ, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): “ú–{–ƒŒ‰ÈŠw‰ï‘æ66‰ñŠwpW‰ï (2019/5/31), _ŒË.

723783. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆÓŽ¯‰º‘}ŠÇ‚É‚š‚¯‚é’ÁÃ“x‹y‚Ñ‘}ŠÇŽž‹L‰¯‚ÉŠÖ‚·‚éŒã‚ëŒü‚«ŒŸ“¢. –xŽÑ—F‰Ä1, ˆÉ“¡—@Žq2, ‘ºŒ—I‰Ø1, r@«’q1, —é–Ø—D‘Ÿ˜Y1, ‰ª–{_Žk1 (1–ƒŒ, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): “ú–{–ƒŒ‰ÈŠw‰ï‘æ66‰ñŠwpW‰ï (2019/5/31), _ŒË.

723024. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) • –Œ‰ŠŽž‚̉¡Šu–ŒƒŠƒ“ƒpŠÇV¶‚𐧌䂷‚éŽó—e‘ÌŠˆ«’²ß’`”’1 (RAMP1) ‚Ì–ðŠ„. ’ׯ¢—¢1, ˆÉ“¡‹`–ç2, ×–ì‰Á“ÞŽq2, ˆäã’qm3, Œ“cO”ü4, åUdçŠG4, ’†–{CŽi1, ‘卂Žj¹1, ‰ª–{_Žk4, ”n“ˆ³—²2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–ò—, 3Á‰»Ší“à, 4–ƒŒ): ‘æ40‰ñ“ú–{‰ŠÇ¥Ä¶ˆãŠw‰ï (2019/7/16), _ŒË.

723784. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”x‚ª‚ñ‚ɑ΂·‚éƒjƒ{ƒ‹ƒ}ƒu“Š—^Š³ŽÒ‚É‚š‚¯‚é‘яóáv]‚Ì”­¶ (—DG‰‰‘è). r@«’q1, ‹àˆäº•¶1,2, —с@Œol1, ‰Í‘º’ŒŽ÷1, ‰ª–{_Žk1 (1–ƒŒ, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): “ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ï‘æ53‰ñ‘å‰ï (2019/7/19), ŒF–{.

723785. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Œƒ‚µ‚¢‘J‰„«pŒã’ɂɑ΂·‚éÒ‘ŽhŒƒ—Ö@‚Å’É‚Ý‚ÆADL‚ÌŒø‰Ê‚É–µ‚‚𐶂¶‚œ2Ç—á. —с@Œol1, ‹àˆäº•¶1,2, ‰Í‘º’ŒŽ÷1, r@«’q1, ‰ª–{_Žk1 (1–ƒŒ, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): “ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ï‘æ53‰ñ‘å‰ï (2019/7/19), ŒF–{.

723786. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¯ó_ŒoßƒuƒƒbƒN‚ƃXƒeƒƒCƒhƒpƒ‹ƒX—Ö@‚ʼnü‘P‚µ‚œ_Œo’ɐ«‹ØˆÞkÇ‚Ì1—á. ‰Í‘º’ŒŽ÷1, ‹àˆäº•¶1,2, —с@Œol1, r@«’q1, ‰ª–{_Žk1 (1–ƒŒ, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): “ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ï‘æ53‰ñ‘å‰ï (2019/7/19), ŒF–{.

723787. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”x“®–¬ƒJƒe[ƒeƒ‹‚É‚æ‚é”x“®–¬‘¹‚𗈂µV-VA ECMO‚ðŽg—p‚µ‹~–œ‚µ‚œ1—á. ™‘ºŒ›—º1, ì’[ää»Žq1, ˆÀ“¡ŽõŒb1, —é–Ø›’Žk1, ŒË“c‰ë–ç1, ‰ª–{_Žk1 (1–ƒŒ): “ú–{S‘ŸŒŒŠÇ–ƒŒŠw‰ï‘æ24‰ñŠwp‘å‰ï (2019/9/20), ‹ž“s.

723788. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) p‘O‚Ì6•ªŠÔ•às‹——£ (6MD) ‚ÍŒoƒJƒe[ƒeƒ‹“I‘å“®–¬•Ù’uŠ·p (TAVI) ‚É‚š‚¯‚épŒã‚¹‚ñ–Ï”­¶‚ð—\‘ª‚·‚é. ŽR‰º@“Ö1, ˆÀ“¡ŽõŒb1, Œ“cO”ü1, ™‘ºŒ›—º1, ‰ª–{_Žk1 (1–ƒŒ): “ú–{S‘ŸŒŒŠÇ–ƒŒŠw‰ï‘æ24‰ñŠwp‘å‰ï (2019/9/22), ‹ž“s.

723789. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —zˆ³•â•Š·‹C‚ð‚µ‚È‚ª‚ç‹CŠÇŽx‹Ÿ‰ºŒo•@‘}ŠÇ‚ðs‚Á‚œ“ûŽ™‚̍bóãŠÇùN–E‚̈ê—á. —é–؍¹—R”ü1, Œ“cO”ü1, ’†àVˆº”T1, ˆÉ“¡—@Žq2, “¡–ìŽÑ‹M1, ŽÂŒŽŒcŽq1, ¬—ѐç‰Ä1, ‰ª–{_Žk1 (1–ƒŒ, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): “ú–{¬Ž™–ƒŒŠw‰ï‘æ25‰ñ‘å‰ï (2019/11/16), •ÄŽq.

723105. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Potential role of invariant NKT cells in experimental autoimmune myocarditis in mice. ‹g–ì˜a‹v1, ²“¡@‰ë2, Watarai H, ŠâŸº˜a–ç2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–Ɖu): ‘æ48‰ñ“ú–{–ƉuŠw‰ïŠwpW‰ï (2019/12/12), •lŒ.

723029. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –Ɖu×–E‚ÌTPƒVƒOƒiƒ‹‚Í• –Œ‰ŠŽž‚̉¡Šu–ŒƒŠƒ“ƒpŠÇV¶‚𑣐i‚·‚é (TP signaling in immune cells promotes lymphangiogenesis in the diaphragm during peritonitis). ’ׯ¢—¢1, ˆÉ“¡‹`–ç2, Œ“cO”ü3, ×–ì‰Á“ÞŽq2, ‰ª–{_Žk3, ”n“ˆ³—²2 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–ò—, 3–ƒŒ): ‘æ93‰ñ“ú–{–ò—Šw‰ï”N‰ï (2020/3/16-18), Ž†ãŠJÃ.

731104. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) –«áu’É‚Ö‚Ì‘œŠp“IƒAƒvƒ[ƒ`. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): •œ’Ë–«áu’ɍu‰‰‰ï (2019/7/24), •œ’Ë.

731105. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ’ɂ݂̍\‘¢‚ōl‚Š‚é’Á’É–ò‚Ì‘I‘ð. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): ‘æ7‰ñ‰¡•lìèÒ’ŁEŠÖß•aƒZƒ~ƒi[ (2019/8/27), ‰¡•l.

731106. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ‚ª‚ñŠ³ŽÒ‚ɑ΂·‚éƒIƒsƒIƒCƒh’Á’É–ò‚ðÄl‚·‚é. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): ‘æ6‰ñ–L•œ‚ª‚ñŠÉ˜aŒ€‹†‰ï (2019/10/16), ŽD–y.

731107. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ’ɂ݂̍\‘¢‚ōl‚Š‚é’Á’É–ò‚Ì‘I‘ð. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): 2020”N“xŒ€CˆãƒZƒ~ƒi[ (2020/1/18), ‘Š–ÍŒŽ.

731108. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ãŽˆ‚̒ɂ݂̑Ήž. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): ‘æ9‰ñ‰¡•lãŽˆŽèpƒZƒ~ƒi[ (2020/1/31), ‰¡•l.

732127. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒVƒ“ƒ|ƒWƒEƒ€) bó‘BŽèp‚É‚š‚¯‚éˆã—ÈÀ‘S, ƒ`[ƒ€ˆã—Ã: Rapid Response System‚͍bó‘BpŒãèò•”ŒŒŽî‚É‚æ‚éS’âŽ~‰ñ”ð‚É—L—p‚©? Vˆä³N1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): ‘æ1‰ñº˜a‘åŠwbó‘BƒtƒH[ƒ‰ƒ€ŠwpW‰ï (2019/5/18), “Œ‹ž.

732128. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) ƒqƒhƒƒ‚ƒ‹ƒtƒHƒ“‚ðŠˆ‚©‚·. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): ‘æ2‰ñ‘Š–ÍŒŽŠÉ˜aˆã—ÃŒ€‹†‰ï (2019/5/23), ‘Š–Í‘å–ì.

732129. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) Žå‚È’Á’É–ò‚Ì–â‘è“_‚Æ, ‚»‚ê‚ð•â‚€ƒuƒvƒŒƒmƒ‹ƒtƒBƒ“. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): National Symposium on Pain focus. How to optimize opioid treatment for LBP/OA (2019/5/25), “Œ‹ž.

732130. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) ‚ª‚ñŠ³ŽÒ‚Ìáu’ÉŠÇ—. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): ‚ª‚ñáu’É‚ðl‚Š‚é‰ï (2019/6/10), ‘Š–ÍŒŽ.

732131. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) Rapid Response System RRS‚Ƃ͉œ‚©? ‚È‚º•K—v‚©? Vˆä³N1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): ’¹Žæ‘åŠwˆãŠw•”•‘®•a‰@ ˆã—ÈÀ‘SuK‰ï (2019/6/21), •ÄŽq.

732132. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) Rapid Response System RRS‚Ƃ͉œ‚©? ‚È‚º•K—v‚©? Vˆä³N1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): VŠƒ‘åŠwˆãŽ•Šw‘‡•a‰@ ˆã—ÈÀ‘SuK‰ï (2019/6/27), VŠƒ.

732133. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) Rapid Response System RRS‚Ƃ͉œ‚©? ‚È‚º•K—v‚©? Vˆä³N1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): ŠâŽèˆã‰È‘åŠw•‘®•a‰@ ˆã—ÈÀ‘SuK‰ï (2019/7/5), ·‰ª.

732134. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) Rapid Response System RRS‚Ƃ͉œ‚©? ‚È‚º•K—v‚©? Vˆä³N1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): é‹Êˆã‰È‘åŠw‘Ûˆã—ÃZƒ“ƒ^[ ˆã—ÈÀ‘SuK‰ï (2019/7/29), “ú‚.

732135. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) Äl: ƒuƒvƒŒƒmƒ‹ƒtƒBƒ““\•tÜ‚Ì—L—p«. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): M3 Webu‰‰ (2019/8/8), “ú–{‹Ž.

732136. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) ’á—p—ʃtƒFƒ“ƒ^ƒjƒ‹“\•tÜ‚ÌŠˆ—p. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): ‹vŒõ»–òŠ”Ž®‰ïŽÐWebu‰‰‰ï (2019/9/26), WEBã.

732137. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) —Տ°ˆã‚Ì—§ê‚©‚çƒIƒsƒIƒCƒh’Á’É–ò‚ðÄl‚·‚é. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): Cancer Pain Forum in Kanagawa (2019/10/18), ‰¡•l.

732138. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) ƒIƒsƒIƒCƒh’Á’É–ò‚Ì“Á«‚ð’m‚é. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): ‘æ3‰ñˆã—ÈÀ‘SƒZƒ~ƒi[ (2019/10/25), ‘Š–ÍŒŽ.

732139. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (Webu‰‰) ƒqƒhƒƒ‚ƒ‹ƒtƒHƒ“‚ðŠˆ‚©‚·. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): ‚ª‚ñáu’ɊɘaƒPƒAWEBƒZƒ~ƒi[ (2019/10/31), –ŒŒÃ‰®.

732140. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) ‚ª‚ñŠ³ŽÒ‚ɑ΂·‚éÒ‘‚­‚à–Œ‰º’Á’É–@. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): Ò‘‚­‚à–Œ‰º’Á’ɍu‰‰‰ï (2019/11/7), Œú–Ø.

732141. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) ‚ª‚ñŠ³ŽÒ‚ɑ΂·‚éÒ‘‚­‚à–Œ‰º’Á’É–@. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): Ò‘‚­‚à–Œ‰º’Á’ɍu‰‰‰ï (2020/1/9), ”ª‰€Žq.

732142. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) ƒIƒsƒIƒCƒh’Á’É–ò‚Ì“Á«‚ð’m‚é. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): ‘æ1‰ñ’nˆæ–òÜŽt˜A—‹Š‹c‰ï•×‹­‰ï (2020/1/16), ‘Š–ÍŒŽ.

732143. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) —Տ°ˆã‚Ì—§ê‚©‚çƒIƒsƒIƒCƒh’Á’É–ò‚ðÄl‚·‚é. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): Cancer Pain Forum in Chiba (2020/2/5), ç—t.

732144. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) ‚ª‚ñŠ³ŽÒ‚ɑ΂·‚éÒ‘‚­‚à–Œ‰º’Á’É–@. ‹àˆäº•¶1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): Ò‘‚­‚à–Œ‰º’Á’ɍu‰‰‰ï (2020/2/6), ‰¡•l.

733733. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) š\ŒŒŠù‰‚Ì‚ ‚ébó‘BŽî‚É‚æ‚é‹CŠÇÃ–¬áŽ‚ɑ΂µ‚Ä‘Sg–ƒŒ‚ðŽ{s‚µ‚œ1—á. ”öè@‰·1, ˆÀ’B@Œ’1, •Šâ­”V1, ‰ª–{_Žk1 (1–ƒŒ): ŠÖ“ŒbM¥“Œ‹žŽx•”‘æ56‰ñ‡“¯ŠwpW‰ï (2019/9/3), “Œ‹ž.

733734. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) –ƒŒ“±“üŽžƒ}ƒXƒNŠ·‹C•s”\‚ɊׂÁ‚œTreacher Collins syndrome‚Ì“ûŽ™‚ɑ΂µi-gelŽg—p‚É‚æ‚芷‹C‚Æ‹CŠÇ‘}ŠÇ‚ɐ¬Œ÷‚µ‚œÇ—á‚Ì–ƒŒŒoŒ±. ’·“céŽq1, Œ“cO”ü1, –x]ÊD1, ‰ª–{_Žk1 (1–ƒŒ): ŠÖ“ŒbM¥“Œ‹žŽx•”‘æ56‰ñ‡“¯ŠwpW‰ï (2019/9/3), “Œ‹ž.

733735. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) Ò‘‚­‚à–Œ‰º–ƒŒŠÇ—‰º‚Å‘å‘Úƒ^[ƒjƒPƒbƒg‰ðœŒã‚ɍ‚“x™–¬‚ð‚«‚œ‚µ‚œ1—á. ‘ºŒ—I‰Ø1, ŠÖ“cº•F1, ‰¡ŽR—F, ²“¡Ž•F1, ‰ª–{_Žk1, ¬âN°1 (1–ƒŒ): ŠÖ“ŒbM¥“Œ‹žŽx•”‘æ56‰ñ‡“¯ŠwpW‰ï (2019/9/3), “Œ‹ž.

733736. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) –ƒŒ“±“üŒã‚̏dÇƒAƒiƒtƒBƒ‰ƒLƒV[ƒVƒ‡ƒbƒN‚ɑ΂µ, Žèp’†Ž~‚Æ‚È‚Á‚œ‚ª‘Œ‰È‚̘AŒg‚É‚æ‚èÄŽèp‚ðŠ®‹‚µ‚Š‚œˆê—á. ŽR˜H—TO1, ŽR‰º@“Ö1, ãˆä䝗LŽq1, ‰ª–{_Žk1 (1–ƒŒ): ŠÖ“ŒbM¥“Œ‹žŽx•”‘æ56‰ñ‡“¯ŠwpW‰ï (2019/9/3), “Œ‹ž.

'18”N“xˆÈ‘O•ª

[Šwp˜_•¶]

H27-110001. [ŒŽ’˜] Neuroprotective effect of nitite-derived NO in brain injury mediated through the NOS-independent but not the GC/COX/xanthine oxidase/PGIS-dependent pathways. Ando H1, Nara Y, Kosaka Y1, Arai M1,2, Okamoto H1: Kitasato Med J 2016/3; 46 (1): 67-72. (ˆÀ“¡ŽõŒb1, ¬âN°1, Vˆä³N1,2, ‰ª–{_Žk1: 1–ƒŒ, 2V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã)

H29-522001. [uÀ]y“ÁW: PICS W’†Ž¡—ÃŒãÇŒóŒQzPart 3 PICS 3—v‘f@[ƒRƒ‰ƒ€] PICS-F (family) ‚Ƃ͉œ‚©? Vˆä³N1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): INTENSIVIST 2018/1; 10 (1): 98-106.

'18-520001. [‘à] ‰@“à‹}•Ï‚𖢑R‚É–h‚®|RRS‚̍l‚Š•û, “±“üEŒp‘±‚̃AƒCƒfƒBƒA|. Vˆä³N1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): Š³ŽÒˆÀ‘S„iƒWƒƒ[ƒiƒ‹ 2018/6; 52: 10-7.

'18-520002. [‘à] ”x‚Æ”]‚Ì‘ŸŠíƒNƒƒXƒg[ƒN. Vˆä³N1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): —Տ°–ƒŒ 2019/1; 43 (1): 9-15.

[’˜@‘]

'18-620010. [Šwp‘ (•ª’SŽ·•M)]y’N‚à‚±‚±‚Ü‚Å‹³‚Š‚Ä‚­‚ê‚È‚©‚Á‚œ@‚È‚é‚قǐlHŒÄ‹zŠÇ— (ŒÄ‹zŠíƒPƒA2018”N“~‹G‘Š§)z[1Í ŒÄ‹z¶—]@(1) ‹C“¹‚̉ð–U¶—, p.8-18. Vˆä³N1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ), ŠÄC: ˆÀ‘îˆêW, ƒƒfƒBƒJo”Å, ‘åã, 2018/12”­s.

[Šw‰ïEŒ€‹†‰ï“™]

H29-732001. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) Rapid Response System‚Ƃ͉œ‚©? RRS‚Ƃ͉œ‚©? ‚È‚º•K—v‚©? Vˆä³N1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): ˆã—ÈÀ‘S‹³ˆçƒZƒ~ƒi[ (ŽÀ‘H•Ò) 2017@‚æ‚荂“x‚Ȉã—ÈÀ‘S‚ÖŒü‚¯‚Ä (2017/10/21), “Œ‹ž.

H29-732002. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) Rapid response system‚Æ‚Í? ‰@“àS’âŽ~‚ð–h‚®‚œ‚ß‚É‚Ç‚€‚·‚é‚©? Vˆä³N1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): O‘O‘åŠwˆãŠw•”•t‘®•a‰@ˆã—ÈÀ‘Su‰‰ (2017/10/13), O‘O.

H29-732003. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) Rapid response system‚Æ‚Í? Vˆä³N1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): ‰¡•lŽs—§‘åŠwˆãŠw•”•‘®•a‰@ˆã—ÈÀ‘SuK‰ï (2017/9/21), ‰¡•l.

'18-722008. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) bó‘BŠO‰ÈŽ¡—Âɂš‚¯‚éˆã—ÈÀ‘S: bó‘BpŒã‚Ìèò•”ŒŒŽî‚Ì‘Šú”­Œ©‚Ɖî“ü‚ÉRapid Response System‚Í—LŒø‚©? Rapid Response System‚̉”\«‚Æ–â‘è“_. Vˆä³N1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): ‘æ51‰ñ“ú–{bó‘BŠO‰ÈŠw‰ïŠwpW‰ï (2018/10/25), ‰¡•l.

'18-722009. [Šw‰ï (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ‰@“à‹}•Ï‘ΉžƒVƒXƒeƒ€`‚¢‚©‚É“±“ü‚µ‚Ь‰Ê‚ð‚ ‚°‚é‚©` Rapid Response System‚Ì“±“ü, ’è’…‚ÉŠÖ‚í‚éí—ª, “–‰@‚ÌŒ»‹µ, “±“ü, ’è’…‚ÉŠÖ‚í‚éí—ª. Vˆä³N1,2, XˆÀŒbŽÀ, ¬’r•üF, ‘å’J®–ç3, •Šâ­”V1, ” “c”ü’mŒb4, “y‰®Žu•Û4, rˆä—L”ü4, ’¹ˆäWŽO5 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ, 3ŠÅŒì•”, 4ˆã—Â̎¿EˆÀ‘S„iŽº, 5ˆã—ËZp‹³ˆç): ‘æ13‰ñ“ú–{ˆã—Â̎¿EˆÀ‘SŠw‰ïŠwpW‰ï (2018/11/24), –ŒŒÃ‰®.

'18-722010. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) RRS‚ÉŠú‘Ò‚³‚ê‚éˆã—ÈÀ‘S‚Ƃ̘AŒg\ŽŸ¢‘ã‚ÉŒü‚¯‚œV‚µ‚¢—¬‚ê[“–‰@‚ł̏ˆ’uE’ÁÃŽž‚É‚š‚¯‚éRRS‹N“®Ç—á‚ÌŒŸ“¢. ŒàV‹`”V1, •Šâ­”V1, ¬’r•üF, XˆÀŒbŽÀ, ‘å’J®–ç2, ‘ºŒ–Ÿ“ú1, —é–Ø—D‘Ÿ˜Y1, ãˆä䝗LŽq1, ‘å’Ë’q‹v1, Vˆä³N1,3 (1–ƒŒ, 2ŠÅŒì•”, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ46‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ï (2019/3/2), ‹ž“s.

'18-732002. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) uˆã—Âɖ𗧂ƒ`[ƒ€‚Ì‚ ‚è•ûv ˆãŽt‚Ì—§ê‚©‚ç Rapid Response Team‚Ƃ͉œ‚©? Vˆä³N1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): 2018”N“x ‘æ1‰ñŠ³ŽÒˆÀ‘S„i’nˆæƒtƒH[ƒ‰ƒ€ in –k—¢ (2018/5/19), ‘Š–ÍŒŽ.

'18-732003. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) ƒ[ƒNƒVƒ‡ƒbƒN2: ‰@“à‹}•Ï‘Ήž@‹}•Ï‚·‚é‘O‚ÉŒ©‚‚¯‚Ä”õ‚Š‚é‚Æ‚¢‚€l‚Š•û`Rapid Response System`. Vˆä³N1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): ‘æ32‰ñ“Œ–k‹~‹}ˆãŠw‰ï (2018/6/16), ŽRŒ`.

'18-732004. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) Rapid Response System‚Æ‚Í? RRS‚Ƃ͉œ‚©? ‚È‚º•K—v‚©? Vˆä³N1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): ˆÇ—Ñ‘åŠwˆãŠw•”•t‘®•a‰@@ˆã—ÈÀ‘Su‰‰‰ï (2018/10/29), “Œ‹ž.

'18-732005. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) Rapid Response System‚Æ‚Í? RRS‚Ƃ͉œ‚©? ‚È‚º•K—v‚©? Vˆä³N1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): ŽRŒ`Œ§—§’†‰›•a‰@‰@“àŒ€C‰ï (2018/12/2), ŽRŒ`.

'18-732006. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) Rapid Response System‚Æ‚Í? RRS‚Ƃ͉œ‚©? ‚È‚º•K—v‚©? Vˆä³N1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): —®‹…‘åŠwˆãŠw•”•‘®•a‰@Œ€C‰ï (2019/1/25), “ß”e.

'18-732007. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) Rapid Response System‚Æ‚Í? RRS‚Ƃ͉œ‚©? ‚È‚º•K—v‚©? Vˆä³N1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): “ú–{ˆã—Ã}ƒlƒWƒƒ“ƒgŠw‰ï‘æ9‰ñ‰«“ꌧŽx•”ŠwpW‰ï (2019/1/26), “ß”e.

'18-732008. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) Rapid Response System‚Æ‚Í? RRS‚Ƃ͉œ‚©? ‚È‚º•K—v‚©? Vˆä³N1,2 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2–ƒŒ): –ƒ¶”Ñ’Ë•a‰@‰@“àu‰‰‰ï (2019/2/1), ”Ñ’Ë.


—Տ°ŒŸžf’fŠw

[’˜@‘]

620086. [Šwp‘ (•ª’SŽ·•M)]y“à‰ÈŠw‘ 5 ‰ü’è‘æ9”ŁzŒŒŸ÷’`”’‚ÌŽí—Þ‚Æ‹@”\, p.489-11. ‘å’J‰pŽ÷, Žë–ì—Lì1 (1—ÕŒŸŠw), ‘•ÒW: “ìŠw³b, •Ò: ‰º‘ºˆÉˆê˜Y, ’†ŽR‘“X, “Œ‹ž, 2019/8”­s.

'18”N“xˆÈ‘O•ª

[’˜@‘]

'18-620011. [Šwp‘ (•ª’SŽ·•M)]yÅV ŒŸžE‰æ‘œf’fŽ–“T 2018-19”N”Ł@ŒŸž‚ÌŽè‹ZE“K‰žŽŸŠ³E•ÛŒ¯¿‹‚ª‚·‚ׂĂ킩‚ézƒAƒWƒXƒJƒEƒ“ƒg, p.299. Žë–ì—Lì (—ÕŒŸŠw), •Ò’˜: “ú–{—Տ°ŒŸžˆãŠw‰ï, ˆãŠw’ʐMŽÐ, “Œ‹ž, 2018/5”­s.

'18-620012. [Šwp‘ (•ª’SŽ·•M)]yÅV ŒŸžE‰æ‘œf’fŽ–“T 2018-19”N”Ł@ŒŸž‚ÌŽè‹ZE“K‰žŽŸŠ³E•ÛŒ¯¿‹‚ª‚·‚ׂĂ킩‚ézƒ‚[ƒ[ƒ“ƒ^[ƒ‹–@, p.299. Žë–ì—Lì (—ÕŒŸŠw), •Ò’˜: “ú–{—Տ°ŒŸžˆãŠw‰ï, ˆãŠw’ʐMŽÐ, “Œ‹ž, 2018/5”­s.

'18-620013. [Šwp‘ (•ª’SŽ·•M)]yÅV ŒŸžE‰æ‘œf’fŽ–“T 2018-19”N”Ł@ŒŸž‚ÌŽè‹ZE“K‰žŽŸŠ³E•ÛŒ¯¿‹‚ª‚·‚ׂĂ킩‚ézƒtƒBƒbƒVƒ…ƒo[ƒOŽŽŒ±, p.299. Žë–ì—Lì (—ÕŒŸŠw), •Ò’˜: “ú–{—Տ°ŒŸžˆãŠw‰ï, ˆãŠw’ʐMŽÐ, “Œ‹ž, 2018/5”­s.

'18-620014. [Šwp‘ (•ª’SŽ·•M)]yÅV ŒŸžE‰æ‘œf’fŽ–“T 2018-19”N”Ł@ŒŸž‚ÌŽè‹ZE“K‰žŽŸŠ³E•ÛŒ¯¿‹‚ª‚·‚ׂĂ킩‚ézäNã÷”A“¹ƒtƒ@ƒCƒo[ƒXƒRƒs[, p.316. Žë–ì—Lì (—ÕŒŸŠw), •Ò’˜: “ú–{—Տ°ŒŸžˆãŠw‰ï, ˆãŠw’ʐMŽÐ, “Œ‹ž, 2018/5”­s.

'18-620015. [Šwp‘ (•ª’SŽ·•M)]yÅV ŒŸžE‰æ‘œf’fŽ–“T 2018-19”N”Ł@ŒŸž‚ÌŽè‹ZE“K‰žŽŸŠ³E•ÛŒ¯¿‹‚ª‚·‚ׂĂ킩‚ézäNã÷”A“¹‹ŸŒŸž, p.317. Žë–ì—Lì (—ÕŒŸŠw), •Ò’˜: “ú–{—Տ°ŒŸžˆãŠw‰ï, ˆãŠw’ʐMŽÐ, “Œ‹ž, 2018/5”­s.

'18-620016. [Šwp‘ (•ª’SŽ·•M)]yÅV ŒŸžE‰æ‘œf’fŽ–“T 2018-19”N”Ł@ŒŸž‚ÌŽè‹ZE“K‰žŽŸŠ³E•ÛŒ¯¿‹‚ª‚·‚ׂĂ킩‚éz”AŠÇƒJƒe[ƒeƒ‹, p.318. Žë–ì—Lì (—ÕŒŸŠw), •Ò’˜: “ú–{—Տ°ŒŸžˆãŠw‰ï, ˆãŠw’ʐMŽÐ, “Œ‹ž, 2018/5”­s.

'18-620017. [Šwp‘ (•ª’SŽ·•M)]yÅV ŒŸžE‰æ‘œf’fŽ–“T 2018-19”N”Ł@ŒŸž‚ÌŽè‹ZE“K‰žŽŸŠ³E•ÛŒ¯¿‹‚ª‚·‚ׂĂ킩‚ézt᱔AŠÇƒtƒ@ƒCƒo[ƒXƒRƒs[, p.318. Žë–ì—Lì (—ÕŒŸŠw), •Ò’˜: “ú–{—Տ°ŒŸžˆãŠw‰ï, ˆãŠw’ʐMŽÐ, “Œ‹ž, 2018/5”­s.


—AŒŒE×–EˆÚAŠw

[Šwp˜_•¶]

110344. [ŒŽ’˜] Reduction in adverse transfusion reactions with increased use of washed platelet concentrates in Japan-A retrospective multicenter study. Ikebe E, Matsuoka S, Tanaka A, Yonemura Y, Fujii Y, Ohsaka A, Okazaki H, Kitazawa J, Ohtani S1, Nakayama T, Momose S, Miwa I, Taira R, Toyota K, Kino S, Kato H, Hamaguchi I: Transfus Apher Sci 2019/4; 58 (2): 162-8. (‘å’JTˆê1: 1—AŒŒE×–EˆÚA)

110345. [ŒŽ’˜] Characteristics of palliative home care for patients with hematological tumors compared to those of patients with solid tumors. Ishida T1, Ohashi K, Okina C2, Ohashi S, Okina S3, Miyazaki K1, Suzuki T3: Int J Hematol 2019/8; 110 (2): 237-43. (Î“c@—²1, ‰¥çŽq2, ‰¥@‘cœ3, ‹{ø“_“ñ1, —é–Ø—²_3: 1—AŒŒE×–EˆÚA, 2t‘Ÿ“à, 3ŒŒ‰t“à)

110346. [ŒŽ’˜] Characteristics of palliative home care for patients with hematological tumors compared to those of patients with solid tumors. Ishida T1, Ohashi K, Okina C2, Ohashi S, Okina S3, Miyazaki K1, Suzuki T3: Int J Hematol 2019/8; 110 (2): 237-43. (Î“c@—²1, ‰¥çŽq2, ‰¥@‘cœ3, ‹{ø“_“ñ1, —é–Ø—²_3: 1—AŒŒE×–EˆÚA, 2t‘Ÿ“à, 3ŒŒ‰t“à)

310041. [Ç—á•ñ] The clinical outcomes of chronic myeloid leukemia patients harboring alternatively spliced BCR-ABL variants. Ishida T1, Miyazaki K1, Okina S2, Miyata T3, Hayama K3, Higashihara M2, Suzuki T2: Hematology 2019/12; 24 (1): 49-51. (Î“c@—²1, ‹{ø“_“ñ1, ‰¥@‘cœ2, –{‹Ž’m”ü3, ‰HŽRŒdˆÈ3, “ŒŒŽ³–Ÿ2, —é–Ø—²_2: 1—AŒŒE×–EˆÚA, 2ŒŒ‰t“à, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È)

320046. [Ç—á•ñ] Ibrutinib“Š—^’†‚É’ÜŽüˆÍ‰Š‚Æ“÷‰èŒ`¬‚ðŒJ‚è•Ô‚µ”­Ç‚µR¶ÜŽ¡—Âʼnü‘P‚µ‚œ–«ƒŠƒ“ƒp«”’ŒŒ•a. Î“c@—²1, ‹{ø“_“ñ1, ‰HŽRŒdˆÈ2, –x]—Ljê3, —é–Ø—²_4 (1—AŒŒE×–EˆÚA, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ˆã—Éq¶Šw•”, 4ŒŒ‰t“à): —Տ°ŒŒ‰t 2019/5; 60 (3): 153.

[’˜@‘]

620087. [Šwp‘ (•ª’SŽ·•M)]yŒŒ‰tê–åˆãƒeƒLƒXƒg ‰ü’ù‘æ3”Łz•¶Í–â‘è@‹€’ʁ^ˆê”Ê–â‘è 23, p.586, p.588. •¶Í–â‘è@“à‰È^ˆê”Ê–â‘è 7, p.594-6. ‹{ø“_“ñ (—AŒŒE×–EˆÚA), •Ò: “ú–{ŒŒ‰tŠw‰ï, “ì]“°, “Œ‹ž, 2019/10”­s.

620088. [Šwp‘ (•ª’SŽ·•M)]yf—×͂ðã‚°‚é! Ç—á–â‘èW (“à‰È2019”N4ŒŽ‘‘卆)z<‘æ9Í ŒŒ‰t> Ç—á–â‘è@“Á”­«ŒŒ¬”ÂŒž­«Ž‡”Á•aˆÛŽ—Ö@’†‚Ì”DP, p.963-4. ‹{ø“_“ñ (—AŒŒE×–EˆÚA), “ì]“°, “Œ‹ž, 2019/”­s.

620089. [Šwp‘ (•ª’SŽ·•M)]yf—×͂ðã‚°‚é! Ç—á–â‘èW (“à‰È2019”N4ŒŽ‘‘卆)z<‘æ9Í ŒŒ‰t> Ç—á–â‘è@“Ë‘R‚̏oŒŒŒXŒü, p.965-6. ‹{ø“_“ñ (—AŒŒE×–EˆÚA), “ì]“°, “Œ‹ž, 2019/”­s.

620090. [Šwp‘ (•ª’SŽ·•M)]y—Տ°HŠwuÀ —Տ°ˆãŠw‘˜_ ‘æ2”Łz‘æ10Í ŒŒ‰t•aŠw@4. oŒŒ«‘fˆö, p.257-62. ‹{ø“_“ñ (—AŒŒE×–EˆÚA), ŠÄC: “ú–{—Տ°HŠw‹ZŽm‹³ˆçŽ{Ý‹Š‹c‰ï, •Ò: ŽÂŒŽˆê•F, ¬’J@“§, ˆãŽ•–òo”Å, “Œ‹ž, 2020/3”­s.

[Šw‰ïEŒ€‹†‰ï“™]

722238. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) •a‰@î•ñƒVƒXƒeƒ€6”NŠÔ‚Ì•à‚Ý. ‘å’JTˆê (—AŒŒE×–EˆÚA): ‘æ67‰ñ“ú–{—AŒŒE×–EŽ¡—Êw‰ïŠwp‘‰ï (2019/5/24), ŒF–{.

723790. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –{–M‚É‚š‚¯‚é‘¢ŒŒŠíŽŸŠ³Š³ŽÒ‚ɑ΂·‚éÔŒŒ‹…—AŒŒ‚̃wƒ‚ƒOƒƒrƒ“臒l‚ÌŒ»ó. ‰¡à_Í•F, ‰œŽR”üŽ÷, ã“c‹±“T, ˆÉ“¡^Ÿ, “¡ŒŽTˆê˜Y, ’·ˆäˆê_, rìm, –q“c‰ë“T, ‹{ø“_“ñ1, ’r“c˜a•F, ‹I–ìCˆê, “c’†’©Žu, ’·’Jì—Yˆê, “¡–윚ŽO, –q–ì–΋`, Œ–{^‹|, ’|‰º–Ÿ—T, Žºˆäˆê’j (1—AŒŒE×–EˆÚA): ‘æ67‰ñ“ú–{—AŒŒE×–EŽ¡—Êw‰ïŠwp‘‰ï (2019/5/23), ŒF–{.

723791. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠÌŽŸŠ³‚É”º‚€“ñŽŸ«–Ɖu«ŒŒ¬”ÂŒž­Ç‚É‚š‚¯‚é•a‘ÔŒ`¬‹@˜‚̉ðÍ. ²“¡—²Ži1, ‘ëŒû”¹l, ‹›“ˆ°‹I2, “ú‚@‰›2, ‹v•Û@œ1, ‹{ø“_“ñ3, –x]—Ljê1 (1ˆã—Éq¶Šw•”, 2Á‰»Ší“à, 3—AŒŒE×–EˆÚA): ‘æ81‰ñ“ú–{ŒŒ‰tŠw‰ïŠwpW‰ï (2019/10/13), “Œ‹ž.

723792. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) 2nd-line‚̍ж•s—ǐ«•nŒŒ‚ð‘ΏۂƂµ‚œƒƒ~ƒvƒƒXƒ`ƒ€‚Ì‘æ2/3‘Š—Տ°ŽŽŒ±‚Ì•”•ªW’c‰ðÍ. ’·“¡GŽi, Jun Ho Jang, Jong Wook Lee, •yŽR‰Àº, ‹{ø“_“ñ1, ‰P‹nŒ›—S, ‹›“ˆL•F, “¡è’q–Ÿ, ¬™_Žj, Œ‘º@“ž, ²X–ØŒõ, –؍菹O, àV@³Žj, “ú‚“¹O, ¬—Ñ’ŒŽ÷, Žsì@‘, •Ä‘º—YŽm, ‰|’JŒõê€, Œ“c@W, ¬àVŒh–ç, ŽO’JŒŠŽq, ’†”öáÁ“ñ (1—AŒŒE×–EˆÚA): ‘æ81‰ñ“ú–{ŒŒ‰tŠw‰ïŠwpW‰ï (2019/10/11), “Œ‹ž.


‹~–œ‹~‹}ˆãŠw

[Šwp˜_•¶]

110347. [ŒŽ’˜] The prevalence and antibiotic susceptibility of Haemophilus influenzae in the Emergency Intensive Care Unit of Kitasato University Hospital. Yamaya T1, Nihonyanagi S2, Takayama Y2.3, Hanaki H4, Nakatani K1, Kataoka Y1, Asari Y1: Kitasato Med J 2019/9; 49 (2): 106-12. (ŽR’J—§‘å1, “ñ–{–öL2, ‚ŽR—zŽq2.3, ‰Ô–؏G–Ÿ4, ’†’JŒ€“l1, •Ð‰ª—Sˆê1, ó—˜@–õ1: 1‹~–œ, 2ŠŽõŠÇ—Žº, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 4‘呺’q‹L”OŒ€‹†Š)

110348. [ŒŽ’˜] Efficacy of transcatheter arterial embolization for spontaneous extraperitoneal hemorrhage. Maruhashi T1,2, Kashimi F1, Kurihara Y1, Oi M1, Tamura S1, Osada M1, Nishimaki H2, Asari Y1: Kitasato Med J 2019/9; 49 (2): 119-24. (ŠÛ‹ŽFº1,2, Š~Œ©•¶Ž}1, ŒIŒŽ—S‘Ÿ˜N1, ‘åˆä^—“Þ1, “c‘º@’q1, ’·“c^—RŽq1, ŒŠª@”Ž2, ó—˜@–õ1: 1‹~–œ, 2¹ƒ}ƒŠƒAƒ“ƒiˆã‰È‘åŠw)

[’˜@‘]

620091. [Šwp‘ (•ª’SŽ·•M)]y¡“ú‚ÌŽ¡—ÃŽwj 2020”N”Ł@Ž„‚Í‚±‚€Ž¡—µ‚Ä‚¢‚éz1. ‹~‹}ˆã—Á@”x‘¹, p.55-6. •Ð‰ª—Sˆê (‹~–œ), ‘•ÒW: •ŸˆäŽŸ–î, ‚–؁@œ, ¬Žºˆê¬, ˆãŠw‘‰@, “Œ‹ž, 2020/1”­s.

[Šw‰ïEŒ€‹†‰ï“™]

722239. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) dÇŠ³ŽÒ‚ɑ΂·‚é‹Ø“÷—Ê‚ð—p‚¢‚œV‚œ‚ȃGƒlƒ‹ƒM[Á”ï—Ê—\‘ªŽ®. •Ð‰ª—Sˆê1, “c‘º@’q1 (1‹~–œ): ‘æ35‰ñ“ú–{—Տ°‰h—{‘ãŽÓŠw‰ïŠwpW‰ï (2020/2/28), ‹ž“s.

723793. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) dÇ‹~‹}Š³ŽÒ‚ɑ΂·‚é‰h—{ŠÇ—‚̏d—v«. •Ð‰ª—Sˆê1, “c‘º@’q1, ’©ŒG’õ—²1, a’Jh—²1, ‰Ô“‡@Ž‘1, ’†’JŒ€“l1, ó—˜@–õ1 (1‹~–œ): ‘æ22‰ñ“ú–{—Տ°‹~‹}ˆãŠw‰ï‘‰ïEŠwpW‰ï (2019/6/1), ˜a‰ÌŽR.

723794. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰ÄÕ‚è‰ïê‚É‚š‚¯‚éƒKƒXƒ{ƒ“ƒx”š”­‚É”º‚€‘œ”•aŽÒ”­¶Ž–ˆÄ‚ւ̑Ήž. •Ð‰ª—Sˆê1, ’©ŒG’õ—²1 (1‹~–œ): ‘æ22‰ñ“ú–{—Տ°‹~‹}ˆãŠw‰ï‘‰ïEŠwpW‰ï (2019/6/1), ˜a‰ÌŽR.

723795. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) “Ý“It“®–¬‘¹ “–ƒZƒ“ƒ^[‚É‚š‚¯‚鎡—ÃŒoŒ± (Blunt renal arterial injuries: a single center analysis of management strategies and outcomes). Š~Œ©•¶Ž}1, ŒŠª@”Ž2, ŠÛ‹ŽFº11, “c‘º@’q1, ŒIŒŽ—S‘Ÿ˜N1, ƒEƒbƒhƒnƒ€ƒX—æŽq3, Œ‰iŒh“ñ3, ó—˜@–õ1 (1‹~–œ, 2¹ƒ}ƒŠƒAƒ“ƒiˆã‰È‘åŠw, 3•úŽËü (‰æ‘œ)): ‘æ48‰ñ“ú–{IVRŠw‰ï‘‰ï (2019/6/1), •Ÿ‰ª, “ú–{ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒiƒ‹ƒ‰ƒWƒIƒƒW[Šw‰ïŽGŽ 2019/5; 34 (Suppl): p.301.

723796. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) [Ý«äX‘¹‚ɑ΂·‚鎡—Ö@‚ÌŒŸ“¢. •Ð‰ª—Sˆê1, ‰Ô“‡@Ž‘1, ‘“c’q¬1, ó—˜@–õ1 (1‹~–œ): ‘æ33‰ñ“ú–{ŠOŠw‰ï‘‰ïEŠwp‘å‰ï (2019/6/6), ”ªŒË.

723797. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) dÇ‹~‹}Š³ŽÒ‚ɑ΂·‚éNST‚É‚æ‚é‰h—{ŠÇ—. •Ð‰ª—Sˆê1, ó—˜@–õ1 (1‹~–œ): ‘æ47‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ï (2020/3/6), –ŒŒÃ‰®.

723798. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠO«”]“àŒŒŽî‚ɑ΂·‚é_Œo“àŽ‹‹Ÿ“IŒŒŽîœ‹Žp‚Ì—L—p«‚Æ–â‘è“_. ¬òŠ°”V1,2, ŽR–{‘å•ã2, ó—˜@–õ1, ŒG•”rG2 (1‹~–œ, 2”]ŠO): ‘æ43‰ñ“ú–{”]_ŒoŠOŠw‰ï (2020/3/7), ” ª.

733737. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è) IVR‚ª—L—p‚Å‚ ‚Á‚œäB“®–¬‚ւ̐ú’ʂ𔺂Á‚œoŒŒ«ˆÝ’×ᇂ̈ê—á. Žs粉ԓÞ, ŒÃ“¡—¢‰À1, Š~Œ©•¶Ž}1, ŽR“à_Žj1,2, ‹à@@I1, “c‘º@’q1, ŠÛ‹ŽFº1, •Ð‰ª—Sˆê1, ó—˜@–õ1 (1‹~–œ, 2Á‰»Ší“à): ‘æ70‰ñ“ú–{‹~‹}ˆãŠw‰ïŠÖ“Œ’n•û‰ïŠwpW‰ï (2020/1/18), ‘O‹Ž.

733738. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʉ‰‘è) Œëˆù‚µ‚œ‹`Ž•‚É‚æ‚è‹}«ˆÝ–Iâ|D‰Š‚𔭏ǂµ‚œ1—á. ‰Á“¡’q”V, ‘åˆä^—¢“Þ1, ’†’JŒ€“l1, ŽR“à_Žj1,2, ŠÛ‹ŽFº1, ŒIŒŽ—S‘Ÿ˜N1, •Ð‰ª—Sˆê1, ó—˜@–õ1 (1‹~–œ, 2Á‰»Ší“à): ‘æ70‰ñ“ú–{‹~‹}ˆãŠw‰ïŠÖ“Œ’n•û‰ïŠwpW‰ï (2020/1/18), ‘O‹Ž.


‘‡f—ÈãŠw

[Šwp˜_•¶]

521010. [‰ðà] ‚ŒŒˆ³E–«S•s‘S‚ÌŠù‰‚Ì‚ ‚銳ŽÒ‚É‚€‚ÁŒŒ«S•s‘S‚ÌŠÓ•Ê“™‚ð‘Ó‚Á‚Ä‘ˆ«‚³‚¹, Ž€–S‚³‚¹‚œ‚Æ‚µ‚Ä‘¹ŠQ”…ž‚ð‹‚ß‚œŽ–—á. ÂŽR’Œ‘P (‘‡f—Ã): ˆã—Ô»—á‰ðà 2020/2; 84: 66-9.

522130. [uÀ]yƒZƒ~ƒi[z“ª’ɁE‚ß‚Ü‚¢‚ÌŠ¿•ûŽ¡—Ã. ŒÜ–ì—R‰À— (‘‡f—Ã): ƒtƒ@ƒ‹ƒ}ƒVƒA 2020/3; 56 (3): 218-22.

[’˜@‘]

620092. [Šwp‘ (•ª’SŽ·•M)]yŠ¿•ûˆ•ûƒnƒ“ƒhƒuƒbƒNzˆ•û‚ÌŽÀÛ@9. _Œo@14. “ª’É, p.148-58. ŒÜ–ì—R‰À—1 (1‘‡f—Ã), •Ò: ‰Ô—Öšæ•F2 (2“Œ—mˆãŠw‘‡Œ€‹†Š), ˆãŠw‘‰@, “Œ‹ž, 2019/6”­s.

620093. [Šwp‘ (•ª’SŽ·•M)]yzŠÂŠíƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì—˜_‚Æ‹Zp ‰ü’ù‘æ2”ŁzI ‰ð–UŠw‚Ì’mŽ¯@ŒŒŠÇ‚̍\‘¢‚Æ‹@”\, p.19-27. III zŠÂŠíŽŸŠ³‚Ì•a‘Ô‚ÆŽ¡—Á@––œ“®–¬ŽŸŠ³, p.109-23. ÂŽR’Œ‘P1 (1‘‡f—Ã), •Ò: ‘“c@‘ì2, Œ‰i“Ä•F2 (2ˆã—Éq¶Šw•”), ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2020/3”­s.

[Šw‰ïEŒ€‹†‰ï“™]

722240. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) Š¿•û“ü–åƒZƒ~ƒi[@“ª’É‚ÌŠ¿•ûŽ¡—Ã. ŒÜ–ì—R‰À— (‘‡f—Ã): ‘æ70‰ñ“ú–{“Œ—mˆãŠw‰ïŠwp‘‰ï (2019/6/29), “Œ‹ž.

722241. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) Š¿•û–ò‚Ì•›ì—p‚ÉŠÖ‚·‚éƒVƒ“ƒ|ƒWƒEƒ€@Š¿•û–ò‚É‚æ‚éŠÌáŠQ. ŒÜ–ì—R‰À— (‘‡f—Ã): ‘æ70‰ñ“ú–{“Œ—mˆãŠw‰ïŠwp‘‰ï (2019/6/30), “Œ‹ž.

723799. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Š¿•û–ò‚Ì•›ì—p. ŒÜ–ì—R‰À— (‘‡f—Ã): ‘æ47‰ñ“ú–{¬Ž™“Œ—mˆãŠw‰ïŠwpW‰ï (2019/9/29), ‰¡•l.


ˆãŠw•”•‘®ˆãŠw‹³ˆçŒ€‹†ŠJ”­ƒZƒ“ƒ^[

ˆãŠw‹³ˆçŒ€‹†•”–å

[Šw‰ïEŒ€‹†‰ï“™]

713141. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Identification of Topics Explained by Home Doctors to Family Caregivers with Cancer Patients Died at Home: A Quantitative Text Analysis of Actual Speech in All Visits. Chiba H1, Ogata T, Ito M, Kaneko S: World Cancer Actions 2019 (2019/5/9), Valencia, Spain. (ç—tG‹B1, ˆÉ“¡“¹Æ, ”öŒ`—Ï–Ÿ, ‹àŽq‚³‚ä‚è: 1ˆãŠw‹³ˆç)

733739. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰)uƒGƒ“ƒhƒIƒuƒ‰ƒCƒtEƒPƒA‰‡•ŽÒ—{¬Šî‘buÀv‚Ì‹³ˆçŒø‰Ê‚ÉŠÖ‚·‚é•]‰¿Œ€‹† <’†ŠÔ•ñ>. ç—tG‹B1, Žç‰®—˜‰À1, ”öŒ`—Ï–Ÿ, ‚œ‚çàV–M’j, X’JAŒc, ŽOàVm•œ (1ˆãŠw‹³ˆç): ˆê”ÊŽÐ’c–@lƒGƒ“ƒhƒIƒuƒ‰ƒCEƒPƒA‹Š‰ïÝ—§4Žü”NƒVƒ“ƒ|ƒWƒEƒ€ (2019/4/14), “Œ‹ž.


ˆãŠwŒŽ˜_Œ€‹†•”–å

[Šw‰ïEŒ€‹†‰ï“™]

722242. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) SDM‚Æ—Ï—. âV“¡—L‹IŽq (ˆãŠwŒŽ˜_): ‘æ23‰ñ“ú–{ƒAƒNƒZƒXŒ€‹†‰ïŠwpW‰ïE‘‰ï (2019/9/29), ‰¡•l.


ˆã—ËZp‹³ˆçŒ€‹†•”–å

Šut‘Ÿ“à‰ÈŠwv‚ðŽQÆ


ŠwKŽx‰‡Œ€‹†•”–å


ˆã—ÊǗŠwŒ€‹†•”–å

ŠuÁ‰»Ší“à‰ÈŠwv‚ðŽQÆ


ˆã—Ïî•ñ‹³ˆçŒ€‹†•”–å

[Šwp˜_•¶]

110349. [ŒŽ’˜] A spatial similarity of stereochemical environments formed by amino acid residues defines a common epitope of two non-homologous proteins. Nakashima K, Iwashita S, Suzuki T, Kato C, Kohno T1, Kamei Y, Sasaki M, Urayama O, Ohno-Iwashita Y, Dohmae N Song S-Y: Sci Rep 2019/10; 9 (1): 14818. (‰Í–ìr”V1: 1ˆã—Ïî•ñ‹³ˆç)

110350. [ŒŽ’˜] NMR characterization of the interaction between Bcl-xL and the BH3-like motif of hepatitis B virus X protein. Kusunoki H, Tanaka T, Kohno T1, Kimura H, Hosoda K, Wakamatsu K, Hamaguchi I: Biochem Biophys Res Commun 2019/10; 518 (3): 445-50. (‰Í–ìr”V1: 1ˆã—Ïî•ñ‹³ˆç)

[Šw‰ïEŒ€‹†‰ï“™]

723800. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒAƒhƒŒƒiƒŠƒ“Žó—e‘̍זE“à‘æŽOƒ‹[ƒv‚ÆGPCRƒ‚ƒWƒ…ƒŒ[ƒ^[spinophilin‚Æ‚Ì‘ŠŒÝì—p‰ðÍ. •ì—D, Š‹ŠÑŠG—œ“Þ, ‰Y–ì’qŽq, “‡èˆÀŠóŽq, ‰Í–ìr”V1, ×“c˜a’j, Ž›˜eTˆê, ŽáŒ@Š] (1ˆã—Ïî•ñ‹³ˆç): ‘æ58‰ñNMR“¢˜_‰ï (2019) (2019/11/7), ìè.

723801. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) íŽ¥«NMR‚ð—p‚¢‚œYeast Ubiquitin hydrolase 1 (YUH1) ‚̍\‘¢Œˆ’è‹y‚у_ƒCƒiƒ~ƒNƒX‰ðÍ. —§Î@‘×, ’r’J“S•º, ‰ª“c^—R, ŽO“‡³‹K, ”üì@–±, ”ª–؍G¹, ‰Í–ìr”V1, –ؐ엲‘¥, ˆÉ“¡@—² (1ˆã—Ïî•ñ‹³ˆç): ‘æ58‰ñNMR“¢˜_‰ï (2019) (2019/11/9), ìè.


“Œ—mˆãŠw‹³ˆçŒ€‹†•”–å

[Šwp˜_•¶]

110351. [ŒŽ’˜] Analgesic Effects of Ephedra Herb Extract, Ephedrine Alkaloids-Free Ephedra Herb Extract, Ephedrine, and Pseudoephedrine on Formalin-Induced Pain. Nakamori S1, Takahashi J, Hyuga S2, Yang J, Takemoto H1, Maruyama T, Oshima N, Uchiyama N, Amakura Y, Hyuga M, Hakamatsuka T, Goda Y, Odaguchi H2,3, Hanawa T2, Kobayashi Y1: Biol Pharm Bull 2019/6; 42 (9): 1538-44. (’†Xr•ã1, “úŒü{”üŽq2, ’|Œ³—T–Ÿ1, ¬“cŒû_2,3, ‰Ô—Öšæ•F2, ¬—Ñ‹`“T1: 1–òŠw•”, 2“Œ—mˆãŠw‘‡Œ€‹†Š, 3“Œ—mˆãŠw‹³ˆç)

110352. [ŒŽ’˜] Quality Evaluation and Characterization of Fractions with Biological Activity from Ephedra Herb Extract and Ephedrine Alkaloids-Free Ephedra Herb Extract. Yoshimura M, Amakura Y, Hyuga S1, Hyuga M, Nakamori S2, Maruyama T, Oshima N, Uchiyama N, Yang J, Oka H, Ito H, Kobayashi Y2, Odaguchi H1,3, Hakamatsuka T, Hanawa T1, Goda Y: Chem Pharm Bull (Tokyo) 2020/2; 68 (2): 140-9. (“úŒü{”üŽq1, ’†Xr•ã2, ¬—Ñ‹`“T2, ¬“cŒû_1,3, ‰Ô—Öšæ•F1: 1“Œ—mˆãŠw‘‡Œ€‹†Š, 2–òŠw•”, 3“Œ—mˆãŠw‹³ˆç)

320047. [Ç—á•ñ] –k—¢“ŒˆãŒ€f—Ø^‚©‚ç (180): “Ë”­«“ï’®‚ÉŠ¿•ûEèI‹„‚Ì•¹—pŽ¡—ª‘tŒ÷‚µ‚œ1—á. —é–Ø–M•F1, Î–Ñ’B–ç1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): Š¿•û‚̗Տ° 2019/4; 66 (4): 418-22.

320048. [Ç—á•ñ] –k—¢“ŒˆãŒ€f—Ø^‚©‚ç (181): ŠæŒÅ‚È“ªŒz•”‚̏D‘i‚É‘åŽÄŒÓ“’‹Ž‘剩 (÷‚¶) ‚ª—L—p‚Å‚ ‚Á‚œ3Ç—á. Î–Ñ’B–ç1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): Š¿•û‚̗Տ° 2019/5; 66 (5): 511-8.

320049. [Ç—á•ñ] –k—¢“ŒˆãŒ€f—Ø^‚©‚ç (182): ‡–°áŠQE“ª’ɂɑ΂µ’Þ“¡ŽU—¿‚©‚獂––³—JŽU—¿‚É“]•û‚µ‘tŒ÷‚µ‚œ1Ç—á. ¯–ì‘ì”V1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): Š¿•û‚̗Տ° 2019/6; 66 (6): 597-602.

320050. [Ç—á•ñ] –k—¢“ŒˆãŒ€f—Ø^‚©‚ç (183): ”x‚Ì—â‚Š‚ðƒx[ƒX‚É‚µ‚œ—â‚ŠÇ‚ɊѐŠ£›I“’‚ª‘tŒø‚µ‚œ1—á. ¬“cŒû_1,2, ‰Ô—Öšæ•F2 (1“Œ—mˆãŠw‹³ˆç, 2“Œ—mˆãŠw‘‡Œ€‹†Š): Š¿•û‚̗Տ° 2019/7; 66 (7): 703-6.

320051. [Ç—á•ñ] –k—¢“ŒˆãŒ€f—Ø^‚©‚ç (184): ‰º• •”’É‚É“–‹AŽl‹t‰ÁŒàä£äΐ¶›I“’‚ª‘tŒø‚µ‚œŠŠál‚Ì1Ç—á‚Æ, álEŽµálEŠŠál‚ɂ‚¢‚Ä. ˆÉ“¡@„1, ¬“cŒû__1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): Š¿•û‚̗Տ° 2019/9; 66 (9): 865-72.

320052. [Ç—á•ñ] –k—¢“ŒˆãŒ€f—Ø^‚©‚ç (185): Š¿•ûŽ¡—Â̕¹—p‚ª—L—p‚Ÿ‚Á‚œ“•s”D2Ç—á. X—T‹IŽq1, âV“¡ŠG”ü1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): Š¿•û‚̗Տ° 2019/10; 66 (10): 954-8.

320053. [Ç—á•ñ] –k—¢“ŒˆãŒ€f—Ø^‚©‚ç (187): “‡Žž’²Ç‚ÉŠ¿•ûŽ¡—Â̕¹—p‚ª—LŒø‚Å‚ ‚Á‚œ2Ç—á. ‰““¡‘å•ã1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): Š¿•û‚̗Տ° 2019/12; 66 (12): 1146]53.

520019. [‘à] –ƒ‰©‚Ì•›ì—p‚ƃGƒtƒFƒhƒŠƒ“ƒAƒ‹ƒJƒƒCƒhœ‹Ž–ƒ‰©ƒGƒLƒX (EFE) ‚̈À‘S«. ¬“cŒû_1,2, “úŒü{”üŽq2, ŠÖª–ƒ—Žq2, ’†Xr•ã3, ’|Œ³—T–Ÿ3, ‰©@á’O3, ‘哈’Œ_, “ˆ“c“TŠî, —k@‹àˆÜ, “V‘q‹gÍ, “úŒü¹Ži, “àŽR“Þ•äŽq, ¬—Ñ‹`“T3, ŒÑ’ˍ‚Žu, ‡“cKL, ‰Ô—Öšæ•F2 (1“Œ—mˆãŠw‹³ˆç, 2“Œ—mˆãŠw‘‡Œ€‹†Š, 3–òŠw•”): –òŠwŽGŽ 2019/11; 139 (11): 1417-25.

522131. [uÀ] –ƒ‰©‚̎听•ªEƒGƒtƒFƒhƒŠƒ“ƒAƒ‹ƒJƒƒCƒh‚Ì•›ì—p‚ƐV‹K¶–òƒGƒLƒXEFE‚ÌŠJ”­. “úŒü{”üŽq1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): •ÊûBIO Clinica 2019/12; 8 (2): 118-22.

540079. [‚»‚Ì‘Œ (Šñe)] WHO‹Š—̓Zƒ“ƒ^[Šñe2: –k—¢‘åŠw“Œ—mˆãŠw‘‡Œ€‹†Š`“ú–{‚Ì“`“ˆãŠwuŠ¿•ûv‚ð’Ê‚¶‚œWHO‚ւ̍vŒ£`. Žá™ˆÀŠó”T1, ŠÖª–ƒ—Žq1, ¬“cŒû_1,2 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): –Ú‚ÅŒ©‚éWHO 2019/10; 70 (2019H†): 18-9.

[’˜@‘]

620094. [Šwp‘ (•ª’SŽ·•M)]yŠ¿•ûˆ•ûƒnƒ“ƒhƒuƒbƒNzˆ•û‚ÌŽÀÛ@2. zŠÂŠí@3. ‚ŒŒˆ³, p.73-5. 8. •nŒŒ@13. •nŒŒ, 144-7. ¶–ò, èI‹„, EBM, ˆãŽjŠw@EBM, p.353-6. ¬“cŒû_1,2 (1“Œ—mˆãŠw‹³ˆç, 2“Œ—mˆãŠw‘‡Œ€‹†Š), •Ò: ‰Ô—Öšæ•F2, ˆãŠw‘‰@, “Œ‹ž, 2019/6”­s.

[Šw‰ïEŒ€‹†‰ï“™]

712035. [Šw‰ï (‘Û)] (µ‘ҍu‰‰“™) Application of Kampo Medicine (Traditional Japanese Medicine) to high blood pressure. Odaguchi H1,2: 1st Joint Symposium of WHO Collaborating centers for Traditional Medicine in SEARO and WPRO (Faculty of Medicine Siriraj Hospital) (2019/9/13), Thailand. (¬“cŒû_1,2: 1“Œ—mˆãŠw‹³ˆç, 2“Œ—mˆãŠw‘‡Œ€‹†Š)

713142. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Therapeutic and analgesic effects of Ephedrine alkaloids-free Ephedra Herb extract on complete Freud's adjuvant-induced arthritis model mouse. Nakamori S, Miyajima N, Hyuga S, Minami Y, Kazama K, Hiyama M, Endo M, Yang J, Oshima N, Uchiyama N, Amakura Y, Hyuga M, Hakamatsuka T, Goda Y, Odaguchi H1,2, Hanawa T, Kobayashi Y: 67th International Congress and Annual Meeting of the Society for Medicinal Plant and Natural Product Research (2019/9/2), Innsbruck, Austria. (¬“cŒû_1,2: 1“Œ—mˆãŠw‹³ˆç, 2“Œ—mˆãŠw‘‡Œ€‹†Š)

713143. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) A Case-series of 10 Patients with Female Hormonal Imbalance (Chi-no-michi syndrome) successfully treated with nyoshinsan. Mori E1, Oikawa T, Odaguchi H1,2, Hanawa T1: 5th International Symposium for Japanese Kampo Medicine (2019/9/7), Germany. (X@‰lŽq1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1: 1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç)

722243. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)y¶–òƒVƒ“ƒ|ƒWƒEƒ€: Š¿•û–ò—˜—p‚Ì‹ß–¢—ˆ`Å‹ß‚ÌŒ€‹†¬‰Ê‚𓥂܂Š‚ā`zGCP€‹’RCT‚É‚æ‚éˆãŽtŽå“±—Տ°Œ€‹†`EFE‚ÌŒ’N¬l‚ɑ΂·‚éˆÀ‘S«ŽŽŒ±`@«—ˆ‚ÌŠ¿•û–ò‚Ì‚ ‚è‚©‚œ, Š¿•û‚̐V‚œ‚Ȉã–ò•iŠJ”­‚ÌŒ»ó‚â“W–], ˆÀ‘S‚•iŽ¿‚Ȑ¶–ò. ¬“cŒû_1,2 (1“Œ—mˆãŠw‹³ˆç, 2“Œ—mˆãŠw‘‡Œ€‹†Š): ‘æ70‰ñ“ú–{“Œ—mˆãŠw‰ïŠwp‘‰ï (2019/6/30), “Œ‹ž.

722244. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)y•W€‰»ƒVƒ“ƒ|ƒWƒEƒ€zŠ¿•ûfŽ@–@‚Ì•W€‰»‚ɂ‚¢‚Ä. ¬“cŒû_1,2, Vˆä@M, ŽÄŒŽ’Œ—˜, “ˆ“c@–L, •À–Ø—²—Y, ‰Ô—Öšæ•F2, ŽOàk’‰“¹, ‘ºŒTˆê, ŠÖª–ƒ—Žq2, Žá™ˆÀŠó”T2 (1“Œ—mˆãŠw‹³ˆç, 2“Œ—mˆãŠw‘‡Œ€‹†Š): ‘æ70‰ñ“ú–{“Œ—mˆãŠw‰ïŠwp‘‰ï (2019/6/30), “Œ‹ž.

723802. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆã—ØAŒg‚ª—LŒø‚É‹@”\‚µ‚œ‚ÆŽv‚í‚ê‚œŠÔŒ‡«æês‚̈ê—á. ˆÉ“ŒGŒ›1, ˆÉ“¡@„1, ¬“cŒû_1,2 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ68‰ñ (ŒöŽÐ) ‘S“ú–{èI‹„Šw‰ïŠwp‘å‰ïˆ€’m‘å‰ï (2019/5/12), ˆ€’m

723803. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) w•û‹ÉxŠÖ˜AˆãÐ‚É‚æ‚鉜“cŒª‘ ‚̌ÕûŒ€‹†. ¯–ì‘ì”V1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ120‰ñ“ú–{ˆãŽjŠw‰ï‘‰ïEŠwp‘å‰ï (2019/5/18), ˆ€’m.

723804. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Œo—Ž¡—Â̕‹yŠˆ“®‚ɂ‚¢‚Ä. Žü–hˆê•œ1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ120‰ñ“ú–{ˆãŽjŠw‰ï‘‰ïEŠwp‘å‰ï (2019/5/18), ˆ€’m.

723805. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¶B•â•ˆã—à (ART) ‚ÆŠ¿•ûŽ¡—Â̕¹—p‚ª—LŒø‚Ÿ‚Á‚œ“•s”D2Ç—á. X—T‹IŽq1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ70‰ñ“ú–{“Œ—mˆãŠw‰ïŠwp‘‰ï (2019/6/29), “Œ‹ž.

723806. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) A“ª“÷‰èŽîÇ‚ÉŽÄ–p“’‚ª—L—p‚Å‚ ‚Á‚œ1Ç—á. Î–Ñ’B–ç1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1, ‘OŒŽ_Žj (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ70‰ñ“ú–{“Œ—mˆãŠw‰ïŠwp‘‰ï (2019/6/29), “Œ‹ž.

723807. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ã’ɏǂɎµ•š~‰º“’‚ª—LŒø‚Å‚ ‚Á‚œˆê—á. ì“çˆÉW1, ‰Ô—Öšæ•F1, ¬“cŒû_1,2 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ70‰ñ“ú–{“Œ—mˆãŠw‰ïŠwp‘‰ï (2019/6/29), “Œ‹ž.

723808. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–Ž{Ý‚É‚š‚¯‚é—}‚€‚Ǐó‚ð’æ‚·‚銳ŽÒ‚ɑ΂·‚銿•ûŽ¡—Â̌Ÿ“¢. ‰““¡‘å•ã1, ‹yì“N˜Y, ˆÉ“¡@„1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ70‰ñ“ú–{“Œ—mˆãŠw‰ïŠwp‘‰ï (2019/6/29), “Œ‹ž.

723809. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–Ž{Ý‚É‚š‚¯‚é’Ê“±ŽUˆ•û—á‚ÌŒŸ“¢. ŠÛŽR‘׋M1, ‹yì“N˜Y, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ70‰ñ“ú–{“Œ—mˆãŠw‰ïŠwp‘‰ï (2019/6/29), “Œ‹ž.

723810. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‡–°áŠQ‚ɑ΂·‚éèI‹„Ž¡—Â̌ã•ûŽ‹“I’²ž. ˆä“c„l1, ˆÉ“ŒGŒ›1, ˆÉ“¡@„1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ70‰ñ“ú–{“Œ—mˆãŠw‰ïŠwp‘‰ï (2019/6/29), “Œ‹ž.

723811. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹CÕŒŠ‚Ö‚ÌŽhèI‚ª‘å‘Ú‘O–Ê‚ÌჂê‚ɑ΂µ‚Ä‘tŒø‚µ‚œˆêÇ—á. ˆÉ“¡—Yˆê1, ˆÉ“ŒGŒ›1, ˆÉ“¡@„1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ70‰ñ“ú–{“Œ—mˆãŠw‰ïŠwp‘‰ï (2019/6/29), “Œ‹ž.

723812. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Œz’ŏǐ«œ‘Ø‚̏pŒã‚ÌჂê‚ɑ΂µ‚ÄèIŽ¡—ª—LŒø‚Ÿ‚Á‚œ1Ç—á. ‹ß“¡ˆŸŽÑ1, ˆÉ“ŒGŒ›1, ˆÉ“¡@„1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ70‰ñ“ú–{“Œ—mˆãŠw‰ïŠwp‘‰ï (2019/6/29), “Œ‹ž.

723813. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) —‘‘ƒ‹@”\’ቺ‚𔺂€•s”D‚ɑ΂µŠ¿•ûèI‹„Ž¡—Â𕹗p‚µ‚Ä”DP‚µ‚œˆêÇ—á. •Šâ“ށXŽq1, ˆÉ“ŒGŒ›1, ˆÉ“¡@„1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ70‰ñ“ú–{“Œ—mˆãŠw‰ïŠwp‘‰ï (2019/6/29), “Œ‹ž.

723814. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “ú–{‚Å’ñ‹Ÿ‚Å‚«‚é’†‘‚ÌŒ’N’ƒ‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ŽOàV@S1, ’†“‡ˆç”ü1, â“cKŽ¡1, ²‹Ž‰À˜Y1, •ûçH1, ¬—Ñ‹`“T1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ70‰ñ“ú–{“Œ—mˆãŠw‰ïŠwp‘‰ï (2019/6/29), “Œ‹ž.

723815. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŒŽ—¿¶–ò‚̐¶ŽYó‹µ‚É‚š‚¯‚éî•ñŽûW‹y‚їՏ°‚Ö‚ÌŠˆ—p‚ɂ‚¢‚Ä. ¬ò—m‘Ÿ1, â“cKŽ¡1, ²‹Ž‰À˜Y1, •ûçH1, ¬—Ñ‹`“T1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ70‰ñ“ú–{“Œ—mˆãŠw‰ïŠwp‘‰ï (2019/6/29), “Œ‹ž.

723816. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–Œ€‹†Š‚Ì–òŠw•”‚É‚š‚¯‚銿•û‹³ˆç‚̈Ӌ`. …è°“Þ1, ²‹Ž‰À˜Y1, â“cKŽ¡1, •ûçH1, ¬—Ñ‹`“T1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ70‰ñ“ú–{“Œ—mˆãŠw‰ïŠwp‘‰ï (2019/6/29), “Œ‹ž.

723817. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –òŠw‹³ˆç‚É‚š‚¯‚éu—{¶–@‚Æ‚µ‚Ä‚Ì‘Ÿ‹ÉŒvŽw“±‚Ì‹³ˆçŒø‰Ê‚ÌŒŸ“¢. ¬—Ñ‹`“T1, ¬“cŒû_1,2 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ70‰ñ“ú–{“Œ—mˆãŠw‰ïŠwp‘‰ï (2019/6/29), “Œ‹ž.

723818. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–Ž{Ý‚É‚š‚¯‚é—‘‘ƒ‚ª‚ñŠ³ŽÒ‚ɑ΂·‚銿•ûŽ¡—Â̌Ÿ“¢. X@‰lŽq1, ‹yì“N˜Y, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ70‰ñ“ú–{“Œ—mˆãŠw‰ïŠwp‘‰ï (2019/6/30), “Œ‹ž.

723819. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –ƒ‰©‚ÉŠÜ‚Ü‚ê‚éƒGƒtƒFƒhƒŠƒ“ƒAƒ‹ƒJƒƒCƒh‚̐S”‚ɑ΂·‚éì—p‚̉ðÍ. ‰©@á’O1, “úŒü{”üŽq2, “àŽR“Þ•äŽq, “úŒü¹Ži, ‘哈’Œ_, “V‘q‹gÍ, ŒÑ’ˍ‚Žu, ¬“cŒû_2,3, ‰Ô—Öšæ•F2, ¬—Ñ‹`“T1 (1–òŠw•”, 2“Œ—mˆãŠw‘‡Œ€‹†Š, 3“Œ—mˆãŠw‹³ˆç): ‘æ70‰ñ“ú–{“Œ—mˆãŠw‰ïŠwp‘‰ï (2019/6/30), “Œ‹ž.

723820. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŒÃ•û”hŽÊ–{ŒQ‚©‚ç‚̍Ĕ­Œ©. ¯–ì‘ì”V1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ70‰ñ“ú–{“Œ—mˆãŠw‰ïŠwp‘‰ï (2019/6/30), “Œ‹ž.

723821. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) w“Œ‹žèI‹„ˆãŠwŽx‚ɂ‚¢‚Ä. Žü–hˆê•œ1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ70‰ñ“ú–{“Œ—mˆãŠw‰ïŠwp‘‰ï (2019/6/30), “Œ‹ž.

723822. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) SAMP8ƒ}ƒEƒX‚ð—˜—p‚µ‚œ–¢•a•]‰¿ƒ‚ƒfƒ‹‚Æ‚µ‚Ẳ”\«. ˆÉ“¡’ŒŽ÷1, ’|Œ³—T–Ÿ2, ’·’Jìˆ»“ß, ™ŽRç‰À1, “¡“c—¢“Þ, ¬Œû°”ü, ‰iˆä—²”V3, ¬—Ñ‹`“T2, ŽŒŽŠ°Í3, ‹yì“N˜Y, ¬“cŒû_1,4 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2–òŠw•”, 3‘åŠw‰@ŠŽõ§Œä‰ÈŠw•{˜aŠ¿–ò•šŠwŒ€‹†Žº, 4“Œ—mˆãŠw‹³ˆç): ‘æ34‰ñ˜V‰»‘£iƒ‚ƒfƒ‹ƒ}ƒEƒX (SAM) Šw‰ïŠwp‘å‰ï (2019/7/13), ì.

723823. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) LPS—U”­”x‰ŠÇƒ‚ƒfƒ‹‚ɑ΂·‚é•â’†‰v‹C“’‚̍ì—p‚̉ðÍ. ù¶–ëŽq1, o–ì’qŽj, ŠÛŽROŽq2, ‰iˆä—²”V1, ‰Ô—Öšæ•F3, ¬“cŒû_3,4, Xè@_, ŽŒŽŠ°Í1 (1‘åŠw‰@ŠŽõ§Œä‰ÈŠw•{˜aŠ¿–ò•šŠwŒ€‹†Žº, 2ˆã—Éq¶Šw•”, 3“Œ—mˆãŠw‘‡Œ€‹†Š, 4“Œ—mˆãŠw‹³ˆç): ‘æ36‰ñ˜aŠ¿ˆã–òŠw‰ïŠwp‘å‰ï (2019/8/31), •xŽR.

723824. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚ŒŒ“œ•a‘Ô‚Å‚Ì”x”S–Œ–ƉuŒn‚ɑ΂·‚锪–¡ŠÛ÷Ü‚̍ì—p‚̉ðÍ. ŠÝ–{‘åŽu1, ‰iˆä—²”V1, ˆÉ“¡@„2, ‰Ô—Öšæ•F2, ¬“cŒû_2,3, ŽŒŽŠ°Í1 (1‘åŠw‰@ŠŽõ§Œä‰ÈŠw•{ ˜aŠ¿–ò•šŠwŒ€‹†Žº, 2“Œ—mˆãŠw‘‡Œ€‹†Š, 3“Œ—mˆãŠw‹³ˆç): ‘æ36‰ñ˜aŠ¿ˆã–òŠw‰ïŠwp‘å‰ï (2019/8/31), •xŽR.

723825. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •â’†‰v‹C“’‚ÌT×–EˆË‘¶«‘Sg‰ŠÇ‹y‚я¬’°”S–Œ‰Š‚ɑ΂·‚é‰ü‘Pì—p|”’žQ‚Ü‚œ‚Í‘“žQ”z‡Ü‚Ì”äŠr|. ‰““¡^—1, ‰ÌìŽD, ŽŒŽŠ°Í2, ‹yì“N˜Y, ¬“cŒû_1,3, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2‘åŠw‰@ŠŽõ§Œä‰ÈŠw•{˜aŠ¿–ò•šŠwŒ€‹†Žº, 3“Œ—mˆãŠw‹³ˆç): ‘æ36‰ñ˜aŠ¿ˆã–òŠw‰ïŠwp‘å‰ï (2019/9/1), •xŽR.

723826. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –ƒ‰©‚É‚æ‚éc-Met‚̃_ƒEƒ“ƒŒƒMƒ…ƒŒ[ƒVƒ‡ƒ“‚̃ƒJƒjƒYƒ€. “úŒü{”üŽq1, “úŒü¹Ži, ŒÑ’ˍ‚Žu, ‡“cKL, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ36‰ñ˜aŠ¿ˆã–òŠw‰ïŠwp‘å‰ï (2019/9/1), •xŽR.

723827. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˜V‰»‘£iƒ}ƒEƒX‚ð—p‚¢‚œ‘hŽU‚Ì–¢•a§Œä. ˆÉ“¡’ŒŽ÷1, ’·’Jìˆ»“ß, ™ŽRç‰À1, ‰iˆä—²”V2, ŽŒŽŠ°Í2, ‹yì“N˜Y, ¬“cŒû_1,3 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2‘åŠw‰@ŠŽõ§Œä‰ÈŠw•{˜aŠ¿–ò•šŠwŒ€‹†Žº, 3“Œ—mˆãŠw‹³ˆç): ‘æ36‰ñ˜aŠ¿ˆã–òŠw‰ïŠwp‘å‰ï (2019/9/1), •xŽR.

723828. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠÖß‰Šƒ‚ƒfƒ‹ƒ}ƒEƒX‚̓‘gD‘¹‚ɑ΂·‚éƒGƒtƒFƒhƒŠƒ“ƒAƒ‹ƒJƒƒCƒhœ‹Ž–ƒ‰©ƒGƒLƒX‚ÌŒø‰Ê. “ì@‰ÂŒb1, ’†Xr•ã1, “úŒü{”üŽq2, ‰““¡^—2, ‹{“ˆ’Œ‹I, žwŽR”üt, •—ŠÔ—T, ’|“à@ƒ, —k@‹àˆÜ, “àŽR“Þ•äŽq, “úŒü¹Ži, ‘哈’Œ_, “V‘q‹gÍ, ŒÑ’ˍ‚Žu, ‡“cKL, ¬“cŒû_2,3, ‰Ô—Öšæ•F2, ¬—Ñ‹`“T1 (1–òŠw•”, 2“Œ—mˆãŠw‘‡Œ€‹†Š, 3“Œ—mˆãŠw‹³ˆç): “ú–{¶–òŠw‰ï‘æ66‰ñ”N‰ï (2019/9/22), “Œ‹ž.

723829. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’n—“IŠÂ‹«EŽž‘ã“I”wŒi‚É‚æ‚è•Ï‘J‚·‚鏈•û. –x“cL–ž, ¯–ì‘ì”V, ¬“cŒû_1,2, ‰Ô—Öšæ•F2 (1“Œ—mˆãŠw‹³ˆç, 2“Œ—mˆãŠw‘‡Œ€‹†Š): ‘æ47‰ñ“ú–{¬Ž™“Œ—mˆãŠw‰ïŠwpW‰ï (2019/9/29), _“ސì.

723830. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒVƒ\—ސA•š‚Ì1H-NMRƒƒ^ƒ{ƒŠƒbƒNƒvƒƒtƒ@ƒCƒŠƒ“ƒO. ”’”š’C–í1, •œŽR•G1, —Ñ“c—³–í1, •Ÿ“c’B’j1, ‹yì“N˜Y, ‰Ô—Öšæ•F2, ¬“cŒû_2,3, ›ŽŠŒË‰ë”V, ¬“c‰À•F, –ž‰’‹v”üŽq, Ÿº–ì—T”V, ìŒŽM•v, ¬—Ñ‹`“T1 (1–òŠw•”, 2“Œ—mˆãŠw‘‡Œ€‹†Š, 3“Œ—mˆãŠw‹³ˆç): ‘æ8‰ñH•i–òŠwƒVƒ“ƒ|ƒWƒEƒ€ (2019/10/18), Ã‰ª.

733740. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‰º—Ÿ‚É‚à—LŒø‚Å‚ ‚Á‚œ‹AäP䈓’‚̈ê—á. ŠÛŽR‘׋M1, ì“çˆÉW1, ¬“cŒû_1,2, ‰Ô—Öšæ•F1 (1“Œ—mˆãŠw‘‡Œ€‹†Š, 2“Œ—mˆãŠw‹³ˆç): ‘æ29‰ñŠ¿•ûŽ¡—ÃŒ€‹†‰ï (2019/10/6), ‘åã.


4•a‰@˜AŒg‹³ˆçŒ€‹†•”–å

Šu‰º•”Á‰»ŠÇŠO‰ÈŠwv‚ðŽQÆ


ˆã—ÈÀ‘SŠwŒ€‹†•”–å


—Տ°‰ð–U‹³ˆç‹†•”–å


’nˆæˆã—Êw‹³ˆçŒ€‹†•”–å

ŠuS‘ŸŒŒŠÇŠO‰ÈŠwv‚ðŽQÆ


ˆãŠw•”•‘®—Տ°Œ€‹†ƒZƒ“ƒ^[

Šé‰æŠJ”­•”–å

[Šwp˜_•¶]

110353. [ŒŽ’˜] The Current State and Future Prospects of Population Pharmacokinetic Research in Post-marketing Clinical Studies in Japan. Watanabe-Uchida M, Watanabe T1, Narukawa M: Yakugaku Zasshi 2019/10; 139 (10): 1297-303. (“n糒B–ç1: 1—Տ°Œ€‹†EŠé‰æ)

522132. [uÀ]yƒtƒH[ƒ‰ƒ€zŽ¡Œ±‚É‚š‚¯‚é•ïŠ‡“¯ˆÓ‚ÌŒ»ó‚Ɖۑè. “°šœr•F, ‹T“c—LŠóŽq, “n糒B–ç1, ŽŒŽ@~ (11—Տ°Œ€‹†EŠé‰æ): —Տ°–ò— 2019/7; 50 (4): 177-82.

522133. [uÀ]y<‘æ18‰ñCRC‚ƗՏ°ŽŽŒ±‚Ì‚ ‚è•û‚ðl‚Š‚é‰ï‹c 2018 in •xŽR> ƒVƒ“ƒ|ƒWƒEƒ€5: ”F’è—Տ°Œ€‹†RžˆÏˆõ‰ï`”­‘«‚©‚甌”N‚ÌSHINKA`zŽwj‚Æ–@‚Ì‹·ŠÔ‚É‚ ‚ég—Տ°Œ€‹†h‚ÉŠÖ‚·‚é‘Š’kŽ–€|œfœr‚Š‚錀‹†ŽÒ‚š‚æ‚Ñ—Ï—ˆÏˆõ‰ï“™‚©‚ç‚Ì‘Š’k‚𒆐S‚Ɂ|. “n糒B–ç (—Տ°Œ€‹†EŠé‰æ): –ò—‚ÆŽ¡—à 2019/10; 47 (10): 1568-71.

[Šw‰ïEŒ€‹†‰ï“™]

722245. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ˆã—ÖòŠwŒ€‹†‚ÉŽæ‚è‘g‚ވׂ̊î‘b‚ÆŽÀ‘H`—Տ°Œ€‹†‚ÉŽæ‚è‘g‚Þ‚œ‚ß‚ÌŒ€‹†—Ï—‚̃|ƒCƒ“ƒg‚Æ’ˆÓ“_`. “n糒B–ç (—Տ°Œ€‹†EŠé‰æ): ‘æ29‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ï (2019/11/3), •Ÿ‰ª.

723831. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆãŽt‚ð‘ΏۂƂµ‚œgŒ€‹†—Ï—‹³ˆçh‚ÉŠÖ‚·‚éˆÓŽ¯’²ž. “n糒B–ç1, ¬‘q–¢—ˆ, ’|•œ—ŒbŽq, —L“c‰xŽq (1—Տ°Œ€‹†EŠé‰æ): ‘æ40‰ñ“ú–{—Տ°–ò—Šw‰ïŠwp‘‰ï (2019/12/6), “Œ‹ž.


ƒvƒƒWƒFƒNƒgŽÀŽ{•”–å

[Šwp˜_•¶]

110354. [ŒŽ’˜] Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study. Tabuchi H, Katsurabara T, Mori M, Aoyama M, Obara T, Yasuda N, Kawano T, Imai T, Ieiri I, Kumagai Y1: J Clin Pharmacol 2019/5; 59 (5): 688-701. (ŒF’J—YŽ¡1: 1—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg)

110355. [ŒŽ’˜] No Effect of Digoxin on Rosuvastatin Pharmacokinetics in Healthy Subjects: Utility of Oita Combination for Clinical Drug-Drug Interaction Study. Otani N, Wakuda H, Imai H, Kuranari M, Ishii Y, Ito Y, Okubo A, Ogawa O, Takeda K, Ohyama T, Hasunuma T1, Uemura N: Clin Transl Sci 2019/9; 12 (5): 513-8. (˜@À’qŽq1: 1—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg)

110356. [ŒŽ’˜] Overall Similarities and a Possible Factor Affecting Plasma Metabolome Profiles Between Venous and Capillary Blood Samples From 20 Healthy Human Males. Saito K, Ueno S, Nakayama A, Nitta S, Arai K, Hasunuma T1, Saito Y: J Pharm Sci 2019/11; 108 (11): 3737-44. (˜@À’qŽq1: 1—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg)

110357. [ŒŽ’˜] Plasma pentraxin 3 is associated with progression of radiographic joint damage, but not carotid atherosclerosis, in female rheumatoid arthritis patients: 3-year prospective study. Funakubo-Asanuma Y, Aizaki Y, Noma H, Yokota K, Matsuda M, Kozu N, Takebayashi Y, Nakatani H, Hasunuma T1, Kawai S, Mimura T: Mod Rheumatol 2020/11; 30 (6): 959-966. doi: 10.1080/14397595.2019.1681583. Epub 2019 Oct 30. (˜@À’qŽq1: 1—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg)

110358. [ŒŽ’˜] Safety Profiles, Pharmacokinetics, and Changes in Bone Turnover Markers After Twice-Weekly Subcutaneous Administration of Teriparatide in Healthy Japanese Postmenopausal Women: A Single-Blind Randomized Study. Kumagai Y1, Ose A, Tanaka K, Sugimoto T: Clin Pharmacol Drug Dev 2020/1; 9 (1): 87-96. (ŒF’J—YŽ¡1: 1—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg)

110359. [ŒŽ’˜] Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment. Kumagai Y1, Sakaki M, Furihata K, Ito T, Inoue K, Yoshida T, Matsumoto S, Furuno K, Hagino A: Clin Exp Nephrol 2020/3; 24 (Suppl 1): 25-35. (ŒF’J—YŽ¡1: 1—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg)

110360. [ŒŽ’˜] A drug-drug interaction study of a novel, selective urate reabsorption inhibitor dotinurad and the non-steroidal anti-inflammatory drug oxaprozin in healthy adult males. Furihata K, Nagasawa K, Hagino A, Kumagai Y1: Clin Exp Nephrol 2020/3; 24 (Suppl 1): 36-43. (ŒF’J—YŽ¡1: 1—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg)

[’˜@‘]

620095. [Šwp‘ (•ª’SŽ·•M)]y2ƒy[ƒW‚Å—‰ð‚·‚é •W€–ò•šŽ¡—Ãtƒ@ƒCƒ‹ ‘æ3”Łz¡ŒŒ‰tE–ƉuŽŸŠ³@27. ŠÖßƒŠƒEƒ}ƒ`, p.54-5. ’Óc‘א³, ¬ìŽõŽq, ˜@À’qŽq1 (1—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg), •Ò: “ú–{ƒAƒvƒ‰ƒCƒhEƒZƒ‰ƒsƒ…[ƒeƒBƒNƒX (ŽÀ‘H–ò•šŽ¡—Ã) Šw‰ï, “ìŽR“°, “Œ‹ž, 2019/7”­s.

[Šw‰ïEŒ€‹†‰ï“™]

713144. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) A PHASE 1, SINGLE AND MULTIPLE ASCENDING DOSE, STUDY OF TAS5315, A NOVEL HIGHLY SELECTIVE INHIBITOR OF BRUTON'S TYROSINE KINASE IN HEALTHY MALE VOLUNTEERS. Kumagai Y1, Tanaka Y, Murata M, Takeuchi T: EULAR 2019 (2019/6/14), Madrid, Spain. (ŒF’J—YŽ¡1: 1—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg)

722246. [Šw‰ï (‘S‘)] (‹³ˆçu‰‰) —Տ°ŽŽŒ±‚̈À‘S«•]‰¿‚̍l‚Š•û|“]‚΂ʐæ‚̏ñ|. ŒF’J—YŽ¡ (—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg): ‘æ19‰ñCRC‚ƗՏ°ŽŽŒ±‚Ì‚ ‚è•û‚ðl‚Š‚é‰ï‹c 2019 in YOKOHAMA (2019/9/14), ‰¡•l.

722247. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ƒAƒWƒA”‘‚É‚š‚¯‚鎡Œ±‚ÌŒ»ó‚ÆŒüã‚Ö‚ÌŽæ‚è‘g‚Ý. ŒF’J—YŽ¡ (—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg): DIA Global Oncology Development 2020 (2020/1/31), “Œ‹ž.

722248. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ‘Šú—Տ°Œ€‹†‚ւ̏•ŒŸ‚ª‚Å‚«‚éê–å‰Æ. ŒF’J—YŽ¡ (—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg): ‘æ40‰ñ“ú–{—Տ°–ò—Šw‰ïŠwp‘‰ï (2019/12/5), “Œ‹ž.

722249. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ŠÌáŠQ‚É‚š‚¯‚éƒoƒCƒIƒ}[ƒJ[—˜—p. ŒF’J—YŽ¡ (—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg): ‘æ40‰ñ“ú–{—Տ°–ò—Šw‰ïŠwp‘‰ï (2019/12/6), “Œ‹ž.

722250. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ƒAƒJƒfƒ~ƒA‘n–ò‚ƗՏ°ŽŽŒ±. ŒF’J—YŽ¡1, –ì’†”ü˜a (1—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg): ‘æ40‰ñ“ú–{—Տ°–ò—Šw‰ïŠwp‘‰ï (2019/12/6), “Œ‹ž.

723832. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Œ’N¬l‚ð‘ΏۂƂµ‚œR‚ª‚ñÜ“¯“™«ŽŽŒ±‚É‚š‚¯‚铯ˆÓŽæ“Ÿ—Š‚Æ“¯ˆÓ“P‰ñ—Š‚Ì’²ž. ŠâŠÛ•üŽq, Xì”ü—R‹M, •g“cŒ³Žq, Œ‘º‹MŽq, ˜@À’qŽq1 (1—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg): ‘æ40‰ñ“ú–{—Տ°–ò—Šw‰ïŠwp‘‰ï (2019/12/5), “Œ‹ž.

723833. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆãŽtŽå“±Œ€‹†‚̍‘Û˜AŒg„i‚Ì‚œ‚ß‚ÌŒ€‹†. ŒF’J—YŽ¡1, Šâ“c•c (1—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg): ‘æ40‰ñ“ú–{—Տ°–ò—Šw‰ïŠwp‘‰ï (2019/12/6), “Œ‹ž.

723834. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Œ’í¬l‚É‚š‚¯‚郉ƒ“ƒOƒtƒ‹[ƒg–@‚ƍ‚’£H‰–…‹z“ü–@‚Ì”äŠrŽŽŒ±. ŒF’J—YŽ¡1, –ì’†ºŠó, ’·“cˆÀŽj, “c’†—‰pŽq, â–{‘×—, ‘O“cŽÀ‰Ô2, –ƒ¶‰ëŽq (1—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg, 2–òÜ•”): ‘æ40‰ñ“ú–{—Տ°–ò—Šw‰ïŠwp‘‰ï (2019/12/6), “Œ‹ž.

723835. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) CRB‚ðŽ‚œ‚È‚¢ˆã—Ë@ŠÖ‚É‚š‚¯‚é—Տ°Œ€‹†–@‚ɏ]‚Á‚œ“Á’è—Տ°Œ€‹†‚ÌŽÀŽ{‚ÉŒW‚é‰@“àŽè‘±‚«“™‚̐®”õ‚ƍ¡Œã‚̉ۑè. Œ˜e^ŽÀŽq, ”~“c^‹|, à_“c‚©‚È‚Š, ‰–‘«ˆŸ‹I, “cŠ—R, ã™Cˆê, ˜@À’qŽq1 (1—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg): “ú–{—Տ°ŽŽŒ±Šw‰ï‘æ11‰ñŠwpW‰ï‘‰ï (2020/2/14-15), “Œ‹ž.

732147. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) —Տ°Œ€‹†’†Šj•a‰@‚É‚š‚¯‚éŽx‰‡‹@”\|‰ä‚ª‘‚É‚š‚¯‚éARO‚Ì•ûŒü«‚Í?|. ŒF’J—YŽ¡ (—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg): ‘æ13‰ñŒú¶‰ÈŠwR‹c‰ï—Տ°Œ€‹†•”‰ï (2019/6/6), ŽO“c.


ƒoƒCƒIƒGƒVƒbƒNƒX•”–å


‘n–òƒV[ƒYŒ€‹†ŠJ”­•”–å


ˆãŠw•”•‘®V¢‹Iˆã—ÊJ”­ƒZƒ“ƒ^[

æ’[ˆã—×̈æŠJ”­•”–å

(‹g“cˆê¬)
Šu”å”AŠí‰ÈŠwv‚ðŽQÆ

(“c糁@‘)
ŠuÁ‰»Ší“à‰ÈŠwv‚ðŽQÆ

(’·À‰p–Ÿ)
ŠuŽš•@ˆôA‰ÈE“ªèò•”ŠO‰ÈŠwv‚ðŽQÆ

(“c’†@Œ‰)
Šuˆê”ʁE¬Ž™EŠÌ’_äXŠO‰ÈŠwv‚ðŽQÆ

(ŒŽ—¯OŽ÷)
Šu•úŽËü‰ÈŠwi‰æ‘œf’fŠwjv‚ðŽQÆ

(æèG–Ÿ)
Šu¬Ž™‰ÈŠwv‚ðŽQÆ

(’†ŒG•F)
Šu¬Ž™‰ÈŠwv‚ðŽQÆ


‰¡’f“Iˆã—×̈æŠJ”­•”–å

(‹àˆäº•¶)
Šu–ƒŒ‰ÈŠwv‚ðŽQÆ

(ŽR‰ºŒpŽj)
Šuã•”Á‰»ŠÇŠO‰ÈŠwv‚ðŽQÆ

(Vˆä³N)
Šu–ƒŒ‰ÈŠwv‚ðŽQÆ

(²X–ØŽ¡ˆê˜Y)
ŠuŒÄ‹zŠí“à‰ÈŠwv‚ðŽQÆ

(¬—ѐŽ“T)
ŠuÁ‰»Ší“à‰ÈŠwv‚ðŽQÆ

(‚ŽR—zŽq)
Šu–k—¢‘åŠw•a‰@ŠŽõŠÇ—Žºv‚àŽQÆ

[Šwp˜_•¶]

310042. [Ç—á•ñ] Characterization of the IncFII-IncFIB(pB171) Plasmid Carrying bla NDM-5 in Escherichia coli ST405 Clinical Isolate in Japan. Takayama Y1,2, Sekizuka T, Matsui H3, Adachi Y2, Eda R4, Nihonyanagi S2, Wada T5, Matsui M, Suzuki S, Takaso M6, Kitasato H7, Kuroda M, Hanaki H3: Infect Drug Resist 2020/2; 13: 561-6. (‚ŽR—zŽq1,2, ŒˆäGm3, ˆÀ’B@÷2, ]“c—È‘Ÿ˜Y4, “ñ–{–öL2, ˜a“c’B•F5, ‚‘Š»Žm6, –k—¢‰p˜Y7, ‰Ô–؏G–Ÿ3: 1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2ŠŽõŠÇ—Žº, 3–k—¢‘åŠw–k—¢¶–œ‰ÈŠwŒ€‹†Š, 4‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 5äPŒŽ•aEŠŽõ“à, 6®ŠO, 7ˆã—Éq¶Šw•”)

[’˜@‘]

620096. [Šwp‘ (’P’˜)]y–òÜ‘ϐ«@No.5 ƒƒ`ƒVƒŠƒ“‘ϐ«‰©FƒuƒhƒE‹…‹Ûz‚ŽR—zŽq (V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã), ƒTƒ‰ƒ„, ‘åã, 2019”­s.

[Šw‰ïEŒ€‹†‰ï“™]

722251. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ŽüpŠú—\–hR‹Û–ò‚Ì“K³‰»‚Ö‚ÌŽæ‚è‘g‚Ý. ‚ŽR—zŽq (V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ67‰ñ“ú–{‰»Šw—Ö@Šw‰ï‘‰ï (2019/5/9), “Œ‹ž.

722252. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ’–Ú‚µ‚œ‚¢Å‹ß‚̘_•¶: ‘ϐ«‹Û CRE‚Ɗ‹«. ‚ŽR—zŽq (V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ35‰ñ“ú–{ŠÂ‹«ŠŽõŠw‰ï‘‰ïEŠwpW‰ï (2020/2/14), ‰¡•l.

723836. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚š‚¯‚éR‹Û–ò“K³Žg—p‚ÌŽæ‚è‘g‚݂ɂ‚¢‚ā`ˆÏˆõ‰ïŠˆ“®‚ð’Ê‚µ‚ā`. ‚ŽR—zŽq1,2, “ñ–{–öL2,3, ˜a“c’B•F2,4 (1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2ŠŽõŠÇ—Žº, 3—ÕŒŸ•”, 4äPŒŽ•aEŠŽõ“à): ‘æ31‰ñ“ú–{—Տ°”÷¶•šŠw‰ï‘‰ïEŠwpW‰ï (2020/2/1), ‹à‘ò, “ú–{—Տ°”÷¶•šŠw‰ïŽGŽ 2019; 30 (Suppl 1): 322.

732148. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰“™) ŒÄ‹zŠíƒEƒCƒ‹ƒXŠŽõÇ‚̃}ƒl[ƒWƒƒ“ƒg@`¬l—á‚𒆐S‚Ɂ` ƒCƒ“ƒtƒ‹ƒGƒ“ƒU‚Æ”x‰Š. ‚ŽR—zŽq (V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ68‰ñ“ú–{ŠŽõÇŠw‰ï“Œ“ú–{’n•û‰ïŠwpW‰ïE‘æ66‰ñ“ú–{‰»Šw—Ö@Šw‰ï“Œ“ú–{Žx•”‘‰ï ‡“¯Šw‰ï (2019/10/18), å‘ä.


ˆãŠw•”‹³ˆçŒn‹ZpEˆõ

Œ`‘ÔŒn

[Šw‰ïEŒ€‹†‰ï“™]

713001. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) The fine structural approach to clarify the pathophysiological mechanism of orthopedic diseases by analyzing the spinal excurved Medaka mutant, wavy (wy). Nishimaki T1, Uchida K2, Yamada M, Oda S, Oga A, Oota H, Katsumura T3, Takaso M2, Ogawa M3: The 19th Congress of the International Federation of Associations of Anatomists (2019/8/9), London, UK. (Œê r”V1, “à“cŒ’‘Ÿ˜Y2, Ÿ‘ºŒ[Žj3, ‚‘Š»Žm2, ¬ìŒ³”V3: 1Œ`‘ÔŒn, 2®ŠO, 3‰ð–U)


¶•š•š—Œn


•a‘ԁEf—ÃŒn

[Šw‰ïEŒ€‹†‰ï“™]

723096. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¶‘ÌŽŽ—¿•ªÍ‚ðs‚Á‚œƒXƒCƒZƒ“‚ÌŒëH‚É‚æ‚éH’†“Å3—á. ‹g‘º‹vmŽq1, ŠÛ‹ŽFº2, ‘åˆä^—¢“Þ2, ŒIŒŽ—S‘Ÿ˜Y2, ²X–ؐçŽõŽq3, ˆîŠ_‘דl2, ²“¡•¶Žq3, ó—˜@–õ2 (1•a‘ԁEf—ÃŒn, 2‹~–œ, 3–@ˆã): ‘æ41‰ñ“ú–{’†“ÅŠw‰ï‘‰ïEŠwpW‰ï (2019/7/21), é‹Ê.

733017. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) •a—‘gD•W–{ì»Žž‚É‚š‚¯‚éƒLƒVƒŒƒ“‘ã‘Ö•i—˜—p‚ÌŽæ‚è‘g‚݂ɂ‚¢‚Ä. ’†ŠÛ®”ü1, ã–{“Žq1, ‘ºãçŽq2, “ü]@Â2, ²X–ؐçŽõŽq2, ’·–參•œ1, ²“¡•¶Žq2 (1Œ`‘ÔŒn, 2–@ˆã): ‘æ88‰ñ“ú–{–@ˆãŠw‰ïŠwpŠÖ“Œ’n•ûW‰ï (2019/10/12), “Œ‹ž (‘ä•—‚Ì‚œ‚ߎãŠJÃ).

'18”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'18-320001. [Ç—á•ñ] RglycineŽó—e‘̍R‘Ì—z«‚Ìstiff-limbÇŒóŒQ‚Ì1—á. ‘O“cŒ›Œá, Ž…–FŽ÷, ™ŒŽ–FŽq, ‹ààV’Œ”ü1, ”ђˍ‚_2 (1•a‘ԁEf—ÃŒn, 2”]_Œo“à): —Տ°_ŒoŠw 2019/2; 59 (2): 98-101.


—\–hˆãŠwŒn


•ªŽqˆã‰ÈŠwE§ŒäŒn


“Œ•a‰@Œ€‹†Œn


‘gD”|—{ƒZƒ“ƒ^[


DNAŽÀŒ±ƒZƒ“ƒ^[


ƒoƒCƒIƒCƒ[ƒWƒ“ƒOŒ€‹†ƒZƒ“ƒ^[


ˆâ“`Žq‚ŽŸ‹@”\‰ðÍƒZƒ“ƒ^[


Œ’NŠÇ—ƒZƒ“ƒ^[

[Šwp˜_•¶]

110361. [ŒŽ’˜] Serial renal biopsies in normo- and microalbuminuric patients with type 2 diabetes demonstrate that loss of renal function is associated with a reduction in glomerular filtration surface secondary to mesangial expansion. Moriya T1, Yamagishi T, Matsubara M1, Ouchi M: J Diabetes Complications 2019/5; 33 (5): 368-73. (Žç‰®’B”ü1, ŒŒŽ‚Ü‚Ç‚©1: 1Œ’NŠÇ—ƒZ)

110362. [ŒŽ’˜] Vitamin B6 intake and incidence of diabetic retinopathy in Japanese patients with type 2 diabetes: analysis of data from the Japan Diabetes Complications Study (JDCS). Horikawa C1, Aida R1, Kamada C1, Fujihara K1, Tanaka S1, Tanaka S1, Araki A1, Yoshimura Y1, Moriya T1,2, Akanuma Y1, Sone H1 (1Japan Diabetes Complications Study Group): Eur J Nutr 2020/6; 59 (4): 1585-94. doi: 10.1007/s00394-019-02014-4. Epub 2019 May 31. (Žç‰®’B”ü1,2: 2Œ’NŠÇ—ƒZ)

120040. [ŒŽ’˜] u‚±‚±‚ë‚ÌŒ’N’²žv‚©‚ç‚í‚©‚éS—Žx‰‡‚ð—v‚·‚é‰Â”\«‚ª‚‚¢Šw¶‚̐S”zŽ–‚Ì“Á’¥. ŽR“c—TŽq1, Žç‰®’B”ü1 (1Œ’NŠÇ—ƒZ): CAMPUS HEALTH 2019/5; 56 (2): 178-84.

120041. [ŒŽ’˜] Šw¶‘Š’k‚É‚š‚¯‚鍢“—á‚Å‚ ‚é”ñŽå‘Ì“I—ˆ’kŠw¶‚ւ̃JƒEƒ“ƒZƒ‰[‚Ì—‰ð‚ƑΉž‚ÉŠÖ‚·‚é‘S‘’²ž. ‘å’¬’m‹v1, ŽR“c—TŽq1, Î’ˏ¹•Û1, Žç‰®’B”ü1 (1Œ’NŠÇ—ƒZ): CAMPUS HEALTH 2019/5; 56 (2): 224-30.

522134. [uÀ]y˜AÚ: DH—Տ°‚ɖ𗧂 #ŽÐ‰ï‚̃L[ƒ[ƒhz#17 ƒpƒjƒbƒNáŠQ|”­ì‚Ì•sˆÀ‚ɉՂ܂ê, “úí¶Šˆ‚ÉŽxá|. ‹{’n‰p—Y (Œ’NŠÇ—ƒZ): Ž•‰È‰q¶Žm 2019/8; 43 (8): 64-5.

522135. [uÀ]y“ÁW: –«’ɂւ̃Aƒvƒ[ƒ`z–«’ɂƐž_ŽŸŠ³. ‹{’n‰p—Y (Œ’NŠÇ—ƒZ): ÅVž_ˆãŠw 2020/3; 25 (2): 101-6.

540080. [‚»‚Ì‘Œ (”N•ñ)] 2018”N“x‚ðU‚è•Ô‚Á‚Ä. ŽR“c—TŽq (Œ’NŠÇ—ƒZ): –k—¢‘åŠwŒ’NŠÇ—ƒZƒ“ƒ^[”N•ñ 2019; ‘æ3†: 17-9.

540081. [‚»‚Ì‘Œ (”N•ñ)] \˜a“cƒLƒƒƒ“ƒpƒXƒNƒ‰ƒXŽå”C‚ð‘ΏۂɎÀŽ{‚µ‚œƒ[ƒNƒVƒ‡ƒbƒvŒ^Œ€C (2019”N3ŒŽ22“ú) ‚̂܂Ƃ߁|ƒJƒEƒ“ƒZƒ‰[‚©‚ç‚̃ƒbƒZ[ƒW‚ð“Y‚Š‚ā|. ŽR“c—TŽq1, ’†‘º—zŽq1, Žç‰®’B”ü1 (1Œ’NŠÇ—ƒZ): 2019.

540082. [‚»‚Ì‘Œ (Šw‰ï•ñ‘)]y‘æ57‰ñ‘S‘‘åŠw•ÛŒ’ŠÇ—Œ€‹†W‰ïzK10€–Ú‚Æ‘®«‚Æ‚ÌŠÖ˜A‚©‚ç‚Ý‚œA‘åŠwV“ü¶‚̐ž_Œ’N‚Ì“Á’¥: 3”NŠÔ‚Ì”äŠr‚©‚ç. ŽR“c—TŽq1, Î’ˏ¹•Û1, ‘å’¬’m‹v1, ‰ÍŒŽ‹v”üŽq, “c’†‚ ‚ä‚Ý, —§‰Ô@•X, ¬’J^•ä, Žç‰®’B”ü1 (1Œ’NŠÇ—ƒZ): CAMPUS HEALTH 2020/3; 57 (1): 245.

[’˜@‘]

620097. [Šwp‘ (•ª’SŽ·•M)]y’m‚Á‚Ä‚š‚«‚œ‚¢‹H‚Ȑž_ÇŒóEÇŒóŒQ|Ç—á‚©‚çŠw‚ԁ| (ž_‰ÈŽ¡—Êw‘æ34Šª‘Š§†)z45. Œûo“àƒZƒlƒXƒgƒpƒ`[, p.142-4. ‹{’n‰p—Y1 (1Œ’NŠÇ—ƒZ), •Ò:už_‰ÈŽ¡—Êwv•ÒWˆÏˆõ‰ï, •ÒW‹Š—Í: ‘åÎ@’q2, ŒË“c—T”V (2ž_), ¯˜a‘“X, “Œ‹ž, 2019/10”­s.

620098. [Šwp‘ (•ª’SŽ·•M)]y¡“ú‚̐f’fŽwj ‘æ8”ŁzII. ŽŸŠ³•Ò@15. ž_ŽŸŠ³@•ÏŠ·ÇE‰ð—£ÇŒQ, p.1461. ‹{’n‰p—Y (Œ’NŠÇ—ƒZ), ‘•ÒW: ‰iˆä—ÇŽO, ˆãŠw‘‰@, “Œ‹ž, 2020/3”­s.

[Šw‰ïEŒ€‹†‰ï“™]

713145. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Diabetic retinopathy is an additional risk factor for hemodialysis induction and mortality in type 2 diabetic patients. Moriya T1, Matsubara M1, Ouchi M: American Diabetes Association 79th Scientific Sessions (2019/6/7-11), San Francisco, USA. (Žç‰®’B”ü1, ŒŒŽ‚Ü‚Ç‚©1: 1Œ’NŠÇ—ƒZ)

722253. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™)yƒŠƒtƒŒƒbƒVƒƒ[ƒR[ƒX3zŽ•‰Èˆã‚ª’m‚Á‚Ä‚š‚«‚œ‚¢ ž_‰È‚Ì’mŽ¯. ‹{’n‰p—Y (Œ’NŠÇ—ƒZ): ‘æ24‰ñ“ú–{ŒûoŠç–Ê’ÉŠw‰ï (2019/9/28), ìè.

723837. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) î“I‚É—Z‡‚µ‚œ‰Æ‘°‚©‚çŠw¶‚ªŽ©—§‚µ‚Ä‚¢‚­ƒvƒƒZƒX‚ÌŒŸ“¢|Šw¶‚ƉƑ°‚Ì‘ŠŒÝì—p‚ÌŽ‹“_‚©‚ç|. ‘å’¬’m‹v1, ŽR“c—TŽq1, Žç‰®’B”ü1 (1Œ’NŠÇ—ƒZ): “ú–{Šw¶‘Š’kŠw‰ï‘æ37‰ñ‘å‰ï (2019/5/19), “Œ‹ž.

723838. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒNƒ‰ƒXŽå”C‚ÌŠw¶‘Ήž‚ÌŒ»ó‚ƃj[ƒY‚Ì•ªÍ|‹³Eˆõ‚ÌŠw¶‘Ήž‚ɖ𗧂Œ€CƒvƒƒOƒ‰ƒ€‚ÌŠJ”­‚ÉŒü‚¯‚ā|. ŽR“c—TŽq1, ’†‘º—zŽq1, Žç‰®’B”ü1 (1Œ’NŠÇ—ƒZ): “ú–{Šw¶‘Š’kŠw‰ï‘æ37‰ñ‘å‰ï (2019/5/19), “Œ‹ž.

723839. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Œ°«ƒAƒ‹ƒuƒ~ƒ“”A”­Ç‘O‚Ì“ú–{l2Œ^“œ”A•aŠ³ŽÒ‚̐t‹@”\’ቺ‚ð—\‘ª‚·‚é‘gDŠw“IˆöŽq‚Í?|serial biopsy‚É‚æ‚錟“¢|. Žç‰®’B”ü1, ŒŒŽ‚Ü‚Ç‚©1, ŽRŠÝ‹M—m, ‘å“àŠîŽi (1Œ’NŠÇ—ƒZ): ‘æ62‰ñ“ú–{“œ”A•aŠw‰ï”NŽŸŠwpW‰ï (2019/5/23-25), å‘ä.

723840. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “®ì—Ö@‚ƏW’cž_—Ö@‚̃Rƒ“ƒoƒCƒ“ƒhƒZƒ‰ƒs[‚ð“K—p‚µ‚œˆêŽ–—á`‘ΐl‹Ù’£‚Ì‹­‚¢’jŽqŠw¶‚ªŽ©ŒÈƒRƒ“ƒgƒ[ƒ‹ŠŽ‚ðˆç‚ñ‚ŸƒvƒƒZƒX`. Î’ˏ¹•Û1, ŽR“c—TŽq1, Žç‰®’B”ü1 (1Œ’NŠÇ—ƒZ): “ú–{—Տ°“®ìŠw‰ï‘æ27‰ñŠwp‘å‰ï (2019/9/14), “Œ‹ž.

723841. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘åŠw¶”N—î‚̏W’c‚ð‘ΏۂƂµ‚œƒOƒ‹[ƒvƒvƒƒOƒ‰ƒ€‚ÉŠÖ‚·‚錀‹†“®Œü‚Ì•ªÍ. Î’ˏ¹•Û1, ŽR“c—TŽq1, ‘å’¬’m‹v1, Žç‰®’B”ü1 (1Œ’NŠÇ—ƒZ): ‘æ57‰ñ‘S‘‘åŠw•ÛŒ’ŠÇ—Œ€‹†W‰ï (2019/10/9), ŽD–y.

723842. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) K10€–Ú‚Æ‘®«‚Æ‚ÌŠÖ˜A‚©‚ç‚Ý‚œA‘åŠwV“ü¶‚̐ž_Œ’N‚Ì“Á’¥: 3”NŠÔ‚Ì”äŠr‚©‚ç. ŽR“c—TŽq1, Î’ˏ¹•Û1, ‘å’¬’m‹v1, ‰ÍŒŽ‹v”üŽq, “c’†‚ ‚ä‚Ý, —§‰Ô@•X, ¬’J^•ä, Žç‰®’B”ü1 (1Œ’NŠÇ—ƒZ): ‘æ57‰ñ‘S‘‘åŠw•ÛŒ’ŠÇ—Œ€‹†W‰ï (2019/10/9), ŽD–y.

723843. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”ì–ž‘åŠw¶‚Ì‘Ì‘g¬‘ª’è‚Æ‚»‚̉ü‘P‚Ö‚ÌŽæ‚è‘g‚Ý. ŒŒŽ‚Ü‚Ç‚©1, ‹g“c—F‹I1, ‹{’n‰p—Y1, “‰€@”E1, ìã”ü’q‘ã1, ‘“cçH1, …Œû@e1, ‘Oì‰ÀŽq1, Žç‰®’B”ü1 (1Œ’NŠÇ—ƒZ): ‘æ57‰ñ‘S‘‘åŠw•ÛŒ’ŠÇ—Œ€‹†W‰ï (2019/10/9), ŽD–y.

732149. [Šw‰ï (Œ€‹†‰ïE’n•û‰ï)] (ƒVƒ“ƒ|ƒWƒEƒ€)yƒVƒ“ƒ|ƒWƒEƒ€2: ‘åŠw‹³Eˆõ‚Æ•ÛŒ’ŠÇ—‚Ì—L‹@“I‚ȘAŒg‚ð–ÚŽw‚µ‚āzƒJƒEƒ“ƒZƒ‰[‚Ì—§ê‚©‚狳Eˆõ‚Ƃ̘AŒg‚̍\’z. ŽR“c—TŽq (Œ’NŠÇ—ƒZ): ‘æ57‰ñ‘S‘‘åŠw•ÛŒ’ŠÇ—‹Š‰ïŠÖ“ŒbM‰z’n•û•”‰ïŒ€‹†W‰ï (2019/8/29-30), ‘Š–ÍŒŽ, ‘æ57‰ñ‘S‘‘åŠw•ÛŒ’‹Š‰ïŠÖ“ŒbM‰z’n•û•”‰ï 2019; p.41-4.

732150. [Šw‰ï (Œ€‹†‰ïE’n•û‰ï)] (ƒVƒ“ƒ|ƒWƒEƒ€)yƒVƒ“ƒ|ƒWƒEƒ€1: —LŒø‚ÈŠw¶Œ’f‚ÌŽÀŒ»‚ÉŒü‚¯‚āzŽ–Œã‘[’u‚É‚Í, ‚à‚Á‚Æ‚Å‚«‚邱‚Æ‚ª‚ ‚é|“Á‚É’á‘̏dŠw¶‚̃PƒA‚ɂ‚¢‚ā|. …Œû@e (Œ’NŠÇ—ƒZ): ‘æ57‰ñ‘S‘‘åŠw•ÛŒ’ŠÇ—‹Š‰ïŠÖ“ŒbM‰z’n•û•”‰ï (2019/8/29-30), ‘Š–ÍŒŽ.

733741. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)]y‘ã•\zŽç‰®’B”ü (Œ’NŠÇ—ƒZ): ‘æ57‰ñ‘S‘‘åŠw•ÛŒ’ŠÇ—‹Š‰ïŠÖ“ŒbM‰z’n•û•”‰ïŒ€‹†W‰ï (2019/8/29-30), ‘Š–ÍŒŽ.

733742. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‚±‚ÌŠ³ŽÒ‚³‚ñ‚Í”ñ“TŒ^“I“œ”A•a«tÇ‚©? ŒŒŽ‚Ü‚Ç‚© (Œ’NŠÇ—ƒZ): ‘æ57‰ñ“ú–{“œ”A•aŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2020/1/18), ‰¡•l.

'18”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'18-540006. [‚»‚Ì‘Œ (Šw‰ï•ñ‘)]y‘æ56‰ñ‘S‘‘åŠw•ÛŒ’ŠÇ—Œ€‹†W‰ïz‘åŠw¶‚̂₹‚ɑ΂·‚錒NŠÇ—ƒZƒ“ƒ^[‚Ì—LŒø‚ȊȈՉî“ü‘̐§‚̍\’z. ‹g“c—F‹I1, àVŽRŒb”g1, ŒŒŽ‚Ü‚Ç‚©1, ‘Œ (1Œ’NŠÇ—ƒZ): CAMPUS HEALTH. 2019/3: 56 (1): 119-21.


–k—¢‘åŠw•a‰@

ŠÅŒì•”

[Šwp˜_•¶]

120042. [ŒŽ’˜] ŠÅŒì•”’·‚ª”FŽ¯‚·‚éŠÅŒìŽt’·‚Ì‘ì‰z‚µ‚œ¬‰Ê‚ÆŠÖ˜A‚·‚éƒRƒ“ƒsƒeƒ“ƒV[. •Ê•{çŒb (ŠÅŒì•”): “ú–{ˆã—ÁE•a‰@ŠÇ—Šw‰ïŽ 2019/4; 56 (2): 71-9.

120043. [ŒŽ’˜] ‹~‹}ŠÅŒìŽt‚̃^[ƒ~ƒiƒ‹ƒPƒA‚ɑ΂·‚é‘Ô“x‚ÌŽÀ‘Ô. ’Ö”ü’q”Ž1, ˆÉ“Œ—RN2, ŠŽR˜a”ü1 (1ŠÅŒì•”, 2•ºŒÉŒ§—§‘åŠwŠÅŒìŠw•”): ŠÅŒìŒ€‹†W˜^ 2019/7; 26†: 31-40.

120044. [ŒŽ’˜] ŠÅŒìŠÇ—ŽÒ‚̃Rƒ“ƒsƒeƒ“ƒV[‚ÌŠT”O•ªÍ. •Ê•{çŒb (ŠÅŒì•”): “ú–{ŠÅŒìŠÇ—Šw‰ïŽ 2019/12; 23 (1): 160-7.

120045. [ŒŽ’˜] ‚—îŽÒ‚̐ϋɓIpŒã—£°‚𑣂·‚œ‚ß‚ÌŠÅŒìƒPƒAŠm—§‚ÉŒü‚¯‚Ä‚ÌŒŸ“¢|‚—î‘å’°ŠàŠ³ŽÒ‚̏pŒã—£°‚É‚š‚¯‚é•às”‚ƉºŽˆ‹Ø—Í‚Æ‚ÌŠÖ˜A‚©‚ç|. ŒHìL•œ1, ’†ŽR‰hƒ2 (1ŠÅŒì•”, 2ŠÅŒìŠw•”): ŠÅŒìlŠÔHŠw‰ïŽ 2020/3; 1: 31-8.

510012. [‘à] Narrative review on attitudes toward organ donation of undergraduate nurse students. Tsubaki M1, Tougo S, Kobayashi M, Arakawa S1, Yoshida K2: Jpn J Nurs Sci 2020/1; 17 (1): e12291. (’Ö”ü’q”Ž1, rì@‘1, ‹g“cˆê¬2: 1ŠÅŒì•”, 2”å”AŠí)

522136. [uÀ]y˜AÚ: Margaret Newman‚ÌŒ’N‚Ì—˜_‚É“±‚©‚ê‚œ‚Æ‚«, ‚ ‚È‚œ‚Ì‚ª‚ñŠÅŒìŽÀ‘H‚Í‚³‚ç‚ÉŠJ‚©‚ê‚é`‚ª‚ñŠ³ŽÒE‰Æ‘°‚Ƃ̃PƒAƒŠƒ“ƒOƒp[ƒgƒi[ƒVƒbƒv‚ð‘ÌŒ±‚µ‚æ‚€`(‘æ5‰ñ)zNewman—˜_‚É“±‚©‚ê‚œŽæ‚è‘g‚Ý‚ð’Ê‚µ‚ÄŠJŽŠ‚µ‚œŠÅŒìƒ`[ƒ€‚̐¬’·`‚ª‚ñŠ³ŽÒE‰Æ‘°‚̐¶ŠˆKŠµ—§‚Ä’Œ‚µ‚ðŽx‰‡‚·‚éŠO—ˆŠÅŒìŽt‚ÌŠwK‰ï‚ð‚Æ‚š‚µ‚ā`. Ž™‹Ê”ü—R‹I1, ŽOŽŸ^—2, çø“”ü“oŽq1 (1ŠÅŒì•”, 2•‘ –ì‘åŠwŠÅŒìŠw•”): ‚ª‚ñŠÅŒì 2019/5; 24 (4): 399-402.

522137. [uÀ]yƒoƒCƒ^ƒ‹EABC•]‰¿‚ðƒgƒŠƒA[ƒW‚Å‚àŽg‚¢‚±‚È‚·!? “úíf—©‚çÐŠQ‚Ü‚Å‚Ç‚ñ‚ȏê–Ê‚Å‚à–𗧂Â, Œø‰Ê“I‚È‘I•Ê‚ÉŒ‡‚©‚¹‚È‚¢•]‰¿‚Ì‚µ‚©‚œ‚ðg‚ɂ‚¯‚æ‚€!`z‹~‹}ƒgƒŠƒA[ƒW: ‹~‹}ŠO—ˆ‚É‚š‚¯‚é‰@“àƒgƒŠƒA[ƒW. ŠŽR˜a”ü (ŠÅŒì•”): ƒŒƒWƒfƒ“ƒgƒm[ƒg 2019/5; 21 (3): 482-7.

522138. [uÀ]yŠÅŒì: ’nˆæ‚ÉŽ‹–ì‚ðL‚°‚œŠÅŒìŠÇ—”\—Í‚ð|•a‰@ŠÅŒìŠÇ—ŽÒ‚̃}ƒlƒWƒƒ“ƒgƒ‰ƒ_[: “ú–{ŠÅŒì‹Š‰ï”Ł|zu•a‰@ŠÅŒìŠÇ—ŽÒ‚̃}ƒlƒWƒƒ“ƒgƒ‰ƒ_[ “ú–{ŠÅŒì‹Š‰ï”Łv‚̈Ӌ` (À’k‰ï). ‹gì‹v”üŽq1, •Ê•{çŒb2, ‰–“c”ü²‘ã3, •Ÿ“c—TŽq4 (1“ú–{ŠÅŒì‹Š‰ï, 2ŠÅŒì•”, 3Ã“ìˆã—ÑåŠw, 4‚Ü‚¿‚̃i[ƒXƒXƒe[ƒVƒ‡ƒ“”ªç‘ã): ŠÅŒì 2019/6; 71 (9): 39-44.

522139. [uÀ]y“ÁW: Äl!@¬Ž™ŠÅŒìê–åŠÅŒìŽt‚ÌŽÀ‘H‚Æ–ðŠ„zuŠÅŒìŠO—ˆv‚âuê–å•”–åv‚ÅŠˆ–ô‚·‚鏬Ž™ŠÅŒìê–åŠÅŒìŽt@…D¬Ž™ŠÖ˜A•a“‚É‚š‚¯‚éƒvƒƒAƒNƒeƒBƒuƒ‰ƒEƒ“ƒh‚ÌŠˆ“®. ‘å’J®–ç (ŠÅŒì•”): ¬Ž™ŠÅŒì 2019/6; 42 (6): 669-73.

522140. [uÀ]y“ÁW3: lHŒÄ‹zŠÇ—’†‚ÌŽ™‚ÌŠÅŒì`NICUE¬Ž™‰ÈEdÇŽÒŽ{Ý‚Å‚ÌŽÀÛ`z¬Ž™‰È (¬Ž™ICU) ‚ōs‚í‚ê‚élHŒÄ‹zŠÇ—`VlƒXƒ^ƒbƒt‚Ö‚ÌŽw“±‚̍H•v`. •äÏØ•ä (ŠÅŒì•”): ‚±‚Ç‚à‚ƉƑ°‚̃PƒA 2019/6; 14 (2): 65-71.

522141. [uÀ]y“ÁW: “­‚«•û‰üŠv, ‚ª‚Á‚Õ‚èŽl‚Â!zI. ˆãŽt‚Æ""“­‚«•û""‚ÌŒ»ó@ŠÅŒìE‚Ì—§ê‚©‚ç; ŠÅŒìŽt‚Æ""“­‚«•û""‚Ì‚±‚ê‚©‚ç. •Ê•{çŒb (ŠÅŒì•”): ‹~‹}ˆãŠw 2019/8; 43 (9): 1142-7.

522142. [uÀ]y“ÁW: –K–âŠÅŒìŽt‚ª‰î“ü‚Å‚«‚鍂—îŽÒ‚̃|ƒŠƒtƒ@[ƒ}ƒV[uŒž‚炵‚œ‚¢v‚Á‚ÄŒŸ‚Á‚Ä‚¢‚¢!zu–ò‚ª‘œ‚¢vŽ–—á‚ðŠÅŒìŽt‚ªƒAƒZƒXƒƒ“ƒg‚µ‚ÄŒ©‚Š‚œ‰Û‘è (À’k‰ï). ‰ºˆä–ƒ‹IŽq1, “y‰®Žu•Û2, ‰¡ŽR—˜2, ŠŽR˜a”ü2 (1ƒPƒA[ƒY–K–âŠÅŒìƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‘Š–ÍŒŽ“ì, 2ŠÅŒì•”): –K–âŠÅŒì‚ƉîŒì 2019/9; 24 (9): 644-51.

522143. [uÀ]y˜AÚ: ƒrƒWƒ‡ƒ“’B¬‚ÉŒü‚¯‚Ä!@ê]Eê”C‚Å‚È‚¢gƒZƒNƒVƒ‡ƒ“”z’u‚̃XƒyƒVƒƒƒŠƒXƒghŠˆ—pEˆç¬EŽx‰‡ (‘æ‚P‰ñ)zŠÅŒìŽt’·‚É‚æ‚éƒZƒNƒVƒ‡ƒ“”z’uƒŠƒ\[ƒX: ƒi[ƒX‚֑΂·‚銈—pEˆç¬EŽx‰‡‚Ì‘S‘Ì‘œ. ’†“‡ßŽq1, ‹ß“¡‚Ü‚ä‚Ý1, â‰º’qŽìŽq1, ‹TÎ—çŽq1, ŽR–ì•Ó‚Ý‚¿Žq1 (1ŠÅŒì•”): ƒi[ƒXƒ}ƒlƒWƒƒ[ 2019/9; 21 (7): 42-7.

522144. [uÀ]y˜AÚ: ƒrƒWƒ‡ƒ“’B¬‚ÉŒü‚¯‚Ä!@ê]Eê”C‚Å‚È‚¢gƒZƒNƒVƒ‡ƒ“”z’u‚̃XƒyƒVƒƒƒŠƒXƒghŠˆ—pEˆç¬EŽx‰‡ (‘æ2‰ñ)zƒrƒWƒ‡ƒ“‚ƘA“®‚µ‚œƒŠƒ\[ƒX: ƒi[ƒXŠˆ—p‚Ì‚œ‚߂̃c[ƒ‹‚ð—p‚¢‚œ‚©‚©‚í‚è. â‰º’qŽìŽq1, ‹ß“¡‚Ü‚ä‚Ý1, ‹TÎ—çŽq1, ’†“‡ßŽq1, ŽR–ì•Ó‚Ý‚¿Žq1 (1ŠÅŒì•”): ƒi[ƒXƒ}ƒlƒWƒƒ[ 2019/10; 21 (8): 63-9.

522145. [uÀ]y“ÁW: ‚»‚̐l‚炵‚¢¶Šˆ‚ðŽx‚Š‚铧ÍŠÅŒìz5-1. A˜J‚·‚铧ÍŠ³ŽÒ‚ðŽx‚Š‚éƒPƒA|Š³ŽÒ‚ðŽx‚Š‚éŽd‘g‚݂̉ðà; ŽY‹Æ•ÛŒ’Žt‚ÌŽ‹“_‚©‚ç. ‘哇t‹P1, ‰ºŽi‰fˆê2, ’Ö”ü’q”Ž3, “¡ŒãG•ã4 (1“ŒŽÅlŽ–E‘–±•”, 2º˜a‘åŠw•ÛŒ’ˆã—Êw•”, 3ŠÅŒì•”, 4º˜a‘åŠw“¡‚ª‹u•a‰@): —Տ°“§Í 2019/10; 35 (11): 1387-94.

522146. [uÀ]y“ÁW: dÇ‚ÈŽq‚Ç‚à‚Ì‘i‚Š‚ð—‰ð‚·‚é; Œ©“Š‚¹‚È‚¢Çó‚Ì•]‰¿z[dÇ‚ÈŽq‚Ç‚à‚Ì‘i‚Š‚ð—‰ð‚·‚é‚œ‚ß‚ÌŽæ‚è‘g‚Ý] …BPICU‚É‚š‚¯‚é’Á’ɁE’ÁÃŠÇ—‚ÌŽÀÛ; ŠÅŒìŽt‚ƈãŽt‚Ì‹Š“­. ˆÉ“¡FŽq (ŠÅŒì•”): ¬Ž™ŠÅŒì 2019/10; 42 (11): 1405-9.

522147. [uÀ]y˜AÚ: ƒrƒWƒ‡ƒ“’B¬‚ÉŒü‚¯‚Ä!@ê]Eê”C‚Å‚È‚¢gƒZƒNƒVƒ‡ƒ“”z’u‚̃XƒyƒVƒƒƒŠƒXƒghŠˆ—pEˆç¬EŽx‰‡ (‘æ3‰ñ)zƒZƒNƒVƒ‡ƒ“”z’u‚̐ê–åŠÅŒìŽtE”F’èŠÅŒìŽt‚Ö‚ÌŠÅŒìŽt’·‚Ì‚©‚©‚í‚è‚ÉŠÖ‚·‚鎖—ጟ“¢`ƒZƒNƒVƒ‡ƒ“‚̃rƒWƒ‡ƒ“ô’è‚ɏœ_‚𓖂Ăā`. ‹ß“¡‚Ü‚ä‚Ý1, ‹TÎ—çŽq1, â‰º’qŽìŽq1, ’†“‡ßŽq1, ŽR–ì•Ó‚Ý‚¿Žq1 (1ŠÅŒì•”): ƒi[ƒXƒ}ƒlƒWƒƒ[2019/11; 21 (9): 72-7.

522148. [uÀ]y˜AÚ: ƒrƒWƒ‡ƒ“’B¬‚ÉŒü‚¯‚Ä!@ê]Eê”C‚Å‚È‚¢gƒZƒNƒVƒ‡ƒ“”z’u‚̃XƒyƒVƒƒƒŠƒXƒghŠˆ—pEˆç¬EŽx‰‡ (ÅI‰ñ)zƒZƒNƒVƒ‡ƒ“”z’u‚̐ê–åŠÅŒìŽtE”F’èŠÅŒìŽt‚Ö‚ÌŠÅŒìŽt’·‚Ì‚©‚©‚í‚è‚ÉŠÖ‚·‚鎖—ጟ“¢`ƒŠƒ\[ƒXƒi[ƒX‚ÌŠˆ—pEˆç¬EŽx‰‡`. ‹TÎ—çŽq1, ‹ß“¡‚Ü‚ä‚Ý1, â‰º’qŽìŽq1, ’†“‡ßŽq1, ŽR–ì•Ó‚Ý‚¿Žq1 (1ŠÅŒì•”): ƒi[ƒXƒ}ƒlƒWƒƒ[2019/12; 21 (10): 77-81.

522149. [uÀ]y“ÁW: Ž©‚çŠw‚Ñ, ¶‚«‚é—Í‚ðˆç‚ށ|ƒ|[ƒgƒtƒHƒŠƒI‚ªÆ‚ç‚·‚»‚ê‚Œ‚ê‚̃LƒƒƒŠƒAz¡¡‚ÌŽ„‚ɂ‚Ȃª‚éƒ|[ƒgƒtƒHƒŠƒI@“ú–{Ô\ŽšH“cŠÅŒì‘åŠw‚̃LƒƒƒŠƒAƒfƒUƒCƒ“ì¬‚ÉŽæ‚è‘g‚ñ‚Å. ŽO‰Y^‹I (ŠÅŒì•”): ŠÅŒì‹³ˆç 2019/12; 60 (12): 1008-9.

522150. [uÀ]y“ÁW1: –Ÿ“ú‚©‚ç‚Å‚«‚é’N‚Å‚à‚Å‚«‚é‰^“®ŠíáŠQ‚ð•ø‚Š‚œŠ³ŽÒ‚³‚ñ‚̃|ƒWƒVƒ‡ƒjƒ“ƒOE‘̈ʕϊ·z<˜’ÅŽèp•Ò> 04. ˜’ŏpŒã‚̃|ƒWƒVƒ‡ƒjƒ“ƒO`ˆÀÃŽž`. ŠÖª—R‰À1, ‹gŒŽçŒb1, “ì—¢—C‘Ÿ2 (1ŠÅŒì•”, 2ƒŠƒnƒrƒŠ•”): ®Œ`ŠO‰ÈŠÅŒì 2020/2; 25 (2): 114-6.

522151. [uÀ]y“ÁW1: –Ÿ“ú‚©‚ç‚Å‚«‚é’N‚Å‚à‚Å‚«‚é‰^“®ŠíáŠQ‚ð•ø‚Š‚œŠ³ŽÒ‚³‚ñ‚̃|ƒWƒVƒ‡ƒjƒ“ƒOE‘̈ʕϊ·z<˜’ÅŽèp•Ò> 05. ˜’ŏpŒã‚̑̈ʕϊ·`‹Â‰çˆÊÌ‘€‰çˆÊ`. ŠÖª—R‰À1 ‹gŒŽçŒb1, “ì—¢—C‘Ÿ2 (1ŠÅŒì•”, 2ƒŠƒnƒrƒŠ•”): ®Œ`ŠO‰ÈŠÅŒì 2020/2; 25 (2): 117-20.

522152. [uÀ]y“ÁW1: –Ÿ“ú‚©‚ç‚Å‚«‚é’N‚Å‚à‚Å‚«‚é‰^“®ŠíáŠQ‚ð•ø‚Š‚œŠ³ŽÒ‚³‚ñ‚̃|ƒWƒVƒ‡ƒjƒ“ƒOE‘̈ʕϊ·z<ŒšŠÖßŽèp•Ò> 08. ŒšŠÖßpŒã‚̃|ƒWƒVƒ‡ƒjƒ“ƒO. ”’’¹—FŠî1, ¬—Ñ—R‹G1, oŒû—zØ1 (1ŠÅŒì•”): ®Œ`ŠO‰ÈŠÅŒì 2020/2; 25 (2): 121-4.

522153. [uÀ]y“ÁW1: –Ÿ“ú‚©‚ç‚Å‚«‚é’N‚Å‚à‚Å‚«‚é‰^“®ŠíáŠQ‚ð•ø‚Š‚œŠ³ŽÒ‚³‚ñ‚̃|ƒWƒVƒ‡ƒjƒ“ƒOE‘̈ʕϊ·z<ŒšŠÖßŽèp•Ò> 09. ŒšŠÖßpŒã‚̑̈ʕϊ·. ”’’¹—FŠî1, ¬—Ñ—R‹G1, oŒû—zØ1 (1ŠÅŒì•”): ®Œ`ŠO‰ÈŠÅŒì 2020/2; 25 (2): 125-7.

522154. [uÀ]y“ÁW: ICU“üŽº’†‚©‚ç‘Þ‰@‚ÖŒü‚¯‚Ä‚Å‚«‚éŽx‰‡z[dÇŠ³ŽÒ‚Ì‘Þ‰@‚ÉŒü‚¯‚œŽx‰‡‚ÌŽÀÛ] ¬Ž™Š³ŽÒ‚É‚š‚¯‚é‘Þ‰@‚ÉŒü‚¯‚œŽx‰‡‚ÌŒ»ó‚Ɖۑè. ‘å’J®–ç (ŠÅŒì•”): dÇW’†ƒPƒA 2020/2; 18 (6): 49-53.

522155. [uÀ]y‘æ1“ÁW: ‹}«Šú‚Ÿ‚©‚炱‚»Žæ‚è‘g‚ނׂ«‹~‹}EW’†Ž¡—×̈æ‚É‚š‚¯‚éI––ŠúƒPƒAzPart3 ŠÅŒìŽt‚ªŽæ‚è‘g‚Þ‹~‹}EW’†Ž¡—×̈æ‚É‚š‚¯‚éI––ŠúƒPƒA. žÒŒ‹v”üŽq (ŠÅŒì•”): ŠÅŒì‹Zp 2020/3; 66 (3): 241-4.

522156. [uÀ]y˜AÚ: Ž¡—ÑI‘ð‚É‚š‚¯‚éˆÓŽvŒˆ’èŽx‰‡zuŽ¡—Â̒†Ž~EŒp‘±v‚ðl‚Š‚é (‘æ3‰ñ): ˆÓŽvŒˆ’è‚É‚š‚¯‚é–@“I–â‘è. žÒŒ‹v”üŽq (ŠÅŒì•”): ŠÅŒì‹Zp 2020/3; 66 (3):305-8.

[’˜@‘]

620099. [Šwp‘ (•ª’SŽ·•M)]y¬Ž™‚Ì“ü‘Þ‰@Žx‰‡ (¬Ž™ŠÅŒì2019”N7ŒŽ‘Š§†)zŠÅŒìŽt‚Ì–ðŠ„‚ÆŽx‰‡‚ÌŽÀÛ@…AŠO—ˆ‚ōs‚€“ü‰@‘O–Ê’k‚©‚çŽn‚Ü‚é“ü‘Þ‰@Žx‰‡‚ÌŽÀÛ, p.1003-10. –Ø‘º‚ä‚ÝŽq (ŠÅŒì•”), Šé‰æE\¬: •“cŒõŒb, ‚Ö‚é‚·o”Å, “Œ‹ž, 2019/7”­s.

620100. [Šwp‘ (•ª’SŽ·•M)]yƒgƒŠƒA[ƒWƒi[ƒXƒKƒCƒhƒuƒbƒN2020zV. ‘Ώەʂ̃gƒŠƒA[ƒW@1. ¬Ž™. 2. ŒÄ‹z¢“ï, p.178-81. ìã‘å•ã (ŠÅŒì•”), ŠÄC: ˆê”ÊŽÐ’c–@l “ú–{‹~‹}ŠÅŒìŠw‰ï, •Ò: ˆê”ÊŽÐ’c–@l“ú–{‹~‹}ŠÅŒìŠw‰ï ƒgƒŠƒA[ƒWˆÏˆõ‰ï, ‚Ö‚é‚·o”Å, “Œ‹ž, 2019/10”­s.

620101. [Šwp‘ (•ª’SŽ·•M)]yzŠÂŠíƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì—˜_‚Æ‹Zp ‰ü’ù‘æ2”ŁzV ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ (‘˜_)@S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Ž{sŽž‚ÌŠ³ŽÒŠÇ—, p.299-306. Šâ‘º‹M”ü1 (1ŠÅŒì•”), •Ò: ‘“c@‘ì2, Œ‰i“Ä•F2 (2ˆã—Éq¶Šw•”), ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2020/3”­s.

[Šw‰ïEŒ€‹†‰ï“™]

721020. [Šw‰ï (‘S‘)] (“Á•Êu‰‰) ”F’mÇ‚Ì‚ ‚銳ŽÒ‚Ƃ̃Rƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“ƒXƒLƒ‹. 傖Œ—R‰Á—¢ (ŠÅŒì•”): ‘æ16‰ñ“ú–{zŠÂŠíŠÅŒìŠw‰ïŠwpW‰ï@ (2019/11/2), “Œ‹ž.

722254. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒPƒA‚ÌŒ»Û‚ð‚Ђà‚Æ‚­—˜_@Newman—˜_‚É“±‚©‚ê‚œŠÅŒìŽÀ‘H. çø“”ü“oŽq (ŠÅŒì•”): ‘æ24‰ñ“ú–{ŠÉ˜aˆã—Êw‰ïŠwp‘å‰ï (2019/6/22), _“ސì, Palliative Care Research 2019/6; 14 (Suppl): S172.

722255. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) î•ñ‚𐧂·‚éŠÅŒìŠÇ—ŽÒ‚́u¬“ׁv‚𐧂·‚é (“ú–{ˆã—Ïî•ñŠw‰ïŠÅŒì•”‰ï@ƒWƒ‡ƒCƒ“ƒgŠé‰æ). •Ê•{çŒb (ŠÅŒì•”): ‘æ23‰ñ“ú–{ŠÅŒìŠÇ—Šw‰ïŠwpW‰ï (2019/8/24), VŠƒ.

722256. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)y“ú–{ˆã—Ïî•ñŠw‰ïŠÅŒì•”‰ïƒWƒ‡ƒCƒ“ƒgŠé‰æzî•ñ‚𐧂·‚éŠÅŒìŠÇ—ŽÒ‚́u¬“ׁv‚𐧂·‚é|ŽÀ‘H—á|. Ž…›’“ (ŠÅŒì•”): ‘æ23‰ñ“ú–{ŠÅŒìŠÇ—Šw‰ïŠwpW‰ï (2019/8/24), VŠƒ.

722257. [Šw‰ï (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ˆã—Ïî•ñ‚ÌŠˆ—p‚É‚æ‚éŠÅŒìE‚Ì‹Æ–±Œø—Š‰». •Ê•{çŒb (ŠÅŒì•”): ‘æ23‰ñ“ú–{ŠÅŒìŠÇ—Šw‰ïŠwpW‰ï (2019/8/24), VŠƒ.

722258. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv)y‰Æ‘°Žx‰‡ê–åŠÅŒìŽt‚ªs‚€ŠÅŒìŠˆ“®‚Ì“Á«‚ð–Ÿ‚ç‚©‚É‚·‚éz¬Ž™‚ª‚ñŽ–—á‚ð—p‚¢‚œƒWƒFƒlƒ‰ƒŠƒXƒg‚ƃXƒyƒVƒƒƒŠƒXƒg‚ÌŠÅŒì‰î“ü‚©‚ç‚ÌŒŸ“¢. ‚Œ©‹IŽq1, ˆäã—æŽq2, ŸNˆä‘å•ã2, —é–؁@˜a3, ˆÀ•@ˆ»4, Œâ—R—¢5, ¬òDŠG6, ¬’r“Þ‰›6 (1ŠÅŒì•”, 2“ŒŠC‘åŠwˆãŠw•”•ÛŒ’Šw‰È, 3‰Æ‘°Žx‰‡ƒŠƒT[ƒ`ƒZƒ“ƒ^[, 4ŒF–{‘åŠw, 5_“ސ쌧—§•ÛŒ’•ŸŽƒ‘åŠw, 6“ŒŠC‘åŠwˆãŠw•”•t‘®•a‰@): ‘æ26‰ñ“ú–{‰Æ‘°ŠÅŒìŠw‰ïŠwpW‰ï (2019/9/15), ‹ž“s, ‘æ26‰ñ“ú–{‰Æ‘°ŠÅŒìŠw‰ïŠwpW‰ïƒvƒƒOƒ‰ƒ€Ž˜^ 2019/9; p.113.

722259. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‘ŒEŽí‚Æ‹Š“­‚µ‚ÄŽÀ‘H‚·‚éS‘ŸŒŒŠÇŠO‰ÈŽèpŠú‚̃PƒA. “à“¡ˆŸŽ÷ (ŠÅŒì•”): ‘æ16‰ñ“ú–{zŠÂŠíŠÅŒìŠw‰ïŠwpW‰ï (2019/11/2), “Œ‹ž.

722260. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ˆã—ÃŽ–ŒÌ“–Ž–ŽÒ‚Æ‚È‚Á‚œˆãŽt‚ÌŒê‚è‚Ì’†‚©‚çŽx‰‡‚ɂ‚¢‚ÄŠw‚Ô. ì’JOŽq (ˆã—ÃŽx‰‡•”): ‘æ9‰ñ“ú–{ˆã—ÃRƒ“ƒtƒŠƒNƒgEƒ}ƒlƒWƒƒ“ƒgŠw‰ïŠwp‘å‰ï (2020/1/25), •xŽR, ‘æ9‰ñ“ú–{ˆã—ÃRƒ“ƒtƒŠƒNƒgEƒ}ƒlƒWƒƒ“ƒgŠw‰ïŠwp‘å‰ïƒvƒƒOƒ‰ƒ€EŽ˜^W 2019/12; p.16.

723844. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) Ž{Ý“à‚É‚š‚¯‚éê–åŠÅŒìŽtE”F’èŠÅŒìŽt‚̍L•ñŠˆ“®‚Ì’²ž•ñ. Žt‰ªŒbŽq1, ÂúåGº1, Ž‹{”ü‰r1, ŒŒŽ’mŽ}1, “à“¡ˆŸŽ÷1, XˆÀŒbŽÀ1, ‹Ë–{çŒb”ü1, “c‹v•Û”üç‘ã2, ²“¡‹vŽq3 (1ŠÅŒì•”, 2–k—¢Œ€‹†Š•a‰@ŠÅŒì•”, 3–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[ŠÅŒì•”): ‘æ6‰ñ“ú–{CNSŠÅŒìŠw‰ï (2019/6/1), ˆ€’m.

723845. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) R‚ª‚ñÜ“Š—^‚ÌŒŒŠÇŠm•Û‚ðŠÅŒìŽt‚ªs‚€‚œ‚ß‚É•K—v‚È”\—Í‚ÉŠÖ‚·‚éŒã‚ëŒü‚«Œ€‹†. ’̖썁D1, ˆé’J‘•c1 (1ŠÅŒì•”): ‘æ21‰ñ“ú–{ˆã—Ã}ƒlƒWƒƒ“ƒgŠw‰ïŠwp‘‰ï (2019/7/20), ˆ€’m, “ú–{ˆã—Ã}ƒlƒWƒƒ“ƒgŠw‰ïŽGŽ 2019/7; 20 (Suppl): 283.

723846. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ÐŠQŽž‚Ì”ð“‚É‚š‚¯‚éŠÅŒìŽt‚š‚æ‚Ñ–òÜŽt‚̘AŒg‚Ì‚ ‚è•û. ŠŽR˜a”ü1, ‹Tˆä@‰2 (1ŠÅŒì•”, 2Žl“V‰€Ž›‘åŠw): “ú–{ÐŠQˆã—ÖòÜŽtŠw‰ï‘æ8‰ñŠwp‘å‰ï (2019/7/21), ‹{é.

723847. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “ü‰@‘O–Ê’k‚©‚çŽn‚Ü‚é‘œEŽí˜AŒg‚Æ‘Þ‰@Œã‚̐¶ŠˆŽx‰‡|ƒ}ƒ‹ƒgƒŠ[ƒgƒƒ“ƒg‚ðŽó‚¯‚œŽq‚Ç‚à‚Ì‚»‚̉Ƒ°‚Ö‚ÌŽx‰‡‚ðU‚è•Ô‚Á‚ā|. –Ø‘º‚ä‚ÝŽq (ŠÅŒì•”): “ú–{¬Ž™ŠÅŒìŠw‰ï‘æ29‰ñŠwpW‰ï (2019/8/3), –kŠC“¹, “ú–{¬Ž™ŠÅŒìŠw‰ï‘æ29‰ñŠwpW‰ïu‰‰W 2019/7; p.168.

723848. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬Ž™—̈æ‚Ì“ü‰@Žx‰‡‚É‚š‚¯‚é“ü‰@‘O–Ê’k‚Ì–ðŠ„|ŠO—ˆ‚Å‚Ì“ü‰@‘O–Ê’k‚ðU‚è•Ô‚Á‚ā|. ŒIŒŽËŽq1, –Ø‘º‚ä‚ÝŽq1, ˆÉ“¡‚Ý‚ž‚Ù1, Œ“à‰ÀŽq1 (1ŠÅŒì•”): “ú–{¬Ž™ŠÅŒìŠw‰ï‘æ29‰ñŠwpW‰ï (2019/8/3), –kŠC“¹, “ú–{¬Ž™ŠÅŒìŠw‰ï‘æ29‰ñŠwpW‰ïu‰‰W 2019/7; p.196.

723849. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ¬Ž™ŠÅŒìŒp‘±‹³ˆçƒvƒƒOƒ‰ƒ€‚ɂ‚¢‚čl‚Š‚æ‚€|2”N–ڈȍ~‚Ì‹³ˆç‚Ç‚€‚µ‚Ä‚¢‚Ü‚·‚©?|. –Ø‘º‚ä‚ÝŽq (ŠÅŒì•”): “ú–{¬Ž™ŠÅŒìŠw‰ï‘æ29‰ñŠwpW‰ï (2019/8/4), –kŠC“¹, “ú–{¬Ž™ŠÅŒìŠw‰ï‘æ29‰ñŠwpW‰ïu‰‰W 2019/7; p.100.

723850. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ¬Ž™W’†Ž¡—×̈æ‚ňãŽt‚ª‘š‚Š‚œEnd-of-Life‚ðŒ}‚Š‚銳Ž™‰Æ‘°‚Æ‚Ì‘ŠŒÝì—p‚̃vƒƒZƒX. ‚‹Ž@Œb1, ¬“‡‚ЂŎq2 (1ŠÅŒì•”, 2ŠÅŒìŠw•”): “ú–{¬Ž™ŠÅŒìŠw‰ï‘æ29‰ñŠwpW‰ï (2019/8/4), –kŠC“¹, “ú–{¬Ž™ŠÅŒìŠw‰ï‘æ29‰ñŠwpW‰ïu‰‰W 2019/7; p.116.

723851. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ƒLƒƒƒŠƒAƒ[ƒe[ƒVƒ‡ƒ“‚ÌŒø‰Ê|ƒLƒƒƒŠƒAŒ`¬Žx‰‡‚Ə¬Ž™ŠÅŒì‚ÌŽ¿Œüã‚ð–ÚŽw‚µ‚ā|. Î‰ºˆç¶1, Œ“à‰ÀŽq1, ‰i‰ª@–õ1, ²X–Ø”ü˜aŽq1, ’·’J—zŒb1, •œ—Ñ“Þ•c1, “à“¡–΍K1, ŒÃ‘ã–ƒŽq1, ’ҁ@•üŽq2 (1ŠÅŒì•”, 2ŠÅŒìŠw•”): “ú–{¬Ž™ŠÅŒìŠw‰ï‘æ29‰ñŠwpW‰ï (2019/8/4), –kŠC“¹, “ú–{¬Ž™ŠÅŒìŠw‰ï‘æ29‰ñŠwpW‰ïu‰‰W 2019/7; p.131.

723852. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ŠÅŒì•â•ŽÒˆç¬‚ÉŒü‚¯‚œŒ€C‚ÌŽæ‚è‘g‚Ý. ŽR–{]gŽq1, ’–ˆäÍŽq1, ”’’¹—FŠî1, ‰H“c–ì^—R”ü1, “‰€@”E1, ‰¡“cçŒb1, “n•”‡Žq1, ŒÜ“¡—zŽq1, ’JŒû—zŽq1 (1ŠÅŒì•”): ‘æ23‰ñ“ú–{ŠÅŒìŠÇ—Šw‰ïŠwpW‰ï (2019/8/23), VŠƒ, ‘æ23‰ñ“ú–{ŠÅŒìŠÇ—Šw‰ïƒvƒƒOƒ‰ƒ€Ž˜^ (WEB) 2019/8; p.O19-2.

723853. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ŠÅŒìŽt‚ÆŠÅŒì•â•ŽÒ‚Æ‚Ì‹Š“­‚ɂ‚¢‚Ä‚ÌŽæ‚è‘g‚݁`ƒp[ƒgƒi[ƒVƒbƒvƒi[ƒVƒ“ƒOƒVƒXƒeƒ€‚ðŠˆ—p‚µ‚ā`. ‰¡“cçŒb1, ]“cˆêd1, ‹g•”Œb—Žq1, —Ž‡–ƒ‹M1 (1ŠÅŒì•”): ‘æ23‰ñ“ú–{ŠÅŒìŠÇ—Šw‰ïŠwpW‰ï (2019/8/23), VŠƒ, ‘æ23‰ñ“ú–{ŠÅŒìŠÇ—Šw‰ïƒvƒƒOƒ‰ƒ€Ž˜^ (WEB) 2019/8; p.O19-3.

723854. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ‹}«Šú•a‰@‚É‚š‚¯‚éŠÅŒì•â•ŽÒˆç¬`•â²ƒ‰ƒ_[‚ð‚à‚Æ‚É‚µ‚œlÞˆç¬ƒVƒXƒeƒ€‚̍\’z`. ŒÜ“¡—zŽq1, ’–ˆäÍŽq1, ‰H“c–ì^—R”ü1, ”’’¹—FŠî1, “‰€@”E1, ŽR–{]gŽq1, ì’[–[ŠG1, ‰Í“c‘œ‰Á1, à_“c–­Žq1, “n•”‡Žq1 (1ŠÅŒì•”): ‘æ23‰ñ“ú–{ŠÅŒìŠÇ—Šw‰ïŠwpW‰ï (2019/8/23), VŠƒ, ‘æ23‰ñ“ú–{ŠÅŒìŠÇ—Šw‰ïƒvƒƒOƒ‰ƒ€Ž˜^ (WEB) 2019/8; p.O20-2.

723855. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ‹}«Šú•a‰@‚É‚š‚¯‚éŠÅŒì•â•ŽÒˆç¬`•â²ƒ‰ƒ_[ì¬‚Ö‚ÌŽæ‚è‘g‚݁`. ’–ˆäÍŽq1, ŒÜ“¡—zŽq1, ”’’¹—FŠî1, ì’[–[ŠG1, ‰Í“c‘œ‰Á1, à_“c–­Žq1, “‰€@”E1, “n•”‡Žq1, ‰H“c–ì^—R”ü1 (1ŠÅŒì•”): ‘æ23‰ñ“ú–{ŠÅŒìŠÇ—Šw‰ïŠwpW‰ï (2019/8/23), VŠƒ, ‘æ23‰ñ“ú–{ŠÅŒìŠÇ—Šw‰ïƒvƒƒOƒ‰ƒ€Ž˜^ (WEB) 2019/8; p.O20-4.

723856. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) W’†Ž¡—ÃŽº‚É”z‘®‚³‚ê‚œV‘²ŠÅŒìŽt‚Ö‚ÌConcept Based Learning ‚ð—p‚¢‚œ‹³ˆç“IŽx‰‡‚Ì‹Lq. ŽR–{‰À“ (ŠÅŒì•”): ‘æ23‰ñ“ú–{ŠÅŒìŠÇ—Šw‰ïŠwpW‰ï (2019/8/23), VŠƒ, ‘æ23‰ñ“ú–{ŠÅŒìŠÇ—Šw‰ïƒvƒƒOƒ‰ƒ€Ž˜^ (WEB) 2019/8; p.O22-3.

723857. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ƒCƒ“ƒtƒHƒ[ƒVƒ‡ƒ“EƒGƒNƒXƒ`ƒFƒ“ƒW19@•Ï‰»‚ðæŽæ‚肵‚čs“®‚Å‚«‚é•a‰@ŠÅŒìŠÇ—ŽÒ‚ð‚ß‚Ž‚µ‚ā`u•a‰@ŠÅŒìŠÇ—ŽÒ‚̃}ƒlƒWƒƒ“ƒgƒ‰ƒ_[ “ú–{ŠÅŒì‹Š‰ï”Łv‚ÌŠˆ—p`. ‹gì‹v”üŽq1, •Ê•{çŒb2, Šâ•”@m3 (1“ú–{ŠÅŒì‹Š‰ï, 2ŠÅŒì•”, 3‹{è‘Pm‰ï•a‰@): ‘æ23‰ñ“ú–{ŠÅŒìŠÇ—Šw‰ïŠwpW‰ï (2019/8/23), VŠƒ.

723858. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ƒCƒ“ƒtƒHƒ[ƒVƒ‡ƒ“EƒGƒNƒXƒ`ƒFƒ“ƒW40@u‰z‹«“IŠwKv‚ÌŒø‰Ê“IŠˆ—p•û–@‚ɂ‚¢‚Ă̖͍õ. ŽOŽ}Ž–1, ŽR–{‰À“1, Â–öGº1, ‚‹ŽN‰î1, “¡“c—º‰î1, ç–Ø—Ç“Þ‰›1, ]“cˆêd1, –{’Jº”Ž2, —é–؏«Ž÷2, –x@ˆÇŽé2 (1ŠÅŒì•”, 2ƒRƒjƒJƒ~ƒmƒ‹ƒ^): ‘æ23‰ñ“ú–{ŠÅŒìŠÇ—Šw‰ïŠwpW‰ï (2019/8/24), VŠƒ, ‘æ23‰ñ“ú–{ŠÅŒìŠÇ—Šw‰ïƒvƒƒOƒ‰ƒ€Ž˜^ (WEB) 2019/8; p.IE-40.

723859. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒrƒWƒ‡ƒ“‚ƘA“®‚µ‚œƒŠƒ\[ƒXƒi[ƒXŠˆ—p‚Ì‚œ‚ß‚Ì–Ê’kƒV[ƒgì¬‚Æ•]‰¿: ƒZƒNƒVƒ‡ƒ“”z’uƒŠƒ\[ƒXƒi[ƒX‚Ö‚ÌŠÅŒìŠÇ—ŽÒ‚ÌŠÖ‚í‚è. â‰º’qŽìŽq1, ’†“‡ßŽq1, ‹TÎ—çŽq1, ‹ß“¡‚Ü‚ä‚Ý1, ŽR–ì•Ó‚Ý‚¿Žq1, •Ê•{çŒb1 (1ŠÅŒì•”): ‘æ23‰ñ“ú–{ŠÅŒìŠÇ—Šw‰ïŠwpW‰ï (2019/8/24), VŠƒ, ‘æ23‰ñ“ú–{ŠÅŒìŠÇ—Šw‰ïƒvƒƒOƒ‰ƒ€Ž˜^ (WEB) 2019/8; p.P6-22.

723860. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) CRC‚Ì‹Æ–±‚ɍ‡‚킹‚œŽžŠÔŠÇ—‚ÌŽæ‚è‘g‚݁|Žž·o‹Î‚𓱓ü‚µ‚ā|. –쑺¡“úŽq1, ¬‘ò@Šw1, ’ƒ–ØŒhŽq1, Œ”ö”ü’qŽq1, ¬‹{ŽR‘å1, XˆŸ–îŽq1, “üŒË–ì˜a‘ã1, ‰¡“cœÄˆê2, ŒF’J—YŽ¡3 (1ŠÅŒì•”, 2–òÜ•”, 3—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg): ‘æ19‰ñCRC‚ƗՏ°ŽŽŒ±‚Ì‚ ‚è•û‚ðl‚Š‚é‰ï‹c 2019 in YOKOHAMA (2019/9/14), _“ސì, ‘æ19‰ñCRC‚ƗՏ°ŽŽŒ±‚Ì‚ ‚è•û‚ðl‚Š‚é‰ï‹c 2019 in YOKOHAMA ƒvƒƒOƒ‰ƒ€EŽ˜^W 2019/8; p.139.

723861. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) S•s‘SŽ¡—ÃŒã‚É‹ê’É‘ˆ«‚ð”F‚ß‚éS•s‘SŠ³ŽÒ‚Ì‘¶Ý. ŽRèˆè”ü1, “¡“c“S•œ2, Žç‰®ŽµŠC1, “ç“c@Œ’2, ¬–с@’2, ˆ¢ŒÃÆ2 (1ŠÅŒì•”, 2zŠÂŠí“à): ‘æ23‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ï (2019/10/4), L“‡, ‘æ23‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïƒvƒƒOƒ‰ƒ€EŽ˜^W 2019/10; p.399.

723862. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ŽOŽŸ‹~–œ‹~‹}ƒZƒ“ƒ^[‹~‹}ŠO—ˆ‚É‚š‚¯‚éƒOƒŠ[ƒtƒPƒAƒtƒH[ƒ}ƒbƒg‚̉^—p‚ɂ‚¢‚Ä. ¯–쐳—T1, ]ãç»1, •ŸŽmˆ»‰À1, ‰¡aˆç”ü1 (1ŠÅŒì•”): ‘æ21‰ñ“ú–{‹~‹}ŠÅŒìŠw‰ïŠwpW‰ï (2019/10/5), ç—t, ‘æ21‰ñ“ú–{‹~‹}ŠÅŒìŠw‰ïŠwpW‰ïŽ˜^ 2019/9; p.O15-2.

723863. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ƒ|ƒeƒ“ƒVƒƒƒ‹ƒhƒi[‚ɑ΂·‚éŠÅŒìŽt‚̈ӎv’Šo‚Ɖî“ü‚ÌŽÀÛ`Œ“”C‰@“àƒhƒi[ƒR[ƒfƒBƒl[ƒ^[‚Ì‹³ˆç‚©‚ç‚Ý‚Š‚œ‚à‚́`. ã‘º—RŽ—1, ”W–{—³Æ1, ‚‹Ž@Œb1 (1ŠÅŒì•”): ‘æ55‰ñ“ú–{ˆÚAŠw‰ï‘‰ï (2019/10/11), L“‡, ˆÚA 2019/9; 54 (‘‰ï—ÕŽž): 213.

723864. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰)g‘ŸŠíE‘gD’ñ‹Ÿ‚̈ӎv‚ɑ΂·‚éƒAƒ“ƒP[ƒgh‚ðŽg—p‚µ‚œƒIƒvƒVƒ‡ƒ“’ñŽŠ‚ÌŒø‰Ê. ’Ö”ü’q”Ž1,2, ‰ºŽi‰fˆê2, ŒF‘ò^‹|3, “¡ŒãG•ã2, ’·–ì—F‹IŽq1, ‹g“cˆê¬4,5 (1ŠÅŒì•”, 2º˜a‘åŠw‘åŠw‰@•ÛŒ’ˆã—ÊwŒ€‹†‰È, 3º˜a‘åŠw“¡‚ª‹u•a‰@, 4V¢‹Iˆã—ÁEæ’[ˆã—Ã, 5”å”AŠí): ‘æ55‰ñ“ú–{ˆÚAŠw‰ï‘‰ï (2019/10/11), L“‡, ˆÚA 2019/9; 54 (‘‰ï—ÕŽž): 213.

723865. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –éŠÔE‹x“úƒhƒi[î•ñ‚ɑ΂·‚é‘SŠÅŒìŠÇ—ŽÒ‚ւ̏‰“®‘Ήž‚ÌŠg‘å. ‚‹Ž@Œb1, rì–@Žq1, ’†“‡ßŽq1, —é–Ø”üŽ}Žq1, ²“¡^‹IŽq1, ‹g“cˆê¬2,3 (1ŠÅŒì•”, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3”å”AŠí): ‘æ55‰ñ“ú–{ˆÚAŠw‰ï‘‰ï (2019/10/11), L“‡, ˆÚA 2019/9; 54 (‘‰ï—ÕŽž): 286.

723866. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‘œEŽí‚É‚æ‚é‰@“àƒhƒi[ƒR[ƒfƒBƒl[ƒ^[‚Ì–ðŠ„”­Šö‚ÉŒü‚¯‹³ˆç“IŽæ‚è‘g‚Ý. ŠÖ@ˆê”n1, ã‘º—RŽ—1, ¬³]—¢“Þ1, ‚‹Ž@Œb1, rì–@Žq1, ‰¡a@Žq1 (1ŠÅŒì•”): ‘æ55‰ñ“ú–{ˆÚAŠw‰ï‘‰ï (2019/10/11), L“‡, ˆÚA 2019/9; 54 (‘‰ï—ÕŽž): 332.

723867. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”F’mÇ‚̐l‚Ƃ̃Rƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“ƒXƒLƒ‹ƒAƒbƒvƒZƒ~ƒi[. ¬ŽRK‘ã1, •Ðˆä”üØŽq1, 傖Œ—R‰Á—¢2, sr‰Âˆ€3, ˜a“c“Þ”üŽq4 (1ŠÅŒìŠw•”, 2ŠÅŒì•”, 3“Œ•a‰@ŠÅŒì•”, 4–k—¢Œ€‹†Š•a‰@ŠÅŒì•”): ‘æ20‰ñ“ú–{‘Šú”F’mÇŠw‰ïŠwp‘å‰ï (2019/10/20), Šò•Œ, “ú–{‘Šú”F’mÇŠw‰ïŽ 2019/10; 12 (3): 50.

723868. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) –«ŠúŠÅŒìŠwŽÀK‚É‚š‚¯‚é—Տ°‹³ˆõ§“x“±“ü‚Ì•]‰¿ (‘æ1•ñ)|Šw•”‹³ˆõ‚ƗՏ°‹³ˆõ‚ÌŽö‹Æ‰ß’ö•]‰¿‚Ì”äŠr|. –]ŒŽ”ü•ä1, ’†“‡éº1, ç–Ø—Ç“Þ‰›1, ‹{–{ŠG”ü1, –ö“cŒ’–Ÿ1, ’JŒû—zŽq1, ŒŒŽN”ü2, ˆÉ“¡T–ç2, ‹v•ÛŒÜŒŽ2 (1ŠÅŒì•”, 2ŠÅŒìŠw•”): ‘æ50‰ñ“ú–{ŠÅŒìŠw‰ï-ŠÅŒìŠÇ—-ŠwpW‰ï (2019/10/23), –ŒŒÃ‰®, ‘æ50‰ñ“ú–{ŠÅŒìŠw‰ï-ŠÅŒìŠÇ—-ŠwpW‰ïŽ˜^W 2019/10; p.134.

723869. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) –«ŠúŠÅŒìŠwŽÀK‚É‚š‚¯‚é—Տ°‹³ˆõ§“x“±“ü‚Ì•]‰¿ (‘æ2•ñ)|—Տ°‹³ˆõ‚É‚æ‚éŽÀKŽw“±‚̐¬‰Ê‚Ɖۑè|. ’†“‡éº1, –]ŒŽ”ü•ä1, ç–Ø—Ç“Þ‰›1, ‹{–{ŠG”ü1, –ö“cŒ’–Ÿ1, ŒŒŽN”ü2, ˆÉ“¡T–ç2, ‹v•ÛŒÜŒŽ2 (1ŠÅŒì•”, 2ŠÅŒìŠw•”): ‘æ50‰ñ“ú–{ŠÅŒìŠw‰ï-ŠÅŒìŠÇ—-ŠwpW‰ï (2019/10/23), –ŒŒÃ‰®, ‘æ50‰ñ“ú–{ŠÅŒìŠw‰ï-ŠÅŒìŠÇ—-ŠwpW‰ïŽ˜^W 2019/10; p.134.

723870. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) “ü‰@‘OƒIƒŠƒGƒ“ƒe[ƒVƒ‡ƒ“‚ÌŒø‰Ê|‚æ‚萶ŠˆŽÒ‚ÌŽ‹“_‚ɋ߂¯‚ā|. ã“c”ü—é1, Œ‘ºçt1, ‰iˆäD1, ”’’¹—FŠî1, “àŽRŸ•¶2, •Ÿ“‡Œ’‰î2, ‚‘Š»Žm2, ‚•œ®L3 (1ŠÅŒì•”, 2®ŠO, 3ˆã—Éq¶Šw•”): ‘æ46‰ñ“ú–{ŒÒŠÖßŠw‰ïŠwpW‰ï (2019/10/26), ‹{è, ‘æ46‰ñ“ú–{ŒÒŠÖßŠw‰ïŠwpW‰ïƒvƒƒOƒ‰ƒ€EŽ˜^W 2019/10; p.595.

723871. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ŽèŽw‰q¶ŽÀŽ{‰ñ”Œüã‚ð–ÚŽw‚µ‚œŽæ‚è‘g‚݁|ŽèŽw‰q¶„iŽÒ‚Æ‚µ‚Ă̐„iŠˆ“®|. ²“¡ˆº‰Ä1, “n糁@•à1, ‰iˆäD1, ”’’¹—FŠî1, “àŽRŸ•¶2, •Ÿ“‡Œ’‰î2 ‚‘Š»Žm2, ‚•œ®L3 (1ŠÅŒì•”, 2®ŠO, 3ˆã—Éq¶Šw•”): ‘æ46‰ñ“ú–{ŒÒŠÖßŠw‰ïŠwpW‰ï (2019/10/26), ‹{è, ‘æ46‰ñ“ú–{ŒÒŠÖßŠw‰ïŠwpW‰ïƒvƒƒOƒ‰ƒ€EŽ˜^W 2019/10; p.603.

723872. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚ÆŠO—ˆ‚Ƃ̏î•ñŒðŠ·‚É‚š‚¯‚éS•s‘S‘ˆ«—\–h‚ÌŒø‰Ê‚Ɖۑè. ™–썁“ÞŽq1, Šâ‘º‹M”ü1 (1ŠÅŒì•”): ‘æ16‰ñ“ú–{zŠÂŠíŠÅŒìŠw‰ïŠwpW‰ï (2019/11/3), “Œ‹ž.

723873. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬Ž™‘€œ^ÇŽèp‚É‚š‚¯‚ép’†’á‘̉·‚ÌŒŸ“¢. ‰ª‘º^•à1, âV“¡@˜j2, ˆäã@Œº2, ‹{é³s2, ˆä‘º‹M”V2, ”’àV‰hŽ÷2, ’†àVr”V2, ¬ŽR’q‹v3, “à“cŒ’‘Ÿ˜Y2, “c’†”ü1, ‰i‰ª@ò1, ‚‘Š»Žm2 (1ŠÅŒì•”, 2®ŠO, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ53‰ñ“ú–{‘€œ]ÇŠw‰ïŠwpW‰ï (2019/11/8-9), ŒQ”n.

723874. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒhƒNƒ^[ƒJ[o“®Žž‚É‚š‚¯‚éo“®Š—vŽžŠÔ‚š‚æ‚ÑŒ»ê‘؍ݎžŠÔ‚ÆŠÖ˜A‚·‚é—vˆö. ’Ö”ü’q”Ž1, ‰¡aˆç”ü1 (1ŠÅŒì•”): ‘æ39‰ñ“ú–{ŠÅŒì‰ÈŠwŠw‰ïŠwpW‰ï (2019/11/30), Îì, “ú–{ŠÅŒì‰ÈŠwŠw‰ïŠwpW‰ïu‰‰W 2019/11; 39 (suppl): 378.

723875. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ”F’èŠÅŒìŽtEê–åŠÅŒìŽt‚ª‚ª‚ñŠ³ŽÒ‚ÌŽ¡—ÂƏA˜J‚Ì—Œ—§‚Ì‚œ‚ß‚ÉŠm”F‚µ‚Ä‚¢‚é“à—e‚ɂ‚¢‚Ä. ŽRè‹±Žq1, ¬‘ò@2, ”ª–Ø—Ú”ü2, ŽRŠÝ‹MŽq1, ”ԏ ÍŽq2 (1’é‹ž‘åŠw, 2ŠÅŒì•”): ‘æ39‰ñ“ú–{ŠÅŒì‰ÈŠwŠw‰ïŠwpW‰ï (2019/11/30), Îì, “ú–{ŠÅŒì‰ÈŠwŠw‰ïŠwpW‰ïu‰‰W 2019/11; 39 (suppl): 756.

723876. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬Ž™‹s‘Ò—\–hƒ`[ƒ€‚É‚æ‚鏬Ž™‹s‘Ò–éŠÔ‹x“ú‘Ήžƒtƒ[‚̍쐬. ‹à„Ž›‚Ü‚èŽq1, ˆÉ“¡FŽq1, •œ—Ñ“Þ•c1, ‘å’ˁ@“µ1 (1ŠÅŒì•”): “ú–{Žq‚Ç‚à‹s‘Ò–hŽ~Šw‰ï‘æ25‰ñŠwpW‰ï‚Ђ傀‚²‘å‰ï (JaSPCAN HYOGO) (2019/12/22), •ºŒÉ, “ú–{Žq‚Ç‚à‹s‘Ò–hŽ~Šw‰ï‘æ25‰ñŠwpW‰ï‚Ђ傀‚²‘å‰ïŽ˜^W 2019/12; p.288.

723877. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ê–åŠÅŒìŽt‹y‚Ñ”F’èŠÅŒìŽt‚É‚æ‚邪‚ñŠ³ŽÒ‚̏A˜JŽx‰‡‚ÌŒ»ó (‘æ1•ñ). ¬‘ò@1, ”ª–Ø—Ú”ü1, ”ԏ ÍŽq1, ŽRè‹±Žq2, ²X–ØŽ¡ˆê˜Y3 (1ŠÅŒì•”, 2’é‹ž‘åŠw, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ34‰ñ“ú–{‚ª‚ñŠÅŒìŠw‰ïŠwpW‰ï (2020/2/23), “Œ‹ž.

723878. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ê–åŠÅŒìŽt‹y‚Ñ”F’èŠÅŒìŽt‚É‚æ‚邪‚ñŠ³ŽÒ‚̏A˜JŽx‰‡‚ÌŒ»ó (‘æ3•ñ). ”ª–Ø—Ú”ü1, ¬‘ò@1, ”ԏ ÍŽq1, ŽRè‹±Žq2, ²X–ØŽ¡ˆê˜Y3 (1ŠÅŒì•”, 2’é‹ž‘åŠw, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ34‰ñ“ú–{‚ª‚ñŠÅŒìŠw‰ïŠwpW‰ï (2020/2/23), “Œ‹ž.

723879. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) dÇ‹~‹}Š³ŽÒ‚É‚š‚¯‚é”畆ƒgƒ‰ƒuƒ‹‚Ì”­¶‚Ɖh—{ó‘Ô‚ÌŒŸ“¢. ‘Ÿ“c]—œ‰Ô1, Î‘q@ˆ€1, –x²‰lŽq1, Žç‰®—¢¹2, ‰““¡¬Žq2, ‘“c³˜a1, “c‘º@’q3, •Ð‰ª—Sˆê3 (1ŠÅŒì•”, 2‰h—{•”, 3‹~–œ): ‘æ35‰ñ“ú–{—Տ°‰h—{‘ãŽÓŠw‰ïŠwpW‰ï (2020/2/27), ‹ž“s, WEBŽ˜^ 2020; p.P-01-7.

723880. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ”sŒŒÇ‚ÌŒoŽž“IƒAƒZƒXƒƒ“ƒgƒ‚ƒfƒ‹gE-HIGH TECHh‚ÌŠJ”­. žÒŒ‹v”üŽq1, ’rŒ—TŽq2 (1ŠÅŒì•”, 2–ŒŒÃ‰®‘åŠw‘åŠw‰@ˆãŠwŒnŒ€‹†‰È): ‘æ47‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ï (2020/3/6), –ŒŒÃ‰®, WEBŽ˜^ 2020; p.OR1-16-13-2.

723881. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ICU‚É‚š‚¯‚é‘œEŽíƒJƒ“ƒtƒ@ƒŒƒ“ƒXŠˆ—p‚É‚æ‚éI––Šú‹~‹}Š³ŽÒ‰Æ‘°ƒPƒA‚ւ̉e‹¿‚Ɖۑè. ²ì”ü—¢1, ò@•¶Ø1, ’J@Kˆê1, ‚‹Ž@Œb1, •Ð‰ª—Sˆê2 (1ŠÅŒì•”, 2‹~–œ): ‘æ47‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ï (2020/3/7), –ŒŒÃ‰®, WEBŽ˜^ 2020; p.P2-3-9-2.

723882. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ICU‚É‚š‚¯‚é‹}•Ï‘Ήž‚ɑ΂·‚éŽæ‚è‘g‚Ý. ’·’Jì—¢‰ÁŽq1, ’·“à—mˆê1, •ÐŽR@—€1, “à“¡ˆŸŽ÷1, ‰¡a@Žq1 (1ŠÅŒì•”): ‘æ47‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ï (2020/3/8), –ŒŒÃ‰®, WEBŽ˜^ 2020; p.P3-1-4-6.

731109. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) äX‚ª‚ñŠ³ŽÒ‚ÌACP‚ƃ`[ƒ€ˆã—Ã. ”ª–öçt (ŠÅŒì•”): ‹à‘ò‚ª‚ñƒTƒ|[ƒeƒBƒuƒPƒAƒZƒ~ƒi[2019 (2019/8/29), Îì.

731110. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) CKDŠ³ŽÒ‚̐tˆÚA‚ɐt•s‘SŠÅŒì‚Í‚Ç‚€ŠÖ‚í‚ê‚é‚©. –ìŒû•¶”T (ŠÅŒì•”): ’·–쌧“§ÍŠÅŒìŽt‰ïŠwpu‰‰‰ï (2019/12/15), ’·–ì.

731111. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ‰Æ‘°Žx‰‡ê–åŠÅŒìŽt‚Ì’nˆæ˜AŒg. ‚Œ©‹IŽq (ŠÅŒì•”): ‘æ10‰ñTHP”NŽŸW‰ï (2020/3/1), –ŒŒÃ‰®.

732151. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“)y•Û‘¶ŠúE“§ÍEˆÚAˆã—ẪRƒ‰ƒ{z•ïŠ‡“ItˆÚAˆã—Â̐¬Œ÷‚ÉŒü‚¯‚Ä. –ìŒû•¶”T (ŠÅŒì•”): —Ö@‘I‘ðŽx‰‡•×‹­‰ï (2019/4/27), _“ސì.

732152. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒVƒ“ƒ|ƒWƒEƒ€) RTC‚̃‚ƒ`ƒx[ƒVƒ‡ƒ“ˆÛŽ‚ɂ‚Ȃ°‚é•û–@. –ìŒû•¶”T (ŠÅŒì•”): ‘æ35‰ñtˆÚAEŒŒŠÇŠO‰ÈŒ€‹†‰ï (2019/5/17), Šò•Œ, ‘æ35‰ñtˆÚAEŒŒŠÇŠO‰ÈŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^W 2019/5; p.73.

732153. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“)y“Œ‹ž“s“­‚­l‚̃`ƒƒƒCƒ‹ƒhƒvƒ‰ƒ“ƒTƒ|[ƒgŽ–‹Æ: •s”DŽ¡—ÂƎdŽ–‚Ì—Œ—§„iƒVƒ“ƒ|ƒWƒEƒ€z•s”DŽ¡—Â̊T—vEŠé‹Æ‚ÌŽæ‘gŽ–—áÐ‰î. —V²_Žq (ŠÅŒì•”): “Œ‹ž“sŽY‹Æ˜J“­‹Ç (2019/6/26), “Œ‹ž.

732154. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“)y‹~‹}ˆã—ÂƃƒfƒBƒG[ƒVƒ‡ƒ“: ‚»‚̉”\«‚Ɖۑèz‹~‹}Š³ŽÒ‰Æ‘°‚ւ̈ӎvŒˆ’èŽx‰‡‚ƃƒfƒBƒG[ƒVƒ‡ƒ“. ‚‹Ž@Œb (ŠÅŒì•”): JAHM‘æ12‰ñ”NŽŸ‘å‰ï (2019/7/14), “Œ‹ž.

732155. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰) Å‹ß‚̐tˆÚAŽ–î‚ÆRTC‚ª‚©‚©‚í‚é—Ö@‘I‘ðŽx‰‡. –ìŒû•¶”T (ŠÅŒì•”): ‘æ19‰ñPD OASIS (2019/11/29), _“ސì.

732156. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒVƒ“ƒ|ƒWƒEƒ€)yŒð—¬W‰ï…A@˜J–±ŠÂ‹«‰ü‘P‚ÉŠÖ‚·‚éŽæ‚è‘g‚݁|˜J“­ŽžŠÔ‚©‚çl‚Š‚éŠÅŒìŠÇ—‚Ƃ́|zŠÅŒì•â•ŽÒ‚Ì”NŽŸ—L‹‹‹x‰ÉŽæ“Ÿ‚ÌŽæ‚è‘g‚݁`•a“‚ð‚±‚Š‚œ‹Î–±•\ì¬`. ‰Í“c‘œ‰Á (ŠÅŒì•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“Þì ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.40.

733743. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ‘ŸŠí’ñ‹Ÿ‚̑㗝ˆÓŽvŒˆ’è‚ðŽx‚Š‚ég–{l‚ƉƑ°‚̘b‚µ‡‚¢‚Ì—L–³h‚ÉŠÖ‚·‚錻ó. ’Ö”ü’q”Ž1,2, ‰ºŽi‰fˆê2, “¡ŒãG•ã2, ’·–ì—F‹IŽq1, ‹g“cˆê¬3,4 (1ŠÅŒì•”, 2º˜a‘åŠw‘åŠw‰@•ÛŒ’ˆã—ÊwŒ€‹†‰È, 3V¢‹Iˆã—ÁEæ’[ˆã—Ã, 4”å”AŠí): ‘æ30‰ñ_“ސìˆÚAˆãŠw‰ï (2019/6/8), _“ސì, _“ސìˆãŠw‰ïŽGŽ 2019/7; 46 (2): 252-3.

733744. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ¬Ž™W’†Ž¡—ÃŽº‚É‚š‚¯‚éƒGƒ“ƒhEƒIƒuEƒ‰ƒCƒtEƒPƒA‚ÌŽæ‚è‘g‚݁|ŽžŠÔ“I—P—\‚̈قȂéI––Šú‚ð‰ß‚²‚µ‚œƒP[ƒX‚ðU‚è•Ô‚é|. ˆÉ“¡FŽq1, ¬³]—¢“Þ1, •äÏØ•ä1, ‚‹ŽKŒb1 (1ŠÅŒì•”): “ú–{W’†Ž¡—ÈãŠw‰ï‘æ3‰ñŠÖ“ŒbM‰zŽx•”ŠwpW‰ï (2019/7/27), ŽR—œ, “ú–{W’†Ž¡—ÈãŠw‰ï‘æ3‰ñŠÖ“ŒbM‰zŽx•”ŠwpW‰ïƒvƒƒOƒ‰ƒ€EŽ˜^W 2019/6; p.O4-1.

733745. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ¬Ž™W’†Ž¡—ÃŽº‚É‚š‚¯‚é‹CŠÇƒ`ƒ…[ƒuŒÅ’èŠÇ—‚ÌŽÀÛ‚Ɖۑè|Œo•@ŒÅ’è•û–@‚̕ύXŒã1”N‚̃Aƒ“ƒP[ƒg’²ž‚ð‚à‚ƂɁ|. ‘å‹v•Û‘t”ü1, ˆÉ“¡FŽq1 (1ŠÅŒì•”): “ú–{W’†Ž¡—ÈãŠw‰ï‘æ3‰ñŠÖ“ŒbM‰zŽx•”ŠwpW‰ï (2019/7/27), ŽR—œ, “ú–{W’†Ž¡—ÈãŠw‰ï‘æ3‰ñŠÖ“ŒbM‰zŽx•”ŠwpW‰ïƒvƒƒOƒ‰ƒ€EŽ˜^W 2019/6; p.O9-2.

733746. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) PICU‚É‚š‚¯‚éS‘ŸŒŒŠÇpŒãŠ³ŽÒ‚Ì“üŽºŽžƒVƒ~ƒ…ƒŒ[ƒVƒ‡ƒ“ŠwK‚ÌŽæ‚è‘g‚Ý. –ŠCSŒõ1, ˆÉ“¡FŽq1, ‹à„Ž›‚Ü‚èŽq1, ‘å‹v•Û‘t”ü1 (1ŠÅŒì•”): “ú–{W’†Ž¡—ÈãŠw‰ï‘æ3‰ñŠÖ“ŒbM‰zŽx•”ŠwpW‰ï (2019/7/27), ŽR—œ, “ú–{W’†Ž¡—ÈãŠw‰ï‘æ3‰ñŠÖ“ŒbM‰zŽx•”ŠwpW‰ïƒvƒƒOƒ‰ƒ€EŽ˜^W 2019/6; p.O9-3.

733747. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) —LŒø‚ÈŠw¶Œ’f‚ÌŽÀŒ»‚ÉŒü‚¯‚ā@Ž–Œã‘[’u‚É‚Í, ‚à‚Á‚Æ‚Å‚«‚邱‚Æ‚ª‚ ‚é|“Á‚É’á‘̏dŠw¶‚̃PƒA‚ɂ‚¢‚ā|. …Œû@e (ŠÅŒì•”): ‘æ57‰ñ‘S‘‘åŠw•ÛŒ’ŠÇ—‹Š‰ïŠÖ“ŒbM‰z’n•û•”‰ïŒ€‹†W‰ï (2019/8/30), _“ސì, ‘æ57‰ñ‘S‘‘åŠw•ÛŒ’ŠÇ—‹Š‰ïŠÖ“ŒbM‰z’n•û•”‰ïŒ€‹†W‰ïƒvƒƒOƒ‰ƒ€Ž˜^ 2019/8; p.26.

733748. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) Ž©Ó‚Ì”O‚ª‹­‚¢”MŠ³ŽÒ‚̉Ƒ°‚ɑ΂µ‚ẲƑ°ŠÅŒì`ƒAƒMƒ…ƒ‰ƒ‰‚Ì–â‘è‰ðŒˆŒ^‹@Ší—˜_‚ð—p‚¢‚œ‰Æ‘°‰î“ü`. âj•y“ß“Þ1, ‹Ë–{çŒb”ü1, ²ì”ü—¢1, ‘“c³˜a1 (1ŠÅŒì•”): ”MƒtƒH[ƒ‰ƒ€ (2019/8/31), “Œ‹ž.

733749. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ÐŠQ‚Ö‚ÌŽæ‚è‘g‚Ý. ‰ª–ì‚Ý‚ž‚«1, ˜a“cŽÑ–ç‰Á1, ì’[–[ŠG1 (1ŠÅŒì•”): _“ސìPWG (2019/9/18), _“ސì.

733750. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒ|ƒXƒ^[) ¬Ž™, dÇŠ³ŽÒ”À‘—‚ÌŒoŒ±‚Æ‚»‚̉ۑè|ECMO‘•’…Š³ŽÒ‹ó˜H”À‘—€”õ‚ÉDMAT‚ªŠÖ—^‚·‚邱‚Ƃ̈Ӌ`|. ìã‘å•ã1, ŒÃŽs‘¥Œõ1 (1ŠÅŒì•”): ‘æ27‰ñ¬Ž™W’†Ž¡—ρ[ƒNƒVƒ‡ƒbƒv (2019/10/19), ‘åã.

733851. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) “®‰æ‹³Þ‚ð—p‚¢‚œƒXƒg[ƒ}ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚ÌŒø‰Ê. “n•Ó¹D (ŠÅŒì•”): ‘æ42‰ñ_“ސìƒXƒg[ƒ}Œ€‹†‰ï (2019/11/30), _“ސì, ‘æ42‰ñ_“ސìƒXƒg[ƒ}Œ€‹†‰ïƒvƒƒOƒ‰ƒ€Ž˜^W 2019/11; p.9.

733752. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ŠO—ˆ‚É‚š‚¯‚éRRTƒR[ƒ‹‚ÌŒ»ó`ŠO—ˆRRT—v¿‹€—LƒV[ƒg‚ðŠˆ—p‚µ‚ā`. À“c‰Á“ÞŽq1, ‘ì^—R”ü1, ì‘º’q”ü1, ŒK–ŒŽõ”ü1, …ã‚¢‚ÂÝ1 (1ŠÅŒì•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.42.

733753. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ‰@“à‚É‚š‚¯‚éˆç¬•¶‰»‚̏ø¬‹­‰»‚ð–ÚŽw‚µ‚ā`Vl‹³ˆç’S“–ŽÒ‚Ì”CŠú‚ɏœ_‚ð‚ ‚Ä‚Ä`. –x]çŒbŽq1, ”ԏ ÍŽq1, ŽR–{]gŽq1, ŒÃ¯Ž”ü1, ‰iˆäD1, —é–ؐ­@1, ç–Ø—Ç“Þ‰›1, ’JŒû—zŽq1 (1ŠÅŒì•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.45.

733754. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ƒLƒƒƒŠƒAƒ[ƒe[ƒVƒ‡ƒ“‚ÌŒø‰Ê`ƒLƒƒƒŠƒAŒ`¬Žx‰‡‚Ə¬Ž™ŠÅŒì‚ÌŽ¿Œüã‚ð–ÚŽw‚µ‚ā`. ‰i‰ª@–õ1, ²X–Ø”ü˜aŽq1, Î‰ºˆç¶1, ›–삳‚â‚©1, ’·’J—zŒb1, ’ҁ@•üŽq2, •œ—Ñ“Þ•c1, “à“¡–΍K1, ²“¡@—ƒ1, ŒÃ‘ã–ƒŽq1, Œ“à‰ÀŽq1 (1ŠÅŒì•”, 2ŠÅŒìŠw•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.47.

733755. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ŒŒ‰tò‰»ƒZƒ“ƒ^[‚É‚š‚¯‚é‹Æ–±‰ü‘P‚É‚æ‚鎞ŠÔŠO‹Î–±‚̍팞`‘Œ•”E‘ŒEŽí‚Æ‚Ì‹Š“­`. “‰€@”E1, ˆÉ“¡‚Š‚èŽq1, ’·‰ª@‰~1 (1ŠÅŒì•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.48.

733756. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) Donabedian‚́u\‘¢vu‰ß’öv‚ɏœ_‚ð‚ ‚Ä‚œåñ጗\–h‚ÌŽæ‚è‘g‚Ý. Ž‹{”ü‰r1, ²“¡—ÇŽq1 (1ŠÅŒì•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.50.

733757. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) —ΓàáŠ³ŽÒ‚Ì“ü‘Þ‰@Žx‰‡‚ÉŠÖ‚·‚éŽæ‚è‘g‚Ý. ™ŽR•‡”üŽq (ŠÅŒì•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.51.

733758. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) • –Œ“§ÍŠÅŒì‚ÌŽ¿Œüã‚ð–ÚŽw‚µ‚œ‹³ˆçE‹Æ–±‰ü‘P`ŒŒ‰tò‰»ƒZƒ“ƒ^[‚É‚š‚¯‚éPDŠO—ˆ‚ÌŽæ‚è‘g‚݁`. “‰€@”E1, ˆÉ“¡‚Š‚èŽq1, ’·‰ª@‰~1, ²X–؈Œ”ü1, ¬‘q—Ú”ü1 (1ŠÅŒì•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.52.

733759. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒ|ƒXƒ^[) ‰ñ•œŠú‚ÌŠ³ŽÒ‚Æ‚ÌŠÖ‚í‚è`‹}«”­Ç‚ÌŽŸŠ³‚É‚æ‚èAƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“á‚ª‚¢‚Ì‚ ‚銳ŽÒ‚ւ̉î“ü`. •—ŠÔ—œ—_1, ìã‘å•ã1, ‰¡aˆç”ü1 (1ŠÅŒì•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.57.

733760. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) u‰z‹«“IŠwKv‚ÌŒø‰Ê“IŠˆ—p•û–@‚ɂ‚¢‚Ă̖͍õ`“ú–{ŠÅŒìŠÇ—Šw‰ïŠwpW‰ïƒCƒ“ƒtƒHƒ[ƒVƒ‡ƒ“EƒGƒNƒXƒ`ƒFƒ“ƒWŠJÃ•ñ`. ŽR–{‰À“1, ÂúåGº1, ]“cˆêd1, ‚‹ŽN‰î1, ç–Ø—Ç“Þ‰›1, “¡“c—º‰î1, ŽOŽ}Ž–2, –{’Jº”Ž3, —é–؏«Ž÷3, –x@ˆÇŽé3 (1ŠÅŒì•”, 2Œ³ŠÅŒì•”, 3ƒRƒjƒJƒ~ƒmƒ‹ƒ^): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.61.

733761. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ‹}«Šú•a‰@‚É‚š‚¯‚éŠÅŒì•â•ŽÒˆç¬`•â²ƒ‰ƒ_[ì¬‚Ö‚ÌŽæ‚è‘g‚݁`. ‰H“c–ì^—R”ü1, ’–ˆäÍŽq1, ì’[–[ŠG1, ‰Í“c‘œ‰Á1, à_“c–­Žq1, ”’’¹—FŠî1, “‰€@”E1, “n•”‡Žq1, ŒÜ“¡—zŽq1 (1ŠÅŒì•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.62.

733762. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ‹}«Šú•a‰@‚É‚š‚¯‚éŠÅŒì•â•ŽÒˆç¬`•â²ƒ‰ƒ_[‚ð‚à‚Æ‚É‚µ‚œlÞˆç¬ƒVƒXƒeƒ€‚̍\’z`. ŒÜ“¡—zŽq1, ’–ˆäÍŽq1, ‰H“c–ì^—R”ü1, ”’’¹—FŠî1, “‰€@”E1, ŽR–{]gŽq1, ì’[–[ŠG1, ‰Í“c‘œ‰Á1, à_“c–­Žq1, “n•”‡Žq1 (1ŠÅŒì•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.63.

733763. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ŠÅŒì•â•ŽÒˆç¬‚ÉŒü‚¯‚œŒ€C‚ÌŽæ‚è‘g‚Ý. ŽR–{]gŽq1, ’JŒû—zŽq1, ŒÜ“¡—zŽq1, ‰H“c–ì^—R”ü1, ”’’¹—FŠî1, “‰€@”E1, “n•”‡Žq1, ‰¡“cçŒb1, ’–ˆäÍŽq1 (1ŠÅŒì•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.64.

733764. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ‚ª‚ñŠ³ŽÒ‚ðe‚É‚à‚ÂŽq‚Ç‚à‚̃OƒŠ[ƒtƒPƒA‚ðŽÀ‘H‚µ‚Ä‚¢‚éˆã—ÃŽÒ‚Ì’nˆæ˜AŒg‚Å•ø‚­¢“. ‚Œ©‹IŽq1, –û’J˜aŽq2, ’ҍ²ŒbŽq3, ¬“‡‚ЂŎq3, —Ñ”ü“ÞŽq4 (1ŠÅŒì•”, 2“Œ•a‰@ŠÅŒì•”, 3ŠÅŒìŠw•”, 4Œ³–Ú”’‘åŠwŠÅŒìŠw•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.65.

733765. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ‚ª‚ñŠ³ŽÒ‚ðe‚É‚à‚ÂŽq‚Ç‚à‚̃OƒŠ[ƒtƒPƒA‚ðŽÀ‘H‚µ‚Ä‚¢‚éˆã—ÃŽÒ‚Ì’nˆæ˜AŒg‚ÌŽÀÛ. ‚Œ©‹IŽq1, –û’J˜aŽq2, ’ҍ²ŒbŽq3, ¬“‡‚ЂŎq3, —Ñ”ü“ÞŽq4 (1ŠÅŒì•”, 2“Œ•a‰@ŠÅŒì•”, 3ŠÅŒìŠw•”, 4Œ³–Ú”’‘åŠwŠÅŒìŠw•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.66.

733766. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) NICU‚É‚š‚¯‚é‹CŠÇ“à‘}ŠÇŠ³ŽÒ‚Ì•ø‚Á‚±‚ÌŒoŒ±. A“cÊ“sŽq1, ŽRŠÝ”ü•Û1, Œ“à‰ÀŽq1 (1ŠÅŒì•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.67.

733767. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ¬Ž™W’†Ž¡—ÃŽº‚É‚š‚¯‚é‘Þ‰@Žx‰‡ƒJƒ“ƒtƒ@ƒŒƒ“ƒX‚ÌŒ»ó‚Ɖۑè‚ÉŠÖ‚·‚錟“¢. ’†‰€Ê‰Ø1, ˆÉ“¡FŽq1 (1ŠÅŒì•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.68.

733768. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) “àŽ‹‹ŸŽ¡—ÑO–K–â‚ÌŽæ‚è‘g‚݁`•a“ŠÅŒìŽt‚Ƃ̘AŒg‚ð’Ê‚µ‚ā`. ”~ì’q‰ØŽq1, “¡“c–ƒ”üŽq1 (1ŠÅŒì•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.72.

733769. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) M—ŠŠÖŒW‚̍\’z‚ªŠ³ŽÒ‚É‚à‚œ‚ç‚·•Ï‰»`ƒgƒ‰ƒxƒ‹ƒr[ulŠÔ‘ΐlŠÔ‚ÌŠÅŒìv—˜_‚ð—p‚¢‚ĐU‚è•Ô‚é`. ŽsìçŠó1, âV“¡@Œb1, ‚–ìt”ü1 (1ŠÅŒì•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.75.

733770. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ˆãŽtŽQ‰Á‚É‚æ‚éƒCƒ“ƒVƒfƒ“ƒgƒŒƒ|[ƒgƒgƒŠƒA[ƒWƒVƒXƒeƒ€‚̐V‚œ‚ÈŽŽ‚Ý. “y‰®Žu•Û1,2, rˆä—L”ü1,2, ” “c”ü’mŒb1,2 (1ŠÅŒì•”, 2ˆã—Â̎¿EˆÀ‘S„iŽº): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.78.

733771. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ƒR[ƒfƒBƒl[ƒ^[‚É‚æ‚éŽåŽ¡ˆã‚̃Tƒ|[ƒg. ‚‹Ž@Œb (ŠÅŒì•”): “¡“cˆã‰È‘åŠwˆÚAƒZƒ~ƒi[ (2020/1/14), –ŒŒÃ‰®.

733772. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) VlŠÅŒìŽt‚ÖŒðŠ·ƒm[ƒg‚ð—p‚¢‚œƒŠƒtƒŒƒNƒVƒ‡ƒ“Œø‰Ê‚ÌŒŸ“¢. •ÄŽR‰ÄŽÀ1, žÒŒ‹v”üŽq1, ’Ö”ü’q”Ž1, ‰¡aˆç”ü1 (1ŠÅŒì•”): ‘æ70‰ñ“ú–{‹~‹}ˆãŠw‰ïŠÖ“Œ’n•û‰ïŠwpW‰ï (2020/1/18), ŒQ”n, “ú–{‹~‹}ˆãŠw‰ïŠÖ“Œ’n•û‰ïŽGŽ 2020/1; 41 (1): 141.

733773. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ‚ª‚ñŠ³ŽÒ‚ðe‚É‚à‚ÂŽq‚Ç‚à‚̃OƒŠ[ƒtƒPƒA‚ðŽÀ‘H‚µ‚Ä‚¢‚éˆã—ÃŽÒ‚Ì’nˆæ˜AŒg‚ÌŽÀÛ. ‚Œ©‹IŽq1, –û’J˜aŽq2, ¬“‡‚ЂŎq3, ’ҍ²ŒbŽq3, —Ñ”ü“ÞŽq4 (1ŠÅŒì•”, 2“Œ•a‰@ŠÅŒì•”, 3ŠÅŒìŠw•”, 4Œ³–Ú”’‘åŠwŠÅŒìŠw•”): —ߘaŒ³”N“x_“ސ쌧ŠÅŒì‹Š‰ï‘Š–ÍŒŽŽx•”ŠÅŒìŒ€‹†”­•\‰ï (2020/1/18), _“ސì, —ߘaŒ³”N“x_“ސ쌧ŠÅŒì‹Š‰ï‘Š–ÍŒŽŽx•”ŠÅŒìŒ€‹†”­•\‰ïW˜^W 2020/1; p.4.

733774. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ƒ|ƒXƒ^[) A•a‰@ŠO—ˆ‚É‚š‚¯‚éRRTŠˆ“®‚ÌŽæ‚è‘g‚݁`ŠO—ˆRRT‹€—LƒV[ƒg“±“ü‚É‚æ‚éŠÅŒìŽt‚̈ӎ¯‚̕ω»`. À“c‰Á“ÞŽq1, …ã‚¢‚ÂÝ1, ‘ì^—R”ü1, ì‘º’q”ü1 (1ŠÅŒì•”): —ߘaŒ³”N“x_“ސ쌧ŠÅŒì‹Š‰ï‘Š–ÍŒŽŽx•”ŠÅŒìŒ€‹†”­•\‰ï (2020/1/18), _“ސì, —ߘaŒ³”N“x_“ސ쌧ŠÅŒì‹Š‰ï‘Š–ÍŒŽŽx•”ŠÅŒìŒ€‹†”­•\‰ïW˜^W 2020/1; p.44-7.

733775. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) SEED‚ðŽó‚¯‚é“ü‰@Š³ŽÒ‚ɑ΂·‚é‹ê’ɃXƒNƒŠ[ƒjƒ“ƒO‚ÌŽæ‚è‘g‚݁|Ž¡—ÑOŒã‚ÉŠm”F‚·‚éŒø‰Ê‚ɂ‚¢‚ā|. ¡ˆä@—ç1, ¯–ì@Œ’1, ‚–ìt”ü1 (1ŠÅŒì•”): ‘æ16‰ñ‘O—§‘BŠà–§••¬üŒ¹‰i‹v‘}“üŽ¡—ÃŒ€‹†‰ï (2020/1/19), “Œ‹ž, ‘æ16‰ñ‘O—§‘BŠà–§••¬üŒ¹‰i‹v‘}“ü—Ö@Œ€‹†‰ï-Ž˜^EƒL[ƒXƒ‰ƒCƒhW- 2020/1; p.44.

733776. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ŠO‘lŒ€ÇŠÌ‰ŠÇ—á‚É‚š‚¯‚鎡—ʋ«‚Ì‘I‘ð‚ƍ‘Û“]‰@‚ÌŽÀÛ. ’†“‡ßŽq1, ‹›“ˆ°‹I2, “c糔ü“Þ2, “ú‚@‰›2 (1ŠÅŒì•”, 2Á‰»Ší“à): ‘æ19‰ñŠÌˆÚAˆã—ÃtƒH[ƒ‰ƒ€ (2020/2/15), “Œ‹ž.

733777. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) Ò‘‘¹”D•w‚̏oŽY‚Ü‚Å‚ÌŠÇ—`‚»‚̐l‚炵‚³‚ðŠˆ‚©‚µ‚œƒPƒA`. ŽO‰Y^‹I1, ì’[–[ŠG1 (1ŠÅŒì•”): ‘æ33‰ñ_“ސì•ê«‰q¶Šw‰ïŠwpW‰ï (2020/3/7), _“ސì.

733778. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ‘ÙŽ™ŽŸŠ³‚ð—L‚·‚é”D•w‚Ö‚ÌŽüŽYŠúƒ`[ƒ€‚Æ‚µ‚Ä‚ÌŠÖ‚í‚è. ŠC˜VàV‰lŽq1, ’†“à¹’m1, ÎŒŽ¹D1, ‰¬—FŽq1, ¬ìŠì”üŽq1, •œ—Ñ“Þ•c1 (1ŠÅŒì•”): ‘æ33‰ñ_“ސì•ê«‰q¶Šw‰ïŠwpW‰ï (2020/3/7), _“ސì.


—Տ°ŒŸž•”

[Šwp˜_•¶]

120046. [ŒŽ’˜] ACMIA–@‚É‚æ‚éƒ^ƒNƒƒŠƒ€ƒXŒŒ’†”Z“x‘ª’è‚ÉEDTA”Z“x‚ª‹y‚Ú‚·‰e‹¿|‰ü—ÇLOTŽŽ–ò‚Ə]—ˆLOTŽŽ–ò‚Ì”äŠr|. “y•M’q»1, ˆäããYØ1, Ÿ–””ü”g1, ŽÂŒŽ—º‘Ÿ1, “à“cˆêO1, “•ûLˆê1, Žë–ì—Lì1,2 (1—ÕŒŸ•”, 2—ÕŒŸŠw): ˆãŠwŒŸž 2019/7; 68 (3): 514-8.

120047. [ŒŽ’˜] ”]”gŒŸž‚É‚š‚¯‚éƒVƒXƒeƒ€ƒŠƒtƒ@ƒŒƒ“ƒX—U“±‚ÌŠî‘b‚Ɖž—p. ¬–ìàV—T–ç1, —é–؏~Žq1, “•ûLˆê1, Žë–ì—Lì1,2 (1—ÕŒŸ•”, 2—ÕŒŸŠw): ˆãŠwŒŸž 2019/8; 68 (4): 800-5.

522157. [uÀ]y“ÁW: “ú“–’ŒŽž‚É—\Šú‚¹‚ʐ¶‰»ŠwE–ƉuŒŸžƒf[ƒ^‚Əo‘˜‚Á‚œ‚ç|ÄŒŸ‚·‚é‚©, •ñ‚·‚é‚©, ê–å‹ZŽt‚ɘA—‚·‚é‚©|z2Í —\Šú‚¹‚ʃf[ƒ^‚Əo‘˜‚Á‚œŽž‚̑Ήž@1. ¶‰»ŠwŒŸž‚Å—\Šú‚¹‚ʃf[ƒ^‚ª“Ÿ‚ç‚ê‚œ‚ç EƒiƒgƒŠƒEƒ€, ƒJƒŠƒEƒ€, ƒNƒ[ƒ‹. “¡‘º‘Ps (—ÕŒŸ•”): Medical Technology 2019/5; 47 (5): 409-12.

522158. [uÀ]y˜AÚ: —Տ°ŒŸžQ•Az”xÃ–¬—¬“ü”gŒ`‚ÌŒv‘ª•û–@‚Í? ꠓcŠì”V (—ÕŒŸ•”): Medical Tecnology 2019/7; 47 (7): 736-9.

540083. [‚»‚Ì‘Œ (Šw‰ïŽ˜^)]y_“ސ슎õÇˆãŠw‰ï‘æ84‰ñˆãŠw‰ïzèò•””^ᇊ³ŽÒ‚©‚猟o‚µ‚œActinomyces oris‚Ì1—á. ˆÀ’B@÷1, ’†èM•F1, ¬ŠÑ’q¢1, ‹à–؁@—y1, “ñ–{–öL1,2, ˜a“c’B•F2,3, ‚ŽR—zŽq2,4 (1—ÕŒŸ•”, 2ŠŽõŠÇ—Žº, 3äPŒŽ•aEŠŽõ“à, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): _“ސìˆãŠw‰ïŽGŽ 2019/7; 46 (2): 271.

540084. [‚»‚Ì‘Œ (Šw‰ïŽ˜^)]y_“ސ슎õÇˆãŠw‰ï‘æ86‰ñˆãŠw‰ïzŽ¿—Ê•ªÍ–@‚Æ16SrRNAˆâ“`Žq”z—ñ‰ðÍ‚ð—p‚¢‚œSalmonella‘®‹Û‚̋ێ퓯’è‚Ì•]‰¿. Š}ˆäˆÇŽq1, “ñ–{–öL1,2, ˆÀ–{—Ž”n1, ˆÀ’B@÷1, ’†èM•F1, ŸNˆäŒc‘¢1, ˜a“c’B•F2,3, ‚ŽR—zŽq2,4, “•ûLˆê1, Žë–ì—Lì5 (1—ÕŒŸ•”, 2ŠŽõŠÇ—Žº, 3äPŒŽ•aEŠŽõ“à, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 5—ÕŒŸŠw): _“ސìˆãŠw‰ïŽGŽ 2020/1; 47 (1): 114.

[’˜@‘]

620102. [Šwp‘ (•ª’SŽ·•M)]yˆÛŽEŒp‘±‚Ü‚ÅŒ©˜‚Š‚œISO15189Žæ“ŸƒTƒ|[ƒgƒuƒbƒN (—Տ°ŒŸž2019”N10ŒŽ‘Š§†)z¡Part.3 5Í ‹Zp“I—v‹Ž–€@¶—ŒŸž‚©‚ç‚Ý‚œu5.8•5.9 Œ‹‰Ê‚Ì•ñv, p.1258-62. ‰FŽ¡‹Ž‘PŸ1, “à“cˆêO1, “•ûLˆê1 (1—ÕŒŸ•”), •Ò: •œÎ’ŒŒÈ, ˆãŠw‘‰@, “Œ‹ž, 2019/10”­s.

[Šw‰ïEŒ€‹†‰ï“™]

722261. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) “ú–{“dŽqBM8040G‚̃Tƒu•ªÍðŒ‚ð—˜—p‚µ‚œƒLƒƒƒŠƒuƒŒ[ƒVƒ‡ƒ“‚Ì”äŠrŒŸ“¢. ”©ŽR@—D1, “¡‘º‘Ps1, ¬ŽRhŽq1, ‰ª“c—R‹I1, ’†ú±LŽq1, “à“cˆêO1, “•ûLˆê1, Žë–ì—Lì1,2 (1—ÕŒŸ•”, 2—ÕŒŸŠw): “ú–{—Տ°ŒŸžŽ©“®‰»Šw‰ï‘æ51‰ñ‘å‰ï (2019/10/4), ‰¡•l, “ú–{—Տ°ŒŸžŽ©“®‰»Šw‰ï‰ïŽ 2019/8; 44 (4): 471.

722262. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) –k—¢‘åŠw•a‰@—Տ°ŒŸž•”‚É‚š‚¯‚é—Õ’nŽÀK‚ÌŒ»ó. “•ûLˆê (—ÕŒŸ•”): ‘æ66‰ñ“ú–{—Տ°ŒŸžˆãŠw‰ïŠwpW‰ï (2019/11/24), ‰ªŽR, ‘æ66‰ñ“ú–{—Տ°ŒŸžˆãŠw‰ïŠwpW‰ïƒvƒƒOƒ‰ƒ€ 2019/10; p.102.

723883. [Šw‰ï (‘S‘) (ˆê”ʍu‰‰) o¶Œã‚ÉŒoŒ±‚µ‚œæ“V«‰¡Šu–Œƒwƒ‹ƒjƒA‚Ì3—á. —é–ؐ­Žq1, ’†Œ‹vK1, –öŒŽ”ü’qŽq1, “¡ˆä@Ž 1, ‰FŽ¡‹Ž‘PŸ1, ꠓcŠì”V1, “c’†@Œ‰2,3, “•ûLˆê1, Žë–ì—Lì1,4 (1—ÕŒŸ•”, 2V¢‹Iˆã—ÁEæ’[ˆã—Ã, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 4—ÕŒŸŠw): ‘æ44‰ñ“ú–{’Ž‰¹”gŒŸžŠw‰ïŠwpW‰ï (2019/4/28), ‰¡•l, ’Ž‰¹”gŒŸž‹Zp 2019/4; 44 (Ž˜^†): S202.

723884. [Šw‰ï (‘S‘) (ˆê”ʍu‰‰) p‘Of’f‚ª¢“ï‚Å‚ ‚Á‚œ•›ŠÌ‚Ì1—á. –öŒŽ”ü’qŽq1, ‰FŽ¡‹Ž‘PŸ1, ꠓcŠì”V1, —é–ؐ­Žq1, ’†Œ‹vK1, “¡ˆä@Ž 1, “•ûLˆê1, H’J¹Žj2, ŠC’ËMŽj3, Žë–ì—Lì1,4 (1—ÕŒŸ•”, 2•a—Šw, 3ˆê”ʁE¬Ž™EŠÌ’_äXŠO, 4—ÕŒŸŠw): ‘æ44‰ñ“ú–{’Ž‰¹”gŒŸžŠw‰ïŠwpW‰ï (2019/4/28), ‰¡•l, ’Ž‰¹”gŒŸž‹Zp 2019/4; 44 (Ž˜^†): S205.

723885. [Šw‰ï (‘S‘) (ˆê”ʍu‰‰) S–[’†ŠuŒ‡‘¹Ç‚ÌŒo‰ßŠÏŽ@’†‚ɐSƒGƒR[‚É‚Ä”­Œ©‚µ‚œH“¹Šà‚Ì1—á. H“¡—ß—Ç1, ꠓcŠì”V1, ‰““¡—¯”üŽq1, –öŒŽ”ü’qŽq1, ”’J“ߌŽ1, ‰FŽ¡‹Ž‘PŸ1, “•ûLˆê1, Žë–ì—Lì1,2 (1—ÕŒŸ•”, 2—ÕŒŸŠw): ‘æ44‰ñ“ú–{’Ž‰¹”gŒŸžŠw‰ïŠwpW‰ï (2019/4/29), ‰¡•l, ’Ž‰¹”gŒŸž‹Zp 2019/4; 44 (Ž˜^†): S170.

723886. [Šw‰ï (‘S‘) (ˆê”ʍu‰‰) f’f‚É‹ê—¶‚µ‚œ‘å“®–¬•Ù’uŠ·pŒã–«Šú‚̐SùN‰t’™—¯‚Ì1—á. ŠOŽR‚©‚š‚è1, “¡ˆä‹±‘ã1, ŒàV—éŽq1, ‹àˆä’ːçt1, ‘å‹Ž^‹IŽq1, ꠓcŠì”V2, ‰––ì•û–Ÿ1 (1–k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2—ÕŒŸ•”): ‘æ44‰ñ“ú–{’Ž‰¹”gŒŸžŠw‰ïŠwpW‰ï (2019/4/29), ‰¡•l, ’Ž‰¹”gŒŸž‹Zp 2019/4; 44 (Ž˜^†): S172.

723887. [Šw‰ï (‘S‘) (ˆê”ʍu‰‰) factitious hypoglycemia‚̊ӕʂɈقȂéƒCƒ“ƒXƒŠƒ“‘ª’èƒLƒbƒg‚ª—L—p‚Å‚ ‚Á‚œ1Ç—á. “y•M’q»1, ŽÂŒŽ—º‘Ÿ1, ’†èLŽq1, “à“cˆêO1, “•ûLˆê1, “¡ˆä—¢]2, ¬ìŒ°Žj2, Žë–ì—Lì1,3 (1—ÕŒŸ•”, 2“à•ª”å‘ãŽÓ“à, 3—ÕŒŸŠw): ‘æ68‰ñ“ú–{ˆãŠwŒŸžŠw‰ï (2019/5/18-19), ŽRŒû, “ú–{ˆãŠwŒŸžŠw‰ïŽ˜^W 2019/5; 68: 84.

723888. [Šw‰ï (‘S‘) (ˆê”ʍu‰‰) —nŒŒ‰ß’ö‚É‚š‚¯‚éHb‚ÆASTELDHEK‚Ì—no“®‘Ԃɂ‚¢‚Ä. —L”n˜a“Þ1, “y•M’q»1, “¡‘º‘Ps1, ˆ¢•”—L1, ’†èLŽq1, “à“cˆêO1, “•ûLˆê1, Žë–ì—Lì1,2 (1—ÕŒŸ•”, 2—ÕŒŸŠw): ‘æ68‰ñ“ú–{ˆãŠwŒŸžŠw‰ï (2019/5/18-19), ŽRŒû, “ú–{ˆãŠwŒŸžŠw‰ïŽ˜^W 2019/5; 68: 172.

723889. [Šw‰ï (‘S‘) (ˆê”ʍu‰‰) ŒŸž‘OƒvƒƒZƒX‚É‚š‚¯‚éÃ–¬ŒŒ‰tƒKƒXŒŸ‘̂̈À’萫‚ɂ‚¢‚Ä. _“c’mŽq1, “y•M’q»1, ‰Á“¡Žx‰›—›1, ŽÂŒŽ—º‘Ÿ1, ’†èLŽq1, “à“cˆêO1, “•ûLˆê1, Žë–ì—Lì1,2 (1—ÕŒŸ•”, 2—ÕŒŸŠw): ‘æ68‰ñ“ú–{ˆãŠwŒŸžŠw‰ï (2019/5/18-19), ŽRŒû, “ú–{ˆãŠwŒŸžŠw‰ïŽ˜^W 2019/5; 68: 188.

723890. [Šw‰ï (‘S‘) (ˆê”ʍu‰‰) t‰ŠŠ³ŽÒ‚Ì‘’©”A‹y‚ѐŽž”A‚É‚š‚¯‚é”AöŒŒ‚Ì”äŠrŒŸ“¢. ”ђˍ‚¶1, “y•M’q»1, ˆÉ“¡ˆŸ–퍁1, ꠓc˜a•ä1, ŽO‰Y–F“T1, “à“cˆêO1, “•ûLˆê1, Žë–ì—Lì1,2 (1—ÕŒŸ•”, 2—ÕŒŸŠw): ‘æ68‰ñ“ú–{ˆãŠwŒŸžŠw‰ï (2019/5/18-19), ŽRŒû, “ú–{ˆãŠwŒŸžŠw‰ïŽ˜^W 2019/5; 68: 387.

723891. [Šw‰ï (‘S‘) (ˆê”ʍu‰‰) ƒCƒ“ƒXƒŠƒ“ƒAƒiƒƒO»Ü‚ɑ΂·‚éƒCƒ“ƒXƒŠƒ“‘ª’èƒLƒbƒg‚Ì”œ‰ž«”äŠr‚ɂ‚¢‚Ä. “y•M’q»1, ŽÂŒŽ—º‘Ÿ1, ŽO‰Y–F“T1, “à“cˆêO1, Îˆä’Œm2, •Ð‹Ë^l2, Žë–ì—Lì1,3 (1—ÕŒŸ•”, 2ˆã—Éq¶Šw•”, 3—ÕŒŸŠw): ‘æ59‰ñ“ú–{—Տ°‰»Šw‰ï”NŽŸŠwpW‰ï (2019/9/27-29), å‘ä, —Տ°‰»Šw 2019/9; 48 (suppl 1): 266.

723892. [Šw‰ï (‘S‘) (ˆê”ʍu‰‰) tÇ”­Ç‘OŠú“œ”A•aƒ‰ƒbƒg‚̐t”玿‚É‚š‚¯‚éƒ~ƒgƒRƒ“ƒhƒŠƒA‚Ì—Z‡E•ª—ô‚ƃ}ƒCƒgƒtƒ@ƒW[‚ɂ‚¢‚Ä. Îˆä’Œm1, ˆä–{–Ÿ”ü1, •èËŽj1, ’r‰iGŽ÷2, “y•M’q»3, ¬”Š@i3, —é–؉p–Ÿ4, ‰¡ê³“T1, Žsì‘ž•¶1, ’|’†P•v5, •Ð‹Ë^l1 (1ˆã—Éq¶Šw•”, 2’r‰it“à‰ÈƒNƒŠƒjƒbƒN, 3—ÕŒŸ•”, 4–k—¢•ÛŒ’‰q¶ê–åŠw‰@, 5‘Ûˆã—ÕŸŽƒ‘åŠwŽR‰€•a‰@t‘Ÿ“à‰È): ‘æ59‰ñ“ú–{—Տ°‰»Šw‰ï”NŽŸŠwpW‰ï (2019/9/27-29), å‘ä, —Տ°‰»Šw 2019/9; 48 (suppl 1): 288.

723893. [Šw‰ï (‘S‘) (ˆê”ʍu‰‰) ŒŒ’†d’YŽ_”Z“x‘ª’è‚É‚š‚¯‚éy‘f–@‘ª’莎–ò‚ÌŠî‘b“I«”\•]‰¿‚š‚æ‚ÑŒŸ‘̈À’萫‚ɂ‚¢‚Ä. ŽÂŒŽ—º‘Ÿ1, “y•M’q»1, “¡‘º‘Ps1, ’†èLŽq1, “à“cˆêO1, “•ûLˆê1, Žë–ì—Lì1,2 (1—ÕŒŸ•”, 2—ÕŒŸŠw): “ú–{—Տ°ŒŸžŽ©“®‰»Šw‰ï‘æ51‰ñ‘å‰ï (2019/10/3-5), ‰¡•l, “ú–{—Տ°ŒŸžŽ©“®‰»Šw‰ï‰ïŽ 2019/10; 44 (4): 518.

723894. [Šw‰ï (‘S‘) (ˆê”ʍu‰‰) ”A’†—LŒ`¬•ª•ªÍ‘•’uUSCANNER (E) ‚̐«”\•]‰¿‚Ɖ^—pŒø‰Ê‚ɂ‚¢‚Ä. “y•M’q»1, ”ђˍ‚¶1, ˆÉ“¡ˆŸ–퍁1, ꠓc˜a•ä1, ŽO‰Y–F“T1, “à“cˆêO1, “•ûLˆê1, Žë–ì—Lì1,2 (1—ÕŒŸ•”, 2—ÕŒŸŠw): “ú–{—Տ°ŒŸžŽ©“®‰»Šw‰ï‘æ51‰ñ‘å‰ï (2019/10/3-5), ‰¡•l, “ú–{—Տ°ŒŸžŽ©“®‰»Šw‰ï‰ïŽ 2019/10; 44 (4): 538.

723895. [Šw‰ï (‘S‘)] HIV—z«Š³ŽÒ‚æ‚茟o‚µ‚œHistoplasma capsulatum‚̈ê—á. ˆÀ’B@÷1, “ñ–{–öL1,2, ˜a“c’B•F2,3, ‹à–؁@—y1, Š}ˆäˆÇŽq1, ¬ŠÑ’q¢1, ’†èM•F1, ŸNˆäŒc‘¢1, “•ûLˆê1, ‚ŽR—zŽq2,4, Žë–ì—Lì5, ‹v•Ä@Œõ, ‹TˆäŽ•F (1—ÕŒŸ•”, 2ŠŽõŠÇ—Žº, 3äPŒŽ•aEŠŽõ“à, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 5—ÕŒŸŠw): ‘æ31‰ñ“ú–{—Տ°”÷¶•šŠw‰ï‘‰ïEŠwpW‰ï (2020/1/31-2/2), ‹à‘ò, “ú–{—Տ°”÷¶•šŠw‰ïŽGŽ 2019; 30 (Suppl 1): 221.

733779. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ’Ž‰¹”gŒŸž‚ªf’f‚É—L—p‚Å‚ ‚Á‚œŽ‰–bÒ‘‘–ŒáŽ‚Ì1—á. ’†Œ‹vK1, H“¡—ß—Ç1, ꠓcŠì”V1, ‰FŽ¡‹Ž‘PŸ1, Žë–ì—Lì1,2 (1—ÕŒŸ•”, 2—ÕŒŸŠw): JSSŠÖ“ŒbM‰z ‘æ41‰ñ’n•û‰ïŠwpW‰ï (2019/10/14), “Œ‹ž, ’Ž‰¹”gŒŸž‹Zp 2020/2; 45 (1): 85.

733780. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “–‰@‚ÅŒoŒ±‚µ‚œcisA2B3Œ^‚̏Ǘá. ‹ž“c–ž—¢“Þ1, —L”n˜a“Þ1, ³–؈ǓÞ1, “c•”—T“ñ1, ŠâØ•¶Žq1, ŽR•Ó°”ü1, ¬–{”ü“Þ1, “à“cˆêO2 (1—AŒŒ•”, 2—ÕŒŸ•”): 2019”N“x“ú—Õ‹ZŽñ“sŒ—Žx•”EŠÖbMŽx•”ˆãŠwŒŸžŠw‰ï (‘æ56‰ñ) (2019/10/26), H—tŒŽ.

733781. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) œ‘•W–{ƒyƒ‹ƒIƒLƒVƒ_[ƒ[õF—z«×–E‚É‚š‚¯‚éõF«‚ÌŒoŽž“I•Ï‰»‚ɂ‚¢‚Ä. ˆäããYØ1, —é–Ø‘‹I1, ãŒŽ—R‰À—1, ’†Œ@ŒO1, ˆ¢•”—L1, “à“cˆêO1, “•ûLˆê1, Žë–ì—Lì1,2 (1—ÕŒŸ•”, 2—ÕŒŸŠw): ‘æ68‰ñ_“ސ쌧ˆãŠwŒŸžŠw‰ï (2019/11/3), ¬“cŒŽ, “­‚«•û‚Ɛž“x•ÛØ`V‚µ‚¢Žž‘ã@—ߘa‚ɍl‚Š‚é`ƒvƒƒOƒ‰ƒ€Ž˜^W 2019/10; p.32.

'18”N“xˆÈ‘O•ª

[Šwp˜_•¶]

'18-120005. [ŒŽ’˜] ‚“x—zˆ³‘€‚Ƀs[ƒN‚ðŽŠ‚µ‚œƒeƒBƒ“ƒpƒmƒOƒ‰ƒ€‚̗Տ°“I”wŒi‚ÉŠÖ‚·‚錟“¢. ¬”Š@i1, Šâ|“S‰›1, –³‘Ÿ˜Y1, ²‹Ž‹v”üŽq1, “•ûLˆê1, Îˆä’Œm2, Žë–ì—Lì1,3 (1—ÕŒŸ•”, 2ˆã—Éq¶Šw•”, 3—ÕŒŸŠw): ˆãŠwŒŸž 2018/6; 67 (5): 791-6.


•úŽËü•”

[Šwp˜_•¶]

110363. [ŒŽ’˜] Evaluation of a novel reconstruction method based on the compressed sensing technique: Application to cervical spine MR imaging. Takato Y1, Hata H1, Inoue Y2, Matsunaga K2, Hara T2, Komi S1, Nakajima A1: Clinical Imaging 2019/7-8; 56: 140-5. (‚“¡—D‹P1, `@”Ž•¶1, ˆäã—D‰î2, Œ‰iŒh“ñ2, ŒŽ@•q«2, ¬Œ©³‘Ÿ˜Y1, ’†“ˆ@—•1: 1•úŽËü•”, 2•úŽËü (‰æ‘œ))

110364. [ŒŽ’˜] Cortisol-related hippocampal-extrastriate functional connectivity explains the adverse effect of cortisol on visuospatial retrieval. Hakamata Y, Komi S1, Sato E, Izawa S, Mizukami S, Moriguchi Y, Motomura Y, Matsui M, Kim Y, Hanakawa T, Inoue Y2, Tagaya H3: Psychoneuroendocrinology 2019/11; 109: 104310. (¬Œ©³‘Ÿ˜Y1, ˆäã—D‰î2, “cƒ–’J_–M3: 1•úŽËü•”, 2•úŽËü (‰æ‘œ), 3ˆã—Éq¶Šw•”)

[Šw‰ïEŒ€‹†‰ï“™]

723263. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) 3D ASL CBF ‰æ‘œ‚É‚š‚¯‚é•Ó‰•”‚M†ƒA[ƒ`ƒtƒ@ƒNƒg‚ɉe‹¿‚·‚éˆöŽq‚̃tƒ@ƒ“ƒgƒ€‚É‚æ‚錟“¢. “c’†’õl1, `@”Ž•¶1, ’r“cN‹M1, ˆäã—D‰î2 (1•úŽËü•”, 2•úŽËü (‰æ‘œ)): ‘æ75‰ñ“ú–{•úŽËü‹ZpŠw‰ï‘‰ïŠwp‘å‰ï (2019/4/13), ‰¡•l, “ú–{•úŽËü‹ZpŠw‰ï‘æ75‰ñ‘‡Šwp‘å‰ï—\eW 2019; p.341.

723264. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) 3D ASL CBF‰æ‘œ‚É‚š‚¯‚é•Ó‰•”‚ŒŒ—¬ƒA[ƒ`ƒtƒ@ƒNƒg‚ɑ΂·‚鎉–b—}§–@‚ÌŒø‰Ê‚̃tƒ@ƒ“ƒgƒ€‚É‚æ‚錟“¢. “c’†’õl1, `@”Ž•¶1, ˆäã—D‰î2 (1•úŽËü•”, 2•úŽËü (‰æ‘œ)): ‘æ47‰ñ“ú–{Ž¥‹C‹€–ˆãŠw‰ï‘å‰ï (2019/9/21), ŒF–{, “ú–{Ž¥‹C‹€–ˆãŠw‰ïŽGŽ 2019; 39 (Suppl): 290.

733782. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) Localize TG‚ÌŠî‘b“IŒŸ“¢. ‹Ž–{“N–ç1, ¬Œ©³‘Ÿ˜Y1, `@”Ž•¶1 (1•úŽËü•”): “ú–{•úŽËü‹ZpŠw‰ï@‘æ66‰ñŠÖ“ŒŽx•”Œ€‹†”­•\‘å‰ï (2019/11/16), ç—t, ŠÖ“ŒŽx•”Œ€‹†”­•\‘å‰ï2019Ž˜^W 2019; p.65.

733783. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) PROPELLER Multi BladeƒV[ƒPƒ“ƒX‚É‚š‚¯‚éT1ƒRƒ“ƒgƒ‰ƒXƒg‚ÌŠî‘b“IŒŸ“¢. ’†“ˆ@—•1, `@”Ž•¶1, ¬Œ©³‘Ÿ˜Y1 (1•úŽËü•”): “ú–{•úŽËü‹ZpŠw‰ï@‘æ66‰ñŠÖ“ŒŽx•”Œ€‹†”­•\‘å‰ï (2019/11/17), ç—t, ŠÖ“ŒŽx•”Œ€‹†”­•\‘å‰ï2019Ž˜^W 2019; p.104.

733784. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ˆã—Ö@Ž{s‹K‘¥‰ü³‚É”º‚€ŠjˆãŠwf—Âɂš‚¯‚é“–Ž{Ý‚ÌŽæ‚è‘g‚Ý. ‚‹ŽŒc‘Ÿ1, “n糓Ďj1, ˆ¢•”@–L1, _‹{ŽiŒö“ñ1, ‹e’r@Œh1, ˆäã—D‰î2 (1•úŽËü•”, 2•úŽËü (‰æ‘œ)): ‘æ92‰ñ“ú–{ŠjˆãŠw‰ïŠÖ“ŒbM‰z’n•û‰ï (2020/1/25), “Œ‹ž, ŠjˆãŠw 2020; 57 (1): 37.


–òÜ•”

[Šwp˜_•¶]

110365. [ŒŽ’˜] Investigating the risk of bone fractures in elderly patients with type 2 diabetes mellitus: a retrospective study. Horii T1, Iwasawa M1, Kabeya Y, Shimizu J, Atsuda K1,2: BMC Endocr Disord 2019/7; 19 (1): 81. (–xˆä„Žj1, ŠâàV^‹IŽq1, Œú“cKˆê˜Y1,2: 1–òŠw•”, 2–òÜ•”)

110366. [ŒŽ’˜] Effect of resistance of the exercise band on the peak femoral vein velocity during active ankle flexion. Tsuda K1, Takahira N1,2, Ejiri M, Sakai K1, Sakamoto M, Akamine A1,3: Phlebology 2020/4; 35 (3): 176-183. doi: 10.1177/0268355519865164. Epub 2019 Jul 31. (’ÓcWŽi1, ‚•œ®L1,2, âˆäŒ’‘Ÿ1, Ô—䑏•F1,3: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ˆã—Éq¶Šw•”, 3–òÜ•”)

110367. [ŒŽ’˜] Polypharmacy and oral antidiabetic treatment for type 2 diabetes characterised by drug class and patient characteristics: A Japanese database analysis. Horii T1, Iwasawa M1, Kabeya Y, Atsuda K1,2: Sci Rep 2019/9; 9 (1): 12992. (–xˆä„Žj1, ŠâàV^‹IŽq1, Œú“cKˆê˜Y1,2: 1–òŠw•”, 2–òÜ•”)

110368. [ŒŽ’˜] Determination of factors affecting medication adherence in type 2 diabetes mellitus patients using a nationwide claim-based database in Japan. Horii T1, Momo K, Yasu T, Kabeya Y, Atsuda K1,2: PLoS One 2019/10; 14 (10): e0223431. (–xˆä„Žj1, Œú“cKˆê˜Y1,2: 1–òŠw•”, 2–òÜ•”)

110369. [ŒŽ’˜] Comparing treatment intensification and clinical outcomes of metformin and dipeptidyl peptidase-4 inhibitors in treatment-na?ve patients with type 2 diabetes in Japan. Horii T1, Iwasawa M1, Shimizu J, Atsuda K1,2: J Diabetes Investig 2020/1; 11 (1): 96-100. (–xˆä„Žj1, ŠâàV^‹IŽq1, Œú“cKˆê˜Y1,2: 1–òŠw•”, 2–òÜ•”)

110370. [ŒŽ’˜] Effects of pharmacist intervention on polypharmacy in patients with type 2 diabetes in Japan. Horii T1, Atsuda K1,2: BMC Res Notes 2020/3; 13 (1): 183. (–xˆä„Žj1, Œú“cKˆê˜Y1,2: 1–òŠw•”, 2–òÜ•”)

110371. [ŒŽ’˜] The Population Pharmacokinetics of Rifampicin in Japanese Pulmonary Tuberculosis Patients. Nishimura T, Kohno H, Nagai H, Maruoka D, Koike Y, Kobayashi M1,2, Atsuda K1,2: Drug Res (Stuttg) 2020/5; 70 (5): 199-205. doi: 10.1055/a-1122-8129. Epub 2020 Mar 19. (¬—я¹G1,2, Œú“cKˆê˜Y1,2: 1–òÜ•”, 2–òŠw•”)

120048. [ŒŽ’˜] •¡”‚̈ã—Ã`[ƒ€‚Å‹Š“­ŠÇ—‚µ‚œHIVŠŽõŽÒ‚̐tˆÚA. ˆî–ì@Š°1, ¬—я¹G1,2, •“¹—Á•œ1, Îˆä‘å•ã3, ‹g“cˆê¬3,4, ˜a“c’B•F5, Œú“cKˆê˜Y1,2 (1–òÜ•”, 2–òŠw•”, 3”å”AŠí, 4V¢‹Iˆã—ÁEæ’[ˆã—Ã, 5äPŒŽ•aEŠŽõ“à): “ú–{—Տ°tˆÚAŠw‰ïŽGŽ 2019/5; 7 (2): 230-6.

120149. [ŒŽ’˜] ƒoƒ‹ƒvƒŽ_ƒiƒgƒŠƒEƒ€‚ð•ž—p‚µ‚Ä‚¢‚é“œ”A•aŠ³ŽÒ‚É‚š‚¯‚é“œ”A•a–Ô–ŒÇ”­Ç‚ÉŠÖ‚·‚éŽÀ‘Ô’²ž. ”Ñ’Ë’Œl1, ˆÉ—`—RŽq1, âV“¡Œ\Œå1, ì–ìçq1,2, ’†ŽR–G”ü1, t“úˆäŒö”ü1, “¹‘O—mŽj1, ˆäã@Šx1, •œŽR•Ži1,2, Žµ—¢áÁ‹`3, ’†ŒŽ@“w1, Œú“cKˆê˜Y1,4, •ŽR­ˆê1,2 (1–òŠw•”, 2“Œ•a‰@–òÜ•”, 3“à•ª”å‘ãŽÓ“à, 4–òÜ•”): ‚­‚·‚è‚Æ“œ”A•a 2019/6; 8 (1): 138-46.

120050. [ŒŽ’˜] ƒWƒSƒLƒVƒ“‚̏‰Šú“Š—^ÝŒvƒmƒ‚ƒOƒ‰ƒ€‚Ì—L—p«‚ÉŠÖ‚·‚錟“¢. ¬Œ•q²1,2, ¬òŽé”T1, ’––”FŒ³3, ˆ¢ŒÃÆ3, Œú“cKˆê˜Y1,4 (1–òÜ•”, 2ŠŽõŠÇ—Žº, 3zŠÂŠí“à, 4–òŠw•”): “ú–{•a‰@–òÜŽt‰ïŽGŽ 2019/8; 55 (8): 980-4.

120051. [ŒŽ’˜] Š¿•û÷‰t‚š‚æ‚ÑŠ¿•ûƒGƒLƒX»Ü‚̐¬•ª•ªÍ|ƒIƒEƒSƒ“”z‡Š¿•û–ò’†‚̃oƒCƒJƒŠƒ“‚š‚æ‚уoƒCƒJƒŒƒCƒ“—ʁ|. ’Ł@@’1,2, •“c–Ÿ•œ1, ŽÐ–{“TŽq1, ŽOŠªË_1 (1“Œ‹ž–ò‰È‘åŠw–òŠw•”, 2–òÜ•”): “ú–{˜V”NˆãŠw‰ïŽGŽ 2020/1; 57 (1): 72-80.

521011. [‰ðà] ƒ|ƒŠƒtƒ@[ƒ}ƒV[‚Æ–ò•š‘ŠŒÝì—p. ‘O“cŽÀ‰Ô1, ŒF’J—YŽ¡2 (1–òÜ•”, 2—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg): ˜V”N“à‰È 2020/2; 1 (2): 261-70.

522159. [uÀ]y“ÁW: “œ”A•aŠ³ŽÒ‚̃tƒHƒ[ƒAƒbƒv@Œp‘±“I‚È–òŠw“IŠÇ—‚ÆŠ³ŽÒŽx‰‡‚ÌŽÀ‘Hz¡‡•¹Ç/•¹‘¶ŽŸŠ³‚ð—L‚·‚é“œ”A•aŠ³ŽÒ‚ÌŒp‘±“I‚ȃtƒHƒ[ƒAƒbƒv@E‚ª‚ñ. ˆî–ì@Š° (–òÜ•”): –ò‹Ç 2019/7; 70 (8): 94-9.

522160. [uÀ]y“ÁW3: ‹Zp•Ò: ‰Æ‘°‚ðŠª‚«ž‚Þ!@‚—ÍŠ³ŽÒ‚Ì“úí¶Šˆ‚ðŽx‚Š‚éƒPƒAz1. •ž–òŠÇ—. ˆî–ì@Š° (–òÜ•”): “§ÍƒPƒA 2019/10; 25 (10): 926-8.

540085. [‚»‚Ì‘Œ (ƒRƒ‰ƒ€)] ƒRƒ‰ƒ€: –òÜŽt‚©‚ç‚̐V‚µ‚¢–ò•šE’†“ŏî•ñ. ‹ß“¡—¯”üŽq (–òÜ•”): LiSA 2020/2; 27 (2): 204-6.

[’˜@‘]

620103. [Šwp‘ (•ª’SŽ·•M)]y_ŒoŽŸŠ³‚̊ɘaƒPƒAzPart 1 Çó‚²‚Ƃ̊ɘa@1 ŽlŽˆE‘ÌŠ²‹@”\áŠQ‚É”º‚€Çó@B. ŒÅkE–³“®‚É‚æ‚é‹@”\’ቺ@–òÜŽt‚ÌŽ‹“_, p.33. C. áz«‚É‚æ‚é‹@”\’ቺ@–òÜŽt‚ÌŽ‹“_, p.41. 3 ŒÄ‹z‹ØáŠQ‚É”º‚€Çó@A. ŒÄ‹z‹Ø‹Ø—͒ቺ@–òÜŽt‚ÌŽ‹“_, p.81. B. ŒÄ‹zŠíŠŽõÇ@–òÜŽt‚ÌŽ‹“_, p.90. 4 Ž©—¥_ŒoŒnáŠQ‚É”º‚€Çó@–òÜŽt‚ÌŽ‹“_, p.118. 5 ŠeáŠQ‚É‚æ‚Á‚悶‚é‹ê’ɏǏó@A. áu’É, ŠŽŠoáŠQ@–òÜŽt‚ÌŽ‹“_, p.127. B. ŒÄ‹z‹êEŒÄ‹z¢“@–òÜŽt‚ÌŽ‹“_, p.137. E. ”rŸ•ŠÖ˜Aƒgƒ‰ƒuƒ‹@–òÜŽt‚ÌŽ‹“_, p.155. G.‚¹‚ñ–ρ@–òÜŽt‚ÌŽ‹“_, p.171. H. ž_“I‹ê’É –òÜŽt‚ÌŽ‹“_, p.177. Œ‰ª—zŽq1, •ŽR­ˆê2 (1–òÜ•”, 2“Œ•a‰@–òÜ•”), •Ò: ‰¬–ì”üŒbŽq, ¬—эNŽq, ‘‰³—‹MŽq, ’†ŽR—D‹G, ¬“c—LŒá, –ì“c—ÁŽq3, •ž•”–œ—¢Žq, ‰ÔˆäˆŸ‹IŽq (3“Œ•a‰@ŠÅŒì•”), “ìŽR“°, “Œ‹ž, 2019/7”­s.

620104. [Šwp‘ (•ª’SŽ·•M)]y2ƒy[ƒW‚Å—‰ð‚·‚é•W€–ò•šŽ¡—Ãtƒ@ƒCƒ‹@‘æ3”Łz¡_ŒoEž_ŽŸŠ³@30 ƒp[ƒLƒ“ƒ\ƒ“•a, p.60-1. ‹àˆä‹Im, Œ‰ª—zŽq1, ŽR“¡@–ž, ]ŒŽ³_, ’|“à‘s‰î (1–òÜ•”), •Ò: “ú–{ƒAƒvƒ‰ƒCƒhEƒZƒ‰ƒsƒ…[ƒeƒBƒNƒX (ŽÀ‘H–ò•šŽ¡—Ã) Šw‰ï, “ìŽR“°, “Œ‹ž, 2019/7”­s.

620105. [Šwp‘ (•ª’SŽ·•M)]y2ƒy[ƒW‚Å—‰ð‚·‚é•W€–ò•šŽ¡—Ãtƒ@ƒCƒ‹@‘æ3”Łz¡ˆ««Žîᇁ@63 ˆ««ƒŠƒ“ƒpŽî, p.126-7. ‚–ì‘žs, ‹{“‡—¥Žq1, •x“c’Œl (1–òÜ•”), •Ò: “ú–{ƒAƒvƒ‰ƒCƒhEƒZƒ‰ƒsƒ…[ƒeƒBƒNƒX (ŽÀ‘H–ò•šŽ¡—Ã) Šw‰ï, “ìŽR“°, “Œ‹ž, 2019/7”­s.

620106. [Šwp‘ (•ª’SŽ·•M)]y2ƒy[ƒW‚Å—‰ð‚·‚é•W€–ò•šŽ¡—Ãtƒ@ƒCƒ‹@‘æ3”Łz¡ˆ««Žîᇁ@64 ‘œ”­«œ‘Žî, p.128-9. ‚–ì‘žs, ‹{“‡—¥Žq1, •x“c’Œl (1–òÜ•”), •Ò: “ú–{ƒAƒvƒ‰ƒCƒhEƒZƒ‰ƒsƒ…[ƒeƒBƒNƒX (ŽÀ‘H–ò•šŽ¡—Ã) Šw‰ï, “ìŽR“°, “Œ‹ž, 2019/7”­s.

620107. [Šwp‘ (•ª’SŽ·•M)]y2ƒy[ƒW‚Å—‰ð‚·‚é•W€–ò•šŽ¡—Ãtƒ@ƒCƒ‹@‘æ3”Łz¡ˆ««Žîᇁ@65 ”­”M«D’†‹…Œž­Ç, p.130-1. ‚–ì‘žs, ‹{“‡—¥Žq1, Ÿ–“”Í”V (1–òÜ•”), •Ò: “ú–{ƒAƒvƒ‰ƒCƒhEƒZƒ‰ƒsƒ…[ƒeƒBƒNƒX (ŽÀ‘H–ò•šŽ¡—Ã) Šw‰ï, “ìŽR“°, “Œ‹ž, 2019/7”­s.

620108. [Šwp‘ (•ª’SŽ·•M)]y2ƒy[ƒW‚Å—‰ð‚·‚é•W€–ò•šŽ¡—Ãtƒ@ƒCƒ‹@‘æ3”Łz¡ˆ««Žîᇁ@66 R‚ª‚ñ–ò‚É‚æ‚鈫SEšq“f, p.132-3. ¬—ѐœˆê, ‹{“‡—¥Žq1, ‹{–{NŒh, –p@¬˜a (1–òÜ•”), •Ò: “ú–{ƒAƒvƒ‰ƒCƒhEƒZƒ‰ƒsƒ…[ƒeƒBƒNƒX (ŽÀ‘H–ò•šŽ¡—Ã) Šw‰ï, “ìŽR“°, “Œ‹ž, 2019/7”­s.

620109. [Šwp‘ (•ª’SŽ·•M)]y“œ”A•a—×{ƒOƒŠ[ƒ“ƒm[ƒgz1. “œ”A•a—×{Žw“±Žm‚̃XƒXƒ@4. –òÜŽt‚©‚ç@ƒCƒ“ƒXƒŠƒ“’ŽË‚̗×{Žw“± (Ž‹—͏áŠQ, _ŒoáŠQ, ‹Ø—͒ቺ‚𔺂€Š³ŽÒ‚Ö‚ÌŽw“±) (‹­‰»ƒCƒ“ƒXƒŠƒ“—Ö@‚ÆBOT—Ö@‚ÌŽw“±), p.289-95. ˆî–ì@Š°1, Œú“cKˆê˜Y1,2 (1–òÜ•”, 2–òŠw•”), •Ò: Ž›“àN•v, ”’ì@ƒ, ’†ŠOˆãŠwŽÐ, “Œ‹ž, 2019/9”­s.

620110. [Šwp‘ (•ª’SŽ·•M)]yzŠÂŠíƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì—˜_‚Æ‹Zp ‰ü’ù‘æ2”ŁzV ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ (‘˜_)@ŽŸŠ³ŠÇ—‚Ì‚œ‚ß‚Ì‹³ˆçEŽw“±•û–@@…B•ž–òŠÇ—Žw“±‚Ì—˜_‚ÆŽÀÛ, p.285-92. ‹ß“¡—¯”üŽq1 (1–òÜ•”), •Ò: ‘“c@‘ì2, Œ‰i“Ä•F2 (2ˆã—Éq¶Šw•”), ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2020/3”­s.

620111. [Šwp‘ (•ª’SŽ·•M)]y•a‹C‚Æ‚­‚·‚è2020@Šî‘b‚ÆŽÀ‘H Expert's Guide (–ò‹Ç2020”N‘Š§†)z2. ž_E’†•_ŒoŒn‚Ì•a‹C‚Æ‚­‚·‚è@E•s–°, •s–°Ç, p.85-95. Ô—ä‚¿‚©]1, Œú“cKˆê˜Y1,2 (1–òÜ•”, 2–òŠw•”), “ìŽR“°, “Œ‹ž, 2020/3”­s.

[Šw‰ïEŒ€‹†‰ï“™]

713146. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Adaptation of alanine aminotransferase elevations with therapeutic doses of acetaminophen: an exploratory study in healthy subjects. Maeda M1,2, Tanaka R3, Aso M, Sakamoto Y3, Song I3, Ochiai M1, Saito Y, Maekawa K, Arakawa N, Ohno Y, Kumagai Y3,4: EACPT 2019 (14th Congress of the European Association for Clinical Pharmacology and Therapeutics/‘æ14‰ñ‰¢B—Տ°–ò—Ž¡—Êw‰ï‹c) (2019/7/1), Stockholm, Sweden, ‘æ14‰ñ‰¢B—Տ°–ò—Šw‰ï—vŽ| 2019; “dŽqŽ˜^. (‘O“cŽÀ‰Ô1,2, “c’†—‰pŽq3, â–{‘×—3, ‘v@ˆê‘å3, —Ž‡—˜H1, ŒF’J—YŽ¡3,4: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2–òÜ•”, 3—Տ°Œ€‹†ƒZƒ“ƒ^[, 4—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg)

713147. [Šw‰ï (‘Û)] (ƒ|ƒXƒ^[) Comparing clinical characteristics and outcomes of dipeptidyl peptidase-4 inhibitors and metformin in treatment of na?ve type 2 diabetes in an academic teaching hospital in Japan. Iwasawa M1, Horii T1, Kashiwagi S1, Atsuda K1,2: ASHPƒ~ƒbƒhƒCƒ„[ƒ~[ƒeƒBƒ“ƒO2019”N (2019/12/9), Las Vegas, USA, ASHPƒ~ƒbƒhƒCƒ„[ƒ~[ƒeƒBƒ“ƒO2019”N—vŽ| 2019/12; “dŽqŽ˜^. (ŠâàV^‹IŽq1, –xˆä„Žj1, ”–؍ʉØ1, Œú“cKˆê˜Y1,2: 1–òŠw•”, 2–òÜ•”)

723896. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒŠƒlƒ]ƒŠƒh‚ÌŒŒ’†”Z“xƒ‚ƒjƒ^ƒŠƒ“ƒO‚ðs‚¢Ž¡—ª‘tŒ÷‚µ‚œ2Ç—á‚ɂ‚¢‚Ä. ¬Œ•q²1,2, “ñ–{–öL2, ˜a“c’B•F2,3, ‚ŽR—zŽq2,4, Œú“c Kˆê˜Y1 (1–òÜ•”, 2ŠŽõŠÇ—Žº, 3äPŒŽ•aEŠŽõ“à, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ67‰ñ“ú–{‰»Šw—Ö@Šw‰ï‘‰ï (2019/5/11), “Œ‹ž, “ú–{‰»Šw—Ö@Šw‰ïŽGŽ 2019; 67: 1340-7007.

723897. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒIƒLƒVƒRƒhƒ“™•úù‚É‚æ‚éƒIƒsƒIƒCƒh—U”­«•Ö”é (OIC) ‚ɑ΂·‚éƒiƒ‹ƒfƒƒWƒ“’ljÁ“Š—^–@‚ƃtƒFƒ“ƒ^ƒjƒ‹“\•tÜ‚ւ̃XƒCƒbƒ`ƒ“ƒO–@‚Ì—L—p«‚ÉŠÖ‚·‚錟“¢ (ŠÏŽ@Œ€‹†). •œŽR•Ži1, •“¹—Á•œ1, ŽRè‚à‚à2, —é–؁@ˆš2, –{ŠÔ‰ëŽm1, ‘Ÿ“c’q”Ž1, •œ’ËŒöŒÈ1, —с@Œol3, ‹àˆäº•¶3,4, Œú“cKˆê˜Y1,2 (1–òÜ•”, 2–òŠw•”, 3–ƒŒ, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ24‰ñ“ú–{ŠÉ˜aˆã—Êw‰ïŠwp‘å‰ï (2019/6/22), ‰¡•l.

723898. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) Prospective study to investigate the clinical efficacy of G-CSF for Docetaxel + Cisplatin + 5-Fluorouracil (DCF) chemotherapy in patients with esophageal squamous cell carcinoma (ESCC). ›ŒŽ[L1, Œ˜“ce—˜2, “n糍WŽ¯2, Sakamoto Y, Hara H, Fujii H, Nakajima T, Ando T, Kojima T, Ishijima H, Hosokawa A, Hamamoto Y, Muto M, Tahara M, ¬ò˜aŽO˜Y2 (1–òÜ•”, 2Á‰»Ší“à): ‘æ17‰ñ“ú–{—Տ°Žîᇊw‰ïŠwpW‰ï (2019/7/19), ‹ž“s, ‘æ17‰ñ“ú–{—Տ°Žîᇊw‰ï—vŽ| 2019; “dŽqŽ˜^.

723899. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒIƒsƒIƒCƒh—U”­«•Ö”é‚ɑ΂·‚éƒiƒ‹ƒfƒƒWƒ“‚ƃtƒFƒ“ƒ^ƒjƒ‹‚ւ̃XƒCƒbƒ`ƒ“ƒO‚Ì—L—p«‚ÉŠÖ‚·‚éŠÏŽ@Œ€‹†. •œŽR•Ži1, •“¹—Á•œ1, —é–؁@ˆš2, •œ’ËŒöŒÈ1, ‘Ÿ“c’q”Ž1, –{ŠÔ‰ëŽm1, —с@Œol3, ‹àˆäº•¶3,4, Œú“cKˆê˜Y1,2 (1–òÜ•”, 2–òŠw•”, 3–ƒŒ, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): “ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ï‘æ53‰ñ‘å‰ï (2019/7/20), ŒF–{.

723900. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) “œ”A•aê–åE”F’è–òÜŽt—{¬uK‰ï‚Ì—L—p«. ˆî–ì@Š°1, ‘ŠàV­–Ÿ2, “yˆä˜HŽq3, –쑺‹±Žq4, •œŽR‘å“O5, ‹îˆäŒ³•F6, Œú“cKˆê˜Y1,7 (1–òÜ•”, 2‘Š–Í‘ä•a‰@–òÜ•”, 3‰¡{‰ê‹€Ï•a‰@–òÜ‰È, 4Œú–ØŽs—§•a‰@–òÜ‰È, 5H.E.CƒTƒCƒGƒ“ƒXƒNƒŠƒjƒbƒN–òÜ‰Û, 6“¡‘òŽs–¯•a‰@–ò‹Ç, 7–òŠw•”): ‘æ8‰ñ“ú–{‚­‚·‚è‚Æ“œ”A•aŠw‰ïŠwpW‰ï (2019/9/8), ŽD–y, ‘æ8‰ñ“ú–{‚­‚·‚è‚Æ“œ”A•aŠw‰ïŠwpW‰ïƒvƒƒOƒ‰ƒ€EŽ˜^W 2019; •Êû: 143.

723901. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ¬Ž™1Œ^“œ”A•aŠ³Ž™‚̗×{ŠÂ‹«Œüã‚ɑ΂·‚éŽæ‚è‘g‚݁`‹³EˆõŒü‚¯ƒZƒ~ƒi[‚ÌŠJÃ‚ÆŽQ‰ÁŽÒ‚ւ̃Aƒ“ƒP[ƒg’²ž`. ‹{â@ŒO1, ‹k“cˆê‹P2, â–{”~Žq3, ’|“à—DŽq3, Œú“cKˆê˜Y1,4 (1–òÜ•”, 2¬Ž™, 3ŠÅŒì•”, 4–òŠw•”): ‘æ8‰ñ“ú–{‚­‚·‚è‚Æ“œ”A•aŠw‰ïŠwpW‰ï (2019/9/7-8), ŽD–y, ‘æ8‰ñ“ú–{‚­‚·‚è‚Æ“œ”A•aŠw‰ïŠwpW‰ïƒvƒƒOƒ‰ƒ€EŽ˜^W 2019; •Êû: 190.

723902. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) CRC‹Æ–±‚Ì’S“–ƒ`[ƒ€§‚É‚š‚¯‚é‰Û‘è‚ÉŒü‚¯‚œŽæ‚è‘g‚Ý. ³‘º—DŽq1, –쑺¡“úŽq2, ¬‘ò@Šw2, –ìŒûŒbŽq2, í“cˆ€Žq1, ŽR–{–ŸŽq1, ŠÖª’q”ü1, ‰¡“cœÄˆê1, ŒF’J—YŽ¡2 (1–òÜ•”, 2ŠÅŒì•”, 3—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg): ‘æ19‰ñCRC‚ƗՏ°ŽŽŒ±‚Ì‚ ‚è•û‚ðl‚Š‚é‰ï‹c2019 in YOKOHAMA (2019/9/14-15), ‰¡•l, ‘æ19‰ñCRC‚ƗՏ°ŽŽŒ±‚Ì‚ ‚è•û‚ðl‚Š‚é‰ï‹c2019 in YOKOHAMAƒvƒƒOƒ‰ƒ€EŽ˜^W 2019; p.162.

723903. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) æ“V«ƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXŠŽõÇœëŠ³Ž™‚É‚š‚¢‚ăoƒ‹ƒKƒ“ƒVƒNƒƒrƒ‹Œœ‘÷‰t“à•ž‚É‚æ‚莡—Âðs‚Á‚œ1—á. ¬ì—²O1, “c’†—T‘å1, •yàV@~1, ‹ß“¡—¯”üŽq1, çݎ@Šw2, Œú“cKˆê˜Y1,3 (1–òÜ•”, 2¬Ž™, 3–òŠw•”): ‘æ46‰ñ“ú–{¬Ž™—Տ°–ò—Šw‰ïŠwpW‰ï (2019/9/28-29), ŽD–y, ‘æ46‰ñ“ú–{¬Ž™—Տ°–ò—Šw‰ïŠwpW‰ïƒvƒƒOƒ‰ƒ€EŽ˜^W 2019; p.108.

723904. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) Hematological Toxicity of Bendamustine in Patients with Renal Dysfunction. ‹{“‡—¥Žq1, Š™“c_–«2, —é–Ø—²_2, Œú“cKˆê˜Y1,3 (1–òÜ•”, 2ŒŒ‰t“à, 3–òŠw•”): ‘æ81‰ñ“ú–{ŒŒ‰tŠw‰ïŠwpW‰ï (2019/10/11-13), “Œ‹ž, ‘æ81‰ñ“ú–{ŒŒ‰tŠw‰ïŠwpW‰ï—vŽ| 2019; “dŽqŽ˜^.

723905. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) Ã–¬ŒŒðÇðÇ—\–hŽÀŽ{•\‚ðŽg—p‚µ‚œ‰ºŽˆ®Œ`ŠO‰ÈpŒãŠ³ŽÒ‚É‚š‚¯‚錌ð”­¶ƒŠƒXƒNˆöŽq‚̃JƒbƒgƒIƒt’l‚ÌŽZo. Ô—䑏•F1,2, ‚•œ®L2,3, “àŽRŸ•¶4, •Ÿ“‡Œ’‰î4, ’ÓcWŽi3, ‚‹Ž‰Àô3 (1–òÜ•”, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ˆã—Éq¶Šw•”, 4®ŠO): ‘æ46‰ñ“ú–{ŒÒŠÖßŠw‰ïŠwpW‰ï (2019/10/25), ‹{è, ‘æ46‰ñ“ú–{ŒÒŠÖßŠw‰ïŠwpW‰ï (DVD) 2019; “dŽqŽ˜^.

723906. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) Pembrolizumab’PÜ—Ö@‚ªŽ{s‚³‚ê‚œ”ñ¬×–E”xŠàŠ³ŽÒ‚É‚š‚¯‚鑁ŠúŽ€–SƒŠƒXƒNˆöŽq‚ÌŒŸ“¢. Žµ”ö’J[1, X@Ê‰Ä1, ‹{â—Dl1, ˆî–ì@Š°1, ›ŒŽ[L1, Œú“cKˆê˜Y1,2, Œ¬“cÙŽq3, “팎­ˆê˜Y3, Š|ì–¢ŠóŽq3, “ú‹gNO3, Š}“‡^Žu3, •Ÿˆä•ü–ç3, ˆäì@‘3, ‰¡ê³“T4, ŽO“¡@‹v5, ‹v•Û“cŸ4, •Ð‹Ë^l4, —P–؍Ž•F3 (1–òÜ•”, 2–òŠw•”, 3ŒÄ‹zŠí“à, 4ˆã—Éq¶Šw•”, 5ŠÅŒìŠw•”): ‘æ29‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ï (2019/11/3), •Ÿ‰ª, ‘æ29‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ï—vŽ| 2019; “dŽqŽ˜^.

723907. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ‚ª‚ñ‰»Šw—Ö@’²»Žº‚Æ‚ª‚ñ‰»Šw—Ö@ƒZƒ“ƒ^[‚Ì‹Æ–±—Ê‚ÉŠÖ‚·‚éŽÀ‘Ô’²ž. ˆî–ì@Š°1, XŒ³”\m2, ²X–ØŽõŽq1, ’·àV’m“¿3, ‰Pˆä_–Ÿ3, ‹g“c@³3, “n•”ˆêG2, œAŒŽ³‹X2, ŽÂŒŽ‚—Y3, Œú“cKˆê˜Y1,4 (1–òÜ•”, 2º˜a–ò‰È‘åŠw—Տ°–òŠw‹³ˆçŒ€‹†ƒZƒ“ƒ^[, 3ˆÇ—Ñ‘åŠwˆãŠw•”•t‘®•a‰@–òÜ•”, 4–òŠw•”): ‘æ29‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ï (2019/11/4), •Ÿ‰ª, ‘æ29‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ï—vŽ| 2019; “dŽqŽ˜^.

723908. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) •ÛŒ¯–ò‹Ç‚É‚š‚¯‚éƒqƒ„ƒŠEƒnƒbƒg‚Ì—vˆöˆöŽq‚Ì’Tõ. ²X–Ø‘PM1, ‰H“c–Ÿ_2, •œŽR•Ži1,3, Œú“cKˆê˜Y1,3 (1–òÜ•”, 2‘Ûˆã—ÕŸŽƒ‘åŠwˆã—ÕŸŽƒ‘åŠwŒ€‹†‰Èˆã—ÃŒo‰cŠÇ—•ª–ì, 3–òŠw•”): ‘æ29‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ï (2019/11/4), •Ÿ‰ª, ‘æ29‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ï—vŽ| 2019; “dŽqŽ˜^.

723909. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ”xŠàƒiƒuƒpƒNƒŠƒ^ƒLƒZƒ‹{ƒJƒ‹ƒ{ƒvƒ‰ƒ`ƒ“—Ö@‚É‚š‚¯‚éD’†‹…Œž­‚Ì”­Œ»ó‹µ‚ƃŠƒXƒNˆöŽq‚ÌŒŸ“¢. •ÄŽR‘åŽu1, ‰ª–{”ü•ä2, ²X–ØŽõŽq1, ›ŒŽ[L1, ²X–Ø–èˆê˜Y3,4, —P–؍Ž•F4, Œú“cKˆê˜Y1,2 (1–òÜ•”, 2–òŠw•”, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 4ŒÄ‹zŠí“à): ‘æ29‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ï (2019/11/4), •Ÿ‰ª, ‘æ29‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ï—vŽ| 2019; “dŽqŽ˜^.

723910. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) •Û‘¶Šú–«t‘Ÿ•aŠ³ŽÒ‚É‚š‚¯‚é’YŽ_ƒJƒ‹ƒVƒEƒ€‚ÌŽg—p‚ªŒŒŽƒJƒ‹ƒVƒEƒ€’l‚É—^‚Š‚é‰e‹¿. ŽR–{—IŽ÷1, ‰œ˜e—D‰Á1, Œú“cKˆê˜Y1,2 (1–òÜ•”, 2–òŠw•”): ‘æ13‰ñ“ú–{t‘Ÿ•a–ò•š—Ö@Šw‰ïŠwpW‰ïE‘‰ï2019 (2019/11/16), ŒF–{, “ú–{t‘Ÿ•a–ò•š—Ö@Šw‰ïŽ 2019; 8 (“Á•Ê†): S143.

723911. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ˆÝ‚ª‚ñŠ³ŽÒ‚ɑ΂·‚éRamucirumab + Paclitaxel—Ö@‚ÆRamucirumab + nab-Paclitaxel—Ö@‚É‚š‚¯‚é’`”’”A”­Œ»‚Ì”äŠr. ‹{â—Dl1, “ŒM‘Ÿ˜N1, ™‰Y•‡—uŽq1, Œú“cKˆê˜Y1,2 (1–òÜ•”, 2–òŠw•”): ‘æ13‰ñ“ú–{t‘Ÿ•a–ò•š—Ö@Šw‰ïŠwpW‰ïE‘‰ï2019 (2019/11/16), ŒF–{, “ú–{t‘Ÿ•a–ò•š—Ö@Šw‰ïŽ 2019; 8 (“Á•Ê†): S147.

723912. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) HIV—z«ŠO—ˆŠ³ŽÒ‚É‚©‚©‚è‚‚¯–ò‹Ç‚ªŠˆ—p‚³‚ê‚È‚¢—vˆö‚ÌŒŸ“¢|Š³ŽÒƒAƒ“ƒP[ƒg’²ž‚ÌŒv—ʃeƒLƒXƒg•ªÍ|. •“¹—Á•œ1, •yàV@~1, ‰Á“¡@Î2, Ž“cr–ç1, ‰œ˜e’B–ç1, ¬ì—²O1, t“úˆäŒö”ü3, ˜a“c’B•F4, Œú“cKˆê˜Y1,3 (1–òÜ•”, 2ŠÅŒì•”, 3–òŠw•”, 4äPŒŽ•aEŠŽõ“à): ‘æ33‰ñ“ú–{ƒGƒCƒYŠw‰ïŠwpW‰ïE‘‰ï (2019/11/27-29), ŒF–{, ‘æ33‰ñ (2019) “ú–{ƒGƒCƒYŠw‰ïŠwpW‰ïE‘‰ïŽ˜^W 2019/11; 21 (4): 410.

723913. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) R‚ª‚ñÜ’²»Žº‚̉»Šw—Ö@ƒŒƒWƒƒ“ŠÄž‚É‚š‚¯‚éŽÀ‘Ô’²ž. A“c䝗œŠG1, ˆî–ì@Š°1, ²X–ØŽõŽq1, “c‘º˜aŒh1, Œú“cKˆê˜Y1,2 (1–òÜ•”, 2–òŠw•”): “ú–{—Տ°ŽîᇖòŠw‰ïŠwp‘å‰ï2020 (2020/3/21), Ž†ãŠJÃ, ‘æ17‰ñ“ú–{—Տ°Žîᇊw‰ï—vŽ| 2019; “dŽqŽ˜^.

723914. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) –k—¢‘åŠw•a‰@‚É‚š‚¯‚邪‚ñ–ò•š—Ö@ƒTƒ|[ƒgƒ`[ƒ€‚ÌŠˆ“®•ñ. ²X–ØŽõŽq1,2, ”ª–öçt2,3, ‚‹Ž‚©‚š‚é2,3, “c‘º˜aŒh1,2, ˆî–ì@Š°1,2, ’·“c^—R”ü2,3, Œú“cKˆê˜Y1,4, ²X–ØŽ¡ˆê˜Y2,5 (1–òÜ•”, 2–k—¢‘åŠw•a‰@WŠw“I‚ª‚ñf—ÃZƒ“ƒ^[’ʉ@Ž¡—ÃŽº, 3ŠÅŒì•”, 4–òŠw•”, 5V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): “ú–{—Տ°ŽîᇖòŠw‰ïŠwp‘å‰ï2020 (2020/3/21), Ž†ãŠJÃ, ‘æ17‰ñ“ú–{—Տ°Žîᇊw‰ï—vŽ| 2019; “dŽqŽ˜^.

723915. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ‰ºŽˆ®Œ`ŠO‰ÈpŒãŠ³ŽÒ‚É‚š‚¯‚éÃ–¬ŒŒðÇðÇ—\–hŽÀŽ{•\‚̃ŠƒXƒNˆöŽq‚ƏpŒãÃ–¬ŒŒðÇðÇ‚ÌŠÖ˜A«. Ô—䑏•F1,2, ‚•œ®L2,3, •yàV@~1, ’ÓcWŽi2, ‚‹Ž‰Àô2, •Šâ­”V4, Œú“cKˆê˜Y1,5 (1–òÜ•”, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ˆã—Éq¶Šw•”, 4–ƒŒ, 5–òŠw•”): “ú–{–òŠw‰ï‘æ140”N‰ï (2020/3/25-28), ‹ž“s (WebŠJÃ).


ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“•”

[Šwp˜_•¶]

110372. [ŒŽ’˜] Acute Effects of Whole-Body Vibration Training on Endothelial Function and Cardiovascular Response in Elderly Patients with Cardiovascular Disease. Aoyama A1, Yamaoka-Tojo M2, Obara S3, Shimizu E3, Fujiyoshi K4, Noda C4, Matsunaga A2, Ako J4: Int Heart J 2019/7; 60 (4): 854-61. (ÂŽRW‘å1, “ŒžŠ”ü“ÞŽq2, ‰“ŒŽ^ˆê3, Ž…ŠG—¢3, “¡‹g˜a”Ž4, –ì“cçt4, Œ‰i“Ä•F2, ˆ¢ŒÃÆ4: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ˆã—Éq¶Šw•”, 3ƒŠƒnƒrƒŠ•”, 4zŠÂŠí“à)

110373. [ŒŽ’˜] Short-Term Change in Gait Speed and Clinical Outcomes in Older Patients With Acute Heart Failure. Tanaka S1, Kamiya K2, Hamazaki N3, Matsuzawa R3, Nozaki K3, Nakamura T4, Yamashita M4, Maekawa E5, Noda C5, Yamaoka-Tojo M2, Matsunaga A2, Masuda T2, Ako J5: Circ J 2019/8; 83 (9): 1860-7. (“c’†L–í1, _’JŒ’‘Ÿ˜Y2, à_èL–Ÿ3, Œ‘ò—Ç‘Ÿ3, –ìèN•œ3, ’†‘ºŠxŽu4, ŽR‰º^Ži4, ‘OìŒb”ü5, –ì“cçt5, “ŒžŠ”ü“ÞŽq2, Œ‰i“Ä•F2, ‘“c@‘ì2, ˆ¢ŒÃÆ5: 1–ŒŒÃ‰®‘åŠwˆãŠw•”•‘®•a‰@, 2ˆã—Éq¶Šw•”, 3ƒŠƒnƒrƒŠ•”, 4‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 5zŠÂŠí“à)

110374. [ŒŽ’˜] Prognostic value of sarcopenic obesity estimated by computed tomography in patients with cardiovascular disease and undergoing surgery. Yamashita M1, Kamiya K2, Matsunaga A2, Kitamura T6, Hamazaki N4, Matsuzawa R4, Nozaki K4, Tanaka S5, Nakamura T1, Maekawa E6, Masuda T2, Ako J6, Miyaji K6: J Cardiol 2019/9; 74 (3): 273-8. (ŽR‰º^Ži1, _’JŒ’‘Ÿ˜Y2, Œ‰i“Ä•F2, –k‘º@—¥3, à_èL–Ÿ4, Œ‘ò—Ç‘Ÿ4, –ìèN•œ4, “c’†L–í5, ’†‘ºŠxŽu1, ‘OìŒb”ü6, ‘“c@‘ì2, ˆ¢ŒÃÆ6, ‹{’n@ŠÓ3: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ˆã—Éq¶Šw•”, 6S‘ŸŒŒŠÇŠO, 4ƒŠƒnƒrƒŠ•”, 5–ŒŒÃ‰®‘åŠwˆãŠw•”•‘®•a‰@, 6zŠÂŠí“à)

110375. [ŒŽ’˜] Absolute reliability of measurements of muscle strength and physical performance measures in older people with high functional capacities. Suzuki Y1, Kamide N2, Kitai Y, Ando M, Sato H2, Shiba Y2, Sakamoto M2: Eur Geriatr Med 2019/10; 10 (5): 733-40. (—é–ؗǘa1, ão’Œl2, ²“¡t•F2, ŽÄ@Šì’2, â–{”üŠì2: 1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”)

110376. [ŒŽ’˜] Impact of Gait Speed on the Obesity Paradox in Older Patients With Cardiovascular Disease. Nakamura T1, Kamiya K2, Matsunaga A2, Hamazaki N3, Matsuzawa R3, Nozaki K3, Yamashita M1, Maekawa E4, Noda C4, Yamaoka-Tojo M2, Ako J4: Am J Med 2019/12; 132 (12): 1458-65.e1. (’†‘ºŠxŽu1, _’JŒ’‘Ÿ˜Y2, Œ‰i“Ä•F2, à_èL–Ÿ3, Œ‘ò—Ç‘Ÿ3, –ìèN•œ3, ŽR‰º^Ži1, ‘OìŒb”ü4, –ì“cçt4, “ŒžŠ”ü“ÞŽq2, ˆ¢ŒÃÆ4: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ˆã—Éq¶Šw•”, 3ƒŠƒnƒrƒŠ•”, 4zŠÂŠí“à)

110377. [ŒŽ’˜] Rising time from bed in acute phase after hospitalization predicts frailty at hospital discharge in patients with acute heart failure. Nozaki K1, Hamazaki N1, Kamiya K2, Ichikawa T1, Nakamura T3, Yamashita M3, Maekawa E4, Matsunaga A2, Yamaoka-Tojo M2, Ako J4: J Cardiol 2020/6; 75 (6): 587-93. doi: 10.1016/j.jjcc.2019.12.007. Epub 2019 Dec 30. (–ìèN•œ1, à_èL–Ÿ1, _’JŒ’‘Ÿ˜Y2, Žsì‹M•¶1, ’†‘ºŠxŽu3, ŽR‰º^Ži3, ‘OìŒb”ü4, Œ‰i“Ä•F2, “ŒžŠ”ü“ÞŽq2, ˆ¢ŒÃÆ4: 1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 4zŠÂŠí“à)

110378. [ŒŽ’˜] Prevalence and prognosis of respiratory muscle weakness in heart failure patients with preserved ejection fraction. Hamazaki N1, Kamiya K2, Matsuzawa R1, Nozaki K3, Ichikawa T1, Tanaka S4, Nakamura T5, Yamashita M5, Maekawa E6, Noda C6, Yamaoka-Tojo M2, Matsunaga A2, Masuda T2, Ako J6: Respir Med 2020/1; 161: 105834. (à_èL–Ÿ1, _’JŒ’‘Ÿ˜Y2, Œ‘ò—Ç‘Ÿ1, –ìèN•œ3, Žsì‹M•¶1, “c’†L–í4, ’†‘ºŠxŽu5, ŽR‰º^Ži5, ‘OìŒb”ü6, –ì“cçt6, “ŒžŠ”ü“ÞŽq2, Œ‰i“Ä•F2, ‘“c@‘ì2, ˆ¢ŒÃÆ6: 1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3•ºŒÉˆã—ÑåŠw, 4–ŒŒÃ‰®‘åŠwˆãŠw•”•‘®•a‰@, 5‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 6zŠÂŠí“à)

110379. [ŒŽ’˜] Association between sarcopenia and atherosclerosis in elderly patients with ischemic heart disease. Uchida S1, Kamiya K2, Hamazaki N3, Matsuzawa R3, Nozaki K3, Ichikawa T3, Suzuki Y1, Nakamura T1, Yamashita M1, Kariya H3, Maekawa E4, Yamaoka-Tojo M2, Matsunaga A2, Ako J4: Heart Vessels 2020/6; 35 (6): 769-75. doi: 10.1007/s00380-020-01554-8. Epub 2020 Jan 22. (“à“cãđŸ1, _’JŒ’‘Ÿ˜Y2, à_èL–Ÿ3, Œ‘ò—Ç‘Ÿ3, –ìèN•œ3, Žsì‹M•¶3, —é–Ø—T‘Ÿ1, ’†‘ºŠxŽu1, ŽR‰º^Ži1, Š¡’J‰p‹I3, ‘OìŒb”ü4, “ŒžŠ”ü“ÞŽq2, Œ‰i“Ä•F2, ˆ¢ŒÃÆ4: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ˆã—Éq¶Šw•”, 3ƒŠƒnƒrƒŠ•”, 4zŠÂŠí“à)

110380. [ŒŽ’˜] A portable pneumatic compression device to prevent venous thromboembolism in orthopedic patients with the highest risks of both venous thrombosis and bleeding: A case series study. Takahashi Y1, Takahira N2, Shibuya M1,3, Uchiyama K4, Fukushima K4, Iwase D4, Kawamura T4, Miyagi M4, Higashiyama R4, Moriya M4, Sakai K1, Tsuda K1, Sakamoto M2, Akamine A5, Takaso M4: J Orthop Surg (Hong Kong) 2020/1-4; 28 (1): 2309499020905711. doi: 10.1177/2309499020905711. (‚‹Ž‰Àô1, ‚•œ®L2, àF’J^1,3, “àŽRŸ•¶4, •Ÿ“‡Œ’‰î4, Šâ£@‘å4, ‰Í‘º@’Œ4, ‹{é³s4, “ŒŽR—玡4, X’JŒõr4, âˆäŒ’‘Ÿ1, ’ÓcWŽi1, â–{”üŠì2, Ô—䑏•F5, ‚‘Š»Žm4: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ˆã—Éq¶Šw•”, 3ƒŠƒnƒrƒŠ•”, 4®ŠO, 5–òÜ•”)

110381. [ŒŽ’˜] The maximal gait speed is a simple and useful prognostic indicator for functional recovery after total hip arthroplasty. Shibuya M1,2, Nanri Y1, Kamiya K3, Fukushima K4, Uchiyama K4, Takahira N3, Takaso M4, Fukuda M3, Matsunaga A3: BMC Musculoskelet Disord 2020/2; 21 (1): 84. (àF’J^1,2, “ì—¢—C‘Ÿ1, _’JŒ’‘Ÿ˜Y3, •Ÿ“‡Œ’‰î4, “àŽRŸ•¶4, ‚•œ®L3, ‚‘Š»Žm4, •Ÿ“c—Ï–ç3, Œ‰i“Ä•F3: 1ƒŠƒnƒrƒŠ•”, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3ˆã—Éq¶Šw•”, 4®ŠO)

110382. [ŒŽ’˜] Changes in Respiratory Muscle Strength Following Cardiac Rehabilitation for Prognosis in Patients with Heart Failure. Hamazaki N1, Kamiya K2, Yamamoto S3, Nozaki K1, Ichikawa T1, Matsuzawa R1, Tanaka S4, Nakamura T3, Yamashita M3, Maekawa E5, Meguro K5, Noda C5, Yamaoka-Tojo M2, Matsunaga A2, Ako J5: J Clin Med 2020/3; 9 (4): 952. (à_èL–Ÿ1, _’JŒ’‘Ÿ˜Y2, ŽR–{®•œ3, –ìèN•œ1, Žsì‹M•¶1, Œ‘ò—Ç‘Ÿ1, “c’†L–í4, ’†‘ºŠxŽu3, ŽR‰º^Ži3, ‘OìŒb”ü5, –ڍ•Œ’‘Ÿ˜Y5, –ì“cçt5, “ŒžŠ”ü“ÞŽq2, Œ‰i“Ä•F2, ˆ¢ŒÃÆ5: 1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 4–ŒŒÃ‰®‘åŠwˆãŠw•”•‘®•a‰@, 5zŠÂŠí“à)

110383. [ŒŽ’˜] Prognostic value of instrumental activity of daily living in initial heart failure hospitalization patients aged 65 years or older. Yamashita M1, Kamiya K2, Hamazaki N3, Matsuzawa R3, Nozaki K3, Ichikawa T3, Nakamura T1, Maekawa E4, Yamaoka-Tojo M2, Matsunaga A2, Ako J4: Heart Vessels 2020/3; 35 (3): 360-6. (ŽR‰º^Ži1, _’JŒ’‘Ÿ˜Y2, à_èL–Ÿ3, Œ‘ò—Ç‘Ÿ3, –ìèN•œ3, Žsì‹M•¶3, ’†‘ºŠxŽu1, ‘OìŒb”ü4, “ŒžŠ”ü“ÞŽq2, Œ‰i“Ä•F2, ˆ¢ŒÃÆ4: 1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ˆã—Éq¶Šw•”, 3ƒŠƒnƒrƒŠ•”, 4zŠÂŠí“à)

120052. [ŒŽ’˜] äF”Â’f—ôC•œppŒãŠ³ŽÒ‚ɑ΂·‚éãŽˆŒP—û‹@Ší‚Æ‚µ‚Ẵ|[ƒ^ƒuƒ‹ƒXƒvƒŠƒ“ƒOƒoƒ‰ƒ“ƒT[‚Ì—L—p«|•\–Ê‹Ø“d}‚ð—p‚¢‚œ‹ØŠˆ“®•ªÍ|. ²X–؏Gˆê1, Œ©–Ú’q‹I2, ’†àVr”V2, ‚‘Š»Žm2, •Ÿ“c—Ï–ç3, ‚•œ®L3, óˆäŒ›‹` (1ƒŠƒnƒrƒŠ•”, 2®ŠO, 3ˆã—Éq¶Šw•”): “ú–{‹`Žˆ‘•‹ïŠw‰ïŽ 2019/12; 35 (4): 297-301.

320054. [Ç—á•ñ] ã˜rœ‹ßˆÊ’[œÜ‚ɑ΂·‚élHœ“ª’uŠ·pŒã—Ö@‚Ƀ|[ƒ^ƒuƒ‹ƒXƒvƒŠƒ“ƒOƒoƒ‰ƒ“ƒT[‚ðŽg—p‚µ‚œ1—á. ²X–؏Gˆê1, Œ©–Ú’q‹I2, óˆäŒ›‹` (1ƒŠƒnƒrƒŠ•”, 2®ŠO): _“ސìì‹Æ—Ö@Œ€‹† 2020/3; 10 (1): 19-24.

522161. [uÀ]y“ÁW: S•s‘SŠ³ŽÒ‚̍œŠi‹Ø1z—Šw—Ö@Žm‚É‚æ‚鍜Ši‹Ø•]‰¿‚̃|ƒCƒ“ƒg. à_èL–Ÿ (ƒŠƒnƒrƒŠ•”): S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ 2019/6; 25 (1): 50-4.

[’˜@‘]

620112. [Šwp‘ (•ª’SŽ·•M)]yzŠÂŠíƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì—˜_‚Æ‹Zp ‰ü’ù‘æ2”ŁzV ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ (‘˜_)@‰^“®—Ö@, p.244-66. Œ–{‘ì–ç, –x“cˆêŽ÷, _’JŒ’‘Ÿ˜Y1 (1ˆã—Éq¶Šw•”), •Ò: ‘“c@‘ì1, Œ‰i“Ä•F1, ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2020/3”­s.

620113. [Šwp‘ (•ª’SŽ·•M)]yzŠÂŠíƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì—˜_‚Æ‹Zp ‰ü’ù‘æ2”ŁzV ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ (‘˜_)@ŽŸŠ³ŠÇ—‚Ì‚œ‚ß‚Ì‹³ˆçEŽw“±•û–@@…@‰^“®Žw“±‚Ì—˜_‚ÆŽÀÛ, p.274-8. –ìèN•œ1 (1ƒŠƒnƒrƒŠ•”), •Ò: ‘“c@‘ì2, Œ‰i“Ä•F2 (2ˆã—Éq¶Šw•”), ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2020/3”­s.

620114. [Šwp‘ (•ª’SŽ·•M)]yzŠÂŠíƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì—˜_‚Æ‹Zp ‰ü’ù‘æ2”ŁzV ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ (‘˜_)@lHS‘ŸEƒy[ƒXƒ[ƒJEAž‚ÝŒ^œ×“®Ší‚ð‘•’…‚µ‚œŠ³ŽÒ‚ɑ΂·‚éS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“, p.320-31. à_èL–Ÿ1 (1ƒŠƒnƒrƒŠ•”), •Ò: ‘“c@‘ì2, Œ‰i“Ä•F2 (2ˆã—Éq¶Šw•”), ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2020/3”­s.

620115. [Šwp‘ (•ª’SŽ·•M)]yzŠÂŠíƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì—˜_‚Æ‹Zp ‰ü’ù‘æ2”ŁzV ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ (‘˜_)@ŒŒ‰t“§Í‚ðŽó‚¯‚Ä‚¢‚銳ŽÒ‚ɑ΂·‚éS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“, p.332-8. Œ‘ò—Ç‘Ÿ1 (1ƒŠƒnƒrƒŠ•”), •Ò: ‘“c@‘ì2, Œ‰i“Ä•F2 (2ˆã—Éq¶Šw•”), ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2020/3”­s.

620116. [Šwp‘ (•ª’SŽ·•M)]yzŠÂŠíƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì—˜_‚Æ‹Zp ‰ü’ù‘æ2”ŁzV ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ (‘˜_)@ƒTƒ‹ƒRƒyƒjƒAEƒtƒŒƒCƒ‹‚ð‡•¹‚µ‚œŠ³ŽÒ‚ɑ΂·‚éS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“, p.339-46. _’JŒ’‘Ÿ˜Y1 (1ˆã—Éq¶Šw•”), •Ò: ‘“c@‘ì1, Œ‰i“Ä•F1, ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2020/3”­s.

620117. [Šwp‘ (•ª’SŽ·•M)] yzŠÂŠíƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì—˜_‚Æ‹Zp ‰ü’ù‘æ2”ŁzVI ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ (Še˜_)@–«S•s‘S, p.404-22. _’JŒ’‘Ÿ˜Y1, Œ‰i“Ä•F1 (1ˆã—Éq¶Šw•”), •Ò: ‘“c@‘ì1, Œ‰i“Ä•F1, ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2020/3”­s.

[Šw‰ïEŒ€‹†‰ï“™]

713148. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Change in respiratory muscle strength and adverse clinical events in patients with chronic heart failure (International Session AwardŽóÜ‰‰‘è). Hamazaki N1, Masuda T2, Kamiya K2, Matsuzawa R1, Nozaki K1, Ichikawa T1, Yamashita M3, Maekawa E4, Fukaya H4, Yamaoka-Tojo M2, Matsunaga A2, Ako J4: Asia PRevent 2019 (2019/7/13-14), Osaka, Japan. (à_èL–Ÿ1, ‘“c@‘ì2, _’JŒ’‘Ÿ˜Y2, Œ‘ò—Ç‘Ÿ1, –ìèN•œ1, Žsì‹M•¶1, ŽR‰º^Ži3, ‘OìŒb”ü4, [’J‰p•œ4, “ŒžŠ”ü“ÞŽq2, Œ‰i“Ä•F2, ˆ¢ŒÃÆ4: 1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 4zŠÂŠí“à)

713149. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Change in respiratory muscle strength predicts clinical events in patients with chronic heart failure (Nursing and Allied Health Proffesions Investigator Award Runners-Up PrizeŽóÜ‰‰‘è). Hamazaki N1, Masuda T2, Kamiya K2, Matsuzawa R1, Nozaki K1, Ichikawa T1, Tabata M3, Maekawa E4, Noda C4, Yamaoka-Tojo M2, Matsunaga A2, Ako J4: ESC Congress 2019 (2019/8/31-9/4), Paris, France. (à_èL–Ÿ1, ‘“c@‘ì2, _’JŒ’‘Ÿ˜Y2, Œ‘ò—Ç‘Ÿ1, –ìèN•œ1, Žsì‹M•¶1, “c”š@–«3, ‘OìŒb”ü4, –ì“cçt4, “ŒžŠ”ü“ÞŽq2, Œ‰i“Ä•F2, ˆ¢ŒÃÆ4: 1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3–L‹Ž‘n‘¢‘åŠw, 4zŠÂŠí“à)

713150. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Atrial fibrillation is not associated with the responses to exercise training in heart failure patients with preserved ejection fraction. Hamazaki N1, Masuda T2, Kamiya K2, Matsuzawa R1, Nozaki K1, Ichikawa T1, Tabata M3, Maekawa E4, Fukaya H4, Yamaoka-Tojo M2, Matsunaga A2, Ako J4: ESC Congress 2019 (2019/8/31-9/4), Paris, France. (à_èL–Ÿ1, ‘“c@‘ì2, _’JŒ’‘Ÿ˜Y2, Œ‘ò—Ç‘Ÿ1, –ìèN•œ1, Žsì‹M•¶1, “c”š@–«3, ‘OìŒb”ü4, [’J‰p•œ4, “ŒžŠ”ü“ÞŽq2, Œ‰i“Ä•F2, ˆ¢ŒÃÆ4: 1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3–L‹Ž‘n‘¢‘åŠw, 4zŠÂŠí“à)

713151. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Pupillary area predicts all-cause mortality in patients with cardiovascular disease. Nozaki K1, Kamiya K2, Hamazaki N1, Ichikawa T1, Nakamura T3, Yamashita M3, Maekawa E4, Matsunaga A2, Yamaoka-Tojo M2, Ako J4: ESC Congress 2019 (2019/8/31-9/4), Paris, France. (–ìèN•œ1, _’JŒ’‘Ÿ˜Y2, à_èL–Ÿ1, Žsì‹M•¶1, ’†‘ºŠxŽj3, ŽR‰º^Ži3, ‘OìŒb”ü4, Œ‰i“Ä•F2, “ŒžŠ”ü“ÞŽq2, ˆ¢ŒÃÆ4: 1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 4zŠÂŠí“à)

713152. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Kinematic analysis of trunk movements during reaching in preterm, very low birth weight and full-term infants Nomura Y1, Sato H2, Ooka M3, Kemmochi M3: 2019 American Academy for Cerebral Palsy and Developmental Medicine (2019/9/18-21), Anaheim, CA, USA. (–쑺—DŽq1, ²“¡t•F2, ‘剪–ƒ—3, çݎ@Šw3: 1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3¬Ž™)

722265. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™)yHot topics in CVD 2019zSŽŸŠ³Š³ŽÒ‚É‚š‚¯‚éŒÄ‹z‹@”\•]‰¿‚̗Տ°“IˆÓ‹`. à_èL–Ÿ (ƒŠƒnƒrƒŠ•”): ‘æ4‰ñ“ú–{SŒŒŠÇ—Šw—Ö@Šw‰ïE‘æ6‰ñ“ú–{“œ”A•a—Šw—Ö@Šw‰ï‡“¯Šwp‘å‰ï (2019/9/14), ‰«“ê.

722266. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) ƒXƒe[ƒWC‚̉^“®—Ö@‚ÌŽÀÛ. –ìèN•œ1, _’JŒ’‘Ÿ˜Y2, à_èL–Ÿ1, ’†‘ºŠxŽj3, ‘OìŠG”ü4 (1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 4zŠÂŠí“à): ‘æ23‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ï (2019/10/4-6), L“‡.

722267. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) SƒŠƒn‚ðtƒŠƒn‚ÉŠˆ‚©‚·@–«S•s‘SŠ³ŽÒ‚ɑ΂·‚é‰^“®—Ö@‚ÌŒø‰Ê‚ɐt‹@”\‚̒ቺ‚͉e‹¿‚·‚é‚©? à_èL–Ÿ (ƒŠƒnƒrƒŠ•”): ‘æ10‰ñ“ú–{t‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ï (2020/2/22), “Œ‹ž.

722268. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰“™) t‘ŸˆÚAŒã‘Šú‚©‚çs‚€‰^“®—Ö@‚ÌŒø‰Ê‚ƈÀ‘S«. Œ‘ò—Ç‘Ÿ1, ŽR–{®•œ2, Žsì‹M•¶1, Îˆä‘å•ã3, –ìŒû•¶”T4, Œ‰i“Ä•F5, ‹g“cˆê¬3,6 (1ƒŠƒnƒrƒŠ•”, 2‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 3”å”AŠí, 4ŠÅŒì•”, 5ˆã—Éq¶Šw•”, 6V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ10‰ñ“ú–{t‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ï (2020/2/22), “Œ‹ž.

723916. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) •êŽwCMŠÖßÇ‚ɑ΂·‚é–k—¢Ž®‹@”\“I‘•‹ï‚ÌŒø‰Ê‚ÌŒŸØ|ˆ³ƒZƒ“ƒT‚ð—p‚¢‚œ’è—Ê“I•ªÍ|. ²X–؏Gˆê1, ¬ÀŒ«Ž¡2, •ì_Žm2, ‘å’|—IÆ2, Œ©–Ú’q‹I2, ‚•œ®L3, ‚‘Š»Žm2 (1ƒŠƒnƒrƒŠ•”, 2®ŠO, 3ˆã—Éq¶Šw•”): ‘æ62‰ñ“ú–{ŽèŠO‰ÈŠw‰ïŠwpW‰ï (2019/4/18-19), ŽD–y.

723917. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –«Šú‚—îSŒŒŠÇŽŸŠ³Š³ŽÒ‚É‚š‚¯‚éŽè’i“I“úí¶Šˆ“®ì‚ƍ¶ŽºŠg’£”\‚ÌŒoŽž“I•Ï‰»‚ÌŠÖ˜A (YIA—DGÜŽóÜ). Š¡’J‰p‹I1, “Œé”ü“ÞŽq2, ‰“ŒŽ^ˆê1, –ì“cçt3, ŠÖªŒb”üŽq4, ‚‹Ž—R”ü4, ÂŽRW‘å5, Œ‰i“Ä•F2, ˆ¢ŒÃÆ3 (1“Œ•a‰@ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3zŠÂŠí“à, 4“Œ•a‰@ŠÅŒì•”, 5‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ55‰ñ“ú–{zŠÂŠí•a—\–hŠw‰ïŠwpW‰ï (2019/5/11-12), •Ÿ‰ª.

723918. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‰^“®—Ö@’ïR«‚ɐg‘ÌŠˆ“®—Ê‚ª’ቺ‚·‚éŒyÇƒp[ƒLƒ“ƒ\ƒ“•aŠ³ŽÒ‚Ì”ñ‰^“®Çó‚Ì“Á’¥. —é–ؗǘa1, Œ“c—²Žq1, ão’Œl2, ŽÄ@Šì’2, ì’[—ÇŽ¡1, •œ‰ê‚悵‚Ý1, ‰iˆä^‹MŽq3, ŒŽR˜a—˜3, •Ÿ“c—Ï–ç1,2 (1“Œ•a‰@ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3”]_Œo“à): ‘æ60‰ñ“ú–{_ŒoŠw‰ïŠwp‘å‰ï (2019/5/22-25), ‘åã.

723919. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŒyÇƒp[ƒLƒ“ƒ\ƒ“•aŠ³ŽÒ‚É‚š‚¯‚é”ñ‰^“®Çó‚͐g‘ÌŠˆ“®—ÊŒž­‚ð—\‘ª‚·‚éˆöŽq‚Å‚ ‚é. Œ“c—²Žq1, —é–ؗǘa1, ão’Œl2, ŽÄ@Šì’2, ì’[—ÇŽ¡1, •œ‰ê‚悵‚Ý1, ‰iˆä^‹MŽq3, ŒŽR˜a—˜3, •Ÿ“c—Ï–ç1,2 (1“Œ•a‰@ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3”]_Œo“à): ‘æ60‰ñ“ú–{_ŒoŠw‰ïŠwp‘å‰ï (2019/5/22-25), ‘åã.

723920. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆÛŽŠúSŒŒŠÇŽŸŠ³Š³ŽÒ‚É‚š‚¯‚éŠO—ˆS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚ÍŽè’i“I“úí¶Šˆ“®ì‚ðŒüã‚³‚¹‚é. Š¡’J‰p‹I1, “ŒžŠ”ü“ÞŽq2, ‰“ŒŽ^ˆê1, –ì“cçt3, ŠÖªŒb”üŽq4, ‚‹Ž—R”ü4, ÂŽRW‘å5, “ï”g‘–퍁3, ŒSŽRŒbŽq3, Œ‰i“Ä•F2, ˆ¢ŒÃÆ3 (1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3zŠÂŠí“à, 4“Œ•a‰@ŠÅŒì•”, 5‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ25‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ï (2019/7/13), ‘åã.

723921. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚—îS•s‘SŠ³ŽÒ‚É‚š‚¯‚鏉‰ñ—£°Žž‚̃xƒbƒh‚©‚ç‚Ì‹N‚«ã‚ª‚莞ŠÔ‚Í‘Þ‰@Žž‚̃tƒŒƒCƒ‹‚ð—\‘ª‚·‚é. –ìèN•œ1, _’JŒ’‘Ÿ˜Y2, à_èL–Ÿ1, Œ‘ò—Ç‘Ÿ1, Žsì‹M•¶1, ’†‘ºŠxŽj3, ŽR‰º^Ži3, ‘OìŠG”ü4, Œ‰i“Ä•F2, ‘“c@‘ì2, ˆ¢ŒÃÆ4 (1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 4zŠÂŠí“à): ‘æ25‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ï (2019/7/13-14), ‘åã.

723922. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ˆÛŽŠúSŒŒŠÇŽŸŠ³Š³ŽÒ‚É‚š‚¯‚éŠO—ˆS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚ÍŽè’i“I“úí¶Šˆ“®ì‚ðŒüã‚³‚¹‚é. Š¡’J‰p‹I1, “ŒžŠ”ü“ÞŽq2, ‰“ŒŽ^ˆê1, –ì“cçt3, ŠÖªŒb”üŽq4, ‚‹Ž—R”ü4, ÂŽRW‘å5, “ï”g‘–퍁3, ŒSŽRŒbŽq3, Œ‰i“Ä•F2, ˆ¢ŒÃÆ3 (1“Œ•a‰@ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3zŠÂŠí“à, 4“Œ•a‰@ŠÅŒì•”, 5‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): ‘æ25‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ï (2019/7/13-14), ‘åã.

723923. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‹}«‘å“®–¬‰ð—£Š³ŽÒ‚É‚š‚¯‚é‘Þ‰@Žž‰^“®‹@”\‚ÉŠÖ‚·‚錟“¢: ‹}«Š¥ÇŒóŒQ‚Æ‚Ì”çŠp. Žsì‹M•¶1, _’JŒ’‘Ÿ˜Y2, à_›œL–Ÿ1, Œ‘ò—Ç‘Ÿ1, –ìèN•œ1, ’†‘ºŠxŽj3, ŽR‰º^Ži3, ™–썁“ÞŽq1, Šâ‘º‹MŽq1, ‘OìŒb”ü4, “ŒžŠ”ü“ÞŽq2, –ì“cçt4, Œ‰i“Ä•F2, ‘“c@‘ì2, ˆ¢ŒÃÆ4 (1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 4zŠÂŠí“à): ‘æ25‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ï (2019/7/13-14), ‘åã.

723924. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) œ‘e頏NJ³ŽÒ‚É‚š‚¯‚鍘’É‚É‹Nˆö‚·‚é•àsáŠQ‚Æ‹Ø“÷—Ê‚ÌŠÖ˜A. “ì—¢—C‘Ÿ1, Œ©ˆä“c˜a³1, ŒŠÛƒ‰À1, àF’J^, ŽO•œ—º‘Ÿ1, ‹{é³s2, ˆäã@Œº2, ’†àVr”V2, ˆä‘º‹M”V2, âV“¡@˜j2, ”’àV‰hŽ÷2, ‚‘Š»Žm2 (1ƒŠƒnƒrƒŠ•”, 2®ŠO): ‘æ27‰ñ“ú–{˜’ÉŠw‰ï (2019/9/13-14), _ŒË.

723925. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –«S•s‘SŠ³ŽÒ‚É‚š‚¯‚鍜Ši‹Ø—Ê‚ÌŒž­‚Í1”NŒã‚̍¶ŽºS‹Ød—Ê‚Ì‘‰Á‚ð—\‘ª‚·‚é. ‰Á“¡—m•œ1, ÂŽRW‘å1, ’·“cŒ’Æ1, —MŽRž”Í1, ‰“ŒŽ^ˆê2, Š¡’J‰p‹I3, _’JŒ’‘Ÿ˜Y4, ˆ¢ŒÃÆ5, Œ‰i“Ä•F4, “ŒžŠ”ü“ÞŽq4 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2“Œ•a‰@ƒŠƒnƒrƒŠ•”, 3ƒŠƒnƒrƒŠ•”, 4ˆã—Éq¶Šw•”, 5zŠÂŠí“à): ‘æ4‰ñ“ú–{SŒŒŠÇ—Šw—Ö@Šw‰ïE‘æ6‰ñ“ú–{“œ”A•a—Šw—Ö@Šw‰ï‡“¯Šwp‘å‰ï (2019/9/14), ‰«“ê.

723926. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “µE–ʐς͐S•s‘SŠ³ŽÒ‚Ì—\Œã‚ð—\‘ª‚·‚éV‚œ‚ÈŽw•W‚Å‚ ‚é (YIAÅ—DGÜŽóÜ). –ìèN•œ1, _’JŒ’‘Ÿ˜Y2, à_èL–Ÿ1, ’†‘ºŠxŽj3, ŽR‰º^Ži3, ‘OìŠG”ü4, Œ‰i“Ä•F2, “ŒžŠ”ü“ÞŽq2, ˆ¢ŒÃÆ4 (1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 4zŠÂŠí“à): ‘æ23‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ï (2019/10/4-6), L“‡.

723927. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ‚—î‹•ŒŒ«SŽŸŠ³Š³ŽÒ‚É‚š‚¯‚éŽè’i“I“úí¶Šˆ“®ì‚ÌŽÀsó‹µ‚Í‚»‚ÌŒã‚̐S•s‘S“ü‰@‚ɉe‹¿‚·‚é. Š¡’J‰p‹I1, “ŒžŠ”ü“ÞŽq2, ‰“ŒŽ^ˆê3, –ìèN•œ1, –ì“cçt4, ŒSŽRŒbŽq4, ŠÖªŒb”üŽq5, ‚‹Ž—R”ü5, Œ‰i“Ä•F2, ˆ¢ŒÃÆ4 (1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3“Œ•a‰@ƒŠƒnƒrƒŠ•”, 4zŠÂŠí“à, 5“Œ•a‰@ŠÅŒì•”): ‘æ23‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ï (2019/10/4-6), L“‡.

723928. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) lHŒÒŠÖß’uŠ·pŒãŠ³ŽÒ‚É‚š‚¯‚éŒÒŠÖßŠO“]‹Ø—͂̉ñ•œ‚ɉe‹¿‚ð‹y‚Ú‚·ˆöŽq‚ÌŒŸ“¢. àF’J^1, “ì—¢—C‘Ÿ1, •Ÿ“‡Œ’‰î2, “àŽRŸ•¶2, ‚•œ®L3, ‚‘Š»Žm2 (1ƒŠƒnƒrƒŠ•”, 2®ŠO, 3ˆã—Éq¶Šw•”): ‘æ46‰ñ“ú–{ŒÒŠÖßŠw‰ïŠwpW‰ï (2019/10/25-26), ‹{è.

723929. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) lHŒÒŠÖß‘S’uŠ·pŠ³ŽÒ‚É‚š‚¢‚ÄŽèp‘O‚̉h—{•s—ǂ͏pŒã‘Šú‚Ì•àsŠl“Ÿ‚ð’x‰„‚³‚¹‚é. “ì—¢—C‘Ÿ1, àF’J^1, •Ÿ“‡Œ’‰î2, “àŽRŸ•¶2, ‚•œ®L3, ‚‘Š»Žm2 (1ƒŠƒnƒrƒŠ•”, 2®ŠO, 3ˆã—Éq¶Šw•”): ‘æ46‰ñ“ú–{ŒÒŠÖßŠw‰ïŠwpW‰ï (2019/10/25-26), ‹{è.

723930. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŒyÇƒp[ƒLƒ“ƒ\ƒ“•aŠ³ŽÒ‚̐g‘Ì‹@”\‚š‚æ‚ÑQOL‚ɑ΂·‚鋳ˆç“I—Šw—Ö@ƒvƒƒOƒ‰ƒ€‚Ì—L—p«. —é–ؗǘa1, Œ“c—²Žq1, ão’Œl2, ŽÄ@Šì’2, ì’[—ÇŽ¡1, •œ‰ê‚悵‚Ý1, ‰iˆä^‹MŽq3, ŒŽR˜a—˜3, •Ÿ“c—Ï–ç2 (1“Œ•a‰@ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3”]_Œo“à): ‘æ3‰ñ“ú–{ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ˆãŠw‰ïH‹GŠwpW‰ï (2019/11/15-17), Ã‰ª.

723931. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ’Ž’áo¶‘̏dŽ™‚Ì”­’BƒtƒHƒ[ƒAƒbƒv‚É‚š‚¯‚éƒAƒ‹ƒo[ƒ^“û—cŽ™‰^“®”­’BŒŸž–@‚ÌŽg—p|V”Å‚jŽ®ŒŸž‚ÌŒ‹‰Ê‚Æ‚Ì”äŠr|. –쑺—DŽq1, …–ìŒö•ã1, à_èL–Ÿ1, ’†‰€“NŽ¡1, ’ÍèS–ç2, Œì@‰p2, ‘剪–ƒ—3, Œ•Ž@Šw3, •Ÿ“c—Ï–ç1,4 (1ƒŠƒnƒrƒŠ•”, 2—Տ°S—Žº, 3¬Ž™, 4ˆã—Éq¶Šw•”): ‘æ6‰ñ“ú–{¬Ž™—Šw—Ö@Šw‰ï (2019/11-16-17), •Ÿ‰ª.

723932. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŠO—ˆŒyÇƒp[ƒLƒ“ƒ\ƒ“•aŠ³ŽÒ‚É‚š‚¯‚é‰^“®—Ö@‘OŒã‚ÌQOL•Ï‰»‚É‚Í”ñ‰^“®Çó‚ªŠÖ˜A‚·‚é. Œ“c—²Žq1, —é–ؗǘa1, ão’Œl2, ŽÄ@Šì’2, ì’[—ÇŽ¡1, •œ‰ê‚悵‚Ý1, ‰iˆä^‹MŽq3, ŒŽR˜a—˜3, •Ÿ“c—Ï–ç2 (1“Œ•a‰@ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”, 3”]_Œo“à): ‘æ6‰ñ“ú–{’nˆæ—Šw—Ö@Šw‰ïŠwp‘å‰ï (2019/12/14-15), ‹ž“s.

723933. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) æs“ItˆÚAŠ³ŽÒ‚É‚š‚¯‚錒NŠÖ˜AQOL‚Ɛg‘ÌŠˆ“®—ʂ̈ڐA‘OŒã•Ï‰». Žsì‹M•¶1, Œ‘ò—Ç‘Ÿ2, ŽR–{®•œ3, –ìŒû•¶–ì4, ˆä‘º—L•P4, Îˆä‘å•ã5, ‹g“cˆê¬5,6 (1ƒŠƒnƒrƒŠ•”, 2•ºŒÉˆã—ÑåŠw, 3‘åŠw‰@ˆã—ÃŒ€‹†‰È, 4ŠÅŒì•”, 5”å”AŠí, 6V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ53‰ñ“ú–{—Տ°tˆÚAŠw‰ï (2020/2/19-21), “Œ‹ž.

723934. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) –{–M‚É‚š‚¯‚étˆÚA‘Ò‹@ŽÒ‚̐g‘Ì‹@”\‚Ɛg‘ÌŠˆ“®—Ê‚ÉŠÖ‚·‚éŽÀ‘Ô’²ž|’nˆæÝZŽÒ‚Æ‚Ì”äŠr|. ²“¡ˆ»‰Ô1, ŽR–{®•œ1, Œ‘ò—Ç‘Ÿ2, Žsì‹M•¶2, Îˆä‘å•ã3, –ìŒû•¶”T4, –k“‡˜aŽ÷3, åŒŽ–ƒ—FŽq5, _’JŒ’‘Ÿ˜Y6, Œ‰i“Ä•F6, ‹g“cˆê¬3,7 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ƒŠƒnƒrƒŠ•”, 3”å”AŠí, 4ŠÅŒì•”, 5t‘Ÿ“à, 6ˆã—Éq¶Šw•”, 7V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ10‰ñ“ú–{t‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ï (2020/2/22), “Œ‹ž.

723935. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¶Žº•â•lHS‘ŸAž‚ݏp‘O‚̐S•s‘SŠ³ŽÒ‚ɑ΂·‚é‰^“®—Ö@‚̈À‘S«‚ÆŒø‰Ê. à_èL–Ÿ1, –k‘º@—¥2, ¬–с@’3, ’†“‡ßŽq4, ‘OìŒb”ü3, –ìèN•œ1, Žsì‹M•¶1, ŒÜ\—’ˆŸŠóŽq4, ™–썁“ÞŽq4, ŽR–{˜ÐŽq4, _’JŒ’‘Ÿ˜Y5, ˆ¢ŒÃÆ3, ‹{’n@ŠÓ2 (1ƒŠƒnƒrƒŠ•”, 2S‘ŸŒŒŠÇŠO, 3zŠÂŠí“à, 4ŠÅŒì•”, 5ˆã—Éq¶Šw•”): ‘æ48‰ñlHS‘Ÿ‚ƕ⏕zŠÂ§˜b‰ïŠwpW‰ï (2020/2/28-29), ŽD–y.

732157. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (‹³ˆçƒZƒ~ƒi[) —Šw—Ö@Žm‚ªŠ©‚ß‚é—Տ°Œ€‹†. à_èL–Ÿ (ƒŠƒnƒrƒŠ•”): “ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ï‘æ4‰ñŠÖ“ŒbM‰zŽx•”’n•û‰ï (2019/9/21), VŠƒ.

733785. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) tˆÚAŒã‘Šú‚©‚ç‚̉^“®—Ö@‚É‚æ‚ég‘Ì‹@”\‚̉ü‘P. ŽR–{®•œ1, Œ‘ò—Ç‘Ÿ2, Îˆä‘å•ã3, –ìŒû•¶”T4, Žu‘º‘sˆê˜N3, –k“‡˜aŽ÷3, åŒŽ–ƒ—F5, Œ‰i“Ä•F6, ‹g“cˆê¬3,7 (1‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 2ƒŠƒnƒrƒŠ•”, 3”å”AŠí, 4ŠÅŒì•”, 5t‘Ÿ“à, 6ˆã—Éq¶Šw•”, 7V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ97‰ñ_“ސìtŒ€‹†‰ï‘‰ïEŒ€‹†W‰ï (2019/6/1), ‰¡•l.

733786. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‰ñ•œŠúƒŠƒn•a“‚É‚š‚¯‚é‘ŒEŽí˜AŒg‚ð‹­‰»‚µ‚œTransfer Package‚É‚æ‚薃ბ€ãŽˆ‚ÌŽg—p•p“x‚ªŒüã‚µ‚œ1Ç—á. Îˆä‚ä‚œ1, ²X–؏Gˆê1, ‘º”öç‰ØŽq1, ‘O“c”ü¹Ž÷1, _•Û•‘¥1, •Ÿ“c—Ï–ç2 (1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”): ‘æ17‰ñ_“ސ쌧ì‹Æ—Ö@Šw‰ï (2019/7/21), ‰¡•l.

733787. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‰ñ•œŠú•a“‚É‚ÄŽá”N«”][ÇŽÒ‚ɑ΂µ, Ý‘î•œ‹A‚ƎЉïŽQ‰Á‚ð–ÚŽw‚µ–{l‚Æ•ƒ‚ªˆÀ’肵‚œ¶Šˆ‚ðŠl“Ÿ‚µ‚œÇ—á. ‘O“c”ü¹Ž÷1, ²X–؏Gˆê1, ¬—шŸ—¢1, Îˆä‚ä‚œ1, ¬ŒŽ—R‹M1, _•Û•‘¥1, ³–ØàôŽq2, •Ÿ“c—Ï–ç3 (1ƒŠƒnƒrƒŠ•”, 2–k—¢‘åŠwƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‰È, 3ˆã—Éq¶Šw•”): ‘æ17‰ñ_“ސ쌧ì‹Æ—Ö@Šw‰ï (2019/7/21), ‰¡•l.

733788. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ”]ŽîᇏpŒã‚̐‹s‹@”\áŠQ‚É‚æ‚è‰ÆŽ–‚ƈ玙‚ª¢“ï‚Æ‚È‚Á‚œÇ—á‚ɑ΂µ’nˆæ˜AŒg‚Ì‹­‰»‚ð}‚èˆÀ’肵‚œÝ‘Šˆ‚ÉŽŠ‚Á‚œˆêÇ—á. “cŒû°‹M1, ²X–؏Gˆê1, ŒˆäˆŸ¹”ü1, ç—tŽü•œ1, _•Û•‘¥1 (1ƒŠƒnƒrƒŠ•”): ‘æ17‰ñ_“ސ쌧ì‹Æ—Ö@Šw‰ï (2019/7/21), ‰¡•l.

733789. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) TissueExpander‚ð—˜—p‚µ‚œˆêŽŸ“û–[ÄŒšpŒã‚̃ŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚É‚š‚¯‚é“Á’¥. ’|“àŠ°l1, _•Û•‘¥1, “c“‡@ç1, ŽR–{–Ÿ”ü1, ‚‹Ž‘ãŽq2, •Ÿ“c—Ï–ç2 (1ƒŠƒnƒrƒŠ•”, 2ˆã—Éq¶Šw•”): ‘æ17‰ñ_“ސ쌧ì‹Æ—Ö@Šw‰ï (2019/7/21), ‰¡•l.

733790. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) äF”‘åEL”͈͒f—ôŽÒ‚̏pŒã3`6ƒ–ŒŽ‚ÌŠOù‹Ø—͂̐„ˆÚ‚ƗՏ°Çó‚ÌŠÖ˜A«. ²X–؏Gˆê1, Œ©–Ú’q‹I2, ’|“àŠ°l1, _•Û•‘¥1, –Œ‘q’Œd2, ’†˜e[Í2, •Ÿ“c—Ï–ç3, ‚•œ®L3, ‚‘Š»Žm2 (1ƒŠƒnƒrƒŠ•”, 2®ŠO, 3ˆã—Éq¶Šw•”): ‘æ16‰ñŒš‚̉^“®‹@”\Œ€‹†‰ï (2019/10/25-26), ’·–ì.

733791. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) äF”C•œp‘OŒã‚ÌŒšŠÖß‹ü‹ÈE‰º‚ˆÝŠOù‹Ø—Í”ä‚Æáu’É‚Æ‚ÌŠÖ˜A. ’|“àŠ°l1, Œ©–Ú’q‹I2, ²X–؏Gˆê1, _•Û•‘¥1, ’†àVr”V2, ‚‘Š»Žm2, •Ÿ“c—Ï–ç3 (1ƒŠƒnƒrƒŠ•”, 2®ŠO, 3ˆã—Éq¶Šw•”): ‘æ16‰ñŒš‚̉^“®‹@”\Œ€‹†‰ï (2019/10/25-26), ’·–ì.

733792. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ’m‚Á‚Ä‚š‚­‚ׂ«Š³ŽÒˆÚ‘—‹Zp. _•Û•‘¥ (ƒŠƒnƒrƒŠ•”): 2019”N“x—Տ°ŒŸž‹ZŽt‚Ì‚œ‚߂̃xƒbƒhƒTƒCƒhŽÀ‘HuK‰ï (2019/10/5-6) ‘Š–Í‘å–ì.

733793. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “ú–{‚Ɛ¢ŠE‚̍ì‹Æ—Ö@‚Ì“®Œü. _•Û•‘¥ (ƒŠƒnƒrƒŠ•”): “ú–{ì‹Æ—Ö@Žm‹Š‰ïŒ»EŽÒuK‰ï (2019/11/23), ‰¡•l.

733794. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “ú–{ì‹Æ—Ö@Žm‹Š‰ï—Տ°ŽÀKŽw“±ŽÒuK‰ï. _•Û•‘¥ (ƒŠƒnƒrƒŠ•”): “ú–{ì‹Æ—Ö@Žm‹Š‰ï—Տ°ŽÀKŽw“±ŽÒuK‰ï (2019/12/7-8), ¬“cŒŽ.

733795. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) “ú–{ì‹Æ—Ö@Žm‹Š‰ï—Տ°ŽÀKŽw“±ŽÒuK‰ï. _•Û•‘¥ (ƒŠƒnƒrƒŠ•”): “ú–{ì‹Æ—Ö@Žm‹Š‰ï—Տ°ŽÀKŽw“±ŽÒuK‰ï (2020/1/25-26), ¬“cŒŽ.


‰h—{•”

[Šwp˜_•¶]

120053. [ŒŽ’˜] tˆÚAƒŒƒVƒsƒGƒ“ƒg‚É‚š‚¯‚éˆÚA‘OOGTTŒ‹‰Ê‚Ɖh—{Šw“IŽw•W‚ÌŒŸ“¢. ‹g“c•üŽq1, —с@“N”Í2, Îˆä‘å•ã3, –ìŒû•¶”T4, ²“¡ÆŽq1, Žµ—¢áÁ‹`2, ‹g“cˆê¬2,5 (1‰h—{•”, 2“à•ª”å‘ãŽÓ“à, 3”å”AŠí, 4ŠÅŒì•”, 5V¢‹Iˆã—ÁEæ’[ˆã—Ã): “ú–{•a‘Ô‰h—{Šw‰ïŠw‰ïŽ 2019/10; 22 (4): 245-51.

522162. [uÀ]y“ÁW: ‚¢‚ÜŠw‚Ñ‚È‚š‚µ‚œ‚¢! “§Íƒi[ƒX‚É•K—v‚ȘV”NŠÅŒì‚Ì’mŽ¯‚Æ‹Zpz<“ÁW3> ‹Zp•Ò: ‰Æ‘°‚ðŠª‚«ž‚Þ! ‚—ÍŠ³ŽÒ‚Ì“úí¶Šˆ‚ðŽx‚Š‚éƒPƒA@2. HŽ–ŠÇ—. ‹g“c•üŽq (‰h—{•”): “§ÍƒPƒA 2019/9; 25 (10): 929-31.

522163. [uÀ]y“ÁW: ‚Ç‚€‚·‚é!?@”D•w‚̉h—{ŠÇ—E‰h—{Žw“±|”DP‡•¹Ç‚ւ̑Ήž‚ðŠÜ‚߂āz”DP“œ”A•aŠ³ŽÒ‚ɑ΂·‚é‰h—{Žw“±‚̃|ƒCƒ“ƒg. lŒ©–ƒ”üŽq (‰h—{•”): —Տ°‰h—{ 2019/11; 135 (6): 789-96.

522164. [uÀ]y“ÁW1zƒRƒ“ƒrƒj, ƒX[ƒp[‚ÌŠˆ—p–@. lŒ©–ƒ”üŽq (‰h—{•”): ŒŽŠ§“œ”A•aƒ‰ƒCƒt‚³‚©‚Š 2019/12 59 (12): 5-16.

522165. [uÀ]y˜AÚz“œ”A•a—×{Žw“±Žm”F’è‹@\ƒjƒ…[ƒX [204]. lŒ©–ƒ”üŽq (‰h—{•”): ŒŽŠ§“œ”A•aƒ‰ƒCƒt‚³‚©‚Š 2019/12 59 (12): 55.

[’˜@‘]

620118. [Šwp‘ (•ª’SŽ·•M)]yzŠÂŠíƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì—˜_‚Æ‹Zp ‰ü’ù‘æ2”ŁzV ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ (‘˜_)@ŽŸŠ³ŠÇ—‚Ì‚œ‚ß‚Ì‹³ˆçEŽw“±•û–@@…A‰h—{ŠÇ—Žw“±‚Ì—˜_‚ÆŽÀÛ, p.279-84. ‹ß“¡‰{Žq1 (1‰h—{•”), •Ò: ‘“c@‘ì2, Œ‰i“Ä•F2 (2ˆã—Éq¶Šw•”), ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 2020/3”­s.

[Šw‰ïEŒ€‹†‰ï“™]

713153. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Multidisciplinary Predialysis Team education for patients with Diabetes Nephropathy reduced cost for admission at the induction of hemodialysis and subsequent mortality. Hitomi M1, Sato T1, Moriya T2: American Diabetes Association 79th Scientific Sessions (‘æ79‰ñ•Ä‘“œ”A•aŠw‰ï) (2019/6/7-11), San Francisco, USA, Diabetes 2019/6; 1: A174. (lŒ©–ƒ”üŽq1, ²“¡ÆŽq1, Žç‰®’B”ü2: 1‰h—{•”, 2Œ’NŠÇ—ƒZ)

722269. [Šw‰ï (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) ƒTƒ‹ƒRƒyƒjƒA‚ɑ΂·‚郌ƒ“ƒoƒ`ƒjƒu“±“üŽž‚̉h—{—Ö@‚Ì•K—v«. ‹e’r“Þ•äŽq1, ‹›“ˆ°‹I2, “ú‚@‰›2 (1‰h—{•”, 2Á‰»Ší“à): ‘æ26‰ñ“ú–{–å–¬ˆ³˜ŽiÇŠw‰ï‘‰ï (2019/9/12-13), ‰ºŠÖ, ‘æ26‰ñ“ú–{–å–¬ˆ³˜ŽiÇŠw‰ï‘‰ïƒvƒƒOƒ‰ƒ€Ž˜^ 2019/8; 25 (3): 117.

722270. [Šw‰ï (‘S‘)] (•ŽYŽtW’†uÀ)y–Ÿ“ú‚©‚ç‚Ì“œ‘ãŽÓˆÙí”D•w‚̃PƒA‚ɐ¶‚©‚¹‚é‰h—{Žw“±z“œ‘ãŽÓˆÙí”D•w‚̐HŽ–—Ö@‚ÌŽÀÛ. lŒ©–ƒ”üŽq (‰h—{•”): ‘æ35‰ñ“ú–{“œ”A•aE”DPŠw‰ï”NŽŸŠwpW‰ï (2019/11/22), “Œ‹ž, “œ”A•a‚Æ”DP 2019/10; 19 (3): 25.

722271. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‘œEŽí‚ōs‚€tˆÚAƒŒƒVƒsƒGƒ“ƒg‚̉h—{‚ƃŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“. ‹g“c•üŽq1, Îˆä‘å•ã2, –ìŒû•¶”T3, ˆä‘º—[•P3, X‰ª—DŽq1, ‹v•Û“cˆ€”ü1, –k“‡˜aŽ÷2, ˆ¢•”“N–ç4, ’|“àN—Y4, ‹g“cˆê¬2,5 (1‰h—{•”, 2”å”AŠí, 3ŠÅŒì•”, 4t‘Ÿ“à, 5V¢‹Iˆã—ÁEæ’[ˆã—Ã): ‘æ10‰ñ“ú–{t‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ï (2020/2/22), “Œ‹ž, ‘æ10‰ñ“ú–{t‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŽ˜^W (WebŒfÚ) 2020/1; p.25.

723936. [Šw‰ï (‘S‘)] (ˆê”ʉ‰‘è) V‹KˆÛŽŒŒ‰t“§Í‚ÌŒv‰æ“±“ü‚Ì—L–³‚ª‰h—{ŠÇ—‚É‹y‚Ú‚·‰e‹¿‚ÌŒŸ“¢. ‹g“c•üŽq1, ÂŽR“ŒŒÜ2, X‰ª—DŽq1, ³–Ø‹M‹³2, “à“¡³‹g2, ²–ì@—²2, ’|“àN—Y2 (1‰h—{•”, 2t‘Ÿ“à): ‘æ64‰ñ“ú–{“§ÍˆãŠw‰ïŠwpW‰ïE‘‰ï (2019/6/29), ‰¡•l, ‘æ64‰ñ“ú–{“§ÍˆãŠw‰ïŽ˜^W (WebŒfÚ) 2019/6.

723937. [Šw‰ï (‘S‘)] (—v–]‰‰‘è) ’·ŠúICUÝŽº‹~‹}Š³ŽÒ‚É‚š‚¯‚é’`”’Ž¿“Š—^—ʂƐg‘Ì‹@”\‚É—^‚Š‚é‰e‹¿. [‘ò²ŒbŽq1, •Ð‰ª—Sˆê2, Žç‰®—¢¹1, ‰““¡¬Žq1, ‹yì‚ ‚ž‚³1, ‹{è“¹‹P3, “c‘º’qŽq4, –x²‰lŽq5, ‘Ÿ“cŽ¡‘ã5, ¬–ì—Ç‘Ÿ6, ³–؈ǓÞ6, ‘åìŒŽ—TŽ÷7, ²“¡ÆŽq1, ó—˜@–õ2 (1‰h—{•”, 2‹~–œ, 3ƒŠƒnƒrƒŠ•”, 4ˆã—Éq¶Šw•”, 5ŠÅŒì•”, 6—ÕŒŸ•”, 7–òÜ•”): ‘æ35‰ñ“ú–{—Տ°‰h—{‘ãŽÓŠw‰ïŠwpW‰ï (2020/2/28), Ž†–ÊŠJÃ, ‘æ35‰ñ“ú–{—Տ°‰h—{‘ãŽÓŠw‰ïŠwpW‰ïƒvƒƒOƒ‰ƒ€W 2020/1; 35: 051-4.

733796. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‚»‚ê‚Œ‚ê‚̐³‰ð‚ÉŒü‚¯‚œŽŽsöŒë‚ÌŽx‰‡. lŒ©–ƒ”üŽq (‰h—{•”): “œ”A•aŽ¡—ÃXƒLƒ‹ƒAƒbƒvƒZƒ~ƒi[ (2019/7/5), ç—t.

733797. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‘œEŽí‰î“ü‚Í“œ”A•a«tÇ (tÇ) Š³ŽÒ‚Ì“§Í“±“üŽž‚ɗǍD‚ÈŒø‰Ê‚ð‚à‚œ‚ç‚·‚©. lŒ©–ƒ”üŽq1, ²“¡ÆŽq1, Žç‰®’B”ü2 (1‰h—{•”, 2Œ’NŠÇ—ƒZ): “Œ‹ž—Տ°“œ”A•aˆã‰ï (2019/7/27), “Œ‹ž.

733798. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‚—î’×ᇐ«‘å’°‰ŠŠ³ŽÒ‚̉h—{ŠÇ—‚ɂ‚¢‚Ä. ‘Ÿ“c—TŽq (‰h—{•”): ‘æ26‰ñ_“ސìIBDŒ€‹†‰ï (2019/10/3), ‰¡•l.

733799. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) Ç—ጟ“¢‰ï. lŒ©–ƒ”üŽq (‰h—{•”): ‚³‚ª‚Ý“œ”A•aƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2019/10/25), ‘Š–ÍŒŽ.

733800. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ”DP“œ”A•a‚̉h—{ŠÇ—. lŒ©–ƒ”üŽq (‰h—{•”): ’¹ŽæŒ§’†‰›•a‰@E“œ”A•a—×{Žw“±uK‰ï (2019/12/15), ’¹Žæ.


•a‰@•a—•”

[Šwp˜_•¶]

320055. [Ç—á•ñ] p‘O‚ÌäX‘ŸEUS-FNA‚É‚æ‚èf’f‚µ‚Š‚œè÷—±×–EŽî‚Ì1—á. âŒû@”E1, Š`ÀœA–M1, ‘Ÿ“cœŽq1, ŽR‰º˜a–ç1, ‹g“c@Œ÷2, ŽOŽ}@M2 (•a—•”, 2•a—): _“ސ쌧—Տ°×–EŠw‰ïŽ 2019/8; 24 (1): 17-20.

[Šw‰ïEŒ€‹†‰ï“™]

723938. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) _“ސ쌧‚É‚š‚¯‚éHEõFž“xŠÇ—’²ž•W–{‚ÌRGB‰ðÍ’l‚ð—˜—p‚µ‚œ×–Eƒ‚ƒfƒ‹‚Ì—L—p«. âŒû@”E1, ¬ŽR“c—Ts2, ‹œ“c“ÖŽj3, ˜a“cŒõ•œ4, à_‘º®–ç5, ‰¡‰®£—¢6, ‹{è¬•S‡7, “‡“c’ŒŽ÷3 (1•a—•”, 2“ŒŠC‘åŠw•a‰@, 3¹ƒ}ƒŠƒAƒ“ƒiˆã‰È‘åŠw•a‰@, 4‘Š–ÍŒŽ‹Š“¯•a‰@, 5‰¡•l˜JÐ•a‰@•a—f’f‰È, 6ìèŽs—§ìè•a‰@, 7¬“cŒŽŽs—§•a‰@—Տ°ŒŸž•a—): ‘æ68‰ñ“ú–{ˆãŠwŒŸžŠw‰ï (2019/5/19), ‰ºŠÖ, ˆãŠwŒŸž 2019/5; 68 (•Êû): 222.

723939. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) ƒzƒ‹ƒ}ƒŠƒ“ƒQƒ‹ŒÅ’è‚ÌŒŸ“¢. ŽR‰º˜a–ç1, ‰¡ŽR‚¢‚³‚Ý1, âŒû@”E1, ‹vê@Ž÷1, ‹g“c@Œ÷2, ŽOŽ}@M2 (1•a—•”, 2•a—): ‘æ68‰ñ“ú–{ˆãŠwŒŸžŠw‰ï (2019/5/19), ‰ºŠÖ, ˆãŠwŒŸž 2019/5; 68 (•Êû): 244.

723940. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) “ú—Õ‹Z•a—ŒŸž•W€‰»Ž–‹Æ@ƒAƒ“ƒP[ƒg’²ž•ñ@“®Œü’²ž (1). âªˆê1, “Œ@@Šw2, —с@—TŽi3 ŒŒŽ^“Þ”ü4, ŽR‰º˜a–ç5, Î“cŽ¬6 (1Ã‰ªŒ§—§‚±‚Ç‚à•a‰@, 2”ŸŠÙ•a‰@—Տ°ŒŸž‰È, 3Ž ‰êˆã‰È‘åŠwˆãŠw•”•t‘®•a‰@, 4“‡ªŒ§—§’†‰›•a‰@ŒŸž‹Zp‰È, 5•a—•”, 6L“‡‘åŠwˆãŠw•”•t‘®•a‰@•a—f’f‰È): ‘æ68‰ñ“ú–{ˆãŠwŒŸžŠw‰ï (2019/5/19), ‰ºŠÖ, ˆãŠwŒŸž 2019/5; 68 (•Êû): 576.

723941. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) “ú—Õ‹Z•a—ŒŸž•W€‰»Ž–‹Æ@ƒAƒ“ƒP[ƒg’²ž•ñ@“®Œü’²ž (2). âªˆê1, “Œ@@Šw2, —с@—TŽi3, ŒŒŽ^“Þ”ü4, ŽR‰º˜a–ç5, Î“cŽ¬6 (1Ã‰ªŒ§—§‚±‚Ç‚à•a‰@, 2”ŸŠÙ•a‰@—Տ°ŒŸž‰È, 3Ž ‰êˆã‰È‘åŠwˆãŠw•”•t‘®•a‰@, 4“‡ªŒ§—§’†‰›•a‰@ŒŸž‹Zp‰È, 5•a—•”, 6L“‡‘åŠwˆãŠw•”•t‘®•a‰@•a—f’f‰È): ‘æ68‰ñ“ú–{ˆãŠwŒŸžŠw‰ï (2019/5/19), ‰ºŠÖ, ˆãŠwŒŸž 2019/5; 68 (•Êû): 577.

723942. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚É‚š‚¯‚éƒKƒCƒhƒ‰ƒCƒ“•ñ—lŽ®‚É‚æ‚é‘Á‰t‘B×–Ef‚̐ž“xŠÇ—. âŒû@”E1, Š`ÀœA–M1, ‘º“c从Ñ1, ŠÚ—Ñ–­Žq1, ŽR‰º˜a–ç1, Š“cç”ü”T2, ‹g“c@Œ÷2, ŽOŽ}@M2 (1•a—•”, 2•a—): ‘æ60‰ñ“ú–{—Տ°×–EŠw‰ï‘‰ï (tŠú‘å‰ï) (2019/6/7), “Œ‹ž, “ú–{—Տ°×–EŠw‰ïŽGŽ 2019/6; 58 (•âû1†): 223.

723943. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) “û“ªŠà‚Æàh–E«ŽîᇂƂ̊ӕʂð—v‚µ‚œNIFTP‚Ì1—á. âŒû@”E1, ‘º“c从Ñ1, ‰¡ŽR‚¢‚³‚Ý1, ŽR‰º˜a–ç1, Š“cç”ü”T2, ‹g“c@Œ÷2, ŽOŽ}@M2 (1•a—•”, 2•a—): ‘æ58‰ñ“ú–{—Տ°×–EŠw‰ïHŠú‘å‰ï (2019/11/16), ‰ªŽR, “ú–{—Տ°×–EŠw‰ïŽGŽ 2019/11; 58 (•âû2†): 636.

731112. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (“Á•Êu‰‰) ˆâ“`ŽqŒŸž‚ÌŠî‘b (‘gDŒŸ‘ÌŽæ‚舵‚¢‚ðŠÜ‚ß‚œ). ŽR‰º˜a–ç (•a—•”): •œ¬30”N“x@”F’è•a—ŒŸž‹ZŽt@Žw’èuK‰ï (2019/7/6), “Œ‹ž, Žw’èuK‰ïƒeƒLƒXƒg (—ߘaŒ³”N“x”Å) 2019/7.

732158. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰) ”xŠà–Ɖuƒpƒlƒ‹‚̐õFƒT[ƒxƒCŒ‹‰Ê‚Æ•W–{ì»‚̐ž“xŠÇ—‚ðŠÜ‚Þ’mŽ¯‚ɂ‚¢‚Ä. ŽR‰º˜a–ç (•a—•”): ‘æ4‰ñ’†•”Œ—”F’è•a—ŒŸž‹ZŽtŠé‰æE•a—‹ZpŒ€C‰ï (2019/7/13), –ŒŒÃ‰®‘åŠw, ‘æ4‰ñ’†•”Œ—”F’è•a—ŒŸž‹ZŽtŠé‰æE•a—‹ZpŒ€C‰ïƒeƒLƒXƒg 2019.

732159. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (µ‘ҍu‰‰) –Ɖu‘gD‰»Šw‚̐ž“xŠÇ—. ŽR‰º˜a–ç (•a—•”): “ú–{—Տ°‰q¶ŒŸž‹ZŽt‰ï•a—×–E•”–åŽx•”Œ€C‰ï@‘æ28‰ñ“ú—Õ‹ZŠÖbMŽx•”EŽñ“sŒ—Žx•”@•a—×–EŒŸžŒ€C‰ï (2020/1/19), é‹Ê, ‘æ28‰ñ“ú—Õ‹ZŠÖbMŽx•”EŽñ“sŒ—Žx•”@•a—×–EŒŸžŒ€C‰ïƒeƒLƒXƒg 2020/1; p.21-6.

733801. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) “]ˆÚ«”xŽîᇂð‹^‚í‚ê‚œ‰ŠÇ«‹ØüˆÛ‰è×–EŽîᇂÌ1—á. —é–ؘa‰À“Þ1, Š`ÀœA–M1, ‰¡ŽR‚¢‚³‚Ý1, âŒû@”E1, ŽR‰º˜a–ç1, ˆêŒË¹–Ÿ2, Š“cç”ü”T2, ‹g“c@Œ÷2, ²“¡”Vr3, ‘º‰_–FŽ÷2, ŽOŽ}@M2 (1•a—•”, 2•a—, 3ŒÄ‹zŠíŠO): ‘æ38‰ñ_“ސ쌧—Տ°×–EŠw‰ïŠwpW‰ï (2019/11/23), _“ސì, _“ސ쌧—Տ°×–EŠw‰ïŽ 2019/11; 24 (2): 26.


ME•”

[Šwp˜_•¶]

522166. [uÀ]y“ÁW: —Տ°HŠw‹ZŽmVl‹³ˆç‚̏[ŽÀ‚ð–ÚŽw‚µ‚ā|ƒtƒŒƒbƒVƒƒ[‚ð‚Ç‚Ì‚æ‚€‚Ɉç‚Ä‚é‚©|zŠe‹Æ–±‚ł̐Vl‹³ˆç‚ÌŽÀÛ‚ÆŽw“±‚̃|ƒCƒ“ƒg: ŽèpŽºŠÖ˜A‹Æ–±. —§–ì@‘ (ME•”): Clinical Engineering 2019/7; 30 (7): 645-51.

522167. [uÀ]y“ÁW: —Տ°HŠw‹ZŽmVl‹³ˆç‚̏[ŽÀ‚ð–ÚŽw‚µ‚ā|ƒtƒŒƒbƒVƒƒ[‚ð‚Ç‚Ì‚æ‚€‚Ɉç‚Ä‚é‚©|zƒvƒŠƒZƒvƒ^[ƒVƒbƒv‚Ì“±“ü‚ÌŒø‰Ê. “ŒžŠŒ\ˆê1, ‹âì”ü¹‹I (1ME•”): Clinical Engineering 2019/7; 30 (7): 658-63.

522168. [uÀ]yCVSAPƒVƒ“ƒ|ƒWƒEƒ€: ‘ÌŠOzŠÂ‚Ö‚Ì‹Ù‹}conversion|‘Ώˆ‚Æ‚»‚Ì”õ‚Š‚ɂ‚¢‚čl‚Š‚é|z‹Ù‹}‘ÌŠOzŠÂ‚ɑ΂·‚é‘ÌŠOzŠÂ‹ZŽm‚Ì–ðŠ„‚ÉŠÖ‚·‚錟“¢. “ŒžŠŒ\ˆê1, ˆÀ–ì@œ, —é–ØŒ’ˆê, Œã“¡@•, ‘O’†‘¥•, –ì“c­G, ‹{–{‘Žj, r–؍NK (1ME•”): ‘ÌŠOzŠÂ‹Zp 2020/3; 47 (1): 67-75.

[Šw‰ïEŒ€‹†‰ï“™]

722272. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰) ˆã—Ë@Ší’†‰›ŠÇ—‘̐§‚É‚š‚¯‚é—Տ°HŠw‹ZŽm‚Ì–ðŠ„. “ŒžŠŒ\ˆê1, “¡ˆä³ŽÀ1 (1ME•”): ‘æ94‰ñ“ú–{ˆã—Ë@ŠíŠw‰ï‘å‰ï(2019/6/15), ‘åã, ˆã—Ë@ŠíŠw 2019/4; 89 (2): 131.

722273. [Šw‰ï (‘S‘)] (µ‘ҍu‰‰)y3Šw‰ï‡“¯CVSAP ƒVƒ“ƒ|ƒWƒEƒ€z‘ÌŠOzŠÂ‚Ö‚Ì‹Ù‹}conversion?‘Ώˆ‚Æ‚»‚Ì”õ‚Š‚ɂ‚¢‚čl‚Š‚é? “ŒžŠŒ\ˆê (ME•”): “ú–{S‘ŸŒŒŠÇ–ƒŒŠw‰ï‘æ24‰ñŠwp‘å‰ï(2019/9/20), ‹ž“s, Cardiovascular Anesthesia 2019/9; 23 (suppl): 115.

722274. [Šw‰ï (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“)y¬Ž™‘ÌŠOzŠÂ[“U—Ê‚Ì‚ ‚̍ ‚ƍ¡|^‚Ì’áNP‚ð‹‚ß‚Äz“–‰@‚̏¬Ž™lHS”x‚É‚š‚¯‚é’áNP‚Ö‚ÌŽæ‚è‘g‚Ý. ‘哇O”V1, “ŒžŠŒ\ˆê1, ŒÃ•œ@‘1, •“cÍ”1, ŠC˜Vª’q‘ã1, ŒKŒŽŽÑˆß1, ‹{’n@ŠÓ2 (1ME•”, 2S‘ŸŒŒŠÇŠO): ‘æ45‰ñ“ú–{‘ÌŠOzŠÂ‹ZpˆãŠw‰ï‘å‰ï(2019/10/6), –ŒŒÃ‰®, ‘ÌŠOzŠÂ‹Zp 2019/9; 46 (3): 274.

722275. [Šw‰ï (‘S‘)] (ŠwpƒZƒbƒVƒ‡ƒ“) ‘ÌŠOzŠÂ‚Ö‚Ì‹Ù‹}conversion|‘Ώˆ‚Æ‚»‚Ì”õ‚Š‚ɂ‚¢‚čl‚Š‚é|. “ŒžŠŒ\ˆê (ME•”): ‘æ45‰ñ“ú–{‘ÌŠOzŠÂ‹ZpˆãŠw‰ï‘å‰ï(2019/10/6), –ŒŒÃ‰®, ‘ÌŠOzŠÂ‹Zp 2019/9; 46 (3): 282.

723944. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŽèpŽx‰‡ƒƒ{ƒbƒg‚É‚š‚¯‚é—Տ°HŠw‹ZŽm‚ÌŠÖ‚í‚è`5”NŠÔ‚̃gƒ‰ƒuƒ‹“à—e‚æ‚è`. —§–ì@‘1, “ŒžŠŒ\ˆê1, ŒÃ•œ@‘1, “¡ˆä³ŽÀ1, ì“‡Ê‰Ø1 (1ME•”): ‘æ29‰ñ“ú–{—Տ°HŠw‰ï(2019/5/18), ·‰ª, “ú–{—Տ°HŠw‹ZŽm‰ï‰ïŽ 2019/4; 66: 187.

723945. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) “–‰@‚É‚š‚¯‚éˆã—Ë@Ší‚̐Ž‘|‚ÉŠÖ‚·‚錟“¢. “ŒžŠŒ\ˆê1, “¡ˆä³ŽÀ1, –؉ºt“Þ1, •“cÍ”1, —§–ì@‘1, ‘哇O”V1, ‹âì”ü¹‹I1, ŒÃ•œ@‘1 (1ME•”): ‘æ29‰ñ“ú–{—Տ°HŠw‰ï(2019/5/18), ·‰ª, “ú–{—Տ°HŠw‹ZŽm‰ï‰ïŽ 2019/4; 66: 214.

723946. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ŽèpŽx‰‡ƒƒ{ƒbƒg‚É‚š‚¯‚é—Տ°HŠw‹ZŽm‹Æ–±Œø—Š‰»‚Ö‚ÌŽæ‚è‘g‚݁|ƒƒ{ƒbƒgƒVƒXƒeƒ€”z’u‚̍H•v|. —§–ì@‘1, “ŒžŠŒ\ˆê1, ŒÃ•œ@‘1, “¡ˆä³ŽÀ1, ì“‡Ê‰Ø1 (1ME•”): ‘æ41‰ñ“ú–{ŽèpˆãŠw‰ï‘‰ï(2019/9/27), “Œ‹ž, “ú–{ŽèpˆãŠw‰ïŽ 2019/7; 40 (suppl): 167.

723947. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ¬Ž™lHS”x‚É‚š‚¯‚鈳•Â“x’²®•û–@‚̈Ⴂ‚É‚æ‚é—Տ°ƒf[ƒ^[‚Ì”äŠr. ‘哇O”V1, “ŒžŠŒ\ˆê1, ŒÃ•œ@‘1, •“cÍ”1, ŠC˜Vª’q‘ã1, ŒKŒŽŽÑˆß1, ‹{’n@ŠÓ2 (1ME•”, 2S‘ŸŒŒŠÇŠO): ‘æ45‰ñ“ú–{‘ÌŠOzŠÂ‹ZpˆãŠw‰ï‘å‰ï(2019/10/6), –ŒŒÃ‰®, ‘ÌŠOzŠÂ‹Zp 2019/9; 46 (3): 282.

733802. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ECMO‰ñ˜Hƒvƒ‰ƒCƒ~ƒ“ƒOƒ‰ƒCƒ“‚ÉŠÖ‚·‚錟“¢. •œ–ö@Œõ1, “ŒžŠŒ\ˆê1, –؉ºt“Þ1, “c‘º”ü¹‹I1, ’†‘º‹±Žq1 (1ME•”): ‘æ26‰ñ“ú–{‘ÌŠOzŠÂ‹ZpˆãŠw‰ïŠÖ“ŒbM‰z’n•û‰ï‘å‰ï(2019/4/14), b•{, ‘ÌŠOzŠÂ‹Zp 2019/10; 46 (3): 274.


—Տ°ŽŽŒ±ƒZƒ“ƒ^[


ˆã—Â̎¿EˆÀ‘S„iŽº

[Šwp˜_•¶]

540086. [‚»‚Ì‘Œ (•¶Œ£Ð‰î)] ˆã—Ï]Ž–ŽÒ‚̉ߏd˜J“­‚ƈã—ÈÀ‘S‚Æ‚ÌŠÖ˜A‚ɂ‚¢‚Ä. rˆä—L”ü1, ˆäã²b2, ]Œû@®2, ‰Â’m—IŽq2, ˆäã—äŽq, ’ç@–Ÿƒ2 (1ˆã—Â̎¿EˆÀ‘S„iŽº, 2ŒöO‰q¶): ŽY‹ÆˆãŠwƒWƒƒ[ƒiƒ‹ 2019/11; 42 (6): 84-7.


ŠŽõŠÇ—Žº

[Šwp˜_•¶]

120050. [ŒŽ’˜] ƒWƒSƒLƒVƒ“‚̏‰Šú“Š—^ÝŒvƒmƒ‚ƒOƒ‰ƒ€‚Ì—L—p«‚ÉŠÖ‚·‚錟“¢. ¬Œ•q²1,2, ¬òŽé”T2, ’––”FŒ³3, ˆ¢ŒÃÆ3, Œú“cKˆê˜Y2,4 (1ŠŽõŠÇ—Žº, 2–òÜ•”, 3zŠÂŠí“à, 4–òŠw•”): “ú–{•a‰@–òÜŽt‰ïŽGŽ 2019/8; 55 (8): 980-4.

120054. [ŒŽ’˜] BŒQ—nŒŒ«ƒŒƒ“ƒT‹…‹Û•Û‹Û”D•w‚É‚š‚¯‚é䰖ŒŒŒŽ•ª•z‚Ì”NŽŸ•Ï‰»‚ÉŠÖ‚·‚錟“¢. “ñ–{–öL1,2, ‚ŽR—zŽq1,3, ˜a“c’B•F1,4, ˆÀ’B@÷2, ¬Œ•q²1, ²X–ØŒ°Žq1, ‚é—R”üŽq1, [–xMŽq1, “IêŒ’‘Ÿ5, Žë–ì—Lì5 (1ŠŽõŠÇ—Žº, 2—ÕŒŸ•”, 3V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 4äPŒŽ•aEŠŽõ“à, 5—ÕŒŸŠw): –k—¢ˆãŠw 2019/12; 49 (2): 87-98.

310042. [Ç—á•ñ] Characterization of the IncFII-IncFIB(pB171) Plasmid Carrying bla NDM-5 in Escherichia coli ST405 Clinical Isolate in Japan. Takayama Y1,2, Sekizuka T, Matsui H3, Adachi Y2, Eda R4, Nihonyanagi S2, Wada T5, Matsui M, Suzuki S, Takaso M6, Kitasato H7, Kuroda M, Hanaki H3: Infect Drug Resist 2020/2; 13: 561-6. (‚ŽR—zŽq1,2, ŒˆäGm3, ˆÀ’B@÷2, ]“c—È‘Ÿ˜Y4, “ñ–{–öL2, ˜a“c’B•F5, ‚‘Š»Žm6, –k—¢‰p˜Y7, ‰Ô–؏G–Ÿ3: 1V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã, 2ŠŽõŠÇ—Žº, 3–k—¢‘åŠw–k—¢¶–œ‰ÈŠwŒ€‹†Š, 4‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È, 5äPŒŽ•aEŠŽõ“à, 6®ŠO, 7ˆã—Éq¶Šw•”)

[Šw‰ïEŒ€‹†‰ï“™]

723896. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒŠƒlƒ]ƒŠƒh‚ÌŒŒ’†”Z“xƒ‚ƒjƒ^ƒŠƒ“ƒO‚ðs‚¢Ž¡—ª‘tŒ÷‚µ‚œ2Ç—á‚ɂ‚¢‚Ä. ¬Œ•q²1,2, “ñ–{–öL1, ˜a“c’B•F1,3, ‚ŽR—zŽq1,4, Œú“c Kˆê˜Y2 (1ŠŽõŠÇ—Žº, 2–òÜ•”, 3äPŒŽ•aEŠŽõ“à, 4V¢‹Iˆã—ÁE‰¡’f“Iˆã—Ã): ‘æ67‰ñ“ú–{‰»Šw—Ö@Šw‰ï‘‰ï (2019/5/11), “Œ‹ž, “ú–{‰»Šw—Ö@Šw‰ïŽGŽ 2019; 67: 1340-7007.

732160. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï) (µ‘ҍu‰‰) ‘œÜ‘ϐ«‹Û‚©‚ç‚Ý‚œŽèŽw‰q¶‚Ì•K—v«. “ñ–{–öL (ŠŽõŠÇ—Žº): –k—¢‘åŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[@‘呺‹L”OŠÙ2019”N“x‘æ1‰ñ‰@“àŠŽõ–hŽ~‘΍ôŒ€C‰ï (2019/9/6), é‹Ê.

733803. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï) (ˆê”ʍu‰‰) R‹Û–ò“K³Žg—p‚Ö‚ÌŽæ‚è‘g‚݁|ASTŠˆ“®‚ÌŒ»ó‚𓥂܂Š‚ā|. ¬Œ•q²1,2 (1ŠŽõŠÇ—Žº, 2–òÜ•”): Œ§‰›ƒtƒ@[ƒ}ƒVƒXƒg (2019/7/11), “Œ‹ž.


f—Ïî•ñŠÇ—Žº


—Տ°S—Žº

[’˜@‘]

620119. [Šwp‘ (•ª’SŽ·•M)]yEOLC for ALL ‚·‚ׂĂ̐l‚ɃGƒ“ƒhƒIƒuƒ‰ƒCƒtƒPƒA‚ÌŒõ‚ð@_Œo“ï•a‚̊ɘaƒPƒAzPart 1 Çó‚²‚Ƃ̊ɘa@5. ŠeáŠQ‚É‚æ‚Á‚悶‚é‹ê’ɏǏó@H. ž_“I‹ê’Ɂ@—Տ°S—Žm‚ÌŽ‹“_, p.179. I. ƒXƒsƒŠƒ`ƒ…ƒAƒ‹EƒyƒCƒ“@—Տ°S—Žm‚ÌŽ‹“_, p.186. Part 2 ‚»‚Ì‘ŒŠÉ˜a“IŽ‹“_‚ð‚à‚‚ׂ«Ž–€@7. •a–Œ’m@—Տ°S—Žm‚ÌŽ‹“_, p.213. 8. ‹Š“­ˆÓŽuŒˆ’è@—Տ°S—Žm‚ÌŽ‹“_, p.219. ‹ù’J”ü‰Ø1, AŒ”ü”¿2 (1—Տ°S—Žº, 2“Œ•a‰@—Տ°S—Žº), •Ò: ‰¬–ì”üŒbŽq, ¬—Ñ—fŽq, ‘‰³—‹MŽq, ’†ŽR—D‹G, ¬“c—LŒá, –ì“c—ÁŽq, •ž•”–œ—¢Žq, ‰ÔˆäˆŸ‹IŽq, “ìŽR“°, “Œ‹ž, 2019/7/”­s.


ƒg[ƒ^ƒ‹ƒTƒ|[ƒgƒZƒ“ƒ^[


ŠÉ˜aƒPƒAŽº


ˆÚAˆã—ÃŽx‰‡Žº


—Տ°Œ€‹†Žx‰‡Žº

[Šw‰ïEŒ€‹†‰ï“™]

723948. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ˆãŽtŽå“±Œ€‹†‚̍‘Û˜AŒg„i‚Ì‚œ‚ß‚ÌŒ€‹†. Šâ“c•c1, ŒF’J—Y“ñ2 (1—Տ°Œ€‹†Žx‰‡Žº, 2—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg): ‘æ40‰ñ“ú–{—Տ°–ò—Šw‰ïŠwp‘‰ï (2019/12/4-6), “Œ‹ž, —Տ°–ò— 2019; 50: S316.


ƒOƒ[ƒoƒ‹—Տ°Œ€‹†Žx‰‡ƒZƒ“ƒ^[

[Šw‰ïEŒ€‹†‰ï“™]

713154. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) The prognosis of patients with recurrent or persistent ovarian clear cell carcinoma: Results from a randomized phase III study (JGOG3017/GCIG). Kondo E, Tabata T, Suzuki N, Aoki D, Kato K, Hamano T, Kotera Y1, Tokuyama O, Fujiwara K, Kimura E, Terauchi F, Sumi T, Okamoto A, Yaegashi N, Enomoto T, Sugiyama T: American Society of Clinical Oncology 2019 Annual Meeting (2019/5/31-6/4), Chicago, USA. (¬Ž›—Ç•v1: 1ƒOƒ[ƒoƒ‹—Տ°Œ€‹†Žx‰‡ƒZ)

713155. [Šw‰ï (‘Û)] (ˆê”ʍu‰‰) Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) 50 mg/m2 and 40 mg/m2 in patients with platinum-resistant Mullerian carcinoma (JGOG3018). Yabuno A, Tabata T, Michimae H, Oishi T, Nonaka M1, Takano M, Hirata T, Fujiwara K, Sugiyama T: American Society of Clinical Oncology 2019 Annual Meeting (2019/5/31-6/4), Chicago, USA. (–ì’†”ü˜a1: 1ƒOƒ[ƒoƒ‹—Տ°Œ€‹†Žx‰‡ƒZ)

722276. [Šw‰ï (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒAƒJƒfƒ~ƒA‘n–ò‚ƗՏ°ŽŽŒ±. –ì’†”ü˜a1, ŒF’J—YŽ¡2 (1ƒOƒ[ƒoƒ‹—Տ°Œ€‹†Žx‰‡ƒZ, 2—Տ°Œ€‹†EƒvƒƒWƒFƒNƒg): ‘æ40‰ñ“ú–{—Տ°–ò—Šw‰ïŠwpW‰ï‘‰ï (2019/12/6), “Œ‹ž, —Տ°–ò— 2019/11; 50: S187.

723949. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) •iŽ¿ƒ}ƒlƒWƒƒ“ƒg‚ÉŠÖ‚·‚é‘̐§®”õ‚ÌŽæ‚è‘g‚Ý (–k—¢‘åŠw•a‰@‚ÌŽæ‚è‘g‚Ý1). ‰¬ŒŽ@–L1, ‘ºã–­Žq1, ŽðˆäˆºŽq1, –ì’†”ü˜a1, “n•Ó—•F1, ¬Ž›—Ç•v1 (1ƒOƒ[ƒoƒ‹—Տ°Œ€‹†Žx‰‡ƒZ): ‘æ40‰ñ“ú–{—Տ°–ò—Šw‰ïŠwpW‰ï‘‰ï (2019/12/6), “Œ‹ž, —Տ°–ò— 2019/11; 50: S318.

723950. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) DM‹Æ–±‚ÌŒø—Š‰»‚Æ‚µ‚Ä‚ÌCRFŠÇ—ƒtƒ@ƒCƒ‹‚ÌŠJ”­E“±“ü (–k—¢‘åŠw•a‰@‚ÌŽæ‚è‘g‚Ý2). ÎX‹v”üŽq1, ™@“~”~1, ŽðˆäˆºŽq1, “n•Ó—•F1, Ü–{—SŽ¡1, ¬Ž›—Ç•v1 (1ƒOƒ[ƒoƒ‹—Տ°Œ€‹†Žx‰‡ƒZ): ‘æ40‰ñ“ú–{—Տ°–ò—Šw‰ïŠwpW‰ï‘‰ï (2019/12/6), “Œ‹ž, —Տ°–ò— 2019/11; 50: S318.


–k—¢‘åŠw“Œ•a‰@

“Œ•a‰@ŠÅŒì•”

[Šw‰ïEŒ€‹†‰ï“™]

723951. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) •a‰@‚©‚玩‘î‚É‘Þ‰@‚µ‚œ“Æ‹‚—îŽÒ‚̐¶Šˆ‘ÌŒ±`‘Þ‰@Œã1ƒ–ŒŽŠÔ‚ɏœ_‚𓖂Ăā`. ‘å‰i—¢”ü (“Œ•a‰@ŠÅŒì•”): “ú–{˜V”NŠÅŒìŠw‰ï‘æ24‰ñŠwpW‰ï (2019/6/7), å‘ä, “ú–{˜V”NŠÅŒìŠw‰ï‘æ24‰ñŠwpW‰ïŽ˜^W 2019/6; p.145.

723952. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) Žq‚Ç‚à‚̃OƒŠ[ƒtƒPƒA‚ðŽÀ‘H‚µ‚Ä‚¢‚éˆã—ÃŽÒ‚Ì’nˆæ˜AŒg‚Å•ø‚­¢“‚ÉŠÖ‚·‚錀‹†. ¬“‡‚ЂŎq1, ’ҍ²ŒbŽq1, –û’J˜aŽq2, ‚Œ©‹IŽq3, —Ñ”ü“ÞŽq4 (1ŠÅŒìŠw•”, 2“Œ•a‰@ŠÅŒì•”, 3ŠÅŒì•”, 4Œ³–Ú”’‘åŠwŠÅŒìŠw•”): ‘æ24‰ñ“ú–{ŠÉ˜aˆã—Êw‰ïŠwp‘å‰ï (2019/6/21), _“ސì, Palliative Care Research 2019/6; 14 (Suppl): S343.

723953. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚̐S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“•”–å‚É‚š‚¯‚é‘œEŽí‚ðŠÜ‚ß‚œ‹}•ÏƒVƒ~ƒ…ƒŒ[ƒVƒ‡ƒ“‚ÌŽÀ‘H‚Æ–â‘è“_. ŠÖªŒb”üŽq1, ‚‹Ž—R”ü1, V•á’mŒb1, ‰“ŒŽ^ˆê2, Š¡’J‰p‹I2, “ŒžŠ”ü“ÞŽq3, –ì“cçt4, ˆ¢ŒÃÆ4 (1“Œ•a‰@ŠÅŒì•”, 2“Œ•a‰@ƒŠƒnƒrƒŠ•”, 3ˆã—Éq¶Šw•”, 4zŠÂŠí“à): ‘æ25‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ï (2019/7/13), ‘åã, ‘æ25‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïƒvƒƒOƒ‰ƒ€W 2019/7; p.P-213.

723954. [Šw‰ï (‘S‘)] (ˆê”ÊŒû‰‰) “–ƒZƒ“ƒ^[‚É‚š‚¯‚éŠÅŒìŽt“Á’èsˆ×‚ÌŠˆ“®‚ÌŒ»ó‚Ɖۑè. ˆÉ¥–ŒŽáØ (“Œ•a‰@ŠÅŒì•”): ‘æ45‰ñ“ú–{dÇSgáŠQŠw‰ïŠwpW‰ï (2019/9/20), ‰ªŽR, “ú–{dÇSgáŠQŠw‰ïŽ 2019/8; 44 (2): 376.

723955. [Šw‰ï (‘S‘)] (ƒ|ƒXƒ^[) ƒƒ`ƒSƒ`ƒ““±“üŽž‚Ì•ÛŽŒÜŽg—p•û–@‚ÌŽw“±‚É‚æ‚é”畆Çó‚̉ü‘P. ˜a‰Æ•‚Šó1, ‰iˆä^‹MŽq2, –ì“c—ÁŽq1, Ž›“‡–ƒ”ü1, ‚‹Ž—R”ü1, âV“¡^Žì1, V•á’mŒb1, ‰iˆärs2, ‹ß“¡—TŽq2, ŒŽR˜a—˜2 (1“Œ•a‰@ŠÅŒì•”, 2”]_Œo“à): ‘æ60‰ñ“ú–{_ŒoŠw‰ïŠwp‘å‰ï (2019/5/25), ‘åã, —Տ°_ŒoŠw 2019/11; 59 (Suppl): S450.

733804. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ”F’m‚É“­‚«‚©‚¯‚Ä—^–òƒCƒ“ƒVƒfƒ“ƒgíŒž. ‘ëàVD1, ŒFâ^—R”ü1 (1“Œ•a‰@ŠÅŒì•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.46.

733805. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ƒXƒ^ƒbƒt‚ÌŠÅŒìŠÏ‚̏ø¬‚ÉŒü‚¯‚œŽæ‚è‘g‚݁`ŠÅŒì‚ÌŠT”O‰»‚̉ߒö‚ð’Ê‚µ‚ā`. –{–ìçŠG”ü1, V•á’mŒb1 (1“Œ•a‰@ŠÅŒì•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.53.

733806. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ‰Æ‘°‚ƃp[ƒgƒi[ƒVƒbƒv‚ðŒ‹‚Ñ‚È‚ª‚çA‰Æ‘°‹@”\‚ð•Û‚‚œ‚߂̉Ƒ°Žx‰‡. ‹â’J‚Š‚è‚©1, ˆÉ¥–ŒŽáØ1, –Ñ’Ë—R”üŽq1 (1“Œ•a‰@ŠÅŒì•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.55.

733807. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) dÇSgáŠQŽ™‚̃Vƒ‡[ƒgƒXƒeƒC—˜—p‚É”º‚€‰Æ‘°‚̐¶Šˆ‚̕ω»`ˆã—ÂƕŸŽƒ‚𕹂¹‚à‚Â’†ŠÔŽ{Ý‚É‚š‚¢‚č¡Œã‚ÌŽæ‚è‘g‚Ý‚ðl‚Š‚é`. “cK–ŸŽq1, ˆÉ¥–ŒŽáØ1, –Ñ’Ë—R”üŽq1 (1“Œ•a‰@ŠÅŒì•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.56.

733808. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) Ž¡—Ã’ïR«“‡Žž’²ÇŠ³ŽÒ‚Ì’nˆæˆÚsŽx‰‡`‘œEŽí˜AŒg‚É‚æ‚é‘Þ‰@Œã‚̐¶Šˆ‚ðŒ©˜‚Š‚œ‰î“ü`. ”óŒû’m1, ŒFâ^—R”ü1 (1“Œ•a‰@ŠÅŒì•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.58.

733809. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ž__Œo‰ÈŽ¡—ÃZƒ“ƒ^[‚̃_ƒEƒ“ƒTƒCƒWƒ“ƒO‚ÉŒü‚¯‚œŽæ‚è‘g‚݂ƍ¡Œã‚̉ۑè`’nˆæ•ïŠ‡ƒPƒA‚ÌŽÀ‘H‚ð–ÚŽw‚µ‚œ‘œEŽí˜AŒg`. ŒFâ^—R”ü1, ŽRŒû–ŸŽq1, ’†ŒŽ”ü‰Ä1, –{–ìçŠG”ü1 (1“Œ•a‰@ŠÅŒì•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.59.

733810. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ‘åŠw•a‰@‚É‚š‚¯‚鐞_‰È–K–âŠÅŒì‚̈Ӌ`‚Ɖۑè. ’†ŒŽ”ü‰Ä1, ŒFâ^—R”ü1, –û’J˜aŽq1 (1“Œ•a‰@ŠÅŒì•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.60.

733811. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) _ŒoŽš‰ÈE‚ß‚Ü‚¢ƒZƒ“ƒ^[—§‚¿ã‚°Œã3”NŠÔ‚Ì“ü‰@Š³ŽÒ‚ÌŽÀ‘Ô•ñ. ¬ˆä”ü•ä1, ‘å‰i—¢”ü1, –Ñ’Ë—R”üŽq1 (1“Œ•a‰@ŠÅŒì•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.69.

733812. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ‰‚߂Ď󂯎‚ž_ŽŸŠ³‚ÌŠ³ŽÒ‚ÆŠÖ‚í‚é’†‚Å•ø‚¢‚œŠŽî‚̕ω»‚ÆŠÖŒW\’z`ƒgƒ‰ƒxƒ‹ƒr[‚Ì—˜_‚ð—p‚¢‚ĐU‚è•Ô‚é`. A–؉·”ü1, ŒFâ^—R”ü1 (1“Œ•a‰@ŠÅŒì•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.73.

733813. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) “Ë”­“I‚È•sˆÀ‚©‚玩sˆ×‚ðŒJ‚è•Ô‚·Š³ŽÒ‚Ì—‰ð‚ÆŠÅŒì`ƒgƒ‰ƒxƒ‹ƒr[‚Ì—˜_‚ð—p‚¢‚ĐU‚è•Ô‚é`. •’J”ü÷1, ŒFâ^—R”ü1 (1“Œ•a‰@ŠÅŒì•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.74.

733814. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) ƒƒ`ƒSƒ`ƒ““±“üŽž‚É‚š‚¯‚é•ÛŽŒÜŽg—p•û–@‚ÌŽw“±‚Ɣ畆Çó‚̉ü‘P. ˜a‰Æ•‚Šó1, –ì“c—ÁŽq1, Ž›“‡–ƒ”ü1, âV“¡^Žì1, ‚‹Ž—R”ü1, V•á’mŒb1, ‰iˆä^‹MŽq2 (1“Œ•a‰@ŠÅŒì•”, 2”]_Œo“à): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.77.

733815. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ÊŒû‰‰) S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“•”–å‚É‚š‚¯‚é‘œEŽí‚ðŠÜ‚ß‚œ‹}•ÏƒVƒ~ƒ…ƒŒ[ƒVƒ‡ƒ“‚ÌŽÀŽ{‚Ɖۑè. ŠÖªŒb”üŽq1, ‚‹Ž—R”ü1, V•á’mŒb1, Š ’J‰p‹I2, ‰“ŒŽ^ˆê2, “ŒžŠ”ü“ÞŽq3 (1“Œ•a‰@ŠÅŒì•”, 2“Œ•a‰@ƒŠƒnƒrƒŠ•”, 3ˆã—Éq¶Šw•”): ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ï (2019/12/21), _“ސì, ‘æ19‰ñ–k—¢ŠÅŒìŒ€‹†‰ïƒvƒƒOƒ‰ƒ€EŽ˜^ 2019/11; p.79.


“Œ•a‰@—Տ°ŒŸž•”

[Šwp˜_•¶]

120055. [ŒŽ’˜] _“ސ쌧—Տ°ŒŸž‹ZŽt‰ï¶—Œ€‹†”Ç•œt’®Šoê–åƒOƒ‹[ƒv‚ÅŽÀŽ{‚µ‚œƒAƒ“ƒP[ƒg’²žŒ‹‰Ê‚©‚猩‚œ’®ŠoŒŸž‚ÌŒ»ó‚Ɖۑè. ¬”Š@i1, Šâ|‹Ô‰›2, ™–{—I‰Ø3, —é–Ø“TŽq4, ¬ŒŽ‚³‚š‚è4, ŒŒŽ—R”üŽq5, ’Jƒ–é—Ç‘Ÿ6, ’r“c@—E7 (1“Œ•a‰@—ÕŒŸ•”, 2—ÕŒŸ•”, 3ˆÉšŒŽ‹Š“¯•a‰@—Տ°ŒŸžŽº, 4“ŒŠC‘åŠwˆãŠw•”•t‘®•a‰@f—ËZp•”f—ËZp‰È, 5º˜a‘åŠw]“Œ–LF•a‰@—Տ°•a—ŒŸž•”, 6‘å˜aŽs—§•a‰@—Տ°ŒŸž‰È, 7Ï¶‰ï‰¡•lŽs“ì•”•a‰@’†‰›ŒŸž•”): _“ސ쌧—Տ°ŒŸž‹ZŽt‰ïŽGŽ 2019/12; 54 i171j: 1-5.

521012. [‰ðà] ’®—ÍŒŸžƒ}ƒXƒLƒ“ƒO–@‚ÌŠî–{“I‚ȍl‚Š•û‚Æ‚»‚Ì•û–@. ¬”Š@i (“Œ•a‰@—ÕŒŸ•”): “Œ‹ž“sˆãŠwŒŸž 2019/6; 47 (2): 137-8.

[Šw‰ïEŒ€‹†‰ï“™]

723956. [Šw‰ï (‘S‘) (ˆê”ʍu‰‰) ‚œ‚±‚‚ڌ^S‹ØÇ‹^‚¢‚ō¶Žº“àŒŒð‚ð”F‚ß‚œALS‚Ì1—á. ‘ŽR–ƒ‹LŽq1, –ØŒŽƒŽq1, •œ“cçL1, ‹{‰º‰ÀŽq1, –F“c@v1, ‘“ãç»1, ‰““¡@—m1, Žë–ì—Lì1,2 (1“Œ•a‰@—ÕŒŸ•”, 2—ÕŒŸŠw): ‘æ44‰ñ“ú–{’Ž‰¹”gŒŸžŠw‰ïŠwpW‰ï (2019/4/29), ‰¡•l, ’Ž‰¹”gŒŸž‹Zp 2019/4; 44 (Ž˜^†): S166.

733816. [Šw‰ï (’n•û‰ïEŒ€‹†‰ï)] (ˆê”ʍu‰‰) ‚ŒŒˆ³‚ðŒ_‹@‚É‹ô‘R”­Œ©‚³‚ê‚œŽá”N«• •”‘å“®–¬kóÇ‚Ì1Ç—á‚ɂ‚¢‚Ä. ‰““¡—¯”üŽq1, ’†Œ‹vK1, ꠓcŠì”V1, ‰FŽ¡‹Ž‘PŸ1, “•ûLˆê1, •œ“cŒõ”Ž2, Žë–ì—Lì1,3 (1“Œ•a‰@—ÕŒŸ•”, 2‘Š–ÍŒŽ•a‰@, 3
—ÕŒŸŠw): ‘æ17‰ñ–k—¢ŒŒŠÇƒtƒH[ƒ‰ƒ€ (2019/6/3), ‘Š–ÍŒŽ, –k—¢ŒŒŠÇƒtƒH[ƒ‰ƒ€ƒvƒƒOƒ‰ƒ€EŽ˜^W 2019/6; p.3.


“Œ•a‰@–òÜ•”

[Šwp˜_•¶]

220006. [€ŒŽ’˜] yŽÀ‘H•ñz–k—¢‘åŠw•a‰@E–k—¢‘åŠw“Œ•a‰@‚̉ü’ù–òŠw‹³ˆçƒ‚ƒfƒ‹EƒRƒAƒJƒŠƒLƒ…ƒ‰ƒ€ŽÀŽ{‘O•a‰@ŽÀ–±ŽÀK‚É‚š‚¯‚é‘ã•\“I8ŽŸŠ³‚ÌŽÀŽ{ó‹µ’²ž. t“úˆäŒö”ü1, –Ñ—˜‡ˆê1, “c’†@—å1, ’†ŽR–G”ü1, ”ò“c—[‹I1,2, ì–ìçq1,2, ¬—я¹G1, •œŽR•Ži1,2, •ŽR­ˆê1,2, Œú“cKˆê˜Y1,3 (1–òŠw•”, 2“Œ•a‰@–òÜ•”, 3–òÜ•”): –òŠw‹³ˆç 2020/1; 3: 179-84.


“Œ•a‰@—Տ°S—Žº

[Šw‰ïEŒ€‹†‰ï“™]

723957. [Šw‰ï (‘S‘)] (ˆê”ʍu‰‰) ƒMƒƒƒ“ƒuƒ‹áŠQ‚É‚š‚¯‚édÇ“x‚ÆŠ®‘SŽå‹`‚Æ‚Ì‘œŽŸŒ³“I‚ÈŒŸ“¢. •ûŒcŽO˜Y1, “à“c–ƒˆß2, ’©‘q’•¶2,3 (1“Œ•a‰@—Տ°S—Žº, 2ž_, 3‘åŠw‰@ˆã—ÃŒnŒ€‹†‰È): “ú–{”F’mEs“®—Ö@Šw‰ï‘æ45‰ñ‘å‰ï (2019/8/30), –ŒŒÃ‰®.